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and use in the operating room. We compared our 
data to a near-contemporary pre-deployment cohort 
from the same institution, matched for surgeon, 
pathologist, histology, and extent of resection. 
Appropriate statistical methods were used for all 
comparisons. 
Results: mLN were examined in all cases in which 
the kit was used. The median number of mLN 
examined was 0.5 in the control group, compared 
to a median of 10 in the case group. Stations 4 
and 7 had signiÀcantly increased number of LNs 
examined. The percentage of resections that attained 
the NCCN deÀnition of good quality resection 
and the proportion of resections that would have 
been eligible for the RADIANT trial increased 
signiÀcantly. Attainment of the more stringent 
ACOSOG deÀnition of good quality resection 
improved slightly (Table). The duration of surgery 
and post-operative complication rates were similar 
between cases and controls. Thirty percent of 
the cases performed with the kit had one or more 
positive mLN, compared to 8% of the controls. 
Case Control P-value 
Median Range Interquartile 
Range 
Median Range Interquartile 
Range 
# mLN examined 10 (5,12) (9,11) 0.5 (0,6) (0,5) 0.0078 
# mLN positive 0 (0,3) (0,1) 0 (0,3) (0,0) 0.99 
Station 4 4 (0,8) (1,4) 0 (0,2) (0,0) 0.0078 
Station 7 1.5 (0,3) (1,2) 0 (0,1) (0,0) 0.0313 
Station 8 1 (0,5) (0,2) 0 (0,1) (0,0) 0.0625 
Station 9 1 (0,2) (0,1) 0 (0,1) (0,1) 0.0625 
Station 10 1 (0,4) (1,2) 0 (0,6) (0,1) 0.47 
RADIANT trial eligibility 90% 10% 0.0078 
NCCN GQR criteria 80% 10% 0.0156 
ACOSOG Z0030 criteria 20% 10% 1.0 
Median surgery time, minutes 
(range) 
158 (79,231) 151 (80,208) 0.9 
Median hospital length of stay, 
days (range) 
6 (0,26) 6.5 (3,27) 0.99 
Median intra-op blood 
transfusion, units (range) 
0 (0,2) 0 (0,0) -- 
Median estimated blood loss, 
mL (range) 
300 (100,1000) 250 (100,500) -- 
Median ICU days (range) 2.5 (0,23) 3 (1,4) -- 
Median chest tube days 
(range) 
3 (2,15) 5 (2,15) -- 
Median frequency post-op 
MI (range) 
0 (0,0) 0 (0,0) -- 
Median frequency post-op 
pneumonia (range) 
0 (0,2) 0 (0,0) -- 
Median frequency post-op 
arrhythmia (range) 
0 (0,1) 0 (0,1) -- 
Conclusion: The use of a specialized specimen 
collection kit for mLN examination is feasible, 
was associated with markedly improved mLN 
examination and mapping, and detection of more 
metastatic disease in the mLNs. There was no 
increase in OR time, post-operative or peri-operative 
morbidity/mortality, or hospital length of stay. 
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P1.305 INFLUENCE OF A SPECIAL 
SURGICAL SPECIMEN COLLECTION 
KIT ON THE QUALITY OF 
MEDIASTINAL LYMPH NODE 
EXAMINATION DURING RESECTION OF 
LUNG CANCER.
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Background: Mediastinal lymph node (mLN) 
status is the key determinant of prognosis and post-
operative therapy after curative-intent resection of 
non-small cell lung cancer (NSCLC). There is some 
controversy about the optimal LN examination 
procedure, but systematic nodal dissection is 
widely advocated. Random examination or lack of 
examination is associated with inferior survival. 
However, a 2001 American College of Surgeons 
survey revealed that 42% of resections had no mLNs 
examined, identical to our Memphis cohort in which 
a median of 1 mLN was examined, and 85% of 
resections had no mLN mapping. In the Memphis 
cohort, no mLNs were examined in 35% and 52% of 
patients with ‘pN0’ and ‘pN1’ disease, respectively; 
station 10 was not speciÀcally identiÀed in 59%; 
only 24% met resection criteria for eligibility for 
the RADIANT trial, 0.9% met eligibility for the 
ACOSOG Z0030 trial, and only 8% met the NCCN 
deÀnition of good quality resection. Suboptimal 
hilar and mLN examination accounted for most 
quality failures. We tested the effect of a corrective 
intervention using a pre-labeled specimen collection 
kit with separate containers for stations 2-10 to 
improve examination during curative-intent resection 
of NSCLC. 
Methods: Case-control study to test kit deployment 
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additional negative nodes from SMLD (S(-)D(-)), 
negative nodes in SS but additional positive nodes 
from SMLD (S(-)D(+)), positive nodes in SS (S(+)
D(+)). cN2 (p=0.001) and CEA level (p=0.000) were 
correlated with pN status. There was signiÀcant 
overall survival difference between non-N2 group 
and N2 group (p=0.003), but not between S(-)D(+) 
and S(+)D(+) in N2 subgroups (p=0.980).
Conclusion: SMLD may harvest about three times 
of mediastinal lymph nodes as compared to SS. SS 
is more likely to affect the completeness of surgery 
instead of underrating pathological stage.
Keyword: systematic mediastinal lymph node 
dissection; systematic sampling; self-controlled 
study
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.307 SURGICAL RESULTS OF 
SUPERIOR SULCUS TUMORS IN OUR 
INSTITUTE.
Motoohiro Yamashita1, Hiroshi Suehisa1, Yuka 
Katou2, Shigeki Sawada1, Toshiyuki Kozuki2, 
Naoyuki Nogami2, Tetsu Shinkai2 
1Thoracic Surgery, Shikoku Cancer Center/Japan, 
2Thoracic Oncology, Shikoku Cancer Center/Japan
Background: Superior sulcus tumors (SST) often 
has the anatomical limitations to complete resection. 
Recently, preoperative chemoradiotherapy showed 
to improve the rate of complete resection and its 
prognosis. 
Methods: Clinical records of all patients operated 
on for superior sulcus tumors in Shikoku Cancer 
Center between 1993 and 2010 were reviewed 
retrospectively. 
Results: Thirty-two patients (mean age 60, 30~79, 
31 men and one woman) underwent thoracotomy on 
this period. All patients underwent lung and chest 
wall resection. Surgical approaches were as follows; 
posterolateral thoracotomy(n=28), combined 
transcervical and transthoracic approach(n= 4). 
Pathologic stage were IIB, IIIA, and IIIIB were 
in 20 cases, 5 cases, and 2 cases, respectively. 
Histology type were Squamous cell carcinoma, 
adenocarcinoma, large-cell carcinoma were in 14 
cases, 11 cases, 7 cases, respectively. Resection was 
complete in 21 cases(66%). Operative mortality was 
0 %. The overall 3-year and 5 year survival rate were 
55%, and 43%, respectively. Five year survival was 
signiÀcantly higher after complete resection than 
Keywords: Operative Intervention, Pathologic 
staging, Systematic mediastinal nodal dissection, 
Quality improvement
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.306 COMPARISON OF SYSTEMATIC 
MEDIASTINAL LYMPH NODE 
DISSECTION VERSUS SYSTEMATIC 
SAMPLING FOR LUNG CANCER 
STAGING AND COMPLETENESS OF 
SURGERY
Nan Wu1, Shi Yan2, Chao Lv2, Yue Yang2 
1Department Of Thoracic Surgery 2, Peking 
University School Of Oncology/China, 2Peking 
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Background: The best method for performing 
mediastinal lymphadenectomy after a major 
pulmonary resection in lung cancer patients is still in 
dispute. This self-controlled prospective study was 
designed to investigate the efÀcacy of systematic 
sampling (SS), compared to systematic mediastinal 
lymph node dissection (SMLD), for pathological 
staging and completeness of surgery.
Methods: Over 11 months, 111 patients were 
enlisted. All were diagnosed with lung cancer 
and treated by pulmonary resection. Surgeons 
systematically sampled mediastinal lymph nodes 
prior to pulmonary resection, and after pulmonary 
resection SMLD was performed to each patient 
using the standard procedure of Mountain [1]. The 
number of collected lymph nodes from each station 
was recorded for the different procedures, and the 
negative predictive values of mediastinal lymph node 
stations by SS were calculated. 
Results: After SMLD, pN status was classiÀed as 
N0 in 57 cases, N1 in 28, and N2 in 26. SS detected 
38.2% of pooled nodes and 37.6% of pooled 
positive nodes collected from SMLD. Pathological 
diagnosis after SS was underrated in 9 cases (8.1%), 
compared to staging after SMLD. However, surgery 
was incomplete in 24 cases (21.6%) if SMLD was 
not performed after sampling. Negative predictive 
value for SS was 86.8% on the right side, and 
95.1% on the left. Three categories were generated 
according to pN status: negative nodes in SS and 
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between the presentation of the primary tumor 
and that of metastases (DFI) was of 28,68 months 
(range:0-19 years). The age ranging was from 
21-80 years (medium 50,1). We removed 319 
metastases (medium 1,58; range: 1-7), conÀrmed by 
Histologycal examination. The size of the lesions 
was from 1 to 8 cm, (medium: 2,58 cm). The 
medium stay in hospital has been of 8,1 days (range 
6-24), and were estimated also the post-operative 
pain and the complication (12,8%). The type of lung 
resection was wedge resection (53,7%), pneumotomy 
(38,5%), segmentectomy (4,9%), lobectomy (2,9%). 
After lung metastasectomy patients were followed up 
for 12-180 months (median. 65,8months). 
Results: The DFI was of 8,74 months (range 0-27 
months), while survival after metastases resection 
was of 24,37 months (range 2-10 years). Until today 
53 patients are alive, medium follow-up of 65,8 
months (range 12 months-15 years), and only one 
with disease recurrence. The 1 year survival was 
76.2%, 3 years= 44.1%, 5 years= 28.3% and 10 
years= 16,2%. We considered several prognostic 
factors: Histology, DFI, number of metastasis, 
number of resection, mono/bilaterality, type of 
resection and diameter of the metastases. 
Conclusion: Resection of lung metastases has low 
mortality and morbidity and in our experience it 
correlated with prolonged postoperative survival. 
The surgery of the pulmonary metastases is today 
a valid treatment for patients at M1 stage, in good 
general and respiratory conditions and with an 
effective control of primary tumor. 
Keywords: lung resection, pulmonary metastases
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P1.309 A NOVEL PARENCHYMA SAVING 
TECHNIQUE FOR THE RESECTION OF 
THE RIGHT TRACHEOBRONCHIAL 
ANGLE TUMORS
Seyda O. Kaya, Serpil Sevinc, Kenan C. Ceylan 
Thoracic Surgery, Dr Suat Seren Chest Disease And 
Thoracic Surgery Training And Education Hospital/
Turkey
Background: Resection of tracheobronchial angle 
tumors is one of the most complicated procedures in 
thoracic surgery. Tracheal sleeve pneumonectomy 
was generally the choice of resection in such tumors. 
Forming a new carina was Àrst described by Barcley 
and double-barrel method was then described 
after incomplete resection(60% vs. 20%, p<0.02). 
The preoperative treatment improved the complete 
resection rate (surgery alone; 12/19, preoperative 
treatment; 10/13) . Age, tumor size and histology 
type did not affect on the survival outcome. 
Conclusion: Superior sulcus tumor remains a severe 
illness, but long term survival can be achieved in the 
complete resection cases. The preoperative treatment 
improves complete resection rate, and may improve 
long term survival subsequently. 
Keywords: Superior sulcus tumor, Surgery, 
Preoperative treatment
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.308 SURGICAL TREATMENT OF 
PULMONARY METASTASIS: OUR 
EXPERIENCE
Salvatore Griffo1, Giuseppe De Luca2, Francesco 
Petteruti2, Antonella Luciano2, Lucia Beneduce3, 
Dino Casazza3 
1Thoracic Surgery Unit, University Of Naples “ 
Federico Ii”/Italy, 2Cardiothoracic And Vascular 
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Background: Lung metastases from a primary 
extrapulmonary malignancy are often a manifestation 
of widespread dissemination; however, some 
patients have no other evidence of disease. Extensive 
experience with pulmonary metastasectomy in a 
number of different cancers has conÀrmed that 
resection can substantially prolong survival and 
cure some patients . Based upon these observations, 
aggressive resection of isolated pulmonary 
metastases has become a widely accepted treatment 
for appropriately selected patients. The surgical 
treatment of pulmonary metastases today represents 
a procedure of tried therapeutic effectiveness, 
with 5 years survival from the 20 to 40%. We 
retrospectively reviewed our experience of surgical 
treatment of pulmonary metastasis. 
Methods: From 1995 to the 2010, in 165 patients 
we performed 205 surgical and curative resections 
of pulmonary metastases ( 40 of them were 
operated two times). The range of the free interval 
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such neoplasms is exceedingly rare. There are strong 
associations with smoking and asbestosis. 
Methods: In this study, we describe a unique 
case of sarcomatoid carcinoma in a 43 year old 
man who has smoked 75 pocket/year and in 
whom the sarcomatous component of the tumor 
was a rhabdomyosarcoma and the carcinomatous 
component was an squamous type.
Results: The patient underwent thoracotomy with 
left pneumonectomy. Histological examination of the 
resected specimen showed squamous cell carcinoma 
and rhabdomyosarcoma components.
Conclusion: The authors know of no previous report 
of a sarcomatoid carcinoma of the lung in which the 
carcinomatous component is a squamous. 
Keyword: Lung carcinosarcoma, endobronchial 
type, rhabdomyosarcoma.
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P1.311 CLINICAL OUTCOMES OF 
THORACOSCOPIC LOBECTOMY
Arif K. Allakhverdiev, Konstantin K. Laktionov, 
Mikhail M. Davydov, Antonio K. Chekini 
Thoracic Surgery, Thoracic Surgeon/Russian 
Federation
Background: Many thoracic surgeons are 
now advocating the use of minimally invasive 
thoracoscopic surgery to perform lobectomies for 
early-stage primary NSCLC, with the objective 
of lessening postoperative morbidity while still 
providing a good oncologic outcome. This series is 
reviewed to assess these issues. 
by Mathey and collegues. Choosing the suitable 
technique of anastomosis can be challenging in cases 
with high-calibre mismatch. In this study, we present 
our experience of carinoplasty technique for such a 
difÀcult situation.
Methods: The cases with right tracheobronchial 
angle tumors operated in 2009 and 2010 are 
reviewed. A right upper sleeve lobectomy 
with hemicarinal resection and one-stoma type 
carinoplasty including the formation of a new carina 
is applied in all cases.
Results: Seven patients are operated in 18 months 
period. All patients had a complete resection. One 
early postoperative (30 days) mortality was seen. 
One patient had hemopthysis and bronchopleural 
Àstula the operation, had a completion 
pneumonectomy and died at the tenth postoperative 
day. Two patients had atelectasis at the contralateral 
lung that needed bronchoschopy. Five patients are 
alive and disease free so far.
Conclusion: Resection of the right tracheobronchial 
angle tumors can be applied safely by saving the 
uneffected part of the ipsilateral lung by our techniqe 
. It is also more practical when compared to other 
previously described techniques .The one-stoma 
type of carinoplasty technique that we used can be 
performed to overcome the high-calibre mismatch.
Keywords: bronchoplasty, Lung cancer, Surgery
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SARCOMATOID CARCINOMA 
OF THE LUNG WITH 
RHABDOMYOSARCOMATOUS 
COMPONENTS, A CASE REPORT.
Figen Turk1, Gökhan Yuncu1, Ferda Bir2, Yasin 
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Background: Lung carcinosarcoma is an infrequently 
biphasic tumors composed of carcinomatous 
and sarcomatous components. It is divided into 
endobronchial (squamous type) and peripheral 
(glandular type) categories. The carcinomatous 
component is usually a squamous carcinoma, and 
the sarcomatous component usually resembles a 
Àbrosarcoma or a malignant Àbrous histiocytoma. 
The presence of rhabdomyoblastic differentiation in 
S906 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
lung resection for the large cell lung cancer patients 
in our institute. In this study, we try to exam of 
clinical outcome of large cell lung cancer patients.
Methods: In 2004-2009, we performed lung resection 
for 422 primary lung cancer patients. In those patients, 
16 cases were for large cell lung cancer.
Results: The range of age is 48-78 year old, the 
average is 67.2 year old. The each pathological 
stage of those patients were p-IA:1 case (6.3%), 
IB: 2 cases (12.5%), IIA: 3 cases (18.8%), IIB: 2 
cases (12.5%), IIIA: 6 cases (37.5%), IIIB: 2 cases 
(12.5%). The performed operations were lobectomy 
for 10 cases (62.5%), bi-lobectomy for 2 cases 
(12.5%), pneumonectomy for 1 case (6.3%), partial 
resection for 3 cases (18.8%). Six patients of those 
16 patients had any preoperative complication. Two 
patients had Chronic Obstructive Lung Disease 
(COLD), 2 patients had pneumoconiosis, 1 patient 
had Interstitial pneumonia (IP), 1 patient had heart 
failure. Four patients had postoperative complication. 
Two patients had prolonged thoracic effusion, 1 
patient had pulmonary atelectasis, 1 patient had 
Acute Respiratory Distress Syndrome (ARDS) and 
died on 8 postoperative days. All 3 patients who 
were stage I that were Àne without recurrence, but 
5 patients of the 13 patients who were stage II or III 
that were died with primary disease. 
Conclusion: The surgical treatment for large cell 
lung cancer patients is feasible for the case without 
lymph node metastasis. If lymph node metastasis is 
positive, patient has a poor prognosis. 
Keywords: large cell lung cancer, Surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.313 SURVIVAL ANALYSIS OF 
171 PATIENTS WITH SURGICALLY 
RESECTED NON-SAMLL CELL LUNG 
CANCER
Jun Zhang, Libo Han, Yu Li, Baosen Zhou, Anguang He 
Department Of Molecular Targeted Therapeutics 
Of The First Hospital Of China Medical University, 
Lung Cancer Center The First Hospital Of China 
Medical University/China
Background: To summarize the treatment results 
of recentlly resected non-small cell lung cancer 
Methods: From 2008 to 2009, we performed 51 
thoracoscopic lobectomies in 19 women (37,2%) 
and 32 men (62,8%), with a mean age of 55.3 years. 
All operated patients had clinical stage I or II of 
lung cancer. Right upper lobectomy met 14(27,5%), 
midell – 8(15,7%) and lower – 17(33,3%) from the 
total number of operated patients. Left completed 
8(15,7%) lower and 4(7,8%) upper lobectomy. 
Of the primary lung cancers, 39 (76,5%) were 
adenocarcinoma. All patients with primary lung 
cancer performed hilar and mediastinal lymph node 
dissection. There are some discussions over approach 
to VATS. Some authors perform VATS using 
minithoracotomy in the beginning of an operation, 
whereas others prefer using exclusively 4-5 ports. In 
our research we have made minithoracotomy only 
for removal of a lung at the end of an operation. 
Results: Thoracoscopic lobectomy and mediastinal 
lymph dissection was successfully performed in 
47 patients (92,1%); 4(7,9%) patients required 
conversion to thoracotomy to control bleeding 
in the setting of dense hilar adenopathy. There 
were no intraoperative and perioperative deaths. 
Ð¡omplications included pneumonia - 4 patients and 
prolonged air leak - 2 patients. Median time to chest 
tube removal was 3 days, and median length of stay 
was 6 days. 
Conclusion: Thoracoscopic lobectomy is safe and 
feasible for pulmonary resection. This minimally 
invasive approach may allow patients to beneÀt from 
lobectomy with shorter recovery times and hospital 
stays compared with conventional open thoracotomy.
Keyword: lung cancer, thoracoscopic lobectomy, 
clinical outcomes, surgry
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.312 CLINICAL EXAMINATION OF 
LARGE CELL LUNG CANCER
Toshihiko Moroga, Takafumi Hashimoto, Keita 
Tokuishi, Michiyo Miyawaki, Satoshi Yamamoto, 
Shin-Ichi Yamashita, Katsunobu Kawahara 
Surgery Ii, Oita University Faculty Of Medicine/
Japan
Background: Lung cancer has been the most course 
of death in Japan. We choice the patients performed 
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P1.314 PULMONARY EMBOLISM AFTER 
PNEUMONECTOMY. WHICH PATIENTS 
ARE AT RISK?
Emilia Polimeno, Francesco Leo, Leonardo Duranti, 
Simone Furia, Luca Tavecchio, Barbara Conti, Paolo 
Scanagatta, Ugo Pastorino 
Thoracic Surgery Dept, National Cancer Institute/Italy
Background: Postoperative pulmonary embolism 
(PE) is a rare event in thoracic surgery (<1%). Few 
data are available on incidence, risk factors and 
clinical outcome of PE after pneumonectomy, in 
which an elevated mortality is expected. The aim of 
the study was to review a single-center experience in 
the management of this problem. 
Methods: Clinical records of patients who 
underwent pneumonectomy in the period January 
2005 – December 2010 were reviewed searching 
for cases of PE detected by CT scan, perfusion 
scan or autopsy. Patients were classed according 
to the type of pneumonectomy performed: 
standard pneumonectomy (group A), extended 
pneumonectomy (pneumonectomy associated with 
atrial, carinal, caval or chest wall resection and 
completion pneumonectomy, group B), extrapleural 
pneumonectomy for mediastinal tumors (group 
C) and pleuropneumonectomy (group D). PE was 
considered as outcome variable in univariate analysis 
testing all covariates as risk factors. Covariates 
considered clinically relevant or statistically 
signiÀcant were included in the multivariate model. 
Results: In the considered period, 179 consecutive 
pneumonectomies were performed and 6 cases of 
PE occurred (overall incidence 3.3%). Two of them 
died early in the postoperative period and one died 
of cardiac arrest one month after discharge (overall 
mortality 50%). No case was recorded in group A 
and group B. Two cases were recorded in group C 
(9%) and both survived with medical treatment. 
After pleuro-pneumonectomy, four cases of PE 
occurred and three of them died. At univariate 
analysis, extrapleural dissection and diaphragmatic 
resection resulted as being signiÀcant risk factors for 
PE (p=0.0003 and 0.004 respectively). The role of 
both factors was conÀrmed at multivariate analysis. 
Conclusion: Pulmonary embolism after 
pneumonectomy is three times more frequent than 
after lesser resection, with an overall mortality 
of 50%. Pneumonectomy requiring extrapleural 
dissection or complete diaphragm removal is at 
(NSCLC), to investigate the prognostic factors for 
surgically treated NSCLC.
Methods: Survival analysis was conducted in 171 
cases of resected NSCLC.
Results: Fifty-four cases of squamous cell 
carcinoma and 117 cases of adenocarcinoma of 
the lung received surgically resection. Hilar and 
mediastinal lymph tissues were systematically 
dissected; 884 groups with 1041 lymph nodes were 
dissected, averaged 5.2 groups/case, and 6.1 nodes/
case; among them, 479 groups with 554 mediastinal 
lymph nodes were dissected, averaged 2.8 groups/
case and 3.2 nodes/case. The rate of mediastinal 
lymph node metastasis is 20.9% (100/479), and 
the ratio of mediastinal lymph node metastasis is 
21.5% (119/554). There are 47 N2 cases, 14 cases 
were found without N1 lymph node metastssis; the 
ratio of skip mediastinal lymph node metastasis 
is 29.8%. The 5-year survival rate for this group 
of resected NSCLC is 52.5%. Univariate analysis 
revealed that gender, age, smoking status, and tumor 
location, histology are not important prognostic 
factors, without statistically signiÀcant effects on 
survival (P>0.05); however, pathological stages 
(pTNM stages), tumor size (T factor), lymph 
nodes’ metastasis (N factor), and postoperative 
adjuvant chemo-radiation therapy are important 
prognostic factors affecting the postoperative 
survival signiÀcantly (P<0.05). The 5-year survival 
rates in stage I, II, III were 68.4%, 50%, and 30.3%, 
respectively (P=0.000). Patients who received 
postoperative chemo-radiation therapy (49 cases) 
had a higher 5-year survival rate of 68.5% when 
compared with those who received surgery only 
but without adjuvant chemo-radiation (122 cases) 
whose 5-year survival was 46.2% (P=0.008). Cox 
proportion hazard model analysis revealed that 
pathological stages and postoperative chemo-
radiation therapy are independent prognostic factors 
(P<0.05). 
Conclusion: Pathological stages and postoperative 
chemo-radiation therapy are independent prognostic 
factors for resected NSCLC. Standardized systematic 
lymph node dissection should be performed to 
prevent cancer metastasis left, due to the relatively 
higher ratio of mediastinal lymph node metastasis 
and the higher ratio of skip mediastinal lymph node.
Keywords: Survival analysis, Mediastinal lymph 
node dissection, lung neoplasm, Non-small cell lung 
cancer
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selection for the segmentectomy is still important.
Keywords: segmentectomy, peripheral lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.316 FACTORS AFFECTING THE 
PROGNOSIS AFTER RESECTION IN 
NON-SMALL CELL LUNG CANCER 
WITH CHEST WALL / PARIETAL 
PLEURA INVASION
Ahmet Ucvet, Soner Gursoy, Sinan Anar, Ali ata 
Ozturk, Sener Yildirim, Serdar Sirzai, Seyda O. Kaya 
Department Of Thoracic Surgery, Izmir Dr. Suat 
Seren Chest Disease And Thoracic Surgery Training 
Hospital/Turkey
Background: Factors affecting the prognosis after 
resection in non-small cell lung cancer with chest 
wall / parietal pleura invasion
Methods: The primary treatment of non-small cell 
lung cancer with chest wall / parietal pleura invasion 
is un-block anatomic resection of chest wall and 
involved lung paranchima. In the study, it was aimed 
to evaluate the factors affecting the postoperative 
survival time in these patients.
Patients undergone to surgical treatment between 
June-1995 and June-2005, for NSCLC with chest 
wall / parietal pleura invasion were included. The 
demographic characteristics, preoperative symptoms, 
operative procedures, tumor cell type and diameter 
of tumor, lymph node involvement and stage of 
disease were assessed.
Results: There were 105 men and 2 women with an 
average age of 61,3 years. The mean follow-up was 
26,5 months, the median survival was 37,0 months 
and 5 year survival was 42,8%. There were 101 
complete and 6 incomplete resections, while 5 year 
survival was 34,2% and 2 year survival was 0%, 
respectively (p=0,001). 5 year survival was longer in 
tumors with a diameter lower than 3 cm, than those 
higher than 3 cm. Three independent prognostic 
factor were the diameter of tumor, type of resection 
and concurrent diseases. Operative mortality was 
9,6%. Concurrent diseases and pneumonectomy 
were independent factors for operative mortality. 
The recurrence was 60,7%. Independent factors 
for occurrence of metastasis were neoadjuvant 
higher risk of PE (12.5%) and should probably 
require a more aggressive anticoagulative 
prophylactic treatment. 
Keywords: pneumonectomy, pulmonary embolism
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.315 CLINICAL EXAMINATION OF 
RECURRENT CASES AFTER LUNG 
SEGMENTECTOMY FOR PRIMARY 
LUNG CANCER
Satoshi Yamamoto1, Katsunobu Kawahara1, Shinichi 
Yamashita1, Michiyo Miyawaki2, Keita Tokuishi2 
1Sergery Ii, Oita University Faculty Of Medicine/
Japan, 2Surgery Ii, Oita University Faculty Of 
Medicine/Japan
Background: Recently, lung segmentectomy is 
popular operation for small peripheral primary 
lung cancer. However, the indication of lung 
segmentectomy for primary lung cancer is still 
controversial. So, we attempt to exam the outcome of 
lung segmentectomy for primary lung cancer patients 
in our institute.
Methods: In 2004-2010, 463 patients of primary 
lung cancer had lung resection. In those patients, 95 
(20.5%) cases had lung segmentectomy. We choose 
those patients for study.
Results: Each segmentectomy performed 
right S1 segmentectomy for three cases, right 
S1+2 segmentectomy for one case, right S2 
segmentectomy for four cases, right S2+3a for 
two cases, right S2+6 segmentectomy for one 
case, right S3 segmentectomy for three cases, 
right S7+8 segmentectomy for two cases, right 
S8 segmentectomy for one case, right basal 
segmentectomy for two cases. In the left side, 
left S1+2 segmentectomy for three cases, left 
linglar segmentectomy for 14 cases, left S4+5 
segmentectomy for one case, left S6 segmentectomy 
for seven cases, left S8+9 segmentectomy for one 
case, left basal segmentectomy for two cases, left 
S9+10 segmentectomy for two cases. In those 
patients, recurrent cases were seven (7.4%). The 
local recurrence suspected in three cases of the seven 
recurrent cases after segmentectomy.
Conclusion: The segmentectomy for primary lung 
cancer is feasible surgical treatment for peripheral 
small lung cancer. However, there is a risk of 
recurrent in several percent in segmental resection 
for primary lung cancer, so the severe indicated 
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in female (75%). The mean age was 59.56 ± 9.35. 
Pooled PPV, NPV, sensitivities and speciÀcities for 
staging the mediastinum were as follows: for CT 
scanning sensitivity 56%, speciÀcity 75%, positive 
predictive value (PPV) 54%, negative predictive 
value (NPV) 77%; for PET-CT scanning: sensitivity 
74%, speciÀcity 76%, PPV 59%, NPV 87%. The 
accuracy of thorax CT was 69%, accuracy of PET-
CT was 75% in the mediastinal lymph nodes. NPV 
of mediastinoscopy was 93%, PPV 100%, sensitivity 
94%, speciÀcity 100% and accuracy was 97%.
Conclusion: PET-CT results do not provide 
acceptable accuracy rates. Mediastinoscopy still 
remains the gold standart for mediastinal staging of 
NSCLC.
Keywords: Non-small cell lung cancer, PET-CT, 
Mediastinoscopy
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.318 RESECTION OF LOCALLY 
ADVANCED (PT4) NON-SMALL 
CELL LUNG CANCER INVADING 
CARDIAC STRUCTURES WITH 
CARDIOPULMONARY BYPASS
Vladzimir Zharkov, Sergey Yeskov, Sergey 
Korobach 
Thoracic Surgery, N.n. Alexandrovs Cancer 
Research Center/Belarus
Background: The data related to the treatment 
of locally advanced non-small cell lung cancer 
(NSCLC) requiring resection of cardiac structures 
are rather scarce. It is widely believed that locally 
advanced (T4) NSCLC is not a matter for surgical 
resection. The purpose of the study was to evaluate 
the beneÀt of surgery with cardiopulmonary bypass 
in such patients.
Methods: We retrospectively reviewed our 
prospective database of all 11 patients who 
underwent en bloc lung and heart resection for 
NSCLC between January 2003 and December 2010 
by using cardiopulmonary bypass (CPB).
Results: The patient’s age ranged from 46 to 71 
years. IIIB stage was established in all 11 cases, 
pT4N0M0 in 3 cases, pT4N1M0 in 4, pT4N2M0 in 
4 cases. Left atrium was resected in 9 of them. Both 
right and left atria were resected in 2 cases. In all 
patients the defect of atrial wall was repaired with 
bovine pericardial patch. Additionally vena cava 
superior was resected in 1 case, vena cava inferior-1, 
therapy and type of resection. Factors not affecting 
the survival were age, extrapleural or chest wall 
dissection, histology and differentiation of tumor, 
chest wall or parietal pleura invasion, N stage, 
stage, neoadjuvant therapy, the presence of adjuvant 
therapy, method of adjuvant therapy and the width of 
chest wall resection.
Conclusion: The surgical resection in non-small cell 
lung carcinoma (NSCLC) with chest wall / parietal 
pleura invasion (T3) is an effective treatment. The 
absence of concurrent disease, small diameter 
of tumor and complete resection are the good 
prognostic factors.
Keywords: Lung cancer, Surgery, chest wall 
invasion
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P1.317 CLINICOPATHOLOGIC 
COMPARISON OF COMPUTED 
TOMOGRAPHY, POZITRON 
EMISSION TOMOGRAPHY 
AND MEDIASTINOSCOPY FOR 
MEDIASTINAL STAGING
Kenan C. Ceylan, Deniz Akpinar, Ali H. Arpat, 
Seyda O. Kaya 
Thoracic Surgery, Dr. Suat Seren Chest Diseases And 
Thoracic Surgery Training And Research Hospital/
Turkey
Background: The aim of this study; to determine 
the value of mediastinal lymph node metastases, to 
compare the concordance of clinical and pathological 
staging results and to evaluate of the cases with 
surgically treated primary non-small cell lung cancer 
(NSCLC).
Methods: The study included total 320 NSCLC 
patients (287 male, 33 female) that were evaluated 
CT and PET-CT between 2005 and 2011. The 
patients who underwent proven N2 or N3 diseases 
with mediastinoscopy and thoracotomy were 
included the study. Thorax computed tomography 
(CT) and PET-CT used to evaluate of clinical 
nodal staging. Involvement of mediastinal lymph 
nodes was veriÀed to compare the sensitivity and 
speciÀcity of mediastinoscopy and the related 
PET results. All the surgically removed tissue was 
examined histopathological study for pathologic 
staging. 
Results: The most common type was squamous cell 
carcinoma in male (61.2%) and adenocarcinoma 
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DFS(p=0.0005,OR=2.0857,95%CI 1.3820~3.1478); 
and in the same N stage, the low-LNR group is 
better than the high in OS and DFS;(4)StratiÀcation 
into High-, Medium-, and Low-Risk groups, 
based on High- (LNR: >18%, N-status:N2) and 
Intermediate- (LNR: >18%, N-status:N1; LNR: 
<18%, N-status:N2), Low-Risk Factors (LNR: 
<18%, N-status:N1) efÀciently predicted outcomes. 
The OS and DFS decreased along with the increase 
of the risk groups(p<0.0001).
Conclusion: The LNR is a predictable factor which 
can help to accurate the prognosis and treatment of 
NSCLC, and improve TNM system for NSCLC.
Keywords: Carcinoma, Non-Small-Cell Lung 
Cancer, Lymph nodes, Lymphatic metastasis
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P1.320 VIDEO-ASSISTED 
THORACIC SURGERY REDUCES 
THE POSTOPERATIVE ACUTE 
EXACERBATION OF INTERSTITIAL 
PNEUMONIA COMBINED WITH LUNG 
CANCER
Michihiko Tajiri1, Takahiro Omori1, Joji Samejima1, 
Koh Takahashi1, Tae Iwasawa2, Takashi Ogura3 
1General Thoracic Surgery, Kanagawa 
Cardiovascular And Respiratory Center/Japan, 
2Radiology, Kanagawa Cardiovascular And 
Respiratory Center/Japan, 3Thoracic Oncology, 
Kanagawa Cardiovascular And Respiratory Center/
Japan
Background: Postoperative acute exacerbation 
(AE) of interstitial pneumonia (IP) is a serious 
complication in the surgical treatment for primary 
lung cancer combined with IP. Once exacerbated, the 
prognosis is extremely poor. Meanwhile, we have 
constructed a new strategy for surgical resection of 
primary lung cancer, of which the complete video-
assisted thoracic surgery (c-VATS, CV) is the basic 
surgery, and have decreased postoperative morbidity 
and mortality rate. We retrospectively reviewed 
consecutive patients who underwent lung surgery, 
either the conventional surgery or the new strategy, 
for lung cancer combined with IP.
Methods: 667 patients underwent the surgical lung 
resection for primary lung cancer at our hospital 
between January 2004 and December 2010. 
We performed surgeries via conventional open 
thoracotomy (COT) in 267 cases from January 2004 
truncus pulmonalis in 3 cases. Carinal resection was 
performed in 4 cases, resection of the aorta - in 2. 
Postoperative morbidity and mortality rates were 
54,5 % and 36,4 %, respectively. Three of patients 
live Àve years or more. Two of them were staged as 
pT4N2M0.
Conclusion: Our results suggest that long term 
survival achievable in patients with locally advanced 
NSCLC invading cardiac structures even in N2 
disease. CBP doesn’t preclude long term survival in 
such patients.
Keywords: cardiopulmonary bypass, Locally 
advanced non-small cell lung cancer
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P1.319 THE VALUE OF METASTASIC 
LYMPH NODES RATIO(LNR) IN 
PREDICTING THE PROGNOSIS OF NON-
SMALL CELL LUNG CANCER PATIENTS.
Yue Li1, Bing-Sheng Sun1, Zhenfa Zhang1, Lian-Min 
Zhang1, Chang-Li Wang2 
1Cancer Institute And Hospital Of Tianjin Medical 
University,/China, 2Lung Cancer Department, 
Cancer Institute And Hospital Of Tianjin Medical 
University,/China
Background: To investigate the relationship 
between metastatic lymph node ratio and prognosis 
of non-small cell lung cancer.
Methods: 301 patients with N1 and N2 NSCLC who 
underwent curative pulmonectomy were analyzed 
retrospectively. The correlations between LNR 
and clinical and pathological data were analyzed 
using Ƶ2 testing analysis. The inÁuence of LNR on 
overall survival time(OS) and disease free survival 
time(DFS) of patients was identiÀed with univariate 
Kaplan-Meier survival analysis and multivatiate Cox 
proportional hazard model analysis. The risk groups 
were classiÀed by LNR associated with N stage.
Results: (1)LNR correlated with age, smoking 
status, pathological type, clinical stage and N 
stage(p<0.05).(2)LNR correlated with positive 
lymph nodes, resected lymph nodes and the 
number of positive lymph node station(p<0.0001)
(3)Kaplan-Meier survival analysis identiÀed that 
the LNR inÁuenced signiÀcantly OS(p<0.0001)
and (p<0.0001),Cox proportional hazard model 
showed the high LNR was an independent 
poor prognostic factor for OS (p<0.0001, 
OR=2.7973, 95%CI 1.8917~4.1362)and 
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suggest that VATS contributes to reduce the onset of 
postoperative AE of IP.
Keywords: Lung cancer, interstitial pneumonia, 
acute exacerbation, video-assisted thoracic surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.321 NON-SMALL CELL LUNG 
CANCER INVADING THE SPINE: THE 
ROLE OF EN-BOC RESECTION
Joachim Schirren1, Tina Dönges1, Michael Melzer2, 
Robert Schönmayr2, Michael Eberlein3, Servet 
Bölükbas1 
1Thoracic Surgery, Dr. Horst Schmidt Klinik/
Germany, 2Neurosurgery, Dr. Horst Schmidt Klinik/
Germany, 3Division Of Pulmonary And Critical 
Care Medicine, Johns Hopkins University School Of 
Medicine/United States Of America
Background: The aim of the study was to illustrate 
our surgical en-bloc approach and to evaluate the 
outcome and survival of non-small cell lung cancer 
(NSCLC) invading the spine.
Methods: All patients undergoing lung resection 
with en bloc hemivertebrectomy or total 
vertebrectomy for NSCLC were retrospectively 
reviewed from our prospective database of 
between January 2003 and December 2008 in an 
individualized multimodality treatment concept. 
Kaplan-Meier method was applied to estimate 
survival. Log-rank analyses were used for 
comparisons of two groups.
Results: Twenty-eight patients with NSCLC 
invading the spine (aged 58.9±12.9 years) were 
identiÀed at a single center. Eight of those 
patients were inoperable at the time of diagnosis. 
Twenty patients underwent resection with en bloc 
hemivertebrectomy (n=16) or total vertebrectomy 
(n=4). Induction chemotherapy was given to 6 
patients (30%). Complete resection rate (R0) was 
achieved in 16 patients (80%). Morbidity and 
mortality rates were 40% and 0%, respectively. 
Adjuvant radiation (n=14) or chemoradiation 
(n=6) were administered with 66Gy. The mean 
survival was 46.0 months. Five-year-survival for 
patients who underwent surgery (n=20) was 47%. 
Inoperability was associated with poorer survival 
to March 2007. 400 patients underwent surgical lung 
resection under the new strategy between April 2007 
and December 2010.
We basically performed CV for primary lung 
cancer. We used 4 access-ports and monitoring 
vision only when performing either a lobectomy 
or others via CV. If performing CV was found 
difÀcult, we switched to the Hybrid VATS (HV) or 
the anterolateral thoracotomy (AT). We elongated 
the incision to 6 or 8 cm when performing HV and 
used a small rib-opener to allow for partial direct 
vision. We further elongated the incision to 10 or 
12 cm on the anterolateral side of the trunk when 
performing AT. In the extensive case, we performed 
the regular thoracotomy (RT) from the outset using 
a posterolateral or a median sternal incision. We 
named this strategy CHART.
IP was diagnosed by a pulmonologist and a 
radiologist at our hospital, based on evaluation of 
preoperative CT images of patients. IP was classiÀed 
into three patterns: IPF/UIP pattern, NSIP pattern 
and combined pulmonary Àbrosis and emphysema 
(CPFE) pattern. We also analyzed other clinical 
data such as patient’s background, hematological 
examinations, pulmonary function tests and 
operation-related factors.
Results: In COT group, 61 patients presented 
with IP (22.8%). 49 of them underwent major lung 
resection other than partial resection. Among them 
Àve patients showed the onset of postoperative 
AE (10.2%). Four of them were with IPF/UIP, and 
three died due to AE. On the other hand, four of 
14 IPF/UIP patients (28.6%) went on to develop 
postoperative AE.
In CHART group, 68 patients presented with IP 
(17.0%). 48 of them underwent major lung resection 
other than partial resection. 37 patients underwent 
CV (77.1%). 3 patients underwent HV (6.3%). 5 
patients underwent AT (10.4%). 3 patients underwent 
RT (6.3%).
Interestingly, no patients in this group developed 
postoperative AE.
In preoperative parameters that include gender, age, 
BMI, preceding diseases, and pulmonary function, 
there were not signiÀcant differences between 
COT group and CHART group. In perioperative 
parameters, infusion volumes, in/out balance and 
blood loss were signiÀcantly less in CHART group. 
Operation time was not signiÀcantly different 
between them. Postoperative CPK was signiÀcantly 
lower in CHART group.
Conclusion: Our results, though retrospective, 
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(LND 61.8±12.4 vs. 60.8±9.6 years), gender, co-
morbidities, type of sleeve resection (bronchial 
vs. bronchovascular), number of dissected lymph 
nodes (LND 40.0±12.4 vs. 36.7±14.0), histology 
and completeness of resection (LND 96.7% vs. 
98.0%), respectively. More patients had induction 
chemotherapy in AND group (p=0.049). Similar 
short-term results were monitored with regard 
to morbidity rate (LND:34.2%, AND:44.0%), 
secondary pneumonectomy (LND:1.7%, AND:4.0%) 
and mortality rate (LND:5.0%, AND:6.0%), 
respectively. Better 5-year-survival rate and mean 
survival were observed in LND (LND:80.8 months; 
AND:37.7 months; p=0.014; LND:67%; AND:42%). 
In the long-term, more distant metastases were 
identiÀed in AND group (26.0% vs. 14.2%, 
p=0.079) in comparison of identical locoregional 
recurrence (LND:1.7%; AND:0%). Mean time to 
the development of distant metastases was similar 
(LND:19.1 months; AND:12.4 months; p=0.2) in 
event of metastazing.
Conclusion: Lymph node involvement is a negative 
prognostiÀcator with regard to long-term survival. 
Sleeve resections in AND are not associated with 
higher morbidity and mortality. Sleeve resections 
in AND are correlated with promising long-term 
survival and unexpected high local control of the 
disease as a result of high complete resection rates. 
Further investigation for the systemic control of the 
disease is warranted because of high rates of distant 
failure.
Keywords: NSCLC, Stage IIIA, Stage IIIb, Sleeve 
resection
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P1.323 COMPARISON OF THE 
SURVIVALS OF THE SUBGROUPS OF 
STAGE IIA ACCORDING TO NEW TNM 
STAGING
Ozan Usluer1, Seyda O. Kaya1, Ozgur Samancilar1, 
Kenan C. Ceylan2, Saban Unsal2 
1Thoracic Surgery, Dr. Suat Seren Chest Diseases 
And Thoracic Surgery Training And Research 
Hospital/Turkey, 2Thoracic Surgery, Dr Suat Seren 
Chest Disease And Thoracic Surgery Training And 
Education Hospital/Turkey
Background: In this study, the survivals of the 
subgroups of stage IIA according to new TNM 
staging are analyzed and evaluated.
(14.0 months; p=0.004). Sublobar resections 
(p=0.002) and incomplete resections (p=0.02) were 
negative prognostiÀcator. A trend towards prolonged 
survival were observed in patients with adjuvant 
chemoradiation (p=0.088), hemivertebrectomy 
(p=0.062) and age over 70 years (p=0.076), 
respectively.
Conclusion: En-bloc lung resections with 
hemivertebrectomy or total vertebrectomy offer 
promising long-term survival in highly selected 
patients with NSCLC invading the spine within 
multimodality treatment concepts. Acceptable 
morbidity and mortality can be achieved in these 
extended resections in specialized centers. Patients 
aged over 70 years should be selected very 
cautiously for surgery. Sublobar resections should be 
avoided whenever possible.
Keywords: NSCLC, Vertebrectomy, En-bloc 
resection, multimodality treatment
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P1.322 SLEEVE RESECTIONS IN 
CENTRALLY LOCATED NON-SMALL 
CELL LUNG CANCER AND ADVANCED 
NODAL DISEASE
Joachim Schirren1, Michael Eberlein2, Servet 
Bölükbas1 
1Thoracic Surgery, Dr. Horst Schmidt Klinik/
Germany, 2Division Of Pulmonary And Critical 
Care Medicine, Johns Hopkins University School Of 
Medicine/United States Of America
Background: The aim of this investigation was 
to contrast the short-term and long-term results of 
sleeve resections in centrally located non-small cell 
lung cancer (NSCLC) depending on limited nodal 
disease (N0/N1, LND) and advanced nodal disease 
(N2/N3, AND).
Methods: All NSCLC-patients undergoing sleeve 
resections for centrally located NSCLC were 
reviewed from our prospective database between 
January 1999 and December 2008. Patients’ 
characteristics, morbidity, mortality, locoregional 
recurrence, distant recurrence and survival were 
analyzed corresponding to LND and AND.
Results: One-hundred seventy sleeve resections 
out of 213 consecutive sleeve resections were 
performed for ventrally located NSCLC (LND: 
n=120; AND: n=50). There were no statistically 
differences between the both groups for age 
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survival of the patients are evaluated. The patients 
are also devided into two groups: group A included 
the patients having less than nine lymph nodes 
dissected where group B included the patients with 
nine or more dissected nodes and the survival of the 
two groups are also compared.
Results: The survival decreases as the total number 
of lymphy nodes dissected decreases. The survival is 
lower in the group having less than nine total number 
of lymph nodes dissected and both of the results are 
statistically signiÀcant (p<0.05).
Conclusion: The number of lymph nodes dissected 
effects the survival even in N0 patients in non-small 
cell lung cancer. The surgeons must show every 
effort to dissect as much lymph nodes as they can 
during lung cancer surgery.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.325 DOES NEOADJUVANT THERAPY 
AFFECT MORTALITY AND MORBIDITY 
IN PATIENTS WHO UNDERWENT 
SLEEVE RESECTION FOR LUNG 
CANCER?
Adnan Sayar, Necatú Çitak, SongÜl BÜyÜkkale, 
Muzaffer Metún, Abdulazúz KÖk, Nur Ürer, Alper 
Çelúkten, Atúlla GÜrses 
Thoracic Surgery, Yedikule Thoracic Surgery And 
Chest Disease Research And Education Hospital/
Turkey
Background: Sleeve resections enable the 
preservation of lung parenchyma for patients 
with benign or malignant tumors. Neoadjuvant 
therapy have a potential impact on the results of 
lung resections. The aim of the study was to assess 
the outcome after neoadjuvant therapy and sleeve 
resection in patients with non-small cell lung cancer 
(NSCLC).
Methods: Between 2000 and 2011, 91 patients 
with NSCLC who underwent sleeve resections 
were retrospectively investigated. The patients was 
subdivided into two groups; Group R underwent a 
sleeve resection without preoperative therapy [n = 
76] and Group NR received neoadjuvant therapy 
before sleeve resection [n = 15]. The two groups 
were compared with respect to the demographic data 
Methods: The medical records and the follow-up 
data of the patients operated for non-small cell lung 
cancer between January 2005 and December 2009 
is analyzed retrospectively. The pateints are staged 
according to the new TNM staging. The survival 
data of 78 patients with tumors of T2bN0M0 (n=48), 
T1aN1M0 (n=9), T1bN1M0 (n=5), T2aN1M0 
(n=16) which forms the subgroups of stage IIA 
according to new TNM staging are compared.
Results: There is no statistically signiÀcant survival 
difference between the subgroups of the stage IIA 
according to new TNM staging. 
Conclusion: The subgroups of the stage IIA of the 
new TNM staging for non-small cell lung cancer 
forms an homogenious group by means of survival 
for operated patients.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.324 THE EFFECT OF THE NUMBER 
OF LYMPH NODES DISSECTED ON 
SURVIVAL IN OPERATED N0 NON-
SMALL CELL LUNG CANCER PATIENTS
Ozan Usluer1, Seyda O. Kaya1, Ozgur Samancilar1, 
Kenan C. Ceylan2, Serpil Sevinc3 
1Thoracic Surgery, Izmir Dr Suat Seren Chest 
Disease And Thoracic Surgery Hospital/Turkey, 
2Thoracic Surgery, Dr. Suat Seren Chest Diseases 
And Thoracic Surgery Training And Research 
Hospital/Turkey, 3Thoracic Surgery, Izm×r Dr Suat 
Sren Chest Disease And Thoracic Surgery/Turkey
Background: In this study, the effect of the number 
of lymph nodes dissected on survival in operated N0 
non-small cell lung cancer patients is investigated.
Methods: The medical records and the follow-up 
data of the patients operated for non-small cell lung 
cancer between January 2005 and December 2009 
is analyzed retrospectively. One hundered-forty-
one patients without neoadjuvant treatment which 
were applied lobectomy or pneumonectomy and 
mediastinal lymph node dissection with pathological 
stage T1aN0M0 (n=35), stage T1bN0M0 (n=33) 
and stage T2aN0M0 (n=73) (stage I according to 
new TNM staging) are included in the study. The 
signiÀcance between the total number of dissected 
lymp nodes from both N1 and N2 stations and the 
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(44patients) who underwent curative open operation. 
The inÁuence of comorbidity (cardiac, pulmonary, 
second primary cancer, anemia, diabetes mellitus etc) 
in postoperative complication were also analyzed. 
None of the patient received preoperative chemo 
and/or-radiotherapy. Type of surgery, histology type 
of tumors was compared in both groups.
Results: No signiÀcant difference was observed 
in the comorbidities between elderly and young 
patients. The 30-day operative mortality rates were 
6.25% in elderly population, postoperative morbidity 
was -  40.0% - signiÀcantly higer in elderly lung 
cancer population (p0.05).
Conclusion: Elderly patients undergoing curative 
surgery for lung cancer have a higher risk of 
developing postoperative complications, but 
mortality rates is equal to younger population. 
Age or the presence of comorbidity should not be 
considered contraindications for lung resection. 
Additional functional evaluation is indicated in 
speciÀc subgroup of elderly lung cancer patients.
Keywords: elderly patients, Lung cancer, 
comorbidities
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.327 SINGLE CENTRE COMPARISON 
OF THORACOSCORE AND EUROPEAN 
SOCIETY OUTCOME SCORE IN THE 
SURGICAL RESECTION OF NON-SMALL 
CELL LUNG CANCER
Annabel Sharkey1, Justine Downing2, David 
Hopkinson2, Timothy Locke2, John Edwards2, Jagan 
Rao2 
1Cardiothoracic Surgery, Northern General Hospital/
United Kingdom, 2Northern General Hospital/United 
Kingdom
Background: Calculation of risk scores, such 
as Thoracoscore (TS) and the European Society 
Outcome Score (ESOS), have been proposed as a 
useful aid to determine operative outcome in thoracic 
surgery. The role of risk scores in assessing primary 
lung cancer surgery quality outcomes related to the 
surgeon, including later outcomes, is not clear, nor 
how the TS and ESOS compare. 
Methods: Data were collected prospectively on 
482 consecutive patients undergoing lung resection 
for primary non-small-cell lung cancer from Aug 
2007 – Mar 2010. ESOS and TS were calculated 
retrospectively. The correlation between ESOS 
and clinical outcomes.
Results: The type of resections performed were 81 
sleeve lobectomies or bilobectomies (in 16 patients 
with pulmonary artery reconstruction), 4 sleeve 
lobectomies with carinal resection and 6 sleeve 
pneumonectomies. The overall surgical mortality 
(in hospital or 30-days) was 4.3% (n = 4) and more 
common in R group compared to NR group (5.2% vs 
0%, p = 0.369). The incidence of complication was 
28.9% (22 of 76) with 9.2% (7 of 76) anastomosis-
related complications (bronchopleural Àstula = 6; 
bronchovascular Àstula = 1 ) in the R group. In the 
NR group the complication rate was 26.7% (4 of 15) 
without any anastomosis-related problems. Five-year 
survival in the R group was 53.7% compared with 
43.1% in the NR group (p = 0.426).
Conclusion: Neoadjuvant therapy did not increase 
anastomosis-related complications and mortality 
in patients with sleeve resection and achieved 
comparable survival rates
Keywords: Lung cancer, Surgical treatment, Sleeve 
resections, Neoadjuvant Therapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.326 AGE-RELATED RISK 
ASSESSMENT FOR LUNG CANCER 
SURGERY IN ELDERLY PATIENTS
Nazar Lukavetskyy, Taras Fetsych 
Oncology Department, Lviv Medical University/
Ukraine
Background: The elderly population is 
heterogeneous, ranging from healthy seniors with 
no disability and few comorbidities to frail seniors 
who are disabled and have multiple comorbidities. 
This makes the assessment and management of this 
population challenging, especially when deciding 
on cancer treatment modalities. The purpose of 
the present study was to identify preoperative risk 
factors related to age of the patients focusing on 
comorbidities.
Methods: Retrospective review of the clinical 
records of all patients operated on thoracic 
department in 2000-2003. A comparison was carried 
out between patients with lung cancer 70 years and 
older (38 patients), and younger lung cancer patients 
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P1.328 CLINICAL ANALYSIS OF THE 
CHARACTERISTICS OF THORACIC 
LYMPH NODES METASTASIS PATTERNS 
WITH NON-SMALL CELL LUNG 
CANCER
You B. Cui, Shi Y. Feng, Xue Shan, Tian Y. Lu, Yong 
X. Wang 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: Lymph node metastasis is not only 
one of the most common and main means of the lung 
cancer’s transfer, but also is one of the important 
factors which affects the lung cancer’ T stage and the 
prognosis. The aim of this study is to investigate the 
characteristics and patterns of lymph node metastasis 
in non-small cell lung cancer and to provide 
evidence for determining the range of lymph node 
dissection.
Methods: Combined with systematic lymph 
node dissection according to the grouping system 
proposed by Naruke 218 patients with non-small cell 
lung cancer underwent lobectomy or pneumoectomy 
in our hospital were retrospectively analyzed, 
Compare the thoracic lymph nodes Metastasis 
Patterns of different clinical T stage, pathological 
type and the different initial locations .
Results: A total of 3509 lymph nodes were dissected 
from 1308 group s of 218 patients, there were 16.1 
group s on the average in each case.623 lymph 
nodes from 283 groups were conÀrmed to have 
metastasis. The metastasis rates of thoracic lymph 
nodes were 47.5%. There was close correlation 
between lymph node metastasis and T stage. The 
metastasis rate of adenocarcinoma was much higher 
than that of squamous cell carcinoma (P<0.01). 
Mediastinal lymph nodes metastasis was used to 
uppermediastinum from upper lobe cancer, while 
both upper and lower mediastinums were the 
metastasis sites for lower lobe cancers (including 
middle lobe). 
Conclusion: The frequency of lymph node 
metastasis signiÀcantly correlate with size of 
primary tumor , T stage, initial location and 
pathological type. It is necessary to perform systemic 
lymphadenectomy during pulmonary resection. 
Keyword: Thoracic Lymph Nodes；Clinical 
Analysis；NSCLC; Lymphadenectomy
and TS was analysed. Differences between four 
consultant surgeons and survival outcomes were 
assessed. 
Results: Both TS and ESOS were calculated in 
340 patients. TS could not be calculated from 
available data in 120 cases and ESOS in 48: these 
were excluded from further analysis. There was 
a signiÀcant correlation between TS and ESOS 
(r= 0.527, p<0.001), although there were notable 
outliers. In those cases with scores above the median 
for both ESOS and TS, this correlation was lost. 
Median TS was 1.97 (range 0.26 to 12.6), the mean 
2.48 (standard deviation 1.93). Median ESOS was 
2.18 (0.29-7.36), the mean 2.44 (SD 1.33). The 
observed in-hospital mortality was 11 patients 
(3.2%). There were no signiÀcant differences in the 
mean TS and ESOS of patients undergoing surgery 
by different surgeons. Variable Life Adjusted Display 
analysis showed that both scores underestimated 
actual in-hospital mortality (VLAD value -2.7 for 
ESOS and -2.82 for TS). Surgeon-speciÀc VLAD 
plots demonstrated the differences in outcome 
between surgeons. 
Conclusion: There was a positive correlation 
between TS and ESOS, although this was lost at 
higher values. Both TS and ESOS under-predicted 
mortality. Further work with co-ordination between 
centres is required to determine the accuracy of TS 
and ESOS in predicting mortality and its potential 
use as a measure of quality of service provision. 
Keywords: Thoracoscore, Risk StratiÀcation, lung 
resection
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count were gradually reduced within the experience 
of 20-30 case for each surgeon, and then both 
indicators reached the plateau. Four young surgeons 
newly learned and completed this procedure until 
now.
Conclusion: Pure VATS lobectomy using bipolar 
scissors through Áexible scope is useful, reasonable 
and feasible for cStageIA NSCLC.
Keyword: lung cancer, VATS lobectomy
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P2.001 REDUCTION OF THE 
METASTATIC ACTIVITY OF HYPOXIC 
LUNG CANCERS AND POTENTIATION 
OF CHEMOTHERAPY IN VITRO AND IN 
VIVO USING CYTOKINE.
Danli Wu1, Isere Kuiatse2, Mamatha 
Seethammagari3, Adrian Lee2, Patricia Yotnda1 
1Medicine, Baylor College Of Medicine/United 
States Of America, 2Department Of Pharmacology 
And Chemical Biology, University Of Pittsburgh 
Cancer Institute, University Of Pittsburgh/United 
States Of America, 3Immunology, Baylor College Of 
Medicine/United States Of America
Background: Integrins expressed by tumor cells 
are strongly implicated in various cell functions 
including those promoting metastasis (invasion, 
migration, adherence, and survival) and have also 
been linked to chemoresistance. Our recent study 
demonstrated that hypoxia signiÀcantly increases 
the expression of several integrins at the cell surface 
of lung cancer cells. In this study, we describe a 
new anti-cancer role for cytokine we show that our 
cytokine markedly inhibits the expression of aVb5, 
aVb3, and b1 integrins on lung cancer cells both in 
normoxia and in hypoxia, inhibits metastases and 
invasion, and chemosensitise lung cancer cells in 
vitro and in vivo.
Methods: The effects of our cytokine on 
integrins expression in hypoxia and normoxia was 
investigated using a proliferation, adhesion, invasion, 
migration, 3D matrigel and colony assays and lung 
cancer cell lines. The modulation chemoresistance 
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P1.329 UTILITY AND FEASIBILITY OF 
PURE VATS LOBECTOMY BY USING 
BIPOLAR SCISSORS THROUGH 
FLEXIBLE THORACOSCOPE
Yoshinori Yamashita, Hiroaki Harada, Keizo Misumi 
General Thoracic Surgery, Kure Medical Center/
chugoku Cancer Center/Japan
Background: To evaluate utility and feasibility of 
our techniques of VATS lobectomy using bipolar 
scissors under monitor-view through Áexible 
thoracoscope retrospectively. Especially, we would 
like to show utility and feasibility of our methods.
Methods: From April 2003, we performed VATS 
lobectomy via a pure thoracoscope view (Pure 
VATS) in 120 cases with cStageIA non-small cell 
lung cancer (NSCLC). The operative Àeld of the 
view was accessed strictly via a monitor, thus 
avoiding spreading intercostal space. A Áexible 
thoracoscope, which can contribute more resolved 
view, was inserted through the seventh or eighth 
intercostal space. A 2 to 4 cm minithoracotomy was 
made by cutting only intercostal muscle as same 
as the skin incision (2 to 4 cm) without the use of 
a rib spreader. The mini-thoracotomy and three 
other 0.5 to 1.0 cm ports were added. The operator 
usually placed on the front of the patients and mini-
thoracotomy wound enabled the operator’s right 
hand to hold the bipolar scissors which was useful 
for cutting, coagulating and dissecting without 
switching instruments. The operator’s left hand 
was usually holding pick-up through 5mm port. 
Systematic mediastinal lymph node dissection was 
performed by means of an enlarged clear view in the 
same extent as the conventional open thoracotomy. 
Only difference of the technical maneuver from the 
conventional open thoracotomy was the direction of 
operator’s eyes to the monitor.
Results: Average operation time, bleeding count 
and length of hospital stay were 220 minutes, 
105 g, and 7.2 days, respectively. Only required 
painkiller for postthoracotomy pain was suppository 
diclofenac sodium, which was 11.0 mg on average 
within one week. Five cases (4.1%) were converted 
to the conventional thoracotomy. Postoperative 
complication was seen in 10 cases (8.3%), e.g., 
prolonged air leakage in three cases. Port recurrence 
was not seen . One case (0.8%) was died of cerebral 
infarction within 30 days. As to learning curve of 
this surgical technique, operation time and bleeding 
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Methods: We investigated the potential use of the 
PRIMA-1 in treatment of lung cancers. Human 
lung cancer cell lines containing mutant (H211, 
H1155), wild type (A549) or null (H1299) p53 
were analyzed with Western immunoblot analysis, 
TaqMan microRNA Real-Time PCR, MTT and Áow 
cytometry for apoptosis. To evaluate feasibility and 
preliminary activity of PRIMA-1 on spontaneous 
lung tumors in vivo, we tested PRIMA-1 in our 
previously described transgenic mouse lung tumor 
model in which the human mutant p53(273H) is 
expressed in a lung speciÀc manner, under the 
control of the surfactant protein C promoter. We 
treated the mutant p53 lung tumor bearing mice with 
PRIMA-1 at a dose of 100 mg/kg every other day for 
two weeks. Lung tumor bearing mice were identiÀed 
with a micro–computed tomography (micro-CT) 
system and pre- and post-treatment tumor volumes 
were estimated based on the micro-CT images. 
Results: PRIMA-1 induced apoptosis in the H211 
and H1155 cells, but was less toxic to the A549 and 
H1299 cells. Western blot analysis showed cleavage 
of PARP (poly [ADP-ribose] polymerase) in H211 
and H1155 cells following treatment of PRIMA-1. 
In contrast, no cleavage of PARP was observed 
in the A549 and H1299 cells. TaqMan microRNA 
assay showed that the expression of microRNA 34a 
was increased in the H211 and H1155 cells post 
treatment, whereas no signiÀcant increase was found 
in the A549 and H1299 cells. In addition, Àve lung 
tumor bearing mice received the PRIMA-1, and a 
control group of 4 lung tumor mice received PBS 
every other day for two weeks. A repeat CT scan 
was obtained the week after the last treatment. In 
the control group tumor volume increased more 
than 25% during the treatment cycle in all cases. 
However, in treated mice, tumor volume increased 
more than 25% in one mouse, and decreased less 
than 50% in two mice, with a more than 50% 
reduction in two mice. 
Conclusion: The above results suggest that 
PRIMA-1 is a highly selective small molecule toxic 
to p53 mutant cells in vitro and in vivo which could 
serve as a prototype for the development of effective 
systemic p53-targeting agents. The study on animal 
lung tumors suggests the potential feasibility of 
using p53 restoring activity small molecules to treat 
lung cancer. 
Keywords: PRIMA-1, p53 mutation, Non-small cell 
lung cancer
to Mitomycin, Docetaxel and Doxorubicin by our 
cytokine on these cells was investigated in vitro and 
in a xenograft model of lung cancer.
Results: Our phenotypic and functional studies 
revealed the anti-invasion and anti-metastatic activity 
of our cytokine on lung cancer cells as treated 
cancer cells lose their ability to adhere, proliferate, 
migrate, invade, form colonies, and are signiÀcantly 
less efÀcient at inÀltrating the lungs in vivo. 2-We 
also demonstrate that this cytokine signiÀcantly 
increases the efÀcacy of Mitomycin-C, Doxorubicin, 
and Docetaxel on resistant cancer cells both in vitro 
(normoxia and in hypoxia) and in vivo. 
Conclusion: We propose to combine immunotherapy 
with currently used low efÀcient chemotherapeutic 
agents to potentiate their antitumor efÀciency for 
the treatment of chemoresistant tumors. This would 
allow the use of lower doses of chemotherapy, 
and consequently prevents their associated side 
effects and toxicity. Such combined therapies would 
efÀciently eradicate primary and metastatic resistant 
lung cancers.
Keyword: Lung cancer, hypoxia , combined 
chemotherapy
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P2.002 TARGETING MUTANT P53 IN 
NON-SMALL CELL LUNG CANCER 
WITH PRIMA-1
Wenrui Duan1, Li Gao2, Gregory A. Otterson2, 
Miguel A. Villalona-Calero2 
1Comprehensive Cancer Center, The Ohio State 
University/United States Of America, 2Ohio State 
University/United States Of America
Background: The tumor suppressor protein p53 is 
a key regulator of cell cycle control, apoptosis, and 
genomic stability in response to various cellular 
stresses. Restoration of p53 function in tumors is a 
potential approach for lung cancer therapy because 
p53 mutations are found in more than 50% of 
lung cancers. The small molecule PRIMA-1 (p53-
dependent reactivation and induction of massive 
apoptosis) has been shown to restore the tumor 
suppression function of p53 and to induce apoptosis 
in human tumor cells containing mutant p53. 
This is believed to be mediated by a change in the 
conformation of mutated p53 protein, restoring DNA 
binding and activation of p53 target genes. 
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intracellular signal transduction. Phosphorylation 
of EGFR was high in the CTOSs with active EGFR 
mutations even in the starvation culture conditions. 
Erlotinib was able to diminish the phosphorylation 
of EGFR. In terms of the intracellular signalling, 
phosophorylation of AKT was observed in the 
EGFR mutants in the starvation conditions, while 
AKT was activated only after treatment with EGF in 
the CTOSs with wild type EGFR. Downregulation 
of AKT phosphorylation by erlotinib was well 
correlated with the sensitivity of CTOSs to the drug.
Conclusion: Accessing the intracellular signalling from 
patient tumor samples might be useful for predicting 
sensitivity of molecular targeting drugs for individual 
patients, and give an excellent platform for investigating 
the mechanism of resistance to these drugs.
Keywords: chemosensitivity, primary culture, Non-
small cell lung cancer
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P2.004 62CUATSM AND 62CUPTSM PET 
IS A USEFUL IMAGING TOOL FOR 
HYPOXIA AND PERFUSION IN LUNG 
CANCER
Tian Zhang1, Diane R. Fels2, Katherine S. Hansen2, 
Shiva K. Das2, Terence Z. Wong3, Mark W. 
Dewhirst2, Gordana Vlahovic1 
1Department Of Medicine, Division Of Oncology, 
Duke University Medical Center/United States Of 
America, 2Department Of Radiation Oncology, Duke 
University Medical Center/United States Of America, 
3Department Of Radiology, Duke University Medical 
Center/United States Of America
Background: Hypoxia is a characteristic of many 
tumors and portends a worse prognosis in several 
tumor types including lung, cervical, prostate, 
and rectal cancers. Unlike cervical, prostate, 
and rectal malignancies, lung cancers present a 
unique challenge in measuring hypoxia, given 
difÀculty of invasive biopsies and rate of post-
biopsy complications. Noninvasive imaging studies 
detecting hypoxia using isotopes of copper-diacetyl-
bis (N4-methylthiosemicarbazone), CuATSM, 
have predicted prognosis and treatment outcomes 
in a few small feasibility cervical cancer and lung 
cancer trials. Although PET scans imaging hypoxia 
are helpful, these images may not identify all the 
areas of hypoxia. Hence, we hypothesize that 
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P2.003 A NOVEL PRIMARY CULTURE 
SYSTEM OF CANCER CELLS FROM 
LUNG CANCER PATIENTS
Jiro Okami1, Hiroko Endo2, Hiroaki Okuyama2, Ken 
Kodama1, Masahiko Higashiyama1, Masahiro Inoue2 
1General Thoracic Surgery, Osaka Medical Center 
For Cancer And Cardiovascular Diseases/Japan, 
2Biochemistry, Osaka Medical Center For Cancer 
And Cardiovascular Diseases/Japan
Background: Primary culture of cancer cells has 
been expected to be useful for investigating biology 
of lung cancer or predicting chemosensitivity for 
individual patients, although it is hampered by the 
technical difÀculties up to the present. Recently, 
we established a novel primary culture system for 
colorectal cancer.
Methods: Surgical specimens were mechanically and 
enzymatically digested into fragments. These fragments 
(organoids) spontaneously formed spheroids. We 
named the spheroid as CTOS (cancer tissue-originated 
spheroid). CTOS consisted of pure epithelial cells 
without trace of the host cells, including Àbroblasts, 
endotherial cells, macrophages, and other blood cells. 
CTOSs were able to be prepared in high efÀciency. 
The cancer cells in CTOS were stable only when the 
cell-cell contact was maintained. CTOS was able to be 
cultured and propagated in vitro, and formed xenograft 
tumors in immunodeÀcient mice. The characters of the 
original patient tumors, including morphology, KRAS 
mutations, and p53 staining pattern was preserved in 
the xenograft tumors. Here we applied the method to 
the lung cancer.
Results: We obtained CTOS from 54 out of 72 
(75.0%) non-small cell lung cancer (NSCLC) 
patients. CTOSs consisted of pure epithelial 
cells, were stable in the spheroid form, able to be 
expanded in vitro. The tumors in immunodeÀcient 
mice preserved the characters of the original patient 
tumors. We performed chemosensitivity assay using 
CTOS in vitro and in vivo. Sensitivity for CDDP or 
erlotinib was differed among patients. The results of 
the in vitro assay were in parallel with those of the 
treatment of the mice with corresponding xenograft 
tumors. In addition, change of pathway activation 
can be analysed with CTOS for molecular targeted 
reagents, such as erlotinib. We obtained CTOS from 
the tumors with or without EGFR active mutations, 
and examined the effect of erlotinib treatment on 
Copyright © 2011 by the International Association for the Study of Lung Cancer S919
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Department Of Internal Medicine, Division Of 
Pulmonary Medicine, Infectious Diseases And 
Oncology , Nippon Medical School, Tokyo, Japan, 
Nippon Medical School Hospital/Japan
Background: It is consequently desirable to Ànd 
more appropriate therapeutic opportunities for 
NSCLC. Recently, molecularly targeted therapy 
for cancer has made substantial progress. HDAC 
inhibitors, including suberoylanilide hydroxamic 
acid (SAHA), have demonstrated therapeutic 
beneÀts as monotherapy in hematologic, breast, and 
bladder malignancies, as well as mesothelioma and 
NSCLC, without evidence of severe adverse events. 
Recently, it has been demonstrated that combinations 
of HDAC inhibitors with well-established 
chemotherapeutic agents have synergistic antitumor 
effects via the modulation of biomarkers by HDAC 
inhibitors. We clariÀed the predictive markers to 
select patients receiving this treatment and found 
a new strategy against lung cancer by using S-1, a 
novel oral Áuorouracil anticancer drug for clinical 
use against NSCLC in Japan. 
Methods: To assess the potential for HDAC-
inhibitor-based treatment in NSCLC, we analyzed 
the antitumor effects of trichostatin A (TSA) and 
SAHA (vorinostat) in a panel of 16 NSCLC cell lines 
via MTT assay. To identify a molecular model of 
sensitivity to HDAC inhibitor treatment in NSCLC, 
we conducted a gene expression proÀling study with 
cDNA arrays on the same set of cell lines and related 
the cytotoxic activity of TSA to corresponding gene 
expression patterns by means of a modiÀed NCI 
program and pathway analysis.
Using the MTT assay, we analyzed the growth-
inhibitory effect of 5-FU/S-1 and SAHA against 
lung cancer cells. The mRNA and protein 
expressions of Thymidylate synthase (TS), 
Dihydropyrimidine dehydrogenase (DPD) and 
Orotate phosphoribosyltransferase (OPRT), which 
are metabolites of 5-FU, were analyzed in these 
cells. In order to clarify the mechanism of the 
synergistic effect of SAHA and 5-FU, we examined 
the change of the 5-FU metabolism expressions and 
their regulator including p21waf1/cip1 and Rb-E2F1 
pathway.
Results: There was a strong correlation between the 
responsiveness to TSA and SAHA (P<0.0001). We 
used 9 genes including PDCD4 to regulate p21 waf1/
cip1 activity, which were identiÀed with gene-drug 
sensitivity correlation and pathway analysis, to build 
a support vector machine algorithm model, by which 
another PET imaging agent, copper-pyruvaldehyde-
bis(N4-methylthiosemicarbazone), 62CuPTSM, can 
detect areas of perfusion, which would augment the 
information obtained in 62CuATSM PET scans. 
Methods: In order to characterize tumors based on 
both perfusion and hypoxia, we have studied ten 
patients with localized or advanced lung cancer using 
both novel 62CuATSM and 62CuPTSM PET scans. 
In addition, proteomic arrays looking at speciÀc 
targets important for proangiogenic, survival, and 
proinÁammatory responses were assessed. 
Results: Our initial experience of characterizing lung 
cancer hypoxia using 62CuATSM and 62CuPTSM PET 
scans showed that with kinetic analysis of the 62CuATSM 
and 62CuPTSM scans, visualization of areas with hypoxia 
and perfusion is feasible. Within this patient group, all 
tumors exhibited some degree of hypoxia. Despite the 
small sample size, a positive relationship was noted 
between VEGF and sFLT-1 levels and noninvasive 
62CuATSM and 62CuPTSM PET imaging. 
Conclusion: This initial series of the 62CuATSM and 
62CuPTSM PET scans demonstrate that evaluating 
localized or advanced lung cancer by visualization of 
hypoxia and perfusion is feasible and noninvasive. 
The novelty of having both perfusion and hypoxia 
imaging markers allows for more comprehensive 
analysis of these tumors. This imaging modality, 
along with future proteomics analysis, could 
potentially be useful as biomarkers for lung cancer 
treatment and prognosis. Further investigation 
will be undertaken to assess the potential role of 
62CuATSM and 62CuPTSM PET imaging techniques 
combined with proteomics as alternatives to invasive 
biopsy techniques in routine clinical care. 
Keywords: PET imaging, Perfusion, Lung cancer, 
Hypoxia
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P2.005 THE ANTICANCER EFFECT OF 
HISTONE DEACETYLASE INHIBITORS 
AND COMBINATION WITH THE 
CYTOTOXIC AGENTS IN LUNG CANCER 
CELLS: BIOLOGICAL ANALYSES FOR 
FUTURE CLINICAL APPLICATION
Masaru Toyokawa, Rintaro Noro, Akihiko Miyanaga, 
Kazuhiro Kitamura, Seiji Kosaihira, Yuji Minegishi, 
Tetsuya Okano, Masahiro Seike, Chie Soeno, Kiyoko 
Kataoka, Kuniko Matsuda, Akinobu Yoshimura, 
Akihiko Gemma 
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carcinoma. 
Methods: We assessed the effects of GDC-0449 (20 
nM) and down regulation of Shh via siRNA on the 
EMT features of A549-M (A549 cells exposed to 
TGF-ơ1 for 21 days) and of H1299 cell line, which is 
known to have EMT features. Assessment included 
the effects on the mRNA levels of E-cadherin and 
Zeb1 a regulator of EMT, clonogenic growth (colony 
formation assay), cell motility (wound healing assay) 
and invasion (matrigel assay) and the inÁuence on 
the activity of erlotinib and cisplatin in these cell 
lines (MTT assay).
Results: A549-M cells had signiÀcantly higher rate 
of clonogenic growth, cell motility and invasion 
compared to A549 cells and showed higher 
resistance to erlotinib and cisplatin. A549-M cells 
had higher mRNA levels of Shh and Zeb1 and 
reduced levels of E-cadherin than A549 cells. GDC-
0449 reduced clonogenic growth, cell motility and 
invasion of A549-M and H1299 cells and reduced 
the mRNA levels of Zeb1 and increased the levels 
of E-cadherin in both cell lines. Pre-treatment with 
GDC-0449 signiÀcantly enhanced the activity 
of erlotinib (5 and 10 mM) and cisplatin (1mM-
10mM) in both cell lines (p < 0.05). Similar results 
were observed in each of the cell lines with down 
regulation of Shh by siRNA. 
Conclusion: GDC-0449, a hedgehog inhibitor can 
attenuate EMT features in NSCLC cell lines. It can 
also enhance the activity of erlotinib and cisplatin in 
NSCLC cell lines that are intrinsically resistant to 
these agents. 
Keyword: EMT and hedgehog and GDC-0449
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P2.007 COMPARISON OF POTENTIAL 
VALUES OF HYALURONIC ACID 
AND VASCULAR ENDOTHELIAL 
GROWTH FACTOR IN THE PLEURAL 
FLUID OF MALIGNANT PLEURAL 
MESOTHELIOMA
Nobukazu Fujimoto, Kenichi Gemba, Michiko 
Asano, Sae Wada, Katsuichiro Ono, Shinji Ozaki, 
Takumi Kishimoto 
Respiratory Medicine, Okayama Rosai Hospital/
Japan
Background: Malignant pleural mesothelioma 
(MPM) is a highly aggressive neoplasm strongly 
sensitive cell lines were distinguished from resistant 
cell lines.
Combined treatment with low-dosage SAHA 
enhanced 5-FU/S-1 mediated cytoxicity and 
the synegistic effect in 5-FU-resistant cells. 
5-Fluorouracil-resistant lung cancer cells displayed 
high expression of TS mRNA and protein. SAHA 
down-regulated TS mRNA and protein expression, 
as well as repressed the rapid induction of this factor 
during 5-FU treatment, in all examined cell types, 
also examined the status of the Rb-E2F1 pathway, 
with SAHA up-regulating p21waf1/cip1 expression 
via promoter histone acetylation; this, in turn, 
blocked the Rb-E2F1 pathway.
Conclusion: In conclusion, our results suggest that 
HDAC inhibitors may be promising anticancer 
drugs for NSCLC and that the 9-gene classiÀer is 
useful for predicting the sensitivity of NSCLCs to 
HDAC inhibitors and may contribute to achieving 
individualized therapy for patients with NSCLC. 
SAHA enhanced S-1 sensitivity in lung cancer 
cells, and this combination therapy may be effective 
against lung cancer.
Keywords: SAHA, HDAC, NSCLC, S-1
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P2.006 GDC-0449, A HEDGEHOG (HH) 
PATHWAY INHIBITOR CAN ATTENUATE 
EPITHELIAL MESENCHYMAL 
TRANSITION (EMT) PHENOTYPE IN 
NON-SMALL CELL LUNG CANCER 
(NSCLC) CELLS LINES AND CAN 
ENHANCE THE EFFECTS OF 
ERLOTINIB AND CISPLATIN.
Shirish Gadgeel1, Main Maitah2, Shadan Ali2, 
Patricia Lorusso1, Fazlul Sarkar2 
1Oncology, Karmanos Cancer Institute/wayne State 
University/United States Of America, 2Pathology, 
Karmanos Cancer Institute/wayne State University/
United States Of America
Background: EMT, characterized by low E-cadherin, 
has been proposed as a mechanism for tumor invasion, 
metastases and resistance to therapeutic agents in many 
cancers, including NSCLC. The Hh pathway may 
play a role in inducing EMT. An important ligand of 
the pathway is Sonic hedgehog (Shh). GDC-0449, an 
inhibitor of Hh pathway, has shown promising activity 
in tumors with activated Hh pathway such as basal cell 
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P2.008 ADENOSINE AND A2B 
ADENOSINE RECEPTOR IN 
REGULATION OF TUMOR-
INFILTRATING MYELOID CELLS
Sergey Ryzhov1, Sergey V. Novitskiy1, Anna E. 
Goldstein1, Asel K. Biktasova1, Igor Feoktistov1, 
Mikhail M. Dikov2 
1Vanderbilt University/United States Of America, 
2Cancer Biology, Vanderbilt University/United States 
Of America
Background: Adenosine, a naturally occurring 
nucleotide, exerts its biological effects by interacting 
with a family of adenosine receptors A1, A2A, A2B, 
and A3 all associated with important physiological 
processes. The endogenous adenine nucleotides and 
adenosine are normally present at low concentrations 
in the extracellular milieu. However, metabolically 
stressful conditions, including inÁammation and 
hypoxia characteristic for solid tumors, result in 
dramatic increase in extracellular concentrations 
of adenosine. Our data demonstrate that adenosine 
signaling through adenosine receptor A2B strongly 
modulates differentiation and function of tumor-
inÀltrating myeloid cells.
Methods: Using in vitro cell culture model, we 
investigated the effects of adenosine and A2B 
adenosine receptor signaling on differentiation and 
function of dendritic cells and CD11b+Gr1+ myeloid 
cells. The role of host A2B receptor in the regulation 
of recruitment and function of tumor-inÀltrating 
immune cells was examined in mouse tumor model 
experiments.
Results: Stimulation of A2B adenosine receptor 
skews dendritic cell (DC) differentiation diverting 
them from normal immune protective phenotype 
toward less mature immune suppressive DCs 
with pro-angiogenic and tumor-growth promoting 
properties both in vitro and in vivo. We have also 
identiÀed adenosine as an important metabolite that 
induces generation and tumor recruitment of myeloid 
derived suppressor cells (MDSC) via activation 
of A2B receptor. SigniÀcantly higher proportion 
of CD11b+Gr1high cells was generated in vitro 
from hematopoietic progenitors in the presence 
of adenosine, which mostly induced generation 
of Ly-6G+CD11b+Gr1high cells. Adenosine 
differentially regulated production of arginase, 
iNOS, and reactive oxygen species (ROS) in subsets 
associated with asbestos exposure, primarily arising 
from the surface serosal cells of the pleura. Patients 
with MPM often develop pleural Áuid as initial 
presentation. However, cytological diagnosis with 
the pleural Áuid is usually difÀcult and has limited 
utility. Useful molecular marker for the diagnosis 
especially is urgently needed. The aim of the present 
study is to compare the clinical value of hyaluronic 
acid (HA) and vascular endothelial growth factor 
(VEGF) in the pleural Áuid of MPM.
Methods: Pleural Áuids were collected from 47 
patients with MPM, 65 with lung cancer (LC), 
57 with benign asbestos pleurisy (BAP), and 
37 with other pleural diseases (others). HA and 
VEGF concentrations were determined. All data 
were analyzed by using non-parametric two-sided 
statistical tests.
Results: The median concentrations of HA in 
MPM, LC, BAP, and others were 67900 (range, 
7920-2630000), 19500 (2880-147000), 27300 
(900-118000), and 23000 (2690-108000)ng/mL, 
respectively. HA concentration was signiÀcantly 
higher in MPM than in other groups (P=0.001). The 
area under the ROC curve (AUC) values of MPM 
diagnosis was 0.795 for differential diagnosis from 
other groups. The median concentration of VEGF in 
MPM, LC, BAP, and others were 321.9 (range, 13.5-
2222.7), 286.6 (15.6-2221.0), 457.7 (23.3-2222.7), 
and 209.6 (26.6-1321.7)ng/mL, respectively. VEGF 
concentration was signiÀcantly higher in MPM 
than in others (P=0.031), but it demonstrated no 
difference between MPM and LC or BAP. HA was 
higher in earlier clinical stages (I and II) than in 
advanced stages (III and IV)(P=0.011); otherwise, 
VEGF was higher in the advanced stages (P=0.043). 
HA was higher in epithelioid subtype of MPM than 
in sarcomatoid subtype (P=0.033); otherwise, VEGF 
tended to be higher in sarcomatoid subtype than 
in epithelioid subtypes (P=0.094). VEGF value in 
the sarcomatoid subtype of MPM was signiÀcantly 
higher than in LC (P=0.019).
Conclusion: HA and VEGF in the pleural Áuid of 
MPM demonstrated different features. HA seems 
to be more useful for the differential diagnosis of 
MPM with other diseases than VEGF. VEGF might 
be useful as a diagnostic marker for sarcomatoid 
subtype of MPM.
Keywords: mesothelioma, asbestos, VEGF, 
hyaluronic acid
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P2.009 5-AZA-2’-DEOXYCYTIDINE/
VALPROATE COMBINATION 
INDUCES CTL RESPONSE AGAINST 
MESOTHELIOMA
Fabien Gueugnon, Sabrina Leclercq, Benoit Boutin, 
Flora Guillot, Christophe Blanquart, Anne Rogel, 
Martine Padieu, Daniel Pouliquen, Jean-François 
Fonteneau, Marc Gregoire 
U892, Inserm/France
Background: Malignant pleural mesothelioma 
(MPM) is an aggressive tumor of the pleura, usually 
associated with chronic asbestos exposure. MPM 
treatments include chemotherapy, radiotherapy 
and surgery, but are of limited efÀcacy, urging 
the development of new therapeutic strategies. 
Numerous preclinical and clinical studies have 
proved that epigenetic drugs have a potent anti-
cancer activity and promising therapeutic potential. 
The aim of this study was to evaluate the anticancer 
effect of a DNA methyltransferase inhibitor, 5-aza-
2’-deoxycytidine (5-azaCdR), and two histone 
deacetylase inhibitors, valproic acid (VPA) and 
suberoylanilide hydroxamic acid (SAHA). 
Methods: Human mesothelioma cell lines, derived from 
pleural effusions, were treated with each epigenetic drug, 
either alone or in combinations. The cytotoxic effects 
on treated cells, and the expression of speciÀc tumor 
antigens, were evaluated. The recognition of treated 
cells by a speciÀc CD8+ T-cell clone was also measured. 
Additionally, the effect of combined treatments was 
tested in a murine model of mesothelioma. 
Results: We showed that VPA and SAHA synergized 
with 5-azaCdR to kill MPM cells and to induce 
tumor antigen expression (such as NY-ESO-1, 
MAGE-A1 and MAGE-A3) in the remaining 
living tumor cells. As a consequence, tumor cells 
expressing these antigens were recognized and 
lysed by speciÀc CD8+ cytotoxic T-cells. In vivo, 
treatment with 5-azaCdR/VPA inhibited tumor 
growth and promoted lymphocyte inÀltration and an 
immune response against tumor cells. 
Conclusion: Appropriate epigenetic drug 
combinations, in addition to inducing mesothelioma 
cell death, also affect the immunogenic status of 
these cells. This property could be exploited in 
clinical investigations to develop MPM treatments 
combining chemotherapeutic and immunotherapeutic 
approaches. 
of CD11b+Gr1+ cells. CD11b+Gr1high cells 
isolated from mouse tumors or generated in vitro 
expressed predominantly A2B and A2A receptors. 
The key feature of these cells was high expression 
of 5’-nucleotidase/CD73 that converts AMP into 
adenosine. The ability of CD11b+Gr1high cells 
to produce adenosine from AMP presents a novel 
mechanism of immune suppression by MDSC: 
upon interaction with T cells CD11b+Gr1high 
MDSC generate adenosine from AMP present at 
high levels in inÁamed tumor tissue, the generated 
adenosine inhibits T cell proliferation and function 
via activation of A2A receptor expressed on T 
lymphocytes. There were signiÀcantly higher 
numbers of CD11b+Gr1high MDSC in tumors 
of wild type mice compared to A2B-/- knockout 
animals, thus indicating the role of A2B receptor 
in their generation and tumor accumulation. 
Tumor-bearing A2B-/- knockout mice exhibited 
signiÀcantly attenuated tumor growth and longer 
survival compared to wild type controls. Tumors 
in these mice contained signiÀcantly lower levels 
of VEGF and displayed decreased vascular density 
compared to tumors growing in wild type animals.
Conclusion: Adenosine is an important metabolite 
increased in solid tumors; its secretion beneÀts 
tumor by inducing tumor immune inÀltrate to 
produce factors that promote tumor angiogenesis 
and suppress anti-tumor immunity. A2B receptor 
is a primary mediator of the adverse effects of 
adenosine on tumor-inÀltrating myeloid cells. 
Given the profound effect that adenosine signaling 
through A2B receptor has on differentiation and 
cytokine secretion of tumor inÀltrating immune 
cells as well as tumor growth and vascularization, 
it is conceivable that the A2B adenosine receptor 
might be an important therapeutic target in cancer. 
This receptor is an especially attractive target for 
therapy, as due to its low afÀnity to adenosine it 
stays silent under normal conditions and becomes 
active only at pathologically high adenosine levels.
Keywords: Adenosine, A2B adenosine receptor, 
Cancer, Immune inÀltrate
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correlated with the pharmacological properties of 
this HDACi for the growth inhibition of cancer cells.
Conclusion: We, thus, demonstrated the 
applicability of BRET technology for the screening 
and characterization of new HDACi compounds 
in living cells, and identiÀed a very interesting 
benzafuranone HDACi.
Keywords: Cancer, HDAC inhibitors, BRET
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P2.011 AN IMMUNOCOMPETENT 
ORTHOTOPIC MOUSE MODEL 
OF MALIGNANT PLEURAL 
MESOTHELIOMA PERMITS 
PLEURAL TUMOR IMMUNE 
MICROENVIRONMENT 
CHARACTERIZATION AND 
INTRAPLEURAL INTERLEUKIN-12 
THERAPY
Christos Colovos1, Adam J. Bograd1, Michael J. 
Cavnar1, Luis Rodriguez1, Valerie W. Rusch1, Michel 
Sadelain2, Prasad S. Adusumilli1 
1Department Of Surgery, Thoracic Service, Memorial 
Sloan Kettering Cancer Center/United States Of 
America, 2Center For Cell Engineering, Memorial 
Sloan Kettering Cancer Center/United States Of 
America
Background: Malignant pleural mesothelioma 
(MPM) is a regionally aggressive disease localized 
to the pleura. Pre-clinical immunotherapy in 
mouse MPM models provide the basis for 
immunomodulation of the tumor microenvironment 
and are typically performed in heterotopic Áank or 
peritoneal tumor models. To better recapitulate and 
characterize pleural tumor immune cell inÀltration 
and assess intrapleural therapy, we seek to establish 
an orthotopic MPM mouse model.
Methods: BALB/c mice were intrapleurally 
inoculated with AB12 (murine mesothelioma) 
and assessed for tumor burden by MRI tumor 
volume averaging. To determine the biokinetics of 
intrapleural therapy, mice were intravenously or 
intrapleurally injected with recombinant murine 
interleukin-12 (0-100ng rmIL-12) and serial serum 
rmIL-12 levels were measured. Pleural tumor-
bearing mice were treated with intrapleural rmIL-12 
(0,10, 50ng) and monitored for survival. Tumors 
were examined for immune cell inÀltration by 
Keywords: immunotherapy, mesothelioma, 
epigenetic drugs, tumor antigen
Poster Session 2 – Preclinical Models Tuesday, 5 July 2011 12:15-
14:00
P2.010 PHARMACOLOGICAL 
CHARACTERIZATION OF A HISTONE 
DEACETYLASE INHIBITOR 
AND TUMOR CELL-GROWTH 
INHIBITION PROPERTIES OF NEW 
BENZOFURANONE COMPOUNDS.
Christophe Blanquart1, Manon François1, Cedric 
Charrier2, Philippe Bertrand2, Marc Gregoire1 
1U892, Inserm/France, 2Umr 6514, Cnrs/France
Background: Epigenetic modiÀcations, such as 
DNA methylation or histone acetylation, are early 
events in cell tumorigenesis. The consequences 
of these modiÀcations are repression of gene 
transcription and, notably, of tumor suppressor 
gene transcription. New therapeutic strategies aim 
to normalize the epigenetic status of cancer cells. 
Histone deacetylase inhibitors (HDACi) have 
shown promising effects against proliferation and 
resistance to apoptosis of a large number of cancer 
cells. Vorinostat, a hydroxamate HDACi, has been 
approved by the U.S. Food and Drug Administration 
(FDA) for the treatment of refractory cutaneous 
T-cell lymphoma (CTCL). However, HDACi 
are poorly speciÀc, present toxicities and many 
have very low half-lives in the plasma. Thus, the 
development of new compounds is necessary in 
order to increase the potential of HDACi in cancer 
treatment.
Methods: We designed an assay, based on 
bioluminescence resonance energy transfer (BRET) 
technology, to screen and characterize HDACi 
activity in living cells. Using our speciÀc and 
reproducible BRET assay, we characterized the 
pharmacological properties of a benzofuranone 
HDACi for the induction of histone acetylation 
and performed a comparison with the properties 
of suberoylanilide hydroxamic acid (SAHA) and 
valproic acid (VPA). Evaluation of cancer cells 
growth inhibition by HDACi was evaluated using 
viable cell counting reagent.
Results: We deÀned a benzofuranone HDACi 
compound that induced histone acetylation at 
nanomolar concentrations and showed an increased 
duration of histone acetylation. These properties 
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Background: Oncolytic virotherapy is a novel 
targeted therapeutic approach that utilises direct 
tumour lysis and generation of secondary anti-
tumour immune responses. Coxsackievirus A21 
(CVA21) is a naturally occurring “common cold” 
virus that within pre-clinical studies displays both 
in vitro and in vivo oncolytic activity across a 
wide spectrum of cancers. Natural infection by 
CVA21 is usually self-limiting within the upper 
respiratory tract. CVA21 targets human cancerous 
cells by binding to the N-terminal domain of surface 
expressed human intercellular adhesion molecule-1 
(ICAM-1). Subsequent infection, viral replication 
and rapid cytolysis of the targeted cell results in 
systemic release of progeny virus. ICAM-1 is highly 
expressed on the surface of numerous human cancers 
including lung, pancreatic, breast, prostate, head/
neck cancer and melanoma. ICAM-1 expression 
levels often correlate with the degree of metastatic 
spread of the malignancy. CAVATAKTM is the name 
of a proprietary formulation of Coxsackievirus A21 
and it is currently being evaluated in Phase I trials in 
patients with late stage melanoma, prostate cancer, 
breast cancer and recurrent Head/Neck cancer. 
Methods: In vitro cultures of NSCLC (n=3) and 
SCLC (n=2) lines were assessed for surface ICAM-
1 expression levels and for relative susceptibility to 
challenge by varying input multiplicities of CVA21. 
To assess the oncolytic capacity of CVA21 in vivo, 
human NSCLC cancer xenografts were propagated 
as subcutaneous Áank tumours in SCID Balb/C mice 
and administered the CVA21 viral formulation (~108 
TCID
50
) via a single intratumoural injection. 
Results: Moderate to high levels cell surface 
ICAM-1 expression were observed following 
Áow cytometric analysis of a panel of both human 
NSCLC and SCLC in vitro cultures. High lCAM-
1 expressing NSCLC and SCLC cells displayed 
signiÀcant susceptibility to rapid multi-cycle 
replication and cell cytolysis following in vitro 
challenge with CVA21. Intratumoural injection of a 
single dose of CVA21 in subcutaneous xenografts of 
the NSCLC line H157 in SCID Balb/C mice resulted 
in rapid cancer cell destruction and subsequent 
reductions in tumour burden. The viral-mediated 
oncolysis of the H157 xenografts was accompanied 
by the release of progeny virus as observed by 
increases in the systemic load of infectious CVA21. 
Conclusion: Coxsackievirus A21 displays 
signiÀcant pre-clinical oncolytic activity against 
human lung cancer cells both within in vitro and 
in vivo environments. The presented pre-clinical 
immunohistochemistry (IHC) and Áow cytometry 
(FCM).
Results: In this immunocompetent, orthotopic, MPM 
model, gross pleural disease resembling human 
MPM is Àrst detectable within 7-14 days by MRI 
(encasing the heart, lungs, and diaphragm; Figure 
1a and b). Mice succumb to disease in 20-30 days 
(median survival 23 days). IHC conÀrmed pleural 
tumor immune cell inÀltration of T lymphocytes, 
tumor-associated neutrophils, and tumor-
associated macrophages. Harvested pleural tumors 
revealed cells associated with immunostimulation 
(dendritic cells, helper and cytotoxic T cells) and 
immunosuppression (regulatory T cells, tumor-
associated macrophages, myeloid-derived suppressor 
cells) by FCM (Figure 1c). Intrapleural rmIL-12 
resulted in 4-fold lower systemic rmIL-12 levels 
when compared to intravenous dosing one hour after 
administration. Furthermore, repeated intrapleural 
injections of rmIL-12 result in prolonged survival 
(31 vs. 23 days, n=22, p=0.0003; Figure 1d).
Conclusion: Our immunocompetent, orthotopic, 
murine MPM model resembling human disease 
facilitates (a) non-invasive tumor burden imaging, 
(b) harvesting pleural tumor to characterize tumor-
associated immune cells, (c) multiple intrapleural 
injections, and (d) intrapleural therapy. Our 
preliminary results suggest that intrapleural rmIL-
12 therapy increases survival in this MPM mouse 
model.
Keywords: mesothelioma, Orthotopic 
Immunocompetent Mouse Model, Tumor/Immune 
Microenvironment, Pleural therapy
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P2.012 ONCOLYTIC ACTIVITY OF 
COXSACKIEVIRUS A21 IN HUMAN 
LUNG CANCER: A NOVEL TARGETED 
ANTI-CANCER STRATEGY.
Yvonne W. Vern Yee, Su Han Chan, Darren Shafren, 
Gough Au 
School Of Biomedical Sciences And Pharmacy, The 
University Of Newcastle/Australia
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observed in all four TKI-resistant CALU-3 cell 
lines. All four TKI-resistant CALU-3 cells showed 
increased invasion, migration and anchorage-
independent growth. Together, these data suggest 
epithelial to mesenchymal transition (EMT) in 
TKI-resistant CALU-3 cells. Treatment with several 
agents which target AKT, MET or IGF-1R did not 
affect TKI-resistant CALU-3 cell proliferation. 
In contrast, treatment with MSC19363669B and 
selumetinib, two selective MEK inhibitors, caused 
inhibition of cell proliferation, invasion, migration, 
anchorage-independent growth in vitro and of tumor 
growth in vivo of all four TKI-resistant CALU-3 cell 
lines. 
Conclusion: data suggest that resistance to four 
different TKIs is characterized by EMT, which is 
MEK-inhibitor sensitive in human CALU-3 lung 
adenocarcinoma. 
Keywords: acquired resistance, EMT, Lung cancer, 
erlotinib
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P2.014 RECOMBINANT HUMAN 
ENDOSTATIN NORMALIZES TUMOR 
VASCULATURE AND ALLEVIATES 
HYPOXIA IN LEWIS LUNG 
CARCINOMAS
Ming Chen, Fang Peng, Zu M. Xu, Jin Wang, Yong 
Bao, Yuan Y. Chen, Xiao Hu, Yan Wang, Qi C. Zhou, 
Hong L. Ma 
Radiation Oncology, Sun Yat-Sen University Cancer 
Center/China
Background: Tumor vessels are structurally and 
functionally abnormal with defective endothelium, 
pericyte coverage, and basement membrane. 
Most antiangiogenic cancer therapies focus on the 
destruction of solid tumors by eradication of their 
supporting vasculature. However, antiangiogenic 
therapy may “normalize” the tumor vasculature for 
a short period of time, thereby providing a window 
of opportunity for enhanced sensitivity to radiation 
treatment.We investigated whether recombinant 
human endostatin created a “vascular normalization 
window” within tumors prior to vascular pruning to 
alleviate hypoxia in Lewis lung carcinomas in mice.
Methods: (1)Kinetic changes in morphology of 
tumor vasculature in response to treatment with 
recombinant human endostatin were detected under 
Àndings establish proof of concept for the potential 
application of oncolytic virotherapy with CVA21 as 
a novel targeted anti-lung cancer therapeutic within 
the clinical environment. 
Keywords: Viral oncolysis, Coxsackievirus A21, 
Virotherapy
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P2.013 ANTITUMOR ACTIVITY OF MEK 
INHIBITORS IN HUMAN LUNG CANCER 
CELLS WITH ACQUIRED RESISTANCE 
TO DIFFERENT TYROSINE KINASE 
INHIBITORS AND WITH EPITHELIAL 
TO MESENCHYMAL TRANSITION
Floriana Morgillo1, Tina Cascone2, Pierre Saintigny2, 
John V. Heymach2, Fortunato Ciardiello1 
1Dipartimento Medico Chirurgico Di Internistica 
Clinica E Sperimentale, Seconda Università Dgeli 
Studi Di Napoli/Italy, 2Thoracic Head & Neck 
Medical Oncology, Ut MD Anderson Cancer Center/
United States Of America
Background: Despite impressive clinical successes 
with different kinase-targeted therapies, most 
cancer patients with an initially responsive disease 
eventually experience relapse as a result of acquired 
drug resistance to these agents. The aim of the 
present work was to examine the cellular alterations 
and the molecular mechanisms which are correlated 
with acquired resistance induced by four different 
TKIs, such as erlotinib, geÀtinib, vandetanib and 
sorafenib. 
Methods: An in vitro model of acquired resistance 
to these TKIs was developed by continuously 
treating the human lung adenocarcinoma cell 
line CALU-3 with escalating doses of each drug.
Tascritional proÀling was performed with Agilent 
whole genome microarrays.Western blot, MTT, 
ELISA,migration, invasion and anchorage-
independent colony growth assays were conducted in 
vitro and in vivo in sensitive (WT) and TKI-resistant 
CALU-3 cell lines.
Results: As compared to WT CALU-3 cells, in TKI-
resistant CALU-3 cell lines a signiÀcant increase in 
the expression of activated, phosphorylated MET, 
IGF-1R, AKT, MEK, MAPK, and of survivin was 
observed. Down-regulation of E-cadherin and 
amphiregulin mRNAs and up-regulation of vimentin, 
VE-cadherin, HIF-1a and VEGFR-1 mRNAs were 
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Conclusion: Recombinant human endostatin can 
normalize tumor vasculature within day 3 to 7, 
leading to improved tumor oxygenation. The results 
provide important experimental basis for combining 
recombinant human endostatin with radiation therapy 
in human tumors.
Keywords: endostatin, tumor vascular 
normalization, Radiation Therapy, anti-angiogenesis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.015 ONCOLYTIC ACTIVITY 
OF MEASLES VIRUS AGAINST 
MESOTHELIOMA AND LUNG 
CANCER: POTENTIAL ROLE OF 
HSP70, CALRETICULIN AND HMGB1 
IMMUNOGENIC MOLECULES
Marc Gregoire1, Nicolas Boisgerault1, Jean-Baptiste 
Guillerme1, Daniel Pouliquen1, Frédéric Tangy2 
1U892, Inserm/France, 2Laboratoire De Génomique 
Virale Et Vaccination, Pasteur Institute/France
Background: Cancer virotherapy has recently 
emerged as a hopeful alternative therapeutic 
strategy in the aim of better responding to the 
diversity of cancerous pathologies. It is based on 
the preferential tropism of certain viruses for tumor 
cells; such property is exhibited naturally by an 
attenuated vaccine strain of measles virus (MV). We 
a confocal microscope with immunoÁuorescent 
staining in Lewis lung carcinomas in mice.(2)The 
time course of hypoxic tumor fraction was assessed 
with immunohistochemical staining.(3)Effects on 
tumor growth were monitored as indicated in the 
growth curve of tumors.
Results: Vascularity of the tumors was reduced over 
time by recombinant human endostatin treatment 
and signiÀcantly regressed for 9 days relative to the 
control group (Fig 1a-b). During recombinant human 
endostatin treatment, pericyte coverage increased by 
day3, increased markedly by day 5, and fell again by 
day 7 (Fig 1c-f). The vascular basement membrane 
(BM) was thin and closely associated with 
endothelial cells after recombinant human endostatin 
treatment, but appeared thickened, loosely associated 
with endothelial cells in control tumors (Fig 1g-n). 
The decrease in hypoxic tumor fraction on the 5th 
day after treatment was also found (Fig 2a). Tumor 
growth was not accelerated 5 days after recombinant 
human endostatin treatment (Fig 2b). 
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P2.016 COMBINATION THERAPY WITH 
VORINOSTAT AND ADENOVIRUS-FASL 
IN LUNG CANCER CELL LINES
Choon-Taek Lee, Mi-Young Park, Dal Rae Kim, 
Hyo-Jeong Lim, Jong Sun Park, Young Jae Cho, Sei-
Won Lee, Ho-Il Yoon, Jae-Ho Lee 
Internal Medicine, Seoul National University 
Bundang Hospital/Korea
Background: FasL (CD95L), a membrane protein of 
TNF family, induces strong apoptosis in cancer cells 
by binding with Fas receptor. Systemic toxicities 
of FasL limit the clinical use for cancer therapy. To 
avoid the systemic toxicities of FasL, we performed 
adenoviral gene therapy of FasL with vorinostat 
that can enhance the adenoviral transduction and its 
transcription in lung cancer cell lines.
Methods: Adenovirus expressing FasL (ad-FasL) 
was replication-defective by E1 deletion and driven 
by CMV promoter. Vorinostat (SAHA), a HDAC 
inhibitor, was provided by Merck. Production of 
FasL from lung cancer cell lines was measured by 
ELISA kit after transduction of ad-FasL along with 
vorinostat. The interaction of ad-FasL and vorinostat 
was analyzed by Calcusyn software. The effects of 
ad-FasL and vorinostat on apoptotic pathway were 
analyzed by NF-ƩB assay and Western blot assay for 
apoptosis related proteins.
Results: Transduction with ad-FasL produced FasL 
from lung cancer cells and the addition of vorinostat 
increased FasL production by 10 fold. Strong synergism 
of ad-FasL and vorinostat in antitumor effect was 
found in all lung cancer cell lines tested. Cells showing 
early apoptotic change were signiÀcantly increased 
by combining ad-FasL and vorinostat. Addition of 
vorinostat effectively suppressed NF-ƩB activation 
induced by ad-FasL. Enhanced phosphorylation of 
Akt, increased cleavage of caspase-3 and PARP and 
suppression of antiapoptotic molecucle, Bcl-2 were 
found by combining ad-FasL and vorinostat in lung 
cancer cell lines.
Conclusion: Combination of ad-FasL and 
vorinsostat showed a strong synergistic interaction 
on antitumor activity. This synergistic interaction 
was mediated by enhanced FasL production and 
enhanced induction of apoptosis.
Keywords: adenovirus, FasL, Vorinostat, gene 
therapy
previously showed that MV was able to efÀciently 
infect and kill mesothelioma tumor cells. Infected 
mesothelioma cells were able to induce spontaneous 
maturation of dendritic cells and subsequently to 
prime cancer antigen-speciÀc T CD8 response.Thus, 
danger signals are probably expressed after measles 
vaccine infection of the cancer cells. These signals 
would be involved in the immunogenic properties of 
such oncolytic strategy.
Methods: Meso11, Meso13, Meso47, Meso56, 
Meso96 epithelioid mesothelioma cell lines and 
ADK3, ADK117, ADK153 lung adenocarcinoma 
cell lines were established and characterized in 
our laboratory from pleural effusion collected 
by thoracocentesis of cancer patients with their 
informed consent. A549 lung adenocarcinoma cell 
line and MSO-1 normal mesothelial cells were 
purchased from tebu-bio (Le Perray-en-Yvelines, 
France). All cell lines were exposed to Measles 
vaccine infections, performed at MOI=1.0 for 2 
hours at 37°C. Cell death was determined 3 days 
after infection using Apoptosis Detection Kit.Three 
days after infection, tumor cells were analyzed for 
intracellular HSP70expression, membrane bound 
calreticulin (Áow cytometry), and HMGB1 release 
into cell supernatant (ELISA)
Results: We found that MV infection oÀs speciÀc 
for cancer cells but not on healthy ones. The MV 
vaccine demonstrated oncolytic properties and 
induced an immunogenic apoptosis. The dead cells 
are associated with synthesis of HSP70, translocation 
of calreticulin to cell surface and release of HMGB1 
in these cells lines in vitro.
We also demonstrated that MV exhibited comparable 
properties in vivo against human mesothelioma and 
lung cancer xenografts.
Conclusion: These molecules are expected to play 
an essential role in the activation of the adaptive 
immune response by acting on dendritic cells that 
spontaneously matured after having been co-cultured 
with MV-infected tumor cells. The immune side 
of cancer virotherapy remains poorly documented, 
but it opens exciting outlooks in order to combine 
direct viral oncolysis with long-term protection 
by enhancing a potential cancer-speciÀc immune 
memory. SpeciÀc targeting of CD46 complement 
regulatory protein would also offer an alternative 
approach to complement-based strategies against 
tumor cells resistant to complement. 
Keywords: oncolytic properties, mesothelioma, lung 
adenocarcinoma, measles vaccine
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the Late Breaking Abstract Supplement, available 
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P2.018 RGD-LIPOSOMES: PROSPEROUS 
CHEMOTHERAPY DRUG CARRIERS 
EXERTING ANTITUMOR EFFECT VIA 
TWO WAYS
Shuyan Meng, Bo Su, Wei Li, Caicun Zhou 
Cancer Department, Cancer Institute Of Tongji 
University School Of Medicine, Shanghai Pulmonary 
Hospital/China
Background: Angiogenesis is crucially required for 
solid tumor growth and metastasis, tumor vasculature 
has been considered to be an ideal target for cancer 
treatment. Arg-Gly-Asp (RGD) containing peptides 
with high afÀnity to av-integrins are promising 
ligands for the generation of vascular targeting 
agents. RGD containing peptides themselves were 
reported had the ability of tumor growth inhibition 
by blocking the angiogenesis pathway. Liposomes 
have been proved to be good drug-delivery systems 
because of their property of safety, biocompatibility 
and biodegradability. They were FDA approved and 
available for cancer treatment. In present study, a 
kind of RGD containing lipopeptide was conjugated 
to the surface of stealth liposomes for the purpose of 
developing active targeted antitumor drug carriers to 
inhibit tumor growth via both peptides themselves 
and the loaded drugs.
Methods: A 12-mer peptide containing a cyclic 
RGD sequence was selected to be the targeting 
molecular, which was coupled with a KGG-palmitic 
acid conjugate to make up a kind of lipopeptide. 
Lipids, cholesterol and the lipopeptide were then 
mixed together in chloroform to prepare RGD-
liposomes with thin-Àlm hydration method. RGD-
paclitaxel liposomes were also prepared in the 
same way. Cell growth inhibitory study and scratch 
migration experiment were performed to access 
the toxicity of the RGD containing peptide. The 
IC50 value and cellular uptake of RGD-paclitaxel 
liposomes were determined to conÀrm the peptide 
mediated cellular internalization. 
Results: While cultivated in the media supplemented 
with 400 200ƫmol/L RGD containing peptide 72h, 
the growth rate of A549 (a human lung carcinoma 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.017 MODULATION OF PRO-SURVIVAL 
AND PRO-APOPTOTIC SIGNALING 
IN NON-SMALL CELL LUNG CANCER 
(NSCLC) BY 22ȕ-HYDROXYOLEANONIC 
ACID.
Manu Sharma1, Anurag Rakhi2, M. Janlav3 
1Department Of Biotechnlogy And Bioinformatics, 
Jaypee University Of Information Technology/
India, 2Rayat Institute Of Pharmacy/India, 3National 
Medical University/Mongolia
Background: Lung cancer is the leading cause of 
cancer-related deaths all over the world. Prevailing 
treatment options have limited therapeutic success in 
lung cancer, particularly non-small cell lung cancer 
(NSCLC), as it becomes resistant to therapy. Hence, 
better therapeutic options are immediately required 
for lung cancer. 22ơ-hydroxyoleanonic acid is a 
semisynthetic triterpenoid, which is synthesized 
from pentacyclic triterpenoid Lantadene A and 
been recently examined for its anticancer effect on 
different cancers
Methods: To determine the anticancer effect of 
22ơ-hydroxyoleanonic acid on NSCLC cell lines 
H460 and A549, cell viability, apoptotic, Western 
blot and reporter assays were performed.
Results: 22ơ-hydroxyoleanonic acid signiÀcantly 
inhibited the growth of H460 cells compared to 
A549 cells and down-regulated the expression of 
EGFR/Neu and its downstream signaling (Akt, 
NF-ƩB, Bcl-2 and survivin) in H460 cells. In 
addition, 22ơ-hydroxyoleanonic acid up-regulated 
the expression of p53 and p21 causing cell cycle 
arrest in the G
2
/M-phase by down-regulating G
2
/M 
regulatory proteins (cyclinB1 and Cdc25B) in 
H460 cells. Furthermore, it activated the JNK/p38 
signaling, leading to caspase-3 activation resulting in 
the induction of apoptosis.
Conclusion: 22ơ-hydroxyoleanonic acid exerted 
anticancer activity on NSCLC cells by modulating 
the pro-survival and pro-apoptotic signaling that 
causes induction of apoptosis. 
Keywords: apoptosis, cyclinB1 and Cdc25B, JNK/
p38 signaling
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cyanidin, malvidin, peonidin and petunidin) have 
received increasing attention for their anticancer 
effects. While these anthocyanidins have been 
tested individually, their combinatorial effects as a 
mixture (as present in blueberry, bilberry and Indian 
blackberry Jamun) has not been explored. Also, 
their use as adjunctive therapeutic agents is largely 
unknown. In this study we assessed the effect of 
these anthocyanidins and their mixture to inhibit the 
proliferation and metastasis of a highly aggressive 
NSCLC cells. Furthermore, their ability to sensitize 
the NSCLC cells to conventional chemotherapeutic 
drug paclitaxel was also explored.
Methods: The H1299 cell line, established from 
a metastatic lung cancer, was treated in vitro with 
individual anthocyanidins and their equimolar 
mixture and cell viability, cell cycle progression, 
apoptosis and cell migration was measured 
through standard assays. Western blot and miRNA 
analysis were employed for the determination of 
the molecular targets. In-vivo anti-tumor effects of 
the most potent anthocyanidin, delphinidin and the 
anthocyanidin mixture, isolated from black currant 
and bilberry, respectively were also determined 
using nude mouse xenograft model. Finally, 
chemosensitizing effects of the anthocyanidin 
mixture were assessed by measuring cell viability 
after treatment of cells with anthocyanidin mixture in 
combination with paclitaxel.
Results: We demonstrate that all the Àve 
anthocyanidins resulted in inhibition of H1299 
cell proliferation and migration, however, an 
equimolar mixture of all Àve at lower concentrations 
elicited signiÀcantly higher antiproliferative and 
antimetastatic effects, indicating synergism. The 
induction of cell cycle arrest and apoptosis was 
also signiÀcantly greater with the mixture than 
either agent alone. Notably, both the mixture of 
anthocyanidins and the most potent anthocyanidin 
delphinidin reduced the H1299 tumor xenograft 
growth by ~ 60%; however, the effective dose 
of anthocyanidin mixture (0.5 mg/dose) was 
3-times lower than delphinidin (1.5 mg/dose) 
further emphasizing synergism. The superior 
antiproliferative and apoptotic effects of the 
combinatorial treatment seemed to result from 
attack on different or overlapping molecular targets 
associated with cell proliferation, apoptosis and 
metastasis viz the oncogenic NOTCH1, WNT1, 
c-myc, cyclin D1 and cyclin B1 proteins, the cell 
survival kinase pERK and the metastatic mediators 
MMP9 and VEGF. All this was coupled with 
cell line) cells and human umbilical vein endothelial 
cells (HUVEC) were reduced 37.3% and 43.3% 
individually. RGD-paclitaxel liposomes exhibited 
the greatest cytotoxicity than conventional marketed 
paclitaxel (Taxol) and non-targeted paclitaxel 
liposomes. Reduced migration ability was observed 
in both cell lines after 24h incubation in media 
containing RGD-paclitaxel liposomes than Taxol 
or non-targeted paclitaxel liposomes. The IC50 
value of Taxol, paclitaxel liposomes and RGD-
paclitaxel liposomes were 6.03mg/mL, 3.37mg/mL, 
1.46mg/mL individually in A549 cells(P 0.05) and 
6.56mg/mL, 4.56mg/mL, 3.40mg/mL individually 
in HUVEC(P 0.05). Cellular uptake of liposomal 
paclitaxel was higher than that of Taxol. Moreover, 
RGD-paclitaxel liposomes showed a 1.5-fold 
increase in uptake in A549 cells and a 2-fold increase 
in uptake in HUVEC (P 0.05) than non-targeted 
paclitaxel liposomes. 
Conclusion: RGD-paclitaxel liposomes could exert 
strengthened antitumor effect both by blocking the 
integrin pathway and targeting delivery of paclitaxel. 
RGD based strategy could be used to enhance 
antitumor effect of chemotherapy drugs encapsulated 
in nanocarriers.
Keyword: targeted liposomes
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P2.019 BERRY ANTHOCYANIDINS 
SYNERGISTICALLY SUPPRESSES 
NON-SMALL-CELL LUNG CANCER 
CELL GROWTH AND METASTASIS 
AND ENHANCES SENSITIVITY TO 
THE CHEMOTHERAPEUTIC DRUG 
PACLITAXEL
Hina Kausar1, Jeyaprakash Jeyabalan1, Farrukh Aqil1, 
Deepika Chabba2, Jasmeen Sidana2, Inder P. Singh2, 
Ramesh C. Gupta1 
1James Graham Brown Cancer Center, University 
Of Louisville/United States Of America, 2National 
Institute Of Pharmaceutical Education And 
Research/India
Background: Lung cancer still continues to 
represent the largest cause of cancer mortality, 
thus making the search for new anti-cancer agents 
imperative for their use in cancer therapy and/
or as adjuvants to existing chemotherapeutic 
options. Lately, berry anthocyanidins (delphinidin, 
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in MPM and to investigate the impact of blocking 
FGFR-mediated signals with genetic constructs 
and speciÀc tyrosine kinase inhibitors on MPM cell 
growth and signalling pathways. 
Methods: Expression of FGF/FGFR molecules 
was screened by qRT PCR in MPM cell lines 
(n=10) and one normal mesothelial cell line. FGFR 
inhibition was achieved with FGFR-speciÀc tyrosine 
kinase inhibitors and by adenoviral transduction 
with dominant-negative FGFR constructs fused 
to green-Áuorescence protein (dnFGFR1). The 
impact of inhibition and stimulation of FGF/FGFR 
molecules was investigated by MTT and clonogenic 
assays as well as by spheroid formation assays and 
videomicroscopy. The effect on downstream signal 
transduction was assessed by immunoblotting with 
phosphorylation site-speciÀc antibodies. In addition, 
potentially additive or synergistic antineoplastic 
activity of FGFR1 inhibitors in combination with 
clinically applied chemotherapeutics and other 
targeted drugs against MPM were evaluated.
Results: Expression analysis revealed high 
overexpression of FGFR1 in all investigated 
MPM cell lines compared to all other receptors. 
Concerning the expression of the ligands, high 
transcript levels of FGF2 and FGF18 were 
detected, whereas FGF3 and FGF4 were generally 
undetectable in all cell models. Inhibition of FGFR1 
by the speciÀc Inhibitor PD166866 lead to decreased 
proliferation and migration in all cell lines tested, 
which was further conÀrmed in selected cases by 
adenoviral expression of dnFGFR1. In contrast, 
stimulation with FGF2 showed remarkably increased 
migration and signiÀcant changes in morphology 
accompanied by distinct changes in cellular signal 
transduction pathways. Inhibition of FGFR signals 
also markedly reduced spheroid formation ability of 
MPM cell lines. Combination of FGFR inhibition 
with chemotherapeutic agents e.g. cisplatin, 
trabectedin, temsirolimus, lead to increased efÀcacy 
with respect to cell viability.
Conclusion: Taken together these data suggest 
that FGFR signals are important for proliferation, 
survival, migration and chemoresistance of 
mesothelioma cells and their inhibition should 
be further evaluated as a potential new treatment 
strategy in MPM. 
Keywords: pleural mesothelioma, Fibroblast growth 
factors, receptor tyrosine kinase
enhanced cleavage of the antiapoptotic molecule 
Bcl2 and PARP protein. The anthocyanidin mixture 
also induced the expression of four miRNAs (miR-
126, miR125a-5p, miR200c and miR-34a) frequently 
downregulated in NSCLC and implicated in lung 
cancer growth, metastasis and chemoresistance. 
Additionally, the combination of low concentrations 
of anthocyanidins (1:1 mixture) was sufÀcient to 
induce 50 percent growth inhibition and enhanced 
apoptosis in combination with low dose Paclitaxel 
(1 nM), thus reducing the IC50 dose of paclitaxel by 
5-8 folds.
Conclusion: Our results suggests that increased 
consumption of bilberry, blueberry, or Indian 
blackberry (jamun) rich in this mixture of 
anthocyanidins would be useful for the prevention/
treatment of NSCLC or as adjuvants to enhance the 
effects of existing chemotherapeutic options.
Keywords: Growth & Metastasis, Lung cancer, 
Anthocyanidins, Chemotherapeutic Adjuvant
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.020 EVALUATION OF THE 
FIBROBLAST GROWTH FACTOR 
RECEPTOR AXIS AS POTENTIAL 
THERAPY TARGET IN MALIGNANT 
PLEURAL MESOTHELIOMA
Karin Schelch1, Mir Alireza Hoda2, Julia Muenzker1, 
Bahil Ghanim2, Martin Filipits1, Balazs Hegedus2, 
Balazs Dome2, Walter Berger1, Walter Klepetko2, 
Michael Grusch1 
1Institute Of Cancer Research, Department Of 
Internal Medicine I, Medical University Vienna/
Austria, 2Division Of Thoracic Surgery, Medical 
University Vienna/Austria
Background: Malignant pleural mesothelioma 
(MPM) is an aggressive malignancy with poor 
outcome and limited therapeutic options. Fibroblast 
growth factors (FGF) and their receptors have been 
identiÀed as potential therapy targets in several 
tumor types but have not been systematically 
investigated in MPM so far. Aim of the present 
investigation was to provide a systematic analysis 
of the expressed FGF as well as FGFR molecules 
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MNL8237 has synergistic activity in lung cancer 
cell lines in vitro and in vivo. Western blot analysis 
to investigate signaling events is ongoing. A clinical 
trial in patients with advanced NSCLC testing this 
combination is now ongoing at our center.
Keywords: EGFR, Lung cancer, aurora a
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P2.022 ANTIPROLIFERATIVE EFFECT 
OF ARSENIC TRIOXIDE IN NON-SMALL 
CELL LUNG CARCINOMA (NSCLC)
Sze Kwan Lam, Chunyan Zheng, James Chung-Man 
Ho 
Medicine, The University Of Hong Kong/Hong Kong
Background: Arsenic trioxide (ATO) has been 
proven to be an effective treatment in acute 
promyelocytic leukemia and its activity has 
also been noted in some other solid tumors. The 
objectives of this study were to examine the in vitro 
effects of ATO in cell proliferation and the molecular 
mechanisms underlying the ATO induced cellular 
responses in NSCLC cell lines. 
Methods: A panel of seven NSCLC cell lines 
(obtained from ATCC) was employed for our 
experiments. Effects of treatment (48 hours) 
with ATO at different concentrations were 
studied using standard MTT assay (cellular 
viability), PE-conjugated annexin-V and 7-amino-
actinomycin (7-AAD) assay (apoptotic fractions by 
phosphatidylserine (PS) externalization), and JC-1 
staining (mitochondrial transmembrane potential). 
Expression of pro-apoptotic and anti-apoptotic 
proteins were studied by Western blotting.
Results: ATO inhibited the growth of NSCLC 
cell lines H23, H358, HCC827, H1650, H1975, 
HCC2935 and HCC4006 with an IC50 value of 1.9 
ƫM, 16.5 ƫM, 2.0 ƫ M, 3.6 ƫM, 2.8 ƫ M, 10 ƫM and 
5.2 ƫ M, respectively. Only H23 cells treated with 
2 ƫM ATO displayed PS externalization (increased 
by 10.7%, p<0.05). After incubation with 5 ƫM 
ATO for 24 hours, H23, H358, HCC827, H1650, 
H1975, HCC2935 and HCC4006 cells undergoing 
mitochondrial membrane depolarization were 
increased by 12.4%, 18.4%, 6.9%, 20.3%, 18.6%, 
6.2% and 4.8%, respectively (p<0.05). From our 
preliminary result, Bcl-2 (anti-apoptotic factor) 
was down-regulated in all NSCLC cell lines except 
HCC4006. The level of Bax (pro-apoptotic factor) 
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P2.021 AURORA-A KINASE AND EGFR 
INHIBITION ACT SYNERGISTICALLY 
IN NON-SMALL CELL LUNG CANCER 
(NSCLC) CELL LINES
Xiaofan Pan1, Jiping Zhang1, Igor Astsaturov1, Brian 
Egelston2, Hossein Borghaei1 
1Medical Oncology, Fox Chase Cancer Center/
United States Of America, 2Biostatistics, Fox Chase 
Cancer Cenetr/United States Of America
Background: NSCLC is the leading cause of cancer 
related death in the US. Inhibitors of the epidermal 
growth factor receptor (EGFR) are active in only 
a subset of patients. Capitalizing on our recent 
observation of synergistic activity of combined 
inhibition of EGFR and Aurora-A pathways1, we 
investigated combined activity of Aurora-A and 
EGFR antagonists in several refractory lung cancer 
cell lines in culture and xenograft models.
Methods: The Aurora-A gene copy number in 
Àve human lung cancer cell lines (A549, H322M, 
H358, H1299 and PC-9) with known EGFR and 
KRas status was determined by genomic qPCR. The 
cytotoxcity of erlotinib (E) and MLN8237 (MLN, 
Millennium) were determined for each cell line using 
Cell Titer Blue assay. We used the Chou-Talalay 
method2 to establish combined activity of MLN 
and E. Animal xenograft studies with A549 and 
H322M lung cancer cell lines were conducted by 
sub-Q inoculations of 4M cells and treatment given 
on daily (E) or BID (MLN) basis. Tumor sizes were 
monitored thrice weekly. Activity of Aurora A and 
EGFR effectors: AKT and RalA, was determined in 
tumor tissues.
Results: The AURKA copy number was 4.37 in 
PC-9 cells, the other cell lines had normal or low 
(A549 1.8) copy numbers. PC-9 was most sensitive 
to both E and MLN with IC50 0.031 uM and 3.05 
uM, respectively. Contrastingly, A549 was resistant 
to either of the drugs (IC50, E=24.4 uM and MLN= 
30.5 uM). Combined treatment of A549 xenografts 
with erlotinib (10 mg/kg/day) or MLN8237 (20mg/
kg/bid) showed tumor regression while either agent 
alone were less effective. Similar tumor blocking 
effect was observed in H322M xenografts. Western 
blot analysis of the tumor lysates to investigate 
signaling inhibition in the combined treatment group 
is ongoing and data will be presented at the meeting.
Conclusion: Combination therapy with erlotinib and 
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cells for 48hrs exposure. After treatment of ATO 
and cisplatin, moderate synergistic cytotoxicity and 
additive effect were found in resistant and sensitive cell 
lines respectively (CI = 0.5-0.9). On the other hand, 
antagonism was shown in the combination of ATO and 
VP-16 in all cell lines (CI = 0.9-2). When combined 
with standard chemotherapeutic doublet (cisplatin and 
VP-16), ATO did not potentiate the cytotoxic effect 
with CI >=1. Using H841 (adhering cell line) as a 
model, there was time- and dose-dependent increase in 
apoptotic fractions upon ATO treatment. Mitochondrial 
depolarization was induced in ATO-treated cells. The 
combination of ATO and VP-16 resulted in diminished 
cell death and mitochondrial depolarization when 
compared with single treatments. The ratio of GSH/
GSSG (reduced/oxidized glutathione) decreased in 
H841 cells treated with ATO, cisplatin or VP-16 in 
a dose-dependent manner, but increased by 10 folds 
when treated with both ATO and VP-16. ATO induced 
up-regulation of cleaved caspase-3 (pro-apoptotic) and 
down-regulation of Bcl-2 (anti-apoptotic). However, 
combined treatment with ATO and VP-16 failed to alter 
Bcl-2 expression.
Conclusion: ATO induced cell death in SCLC cell 
lines through apoptosis. There is potential synergism 
between ATO and cisplatin, while antagonism is 
evident in combination of ATO and VP-16. Future 
studies to explore the role of ATO as single agent or 
in combination with cisplatin in treatment of SCLC 
are warranted.
Funding support: partially funded by the Hong Kong 
Anti-Cancer Society Cancer Research Grant 2010 
and Simon K.Y. Lee Foundation research grant
Keywords: arsenic trioxide, Small cell lung cancer
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P2.024 CLINICOPATHOLOGIC AND 
MOLECULAR FEATURES OF YOUNG 
CHINESE PATIENTS WITH PRIMARY 
LUNG CANCER
Huajun Chen1, Jin-Ji Yang1, Zhi-Hong Chen2, Xu-
Chao Zhang2, Jian Su2, Yi-Long Wu3 
1Devision 1 Of Pulmonary Oncology, Guangdong 
General Hospital/China, 2Medical Research Center, 
Guangdong General Hospital/China, 3Guangdong 
Lung Cancer Institute, Guangdong Academy Of 
Medical Sciences & Guangdong General Hospital/
China
remained unchanged. 
Conclusion: ATO, at clinically achievable 
concentrations, can induce apoptosis in NSCLC cell 
lines. Further exploration of its mechanisms and in 
vivo studies for treatment of NSCLC are warranted.
Funding support: Simon K.Y. Lee Foundation 
research grant
Keywords: arsenic trioxide, Non-small cell lung 
cancer
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P2.023 IN-VITRO STUDY OF ARSENIC 
TRIOXIDE AND CHEMOTHERAPEUTIC 
AGENTS IN SMALL CELL LUNG 
CARCINOMA
Chunyan Zheng, Sze Kwan Lam, James Chung-Man 
Ho 
Medicine, The University Of Hong Kong/Hong Kong
Background: Arsenic trioxide (ATO), an anti-tumor 
agent with multi-faceted mechanisms of action, 
has become a breakthrough treatment for acute 
promyelocytic leukemia in recent years. There have 
been preliminary data about the potential activity of 
ATO in solid tumours, including small cell lung cancer 
(SCLC). As SCLC is considered a chemo-sensitive 
malignancy, we conducted an in-vitro study examining 
the cytotoxic effects as well as the mechanisms of 
ATO, clinically effective chemotherapeutic agents, or a 
combination of both in a SCLC cell line model.
Methods: Six SCLC cell lines (H-187, DMS-79, 
H-526, H-69, H209 and H841) obtained from 
ATCC were treated with drugs (ATO, cisplatin 
and/or etoposide [VP-16]). The cell viability after 
treatment was assessed by MTT assay. The effects 
of combination treatment were determined by 
isobologram analysis (combination index, CI) using 
standard computer software (CalcuSyn, Biosoft, 
USA). The proportion of cells undergoing early 
apoptosis was detected by annexin-V/7-AAD assay 
with Áow cytometry. Mitochondrial depolarization 
was determined by JC-1 staining. Western Blotting 
was utilized to measure the apoptotic factors 
(caspase-3, caspase-8, Bcl-2, Bax).
Results: ATO, cisplatin and VP-16 induced cell 
death in time- and dose-dependent manner. Cells 
were sensitive to ATO (IC50 < 5 ƫM), as well as 
cisplatin and VP-16 (IC50 < 10 ƫM) except DMS79 
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P2.025 CISPLATIN RESISTANT 
NSCLC CELLS BLOCK ACID 
SPHINGOMYELINASE DEPENDENT 
CASPASE 8 ACTIVATION BUT 
CONSERVE DEATH RECEPTOR 
SIGNALLING
Ian Paul1, Alexander Chacko1, Nyree Crawford1, 
Martin Barr2, Kenneth J. O’Byrne3, Daniel B. 
Longley1, Dean A. Fennell1 
1Centre For Cancer Research And Cell Biology, 
Queen’s University Belfast/United Kingdom, 2Trinity 
College Dublin/Ireland, 3Oncology (Hope), St 
James’s Hospital/Ireland
Background: Failure to efÀciently induce 
apoptosis contributes to multidrug resistance in 
NSCLC. Although mitochondrial BAX and BAK 
cooperate in enabling mitochondrial apoptosis, their 
requirement has not been robustly established in 
relation to cisplatin, the most widely used drug in the 
treatment of NSCLC. Here we show that cisplatin 
bypasses mitochondrial apoptosis via activation of 
the extrinsic death pathway. This route is blocked 
in cisplatin resistance, however death receptor 
signalling remains intact.
Methods: We engineered mitochondrial apoptosis 
defective NSCLC cells by stably silencing BAX and 
BAK using short hairpin RNAs in H460 and H1299 
cells. Apoptosis signalling in response to cisplatin 
was assessed using western blot and by cell cycle 
analysis of PI stained ethanol Àxed cells. Functional 
dependence of components of the apoptotic 
pathways was determined using RNA interference.
Results: Apoptosis block in NSCLC cells stably 
expressing BAX and BAK short hairpin RNAs in 
H460 and H1299 cells was conÀrmed by resistance 
to BID BH3 peptide, and lack of caspase 9 cleavage 
following staurosporine, bortezomib and cisplatin. 
However, apoptosis still occurred as evidenced 
by caspase 3/PARP cleavage and hypodiploidy. 
Cisplatin potently induced the extrinsic pathway 
initiator caspase 8. Silencing caspase 8 expression 
by RNA interference, rescued from cisplatin but 
only in BAX BAK silenced cels. Caspase 8 cleavage 
induced by cisplatin was dependent on DR4, DR5 
and FADD, and required acid sphingomyelinase. 
In contrast, cisplatin resistant cells, although 
undergoing cell cycle arrest, H2AX phosphorylation 
and p53 stabilisation in response to cisplatin, failed 
Background: Incidence and prevalence of lung 
cancer was on the rise in young adults. This study 
was to investigate the clinical characteristics and 
molecular features of these young patients.
Methods: The study was a retrospective review of 
young patients with primary lung cancer referred to 
Guangdong General Hospital over a 6-year period 
from 2004 to 2010. Data regarding demographics, 
histology, tumor staging, and treatment efÀcacy 
were obtained from all patients. EGFR and KRAS 
mutation was detected on tumor samples by direct 
sequencing.
Results: 63 patients of the age from 17 to 35 were 
enrolled. The average age of the population was 
30.0. None of them was exposed on chemical 
contact. One patient had family history of 
malignancy. 11.1% (7/63) of these patients were 
students. 10 patients were light smokers, and the 
rest were non-smokers. 54 cases (85.7%) were 
diagnosed as adenocarcinoma. And only 6.3% 
(4/63) of these patients were diagnosed as early 
stage disease in the Àrst hospitalization. EGFR 
and KRAS mutations were detected in 16 cases; 
four patients (25.0%) with active EGFR mutation 
were found. 40 patients received platinum-based 
doublet chemotherapy in the Àrst line setting. The 
chemotherapy achieved disease control rate as 
77.5% (18 SD and 13 PR). 22.5% (9/40) of these 
young patients were refractory to chemotherapy. 
2 cases with EGFR active mutation received 
EGFR TKI treatment, and 1 case achieved PR, 
another patient was assessed as SD. 12.7% (8/63) 
patients refused any anti-cancer treatment after the 
established diagnosis.
Conclusion: The study implies that genetic 
background or exposure to Àrst-hand cigarette could 
not fully explain the prevalence of primary lung 
cancer in Chinese young adults. Adenocarcinoma 
was predominant in young patients. Early detection 
was warranted and social support was required as 
many young patients quit treatment.
Keywords: young adult, primary lung cancer
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molecule 6). Urease, sourced from jack beans 
(Canavalia ensiformis), is a hexameric enzyme 
consisting of six identical subunits of approximately 
91 kDa each. LDOS47 tumour suppression activity: 
Varying amount of LDOS47 was injected in A549 
xenograft and the growth of the tumour is monitored. 
In a separate experiment, LDOS47 is premixed with 
A549 and the complex is injected through the tail 
vein of the mice. Groups of mice were sacriÀced at 
the third and tenth week. Lung nodules formed by 
A549 colonization were counted. LDOS47 Imaging: 
Varying amounts of LDOS47 labelled with Cy5.5 
were injected into A549 xenograft mice. At various 
time intervals, animals were anaesthetized and 
transferred to a specially constructed light tight box 
equipped with CCD camera, laser diode to capture 
images. Tumour pH measurement: Tumour bearing 
mice were positioned vertically in a 11.7T magnet 
and a custom built surface coil is used to acquire 
1H-MRI and 32P-MRS signal. Pi, PME, PDE and 
ATP signals were used to monitor, tumour pH, 
growth, and tissue energetic. The pH of the tumour 
was also measured separately using a microelectrode. 
Results: LDOS47 tumour suppression activity: 
LDOS47 suppresses A546 tumour in a dose 
dependent manner. Effective dose was observed at 
35U/kg. Premixing LDOS47with A549 cells prior 
to injection signiÀcantly reduced the ability of A549 
cells to colonize the lungs. At ten weeks most of the 
inhibition is overcome. LDOS47 Imaging: LDOS47 
Áuorescence peaked at 48 hours post injection. 
Calculations indicated that the maximal Áuorescence 
is seen at 48 hours. Free dye injected into control 
or tumour bearing mice is not accumulated in any 
tissues examined upon necropsy and is cleared from 
the mice within 2 hours. Tumour pH measurement: 
Preliminary data showed the magnet/coil set up was 
effective in measuring tumour pH. The effects of 
LDOS47 on tumour alkalization are being studied. 
Conclusion: LDOS47 is able to target tumour in 
vivo and reduces tumour growth. Fluorescence 
imaging data showed the molecule was retained 
at the tumour for a signifciant period of time and 
LDOS47 prevented tumour cells to colonize distant 
organ. Tumour pH data are being collected. 
Keywords: Tumour microenvironment, Tumour 
alkalization, Imaging, MRS
induce caspase 8 and undergo apoptosis. However, 
these cells conserved sensitivity to death receptor 
signalling mediated by TRAIL or FLIP silencing.
Conclusion: Cisplatin mediates apoptosis through a 
redundant pathway involving acid syngomyelinase 
dependent caspase 8. This signalling is lost in 
cisplatin resistant NSCLC but can be bypassed 
by death receptor activation or FLIP silencing. 
Strategies to effectively target this conserved 
pathway should bypass platinum resistance to restore 
apoptosis signalling.
Keywords: caspase 8, Non small cell lung cancer, 
apoptosis, Cisplatin
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P2.026 TREATING LUNG TUMOUR 
THROUGH ALKALIZATION
Heman Chao1, Wah Wong2, Carl De Luca2, Baomin 
Tian2, Elda Hegmann3, Eilean Mckenzie-Matwiy3, 
Kim Gaspar2, John Docherty2, Don Segal2 
1Drug Development, Helix Biopharma Corp/Canada, 
2Helix Biopharma Corp/Canada, 3NRC-Institute For 
Biodiagnostics/Canada
Background: Many solid human tumors generate 
an acidic and hypoxic microenvironment due to 
altered metabolic pathways and aberrant tumor 
vasculature. These acidic conditions reportedly 
activate proteases which digest the extracellular 
matrix and allow phagocytosis of non-tumor cells, 
leading to invasiveness and metastatic behaviour. 
In has been suggested that tumor acidosis affects 
chemotherapy by promoting resistance to (i) weakly 
basic chemotherapeutic agents by altering their 
intracellular/extracellular partition coefÀcient and 
(ii) radiation therapy by suppressing early steps 
of apoptotsis and reducing the degree of radiation 
induced Àxation. LDOS47, an immunoconjugate 
cancer therapeutic, targets this unique tumor 
microenvironment by localizing urease to lung 
tumor using a speciÀc antibody. Urease coverts the 
abundant metabolite urea to ammonia, increasing the 
local pH and exerts a cytotoxic effect on cancer cells 
in culture and xenograft models. 
Methods: Production LDOS47: LDOS47 is 
constructed by covalently linking a single urease 
hexamer to AFAIKL2 (a recombinant camelid 
single domain antibody directed against CEACAM6 
(Carcinoembryonic antigen-related cell adhesion 
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Conclusion: The ability of lovastatin to target 
multiple stress pathways enhances its ability to 
co-operate with geÀtinib enhancing the potential 
therapeutic beneÀt of this combination of agents.
Keywords: lovastatin, LKB1/AMPK, metabolic 
stress
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.028 MECHANISM(S) OF ACTION 
AND POTENCY OF HSP90 INHIBITOR 
GANETESPIB IN SMALL CELL LUNG 
CARCINOMA CELLS
Dae Ho Lee, Chien-Hao Lai, Yisong Wang, Giuseppe 
Giaccone 
Mob, Nci/nih/United States Of America
Background: Ganetespib (formerly STA-9090, 
Synta Pharmaceuticals) is a second generation 
Hsp90 inhibitor, which is a resorcinol-containing 
compound with a novel structure that is unrelated to 
the geldanamycin class of Hsp90 inhibitors. It binds 
to the ATP-binding domain of Hsp90 and is a potent 
Hsp90 inhibitor through degradation of Hsp90 client 
onco-proteins in cancer cells. At low nanomolar 
concentrations, ganetespib potently inhibits cell 
proliferation and induces apoptosis in a variety of 
cancer cell lines including many receptor tyrosine 
kinase inhibitor- and 17-AAG (geldanamycin class 
of Hsp90 inhibitor)-resistant cell lines, and in several 
tumor xenograft models. Based on preclinical 
activity of other Hsp90 inhibitors, small cell lung 
cancer appears like a promising tumor target for this 
class of agents.
Methods: IC50 was determined by MTS assay 
according to the manufacturer’s instructions. Cell 
cycle proÀling and cell viability were analyzed by 
Áow cytometry on propidium iodide stained cells 
and by trypan blue exclusion on Auto T4 Cellometer 
(Nexcelom Bioscience) respectively.
Results: Using 12 small cell lung carcinoma (SCLC) 
cell lines, we demonstrate that ganetespib (IC50: 
30.9+ 16.6 nM) is much more potent than 17-AAG 
(IC50: 16+47 uM) in MTS assays. In addition, at 
the concentrations of IC50 or 3-60 times over IC50, 
ganetespib exhibits cytostatic effect by arresting cells 
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P2.027 LOVASTATIN INDUCES 
METABOLIC STRESS THROUGH LKB1/
AMPK ACTIVATION: POTENTIAL 
THERAPEUTIC IMPLICATIONS
Laurie Ma, Nima Niknejad, Jim Dimitroulakos 
Cancer Therapeutics, Ottawa Hospital Research 
Institute/Canada
Background: Cellular stress responses trigger 
signaling cascades that inhibit proliferation and 
protein translation to help alleviate the stress or if 
the stress cannot be overcome induce apoptosis. 
In recent studies, we demonstrated the ability of 
lovastatin, an inhibitor of mevalonate synthesis, 
to induce the integrated stress response as well as 
inhibiting epidermal growth factor receptor (EGFR) 
and AKT activation. In this study, we evaluated the 
effects of lovastatin on the activity of the AMPK/
LKB1 pathway that is activated upon cellular energy 
shortage and can interact with the above pathways.
Methods: The activity of LKB1 and AMPK were 
assessed employing phosphospeciÀc antibodies 
to these proteins and visualized through Western 
blot analysis. Affects on tumour cell cell viability 
coincident with lovastatin and metformin treatments 
were determined by the MTT assay. ADP/ATP ratios 
were also determined following treatments. Cell 
lines evaluated included NSCLC, squamous cell 
carcinomas and murine embryonic Àbroblasts, both 
wild type and gene knockout LKB1 variants.
Results: In the NSCLC and squamous cell carcinoma 
cell lines , lovastatin treatment (1-25microM, 24hrs) 
induced LKB1 and AMPK activation similar to 
metformin (1-10nM, 24hrs), an inducer of this 
pathway. Lovastatin treatment also decreased 
cellular ADP/ATP ratios, a trigger for LKB1/AMPK 
activation. The cytotoxic effects of lovastatin were 
attenuated in LKB1 null MEFs indicating a role 
for this pathway in regulating lovastatin-induced 
cytotoxicity. Similarly, in the LKB1 deÀcient cells, 
the cytotoxic effects of both lovastatin and metformin 
were also attenuated. Of clinical relevance, lovastatin 
induces synergistic cytotoxicity in combination with 
the EGFR inhibitor geÀtinib. In two LKB1 deÀcient 
(A549, HeLa) and expressing (SCC9, SCC25) cell 
lines, metformin enhanced geÀtinib cytotoxicity 
that was limited to the expressing cell lines while 
both groups showed enhanced cytotoxic effects with 
lovastatin treatments.
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A549 and SW1573 NSCLC cells displaying IC
50
 
values of 12.6, 8.7 and 1.7 nM, respectively. In 
addition, we established a model for acquired 
bortezomib resistance in these cells by exposing 
cells to gradually increasing concentrations of 
bortezomib starting from 5nM to 80 or 200 nM 
for H460, 40 or 100 nM for A549 as well as 30 or 
150 nM for SW1573. These bortezomib-resistant 
cell lines, named H460BTZR
80
, H460BTZR 
200
, 
A549BTZR 
40
, A549BTZR
100
, SW1573BTZR
30
 and 
SW1573BTZR
150
, displayed 8 to 70- fold bortezomib 
resistance. Expression of the proteasome subunits 
was determined by Western blot. Proteasome activity 
was examined using a cell based proteasome activity 
assay and in gel digestion of the suc-LLVY-amc 
substrate. FACS analysis was used to determine cell 
cycle analysis. Furthermore, sequence analysis was 
performed to detect mutations in the ơ5 subunit. In 
addition, other proteasome inhibitors were used to 
examine cross resistance in the bortezomib-resistant 
cells.
Results: Examinations into the mechanisms of 
intrinsic bortezomib resistance revealed that high 
basal chymotrypsin- and caspase-like proteasome 
activities are correlated with intrinsic bortezomib 
resistance in wild type cell lines (R2=0.99, P<0.05). 
However, no marked differences were detected 
in the expression levels of the ơ5-subunits of 
the proteasome. Characterization of the acquired 
bortezomib-resistant cells showed that higher 
bortezomib concentrations were required to 
accumulate ubiquitinated proteins, induce G2/M 
cell cycle arrest and cell death when compared to 
their parental counterparts. Overall the amount 
of cell death reduced even at higher bortezomib 
concentrations when compared to parental cells 
treated with equitoxic drug doses. Furthermore, 
augmented levels of the constitutive ơ-subunits and 
the Ơ7 subunit were detected in bortezomib-resistant 
cells which corresponded to increased formation of 
the proteasome. However, basal proteasome activity 
was markedly reduced in bortezomib-resistant cells 
when compared to the parental cells. Moreover, 
sequence analyses of the bortezomib binding pocket 
encoded by exon 2 of the PSMB5 gene revealed 
Ala49Thr, Met45Val and Cys52Phe mutations which 
have never been described for solid tumor cells. 
Additionally, we observed cross-resistance to other 
proteasome inhibitors that speciÀcally target the 
ơ-subunits of the proteasome. Interestingly, no cross-
resistance was found to 5-amino-8-hydroxyquinoline 
(5AHQ), a novel non-competitive proteasome 
at G2/M on all the SCLC cell lines studied so far. 
Cells survive for as long as 6 days in the presence of 
ganetespib. Intriguingly, cell viability precipitously 
drops upon ganetespib withdrawal following 48-72 
h treatment. We are investigating the mechanism of 
cell death occurring after drug withdrawal (mitotic 
catastrophe after release from G2 arrest or cell death 
in the next cell cycle). In addition we are evaluating 
the molecular mechanism(s) of ganetespib action in 
xenograft models of SCLC.
Conclusion: Our study suggests that ganetespib is a 
potent inhibitor of SCLC cell growth via induction 
of G2/M arrest. The fact that ganetespib withdrawal 
induces precipitous cell death suggests that 
ganetespib intermittent treatment strategy might be 
considered for the ongoing phase II studies in SCLC.
Keywords: Ganetespib, Hsp90 inhibitor, SCLC
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P2.029 MECHANISMS OF ACQUIRED 
BORTEZOMIB RESISTANCE IN 
NON-SMALL CELL LUNG CANCER: 
OVEREXPRESSION OF THE 
PROTEASOME AND MUTATIONS IN THE 
ȕ5 PROTEASOME SUBUNIT.
Leonie H.A.M. De Wilt1, Gerrit Jansen2, Yehuda G. 
Assaraf3, Johan Van Meerloo4, Jacqueline Cloos4, 
Aaron D. Schimmer5, Godefridus J. Peters1, Frank 
A.E. Kruyt6 
1Medical Oncology, VU University Medical Center/
Netherlands, 2Rheumatology, VU University Medical 
Center/Netherlands, 3Technion-israel Institute Of 
Technology/Israel, 4Pediatric Oncology/Hematology, 
VU University Medical Center/Netherlands, 
5Princess Margeret Hospital/Canada, 6University 
Medical Center Groningen/Netherlands
Background: The proteasome inhibitor bortezomib 
(Velcade®) is registered for the treatment of 
multiple myeloma and is being investigated for 
activity in solid tumors such as non-small cell 
lung cancer (NSCLC). Bortezomib predominantly 
inhibits proteasome subunit ơ5 and mutations in this 
subunit were recently associated with bortezomib 
resistance in leukemic cell line models. We studied 
the molecular mechanisms underlying intrinsic and 
acquired bortezomib resistance in NSCLC cells. 
Methods: A panel of NSCLC with differential 
intrinsic bortezomib sensitivities was used; H460, 
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silencing (si)-RNAs or negative control si-RNA for 2-6 
days to measure the effect of speciÀc SFK inhibition on 
cell proliferation and signal transduction. EGF served 
as the ligand to trigger EGFR. Cell proliferation was 
measured using Calcein AM added during the last 2 
hours of culture. Signal transduction was measured 
by Western blotting with speciÀc antibodies directed 
against phosphorylated amino acids of signaling 
molecules such as anti-EGFR Y845 or Y1068 of 
protein lysates separated on SDS-PAGE. 
Results: Our Àndings revealed the promiscuity 
of EGFR in association and dimerizations with 
other receptor chains including erbB3, erbB2, and 
c-Met. Heterodimerization with EGFR led to their 
activation by EGFR as revealed by phosphorylation 
on activation sites and Inhibition thereof with 
EGFR kinase inhibitors. SFK were determined to 
be critical to the constitutive activation process as 
the pan-src family kinase inhibitor PP2 inhibited 
EGFR phosphorylation. In the constitutively 
activated Calu3 cell line, Lyn a SFK known for its 
critical role in B-cell lymphomas was found to be 
expressed and was determined to be critical to the 
activation of EGFR. Immunoprecipitation studies 
revealed that Lyn was present in a complex with its 
regulatory proteins Cbp, Lsk, along with RACK1, a 
component of lipid rafts in cell membranes. Silencing 
(si)-RNA experiments demonstrated that the loss of 
Lyn translation and decreased expression resulted in 
decreased phosphorylation of EGFR and decreased 
cell proliferation. Lyn si-RNA further down-regulated 
ligand mediated- EGF signaling as evidenced by 
decreased EGFR and c-Met phosphorylation. 
Conclusion: Constitutive activation of EGFR 
in NSCLC cells that lack activation mutations is 
driven by SFK. In Calu3 cells Lyn is responsible for 
EGFR activation and downstream signaling. Lyn 
was found in complexes with src-kinase regulatory 
proteins and RACK1. RACK1, a component of 
lipid rafts, probably serves as scaffolding in tumor 
cell membranes for an EGFR-Lyn activation unit 
which is responsible for its constitutive activation. 
Drawing other growth factor receptors into these 
membrane units result in a signiÀcant expansion of 
growth pathways triggered. Preventing constitutive 
activation of EGFR with a SFK inhibitor in 
conjunction with EGFR TKI inhibitors would 
prevent its association with other growth factor and 
dramatically decrease the signaling pulse driving 
NSCLC cell survival. 
Keywords: Src family kinase, c-Met, si-RNA, 
EGFR activation
inhibitor that targets the Ơ-subunit. 
Conclusion: Taken together, these Àndings establish 
a correlation between bortezomib-sensitivity and 
low basal levels of proteasome activity. In addition, 
acquired resistance to bortezomib in NSCLC was 
associated with increased proteasome formation 
and mutated ơ5-subunits that may compromise 
bortezomib binding as well as the binding of 
protein substrates. Furthermore, Ơ-subunit-speciÀc 
proteasome inhibitors can efÀciently used to bypass 
bortezomib resistance. 
Keywords: bortezomib resistance, ơ5 proteasome 
subunit, Mutations
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P2.030 ROLE OF SRC FAMILY KINASES 
(SFK) IN THE CONSTITUTIVE 
ACTIVATION OF THE EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) 
IN NON-SMALL CELL LUNG CANCER 
(NSCLC) CELL LINES.
Janet M.D. Plate1, Marcherie L. Davis1, Christina L. 
Fhield2, Jeffrey A. Borgia2, Parnetta Sutton1, Philip 
Bonomi1 
1Medicine, Division Of Oncology & Hematology, 
Rush University Medical Center/United States Of 
America, 2Biochemistry, Rush University Medical 
Center/United States Of America
Background: Constitutive activation of EGFR 
signaling has a prominent role in driving NSCLC 
tumor cell proliferation. Gene mutations, 
ampliÀcation and overexpression of EGFR account 
for some but not all cases of its constitutive 
activation. In preclinical studies we investigated 
signaling pathways to determine the mechanisms 
of EGFR constitutive activation in the absence of 
its mutation, ampliÀcation and overexpression in a 
representative NSCLC line, Calu3. Other NSCLC 
cell lines were surveyed including one with both an 
activating and TKI resistance mutation, H1975.
Methods: Protein lysates were prepared from NSCLC 
cancer cell lines obtained from and cultured according 
to ATCC guidelines. These lysates were used for 
immunoprecipitations, Western blotting and luminex 
bead assays. Cells were cultured with medium alone or 
in a variety of kinase inhibitors including EGFR, c-Met, 
and SFKs before lysates were harvested. Cells were 
transfected with a pool of either four Lyn gene targetted 
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resistance to bortezomib and other non-toxic agents. 
SAHA may prove effective in novel treatment 
combinations.
Keywords: apoptosis, 3D cell culture, mitochondria, 
Chemotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.032 THE EFFECTS OF VITAMIN D 
ON THE TUMORIGENESIS OF LUNG 
SQUAMOUS CELL CARCINOMA IN 
A CARCINOGEN INCDUCED MOUSE 
MODEL.
Sarah A. Mazzilli1, Mary E. Reid2, Barbara A. 
Foster1, Donald L. Trump2, Candace S. Johnson1 
1Pharmacology & Therapeutics, Roswell Park 
Cancer Institute/United States Of America, 
2Department Of Medicine, Roswell Park Cancer 
Institute/United States Of America
Background: Lung cancer accounts for the majority 
of cancer mortality. The need for further knowledge 
for prevention and treatment of lung cancer is 
crucial as no preventive agents and few screening 
guidelines have been established for lung cancer. 
Epidemiological studies indicate that low serum 
levels of 25(OH)D3 are strongly associated with 
increased risk and poor prognosis of lung cancer. 
In addition, calcitriol, the active metabolite of 
vitamin D, induces cell cycle arrest, apoptosis and 
differentiation with few toxicities, which makes 
vitamin D an attractive agent for chemoprevention of 
lung cancer. To investigate the preventive effects of 
vitamin D on lung SCC pre-clinical studies are being 
conducted using a carcinogen-induced (CI) mouse 
model of lung SCC. The CI model uses N-nitroso-
tris-chloroethylurea (NTCU) applied topically to the 
back of a SWR/J mouse twice weekly. Following 
15 weeks of NTCU treatment, these mice begin 
to develop bronchial epithelial hyperplasia and 
with time disease progresses through metaplasia, 
carcinoma in situ, and ultimately forming lung SCC 
by approximately 35 to 40 weeks. Previous studies 
by Yian Wang et al. demonstrate that 100% of 
SWR/J mice develop microinvasive lung SCC by 40 
weeks; no other histologies are noted.
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P2.031 SAHA SENSITIZES 
MESOTHELIOMA SPHEROIDS TO 
BORTEZOMIB-INDUCED APOPTOSIS 
BY RESTORING LEVELS OF PRO-
APOPTOTIC NOXA.
Dario Barbone1, Daniel B. Longley2, Dean A. 
Fennell2, V. Courtney Broaddus1 
1Lung Biology Center, UCSF/United States Of 
America, 2CCRCB, Queen’s University Belfast/
United Kingdom
Background: Mesothelioma displays a stubborn 
chemoresistance that can be modeled in 3D cell 
culture (spheroids) where cells acquire multicellular 
resistance to chemotherapy. Acquired multicellular 
resistance of spheroids is mediated by the Bcl-2 
family of proteins at the level of mitochondria, 
where apoptotic signals are integrated and executed. 
Proteasome inhibitors, such as bortezomib, are 
thought to induce apoptosis via the alteration of 
Bcl-2 protein expression. We considered that the 
underlying molecular mechanism of bortezomib 
resistance could be studied in 3D spheroids.
Methods: We asked whether mesothelioma 
spheroids were resistant to bortezomib and if so, 
whether resistance derived from the Bcl-2 repertoire 
of mesothelioma spheroids. We then investigated 
ways to restore the apoptotic sensitivity of spheroids 
to bortezomib.
Results: Mesothelioma cells grown as spheroids 
acquired resistance to bortezomib and, compared to 
cells in monolayers, showed a lack of upregulation 
of pro-apoptotic Noxa. Among many agents tested, 
SAHA, a histone deacetylase inhibitor, was able 
to restore Noxa protein levels in spheroids upon 
treatment with bortezomib and eliminated all 
acquired multicellular resistance. Ablation of Noxa 
by siRNA conÀrmed that SAHA sensitization of 
bortezomib-induced apoptosis relies on Noxa. 
Furthermore, while it did not induce signiÀcant 
apoptosis when given alone, SAHA proved to be 
very effective in 3D when combined with other non-
toxic agents such as ABT-737 (a Bcl-2 inhibitor) 
and tunicamycin (an inducer of the unfolded protein 
response), suggesting new intriguing avenues to treat 
mesothelioma.
Conclusion: In sum, studying 3D mesothelioma 
spheroids allowed us to uncover a potentially 
therapeutic role for SAHA in ablating multicellular 
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P2.033 EVIDENCE OF SIGNIFICANT 
EFFICACY OF THE ONCOLYTIC VIRUS, 
REOVIRUS, FOR THE TREATMENT OF 
LUNG CANCER
Amelia Kellar1, Natalie Ronaghan1, Zhong qiao Shi1, 
Chandini Thirukkumaran1, Don Morris2 
1Oncology, University Of Calgary/Canada, 
2Medicine, University Of Calgary/tom Baker Cancer 
Centre/Canada
Background: Lung cancer is the leading cause of 
cancer mortality worldwide. It is estimated that 
approximately 1,529,560 people were diagnosed 
with cancer in 2010, resulting in approximately 
569,490 deaths. Surgical resection and aggressive 
chemotherapies prove to be only marginally effective 
as Àve-year survival ranges from 13% in men and 
17% in women. Reovirus (RV), a double-stranded 
RNA virus, has been shown to be effective against a 
myriad of cancers through its ability to preferentially 
lyse cancer cells with aberrant Ras or other pathway 
signaling. In this study, we investigate the potential 
of RV (serotype 3, strain Dearing) as a novel 
treatment for both non-small cell and small-cell lung 
cancer in vitro and in vivo. 
Methods: RV-induced cytotoxicity was assessed 
by WST-1 viability assays for both NSCLC cell 
lines: (A549, H460, H1299, HCC4006, H1975, 
H226, HCC827, HCC2935) and SCLC cell lines: 
(DMS-53, and H69) in vitro. RV and chemotherapy 
combination studies were conducted for the DMS-
53, H69, HCC827 and H226 cell lines, evaluating 
the cytotoxic effects of reovirus in combination 
with each of the following: cisplatin, pemetrexed, 
etoposide, and erlotinib using the constant-ratio 
design and combination index method of Chou 
Talalay. In order to further evaluate the potential 
of RV as novel therapeutic for lung cancer, three 
xenograft models (H460, H1299 and DMS-53) were 
utilized to test RV-induced cytotoxicity alone and in 
combination with chemotherapy in vivo. 
Results: RV induces cytotoxic effects at a 
multiplicity of infection (MOI) of 40 within 48h 
for both NSCLC cell lines: (A549, H460, H1299, 
HCC4006, H1975, H226, HCC827, HCC2935) 
and SCLC cell lines: (DMS-53, and H69) in 
vitro. These Àndings are particularly unique for 
SCLC, in that effective therapies are limited. 
Interestingly, preliminary data also suggests that RV 
Methods: We are investigating the effects of 
vitamin D on cancer progression in the CI model 
by examining the effects of a vitamin D deÀcient 
diet, as well as a a sufÀcient diet with weekly 
intraperitoneal (IP) injections of calcitriol (80 ug/
kg). Disease state is determined by histological 
evaluation using hematoxylin and eosin staining and 
immunohistochemical staining of cytokeratin 5/6 and 
p63. Changes in vitamin D receptor (VDR) status 
and the expression of VDR regulated genes and 
proteins involved in cell cycle arrest, apoptosis and 
differentiation are being examined.
Results: AAnimals treated with NTCU and are on a 
vitamin D deÀcient diet, sufÀcient diet or sufÀcient 
diet with IP of calcitriol, have average serum 25(OH)
D3 levels of 15 nmol/L, 70 nmol/L and 75 nmol/L 
respecitvly. The average serum level of a mouse 
on a normal mouse chow is 70- 90 nmol/L, thus 
demonstrating that the mice on a deÀcient diet are 
deÀcient. The NTCU treated mice who were on a 
diet sufÀcient in vitamin D and received calcitriol 
maintain their weight and are better groomed 
than mice on a sufÀcient diet who did not receive 
calcitriol and even more so than those on the 
deÀcient diet. Preliminary histological evaluation 
of the NTCU treated sufÀcient groups at 15 weeks 
indicated the presence of bronchial epithelial 
hyperplasia regardless of calcitriol treatment. The 
histology of lungs from the NTCU treated mice on 
the vitamin D deÀcient mice taken at approximately 
15 weeks of treatment, revealed more advanced 
disease (hyperplasia, metaplasia and carcinoma in 
situ) than those on a sufÀcient diet alone.
Conclusion: This study indicates that mice deÀcient 
in vitamin D may develop disease at a more rapid 
rate. These studies provide evidence that vitamin D 
status may play an important role in progression of 
lung SCC. Supported by NIH/NCI R01-CA-067267.
Keywords: Lung Squamous Cell Carcinoma, Pre-
Clinical study, Vitamin D
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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similar in a range of MM cells, and siRNA-mediated 
knockdown led to > 90% knockdown of mRNA and 
growth inhibition. YM155 treatment led to growth 
inhibition in all cell lines tested. Interestingly, 
toxicity was more pronounced in cell lines of 
epithelioid origin (IC50 from 1 to 12 nM) than those 
derived from biphasic tumours (IC50 175 and 810 
nM). Expression analysis revealed no signiÀcant 
differences in mRNA levels of any IAP family in 
any of the cell lines, but there was a general trend 
towards lower OCT1 and higher ABCB1, ABCG2, 
ABCA6 and ABCA10 expression in the biphasic 
lines. Further studies with speciÀc inhibitors and 
siRNA-mediated knockdown of these transporters 
revealed their involvement in YM155 toxicity.
Conclusion: YM155 is effective in inhibiting growth 
of MM cells, with cells of epithelioid origin more 
sensitive. Biphasic cell lines display higher ABC 
transporter expression and were more resistant to 
YM155 suppression of survivin. Further pre-clinical 
testing is needed to determine whether YM155 is a 
potential therapeutic option for epithelioid MM.
Keywords: Malignant mesothelioma, survivin, ABC 
transporters
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P2.035 SILENCING OF TYMS AND 
PLK1 SENSITISES MALIGNANT 
MESOTHELIOMA CELLS TO 
GEMCITABINE
Glen Reid1, Sumedha Gattani1, Michaela B. 
Kirschner1, Lyn J. Schedlich1, Rayleen Bowman2, 
Kwun M. Fong2, Nico Van Zandwijk1 
1Asbestos Diseases Research Institute, University 
Of Sydney/Australia, 2Department Of Thoracic 
Medicine, The Prince Charles Hospital/Australia
Background: Pemetrexed with cisplatin is 
considered the chemotherapy standard for 
malignant mesothelioma (MM). The antimetabolite 
gemcitabine has also demonstrated some activity 
in MM. In other solid tumours the cytotoxicity 
of gemcitabine is increased by inhibiting DNA 
damage checkpoints. We have used RNAi to identify 
gemcitabine sensitising genes in MM.
Methods: We used an RNAi-based chemogenetic 
screen to investigate the ability of 100 genes 
to modulate the sensitivity of MM cell lines to 
gemcitabine treatment. In the primary screen, cells 
in combination with chemotherapy has potentially 
synergistic cytotoxic effects in vitro. In addition, 
current xenograft data indicates that both the H460 
and H1299 cell lines are intrinsically sensitive to RV 
in vivo. Updated results will be presented. 
Conclusion: These preclinical results suggest that 
RV holds promise as a novel therapeutic for both 
non-small cell and small cell lung cancer and that 
it warrants further investigation in clinical trials. 
There is currently a phase III clinical trial for RV 
in combination with carboplatin for the treatment 
of NSCLC. These results may suggest that other 
combinations should be examined and that RV may 
have the potential to revolutionize therapy for SCLC. 
Keywords: Chemotherapy, Reovirus, Non-small cell 
lung cancer, Small-cell lung cancer
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P2.034 THE INHIBITOR OF SURVIVIN 
EXPRESSION, YM155, SHOWS SUBTYPE-
SPECIFIC ACTIVITY IN MALIGNANT 
MESOTHELIOMA CELLS
Lyn J. Schedlich1, Sumedha Gattani1, Nico Van 
Zandwijk1, Glen Reid2 
1Asbestos Diseases Research Institute, University Of 
Sydney/Australia, 2*, Asbestos Diseases Research 
Institute, University Of Sydney/Australia
Background: Survivin is a member of the 
inhibitor of apoptosis (IAP) family of proteins. 
Through inhibition of caspase activity, it is a 
negative regulator of apoptosis. Expressed highly 
in most tumours, including mesothelioma, but not 
in normal tissues, survivin is a target for cancer 
therapy. YM155 is a small molecule that selectively 
suppresses survivin expression at the transcription 
level. It inhibits growth of a range of tumours, both 
in vitro and in vivo, and is currently being tested in 
early clinical trials. This molecule has not yet been 
investigated in malignant mesothelioma (MM).
Methods: The mRNA expression of survivin, other 
IAPs, and genes related to YM155 toxicity were 
measured by RT-pPCR in a series of MM cell lines. 
The importance of survivin in the same cell lines 
was assessed by proliferation and cell cycle analysis 
following siRNA-mediated knockdown. Growth 
inhibitory effects of YM155 were measured by 
standard proliferation assays.
Results: Survivin mRNA expression was found to be 
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United States Of America
Background: The EGFr inhibitors (e.g. Tarceva) 
have been effective in preventing cancer in multiple 
animal models including lung cancer, ER+ and ER- 
breast cancer, head and neck and urinary bladder 
cancer. Although Tarceva is less toxic than most 
classical cytotoxic therpaies,, the development 
of a skin rash in >50% of patients is a signiÀcant 
impediment to its use in an adjuvant setting or any 
preventive setting. We therefore tested whether 
alternative dosing regimens would still achieve 
efÀcacy in a preclinical model.
Methods: Female Sprague Dawley Rats were 
administered a single IV dose of methylnitrosourea 
at 50 days of age. Prevention Study: Beginning 5 
days later rats were administered Tarcebva (6 mg/
KgBW) by gavage. In the Àrst study three proteocls 
were employed : 1) dosing with Tarceva (6mg/
KgBW) 7 days per seek, 2) Dosing with Tarceva 
(6mg/KgBW) for 2 days followed by 2 days of 
vehicle treatment. 3) Weekly treatment with a 42 mg/
KgBW dose of Tarceva. Therapy Study: Beginning 
when palpable mammary tumors Àrst appeared 
(roughly 5-8 weeks after MNU) tumor bearing 
rats were randomized to treatments 1 or 3 above. 
Pharmacokinetic Study Following treatments 1 or 3 
listed above serum levels of Tarceva and an active 
hydroxylated metabolite were deterimened in the 
serum of tumor bearing rats.
Results: Prevention Study: Preventive treatments 
1 daily) 2 2days on/2 dasy off 3 weekly dosing 
reduced the multiplcity of tumors by 85%, 67% and 
89% respectively. They were even more effective 
in reducing total tumor volume [No of tumorsxsize 
of tumors]. Therapy Study: Therapeutic Studies 
1) daily (6mg/KgBW) 2) Weekly dosing [42 mg/
KgBW] both caused >50% reductions of tumor 
size over 42 days. In contrast tumor size increased 
>200% in vehicle treated controls. Pharmacokinetic 
Studies Determination of serumo levels of Tarceva 
and an active hydroxylated metabolite showed that 
following daily dosing active Tarceva levels were 
achieved for roughly 16 hours per day. In contrast 
for the weekly dosing effective serum levels were 
achieved for <54 hours. 
Conclusion: These data show that a profoundly 
altered dosing of Tarceva in a preclinical model is 
highly effective The results are surprising since the 
PK data would imply that we probably achieved 
effective serum levels for only 2-21/2 days out 
were transfected individually with 200 siRNAs (2 
per gene) at a Ànal concentration of 1 nM, and 24 
h later they were treated with 10 nM gemcitabine. 
Effects on proliferation were assessed and 
combination therapy was compared with siRNA and 
gemcitabine treatment alone. Hits from the primary 
screen were further investigated with a full dose 
response curve for gemcitabine.
Results: The knockdown of a several genes 
sensitised MM cell lines to gemcitabine. This 
included genes previously shown to be involved in 
gemcitabine cytotoxicity, such as CHK1, RRM1 and 
RRM2. RRM1 knockdown increased gemcitabine 
sensitivity by 4- to 5-fold, and CHK1 and RRM2 
knockdown reduced IC50 values by 2- to 2.5-fold. 
As expected the inhibition of DCK1, the kinase 
responsible for phosphorylation of gemcitabine 
to its active form, led to 3-fold resistance of cells 
and provides internal validation of the assay. 
Interestingly, PLK1 and TYMS silencing also 
increased the toxicity of gemcitabine by greater 
than 2-fold. This phenomenon was seen in all MM 
cell lines but was not observed in the lung cancer 
cell line A549. Additional studies investigating the 
combination of small molecule inhibitors of these 
target genes with gemcitabine will be presented.
Conclusion: A chemogenetic RNAi-based screen 
identiÀed a number of genes involved in the 
sensitivity of MM cells to gemcitabine. Small 
molecules speciÀc for these targets can be combined 
with gemcitabine and warrant further testing in pre-
clinical models. Similar screens could be used to 
identify targets to synergise with pemetrexed and 
cisplatin, and could lead to new treatment options for 
MM.
Keywords: gemcitabine, polo-like kinase, Malignant 
mesothelioma
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P2.036 ALTERNATIVE DOSING 
REGIMENS WITH TARCEVA IN A 
PRECLINCAL BREAST CANCER 
MODEL: EFFECTS ON EFFICACY AND 
POTENTIAL EFFECTS ON TOXICITY. 
IMPLICATIONS FOR LUNG CANCER 
TREATMENT
Ronald A. Lubet1, Eva Szabo1, Clinton J. Grubbs2 
1Div. Of Cancer Prevention, National Cancer 
Institute (USA)/United States Of America, 2Dept Of 
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Cell Lung Cancers We employed an adenovirus Cre 
virus to speciÀcally knock out in lung Áoxed copies 
of both TrpP53 and RB1. This model was initially 
developed by Meuwissen and co workers [2003]. 
Adenovirus Cre Virus was administered to mice 
via the trachea. Mice develop multiple dysplasias 
within 5 months following virus treatment and 
large small cell lung cancers within 7-9 months. 
In the present study mice were treated with the 
RXR agonist Bexarotene beginning at the time of 
treatment with the Adenovirsu Cre virus at a dose 
of 1000mg/KgBW per day 5 days per seek. Animals 
were kept for a period of 9 mosths foloowing 
traeatment with adeno-Cre virus and sacriÀced 
at that time. Tumor incidence and size were 
determined at sacriÀce.
Results: Therapeutic Study Of Adenocarcinomas. 
At the time that Bxarotene treatment was intiated 
most mice had multiple adenomas and possibly 
an ocassional microscopic adenocarcinoma. 
Twelve weeks of treatment at this more treatment 
decresed the imultiplicity of adenomas roughly 
40%, tumor volume 50% and reduced development 
of adenocarcinomas >50%. Prevention sTudy 
Of Bexarotene In Samll Cell Lung Cancer: 
Exposure of mice to bexarotene beginning at the 
time of exposure to the Adenovirus-Cre virus 
administration resulted in profound prevention 
of development of small cell lung cancer. Tumor 
multiplcity was decreased roughly 80% and tot al 
tumor volume[multiplcity x size] was decreased 
almost 90%. 
Conclusion: Bexarotente wa relatively effective 
in blocking the growth and progression of lung 
tumors (adenomas/adenocarcinomas) when 
initated at a time when adenomas already exist. 
The agent appeared relatively effective in blocking 
progression of these tumors . Furthermore 
Bexarotene was effective in preventing the 
development of small cell lung cancer in a 
transgenic model in which an Adenovirus -Cre 
virus is used to KO P53 and RB1 in Áoxed mice. 
The efÀcacy of this agent must be determined when 
treatment is intiated at later time periods.
Keywords: Small cell lung cancer, transgenic 
model, RXR agonist (Bexarotene)
of 1 week. The more important clinical question, 
which we cannot address in animals, is whether 
this alternative dosing may strikingly decrease the 
rash which is associated with Tareceva treatment in 
humans. This will have to be addressed clinically but 
may have impliications for the use of this agent both 
in adjuvant and potentially preventive settings. 
Keywords: EGFr Inhibitors, Prevention, Altered 
Dosing
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P2.037 EFFICACY OF THE RXR AGONIST 
BEXAROTENE IN PRECLINICAL 
MODELS OF ADENOCARCINOMA OF 
THE LUNG AND SMALL CELL LUNG 
CANCER
Yian Wang1, Ronald A. Lubet2, Ming You3 
1Department Of Surgery, Washington University 
School Of Medicine/United States Of America, 2Div. 
Of Cancer Prevention, National Cancer Institute 
(USA)/United States Of America, 3Head Cancer 
Center, Medical College Of Wisconsin Cancer 
Center/United States Of America
Background: The RXR agonist Bexarotene is 
effective in the prevention and lung adenomas in 
the standrd A/J model of lung adenoma formation. 
Furthermore it has shown activity in NSCLC in 
clinical settings as well. We examined the efÀcacy 
of Bexarotene in two models of lung cancer in mice 
. In the Àrst model vinyl carbamate is employed 
in A/J mice with a grem line P53 mutation which 
then develop both adenomas and adenocarcinomas 
with Ki Ras mutations i. In the second model a 
transgenic mouse with localized KO of both RB 
and P53 were employed to generatre mice with 
small cell lung cancer.
Methods: Treatment Of Lung Adenomas/
Carcinomas A/J mice bearing a a dominant 
negative P53 mutation . Six week old A/J mice 
were treated with vinyl carbamate i.p. At 16 
weeks after treatment with vinyl carbamate a time 
at which treated mice have multiple adenomas 
and potentially a limited number of microscopic 
adenocarcinomas they were treated for a period 
of 12 weeks (16-28 weeks post vinyl carbamate) 
with Bexarotene (100 mg/KgBW) by gavage on a 
daily basis. mice were sacriÀced at 28 weeks after 
dosing with vinyl carbamate. Prevention Of Small 
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Homology Domain 3 (BH3)-mimetic, such as ABT-
737, to eradicate the early resistant tumor cells that 
emerged in TKI evasion. 
Results: Using HCC827, PC-9 (erlotinib-sensitive) 
and H1975 (CL-387,785-sensitive) lung cancer 
cells under corresponding TKI treatments, we 
identiÀed and characterized the adaptive emergence 
of resistant survivor cells that functionally evaded 
targeted inhibitors early by day 9 in treatment. 
These early resistant tumor cells exhibited 
MET-independent BCL-2/BCL-XL prosurvival-
antiapoptotic signaling dependence, a cellular 
quiescence-like state, and TKI-resistant phenotype 
having IC
50
 viability as high as 100-fold above 
the parental cells. In vitro culture and in vivo 
xenograft model veriÀed that reactivated BCL-2/
BCL-XL signal path and its transcriptional activator 
p-STAT3[Y705] were present within the residual 
tumor survivor cells after initial tumor response to 
targeted TKI therapies. Finally, our study results 
showed that disrupting the mitochondrial BCL-2/
BCL-XL pathway machinery as “Achilles’ heel” of 
the HCC827 early survivor cells evaded erlotinib, 
using BCL-2 Homology Domain 3 (BH3)-mimetic 
such as ABT-737, eradicated the early-resistant 
tumor cells. RNAi studies veriÀed that dual RNAi 
knockdown of BCL-2/BCL-XL (but not BCL-2 
alone) recapitulated the results seen with ABT-737 
inhibition. Our in vivo HCC827-luc lung tumor 
xenograft assay with preemptive use of ABT-737 
in conjunction with EGFR inhibitor in NSCLC 
demonstrated that the “early” TKI-resistant tumor 
evader cells were susceptible to the BH3-mimetic 
and can be eradicated to ultimately achieve more 
durable response with prolonged remission. 
Conclusion: Taken together, our results revealed 
a role of reactivated STAT3, and BCL-2/BCL-XL 
as potential markers for early tumor resistance 
evading targeted inhibitors in lung cancer. We also 
provide evidence to support targeting the intrinsic 
BCL-2/BCL-XL antiapoptotic pathway machinery 
in the resistant evader cells using BH3-mimetic, 
which can overcome or prevent early resistance 
emergence against TKI. Further prospective clinical 
investigations using BH3-mimetic combined with 
targeted TKIs are warranted for optimized therapy 
and to impact on long-term clinical outcome. 
Keywords: erlotinib, Resistance, Bcl-2, ABT-737
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P2.038 TARGETING MET-INDEPENDENT 
EARLY-RESISTANT LUNG CANCER 
CELLS EVADING ERLOTINIB BY 
BH3-MIMETIC ABT-737 TO DISRUPT 
THE BCL-2/BCL-XL SIGNALING 
DEPENDENCE
Patrick C. Ma1, Weiwen Fan1, Zhe Tang2, Lihong 
Yin1, Rakesh Bagai2, Said Hafez-Khayyata3, Pingfu 
Fu4, Henry Koon2, Balazs Halmos5, Bei Morrison1 
1Translational Hematology And Oncology Research, 
Cleveland Clinic Taussig Cancer Institute/United 
States Of America, 2Medicine, Case Western Reserve 
University/United States Of America, 3Pathology, 
Case Western Reserve University/United States 
Of America, 4Biostatistics, Case Western Reserve 
University/United States Of America, 5Medicine, 
Columbia University/United States Of America
Background: The recent clinical use of epidermal 
growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) in lung cancer represents a new 
paradigm of personalized targeted cancer therapy. 
Nonetheless, molecularly-targeted therapy is still 
largely limited by the inevitable recurrent resistant 
disease even in initially responders, ultimately 
diminishing the impact on their long-term clinical 
utility. Both mutational (e.g. T790M-EGFR) and 
non-mutational mechanism (e.g. MET genomic 
ampliÀcation) have been found to partially 
account for acquired tumor resistance against 
small molecule EGFR-TKI after chronic exposure. 
Other resistant mechanisms enabling tumor cells 
to escape the efÀcacy of geÀtinib/erlotinib remain 
elusive. Better insights into previously unknown 
resistance mechanisms would be crucial to further 
discover novel therapeutic strategies to overcome 
therapeutic. 
Methods: With emphasis on early molecular 
changes within the residual tumor cells post-
treatment, we investigated drug-sensitive lung 
adenocarcinoma cell lines using EGFR inhibitors, 
alone or in combination with MET inhibitors, 
using both in vitro and in vivo short-term treatment 
models. We investigated the effects of EGFR-TKI 
treatment on Signal Transducer and Activator of 
Transcription 3 (STAT3) and B-cell lymphoma 
protein 2 (BCL-2)/BCL-XL family members in 
lung cancer cell lines and murine xenografts model. 
We also tested the therapeutic efÀcacy of BCL-2 
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Fevranoglou1, Aris Polyzos2, Kostas N. Syrigos1 
1Oncology Unit, University Of Athens, Medical 
School/Greece, 21st Department Of Medicine, 
University Of Athens, Medical School/Greece
Background: Angiogenesis has been proven to be 
a process related to the migration, proliferation and 
metastasis of cancer cells. Its predominant moderator 
is the VEGF which imposes its angiogenetic action 
through the transmembran receptors VEGFR1 and 
VEGFR2. The prognostic value of the measurement 
of these factors in the blood serum of patients is still 
controversial while their evaluation in the washing 
has not been studied sufÀciently. 
Methods: We try to deÀne the VEGF, VEGFR1 
and VEGFR2 and the ratios of VEGF/VEGFR1 
and VEGF/VEGFR2 in the blood serum and the 
bronchial washing of patients with newly diagnosed 
non-small cell lung cancer (NSCLC) and their 
correlation with the basic clinical characteristics of 
the patients and the tumors, the treatment response 
of those who had chemotherapy, the progression 
free survival (PFS) and the overall survival (OS) of 
the patients. We will also investigate the correlation 
of positive VEGF immunohistochemistry with 
concentration of angiogenic markers in serum and 
washing. Forty patients with newly diagnosed 
NSCLC participated in the current study. The 
measurement of the circulating and washing levels of 
VEGF, VEGFR1 and VEGFR2 was carried out with 
the sandwich enzyme-linked immunosorbent assay 
(ELISA). For immunohistochemistry we have used 
speciÀc anti- VEGF (Biogenex, San Ramon, CA). 
Results: Circulating VEGF levels is correlated with 
T descriptors in TNM staging system (Ƙ=0.021), 
as well as the ratio VEGF/VEGFR2 in serum and 
washing (Ƙ= 0.03. and Ƙ=0.040 relatively). From 
those who were treated with chemotherapy, best 
responses were observed in lower concentrations 
of VEGF in serum and washing (Ƙ<0.001). Higher 
concentrations of VEGF in washing are correlated 
with worse overall survival (HR 2.208, 95%CI 
1.132-4.308, P=0.020) and PFS (HR 2.265, 95%CI 
1.145-4.483, P=0.019). Similar results for OS and 
PFS were observed with high values of the VEGF/
VEGFR2 ratio in washing (HR 3.056, 95%CI 1.483-
6.297, P=0.002 for survival and HR 3.067, 95%CI 
1.508-6.236, P=0.002 for PFS). Multivariate Cox 
analysis revealed as independent markers for overall 
survival VEGFR2 levels in serum and washing 
(Ƙ=0.017 ƩƠƨ Ƙ=0.004 relatively), while for PFS 
independent markers were VEGFR1 (Ƙ= 0.004), 
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P2.039 EVALUATION OF KRAS GENE 
MUTATION AND COPY NUMBER GAIN 
IN NON-SMALL CELL LUNG CANCER
Hidefumi Sasaki, Katsuhiro Okuda, Yu Hikosaka, 
Satoru Moriyama, Motoki Yano, Yoshitaka Fujii 
Oncology, Immunology And Surgery, Nagoya City 
University Graduate School Of Medical Sciences/
Japan
Background: Recent studies for the characterization 
of the lung cancer genome have suggested that 
Kras gene was frequently ampliÀed and correlated 
with activating mutations of Kras, which occur in 
approximately 5-10% of Japanese lung cancers.
Methods: We analyzed Kras mutation and Kras copy 
number in 172 Japanese non-small cell lung cancer 
(NSCLC) cases and their relation to the survival of 
patients. We also studied using Áuorescence in situ 
hybridization (FISH) to provide direct evidence of 
Kras ampliÀcation in 40 clinical specimens.
Results: In 172 NSCLC cases, increased Kras copy 
number was existed in 19 (11.0%) cases. Increased 
Kras gene copy number was correlated with Kras 
mutation. However Kras gene copy number gain was 
not correlated with gender, pathological subtypes, 
stages and smoking status. Increased Kras copy 
number was not associated with overall survival 
in these 172 cases, however, increased Kras copy 
number plus Kras mutant patients were signiÀcantly 
worse prognosis when compared with the Kras 
wild type and Kras not increased patients. From 
the FISH analysis, Kras polysomy or ampliÀed 
patients showed signiÀcantly worse prognosis when 
compared to Kras disomy patients.
Conclusion: Kras mutation plus increased copy 
number was a predictor of poor clinical outcome in 
patients with NSCLC.
Keywords: Kras, Lung cancer, copy number, FISH
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P2.040 VASCULAR ENDOTHELIAL 
GROWTH FACTOR AND HIS 
RECEPTORS, VEGFR-1 AND VEGFR-2, IN 
AIRWAYS OF PATIENTS WITH NSCLC.
Andriani G. Charpidou1, Ioannis Gkiozos1, 
Anastasia Eleftheraki1, Manolis Gratsias1, Christina 
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inhibitor. The overall EGFR mutation rates 
of Korean patients were reported to be lower 
than in other East Asian countries. To provide 
comprehensive data of EGFR mutation status of lung 
cancer in Korea, The Cardiopulmonary Pathology 
Study Group of Korean Society of Pathologists 
initiated a nationwide survey.
Methods: We summarized 1,753 EGFR mutation 
reports from 15 hospitals made between January 
2009 and December 2009. We compared EGFR 
mutations with patient age, gender, history of 
smoking, histologic diagnosis, specimen type, 
procurement site, tumor cell dissection, and 
laboratory status.
Results: The overall EGFR mutation rate was 34.3% 
in non-small cell lung cancer. Adenocarcinoma 
histologic type showed a 43.3% EGFR mutation 
rate. EGFR mutation rates were signiÀcantly 
higher in woman, patients who never smoked, 
adenocarcinoma, and excisional biopsy specimen. 
EGFR mutation rates did not differ with patient age, 
laboratory status, tumor dissection, or procurement 
site.
Conclusion: EGFR mutation rates and status were 
similar to those in published data from other East 
Asian countries.
Keywords: lung, Cancer, Epidermal growth factor 
receptor, Mutation
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P2.042 URINE DIACETYLSPERMINE 
AS A NOVEL TUMOUR MARKER FOR 
LUNG CANCER
Masato Kato1, Nobuko Tsuruta2, Kazuyuki Higuchi2, 
Daiki Moriyama1, Nobusige Yamagata1, Koutarou 
Matsumoto1, Hiroyuki Konomi1, Masayuki Ookido1, 
Hitosi Ichimiya1 
1Surgery, Hamanomchi General Hospital/Japan, 
2Resipiratory Medicine, Hamanomchi General 
Hospital/Japan
Background: Serum carcinoembryonic 
antigen(CEA) , cytokeratin 19 
fragment(CYFRA21-1) and pro-gastrin-releasing 
peptide(Pro-GRP) have been used as tumour markers 
for non small cell lung cancers(NSCLC) and small 
cell lung cancer (SCLC). A novel urine tumour 
marker,diacetylspermine, was compared with the 
three conventional serum tumour markers in 308 
VEGF/VEGFR1 (Ƙ=0.033) and VEGF/VEGFR2 
(Ƙ=0.007) in washing. No correlation was noted 
between IHC-VEGF and circulating or washing 
angiogenic markers. 
Conclusion: The circulating VEGF levels are 
controversial. Nevertheless, the deÀnition of 
angiogenic markers in bronchial washing could 
recognize a high risk group of patients who could 
beneÀt from an aggressive initial therapeutic 
approach. 
Keywords: angiogenesis, prognostic markers, Non-
small cell lung cancer
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P2.041 EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATION ANALYSIS OF 
NON-SMALL CELL LUNG CANCER IN 
SOUTH KOREA: SUMMARY FROM A 
NATIONWIDE SURVEY
Wan-Seop Kim1, Yoo Duk Choi2, Jeong Wook Seo3, 
Joung Ho Han4, Mi Jin Kim5, Lucia Kim6, Geon 
Kook Lee7, Chang Hun Lee8, Mee Hye Oh9, Gou 
Young Kim10, Sun Hee Sung11, Kyo Young Lee12, 
Sun Hee Chang13, Mee Sook Rho14, Han Kyeom 
Kim15, Soon Hee Jung16, Se Jin Jang17 
1Pathology, Kunkuk University Medical Center/
Korea, 2Chonnam National University Medical 
School/Korea, 3Seoul National University College 
Of Medicine/Korea, 4Samsung Medical Center, 
Sungkyunkwan University School Of Medicine/
Korea, 5Yeungnam University College Of Medicine/
Korea, 6Inha University College Of Medicine/Korea, 
7National Cancer Center/Korea, 8Busan National 
University School Of Medicine/Korea, 9Cheonan 
Hospital, Soonchunhyang University College Of 
Medicine/Korea, 10Kyunghee University College 
Of Medicine/Korea, 11Ehwa Women’s University 
School Of Medicine/Korea, 12Seoul St. Mary’s 
Hospital, Catholic University Of Korea/Korea, 13Inje 
University Ilsan Paik Hospital/Korea, 14Dong-a 
University College Of Medicine/Korea, 15Korea 
University College Of Medicine/Korea, 16Yonsei 
University Wonju College Of Medicine/Korea, 17Asan 
Medical Center, University Of Ulsan College Of 
Medicine/Korea
Background: Epidermal growth factor receptor 
(EGFR) mutation analysis is a primary test for 
predicting the response to EGFR-tyrosine kinase 
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Conclusion: These results indicate that urinary 
DiAcSpm is a more sensitive marker than CEA, 
CYFRA21-1 and that it can efÀciently detect lung 
cancer at early stages.
Keyword: urine diacetylspermine, tumour marker, 
lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.043 THE POTENTIAL BIOLOGICAL 
ROLE OF FIBROBLAST GROWTH 
FACTOR-9 IN MALIGNANT 
MESOTHELIOMA
Ai Ling Tan1, Mulugeta Worku2, Helen Davies3, 
Eleanor Mishra3, Ross Sadler3, Jenette Creaney4, 
Sally Lansley1, Rob Davies3, Y. C. Gary Lee1 
1Pleural Disease Unit, Lung Institute Of Western 
Australia/Australia, 2University College London/
United Kingdom, 3University Of Oxford/United 
Kingdom, 4University Of Western Australia/Australia
Background: Malignant mesothelioma (MM) kills 
one patient every 4 hours in the UK and 800 patients 
each year in Australia. Currently, there are no 
effective treatments for MM and the median survival 
period is ~9 months. Identifying novel key molecules 
in the pathobiology of MM is urgently needed in 
order to develop new therapies and biomarkers. 
Methods: cDNA (Affymetrix) microarray was 
used to proÀle 22 prospectively-collected, well-
characterised human thoracoscopic pleural tissue 
biopsies to assess the differential regulation of 
genes in MM. The over-expression of novel genes 
in pleural biopsies was conÀrmed using RT-
PCR. Pleural Áuid FGF-9 levels in patients and 
cytokine levels from in vitro experiments were 
measured using commercially available ELISA 
kits. Proliferation was measured using a surrogate 
WST-1 assay while cell invasion was assessed using 
Matrigel assay.
Results: From our microarray data, we found that 
Àbroblast growth factor-9 (FGF-9) was the leading 
novel candidate gene with a median overexpression 
of 17 fold in MM over metastatic pleural carcinomas 
and benign pleuritis. The over-expression of FGF-
9 was conÀrmed in pleural biopsies from a second 
patients with lung cancer.
Methods: The series consisted of 308 patients with 
lung cancer who were treated in Hamanomachi 
General Hospita, Fukuoka, Japan from August 
2003 to September 2010. The 308 patients were 
199 men and 109 women and their age ranged 
from 25 to 89 years with a mean of 66.9±10.4 
years. 296 patients with NSCLC and 12 patients 
with SCLC were enrolled in this study. Urine 
diacetylspermine(DiAcSpm) , serum CEA, 
CYFRA21-1 and Pro-GRP were examined in 
these patients. A urine tumour marker, DiAcSpm 
was measured by using ELISA system, which was 
created by Transgenic Co.Ltd, Kumamoto, Japan. 
The cut off level was set at 325nmol/g Creatinine. 
The serum levels of CEA, CYFRA21-1 and Pro-
GRP were measured in the Clinical Laboratory of 
Hamanomchi General Hospital. Their cut-off levels 
were 5.0ng/ml, 3.5ng/ml and 45.9pg/ml respectively. 
The clinical stage of lung cancer was determined 
according to TNM ClassiÀcation of Lung Cancer by 
the IASLC 2009.The 98 patients were Stage IA, 68 
patients-Stage IB, 12 patients-Stage IIA, 20 patients-
Stage IIB, 41 patients-Stage IIIA, 39 patients-Stage 
IIIB and 30 patients-Stage IV, respectively. Mean 
values were compared by McNemar test and P<0.05 
was considered as statistically signiÀcant.
Results: The sensitivity of urine DiAcSpm 
was 46.4% and was higher than that of serum 
CEA(32.7%) and serum CYFRA21-1(23.7%). The 
speciÀcity of urine DiAcSpm(90.6%) was higher 
than that of serum CEA(85.7%) and lower than that 
of serum CYFRA21-1(93.7%). The sensitivity of 
urine DiAcSpm and other markers was compared 
among lung cancer patients grouped according 
to tumour stage. The proportion of positivies 
with respect to each marker increased with the 
progression of the cancer, but the sensitivity of 
DiAcSpm was higher than the snesitivities of CEA 
and CYFRA21-1 at every clinical stage. Especially, 
DiAcSpm was elevated in 48.2% of early-stage(stage 
IA+IB) lung cancers in patients , whereas 24.2% 
and 11.4% of these patients were CEA- and 
CYFRA21-1-positive, respectively. Pathologically, 
the sensitivities of DiAcSpm were 39.5% in patients 
with adenocarcinoma, 62.0%(SCC), 53.8%(Ad-
SCC) and 66.7%(SCLC) , whereas the sensitivities 
of CEA and CYFRA21-1 were 31.3% and 17.3% 
in adenocarcinoma, 33.0% and 47.6% in SCC, 
15.4% and 38.5% in Ad-SCC respectively, and the 
sensitivity of Pro-GRP was 88.9% in patients with 
SCLC.
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1Division Of Pulmonary, Critical And Sleep 
Medicine, Department Of Respiratory, Chang Gung 
Memory Hospital At Keelung/Taiwan, 2Chang Gung 
Memorial Hospital At Keelung/Taiwan, 3Chang 
Gung Memorial Hospital At Linkou/Taiwan, 4Chang 
Gung University, Taoyuan/Taiwan
Background: Microparticles (MPs) are small 
membrane vesicles shed from the cell surface in 
response to various stimuli and are considered to 
be involved in the pathophysiology of disease. 
In cardiovascular disease, platelet-derived 
microparticles (PMPs) are a marker of platelet 
activation and associate with thrombotic events. 
Endothelial microparticles (EMPs) are associated 
with endothelial activation in various vascular 
diseases. Most cancer patients have activated 
circulating platelets and high levels of angiogenesis. 
The aim of this study is to evaluate the levels of 
circulating PMPs and EMPs in patients with lung 
cancer and investigate their correlation with the 
activation of angiogenesis and coagulation. 
Methods: This study included 44 consecutive 
patients with newly diagnosed lung cancer and 19 
control subjects. MPs were measured in platelet-
poor plasma and stained using cell speciÀc 
Áuorescence-labeled monoclonal antibodies: anti-
CD42b-phycoerythrin and anti-VE-cadherin -PE on 
a Áow cytometer. Plasma concentrations of vascular 
endothelial growth factor (VEGF), thrombin-
antithrombin complexes (TATs) and prothrombin 
activation fragment (F
1+2
) were measured by enzyme-
linked immunosorbent assay. 
Results: There were no differences between the 
lung cancer and control groups in age (P= 0.511) 
or gender (P=0.095). The percentages of those 
with hypertension and diabetes mellitus were not 
signiÀcantly different between groups. Twenty-
eight patients had adenocrcinoma, 7 squamous cell 
carcinoma, and 9 small cell carcinoma. Thirty-eight 
patients (86%) had advanced stage (III and IV) 
disease. Platelet counts were signiÀcantly higher in 
patients than controls (290± 19 x103/ƫl versus 215± 
11 x103/ƫl, P=0.034). The median concentrations 
of CD42b+ PMPs and VE-cadherin+ EMP were 
higher in patients than controls (1964/ƫl vs 1148/ƫl, 
P=0.006; 365/ƫl vs 256/ƫl, P=0.04; respectively). 
The median levels of plasma VEGF and TATs in 
patients were signiÀcantly higher than in controls 
(61.7pg/ml vs 44.8pg/ml, P= 0.006; 3.66ƫg/l vs 
1.2ƫg/l, P=0.003; respectively). The circulating PMP 
and EMP levels signiÀcantly correlated with the 
patient cohort (n=24) with a median of 35-fold 
increase. In addition, in the Oxford cohort of 273 
prospectively-collected undiagnosed pleural Áuids, 
pleural Áuid FGF-9 levels in MM patients (n=43) 
were 7.2 fold and 4.6 fold higher than in metastatic 
pleural cancers (n=137) and benign pleuritis 
(n=103), p<0.05 for both. Similarly, we found that 
in an independent cohort (Perth, Western Australia), 
pleural Áuid FGF-9 levels in MM patients (n=205) 
were 12.5 fold and 11.3 fold higher than metastatic 
pleural cancers (n=210) and benign pleuritis 
(n=224), p<0.05 for both. The sensitivity and 
speciÀcity for this novel protein at a cut-off value of 
559 ng/mL was 77% and 85% respectively. The area 
under the curve was 0.859, which is comparable to 
that of other MM biomarkers such as mesothelin. 
FGF-9 is important in the pathobiology of MM. 
Exogenous FGF-9 (at 100 ng/mL) induces dose- 
and time-dependent proliferation of both human 
and murine MM cells up to 2 fold over serum-free 
control. Furthermore, exogenous FGF-9 (100 ng/
mL) induces a dose- and time- dependent release of 
IL-8 (or MIP-2), VEGF and MCP-1 from human and 
murine MM cells by 3, 2 and 2.5 fold respectively 
over serum-free treated controls. These cytokines are 
known to be playing a role in the MM pathobiology 
and they were signiÀcantly inhibited with the 
addition of ERK inhibitor, PD98059, JNK inhibitor, 
SP600125, and p38 inhibitor, SB203580 (p<0.05 for 
all). In addition, FGF-9 induces MM cell invasion 
(Matrigel assay) in vitro. The addition of pleural 
Áuid containing high levels of FGF-9, to human MM 
cells (as an ex-vivo model), signiÀcantly induces the 
release of the above-mentioned cytokines thereby 
further supporting a role for FGF-9 in cytokine 
release important in MM pathobiology. 
Conclusion: MM produces high levels of FGF-9 
which potently induces MM cell proliferation and 
cytokine release. 
Keywords: FGF-9, mesothelioma
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P2.044 ELEVATED CIRCULATING 
PLATELET AND ENDOTHELIAL 
MICROPARTICLES IN PATIENTS WITH 
LUNG CANCER
Jo Chi Tseng1, Chung Ching Hua2, Bor Yiing Jiang2, 
Hung Jie Chen2, Yu Chih Liu2, Chih Teng Yu3, Ching 
Ping Tseng4 
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(normal p21 expression: 14 months, abnormal p21 
expression: 21 months - p=0,02). The other markers 
did not show signiÀcant correlation with survival. 
Multivariate analysis showed an independent 
prognostic role for clinical stage and for the 
expression of p21. 
Conclusion: In the present study, clinical stage and 
the p21 expression correlated with poor outcome in 
patients with locally advanced NSCLC. 
Keywords: Non small cell lung cancer, prognostic 
value, proteic expression
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.046 BLOOD-BASED BIOMARKERS 
ASSOCIATED WITH OUTCOMES 
IN ADVANCED NON-SMALL CELL 
LUNG CANCER TREATED WITH 
BEVACIZUMAB PLUS CHEMOTHERAPY
Yi-Sheng Huang1, She-Juan An2, Zhi-Hong Chen2, 
Jian Su2, Yan Yang1, Jian-Guang Chen2, Hong-Hong 
Yan2, Qiu-Xiong Lin2, Jin-Ji Yang1, Xue-Ning Yang1, 
Qing Zhou1, Xu-Chao Zhang2, Yi-Long Wu1 
1Division Of Pulmonary Oncology, Guangdong 
General Hospital/China, 2Medical Research Center, 
Guangdong General Hospital/China
Background: It’s difÀcult to identify which patients 
will beneÀt most from the bevacizumab treatment. 
So we sought to Ànd blood-based biomarkers 
that can be used to predict efÀcacy in advanced 
non-small cell lung cancer patients treated with 
bevacizumab plus chemotherapy.
Methods: Blood was collected before treatment and 
after six weeks of therapy from patients who were 
participating in an phase 4 trial. Plasma vascular 
endothelial growth factor (VEGF) levels were 
evaluated by ELISA.
Results: A total of eight single nucleotide 
polymorphisms in four candidate genes were 
analyzed by PCR and sequencing. A total of 45 
patients enrolled in a clinical trial at Guangdong 
General Hospital between August 2007 and March 
2008 were used as subjects. The median OS were 
25.6 and 13.4 months in the low and high groups 
respectively, when the median posttreatment plasma 
VEGF level (46.63pg/ml) was used as the cut-off 
point (P=0.0284). Patients carrying the AA genotype 
at the -6C>A polymorphism in laminin 5 (LN5) were 
more likely to exhibit reduced hemoglobin compared 
plasma levels of VEGF (r=0.495, P=0.001; r=0.395, 
P=0.01) in the patients. PMP levels negatively 
correlated with TATs and F1+2(r = -0.74, P= 0.642; 
r = -0.117, P= 0.461) but were not signiÀcantly 
different. There was no signiÀcant association 
between TATs or F1+2 and VE-cadherin+EMP. 
Conclusion: We demonstrated the levels of 
circulating PMPs and EMPs are signiÀcantly 
elevated in patients with lung cancer. Our results 
highlight a potential link between PMPs and plasma 
VEGF levels. This possibility may be the expression 
of complicated interaction between platelet 
activation and tumor angiogenesis. VE-cadherin+MP 
might be a potential marker of endothelial activation 
during tumor angiogenesis. 
Keywords: platelet microparticles, endothelial 
microparticles, Lung cancer
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P2.045 PROGNOSTIC VALUE OF THE 
PROTEIC EXPRESSION PROFILE IN 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CARCINOMA.
Igor P. Morbeck, Jefferson L. Gross, Victor Andrade, 
Ricardo Fogaroli, Fábio Haddad, Riad Younes 
Thoracic Oncology, AC Camargo Hospital/Brazil
Background: Lung cancer is the most common 
cause of death from cancer worldwide. Identifying 
potentially predictive cellular markers of prognosis 
in non-small cell lung cancer (NSCLC) is becoming 
increasingly relevant. This study evaluated the 
prognostic impact of the expression of cellular and 
molecular markers in the determination of overall 
survival. 
Methods: This is a retrospective study of 64 
patients with locally advanced NSCLC, treated 
with radiotherapy alone or associated with 
chemotherapy. Tumor samples were analyzed 
through immunohistochemistry (IHC) for the 
proteic markers: p21, p27, p53 and pRb. Normal or 
abnormal expressions were correlated with survival 
by univariate and multivariate analyses that also 
included potential prognostic factors as age, sex, 
histology, clinical stage and treatment modality. 
Results: Clinical stage showed signiÀcant 
correlation with median overall survival (IIIA: 34 
months, IIIB: 13 months - p=0.01). Median overall 
survival correlated with p21-marker expression 
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Methods: Lung adenocarcinoma samples were 
obtained from consenting 10 patients who underwent 
pulmonary resection for treatment of lung cancer. 
The study is to be approved by the Research Ethics 
Board at Kansai Medical University. Tumor tissues 
were mechanically dissociated and incubated with 
Collagenase/Dispase (Roche) and DNase I (Roche), 
followed by magnetic bead separation to remove 
dead cells (Miltenyi Biotec). The lung cancer 
cells were magnetically labeled and separated 
by antibodies. Cancer cells in 5 specimens were 
sorted with antibody of CD133 and 5 samples 
were separated with antibody of EGFR. CD133 
Cell Isolation Kit (Miltenyi Biotec) were used in 
cell separation of CD133 positive cells and EGFR 
antibody conjugated to magnetic beads (R&D) were 
used in EGFR positive cells. Exons 18 through 22 
of EGFR are were assessed by quantitative real-time 
polymerase chain reaction, and exon 1 of K-ras and 
exon 5 through 8 of p53 by sequencing.
Results: In CD133 analysis, CD133 expression of 
cancer cells in Àve lung cancer samples ranged from 
1.8% to 24.8% (1.8, 2.7, 5.6, 10.4 and 24.8). Two 
cases of bronchiolo-alveolar carcinoma showed 
lower levels of CD133 expression (1.8% and 2.7%) 
than three cases of papillary adenocarcinoma. 
Among Àve cases, there were four cases that had 
EGFR mutation, no case of K-ras mutation, two 
cases of p53 mutation. There was no difference in 
mutation status of EGFR, K-ras and p53 between 
CD133 positive cells and negative cells. In EGFR 
analysis, there was no difference in mutation status 
of EGFR, K-ras and p53 between sorted cells by 
EGFR antibody.
Conclusion: In our analysis, sorted cancer cells 
of lung adenocarcinoma by CD133 and EGFR did 
not have any difference in gene mutation status of 
EGFR, K-ras and p53. 
Keywords: Adenocarcinoma, EGFR, Kras, P53
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P2.048 NOVEL BIOMARKERS IN 
NON-SMALL CELL LUNG CANCER 
DISTINGUISH SQUAMOUS-
CELL CARCINOMA AND 
ADENOCARCINOMAS SAMPLES.
Abel Sanchez-Palencia1, Mercedes Gomez-Morales2, 
Laura Boyero3, Jose Antonio Gomez-Capilla3, Mª 
Esther Fárez-Vidal3 
to patients carrying the CA/CC genotype (OR=8.364, 
x2=5.34, P=0.021). Similar associations were found 
at the -89A>G and -260C>A polymorphisms in 
LN5. Patients with the CC genotype at the -6C>A 
polymorphism in LN5 had an increased risk of 
neutropenia than those with the CA/AA genotype 
(OR=4.444, X2=5.116, P=0.030).
Conclusion: Our results show improved survival 
in patients with lower posttreatment plasma VEGF 
levels treated with bevacizumab plus chemotherapy; 
thus, the posttreatment plasma VEGF level may be a 
promising biomarker to predict clinical beneÀt early 
in the course of therapy. Polymorphisms in LN5 
were associated with a reduced level of hemoglobin 
and neutropenia.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.047 MUTATION STATUS OF 
EGFR, K-RAS AND P53 IN SORTED 
ADENOCARCINOMA CELLS
Hiroyuki Kaneda, Takahito Nakano, Tomohito Saito, 
Kenichiro Minami, Toshifumi Konobu, Yukihito 
Saito 
Thoracic Surgery, Kansai Medical University 
Hirakata Hospital/Japan
Background: Recent evidence indicates that tumors 
contain a small population of cancer cells that are 
responsible for tumor maintenance and spreading. 
Lung cancer was reported to contain a rare population 
of CD133 positive cancer cells able to self-renew and 
generate an unlimited progeny of non-tumorigenic 
cells. The presence of somatic mutations in the kinase 
domain of the epidermal growth factor receptor 
(EGFR) correlates with tumor sensitivity to the EGFR 
inhibitors, erlotinib and geÀtinib. Some modiÀcations 
of EGFR gene that causes resistance to geÀtinib 
is reported to be sometimes present in a minor 
population of tumor cells. We hypothesize that small 
proportion of the tumor cells that have speciÀc gene 
mutation affect clinical tumor behavior, such as drug 
resistance. We aim to examine whether there is any 
difference of gene mutation in EGFR, K-ras and p53 
between CD133 positive cells and negative cells in 
lung adenocarcinoma. 
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P2.049 ANALYSIS OF SINGLE 
NUCLEOTIDE POLYMORPHISMS AND 
RADIATION SENSITIVITY ASSESSED 
WITH AN OBJECTIVE RADIOLOGICAL 
ENDPOINT
Chris R. Kelsey1, Lauren Jackson1, Scott Langdon2, 
Kouros Owzar2, Jessica Hubbs3, Zeljko Vujaskovic1, 
Shiva Das1, David Yoo1, Lawrence B. Marks3 
1Department Of Radiation Oncology, Duke 
University Medical Center/United States Of 
America, 2Duke University Medical Center/United 
States Of America, 3Radiation Oncology, University 
Of North Carolina/United States Of America
Background: It is clinically apparent that some 
cancer patients are more sensitive to the adverse 
effects of radiation therapy (RT) than others. This 
variation may be due, in part, to underlying genetic 
make-up. Recent studies have shown that single 
nucleotide polymorphisms (SNPs) within genes 
involved in DNA damage recognition, DNA repair, 
and chronic inÁammation are associated with 
adverse effects after RT. The endpoints studied have 
been largely subjective. Herein we report a study 
evaluating SNPs in 24 candidate genes and their 
association with RT sensitivity using an objective 
radiological endpoint. 
Methods: As part of an IRB-approved prospective 
clinical study, patients undergoing thoracic RT for 
lung cancer had pre-RT and serial post-RT single 
photon emission computed tomography (SPECT) 
lung perfusion scans (providing a 3D map of 
regional perfusion). Changes in regional perfusion 
after RT were related to regional RT dose (via image 
fusion) yielding a patient-speciÀc dose response 
curve (DRC). The DRC slope is independent of 
irradiated volume and is taken as a reÁection of the 
patient’s inherent sensitivity to RT. The DRC was 
obtained from the non-tumor bearing contralateral 
lung to avoid issues related to reperfusion after 
treatment of central tumors. DNA was extracted 
from patient blood samples using the QIAamp DNA 
Blood Mini Kit (Qiagen). Primer pairs for each 
SNP were designed using the NCBI/Primer Blast 
program. SNPs were determined using a combination 
of High Resolution Melting and TaqMan assays. 
Genotypes were compared against the slope of the 
DRC using the Kruskal-Wallis test. We evaluated 
51 SNPs within 24 genes involved in DNA damage 
1Thoracic Surgery, Virgen De Las Nieves University 
Hospital/Spain, 2Pathology, School Of Medicine. 
University Of Granada/Spain, 3Biochemistry An 
Molecular Biology 3 And Immunology, School Of 
Medicine. University Of Granada/Spain
Background: Despite advances in early detection 
and standard treatment, non-small-cell lung cancer 
is often diagnosed at an advanced stage and carries a 
poor prognosis. Greater knowledge of the molecular 
origins and progression of lung cancer may lead to 
improvements in the treatment and prevention of the 
disease. 
Methods: Microarray analysis was performed on a 
set of 46 tumour samples and 45 paired non-tumour 
samples of non-small cell lung cancer (NSCLC) 
samples in order to establish gene signatures in 
primary adenocarcinomas and squamous-cell 
carcinomas, determine differentially expressed gene 
sequences at different stages of the disease and 
identify sequences with biological signiÀcance for 
tumour progression. After the microarray analysis, 
the expression level of 92 selected genes was 
validated by qPCR and the robust Bonferroni test in 
an independent set of 70 samples composed of 48 
tumour samples and 22 non-tumour samples. Kaplan 
Meier survival curves for patients were analyzed for 
the microarray samples 
Results: The differentially expressed gene sequences 
validated by qPCR distinguished tumour phenotype 
(tumour vs. non-tumour samples); adenocarcinoma 
vs. squamous-cell carcinomas (including stages 
I and IB) and differentiation grades [FDR0.05; 
Bonferroni0.05]. An acceptable agreement 
(CCC)15 was found between microarray and qPCR 
results.
The Breslow (generalized Wilcoxon), Tarone-Ware 
and Log-Rank (Mantel-Cox) tests yielded highly 
signiÀcant differences (p<0.001), showing short 
survival times for patients with tumour recurrence.
Conclusion: Besides conÀrming the signiÀcant 
NSCLC-related gene changes previously reported 
in gene expression proÀle analyses (e.g., genes 
for keratins), our study has identiÀed further 
differentially expressed genes of importance in 
NSCLC. 
Keywords: Microarray/qPCR, NSCLC, Biomarkers, 
Expression proÀling
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upon resection. In various tumors, expression of 
cancer stem-like cell (CSC) markers such as CD133 
is prognostically unfavorable. However, in lung 
cancer data about the prognostic signiÀcance of CSC 
markers are scanty and conÁicting. 
Methods: We performed an immunohistochemical 
analysis of the CSC markers CD117, CD133 and 
breast cancer resistance protein 1 (BCRP1) in a 
total of 142 completely resected stage I-IIIA non-
small cell lung cancer (NSCLC) patients with a 
median potential follow-up time of 56.5 months. The 
expression of CSC markers was related to clinico-
pathological characteristics, blood parameters, 
angiogenic features, relapse and survival. 
Results: In univariate analysis, BCRP1 expression 
was associated with the proportion of metastatic 
lymph nodes (p0.022), CD117 expression with 
histology (p0.005) and CD133 expression with 
tumor size (p0.021) and T status (p0.002). Blood 
parameters showed no association with clinico-
pathological characteristics, whereas microvessel 
density (MVD) was linked to histology (p0.039) 
and vascular architecture to T status (p0.029). Cox 
proportional hazards regression analysis revealed 
no prognostic signiÀcance of CSC markers, but an 
increased risk of disease-related mortality in patients 
with pretherapeutic anemia [hazard ratio (HR)4.2, 
95%CI1.5-12.0, p0.008] or elevated neuron-speciÀc 
enolase levels [NSE; HR4.3, CI1.4-12.8, p0.009]. 
Moreover, anemia was associated with an increased 
risk of relapse [HR3.4, 95%CI1.4-8.4, p0.007]. 
Conclusion: Expression of CSC markers appeared 
to be associated with clinico-pathological 
characteristics, but not with prognosis in resected 
NSCLC. In contrast, pretherapeutic anemia and 
increased NSE levels may indicate an unfavorable 
prognosis. 
Keywords: Cancer Stem-Like Cell Markers, Non-
small cell lung cancer, Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
recognition and repair, Àbrosis, and chronic 
inÁammation as well as SNPs that have previously 
been associated with RT sensitivity. Review of the 
literature identiÀed the following genes for study: 
TGFB1, RAD21, RAD51, RAD52, ATM, TP53, 
XRCC1, XRCC2, XRCC3, ERCC2, ERCC5, 
NOS2A, SOD2, ATR, APE1, BRCA1, BRCA2, 
HIF1A, LIG4, GRP, MSH3, MLH1, IL12RB2, and 
ABCA1. 
Results: 39 self-reported Caucasian patients with 
pre-RT and ³ 6 month post-RT SPECT scans and 
blood samples were identiÀed. Of the 51 SNPs 
evaluated, 2 exhibited deviation from Hardy-
Weinberg equilibrium and in 9 only the heterozygote 
genotype was observed. Of the remaining 40 SNPs, 
an association between genotype and increasing 
slope of the DRC was noted with four including C(-
509)T in TGFB1 (rs1800469), G(1301)A in XRCC1 
(rs25487), T(1939)C in LIG4 (rs1805386) and 
G(3748)A in BRCA1 (rs16942). 
Conclusion: This small study suggests that 
polymorphisms within genes involved in repair 
of DNA damage (XRCC1, LIG4, BRCA1) and 
Àbrosis (TGFB1) are associated with RT sensitivity. 
SigniÀcantly, we used an objective measure of RT 
sensitivity, which is independent of the dose and 
volume of normal tissue irradiated. Supported in part 
by grant NIH R01 CA69579 (LM) and NIH R01 
CA115748 (SD) 
Keywords: single nucleotide polymorphism, 
radiation sensitivity, SNP
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P2.050 PROGNOSTIC SIGNIFICANCE 
OF CANCER STEM-LIKE CELL 
MARKERS, BLOOD PARAMETERS AND 
ANGIOGENIC FEATURES IN RESECTED 
NON-SMALL CELL LUNG CANCER
Esther Herpel1, Katrin Jensen2, Arne Warth1, Philipp 
A. Schnabel1, Thomas Muley3, Michael Meister3, 
Michael Thomas3, Felix J.F. Herth3, Hendrik 
Dienemann3, Hans Hoffmann3, Sandra Gottschling3 
1Institute Of Pathology, University Of Heidelberg/
Germany, 2Institute Of Medical Biometry And 
Informatics, University Of Heidelberg/Germany, 
3Thoraxklinik, University Of Heidelberg/Germany
Background: Lung cancer is the leading cause of 
cancer-related death world-wide and curable solely 
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the history of smoking (p = 0.02; OR: 3.4 95% 
CI (1.3–10.5) and concurrent chemotherapy (p = 
0.024; OR: 3.3 (1.2-9.0). Of dosimetric parameters, 
MLD  18 had the highest correlation with RP (p = 
0.09; OR: 2.2 (0.9-5.6). There was no statistically 
signiÀcant univariate correlation found between 
the genotypes of each TGFơ1 SNPs and RP. 
Multivariate regression analysis identiÀed smoking 
history, concurrent chemotherapy, and MLD as most 
associated with RP. None of the TGFơ1 SNPs had a 
signiÀcant correlation with RP when included in the 
modeling. 
Conclusion: Our study showed no signiÀcant 
association between development of RP and any 
of three TGFơ1 SNPs examined when accounting 
for dosimetric and other clinical factors. Additional 
studies will be required to identify genetic risk 
factors for RP. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.052 A NON-INVASIVE SYSTEM FOR 
MONITORING RESISTANCE TO EGFR 
TYROSINE KINASE INHIBITORS WITH 
PLASMA DNA
Tomomi Nakamura1, Naoko Sueoka-Aragane2, 
Kentaro Iwanaga3, Akemi Sato2, Kazutoshi Komiya2, 
Tomonori Abe2, Norio Ureshino2, Shinichiro 
Hayashi2, Shinya Kimura2, Eizaburo Sueoka2 
1Saga University, Saga University/Japan, 2Saga 
University/Japan, 3Saga Prefectural Hospital 
Koseikan/Japan
Background: EGFR tyrosine kinase inhibitors 
(EGFR-TKIs) are widely used to treat lung 
adenocarcinomas with EGFR activating mutations. 
However, half of patients acquire resistance because 
of the gatekeeper T790M mutation. Non-invasive 
mutation detection system is desired considering 
the difÀculty in obtaining tissue specimens during 
disease progression. 
Methods: Sixty-seven plasma DNA samples from 
forty-nine lung adenocarcinoma patients and thirty 
healthy volunteers were evaluated. T790M in plasma 
DNA was determined using the MBP-QP method. 
The method combines mutation-biased PCR (MBP) 
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.051 VALIDATION OF 
PURPORTED SINGLE NUCLEOTIDE 
POLYMORPHISMS (SNPS) IN THE 
TRANSFORMING GROWTH FACTOR 
ȕ1 (TGFȕ1) GENE AND RISK OF 
RADIATION PNEUMONITIS (RP).
Su Woon Kim1, Cheng Lu2, Abul K. Azad2, Wei Xu2, 
Patricia E. Lindsay1, Geoffrey Liu3, Andrew Hope1 
1Radiation Oncology, Princess Margaret Hospital 
And University Of Toronto/Canada, 2Biostatistics, 
Princess Margaret Hospital And University 
Of Toronto/Canada, 3Medical Oncology And 
Hematology, Princess Margaret Hospital And 
University Of Toronto/Canada
Background: A recent study has suggested an 
association between TGFơ1 single nucleotide 
polymorphisms (SNPs) rs1982073:T869C and risk 
of radiation pneumonitis (RP). A validation study 
was performed to determine if this association 
existed in our lung cancer population. 
Methods: Patients with non-small cell lung 
cancer (NSCLC) treated with radiation with 
stored blood samples were identiÀed. All patients 
received deÀnitive radiotherapy with or without 
chemotherapy. Three SNPs of the TGFơ1 gene 
rs1800469, rs1800470 (previously rs1982073) 
and rs1800471 were genotyped. We genotyped 
rs1800470 and rs1800471 by direct sequencing and 
rs1800469 by Taqman assay. Patient characteristics, 
treatment information, and toxicity were collected 
retrospectively using the electronic patient charts. 
RP was graded using the CTCAE V3. Association 
between the risk of grade  2 RP and TGFơ1 SNPs 
as well as the dosimetric parameters were performed 
using logistic regression. Interactions between the 
SNPs and the risk of RP were further performed 
using additive, co-dominant, dominant and recessive 
models as well as haplotype analysis. The statistical 
analysis was applied using SAS 9.2. 
Results: Of the 103 patients with stored samples, 
thirty six patients (35%) developed RP (31 patients 
with grade 2 and 5 patients with grade 3). The 
median time to develop RP was 8.8 months. 
The median dose of radiation was 66 Gy and 
median MLD and V20 were 16.3 Gy and 28.9 
% respectively. Of the total 103 serum samples 
analyzed, genotypes were available from 99 patients. 
On univariate analysis, RP was correlated with 
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detection and prognosis prediction of lung cancer 
by performing proteome analysis of human lung 
adenocarcinoma.
Methods: We assessed high frequently 
overexpressed proteins in 12 lung adenocarcinoma 
samples compared to adjacent normal tissue samples 
by LC-MS/MS coupled with iTRAQ technology 
and validated the expression of target proteins 
by immunohistochemistry in 268 cases with 
lung adenocarcinoma. Then, we measured serum 
levels of biomarker candidate proteins with 111 
lung adenocarcinoma patients and 46 non-cancer 
controls using ELISA method and we evaluated 
candidate proteins as diagnostic biomarkers of lung 
adenocarcinoma with ROC curve analysis. Statistical 
analysis of the association between the expression 
levels of candidate proteins and clinicopathological 
variables, and survival analysis using Kaplan-Meier 
curves for overall survival with log-rank test was 
also assessed to evaluate as prognostic biomarkers of 
lung adenocarcinoma.
Results: LC-MS/MS analyses indicated that 
anterior gradient protein 2 homolog (AGR2) was a 
potential biomarker of human lung adenocarcinoma 
and AGR2 was stained in 94% of 268 lung 
adenocarcinoma tissues. ELISA assay showed that 
serum AGR2 level of lung adenocarcinoma patients 
was signiÀcantly higher than that of non-cancer 
controls. The optimal cut-off point was detected 
with ROC curve (the AUC 0.858), the sensitivity 
and speciÀcity of this cut-off point was 65.8% and 
87%, respectively. Kaplan-Meier curves for overall 
survival showed that positive serum expression level 
of AGR2 (above the cut-off point) was signiÀcantly 
associated with poor prognosis compared to negative 
expression (log-rank test; p=0.037).
Conclusion: In this study, it is showed that 
AGR2 has possibility to be a novel biomarker for 
diagnosis and prognosis of lung adenocarcinoma. 
Further studies are required to clarify the biological 
signiÀcance of AGR2 overexpression in lung 
adenocarcinoma and Ànally to evaluate its usefulness 
as a novel diagnostic or prognostic biomarker to 
reach adequate therapeutic modality in clinical 
practice.
Keywords: lung adenocarcinoma, AGR2, biomarker, 
proteomics
and genotyping, the latter based on analysis of the 
melting curve of the probe DNA binding the target 
mutated site using a Áuorescence quenching probe 
(QP) system. 
Results: The detection limit was two copies of 
control plasmid and 0.2 ng of genomic DNA. The 
mutant plasmid could be detected when it accounted 
for as little as 0.3% of a mixture of plasmids carrying 
EGFR exon 20 with or without T790M. The T790M 
mutation was detected in plasma DNA from ten of 
nineteen patients (53%) who acquired resistance, 
but not in non-responders, patients responding to 
treatment, or those not treated with EGFR-TKI. 
Other mutation detection systems, such as the 
nucleic acid-locked nucleic acid PCR clamp (PNA-
LNA PCR clamp), the cycleave PCR technique, and 
allele-speciÀc oligonucleotide PCR, detected T790M 
in three, four, and six patients, respectively, among 
ten in which T790M was detected by the MBP-QP 
method. 
Conclusion: The MBP-QP method is simple, 
sensitive, and—intriguingly—reÁective of clinical 
course, compared with the other three mutation-
detection systems. Thus, the MBP-QP method is an 
ideal non-invasive monitoring system for detecting 
T790M in plasma samples. 
Keywords: T790M, plasma DNA, Lung cancer, 
EGFR-TKI
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P2.053 AGR2 AS A NOVEL USEFUL 
BIOMARKER OF HUMAN LUNG 
ADENOCARCINOMA
Kyukwang Chung1, Noritoshi Nishiyama1, Hiroaki 
Komatsu1, Shoji Hanada1, Nobuhiro Izumi1, Koshi 
Nagano1, Hideki Wanibuchi2, Shigefumi Suehiro1 
1Thoracic Surgery, Osaka City University Graduate 
School Of Medicine/Japan, 2Pathology, Osaka City 
University Graduate School Of Medicine/Japan
Background: Lung cancer is the leading cause of 
cancer death in the worldwide. Despite advances in 
early diagnostic methods and treatment modarities, 
lung cancer is often diagnosed at an advanced stage 
and has a poor prognosis. There is a need for the 
development of new biomarkers for early detection, 
deÀning cancer risk, prognosis, and therapy targets. 
The purpose of this study was to search useful 
biomarkers for clinical treatment including early 
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of pts had a metastatic disease and 22% IIIB 
stage. Histology was: squamous carcinoma 25/50, 
adenocarcinoma 18/50, bronchiolar-alveolar 
adenocarcinoma 2/50, undifferentiated 5/50. All 
pts were treated with one or more therapeutic 
lines. Clinical and outcome data were collected. 
Genomic DNA was isolated from peripheral 
blood lymphocytes of pts, using Puregene 
Genomic DNA PuriÀcation System. Genotyping 
for MTHFR polymorphisms was carried out by 
DG-DGGE (double gradient-denaturing gradient 
gel electrophoresis), for p53 codon 72 (Arg/
Pro) with the use of Áuorogenic allele-speciÀc 
oligonucleotide TaqMan probes on a 7900HT 
Fast Real-Time PCR System and for TS Promoter 
Polymorphisms with PCR and subsequent 
electrophoresis on 3% agarose gel. Patients 
outcome data were compared with TS VNTR, 
MTHFR SNPs and/or p53 codon 72 polimorphisms 
expression. A multivariate analysis was performed. 
Results: We have recorded no signiÀcant 
correlation among TTP and OS data and the 
individual expression of MTHFR SNPs, TS tandem 
repeats, and p53 codon 72 polymorphisms. No 
difference in TTP were recorded in the multivariate 
analyses including the TS, MTHFR and p53 codon 
72 genotypes. However, the combined MTHFR 
CT677/AC1298 genotype was signiÀcantly 
associated with longer survival (34,5 months 
p<0,05) also in association of TS genotype 
homozygous for triple repeats (3R/3R), (29,5 
months p<0,05). 
Conclusion: Although preliminary, these data 
support the role of MTHFR and TS genotypes as 
prognostic markers in NSCLC pts. Genotyping 
for p53 codon 72 polimorphisms do not predict 
for patients’ outcome. Further validation and 
investigation of the involvement of genotypes of 
folate metabolizing enzyme are needed to conÀrm 
these Àndings and to evaluate their correlation with 
chemotherapy metabolism and activity. 
Keywords: Non small cell lung cancer, MTHFR 
polymorphisms, TS promoter variants, p53 codon 
72 mutations
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P2.054 FOLATE PATHWAY 
IMPLICATIONS IN ADVANCED 
NON SMALL CELL LUNG CANCER 
(NSCLC): IMPACT OF THYMIDYLATE 
SYNTHASE (TS) PROMOTER AND 
METHLYLENETETRAHYDROFOLATE 
REDUCTASE (MTHFR) C677T AND 
A1298C VARIANTS EXPRESSION 
ON PATIENTS’ OUTCOME AND 
CORRELATION WITH P53 CODON 72 
MUTATIONS.
Tindara Franchina1, Nicola Caristi1, Claudia Proto1, 
Giuseppe Chiofalo1, Giuseppe Toscano1, Giuseppina 
R.R. Ricciardi1, Francesca Colonese1, Daniela 
Caccamo2, Riccardo Ientile2, Vincenzo Adamo1 
1Department Of Human Pathology, Unit Of 
Integrated Therapies In Oncology, University 
Hospital/Italy, 2Department Of Biochemical, 
Physiological And Nutritional Sciences, University 
Hospital/Italy
Background: Folate depletion and its resultant 
reduction of DNA synthesis and DNA methylation 
must be toxic to malignant cells, resulting in DNA 
damage and hypomethylation. Paradoxically, 
inhibition of folic acid metabolism has been 
used as a mechanism for successful elimination 
of malignant cells, but insufÀcient folic acid 
levels in normal cells have been associated with 
malignant transformation. TS and MTHFR are 
involved in folate metabolism. Two functional 
single nucleotide polymorphisms (SNPs) in the 
5,10 methylenetetrahydrofolate reductase gene, 
C677T and A1298C lead to decreased enzymes 
activity and affect chemosensitivity of tumor cells. 
Also TS expression is inÁuenced by a variable 
number of tandem repeats (VNTR) in TS gene. 
Hypometylation of the p53 tumor suppressor gene 
has been described in folate depletion. p53 codon 
72 polymorphisms inÁuencing the function of the 
protein seems to increase the risk of developing 
lung cancer. We investigated whether MTHFR 
SNPs and TS tandem repeats were associated with 
time to progression (TTP) and overall survival 
(OS) in 50 locally advanced and metastatic NSCLC 
patients and evaluated the correlations with p53 
codon 72 polymorphisms. 
Methods: Pts (36 M/14 F) median age was 61.5 
(range 45-84). ECOG PS 0/1/2/: 15/21/14. 78% 
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Conclusion: Tumor-inÀltrating T cell distribution 
suggested by FOXP3+/CD8+ T cell ratio can be a 
marker for effectiveness of chemotherapy in patients 
with NSCLC.
Keywords: Non-small cell lung cancer, regulatory T 
cell, tumor-inÀltrating T cells, induction therapy
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.056 HIGHLY SENSITIVE DETECTION 
OF SOMATIC EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) GENE 
MUTATIONS IN CIRCULATING TUMOR 
CELLS (CTC) FROM PATIENTS WITH 
NON-SMALL CELL LUNG CANCER 
(NSCLC) TREATED WITH CISPLATIN/
PEMETREXED OR AFATINIB
Frank Breitenbuecher1, Sandra Hoffarth1, Thomas 
C. Gauler1, Sarah L. Stergar1, Stefan Kasper1, Jens 
Köhler1, Karl Worm2, Angela Märten3, Kurt W. 
Schmid2, Martin Schuler1 
1Dept. Of Medicine (cancer Research), West German 
Cancer Center, University Hospital Essen/Germany, 
2Institute Of Pathology And Neuropathology, 
University Hospital Essen, University Of Duisburg-
essen/Germany, 3Medical Affairs Germany, 
Boehringer Ingelheim Pharma GmbH & Co. KG/
Germany
Background: Activating somatic mutations in the 
EGFR gene deÀne a group of genetically dependent 
pulmonary adenocarcinoma, which are exquisitely 
sensitive to treatment with EGFR tyrosine kinase 
inhibitors (EGFR-TKI). Hence, EGFR mutation 
status has been established as a biomarker to guide 
therapeutic decisions in advanced NSCLC patients. 
The majority of activating mutations cluster in 
exons 19 and 21 of the EGFR gene. Another type 
of EGFR mutations leading to a T790M amino acid 
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P2.055 PATHOLOGIC COMPLETE 
RESPONSE TO INDUCTION THERAPY 
OF NON-SMALL CELL LUNG CANCER 
IS ASSOCIATED WITH FOXP3+/CD8+ 
TUMOR-INFILTRATING T CELL RATIO
Hiroyuki Tao1, Hiromasa Yamamoto1, Yusuke 
Mimura2, Eisuke Matsuda1, Seiki Kobayashi1, 
Kazunori Okabe1, Kazurou Sugi1 
1Thoracic Surgery, Nho Yamaguchi-ube Medical 
Center/Japan, 2Clinical Research, Nho Yamaguchi-
ube Medical Center/Japan
Background: Survival beneÀts of induction therapy 
followed by surgery for locally advanced non-
small cell lung cancer (NSCLC) have been shown, 
but factors inÁuencing chemo-sensitivity remain 
unclear. Anti-cancer agents are suggested to mediate 
cytotoxic effect not only directly on tumor cells but 
also through the immune system. We investigated 
the relationship between T cell distribution 
in tumor stroma and pathologic responses to 
chemoradiotherapy in patients with locally advanced 
NSCLC.
Methods: We chose 20 patients with c-stage IIB 
to IIIB NSCLC who underwent platinum-based 
chemotherapy and concurrent radiation followed by 
surgery from January 2006 to January 2011. Tumor-
inÀltrating T cells expressing CD8 or FOXP3 were 
detected by immunohistochemical staining from 
biopsy and surgically removed specimens. FOXP3+/
CD8+ T cell ratio was calculated based on the cell 
count at 200x magniÀcation.
Results: Patients characteristics were as follows: 
18 males, with average age of 60.9 years (range 
of 42-74), 7 adenocarcinomas, 9 squamous cell 
carcinomas, 2 adenosquamous carcinomas, and 2 
undetermined NSCLCs. Pathologic responses were 
NC for 3, PR for 11, and CR for 6 patients. The mean 
values of FOXP3+/CD8+ T cell ratio in operative 
specimens were 1.11 for p-NCs, 0.32 for p-PRs, and 
0.12 for p-CRs (P = 0.004). Pre-treatment TBLB 
specimens were available in 11 patients (3 p-NCs, 6 
p-PRs, and 2 p-CRs). FOXP3+/CD8+ T cell ratios in 
operative specimens after induction therapies were 
elevated compared with that of biopsy specimens in 
p-NC patients, whereas the ratios were decreased in 
p-PR and p-CR patients. 
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Mutation signal intensities correlated with clinical 
treatment response. This technology could be useful 
for rapid, non-invasive stratiÀcation of NSCLC 
patients for mutation-triggered personalized 
pharmacotherapies. Sequential analyses may 
facilitate “online monitoring” of treatment response 
at a genomic level. 
Keywords: circulating tumor cells, epidermal 
growth factor receptor (EGFR) gene mutations, Non-
small cell lung cancer (NSCLC)
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P2.057 TRANSKETOLASE INVOLVED 
CANCER CELL PROLIFERATION 
AND VEGF SECRETION IN LUNG 
ADENOCARCINOMA ASSOCIATED 
MALIGNANT PLEURAL EFFUSION
Chien-Chung Lin1, Wu-Chou Su2 
1Department Of Internal Medicine, National Cheng 
Kung University Hospital/Taiwan, 2Division Of 
Hematology/oncology, Department Of Internal 
Medicine, National Cheng Kung University Hospital 
And College Of Medicine/Taiwan
Background: Transketolase (TKT), the key 
enzyme in the pentose phosphate pathway, which 
mediates the conversion of glucose to ribose 
phosphate, is used in the biosynthesis of nucleic 
acids and nucleotides. TKT and the isoenzyme 
of transketolase, transketolase-like (TKTL)-1, 
have been demonstrated to play a pivotal role in 
cancer cell proliferation. However, cancers are 
heterogeneous, representing not only involved 
in proliferative activity but also the potential for 
metastasis and angiogenesis and the correlation with 
TKT were not well demonstrated. Malignant pleural 
effusion (MPE) accompanying lung adenocarcinoma 
indicates poor prognosis and early metastasis. 
Cancer cells that proliferate in MPE are anchorage 
independent and VEGF plays the key mediator in 
pleural effusion formation by increasing vascular 
permeability. In our previous study, we found high 
TKT expression in MPE in micro-array analysis. 
In our recent study, we plan to verify the aberrant 
expression of TKT in primary lung cancer tissue, 
metastatic pleural tumor, and MPE. We further 
investigate the effect of inhibition of TKT on lung 
cancer cell proliferation, anchorage-independent 
growth, and VEGF secretion.
substitution has been found in up to 65% of patients 
acquiring resistance to EGFR-TKI, as well as in 
rare cases of primary resistance. In clinical practice, 
EGFR mutations are determined in fresh or archival 
tumor biopsies, which do not necessarily reÁect the 
status of all current tumor manifestations. Sequential 
biopsies or biopsies of multiple tumor lesions are 
not routinely performed for patient safety. The 
availability of non-invasive methods for repetitive 
determination of prognostic and predictive genetic 
biomarkers would greatly facilitate personalized 
treatment strategies in lung cancer. Against this 
background we reasoned whether circulating 
tumor cells (CTC) spreading via the bloodstream, 
which may be derived from different disease 
sites (primary tumor, metastases) with potentially 
diverse genotypes, are suited for EGFR mutation 
analysis in NSCLC. Potential applications include 
rapid genotyping prior to EGFR-TKI treatment, 
monitoring of treatment-induced reduction of the 
patient’s systemic tumor burden, as well as early 
detection of disease relapse and drug resistance.
Methods: We have developed a highly sensitive 
“real time” PCR-based method using individually 
designed probes to detect >90% of all activating 
EGFR mutations (including the majority of 
DelEx19 variants) as well as the T790M mutation 
to analyze CTC isolated from peripheral blood (PB) 
of EGFR–mutant NSCLC patients treated at our 
center in an IEC-approved diagnostic pilot study. 
Written informed consent was obtained from all 
patients. Sampling of 40ml of PB, isolation of CTC 
and EGFR mutation analysis was conducted in 10 
patients either treated with chemotherapy or the 
irreversible erbB family blocker afatinib within 7 
days prior to start of therapy, and at regular visits 
thereafter. An additional analysis was performed at 
clinical progression and/or termination of therapy. 
Results: Combining immunomagnetic CTC 
enrichment with mutation-speciÀc PCR analysis we 
were able to detect EGFR mutations at sensitivities 
ranging from 0.2% up to 0.0005% against a 
background of wild type alleles. In this pilot study, 
mutations were detected in CTC-derived genomic 
DNA from all 10 patients suffering from advanced 
NSCLC with known EGFR mutations. Clearance of 
peripheral blood from EGFR mutation-positive CTC 
correlated with clinical and radiological response to 
afatinib or chemotherapy.
Conclusion: We have successfully developed a 
diagnostic strategy for highly sensitive detection 
of EGFR mutations in CTC from NSCLC patients. 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.058 ALDH7A1 EXPRESSION IS 
ASSOCIATED WITH RECURRENCE 
IN PATIENTS WITH RESECTED NON-
SMALL CELL LUNG CARCINOMA
Bo Lu 
Rad Onc, Thomas Jefferson Univ/United States Of 
America
Background: The aldehyde dehydrogenase 
(ALDH) enzymes are important for detoxiÀcation of 
endogenous and exogenous aldehydes. Expression of 
ALDH family members has recently been described 
as a potential marker for tumor-initiating cancer stem 
cells in a variety of human malignancies, including 
lung cancer. We were interested to determine 
whether expression of ALDH7A1, a member of 
the ALDH family, has prognostic signiÀcance in 
resected non-small cell lung carcinoma (NSCLC).
Methods: Tumor specimens were obtained for 107 
patients with completely resected stage I through 
stage III NSCLC from parafÀn-embedded tissue 
microarrays and stained with an antibody speciÀc 
for ALDH7A1. Staining patterns were graded by a 
pathologist based on the intensity of staining and the 
percentage of cells stained. A staining score index 
was calculated by multiplying intensity score by the 
percentage area with positive staining.
Results: Positive ALDH7A1 staining was identiÀed 
in 46 patients, and negative staining was noted 
in 48 patients, with 13 tumor sections missing. 
Multivariate analysis demonstrated that NSCLC 
patients with positive ALDH7A1 expression had 
decreased overall survival relative to ALDH7A1-
negative tumors, although this did not reach 
signiÀcance (hazard ratio 1.42, 95% conÀdence 
interval 0.84 to 2.389; p=0.192). However, patients 
with ALDH7A1-expressing NSCLC tumors had 
a signiÀcantly higher incidence of lung cancer 
recurrence compared to patients with ALDH7A1-
negative tumors (hazard ratio 6.24, 95% conÀdence 
interval 2.06 to 18.86; p=0.001).
Conclusion: These data indicate that ALDH7A1 
staining is present in a substantial number of NSCLC 
tumors and may be a biomarker predictive for 
Methods: Immuno-histochemical and immuno-
Áuorescence staining were used to conÀrm 
the aberrant TKT in tumor cells. Oxythiamine 
(transketolase inhibitor) was used to investigate 
the signiÀcance of TKT on the proliferation of 
lung cancer cells via MTT assays. PC14PE6/AS2 
cells were transfected with siRNA against human 
TKT expression (TKT siRNA) and mismatch 
control oligonucleotides (scramble siRNA). Cell 
proliferation after transfection was detected by Áow 
cytometry analysis with proliferation-associated 
antigen Ki-67 and cell colony formation assay. To 
investigate the signiÀcance of TKT on anchorage 
independent cell growth, PC14PE6/AS2 cells 
were maintained in ultra-low attachment plate to 
investigate the effects on cells clusters formation. 
ELISA of VEGF secretion of the conditioned 
medium and the in vivo permeability assay (Miles 
permeability assay) were performed to evaluate if 
knockdown of TKT can down-regulate VEGF and 
lead to diminished vessel permeability. 
Results: Immuno-histochemical analyses of 48 
lung adenocarcinoma specimens showed higher 
staining scores for TKT in tumor tissue than in 
adjacent healthy tissue. Oxythiamine inhibited the 
proliferation of lung cancer cells dose-dependently 
. MTT assays showed that the IC
50
s of all cells were 
around 10-20 mM. The transfection of TKT siRNA 
into cells suppressed cell clusters formation and 
proliferation; the proportion of ki-67 staining was 
lower in cells (54%) than in the scramble control 
(74%). The rate of colony growth also decreased 
(20%) by colony formation assay. ELISA of VEGF 
secretion of the conditioned medium revealed 
decreased VEGF secretions in si-TKT PC14PE6/
AS2 cells compared to the si-scramble controls. 
Miles permeability assay showed that knockdown of 
TKT can lead to diminished vessel permeability. The 
areas of dye leakage induced by conditioned medium 
from TKT siRNA PC14PE6/AS2 cells were smaller 
than the leakage area from scramble transfected 
cells. 
Conclusion: Transketolase is important not only 
in cancer cell proliferation but also in anchorage 
independent cell growth and VEGF secretion in 
MPE. This study reveals the signiÀcance of the 
pentose phosphate pathway in MPE formation, 
which may facilitate the development of new 
treatment strategies for MPE-associated lung 
adenocarcinoma.
Keywords: transketolase, Lung cancer, VEGF, 
anchorage-independent growth
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cell motility and causes metastasis. The expression 
of actinin-4 protein is closely associated with a 
poor outcome in patients with cancers of the breast, 
colorectum, pancreas, and ovary. Here we report 
that increased expression and gene ampliÀcation of 
actinin-4 can identify a distinct subset of patients 
with stage I lung adenocarcinoma in whom the 
outcome will be extremely unfavorable even after 
complete resection of their tumors. This subset of 
patients requires intensive medical attention and 
might beneÀt from adjuvant chemotherapy. 
Methods: We performed a retrospective 
analysis of multiple cohorts totaling 1744 
patients who underwent complete resection 
of lung adenocarcinoma. The expression of 
actinin-4 protein in the tumors was evaluated 
immunohistochemically, and the copy number of 
the actinin-4 (ACTN4) gene was determined by 
Áuorescence in situ hybridization. 
Results: AmpliÀcation of the ACTN4 gene was 
signiÀcantly correlated with smoking history 
(P = .02), pathological stage (P = .002), and 
histological differentiation (P < .001). Overall 
survival was signiÀcantly worse for patients 
with all stages from stage I to IV, and stage I 
lung adenocarcinoma harboring ACTN4 gene 
ampliÀcation than for those whose tumors showed 
no such gene ampliÀcation (P < .001 and P < .001). 
Multivariate analysis revealed that ACTN4 gene 
ampliÀcation in all stages from stage I to IV , and 
stage I lung adenocarcinoma was an independent 
factor associated with a higher risk of death 
(hazard ratio, 2.65 ; P < .001 and 6.78; P < .001). 
The 5-year survival rate of patients with stage I 
lung adenocarcinoma showing increased actinin-4 
protein expression and ACTN4 gene ampliÀcation 
was 63%, 70% and 55%, whereas that of patients 
whose tumors lacked gene ampliÀcation was 86%, 
93% and 87%, and that of patients whose tumors 
lacked actinin-4 protein expression was 97, 96% 
and 90% in three independent cohorts. The former 
had signiÀcantly worse overall survival than either 
of the latter in every cohort (P < .001). 
Conclusion: AmpliÀcation of the actinin-4 gene 
deÀnes a subset of stage I lung adenocarcinoma 
with a distinct outcome. 
increased incidence of cancer recurrence in patients 
with surgically resected NSCLC. 
Keywords: aldh, stem cell, NSCLC, biomarker
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P2.059 AMPLIFICATION OF THE ACTN4 
GENE IN STAGE I ADENOCARCINOMA 
OF THE LUNG
Rintaro Noro1, Kazufumi Honda2, Koji Tsuta3, 
Genichiro Ishii4, Akiko M. Maeshima3, Koh Furuta5, 
Tatsuhiro Shibata6, Hitoshi Tsuda3, Atsushi Ochiai4, 
Tomohide Sakuma7, Nobuhiko Nishijima8, Akihiko 
Gemma1, Hisao Asamura9, Kanji Nagai10, Tesshi 
Yamada2 
1Department Of Internal Medicine, Division Of 
Pulmonary Medicine, Infectious Diseases And 
Oncology , Nippon Medical School, Tokyo, Japan, 
Nippon Medical School Hospital/Japan, 2The 
Division Of Chemotherapy And Clinical Research, 
National Cancer Center Research Institute/Japan, 
3Pathology And Clinical Laboratory Division, 
National Cancer Center Hospital/Japan, 4Pathology 
Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan, 
5Division Of Clinical Laboratories, National 
Cancer Center Hospital/Japan, 6Division Of Cancer 
Genomics, National Cancer Center Research 
Institute/Japan, 7Mitsui Knowledge Industry, Mitsui 
Knowledge Industry/Japan, 8Pulmonary Medicine 
Infection And Oncology, Nippon Medical School 
Hospital/Japan, 9Thoracic Surgery, National Cancer 
Center Hospital/Japan, 10Division Of Thoracic 
Oncology, National Cancer Center Hospital East/
Japan
Background: Even if detected at an early stage, 
a substantial number of lung cancers relapse after 
surgery. Patients with such tumors are likely to 
beneÀt from adjuvant therapy, but no method for 
discriminating them has been established. Actinin-4 
is an actin-binding protein that we originally 
identiÀed as being associated with enhanced cell 
motility. Knockdown of actinin-4 suppresses 
the migration and invasiveness of cancer cells. 
Conversely, its overexpression in mice increases 
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These results validate our earlier observations, now 
in a larger and independent patient cohort. 
Conclusion: Together with recent data 
demonstrating expression of C4.4A in a fraction 
of atypical adenomatous hyperplasias, the putative 
AC precursor lesion, the present results further 
substantiate the potential clinical value of C4.4A as a 
prognostic marker in this histologic subtype of lung 
cancer. 
1Jacobsen B and Ploug M. Curr. Med. Chem (2008) 
15, 2559-2573 2Hansen LV et al. Lung Cancer (2007) 
58, 260-266 
Keywords: survival, immunohistochemistry, 
LYPD3, Prognosis
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P2.061 ANALYSIS OF PTEN MUTATION 
STATUS IN CHINESE PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
Jian Su, She-Juan An, Ying Huang, Shi-Liang Chen, 
Wei-Bang Guo, Zhi-Hong Chen, Hong-Yan Tang, 
Xie Zhi, Jian-Guang Chen, Xu-Chao Zhang, Yi-Long 
Wu 
Medical Research Center, Guangdong Lung Cancer 
Institute, Guangdong General Hospital/China
Background: Tumor suppressor Phosphatase 
and Tensin Homolog (PTEN) protein is a lipid 
phosphatase that dephosphorylates PIP3 and 
negatively regulates PIP3 levels and PI3K/Akt 
pathway activity that controls cell cycle progression, 
growth and inhibition of apoptosis. The identiÀcation 
of somatically tumor mutations is increasingly 
important in the clinical management of cancer. The 
aim of this study is to detect somatic mutations of 
PTEN in patients with non-small cell lung cancers 
(NSCLCs).
Methods: The DNA was isolated from 76 tumor 
tissues obtained from Guangdong Lung Cancer 
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.060 C4.4A IS A PROGNOSTIC 
INDICATOR IN NON-SMALL CELL 
LUNG CANCER PATIENTS WITH 
ADENOCARCINOMAS
Benedikte Jacobsen1, Thomas Muley2, Michael 
Meister2, Hendrik Dienemann3, Ib Jarle Christensen1, 
Eric Santoni-Rugiu4, Ole Didrik Lærum5, Michael 
Ploug1 
1Finsen Laboratory, Copenhagen University 
Hospital/Denmark, 2Translational Research Unit, 
Thoraxklinik/university Of Heidelberg/Germany, 
3Department Of Surgery, Thoraxklinik, University 
Of Heidelberg/Germany, 4Department Of Pathology, 
Copenhagen University Hospital/Denmark, 
5Department Of Pathology, Haukeland University 
Hospital/Norway
Background: The glycolipid-anchored membrane 
protein C4.4A is a structural homolog of the 
urokinase-type plasminogen activator receptor 
(uPAR) and a member of the Ly6/uPAR/a-neurotoxin 
protein domain family.1 We have recently shown 
C4.4A to be induced in early precursor lesions of 
non-small cell lung cancer and to be a histologic 
biomarker for poor prognosis in this disease.2
Methods: In the present study, we have undertaken 
an immunohistochemical, retrospective study on the 
expression of C4.4A in 229 formalin-Àxed, parafÀn-
embedded non-small cell lung cancer cases. For each 
patient, one tissue section from the periphery and one 
from the center of the tumor were stained with our 
well-characterized polyclonal anti-C4.4A antibody. 
C4.4A levels were scored semi-quantitatively for 
intensity and frequency of positive tumor cells (range 
0-16) and statistically correlated to survival.
Results: Expression of C4.4A was more pronounced 
in squamous cell carcinomas (SCC) compared to 
adenocarcinomas (AC), with median tumor center 
scores of 8.0 and 1.3, respectively. Consequently, 
statistical analysis of survival was performed 
separately for 88 AC and 104 SCC patients. C4.4A 
score for the tumor center was, together with 
pathological stage, a highly signiÀcant prognostic 
factor in the AC group both in univariate (p-value = 
0.0003; Hazard ratio (95% CI) = 1.48 (1.14-1.91)) 
and multivariate analysis (p-value = 0.0006; Hazard 
ratio (95% CI) = 1.72 (1.26-2.35)), demonstrating 
decreasing survival with increasing score. Only 
pathological stage was signiÀcant for the SCC group. 
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Background: There is currently no validated test 
predicting tumour sensitivity to cisplatin-based CT 
in advanced NSCLC while the usefulness of some 
biomarkers (ERCC, RMM1) has been suggested. The 
primary aim of this prospective study is to identify 
predictive factors for response to CT in patients with 
advanced NSCLC using high throughput techniques 
by comparing the transcriptome (miRNAs and 
mRNAs) and the genetic background (SNPs) of 
responders and non responders. This approach allows 
investigating thousands of molecular markers in a 
same experiment with a small endobronchial sample.
Methods: Patients with suspected lung cancer were 
screened for inclusion. Those with pathologically 
proven advanced or metastatic NSCLC with an 
assessable lesion and who will receive Àrst-line CT are 
eligible. Three biopsies from the primary lung tumour, 
with a control sample from normal bronchial tissue, 
are prospectively collected during a conventional 
bronchoscopy. One is formalin Àxed and parafÀn 
embedded for pathological diagnosis. The second 
biopsy is used for miRNAs, mRNAs and DNAs 
analyses and the third is frozen in liquid nitrogen to 
store it in a tissue bank. Predictive factors for response 
to CT will be assessed in successive cohorts of 50 
patients, this number allowing enough power to Ànd 
a discriminant signature among responders and non-
responders to conventional Àrst-line CT.
Results: From April 2009 until January 2011, 114 
patients with suspected primary lung cancer were 
registered. As expected, a signiÀcant number of patients 
were ineligible because NSCLC histology cannot be 
conÀrmed (n=25) or no tumoural tissue can be obtained 
during diagnostic bronchoscopy (tumour not accessible 
n=15, absence of neoplastic tissue in the biopsy 
n=12, other reason n=7). Nine patients did not receive 
chemotherapy. At the time of analysis, the status of 2 
bronchial samples among 46 eligible patients is pending 
on ongoing work-up. Forty-four samples were analysed 
by spectrophotometry for mRNA quantity and purity 
for microarrays analyses. Thirty-eight were considered 
adequate. No serious complication occurred during 
bronchoscopy.
Conclusion: This feasibility study demonstrates the 
capability to obtain adequate endobronchial lung 
cancer sampling for mRNA analyses in a substantial 
number of unselected NSCLC patients without 
signiÀcant complications. The study is recruiting 
further patients before searching a predictive 
signature for response to chemotherapy.
Keywords: Non small cell lung carcinoma, 
Predictive biomarkers, Chemotherapy
Institute’s tumor bank. The sequences of exons 
1-9 of PTEN gene were assayed using PCR and 
DNA sequencing methods. The relationship of the 
PTEN mutation rate with the clinical parameters 
was analyzed using Fisher’s exact test. A two-
tailed P-value of <0.05 was considered statistically 
signiÀcant.
Results: Of these 76 patients, 52 were squamous 
cell carcinoma, 24 were adenocarcinoma; 28 were 
IB stage, 26 were IIA/IIB stage, and 22 were IIIA 
stage; 58 were male, 18 were female; The mean age 
of these patients was 59.37 years, range from 26-82 
years. The PTEN mutation rate is 7.9% (6/76) in all 
of these patients. Of these 6 mutations, 3 in exon 8, 
1 in exon 1, 1 in exon 2, and 1 in exon 5. We didn’t 
Ànd mutations in exon 3, exon 4, exon 6, exon 7, and 
exon 9. The mutation rate in adenocarcinoma and 
squamous cell carcinoma were 8.3% (2/24) and 7.7% 
(4/52), respectively (P=1.000); in stage IB, IIA/IIB, 
and IIIA were 10.7% (3/28), 3.8% (1/26) and 9.1% 
(2/22), respectively (P=0.664); in male and female 
were 8.6% (5/58) and 5.6% (1/18), respectively 
(P=1.000); in non-smokers and smokers were 2.7% 
(1/37) and 10.5% (4/38), respectively (P=0.358).
Conclusion: The present study indicated that the 
mutations of PTEN in patients with non-small cell 
lung cancer are frequently present in exon 8. And 
the mutation rate is not related with the gender, 
histology, smoking status, and clinical stages of the 
patients. These Àndings need to be veriÀed in a large 
sample size in the future.
Keywords: PTEN, Mutation, Lung cancer
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P2.062 ARE BIOLOGICAL FACTORS 
ABLE TO PREDICT RESPONSE TO 
CHEMOTHERAPY (CT) IN ADVANCED 
NON SMALL CELL LUNG CANCER 
(NSCLC)? A FEASIBILITY STUDY OF 
TUMOUR SAMPLINGS.
Thierry Berghmans1, Céline Mascaux1, Jean-Jacques 
LaÀtte2, Anne-Pascale Meert1, Arnaud Scherpereel2, 
Marianne Paesmans3, Ingrid Cstoth1, Lucas Willems4, 
Nathalie Leclercq1, Jean-Paul Sculier1 
1Intensive Care And Thoracic Oncology, Institut 
Jules Bordet/Belgium, 2Pneumology, Chru Lille/
France, 3Data Centre, Institut Jules Bordet/Belgium, 
4University Of Agronomic Sciences Of Gembloux/
Belgium
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adenocarcinoma, vascular endothelial growth factor, 
soluble intercellular adhesion molecule-1
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P2.064 MAINTENANCE BEVACIZUMAB 
MONOTHERAPY INCREASES 
HEMOGLOBIN (HGB) IN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
LUNG ADENOCARCINOMA (NSCLC-AD)
Jonathan W. Riess1, Aaron Logan2, Yelena 
Krupitskaya1, Christelle Clement-Duchene1, Calvin 
Kuo2, Heather Wakelee1 
1Oncology, Stanford University/United States Of 
America, 2Hematology, Stanford University/United 
States Of America
Background: Inhibitors of vascular endothelial 
growth factor (VEGF) have been widely studied as 
therapeutics for a range of malignancies. Stringent 
VEGF inhibition in mice and non-human primates 
increases hemoglobin (Hgb) due to a combination 
of plasma volume contraction and increased 
erythropoiesis. The latter is mediated by elevated 
hepatic erythropoietin (Epo) production. Studies 
in renal cell carcinoma (RCC) have documented 
increased Hgb levels in patients receiving sorafenib 
and sunitinib, tyrosine kinase inhibitors with anti-
VEGF receptor activity. We evaluated the effect of 
VEGF inhibition on Hgb level in a phase II trial 
of NSCLC-Ad patients that included maintenance 
bevacizumab monotherapy. 
Methods: Patients with newly diagnosed advanced 
NSCLC-Ad received 4-6 cycles of carboplatin, 
gemcitabine, and bevacizumab followed by 
bevacizumab monotherapy dosed at 15 mg/kg every 
three weeks until evidence of disease progression 
(Clement-Duchene et al, JTO 2010.) No patient 
analyzed received erythropoiesis stimulating agents 
or red blood cell transfusions while on study. 
Baseline reticulocyte count, Hgb and Epo levels 
at the start of chemotherapy were compared to the 
median reticulocyte count, Hgb and Epo levels 
calculated from all measurements obtained after two 
cycles of bevacizumab monotherapy until 3 weeks 
after discontinuation of maintenance bevacizumab. 
These timepoints were chosen to minimize the 
confounding effects from hematologic recovery after 
induction with myelosuppressive therapy. 
Results: Forty patients were consented for this 
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P2.063 ROLE OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR 
AND SOLUBLE INTERCELLULAR 
ADHESION MOLECULE-1ON CONTROL 
OF PLEURAL EFFUSION AND SURVIVAL 
IN PATIENTS WITH HUMAN LUNG 
ADENOCARCINOMA
Qian Qian1, Ping Zhan2, Like Yu2, Yong Song3 
1First Department Of Respiratory Medicine, Nanjing 
Chest Hospital/China, 2Nanjing Chest Hospital/
China, 3Department Of Respiratory, Nanjing 
University, Jinling Hospital/China
Background: The mechanisms by which vascular 
endothelial growth factor (VEGF) and soluble 
intercellular adhesion molecule-1 (sICAM-1) 
contribute lung cancer growth have not been fully 
elucidated. This study aimed to assess the role of 
VEGF and sICAM-1 in survival and control of 
pleural effusions (PE) in patients with primary 
human lung adenocarcinoma.
Methods: Using enzyme-linked immunoadsorbent 
assay, the concentrations of VEGF and sICAM-1 
were measured in pleural effusions and serum from 
a total of 79 lung adenocarcinoma patients with 
malignant pleural effusions (MPE) and 24 patients 
with tuberculosis. Data were correlated with the 
efÀcacy of MPE control and survival.
Results: Compared to patients with tuberculosis, 
the levels of VEGF and sICAM-1 in both PE and 
serum were signiÀcantly higher in patients with lung 
adenocarcinoma. Statistically signiÀcant correlation 
was observed between PE VEGF levels and MPE 
control. PE VEGF2760 pg/mL was used as a cut-
off point for failure to MPE control (odds ratio=7.06; 
95% conÀdence interval (CI), 2.40-20.78; P<0.001). 
The median progression-free survival (PFS) from 
response assessment was 3 months. In a multivariate 
analysis, PE VEGF (hazard ratio [HR], 1.16; 95%CI, 
1.02-1.32), serum sICAM-1 (HR, 1.90; 95%CI, 
1.17-3.07) were conÀrmed as independent prognostic 
factors for PFS.
Conclusion: The level of VEGF in PE appears to 
be a reliable surrogate marker in evaluating the 
therapeutic efÀcacy in the control of MPE and this, 
together with serum level of sICAM is potential 
survival factors in lung adenocarcinoma patients 
with MPE.
Keywords: malignant pleural effusion, lung 
S962 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
And Translational Research Of Cancer - Ficmac/
Colombia, 3Sanitas/Colombia, 4Clínica Astorga/
Colombia, 5Instituto De Cancerología - Clínica 
Las Américas/Colombia, 6Fundación Universitaria 
Ciencias De La Salud - Fucs/Colombia, 7Instituto 
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Spain
Background: Driver mutations occur in genes 
that encode signalling proteins critical for cellular 
proliferation and survival. In lung cancer, these 
mutations include EGFR, KRAS, BRAF and EML4/
ALK. 
Methods: We evaluated the feasibility of screening 
228 NSCLC patients in Colombia by analyzing 
tumor tissue by DNA sequencing.
Results: The study included 152 females (67%) 
and 76 males (33%) with a mean age of 59 (SD ± 
13); 63% of the patients had adenocarcinoma, 6% 
presented non-speciÀc tumors, 1.8% had large cell 
carcinomas, 2.6% had squamous cell carcinomas. 
Histological subtype was non-speciÀc in 12.3%. 
According to tobacco consumption (n=173), 60%, 
20% and 3% were non-smokers, ex-smokers 
or active smokers respectively. 57 patients had 
activating mutations (25%) in the EGFR, 40 with 
E19 deletion (70% of mutated subjects) and 17 with 
the in-frame L858R mutation (30%). Almost all with 
the E19 deletion were non-smokers (86%), as well 
as those affected by the E21 mutation (75%). 11% of 
tumors were positive for K-ras mutations (n=114), 
one patient (3.8%) was positive for the ALK/ELM4 
fusion gene (n=26). BRAF (V600E) mutations were 
not detected (n=60). 
Conclusion: The frequency of mutations in EGFR 
in NSCLC patients from Colombia was greater 
than that reported in other western countries; the 
distribution favoured the presence of the E19 
deletion and the proportion of ALK/ELM4 is in 
agreement with previous data. To our knowledge, 
this study represents the Àrst comprehensive analysis 
of major oncogenic mutations found in a large cohort 
of lung cancers from Latin America. 
Keywords: Latin America, Genetic proÀling, Non-
small cell lung cancer, Somatic mutations
correlative study. The data from twenty-two 
patients (55%) who received more than two cycles 
of maintenance bevacizumab were analyzed. 
Hemoglobin increased signiÀcantly from 12.9 g/
dL at the initiation of chemotherapy to a median of 
13.8 g/dL (p=0.01) after 2 cycles of maintenance 
bevacizumab, an increase of 7%. In 7 patients 
who had both Epo level and reticulocyte count 
collected before the initiation of chemotherapy, 
pre-treatment Epo level was 17 mU/mL and after 
2 cycles of bevacizumab the median Epo level was 
not signiÀcantly different at 19 mU/mL. Median 
reticulocyte count was also not signiÀcantly different 
at 72.6 K/L before chemotherapy and a median 
of 53.3 K/ƫL after two cycles of maintenance 
bevacizumab. 
Conclusion: Maintenance bevacizumab led to 
signiÀcantly higher Hgb levels than baseline pre-
treatment Hgb. Median Epo level and reticulocyte 
count were similar at the start of chemotherapy 
and after maintenance bevacizumab, but the small 
number of patients who had serum Epo level and 
reticulocyte count collected before chemotherapy 
limits the interpretation of this Ànding. Based 
on these results showing an increase in Hgb 
with maintenance bevacizumab in patients with 
advanced NSCLC-Ad and mouse models where 
high-level VEGF inhibition increases hepatic Epo 
and Hgb levels, further investigation of erythrocytic 
parameters for NSCLC-Ad patients receiving 
bevacizumab and other VEGF inhibitors are 
warranted. 
Keywords: bevacizumab, hemoglobin
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P2.065 SCREENING FOR MUTATIONS 
IN COLOMBIAN METASTATIC NON-
SMALL-CELL LUNG CANCER (NSCLC) 
PATIENTS (ONCOLGROUP)
Andrés F. Cardona1, Silvia J. Serrano2, Pedro L. 
Ramos3, Ricardo Duarte3, Hernán Carranza1, Carlos 
J. Castro1, Mauricio Lema4, Carlos A. Vargas1, Juan 
A. Jiménez5, Pilar Archila6, Ruben D. Salazar4, 
Diana Torres7, Ricardo E. Bruges8, Joaquín Guerra9, 
Marcela Urrego10, Henry A. Becerra1, Carlos 
Bonilla8, Rafael Rosell11 
1Clinical And Translational Oncology Group, 
Fundación Santa Fe De Bogotá/Colombia, 
2Molecular Biology, Foundation For Clinical 
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months compared to 23.4 mo in pt with at least 
one D allele (p=0.08). All XPD-312N/N pt were R 
(n=6) compared to 63% R in XPD-312D/D or D/N 
pt (p=0.08). Multivariate cox regression analyses 
revealed performance status (p=0.006), XPD-
312N/N (p=0.038), GSTT1 (p=0.03) and surgical 
resection (p=0.001) as independent predictors of OS.
Conclusion: DNA-repair and GST polymorphisms 
may be associated with clinical outcome in NSCLC 
patients with localized disease and multimodal 
chemoradiation.
Keywords: pharmacogenetics, NSCLC, 
polymorphism
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P2.067 N-ACETYLGALACTOSAMINYL-
TRANSFERASE-6 AS A POTENTIAL 
BIOMARKER FOR LUNG CANCER BY 
IMMUNOHISTOCHEMISTRY.
Nora Berois1, Ana Masllorens2, Diego Touya2, Pablo 
Dibarboure2, Luis Ubillos2, Guillermo Carriquiry2, 
Mariella Rondan2, Eduardo Osinaga3, Mario 
Varangot2 
1Institut Pasteur Montevideo/Uruguay, 2Facultad De 
Medicina/Uruguay, 3Laboratory Of Glycobiology 
And Tumor Immunology, Institut Pasteur 
Montevideo/Uruguay
Background: Altered O-glycosylation in cancer 
leads to an aberrant expression of immature 
carbohydrate structures (Tn, TF and sialyl-Tn 
antigens). The UDP-N-acetyl-D-galactosamine-
polypeptide N-acetylgalactosaminyltransferases 
(ppGalNAc-T) enzymes regulate the initial steps 
of mucin O-glycosylation and could be responsible 
for the altered glycosylation observed in cancer. In 
recent years the enzyme ppGalNAc-T6 has attracted 
attention as a new marker for breast and gastric 
tumors. GALNT6 gene is expressed in a restricted 
pattern, being mainly in normal placenta, trachea, 
brain, pancreas and Àbroblast cells. We previously 
found aberrant expression of ppGalNAc-T6 
in breast and colon cancer, observing that this 
glycosyltransferase may be implicated in changes in 
O-glycan patterns in tumor cells. Considering that 
abnormal O-glycosylation is frequently observed 
in lung cancer, the aim of this work was to assess 
ppGalNAc-T6 expression in malignant lung cells.
Methods: ppGalNAc-T6 expression was evaluated 
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P2.066 ASSOCIATION BETWEEN DNA-
REPAIR GENE AND GLUTATHIONE 
S-TRANSFERASE GENE 
POLYMORPHISMS AND CLINICAL 
OUTCOME IN PATIENTS (PT) WITH 
LOCALIZED NON-SMALL-CELL LUNG 
CANCER (NSCLC) TREATED WITH 
SEQUENTIAL RADIOCHEMOTHERAPY
Birgit Krassler1, Eray Goekkurt2, Michael 
Kramer3, Gerhard Ehninger3, Gert Höffken1, Jan 
Stoehlmacher-Williams3 
1Oncology, FKH Coswig/Germany, 2University 
Hospital Aachen/Germany, 3Medical Oncology, 
University Dresden/Germany
Background: To evaluate the impact of DNA-repair 
and glutathione S-transferase gene polymorphisms 
on clinical outcome measured by progression-free 
(PFS) and overall survival (OS) in patients with 
localized non-small-cell lung cancer (NSCLC).
Methods: DNA for genotyping was extracted from 
archived parafÀn embedded formalin-Àxed tumor 
tissues. Genotyping was performed using PCR-
based methods. Genomic polymorphisms of ERCC1, 
XRCC1, XRCC2, XPA, GSTP1, GSTT1 and 
GSTM1 were analyzed using PCR-based methods.
Results: 116 pt with NSCLC Ib-IIIb 85% received 
cisplatin-based chemotherapy (cx) prior to radiation. 
Pt demographics: median age 63 years; ECOG 0/1 
and 2: 90%, 10%; 87% male/13% female; 90% of 
pt got local treatment (radiation and/or resection) 
following cx. Responses: 72 pt (62%) complete 
or partial remission, 32 pt (27%) stable disease 
and 14 pt (11%) progressive disease (PD). Median 
follow up time was 23.1 months (mo). Relapse or 
PD was observed in 80% of cases. Median OS of 
all pt was 23.4 mo and median PFS was 9.8 mo. 
GSTP1-105Val/Val genotype was associated with 
superior PFS and OS. In this group the median was 
not reached whereas median OS for heterozygots 
or homozygous wildtypes was 23.4 mo (p=0.056). 
Median PFS for GSTP1-105Val/Val was 24.4 
mo compared to 9.8 mo (p=0.048). Moreover, all 
GSTP1-105Val/Val patients (n=8) were responders 
(R) to cx compared to only 59% R in pt with at least 
one Ile allele (p=0.023). Pt with a GSTT1 deletion 
showed shorter OS with 10.7 mo compared 23.8 mo 
in pt without a GSTT1 deletion (p=0.12). Median 
OS in the XPD-312N/N genotype group was 69.7 
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(S100A7 and S100A11), induction of apoptosis 
(S100A8/A9), intracellular trafÀcking of membrane 
proteins (S100A10) and ultimately, binding to 
p53 and modulation of its function (S100A2, 
S100A4 and S100A6). We have previously shown 
that S100A6 and S100A4 are expressed in a p53-
dependent way in lung cancer cells (Orre et al. Mol 
Cell Proteomics 2007) and that S100A6 levels have 
prognostic implication in stage I NSCLC (De Petris 
et al. Lung Cancer 2009). The aim of the present 
study is to evaluate the tumor expression of diverse 
S100 proteins in specimens of surgically resected 
NSCLC in correlation with clinical outcomes.
Methods: Expression of S100A2, S100A4, S100A6, 
S100A7, S100A8, S100A9, S100A10, S100A11 and 
p53 was determined by immunohistochemistry on 
archival formalin-Àxed parafÀn embedded tumor 
specimens from 494 patients with node-negative 
stage I (6th TNM) NSCLC who received curative 
surgical resection, without peri-operative chemo- or 
radiotherapy. Tumors were mainly adenocarcinomas 
(54%) and squamous-cell carcinomas (32%). Half 
of the cases were on stage IA. Median follow up of 
censored cases was > 10 years. 
Results: Positive immunoreactivity for p53, 
S100A2, S100A4, S100A6, S100A7, S100A8, 
S100A9, S100A10 and S100A11 was observed in 
45%, 37%, 33%, 65%, 63%, 34%, 49%, 33% and 
75% of cases, respectively. S100A8, S100A9 and 
p53 were signiÀcantly more expressed in squamous-
cell tumors and in those with a lower grade of 
differentiation. Conversely, S100A4 and S100A6 
were more expressed in adenocarcinomas and in 
well differentiated tumors. Higher expression of 
S100A4 and S100A10 was associated with the 
development of brain metastasis as the Àrst site of 
tumor recurrence (chi-square p=0.04). In terms of 
survival outcomes, p53 was a negative prognostic 
factor of overall survival (log-rank p=0.02), but this 
was not conÀrmed on multivariate analysis adjusted 
by stage, histology and grading (HR for p53 negative 
vs positive 0.92, 95% CI 0.84-1.04; p=0.1). Further 
analyses by histology and p53 status showed that 
in p53-negative adenocarcinomas (n=153) the low/
negative expression of S100A2 was an independent 
prognostic factor of shorter time-to-progression 
(multivariate analysis, adjusted by stage and 
grading; HR 1.38, 95% CI 1.00-1.96; p=0.04). In 
p53-positive squamous-cell tumors (n=88) the low/
negative expression of S100A10 was an independent 
prognostic factor of longer time-to-progression (HR 
0.66, 95% CI 0.48-0.91; p=0.01).
in a panel of human lung cancer cell lines using 
both RT-PCR and Westen blot assays. Using the 
monoclonal antibody T6.3 (Berois, J. Histochem. 
Cytochem. 2006, 54:317) we determined by 
immunohistochemistry ppGalNAc-T6 expression in 
lung cancer and in normal lung tissues. 
Results: Expression of ppGalNAc-T6 was found 
in A549, H526, H838, H1703, H1755, H1650, 
H1975 and MES1 lung cancer cell lines. We do not 
observed ppGalNAc-T6 expression in the H69AR 
small cell lung cancer (SCLC) cell line. In formalin-
Àxed tissues ppGalNAc-T6 expression was observed 
in 45/49 (91.8%) lung cancers, and in 0/8 normal 
lung samples. The staining pattern observed in 
adenocarcinoma and epidermoid cancer is shown in 
Figures 1 and 2, respectively.
Conclusion: This report is the Àrst evidence of 
aberrant expression of ppGalNAc-T6 in lung 
cancer. We found that ppGalNAc-T6 is a novel 
immunohistochemical marker for non-small cell lung 
cancer. In order to determine the potential clinical 
value of this marker now is necessary to extend our 
observations in a follow-up study of a larger number 
of cases.
Keywords: O-glycosylation, Glycosyltransferases, 
tumor markers, Lung cancer
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P2.068 CLINICAL IMPLICATIONS OF 
THE TUMOR EXPRESSION OF S100 
PROTEINS IN NON-SMALL-CELL LUNG 
CANCER
Luigi De Petris1, Lena Kanter2, Flavia Melotti1, Per 
Bergman3, Karl-Gustav Kölbeck4, Henrik Hellborg5, 
Jan Adolfsson5, Rolf Lewensohn1, Janne Lehtiö1 
1Oncology And Pathology, Karolinska Institutet/
Sweden, 2Pathology And Cytology, Karolinska 
University Hospital Solna/Sweden, 3Cardiothoracic 
Surgery And Anesthesiology, Karolinska University 
Hospital Solna/Sweden, 4Pulmonary Medicine And 
Allergology, Karolinska University Hospital Solna/
Sweden, 5Onkologiskt Centrum Stockholm And 
Gotland Region/Sweden
Background: The S100-protein family is a group of 
proteins that share the same calcium-binding motif 
but play different roles in a variety of intracellular 
and extracellular mechanisms, such as increase of 
cell motility (S100A4), promotion of cell-cycle arrest 
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smoking status, histology, EGFR or k-ras mutations 
are considered to be predictive for response or 
resistance to EGFR-TKIs. 
Methods: In this study, pretherapeutic tissue 
specimens of German patients with advanced 
NSCLC, who experienced long-term response to 
geÀtinib (3 years) within the International Iressa 
Expanded Access Program (EAP) were analyzed. 
Of 1,925 patients enrolled, who had progressive 
disease after at least one course of chemotherapy 
or radiation or were ineligible for both, 20 (1.0%) 
long-term responders (LTR) were identiÀed; 11 with 
appropriate tissue specimens available. These were 
analyzed for EGFR and k-ras mutations, EGFR 
and c-met ampliÀcation, and protein expression 
of EGFR, E-cadherin, CD133 and breast cancer 
resistance protein (BCRP1). The results were 
compared to those of intermediate responders (IR) 
showing a median response of 8.6 months and 
primary resistant patients (RP). The distribution of 
gender, histology and smoking status in the LTR, IR 
and RP group was matched. 
Results: Each group consisted of 6 women and 5 
men, who had received at least 1 previous therapy. 1 
patient had a squamous cell carcinoma (SCC) and 10 
patients an adenocarcinoma. 6/11 patients were never 
smokers. Except for the number of metastatic sites 
(LTR: 0.8±0.4, IR: 2.2±1.0, RP: 1.7±0.9, p<0.05), 
the clinico-pathological characteristics of the various 
groups showed no signiÀcant differences. All LTR, 
but the SCC had EGFR mutations. In turn 5/11 RP 
showed k-ras, but no EGFR mutations. 8/11 IR had 
EGFR and 3/11 k-ras mutations, of which 2 occurred 
concomitantly with EGFR mutations. 1 LTR had 
an EGFR, 1 RP a c-met and 1 IR both, an EGFR 
and c-met ampliÀcation. EGFR and E-cadherin 
expression was not different between the groups, 
whereas CD133 was exclusively expressed in LTR 
(LTR: 4/10, IR: 0/11, RP: 0/11, p<0.05) and BCRP1 
predominantly in responders (LTR: 7/10, IR: 7/11, 
RP: 1/10, p<0.05). The median PFS to geÀtinib 
was 61.4 months in LTR, 8.6 months in IR and 1.1 
months in RP. The median survival was 85.1, 18.0 
and 16.1 months, respectively. Remarkably, the LTR 
showed also a signiÀcantly longer median PFS to 
previous therapies than IR or RP (LTR: 13.6 months, 
IR: 5.6 months, RP: 7.8 months, p<0.05). This 
suggests not only a predictive, but also a prognostic 
impact of the molecular properties of LTR. 
Conclusion: These data demonstrate that 
pretherapeutic tissue specimens and established 
biomarkers predict response to geÀtinib in pretreated 
Conclusion: In this study we perform a broad 
evaluation of the clinical signiÀcance of the 
expression of several members of the S100 protein 
family in NSCLC. In light of recent research on 
functional relation between S100 proteins and p53, 
our results may elucidate the prognostic impact and 
functional effect of p53 in lung cancer by parallel 
detection of relevant S100-proteins. 
Keywords: early-stage NSCLC, Biomarkers, 
Prognosis, S100 proteins
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P2.069 THE GEFITINIB LONG-TERM 
RESPONDER (LTR) – A CANCER STEM-
LIKE CELL STORY? INSIGHTS FROM 
MOLECULAR ANALYSES OF GERMAN 
LONG-TERM RESPONDERS TREATED 
IN THE IRESSA EXPANDED ACCESS 
PROGRAM
Sandra Gottschling1, Esther Herpel2, Wilfried 
Eberhardt3, Ulrich Gatzemeier4, Jürgen R. Fischer5, 
Claus-Henning Köhne6, Cornelius Kortsik7, Thomas 
Kuhnt8, Thomas Muley9, Michael Meister9, Helge 
Bischoff10, Philipp A. Schnabel2, Roland Penzel2, 
Michael Thomas10 
1Thoracic Oncology & Translational Research Unit, 
Thoraxklinik/University Of Heidelberg/Germany, 
2Institute Of Pathology, University Of Heidelberg/
Germany, 3Internal Medicine [Cancer Research], 
University Duisburg-essen/Germany, 4Oncology 
Center, Hospital Großhansdorf/Germany, 5Internal 
Medicine Ii, Hospital Löwenstein/Germany, 
6Oncology/hematology, Hospital Oldenburg/
Germany, 7Pneumology, St. Hildegardis Hospital 
Mainz/Germany, 8Radiology Center, University 
Rostock/Germany, 9Translational Research Unit, 
Thoraxklinik/University Of Heidelberg/Germany, 
10Thoracic Oncology, Thoraxklinik/University Of 
Heidelberg/Germany
Background: Lung cancer is the leading cause of 
cancer-related death world-wide and has a poor 
prognosis. In selected patients with advanced non-
small cell lung cancer (NSCLC) the epidermal 
growth factor receptor (EGFR) tyrosine kinase 
inhibitor (TKI) geÀtinib (Iressa) shows response 
rates 70% and a signiÀcant prolongation of 
progression free survival (PFS). Clinico-pathological 
and molecular characteristics such as gender, 
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The inÁuence of necrosis and the percentage of 
malignant tumor tissue necessary for the analysis are 
registered. Information on smoking habits, treatment, 
TNM stage and survival is also collected. We aim to 
include 100 mutated patients. Assuming a mutation 
rate around 10% 1000 tumors should be tested 
(95% CI 83-120 patients positive). The mutations 
will be detected by therascreen EGFR RGQ PCR 
Kit (selective site-speciÀc detection of 29 somatic 
mutations in the EGFR oncogene, Qiagen).
Results: 65 patients have been included per month. 
By February 2011 590 patients were included. We 
expect to be able to present data for 850 patients 
with NSCLC tested for EGFR mutations. All 
data will be presented including an algorithm for 
optimal selection of patients to be tested for EGFR 
mutations. 
Conclusion: Data for 850 patients with NSCLC 
tested for EGFR mutations will be presented and an 
algorithm for optimal selection of patients will be 
developed. 
Keywords: EGFR mutations, NSCLC, population 
based, test algorithm
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.071 A PHASE IB WINDOW OF 
OPPORTUNITY CLINICAL STUDY WITH 
EVEROLIMUS IN PATIENTS WITH 
RESECTABLE NON-SMALL CELL LUNG 
CANCER (NSCLC)
Taofeek K. Owonikoko1, Seth Force1, Gabriel Sica1, 
Rabih Bechara2, R D. Harvey1, Shi-Yong Sun1, Nabil 
Saba1, Jaqueline Rogerio3, Anthony Gal1, Scott 
Kono1, Daniel Miller1, Suresh Ramalingam1, Fadlo 
R. Khuri1 
1Winship Cancer Institute, Emory University/United 
States Of America, 2Winship Cancer Institute; 
Division Of Pulmonology, Emory University/United 
States Of America, 3Novartis Oncology/United States 
Of America
Background: Preclinical and clinical correlative 
studies implicate aberrant mTOR pathway activity in 
lung cancer. We conducted this study to demonstrate 
the biologic activity of everolimus, an allosteric 
patients. Moreover, they suggest that markers 
indicating cancer-stem like cells, i.e. CD133 and 
BCRP1 may characterize a subgroup of favorable 
LTR and thus matter of interest for further 
evaluation. 
Keywords: Non-small cell lung cancer, epidermal 
growth factor receptor tyrosine kinase inhibitor, 
cancer stem-like cell, biomarker
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P2.070 DANISH POPULATION BASED 
STUDY OF THE PREVALENCE OF 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATIONS IN NON 
SMALL CELL LUNG CANCER (NSCLC) 
(DAPPER STUDY)
Birgit G. Skov1, Estrid Høgdall2, Paul Clementsen3, 
Mark Krasnik4, Klaus R. Larsen5, Jens B. Sørensen6, 
Anders Mellemgaard7 
1Pathology, Bispebjerg University Hospital/
Denmark, 2Pathology, Herlev University Hospital/
Denmark, 3Pulmonology, Gentofte University 
Hospital/Denmark, 4Copenhagen University 
Hospital, Rigshospitalet/Denmark, 5Pulmonology, 
Bispebjerg University Hospital/Denmark, 6Oncology, 
Copenhagen University Hospital, Rigshospitalet/
Denmark, 7Oncology, Herlev University Hospital/
Denmark
Background: Mutations in the EGFR gene in 
NSCLC identify patients sensitive to tyrosine kinase 
inhibitors. The mutations are more prevalent in 
Asian population compared to Caucasian. However 
estimates of mutation frequencies are only available 
from selected patient cohorts. The true incidence 
in an unselected Caucasian (Danish) population is 
unknown.
The study will assess the incidence of EGFR 
mutations in a large population based cohort, and 
the correlation between mutation and gender, age, 
ethnicity, smoking habits, as well as clinical and 
pathological data.
Methods: Since June 2010, all patients with NSCLC 
diagnosed in a well deÀned population of 1.2 million 
in the Copenhagen area are included in this single 
center study. Detailed information regarding type 
and location of the obtained material is registered. 
A speciÀc focus is on whether cytologic material 
(all types included) is suitable for mutation studies. 
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pathway modulation. Acknowledgements: This 
study was supported by NCI grant P01 CA116676. 
Everolimus was provided by Novartis Oncology. 
FRK, TKO, SS, and SSR are Georgia Cancer 
Coalition Distinguished Cancer Scholars. 
Keywords: Lung cancer, mTOR, biomarker, 
everolimus
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P2.072 CLINICAL SIGNIFICANCE OF 
IGF-1R AND MMP-7 EXPRESSION IN 
PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
Taketsugu Yamamoto1, Takashi Oshima2, Kazue 
Yoshihara2, Teppei Nishii3, Hiromasa Arai3, Kenji 
Inui3, Hiroyuki Adachi1, Yasushi Rino1, Munetaka 
Masuda1, Toshio Imada1 
1Surgery, Yokohama City University/Japan, 
2Gastroenterological Center, Yokohama City 
University Medical Center/Japan, 3Respiratory 
Center, Yokohama City University Medical Center/
Japan
Background: Insulin-like growth factor-1 receptor 
(IGF-1R) is a tyrosine kinase receptor implicated 
in the pathogenesis of several malignancies and 
expected to be a molecular target in non-small 
cell lung cancer (NSCLC). A number of IGF-1R 
inhibitors are currently investigated in several 
clinical trials. A phase II study concluded that 
Àgitumumab, a selective inhibitor of the IGF-1R, 
increases the response rate and progression–free 
survival beneÀt of paclitaxel and carboplatin as Àrst-
line treatment of patients with advanced NSCLC. 
In vitro studies showed that expression of IGF-1R 
correlates with sensitivity to IGF-1R inhibitors. 
Matrix metalloproteinase-7 (MMP-7) is a member 
of the MMP family, and plays an important role 
in tumorigenesis, tumor invasion, and metastasis. 
Recent studies showed that MMP-7 regulates the 
bioavailability of insulin-like growth factors. The 
purpose of this study was to clarify the clinical 
siginiÀcance of the IGF-1R and MMP-7 in NSCLCs.
Methods: We examined the clinical signiÀcance 
of IGF-1R and MMP-7 expression in 78 
postsurgical patients in non-small-cell lung cancer. 
Immunohistochemistry was used to measure the 
expressions. The percentage of stained cells (0-
100%) was multiplied by the staining intensity (0-3). 
inhibitor of mTOR pathway, in patients with 
resectable NSCLC. 
Methods: Patients with surgically resectable 
NSCLC (Stage I-III) underwent baseline tumor 
biopsy and FDG PET scan followed by treatment 
with everolimus (5 or 10mg daily for 21 to 28 
days). Blood samples for pharmacokinetic (PK) 
assay for drug levels were collected at 0.5, 1, 2, 5, 
8 and 24 hours post drug ingestion on Days 1, 8 
and 21. A repeat PET scan was obtained within 24 
hours prior to surgery. Control group patients did 
not receive everolimus but also had two PET scans 
at least 2 weeks apart prior to surgery. Evidence 
of target engagement and biological activity was 
assessed in vivo by PET imaging and ex vivo by 
immunohistochemical detection of markers of 
mTOR pathway activation (total and phosphorylated 
mTOR, Akt, S6, eIF4e, EBP1) in baseline tumor 
tissue and in resected surgical specimens.
Results: Sixteen patients have been enrolled 
including 14 on the experimental and 2 on the 
control arm. Age (median 63 yrs; range 44-77), 
gender: (8/8 –M/F), stage (I - 12; II - 2; III - 2); 
histology (adenocarcinoma - 10; squamous - 4; 
others - 2). All patients underwent surgery as 
planned. Comparison of paired baseline and 
resected tumor specimens showed consistent 
upregulation of p-Akt, an upstream event, whereas 
p-S6 expression, a downstream marker was not 
consistently downregulated in the initial cohort 
of patients treated with 5mg dose of everolimus. 
Analysis of FDG activity within the tumor mass 
on the baseline and the repeat PET scan showed 
a reduction in SUVmax in everolimus-treated 
patients (mean SUVmax reduction of -20%; range 
-54% to +20%), while control subjects showed a 
+42% increase in SUVmax in paired PET scans. 
Preliminary PK analysis in patients treated at the 
5mg dose was consistent with previous experience 
in other population with no signiÀcant accumulation 
over time.
Conclusion: Everolimus showed measurable 
biologic activity in vivo and ex vivo at the level of 
the tumor in NSCLC patients. At the commonly 
studied dose in NSCLC of 5 mg per day, everolimus 
did not result in consistent downregulation of pS6, 
an established downstream biomarker of pathway 
inhibition. Our result raises the possibility that the 
5mg dose may be inadequate to completely abrogate 
aberrant mTOR signaling in NSCLC patients. 
Ongoing enrolment to the 10mg dose cohort will 
provide additional insight into dose-dependent 
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corelate the expression of multiple mRNA markers 
in bronchoscopy obtained cancer specimens with 
clinical outcome of locally advanced NSCLC and 
LD-SCLC patients treated with radiotherapy and 
chemotherapy.
Methods: Between January 2007 and December 
2008 bronchoscopy cancer specimens were taken 
from 110 patients. We were able to isolate RNA 
and perform gene expression analysis in 90 out of 
110 cases (81%), including 53 NSCLC, 22 SCLC 
and 16 specimens with other or not speciÀed cancer 
type. The majority of 90 patients were treated 
with radiotherapy (78%), 62% had platinum-based 
chemotherapy, only three individuals (3%) had 
surgery. Quantitative real time PCR was carried out 
by ABI 7900 HT machine, with Universal Probe 
Library (Roche) Áuorescent probes. The genes 
selected for the analysis were ERCC1, EGFR, 
BRCA1, CSF1, CA9, DUSP6, STAT1, ERBB3, 
MMD, FN1, and CDKN1B. The inÁuence of 
gene expression on survival was analysed using 
univariate and multivariate Cox regression model. 
Results: The expression of four genes (BRCA1, 
CA9, CDKN1B and CSF1) differed signiÀcantly 
between NSCLC and SCLC. The difference for 
two other genes (STAT1, EGFR1) was on the 
bordrerline of signiÀcance. By contrast, there 
were no signiÀcant differences between gene 
expression in squamous cell cancer (33 patients) vs. 
adenocarcinoma (11 patients). A multivariate Cox 
regression model has shown a signiÀcant impact 
of FN1 (p=0.002, RR=3.1) and ERCC1 (p=0.004, 
RR=0.32) expression on overall survival in a group 
of 53 patients with NSCLC, while CA9 (p=0.15, 
RR=1.7) has shown a non-signiÀcant trend. 
Conclusion: These results support the studies 
that demonstrate the feasibility of multiple 
gene expression analysis in bronchoscopy 
obtained cancer specimens as prognostic and 
predictive markers in combined radiotherapy and 
chemotherapy for locally advanced NSCLC and 
LD-SCLC. Study supported by N N403 2906 36 
grant 
Keyword: molecular markers, radiotherapy, 
chemotherapy, bronchoscopy, NSCLC, SCLC
The Ànal score ranged from 0-400, The sample was 
classiÀed as high staining when the Ànal score was 
above median score
Results: A high staining of IGF-1R and MMP-7 was 
noted in 41 patients (53%) and in 42 (54%) cases, 
respectively. IGF-1R expression was associated with 
pathological stage and recurrence (P=0.03 and 0.006, 
respectively). Overall survival was signiÀcantly 
lower in patients with IGF-1R-high NSCLCs than 
in those with IGF-1R-low NSCLCs (P=0.011). 
Expression of MMP-7 was not signiÀcantly 
associated with survival. Among patients with 
IGF-1R-low and MMP-7-low, overall survival 
was signiÀcantly better when compared with other 
groups. Multivariate analysis showed low expression 
of both IGF-1R and MMP-7 was signiÀcantly 
associated with better overall survival. (HR 3.808; 
95% CI 1.586-9.145, p=0.003)
Conclusion: Immunohistochemical expression of 
IGF-1R and MMP-7 might be a useful biomarker for 
postoperative prognosis in NSCLCs. 
Keyword: IGF-1R
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P2.073 PREDICTING THE EFFECT 
OF RADIOTHERAPY AND 
CHEMOTHERAPY IN COMBINED 
TREATMENT FOR LOCALLY 
ADVANCED LUNG CANCER BASED ON 
GENE EXPRESSION ANALYSIS
Rafal Suwnski1, Artur Klusek2, Tomasz 
Tyszkiewicz3, Malgorzata Kowalska3, Bogna 
Klusek3, Marzena Gawkowska-Suwinska4, Jerzy 
Kozielski5, Michal Jarzab3 
1Radiation Onclogy, Maria Sklodowska-Curie 
Memorial Cancer Center And Institute Of Oncology, 
Gliwice Branch/Poland, 2Comprehensive Medical 
Center, Chorzow/Poland, 3M. Sklodowska-Curie 
Memorial Cancer Institute And Center Of Oncology, 
Gliwice Branch/Poland, 4Maria Sklodowska-
Curie Memorial Cancer Center And Institute Of 
Oncology, Gliwice Branch/Poland, 5Department Of 
Pulmonology, Zabrze/Poland
Background: Several studies have shown the 
prognostic and predictive potential of molecular 
markers in combined therapy for lung cancer. Most 
of these studies refered, however, to operable early 
stage NSCLC. The aim of the present study is to 
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and mutations were detected in as few as 20 cells. 
Conclusion: EGFR and k-ras analyses proved 
technically feasible in cytological specimens, 
which can thus be considered a valid alternative to 
histological material. As few as 20 cells are required 
to perform the analysis, thus permitting slide 
conservation in pathology archives. 
Keywords: Non small cell lung cancer, cytological 
specimens, EGFR, K-ras
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P2.075 PILOT STUDY TO MEASURE 
CIRCULATING ENDOTHELIAL CELLS 
(CECS) IN PATIENTS WITH NON-SMALL 
CELL LUNG CANCER (NSCLC)
Nathan Pennell1, Nooshin Hashemi Sadraei1, Julia 
Samsa1, Lisa Henderson1, Ronald Grane2, Ernest 
Borden2 
1Solid Tumor Oncology, Cleveland Clinic Taussig 
Cancer Center/United States Of America, 
2Translational Hematology And Oncology Research, 
Cleveland Clinic Taussig Cancer Center/United 
States Of America
Background: CECs reÁect vascular turnover and 
are elevated in many patients with cancer. CECs 
are a potential biomarker for both risk of recurrence 
following surgical resection and for beneÀt from 
antiangiogenic therapies in patients with NSCLC. 
We utilized CellSearch (Veridex, New Jersey) to 
quantitate CECs in both early and late stage NSCLC 
pts before and after stage speciÀc treatment.
Methods: In this pilot study, 10 patients with early 
stage (AJCC stage I-IIIA) NSCLC had CECs tested 
within one week prior to surgical resection, and 
again when possible at the Àrst post-op visit. In 
addition, 6 pts with metastatic NSCLC were tested 
prior to initiation of chemotherapy plus bevacizumab 
and again immediately prior to cycle 3 of treatment. 
CECs were enumerated as nucleated, CD146+/
CD105+/CD45- cells in 4 mL of blood utilizing the 
CellSearch immunomagnetic selection technology.
Results: Using normal subjects as controls, we 
established the upper limit of normal for CECs to be 
26 with a standard deviation of 4, and >38 CECs was 
considered elevated. 10 pts with early-stage NSCLC 
were tested prior to surgery (stage IA (n=2), IB 
(n=5), IIB (n=1), and IIIA (n=2)), while 4 pts to date 
have had post-op draws. 4 pts (40%) had elevated 
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P2.074 EGFR AND K-RAS ANALYSIS IN 
CYTOLOGICAL SPECIMENS FROM NON 
SMALL CELL LUNG CANCER
Maurizio Puccetti1, Paola Ulivi2, Elisa Chiadini2, 
Laura Capelli2, Piero Candoli3, Wainer Zoli2 
1Pathology Unit, Lugo Hospital/Italy, 2Biosciences 
Laboratory, I.r.s.t./Italy, 3Pneumology And 
Respiratory Endoscopy Unit, Lugo Hospital/Italy
Background: EGFR gene mutations in patients 
with non small cell lung cancer (NSCLC) have been 
correlated with response to treatment with tyrosine 
kinase inhibitors. In addition, k-ras mutations may 
be involved in resistance to anti-EGFR therapy and 
might therefore be useful for treatment decision 
making in the future. The paucity of histological 
material is often the main reason for not being able 
to perform molecular analyses, and cytological 
material could be a valid alternative. We evaluated 
the possibility of determining EGFR and k-ras 
mutations in cytological samples and compared the 
sensitivity of this methodology with that used in 
histological samples. 
Methods: Fifty-one patients were prospectively 
analyzed for EGFR (exons 18, 19 and 21) and k-ras 
(exon 2) mutations. Cytological specimens were 
obtained during bronchoscopy using Wang needle 
aspiration. Needle aspirates were placed on a slide, 
Àxed with cytoÀx and stained with Fast Quick Rapid 
(Diapath) or Papanicolau. Non-tumor cells were 
carefully removed from slides and DNA extraction 
was only performed on selected cells (> 90% tumor 
cells). EGFR and k-ras analyses were performed 
by both direct sequencing and pyrosequencing. 
Histological specimens were available for 15 patients 
and molecular analyses were also performed on these 
samples. 
Results: 6 (12%) and 12 (24%) patients had EGFR 
or k-ras mutations, respectively. EGFR mutations 
were 1 exon 18 point mutations (G719S), 3 exon 
19 deletions (E746_A750) and 2 exon 21 point 
mutations (L858R, L861Q), whereas k-ras mutations 
were all on codon12 (7 G12C, 3 G12V, 1 G12D, 
1 G12A). When possible, all mutations were 
further conÀrmed in histological tissue. None of 
the wild type cytological specimens was mutated 
in the histological samples. All mutated cases were 
adenocarcinoma. In 3 patients with gene mutations, 
analyses were conducted on a scalar number of cells, 
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from 404 patients who had undergone surgical 
resection or bronchoscopy in Chiba Cancer Center 
from 2007 to 2009. Copy number abberations of the 
tumors from ALK-positive patients were detected 
by comparative genomic hybridization (CGH) using 
oligo array.
Results: There were 15 patients with ALK positive-
lung cancer in 404 lung cancers. Of 15 patients, ten 
tumors were analyzed by array-CGH. Chromosomal 
instabilities were detected in 9 patients. The number 
of the regions with copy number abberation were 
between 4 to 20 in each patient. In one patient 
with ALK-EML4 lung cancer who was treated by 
ALK-inhibitor, the copy number abberation was 
remerkably increased in brain metastases from 
primary lung tumor. 
Conclusion: The additional copy nnumber 
abberations in metastatic tumor may relate to the 
mechanism of reccurent in patient with ALK-
inhibitor treatment.
Keywords: copy number, ALK
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.077 PROGNOSTIC EFFECT 
OF EPITHELIAL AND STROMAL 
LYMPHOCYTE INFILTRATION IN NON-
SMALL CELL LUNG CANCER.
Khalid Al-Shibli1, Samer Al-Saad2, Tom Donnem2, 
Magnus Persson2, Roy Bremnes2, Lill-Tove Busund2 
1Pathology, Nordlands Central Hospital/Norway, 
2University Hospital Of Northern Norway/Norway
Background: The major value of prognostic 
markers in potentially curable non-small cell lung 
cancer (NSCLC) should be to guide therapy after 
surgical resection. In this regard, the patients’ 
immune status at the time of resection may be 
important and also measurable. The immune system 
has paradoxical roles during cancer development. 
However, the prognostic signiÀcance of tumor-
inÀltrating lymphocytes is controversial. The aim of 
this study is to elucidate the prognostic signiÀcance 
of epithelial and stromal lymphocyte inÀltration in 
NSCLC. 
Methods: Tissue microarrays from 335 resected 
NSCLC, stage I to IIIA were constructed from 
duplicate cores of viable and representative 
neoplastic epithelial and stromal areas. 
Immunohistochemistry was used to evaluate the 
CECs prior to surgery (mean 43.7, range 11-162) and 
all 4 pts (100%) tested approximately 1 month post-
op had elevated CECs (mean 110, range 49-173). 
There was no relationship between stage or histology 
and elevated CECs. In the advanced NSCLC group, 
2 of 6 pts (33%) had elevated CECs immediately 
prior to initiating chemotherapy plus bevacizumab 
(mean 42.1, range 11-124) and 2 of 3 pts (67%) 
prior to cycle 3 (mean 115, range 21-207). One of 
the post-treatment pts had a normal CEC level at 
baseline and the level increased post-bevacizumab 
treatment, and one had elevated CECs at baseline 
which remained stably elevated. No outcomes data 
were available at the time of this submission.
Conclusion: CECs are elevated in a substantial 
proportion of early and late stage NSCLC patients, 
and can be readily measured throughout treatment. 
Future studies will attempt to assess CEC numbers as 
prognostic markers for recurrence after resection and 
for treatment effect in advanced disease. Because 
it is semi-automated, validated, and has potential 
for study reproducibility, we chose to utilize the 
CellSearch platform for extending studies serially in 
patients. We realize that CECs with other markers 
such as CD34 or CD133, different kinetics, or 
differentiation may of course be missed.
Keywords: prognostic, biomarker, early stage lung 
cancer, Advanced Lung Cancer
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P2.076 COPY NUMBER ABBERATION 
IN NON-SMALL CELL LUNG CANCER 
WITH ALK FUSION PROTEIN
Sana Yokoi1, Hideki Kimura2, Hajime Kageyama1, 
Toshihiko Iizasa2, Miki Ohira2, Hiroki Nagase2, 
Akira Nakagawara2 
1Cancer Genome Center, Chiba Cancer Center 
Research Institute/Japan, 2Chiba Cancer Center/
Japan
Background: Lung cancer with ALK fusion protein 
accounts for 5% of non-small cell lung cancer 
(NSCLC). The patients with ALK-positive lung 
cancer are treated by speciÀc inhibitor of ALK. 
The effect of ALK inhibitor is very good, however 
reccurence was observed in these patients.
Methods: ALK-positive NSCLC patients were 
selected by immunohistochemistry and reverse 
transcription-polymerase chain reaction (RT-PCR) 
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or protein phosphorylation sites. Differences in 
signal intensities between normal and tumor tissues 
and their association with clinical parameters 
were analyzed with analysis of variance, some 
of them were validated by Western blot and/or 
immunohistochemical analyses.
Results: We found that 18 molecules were 
signiÀcantly different (p<0.05) by at least 30% 
between normal and tumor tissues. Most of those 
molecules play roles in cell proliferation (cyclin 
B1), DNA damage response (ATM, CHK2, and 
Ku80), signal transduction (14-3-3zeta, IGFBP2, 
p38-pT180, IRS-pS307, Src, PI3K-p85, mTOR, 
and Stat5), or lipid metabolism (COX2 and ACC-
1pS79) or function as cell surface/matrix proteins 
(caveolin 1, CD31, and collagen type VI). Analysis 
on association with clinical parameters revealed 
that Ku80 levels were signiÀcantly higher in 
tumors of nonsmokers than in those of smokers. 
Cyclin B1 levels were signiÀcantly higher in poorly 
differentiated tumors than in well or moderately 
differentiated tumors. The levels of Àve molecules 
were signiÀcantly higher in neuroendocrinal 
tumors than in other types of tumors. A comparison 
with a separate RPPA proÀling on another set of 
patient samples showed that the results were highly 
repeatable. 
Conclusion: Molecules involved in DNA damage 
response, signal transductions (in the PI3K/AKT/
mTOR, Src/Stat, and MAP kinase pathways), lipid 
metabolism, and cell proliferation were drastically 
aberrant in lung cancer tissues and some of those 
could be useful for molecular diagnosis of lung 
cancers. 
Keywords: DNA damage, primary tumor, 
Biomarkers, signal transduction
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P2.079 HE4 EXPRESSION IS ASSOCIATED 
WITH WORSE PROGNOSIS IN 
PULMONARY ADENOCARCINOMA
Shin-Ichi Yamashita1, Keita Tokuishi1, Toshihiko 
Moroga1, Takafumi Hashimoto1, Mirei Kamei1, Shuji 
Suehiro1, Kiyoshi Ono1, Satoshi Yamamoto1, Masao 
Chujo1, Kazuyuki Ohbo2, Katsunobu Kawahara1 
1Surgery Ii, Oita University/Japan, 2Histology And 
Cell Biology, Advanced Medical Research Center, 
Yokohama City University, School Of Medicine/
Japan
epithelial and stromal CD4+, CD8+, and CD20+ 
lymphocytes. 
Results: In univariate analyses, increasing numbers 
of epithelial CD8+ (P = 0.023), stromal CD8+ (P 
= 0.002), epithelial CD20+ (P = 0.023), stromal 
CD20+ (P < 0.001), and stromal CD4+ (P < 0.001) 
lymphocytes correlated signiÀcantly with an 
improved disease-speciÀc survival. No such relation 
was noted for epithelial CD4+ cells. Furthermore, a 
low level of stromal CD8+ lymphocyte inÀltration 
was associated with an increased incidence of 
angiolymphatic invasion (P = 0.032). In multivariate 
analyses, a high number of stromal CD8+ (P = 
0.043) and CD4+ (P = 0.002) cells were independent 
positive prognostic factors for disease-speciÀc 
survival. 
Conclusion: High densities of CD4+ and CD8+ 
lymphocytes in the stroma are independent positive 
prognostic indicators for resected NSCLC patients. 
This may suggest that these cells are mediating a 
strong antitumor immune response in NSCLC. 
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P2.078 ABERRANT SIGNAL 
TRANSDUCTION AND DNA DAMAGE 
RESPONSE PATHWAYS IN PRIMARY 
LUNG CANCER
Yong He1, Zhen Zhou2, Wayne L. Hofstetter3, Yanbin 
Zhou3, Wenxian Hu3, Apar Pataer3, Arlene M. 
Correa3, Yiling Lu3, Jing Wang3, Lixia Diao3, Lauren 
A. Byers3, Ignacio Wistuba3, Jack A. Roth3, Stephen 
G. Swisher3, John V. Heymach3, Bingliang Fang4 
1Thoracic Surgery, Daping Hospital/China, 
2Shanghai Lung Tumor Clinic Medical Center/China, 
3MD Anderson Cancer Center/United States Of 
America, 4Thoracic & Cardiovascular Surgery, MD 
Anderson Cancer Center/United States Of America
Background: Because cell signaling and cell 
metabolic pathways are executed through proteins, 
characterizing protein signatures in tumor tissues is 
required to identify key nodes in signaling networks 
whose alteration is associated with malignancy. This 
study aimed to determine protein proÀles in primary 
lung cancer tissues. 
Methods: Case-matched normal and tumor samples 
from 101 lung cancer patients, mostly non-small 
cell lung cancer, were analyzed with reverse-
phase protein array assay for 127 proteins and/
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P2.080 CLINICAL AND PATHOLOGICAL 
ANALYSES OF ISOLATED TUMOR 
CELLS IN NON SMALL CELL LUNG 
CANCER -CLINICOPATHOLOGICAL 
PARAMETERS AFFECTING ISOLATED 
TUMOR CELL MORPHOLOGY IN NON 
SMALL CELL LUNG CANCER
Soichiro Funaki1, Noriyoshi Sawabata1, Abulimiti 
Abulaiti1, Tomoyuki Nakagiri1, Yasushi Shintani1, 
Yoshiki Kadota1, Masayoshi Inoue1, Masato 
Minami1, Eiichi Morii2, Katuyuki Aozasa2, 
Meinoshin Okumura1 
1Department Of General Thoracic Surgery, Osaka 
University Graduate School Of Medicine/Japan, 
2Department Of Pathology, Osaka University 
Graduate School Of Medicine/Japan
Background: The presence of isolated tumor cells 
(ITCs) in the pulmonary vein (PV) of a lung resected 
for lung cancer has been reported to be a prognostic 
factor. Previous investigations noted correlations 
between prognosis and the presence or amount 
of ITCs, though few studies have investigated 
the clinical and histopathological implications of 
the morphological characteristics of those cells. 
We assessed the clinical and histopathological 
implications of ITCs in the PV using a novel 
enrichment approach that maintained their 
morphological characteristics. 
Methods: We studied 130 consecutive patients with 
primary non-small-cell lung cancer (NSCLC) who 
did not undergo preoperative chemo- or radiation 
therapy (p-stage I in 103, II in 17, III or IV in 10).To 
examine vessel invasion of primary tumors, surgical 
specimens were Àxed with 10% formalin and 
embedded in parafÀn, then evaluated pathologically 
by hematoxylin and eosin (HE), and elastic van 
Gieson (EVG) staining. Blood samples were drawn 
from the PV draining the lung just after pulmonary 
resection, and ITCs were enriched with a CD45-
negative selection method and density-gradient 
centrifugation, followed by Papanicolaou staining 
using 1 ml of PV blood. The ITCs were classiÀed 
into 4 types based on patterns of cluster formation: 
no tumor cells (N), singular tumor cells (S), clustered 
cells (0.2 mm) (CS), and bulky clustered cells (>0.2 
mm) (BCS). We evaluated the relations between 
ITC morphology, and clinical data and pathological 
results of the primary tumor - tumor marker 
Background: Human epididymis 4 (HE4) gene 
product, also known as Whey-Acidic-Protein (WAP) 
four-disulphide core domain protein 2 (WFDC2), 
was identiÀed as the transcript expressed in the 
epididymis and respiratory tract. HE4 is also 
expressed in lung adenocarcinoma, however, the 
function of this protein in lung adenocarcinoma 
remains unclear. We investigated the possibility of 
HE4 to predict survival for patients with pulmonary 
adenocarcinoma. 
Methods: One hundred and forty-one patients 
with pulmonary adenocarcinoma underwent 
surgery in our institute from 2000 to 2008. We 
used immunohistochemical analysis to determine 
the expression of HE4 and compared with the 
clinicopathological factors and survival. HE4 
expression of lung adenocarcinoma cell lines were 
investigated by immunoÁuorescent staining and RT-
PCR. 
Results: Fifty-seven of 141 cases (40%) 
were HE4 positive and Àve of six cell lines 
expressed HE4 protein and mRNA. We found no 
correlation between HE4 expression by IHC and 
clinicopathological factors, however, bronchiolo-
alveolar carcinoma subtype was signiÀcantly 
associated with HE4 expression. Five-year disease-
free survival in the HE4-positive group (44.6%) 
was signiÀcantly different from that in the negative 
group (79.3%, p=0.006) by immunohistochemisty. 
The Àve-year overall survival rate was 60.1 % in the 
HE4-positive group, as compared with 86 % in the 
HE4-negative group (p=0.02). In multivariate Cox 
regression analysis, positive HE4 protein expression 
was a worse prognosis factor of disease-free and 
overall survival (HR =2.6, 95%CI = [1.3–5.3], p 
= 0.008; HR =2.6, 95%CI = [1.1–6.2], p = 0.04, 
respectively), in addition to nodal status as a 
powerful value. 
Conclusion: Our study demonstrated that patients 
with HE4-positive adenocarcinoma had a worse 
prognosis than patients with HE4-negative 
adenocarcinoma. HE4 might be a powerful tool 
to stratify worse candidate groups in lung cancer 
patients. 
Keyword: lung, adenocarcinoma, HE4, prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: Human achaete scute homologue1 
(hASH-1) is a transcription factor that regulates 
neuroendocrine (NE) phenotype, cell growth and 
apoptosis in cancer models. No data are available 
on its role in non-small cell lung cancer (NSCLC). 
Therefore, the aims of this study were to correlate 
hASH-1 mRNA and protein expression with 
neuroendocrine phenotype and clinical pathological 
variables in a consecutive series of NSCLC tumour 
tissues, and to deÀne the capability of hASH-1 
to induce neuroendocrine differentiation and to 
modulate cell growth, apoptosis, invasive capacity 
and drug responsiveness in NSCLC cells in vitro. 
Methods: H-ASH-1 expression was determined 
in 81 consecutive NSCLC cases using 
immunohistochemistry and quantitative PCR; its 
functional role in vitro was evaluated by means 
of MTT test, apoptosis assay, matrigel assay, and 
pharmacological sensitivity tests to pemetrexed and 
cisplatin onto four wild-type and lentiviral hASH-1-
transfected NSCLC cell lines. 
Results: H-ASH-1 protein was detected in 15/81 
cases, correlated with hASH-1 mRNA and NE 
phenotype but not with clinical-pathological 
variables. In vitro, hASH-1 transfection variably 
induced NE phenotype, promoted cell growth, 
inhibited invasive capacities and induced resistance 
to pemetrexed with concurrent increase in NE 
markers expression.
Conclusion: H-ASH-1 seems to be a relevant player 
in NSCLC tumor biology since is expressed in a 
subset of NSCLC, and modulates neuroendocrine 
phenotype and tumor properties in vitro; moreover, 
its capability to develop resistance to conventional 
chemotherapeutic agents identify hASH-1 as a 
possible target to modulate chemotherapy sensitivity 
in NSCLC patients 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
serum CEA, CT/FDG-PET Àndings including 
maximal standard uptake value (SUV max), and 
histopathological analysis including vessel invasion 
by primary tumors. 
Results: ITCs were detected in 96 patients (73.8%), 
of which the BCS type was observed in 3, CS in 41, 
S in 52, and N in 34. Cancer recurrence occurred in 
34 cases (26%), 21 in the combined CS/BCS group, 
11 in S, and 2 in N. Log-rank analysis revealed that 
the disease-free survival rate was exclusively worse 
in patients with clustered ITCs as compared with the 
other 2 groups (p<0.01). As for clinical features, the 
clustered cancer cell-positive ratio was high in cases 
with a high levels of serum CEA and SUV max, 
and a high solid component ratio in CT Àndings as 
compared to cases with low levels of those factors. 
Furthermore, there was a possible strong correlation 
between the positive ratio of vessel invasion by 
primary tumors and presence of ITCs in the PV, as 
the positive ratio of vessel invasion was 79% in the 
combined CS/BCS group, while that was 40% in S 
and 9% in N (p<0.0001). 
Conclusion: Our method was useful to detect and 
enrich ITCs from the PV, and showed the clinical 
relevance of their morphology in lung cancer cases. 
The presence of ITC clusters may be a prognostic 
biomarker for patients with resected NSCLC. 
Furthermore, the presence of clustered cancer 
cells may be strongly related with clinical and 
histopathological features including vessel invasion 
of primary tumors. 
Keyword: lung cancer, isolated tumor cells, 
histopathology, vessel invasion
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P2.081 HUMAN ASH-1 EXPRESSION IS 
ASSOCIATED TO NEUROENDOCRINE 
DIFFERENTIATION IN VIVO, AND 
MODULATES PROLIFERATION, 
INVASION AND DRUG 
RESPONSIVENESS IN VITRO OF NON-
SMALL CELL LUNG CANCER
Ida Rapa1, Paolo Ceppi1, Cristina Migliore2, Jessica 
Giorcelli1, Marisa Pautasso3, Silvia Novello4, Silvia 
Giordano2, Marco Volante1, Mauro Papotti1 
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S974 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.083 CDRS AS AN EARLY DETECTION 
MARKER FOR NON-SMALL CELL LUNG 
CANCER USING MASS SPECTROMETRY
Dominique De Costa1, Ingrid Broodman2, Martijn M. 
Vanduijn2, Wim Calame3, Christoph Stingl2, Lennard 
J.M. Dekker2, Rene Vernhout1, Matthijs Oudkerk4, 
Willem Mali5, Henk Hoogsteden1, Peter A.E. Sillevis 
Smitt2, Theo M. Luider2, Rob J. Van Klaveren1 
1Pulmonary Medicine, Erasmus Medical Center/
Netherlands, 2Neurology, Erasmus Medical Center/
Netherlands, 3Statistical BV/Netherlands, 4Radiology, 
Umc Groningen/Netherlands, 5Radiology, UMC 
Utrecht/Netherlands
Background: Late diagnosis is the main reason 
for a high lung cancer mortality rate. Although CT 
screening has improved the early detection of lung 
cancer, a more sensitive and speciÀc early detection 
method is needed. Therefore, biomarker discovery 
is of great importance for early detection of lung 
cancer.
Alterations in protein structure or expression in 
tumors may induce an increase of the immune 
response resulting in speciÀc antibody production. 
As this immune response is expected to occur at 
an early disease stage, speciÀc sequences of the 
antigen binding sites of antibodies (CDRs) might 
discriminate lung cancer patients from controls at a 
stage that effective therapy can be applied.
Methods: Forty lung cancer patients and 40 controls, 
recruited from the randomized lung cancer screening 
trial NELSON were used. IgG was isolated from 
serum and digested with immobilized papain into Fab 
and Fc. An anti-Fc afÀnity column was used to purify 
Fab from the digested mixture and further puriÀed 
by SDS-PAGE. The Fab containing gel bands were 
excised and enzymatically digested. The resulting 
Fab peptides were measured on a nano-LC-Orbitrap-
Mass-Spectrometry system. Quantitative analysis 
was performed by the software package Progenesis. 
Mascot was used for database searches against the 
human NCBInr database. De novo sequencing was 
performed by Peaks Studio software. CDRs were 
identiÀed by homology to the IMGT database. 
Statistical analyses were performed in Stata. 
Results: From the lung cancer patients, 60% were 
diagnosed within one year after blood sampling. From 
these patients, 88% were men and the average age 
was 64 years. All 40 cases were former smokers, 53% 
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P2.082 CHARACTERISTICS OF LUNG 
CANCER IN WOMEN: IMPORTANCE OF 
HORMONAL AND GROWTH FACTORS.
Isabelle Rouquette1, Valérie Lauwers2, Laurent 
Brouchet3, Julie Milia4, Camille Allera1, Yvan 
Nicaise1, Marie-Bernadette Delisle1, Alain Didier4, 
Julien Mazieres4 
1Pathology, Chu Toulouse/France, 2Epidemiology, 
Chu Toulouse/France, 3Thoracic Surgery, Chu 
Toulouse/France, 4Thoracic Oncology, Chu 
Toulouse/France
Background: The incidence of lung cancer is 
increasing dramatically in women. Lung cancer 
occurring in women displays some speciÀc 
epidemiological, clinical and pathological 
characteristics suggesting that lung carcinogenesis is, 
at least in part, distinct in women. 
Methods: We aim to analyze the clinico-
pathological characteristics of lung cancer and to 
compare the immunohistochemical expression of 
hormonal receptors (Estrogen Receptor [ER] a 
and b, Progesterone receptors [PR]) and growth 
factors (EGFR, Her2) and the status of EGFR and 
K-Ras mutations in two groups of surgically treated 
patients, 50 men and 50 women. We also aim to 
deÀne the prognostic value of each biomarker. 
Results: Lung cancer occurring in women is less 
associated with tobacco use than in men. EGFR 
is more frequently mutated in women but also 
overexpressed by using a 10% positivity threshold 
score. No signiÀcant difference was observed 
for Her2 expression and K-Ras mutation. ERa 
expression is more frequently found in women when 
compared with men. ERb is also more frequently 
expressed without reaching signiÀcance. We then 
analyzed the prognostic value of all clinical and 
biological data. After multivariate analysis we found 
that the presence of lymphatic embols was associated 
with a worse disease free survival (p = 0.012) and 
that tumors without bronchioloalveolar component 
have a shorter time to progression. REa expression 
was associated with a better prognostic (p = 0.007). 
Conclusion: We identiÀed speciÀc genetic 
alterations or hormonal proÀles in women that 
may help in deÀning lung cancer prognosis after 
surgery and pave the way for a gender-based targeted 
therapy.
Keywords: Women, Lung cancer, EGFR, Estrogen
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Background: Hypoxia leads to changes in tumor 
cell metabolism such as increased glycolysis. 
Markers related to hypoxia and glycolysis could 
be prognostic indicators in non-small cell lung 
cancer (NSCLC). In this study, glucose transporter 
1 (GLUT1) and monocarboxylate transporter 4 
(MCT4) expression were correlated with survival in 
stage I, II and resectable stage IIIA NSCLC.
Methods: GLUT1 and MCT4 expression 
were determined in 85 NSCLC biopsies 
using immunohistochemical techniques and a 
computerized image analysis system. Markers 
were analyzed for the adenocarcinoma (n=41) 
and squamous cell carcinoma (n=35) subgroups 
separately. Patients were retrospectively evaluated 
for relapse and survival.
Results: Squamous cell carcinomas demonstrated 
higher GLUT1 expression, relative to 
adenocarcinomas. In adenocarcinomas, high GLUT1 
expression correlated with a poor differentiation 
grade and positive lymph nodes at diagnosis. The 
ratio GLUT1:MCT4 was <1 in adenocarcinomas and 
>1 in squamous cell carcinomas. In squamous cell 
carcinomas, GLUT1 and MCT4 expression increased 
with increasing distance from the vasculature, 
whereas upregulation of MCT4 was already found 
at closer distance from vessels in adenocarcinomas. 
High GLUT1 plus high MCT4 expression 
correlated with a poor disease-speciÀc survival in 
adenocarcinomas (p=0.032).
Conclusion: A different tumor metabolism was 
found for adenocarcinomas and squamous cell 
carcinomas. Adenocarcinomas rely mainly on 
aerobic glycolysis for ATP production, whereas 
the behavior of squamous cell carcinomas is more 
physiological, i.e. mitochondrial oxidation with 
anaerobic glycolysis where appropriate. High 
GLUT1 plus high MCT4 expression denoted an 
aggressive tumor behavior in adenocarcinomas. This 
subgroup of tumors may beneÀt from new treatment 
approaches, such as MCT4 inhibitors.
Keywords: Hypoxia, microenvironment, 
metabolism, GLUT1
were current smoker and 25% had a COPD history. 
Forty-one percent of the cases were diagnosed with 
adenocarcinoma and 11% with squamous cell lung 
carcinoma. Forty-eight percent were diagnosed with a 
different histology, such as large cell neuroendocrine 
tumors. The control group consisted of 93% men with 
an average age of 61 years. All controls were former 
smokers without COPD history.
After Fab puriÀcation and mass spectrometry (MS) 
measurement of Fab samples we were able to observe 
477 different CDR1 peptide sequences, 864 CDR2 
and 101 CDR3 peptide sequences in all 80 samples 
measured.
We performed a multivariate analysis, logistic 
stepwise regression, on the data obtained from the 
lung cancer patients and controls to search for a 
statistical prediction model consisting of a set of MS 
signals (regression model) that could distinguish lung 
cancer patients from controls. We observed a model 
consisting of nine masses with a p-value of <0.001. 
From the nine masses we observed 1 CDR1 sequence, 
3 CDR2 sequences and 1 Framework sequence. The 
four other peptides were not identiÀed yet.
We performed an internal validation of the predictive 
model by determining the sensitivity and speciÀcity, 
yielding values of 77% and 92%, respectively. 
We also intend to validate this model in a new 
independent lung cancer and control sample set.
Conclusion: To our knowledge this is a new 
approach for early detection of lung cancer, which is 
able to distinguish lung cancer cases from controls 
with 77% sensitivity and 92% speciÀcity. 
Keywords: Early detection biomarker, NSCLC, 
Immunoglobulin, proteomics
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P2.084 DIFFERENCES IN 
BIOLOGICAL BEHAVIOR BETWEEN 
ADENOCARCINOMAS AND SQUAMOUS 
CELL CARCINOMAS IN NON-SMALL 
CELL LUNG CANCER: CORRELATIONS 
AND PROGNOSTIC VALUE OF GLUT1 
AND MCT4 EXPRESSION
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2.99 ng/mL (1.76-6.01) versus 0.99 ng/mL (0.51-
1.83) and 1.47 ng/mL (0.80-1.56), respectively, P < 
0.0001. Conversely, the galectin-3 concentration was 
lower in mesothelioma: 11.50 ng/mL (6.73-23.53) 
versus 24.74 ng/mL (20.42-70.35) and 17.64 ng/mL 
(14.81-24.68), respectively, P < 0.0001. The area 
under the receiver-operator characteristic curves 
for CCL2 were 0.8030 (95% conÀdence interval 
0.7061-0.8998) and 0.7716 (0.6429-0.9003) for 
differentiating mesothelioma from adenocarcinoma 
or benign effusions, respectively. Similarly, the AUC 
obtained for galectin-3 were 0.7980 (0.7019-0.8942) 
and 0.6923 (0.5647-0.8200), respectively. 
Conclusion: Type-III collagen, CCL2 and 
galectin-3 are promising new diagnostic markers for 
mesothelioma.
Keywords: mesothelioma, Microarray, biomarker, 
Pleural effusion
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P2.086 AN IMMUNOHISTOCHEMICAL 
PROFILE FOR PREDICTING RESPONSE 
TO CISPLATIN/VINORELBINE 
THERAPY IN MALIGNANT PLEURAL 
MESOTHELIOMA
Zarah G. Zimling1, Cecilia Bech2, Eric Santoni-
Rugiu1, Jens B. Sorensen2 
1Department Of Pathology, University Hospital Of 
Copenhagen, Rigshospitalet/Denmark, 2Department 
Of Oncology, University Hosptal Of Copenhagen, 
Rigshospitalet/Denmark
Background: Malignant pleural mesothelioma 
(MPM) has a poor prognosis and only a small 
minority of patients is diagnosed at an early stage 
in which curative multimodality-treatment is 
possible. Inoperable patients receive platinum-
based palliative chemotherapy. Customizing 
chemotherapy based on chemosensitivity prediction 
may improve outcome in this cancer disease with 
a generally poor outcome. The cytotoxic effect of 
cisplatin depends on the formation of DNA cross-
links that hinders replication. This effect can be 
overcome by the DNA repair system that replaces 
the damaged DNA. Over-expression of key enzymes 
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P2.085 IDENTIFICATION OF NOVEL 
MARKERS FOR THE DIAGNOSIS 
OF MALIGNANT PLEURAL 
MESOTHELIOMA
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Blanquart1, Christine Sagan2, Laurent Cellerin3, 
Martine Padieu1, Christian Perigaud4, Arnaud 
Scherpereel5, Marc Gregoire1 
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Background: Despite recent improvements, the 
diagnosis and treatment of malignant pleural 
mesothelioma (MPM) is still a major challenge. Due 
to the unspeciÀc symptoms and tissue polymorphism 
of this cancer, MPM can be confused with benign 
pleural diseases or with pleural metastasis of 
adenocarcinomas, especially from lung origin.
Because an accurate diagnosis is crucial, both for 
the management of MPM patients and also for the 
settlement of Ànancial compensation for individuals 
with a history of asbestos exposure, the development 
of new tools and the improvement of existing 
diagnostic procedures are of major interest. 
Methods: In order to identify novel markers able 
to improve diagnostic accuracy, we performed a 
genome-wide gene expression analysis on tumor cell 
lines established from pleural effusions. The levels 
of new markers were assessed in tumor biopsies by 
immunohistochemistry and in pleural Áuids using 
enzyme-linked immunosorbent assays. 
Results: We proÀled 51 biological samples 
corresponding to triplicates of 13 mesothelioma and 
4 lung adenocarcinoma cell lines. Our microarray 
analysis led to the identiÀcation of genes encoding 
novel cellular and soluble markers whose expression 
was validated by RT-qPCR. Immunohistochemical 
staining of tumor biopsies with anti-type-III 
collagen antibodies were positive in mesothelioma 
cells but not in adenocarcinoma cells. (CCL2) 
concentration was signiÀcantly higher in patients 
with mesothelioma (n = 61) than in subjects with 
adenocarcinoma (n = 25) or with benign pleural 
effusion (n = 15): median (interquartile range) = 
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P2.087 PULMONARY VEIN 
CIRCULATING TUMOUR CELLS FROM 
PATIENTS UNDERGOING CURATIVE 
RESECTION OF NON-SMALL CELL 
LUNG CANCER.
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Shah3, Richard Booton1, Caroline Dive4, Fiona H. 
Blackhall5 
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Background: Circulating tumour cells (CTCs) are 
postulated to have a critical role in the development 
of metastatic disease. Relapse at distant sites 
remains a major challenge to improved survival in 
patients with early stage non-small-cell lung cancer 
(NSCLC) despite curative intent surgery. Standard 
imaging techiniques are unable to reliably detect 
micrometastatic disease, therefore detection of CTCs 
may help identify patients at high risk of metastasis. 
We have previously reported that the prevalence of 
CTCs in peripheral blood of patients with advanced 
stage NSCLC, using the CellSearch system, is low 
and that CTCs are absent in patients with stage 
III disease. We hypothesize that CTC numbers 
are higher in the pulmonary vein of patients with 
early stage NSCLC and that presence of CTCs will 
correlate with clinical outcome. We initiated a study 
to determine the number of CTCs in the tumour 
draining pulmonary vein in patients undergoing 
resection of early stage NSCLC. The speciÀc aims 
of this study are to: 1. Enumerate and compare CTC 
numbers in peripheral blood (pre-operatively) and 
tumour draining pulmonary vein (intra-operatively) 
in different DNA-repair pathways has been linked 
to chemotherapy resistance. Nucleotide excision 
repair (NER) is the main pathway involved in 
replacing cisplatin-induced DNA damage. Excision 
repair cross-complementation group 1 enzyme 
(ERCC1) recognizes and cuts out the damaged 
DNA. Breast cancer 1 (BRCA1) is a component 
of multiple DNA-repair pathways and decreased 
expression is linked to sensitivity towards DNA-
damaging agents. BRCA1 may also play a role in 
mitotic-spindle formation and seems to be required 
for spindle-poison sensitivity. The aim of the study 
was to explore the baseline expression of DNA 
repair proteins in MPM, and their ability to predict 
survival. 
Methods: Fifty-four consecutive inoperable MPM 
patients were enrolled between February 2003 and 
September 2006 into a phase II trial with cisplatin 
and vinorelbine. Formalin-Àxed parafÀn-embedded 
histologic tumor specimens were retrospectively 
evaluated by immunohistochemistry (IHC) for 
ERCC1 and BRCA1 expression. To assess protein 
expression we used a semi-quantitative H-score 
(staining intensity multiplied by a proportion-score 
based on the percentage of positive tumor cells). For 
each marker the median value of the H-scores was 
set as a cut-off point to separate positive (H-score > 
median) from negative (H-score  median) tumors. 
Results were correlated to clinical outcome such as 
response to chemotherapy, progression-free survival 
(PFS) and overall survival (OS).
Results: Fifty patients had tumor-tissue available for 
IHC. For ERCC1 the median H-score was 2, yielding 
20 positive and 30 negative tumors. There was no 
signiÀcant difference in OS between positive and 
negative tumors. There was no signiÀcant difference 
in response rate between the two populations. The 
median PFS was 10.9 months [CI.95% 5.6; 16.7 
months] in the ERCC1-negative tumor group and 
6.7 months [4.4; 7.2 months] in the ERCC1-positive 
group (p=0.052). Multivariate Cox regression 
revealed ERCC1-positive patients to have a 
signiÀcantly higher risk for progression (HR=2.24, 
95% conÀdence limits= [1.16; 4.34], p=0.0163) 
compared to ERCC1-negative patients. Scoring of 
immunostainings for BRCA1 and correlation with 
clinical data are in progress. The results will be 
available at the time of the 14th WCLC 2011. 
Conclusion: Negative immunohistochemical 
ERCC1 staining predict signiÀcant higher PFS 
in patients with MPM. Analysis of the impact of 
BRCA1 will be available at the meeting.
S978 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: Elevated levels of cytokeratin 19 
fragments CYFRA 21-1 are found in serum from 
patients with lung cancer. Several studies have 
shown that lung cancer progression leads to an 
increase in CYFRA 21-1 while the response to 
therapy leads to decrease in CYFRA 21-1. We 
investigated if successive 50% increase in serum 
levels of CYFRA 21-1 can classify patients as 
suspects for disease progression. Additionally, we 
evaluated if a one third reduction in CYFRA 21-1 
levels from an immediately preceding time point is 
an indicator of response to therapy.
Methods: This was a retrospective clinical study 
utilizing remnant serial serum samples from a 
heterogeneous group of subjects diagnosed with lung 
cancer at various stages of disease. One hundred 
patients were followed for an average of 10 months 
and a maximum of 6 years. On average, each subject 
provided a baseline and 3.1 follow-up visits, spaced 
at an average of 101 days. The subject’s clinical 
status was classiÀed as: no evidence of disease 
(NED), responding to treatment, stable disease, 
and progression. Blood samples from each visit 
were assayed for CYFRA 21-1 using CYFRA 21-1 
Enzyme Immunometric Assay (EIA) (Fujirebio 
Diagnostics, Inc.). CYFRA 21-1 EIA is based on 2 
monoclonal antibodies speciÀc for cytokeratin 19 
(BM 19.21 and KS 19.1). Sensitivity, speciÀcity, 
positive predictive value (PPV) and negative 
predictive value (NPV) values were determined.
Results: A total of 414 samples from 100 subjects 
were evaluated. The mean age was 59 years (range 
34-82) and Àfty-seven percent of subjects were 
male. To assess the performance of CYFRA 21-1 
for the detection of disease progression a 50% 
increase from the immediately preceding draw 
was considered signiÀcant. Out of three hundred 
and fourteen longitudinal sample pairs 85 were 
clinically progressing and 229 had no progression 
from the previous visit. The cutoff of a 50% increase 
in CYFRA 21-1 offered a sensitivity of 45.9%, a 
speciÀcity of 87.9%, PPV of 57.4% and NPV of 
81.3% for detecting lung cancer progression. To 
evaluate if a signiÀcant reduction in CYFRA 21-1 
is an indicator of response to therapy we used 284 
samples from 91 subjects. The cutoff of at least 
one-third decrease in CYFRA 21-1 levels from the 
previous reading offered a sensitivity of 37.6%, a 
speciÀcity of 83.0%, PPV of 39.6% and NPV of 
81.8% for detecting response to therapy.
Conclusion: Serial measurement of CYFRA 21-1 is 
a reliable serum biomarker test for use as an aid in 
2. Compare morphology of CTCs with primary 
tumour specimens. 3. Examine the association of CTC 
numbers with clinical characteristics including smoking 
exposure stage and progression free/overall survival.
Methods: This study is a surgical case series. 
Inclusion criteria: patients attending the Thoracic 
Surgical Department of the University Hospital of 
South Manchester (UK) for curative resection of 
NSCLC. Exclusion criteria: patients with a prior 
diagnosis of malignancy or who have received 
chemotherapy. The aim is to recruit 30 patients 
into this pilot study. A risk factor questionnaire 
is completed. Ten ml blood samples are taken 
pre-operatively from a peripheral site and intra-
operatively from the pulmonary vein draining 
the cancer bearing lobe prior to vessel ligation or 
resection. Samples are processed using 7.5ml blood 
according to standard operating procedures with the 
CellSearch system, at the Clinical and Experimental 
Pharmacology Group, Paterson Institute for Cancer 
Research, Manchester, UK. Patients will be followed 
up for a period of 5 years or until recurrence occurs.
Results: Preliminary data suggests the number of 
CTCs isolated from the tumour draining pulmonary 
vein is higher than in peripheral blood. Further data 
will be presented.
Conclusion: This pilot study supports the hypothesis 
that higher numbers of CTCs are detectable in the 
tumour draining pulmonary vein than peripheral 
blood, in patients with early stage NSCLC. This may 
have important relevance for clinical outcome, to be 
determined from ongoing follow-up over 5 year period
Keywords: Circulating tumour cells, Pulmonary 
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P2.088 A RETROSPECTIVE 
LONGITUDINAL STUDY OF THE 
CYFRA 21-1 EIA ASSAY AS AN AID IN 
MONITORING PATIENTS DIAGNOSED 
WITH LUNG CANCER
Christina Hall1, Ulrika Dahlén1, Karin Majnesjö1, 
Maria Hellman1, Rachel Radwan2, Zivjena Vucetic3, 
Grady Barnes3 
1Clinical Research, Fujirebio Diagnostics AB/
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And ScientiÀc Affairs, Fujirebio Diagnostics, Inc./
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water in the past. Individuals older than 40 years of 
age who had smoked  20 pack years, environmental 
exposure to arsenic and or a family history of LC 
were selected. Each participants provided an induced 
sputum sample for AQC, and a blood sample for 
DR70 and genomic biomarkers studies. Those with 
AQC DNA index 2.3 and atypical nuclei in sputum 
or DR70 positive test were invited for AFB studies.
Results: AQC was done in 228 voluntaries. A h, 
indeterminate or low score for malignancy was 
observed in 18%, 31% and 51 %, respectively. Of 
18% who had a high AQC score 2% were positive 
for DR70. DR70 was positive in 90% of clinically 
diagnosed LC patients (positive controls). Up 
until now, 62% of the participants with high AQC 
scores have been analyzed by AFB. 20.8 % of 
them were found to have squamous metaplasia or 
mild dysplasia. Very high frecuency (0.961) for the 
mutated allele (G) was found, this is the highest 
frequency described for this SNP in different 
populations.
Conclusion: Our preliminary results suggest that 
further work need to be done to evaluate genomic 
biomarkers, AQC in sputum cells, DR70 and AFB 
for identiÀcation of at risk of LC in Chile. This 
research was supported by INNOVA CORFO. 
Keyword: Lung cancer biomarkers
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.090 MUTATIONS OF THE CATALYTIC 
SUBUNIT ALFA OF PI3K (PIK3CA) IN 
ERLOTINIB-TREATED NON-SMALL-
CELL LUNG CANCER (NSCLC) 
PATIENTS (P) WITH EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) 
MUTATIONS
Miguel Angel Molina1, Amaya Gasco2, Enric 
Carcereny3, Jose Javier Sanchez4, Jordi Bertran-
Alamillo2, Clara Mayo2, Erika Aldeguer2, Ana 
Jimenez-Capitan2, Zaira Yeste2, Carlota Costa2, 
Susana Benlloch2, Alex Martinez3, Cristina Buges3, 
Joaquim Bosch5, Dolores Isla6, Manuel Domine7, 
Mariano Provencio8, Jose Miguel Sanchez Torres9, 
Carlos Camps10, Miquel Taron3, Rafael Rosell3 
1Oncology, Pangaea Biotech, Dexeus University 
monitoring disease progression during the course of 
disease and treatment in lung cancer patients.
Keywords: CYFRA 21-1 biomarker, lung cancer 
monitoring, diagnostic test
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P2.089 DETECTION OF PRENEOPLASIC 
LESIONS USING BIOLOGICAL 
AND GENOMIC LUNG CANCER 
BIOMARKERS IN A HIGH RISK 
CHILEAN POPULATION
Marta I. Adonis1, Marco Chahuan2, Ulises Urzua3, 
Veronica R. Miranda4, Jose Diaz1, Pablo Avaria1, 
Alcides Zambrano5, Monica Campos6, Yasna 
Cisterna7, Hugo Benitez5, Stephen Lam8, Lionel Gil1 
1Icbm, Molecular And Celullar Biology, Faculty 
Of Medicine/Chile, 2Adult Lung Department, San 
Borja Arriaran Hospital/Chile, 3Icbm, Molecula 
And Celullar Biology, Faculty Of Medicine/Chile, 
4Patology Department, Barros Lucos Trudeau 
Hospital/Chile, 5Phatology Department, Antofagasta 
Hospital/Chile, 6Oncology Department, San Borja 
Arriaran Hospital/Chile, 7Clinical Laboratory, La 
Portada Clinic/Chile, 8Lung Tumor Group, Bcca/
Canada
Background: Lung Cancer (LC) is the leading 
cause of cancer mortality world wide and the second 
one in Chile, where every year nearly 2500 persons 
died from LC, furthermore, between 1990 and 2008 
the LC mortality rate for 100.000 inhabitants for 
the whole country, both genders, increased from 
10.8 to 14.6. Although, cigarette smoking is the 
major risk factor, genetic diversity and exposure 
to environmental or occupational pollutants must 
also be considered, especially in those cities highly 
exposed to environmental carcinogens. Evaluation 
of risk assessment and early-detection strategies 
are important for LC control in Chile. Objective: 
The objective of the study is to evaluate LC risk 
biomarkers and early LC detection technologies to 
detect pre-neoplastic lesions and early lung cancer 
using Genomic Biomarkers (SNPs), DR70® (Onko 
Sure), Automated Quantitative Cytometry (AQC) 
of induced sputum cells and AutoÁuorescence 
Broncoscopy (AFB).
Methods: A LC Risk Survey was conducted in 
Metropolitan Santiago and Antofagasta region; the 
latter has high levels of arsenic exposure in drinking 
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P2.091 ASSOCIATION BETWEEN TS 
EXPRESSION LEVELS AND RESPONSE 
TO PEMETREXED IN MPM: FACT OR 
FICTION?
Fabian Mairinger1, Claudia Vollbrecht2, M 
Hatz3, Elvira Stacher4, Iris Halbwedl4, Franz 
Quehenberger5, Thomas Mairinger6, Helmut H. 
Popper4 
1Biotechnology, Lausitz University Of Applied 
Sciences/Germany, 2Biotechnology, 1lausitz 
University Of Applied Sciences/Germany, 3Centre 
For Medical Research, Medical University/Austria, 
4Institute Of Pathology, Medical University Graz/
Austria, 5Institute For Medical Informatics, Statistics 
And Documentation, Medical University Graz/
Austria, 6Pathology, Helios Klinikum/Germany
Background: Malignant mesothelioma is a highly 
aggressive tumour arising from mesothelial lined 
surfaces like the peritoneum and, more often, the 
pleura (malignant pleural mesothelia, MPM). 
Antifolates are actually considered the most 
promising cytotoxic drugs for MPM. Pemetrexed, 
an antifolate mainly inhibiting thymidylate synthase 
(TS), but also dihydrofolate reductase (DHFR), 
glycinamide ribonucleotide formyltransferase 
(GARFT) and aminoimidazole carboxamide 
ribonucleotide formyltransferase (AICARFT), is 
the Àrst and only drug approved by the FDA for 
treatment of mesothelioma but show different 
response rates. The aim of the study is to Ànd a 
potential correlation between TS, GARFT and/
or AICARFT levels in MPM and their response 
to pemetrexed, potentially resulting in a reliable 
predictive factor for MPM treatment.
Methods: 63 patient samples were tested 
immunohistochemically and via qPCR for TS, 
GARFT and AICARFT levels. In addition, 
two enzymes involved in antifolate transport 
(RFC) and activation (FPGS) were tested 
immunohistochemically. Distribution patterns were 
analysed and, if possible, a cut-off was deÀned. 
Mortality statistics and clinical data were evaluated 
to determine a potential effect of pemetrexed 
application correlated to TS, GARFT and/or 
AICARFT levels. For IHC a tissue microarray 
was established. Evaluation of expression levels 
were done with a commercial TaqMan® Gene 
Expression-assays (Applied Biosystems®) using 
Institute/Spain, 2Pangaea Biotech, Dexeus University 
Institute/Spain, 3Oncology, Catalan Institute Of 
Oncology, Hospital Germans Trias I Pujol/Spain, 
4Statistics, Autonomous University Of Madrid/
Spain, 5Catalan Institute Of Oncology, Hospital 
Josep Trueta/Spain, 6Hospital Lozano Blesa/
Spain, 7Oncology, Fundacion Jimenez-diaz/Spain, 
8Oncology, Hospital Puerta De Hierro/Spain, 
9Hospital 12 De Octubre/Spain, 10Hospital General 
De Valencia/Spain
Background: Stage IV NSCLC p with EGFR 
mutations treated with erlotinib had a median 
progression-free survival (PFS) of 14 months (m) 
and median survival (MS) of 27 m in our experience. 
However, EGFR mutations can only imperfectly 
predict outcome. PIK3CA mutations occur in 
several tumors and have prognostic and therapeutic 
implications. We examined the presence and 
potential inÁuence of PIK3CA mutations on outcome 
to erlotinib in NSCLC p with EGFR mutations. 
Methods: PIK3CA mutation status was assessed 
in pretreatment parafÀn-embedded tumor samples 
from 118 advanced NSCLC p with EGFR mutations 
treated with erlotinib. E542K, E545K and H1047R 
mutations were screened by 5’-nuclease PCR 
(Taqman) assay and conÀrmed by standard PCR 
followed by sequencing. 
Results: PIK3CA mutations were detected in 6 
of 118 patients (5.1%). 84% of p with PIK3CA 
mutations had adenocarcinomas vs 50% of p with 
wild-type (wt) PIK3CA (P=0.01). Response rate 
was 50% for p with mutations vs 70% for p with wt 
PIK3CA (P=0.03). There were no other differences 
between p with and without PIK3CA mutations. 2 of 
the 6 p with PIK3CA mutations had the uncommon 
L861Q mutation in exon 21 of EGFR. 1 of the 6 p 
had complete response; 2 had partial response; 3 
had progressive disease. There was a non-signiÀcant 
trend towards shorter PFS for the 6 p with PIK3CA 
mutations (9 vs 16 m; P=0.59). MS was not reached 
for the 6 p with PIK3CA mutations, while it was 29 
m for p with wt PIK3CA (P=0.09). 
Conclusion: PIK3CA mutations can be present in 
some EGFR-mutant NSCLC p, with lower response 
and a trend towards shorter PFS. Treatment with 
EGFR tyrosine kinase inhibitors plus PIK3CA 
inhibitors should be tested in this small subset of p 
with double mutations. 
Keywords: Non-small cell lung cancer, EGFR 
mutations, PIK3CA
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Background: DAB2IP loss promotes primary tumor 
growth by activating Ras and drives metastasis 
through NFkB, serving as a signaling scaffold to 
coordinately regulate these pathways. DAB2IP 
is frequently methylated in lung cancer, and 
methylation in the m2a region is a key regulatory 
factor for DAB2IP expression in prostate cancer. We 
examined DAB2IP methylation in cell lines and in 
serum from erlotinib-treated NSCLC p with EGFR 
mutations. 
Methods: In human lung, breast and colorectal 
cancer cell lines, we analyzed DAB2IP promoter 
methylation in regions m2a and m2b by methylation-
speciÀc PCR (MSP) and bisulÀte genomic 
sequencing. In circulating serum DNA from 152 
erlotinib-treated NSCLC p with EGFR mutations, we 
analyzed methylation in the m2a and m2b promoter 
regions of DAB2IP by MSP. Methylation status was 
correlated with clinical outcome. 
Results: Methylation was detected in the m2a 
region of 42 (27.63%) p, and in the m2b region in 
51 (33.55%) p. There were no major differences in 
clinical characteristics (age, gender, smoking history, 
EGFR mutation type, metastatic sites) between 
p with methylation in the m2a region and p with 
methylation in the m2b region. Overall progression-
free survival (PFS) was 15 months (m), and median 
survival (MS) 28 m for all 152 p. For the 41 p with 
bone metastases (mets), PFS was 14 m for 30 p 
without methylation in the m2a region vs 8 m for 11 
p with methylation in the m2a region (P=0.01), and 
MS was 23 m vs 10 m, respectively (P=0.19). For 
the 57 p with distant mets but no lung mets, PFS was 
18 m for 36 p without methylation in the m2a region 
vs 10 m for 21 p with methylation in the m2a region 
(P=0.01), and MS was 24 m vs 16 m, respectively 
(P=0.03). No differences in either PFS or MS were 
observed according to the methylation status of the 
m2b region. 
Conclusion: Methylation in the m2a region of 
DAB2IP in serum DNA correlates with PFS and MS 
to erlotinib in NSCLC p with EGFR mutations with 
non-lung mets. Surveillance of DAB2IP methylation 
status in circulating DNA could be a useful tool 
optimized primer and probe concentrations. qPCR 
and data analysis was performed on a Roche® 
LightCycler® 480. Immunohistochemistry was 
done as recommended by the manufacturers, and 
the reactions were evaluated semiquantitatively 
by multiplying staining intensity by percentage 
of positive tumour cells. Correlation analysis was 
performed using a self-programmed algorithm for 
the R software.
Results: qPCR analysis did not show a difference 
in expression pattern of GARFT and AICARFT, 
TS gene expression rendered two distinct groups. 
Results of the immunohistochemical investigation 
showed a heterogeneous staining pattern of all 
enzymes. Statistical analysis of data did not show 
any signiÀcant correlation between one of the 
enzyme-expressions and response to pemetrexed 
treatment.
Conclusion: Our results showed that in MPM, in 
contrast what might be valid in lung carcinoma, 
the TS gene and protein expression levels have 
no inÁuence on a response to pemetrexed therapy. 
Furthermore, GARFT and AICARFT expression 
show no deregulation administered over all patient 
samples, GARFT seems to be a potent house-keeping 
gene in MPM. Also FPGS and RFC expression can 
not be used as markers for a response to pemetrexed, 
a possible inÁuence of several published mutations 
of these enzymes has to be proven. As pemetrexed 
nevertheless has proven its therapeutic use, other 
pathways of drug reaction are being investigated.
Keywords: mesothelioma, biomarker and treatment 
correlation, thymidylate synthase, GARFT, DHFR, 
AICARFT
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P2.092 DAB2 INTERACTIVE PROTEIN 
(DAB2IP) METHYLATION IN SERUM 
DNA OF NON-SMALL-CELL LUNG 
CANCER (NSCLC) PATIENTS (P) WITH 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATIONS
Jose Luis Ramirez1, Miquel Taron1, Jose Javier 
Sanchez2, Susana Benlloch3, Rafael Rosell1, Monica 
Botia1, Maria Perez-Cano1, Pedro Mendez1, Montse 
Tierno1, Cristina Queralt1, Itziar De Aguirre1, Belen 
Sanchez1, Alex Martinez1, Cristina Buges1, Joaquim 
Bosch4, Bartomeu Massuti5, Carlos Camps6, Jose 
Miguel Sanchez Torres7, Teresa Moran1 
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levels of Musashi 2, BRCA1, EZH2 and RAP80 
according to histological subtype. The median 
Musashi 2 mRNA expression was 4 times higher in 
SCLC than in NSCLC (adenocarcinoma, SCC, LCC) 
(P<0.001); BRCA1 expression was 3 times higher 
(P<0.001); EZH2 was 7 times higher (P<0.001); 
RAP80 was 2 times higher (P=0.011). There were 
no differences in expression levels of any of the 11 
genes analyzed according to p age, smoking history 
or source of the tumor sample. NSCLC p with K-ras 
mutations had higher expression of both AEG-1 and 
NFKBIA than p with wild-type K-ras (P=0.04). 
Conclusion: Musashi 2, BRCA1, EZH2 and RAP80 
expression was signiÀcantly higher in SCLC p. 
Further investigation is warranted to examine the 
potential association between expression of these 
genes and response to platinum regimens and 
radiotherapy in SCLC. Elevated AEG-1 levels 
associated with K-ras-mutant tumors could identify a 
subgroup of NSCLC p with poor prognosis. 
Keywords: RAP80, Non-Small-Cell Lung Cancer, 
BRCA1, NFkB
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P2.094 FEASIBILITY OF EGFR AND 
KRAS MOLECULAR TESTING ON 
CYTOLOGIC SPECIMENS FROM NON 
SMALL CELL LUNG CARCINOMAS
Dominique H. Grunenwald1, Virginie Poulot2, Valerie 
Gounant3, Jocelyne Fleury4, Martine Antoine5, 
Magalie Colombat5, Jalal Assouad3, Marie Wislez6, 
Jean-François Bernaudin4, Jacques Cadranel6, Roger 
Lacave2 
1Thoracic Surgery, Department Of Thoracic 
Surgery. Hopital Tenon/France, 2Genomic Platform. 
Histology And Tumoral Biology. Hopital Tenon/
France, 3Department Of Thoracic Surgery. Hopital 
Tenon/France, 4Histology And Tumor Biology. 
Hopital Tenon/France, 5Department Of Pathology. 
Hopital Tenon/France, 6Department Of Pneumology. 
Hopital Tenon/France
Background: Somatic mutations in the epidermal 
growth factor receptor (EGFR) and KRAS are 
present in a subset of patients with non-small cell 
lung cancer (NSCLC), and may be of predictive 
value for response to treatment with tyrosine 
kinase inhibitors (TKIs). The recent approval of 
an EGFR-TKI for the treatment of patients with 
to predict outcome to erlotinib in EGFR-mutated 
NSCLC p with non-lung mets. 
Keywords: DAB2IP, methylation, Non-small cell 
lung cancer, EGFR
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P2.093 DIFFERENTIAL EXPRESSION OF 
BRCA1, RAP80 AND GENES INVOLVED 
IN THE NUCLEAR FACTOR ɤB (NFɤB) 
AND NOTCH SIGNALLING PATHWAYS 
IN NON-SMALL-CELL LUNG CANCER 
(NSCLC) AND SMALL-CELL LUNG 
CANCER (SCLC) PATIENTS (P)
Ignacio Magri1, Mariacarmela Santarpia2, Maria 
Sanchez-Ronco3, Santiago Viteri4, Carlota Costa4, 
Amaya Gasco1, Nuria Mederos4, Maria Gonzalez-
Cao1, Fernanda Salazar4, Jordi Bertran-Alamillo4, 
Eduardo Richardet5, Ana Jimenez-Capitan4, Miguel 
Angel Molina4, Zaira Yeste4, Erika Aldeguer4, Teresa 
Moran6, Giuseppe Altavilla2, Susana Benlloch4, 
Miquel Taron6, Rafael Rosell6 
1Oncology, Pangaea Biotech, Dexeus University 
Institute/Spain, 2University Hospital Policlinico G 
Martino/Italy, 3University Of Alcala De Henares/
Spain, 4Pangaea Biotech, Dexeus University 
Institute/Spain, 5Oncology, Instituto Oncológico De 
Córdoba/Argentina, 6Oncology, Catalan Institute Of 
Oncology, Hospital Germans Trias I Pujol/Spain
Background: Genetic diversity in lung cancer 
according to histological subtype has not been fully 
explored. BRCA1 and RAP80 inÁuence response 
to chemotherapy. Musashi 2 activates HES-1 in the 
Notch pathway, and HES-1 can abrogate CYLD. 
A20, AEG-1, EZH2 and TRAF6 are also involved 
in NFkB activation. We have examined mRNA 
expression of BRCA1, RAP80 and components of 
the NFkB and Notch pathways in lung cancer p. 
Methods: mRNA expression of Musashi 2, CYLD, 
HES-1, A20, EZH2, AEG-1, TRAF6, NFKBIA, 
RelA, BRCA1 and RAP80 was analyzed by 
quantitative RT-PCR in tumor samples from 85 lung 
cancer p (77 NSCLC, 8 SCLC). 
Results: p characteristics: 51 males; median age, 
59; 33 smokers, 26 ex-smokers; 49 adenocarcinoma, 
10 large cell carcinoma (LCC), 18 squamous cell 
carcinoma (SCC), 8 SCLC. Source of tumor sample: 
36 primary tumor, metastasis, 15. 11 p had K-ras 
mutations. There were differences in the expression 
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P2.095 MOLECULAR PROGNOSTIC 
FACTORS IN NON-SMALL CELL LUNG 
CANCER PATIENTS WHO RECEIVED 
CURATIVE RADIOTHERAPY AND 
CHEMOTHERAPY
Deniz Yalman1, Gözde úücan1, Serdar Özkök1, Deniz 
Nart2, Senem Demirci1, Gürsel Çok3 
1Radiation Oncology, Ege University Faculty Of 
Medicine/Turkey, 2Patholgy, Ege University Faculty 
Of Medicine/Turkey, 3Pulmonolgy, Ege University 
Faculty Of Medicine/Turkey
Background: To determine the molecular 
prognostic factors which effect treatment results in 
locally advanced non-small cell lung cancer (LA-
NSCLC) patients who received radiotherapy and 
chemotherapy for curative intent. 
Methods: Between January 2000 and December 
2008, 76 LA-NSCLC patients whose pathologic 
slides were available for immunohistochemical 
analysis were evaluated for ERCC1, RRM1, MMP7, 
and VEGF expression.
Results: Positive prognostic factors for overall 
survival in univariate log-rank analysis were weight 
loss  5% (p=0.04), epidermoid histology (p=0.04), 
N0-1 stage (p<0.01), high expression level of MMP7 
(p=0.05), good response to treatment (p<0.01). 
Positive prognostic factors in multivariate Cox 
regression analysis were high level of Karnofsky 
Performance Status (p=0.05), epidermoid histology 
(p=0.02), and good response to treatment (p<0.01). 
Positive prognostic factors which inÁuenced disease-
free survival were epidermoid histology (p<0.01), 
good response to treatment (p<0.01), high expression 
levels of ERCC1 (p=0.02) and MMP7 (p=0.02) 
in univariate analysis, and epidermoid histology 
(p<0.01), N0-1 stage (p<0.01), good response to 
treatment (p=0.01) in multivariate analysis. Positive 
prognostic factors for locoregional recurrence-free 
survival were concomitant chemotherapy (p=0.03), 
good response to treatment (p=0.05), high expression 
levels of ERCC1 (p=0.03) and MMP7 (0.03) in 
univariate analysis. High expression level of ERCC1 
was found to increase treatment response rate 
(p=0.05), decrease the risk of recurrence (p=0.02), 
prolong the duration of overall survival but without 
statistical signiÀcance (p=0.32), inÁuence disease-
free (p=0.02) and locoregional recurrence-free 
survival rates (p=0.03). High expression level of 
unresectable stage IIIB or IV adenocarcinomas of 
the lung harboring EGFR mutations encourages to 
develop testing techniques on cytologic specimens, 
instead of tissue biopsies, which are sometimes 
unavailable.
Methods: DNA was extracted from cytologic 
specimens of 39 patients from bronchial 
brush (n=5), lavage (n=2), transthoracic and 
transbronchial needle aspiration (TBNA) (n=20), 
pleural or pericardial Áuids (n=9), subcutaneous 
nodule or peripheral lymph node (n=3). The 
adequacy of cytologic specimens submitted for 
EGFR/KRAS molecular testing, including echo-
guided TBNA, for direct sequencing method was 
evaluated.
Results: Tumor cells represented 5-80% of overall 
cellularity. ConÀrmed adenocarcinomas were 
present in 27 patients. Available DNA was extracted 
from all specimens, both in terms of yielding 
and quality. DNA recovering ranged from 3.4 to 
339.6 ng/ï l and 260/280 OD ratio was > 1.54 in 
all patients, including those with poor cellularity 
rate. DNA sequencing was available for EGFR 
exon-18, -19, -20 and -21 in 37/39, 36/39, 37/39 
and 38/39 patients respectively and for KRAs in all 
patients. Abnormalities were found in 8 (20,5%) of 
39 patients. Exon 18 mutations, exon 19 deletions, 
exon 20 mutations, and exon 21 L858R mutations 
were detected in 2/37 (5.5%), 4/36 (11%), 1/37 
(2.7%), and 1/38 (2.6%) cases, respectively. KRAS 
mutations in exon 2 were revealed in 11 patients 
(28%). The overall EGFR/KRAS mutations proÀle 
from this small series including only cytologic 
specimens was consistent with that usually obtained 
from tissue biopsies except for EGFR exon 21.
Conclusion: Direct sequencing of DNA from 
cytologic material is accurate for the detection 
of EGFR and KRAS mutations in patients with 
NSCLC. Extracted DNA recovering was sufÀcient 
despite important variability, whatever the tumoral 
cellularity. Cytologic specimens may challenge 
tissues biopsies when needed to check EGFR/
KRAS mutational status in patients candidate for 
TKIs treatment.
Keywords: EGFR mutations, cytology, NSCLC
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free, recurrence, and death. Heath-state transitions 
depended on stage, chemotherapy use, and risk 
strata. The sensitivity (82%) and speciÀcity (66%) 
for predicting 5-year recurrence were derived from a 
meta-analysis of publicly available expression data 
and laboratory evaluations of stored tumor samples. 
The model included costs for the multi-marker assay, 
chemotherapy treatment and administration, disease 
monitoring, and post-recurrence medical care. 
Time spent in each health state was adjusted by the 
commensurate utility value. The model outcomes 
were expressed in terms of incremental costs, life-
years gained, quality adjusted life-years gained 
(QALYs), and the incremental cost-effectiveness 
ratio (ICER).
Results: The multi-marker assay provided an 
average increase in QALYs and costs of 0.13 and 
$4,312, respectively, with an incremental cost-
effectiveness ratio (ICER) of $33,701/QALY. 
The results were most sensitive to estimates of 
chemotherapy beneÀt in high-risk patients and 
the utility value during chemotherapy treatment. 
Threshold analyses indicated that the assay would 
yield an ICER <$50,000/QALY for sensitivity 
and speciÀcity values  70% and hazard ratios for 
the impact of chemotherapy on recurrence risk 
below 0.8 in high-risk patients. Using baseline test 
characteristics, the ICER remained below $50,000/
QALY for test cost below $5,200.
Results: 
Intervention Test cost 
Chemotherapy 
Cost 
Monitoring 
Cost 
Post-
Recurrence 
Cost 
Total cost LYs QALYs % Receiving chemotherapy 
Multi-marker 
Assay $3,200 $3,337 $12,230 $17,721 $25,372 6.47 5.25 52% 
No Testing $0 $1,415 $11,762 $18,607 $21,059 6.31 5.12 22% 
Difference $3,200 $1,922 $467 -$886 $4,312 0.16 0.13 30% 
ICER (Incremental cost per LY or per QALY) $26,449 $33,701 
Abbreviations: LY: life-year; QALY: quality adjusted life-year, ICER: incremental cost-effectiveness ratio 
Conclusion: A predictive multi-marker assay with 
moderate accuracy has the potential to efÀciently 
improve outcomes in early-stage NSCLC. Early-
phase decision analyses can provide useful target test 
characteristics for development programs. As part of 
test validation, it is essential to understand levels of 
chemotherapy beneÀt by patient risk strata.
Keywords: Early Stage NSCLC, recurrence, Multi-
marker assay, prognostic
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
MMP7 did not have an impact on treatment response 
and recurrence rates however it inÁuences the 
duration and rates of overall (p=0.05), disease-free 
(p=0.02) and locoregional recurrence-free survival in 
a positive way. The expression levels of RRM1 and 
VEGF did not have impact on treatment response, 
recurrence rates, and the duration and rates of 
overall, disease-free, and locoregional recurrence-
free survival. 
Conclusion: ERCC1 and MMP7 were molecular 
prognostic factors that inÁuence survival and 
treatment response in LA-NSCLC patients who 
receive RT and CT. These Àndings should be 
clariÀed with prospective clinical trials with higher 
number of patients. 
Keywords: Non-small cell lung cancer, molecular 
prognostic factors
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P2.096 EARLY-PHASE DECISION 
MODELING IN LUNG CANCER 
TO PROJECT THE VALUE OF A 
PROGNOSTIC NSCLC MULTI-MARKER 
SIGNATURE
Josh J. Carlson1, Diego Ossa2, Axel Schloesser2, 
David L. Veenstra1, Scott D. Ramsey3, Louis P. 
Garrison1 
1Pharmacy, University Of Washington/United 
States Of America, 2Health Economics & Outcomes 
Researc, Novartis Molecular Diagnostics - Novartis 
Pharma Ag/Switzerland, 3Population Health 
Sciences, Fred Hutchinson Cancer Research Center/
United States Of America
Background: Molecular signatures may provide 
additional information beyond histological staging 
about the likelihood of relapse and the beneÀt of 
adjuvant chemotherapy in early-stage non-small cell 
lung cancer (NSCLC).
Methods: We developed a Markov-type decision-
analytic model to evaluate the clinical and economic 
impacts of a predictive multi-marker assay in early-
phase development compared to standard care. In 
the standard care arm, stage I patients were assumed 
to be observed and stage II patients were assumed 
to receive chemotherapy. In the testing arm, high-
risk patients received chemotherapy and low risk 
patients were observed. After initial treatment, 
patients could experience three health states: disease-
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BAC components (non-BAC). BAC/AWBF tumors 
were further assessed for the presence of mucinous 
features.
Results: EGFR and KRAS mutations were found in 
76 (41.8%) and 30 (16.5%) cases, respectively. In 
the KRAS mutant group, BAC/AWBF was found 
in 22 cases, which included 10 non-mucinous and 
12 mucinous tumors. Of 19 cases with mucinous 
BAC/AWBF, KRAS mutations were detected in 12 
(63.2%), but no EGFR mutation was detected. In the 
KRAS mutant group, BAC/AWBF had signiÀcantly 
earlier pathological stages (p=0.032) and more 
favorable prognoses (P=0.004) than did non-BAC. 
Mucinous BAC/AWBF showed less smoking history 
(p=0.043, p=0.001) than did non-mucinous BAC/
AWBF and non-BAC. Furthermore, transversion 
type KRAS mutations were more common in non-
BAC (p=0.039). 
Conclusion: KRAS-mutated adenocarcinomas can 
be divided into BAC/AWBF and non-BAC types. 
Non-BAC adenocarcinoma is related to smoking 
history and has a poor prognosis. BAC/AWBF 
adenocarcinoma, however, has a more favorable 
prognosis, and mucinous BAC/AWBF has little 
relationship to smoking history.
Keywords: Lung cancer, Adenocarcinoma, KRAS 
mutation, mucinous bronchioloalveolar carcinoma
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P2.098 THYMIDYLATE SYNTHETASE 
MRNA EXPRESSION IN LUNG 
CANCER PATIENTS TREATED WITH 
PEMETREXED
Tetsuo Shimizu1, Yoko Nakanishi2, Yoshiko 
Nakagawa1, Toshio Sugane1, Ichiro Tsujino1, Yasushi 
Ouchi1, Toshinori Oinuma2, Noriaki Takahashi1, Shu 
Hashimoto1, Norimichi Nemoto2 
1Respiratory Medicine, Nihon University School 
Of Medicine/Japan, 2Pathology, Nihon University 
School Of Medicine/Japan
Background: Pemetrexed (PMT), a multitargeted 
antifolate drug, inhibits thymidylate synthetase 
(TS) potently. PMT is effective in non-small-
cell lung cancer (NSCLC) patients with non-
squamous cell carcinoma. TS expression is lower 
in adenocarcinoma compared with squamous 
cell carcinoma. The relationship between clinical 
effectiveness of PMT and TS expression in lung 
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P2.097 CLINICOPATHOLOGICAL 
FEATURES OF LUNG 
ADENOCARCINOMA WITH KRAS 
MUTATIONS
Seiichi Kakegawa, Kimihiro Shimizu, Tetsuhiro 
Nakano, Masayuki Sugano, Yohei Miyamae, 
Mitsuhiro Kamiyoshihara, Osamu Kawashima, 
Izumi Takeyoshi 
Thoracic And Visceral Organ Surgery, Gunma 
University Graduate School Of Medicine/Japan
Background: KRAS and epidermal growth factor 
receptor (EGFR) mutations are thought to play 
an important role in the carcinogenesis of lung 
adenocarcinoma. The occurrence of these two 
oncogenic mutations is mutually exclusive, and 
they exhibit many contrasting characteristics, such 
as gender, smoking history, pathological features, 
response rate to molecular-targeted agents, and 
prognostic implications. KRAS mutations have been 
widely hypothesized to be related to direct tobacco 
exposure. It was, however, recently reported that 
KRAS status cannot be readily predicted on the 
basis of smoking history alone. KRAS mutations 
are frequently found in adenocarcinomas with 
mucinous bronchioloalveolar carcinoma, occurring 
in 28–86% of cases. Mucinous BAC was reported 
to be more often associated with non-smoking 
status. Several meta-analyses revealed that KRAS 
mutations may be associated with shortened 
survival; however, some studies reported that KRAS 
mutations are not independently associated with 
prognosis in patients with lung adenocarcinoma. 
As noted above, clinicopathological Àndings of 
KRAS-mutated adenocarcinoma cases have not yet 
been fully clariÀed. We analyzed the relationship 
between the KRAS mutation and corresponding 
clinicopathological Àndings, focusing on non-
mucinous and mucinous bronchioloalveolar 
elements. 
Methods: EGFR and KRAS mutations were 
detected in DNA samples extracted from 182 
surgically resected tissues of lung adenocarcinomas 
by Smart AmpliÀcation Process. The relationships 
between gene mutation status and clinicopathological 
features were analyzed. All adenocarcinoma cases 
were divided into bronchioloalveolar carcinoma 
(BAC), adenocarcinoma with bronchioloalveolar 
features (AWBF), and adenocarcinoma without 
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Background: hnRNP A1 is a member of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) 
family, which binds pre-mRNA and plays multiple 
roles in the regulation of mRNA metabolism,such as 
mRNA alternative splicing, transport and stability. 
hnRNP A1 is also involved in the regulation of 
transcription, maintenance of telomeres, and 
microRNA processing. hnRNP A1 expression is 
deregulated in multiple types of cancer. In the 
present study we examined the expression and role 
of hnRNP A1 in human non-small cell lung cancer 
(NSCLC).
Methods: hnRNP A1 expression was evaluated 
by immunohistochemistry in 81 NSCLC tumors 
and their normal counterparts. We also analyzed 
the expression of hnRNP A1 in a panel of NSCLC 
cell lines. To study the role of this factor in lung 
cancer, hnRNP A1 expression was transiently 
down-regulated by siRNA in selected lung cancer 
cell lines. The effects of hnRNPA1 inhibition on 
proliferation and anchorage-independent growth 
were evaluated. The potential involvement of STAT3 
in the hnRNPA1 mediated inhibition of anchorage-
independent growth was analyzed through several 
technical approaches. Finally, STAT3 and phospho-
STAT3 expression was analyzed in lung cancer 
samples by immunohistochemistry.
Results: In most of the tumors, as in normal lung 
tissue, the expression of hnRNP A1 was nuclear; 
however, some carcinomas also showed cytoplasmic 
localization of this protein. Transient downregulation 
of hnRNP A1 did not affect anchorage-dependent 
proliferation, but strongly enhanced anchorage-
independent growth. We next investigated the 
molecular mechanisms by which hnRNP A1 exerted 
this effect. We analyzed the expression of STAT3, 
a transcription factor involved in anchorage-
independent growth, resistance to anoikis, invasion, 
and metastasis. We found that down-regulation 
of hnRNP A1 increased the expression of STAT3 
at both the mRNA and protein levels. In addition, 
higher levels of phospho-STAT3, the activated form 
of STAT3, were found when hnRNP A1 was down-
regulated and cells were subjected to anchorage-
independent conditions. Moreover, hnRNP A1 
speciÀcally bound and stabilized STAT3 mRNA. 
Finally, we found that in the series of lung tumors 
analyzed, low levels of hnRNP A1 tended to be 
cancer cells is unknown. The purpose of this study 
is to determine whether TS expression affects 
therapeutic efÀcacy of PMT. 
Methods: The subjects were NSCLC patients who 
treated with PMT. Samples were gotten by tumor 
biopsy before treatment. We dissected cancer 
cells from formalin-Àxed parafÀn-embedded 
tissue by using a laser microdissection. TS 
mRNA was analyzed by using real-time RT-PCR. 
TS protein expression was evaluated by using 
immunohistochemistry. We assessed the association 
between TS expression and therapeutic efÀcacy of 
PMT.
Results: Twenty-nine patients were enrolled. The 
median age was 67 years. Seventy-two percent of 
patients had a previous treatment with chemotherapy. 
Overall response rates were 27.6% for PMT. Median 
progression free survival (PFS) was 16.7weeks for 
PMT. TS mRNA expression could be evaluated in 
all samples. TS mRNA levels ranged from 0.001 
to 33.590 (mean 2.451). TS mRNA expression was 
signiÀcantly lower in response group (CR+PR) 
compared with non-response group (SD+PD) 
(0.223±0.083 versus 3.195±1.752, p<0.001). TS 
protein expression was signiÀcantly lower in 
response group compared with non-response group 
(p=0.030). PFS was statistically superior for lower 
TS mRNA expression patients compared with higher 
TS mRNA expression patients (18.0 versus 15.0 
weeks, p=0.047).
Conclusion: We could analyze TS mRNA 
expression in lung cancer cells speciÀcally from 
biopsy specimens by using a laser microdissection. 
TS mRNA expression affected therapeutic efÀcacy 
of PMT. TS mRNA expression may be usefull 
predictive biomarker for NSCLC patients received 
PMT.
Keywords: Thymidylate synthetase, Pemetrexed, 
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P2.099 EXPRESSION OF HNRNP A1 BY 
NON-SMALL CELL LUNG CANCER 
CELLS REGULATES ANCHORAGE-
INDEPENDENT GROWTH THROUGH 
THE ACTIVATION OF STAT3
Maria J. Pajares1, Teresa Ezponda1, Jackeline 
Agorreta1, Elena Martínez1, Akiko Tamura2, Luis M. 
Montuenga1, Ruben Pio1 
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chi-square or Fisher’s exact test. Overall survival 
(OS) and relapse-free survival (RFS) were analyzed 
by the Kaplan-Meier method and comparison 
between them was done using the Log-rank test. 
Multivariate analysis for survival was calculated by 
proportional hazards model of Cox.
Results: CD 74 expression in more than 50% of the 
cells in tumor and stroma was observed in 14.1% 
and 56.1% respectively. The positivity of CD74 in 
more than 50% of the cells, when evaluated in the 
tumor, correlated with better relapse-free survival 
(RFS, 3 years: 93.3% vs. 67.8%, p = 0.018) and was 
associated signiÀcantly with female gender (p = 
0.003), nonsmokers (p = 0.019), bronchioloalveolar 
and adenocarcinoma histologic types (p = 0.001) 
and stage I (p = 0.001), factors associated to good 
prognosis. Expression of TGFB1 in more than 
50% of the cells in tumor and stroma was observed 
in 21.1% and 10.2% respectively. TGFB2 was 
positive in 52.8% in tumor and 30.7% in stroma. 
TGFB1 and TGFB2 did not correlate with OS and 
RFS. In multivariate analysis for RFS and OS, only 
pathological stage was identiÀed as an independent 
determinant of prognosis.
Conclusion: In the present study, we observed 
that CD74 was determinant of better relapse free 
survival, but it is not an independent prognosticator. 
Expression of TGFB1 and TGFB2 was not correlated 
to prognosis in this group of patients.
Keywords: non-small cell llung cancer, Surgery, 
Prognosis, inÁammatory
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P2.101 THE CONTRIBUTION OF 
BIOMARKERS TO ASSESS THE 
LEVEL OF INDIVIDUAL RISK IN THE 
SELECTION OF HIGH PREVALENCE 
SUBJECTS FOR CT SCAN LUNG 
CANCER SCREENING
Francesca M. Carozzi1, Simonetta Bisanzi1, Andrea 
Lopes Pegna2, Francesco Giusti3, Laura Carrozzi4, 
Mario Mascalchi5, Fabio Falaschi6, Giulia Picozzi7, 
Eugenio Paci3 
1Biomolecular Lab., Ispo/Italy, 2Pneumology Dept, 
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Pneumology, Aou Pisa/Italy, 5Diagnostic Imaging, 
Aou Careggi/Italy, 6Diagnostic Imaging, Aou Pisa/
Italy, 7Diagnostic Imaging, Asl Pistoia/Italy
associated with high levels of phospho-STAT3.
Conclusion: Our data demonstrate that the 
expression of hnRNPA1 by lung cancer cells 
regulates anchorage-independent growth through a 
STAT3 dependent mechanism. 
Keywords: hnRNPA1, STAT 3, Lung cancer
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P2.100 CD74, TGFB1 AND TGFB2 
PROTEIN EXPRESSION ANALYSIS IN 
RESECTED NON-SMALL CELL LUNG 
CANCER AND ITS CORRELATION WITH 
CLINICAL OUTCOMES
Jefferson L. Gross1, Milton J.D.B. Silva2, Vladmir 
C.C. Lima2, Clovis A.L. Pinto3, Andreia C. Melo4, 
Carlos G.M. Ferreira4, Fernando A. Soares3 
1Thoracic Surgery, Hospital A C Camargo/Brazil, 
2Clinical Oncology, Hospital A C Camargo/Brazil, 
3Pathology, Hospital A C Camargo/Brazil, 4Instituto 
Nacional Do Cancer/Brazil
Background: Surgery remains the main curative 
option for non-small lung cancer (NSCLC) patients, 
but it is reserved to early stages. Adjuvant treatment, 
mainly chemotherapy, is offered to a high proportion 
of these patients. Even for patients with early stages 
NSCLC, the clinical behavior might be different after 
surgical resection. Recent studies have shown that 
aspects of the inÁammatory process can inÁuence the 
behavior of tumors. The CD74, TGFB1 and TGFB2 
play a key role in regulating the inÁammatory 
process. This aim of this study is to evaluate the 
expression of CD74, TGFB1 and TGFB2 in tumor 
and stroma, and correlate with clinicopathologic 
features and prognosis for overall and relapse free 
survival in patients with NSCLC who underwent 
curative resection.
Methods: From Jan 2003 to Dec 2007 we 
retrospectively review clinical and pathological data 
of patients with NSCLC who were submitted to 
complete surgical resection. One hundred twenty-
nine patients with localized NSCLC operated 
without prior therapy and with availability of 
pathological material and clinical outcome were 
evaluated by immunohistochemical staining for 
CD74, TGFB1 and TGFB2 in tumor and stroma. 
Cases were analyzed according to the intensity and 
percentage of positive cells. Association between 
variables was performed according the method of 
S988 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
screening test is on going. Results untill now conÀrm 
the hypothesis that biolmolecular marker might 
be a complementary source of informnation in the 
assessment of individual lung cancer risk. This 
results can be helpful in the design of an efÀcient 
strategy for lung cancer screening integrating 
individual risk assessment with biomarkers and CT 
Scan screening. 
Keyword: CT SCan Screenng
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.102 BRAF AND PIK3CA GENE 
MUTATION STATUS IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
Zhi-Hong Chen1, She-Juan An1, Zhi Xie2, Ai-Lin 
Guo2, Jian-Guang Chen2, Hong-Hong Yan2, Jian Su2, 
Zhi-Yong Chen2, Xu-Chao Zhang2, Yi-Long Wu2 
1Medical Research Center, Guangdong Lung Cancer 
Institute, Guangdong General Hospital/China, 
2Medical Research Center, Guangdong General 
Hospital/China
Background: SpeciÀc mutations of the epidermal 
growth factor receptor (EGFR) gene are predictive 
for favorable response to tyrosine kinase inhibitors 
(TKIs) and are associated with a good prognosis. 
Nevertheless, tumor that initially responds to EGFR-
TKIs almost inevitably becomes resistant later. Other 
mechanisms of resistance to EGFR inhibitors could 
involve activating mutations of the other main EGFR 
effector pathway, i.e., the phosphoinositide-3-kinase/
phosphate pathway and BRAF-MEK-ERK pathway. 
The aim of this study was to investigate the mutation 
status of phosphoinositide-3-kinase catalytic alpha 
(PIK3CA) and BRAF gene in patients with non-
small cell lung cancer (NSCLC).
Methods: A total of 242 patients with NSCLC 
from 2007 to 2009 with available archival tissue 
specimens were included. The hot-spot mutations 
of exon 11 and exon 15 of the BRAF oncogenes 
and the exon 9 and exon 20 in the PIK3CA gene 
were screened by high-resolution melting analysis 
(HRMA) method, and the mutation positive samples 
were conÀrmed by direct sequencing.
Results: Of thees 242 cases, 170 were 
Background: Early detection of biological markers 
promise to complement the ability of low-dose CT 
to detect lung cancer. In previous study we shown 
the possibility of integrating the CT Scan screening 
and the result of biomarkers in the screening for lung 
cancer process. In this study we will present further 
data supporting this assessment as a tool to improve 
positive predictive models of individual breast 
cancer risk.
Methods: A randomised controlled screening trial 
for early lung cancer detection with low-dose CT is 
ongoing in Tuscany, Italy, in a cohort of 1406 high-
risk (smokers and ex smokers (less than 8 years) 
active asymptomatic subjects. Several markers 
were analyzed on sputum and plasma samples at 
baseline, in particular genetic instability (LOH, 
MSI), and plasma DNA quantiÀcation. Evaluation of 
biomarkers was shown to be of special interest and a 
larger study has been carried out for several groups 
of subject. In this presentation data are presented 
for the group of subjects with 4 negative CT Scan 
screening tests who were assessed for biomarkers at 
baseline. 
Results: 96.4% of subjects enrolled in the Italung 
trial accepted to donor peripheral blood and 
uninduced sputum. In a Àrst analysis we published 
results on 98 subjects: cases of screen-detected lung 
cancer; controls negative at baseline CT screening, 
and subjects positive for non-calciÀed nodule (NCN 
 5mm and NCN3mm at repeated) at baseline but 
negative for cancer at the follow-up CT examination. 
Allelic imbalance showed good performance for 
screening of NCN 5mm. Results of the study 
including the lung cancer cases detected at repeated 
rounds (1,2,3) and in a larger sample of subjects 
which were classiÀed as always negative for NCN 
in all the 4 screening rounds showed that subjects 
negative at all the 4 screening round were negative at 
escreate analysis in the 75% of subjects assuming a 
cut off of 23% (133 out of 175 subjects , with the 8% 
of inadequate sputum) . The average DNA plasma in 
this group (N=175) was 3.6 ng DNA/ml plasma (SD 
2.7). Ever CT Scan negative subjects (i.e. any NCN 
duing the4 screening cycle) in the 81.4% were under 
the cutoff of 5 ng of plasma DNA. 
Conclusion: In this conÀrmitory study based on 
large number of ever CT Scan negative subjects the 
value of molecular biomarkers in the assessment of 
the individual risk of lung cancer was important in 
the classiÀcation of subjects . A full evaluation of 
lung cancer cases at repeated screening test and of 
the groups in whom a NCN was detected at repeated 
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and dasatinib, and miRs were extracted. To assess 
miR expression proÀles, we used TaqMan® Array 
MicroRNA Cards (Applied Biosystems). Western 
Blotting was performed using anti-Src, anti-
phospho-Src, anti-ID1 and anti-Actin antibodies. 
miR transcript levels were conÀrmed by real-time 
quantitative RT-PCR. Lentiviral vectors were used 
to express pre-miR and anti-sense-miR. Migration 
and invasion were tested using wound healing and 
transwell assays, respectively. Formalin-Àxed and 
parafÀn-embedded adenocarcinoma samples and 
matched alveolar lung tissue from 23 patients were 
used for miR expression analysis. P-values < 0.05 
were deÀned as statistically signiÀcant. 
Results: Upon incubation of A549 lung cancer cells 
with the Src inhibitor saracatinib, miR-29b and 
miR-381 were the most highly upregulated miRs 
with a binding site in the ID1 3’UTR. miR-29b 
and/or miR-381 suppressed the level of ID1 and 
signiÀcantly reduced cell migration a hallmark of 
the Src-ID1 pathway. Inhibition of endogenous miR-
29b or miR-381 markedly enhanced ID1 expression. 
miR-29b repression resulting in increased ID1 levels 
signiÀcantly increased lung cancer cell migration and 
invasion. In addition the effects of the Src inhibitors 
saracatinib and dasatinib on migration and invasion 
were signiÀcantly attenuated in these cells. In human 
lung adenocarcinoma samples, miR-29b and miR-
381 were signiÀcantly downregulated compared with 
matched alveolar lung tissue (p=0.031 and p=0.007). 
Tumor miR-29b expression negatively correlated 
with the previously determined ID1 nuclear H-score 
(p=0.0446). Moreover, tumor miR-29b and miR-381 
levels were signiÀcantly associated with event-free 
survival (p=0.03 and p=0.003) and overall survival 
(p=0.04 and p=0.02). 
Conclusion: We identiÀed ID1 as novel target of 
miR-29b and miR-381. Our results further indicate 
that miR-29b and miR-381 are dysregulated in 
human lung adenocarcinoma, are involved in lung 
cancer cell migration and invasion via the Src-ID1 
signaling pathway and modulate the resistance to Src 
kinase inhibitors in lung cancer cells. 
Keywords: Inhibitor of differentiation protein 1, 
SRC, Lung cancer, miR-29b and miR-381
adenocarcinoma, 52 were squamous cell carcinoma, 
and 20 were the others. 6 were I stage, 14 were II 
stage, and 222 were III and IV stage; 166 were male, 
76 were female; The mean age of these patients 
was 58 years, range from 23-88 years. The PI3KCA 
activation mutation rate was 2.48% (6/242), 1.66% 
(4/242) in exon 9 and 0.83% (2/242) in exon 20. 
The mutations in exon 9 included E545K(3 cases) 
and E545K and T544T(1 case). H1046R mutation 
was found in exon 20(2 cases). BRAF activation 
mutation rate was found in 2.48% cases (6/242), 
1.66%(4/242) in exon 15 and 0.83%(2/242) in exon 
11. The mutation in exon 15 was V600E (4 cases). 
Two activating mutations were found in exon 11, 
S446G and G460R. HRMA revealed abnormal 
melting proÀles in 1 case harboring mutations in 2 
different genes simultaneously.
Conclusion: Our study indicated that PIK3CA and 
B-RAF have a low frequency mutation in patients 
with NSCLC. This may have a potential signiÀcance 
for the target therapy.
Keywords: B-RAF, Lung cancer, PIK3CA
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P2.103 MIR-29B AND MIR-381 
ARE DYSREGULATED IN LUNG 
ADENOCARCINOMA AND MODULATE 
RESISTANCE TO SRC INHIBITORS IN 
LUNG CANCER CELLS
Sacha I. Rothschild1, Mario P. Tschan2, Rolf Jaggi2, 
Martin F. Fey3, Mathias Gugger4, Oliver Gautschi5 
1Department Clinical Research, University Of Bern/
Switzerland, 2Department Of Clinical Research, 
University Of Bern/Switzerland, 3Department Of 
Medical Oncology, Inselspital, Bern University 
Hospital/Switzerland, 4Institute Of Pathology, 
University Of Bern/Switzerland, 5Medical Oncology, 
Luzerner Kantonsspital/Switzerland
Background: The Src kinase regulates cancer cell 
invasion through ID1, both are frequently over-
expressed in human lung adenocarcinoma. The 
current study aimed at identifying microRNAs 
(miRs) controlled by Src that target ID1, and to test 
if modulation of these miRs in lung cancer cells lead 
to resistance against Src inhibitors. 
Methods: The study included the human lung 
cancer cell lines A549, H460 and H1299. Cells 
were incubated with the Src inhibitors saracatinib 
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P2.105 NEW BIOMARKERS INVOLVED 
LUNG CANCER DEVELOPMENT IN 
COPD PATIENTS.
Mª Dolores Pastor1, Ana Nogal1, Sonia Molina-
Pinelo1, M. J. De Miguel2, Eduardo Márquez-
Martín2, Ana Salinas1, Amancio Carnero1, Luis Paz 
Ares2 
1Molecular Oncology And New Therapis, Biomedical 
Research (IBIS)/Spain, 2Molecular Oncology And 
New Therapis, Hospital Universitario Virgen Del 
Rocio/Spain
Background: Lung cancer (LC) and chronic obstructive 
pulmonary disease (COPD) are both smoking related 
illnesses. Approximately 65% of all LC patients 
present COPD, which suggests that COPD is a risk 
factor for the development of LC and that there must 
be common pathophysiological mechanisms to both 
diseases. Immune dysfunction, abnormal activation of 
NF-Ä¸B, epithelial-mesenchymal transition, alterations 
of the degradation of extracellular matrix, among 
others have been implicated in the development of 
both diseases by several studies. Nonetheless, the 
most important mechanism shared by LC and COPD 
is chronic inÁammation that causes alterations in the 
bronchial epithelium. Previous studies highlight the role 
of cytokines (IL-8,IL-1,IL-6), chemokines (RANTES, 
MCP-1), matrix metalloproteinases (MMP-9, MMP-3) 
and growth factors (TGF, VEGF) in the inÁammatory 
process that takes place in both diseases. However, 
the understanding of the inÁammatory mechanisms 
involved in LC and COPD is still limited. With this 
study we aimed at analyzing 80 markers (cytokines and 
growth factors) in BAL samples from patients with LC, 
COPD, LC and COPD and without LC or COPD by 
ELISA arrays, in order to obtain a possible predictive 
biomarker proÀle of LC in patients with COPD. 
Methods: In order to analyse the bronchoalveolar 
lavage Áuid protein proÀles from four different groups 
of patients (with COPD, with LC, with COPD and LC 
and without COPD or LC), samples were collected from 
60 individuals (15 per group) from the Virgen del Rocío 
Hospital (Seville, Spain) who had required Áexible 
bronchoscopy for diagnostic reasons. Approximately 
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P2.104 ELEVATED SURVIVIN IS 
PROGNOSTIC SIGNIFICANCE FOR 
NON-RESPONSE TO CHEMOTHERAPY 
AND REDUCED SURVIVAL IN LUNG 
CANCER WITH MALIGNANT PLEURAL 
EFFUSIONS
Euntaik Jeong, Hakryul Kim, Dosim Park, Kieun 
Hwang 
Internal Medicine, Wonkwang University Hospital/
Korea
Background: It is still often difÀcult for clinicians to 
conÀrm malignant pleural effusions (MPE). Survivin 
has been shown to inhibit apoptosis, enhance 
proliferation and promote angiogenesis. This study 
aimed to evaluate the diagnostic accuracy, and 
prognostic role of survivin in lung cancer with MPE. 
Methods: Pleural effusion samples were collected 
from 67 lung cancer patients (58 lung cancers; 9 
extrathoracic tumors), and from 68 patients with 
various benign conditions (31 with pneumonia; 
37 with tuberculosis). Concentrations of pleural 
Áuid survivin, Cyfra 21-1, and carcinoembryonic 
antigen (CEA) were measured simultaneously by 
enzyme-linked immunosorbent assay (ELISA). The 
sensitivity, speciÀcity, and accuracy were calculated 
by receiver operating characteristic (ROC) analysis. 
The expression proÀle of survivin in pleural Áuid, 
and its association with survival, were investigated. 
Results: Survivin levels were signiÀcantly elevated 
in patients with MPE, especially primary lung cancer 
than in those of benign origin. Survivin, Cyfra 
21-1, and CEA varied in diagnostic accuracy for 
differentiating MPE from benign pleural effusion by 
67.5%, 68.3%, and 93.4%, respectively. Lung cancer 
patients with MPE who were positive for survivin 
expression were more refractory to chemotherapy 
(P = 0.003). Elevation of Prx1 was correlated with a 
reduced overall survival in univariate (P = 0.0001) 
and multivariate (P = 0.004) analyses. 
Conclusion: Using the appropriate cut-off points, 
CEA currently provides the best diagnostic accuracy 
for patients with MPE. Survivin may be a useful 
adjunct of the conventional algorithm for diagnosing 
lung cancer with MPE. These Àndings suggest that 
elevated survivin expression may predict a poor-
response to chemotherapy and shorter survival in 
lung cancer patients with MPE. 
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mutation and TKIs therapy, ERCC1 gene expression 
and platinum based-drugs, RRM1 gene expression 
and gemcitabine. 
Methods: From Mar. 2010 to Feb. 2011, we 
performed real time PCR to detect the mutation 
status of EGFR (exons 18, 19 and 21) and KRAS 
(codons 12 and 13), as well as the expression level 
of ERCC1, RRM1, TYMS, TUBB3, VEGF and 
BRCA1 in 90 NSCLC patients 
Results: 90 NSCLC patients were enrolled (median 
age 64, ranged 25~83; 58 males and 32 females; 42 
adenocarcinomas, 15 squamous-cell carcinomas, and 
33 other subtypes). Among the specimens, there were 
68 fresh tissues, 16 FFPE samples, 4 whole blood 
samples and 2 pleural effusion samples. The results 
showed that the mutation rate of EGFR and KRAS 
was 18.5% (15/81) and 11.1% (9/81), respectively. 
EGFR and KRAS mutation were mutually exclusive. 
The high level expression rate of ERCC1, RRM1, 
TYMS, TUBB3, VEGF and BRCA1 was 18.8% 
(16/85), 14.1% (12/85), 7.1% (6/84), 30.6% (26/85), 
21.1% (16/76) and 8.4% (7/83), respectively. 
Conclusion: The data base has been set up 
successfully and the data were still increasing. 
We treated our patients according to their gene 
status. Further investigations are needed to study 
the relationship between gene status and patients’ 
response and survival.. 
Keyword: gene mutation; gene expression; lung 
cancer; data base
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P2.107 A PROSPECTIVE STUDY 
EXPLORING SERUM TUMOR MARKER 
PREDICTING OBJECTIVE RESPONSE 
AND SURVIVAL IN PATIENTS WITH 
ADVANCED NON-SMALL-CELL LUNG 
CANCER
Xue Hou, Xiang-Yun Ye, Lin-Ping Gu, Shun Lu 
Shanghai Lung Tumor Clinical Center, Chest 
Hospital AfÀliated To Shanghai Jiao Tong 
University/China
Background: The clinical relevance of 
serum tumor marker, including cytokeratin 19 
4-8 ml of sample was available to our experiments. Due 
to its low protein content, BALF samples needed to be 
concentrated before use. In order to study the protein 
proÀles of the four groups of patients, a cytokine and 
growth factor screening was performed. The protein 
array used in this study is a commercially available array 
kit that analyses the expression levels of 80 cytokines 
and growth factors (Quantibody® Human Cytokine 
Antibody Array 1000 – RayBiotech, Norcross, GA, 
USA). Validation of the cytokine arrays results was 
performed through western blot.
Results: The analysis of the 80 cytokines and 
growth factor arrays in BAL samples from 60 
patients from each group was performed using the 
scanner GenePix and the BABILOMICS software 
to create heat maps (using the samples’ Euclidian 
distance). This analysis revealed the differential 
expression of 17 markers (EGF, VEGF, IGFBP2, 
GDF15, TIMP1, TNFR I, TNFR II, IL-8, IL-1a, 
IL-1ra, IL6sR, ICAM-1, Eotaxin 2, MCP1, MIG, 
MIP1b and MIP1d). The most noticeable changes 
were observed between the control group and the 
remaining groups as well as differences between 
adenocarcinoma and squamous cell carcinoma, with 
the latter one resembling the expression that occurs 
in patients with only COPD. The array data was later 
on validated by western blot with speciÀc antibodies, 
conÀrming the results of the previous technique. 
Conclusion: The citokines have important paper 
in cronical inÁamation process in both disease lung 
cance and COPd.
Keywords: citokines, grow factors, Lung cancer, 
COPD
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P2.106 SPECIFIC GENE MUTATIONS 
AND EXPRESSION STATUS IN NSCLC
Yi Zhang, Xiuyi Zhi, Mu Hu 
Thoracic Surgery Dept., Beijing Lung Cancer 
Center, CMA/China
Background: In NSCLC, mutations and expression 
levels of speciÀc genes in cancer cells have been 
shown to affect the response rates to related target 
–therapies or chemo-therapies. For instance, EGFR 
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Viteri4, Carlota Costa4, Amaya Gasco4, Maria 
Gonzalez-Cao3, Nuria Mederos4, Fernanda Salazar4, 
Jordi Bertran-Alamillo4, Ana Jimenez-Capitan4, 
Giuseppe Altavilla5, Susana Benlloch4, Zaira Yeste4, 
Erika Aldeguer4, Miquel Taron6, Rafael Rosell6 
1Oncology, University Hospital Policlinico G 
Martino/Italy, 2University Of Alcala De Henares/
Spain, 3Oncology, Pangaea Biotech, Dexeus 
University Institute/Spain, 4Pangaea Biotech, Dexeus 
University Institute/Spain, 5University Hospital 
Policlinico G Martino/Italy, 6Oncology, Catalan 
Institute Of Oncology, Hospital Germans Trias I 
Pujol/Spain
Background: Little is known about the potential 
effect of genetic alterations in the NFkB and Notch 
pathways on NSCLC p. Musashi 2 activates HES-
1 in the Notch pathway, and HES-1 can abrogate 
CYLD. A20, AEG-1, EZH2 and TRAF6 are also 
involved in NFkB activation. BRCA1 and RAP80 
are modulators of cisplatin-based chemotherapy. 
Mutations in NFKBIA and DUSP22, which prevent 
NFkB activation, were described in the sequencing 
exome of a single NSCLC p, together with K-ras 
mutations. 
Methods: mRNA expression of Musashi 2, CYLD, 
HES-1, A20, EZH2, AEG-1, TRAF6, NFKBIA, 
RelA, BRCA1 and RAP80 was analyzed by 
quantitative RT-PCR in tumor samples from 60 
advanced NSCLC p. Expression levels by terciles 
were correlated with clinical characteristics and 
outcome to chemotherapy. Mutations in NFKBIA 
and DUSP22 were sequenced in 28 and 21 patients, 
respectively, and in 12 cancer cell lines. 
Results: p characteristics: 36 male; 39 
adenocarcinomas; 22 smokers; 23 bone metastases; 9 
EGFR mutations; 10 K-ras mutations. No NFKBIA 
or DUSP22 mutations were observed in any of the p 
or cell lines. PFS was 12.3 months (m) for p in the 
lowest tercile of AEG-1 expression vs 9.3 m for p in 
the intermediate tercile and 4.8 for p in the highest 
tercile (P=0.002). The multivariate analysis showed 
that only AEG-1 expression was associated with 
shorter PFS (HR, 1.43; P=0.006). Expression levels 
of the other genes did not correlate with outcome. 
However, we had previously generated a two-gene 
risk model based on AEG-1 and BRCA1 expression: 
p with high levels of both genes are considered high-
risk, p with low levels of both genes are low-risk, 
and p with high levels of one and low levels of the 
other gene are intermediate-risk. In the present study, 
PFS was 13 m in the low-risk group, while it was 7.6 
fragment(CYFRA21-1), CA125, CA 19-9, and 
carcinoembryonic antigen (CEA) as surrogate 
biomarker in advanced non-small cell lung cancer is a 
matter of debate.
Methods: Serum levels of above four tumor markers 
during chemotherapy were studied prospectively with 
radioimmunoassay at baseline and after 2 courses in 
patients with advanced NSCLC. Data were correlated 
with radiologic objective response (OR) after 4 courses 
and survival. 
Results: Ninety-two patients were evaluable for 
serologic response assessment after 2 chemotherapy 
courses, and radiologic response assessment after 4 
courses. CA125 reduction was statistically different in 
patients with objective response and progressive disease 
(P=0.036). Receiver operating characteristic curves 
(ROC) analysis demonstrated declines of CA125 and 
CYFRA21-1 predicting an OR to chemotherapy, with 
the AUC of 0.764 (95%CI, 0.664- 0.846; P=0.0001), 
a sensitivity of 74.63%, and speciÀcity of 84% for 
CA125, and the AUC of 0.646 (95%CI, 0.539 - 0.744; 
P=0.0175), a sensitivity of 77.27%, and speciÀcity of 
64% for CYFRA21-1, respectively. Survival analysis 
demonstrated median progression-free survival was 
10 months for patients with CYFRA21-1 response 
compared with 7 months for patients without serologic 
response (P=0.003). The 1-year overall survival rate 
was 79.2% for patients with CYFRA21-1 response and 
72.5% for patients with CA125 response compared 
with 38.6% and 70.8% for patients without response, 
respectively (P=0.012 and P=0.037, respectively). 
Multivariate COX analysis indicated CYFRA21-1 
response as independent prognostic factors for PFS 
(HR=0.353, P=0.0005) and OS (HR=0.558, P=0.012). 
Conclusion: CYFRA 21-1 appeared to be a reliable 
surrogate marker of chemotherapy efÀcacy and 
survival in patients with advanced NSCLC.
Keywords: tumor marker, Non-Small-Cell Lung 
Cancer
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P2.108 THE NUCLEAR FACTOR ɤB 
(NFɤB) AND NOTCH SIGNALLING 
PATHWAYS AND BRCA1 MRNA 
EXPRESSION IN STAGE IV NON-
SMALL-CELL LUNG CANCER (NSCLC) 
PATIENTS (P)
Mariacarmela Santarpia1, Maria Sanchez-Ronco2, 
Ignacio Magri3, Miguel Angel Molina4, Santiago 
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P2.110 BUILDING A COMPREHENSIVE 
DATABASE FOR THE LUNGSCAPE 
PROJECT: A WAY TO BRIDGE 
GENOMICS AND CLINICAL PRACTICE 
IN THE EUROPEAN THORACIC 
ONCOLOGY PLATFORM (ETOP).
Solange Peters1, Fiona Blackhall2, Paolo Boffetta3, 
Keith M. Kerr4, Miquel Taron5, Lukas Bubendorf6, 
Fortunato Ciardiello7, Rafael Rosell8, Walter Weder9, 
Rick King10, Ralf Stahel11 
1Lausanne University Hospitals, Lausanne Cancer 
Center/Switzerland, 2The Christie NHS Foundation 
Trust/United Kingdom, 3International Prevention 
Research Institute And Mount Sinai School Of 
Medicine/France, 4Aberdeen Royal InÀrmary/United 
Kingdom, 5Oncology, Catalan Institute Of Oncology, 
Hospital Germans Trias I Pujol/Spain, 6Departement 
Of Pathology, University Hospital Basel/Switzerland, 
7Dipartimento Medico Chirurgico Di Internistica 
Clinica E Sperimentale, Seconda Università 
Dgeli Studi Di Napoli/Italy, 8Instituto Catalán De 
Oncología - Ico/Spain, 9Thoracic Surgery, University 
Hospital Zurich/Switzerland, 10Left Brain Solutions 
Sa/Switzerland, 11University Hospital Zürich/
Switzerland
Background: Since the identiÀcation of activating 
EGFR mutations, a number of distinct oncogenic and 
transforming driver mutations have been described in 
non-small lung cancer (NSCLC), affecting a growing 
patient population, and helping to deÀne therapeutic 
strategies. The Lungscape project aims at building 
a virtual biobank to facilitate an international high-
quality analysis of large numbers of tumors for 
genetic alterations linked to clinical and biological 
characteristics. Lungscape is evolving in step-wise 
fashion, starting with a retrospective analysis of 1500 
completely resected NSCLC in 10-15 European 
institutions and then moving to samples from 
advanced disease. Finally, prospective trials will be 
designed to test treatment of molecularly deÀned 
tumors.
Methods: While tumor samples will be banked 
locally, a central electronic database will store 
anonymized comprehensive molecular and 
clinical data. Participating centers will use a 
secure web-based application to enter data into 
the central database. The system will capture 
detailed pathological parameters like tumor stage, 
m for the intermediate-risk group and 5.3 m for the 
high-risk group (P=0.02). 
Conclusion: NSCLCs have variegated gene 
expression. AEG-1 and BRCA1 mRNA expression is 
a genetic signature that can be used as a prognostic 
model for the management of NSCLC p. 
Keywords: NFkB, Notch pathways, Non-Small-Cell 
Lung Cancer, BRCA1 mRNA expression
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.109 TUMOR HETEROGENEITY AND 
MOLECULAR DIAGNOSTICS: KRAS 
MUTATION DETECTION IN SITU USING 
PADLOCK PROBES AND ROLLING 
CIRCLE AMPLIFICATION
Johan Botling, Ida Grundberg, Juliana Imgenberg-
Kreuz, Karolina Edlund, Magnus Sundström, Patrick 
Micke, Mats Nilsson 
Department Of Immunology Genetics And Pathology, 
Uppsala University/Sweden
Background: The impact of activating KRAS mutations 
on EGFR inhibitor therapy in non-small cell lung cancer 
(NSCLC) is debated. Also, little is known about the role 
of KRAS mutations during lung cancer tumorigenesis, 
and if tumor heterogeneity with regard to mutation status 
is important for treatment response and prognosis.
Methods: We have developed an RNA-based 
genotyping assay that targets KRAS-mutations in 
codon 12 and 13 in situ on tissue slides by the use of 
multiple mutation speciÀc padlock probes and rolling-
circle ampliÀcation.
Results: KRAS genotyping was performed on 
cytologic tumor imprints as well as on fresh-frozen 
and formalin-Àxed parafÀn-embedded tissue sections 
from NSCLC and colon cancer specimens. The results 
were concordant with pyrosequencing data from 
of corresponding crude tissue extracts. Moreover, 
the distribution of wild type (green rolling-circle 
products) and mutated (red rolling-circle products) 
KRAS alleles could be determined for single cancer 
cells in different parts of the tumors.
Conclusion: This in situ method offers single cell 
mutation detection for diagnostics and holds great 
promise as a tool to investigate the role of oncogenic 
mutations in complex tumor tissues without the use 
of microdissection.
Keywords: Kras, Mutation, padlock probe, EGFR 
therapy
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Metz, Lynn Mathew, Audrey Sorensen, Abraham 
Chachoua 
Thoracic Oncology, New York University School Of 
Medicine/United States Of America
Background: Standard Àrst line therapy for 
NSCLC is platinum-based doublet with / without 
biologic agents but responses remain variable. 
Clearly, new approaches are needed to predict 
beneÀt from chemotherapy in NSCLC. Except for 
EGFR mutation, the clinical utility of tissue-based 
biomarkers such as ERCC1, RRM1, thymidylate 
synthetase (TS), and K-ras remains uncertain. 
We conducted a retrospective analysis of Stage 
IV NSCLC patients diagnosed and treated at our 
institute over a 2 year period to correlate Àve 
commercially available biomarkers with best overall 
response to Àrst line platinum-based treatment and 
overall survival.
Methods: Approximately 550 patients with Stage 
IV NSCLC patients were treated at NYU Clinical 
Cancer Center during 2008 and 2009. Of these, 65 
patients fulÀlled the following eligibility criteria for 
this retrospective study: biopsy-proven, available cell 
blocks from Stage IV patients; measurable lesion/s 
by imaging studies; tumor specimen expression of 
ERCC-1, RRM-1, EGFR, TS and for EGFR and 
K-ras mutation analysis performed by Response 
Genetics Inc. Best overall response to Àrst line 
treatment was classiÀed as “clinical beneÀt” (CR, 
PR, SD) or Failure (PD). Survival was deÀned 
from start of treatment until death from any cause. 
Continuous variables such as age at diagnosis, and 
ratio of gene transcripts of: EGFR, ERCC1, RRM1, 
TS, were described by means, standard deviations, 
medians and ranges. Associations between 
gene expressions were assessed using Pearson’s 
correlation coefÀcient (R). Categorical variables, 
such as EGFR and K-ras mutation status, gender, 
performance status, histology and response, were 
described by frequency distributions. Associations 
between histological types and gene expressions 
were assessed using Fisher’s exact test. Multivariate 
logistic modeling was used to assess individual and 
combined effects of the gene expressions on clinical 
beneÀt to Àrst line platinum-based chemotherapy. 
The Kaplan-Meier method was used to plot survival 
curves and to estimate the median survival with a 
95% ConÀdence Interval. Cox proportional hazards 
model was used to assess individual and combined 
effects of the gene expressions on survival. All tests 
were done at a 5% signiÀcance level. 
grade, histological subtype (including diagnostic 
immunohistochemistry), precise surgical procedure 
as well as patient characteristics, including age, 
gender, ethnicity, smoking status, and complete 
oncologic history including at least 3 years of 
documented follow-up. Genetic alterations will 
be progressively recorded, with a basic query for 
EGFR mutations and overexpression/ampliÀcation 
as well as EML4-ALK translocation. Data on 
KRAS, BRAF and HER-2 mutations, MET 
mutations and overexpression/ampliÀcation will 
be recorded if already performed and gradually 
implemented for every sample. Additional gene 
abnormalities, e.g regarding PI3K/PIK3CA, 
LKB1, PTEN, b-catenin, TRAIL-R2 genes will be 
added to molecular pathology parameters, based 
on available functional data in the literature and 
potential therapeutic interventions. In accordance 
with prevailing knowledge, special attention will 
be paid to enriching the virtual biobank with rare 
mutation-harboring tumors coupled with complete 
clinical records.
Results: The database is based upon an extensible 
information module, enabling the quick 
accommodation of changing data capture analysis 
needs across different studies. Its capabilities 
include secure data collection from multiple sites, 
a central and unique data review and acceptance 
workÁow, and integrated charting. The attribute 
deÀnitions are linked directly to end-user 
query-building and data retrieval, without any 
reprogramming. These parameterized data sets are 
directly available for time-series and cross-sectional 
statistical analysis and visualization. All activities 
will be coordinated by the ETOP ofÀce
Conclusion: Lungscape will enable investigators 
to generate biological hypothesis for personalized 
treatment approaches and provide an adequate trial 
platform for hypothesis testing.
Keywords: virtual biobank, NSCLC rare genetic 
alterations, ETOP, clinical database
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P2.111 RRM-1 IS PREDICTIVE OF 
CLINICAL BENEFIT FROM FIRST LINE 
PLATINUM DOUBLET THERAPY IN 
NON-SMALL CELL LUNG CANCER
Nagashree Seetharamu, Harvey I. Pass, Benjamin 
Levinson, Marc Ballas, Sabina Musovic, Michael 
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and the potential prognostic value of plasma mtDNA 
concentrations.
Methods: After informed consent, lung cancer 
patients who had adenocarcinoma and were going to 
receive erlotinib treatment were enrolled. Patients’ 
plasma were collected immediately before starting 
erlotinib treatment, day 15 and day 29 after starting 
erlotinib treatment, when patients’ disease were 
progressed.
Results: Of 53 enrolled patients, best erlotinib 
treatment response was partial response in 26, stable 
disease in 13, and progressive disease in 14. mtDNA 
concentrations are shown in Table 1. Plasma mtDNA 
concentrations was signiÀcantly decreased on day 15 
comparing day 0 levels in patients with progressive 
disease (p=0.028). Plasma mtDNA concentrations 
were similar or elevated on day 15 comparing day 
0 levels in patients with partial response (p=0.808). 
The concentration of plasma mtDNA did not 
correlated with time to disease progression.
Conclusion: Plasma mtDNA levels did not 
correlated with patient’s time to disease progression 
when patients received erlotinib treatment. Its’ level 
was decreased on day 15 of those patients who 
had disease progressed to erlotinib treatment later. 
Table . Plasma free mitochondrial DNA levels in 53 
erlotinib treatment patients 
Concentrations (copies/mL) Partial response Stable disease Progressive disease 
Day patient No 26 3 4 
mean, SEM* 297, 757 26, 874 3776, 3 
range 54-75 228-644 63-2733 
Day 5 patient No 23 3 
mean, SEM* 39, 986 774, 22 568, 387 
range 26-25 6-2395 54-4925 
Day 29 patient No 24 8 
mean, SEM* 277, 473 2935, 948 359, 667 
range 56-7587 7-9383 39-4637 
Day PD patient No 7 5 9 
mean, SEM* 88, 446 694, 27 6387, 289 
range 46-3287 57-45 73-6827 
*SEM, standard error of mean; Day PD, day of 
disease progression. 
Keywords: Adenocarcinoma, erlotinib, 
mitochondrial DNA
Results: EGFR and TS gene transcript ratios did 
not predict clinical beneÀt to platinum doublets or 
survival. In univariate model, RRM-1 expression 
levels were highly predictive of resistance to 
platinum-based therapy (platinum/pemetrexed 
being the most common regimen), odds ratio (OR) 
of 0.40 (95% CI: 0.19-0.86). Similarly, ERCC-
1 expression levels were predictive of treatment 
resistance (OR=0.54, 95% CI: 0.29-1.02); however, 
not statistically signiÀcant (p=0.06). When tested 
in a multivariate model (including: EGFR, ERCC-
1, TS), RRM-1 retained its predictive effect 
(OR=0.35, 95% CI: 0.14-0.86).Presence of EGFR 
mutation was also highly predictive of response to 
platinum doublet (p=0.03). ERCC-1 was positively 
correlated with RRM-1; R=0.36 (p=0.003), as well 
as with TS; R=0.27 (p=0.027) ERCC-1 expression 
levels (controlling for EGFR, ERCC-1, TS-2) were 
independently predictive of decreased survival; 
hazard ratio of 1.76 (95% CI: 1.12-2.77). 
Conclusion: RRM1 levels predict responses 
to platinum doublet therapies in lung cancer, 
while ERCC-1 levels are prognostic for survival. 
Correlation of ERCC-1 with RRM-1 and TS suggests 
that these markers may co-operate in resistance to 
platinum based regimens. 
Keywords: ERCC-1, RRM-1, TS, EGFR, K-ras, 
NSCLC, Biomarkers
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P2.112 MITOCHONDRIAL FREE 
CIRCULATING DNA CONCENTRATIONS 
AND THEIR RELATIONSHIP TO 
ERLOTINIB TREATMENT IN PATIENTS 
WITH ADENOCARCINOMA OF THE 
LUNGS
Yuh-Min Chen1, Chu-Yun Huang2, Chieh-Hung 
Wu2, Chun-Ming Tsai2, Yu-Chin Lee2, Reury-Perng 
Perng2, Jacqueline Whang-Peng3 
1Chest Department, Taipei Veterans General 
Hospital/Taiwan, 2Taipei Veterans General Hospital/
Taiwan, 3Taipei Medical University/Taiwan
Background: It has been found that change of 
circulating free mitochondrial DNA (mtDNA) 
concentrations are correlated with chemotherapeutic 
effects in solid tumors. Present study was to 
determine and compare changes of plasma mtDNA 
concentrations before and after erlotinib treatment, 
S996 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Asselti3, Rossana Daprile3, Giovanni Simone3 
1Clinical Experimental Oncology Laboratory, Istituto 
Tumori ‘g. Paolo Ii’/Italy, 2Medical Oncology, 
Istituto Tumori ‘g. Paolo Ii’/Italy, 3Department Of 
Pathology, Istituto Tumori ‘g. Paolo Ii’/Italy
Background: Lung cancer is the principal cause 
of cancer-related mortality in industrialized 
countries, with over 250.000 new cases each year 
in Italy. NSCLC which includes adenocarcinoma 
(ADC), squamous cell carcinoma (SCC), large 
cell carcinoma (LCC), and bronchioloalveolar 
carcinoma, accounts for nearly 85% of all cases. In 
the last years, there has been a remarkable increase 
in the understanding of the biological mechanisms 
that underlie lung cancer development, which 
has led to the identiÀcation of novel markers and 
therapeutic targets. A major focus of research has 
been the development of molecularly targeted agents 
and the identiÀcation of biomarkers for patient 
selection. The Na+/H+ exchanger regulatory factor 1 
(NHERF1) is an adaptor molecule that leads several 
cellular receptors and other proteins to the plasma 
membrane of different types of cells. Our previous 
studies showed that NHERF1 alterations correlate 
with the progression and invasiveness of primary 
breast (Mangia, Histopathology 2009) and metastatic 
colorectal cancers. Aim of this study was to evaluate 
the role of NHERF1 in primary and metastatic 
lung nodules as a potential new marker of tumor 
progression.
Methods: Differences of NHERF1 expression in the 
membrane, cytoplasmic and nuclear compartment 
were studied by immunohistochemistry. We 
evaluated 38 parafÀn-embedded cell block FNA of 
lung nodules from 23 primary NSCLC (8 SCCs, 4 
LCCs and 11 ADCs), and 15 lung metastases from 
different sites (3 breast, 5 colorectal, 2 kidney, 2 
uterus, 1 prostate, 1uretelial,1 hypopharynx).
Results: In the 38 cell blocks we observed a 
different NHERF1 expression comparing membrane, 
cytoplasmic and nuclear compartments. The 
nuclear NHERF1 staining was increased compared 
to cytoplasmic and membrane expression; the 
difference was statistically signiÀcant (P=0.001) 
when nuclear versus membrane staining was 
considered. When we examined only the 23 primary 
NSCLC, there was no signiÀcant difference of 
NHERF1 expression in the three cell compartments. 
Moreover, in the 15 metastatic lung nodules, 
NHERF1 expression showed a trend similar to total 
lung nodules, and nuclear NHERF1 level expression 
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P2.113 ALK GENE COPY NUMBER 
GAIN AND AMPLIFICATION IN NSCLC: 
ITS FREQUENCY AND HISTOLOGIC 
FEATURES
Seol-Bong Yoo, Hyojin Kim, Jin Ho Paik, Xianhua 
Xu, Jin-Haeng Chung 
Pathology, Seoul National University Bundang 
Hospital/Korea
Background: In non-small-cell lung carcinoma 
(NSCLC), ALK gene copy number gain and 
ampliÀcation have not been extensively investigated.
Methods: A total of 452 NSCLC samples were 
analyzed by Áuorescence in situ hybridization 
(FISH) and chromogenic in situ hybridization 
(CISH) for ALK and EGFR gene status. ALK gene 
copy number gain/ampliÀcation and EGFR gene 
polysomy/ampliÀcation were evaluated. EGFR 
mutation was examined by direct sequencing method 
in the available cases. 
Results: Ninety-six cases (21.2%) showed ALK 
gene copy number gain and 16 (3.5%) ampliÀcation. 
The cases with ALK gene copy number gain 
consisted of 47 adenocarcinomas (ADCs) (49.0%), 
41 squamous cell carcinomas (SCCs) (42.7%), 5 
adenosquamous carcinomas (5.2%), and 3 the others 
(3.0%). The ALK gene ampliÀcation showed 7 
ADCs (43.7%), and 9 SCCs (56.3%). There was an 
association between ALK gene copy number gain 
and EGFR polysomy in ADC (p= 0.026) compared 
to SCC (p= 0.064). There was no association 
between ALK gene copy number gain/ampliÀcation 
and EGFR gene ampliÀcation/mutation in NSCLC. 
Conclusion: ALK gene copy number gain was not 
infrequently found in NSCLCs and the incidence 
was similar between ADC and SCC. In addition, 
ALK gene copy number gain was associated with 
EGFR polysomy in ADC.
Keyword: Non-small-cell lung cancer, ALK, EGFR, 
gene copy number, ampliÀcation, polysomy
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P2.114 NHERF1 AS A POTENTIAL NEW 
MARKER FOR LUNG CANCER
Annita Mangia1, Domenico Galetta2, Concetta 
Saponaro1, Andrea Malfettone1, Maria Consilia 
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for advanced/metastatic NSCLC (median age 60 
years, 82% males, 58% adenocarcinomas and 30% 
squamous cell carcinomas, ECOG Performance 
status 0-1: 86%). PKM2 was successfully ampliÀed 
in all specimens. Time to tumor progression 
(TTP) was signiÀcantly lower in patients with 
overexpression of PKM2 (4.9 vs. 6.4 months for 
high and low expression, respectively, p=0.028). 
Similarly, median overall survival (mOS) was 
signiÀcantly decreased in patients with upregulation 
of PKM2 (10.1 vs. 17.0 months for high and low 
expression, respectively, p=0.01). Multivariate 
analysis revealed that PKM2 high mRNA expression 
(HR: 1.6, p=0.02), stage IV disease (HR: 4.2, 
p=0.03) and ECOG PS 2 (HR: 5.9, p=0.022) as 
independent prognostic factors for decreased TTP. 
Similarly, PKM2 high mRNA expression (HR: 1.9, 
p=0.02), stage IV disease (HR: 4.5, p=0.03) and 
ECOG PS 2 (HR: 6.1, p=0.002) were revealed as 
independent prognostic factors for decreased mOS.
Conclusion: These results provide evidence that 
the PKM2 mRNA expression could be used as a 
predictive factor for sensitivity to cisplatin-based 
chemotherapy. The results should be validated 
prospectively in an independent patient cohort. 
Keywords: chemosensitivity, PKM2, NSCLC, 
Cisplatin
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P2.116 ADVANCED NSCLC: 
PROGNOSTIC ROLE OF THE 
EXPRESSION OF MYELOID-DERIVED 
SUPPRESSOR CELLS RELATED 
MARKERS IN PERIPHERAL BLOOD 
SAMPLES.
Elena Caballero1, Aida Artigot1, Elena Sanmartin1, 
Marta Usó1, Sandra Gallach1, Rafael Sirera2, Rafael 
Rosell3, Carlos Camps4, Eloisa Jantus Lewintre1 
1Molecular Oncology Laboratory, General 
University Hospital Research Foundation, Valencia/
Spain, 2Biotechnology, Polytechnic University Of 
Valencia/Spain, 3Oncology, Catalan Institute Of 
Oncology, Hospital Germans Trias I Pujol/Spain, 
4Oncology, General University Hospital Of Valencia/
Spain
Background: Myeloid-derived suppressor cells 
(MDSC) are found in most patients with advanced 
cancers, and are potent inhibitors of innate and 
was higher than membrane expression (P =0.028).
Conclusion: Our Àndings demonstrated that 
parafÀn-embedded cell block FNA of lung nodules 
provide useful material to detect NHERF1 status. 
Expression levels of NHERF1 in different cellular 
compartments suggest a dynamic role of this 
marker in lung cancer. The high nuclear NHERF1 
expression appears to contribute to the malignant 
metastatic process, as previously demonstrated in 
metastatic colorectal cancer. Further studies focusing 
this approach are ongoing in our institution.
Keywords: Lung cancer, Nherf1, cell block FNA
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P2.115 PKM2 AS A BIOMARKER FOR 
CHEMOSENSITIVITY TO CISPLATIN-
BASED CHEMOTHERAPY IN 
METASTATIC/ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC)
Ch. Papadaki1, M. Sfakianaki1, E. Lagoudaki2, G. 
Ioannidis1, E. Tsakalaki1, M. Trypaki1, G. Giagkas1, 
S. Pontikakis1, E. Stathopoulos2, D. Mavroudis3, V. 
Georgoulias3, J. Souglakos3 
1Laboratory Of Tumor Cell Biology, School Of 
Medicine, University Of Crete/Greece, 2Laboratory 
Of Pathology, University General Hospital Of 
Heraklion/Greece, 3Department Of Medical 
Oncology And Laboratory Of Tumor Cell Biology, 
University General Hospital Of Heraklion And 
School Of Medicine, University Of Crete/Greece
Background: Tumour cells have been shown to 
express exclusively the embryonic M2 isoform of 
pyruvate kinase (PKM2), which is a key enzyme 
that regulates aerobic glycolysis in tumor cells. 
Use of RNA interfering (RNAi) targeting PKM2 
signiÀcantly inhibits tumor growth when combined 
with cisplatin in xenograft models. We evaluated 
the predictive signiÀcance of PKM2 in patients with 
stage IIIB (with pleural effusion) or IV NSCLC 
treated with cisplatin-based chemotherapy in the 1st 
line setting. 
Methods: PKM2 mRNA expression was analysed by 
RT-qPCR in FFPE primary tumors from 148 NSCLC 
patients after microdissection for the selection of 
cancer cells. The analysis was performed with a set 
of primers and probes which amplify only the M2 
isoform.
Results: The patients’ characteristics were all typical 
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P2.117 EVALUATION OF HIGHLY 
SENSITIVE PNA-LNA PCR CLAMP 
METHOD FOR EGFR L858R 
MUTATION DETECTION IN LUNG 
ADENOCARCINOMA PATIENTS.
Michal Skronski1, Tomoaki Tanaka2, Adam 
Szpechcinski1, Renata Langfort3, Koichi Hagiwara2, 
Tadeusz Orlowski4, Joanna Chorostowska-Wynimko1 
1Laboratory Of Molecular Diagnostics And 
Immunology, National Institute Of Tuberculosis And 
Lung Diseases/Poland, 2Department Of Respiratory 
Medicine, Saitama Medical University/Japan, 3Dept. 
Of Pathology, National Institute Of Tuberculosis 
And Lung Diseases/Poland, 4Dept. Of Thoracic 
Surgery, National Institute Of Tuberculosis And Lung 
Diseases/Poland
Background: Direct sequencing is widely accepted 
method for EGFR mutation identiÀcation, but 
has limited sensitivity. It often requires additional 
procedures, like microdissection, to enrich the 
sample in cancer cells, when their content in 
tissue specimen is less than 50%. PNA-LNA PCR 
clamping represents allele-speciÀc approach to 
gene analysis and demonstrates potent accuracy and 
ability to detect mutant alleles even if present in low 
fraction of cells.
Methods: 79 DNA samples isolated from fresh-
frozen and FFPE tissues, which mutation status was 
formerly conÀrmed by sequencing, were analyzed by 
PNA-LNA PCR clamping for EGFR point mutation 
L858R in exon 21.
Results: L858R mutation was detected in 8/79 
(10%) samples by direct sequencing, whereas in 
12/79 (15%) samples by PNA-LNA PCR clamping. 
All mutant-positive samples by sequencing were 
correctly determined by PNA-LNA PCR clamp. 
The remaining 4 L858R mutant-positive samples 
were recognized as wild type by sequencing. Two 
of them contained only 5% and 20% of cancer cells, 
respectively. Surprisingly, in the other two samples 
PNA-LNA PCR clamping method detected only low 
levels of EGFR mutant allele, despite the cancer cell 
contents were high (100% and 80%).
Conclusion: PNA-LNA PCR clamp technique 
enables sensitive and reliable detection of EGFR 
mutant allele in specimens with cancer cell content 
insufÀcient for direct sequencing or genetically 
heterogenous. Regarding its extremely high 
adaptive immunity. Marker genes associated with 
the presence of MDSC are CD11b, CD18, CD115, 
GR1, IL-4RƠ and IL-13. The aim of this study was 
to determine the expression level of these genes by 
qRT-PCR in patients with advanced non-small cell 
lung cancer (NSCLC) and to correlate them with 
clinico-pathological and prognostic variables. 
Methods: RNA was isolated from peripheral blood 
collected from NSCLC patients (n=50) and controls 
(n=54). qRT-PCR was performed to analyze the 
expression of CD11b, CD18, CD115, GR1, IL-4RƠ 
and IL-13. Relative expression was normalized by 
endogenous genes (GAPDH and ơ-actin) using the 
PfafÁ formulae. Statistical analyses were considered 
signiÀcant at p<0.05. 
Results: 
We found signiÀcant differences in the expression 
levels of 3 analyzed genes (CD115, GR1 and IL4a) 
and in other two differences were borderline (CD11b, 
p=0.061; and IL13, p=0.068) between patients and 
controls. Pair-matched samples comparing pre and 
post-treatment expression levels of CD18, GR1 and 
IL4Ra showed that they were signiÀcantly reduced 
after chemotherapy. Lower levels of expression 
of CD11b were related with progressive disease 
(p=0.005). The prognostic impact of the studied 
variables was assessed by Cox univariate analysis 
(see Table) and Kaplan-Meier plots. We found that 
those patients with baseline CD11b expression below 
the median had signiÀcant worse progression-free 
(p= 0.005) and overall survival (p=0.013). Table: 
Univariate Cox analysis for CD11b
Conclusion: This study shows that it is possible 
to detect and quantiÀed MDSC-related markers 
in peripheral blood samples of advanced NSCLC 
patients. The expression of the analyzed genes, 
especially CD11b, could have prognostic value in 
advanced NSCLC. (This work was supported in part, 
by a grant [RD06/0020/1024] from Red Temática 
de Investigación Cooperativa en Cáncer, RTICC, 
Instituto de Salud Carlos III (ISCIII), Spanish 
Ministry of Science and Innovation & European 
Regional Development Fund (ERDF) “Una manera 
de hacer Europa”) 
Keywords: Advanced NSCLC, prognostic, Myeloid-
derived suppressor cells
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speciÀed, 5 LCC and 2 adenosquamous carcinoma. 
Due to the limited amounts of tissue (especially 
cytologic) specimens available, total RNA 
extraction was possible in 64 out of 87 cases and 
TS gene expression was assessed using RealTime 
PCR. TS protein expression was performed using 
immunohistochemistry in all cases and scored with 
2 Methods: the Àrst considering only the percentage 
of TS positive tumor cells in the tissue (TS%) and 
the second (TS H-SCORE), obtained multiplying 
the percentage of TS positive tumor cells and the 
staining intensity. Staining intensity was classiÀed 
as 0 (no staining), +1 (weak), +2 (moderate), or +3 
(strong). Statistical analyses were performed using 
the STATISTICA7.0 software. 
Results: TS mRNA expression was assessed using 
the 2-ƋƋCt method, using ơ-Actin to normalize 
data and a total RNA (Stratagene) as calibrator. 
Gene expression analysis (median 8.08) showed 
signiÀcantly higher TS mRNA levels in non-
ADC compared to ADC (p=0.02), while no other 
correlation with clinico-pathological data (age, 
gender, stage) or with TS protein expression (TS 
H-SCORE and TS%) were found. Statistical 
analyses for TS protein expression were separately 
performed using TS% (median 30%) and TS 
H-SCORE (median 55) data, respectively. In both 
these two groups, no correlation between protein 
expression and both gender and age, respectively, 
was found. A statistically signiÀcant superior 
TS protein expression in non-ADC compared to 
ADC specimens was found only for TS H-SCORE 
(p=0.012), without any statistical signiÀcance with 
TS% (p=0.146). Similar results were observed 
when TS protein expression was correlated with 
disease extent: TS H-SCORE (p=0.028) but not 
TS% (p=0.186) was signiÀcantly higher in stage IIIB 
compared to stage IV patients. As expected response 
to therapy was associated with a better survival (log 
rank test P=0.00039). Overall survival analyses are 
ongoing.
Conclusion: This retrospectively study consistently 
conÀrmed the differential expression of TS among 
the different histotypes of NSCLC. Standardization 
of TS assessment techniques, at the mRNA or 
protein level, may help clinicians to select the most 
appropriate group of patients to be be trreated with 
pemetrexed-based therapies.
Keywords: immunohistochemistry, Thymidylate 
synthase, Pemetrexed, real-time PCR
sensitivity, PNA-LNA PCR clamping should be 
validated thoroughly prior implementation into 
EGFR diagnostic routine to prevent overdiagnosis.
Keywords: EGFR, FFPE tissue, L858R mutation, 
PNA-LNA PCR clamp
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.118 ASSESSMENT OF THYMIDYLATE 
SYNTHASE (TS) MRNA AND PROTEIN 
EXPRESSION IN NON SMALL CELL 
LUNG CANCER PATIENTS TREATED 
WITH PEMETREXED-BASED 
THERAPIES.
Valentina Monica1, Silvia Novello1, Emilio Bria2, 
Michele Milella2, Paolo Visca3, Marco Lo Iacono1, 
Federica Cuppone3, Marina Longo1, Francesco 
Cognetti2, Giorgio Scagliotti1 
1Department Of Clinical And Biologica Sciences, 
University Of Turin, Aou San Luigi/Italy, 
2Department Of Medical Oncology, Regina Elena 
National Cancer Institute/Italy, 3Department Of 
Pathology, Regina Elena National Cancer Institute/
Italy
Background: In non-small cell lung cancer 
(NSCLC), higher TS levels have been reported 
in both squamous cell (SCC) and large cell 
carcinoma (LCC) compared to adenocarcinoma 
(ADC). Antifolates are part of the therapeutic 
armamentarium for NSCLC and pemetrexed has 
consistently showed a selective beneÀt in patients 
with non-squamous NSCLC. Aim of this study was 
to retrospectively assess TS expression, at both 
mRNA and protein levels, in a series of pemetrexed-
treated patients, as a potential predictive factor of 
efÀcacy. 
Methods: TS expression levels were analysed in two 
series of both histological and cytological formalin-
Àxed and parafÀn embedded specimens (FFPE) from 
patients treated with pemetrexed-based regimens: 
the Àrst series was collected at San Luigi Hospital 
(n=52) including 42 ADC, 6 SCC, 4 NSCLC-not 
otherwise speciÀed, the second series was collected 
at Regina Elena National Cancer Institute (n=34) 
including 16 ADC, 8 SCC, 3 NSCLC-not otherwise 
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addition, center and histology (adenocarcinoma vs 
squamous and large cell carcinoma) were statistically 
signiÀcant in univariate analysis. For analysis by 
histology, the HR was 2.81 (95% CI: 1.05-7.51), 
with median OS of 12.4 months (95% CI: 6.3 
months - undeÀned) for adenocarcinoma patients and 
4.7 months (95% CI: 1.6-10.9 months) for squamous 
and large cell carcinoma patients. Stratifying by 
histology, only adenocarcinoma patients have 
sufÀcient numbers to attempt further analysis. For 
VeriStrat good vs poor the HR is 0.45 and log-rank 
p value = 0.21; however this result has limited value 
due to only 7 of the 34 adenocarcinoma patients 
being classiÀed as VeriStrat poor
Conclusion: The proteomic classiÀer VeriStrat may 
identify a subset of patients that derives signiÀcant 
clinical beneÀt from upfront treatment of advanced 
NSCLC patients with EGFR/VEGF inhibitors. These 
Àndings should be conÀrmed in prospective studies. 
Keywords: proteomics, VEGF EGFR inhibition
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P2.120 ESTROGEN UP-REGULATES 
OSTEOPONTIN EXPRESSION AND 
SYNERGY WITH EPIDERMAL GROWTH 
FACTOR PROMOTE LUNG CANCER 
CELL MIGRATION
Ming-Fang Tsai1, Li-Han Hsu2, Chang-Ru Wu1, Shu-
Ching Hsieh1, Ko-Jiunn Liu3, Shu-Huei Kao1 
1Graduate Institute Of Medical Science, School Of 
Medical Laboratory Science And Biotechnology, 
Taipei Medical University/Taiwan, 2Division Of 
Pulmonary And Critical Care Medicine, Koo 
Foundation Sun Yat-sen Cancer Center/Taiwan, 
3National Institute Of Cancer Research, National 
Health Research Institutes/Taiwan
Background: Estrogen has been postulated to 
contribute to the development and progression of 
non-small cell lung cancer. It’s also recognized 
that osteopontin (OPN) plays an important role in 
tumor progression and metastasis. We explored the 
characteristics of estrogen, and investigated the 
connections between estrogen and OPN in lung 
cancer cells migration, including the signaling 
pathway involved. The separate and combined effect 
of Tamoxifen - an estrogen receptor (ER) antagonist, 
and GeÀtinib - an epidermal growth factor receptor 
(EGFR) antagonist, on the cancer cell migration 
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P2.119 THE PROTEOMIC CLASSIFIER 
VERISTRAT® IDENTIFIES ADVANCED 
NON SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS GAINING CLINICAL 
BENEFIT FROM TREATMENT 
WITH FIRST LINE SORAFENIB AND 
ERLOTINIB.
Egbert F. Smit1, Heinrich Roder2, Julia Grigorieva2, 
J. Roder2, Joline S.W. Lind3, Anne-Marie 
Dingemans4, Harry J.M. Groen5 
1Pulmonary Diseases, Vrije Universiteit Medical 
Centre/Netherlands, 2Biodesix/United States Of 
America, 3Vrije Universiteit Medical Centre/
Netherlands, 4Academic Hospital Maastricht/
Netherlands, 5Pulmonary Medicine, Umc Groningen/
Netherlands
Background: We recently reported the result of a 
phase II study of Àrst line erlotinib and sorafenib in 
unselected patients with advanced NSCLC (Lind et 
al Clin. Cancer Res 16,3078,2010). In an attempt to 
Ànd biomarkers predictive for overall survival we 
analyzed pretreatment derived serum samples for 
proteomic signatures in the previously described 
serum matrix-assisted laser desorption ionization 
proteomic classiÀer (VeriStrat). 50 patients 
were enrolled in the phase II study of which 49 
pretreatment serum samples could be analyzed.
Methods: Overall survival (OS) data was analyzed 
using conventional survival analysis methods. 
Univariate analysis was performed using the Mantel-
Haenszel method and log-rank p values (with 
PRISM) and the Cox proportional hazards method, 
with associated p values (SAS). ConÀdence intervals 
for median survival estimates were calculated using 
SAS. 
Results: VeriStrat classiÀcation identiÀed 33 
(67%) as predicted to have “good” and 15 (31%) 
predicted to have “poor” outcomes; 1 sample was of 
indeterminate classiÀcation VeriStrat classiÀcation 
was not predictive of disease control rate nor of 
EGFR mutation (n=7) status in this cohort. VeriStrat 
good patients had statistically signiÀcantly improved 
OS compared with VeriStrat poor patients. The 
hazard ratio (HR) between groups was 0.30 (95% 
CI: 0.12-0.74), log-rank p = 0.009. The median OS 
was 13.7 months (95% CI: 12.0 months-undeÀned) 
for VeriStrat good patients and 5.6 months (95% 
CI: 1.6-7.6 months) for VeriStrat poor patients. In 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1001
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: To investigate the clinical value 
of combined detection of the tumor makers 
carcinoembryonic antigen (CEA), neuro-speciÀc 
enolase (NSE), carbohydrate antigen 211 (CA211) 
squamous cell carcinoma associated antigen (SCC) and 
cytokeratin fragment 19(CYFRA21-1) of the serum and 
the pleural effusion in patients with lung cancer,and to 
Ànd some clues in the diagnosis of lung cancer.
Methods: Using electrochemiluminescence 
immunoassay and immunoradiometric assay, the Àve 
tumor makers in the serum and the pleural effusion 
were measured in 65 lung cancer patients, 52 benign 
pulmonary diseases patients and 50 normal controls.
Results: In lung cancer group ,the levels of Àve tumor 
makers in the serum and the pleural effusion were 
signiÀcantly higher than those in benign pulmonary 
diseases group and normal control group (P<0. 05), but 
there was no signiÀcant difference in benign pulmonary 
diseases group and normal control group (P>0. 05). 
For different pathology of lung cancer, there was 
signiÀcant difference in Àve tumor makers in the serum 
and the pleural effusion(P<0. 05), the level of CEA was 
signiÀcantly higher in adenocarcinoma (P<0. 05) and 
SCC in lung squamous cell carcinoma(P<0. 05), while 
NSE in the small cell lung cancer(P<0. 05). Combined 
detection of these tumor markers has more sensitivity 
than single detection. In the pleural effusion, sensitivity, 
speciÀcity and positive predictive value of Àve tumor 
markers in lung cancer group were 99.28%, 91.17% 
and 98·23% and were 92.71%, 62.52% and 88.20% in 
the serum.
Conclusion: Combined detection of Àve tumor 
makers in the serum and the pleural effusion has a 
high sensitivity and positive predictive value for the 
diagnosis of lung cancer, and different tumor maker 
will provide a scientiÀc and reliable evidence for 
differentiation the pathology of lung cancer.
Keyword: Lung cancer; Tumor marker; CEA; NSE; 
SCC; CYFRA 21- 1; CA211;Combined detection.
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P2.122 ARRAY CGH ANALYSIS OF 
SMALL-SIZED ADENOCARCINOMA OF 
THE LUNG
Yuko Minami1, Yoshihiko Murata2, Masayuki Noguchi1 
1Department Of Pathology, Graduate School Of 
Comprehensive Human Sciences, University Of 
Tsukuba/Japan, 2Graduate School Of Comprehensive 
Human Sciences, University Of Tsukuba/Japan
were also studied.
Methods: A549 and PE089 lung cancer cell lines 
were used for in vitro studies. Pleural effusions 
from patients with lung adenocarcinoma were 
collected for the measuring of the estrogen and OPN 
concentrations as well as their impact on lung cancer 
cell lines.
Results: ER- ơ is the predominant receptor type 
in lung cancer cell lines. Estrogen promoted 
cancer cell proliferation, migration, and matrix 
metalloproteinase 2 activity. Confocal microscopy 
and Western blotting revealed ER-ơ translocation 
out of mitochondria and mitochondrial swelling 
on the stimulation of estrogen. The mitochondrial 
respiratory complexes were attenuated. Estrogen 
induced OPN expression. Osteopontin promoted 
cancer cell migration through ƠƬơ3 integrin binding. 
Estrogen and OPN concentrations were both elevated 
and positively correlated in the malignant pleural 
effusion from patients with lung adenocarcinoma. 
Estrogen and OPN affected cell migration through 
activation of MEK-ERK pathway, which is a 
common downstream pathway of EGFR activation. 
Synergistic effect of ER antagonist and EGFR 
antagonist on the inhibition of lung cancer cells 
migration was noted.
Conclusion: Estrogen up-regulates OPN expression 
and synergy with epidermal growth factor which 
promote lung cancer cell migration. Estrogen, with 
its receptor and OPN, has the potential to be a 
prognosticator and a new therapeutic target in lung 
cancer. Understanding the receptors status of patients 
and tumor characteristics could help better direct the 
selection of targeted treatment.
Keywords: Epidermal growth factor receptor 
(EGFR), Estrogen, Lung cancer, osteopontin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.121 VALUE OF CEA, NSE, CA211, SCC 
AND CYFRA21-1 IN THE DIAGNOSIS OF 
LUNG CANCER
You B. Cui, Xue Shan, Yong X. Wang, Tian Y. Lu, 
Ping Zhang, Da Zhou 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
S1002 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Further studies will be required to elucidate the 
target oncogenes involved in the transformation of in 
situ adenocarcinoma to invasive adenocarcinoma.
Keywords: small-sized adenocarcinoma, Array CGH
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P2.123 NON-SMALL CELL LUNG 
CANCER (NSCLC) GENOTYPING IN A 
BRAZILIAN COHORT
Andreia C.D. Melo1, Haynna K.P. Inada1, Milton 
Barros2, Simone B.S.P. Terra1, Claudia Ligorio3, 
Emiko Sugawara4, Isabele A. Small1, Fernando A. 
Soares2, Federico Cappuzzo5, Kengo Takeuchi4, 
Carlos G.M. Ferreira1, Cinthya Sternberg1 
1Clinical Research Department, Instituto Nacional 
Do Câncer/Brazil, 2Hospital A.c. Camargo/Brazil, 
3Department Of Hematology And Oncology, 
University Of Bologna/Italy, 4Japanese Foundation 
For Cancer Research/Japan, 5Istituto Toscano 
Tumori-ospedale Civile/Italy
Background: Lung cancer is the leading cause 
of cancer-related deaths worldwide and NSCLC 
represents 85% of lung tumors. The major 
recurrent molecular alterations found among 
NSCLC tumor samples are either mutation, 
ampliÀcation or inversion/fusion detected in genes 
such as EGFR, KRAS, BRAF, MET and ALK. 
Cell signaling elicited by these altered pathways 
interferes with normal cell function and is thought 
to play a fundamental role in the carcinogenesis 
and progression of lung cancer. As molecular 
diagnosis will determine the therapy of choice 
and might differ utterly in each case, detection 
of such alterations is crucial for proper NSCLC 
management. Differences in the frequency of 
those targets have been observed among different 
populations, particularly EGFR mutation between 
Asian and Caucasian. Brazilian population is 
genetically heterogeneous and highly mixed, and a 
report of NSCLC genotyping in such population is 
missing. 
Methods: 162 parafÀn-embedded cases of 
NSCLC radically resected from 2003 to 2007 were 
retrospectively collected at two different cancer 
centers in Brazil and were analyzed for EGFR 
(exons 18 to 21), KRAS (exon 2) and BRAF (exons 
11 and 15) mutational status by direct bidirectional 
gene sequencing and for MET ampliÀcation and 
Background: It is well known that lung cancer is 
closely associated with gene abnormality. Recently, 
comprehensive studies of advanced lung carcinoma 
have demonstrated that many oncogenes have 
an impact on its prognosis. However, there have 
been no detailed studies of genetic abnormalities 
in early small-sized adenocarcinoma of the lung. 
In order to clarify the early genetic abnormalities 
present in this type of cancer, we examined the 
whole genome of surgically resected lung cancer 
specimens using array-based comparative genomic 
hybridization (array-CGH), and found a region 
in early but advanced adenocarcinoma that was 
signiÀcantly ampliÀed in comparison with in situ 
adenocarcinoma.
Methods: Six in situ adenocarcinomas (types A and 
B, Noguchi classiÀcation: Noguchi M. et al., Cancer 
1995), and 9 small but advanced adenocarcinomas 
(types D and E, Noguchi classiÀcation) were 
evaluated using array-CGH (CancerArray-800: 
Inazawa J. et al. Cancer Science 2004). The tumors 
were methanol-Àxed and parafÀn-embedded, and 
the tumor cells were selected by laser-capture 
microdissection (LM200, Olympus). The genomic 
DNA of the tumor cells and corresponding normal 
cells was then extracted and evaluated by array-
CGH. The results were compared with the outcomes 
of individual cases, and the signiÀcance of any 
correlations was analyzed by t test and C-clustering.
Results: Array-CGH analysis revealed that types 
A and B in situ adenocarcinoma and types D and 
E adenocarcinoma exhibited a novel type of copy 
number proÀle, with signiÀcant differences in the 
copy number of 33 genes on various chromosomes. 
These abnormalities were observed at 1q.32.1, 3q, 
4q.35.2, 5q, 8p11.21, 11p15.5, and 15q21.1. In 
particular, types D and E adenocarcinoma showed 
signiÀcantly higher copy numbers at 3q21-tel than 
types A and B adenocarcinoma.
Conclusion: Previous reports have indicated that 
chromosome 3 is frequently rearranged in various 
carcinomas, and that this region is likely involved 
in the tumorigenesis of lung adenocarcinoma. 
Our results also demonstrated DNA gains on the 
long arm of chromosome 3 more frequently in 
types D and E adenocarcinoma than in types A 
and B in situ adenocarcinoma. Types D and E 
adenocarcinoma were small but advanced, and 
showed a less favorable outcome than types A and 
B in situ adenocarcinoma. These results indicate 
that ampliÀcation of 3q21-tel might be related to 
malignant transformation of lung adenocarcinoma. 
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P2.124 EFFECTS OF CHEMO-
IMMUNOTHERAPY ON CD4+CD25+ 
REGULATORY T CELLS IN NON SMALL 
CELL LUNG CANCER (NSCLC).
Andreas Pircher1, Gabriele Gamerith2, Anneliese 
Gaechter2, Anna M. Wolf1, Guenther Gastl1, 
Wolfgang Hilbe1, Dominik Wolf1 
1Internal Medicine V, Medical University Innsbruck/
Austria, 2Internal Medicine I, Medical University 
Innsbruck/Austria
Background: The combination of chemotherapy 
and anti-EGFR monoclonal antibodies has proven 
clinical efÀcacy in non small cell lung cancer 
(NSCLC). However, the mechanism of its clinical 
activity remains elusive so far. Direct effects on the 
tumor cells as well as immuno-mediated effects 
might both be involved. CD4+CD25highFoxP3+ 
regulatory T cells (Treg) play a key role for 
maintenance of tolerance in rodents and men. Recent 
reports emphasized the important role of increased 
Treg levels in patients with epithelial malignancies 
for tumor immune escape. The aim of the current 
study is to determine i) the role of Treg levels 
on therapeutic response and ii) the impact of the 
neoadjuvant chemo-immunotherapy on the Treg 
compartment.
Methods: 30 patients suffering from NSCLC (stage 
IB – IIIA) were included in a neoadjuvant clinical 
study protocol (INN06 study) and received up to 
two cycles of chemo-immunotherapy (Cetuximab 
+ Docetaxel + Cisplatin) prior to surgery. Treg 
were measured in peripheral blood (PB) in a 
Àxed schedule which included quantitative and 
functional assessment prior to initiation of therapy 
and prior to every cycle thereafter as well as at 
the end of neoadjuvant therapy. Relative and 
absolute quantiÀcation using TruCount beads of 
Treg was assessed by Áow cytometry. In parallel, 
the proliferative capacity of Treg was measured by 
EZ4U assay of magnetically isolated CD4+CD25+ 
and the respective control CD4+CD25- T cell 
populations.
Results: In comparison to baseline, Treg 
levels signiÀcantly decreased during chemo-
immunotherapy (227/l prior to treatment initiation 
and 120/l at the end of neoadjuvant treatment), 
whereas the total CD4+ T cell compartment remained 
constant (1238/l and 1398/l, respectively). Of 
ALK rearrangement status by FISH in tissue 
microarray sections. 
Results: Evaluation of valid information has 
shown that median patient age was 62.8 years; 
52.9% were male. At diagnosis, 13.8% were never 
smokers, 46.9% current and 39.3% former smokers. 
Histology analysis has shown that 55.6% of tumors 
were adenocarcinoma, 7.2% bronchioloalveolar and 
32.7% squamous cell carcinoma. EGFR analysis 
was successful in 150 cases and mutations were 
identiÀed in 25.3% (n=38) of the patients (6, 19, 
13 and 5 mutations in exons 18, 19, 20 and 21 
respectively; 5 cases encompassing mutations in 2 
different exons); 52.8% of mutated cases for EGFR 
were adenocarcinoma, 8.3% bronchioloalveolar 
and 36.1% squamous cell carcinoma. Remarkably, 
the percentage of mutation detected in exon 21 was 
lower than that described on literature, contrasting 
with the higher incidence of exon 18 and 20 
mutations. KRAS mutations were observed in 30 
out of 148 analyzed cases (20.3%), in which 76.7% 
were adenocarcinomas. 13 out of 145 patients 
harbored BRAF mutations (9.0%), predominantly 
in squamous histology (61.5%), 8 were found 
in exon 11, 5 in exon 15. Finally, MET gene 
increased copy number (mean 5 copies/cell) was 
observed in 21 out of 152 evaluated cases (13.8%), 
where 73.7% represented adenocarcinomas. ALK 
rearrangement was present in 4 out of 161 cases 
(2.5%), 3 of them exhibiting adenocarcinoma and 1 
bronchioloalveolar histology. 
Conclusion: The prevalence of molecular deÀned 
patient subsets in our cohort was only slightly 
different to American, European and Asiatic 
published series. The histological subdivision 
of NSCLC into distinct molecular groups based 
on speciÀc mutations or gene ampliÀcation/
abnormal fusion is a promising strategy for patient 
stratiÀcation, leading to potentially sensitive 
patient selection and informed drug choice. To 
our knowledge, this study represents the Àrst 
comprehensive analysis known NSCLC genotyping 
in a large cohort of Brazilian patients.
Keywords: Non-small cell lung cancer, genotyping
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gene gain has also regarded as a predictive marker. 
In order to understand the predictive nature of 
any biomarker an understanding of the prognostic 
signiÀcance is also necessary
Methods: We performed a systematic computerized 
search of MEDLINE (PubMed; from inception to 
16th January, 2011) to identify all published articles 
reporting on EGFR gene copy number analysis 
in NSCLC. Outcomes included overall survival 
(OS), progression-free survival (PFS), and time-
to-progression (TPP) in untreated populations. 
Summary hazard ratios (HR) for time-to-event 
outcomes and corresponding conÀdence intervals 
were estimated using Àxed and random effects meta-
analysis.
Results: From 68 potential articles, 12 eligible 
studies comprising 540/1245 (43.4%) total patients 
with EGFR gene gain provided data on OS. By 
random effects, the summary HR for OS was 1.14 
(0.94-1.38) for patients with EGFR gene gain versus 
wild-type patients. There was no sign of study 
heterogeneity, and no differences between random 
and Àxed effects modeling. Effects were consistent 
between subgroups based on ethnicity (HR=1.01 
[0.79-1.30] versus 1.36 [0.96-1.92], Whites versus 
Asians) method of gene gain analysis (HR=1.08 
[0.87-1.34] versus 1.5 [0.83-2.7] CCS versus other) 
and stage (HR=1.15 [0.91-1.46] to 1.09 [0.71-1.67] 
stages I-III versus I-IV).
Conclusion: It does not appear that EGFR copy 
number gain in NSCLC is associated with survival. 
The histological and molecular complexity of NSCLC 
does however introduce some limitations into the 
analysis of gene gain. Prospective studies that allow 
for interaction to be determined according to speciÀc 
biomarkers will provide additional real-time data 
regarding the prognostic signiÀcance of EGFR gene 
gain and its implications in personalized medicine.
Keywords: Gene Gain, Epidermal growth factor 
receptor, Prognosis
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P2.126 ROLE OF HORMONE RECEPTOR 
EXPRESSION IN PATIENTS WITH 
ADVANCED STAGE LUNG CANCER 
TREATED WITH CHEMOTHERAPY.
Silvia Novello, Valentina Monica, Marina Longo, 
Paolo Pessina, Tiziana Vavalà, Barbara Felice, 
Giorgio Scagliotti, Mauro Papotti 
note, FoxP3 expression was unaffected in the 
CD4+CD25high Treg compartment. Ex vivo cultures 
of puriÀed Treg from PB conÀrmed the anergy 
phenotype of the CD4+CD25+ population, thus 
excluding that these cells are activated T cells. 
Correlative data with clinical endpoints are currently 
under investigation and will be presented at the 
meeting.
Conclusion: The observed decrease of Treg but 
not of total CD4+ T cells throughout chemo-
immunotherapy suggests that Treg are predominantly 
affected by the neoadjuvant treatment. As an 
alternative, reduction of the tumor load might also 
contribute to reduced Treg burden. Future studies 
will clarify whether the observed Treg frequencies 
prior to and during chemo-immunotherapy are 
correlated with clinical response to therapy via 
modulation of mAb-induced anti-cancer effects 
(e.g. antibody dependent cell-mediated cytotoxicity 
ADCC).
Keywords: Regulatory T Cells (Treg), Chemo- 
immunotherapy, Neoadjuvant Therapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.125 PROGNOSTIC SIGNIFICANCE OF 
EGFR GENE COPY NUMBER GAIN IN 
NSCLC: A SYSTEMATIC REVIEW AND 
META-ANALYSIS
Anna Chaimani1, Issa Dahabreh2, Helena Linardou3, 
Federico Cappuzzo4, Christos Papadimitriou5, Paris 
Kosmidis6, Dimitrios Bafaloukos3, Fotios Siannis1, 
Samuel Murray7 
1University Of Athens/Greece, 2University 
School Of Medicine, Boston/United States Of 
America, 3Metropolitan Hospital/Greece, 4Istituto 
Toscano Tumori-ospedale Civile Di Livorno/Italy, 
5Alexandras Hospital/Greece, 6Hygeia Hospital/
Greece, 7Oncology, Genekor/Greece
Background: Epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs) have 
become an established treatment modality for 
advanced non-small-cell lung cancer (NSCLC). 
Although beneÀts with TKIs appear most prominent 
in patients with somatic EGFR mutations, EGFR 
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in prospective trials. Preclinical data indicate the 
efÀcacy of aromatase inhibitors in lung cancer and 
this study conÀrmed a potential role of aromatase in 
lung cancer patients. 
Keywords: hormonal status, immunohistochemistry, 
Lung cancer, advanced stage
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P2.127 MITOCHONDRIAL VDAC2 IS 
TRANSCRIPTIONALLY REGULATED BY 
P63 AND CONFERS SHORTER SURVIVAL 
IN NON-SMALL CELL LUNG CANCER
Benjamin Wilson1, Simon Mcdade1, Claire Grills2, 
Dean A. Fennell1 
1Centre For Cancer Research And Cell Biology, 
Queen’s University Belfast/United Kingdom, 2Centre 
For Cancer Bioinformatics, Queen’s University 
Belfast/United Kingdom
Background: Resistance to apoptosis is a hallmark 
of cancer and a major problem limiting the 
effectiveness of treatment in non-small cell lung 
cancer (NSCLC). The mitochondrial dependant 
anion channel isoform 2 (VDAC2) gene is ampliÀed 
in cancers, and inhibits apoptosis by binding to, 
and preventing activation of BAK(1). VDAC2 is 
required for cancer cell cytotoxicity of a new class 
of drugs called erastin(2) however the variability of 
VDAC2 expression in NSCLC is unknown. Here 
we show that VDAC2 is prognostic in NSCLC, and 
using gene expression meta-analysis, identify p63 
as a critical transcriptional regulator and potential 
biomarker for classifying erastin sensitive NSCLC.
Methods: Using gene expression meta-analysis of 
601 tumours from 7 public gene expression datasets 
in NCBI GEO a meta-signature was generated, 
corresponding VDAC2 overexpression in NSCLC. 
The transcription factor, p63 was included in the 
meta-signature and so we set to investigate any link 
further. P63 is an already established biomarker in 
squamous lung tumours and so VDAC2 expression 
was determined using regression analysis to establish 
any correlation between the two. We identiÀed a 
potential p63 binding site in VDAC2 implicating 
potential transcriptional regulation. This was veriÀed 
by chromatin immunoprecipitation sequencing 
(ChIPseq).
Results: We identiÀed VDAC2 as an independent 
prognostic factor in both univariate and multivariate 
Department Of Clinical And Biological Sciences, 
University Of Turin, Aou San Luigi/Italy
Background: In lung cancer epidemiologic 
evidence supporting a role for hormonal status has 
been inconsistently reported and the mechanism 
modulating the expression and function of hormonal 
receptors in this disease remains still unclear. We 
aimed to retrospectively assess potential correlations 
between sex-linked hormone receptor expression 
and the clinical outcome of patients with advanced 
stage lung cancer treated with chemotherapy and 
sufÀcient amounts of tumour tissue available 
for immunohistochemical analyses, in a single 
institution.
Methods: One hundered and thirty consecutive cases 
(100 men) diagnosed at San Luigi Hospital in the 
period of time from January, including 2008 to June 
2010 were considered including 57 adenocarcinomas 
(AC), 34 squamous cell carcinomas (SCC), 5 large 
cell carcinomas (LCC) and 24 small cell lung cancer 
(SCLC); the remaining ten cases were “NSCLC-
NOS” (non small cell lung cancer-not otherwise 
speciÀed). The immunodetection of estrogen 
receptors (ERa and ERơ), progesterone receptor 
(PR), EGFR and ERCC1 was scored assessing 
both staining intensity and extension; aromatase 
reactivity (AR) was scored as 0 (totally negative) or 
1 (presence of cytoplasmic staining).
Results: ERơ nuclear expression was higher than 
ERa and PR, which had a weak or null expression, 
mainly in women. According to median expression 
levels, no signiÀcant correlation was found between 
ERơ and AR with age, sex, stage of disease, response 
to chemotherapy and histology. EGFR expression 
was signiÀcantly higher in SCC (p=0.002) as well 
as ERCC1 (p=0.01). In males AR positive tumours 
(23%) had a worse outcome (p=0.03) as well as 
those NSCLC with high ERb expression. In NSCLC 
group, males with tumours AR negative and low 
ERCC1 expression had a better outcome than those 
patients with high levels of both proteins (p=0.026). 
Furthermore, the association of low levels of both 
ERCC1 and ERb in NSCLC patients resulted 
in better outcome compared to those NSCLC 
expressing at least high levels of either ERCC1 or 
ERb (p=0.02). 
Conclusion: Contradictive data are reported about 
the role of hormonal status in lung cancer. In this 
retrospective study we detected a mild association 
between hormonal receptor status and prognosis in 
males more than in females, that should be validated 
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whether FISH abnormalities and other clinical 
features could predict likelihood of carcinoma in 
patients with indeterminate peripheral lung lesions 
after a negative initial bronchoscopic evaluation. 
Methods: A retrospective review of medical 
records was performed to identify patients who 
had a negative bronchoscopic evaluation for an 
indeterminate peripheral nodule that included a 
bronchial brushing for routine cytology and FISH 
testing. Only patients with clinical follow-up after 
bronchoscopy were included in this study (N=149 
specimens from 147 patients; median time to last 
follow-up=65 days). ReÁex FISH testing using 
probes directed to 5p15, 7p12 (EGFR), 8q24 (MYC), 
and centromere 6 (Abbott Molecular Inc. Des 
Plaines, IL) was performed on residual cytology 
specimens diagnosed as negative (n=130), atypical 
(n=10) or suspicious (n=9). FISH testing results 
included negative (n=127) and polysomy (n=22). A 
polysomy result was rendered when a minimum of 
Àve cells were identiÀed having three or more copies 
in at least two of the four loci evaluated by FISH, 
with at least one locus having Àve or more copies. 
The primary outcome was time to malignancy. 
Pathology conÀrmation and/or clinical indication 
of disease progression/metastasis during clinical 
follow-up were considered evidence of malignancy 
(50/147 patients, 34%). Hazard ratios (HR) for 
test results and clinical features were calculated 
using Cox proportional hazards regression model 
analyses using SAS version 9 (Cary, NC). The robust 
sandwich variance estimates were used to account 
for the two patients with an additional specimen. 
P values < 0.05 were considered statistically 
signiÀcant. 
Results: The mean age of the 147 patients was 
67.6 years (SD: 11.2, range 35-91) and 86 (59%) 
were males. Most patients (78%) had a smoking 
history having 33.9 mean pack years (SD: 35.0, 
range 0-200). Peripheral nodule CT measurements 
were available in 135/149 of nodules with a mean 
lesion size of 2.8 cm (SD: 1.6, range 0.5-10.5) and 
33 (22%) nodules showed spiculation. On univariate 
analysis, a polysomy FISH result (HR=4.04, 
P<0.001), pack years (HR=1.01 per year, P<0.001), 
spiculation (HR=2.55, P=0.003), age (HR=1.03 
per year, P=0.019) and a suspicious cytology result 
(HR=2.29, P=0.034) were signiÀcant predictors of 
malignancy over time. Polysomy FISH (HR=3.87, 
CI=2.03-7.40, P<0.001), pack years (per pack year 
up to 50: HR=1.03, CI=1.01-1.04, P<0.001), and 
spiculation (HR=2.11, CI=1.14-3.90, P=0.018) were 
analyses (versus histology, gender, age, and stage). 
A conserved 6 gene-metasignature was identiÀed 
comprising ANKRD27, BICD2, IL6ST, MEF2C, 
PCYT1A, and p63. Most of these genes were shown 
by promoter sequence interrogation, ChIPseq, and 
qPCR validation to be p63 targets. Silencing p63 by 
siRNA in squamous NSCLC cells led to VDAC2 
down-regulation. Silencing either VDAC2 or p63 
caused resistance to erastin, a potent inducer of cell 
death. We then validated the correlation between 
VDAC2 and p63 expression in vivo. Using qRTPCR 
in 20 tumour samples, 10 squamous and 10 non-
squamous it was found that VDAC2 was elevated 
signiÀcantly in the high p63 expressing squamous 
subset only.
Conclusion: In summary, using meta-signature 
analysis of large scale gene expression data, we 
have discovered a therapeutically relevant biological 
connection between p63 and VDAC2. Since p63 
expression is found selectively in the squamous 
tumours, we propose that this group of cancers 
might be selectively targeted by erastins, facilitating 
personalized therapy with this agent.
Keywords: VDAC2, p63
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P2.128 DEVELOPMENT OF A 
MULTIVARIATE MODEL USING 
FLUORESCENCE IN SITU 
HYBRIDIZATION AND CLINICAL 
FEATURES TO PREDICT THE 
LIKELIHOOD OF CARCINOMA IN 
PATIENTS WITH INDETERMINATE 
PERIPHERAL LUNG NODULES
Jesse S. Voss1, Fabien Maldonado2, Sarah M. 
Jenkins3, Michael R. Henry1, Amy C. Clayton1, 
Kevin C. Halling1 
1Laboratory Medicine And Pathology, Mayo Clinic/
United States Of America, 2Pulmonology, Mayo 
Clinic/United States Of America, 3Biomedical 
Statistics And Informatics, Mayo Clinic/United 
States Of America
Background: Previous studies have demonstrated 
the utility of routine cytology with reÁex 
Áuorescence in situ hybridization (FISH) on 
bronchial brushing specimens of indeterminate 
peripheral lung nodules for the diagnosis of lung 
cancer. The goal of this study was to determine 
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genetic effects on COPD risk with and without lung 
cancer. Fisher’s combination test assessed the gene-
based effects. COPD cumulative risk model was 
calculated using the most signiÀcant SNPs.
Results: Twenty SNPs from 12 genes were found to 
be signiÀcantly associated with COPD risk (P<0.01); 
gene-based analyses conÀrmed 2 genes (GCLC and 
GSS) and identiÀed additional 3 (GSTO2, ERCC1, 
and RRM1). Carrying 12 high-risk alleles may 
increase COPD risk by 2.7-fold; 8 SNPs altered the 
risk of COPD with lung cancer 3.1-fold, and 4 SNPs 
altered the risks of COPD without lung cancer 2.3-
fold.
Conclusion: Our Àndings indicate that multiple 
genetic variations in 3 selected pathways contribute 
to COPD risk; GCLC, GSS, GSTO2, ERCC1, 
and RRM1 may be susceptibility genes to COPD. 
Functional studies are needed to elucidate the 
mechanisms of these genes in COPD development. 
Keywords: inÁammation response pathway, 
chronic obstructive pulmonary disease, glutathione 
metabolism pathway, DNA repair pathway
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P2.130 PEMETREXED EXHIBITS THE 
ANTI-METASTASIS ACTIVITY IN NON-
SMALL CELL LUNG CANCERS
Ming-Fang Wu1, Wan-Jung Yang2, Jiunn-Liang Ko3 
1Div Of Medical Oncology And Chest Medicine, 
Chung Shan Medical University Hospital/Taiwan, 
23. Institute Of Medical And Molecular Toxicology, 
Chung Shan Medical University/Taiwan, 3Institute 
Of Medical And Molecular Toxicology, Chung Shan 
Medical University/Taiwan
Background: Pemetrexed has been approved for 
second and Àrst-line treatment in non-small cell lung 
cancer (NSCLC) patients. Recently, there are some 
clinical biomarkers for predicting the therapeutic 
response. But, little report was discussed the 
inhibition of tumor cells metastasis by pemetrexed. 
The aim of this study is to establish the correlation 
between the changing of new biomarker levels and 
the anti-metastasis.
Methods: Human NSCLC cell lines, with variable 
expression of the known molecular determinants of 
pemetrexed sensitivity, were exposed to pemetrexed. 
Antitumor effect was measured by growth inhibition 
by MTT assay. Using Superarray cancer pathway 
the most signiÀcant predictors of malignancy over 
time after multivariate analysis and were used to 
create a prediction model (c-statistic=0.78). 
Conclusion: We developed a multivariate 
prediction model using FISH, nodule spiculation 
and smoking pack years which may stratify the 
risk of a patient having lung cancer subsequent to 
a negative bronchoscopic workup. This model may 
be especially useful in predicting a patient’s risk 
of malignancy over time in certain situations when 
these variables are known. Further studies are needed 
to validate this prediction model. 
Keywords: peripheral lung nodule, FISH, cytology, 
bronchial brushing
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P2.129 GENETIC VARIANTS 
ASSOCIATED WITH THE RISK OF 
CHRONIC OBSTRUCTIVE PULMONARY 
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Background: Published studies show that variations 
of genes participating in glutathione metabolism, 
DNA repair, and inÁammatory response pathways 
may alter susceptibility to Chronic Obstructive 
Pulmonary Disease (COPD), but results are 
controversial and inconclusive.
Methods: We evaluated 470 single nucleotide 
polymorphisms (SNPs) from 56 genes in the 3 above 
pathways in 620 cases and 893 controls to identify 
susceptibility markers for COPD risk. Logistic 
regression models were used to assess SNP effects 
on COPD risk adjusting for sex, age, and smoking 
status. StratiÀed analyses assessed differential 
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and 3 SCCs), and it was signiÀcantly correlated 
with poor overall survival (p<0.05). Among them, 
66.7% (6/9) ADCs showed simultaneous loss of 
E-cadherin, while all of the SCCs accompanied 
Wnt1 overexpression. According to the expression 
pattern, the altered expressions of ơ-catenin were 
observed in 28.6% (4/14) from membranous type 
to decreased membranous expression and in 38.1% 
(8/21) from intact membranous to cytoplasmic 
or nuclear transitions. In decreased membranous 
type, 3 tumors were ơ-catenin+/E-cadherin loss/
Wnt1- phenotype, and signiÀcantly correlated with 
loss of E-cadherin (p<0.05). In the cytoplasmic 
or nuclear transition type, there was signiÀcant 
association between ơ-catenin alteration and Wnt1 
overexpression (p<0.05).
Conclusion: These Àndings show that ơ-catenin 
plays a crucial role on tumor metastasis and 
overall survival. In addition, the alteration of 
ơ-catenin might be regulated by EMT pathway 
(cadherin-catenin system) in ADCs with decreased 
membranous type, but mediated by Wnt pathway in 
SCCs with cytoplasmic or nuclear transition types.
Keywords: ơ-catenin, Wnt1, E-cadherin, Non-small 
cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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gene array, a total of 482 genes was screened in 
A549 cell after pemetrexed treatment. Migration 
and invasion ability were determined by Boyden 
chamber and wound healing. Gelatin zymography, 
RT-PCR and western blot were used to analysis 
nm23, lipocalin 2 and E-cadherin expression. 
Results: A549 is sensitive to Pemetrexed, but 
H1355 is a resistant to Pemetrexed. Pemetrexed 
inhibited A549 migration and invasion ability, 
increased E-cadherin expression and decreased EMT 
(endothelial- mesenchymal transition) in A549. 
Pemetrexed decreased MMP-2 activity and increased 
TIMP-1 and TIMP-2 expression in A549. nm23-H1 
and Lipocalin2 were up-regulated expression 
in following exposure to Pemetrexed in A549 
cells. Further, RNA interference (RNAi)-targeted 
Lipocalin2 generated anti-metastasis to Pemetrexed 
in A549 cells. In contrast, inhibition of Nm23-H1 
expression would induce the migration in A549.
Conclusion: From the results in this study, 
nm23-H1, and Lipocalin2 could play a role as 
genetic determinants of therapeutic response and 
inhibition of tumor cells metastasis of Pemetrexed in 
lung cancer.
Keywords: Lipocalin 2, nm23-H1, Pemetrexed, 
Lung cancer
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P2.131 JANUS-FACED FUNCTION OF 
ȕ-CATENIN ON TUMOR METASTASIS IN 
NON-SMALL CELL LUNG CANCER
Xianhua Xu, Jin-Haeng Chung 
Pathology, Seoul National University Bundang 
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Background: ơ-catenin plays a dual role in cells as 
a major structural component of cell-cell adherence 
junctions (EMT pathway) and as a pivotal signaling 
molecule in the Wnt pathway. However, few studies 
have analyzed the functions of ơ-catenin on tumor 
metastasis regarding Epithelial-Mesenchymal 
Transition (EMT) and Wnt pathways.
Methods: To address the dual role of ơ-catenin 
on tumor metastasis, we compared the 
expression of Wnt1, ơ-catenin and E-cadherin by 
immunohistochemistry in 35 primary tumors and the 
corresponding metastatic lesions.
Results: The alterations of ơ-catenin from primary to 
metastatic tumors appeared in 34.3% (12/35, 9 ADCs 
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Background: We have previously reported that 
low expression of Ơ1,6-fucosyltransferase (FT) , 
an enzyme for the core fucosylation of N-glycans, 
is signiÀcantly more prevalent in squamous cell 
carcinomas compared with non-squamous cell 
carcinomas of the lung. GMD generates GDP-
fucose from GDP-mannose, and is imperative for 
the synthesis of all fucosylated oligosaccharides. 
GDP-fucose is transported into the Golgi apparatus 
by GDP-fucose transporter to serve as a substrate of 
FTs.
Methods: In the present study, we examined 
expression of GMD and GDP-fucose transporter by 
immunohistochemistry in 156 surgically resected 
NSCLCs.
Results: High, moderate and low expression of 
GMD was found in 32 (20.5%), 32 (20.5%) and 
92 (59.0%) NSCLCs, respectively. High/moderate, 
low and no expression of GDP-fucose transporter 
was found in 7 (4.5%), 23 (14.7%) and 126 (80.8%) 
NSCLCs, respectively. Low GMD expression was 
signiÀcantly more prevalent in tumors from men 
than in those from women (p = 0.02), in tumors from 
smorkers compared with nonsmokers (p = 0.047), 
and in squamous cell carcinomas compared with 
non-squamous cell carcinomas (p = 0.0003) by the 
Ƶ2 test. Multivariate logistic regression analysis for 
the correlation between GMD expression and various 
characteristics revealed a signiÀcant association 
between low GMD expression and squamous cell 
carcinomas, as compared with non-squamous cell 
carcinomas (low vs. moderate, p = 0.005; low vs. 
high, p = 0.02). Among biological characteristics of 
tumors studied previously in this cohort of NSCLCs, 
Ki-67 labeling index was signiÀcantly higher in 
tumors with low GMD expression than in those with 
high GMD expression (low vs. high, p = 0.003). 
Low expression of Ơ1,6-FT was more prevalent in 
tumors with low GMD expression than in those with 
moderate or high GMD expression (p = 0.002). Low 
GDP-fucose transporter expression was signiÀcantly 
more prevalent in squamous cell carcinomas 
compared with non-squamous cell carcinomas 
(p = 0.003) by the Ƶ2 test. GMD and GDP-fucose 
Research Center, Guangdong Lung Cancer Institute, 
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Background: EML4-ALK mutant lung cancer 
patients have been deÀned as a speciÀc subgroup 
that may beneÀt greatly from ALK inhibitor. Yet the 
algorithm to screen patients with ALK fusion need to 
be optimized in clinic and the exact common variants 
of EML4-ALK fusion need further investigation.
Methods: Clinical samples were routinely tested 
for EML4-ALK fusion by both speciÀc RT-
PCR and RACE-PCR-Sequencing technologies. 
All electrophoresis bands of PCR products and 
sequencing chromatographs were manually analyzed.
Results: In a total of 313 cases of NSCLC, we 
detected 14 cases of EML4-ALK fusion variant 1 
(V1), 7 cases of variant 3 (V3), 5 cases of EML4-
ALK fusion 2, 2 cases of EML4-ALK variant 6 (V6), 
and 1 case of EML4-ALK variant 9 (V9). Overall 
EML4-ALK fusion rate is 9.27%, concordant to 
the data reported previously. Notably, in one case 
harboring V6, the genotypes of multiple sequencing 
showed actually a novel V6 of E13;ins90A20 
(termed as V6b by our group) co-existing with one 
other novel variant of E17ins27;ins125A20, termed 
as V10 by us. In one other case harboring V3, the 
EML4-AK variant was actually a novel variant of 
E6ins36;del33A20, termed as V3c by us.
Conclusion: In routine clinical testing setting, novel 
EML-ALK fusion variants have been identiÀed and 
the most common variant of EML4-ALK fusion is 
V1, suggesting the sequence complexity of ALK 
fusion with EML4 gene.
Keywords: EML4-ALK, gene fusion, Non-small 
cell lung cancer
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P2.133 GDP-MANNOSE-4,6-
DEHYDRATASE (GMD) AND GDP-
FUCOSE TRANSPORTER IN NON-SMALL 
CELL LUNG CANCERS (NSCLCS) : 
THEIR DECREASED EXPRESSION IN 
SQUAMOUS CELL CARCINOMAS BY 
IMMUNOHISTOCHEMISTRY
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Apr 5;9(4):1913-22. 2 Mouse model for lung 
tumorigenesis through Cre/lox controlled sporadic 
activation of the K-Ras oncogene. Meuwissen R et 
al.. Oncogene. 2001 Oct 4;20(45):6551-8. 3 Induction 
of small cell lung cancer by somatic inactivation of 
both Trp53 and Rb1 in a conditional mouse model. 
Meuwissen R et al.. Cancer Cell. 2003 Sep;4(3):181-
9. 
Results: In the secretome samples, up to 2,000 
proteins can be identiÀed with 80% reproducibility 
by label-free, shotgun nanoLC tandem mass 
spectrometry and quantiÀed by spectral counting. 
The beta-binomial test4 is used to Ànd signiÀcant 
differences in protein expression between the 
different secretomes and network analysis is 
performed to provide insight into the underlying 
cellular mechanisms. The secretomes from the 
mouse models are used to Ànd proteins speciÀcally 
secreted by either NSCLC or SCLC, while the 
comparison between the secretomes of the several 
human and mouse cell lines allows extrapolation 
of the results from the mouse models to the human 
situation. Furthermore, the analysis of the cell 
lines with various cisplatin IC50-values permits 
selection of the protein markers that are indicative of 
sensitivity or resistance. The results of the different 
proteomics analyses will be presented along with 
the most promising biomarker candidates and an 
overview of the functional network analysis. 4 Pham 
TV et al.. Bioinformatics. 2010 Feb 1;26(3):363-9.
Conclusion: To our knowledge, this is the Àrst 
secretome proteomics study to discover protein 
biomarkers for lung cancer treatment response 
prediction and monitoring. Our proteomics approach 
has identiÀed numerous known and novel potential 
protein biomarkers for personalized therapy and 
provided new insights in treatment resistance.
Keywords: treatment response prediction, protein 
biomarkers, secretome proteomics
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.135 IGF1R AND SRC ARE 
FUNCTIONALLY ACTIVATED IN 
NON SMALL CELL LUNG CANCER 
(NSCLC) AND TARGETED BY SPECIFIC 
INHIBITORS
Valentina Monica, Marco Lo Iacono, Paolo Ceppi, 
Silvia Novello, Marco Volante, Giorgio Scagliotti, 
Mauro Papotti 
transporter expressions were not associated with 
survival. 
Conclusion: These results indicate that GMD and 
GDP-fucose transporter may be new markers of 
NSCLCs with speciÀcity for histology.
Keywords: GMD, GDP-fucose transporter
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P2.134 SECRETOME PROTEOMICS TO 
IDENTIFY INDICATORS FOR LUNG 
CANCER TREATMENT RESPONSE 
PREDICTION AND MONITORING
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Background: Lung cancer is currently the number 
one cause of cancer-related deaths worldwide. 
Five-year survival rates for both non-small cell 
lung cancer (NSCLC) and small cell lung cancer 
(SCLC) are still less than twenty percent due to late 
stage of presentation, treatment failure and lack of 
biomarkers for personalized therapy. Aim of this 
study is to identify protein biomarkers that can be 
used for treatment response prediction and therapy 
monitoring. 
Methods: Rather than following a broad strategy 
by analyzing the proteome of whole cell or tissue 
lysates, we chose to use a more speciÀc approach 
based on the assumption that the best tumor markers 
are shed or secreted by the tumor and can be 
detected in blood. Secretome (i.e. all proteins shed 
from or secreted by a cell or tissue) proteomics1 
was performed on a set of tumors from conditional 
mouse models for SCLC and NSCLC2,3, a set of 
human and mouse SCLC and NSCLC cell lines 
and a series of human NSCLC cell lines with a 
range of IC50-values for cisplatin (1.5 – 15 M). 
Secretomes were obtained by collecting serum-free 
media from the cell lines or collecting PBS in which 
a tumor tissue piece had been incubated. 1 WorkÁow 
comparison for label-free, quantitative secretome 
proteomics for cancer biomarker discovery: method 
evaluation, differential analysis, and veriÀcation 
in serum. Piersma SR et al.. J Proteome Res. 2010 
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showed modest pro-apoptotic effects when 
administered as a single agent (except in H520 cell 
line, in which Figitumumab alone slightly increased 
the apoptotic rate), a higher rate of apoptotic 
cells was found with the dasatinib/Àgitumumab 
combination in both H1299 and Calu-1 cells. IGF1R 
and SRC mRNA tissue expression analyses showed 
higher IGF1R tumor expression and modulation 
(normal/tumor expression) in squamous cell 
carcinoma as compared to non-squamous histotypes.. 
A strong linear correlation between IGF1R and SRC 
mRNA expression levels was detected, conÀrmed 
by protein expression analysis which demonstrated a 
linear correlation between the phosphorylated forms 
of IGF1R and SRC proteins. 
Conclusion: Our in vitro and tumor tissue data 
preliminarly support the combined inhibition of 
IGF1R and SRC as a novel therapeutic strategy 
for a subset of NSCLC patients with a functionally 
activated status of the IGF1R-SRC pathway. 
Keywords: IGF1R, SRC, Figitumumab, squamous 
cell carcinoma
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P2.136 PROGNOSTIC SIGNIFICANCE OF 
SYSTEMIC INFLAMMATORY RESPONSE 
AND EPIDERMAL GROWTH FACTOR 
RECEPTOR GENE STATUS IN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
LUNG CANCER
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Sakamori, Young Hak Kim, Michiaki Mishima 
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Background: The somatic activating mutation 
of the epidermal growth factor receptor (EGFR) 
gene (EGFR mutation) with EGFR-tyrosine kinase 
inhibitor (EGFR-TKI) treatment has been regarded 
as a prognostic factor for survival in patients with 
non-small cell lung cancer (NSCLC). Elevated level 
of C-reactive protein (CRP), a systemic marker of 
inÁammation, has been also regarded as a prognostic 
factor. No study, however, has been reported about 
the asssociation between systemic inÁammatory 
response and EGFR status.
Methods: We retrospectively analyzed the 
association between systemic inÁammatory response 
and EGFR status in Japanese patients with advanced 
Department Of Clinical And Biological Sciences, 
University Of Turin, Aou San Luigi/Italy
Background: The insulin-like growth factor type I 
receptor (IGF1R) is a tyrosin-kinase receptor highly 
expressed in various solid tumors which regulates 
cell growth, differentiation, survival, transformation 
and metastasis. Its over-expression and gene 
ampliÀcation have been demonstrated in non-small 
cell lung cancer (NSCLC) with special reference to 
the squamous histology. Tyrosine kinase inhibitors 
and monoclonal antibodies showed promising 
blocking effects of IGF1R in pre-clinical studies. 
The tyrosine kinase c-SRC is a signaling transducer 
of different TK receptors and is highly expressed 
in lung cancer tissues and cell lines. We tested in 
four NSCLC cells the effect of Àgitumumab, a 
monoclonal antibody against IGF1R in association 
with a potent c-Src inhibitor, dasatinib (BMS-
354825), and to analyse the presence of a putative 
IGF1R-SRC activated pathway in NSCLC tumor 
tissues. 
Methods: MTT proliferation assay was performed 
in cell lines (adenocarcinoma A549, squamous cell 
carcinoma Calu-1 and H520, large cell carcinoma 
H1299) both at 48 and 72 hours. FACS analysis was 
performed at 72 hours to detect apoptotic events 
following both single agents and combination 
drug administration. Furthermore IGF1R and 
SRC mRNA tissue expression was analysed using 
RealTime PCR in a series of 92 surgical NSCLC 
specimens (including 50 adenocarcinomas, 9 BACs, 
32 squamous cell and one large cell carcinoma) 
and matched normal tissue samples. In 56 of these 
cases, immunohistochemical assessment of the 
activated form of both p-IGF1R and p-SRC, was also 
performed. 
Results: At 72 although not at 48 hours, both 
Figitumumab and Dasatinib alone showed a 
moderate activity in biological triplicates of all cell 
lines, the former with a mild superior effect in H1299 
and Calu-1, compared to A549 and H520 cell lines. 
At the same time, the simultaneous administration 
of the 2 agents resulted in a synergistic increase of 
cell proliferation blockage in three out four cell lines, 
H1299, Calu-1 and A549 cells, as compared to single 
agents efÀcacy, with a combination index (CI) < 1. 
Conversely a strong antagonistic effect was observed 
in H520 cell line. The effect of the concomitant 
administration of Àgitumumab and dasatinib at 72 
hours was also evaluated by means of cell apoptosis 
assay. Although both dasatinib and Àgitumumab 
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P2.137 ANALYSIS OF THE 
PROGNOSTIC ROLE OF REGULATORY 
T-LYMPHOCYTE-ASSOCIATED 
MARKER EXPRESSION IN RESECTABLE 
NSCLC
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Amparo Iraola3, Neus Martinez3, Ricardo Guijarro4, 
Carlos Camps3 
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Spain, 2Biotechnology, Polytechnic University Of 
Valencia/Spain, 3Oncology, General University 
Hospital/Spain, 4Thoracic Surgery, General 
University Hospital/Spain
Background: Regulatory T-lymphocytes (Tregs) 
play a critical role in immune tolerance to tumor 
cells. Several molecules, including CD4, CD8A, 
CD25, CD127, CTLA-4, IL-10 and TGFơ-1 have 
been reported markers of Tregs. Another highly 
speciÀc marker for Tregs is FoxP3, a transcription 
factor which appears to be a master control gene 
for their development and function. The aim of 
this study was to determine the expression of these 
genes by RT-PCR and to correlate them with clinico-
pathological and prognostic variables in NSCLC.
Methods: RNA was isolated from frozen lung 
specimens (tumor and normal lung) from resectable 
NSCLC patients (n=150). RT-PCR was performed 
to analyze the expression of: CD4, CD8A, CTLA-4, 
FoxP3, IL-10, CD25, CD127 and TGFơ-1. Relative 
expression was normalized by an endogenous 
gene (GUSB) using the PfafÁ formulae. Statistical 
analyses were considered signiÀcant at p<0.05.
Results: Tumor samples had signiÀcantly higher 
expression of CD25 (x2.1) and lower expression of 
CD127 (x0.42) than normal lung tissues, reÁecting 
a Treg phenotype inÀltrating the tumor. Survival 
analyses revealed that patients with high FoxP3 
expression had reduced TTP (median 22.1 vs 66.6 
months, p= 0.017) and OS (median 26.8 vs 49.7 
months, p= 0.036) whereas those with high CD4 or 
CD8A expression had improved OS (median 26.8 vs 
48.1 and 27.9 vs 48.1, respectively). A multivariable 
Cox regression model for TTP and OS was built 
using variables that were found signiÀcant in the 
univariate analysis (FoxP3, CD4, and CD8A, nodal 
involvement, tumor size and PS). Regarding TTP 
NSCLC and investigated if they were independent 
prognostic factors for survival. A total of 240 
Japanese patients with advanced NSCLC whose 
EGFR statuses were analyzed participated in this 
study. To assess the systemic inÁammatory response, 
we used Glasgow Prognostic Score (GPS). That is, 
hypoalbuminemia (<35 g/L =1) and a raised CRP 
(>10 mg/L =1) were combined to form a prognostic 
score (0, 1, and 2).
Results: EGFR mutations were found in 107 patients 
(44.6%). The CRP levels were signiÀcantly higher 
and the albumin levels were signiÀcantly lower 
in patients with wild type EGFR than in patients 
with EGFR mutations (19.3 ± 3.6 mg/L vs 4.6 ± 
10.6 mg/L, P <0.0001, and 40.1 ± 4.6 g/L vs 41.3 
± 3.8 g/L, P =0.034, respectively). GPS of 0 was 
signiÀcantly found in patients with EGFR mutations 
(P <0.0001). Based on a multivariable analysis, 
EGFR mutations were signiÀcantly associated with 
GPS of 0 (odds ratio [OR]; 2.93, 95% conÀdence 
interval [CI]; 1.51 - 5.90, P =0.0014). Median overall 
survival (OS) of patients with EGFR mutations 
was signiÀcantly longer than that of patients with 
wild type EGFR (29.7 months vs 12.0 months, P 
<0.0001). There were also signiÀcant differences 
in median OS among patients with GPS of 0, GPS 
of 1, and GPS of 2 (25.5 months vs 14.2 months vs 
4.1 months, P <0.0001). Based on a multivariate 
analysis, ECOG PS of 0 or 1 (hazard ratio [HR], 
0.26; 95% CI, 0.15 - 0.46; P <0.0001), EGFR 
mutations (HR, 0.44; 95% CI, 0.28 - 0.68; P = 
0.0003), and GPS of 0 (HR, 0.44; 95% CI, 0.29 - 
0.69; P =0.0003) were signiÀcantly associated with 
longer OS.
Conclusion: This study showed the association 
between systemic inÁammatory response and EGFR 
status in patients with advanced NSCLC and both 
were independent prognostic factors for survival.
Keywords: Non-small cell lung cancer, epidermal 
growth factor receptor gene mutation, C-reactive 
protein, systemic inÁammatory response
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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in clinical and pathological characteristic were 
evaluated.
Results: Stages of the tumors were IA (n = 20), 
IIB (n = 13), IIA (n = 6), IIB (n = 4), IIIA (n = 10), 
IIIB (n = 8) and IV (n = 12). Histology revealed 
adenocarcinoma (n = 36), squamous carcinoma (n 
= 24), combined adenocarcinoma and squamous 
carcinoma (n = 8), combined small cell lung cancer 
and squamous carcinoma (n = 3), other type (n = 
2). Of the 73 tumors, 36 (49.3%) were positively 
stained for CD133, and 19 (52.7%) of the CD133-
positive tumors were adenocarcinoma. CD133-
negative expressers showed a signiÀcantly longer 
overall survival than CD133-positive expressers 
(62.9 vs. 45.8 months, p=0.047). CD133-negative/
ERCC1-positive expressers showed a prolonged 
overall survival than CD133-positive/ERCC1-
negative expressers (67.9 vs. 54 months, p=0.013). 
CD133-negative/ RRM1-positive expressers showed 
a prolonged overall survival than CD133-positive/
RRM1- negative expressers (60.3 vs. 43.5 months, 
p=0.047). Cox-regression analysis showed that 
TNM, ERCC1 and CD133 were the independent 
prognostic factors. 
Conclusion: CD133 expression is an independent 
prognostic marker and the combination of CD133 
with ERCC1 and/or RRM1 may provide better 
prognostic value in predicting the overall survival of 
the patients with lung cancer. 
Keywords: CD133, DNA repair genes, Lung cancer, 
immunohistochemistry
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.139 HYPONATREMIA IS A 
PROGNOSTIC MARKER OF SURVIVAL 
FOR LUNG CARCINOMA
Claudia Petereit, Okan Zaba, Ishak Teber, Christian 
Grohe 
Internal Medicine, Evangelische Lungenklinik 
Berlin/Germany
Background: Lung carcinoma is the most 
prevalent and most deadly solid tumor worldwide. 
Hyponatremia is frequently observed on the basis 
of SIADH in patients suffering from small cell lung 
carcinoma (SCLC) but also from non small cell lung 
carcinoma (NSCLC). This electrolyte imbalance is 
associated with higher mortality and morbidity. If 
hyponatremia inÁuences median survival of lung 
and OS, this analysis revealed that FoxP3 and PS 
were independent prognostic markers (see table). 
Table: Multivariate Cox regression analysis for time 
to progression (TTP) and overall survival (OS). 
TTP OS 
HR 95% IC P HR 95% IC P 
PS FoxP3 2.08 2.20 1.04-4.15 1.17-4.13 
0.036* 
0.014* 2.13 2.47 
1.10-4.12 
1.32-4.62 
0.024* 
0.004* 
HR, hazard ratio; CI, conÀdence interval; *p<0.05, 
statistically signiÀcant.
Conclusion: FoxP3 is a transcription factor 
necessary and sufÀcient for induction of the 
immunosuppressive functions in Tregs. In 
concordance, our results indicate that high 
expression of FoxP3 in tumor samples is a poor 
prognostic marker for TTP and OS. Furthermore 
the multivariable COX regression analysis showed 
that FoxP3 is an independent prognostic marker. 
Therefore, FoxP3 expression could be used 
as a new biomarker of prognosis in resectable 
NSCLC. Supported by grants PS09-01149 and 
RD06/0020/1024 from ISCIII. 
Keywords: prognostic, Tregs, NSCLC
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P2.138 PROGNOSTIC VALUE OF CD133 
EXPRESSION AND IT’S COMBINATION 
WITH EXPRESSIONS OF ERCC1, RRM1 
AND BRCA1 IN LUNG CANCER
Chunxia Su1, Guotong Xu2, Caicun Zhou1 
1Oncology, Pulmonary Hospital; Tongji University 
School Of Medicine/China, 2Regenerative Medicine 
And Tongji Eye Institute, Tongji University School Of 
Medicine/China
Background: CD133 is one of the most 
representative cancer stem cell markers. This 
study was to investigate the potential prognostic 
value of CD133 expression in lung cancer and it’s 
relationship with the DNA repair genes ERCC1, 
RRM1 and BRCA1.
Methods: Tumor samples from 73 patients (46 
males and 27 females) were immunohistochemically 
examined for the expressions of CD133, ERCC1, 
RRM1 and BRCA1, and their associations with 
overall survival were analyzed. The signiÀcances 
of the expressions of CD133 and DNA repair genes 
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sodium is a relevant prognostic marker of survival 
for small cell and non small cell lung carcinoma. 
Keywords: survival, Hyponatremia, lung carcinoma, 
prognostic marker
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P2.140 DECREASED EXPRESSION OF 
LKB1 IS CORRELATE WITH LOSS 
EXPRESSION OF P16 AND OVER 
EXPRESSION OF P53 AND ADVANCED 
TUMOR STAGE IN NON-SMALL CELL 
LUNG CARCINOMA
Qing Kay Li1, Gloria H. Lewis1, Frederic Askin2, 
Edward Gabrielson3 
1Pathology, Johns Hopkins Medical Institutes/United 
States Of America, 2Pathology, Johns Hopkins 
Medical Institutes At Bayview/United States Of 
America, 3Molecular Pathology, Johns Hopkins 
Medical Institutes/United States Of America
Background: It is well known that about 36% of 
stage I non-small cell lung carcinoma (NSCLC) 
patients will eventually experience recurrent 
disease, even when it is detected at an early stage 
and potentially curative surgery is performed. 
However, the mechanism of tumor progression and 
potential development of drug resistance is still not 
well understood. LKB1, (liver kinase B1), a serine/
thronine kinase, is encoded by LKB1/STK11 gene 
on the chromosome 19p and a primary upstream 
kinase of adenine monophosphate-activated protein 
kinase (AMPK) involved in the regulation of both 
cellular polarity and energy metabolism. Germline 
mutations of LKB1 gene are the leading cause of 
Peutz-Jeghers syndrome and found in 90% of this 
patient population. Somatic mutation of LKB1 is 
associated with a variety of solid tumors and 30-
40% of NSCLC. Recent studies have shown that 
endogenous LKB1 knockdown accelerates cell cycle 
progression through G1/S checkpoint in human 
kidney cell line, and Lkb1-deÀcient enhances tumor 
metastasis in mouse model. The tumor-suppressor 
activity of LKB1 has been suggested to function 
through regulation of p53 and/or the Ink4a/Arf 
pathways. However, the relationship of LKB1, p53 
and p16 has not been well understood. In this study, 
we have investigated the expression and potential 
relationships among LKB1, p16 and p53 in NSCLC.
Methods: TMAs of NSCLC were constructed. A 
tumors remains controversial. In the current study 
we retrospectively analysed if median survival is 
directly impacted by hyponatremia and evaluate 
if hyponatremia is a prognostic marker for lung 
carcinoma. 
Methods: Between 2006 and 2009 we analysed 
2048 lung carcinoma without and 97 (4.7%) with 
hyponatremia in a single center study (Berlin/Tumor-
Centre-Buch, Germany). 
Results: While 14.2% of the SCLC (296 SCLC 
without and 49 SCLC with hyponatremia) developed 
hyponatremia, only 2.7% of the NSCLC patients 
(1752 NSCLC without and 48 NSCLC with 
hyponatremia) where affected. 63 males and 34 
females developed hyponatremia. Overall survival 
(OS) after 2 years was 9.9% ± 6,6 for females and 
35.1% ± 7,6 for males (p=0,08). Hyponatremia 
was mostly observed in stage of advanced disease. 
75.5% of SCLC and 73.3% of NSCLC with 
hyponatremia had distant metastases correponding to 
tumor stage IV. Median survival in lung carcinoma 
with hyponatremia was reduced compared to 
normonatremic average survival (0.84 ± 0.14 vs. 
1.01 ± 0.04 years, p=0,08). Sodium levels below 
125mmol/l where associated with reduced survival 
(OS (2 years) 11,8% ± 6,9 vs. 34,3% ± 8,5, p=0,12). 
Survival curves were similar in hyponatremic 
patients regardless of the lung tumor histogy (OS 
(2 years) 25.2% ± 7,6 for NSCLC vs 23.5% ± 8,5 
for SCLC, p=0,8). Overall survival (2 years) of 
normonatremic patients was 30.8% ± 1,3 (p=0,08). 
Correction of serum sodium above 138mmol/l was 
correlated to extended median survival (1.11 ± 0,12 
years, p=0,007) for both NSCLC and SCLC patients 
while medium survival was only 0.43 years if serum 
sodium could not be elevated above 138mmol/l (0.55 
± 0,22 years, p=0,017 for NSCLC and 0.42 ± 0,1 
years for SCLC, p=0,14). 
Conclusion: These data suggest that hyponatremia 
can inÁuence survival of patients with lung 
carcinoma. The degree of hyponatremia (lowest 
serum sodium) and its normalisation (maximal 
serum sodium) can modify median survival. 
Serum sodium below 125mmol/l is correlated 
with increased mortality. In addition we observed 
a positive correlation between serum sodium and 
tumor stage. This suggests that hyponatremia on the 
basis of SIADH corresponds to tumor mass. Women 
suffering from hyponatremia displayed shorter 
survival, but were overall less frequently affected 
than man (63 men in comparison to 34 women, ratio 
2:1). In summary these data indicate that serum 
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Japan, 3Radiology, Okayama University Graduate 
School Of Medicine/Japan
Background: Computed tomography-guided lung 
needle biopsy (CTNB) is an accurate and useful 
technique for diagnosing lung tumors. However, 
false-negative cases occasionally become apparent 
after lung tumor resection. Epidermal growth factor 
receptor (EGFR) gene mutations are a characteristic 
of non–small-cell lung cancer (NSCLC). Here we 
determined the EGFR mutational status of lung 
tumors misdiagnosed from CTNB specimens but 
correctly diagnosed after surgery.
Methods: Between 2000 and 2008, 1109 CTNBs 
were performed at our hospital; 12 of these tumors 
were diagnosed as non-malignant at CTNB and 
were only correctly diagnosed after surgery. We 
reviewed the pathological Àndings of these CTNB 
sections to identify those that did not contain 
malignant components. DNA was extracted from 
formalin-Àxed parafÀn-embedded tissues of both 
CTNB and surgically resected specimens of these 
cases. The EGFR mutational status was subsequently 
determined using a mutant-enriched PCR assay.
Results: EGFR mutations were detected in CTNB 
specimens (1/12, 8.3 %) and in the corresponding 
surgically resected tumors (3/12, 25%). Two mutant 
cases from surgically resected tumors showed the 
wild-type EGFR gene in CTNB specimens. One case 
harbored the same EGFR mutation in both CNTB 
and surgically resected specimens. 
Conclusion: Our results indicate that the detection 
of EGFR mutations aids the diagnosis of NSCLC in 
pathologically negative CTNB specimens.
Keywords: CT guided biopsy, EGFR mutation
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P2.142 SYSTEMIC INFLAMMATORY 
STATUS AT BASELINE AFFECTS 
SURVIVAL AND BEVACIZUMAB 
ACTIVITY IN NON SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS
Cirino Botta1, Annamaria Guglielmo1, Vito Barbieri2, 
Danilo Rocco3, Marcello Rossi4, Elena Bestoso1, 
Serena Apollinari1, Antonella Licchetta1, Patrizia 
Blardi5, Pierfrancesco Tassone6, Giorgio Chiriacò1, 
Pierosandro Tagliaferri2, Pierpaolo Correale1 
1Oncology, “Maria Alle Scotte” Hospital/Italy, 
2”Magna Graecia” University/Italy, 3A.o. Monaldi/
total of 194 cases were included. Mouse monoclonal 
antibodies against LKB1 protein (1:200 dilution), 
p16 protein (1:250 dilution), and p53 protein (1:100 
dilution) were used, and immunoreactivity was 
scored in both nuclei and cytoplasm using a scale 
from 0 (undetectable) to 2+ (strongly positive). 
Results: Among 194 cases, 166 cases were early 
stage of tumors (pT stage 1 and 2) and 28 cases 
were late stage of tumors (pT stage 3 and 4). The 
expressions of LKB1, p16 and p53 in different stage 
of tumors were summarized in Table 1. In addition, 
the loss of LKB1 expression in squamous cell 
carcinoma and adenocarcinome is 31.3% and 22.5%, 
respectively (P>0.05). Table 1 
Loss of LKB1 Loss of p16 Over expression of p53 
Low tumor stage (1/2) 26.1% (30/115) 53.2% (66/124) 54.8% (23/42) 
High tumor stage (3/4) 40 % (8/20) 73.7% (14/19) 75% (6/8) 
All cases 28.1% (38/135) 55.9% (80/143) 58% (29/50) 
Conclusion: The decreased expression of LKB1and 
p16, and over expression of p53 are common in 
NSCLC. Although there is no signiÀcant difference 
of loss LKB1 expression between squamons cell 
carcinoma and adenocarcinoma, the decreased 
expression of LKB1 and p16, and over expression 
of p53, were correlated with advanced tumor stage. 
Our date suggests that loss of LKB1 expression in 
NSCLC may related to disease aggressiveness and 
dysfunction of p16/INK4A cell cycle-dependent 
signaling pathways.
Keywords: LKB1 expression, p16/INK4A signaling 
pathway, p53 expression, Non-small Cell Lung 
Carcinoma
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P2.141 EGFR MUTATIONAL STATUS 
IN FALSE-NEGATIVE COMPUTED 
TOMOGRAPHY-GUIDED LUNG NEEDLE 
BIOPSY SPECIMENS OF NON-SMALL-
CELL LUNG CANCERS
Junichi Soh1, Tsuyoshi Ueno1, Shinichi Toyooka1, 
Yuho Maki1, Takayuki Muraoka1, Norimitsu 
Tanaka1, Hiroaki Asano1, Kazunori Tsukuda1, Koichi 
Ichimura2, Takao Hiraki3, Hidefumi Mimura3, 
Susumu Kanazawa3, Shinichiro Miyoshi1 
1Cancer And Thoracic Surgery, Okayama University 
Graduate School Of Medicine/Japan, 2Pathology, 
Okayama University Graduate School Of Medicine/
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activity and patients’ survival. Furthermore they 
provided us three potentials and easy-to-do bio-
markers able to predict the outcome of NSCLC 
patients receiving Bev which warrant prospective 
evaluation.
Keywords: bevacizumab, NSCLC, prognostic 
factors
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P2.143 SCREENING FOR EPIDERMAL 
GROWTH FACTOR RECEPTOR 
MUTATIONS ASSOCIATED TO 
TYROSINE-KINASE INHIBITORS IN 
LUNG ADENOCARCINOMA PATIENTS 
FROM ARGENTINA
Claudia Poleri1, Marcelo Castro2, Marcelo Guasti3, 
Martin Plotquin3, Guillermo F. Bramuglia4 
1Pathology, Fundacion Investigar/Argentina, 
2Catedra De Analisis Clinicos Ii, Area Hematologia, 
Facultad De Farmacia Y Bioquimica, Uba-
fundacion Investigar./Argentina, 3Medical 
Department, AstraZeneca, Argentina/Argentina, 
4Catedra De Farmacologia, Facultad De Farmacia 
Y Bioquimica, UBA-Fundacion Investigar/Argentina
Background: Epidermal growth factor receptor 
(EGFR) activating mutations in the EGFR gene 
confer sensitivity to the tyrosine kinase inhibitors 
in patients with lung cancer. No previous studies 
of characterization of EGFR mutations have 
been performed in patients from Argentina. We 
evaluated the feasibility of large-scale screening for 
EGFR mutations in such patients and analyzed the 
association between the mutations and some clinical 
covariables. 
Methods: From March 2010 through December 
2010, lung adenocarcinomas from 166 patients 
from different centers in Argentina were screened 
for EGFR mutations in exons 18, 19, 20, and 21, in 
a central laboratory. All specimens were reviewed 
to ascertain at least 70% neoplastic cells/ nucleated 
cells. Genomic DNA was extracted from macro 
dissected tumor cells of formalin-Àxed parafÀn-
embedded tissue sections and smears. AmpliÀcations 
of exons 18 through 21 of EGFR gene was 
performed using nested primers as published. PCR 
fragments were sequenced and analyzed in both 
forward and reverse directions; mutations were 
veriÀed by three independent ampliÀcations. Patient 
Italy, 4”Maria Alle Scotte” Hospital/Italy, 5Internal 
Medicine, “Maria Alle Scotte” Hospital/Italy, 
6”Magna Graecia” University/Italy
Background: The introduction of Bevacizumab 
(Bev) in the Àrst-line treatment of NSCLC 
patients, has brought a great beneÀt in term of 
progression-free-survival(PFS) and survival (OS). 
However, the toxicity and costs related to these 
treatments, highlight the need of biomarkers capable 
of predicting Bev activity. We investigate the 
prognostic value of several clinical and biologic 
variables in 62 inoperable NSCLC patients who had 
received frontline chemotherapy in combination 
with bevacizumab. Forty-Àve patients had received 
treatment according to the mPEBev regimen (phase 
II study, EUDRACT#2008-00-6051-40) and 17 with 
standard platinum-based chemotherapy between 
December 2008 and February 2010
Methods: Clinical and biologic variables from 
sixty-two metastatic NSCLC patients undergone 
frontline-ciplatinum-based chemotherapy and Bev 
were evaluated for their capability to predict longer 
PFS and OS. The Student-t test, the Pearson Ki-
square test, Kaplan Meier survival curves and Cox 
regression analysis were performed to evaluate the 
correlation among variables and outcome.
Results: Patients showed a 76.6% response rate, a 
median PFS of 8.00 (95% CI 6.64-9.36) months and 
a median OS of 15 (95% CI 10.66-19.34) months. 
In the univariate analysis, baseline neutrophils 
count >7500 cells/ml and neutrophil/lymphocyte 
ratio (NLR) >4 were strongly associated with worse 
PFS and OS (p<0.01) while baseline monocytes 
count > 600 cells/ml was correlated only with 
worse OS (p<0.01). NLR variable was not entered 
into the Cox’s model due to the strong correlation 
with neutrophils count (Pearson Ki square < 0.05). 
Multivariate analysis showed that neutrophils count 
>7500 cells/ml was associated with worse PFS (HR 
2.076; p=0.013) and OS (HR 3.465; p=0.004), while 
monocytes count >600 cells/ml was associated 
only with worse OS (HR 2.218; p=0.048). We then 
created a predictive model based on these three 
prognostic factor in which patients with no adverse 
factor (41% of the group) had a median OS of 20.00 
(95% CI 16.81-23.18) months, while patients with 
at least one adverse factor had a median OS of 7.00 
(95% CI 1.91-12.09) months (p<0.001). 
Conclusion: These results suggest that the systemic 
inÁammatory status at baseline in NSCLC patients 
may play an intriguing role in determining Bev 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1017
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.144 ASSESSMENT OF EGFR, VEGFR, 
AND SELECTED DOWNSTREAM 
SIGNALING MOLECULES IN NON-
SMALL CELL LUNG CANCER
Zhaolin Xu1, Drew Bethune2, Sen R. Yan2, Weei 
Huang2, Gillian Bethune2, Ron Dewar3, Neale 
Ridgway4, Michael Johnston2 
1Pathology, Queen Elizabeth Ii Health Sciences 
Centre And Dalhousie University/Canada, 2Queen 
Elizabeth Ii Health Sciences Centre And Dalhousie 
University/Canada, 3Cancer Care Nova Scotia/
Canada, 4Dalhousie University/Canada
Background: Epidermal growth factor receptors 
(EGFR) and vascular endothelial growth factor receptors 
(VEGFR) are thought to be related to cancer cell 
proliferation and survival. Whether they are associated 
with cancer patient’s clinical outcome is not clear. We 
analyzed EGFR, VEGFR and selected downstream 
signaling molecules in non-small cell lung cancer 
(NSCLC) with pathological and clinical correlation.
Methods: 88 cases of surgically treated NSCLC 
were included in the study. Tissue microarray (TMA) 
of the tumors was prepared. Immunohistochemical 
staining (IHC) for EGFR, VEGFR, Akt, BAD and 
PTEN (phosphatase and tensin homolog deleted 
on chromosome 10) and Áuorescence in situ 
hybridization (FISH) for EGFR were performed 
on TMA sections. The results were correlated with 
pathological characteristics and clinical outcome. 
Results: EGFR overexpression was detected by 
FISH and IHC (66.7% vs. 31.8 %). EGFR assessed 
by FISH was mainly in the form of polysomy 
rather than ampliÀcation, with a tendancy to higher 
rate in high grade tumors (p = 0.08) and positive 
nodal spread (p = 0.07). Squamous cell carcinoma 
showed higher VEGFR expression (p < 0.05). BAD 
expression was associated with later pathologic stage 
(p < 0.05) and weakly with adenocarcinoma. Weaker 
associations were also noticed between PTEN and 
adenocarcinoma (earlier pathologic stage and more 
well-differentiated morphology). Overexpression 
of these factors was not associated with patient’s 
survival including follow-up to 3 years post-surgery.
Conclusion: EGFR, VEGFR, BAD and PTEN are 
associated with certain pathological and clinical 
features in NSCLC.
Keywords: EGFR, VEGFR, BAD, Non-small cell 
lung cancer
age, gender and smoking status were documented. 
Results: Among the Àrst 166 patients with lung 
adenocarcinoma included for somatic EGFR kinase 
domain sequencing, the median age was 62 years 
(SD 11, 020) and 54% were female. Smokers or 
former smokers accounted for 62% of patients, 
38% of the patients were never smokers. 92% of 
specimens submitted were parafÀn embedded. 
Eighteen samples were inadequate so excluded from 
the study. 124 samples of 147 specimens included 
in the study were successfully ampliÀed (84%). 
Among the 124 patients with interpretable results, 31 
(24%) were found to have at least 1 mutation in the 
EGFR kinase domain. The majority of the mutations 
associated with TKI sensitivity were located in 
exon 19 (18/31): Del E746–A750 in 12 cases, Del 
L747–T751 in 2 cases, L747 – E749 del P ins in 
2 cases, and E746– T751 del I ins and p. A743S 
in 1 case each one. Three patients carried L858R 
mutation in exon 21, and non-classic mutations 
L861Q and R831H in exon 21 were observed 
in 6 patients. In 4 patients, mutations related to 
TKI resistance were observed (T790M, p.A767_
V769dupASV and R776H in exon 20). In one patient 
T790M was combined with L858R sensitizatizing 
mutation in exon 21. One patient carried S768I 
mutation in exon 20 with controversial association 
to TKI sensitivity. Non-smokers had more frequently 
TKI sensitivity mutations than smokers and former 
smokers (p=0.002, Fisher test), but we found no 
association between sex and mutation status. 
Conclusion: EGFR mutations related to TKI 
response were characterized from tumor samples 
in a serie of Argentinean patients with lung 
adenocarcinoma. EGFR TKI resistance mutations 
were observed in 4 patients that have no previously 
received TKI treatments. One of the strengths of 
sequencing is that it detects unknown mutations as 
well as known ones. The results showed that large-
scale screening of patients for EGFR mutations, are 
feasible to perform using DNA sequencing with the 
aim of selecting lung cancer patients who beneÀts 
from EGFR TKIs treatment. 
Keywords: EGFR, tirosine kinase inhibitors, 
Adenocarcinoma
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18.6 months. Although our analysis did not observe 
signiÀcant survival association with TTF1 expression 
categories based on IHC scoring system, there was 
modest trend to better survival associated with 
positive TTF1 expression (positive TTF1 vs negative 
TTF1: 20.37 vs 15.27 months; P>0.05). Table 1. 
Association betweenTTF1 pharmacogenetics and 
Immunohistochemical expression in Asian NSCLC 
adenocarcinoma patients. 
# SNP Genotypes TTF1 expression, n p-value 
Negative Positive 
1 -702G>A GG 8 57 0.04 
GA 2 3 
AA 1 0 
2 IVS2+470G>A GG 8 44 0.01 
GA 0 12 
AA 3 2 
3 813_814insGGCGGGGGC wt/wt 8 56 0.04 
wt/ins 0 0 
ins/ins 3 3 
Conclusion: This exploratory study showed 
that polymorphisms in the TTF-1 proto-
oncogene (-702G>A, IVS2+470G>A and 
813_814insGGCGGGGGC) have signiÀcant 
association with its expression level. Further 
investigations are needed to assess the utility of 
the identiÀed SNPs as a biomarker for the clinical 
management of lung adenocarcinoma patients. 
Keywords: Asian NSCLC adenocarcinoma, 
Polymorphisms, IHC, TTF1
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P2.146 DNA HYPERMETHYLATION IN 
PROGRESSIVE ADVANCED NON SMALL 
CELL LUNG CANCER
Milos Pesek1, Lucie Benesova2, Frantisek Bruha1, 
Radka Bittenglova1, Ondrej Fiala1, Frantisek Sefrna1, 
Marta Kopeckova2, Marek Minarik2 
1Department Of Respiratory Diseases And TB, 
University Hospital Plzen/Czech Republic, 2Center 
For Applied Genomics Of Solid Tumors, Genomac 
International/Czech Republic
Background: DNA hypermethylation of tumour-
supressor genes results in decrease of their functions 
and subsequent facilitation of tumour development. 
Epigenetic changes can play the role in cellular 
systems responsible for (i) cell cycle control, (ii) 
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P2.145 ASSOCIATION OF GENETIC 
POLYMORPHISMS WITH 
IMMUNOHISTOCHEMICAL 
EXPRESSION OF THYROID 
TRANSCRIPTION FACTOR 1 (TTF1) IN 
ASIAN NSCLC ADENOCARCINOMA 
PATIENTS.
Wan-Teck Lim1, Onkar Singh2, Edwin Sandaranaj2, 
Anupama Mahajan2, Eng Huat Tan1, Balram 
Chowbay2 
1Department Of Medical Oncology, National Cancer 
Centre Singapore/Singapore, 2Devision Of Medical 
Sciences, National Cancer Centre Singapore/
Singapore
Background: Thyroid transcription factor-1 
(TTF1) is a lineage-dependent proto-oncogene 
highly expressed in patients with adenocarcinoma. 
We evaluated the association of single nucleotide 
polymorphisms (SNPs) and immunohistochemical 
expression level of TTF1 in Asian lung 
adenocarcinoma. 
Methods: Sixty-four SNPs were identiÀed from 
healthy Asian cohorts of three ethnicities: Chinese, 
Malay and Indian. This was compared with 71 
patients with adenocarcinoma. The majority of 
the patients were of Chinese descent. The median 
age was 60 years (range: 34-85 years). Genomic 
DNA was isolated from the peripheral blood 
sample of the patients. The qualitative assessment 
of immunohistochemical expression of TTF1 
was classiÀed as nuclear expression positive and 
negative. Contingency analysis was applied to 
identify the association of TTF1 genotypes and 
IHC categories and Fisher exact test P value was 
calculated. Kaplan-Meier analysis was used to 
estimate survivorship-type functions. Parametric 
log-rank test was adopted to evaluate the possible 
difference in survival across the IHC categories. 
Results: TTF1 was highly expressed in 84% 
(N=60) of the patient samples. Among the 64 
SNPs, three SNPs [-702G>A, IVS2+470G>A and 
813_814insGGCGGGGGC] were signiÀcantly 
associated with the immunohistochemical expression 
level of TTF1 (P=0.04, 0.01 and 0.04 respectively, 
Table 1). The variant alleles (-702A, IVS2+470A 
and 813_814ins) across three SNPs were correlated 
with absence of TTF1 expression. Median overall 
survival of the patients in the present study was 
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hypermethylation, epigenetics
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.147 LUNG CANCER BIOMARKER 
CANDIDATE DISCOVERY BY 
PROTEOMIC PROFILING OF TUMOR-
NORMAL HUMAN LUNG TISSUE PAIRS
Haizhen Zhang1, Jacob Kennedy1, Lik Wee Lee1, 
Chenwei Lin1, Pin Yan1, Jeffrey Whiteaker1, Travis 
Lorentzen1, Marcs Schlesser2, Georg Wendt3, 
Khaled Chalabi3, Georges Decker4, Olivia Roland5, 
Bruno Domon6, Helen J. Ross7, Cheryl Selinsky8, 
Konstantinos Petritis8, Amanda Paulovich1, Guy J. 
Berchem9 
1Fred Hutchinson Cancer Research Center/United 
States Of America, 2Pneumology, Centre Hospitalier 
De Luxembourg/Luxembourg, 3Institut National 
De Chirurgie Cardiaque (incci)/Luxembourg, 
4Clinique Zitha/Luxembourg, 5Labortoire 
D’hémato-Cancérologie Expérimentale, Crp-santé/
Luxembourg, 6Crp-santé/Luxembourg, 7Medical 
Oncology, Mayo Clinic & Ncctg/United States 
Of America, 8Translational Genomics Research 
Institute/United States Of America, 9Hémato-
Cancérologie, Centre Hospitalier De Luxembourg/
Luxembourg
Background: Lung cancer is the main cause of 
cancer-related deaths with a worldwide mortality of 
more than one million per year. More than 2/3rds of 
the patients present with advanced and thus incurable 
disease. The introduction of biomarkers could 
be useful for every stage of the disease including 
diagnosis, prognosis, response to treatment, and 
recurrence. Modern “omics” techniques, including 
mass spectrometry-based proteomics, have shown 
tremendous utility in identifying large numbers of 
proteins as candidate biomarkers.
The wide dynamic range of concentration and 
number of proteins found in plasma make it a 
challenging matrix to perform biomarker discovery 
experiments. An alternative strategy is to perform 
biomarker discovery experiments directly in tissue, 
where mass spectrometry-based proteomics can 
tumour cell proliferation and differentiation, (iii) cell 
adhesion,invasion and metastasis, (iv) regulation 
of apoptosis, as well as (v) DNA repair gene 
transcription and detoxiÀcation of DNA adducts, 
induced by cancer chemotherapy. 
Methods: Epigenetic hypermethylations were 
detected by Multiplex ligation-dependent probe 
ampliÀcation (MLPA) technique. We investigated 
30 genes from the above mentioned cellular 
systems. Tissue samples from patients with 
clinically conÀrmed NSCLC having progressed on 
chemotherapy and targeted therapy were examined. 
Relations between methylations of genes and 
sex, cancer type and stage, smoking status and 
response to therapy were studied in detail. Statistical 
analysis was performed using contingency tables, 
chi-square test, Wilcoxon test and Kruskal Wallis 
analysis. In addition, we have evaluated effect of 
hypermethylations in EGFR and KRAS mutated 
tumours. 
Results: The study comprised 123 patients, 75 
males, 48 females,most frequent cancer types 
were adenocarcinoms (72),squamous cancers 
(32),anaplastic (9) and non speciÀed NSCLC( 10).
All of patiens suffered from tumour stages III and 
IV., more frequent were tumours of stage IV (76). 
Hypermethylation of at least one gene was found 
in 11 patients ( 90.2%).Most frequently methylated 
genes were CDH 13 in 48%,WT 1-in 38.2% , 
APC in 30.1%., RASSF1A in 30.1%, ESR 1 in 
23.6%,CDKN2B -22.8%,PAX5- 19.5%,PAX6- 
13.8%,IGSF4-11.4% and GATA5 -10.6%.
Hypermethylations were found more frequently in 
adenocarcinomas. Most common combinations of 
methylated genes were : CDH 13 and WT1, APC 
and WT1,CDH 13 and PAX6 and APC and CDH13. 
All combinations were signiÀcantly increased in 
adenocarcinomas as well as in EGFR mutated 
tumours. None of epigenetic ganges is related to 
chemotherapy and targeted treatment effectiveness, 
detailed analysis of time to progression and overall 
survival is presented. 
Conclusion: Conclusion :Epigenetic 
hypermethylations of tumour related genes in 
NSCLC are frequent and may be found in several 
different groups of genes simultaneously, particularly 
in adenocarcinomas and in EGFR mutated tumours. 
Epigenetic changes should be understood as 
evidence of diversity of lung cancer lesions and 
potentially serve as prognostic and/or predictive 
factors. This work was supported by Czech Ministry 
of Health grant IGA NS9718. 
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cancer and normal patient plasmas using also a 
mass spectrometry multiplexed assay. The selected 
potentially useful markers will then be validated in 
speciÀc clinical situations.
Keywords: proteomics, Biomarkers, Mass 
spectrometry, Lung cancer
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P2.148 LOW STROMAL CD99 
EXPRESSION IS INDEPENDENTLY 
ASSOCIATED WITH SHORTER 
SURVIVAL IN NSCLC
Karolina Edlund1, Patrick Micke1, Cecilia Lindskog1, 
Akira Saito2, Simon Ekman3, Michael Bergqvist3, 
Fredrik Pontén1, Anders Isaksson3, Hanna 
Göransson3, Karin Jirström4, Mats Lambe2, Anders 
Berglund3, Lars Holmberg5, Arne Östman2, Johan 
Botling1 
1Department Of Immunology Genetics And 
Pathology, Uppsala University/Sweden, 2Karolinska 
Institute/Sweden, 3Uppsala University/Sweden, 4Lund 
University/Sweden, 5King’s College London/United 
Kingdom
Background: The importance of the tumor stroma 
has become evident since the introduction of anti-
angiogenic therapy. The delicate interactions of 
cancer cells with stromal Àbroblasts, inÁammatory 
cells and cells of the vasculature play an essential 
role at all stages of tumorigenesis. However, beside 
angiogenic factors the mechanisms of tumor-stroma 
interactions are pooly understood. The aim of our 
study was to identify stromal proteins with clinical 
relevance in NSCLC. 
Methods: We compiled a list encompassing 200 
potential stromal candidate genes based on available 
literature and gene expression array data generated 
from lung cancer stroma after microdissection. The 
immunohistochemical protein expression of these 
genes in lung cancer was screened in the Human 
Protein Atlas (www.proteinatlas.org). Finally, 15 
proteins were selected that showed a differential 
staining pattern, i.e. variation in stromal staining 
intensity between different lung cancer samples. 
The corresponding antibodies were then applied on 
a tissue microarray (TMA) including 190 NSCLC 
samples and the stromal staining was graded with 
regard to intensity and fraction of stained cells. 
Results: Univariate and multivariate analysis 
sample a larger range and number of proteins 
emanating. The aim of this study is to build a 
biomarker candidate database for lung cancer 
prognosis using proteomics proÀling on both lung 
cancer tumors and their adjacent tissues.
Methods: Data from proteins elevated in tumors 
will be combined with genomic and transcriptomic 
data to prioritize candidates for development of 
quantitative assays to be used in clinical validation 
studies. 19 paired tissue specimens (tumor vs. 
adjacent normal lung tissue) were collected 
following a standard operating procedure. 10 pairs 
were collected from the Centre Hospitalier de 
Luxembourg, and the Cooperative Human Tissue 
Network (CHTN) procured 9 pairs. All tissues 
were shipped and stored at temperatures below 
-75 °C before sample preparation. The tissues 
were lysed and proteins were digested with trypsin 
using previously published methods. The tissue 
digests were subjected to 2-D reverse-phase HPLC 
separation (nanoACQUITY UPLC System, Waters 
Corp, Milford, MA) followed by fragmentation on 
an LTQ Orbitrap Velos mass spectrometer (Thermo 
ScientiÀc, San Jose, CA). Data analysis was 
performed using X!Tandem and OMMSA search 
engines, as well as Xpress for label free quantitative 
analysis.
Results: Initial experiments have identiÀed more 
than 4,000 proteins in tumor and normal tissues. 
Approximately 30% more proteins were identiÀed in 
tumor tissues compared to adjacent “normal” tissues, 
with more than 1,000 proteins found exclusively 
in tumors. Quantitative analysis demonstrated 
high MS1 peak intensity correlations across all 
patients for both tumor and normal sample types. 
Further statistical analysis on the discovery data 
established a list of 140 proteins whose abundance 
was signiÀcantly elevated in tumors. In addition, 
proteomic analysis will be conducted on other types 
of samples from lung cancer patients including 
plasma and pleural effusion Áuid, as well as plasma 
from mice xenografted with human lung tumor 
tissues. Candidate biomarkers will be veriÀed using 
immunoafÀnity enrichment of peptides coupled 
to stable isotope dilution and selected reaction 
monitoring mass spectrometry.
Conclusion: Using this state of the art mass 
spectrometry based proteomic discovery strategy we 
establish extensive lists of potentially new plasma 
biomarkers for use in diagnosis and management 
of lung cancer patients. These biomarkers will then 
be veriÀed using a set of several hundred of lung 
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resectable NSCLC patients and to correlate them 
with clinico-pathological variables and prognosis. 
Methods: RNA was obtained from tumor and 
normal lung specimens from 150 resectable NSCLC 
patients. RT-PCR was performed to assess the 
expression of PIGF, VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3, NRP1 
and NRP2. Relative expression was normalized 
by an endogenous gene (GUS) using the PfafÁ 
formulae. Differences were considered statistically 
signiÀcant at p<0.05. 
Results: We found that tumor samples had a 
signiÀcant higher expression of PIGF and lower 
expression of VEGF-D compared to normal tissue 
(2.55X and 0.030X, respectively). The survival 
analysis revealed that the group of patients with 
high expression of VEGF-A had a signiÀcantly 
reduced TTP (p=0.028) and OS (p=0.008) whereas 
those with values of VEGF-D or VEGF-B below the 
median had reduced OS rate (p=0.004 and p=0.063, 
respectively). Moreover, a subgroup of patients 
characterized by a combination of high expression of 
VEGF-A and low VEGF-D had the worst prognosis 
in terms of TTP (p=0.029) and OS (p<0.0001) 
when compared with other possible combinations 
of both markers. A multivariable Cox regression 
model was built using variables found signiÀcant in 
the univariate analysis. The Cox analysis revealed 
that tumor size, histology and the combined 
variable (VEGF-A and VEGF-D) were independent 
prognostic markers for TTP; whereas nodal status, 
histology and the combined variable (VEGF-A and 
VEGF-D) were independent prognostic markers for 
OS (see table). Table: Multivariate Cox regression 
analysis for TTP and OS 
Variables TTP OS 
HR 95% CI p HR 95% CI p 
Tumor size 2.017 1.05-3.87 0.035* - - - 
Histology 1.865 1.20-2.89 0.005* 1.473 1.01-2.16 0.047* 
High VEGF-A & Low 
VEGF-D 2.733 1.42-5.28 0.003* 2.759 1.49-5.12 0.001* 
Nodal status - - - 1.922 1.05-3.51 0.034* 
HR, hazard ratio; CI, conÀdence interval; *p<0.05, 
statistically signiÀcant. 
Conclusion: VEGF family members are 
master control genes of the angiogenic and 
lymphangiogenic processes and may have a crucial 
role in the prognostic of the disease. We found a 
markedly lower expression of VEGF-D in tumor 
samples compared with normal lung tissue that needs 
to be further investigated. Moreover, the combination 
revealed that strong stromal CD99 expression 
correlated with good prognosis (OR = 2.0 CI: 1.0-
3.8). This association was independent of the relative 
amount of tumor stroma, the amount of inÁammatory 
cells and clinical and pathological parameters 
such as stage and performance status. The relevant 
prognostic impact of stromal CD99 expression was 
further conÀrmed in an independent TMA cohort 
of 240 lung cancer cases (p= 0.017). Furthermore, 
utilizing double staining Áuorescence microscopy, 
we showed that CD99 is differentially expressed in 
stromal lymphocytes as well as in cancer associated 
Àbroblasts. 
Conclusion: We identiÀed the membrane protein 
CD99 (also known as MIC2) as a novel stromal 
factor with prognostic relevance in NSCLC. Further 
studies are warranted to elucidate the functional role 
of CD99 expression in tumorigenesis.
Keywords: tumor stroma, CD99, Prognosis, tissue 
microarray
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P2.149 EXPRESSION OF ANGIOGENIC 
AND LYMPHANGIOGENIC GENES 
AS BIOMARKERS OF PROGNOSIS IN 
EARLY-STAGE NSCLC
Elena Sanmartin1, Eloisa Jantus Lewintre2, Rafael 
Sirera3, Sandra Gallach2, Marta Usó2, Ana Blasco4, 
Cristina Hernando4, Eugenio Palomares4, Ricardo 
Guijarro5, Carlos Camps4 
1Molecular Oncology Laboratory, General 
University Hospital Research Foundation/
Spain, 2Molecular Oncology Laboratory, General 
University Hospital Research Foundation, Valencia/
Spain, 3Biotechnology, Polytechnic University Of 
Valencia/Spain, 4Oncology, General University 
Hospital/Spain, 5Thoracic Surgery, General 
University Hospital/Spain
Background: Angiogenesis, the formation of 
new blood vessels from pre-existing vasculature, 
begins in early stages of the disease and is a key 
step in tumor growth and metastasis. Tumor cells 
dissemination from the primary tumor may also 
occur through the lymphatic system. The process 
of angiogenesis and lymphangiogenesis are mainly 
regulated by VEGF family members. The aim of 
the present study was to analyze the expression of 
angiogenic/lymphangiogenic genes in a cohort of 
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equilibrative nucleoside transporter-1 (hENT1), 
deoxycytidine-kinase (dCK), 5’-nucleotidase (5’-
NT), cytidine-deaminase (CDA), and ribonucleotide-
reductase subunits (RR1 and RR2) were analyzed 
by quantitative-RT-PCR in fresh microdissected 
tumor specimens collected before treatment. 
Frequency distribution of responses above and below 
the median level of biomarkers expression were 
compared using a two-sided Fisher’s exact test 
Results: Patients were treated for at least 2 cycles. 
The best overall responses observed were a 
complete remission in one case (1.7%), 28 (48.8%) 
partial responses and 18 (31.1%) stable diseases, 
while 11 patients experienced disease progression. 
By adopting cut-off values according to median 
expression levels, among all the studied genes, 5’-
NT was the only gene differently expressed in the 
responders (complete and partial response) and no 
responders (stable and progressive disease) patients 
(p=0.016). Indeed, the overexpression of this 
catabolic enzyme was signiÀcantly associated to a 
poor response to treatment. 
Conclusion: This is the Àrst study to demonstrate 
the role of 5’-NT expression on the efÀcacy of 
gemcitabine-cisplatin treatment. The validation of 
this role in future prospective multicenter trials will 
offer new tools for treatment optimization of currently 
available treatments in selected NSCLC patients. 
Keywords: 5-NT, Resistance, platinum/gemcitabine
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P2.151 EML4-ALK FUSION GENE 
IN LUNG ADENOCARCINOMA IN 
THAILAND
Thongbliew Prempree 
Oncology And Gene Therapy Center, Piyavate 
Hospital/Thailand
Background: The EML4-ALK fusion gene 
represents the most recent Molecular Targets 
in NSCLC. Attempts have been made to utilize 
this fusion gene as the prognostic and predictive 
indicator for the treatment of Non-Small-Cell-lung-
Cancer. In the past, we have learned the signiÀcance 
of EGFR, VEGF and KRAS mutations to success 
and failure of NSCLC treated by TKI such as Irressa 
or Tarceva. With the arrival of EML4-ALK fusion 
gene detection, we ask “Should we examine EML4-
ALK fusion gene in all NSCLC prior to starting the 
of high expression of VEGF-A and low expression 
of VEGF-D identiÀed a NSCLC subgroup with 
a poorer prognosis in our cohort of early-stage 
NSCLC. Supported by grants PS09-01149 and 
RD06/0020/1024 from ISCIII. 
Keywords: Prognosis, NSCLC, angiogenesis, 
lymphangiogenesis
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P2.150 5’-NUCLEOTIDASE (CN-II) 
EMERGES AS A NEW PREDICTIVE 
BIOMARKER OF RESPONSE IN 
THE GEMCITABINE-CISPLATIN 
TREATMENT OF NON-SMALL CELL 
LUNG CANCER
Francesca Toffalorio1, Tommaso De Pas2, Elisa 
Giovannetti3, Davide Radice2, Gianluca Spitaleri2, 
Domenico Galetta2, Michela Manzotti2, Romano 
Danesi3, Giuseppe Pelosi4, Lorenzo Spaggiari2, 
Filippo De Braud2 
1Medical Oncology Unit Of Respiratory Tract And 
Sarcomas, New Drug Development Division, European 
Institute Of Oncology/Italy, 2European Institute Of 
Oncology/Italy, 3University Of Pisa/Italy, 4National 
Cancer Institute And University Of Milan/Italy
Background: Pharmacogenetics/genomics studies 
aimed at identify predictive biomarkers have given 
contradictory results in patients with non-small 
cell lung cancer (NSCLC). A possible explanation 
might reside in studies focussed on single candidate 
biomarkers, explored in small size series, without 
standardized unbiased methods, as well as in 
different settings for tumor type, stage and evaluation 
of treatment outcome. 
Therefore we evaluated whether the expression 
levels of all the pivotal genes involved in 
chemosensitivity/resistance to platinum and 
gemcitabine, studied by validated real-time PCR 
methods in laser-microdissected specimens, 
inÁuenced tumor response in patients with NSCLC 
uniformly treated with gemcitabine-platinum-based 
regimens. 
Methods: Response rate was evaluated, according 
to the Response Evaluation Criteria in Solid Tumors 
(RECIST), in 58 chemonaive patients affected 
stage III (50) and IV (8) NSCLC who received 
a platinum and gemcitabine regimen. Excision 
repair cross-complementing 1 (ERCC1), human 
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Background: Antiangiogenic molecules can inhibit 
neovascularization in lung cancer, but their effect 
on circulating endothelial progenitor cells(cEPCs) 
is still unclear. Several hypotheses have been 
proposed that antiangiogenic drugs enhance the 
treatment efÀcacy of cytotoxic chemotherapy, 
including impairing the ability of tumors to regrow 
after therapy. Therefore, our study aims to examine 
the level of cEPCs (VEGFR2+ /CD133+) in the 
peripheral blood of resectable non-small cell 
lung cancer patients(NSCLC) treated by either 
chemotherapy combined with endostar(recombinant 
human endostatin) or chemotherapy alone as 
adjuvant therapy.
Methods: Thirty three patients with resectable 
NSCLC were enrolled. Ten healthy individuals 
were as control. The blood samples of the patients 
were from a clinical trial(NCT01124253). Among 
them,18 patients treated by chemotherapy alone 
and 15 patients treated by chemotherapy combined 
with endostar. Peripheral blood was taken from 
the patients before surgery and after postoperative 
adjuvant therapy. Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll density gradient 
centrifugation. cEPCs labeled with VEGFR2, CD133 
were counted by Áow cytometry. Furthermore, we 
measured VEGFR2, CD133, CD34, and VE-cadherin 
mRNA in blood samples by means of a quantitative 
reverse transcription-PCR approach.
Results: The percentage of cEPCs in the total 
PBMCs was 0.26%±0.14% in NSCLC patients 
without treatment intervention versus 0.045±0.032% 
in healthy controls( p = 0.00). There was a signiÀcant 
difference of cEPCs numbers in stage I—II 
compared with III ( p = 0.027) in the preoperative 
blood samples. The cEPCs numbers were signiÀcant 
lower in the combination therapy group than in 
chemotherapy alone group in the postoperative 
blood samples (p=0.014). Time to disease 
progression(TTP) in the patients with low cEPCs 
number (less than 0.35%) was longer than in those 
with high cEPCs number after adjuvant treatment 
(p =0.00, log rank). The preoperative VEGFR2 
mRNA level was signiÀcantly correlated to disease 
progression ( p = 0.00, log rank test). 
Conclusion: This study showed that NSCLC 
patients had high cEPCs numbers. An early 
antiangiogenic therapy in combination with 
chemotherapy may be beneÀcial for the success of 
resectable NSCLC adjuvant therapy, and cEPCs 
may be a novel biomarker in those patients with no 
measurable targets. 
targeted therapy ?”
Methods: Materials and Methods : 66 lung 
Adenocarcinoma patients’ cancer tissue ( 36 male 
, 30 female ) were screened for EGFR protein 
Overexpression and EML4-ALK expression using 
Immunohistochemical (IHC) technique. EML4-
ALK positivity was further conÀrmed by DNA 
sequencing. EGFR and KRAS mutations were 
identiÀed by DNA sequencing. Targets selection for 
the treatment was done according to genotype. 
Results: Of 66 cancer tissues of NSCLC screened, 
5 cases (7.5%) habored EML4-ALK fusion gene, 5 
cases (7.5%) habored KRAS mutation and 42 (63%) 
habored EGFR mutations. 14 cases (21%) had no 
EGFR mutations but had cKIT and HER2 protein 
Overexpression and gene mutations. Interestingly 
enough, 5 cases who carried EML4-ALK fusion gene 
did not have any EGFR and KRAS mutations. Those 
with EGFR mutations responded to the treatment by 
TKI very well at the rate of 83% (35/42), while those 
with KRAS mutation failed the treatment. 5 cases 
of EML4-ALK fusion gene were excluded from the 
targeted therapy and used chemotheray instead with 
relatively good response 40% (2/5).
Conclusion: Discussion and Conclusion: NSCLC 
with EML4-ALK fusion gene represented a subset of 
lung Adenocarcinoma with unique gene feature and 
clinical feature. This entity should be be identiÀed 
and if found must be treated differently in order 
to acheive success. IdentiÀcation of EML4-ALK 
and KRAS in NSCLC along with EGFR mutations 
should be done routinely prior to TKI or targeted 
therapy to obtain the best possible results. Yes 
EML4-ALK fusion gene should be use as Prognostic 
and Predictive indicators in NSCLC treatment. 
Details of the study will be given in the presentation.
Keywords: EML4-ALK fusion gene, lung cancer 
with EML4-ALK gene
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P2.152 CIRCULATING ENDOTHELIAL 
PROGENITOR CELLS IN RESECTABLE 
NON-SMALL CELL LUNG CANCER 
DURING ADJUVANT CHEMOTHERAPY 
COMBINED WITH ENDOSTAR
Yongfeng Yu, Zhengbo Song, Shun Lu 
Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China
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adenocarcinoma histology (P=0.0343). Correlation 
between clinical parameters and EGFR mutations 
and prognosis are being analyzed. 
Conclusion: The incidence of EGFR mutation 
among the northern Thai lung cancer patients 
is similar to the incidence of EGFR mutation 
worldwide. EGFR mutation status is statistically 
associated with female or adenocarcinoma histology. 
Keywords: Lung cancer, EGFR, Northern Thailand, 
Clinical parameters
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.154 ESTROGEN RECEPTOR 
BETA IN NON-SMALL CELL LUNG 
CANCER AS A MOLECULAR TARGET 
FOR ANTIESTROGEN THERAPY 
– EXPRESSION AND GENDER 
DIFFERENCES
Tatiana A. Bogush1, Alexandra S. Shaturova1, 
Evgeny A. Dudko1, Elena A. Bogush1, Eler E. 
Juraev2, Boris E. Polotsky2, Sergey A. Tjulandin3, 
Mikchail I. Davydov2 
1Laboratory Of Medical Chemistry, N.N. Blokhin 
Russian Cancer Research Center Of The Russian 
Academy Of Medical Sciences/Russian Federation, 
2Surgical Department, N.N. Blokhin Russian Cancer 
Research Center Of The Russian Academy Of 
Medical Sciences/Russian Federation, 3NNn. Blokhin 
Russian Cancer Research Center Of The Russian 
Academy Of Medical Sciences/Russian Federation
Background: Recent investigations demonstrate 
important role of estrogens in occurrence and 
progression of non-small cell lung cancer (NSCLC) 
as well as expression in the lung tumor tissue of 
estrogen receptor beta (ERbeta) that are a good 
prognostic markers of NSCLC. Thus, ERbeta seems 
to be important pathogenetic factor of NSCLC and 
target for antiestrogen therapy. But the data about 
ERbeta in the NSCLC are not numerous till now 
and results differ signiÀcantly because of using 
semiquantitative methods for estimation only. That is 
why we have developed a new immunoÁuorescence 
Áowcytometry methodology for quantitative 
evaluation of ERbeta expression and used it for 
Keywords: circulating endothelial progenitor cells, 
Lung cancer, Chemotherapy, neovascularization
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P2.153 MUTATION ANALYSIS OF EGFR 
GENE OF LUNG CANCER PATIENTS IN 
THE NORTHERN THAILAND
Witthawat Ariyawutyakorn1, Ekkapong 
Roothumnong2, Nirush Lertprasertsuke3, 
Somcharoen Saeteng4, Kanokkan Bumroongkit5, 
Daoroong Kangwanpong2, Sumitra Thongprasert1 
1Medical Oncology, Department Of Internal 
Medicine, Faculty Of Medicine, Chiang Mai 
University/Thailand, 2Biology, Faculty Of Science, 
Chiang Mai University/Thailand, 3Pathology, 
Faculty Of Medicine, Chiang Mai University/
Thailand, 4Surgery, Faculty Of Medicine, Chiang 
Mai University/Thailand, 5Anatomy, Faculty Of 
Medicine, Chiang Mai University/Thailand
Background: Mutations in the tyrosine kinase 
domain of epidermal growth factor receptor (EGFR) 
is mandatory for dramatic responses to EGFR 
tyrosine kinase inhibitors either geÀtinib or erlotinib. 
Lung cancer patients who have mutant EGFR also 
have better responses to systemic chemotherapy and 
longer survival than those who do not have mutation. 
This study aims to investigate the incidence of 
EGFR mutation at tyrosine kinase domain among the 
northern Thai lung cancer patients. 
Methods: Tumor tissues were obtained 
retrospectively from parafÀn blocks of 68 non-small 
cell lung cancer patients who received surgical 
resection at Maharaj Nakorn Chiangmai Hospital, 
Faculty of Medicine, Chiang Mai University between 
January 2007 and December 2009. Tissues were 
subjected to DNA extraction, DNA ampliÀcation by 
polymerase chain reaction and followed by direct 
sequencing. Clinical parameters, including age, sex, 
smoking, histology and TMN stage, were analyzed 
to identify the correlation between these parameters 
and EGFR mutations. 
Results: Ten EGFR mutations were found in 18 out 
of 68 patients (26.47%). Six of which, delE746 – 
A750, delL747 – S752insQ, A839T, V851I, E868G 
and L858, were previously reported mutations. The 
other four, L688F, A722T, G724D and P848S, were 
novel mutations. EGFR mutation status was statistic 
signiÀcant associated with female (P=0.0038) or 
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00551 and N 11-04-00542). 
Keywords: Non-small cell lung cancer, estrogen 
receptor beta, immunoÁuorescence, Áow cytometry
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P2.155 L861Q HETEROZYGOUS 
MUTATION IN EXON 21 MAYBE 
PROMINENT IN PULMONARY 
MUCOEPIDERMOID CARCINOMA
Shun Lu1, Zhengbo Song1, Yongfeng Yu1, Jie Zhang2 
1Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China, 2Department Of Pathology, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China
Background: The incidence of pulmonary 
mucoepidermoid carcinoma PMECï is extremely 
rare. Little is known about its molecule events . 
Although it usually has an indolent behavior, some 
PMEC show more aggressive, with 5-year survival 
as low as 30% for the high-grade or nodes metastasis 
patients. Epidermal growth factor receptor(EGFR) 
mutation status is common in East Asia non-small 
cell lung cancer, but it is unknown for EGFR 
mutation status in PMEC, which has the same 
histological origin from pulmonary epithelium .The 
aim of this study is to detect the EGFR mutation 
status in PMEC so as to discuss the feasibility of 
targeted treatment in this disease.
Methods: From January 2001 through December 
2009, 20 PMEC patients (11 male and 9 female) 
were treated in our center. All of the patients were 
treated with surgery and diagnosed by pathology. 
Sequencing analysis was used to exam exons18-21 
of the EGFR gene mutation.
Results: The exon21 L861Q heterozygous deletion 
mutation was found in Àve patients. The most 
homonymy mutation type was in exon20, an 
SNPc.2607GA (p.Q787Q) was detected in nine 
out of 20 tumor samples . None case was with a 
heterozygous exon19 deletion mutation. One case 
was with a homonymy exon18 mutation (I760I). Six 
cases had no mutation among the 20 patients.
Conclusion: As a meaningful rare EGFR mutation 
type, L861Q heterozygous mutation in exon21 may 
be a potential target of EGFR-directed treatment in 
pulmonary mucoepidermoid carcinoma. The further 
studies are needed in the future.
study ERbeta expression in the NSCLC patients – 
totally and separately in female and male because of 
well known gender differences in NSCLC disease 
progress. 
Methods: NSCLC surgical biopsy specimens of 
32 patients (16 women and 16 men) were analyzed 
by Áowcytometry. Single-cell suspensions were 
incubated with primary and isotype antibodies 
(anti-ERbeta 14C8 and IgG2a, Abcam) overnight 
and with secondary FITC-conjugated antibody 
(F2772,Sigma) for 1.5h. Mean cell Áuorescence and 
number of stained cells were analyzed with WinMDI 
software and Kolmogorov-Smirnov statistical 
approach respectively. ERbeta expression was 
estimated as ratio of the speciÀc parameter (level 
or intensity) to the same isotype one. MCF-7 cell 
culture was characterized and used as a reference for 
the antibody activity control. Three levels of ERbeta 
expression rate were used for the comparison: high 
– more than in 50% of the cells; moderate – in 30-
49%; low – less than in 30% of the cells. 
Results: Generally in all the NSCLC patients 
investigated ERbeta was revealed in about 80% 
of cases with signiÀcant differences in intensity of 
ERbeta expression in various tumors – from 8% to 
77%. Low ERbeta expression was shown in 44%, 
high – in 18% and moderate ERbeta expression 
– in 38% of patients. 2. In women mean ERbeta 
expression level was in about 1,4 times higher 
as compared to men (37% and 27% of patients 
respectively). 3. High ERbeta rate was revealed more 
frequently in women than in men – in 31% and 6% 
of patients respectively. Moderate ERbeta expression 
rate was also often in women than in men – in 50% 
and 31% of patients respectively. Antipodal, low 
ERbeta expression rate was revealed more frequently 
in women than in men – in 19% and 63% of patients 
respectively. 4. The same gender differences were 
shown for high, moderate and low intensity of 
ERbeta expression. 
Conclusion: 1. NSCLC is characterized by ERbeta 
expression in most of the patients with high and 
moderate level in about half of cases. 2. Higher 
ERbeta expression in women than in men could 
be one of the reasons of the gender differences in 
NSCLC disease progress. 3. We believe that at least 
half of the NSCLC patients (especially women) 
with ERbeta expression could beneÀt from adjuvant 
antiestrogen treatment. Thereby of ERbeta have to 
be obligate index among the other tumor markers 
studying in NSCLC patients. Supported by Russian 
Foundation for Basic Research (Grants N 10-04-
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regulated in tumor tissue and genes were down-
regulated.Compared to our macroscopic samples, 
in our LCM sampleset for the adenocarcinoma 
carcinoma, only a minority (-%) of genes appeared 
up- or down-regulated in both conventional 
macroscopic, and laser microdissected samples. 
The squamous cell carcinoma results are being 
analyzed. The top (based on LCM fold-change) up 
and down-regulated candidates for adenocarcinoma 
carcinoma are listed here in Column , and compared 
to macroscopic tissues in Column . [FC=fold change 
tumor versus nontumor]. 
Gene.Symbol FC LCM adj.P.Val LCM FC Macro 
SPINK . 33.9 . 0.012 . 7.8 
OCIAD . 5.9 . 0.000 . 2.6 
--- . 5.4 . 0.018 . 1.1 
SNORAA . 4.6 . 0.026 . 1.7 
--- . 3.6 . 0.006 . 1.5 
BAIAPL . 3.4 . 0.036 . 1.7 
GOLM . 3.4 .0.049 . 2.5 
MUC . 3.2 . 0.006 . 1.5 
EHF . 3.1 . 0.041 . 1.7 
DEPDC . 3.1 . 0.013 . 1.6 
WIF -. -6.5 . 0.006 -. -4.5 
GMFG -. -6.6 . 0.048 -. -1.5 
ABIBP -. -6.6 . 0.003 -. -2.6 
MRC -. -7.8 . 0.034 -. -1.7 
PECAM -. -8.5 . 0.014 -. -2.1 
HBB -. -8.6 . 0.038 -. -2.9 
FMO -. -9.1 . 0.003 -. -3.0 
CAV -. -9.6 . 0.003 -. -2.9 
FABP -. -12.5 . 0.007 -. -8.6 
SFTPC -. -22.6 . 0.008 -. -3.2 
Conclusion: LCM-coupled microarray expression 
proÀling identiÀes a large number of differentially 
expressed transcripts that are distinctly different 
from macroscopic lung tissue samples, suggesting 
that admixture from stromal cells in tumors likely 
is a signiÀcant confounder for expression signatures 
of lung cancer. This implies requisite caution when 
looking at conventional discovery datasets for cancer 
signatures. A microdissected bronchial epithelium 
dataset is currently being accrued to reÀne these 
results. Layering with epigenome-wide data is 
ongoing. 
Keywords: Microarray, transcriptome, Laser 
microdissection, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.156 TRANSCRIPTOME 
COMPARISONS OF LASER 
MICRODISSECTED VS. MACROSCOPIC 
LUNG SAMPLES.
Gaby Marquardt1, Nandita Mullapudi1, Juan Lin2, 
Tao Wang2, Miao Shi1, Simon Spivack1 
1Pulmonary Medicine, Albert Einstein College Of 
Medicine/United States Of America, 2Biostatistics, 
Albert Einstein College Of Medicine/United States 
Of America
Background: Determining cell-speciÀc expression 
patterns in transcriptome discovery endeavors 
may be important for the precision of cancer cell 
signatures. Here we describe the use of an expression 
microarray study on non-small cell lung cancer 
(NSCLC) samples and surrounding tissue, comparing 
macroscopic lung tumor and tissue samples (“grind 
and bind”), versus tumor and alveolar compartment 
cells laser capture microdissected (LCM) from the 
same macroscopic lung samples. 
Methods: An initial set of 32 pairs of 
macroscopic tumor and non-tumor samples (18 
pairs adenocarcinoma, 14 pairs squamous-cell 
carcinoma,) was selected for bulk/macro sampling. 
Of these, all were reanalyzed using laser capture 
microdissection (LCM) for sampling the tumor 
(T) and nontumor (NT) cells. For macroscopic 
samples, 50 to 80 g of tissue was used to isolate 
total RNA. Gene expression proÀle was determined 
using Affymetrix Human Genome Gene 1.0 ST 
genechip. For the LCM samples, from representative 
slides histologically conÀrmed and mapped by a 
pathologist, approximately 1000 tumor or nontumor 
alveolar cells/sample were collected by LCM; 
too few bronchial cells were available to analyze 
by microarray in this Àrst sampleset. cDNA was 
ampliÀed using Nugen Pico ampliÀcation system. 
QA at each step was rigorous, replicates performed, 
and individual samples or batches discarded if sub-
optimal. 
Results: Genes that were differentially expressed 
at least x with an adjusted p-value <. were selected 
as candidate genes. From our macroscopic sample 
set, in the adenocarcinoma group genes were up-
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P2.158 METHYLATION EVENTS IN 
LUNG CANCER: WHOLE GENOME 
EXPLORATIONS OF PAIRED TUMOR 
AND NON-TUMOR CLINICAL SAMPLES
Nandita Mullapudi1, Masako Suzuki2, Melissa 
Fazzari2, Simon Spivack1 
1Pulmonary Medicine, Albert Einstein College Of 
Medicine/United States Of America, 2Genetics, 
Albert Einstein College Of Medicine/United States 
Of America
Background: In lung cancer, hypermethylation of 
speciÀc gene promoters is found during the early 
histological stages. Thus far, surveys of methylation 
have focused on speciÀc gene panels (e.g., 5–20 
genes) while some large-scale studies have examined 
longer gene lists or larger sets of CpG islands. To 
explore common methylation events on a genome-
wide scale, we analyzed the methylation proÀles 
of paired tumor and non-tumor samples using the 
HELP assay, which yields information on 1.2 million 
fragments throughout the genome.
Methods: The HELP (HpaII tiny fragment Enriched 
by Ligation mediated PCR) assay is based on 
restriction enzyme libraries generated by methylation 
sensitive (HpaII) and methylation insensitive (MspI) 
isoschizomers and allows robust assessment of 
methylation status by comparing ratios of HpaII 
to MspI-generated fragments co-hybridized to a 
Nimbelgen custom high-density microarray. A 
wet-lab platform and a bioinformatic and statistical 
pipeline exist at our institution for this purpose. 
Because of template requirements, (3ug total DNA), 
only macroscopic tumor and non-tumor samples 
were rexamined. 
Results: Preliminary analyses of 9 paired 
Adenocarcinoma samples separated tumor and 
non-tumor samples into clades based on their 
HpaII fragment proÀles, although some exceptions 
were observed. We identiÀed 1921 fragments 
(corresponding to 2 CpG sites each) that were highly 
signiÀcant (p=5e-4). Of these, 1781 (93%) were 
hypermethylated in tumor, with the vast majority 
occurring within the gene body or promoter (1234 
loci and 199 loci, respectively). In the opposite 
direction, 140 fragments were signiÀcantly 
hypomethylated in tumor. Of these, 44 were located 
within gene bodies, 3 within non-CGI promoters, and 
93 within repetitive regions. We could identify both 
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P2.157 SIGNIFICANCE OF DELTA-
LIKE LIGAND 4 (DLL4) ON THE 
ANGIOGENESIS IN NON-SMALL CELL 
LUNG CANCER
Yuji Hirami, Katsuhiko Shimizu, Takuro Yukawa, Ai 
Maeda, Koichiro Yasuda, Masao Nakata 
General Thoracic Surgery, Kawasaki Medical 
School/Japan
Background: Delta-like ligand 4 (Dll4) is a Notch 
ligand that is upregulated by vascular endothelial 
growth factor (VEGF) and hypoxia, and is reported 
to have a role in normal embryonic vascular 
development and in tumor angiogenesis. However, 
few studies have investigated the role of Dll4 in non-
small-cell lung cancer (NSCLC). The aim of this 
study was to characterize the expression of Dll4 in 
NSCLC and to assess whether it is associated with 
other angiogenesis, or hypoxic markers.
Methods: ParafÀn-embedded samples of 35 
patients (21 male, 14 female; median age 71 
years) undergoing complete surgical resection 
for pathological IA-IIIA NSCLC were studied 
retrospectively. Immunohistochemistry was used to 
evaluate the expression of the angiogenesis markers, 
including Dll4, VEGF, CD34, platelet-derived 
growth factor receptor (PDFGR)-beta, and hypoxia-
inducible factor (HIF)-1alpha.
Results: The Dll4 expression was observed 
preferentially in the cytoplasm in 57.1% (20 out of 
35) of NSCLC. The expression was not signiÀcantly 
associated with any clinicopathological factors, 
including age, sex, smoking history, histology, 
differentiation, vascular invasion, lymphatic 
permeation, and pathological stage. The Dll4 
expression showed a signiÀcant correlation with the 
VEGF expression (P=0.0024), but did not have any 
correlations with other angiogenesis and hypoxic 
markers. In the cases which expressed VEGF, the 
Dll4 expression was signiÀcantly associated with 
PDGFR-beta expression (P=0.014).
Conclusion: Dll4 is expressed with more than half 
of NSCLC samples, and the expression is associated 
with VEGF. Under VEGF signaling, Dll4 may have 
an important role to induce PDGFR-beta, which 
increase endothelium in NSCLC.
Keywords: DLL4, NSCLC, angiogenesis
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Real-time PCR for gene mutations in exon 19 and 
exon 21 or by Fluorescence in situ hybridization 
(FISH) for gene ampliÀcation. Chi-square (Ƶ2) test 
was performed to analysis the relevance between 
EGFR mutation and gene ampliÀcation in different 
variables. 
Results: The median age was 59 yrs (range: 29-80). 
There were 138 males (67%) and 67 (33%) females. 
Fifty-eight percent (119) of patients were smokers 
and 42% (86) were non-smokers. All the surgical 
specimens were identiÀed with adenocarcinoma in 
147, squamous-cell carcinoma in 52, adenosquamous 
carcinoma in 3, sarcomatoid carcinoma in 2, and 
lymphoepithelioma-like carcinoma in 1. Eleven 
percent (23) of patients pathologically presented 
in stage IA , 30% (62) in stage IB , 3% (5) in stage 
IIA , 12% (25) in stage IIB , 25% (51) in stage IIIA 
, 9% (19) in stage IIIB and 10% (20) in stage IV. 
The mutation frequency in EGFR was 32% (66 
of 205 patients), including deletions in exon 19 
(16%) and point mutations in exon 21 (16%). EGFR 
mutations occured in 60% of females versus 19% of 
males (P=0.000), 57% of non-smokers versus 14% 
of smokers (P=0.000), and 43% of patients with 
adenocarinoma versus 5% of non-adenocarcinoma 
(P=0.000). EGFR gene ampliÀcation was detected 
in 62128 of 205) of patients. The ampliÀcation 
frequency was not associated with age (P=0.624), 
gender (P=0.112), pathological subtype (P=0.190), 
smoking status (P=0.209) and stage (P=0.127). 
No relevance was observed between either EGFR 
gene mutation or ampliÀcation and tumor markers 
including CEA, SCC, NSE, CyFra21-1, and TSGF. 
There was a signiÀcant relevance between EGFR 
gene mutation and gene ampliÀcation (P=0.000). In 
patients with positive mutations, 86% ( 57 of 66) of 
patients involved in gene ampliÀcation. Instead, 45% 
(57 of 128) of patients with positive ampliÀcation 
involved gene mutations. 
Conclusion: EGFR mutations are more common 
in Chinese patients with adenocarcinomas, 
nonsmokers and females.. EGFR gene ampliÀcations 
harbor a high frequency in Chinese patients but 
no relevance is observed between ampliÀcation 
and clinicopathological characteristics.. There is 
signiÀcant relevance between gene mutations and 
ampliÀcations. The EGFR mutation should be used 
as a clinical decision parameter to predict response to 
EGFR-tyrosine kinase inhibitors. 
Keyword: NSCLC, EGFR gene 
mutation,ampliÀcation,
known (e.g: HIC1, TYMS) and as yet unreported 
genes (e.g: (DICER1, HIST1H2AB, HIST1H3C) 
hypermethylated in their promoter regions in tumor 
versus non-tumor.
Conclusion: We show that individual methylation 
events are common in the adenocarcinoma 
genome, and can help differentiate adenocarcinoma 
from surrounding parenchyma. We are currently 
expanding our sample set, including squamous 
cell carcinoma, working on bisulÀte sequencing 
validation of methylation at select loci, functionally 
evaluating those high-resolution loci, as well as 
embarking on integration with other genome-wide 
epigenetic and expression data. Supported by NIH-
5RC1-CA14542 
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P2.159 THE RELEVANCE 
BETWEEN EGFR GENE 
MUTATION AND AMPLIFICATION 
IN CLINICOPATHOLOGICAL 
CHARACTERISTICS IN CHINESE WITH 
NSCLC
Lan J. Zhang1, Ling Cai2 
1Thoracic Surgery, Cancer Centre, Sun Yat-sen 
University/China, 2Radiation Oncology, Cancer 
Centre, Sun Yat-sen University/China
Background: Epidermal growth factor receptor 
(EGFR)-targeted therapy takes an important role 
in the treatment of patients with non-small cell 
lung cancer (NSCLC).. The EGFR mutation and 
ampliÀcation are predictive of response to different 
races with EGFR-targeted therapy. This study 
purposed to investigate the relevance between 
gene mutation and gene ampliÀcation regarding on 
clinical proÀles and pathological characteristics in 
Chinese NSCLC patients. 
Methods: Tumors from 205 operated patients 
of NSCLC from Nov, 2009 to Jan, 2011 were 
selected to determine EGFR gene mutations and 
ampliÀcations. All these subjects had detailed 
demographic and clinical information available from 
Sun Yat-sen University Cancer Center Surveillance 
System. All the tissues were detected either by 
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miR-625, miR-21 and others. Comparing our top 28 
miRNAs with the top 43 miRNAs from Yanaihara/
Harris Cancer Cell 2006 using spotted microarrays, 
we found Àve miRNAs in common; the direction of 
T-NT differences of three of these common miRNAs 
(miR-21, miR-210 and miR-212) were the same. 
Conclusion: MicroRNA expression proÀling was 
performed by high-throughput sequencing, revealing 
28 miRNAs with obvious statistical differences in 
expression between lung tumors and non-tumor 
tissues. Our microRNA expression signature 
was quite different from that of Yanaihara/Harris 
Cancer (Cell 2006) perhaps in part the platform 
(next gen sequencing) differs from Yanaihara’s data 
(microarray), and in part because our data are from 
lung adenocarcinoma tumor tissues only (versus 
all histologies of NSCLC). Studies are ongoing to 
construct small RNA libraries from additional T-NT 
pairs, to validate the results with realtime PCR, and 
to generate microRNA:mRNA inverse correlations to 
test experimentally, using afÀnity binding assays and 
exogenous expression approaches we are developing. 
Keywords: next-gen sequencing, gene regulation, 
microRNA
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P2.161 SERAL ESTRADIOL LEVELS 
IN SQUAMOUS AND ADENOMOUS 
LUNG CANCER AND EXPRESSION 
AND CLINICAL PATHOLOGICAL 
CORELATIONS OF ESTROGEN 
RECEPTORS AND CYP19
Jun Li1, Zhou Wang1, Shuhai Li2 
1Department Of Thoracic Surgery, Provincial 
Hospital AfÀliated To Shandong University/China, 
2Department Of Thoracic Surgery, Qi Lu Hospital, 
Shandong University/China
Background: To Detect the seral estradiol(E2) 
levels in squamous and adenomous lung cancer and 
expression and clinical pathological corelations of 
estrogen receptors and CYP19.
Methods: Seral estradiol levels were dectected by 
RIA in female or postmenopausal women, with 
76 cases of squamous adenomous and 58 cases of 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.160 MICRORNA EXPRESSION 
PROFILES IN LUNG 
ADENOCARCINOMA TISSUES VERSUS 
ADJACENT LUNG TISSUES USING 
NEXT-GEN SEQUENCING
Miao Shi1, Saurabh Gombar2, Tao Wang3, Yousin 
Suh2, Simon Spivack1 
1Pulmonary Medicine, Albert Einstein College Of 
Medicine/United States Of America, 2Genetics, 
Albert Einstein College Of Medicine/United States 
Of America, 3Biostatistics, Albert Einstein College 
Of Medicine/United States Of America
Background: MicroRNAs (miRNAs) are small 
noncoding RNAs about 22 nucleotides in length and 
regulate mRNA expression by binding to 3’UTR 
of mRNAs and causing translation repression 
or degradation of mRNAs. Recent studies have 
revealed that microRNAs play important regulatory 
roles in carcinogenesis. However, how miRNAs 
regulate lung carcinogenesis is generally unknown. 
We used high-throughput sequencing technology 
to investigate miRNA expression proÀles in a 
pilot study of paired lung adenocarcinoma amd 
noncancerous lung tissues. 
Methods: Total RNA was isolated by Trizol 
from 7 pairs of lung adenocarcinoma tissues 
and noncancerous lung tissues, from the same 
patients. Small RNA library of each total RNA was 
constructed with Illumina’s Small RNA Sample 
Prep Kit, followed by high-throughput sequencing. 
Statistical differences in microRNA expression 
between groups were analyzed by GenePattern 
software.
Results: More than 400 miRNAs were detected in 
the small RNA libraries. We compared the same 
346 miRNAs between the two macroscopic sample 
sets (tumor vs. nontumor). There were 28 miRNAs 
with p value3.05E-04 and FDR0.049. Among 
the 28 miRNAs, four miRNAs (miR-195, miR-204, 
miR-551b and miR-598) were downregulated in 
cancer, and the other 24 miRNAs were upregulated 
in cancer, including miR-877, miR-9, miR-212, 
miR301b, miR-708, miR-642, miR-147b, miR210, 
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tissue of lung metastasis patients. We believe 
because in the latter case lung tissue is the only niche 
for metastatic cells it could be considered as the most 
appropriate “normal” control for the comparison 
with NSCLC and adjacent lung tissue.
Methods: Cell suspensions prepared from surgical 
biopsy specimens of NSCLC (37 samples), adjacent 
normal lung tissue (36 samples) and normal lung 
tissue of patients with lung metastasis (33 samples) 
were analyzed by Áow cytometry. Staining procedure 
was performed with FITC-conjugated monoclonal 
antibody to external epitope of Pgp, clone 17F9, 
Becton Dickinson. FITC-conjugated mouse IgG2b, 
k in equivalent concentrations were used as isotypic 
control antibodies. Mean cell Áuorescence as well as 
number of stained cells were analyzed with WinMDI 
software and Kolmogorov-Smirnov statistical 
approach respectively. Pgp expression was estimated 
by two parameters: ratio the mean cell Áuorescence 
of the cells stained with anti-Pgp antibody to the 
mean cell Áuorescence of the cells stained with 
isotypic antibody ratio as well as the number of 
speciÀcally stained cells. 
Results: 1. It was revealed increase Pgp expression 
in NSCLC compared to adjacent normal lung tissue. 
Median of Pgp expression frequency was 48% vs. 
32% (p=0,015) and intensity of Pgp expression in 
about 1,4 times higher (p=0,038). 2. It was not shown 
any difference in Pgp expression frequency (p=0,497) 
and intensity (p=0,265) between NCSLC and normal 
tissue of lung with different cancer metastasis. 3. 
The parameters of Pgp expression were signiÀcantly 
decreased in normal lung tissue of NSCLC patients 
compared to normal lung tissue of the patients with 
lung metastasis (p=0,049 for intensity and p=0,031 for 
frequency of Pgp expression). 
Conclusion: Increase Pgp frequency and intensity in 
NSCLC as compared to adjacent normal lung tissue, 
the close values to these indexes of NCSLC and 
normal tissue of lung with different cancer metastasis 
as well as decrease of Pgp expression in normal lung 
tissue of NSCLC patients compared to normal lung 
tissue of the patients with lung metastasis shows that 
ratio of Pgp in normal lung tissue is an important 
pathogenetic factor of NSCLC. We believe also that 
the decrease of Pgp expression in normal lung tissue 
could be substantial factor promoting the process 
of lung carcinogenesis. Supported by Russian 
Foundation for Basic Research (Grants N 10-04-
00551 and N 11-04-00542). 
Keywords: Non-small cell lung cancer, Pgp, 
pathogenetic factor, Áow cytometry
squamous lung cancer patients. IHC was applied to 
detect the expression of ERÎ±,ERÎ²and CYP19 and 
analyze the clinical correlations with adenomous and 
squamous lung cancer.
Results: E2 levels were signiÀcantly higher in 
adenomous lung cancer patients than those in 
squamous lung cancer patients(P<0.001). The 
expressions of ERƠ,ERơin adenomous lung cancer 
patients were higher than those in squamous lung 
cancer patients(P<0.001). The expression of ERƠin 
female than those in male(P<0.05). The expressions 
of ERơwere higher in highly differentiated 
adenomous lung cancer patients than those in poorly 
differentiated adenomous lung cancer patients. The 
expressions of CYP19 and ERơ were correlated with 
seral E2 expression P<0.01 r =0.561.
Conclusion: The carcinogenesis and development 
of adenomous lung cancer is correlated with E2 
function. The expression of CYP19 and ERơ could 
be a target for anti-endocrine therapy for adenomous 
lung cancer. 
Keywords: Lung cancer, estrogen receptor, CYP19
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P2.162 PGP AS A PATHOGENETIC 
FACTOR OF NON-SMALL CELL LUNG 
CANCER
Tatiana A. Bogush1, Evgeny A. Dudko1, Mikchail 
V. Tikchomirov1, Elena A. Bogush2, Eler E. Juraev2, 
Boris E. Polotsky2, Mikchail I. Davydov2 
1Laboratory Of Medical Chemistry, N.n. Blokhin 
Russian Cancer Research Center Of The Russian 
Academy Of Medical Sciences/Russian Federation, 
2Surgical Department, N.n. Blokhin Russian Cancer 
Research Center Of The Russian Academy Of 
Medical Sciences/Russian Federation
Background: Pgp is an ATP-dependent drug 
efÁux pump for compounds with broad substrate 
speciÀcity. It is responsible for decreased 
environmental carcinogen accumulation in normal 
tissues as well for drug accumulation in tumor cells 
mediating the development of multidrug-resistance 
to anticancer drugs. To answer the question if Pgp is 
a substantial factor taking part in lung carcinogenesis 
we have compared frequency and intensity of Pgp 
expression in normal and tumor tissues of non-
small cell lung cancer (NSCLC) patients as well as 
the parameters in both of these groups with normal 
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relatively higher than squamous carcinoma group 
(1.97±1.32ng/ml) but without signiÀcant statistical 
difference (P>0.05). sPD-L1 level increased 
progressively with progression of lung cancer, which 
was 1.08±0.20ng/ml in stage I-II group,1.93±1.56ng/
ml in stage III group and 2.01±1.32ng/ml in stage IV 
group(compared with stage I-II, P<0.05). Patients 
with N3 metastasis was also found to have a higher 
sPD-L1 expression than N2 and N1 metastasis 
group, which were 2.23±1.77ng/ml, 1.91±1.27ng/ml 
and 1.71±0.94ng/ml respectively, but no signiÀcant 
statistical difference was found among the three 
groups (P>0.05). In patients with malignant pleural 
effusion, sPD-L1 level in effusion (7.21±5.64ng/
ml) was found nearly six fold increased compared 
with corresponding serum oncentration(P<0.01). In 
addition, the dynamic changes of sPD-L1 seemed to 
be correlated with serum tumor markers and could 
reÁect tumor response to chemotherapy according 
to RECIST criteria to some extent. The relationship 
of sPD-L1 with overall survival remained to be 
investigated. 
Conclusion: The existence of circulating sPD-L1 
in human serum and pleural effusion is closely 
correlated with progression of lung cancer and 
might play a potentially important role in local and 
systemic tumor immune tolerate and escape. 
Keywords: soluble programmed death ligand 1 
(sPD-L1), Lung cancer, costimulatory molecule
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P2.164 ROUND ROBIN TEST TO 
EVALUATE THE REPRODUCIBILITY OF 
AN IMMUNOHISTOCHEMICAL SCORE 
WITH THERAPEUTIC RELEVANCE 
THAT DICHOTOMIZES NON-SMALL 
CELL LUNG CANCER INTO TUMORS 
WITH HIGH AND LOW EPIDERMAL 
GROWTH FACTOR RECEPTOR 
EXPRESSION
Josef Rüschoff1, Keith M. Kerr2, Hans Jürgen Grote3, 
Peter Middel4, Anja Von Heydebreck3, Ilhan Celik3, 
Stephan Störkel5 
1Diagnostic Pathology, Institut Für Pathologie 
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Advance Ag/Germany, 5Helios Hospital Wuppertal/
Germany
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.163 INCREASED LEVEL OF SPD-L1 
IN SERUM AND PLEURAL EFFUSION IN 
PATIENTS WITH LUNG CANCER AND 
ITS CLINICAL SIGNIFICANCE
Minhua Shi1, Yongjing Chen2, Yufei Xing1, Jianan 
Huang3, Xueguang Zhang2 
1Department Of Respiratory Medicine, The 2nd 
AfÀliated Hospital Of Soochow University/China, 
2Institute Of Medical Biotechnology, Soochow 
University/China, 3The 1st AfÀliated Hospital Of 
Soochow University/China
Background: Costimulatory signals play important 
roles in the regulation of immune response. PD-1/
PD-L1 pathway delivers a potent co-inhibitory 
signal to T cells, resulting in T cell exhaustion 
and dysfunction. In addition to membrane-
bound costimulatory molecules, soluble forms of 
costimulatory molecules have been found to exert 
important effect in immune regulation in cases with 
tumor, autoimmune diseases, transplantation and 
chronic viral infection. In this study, we investigated 
the existence of sPD-L1 in serum and malignant 
effusion of patients with lung cancer and to evaluate 
its clinical signiÀcance. 
Methods: sPD-L1 in serum from 87 healthy 
volunteers, 68 cases of pneumonia, 90 cases of 
treatment naïve lung cancer between 2008-2010 
were analyzed using ELISA method with our 
previously developed anti-human PD-L1 antibody. 
Effusion sPD-L1 concentration was also determined 
in 16 cases with malignant pleural effusion using the 
same method. Serum tumor marker of CEA, NSE 
and CYFRA211 and cytological study were used 
to conÀrm the diagnosis of malignant effusion. The 
results together with the clinical data in demography, 
phenotype of lung cancer as well as its response to 
treatment over time were analyzed. 
Results: A higher level of sPD-L1 level in patients 
with lung cancer group (1.94±1.35ng/ml) was found 
compared with pneumonia group (1.57±0.83ng/
ml, P<0.05) and control group (0.93±0.26ng/ml, 
P<0.01). No statistical correlation of sPD-L1 with 
age, sex, smoking status, primary size of tumor was 
found in lung cancer group. In subgroup analysis, we 
found sPD-L1 in NSCLC group (2.04±1.34 ng/ml) 
was higher than that in SCLC group (1.29±0.44ng/
ml) (P<0.05). Among NSCLC patients, sPD-L1 
of adenocarcinoma group (2.17±1.43ng/ml) was 
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concordance rate of 74%. 
Conclusion: The RRT demonstrated that assessing 
EGFR expression by this IHC scoring method 
allowed a highly reproducible allocation of NSCLCs 
into high or low EGFR expression groups, based on 
a cut-off score of 200. The study thereby indicates 
that this evaluation of the EGFR IHC score may be 
a clinically reliable method to facilitate the selection 
of patients with NSCLC expressing high levels of 
EGFR for Àrst-line chemotherapy plus cetuximab 
who are those most likely to derive a substantial 
treatment beneÀt.
Keywords: EGFR, immunohistochemistry, Round 
robin test
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P2.165 DIFFERENTIAL EXPRESSION 
OF LONG INTERGENIC NON-CODING 
RNA IN LUNG ADENOCARCINOMA AND 
SQUAMOUS CELL CARCINOMA
Richard Booton, Eleni Tsitsiou, Mark A. Lindsay 
School Of Translational Medicine, The University Of 
Manchester/United Kingdom
Background: Recent studies have identiÀed 
a novel family of long intergenic non-coding 
RNAs (lincRNAs). At the present time, the 
function and mechanism of action of the vast 
majority of lincRNAs is unknown. However, 
there is emerging evidence that lincRNAs 
including HOTAIR, Kcnq1ot1, AIR, XIST and 
lincRNA-p21 are involved in widespread repression 
of gene expression through their interaction with 
chromatin-remodelling complexes. Furthermore, 
the expression of a number of lincRNAs including 
HOTAIR and MALAT-1 has been linked to the 
development of cancer.
Methods: Samples used in this study were the 
tumours and matching control tissue from six 
patients with lung adenocarcinoma and six patients 
with squamous cell carcinoma. Total RNA was 
extracted using the mirVana miRNA isolation 
kit (Ambion) according to the manufacturer’s 
instructions. RNA was eluted in 100 l RNase-free 
water (Promega) and stored at -80°C. lincRNA 
expression proÀling was carried out on total RNA 
extracts by Two-Color Microarray-Based Gene 
Expression Analysis (Agilent Technologies), which 
examined the expression of 27,958 Entrez Gene 
Background: The randomized phase III FLEX 
study demonstrated that the addition of cetuximab 
to chemotherapy signiÀcantly improved overall 
survival compared with chemotherapy alone in the 
Àrst-line treatment of advanced non-small cell lung 
cancer (NSCLC). A positive association between 
high tumor epidermal growth factor receptor 
(EGFR) expression (score 200 as measured by 
immunohistochemistry [IHC] on a continuous scale 
of 0–300) and clinical outcome in patients receiving 
chemotherapy plus cetuximab has been reported. 
This international round robin test (RRT) evaluated 
the inter-observer reproducibility of the EGFR IHC 
score.
Methods: After a feasibility study had been 
completed, a RRT was performed. Serial sections 
of a tissue microarray (TMA) comprising NSCLC 
tumor cores were stained using the DAKO EGFR 
pharmDXTM kit and DAKO autostainer. Staining was 
initially evaluated in a central reference laboratory. 
Ten international expert lung cancer pathologists 
then evaluated EGFR expression for 30 selected 
TMA cores. The selected cores, which included 
tumors of different histologies, were categorized 
after reference evaluation, as clearly high (n=10), 
clearly low (n=11) or equivocal (n=9), relative to 
the threshold EGFR IHC score of 200. The EGFR 
IHC score was calculated as the sum of the products 
of tumor cell membrane staining intensity (graded 
0–3+) and the percentage of cells demonstrating 
each staining intensity, according to the following 
formula: EGFR IHC score = 1 x (% cells staining 
weakly [1+]) + 2 x (% cells staining moderately 
[2+]) + 3 x (% cells staining strongly [3+]). Analysis 
of between-rater agreement was based on the 
allocation of the EGFR IHC score into low (<200) 
and high (200) EGFR expression groups. The 
overall concordance rate with respect to the reference 
evaluation was deÀned as the mean of the per-rater 
concordance rates with respect to the reference 
evaluation. Kappa coefÀcients were calculated for 
the comparison of each rater with the reference 
evaluation.
Results: The RRT showed a high inter-observer 
agreement in EGFR IHC scoring among study 
participants, with an overall concordance rate of 91% 
and a mean kappa coefÀcient of 0.81. Tumors with 
a reference EGFR IHC score clearly below or above 
the cut-off (<150 or 250) were each categorized 
with an almost perfect mean concordance rate of 
98%. Samples with a reference EGFR IHC score 
around the cut-off (150– <250) showed a high mean 
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P2.166 IMPACT OF KRAS MUTATIONS 
(KRASMUT) ON CLINICAL OUTCOME 
IN STAGE IV NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS (PTS) AND 
THEIR RELATIONSHIP WITH OTHER 
BIOMARKERS.
Laia Capdevila, Enric Carcereny, Erika Mijangos, 
Teresa Moran, Sara Cros, Cristina Buges, Alex 
Martinez, Itziar De Aguirre, Miquel Taron, Rafael 
Rosell 
Oncology, Catalan Institute Of Oncology, Hospital 
Germans Trias I Pujol/Spain
Background: Kras accounts for 90% of 
RAS mutations in lung adenocarcinoma and 
approximately 97% of Krasmut in NSCLC involve 
codons 12 or 13. Kras tumour status cannot be 
easily predicted on the basis of smoking history 
alone. Krasmut status might help in the prediction 
of clinical outcome for pts receiving different 
treatments. The role of Krasmut as a predictor of 
response for pts with stage IV NSCLC treated with 
chemotherapy alone is poorly understood. Emerging 
data suggest that Krasmut are negative predictors of 
beneÀt from both adjuvant chemotherapy and anti-
EGFR–directed therapies. 
Methods: From August 2009 to January 2011 we 
analyzed Krasmut in samples from 114 stage IV 
NSCLC pts. We analyzed different types of Kras 
point mutations in codons 12 and 13 by direct DNA 
sequencing from parafÀn-embedded tumor tissue 
(PETT). We also used DNA sequencing from PETT 
to analyze other mutations (EGFR) and mRNA gene 
expression to evaluate BRCA1and RAP80 levels. 
We evaluated the presence of Krasmut according to 
histological subtype. 
Results: Krasmut were found in 21.9% (25 /114) 
Out of pts harboring Krasmut the median age was 59 
y, 64% were male. According to smoking status 8% 
were never smokers, 32% former smokers and 60% 
current smokers. According to histology 72% were 
adenocarcinoma, 12% squamous cell carcinoma and 
8% bronchioloalveolar carcinoma. According to 
PS ECOG 44% were PS0, 32% PS1 and 24% PS2. 
The distribution of metastatic sites was 37.8% lung, 
11.8% lymph nodes ,11.8% CNS and 9.9% bone. 
The frequency of Krasmut subtypes were: G12C 
44%, G12V 20%, G12A 16%, G12D 12%, G13D 
4%, G13V 4%. EGFR mutation was present in 1 
RNA and 7,419 lincRNAs. qRT-PCR was used to 
conÀrm the expression of lincRNAs using the two-
step TaqMan® reverse transcription polymerase 
chain reaction protocol (RT-PCR) and normalized 
to 18S. The 2-(Î”Î”CT) method (Livak & 
Schmittgen, 2001) was used to determine relative-
quantitative levels of individual lincRNAs and were 
expressed as the fold-difference to the control.
Results: Microarray examination revealed 
differential expression of >1200 genes in both 
adeno- and squamous carcinomas, with some of 
the genes exhibiting up to 70-fold change. Of the 
7419 lincRNAs examined, there were 123 up- and 
97 down-regulated in both sample groups with > 2 
fold-change. Further analysis to identify lincRNAs 
with the greatest change in expression (>1000 
Áuorescence units) demonstrated differential 
expression between the adeno- and squamous 
samples; only a small number of lincRNAs in 
adenocarcinomas were identiÀed (5 up-regulated, 
7 down-regulated). In contrast, there were 61 
down-regulated and 12 up-regulated lincRNAs 
in squamous carcinomas. The microarray data 
also revealed there was no correlation between 
the changes in individual lincRNA levels and the 
expression levels of the mRNAs Áanking them. 
Among the characterised lincRNAs, the expression 
levels of HOTAIR were shown to be reduced 
in both squamous and adenocarcinomas, whilst 
MALAT-1 expression was reduced in squamous but 
not adenocarcinoma samples, a result conÀrmed by 
qRT-PCR analysis. This Ànding contradicts other 
studies that have presented an increase in HOTAIR 
and MALAT-1 expression levels in cancer cells.
Conclusion: Development of adeno- and squamous 
cell lung cancer is associated with changes in 
expression of distinct groups of lincRNAs including 
HOTAIR and MALAT-1 that was independent of 
the expression of surrounding genes.
Keywords: intergenic, non-coding RNA, Lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKI’s), notably those with cancers 
that harbor mutated EGFR and wild type kRAS. 
However, certain patients lacking EGFR mutations 
might also beneÀt from TKI treatment. Previously 
(Hilhorst et al, J. Clin. Oncol. 28:7s, 2010 (suppl 
abstr 10566), we have shown that a classiÀer 
based on kinase activity proÀles generated in the 
presence and absence of a kinase inhibitor can 
predict erlotinib response of NSCLC patients in a 
neoadjuvant setting. The aim of the current study 
was to evaluate this classiÀer using a blinded test set 
of patient tumor samples
Methods: Frozen tumor tissue was obtained from 
NSCLC patients (stage IA-IIIA) who were given 
21 days of neo-adjuvant treatment with erlotinib 
prior to complete surgical resection. All specimens 
were analyzed for EGFR and kRAS mutation 
status. Tissue cryosections were lysed in M-PER 
buffer supplemented with phosphatase and protease 
inhibitors. Kinase activity proÀles of the lysates 
were generated in the presence and absence of 
erlotinib on PamChip® microarrays comprising 144 
tyrosine containing peptides derived from known 
human protein phosphorylation sites. Clinical 
response evaluation to erlotinib was based on 
histopathological examination of the tumor tissues 
and metabolic changes. A classiÀer for response 
prediction was established for this training set and 
subsequently applied to a blinded test set of 13 
patients.
Results: Phosphorylation proÀles were ATP 
dependent and differed between the patient samples. 
Addition of erlotinib to the samples resulted in 
inhibition of signals. Based on these on-chip 
inhibition proÀles, a PLS-DA (partial least square 
discriminant analysis) classiÀer was obtained that 
distinguished responders and non-responders in 
the training set of 14 samples. Leave-one-out cross 
validation resulted in correct classiÀcation of 11 
samples (79%). Application to the blinded test 
set of 13 samples resulted in correct prediction of 
outcome for 11 of 13 samples (85%). The training 
set contained one sample with an EGFR exon 19 
mutation, one with an exon 20 in frame deletion 
and 2 samples with kRAS mutations. The test set 
contained two samples with exon 19 mutations and 
two samples with kRAS mutations. These results 
suggest that more patients might be eligible for 
erlotinb treatment. 
Conclusion: This blinded study validates the use 
of a classiÀer based on kinase activity proÀles of 
patient (4%). BRCA expression levels were 36% 
low, 4% intermediate, 0% high and 32% insufÀcient 
sample. RAP80 expression levels were 4% low, 24% 
intermediate, 12% high and 32% insufÀcient sample. 
For pts treated in Àrst line with platinum based 
chemotherapy (21/25) the response rate (RR) was 
as follows Complete response 4%, Partial Response 
12%, Stable Disease 9.5% and Progressive Disease 
47.5%. Time to progression (TTP) was 6.6m and 
Overall Survival (OS) was 12.5m. TTP and OS 
according to Krasmut were: G12C 10.1m/15.4m, 
G12V 5m/14.1m, G12A 2.3m/8.5m, G12D 
9.1m/9.6m ,G13D 3m/8.3m, G13V 3.2m/6.9m. Pts 
received a median of 2 lines of treatment (range 1-5). 
Seven pts (33.3%) were included in speciÀc targeted 
studies for Krasmut pts beyond the second line. No 
differences were found in RR or TTP according to 
PS, gender smoking history, Krasmut subtype and 
BRCA1 or RAP80 levels. No differences were found 
in OS according to gender, smoking history, Krasmut 
subtype and BRCA1 or RAP80 levels except for PS 
(p=0.0033) 
Conclusion: Krasmut were more frequent in 
male, smokers and former smokers and pts with 
adenocarcinoma. PS was associated with differences 
in OS. No other variables were associated with 
differences in RR, TTP or OS. The small sample size 
could explain the lack of differences. 
Keywords: Kras mutations, Non-Small-Cell Lung 
Cancer, stage IV, biomarkers assesment
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P2.167 BLIND PREDICTION OF 
RESPONSE TO NEOADJUVANT 
TREATMENT WITH ERLOTINIB IN 
EARLY STAGE NON-SMALL CELL 
LUNG CANCER (NSCLC) USING KINASE 
ACTIVITY PROFILES.
Riet Hilhorst1, Eva E. Schaake2, Renee Van Pel3, 
Petra Nederlof3, Liesbeth Houkes1, Monique 
Mommersteeg1, Rik De Wijn1, Rob Ruijtenbeek1, 
Michelle M. Van Den Heuvel2, Paul Baas2, Houke 
Klomp2 
1R&d, Pamgene International Bv/Netherlands, 
2Thoracic Oncology, NKI-AVL/Netherlands, 
3Pathology, NKI-AVL/Netherlands
Background: It has been well established that 
subcategories of NSCLC patients may beneÀt from 
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using subsequent qPCR analysis reÁected our 
global screening (p<0.05). Furthermore, a positive 
correlation was noted between miRNA expression 
and early tumour stage (i.e. Stages I & II); although 
the numbers of specimens included was too limited 
to derive a meaningful outcome on this and this trend 
was not observed at Stages III & IV.
Conclusion: Differences in miRNA proÀle identiÀed 
here suggest that circulating miRNAs may have 
potential as diagnostic biomarkers for ADC. Of 
particular interest, this Panel of 8 miRNAs never 
previously associated with serum or with ADC. More 
extensive studies including larger cohorts of serum/
specimens from ADC, as well as other lung cancer 
and controls, are warranted to further explore this 
initial discovery. 
Keywords: Circulating miRNA, Adenocarcinoma, 
Early Tumour Stage
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.169 THE EXPRESSION PROFILE AND 
ROLE OF THROMBOXANE SYNTHASE 
IN NON-SMALL CELL LUNG CANCER: 
CORRELATION WITH PATIENT 
SURVIVAL
Mary Clare Cathcart1, Kathy Gately2, Elaine Kay3, 
Robert Cummins3, Graham P. Pidgeon1, Kenneth J. 
O’Byrne2 
1Department Of Clinical Surgery, Trinity College 
Dublin/Ireland, 2Department Of Clinical Medicine, 
St. James’s Hospital/Ireland, 3Department Of 
Pathology, Beaumont Hospital Dublin/Ireland
Background: Thromboxane synthase metabolizes 
PGH2 into thromboxanes, which are biologically 
active on cancer cells. TXS over-expression has 
been frequently reported in cancers, and has been 
associated a poor prognosis. TXS blockade inhibits 
angiogenesis and induces tumor cell death, providing 
a rationale for intervention. This study aimed to 
determine the expression proÀle of TXS, its link to 
tumor angiogenesis, and if it is prognostic and/or a 
survival factor in NSCLC.
Methods: TXS expression was examined in 
human NSCLC samples (protein and tissue) and 
matched controls by western analysis and IHC. 
TXS metabolite levels were measured in human 
NSCLC plasma samples and age-matched controls 
by EIA. A 200-patient NSCLC TMA was stained 
patients’ own tumor tissue to predict the response to 
treatment. This test that measures drug effects at the 
molecular level, may be an important step towards 
personalized medicine
Keywords: erlotinib, NSCLC, response prediction
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P2.168 CIRCULATING MIRNA AS 
MINIMALLY-INVASIVE BIOMARKERS 
FOR ADENOCARCINOMA OF THE LUNG
Sweta Rani1, Kathy A. Gately2, Kenneth J. O’Byrne2, 
Lorraine O’ Driscoll3 
1Pharmacy & Pharmaceutical Science, Trinity 
College Dublin/Ireland, 2Clinical Medicine, 
Trinity College Dublin/st. James Hospital/Ireland, 
3Pharmacy & Pharmaceutical Sciences, Trinity 
College Dublin/Ireland
Background: Early diagnosis and the ability to 
predict the most relevant treatment option for 
individuals is essential to increase survival time 
for non-small cell lung cancer (NSCLC) patients. 
Adenocarcinoma (ADC) NSCLCs are the single 
biggest cancer killer and so there is an urgent need 
to identify minimally-invasive biomarkers to enable 
its early diagnosis. Recent studies, by ourselves and 
others, analysing circulating miRNAs on a one-at-
a-time basis, suggest that such miRNAs may have 
potential as biomarkers. Our aim here was to apply 
global proÀling approaches to explore if miRNAs 
exist in the peripheral circulation of patients and 
with adenocarcinoma (ADC) and, if so, do they have 
potential as diagnostic biomarkers. 
Methods: This study involved total RNA isolation 
from 80 sera specimens including those from 
patients with ADC of the lung (n=40; equal numbers 
of Stages I, II, III and IV) and age- and gender-
matched controls (n=40 each). 667 miRNAs were 
co-analysed in these specimens using TaqMan low 
density arrays. Individual miRNAs were selected for 
qPCR validation. 
Results: Successful isolation of RNA was achieved 
from all sera specimens. The quantities of RNA in 
ADC and control sera did not differ signiÀcantly. 
A panel of eight miRNAs, however, was found to 
be present at signiÀcantly higher levels in ADC 
compared to control sera. These include miR-30c-1*, 
miR-140, miR-345, miR-616*, miR-146b-3p, miR-
566, miR-550 and miR-939. The trend observed 
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with lung cancer. However, patients who received 
radiotherapy had an increased risk of cardiovascular 
mortality and there has been so far no ideal tool for 
the early noninvasive real-time detection of radiation 
induced myocardial damage. The purpose of this 
study is to determine whether ultrasonic integrated 
backscatter (IBS) can be used as a noninvasive 
device to detect early myocardial damage in 
unresectable locally advanced non-small cell lung 
cancers treated by radiotherapy. 
Methods: Forty six left unresectable locally 
advanced non-small cell lung cancer patients (stage 
IIB-IIIB) treated with Vinorelbine :40 mg/m2, IV, 
day 1 and day 8; Cisplatin: 40 mg/m2, IV, days 
1-3 and radiotherapy: 66 Gy in 33 fractions were 
entered into this study. Calibrated myocardial IBS 
(CMIBS, assessed by comparison of the anterior wall 
(AW), inferior wall (IW), anteroseptum (AS) and 
posterior wall (PW) with pericardial IBS intensity), 
cyclic variation of IBS (CVIBS) and conventional 
echocardiography parameters (LVIDd: the left 
ventricular internal diameter at end-diastole; IVSTd: 
the intraventricular septal thickness at end-diastole; 
PWTd: the posterior wall thickness at end-diastole; 
LVDs: the left ventricular end-systolic dimension; 
EF: the left ventricular ejection fraction; FS: the left 
ventricular fractional shortening. The peak velocity 
of early (E) and late ventricular Àlling (A) were 
also determined for calculating the ratio E/A) were 
investigated before (group A), during (group B, 3 
weeks, the cumulative dose was about 30Gy) and 
after radiotherapy (group C, 6 weeks, the cumulative 
dose was about 60Gy). 
Results: CMIBS of AW and AS were signiÀcantly 
increased after radiotherapy both during (group 
B, p<0.05) and at the end of treatment (group C, 
p<0.05) and meanwhile CVIBS and E/A were 
decreased signiÀcantly throughout the treatment 
period (group B, p<0.05 for both; group C, p<0.01 
for both) compared with the beginning (group A). 
Conclusion: Myocardial IBS offers a promising 
approach for early noninvasive real-time detection 
and characterization of evolution of cardiomyopathy 
induced by radiotherapy in lung cancer patients.
Keywords: Lung cancer, Radiotherapy, Myocardial 
damage, Ultrasonic integrated backscatter
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
for TXS and CD-31. Staining was correlated with 
clinical parameters, including 5-year patient survival. 
TXS expression pattern was correlated CD-31 
(microvessel density). Stable TXS over-expressing 
clones were generated and their effect on tumor 
growth/survival was examined both in-vitro (BrdU) 
and in-vivo (xenograft mouse model).
Results: TXS was over-expressed in human NSCLC 
samples, relative to matched controls. SigniÀcantly 
increased TXS protein and TXB
2
 metabolite levels 
were observed in protein and plasma samples 
respectively. TXS tissue expression were also 
signiÀcantly higher in adenocarcinoma (p<0.001) 
and female patients (p<0.05). While no signiÀcant 
correlation with patient survival was observed, 
TXS expression was signiÀcantly associated with 
microvessel density in the same patients. Stable TXS 
over-expression signiÀcantly increased tumor cell 
growth in-vitro and also increased tumor growth 
(and reduced survival) in-vivo. 
Conclusion: TXS is over-expressed in NSCLC, 
particularly in the adenocarcinoma subtype and 
female patients. While it was not found to be 
prognostic, TXS over-expression signiÀcantly 
increased tumor growth both in-vivo and in-vitro, 
suggesting that TXS promotes tumor survival 
in NSCLC. Our study also noted a signiÀcant 
correlation of TXS with microvessel density, 
suggesting that the pro-tumor effects of TXS 
expression are at least partly mediated via tumor 
angiogenesis. Further studies using our in-vivo 
models will conÀrm preliminary observations.
Keywords: thromboxane B2, thromboxane synthase, 
angiogenesis, in-vivo models
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P2.170 ULTRASOUND MYOCARDIAL 
TISSUE CHARACTERIZATION BY 
INTEGRATED BACKSCATTER DETECTS 
PRECLINICAL MYOCARDIAL DAMAGE 
IN UNRESECTABLE LOCAL ADVANCED 
NON-SMALL CELL LUNG CANCERS 
TREATED BY RADIOTHERAPY
Yong Zhang 
Department Of Surgical Oncology, First Hospital Of 
Xi’an Jiaotong University/China
Background: Radiotherapy plays an important 
role in the multimodality management of patients 
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corresponding normal lung tissues in combination 
with clinical follow-up data led to the identiÀcation 
of two biomarker candidates that have previously not 
been associated with lung cancer. 
Conclusion: Based on the results obtained in this 
study we conclude that activity-based proteomics 
represents a powerful strategy in the seek for 
novel biomarker candidates in human lung 
adenocarcinoma. Liu, Y., Patricelli, M.P. & Cravatt, 
B.F. Activity-based protein proÀling: the serine 
hydrolases. Proceedings of the National Academy 
of Sciences of the United States of America 96, 
14694-14699 (1999). Jessani, N., et al. A streamlined 
platform for high-content functional proteomics of 
primary human specimens. Nature methods 2, 691-
697 (2005). 
Keywords: Biomaker, NSCLC, Activity-based 
proteomics
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.172 EXAMINATION OF 
12-LIPOXYGENASE AS A THERAPEUTIC 
TARGET IN NON-SMALL CELL 
LUNG CANCER: MECHANISMS 
CONTROLLING SURVIVAL AND 
INDUCTION OF APOPTOSIS 
FOLLOWING SELECTIVE INHIBITION
Mary Clare Cathcart1, Vikki Campbell2, Kathy 
Gately3, Robert Cummins4, Elaine Kay4, Graham P. 
Pidgeon1, Kenneth J. O’Byrne3 
1Department Of Clinical Surgery, Trinity College 
Dublin/Ireland, 2Trinity College Dublin/Ireland, 
3Department Of Clinical Medicine, St. James’s 
Hospital/Ireland, 4Department Of Pathology, 
Beaumont Hospital Dublin/Ireland
Background: Platelet-type 12-LOX is an 
arachidonic acid metabolising enzyme resulting in 
the formation of 12(S)-HETE, which stimulates 
tumour cell adhesion, invasion and metastasis. The 
aim of this study was to examine the expression 
proÀle and role of this enzyme in NSCLC, and to 
determine if it is a potential target for intervention 
in-vitro and in-vivo.
Methods: A panel of retrospective resected lung 
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P2.171 ACTIVITY-BASED PROTEOMICS: 
BIOMARKER IDENTIFICATION IN NON-
SMALL CELL LUNG CANCER (NSCLC)
Thomas Wiedl1, Stephan Arni1, Bernd Roschitzki2, 
Jonas Grossmann2, Alex Soltermann3, Sven 
Hillinger1, Ruedi Aebersold4, Walter Weder1 
1Division Of Thoracic Surgery, University Hospital 
Zurich/Switzerland, 2Functional Genomics 
Center Zurich (fgcz)/Switzerland, 3Department Of 
Pathology, University Hospital Zurich/Switzerland, 
4Department Of Biology, Institute Of Molecular 
Systems Biology (imsb), Swiss Federal Institute 
Of Technology Zurich (eth Zurich) And Faculty Of 
Science, University Of Zurich/Switzerland
Background: Lung cancer is the leading cause 
of all cancer related deaths and treatment is still 
suboptimal. Novel biomarkers with a reliable 
predictive signiÀcance which may additionally 
represent therapeutic targets are therefore of utmost 
importance. In biomarker discovery studies transcript 
or protein abundances are typically compared in 
normal versus disease states. However, crucial 
changes in enzymatic activities remain undetected. 
Based on the work of Prof. Cravatt and others, 
activity-based proteomics has become a promising 
option to circumvent this limitation. This study aims 
to establish a robust and high throughput activity-
based proteomics platform and to investigate the role 
of serine hydrolase activity proÀles as prognostic 
biomarkers in lung cancer. 
Methods: A Áuorophosphate derivate (CAS-
Number: 353754-93-5) was used to covalently target 
serine hydrolases in proteomes derived from human 
lung adenocarcinoma biopsies and corresponding 
normal lung tissues (tumor cell content: >50%, 
TNM-stage: I-IV). Tagged proteins were 
subsequently afÀnity puriÀed and analyzed using a 
directed mass spectrometry based approach (LTQ-
FTMS, Thermo Finnigan). Data were qualitatively 
analyzed using the Mascot 2.2 search engine 
and Progenesis LC-MS version 2.5 (Nonlinear 
Dynamics) was employed for relative quantiÀcation. 
Results: The strategy described above results in the 
simultaneous qualitative and quantitative analysis 
of serine hydrolase activities in complex proteomes, 
thereby representing a valid alternative to activity-
based proteomics approaches described so far. The 
analysis of 40 pairs of fresh frozen malignant and 
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P2.173 ANALYSIS OF MTOR SIGNALING 
PATHWAY BIOMARKERS IN NON-
SMALL CELL LUNG CANCER PATIENTS 
TREATED WITH EVEROLIMUS AND 
DOCETAXEL IN A PHASE II CLINICAL 
TRIAL.
Taofeek K. Owonikoko1, Suresh Ramalingam1, 
Janakiraman Subramanian2, Gabriel Sica1, Zhengjia 
Chen1, Madhusmita Behera1, Jaqueline Rogerio3, 
Nabil Saba1, Mourad Tighiouart1, Anthony Gal1, 
Ramaswamy Govindan2, Fadlo R. Khuri1 
1Winship Cancer Institute, Emory University/United 
States Of America, 2Washington University School 
Of Medicine/United States Of America, 3Novartis 
Oncology/United States Of America
Background: mTOR pathway activation is a 
critical oncogenic event in non-small cell lung 
cancer (NSCLC). Based on preclinical evidence 
of enhanced anti-cancer activity of docetaxel 
in combination with everolimus (RAD001) we 
conducted a translational phase II trial in advanced 
NSCLC. We also analyzed tissue-based markers of 
mTOR pathway activation. 
Methods: Advanced stage NSCLC patients 
previously treated with not more than 2 prior 
regimens were enrolled to receive docetaxel (60 
mg/m2 on day 1) and everolimus (5 mg PO QD, 
daily for 19 days) combination on a 3-week cycle 
schedule. The primary endpoint was response 
rate and secondary endpoints included PFS, 
OS and safety assessment. Archival diagnostic 
tumor samples were evaluated for upstream and 
downstream markers of mTOR pathway activation 
(total and phosphorylated mTOR, Akt, S6, eIF4e 
and 4EBP1) by immunohistochemistry. The staining 
intensity of biomarker expression was used for this 
analysis. General linear models were employed 
to test differences in biomarker expression across 
different categories of tumor response and histology. 
The relationship between biomarker expression and 
patient age was assessed by Spearman correlation 
coefÀcient while the median PFS and OS were 
estimated by Kaplan Meier method.
Results: Twenty-eight patients were enrolled. 
Median age was 64 years; gender: male/
female (13/15), Caucasian 19; histology: 
adenocarcinoma-17, squamous-8, NOS-3; ECOG 
performance status: 0 – 4, 1 – 20 and 2 – 2 patients. 
tumours was stained for 12-LOX expression by 
immunohistochemistry. A panel of NSCLC cell 
lines (A-549, SKMES-1, H-460) were treated with 
baicalein (100 nM, 1 M, 10 M), a selective 
inhibitor of 12-LOX, or 12(S)-HETE (100 ng/
ml) and cell survival/proliferation examined by 
BrdU. Apoptosis following 12-LOX inhibition 
was examined (in all three cell lines) by High 
Content Screening and validated by FACS and 
DNA laddering. The effect of 12-LOX inhibition on 
NSCLC tumour growth and survival was examined 
in-vivo using an athymic nude mouse model (H-
460 cell line). Gene alterations following 12-LOX 
inhibition (A-549, SKMES-1 and H-460 cell lines) 
were assessed by quantitative PCR arrays (Cancer 
PathwayFinder arrays to examine expression of a 
panel of 84 genes involved in tumourigenesis), and 
validated by RT-PCR.
Results: 12-LOX expression was observed to a 
varying degree in a range of human lung cancers 
with different histological subtypes. Baicalein 
signiÀcantly reduced proliferation/survival in 
all lung cancer cell lines, while 12(S)-HETE 
signiÀcantly increased proliferation. 12-LOX 
inhibition with baicalein also resulted in a 
signiÀcant increase in apoptosis, demonstrated by 
High Content Screeing (reduced f-actin content 
and mitochondrial mass potential) and conÀrmed 
by FACS and DNA laddering. Treatment with 
baicalein signiÀcantly reduced the growth of 
NSCLC tumours and increased overall survival in 
athymic nude mice. qPCR array data implicated a 
number of apoptosis/angiogenesis genes regulating 
these effects, including bcl-2, VEGF, angiopoietin 
2, IGF-1, integrin A2 and A4.
Conclusion: 12-lipoxygenase is a survival factor 
and potential target in NSCLC, which is correlated 
with apoptosis and angiogenic factor expression. 
Selective targeting of this enzyme may have clinical 
beneÀt for the future treatment.
Keywords: apoptosis, in-vivo models, 
12-lipoxygenase, 12-(S)-HETE
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an overall 5 year survival of <15%. The most 
effective systemic chemotherapy for NSCLC is 
cisplatin-based combination treatment. However, 
chemoresistance is a major therapeutic problem and 
understanding the mechanisms involved is critical 
to the development of new therapeutic strategies, 
including novel biological targeted agents. It 
has been shown that AKT ampliÀcation and the 
mammalian target of rapamycin (mTOR) pathway 
play an important role in cisplatin resistance in 
NSCLC. The PI3K/AKT/mTOR pathway represents 
a novel therapeutic target for overcoming cisplatin 
resistance in NSCLC, and currently there are several 
PI3K inhibitors in clinical trials. 
Methods: A panel of cisplatin resistant NSCLC 
cell lines (H460, SKMES1, A549) were developed 
in our laboratory. H460 parent & resistant cell lines 
were screened for changes in mRNA expression 
using the PI3K ProÀler array (SABiosciences). Gene 
expression changes between the two cell lines were 
validated by QPCR. IkBa protein expression was 
examined by Western blot analysis and High-Content 
Analysis (HCA). IkBa exons 3-5 were ampliÀed 
by nested PCR and sequenced using the AB3130 
sequencer. 
Results: 
The PI3K array identiÀed no difference in NFkB 
mRNA expression between parent and cisplatin 
resistant H460 cells. However an 11.99 fold increase 
in IkBa mRNA expression was identiÀed in the 
cisplatin resistant H460 cells. This was validated 
by QPCR which showed an 11 fold increase in 
expression of the gene (Fig. 1a). Western Blot 
analysis of a panel of cisplatin sensitive and resistant 
lung cancer cells also showed differences in 
expression of IkBa protein (Fig.1b). HCA conÀrmed 
increased levels of IkBa in H460 cisplatin resistant 
A median of 3.5 cycles of therapy was administered. 
Grade 3/4 toxicities (n=11) included neutropenia, 
anemia, headache, fatigue, hyperglycemia, mucositis, 
and dyspepsia. Two patients experienced partial 
response and 13 had stable disease (clinical beneÀt 
rate 54%). The median PFS and OS were 2.3 months 
and 12 months, respectively. Tumor samples were 
available for biomarker analysis in 13 of 28 patients. 
High p-Akt expression was observed in patients 
with response outcome classiÀcation of progressive 
disease (p=0.01) and in patients with squamous or 
NOS histology (p=0.04). High p-Akt also showed 
a negative correlation with age (p=0.03). Similarly, 
cytoplasmic and nuclear staining intensity for total 
Akt showed signiÀcant negative correlation with 
age (p=0.002 for nuclear staining and p=0.05 for 
cytoplasmic staining). The levels of expression of S6 
(p=0.08), pS6 (p=0.09) and p-mTOR (p=0.07) were 
different between disease response categories. There 
was no signiÀcant correlation between the tested 
biomarkers and patients survival outcomes (PFS or 
OS). 
Conclusion: Expression level of p-Akt in diagnostic 
tumor tissue may predict for response in advanced 
NSCLC patients treated with the combination of 
everolimus and docetaxel. The biologic signiÀcance 
and treatment implication of the correlation observed 
between biomarkers of mTOR pathway activation 
and patient age, tumor histology and disease 
response is worthy of further study in future trials of 
agents that target this pathway. Acknowledgements: 
This study was supported by NCI grant P01 
CA116676. Everolimus was provided by Novartis 
Oncology. FRK, TKO, SS, and SSR are Georgia 
Cancer Coalition Distinguished Cancer Scholars. 
Keywords: Biomarkers, Lung cancer, docetaxel and 
everolimus, mTOR pathway
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P2.174 IKBA - A MECHANISM OF 
RESISTANCE TO CISPLATIN IN NSCLC
Susan Heavey1, Martin Barr2, Kenneth J. O’Byrne1, 
Kathy A. Gately1 
1Clinical Medicine, Trinity College Dublin/Ireland, 
2Trinity College Dublin/Ireland
Background: Non-small cell lung cancer (NSCLC) 
is the leading cause of cancer morbidity and 
mortality among western men and women, with 
S1040 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
TMI is deÀned as the geometric mean of normalized 
tumour marker data (Muley et al., Lung Cancer, 
2008) Follow-up data were actualized in Feb 2011 
(median follow-up: 39.3 months). Thirty three 
patients experienced tumour relapse. 17 patients 
died from lung cancer and 3 patients from other 
causes. Statistical analysis was done with SPSS 18.0 
(Chicago, Illinois, USA). 
Results: CEA (cut-off 5.0 ng/ml) and CYFRA 
21-1 (cut-off 3.3 ng/ml) signiÀcantly differentiated 
between patients with low and high risk of 
tumour relapse (univariate HR: 2.3 [95%CI: 1.2-
4.5], p=0.015 and HR: 3.0 [1.4-6.4], p=0.002, 
respectively). The power of differentiation was 
considerably improved by using TMI at a cut-off-
point of 0.58. The 3-year disease-free survival rate 
was 83.8% and 54.0%, respectively (p=0.001)
(Fig.).The univariate hazard ratio (DFS) was found 
to be 3.6 [95%CI: 1.6-8.1]. Eight out of 53 patients 
in the low risk group and 25 out of 59 patients in the 
high risk group experienced tumour recurrence. The 
tumor speciÀc overall survival rate was signiÀcantly 
better (p=0.001) in the low risk group (95.4%) 
compared to high risk patients (77.5%) as deÀned 
by TMI (Fig.). TMI was shown to be a signiÀcant 
prognostic factor for DFS and OS in the multivariate 
analyses. 
A small positive effect of adjuvant chemotherapy 
could be seen in the high risk group (TMI>0.58; 
n=59). The relapse rate was 2 out of 8 patients 
receiving adjuvant chemotherapy compared to 23 
out of 51 patients without adjuvant chemotherapy. 
Surprisingly, patients receiving adjuvant 
chemotherapy in the low risk group (TMI<0.58; 
n=53) had a higher recurrence rate (5/12) as 
compared to patients without adjuvant chemotherapy 
(3/41). 
Conclusion: Stage I patients with elevated TMI 
levels were shown to be at an increased risk of 
tumour relapse and early death and might therefore 
be appropriate candidates for adjuvant therapy. A 
cells compared to parent cells (Fig 1c). No gene 
mutations or deletions were identiÀed in exons 3-5 of 
the IkBa gene 
Conclusion: The transcription factor NFkB is 
involved in cell growth and proliferation and 
regulates the transcription of its own inhibitor IkBa. 
IkBa binds to and retains NFkB in an inactive 
complex in the cytoplasm. Over-expression of IkBa 
has been shown to decrease cell proliferation and 
increase apoptosis. However, here we show IkBa 
over-expression in cisplatin resistant cells compared 
to sensitive cells. No evidence of a truncated IkBa 
protein was detected by Western blot and no gene 
deletions or mutations were detected in exons 3-5. 
Therefore, further work is warranted to elucidate 
whether post-translational modiÀcations of IkBa 
may result in its inability to inhibit NFkB in cisplatin 
resistant cells. 
Keywords: NSCLC, Cisplatin resistance, IkBa, 
PI3K/AKT/mTOR pathway
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P2.175 TUMOR MARKER INDEX 
(TMI) BASED ON CYFRA21-1 AND 
CEA IDENTIFIES P-STAGE I NSCLC 
PATIENTS WITH HIGH RISK OF 
RECURRENCE AND POOR PROGNOSIS.
Thomas R. Muley1, Hans Hoffmann1, Hendrik 
Dienemann2, Michael Thomas3, Felix J.F. Herth4, 
Michael Meister1 
1Translational Research Unit, Thoraxklinik, 
University Of Heidelberg/Germany, 2Dept. Of 
Surgery, Thoraxklinik, University Of Heidelberg/
Germany, 3Dept. Of Thoracic Oncology, 
Thoraxklinik, University Of Heidelberg/Germany, 
4Dept. Of Pneumology And Respiratory Medicine, 
Thoraxklinik, University Of Heidelberg/Germany
Background: TMI has been shown to be a valuable 
tool for risk evaluation in early stage NSCLC. The 
purpose of the prospective study was to analyse the 
value of TMI to predict tumour relapse in p-stage I 
NSCLC patients.
Methods: 112 completely resected patients (71 
male/41 female; 37 SCC, 59 AC, 16 other NSCLC) 
entered the study. 23 patients received adjuvant 
chemotherapy based on clinical considerations. 
Preoperative markers were measured with Elecsys 
Bioanalyzer 2010 (Roche, Mannheim, Germany). 
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clearly up-regulated in ELF samples of NSCLC 
patients independent of the tumor subtype. 
Combined analysis of clinical parameters like nodule 
size and biomarker expression further improved the 
prediction of early malignancies.
Conclusion: Our study indicates that speciÀc 
marker genes in ELF collected by bronchoscopic 
microsampling may be useful to distinguish between 
malignant and benign pulmonary nodules.
Keywords: Endobronchial lining Áuid, Molecular 
biomarkers
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P2.177 VEGF EXPRESSION IN NON-
SMALL CELL LUNG CANCER: 
CORRELATION WITH EFFECTORS OF 
ARACHIDONIC ACID METABOLISM
Mary Clare Cathcart1, Kathy Gately2, Elaine Kay3, 
Robert Cummins3, Graham P. Pidgeon1, Kenneth J. 
O’Byrne2 
1Department Of Clinical Surgery, Trinity College 
Dublin/Ireland, 2Department Of Clinical Medicine, 
St. James’s Hospital/Ireland, 3Department Of 
Pathology, Beaumont Hospital Dublin/Ireland
Background: It is well known that the angiogenic 
factor, VEGF promotes tumour survival in NSCLC, 
with some reports also demonstrating that it is 
prognostic in the disease. The monoclonal anti-
VEGF antibody, bevacizumab can improve NSCLC 
patient survival when used in combination with 
conventional chemotherapy. However, the beneÀts of 
this new agent are generally modest, suggesting that 
novel approaches are warranted. Arachidonic acid-
derived cyclooxygenase (COX) and lipoxygenase 
(LOX) pathways have been investigated in a number 
of cancers and play a role in tumour progression, 
potentially via increased angiogenesis. The aim of 
this study was to investigate the expression proÀle 
of VEGF in NSCLC and to correlate with both 
COX (COX-2, thromboxane synthase) and LOX 
(12-lipoxygenase) pathways. We also wished to 
investigate the effect of these enzymes on overall 
patient survival.
Methods: A 200-patient NSCLC TMA was stained 
for VEGF, COX-2, TXS and 12-LOX. Staining was 
correlated with clinical parameters, including 5-year 
patient survival. VEGF expression pattern was 
correlated with COX-2, TXS, and 12-LOX. VEGF, 
small positive effect of adjuvant chemotherapy could 
be seen in high risk patients. The latter should be 
validated in a larger patient group receiving adjuvant 
chemotherapy. 
Keywords: Tumor marker index, Stage I, risk 
prediction, Prognosis
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P2.176 EARLY DETECTION OF LUNG 
CANCER BY MOLECULAR MARKERS 
IN EDOBRONCHIAL LINING FLUID
Michael Meister1, Nicolas Kahn2, Ralf Eberhardt2, 
Thomas Muley1, Philipp A. Schnabel3, Christian 
Bender4, Marc Johannes4, Denise Keitel4, Holger 
Sültmann4, Felix J. Herth2, Ruprecht Kuner4 
1Translational Research Unit, Thoraxklinik, 
University Of Heidelberg/Germany, 2Dept. Of 
Pneumology And Respiratory Critical Care 
Medicine, Thoraxklinik, University Of Heidelberg/
Germany, 3Institute Of Pathology, University 
Of Heidelberg/Germany, 4Unit Cancer Genome 
Research, Division Of Molecular Genetics, German 
Cancer Research Center And National Center Of 
Tumor Diseases/Germany
Background: Molecular biomarkers in tissues and 
body Áuids represent a promising source to improve 
cancer diagnosis and risk assessment. In the lung, 
early detection of malignancies by less invasive 
methods aims at achieving efÀcient intervention 
and subsequently a reduction of the high mortality 
rate. We investigated whether biomarker analysis in 
endobronchial epithelial lining Áuid (ELF) collected 
by bronchoscopic microsampling may be useful for a 
deÀnitive preoperative diagnosis.
Methods: ELF was collected from subsegmental 
bronchi close to the indeterminate pulmonary 
nodule, which was detected by CT scans, and from 
the contralateral lung. Diagnosis was conÀrmed by 
transbronchial biopsy or surgery. The study included 
51 non-small cell lung cancer patients and 20 benign 
cases. Total RNA was isolated from ELF samples 
and biomarker candidate selection was based on 
Affymetrix U133 Plus 2.0 microarray analysis of a 
subset of ELF samples. Potential biomarkers have 
been further analyzed by rt qRT-PCR in independent 
ELF samples.
Results: Thirteen potential biomarkers have been 
identiÀed. Notably, one biomarker candidate was 
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P2.178 GENETIC VARIATIONS AND 
PATIENT-REPORTED QUALITY OF 
LIFE AMONG NON-SMALL CELL LUNG 
CANCER PATIENTS
Jeff A. Sloan1, Mariza De Andrade1, Paul Decker1, 
Jason WampÁer1, Curtis Olswold1, Matthew Clark2, 
Ping Yang3 
1Health Sciences Research, Mayo Clinic/United 
States Of America, 2Psychiatry And Psychology, 
Mayo Clinic/United States Of America, 
3Epidemiology, Mayo Clinic/United States Of 
America
Background: Recent evidence has suggested a 
relationship between a cancer patient’s self-reported 
baseline quality of life (QOL) and genetic disposition. 
We report an analysis exploring the relationship between 
baseline QOL assessments and candidate genetic 
variations in a large cohort of lung cancer patients.
Methods: QOL data was provided by 1299 non-
small cell lung cancer patients followed at Mayo 
Clinic between 1997 and 2007. Overall QOL and 
subdomains were assessed by either Lung Cancer 
Symptom Scale (LCSS) or Linear Analogue 
Self Assessment (LASA) measures with scores 
transformed to a 0-10 scale with higher scores 
representing better status. Baseline QOL scores 
assessed within 6 months of diagnosis were 
dichotomized as clinically deÀcient (CD) or not. A 
total of 470 SNPs in 56 genes of three biological 
pathways were assessed for association with 
QOL measures. Logistic regression with training/
validation samples was used to test the association of 
SNPs with CD QOL. 
Results: Six SNPs on four genes were replicated 
using our split schemes. Three SNPs in MGMT 
gene, (rs3858300 in adjusted analysis, rs10741191 
and rs3852507 in unadjusted analysis) from DNA 
repair pathway were associated with overall QOL. 
Two SNPs, rs2287396 (GSTZ1) and rs9524885 
(ABCC4), from glutathione metabolic pathway were 
associated with fatigue in unadjusted analysis. In 
adjusted analysis, two SNPs, rs2756109 (ABCC2) 
and rs9524885 (ABCC4), from glutathione 
metabolic pathway were associated with pain.
Conclusion: We identiÀed three SNPs in three 
glutathione metabolic pathway genes, and three SNPs 
in two DNA repair pathway genes associated with 
QOL measures in non-small cell lung cancer patients.
TXS, and 12-LOX metabolite levels (VEGF, TXB
2
, 
12-S-HETE) were measured in human NSCLC 
serum samples by ELISA. VEGF metabolite levels 
were correlated with both TXB
2
 and 12-S-HETE. 
Over-expression of TXS and 12-LOX was carried 
out in NSCLC cell lines (A-549, SKMES-1). The 
effects of over-expression on VEGF secretion was 
examined by ELISA.
Results: All four survival factors (VEGF, COX-
2, TXS, 12-LOX) were expressed to a varying 
degree in NSCLC tissue. Expression of TXS was 
signiÀcantly (p<0.001) correlated with VEGF in 
the same patients. 12-LOX levels were not quite 
signiÀcantly correlated with VEGF (p=0.17). At the 
serum metabolite level, both TXB
2
 and 12-S-HETE 
levels were signiÀcantly (p<0.05) correlated with 
VEGF, while both TXB2 and VEGF levels were 
higher in adenocarcinoma. A similar pattern was 
observed in tissue, with COX-2, TXS and VEGF 
expression levels also signiÀcantly higher in 
adenocarcinoma (p<0.001) and female patients 
(p<0.05). In support of our observations of a 
correlation between VEGF, TXS, and 12-LOX, both 
TXS and 12-LOX over-expression increased VEGF 
secretion in-vitro.
VEGF was not associated with survival in our patient 
cohort (p=0.4). While COX-2 was associated with 
short-term survival (p<0.01), no association with 
overall survival was observed (p=0.2). Neither TXS 
nor 12-LOX were associated with patient survival, 
either alone, or in combination with VEGF.
Conclusion: Our study also demonstrates a link 
between VEGF expression and that of arachidonic-
acid derived TXS and 12-LOX in NSCLC, with 
the strongest association observed between VEGF 
and TXS. The increased VEGF secretion observed 
following overexpression of these enzymes suggests 
that they may play a role in tumour angiogenesis. 
While we did not observe an association with patient 
survival in our cohort, our Àndings suggest that 
these enzymes may promote tumour progression in 
NSCLC, potentially via increased VEGF expression 
and subsequent angiogenesis. This novel concept 
warrants further investigation.
Keywords: 12-lipoxygenase, VEGF, COX-2, 
thromboxane synthase
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intent (chemo-radiotherapy) and 152 with palliative 
intent. Response to chemotherapy was evaluable for 
163 patients, showing 1 complete response (CR), 39 
partial response (PR), 82 stable disease (SD) and 41 
progressive disease (PD). Overall objective response 
rate was 25% (40/163). Median progression free 
survival (PFS) (n=177)was 7.1 months (95% CI 5.9-
8.2). Median overall survival (OS) was 11.4 months 
(95% CI 8.8-14). Response to chemotherapy was 
observed in 25% (12/49) of patients with a KRAS/
BRAF mutation, and 25% (28/114) of patients 
with wild type (WT) KRAS/BRAF. There was a 
trend for higher PD rate in patients with mutated 
KRAS/BRAF than patient with WT KRAS/BRAF 
(16/49, 33% versus 25/114, 22%, p=0.148). PFS 
was signiÀcantly shorter in patients with a KRAS/
BRAF mutation: 5.4 months (95% CI 2.4-8.3) versus 
7.4 months (95% CI 5.8-9.0), p=0.017 for those 
with wild type KRAS. Although OS was worse for 
patients with a KRAS/BRAF mutation, this was not 
signiÀcantly different, 6.3 months (95% CI 2.4-10.2) 
in patients with mutated KRAS/BRAF versus 12.4 
months (95% CI 10.2-14.8) in patients with wild 
type KRAS/BRAF (p=0.082). 
Conclusion: In our series, KRAS/BRAF mutation 
was not predictive for response to platinum-
containing chemotherapy in patients with advanced 
NSCLC. KRAS/BRAF mutation was associated with 
a signiÀcantly shorter PFS but not OS in advanced 
NSCLC patients treated with platinum-containing 
chemotherapy.
Keywords: Kras, BRAF, NSCLC, predictive 
markers
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P2.180 INCREASED BCL-2 EXPRESSION 
IS ASSOCIATED WITH BAX 
PROMOTER HYPERMETHYLATION IN 
NEUROENDOCRINE CARCINOMA (NEC) 
OF THE LUNG.
Marta Batus, Daniel Mcfarland, Lela Buckingham, 
John Coon, Sanjib Basu, Kelly Walters, Mary J. 
Fidler, Jeffrey A. Borgia, Philip Bonomi 
Hematolog/Oncology/BMT, Rush University Medical 
Center/United States Of America
Background: Minimal advances have been made 
in the treatment of NECs, including small cell lung 
cancer (SCLC). Bcl-2 and Bax are key regulators 
Keywords: Lung cancer, Quality of Life, Clinical 
SigniÀcance
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P2.179 PREDICTIVE VALUE OF KRAS 
AND BRAF MUTATIONS IN ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS TREATED WITH 
CHEMOTHERAPY
Anne-Marie Dingemans1, Egbert F. Smit2, Danielle 
Heideman3, Wouter Mellema2, Jules Derks1, 
Robertjan Suylen Van4, Erik Thunnissen3 
1Pulmonology, Maastricht University Medical 
Center/Netherlands, 2Pulmonary Diseases, 
Vrije Universiteit Medical Centre/Netherlands, 
3Pathology, VUMC/Netherlands, 4Department Of 
Pathology, Maastricht University Medical Center/
Netherlands
Background: KRAS mutation is thought to be 
related with poor outcome of patients with non-
small cell lung cancer (NSCLC). The predictive 
value of KRAS and BRAF mutations for response to 
and survival following chemotherapy has not been 
established. 
Methods: From a retrospective database consisting 
of consecutive chemonaive patients with advanced 
NSCLC treated with a platinum doublet from 2 
university hospitals patients cases were selected 
when archive tumor tissue was available for 
molecular analysis. Mutation analysis was performed 
for KRAS exon 1,2 and BRAF exon 15 by high 
resolution melting following sequencing. Response 
to chemotherapy was assessed according to RECIST. 
Results: FFPE-tumour derived DNA was available 
from 188 patients. Of 6 cases the DNA was of 
insufÀcient quality for KRAS and/or BRAF 
mutation analyses, leaving a total of 182 patients 
for further analyses (118 males and 64 females, 
mean age 60 (range 24-83 years). All patients had 
advanced NSCLC (34 stage IIIa, 38 IIIb, 110 IV), 
of which 49% were adenocarcinoma, 27% large 
cell carcinoma, 20% squamous cell carcinoma and 
3% large cell neuroendocrine carcinoma. Of the 
182 patients, 56 (31%) had a KRAS mutation, and 
1 (0.5%) a BRAF mutation. Mutations were mainly 
observed in adenocarcinoma (n=36/89), followed by 
large cell 14/49, squamous cell carcinoma 4/37 and 
LCNEC 2/6. 30 patients were treated with curative 
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resistance to apoptosis. The caspase 8 inhibitor 
FLIP is a major anti-apoptotic protein that is 
over-expressed in several cancer types, including 
mesothelioma and has been linked to drug resistance. 
The histone deacetylase inhibitor Vorinostat has 
been evaluated in a phase III randomised placebo-
controlled trial for patients with relapsed MPM, 
which is due to report in 2011. In order to develop 
clinically relevant predictive biomarkers of 
response, understanding the mechanisms involved in 
Vorinostat-induced apoptosis in MPM is essential.
Methods: The role of FLIP and caspase 8 in 
mediating the effects of Vorinostat in MPM was 
assessed in a panel of seven human MPM cell lines 
and conÀrmed in spheroid and in vivo models. RNA 
interference and protein overexpression approaches 
were used. Cell death was assessed by Áow 
cytometry, Western blotting, caspase activity and 
clonogenic assays.
Results: We found that Vorinostat potently down-
regulated FLIP expression in a panel of MPM cell 
lines (n=7). Vorinostat-induced apoptosis was found 
to be highly caspase 8-dependent in 5/7 MPM cell 
lines examined, and stable FLIP overexpression 
inhibited Vorinostat-induced apoptosis. Importantly, 
FLIP down-regulation was a sufÀcient death signal 
as RNAi-mediated FLIP silencing also activated 
caspase 8 and induced apoptosis. In addition, 
Vorinostat-induced FLIP down-regulation was 
observed in 3D and in vivo models of MPM. 
Moreover, Vorinostat was found to enhance cisplatin- 
and rTRAIL-induced in a FLIP-dependent manner.
Conclusion: These results indicate that FLIP is a 
major target for Vorinostat in MPM and identiÀes 
FLIP, caspase 8 and associated signaling molecules 
as candidate pharmacodynamic and/or predictive 
biomarkers for Vorinostat in this disease.
Keywords: Vorinostat, mesothelioma, c-FLIP, 
caspase 8
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P2.182 MICRORNAS IN PLASMA AS 
POTENTIAL MARKERS FOR DIAGNOSIS 
OF MALIGNANT MESOTHELIOMA
Michaela B. Kirschner1, Lyn J. Schedlich2, Steven C. 
Kao2, James J. Edelman3, Nicola Armstrong4, Arthur 
W. Musk5, Nico Van Zandwijk2, Glen Reid2 
1Asbestos Diseases Research Institute, 
Asbestos Diseases Research Institute/Australia, 
of apoptosis. Previous studies have shown that high 
Bcl-2 and low Bax expression are associated with 
worse outcomes in NEC. The objective of our study 
was to quantify Bax promoter hypermethylation and 
correlated with Bcl-2 expression. 
Methods: Tissues from 150 patients treated as 
SCLC were stained for multiple molecular makers 
including Bcl-2 and Bax. Frequency and intensity of 
expression were measured on a scale of 0-4 (freq 0 
= no expression, freq 1=1-10%, freq 2=11-35%, freq 
3=36-70%, freq 4=71-100%). Methylation analysis 
was performed using pyrosequencing. 
Results: Of the original 150 tissue samples, 64 
samples were analyzed for Bax methylation. Of 
the Bax hypermethylated samples (overall average 
CpG methylation >10%), 73% were Bcl-2 positive 
(freqXint>or=2) vs. 21% of the samples without 
Bax hypermethylation (Chi square p=0.002). At 
Bax promoter CpG site -50 (translation start=+1), 
methylation was 13.0% in the Bcl-2 positive vs. 
7.82% for the Bcl-2 negative samples (p=0.005). 
Analyses of progression free and overall survival are 
ongoing. 
Conclusion: Bax hypermethylation was associated 
with higher Bcl-2 expression in this group of NEC 
patients. There results suggest that it would be 
reasonable to test hypomethylating agents combined 
with cytotoxic agents or with Bcl-2 inhibitors in 
NEC of the lung. 
Keywords: neuroendocrine carcinoma, Bcl-2, BAX, 
methylation
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P2.181 FLIP AS A CRITICAL TARGET 
FOR VORINOSTAT IN MESOTHELIOMA
Jane L. Hurwitz1, Izabela Stasik1, Emma M. Kerr1, 
Caitriona Holohan1, Kelly M. Redmond1, Catherine 
S. Fenning1, Kirsty M. Mclaughlin1, Sara Busacca1, 
Dario Barbone2, V courtney Broaddus2, Patrick G. 
Johnston1, Dean A. Fennell1, Daniel B. Longley1 
1Centre For Cancer Research And Cell Biology, 
Queen’s University, Belfast/United Kingdom, 
2University Of California, San Francisco/United 
States Of America
Background: Malignant pleural mesothelioma 
(MPM) is a rapidly fatal malignancy with a median 
survival of less than 12 months. One of the main 
reasons for the failure of anti-cancer therapies is 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1045
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and control plasma identiÀed a number of potential 
markers for the presence of MM, with preliminary 
data conÀrming a signiÀcantly higher abundance 
of both miR-92a and miR-29c* in patient plasma. 
Taken together these data suggest that circulating 
miRNAs could represent a promising source of 
markers to aid in the diagnosis of MM. 
Keywords: microRNA, biomarker, Malignant 
mesothelioma
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.183 TREGS IN REGIONAL LYMPH 
NODES OF PRIMARY NON-SMALL CELL 
LUNG CANCERS
Candice C. Black1, Mary Jo Turk2, Konstantin H. 
Dragnev3, James R. Rigas3 
1Pathology, Dartmouth Hitchcock Medical Center/
United States Of America, 2Microbiology And 
Immunology, Dartmouth Medical School/United 
States Of America, 3Thoracic Oncology, Dartmouth 
Hitchcock Medical Center/United States Of America
Background: CD4+CD25+ Regulatory T cells 
(Tregs) have been shown to suppress host immune 
responses to a variety of cancers. Nuclear Foxp3 is 
currently the only speciÀc marker for regulatory T 
cells. We previously demonstrated the presence Tregs 
in human non-small cell lung carcinoma (NSCLC) - 
inÀltrating lymphocytes. All induced lymphoid tissue 
was positive for Tregs, although there was a trend 
with greater cell counts in adenocarcinomas (ADC) 
and lower cell counts in squamous cell carcinoma 
(SCC). Currently we tested the draining lymph nodes 
(N1 and N2 stations) from primary lung tumors for 
the presence and quantity of Tregs. 
Methods: After obtaining IRB approval, sixteen 
cases of formalin Àxed parafÀn embedded tissue 
were selected from the pathology archives, 
[12 primary lung carcinomas (5 squamous cell 
carcinoma, 7 adenocarcinoma, 2 inÁammatory (1 
organizing pneumonia and 1 interstitial Àbrosis) and 
2 sarcoid lymph nodes]. A tissue array was created 
with two 1.2-mm cores from each: primary tumor, 
N1 node, N2 node, and control tissue. The array 
was incubated for 20 minutes with 1:100 dilution of 
puriÀed anti-Foxp3 antigen (Biolegend, San Diego, 
CA). The number of positive cells in each array dot 
was counted and average counts were calculated for 
all cases and for ADC and SCC separately. Statistics 
2Asbestos Diseases Research Institute/Australia, 
3Cardiothoracic Surgical Unit, Royal Prince Alfred 
Hospital; The Baird Institute; Faculty Of Medicine, 
University Of Sydney/Australia, 4Garvan Institute/
Australia, 5The University Of Western Australia/
Australia
Background: Malignant Mesothelioma (MM) is 
an aggressive cancer that is primarily caused by 
asbestos exposure. The median survival duration 
of MM is less than one year and the 5 year survival 
rate less than 1%. There is evidence suggesting that 
when MM is treated at an early stage there will be 
considerably better survival outcomes. Recently it 
has been shown that microRNAs (miRNAs) can be 
detected in a range of biological Áuids including 
serum or plasma, and that these circulating miRNAs 
represent a class of potential new biomarkers. In 
addition, speciÀc miRNA expression patterns in 
plasma or serum have been found to be associated 
with the presence of (solid) tumours. Recent studies 
have reported proÀling of MM tumour samples, 
however a speciÀc miRNA pattern in the blood of 
MM patients has yet to be investigated. 
Methods: We have proÀled miRNA expression 
in plasma samples from 3 healthy volunteers and 
5 patients with MM using Agilent 8x15k miRNA 
microarrays. Total RNA from plasma samples was 
isolated using the mirVana PARIS kit with the 
additional use of glycogen. MiRNAs were quantiÀed 
by miRNA speciÀc stem-loop RT-qPCR by absolute 
quantiÀcation using standard curves generated 
from synthetic oligos. Data were analysed in the 
GeneSpring software. Candidate miRNAs identiÀed 
in the arrays were validated by RT-qPCR in a larger 
sample set of 13 MM patients, 5 healthy controls and 
7 patients with coronary artery disease (CAD). 
Results: Microarray-based expression proÀling of 
plasma from 5 MM patients and 3 healthy controls 
identiÀed 17 miRNAs with signiÀcantly differential 
abundance in the two sample groups. 15 of these 
miRNAs were found at higher levels in MM 
patients, with 3 of them being exclusively found 
in patient plasma. Using RT-qPCR we performed 
Àrst validation studies in a small cohort of 13 MM 
patient plasma and 12 control plasma (healthy and 
CAD). These revealed that both miR-92a and miR-
29c* were present at signiÀcantly higher levels in 
the plasma of MM patients compared to both healthy 
and CAD control plasma. Validation of differential 
expression of further candidates is underway. 
Conclusion: MiRNA expression proÀling of patient 
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staged I and II NSCLC, were recruited into this 
study from among those who were evaluated for 
EGFR mutation status between January 2007 
and September 2010 at Ibarakihigashi National 
Hospital. All eligible patients were divided into two 
groups: EGFR mutation positive group (positive 
group) and EGFR wild type group (negative 
group). The results of pulmonary function test were 
compared between the two groups.
Results: There were 23 patients who met the 
criteria, of whom 6 were mutation-positive (all 
males, median age: 73) and the remaining 17 were 
the wild type (males: female, 16:1, median age: 
72). The median smoking history of the positive 
group was 46 pack-year and 4 (66.7%) were 
current smokers, whereas that of the negative 
group were 40 pack-year and 7 (41.1%) were 
current smokers. The pathological feature of all 
patients in the positive group was adenocarcinoma, 
whereas the negative group was comprised of 10 
adenocarcinoma, 6 squamous cell carcinoma, and 
2 large cell carcinoma. In pulmonary function test, 
the median of vital capacity (VC) / predicted VC 
was 93.5% in the positive group and 94.9% in the 
negative group (p = 0.70). In forced expiratory 
volume in a second (FEV
1.0
) / predicted FEV
1.0
, the 
positive group had better result than the negative 
group although the difference was not signiÀcant 
(101.3% v.s 87.6%, p = 0.38). On the other hand, 
FEV
1.0
 / forced VC (FVC) was signiÀcantly higher 
in the positive group than in the negative group 
(73.6% v.s 68.1%, p = 0.042). The same trend was 
observed in FEV
1.0
 / FVC, excluding patients with 
squamous cell carcinoma (73.6% v.s 69.3%, p = 
0.092). 
Conclusion: Despite moderate to heavy smoking 
history, the NSCLC patients with EGFR mutation 
might have normal or mild obstructive defects, 
compared to those with wild type EGFR. The 
NSCLC patients with normal or mild obstructive 
defects should be evaluated for EGFR mutation 
status irrespective of smoking history. 
Keywords: EGFR mutation, smoking history, 
pulmonary function test, non small lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
were calculated from GraphPad Software, Inc. 
Results: The mean number of FoxP3 positive 
cells in the tumors and control lung was 2.7. The 
average for N1 and N2 draining nodes was 64.3 and 
85.1 for all histologies, resp. The average N1 Treg 
count for ADC alone was 126, and for SCC was 3.5 
(p=<0.008, unpaired t-test). The average for N2 for 
ADC and SCC was similar (83.8 and 86.4, resp.). 
Conclusion: These Ànding demonstrate the presence 
of Tregs in the draining N1 and N2 nodes of primary 
lung tumors. The disparity of Tregs between 
histologies conÀrms our previous Àndings. ADC 
histology appears to be associated with signiÀcantly 
higher numbers of Tregs within the closest N1 nodal 
basin, compared to SCC. 
Keywords: Tregs, FoxP3
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P2.184 CORRELATION BETWEEN 
PULMONARY FUNCTION TEST AND 
EGFR MUTATION STATUS IN NON-
SMALL CELL LUNG CANCER PATIENTS 
WITH MODERATE TO HEAVY SMOKING 
HISTORY
Yoshiya Tsunoda1, Shimao Fukai2, Takefumi Saito1, 
Kenji Hayasihara1, Yasuhiro Umedu2, Akimasa 
Sekine1, Kunihiko Miyazaki1, Toru Tanaka1, Yohei 
Yatagai1, Shin-Yuan Lin1, Yukiko Miura1, Ataru 
Moriya3 
1Department Of Respiratory Medicine, National 
Hospital Organization Ibarakihigashi National 
Hospital/Japan, 2Department Of Clinical Research, 
National Hospital Organization Ibarakihigashi 
National Hospital/Japan, 3Department Of Clinical 
Laboratory, National Hospital Organization 
Ibarakihigashi National Hospital/Japan
Background: Epidermal growth factor receptor 
(EGFR) mutations are reported to be more frequent 
in non-small cell lung cancer (NSCLC) patients 
with never and limited smoking history. Although 
smoking status is the strongest predictor of 
harboring an EGFR mutation, there are NSCLC 
patients, albeit a few, who have both moderate-
to-heavy smoking history and EGFR mutations. 
However, the clinical characteristics of those 
patients are not well established.
Methods: Patients, with both more than a 20-
pack year history of smoking and clinically 
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P2.186 ACCURATE ESTIMATION OF DNA 
METHYLATION FREQUENCY IN NON-
SMALL CELL LUNG CANCER
Hongdo Do1, Paul Mitchell2, Thomas John2, 
Alexander Dobrovic1 
1Pathology, Peter MacCallum Cancer Centre/
Australia, 2Joint Austin Ludwig Medical Oncology 
Unit, Austin Health/Australia
Background: Promoter hypermethylation is a 
common epigenetic mechanism for gene silencing 
in NSCLC. DNA methylation detected in tumour 
cells has been suggested as a potential biomarker 
that helps selection of optimal chemotherapeutic 
agents and stratiÀcation of NSCLC patients at 
high risk of recurrence after surgery. Identifying 
methylated genes is best done by a methodology 
that is unlikely to give false positives or negatives. 
We used methylation sensitive HRM as it can give 
a methylation portrait for each assayed region and 
is less prone to false positives than other commonly 
used methodologies.
Methods: DNA was prepared from FFPE sections of 
56 N1 NSCLC tumours and bisulÀte modiÀed. MS-
HRM assays were performed for two sets of genes; 
DNA repair genes (BRCA1, MLH1, XPC, MGMT, 
RAD23B, ERCC1) and genes associated with 
recurrence after surgery (APC, CDH13, RASSF1A 
and p16). Selected MS-HRM positive samples 
were bisulÀte sequenced. MGMT methylation was 
also estimated by SMART-MSP and samples were 
genotyped for the rs1690625 MGMT promoter SNP.
Results: We were unable to replicate previous 
reports of a high incidence of XPC, BRCA1 and 
MLH1 methylation in NSCLC as no methylation 
was detected for any of these genes. One tumour 
showed RAD23B methylation and one tumour 
showed ERCC1 methylation. These are the Àrst 
reports of the methylation of RAD23B and ERCC1 
in NSCLC. A high frequency of DNA methylation 
in the CDH13, APC, CDH13, RASSF1A, and 
CDKN2A (p16) genes was conÀrmed giving an 
overall methylation frequency of 25%, 50%, 32%, 
and 25% respectively. MGMT methylation was seen 
in 7 (12.5%) of tumours but some of these seem 
to be false positives due to constitutional MGMT 
methylation predominantly associated with the T 
allele of the rs1690625 SNP in somatic tissues.
Conclusion: Methodology is critical in accurately 
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P2.185 THE PREVALENCE OF HISTONE 
DEACETYLASE (HDAC) EXPRESSION 
IN KOREAN NON-SMALL CELL LUNG 
CANCER PATIENTS
Heejong Baek1, Jae-Soo Koh2, Chul H. Kim2 
1Thoraxic Surgery, Korea Cancer Center Hospital/
Korea, 2Pathology, Korea Cancer Center Hosital/
Korea
Background: DNA methylation and histone 
modiÀcation are dynamically linked in the pigenetic 
control of gene silencing and they play an important 
role in tumorigenesis. We evaluated the role of 
histone deacetylase (HDAC) in the development 
of lung cancer and the relationship between a 
HDAC overexpression and survivin, p16 and p53 
overexpression. 
Methods: We performed immunohistochemical 
staining for HDAC1, HDAC2, HDAC3, p16, and 
p53 in 129 lung cancer specimens. 
Results: HDAC overexpression was detected in 
51% (HDAC1 and HDAC2) and 64% (HDAC3) 
and it was more frequently seen in the squamous 
cell carcinomas than in the adenocarcinomas 
(p<0.05). There was statistical signiÀcances 
between HDAC overexpression and survivin 
overexpression (p<0.05), but not with p16 and p53 
overexpressions. 
Conclusion: HDAC overexpression might be 
involved in lung carcinogenesis, and especially 
in a squamous cell carcinoma, and a HDAC 
overexpression may be associated with survivin 
overexpression, however, overexpression of these 
genes are not related with patient survival. These 
results suggest that HDAC inhibitors are putative 
therapeutic agents in subgroup of non-small cell 
lung cancer patients. 
Keywords: Non-small cell lung cancer, survivin, 
histone deacetylase
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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9 and 20, AKT1 exon 4, AKT3 exon 3, KRAS exons 
2 and 3, and BRAF exon 15. All HRM positive 
samples were conÀrmed by Sanger sequencing. 
Results: Gain-of-function mutations from the genes 
in the EGFR signalling pathway were detected in 
54% of the NSCLC samples. Forty nine per cent 
of the NSCLC tumours harboured either EGFR 
(36.5%) or KRAS codons 12 and 13 mutations 
(12.5%), which were mutually exclusive. EGFR 
mutations were also detectable in 8.5% of tumours 
with non-ADC histologies and in 21.3% of male 
patients. PIK3CA (3.5%), BRAF (3%), and AKT1 
(0.5%) mutations were less frequently detected. No 
HER2 mutation was identiÀed. EGFR, KRAS, and 
BRAF mutations were mutually exclusive whereas 
concomitant PIK3CA and EGFR mutations were 
detected in four NSCLC tumours.
Conclusion: High resolution melting is a sensitive, 
cost-effective, closed-tube method suitable for 
mutation detection at multiple genes in FFPE 
NSCLC samples. KRAS mutation testing may 
be useful to exclude EGFR mutation positivity in 
some difÀcult clinical samples. Testing for the other 
mutations may be useful where they indicate the use 
of speciÀc therapies.
Keywords: Predictive biomarkers, mutation 
detection, EGFR mutations, high resolution melting
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P2.188 B-CELL LYMPHOMA/LEUKEMIA 
11A (BCL11A) PROTEIN EXPRESSION 
IS ASSOCIATED WITH SURVIVAL IN 
EARLY STAGE NON-SMALL CELL LUNG 
CANCER:A COMPARISON BETWEEN 
BCL11A GENE COPY NUMBER, 
MRNA EXPRESSION AND PROTEIN 
EXPRESSION.
Benyuan Jiang1, Xu-Chao Zhang2, Xue-Ning Yang3, Jin-
Ji Yang1, Qing Zhou4, Hong-Hong Yan5, Yi-Long Wu6 
1Divison I Of Pulmonary Oncology, Guangdong 
Lung Cancer Institute, Guangdong Academy Of 
Medical Sciences & Guangdong General Hospital/
China, 2Division Of Pulmonary Oncology, 
Guangdong Lung Cancer Institute, Guangdong 
General Hospital, Guangdong Academy Of 
Medical Sciences/China, 3Division Ii Of Pulmonary 
Oncology, Guangdong General Hospital/China, 
4Division I Of Pulmonary Oncology, Guangdong 
Lung Cancer Institute, Guangdong General 
assessing methylation status. Detectable methylation 
of the XPC, BRCA1 and MLH1 DNA repair 
genes was absent indicating that their methylation 
frequency is overestimated in the literature. 
Methylation in ERCC1 and RAD23B, although 
rare, was demonstrated for the Àrst time, and may 
offer intriguing boutique targets for therapy. When 
measuring MGMT methylation, it will be important 
to distinguish those tumours that are truly methylated 
from those tumours in which there are background 
levels of constitutional methylation.
Keywords: DNA methylation, Predictive 
biomarkers, prognostic biomarkers
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P2.187 EXTENDED MUTATION 
PROFILING OF THE EGFR SIGNALLING 
PATHWAY IN NON-SMALL CELL LUNG 
CANCER SENT FOR EGFR MUTATION 
TESTING.
Hongdo Do1, Ben Solomon2, Stephen B. Fox1, 
Alexander Dobrovic1 
1Pathology, Peter MacCallum Cancer Centre/
Australia, 2Division Of Cancer Medicine, Peter 
MacCallum Cancer Centre/Australia
Background: The EGFR signalling pathway is a 
pivotal signalling axis for initiation, progression, 
and survival of non-small cell lung cancer. Frequent 
dysregulation of the EGFR signalling pathway by 
gain-of-function mutations makes it an attractive 
target for therapeutic intervention. The establishment 
of cost-effective and sensitive methodology for 
proÀling of somatic mutations in the clinically 
important genes is highly desirable for current and 
future molecularly tailored therapies.
Methods: 200 formalin-Àxed parafÀn-embedded 
NSCLC tumours selected for diagnostic EGFR 
mutation testing were included. The histological 
subtype was predominantly adenocarcinomas (141 
cases) but also included 24 large cell carcinomas, 
10 squamous cell carcinomas, and 25 cases with 
unknown histology. One hundred twenty cases 
were female and 80 cases were male in gender. The 
mutation status of seven selected genes (EGFR, 
KRAS, HER2, PIK3CA, AKT1, AKT3, and BRAF) 
was proÀled using high resolution melting. The 
exons examined for each gene were as follows: 
EGFR exons 18-21, HER2 exon 20, PIK3CA exons 
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P2.189 PRACTICE AND PITFALLS 
OF MUTATION TESTING USING 
FORMALIN-FIXED PARAFFIN-
EMBEDDED TISSUES.
Hongdo Do, Stephen B. Fox, Alexander Dobrovic 
Pathology, Peter MacCallum Cancer Centre/
Australia
Background: Tumour tissues are routinely archived 
after Àxation with 10% buffered formalin and 
embedding in parafÀn. The formalin Àxation causes 
chemical damage to the genetic material. Molecular 
biomarker testing is increasingly performed with 
FFPE samples in both research and diagnostic 
settings. Appropriate design and interpretation 
of assays based on DNA from FFPE tissues, 
particularly when the amount of tumour material is 
limited, is thus essential. In some cases, template 
derived artifacts will be common. These probably 
account for most of the non-canonical mutations 
reported in the literature. 
Methods: A range of methodologies are useful 
for assessing the quality of FFPE specimens. A 
multiplex PCR generating amplicons at different 
sizes (100, 200, 300, 500, 600 bp) was performed to 
assess the degradation of FFPE DNA. A real-time 
ampliÀcation step allows the determination of the 
amount of ampliÀable template. Low copy number-
high resolution melting (LCN-HRM) followed by 
sequencing enables the detection of low frequency 
variants outside the normal analytical sensitivity of 
sequencing. 
Results: FFPE DNA samples that were negative 
by sequencing but positive by high resolution 
melting analysis were further analysed using 
low copy number-high resolution melting (LCN-
HRM). Approximately, a range from one to four 
copies of template was added in individual LCN-
HRM reactions. There was a high intra-sample 
variation in the size of ampliÀable template. 
Smaller amplicon sizes increased the success rate 
of assays. When positive LCN-HRM were Sanger 
sequenced, multiple non-identical sequence changes, 
predominantly transitional base changes (G>A 
or C>T), were often detected. In other cases true 
mutations were detected. 
Conclusion: PCR ampliÀcation using FFPE DNA 
can generate multiple template-mediated artefacts. 
This is particularly a problem when there is a low 
Hospital, Guangdong Academy Of Medical Sciences/
China, 5Medical Research Center, Guangdong 
General Hospital/China, 6Division Of Pulmonary 
Oncology, Guangdong General Hospital/China
Background: Lung cancer is leading cause of 
cancer-related death both worldwide and in China, 
but we continue to have limited understanding of 
the pathophysiology of this disease.The purpose 
of this study was to characterize B-cell lymphoma/
leukemia 11A (BCL11A) mRNA expression ,protein 
expression and gene copy number in surgically 
resected non-small cell lung cancer(NSCLC) in 
relation to patient characteristics and prognosis. 
Methods: One hundred and fourteen patients 
with NSCLC who underwent curative pulmonary 
resection were studied(median follow-up 47.2 
months). BCL11A mRNA expression was evaluated 
by quantitative reverse transcription polymerase 
chain reaction(qRT-PCR) from 114 corresponding 
fresh-frozen saples. BCL11A protein expression 
was assessed by Immunohistochemistry staining 
(n=113).BCL11A gene copy number was extracted 
from previous array-based comparative genome 
hybridization (aCGH) data from the same samples. 
Results: BCL11A copy number, gained more 
frequently in squamous-cell lung cancer(SCC) 
than lung adenocarcinoma(AC)(t=2.97,P=0.005). 
BCL11A gene expression by RT-PCR have an 
oppositive correlation with , A signiÀcantly 
higher average expression level was observed for 
BCL11A in the SCC samples with ampliÀcations 
as compared to those SCC samples without 
ampliÀcations(t=3.54,P=0.023).BCL11A protein 
expression was also higer in SCC than AC 
,and BCL11A protein localized predominantly 
in cellular nucleus of SCC, but in AC, the 
immunohistochemical staining was detectable 
predominantly in cytoplasm of cancer cells.
Mutivariate analysis demonstrated that in early stage 
patients(IA-IIB), BCL11A protein was not only a 
signiÀcant prognostic factor for disease free survival 
[Hazard ratio (HR) 0.176, 95% conÀdence interval 
(CI) 0.047-0.658, P=0.01], but also for overall 
survival [Hazard ratio (HR) 0.171, 95% conÀdence 
interval (CI) 0.059-0.498,P=0.001]. 
Conclusion: BCL11A protein expression is 
higher in squamous-cell lung cancer than lung 
adenocarcinoma and harbors a positive prognostic 
value for early stage(IA-IIB) NSCLC patients. 
Keywords: B-cell lymphoma/leukemia 11A, 
Prognosis, Non-small cell lung cancer
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positive. EGFR gene products could be ampliÀed 
and completely sequenced in only nineteen cases. 
There were four cases of exon 19 in-frame deletion 
only in adenocarcinoma subtype and three exon 21 
missense mutations, two in the adenocarcinoma 
as L858R and P848S whereas one squamous cell 
carcinoma displayed L858R mutation. All exon 19 
deletion mutations were ERCC-1 negative. Exon 21 
mutations were founded in both ERCC-1 positive 
(one cases) and ERCC-1 negative (2 cases). Survival 
of patients having ERCC-1 negative and EGFR 
wild type is compared with those having ERCC-1 
negative and EGFR mutation positive. 
Conclusion: Patients having adenocarcinoma 
subtype with ERCC-1 negative and EGFR mutation 
wild type seemed to live longer than those having 
EGFR mutation positive in comparison to double 
negative tumors. However, this is a single center 
study with limited number of cases. Further study 
with high number cases recruited are in cintinuum.
Keywords: Advanced NSCLC, ERCC-1, EGFR 
mutation
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P2.191 PERFORMANCE OF 
A COMBINATION OF SERUM 
BIOMARKERS, INCLUDING SOLUBLE 
MESOTHELIN-RELATED PEPTIDE 
(SMRP), IN DIAGNOSING MALIGNANT 
MESOTHELIOMA
Asuka Okada1, Kazuya Fukuoka2, Syusai Yamada1, 
Taiichiro Otsuki1, Eriko Masachika1, Hitomi 
Kamiya1, Miki Honda1, Hisaya Okuwa1, Yoshitaka 
Nogi1, Kouji Mikami1, Risa Maeda1, Kuninobu 
Tamura1, Chiharu Tabata1, Takashi Nakano1 
1Division Of Respiratory Medicine, Department Of 
Internal Medicine, Hyogo College Of Medicine/
Japan, 2Cancer Center, Hyogo College Of Medicine/
Japan
Background: Malignant mesothelioma (MM) is 
a rare, progressive malignancy causally linked to 
asbestos exposure. Currently, there are no approved 
screening modalities for the early detection of MM. 
However, recent studies have provided evidence 
that soluble mesothelin-related peptide (SMRP) 
and megakaryocyte potentiating factor (MPF) can 
be useful biomarkers for the serum diagnosis of 
MM. The aim of this study is to evaluate SMRP as a 
mutation frequency and/or limited material for 
analysis. Non-canonical or novel sequence variants, 
especially found with FFPE DNA, need to be 
adequately conÀrmed by testing of independent PCR 
products. 
Keywords: mutation detection, EGFR mutations, 
FFPE, Predictive biomarkers
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P2.190 PREDICTIVE FACTORS OF 
ERCC-1 AND EGFR MUTATION IN 
ADVANCED NSCLC: A SINGLE CENTER 
RETROSPECTIVE STUDY.
Nirush Lertprasertsuke1, Juntima Euathrongchit2, 
Somcharoen Saeteng3, Sumitra Thongprasert3 
1Pathology, Faculty Of Medicine, Chiang Mai 
University/Thailand, 2Radiology, Faculty Of 
Medicine, Chiang Mai University/Thailand, 
3Surgery, Faculty Of Medicine, Chiang Mai 
University/Thailand
Background: Overexpression of ERCC-1 gene 
has been reported to be associated with platinum 
resistance in both early and advanced NSCLC 
patients whereas the mutations at tyrosine kinase 
domain of EGFR gene especially exon 19 deletion 
and exon 21 missense mutation are associated 
with TKI responsiveness. This study is aimed to 
investigate the prevalence of EGFR mutations in 
association with ERCC-1 protein expression in 
advanced NSCLC Thai patients and analyze the 
correlation between ERCC-1 and EGFR mutation 
status to the overall survival after platinum-based 
chemotherapy.
Methods: There were 29 cases of advanced NSCLC 
patients who had sufÀcient tumor tissues and had 
been treated with platinum-based chemotherapy 
as the Àrst-line treatment in Maharaj Nakorn 
Chiangmai Hospital between Jan.2006-Dec.2008. 
The ERCC-1 expression had been assessed with 
immunohistochemistry whereas the EGFR gene 
mutation was performed by conventional PCR 
followed by direct sequencing to identify the 
mutation.
Results: Twenty-nine tumor tissues have been 
analysed. There are 11 cases of squamous cell 
carcinoma and 18 cases of adenocarcinoma . Seven 
cases (63.6%) of squamous cell carcinoma and 
nine cases (50%) of adenocarcinoma were ERCC-1 
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regional lymph nodes of patients with non-small 
cell lung carcinoma (NSCLC) appear to be limited 
to patients with Stage I disease. The prognostic 
signiÀcance of this remains unknown. Such reactions 
are thought to represent a cell-mediated anti-tumour 
response, and have been associated with improved 
outcomes in other solid organ malignancies.
Methods: We performed a retrospective chart review 
of all patients undergoing lobectomy with curative 
intent for NSCLC. Eligible cases were selected on 
the basis of pathologic reports noting, with matched 
controls then drawn from the same surgical cohort
Results: 157 patients underwent lobectomy and 
lymph node dissection. Eight patients with sarcoidal 
granulomas present in regional lymph nodes were 
idenÀed as cases, and matched to 16 control subjects. 
All subjects were staged pN0. Disease recurrence 
was noted in no case subjects, but in 7 (44%) of 
control subjects (p=0.044, c2=4.051).
Conclusion: The presence of sarcoidal reactions 
within regional lymph nodes of NSCLC patients 
predicts a lower rate of disease recurrence following 
deÀnitive surgical resection. The exact mechanism 
by which anti-tumour immunity is achieved remains 
to be elucidated.
Keywords: Granuloma, Anti-tumour immunity, 
recurrence
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P2.193 IMPACT OF DIHYDROFOLATE 
REDUCTASE EXPRESSION FOR 
CLINICAL BENEFIT FROM 
PEMETREXED IN MALIGNANT 
PLEURAL MESOTHELIOMA
Daniel C. Christoph1, Jeremias Wohlschlaeger2, 
Volker Neumann3, Thomas C. Gauler4, Christoph 
Poettgen5, Anja Peglow2, Andrea Tannapfel3, Martin 
Schuler4, Fred R. Hirsch1, Wilfried Eberhardt4, Dirk 
Theegarten2 
1Department Of Medicine, Division Of Medical 
Oncology, University Of Colorado Denver/United 
States Of America, 2Department Of Pathology 
And Neuropathology, University Hospital 
Essen/Germany, 3Institute Of Pathology, Ruhr-
university Bochum/Germany, 4Department Of 
Medical Oncology, West German Cancer Center, 
University Hospital Essen/Germany, 5Department 
Of Radiotherapy, West German Cancer Center, 
University Hospital Essen/Germany
diagnostic marker for MM and investigate whether 
its diagnostic value is enhanced by combination with 
other biomarkers. 
Methods: Serum SMRP levels were measured 
using a quantitative enzyme-linked immunosorbent 
assay, in 96 patients with MM, 55 patients with lung 
cancer, and 39 individuals with asbestos exposure. 
Receiver operating characteristic curves were 
constructed for performance evaluation. Stepwise 
logistic regression analysis was used to select marker 
combinations (MCs).
Results: The sensitivity of SMRP for diagnosing 
MM was 56%, and its speciÀcity for MM versus 
lung cancer and individuals with asbestos exposure 
was 87% and 92%, respectively. The area under the 
curve (AUC) was 0.76 (95% conÀdence interval 
[CI], 0.68–0.83; P < 0.0001) for differentiation 
between MM and lung cancer and 0.78 (95% CI, 
0.71–0.86; P < 0.0001) for differentiation between 
MM and asbestos exposure. For the MC of Áuid 
retention, SMRP, and carcinoembryonic antigen 
(CEA), the AUC for differentiation between MM and 
lung cancer (0.92 [95% CI, 0.88–0.97; P < 0.0001]) 
and differentiation between MM and asbestos 
exposure (0.93 [95% CI, 0.87–1.0; P < 0.0001]) was 
signiÀcantly higher than that for SMRP alone (P = 
0.0001 and 0.0058, respectively).
Conclusion: Combining CEA with SMRP improves 
the diagnostic performance of SMRP alone. Therefore, 
a combination of serum biomarkers, including SMRP 
can facilitate early diagnosis of MM.
Keywords: Malignant mesothelioma, mesothelin, 
soluble mesothelin-related peptide, serum biomarker
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P2.192 SARCOIDAL REACTIONS 
IN REGIONAL LYMPH NODES OF 
EARLY STAGE NON-SMALL CELL 
LUNG CANCER PATIENTS PREDICT 
IMPROVED DISEASE-FREE SURVIVAL: 
A PILOT CASE-CONTROL STUDY
Daniel P. Steinfort1, Magaret Hibbs2, James Grieve3, 
Gary Anderson4, Louis Irving1 
1Respiratory Medicine, Royal Melbourne Hospital/
Australia, 2Ludwig Institute For Cancer Research/
Australia, 3University Of Aberdeen/United Kingdom, 
4University Of Melbourne/Australia
Background: Sarcoidal reactions occuring in 
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DHFR expression in MPM pts treated with PMX is 
warranted. 
Keywords: malignant pleural mesothelioma, 
biomarker for clinical beneÀt, Pemetrexed, 
dihydrofolate reductase (DHFR)
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P2.194 STATHMIN – DRUG SENSITIVITY 
ASSOCIATED PROTEIN OF LUNG 
CANCER
Masaharu Nomura1, Tetsuya Fukuda2, Kiyonaga 
Fujii3, Takeshi Kawamura4, Hiromasa Tojo5, 
Yasuhiko Bando2, Adi F. Gazdar6, Masahiro Tsuboi1, 
Hisashi Ohshiro7, Toshitaka Nagao7, Tatsuo Ohira1, 
Norihiko Ikeda1, Noriko Gotoh4, Harubumi Kato1, 
Gyorgy M. Varga1, Toshihide Nishimura1 
1Surgery I, Tokyo Medical University/Japan, 
2Amr Incorporation/Japan, 3Hokkaido University/
Japan, 4The University Of Tokyo/Japan, 5Osaka 
University/Japan, 6Hamon Center For Therapeutic 
Oncology Research, Pathology, University Of Texas 
Southwestern Medical Center/United States Of 
America, 7Division Of Anatomic Pathology, Tokyo 
Medical University/Japan
Background: The sensitivity of chemotherapy to 
lung cancer is still very low except small cell lung 
carcinoma (SCLC). We planned to Ànd some speciÀc 
proteins related to chemosensitivity from SCLC 
and apply them to non small cell lung carcinoma 
(NSCLC)
Methods: We have selected relatively speciÀc 
proteins from formalin Àxed parafÀn-embedded 
(FFPE) tissues of histologically diagnosed as 
SCLC (n=5), LCC (n=5) and LCNEC (n=4) by 
laser microdissection, liquid chromatography / 
mass spectrometry and semi-quantiÀed method. We 
have knocked out one of characteristic proteins in 
lung cancer cell lines and checked the change of 
sensitivity to usual chemotherapeutic agents.
Results: We identiÀed one of common characteristic 
proteins of SCLC and LCNEC, stathmin, which has 
been reported as one of drug sensitivity associated 
proteins. Stathmin was more expressed in SCLC 
compared to LCNEC immunohistochemically. 
Stathmin was also expressed in NSCLC cell lines, 
H838 and H1299. After knocking out of stathmin 
by siRNA technique, the sensitivity to VP-16 was 
decreased, while the sensitivity to CDDP was increased.
Background: The antifolate pemetrexed (PMX) 
targets multiple enzymes involved in pyrimidine and 
purine synthesis, including thymidylate synthase 
(TS) and dihydrofolate reductase (DHFR). TS 
expression might predict outcome in patients (pts) 
suffering from malignant pleural mesothelioma 
(MPM) and non-small cell lung cancer (NSCLC) 
who are treated with pemetrexed. In contrast 
to pemetrexed’s main target, TS, there is little 
information about the impact of DHFR expression 
on the efÀcacy of PMX. We hypothesized that 
DHFR protein expression may also predict outcome 
following PMX treatment of MPM pts. 
Methods: Tumor samples from 60 pts with MPM, 
treated with PMX combined with platinum (57/60) 
or as a single agent (3/60) were retrospectively 
analyzed. Pre-treatment tumor samples from 33 
pts, post-treatment samples from 11 pts, as well 
as pre- and post-treatment samples from 16 pts 
were considered. DHFR protein expression levels 
were evaluated by immunohistochemistry using 
the H-Scoring system (ranging from 0 to 300), 
which relies on the product of intensity of speciÀc 
tumor cell immunoreactivity (range 0 to 3) and the 
percentage of positive tumor cells. Radiographic 
evaluation of response was performed according to 
RECIST. 
Results: The median pre-treatment H-score for 
DHFR was 105 (range: 40-215) and the median post-
treatment H-score was 110 (range: 10-215). There 
was no signiÀcant association between pre-treatment 
DHFR expression and response or outcome. But 
there was a signiÀcant association between improved 
progression-free survival (PFS) and low DHFR 
protein expression after PMX-treatment using the 
median H-score as the cut-off (median PFS of 254 vs 
123 days; hazard ratio [HR] 0.484, 95% CI, 0.057 to 
0.912). The comparison between the survival curves 
was statistically signiÀcant by using the Wilcoxon 
test (P=0.036) and borderline signiÀcant by using 
the log-rank test (P=0.061). Prolonged overall 
survival (OS) was also associated with low DHFR 
protein expression (median OS of 810 vs 672 days) 
using both tests (P=0.035 by the Wilcoxon test and 
P=0.012 by the log-rank test). 
Conclusion: Here we report the most thorough 
investigation of DHFR expression in tumor 
specimens from pemetrexed-treated MPM pts 
to date. Based on our retrospective study, post-
treatment DHFR protein expression is associated 
with prolonged PFS and OS from PMX-based 
therapy. Further prospective investigation of 
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DNA copy number abundance of each member 
of ErbB family. Kaplan-Meier survival analysis 
was used to generate the survival curve and the 
survival difference between groups was tested by 
log-rank test. Multivariate Cox proportional hazards 
regression was carried out to test the independent 
prognostic factors. 
Results: The proportion of EGFR-activating 
mutations were 118 wild type (45.2%), 70 L858R 
(26.8%), and 73 exon 19 deletion (28.0%), 
respectively. Patients with higher EGFR CN had 
shorten overall survival (p=0.032) and adjusted 
hazard ratio (HR) is 1.89 (95% CI=1.16 to 3.10, 
p=0.011) in all 261 patients. In stratiÀcation analysis 
of EGFR-activating mutation status, EGFR CN 
was not signiÀcant in wild type group and adjusted 
HRs were 2.96 (95% CI=1.02 to 8.57, p=0.046), 
7.25 (95% CI=1.74 to 30.27, p=0.007), 3.53 (95% 
CI=1.58 to 7.87, p=0.002) for L858R, exon 19 
deletion, and all EGFR-activating mutation groups, 
respectively. ERBB2 showed poor prognosis in all 
patients (HR=1.68, 95% CI=1.03 to 2.74, p=0.038) 
but not signiÀcant in wild type or EGFR-activating 
mutations. ERBB3 had signiÀcantly association with 
prognosis in all patients (HR=1.65, 95% CI=1.02 to 
2.68, p=0.042), L858R mutation group (HR=3.98, 
95% CI=1.02 to 15.63, p=0.047), all EGFR-
activating mutation group (HR=2.64, 95% CI=1.17 
to 5.95, p=0.019), respectively but no signiÀcant 
Àndings in wild type and exon 19 deletion groups. 
The similar results were also found in ERBB4 
with signiÀcantly association with prognosis in all 
patients (HR=1.62, 95% CI=1.01 to 2.61, p=0.047), 
L858R mutation group (HR=7.22, 95% CI=2.23 
to 23.36, p=0.001), all EGFR-activating mutation 
group (HR=3.40, 95% CI=1.55 to 7.48, p=0.002), 
respectively but no signiÀcant Àndings in wild type 
and exon 19 deletion groups. 
Conclusion: ErbB family had associations with 
prognosis in lung adenocarcinoma. In addition, the 
effect modiÀcations are found in EGFR, ERBB3, 
and ERBB4 in different EGFR-activating mutation 
status.
Keywords: EGFR mutation, ErbB family, DNA 
copy number, Prognosis
Conclusion: In this study, our Àndings suggested 
that stathmin may be one of proteins associated 
to the chemosensitivity not only SCLC but also 
NSCLC.
Keywords: stathmin, drug sensitivity, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.195 EGFR-ACTIVATING MUTATIONS, 
DNA COPY NUMBER ABUNDANCE OF 
ERBB FAMILY, AND PROGNOSIS IN 
LUNG ADENOCARCINOMA
Hsuan-Yu Chen1, Gee-Chen Chang2, Shinsheng 
Yuan3, Ang Yuan4, Huei-Wen Chen5, Chih-Yi Chen6, 
Chung-Ping Hsu2, Yi-Chiung Hsu1, Jiun-Yi Hsia2, 
Jeremy J. W. Chen7, Sung-Liang Yu5, Ker-Chau Li1, 
Pan-Chyr Yang4 
1Institue Of Statistical Science, Academia Sinica/
Taiwan, 2Taichung Veterans General Hospital/
Taiwan, 3Institute Of Statistical Science, Academia 
Sinica/Taiwan, 4National Taiwan University 
Hospital/Taiwan, 5National Taiwan University/
Taiwan, 6China Medical University Hospital/Taiwan, 
7National Chung Hsing University/Taiwan
Background: Epidermal growth factor receptor 
(EGFR) belongs to the ErbB family which 
comprises four members (EGFR, ERBB2, ERBB3, 
and ERBB4). Mutations of EGFR are present in a 
subpopulation of lung adenocarcinomas and showed 
sensitive to EGFR-TKIs treatment. Recent studies 
showed that members of ErbB family had associated 
with prognosis in lung cancer in RNA expression 
level. However, the association of DNA copy number 
(CN) abundance of ErbB family and prognosis is still 
needed to investigate. In this study, EGFR-activating 
mutation status and DNA abundances of ErbB family 
were measured in 261 lung adenocarcinomas and 
association of prognosis will be explored. 
Methods: 261 lung adenocarcinomas with stage I 
to stage IIIa were enrolled in this study and patients 
with less than 6 months follow-up and died within 1 
month were excluded. The identiÀcation of EGFR-
activating mutation was genotyped by MASS 
spectrum or Sanger sequence assays. Genomic real-
time quantitative PCR was performed to measure 
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(n=12). Univariate analyses for OS showed that 
sex, preoperative and postoperative chemotherapy, 
pT factor, and methylation status were signiÀcant 
prognostic factors (p <0.10). By multivariate analysis 
for OS, only postoperative chemotherapy was a 
signiÀcant prognostic factor (p =0.036). Estimated 
2-year disease-free survival (DFS) for Group 1 
and Group 2 were 14.3% and 76.0%, respectively 
(p=0.002). Univariate analysis for DFS determined 
that postoperative chemotherapy, pT factor, and 
methylation status were signiÀcant (p <0.10). Of 
these factors, both postoperative chemotherapy and 
methylation status were independent prognostic 
factors in multivariate analysis (p=0.007 and 0.023, 
respectively). 
Conclusion: By comprehensive DNA methylation 
proÀling, we identiÀed two subgroups of surgically-
resected SCLC with signiÀcant differences of both 
OS and DFS. Multivariate analysis revealed that 
methylation status was an independent prognostic 
factor for DFS. DNA methylation proÀling will 
allow the subclassiÀcation of SCLC to guide therapy. 
Keywords: Prognosis, Small cell lung cancer, 
methylation, epigenome
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P2.197 GENE EXPRESSION-BASED 
APPROACHES IN DIFFERENTIATION OF 
METASTASES AND SECOND PRIMARY 
TUMOUR
Kristjan Välk1, Tõnu Vooder1, Raivo Kolde2, Retlav 
Roosipuu3, Jaak Vilo2, Andres Metspalu1 
1Biotechnology, University Of Tartu, Institute Of 
Molecular And Cell Biology/Estonia, 2Institute Of 
Computer Science, University Of Tartu, Institute 
Of Computer Science/Estonia, 3Department Of 
Pathology, Tartu University Hospital/Estonia
Background: A 64-year-old male patient was 
diagnosed with 3 consecutive non-small cell lung 
carcinomas (NSCLC). In the current study, we 
applied whole-genome gene expression analysis to 
control, primary and locally recurrent cancer, and 
supposed metastasis samples of a single patient. 
According to our knowledge, there are no published 
papers describing the gene expression proÀles of a 
single patient’s squamous cell lung cancers.
Methods: As the histology and differentiation grade 
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P2.196 GENOME-WIDE DNA 
METHYLATION ANALYSIS OF SMALL 
CELL LUNG CANCER
Yuichi Saito1, Hironori Ninomiya1, Kentaro 
Inamura1, Noriko Motoi1, Hirofuimi Uehara2, 
Mingyon Mun2, Yukinori Sakao2, Sakae Okumura2, 
Ken Nakagawa2, Genta Nagae3, Teruyuki Satoh3, 
Atsushi Kaneda3, Hiroyuki Aburatani3, Yukitoshi 
Satoh4, Yuichi Ishikawa1 
1Division Of Pathology, The Cancer Institute, 
Japanese Foundation For Cancer Research/Japan, 
2Thoracic Surgical Oncology, The Cancer Institute 
Hospital Of Jfcr/Japan, 3Genome Science Division, 
Research Center For Advanced Science And 
Technology, University Of Tokyo/Japan, 4Department 
Of Thoracic Surgery, Kitasato University School Of 
Medicine/Japan
Background: Small cell lung cancer (SCLC) is 
a highly aggressive form of lung cancer, with a 
patient median survival of just over one year. There 
is increasing evidence to suggest that dysregulation 
of the epigenome is involved in lung carcinoma. 
We investigated whether DNA methylation proÀles 
can provide useful molecular subtyping of SCLC in 
terms of etiology and prognosis of SCLC. 
Methods: We analyzed tumor and normal samples 
of 25 patients with SCLC undergoing surgery at 
the Cancer Institute Hospital. Among them, six 
were treated with chemotherapy before surgery. All 
tissues were grossly dissected and snap-frozen in 
liquid nitrogen. Female: male ratio was 8:17 and the 
average age was 68.2 years old. Initial diagnosis of 
each tumor from frozen section was later conÀrmed 
by detailed analysis of parafÀn-embedded sections 
and immunohistochemistry as necessary. Following 
WHO guidelines, the 25 tumors were classiÀed as 
SCLC. 500 ng bisulÀte-converted genomic DNA was 
used for the illumina InÀnium HumanMethylation27 
BeadChip, which enables the direct investigation of 
27,578 individual cytosines at CpG loci throughout 
the genome.
Results: Unsupervised hierarchical clustering of 
methylation data from SCLC samples reveals two 
major subgroups with different prognosis: Group 1 
had a signiÀcantly worse prognosis than Group 2, 
i.e. the overall survival (OS) for 2 years was 45.0% 
and 80.7%, respectively (p=0.008). Methylation 
status of normal lung was quite homogenous 
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between overall survival and CCND1 A870G 
polymorphism status. In metastatic group, median 
overall survival was 5.03 (1.33-14.80) months and 
median overall survival was signiÀcantly shorter 
in patients with A/A genotype than in patients with 
A/G+G/G genotype (2.96 months vs. 8.0 months, 
p=0.006).
Conclusion: CCND1 A/A genotype might be a poor 
prognostic factor in patients with non–small cell lung 
cancer, who has a metastatic disease.
Keyword: Lung cancer cyclin D1 gene 
polymorphism prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.199 NF-KAPPAB ACTIVATION AND 
DISTINCT EXPRESSION OF UBIQUITIN 
E3 LIGASES IN SKELETAL MUSCLE 
OF PATIENTS WITH NON-SMALL CELL 
LUNG CANCER CACHEXIA
Céline Op Den Kamp, Ramon Langen, Annemie 
Schols, Anne-Marie Dingemans 
Department Of Respiratory Medicine, Nutrim 
School For Nutrition, Toxicology And Metabolism, 
Maastricht University Medical Centre+/Netherlands
Background: Cachexia is a frequent paraneoplastic 
feature of lung cancer (NSCLC) and is characterized 
by progressive body weight loss and skeletal muscle 
wasting. The presence of cachexia is associated with 
lower responses to therapy and increased morbidity 
and mortality. In addition, patients with lung cancer 
cachexia report signiÀcantly reduced quality of life. 
Experimental research has shown that increased 
muscular Nuclear Factor kappa B (NF-ƩB) and 
subsequent ubiquitin (Ub) proteasome system (UPS) 
activity plays a causal role in lung cancer-induced 
muscle wasting but this needs veriÀcation in human 
lung cancer cachexia. The aim of this study is to 
investigate muscular NF-ƩB activity and expression 
of E3 Ub-ligases in skeletal muscle of cachectic 
patients with advanced NSCLC. 
Methods: In this prospective study, 14 cachectic 
patients (deÀned by >5% body weight loss in 
preceding 6 months) and 12 non-cachectic patients 
with newly diagnosed advanced stage NSCLC 
of the primary cancer and the supposed metastasis 
differed minimally, but local recurrence was poorly 
differentiated, molecular proÀling of the samples 
was carried out in order to conÀrm or reject the 
hypothesis of second primary cancer.
Results: Principal component analysis of the 
gene expression data revealed distinction of the 
local recurrence. Gene ontology analysis showed 
no molecular characteristics of metastasis in the 
supposed metastasis.
Conclusion: Gene expression analysis is valuable 
and can be supportive in decision-making of 
diagnostically complicated cancer cases.
Keywords: Metastasis, Gene expression proÀle, 
local recurrence
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P2.198 CYCLIN D1 A870G 
POLYMORPHISM AND PROGNOSIS OF 
NON-SMALL CELL LUNG CANCER
Zafer Kocak1, Alaattin Ozen1, Suat Cakina2, Mert 
Saynak1, TevÀk Gulyasar2, Tammam Sipahi2 
1Radiation Oncology, Trakya University Faculty Of 
Medicine/Turkey, 2Biophysics, Trakya University 
Faculty Of Medicine/Turkey
Background: The cyclin D1 (CCND1) A870G 
gene polymorphism is associated to the prognosis 
in patients with resected non-small cell lung cancer. 
Here, we investigated the potential role of Cyclin D1 
(CCND1) A870G gene polymorphisms on prognosis 
in patients with locally advanced and metastatic non-
small cell lung cancer.
Methods: CCND1 A870G genotype was determined 
by polymerase chain reaction and restriction 
fragment length polymorphism analysis of DNA 
extracted from blood. Blood samples were collected 
from newly diagnosed 53 patients with lung cancer.
Results: In patients with non-metastatic group 
(n=33), frequency of cyclin D1 genotype was 30.3% 
for A/A, 51.5% for A/G, and 18.2% for G/G. In 
patients with metastatic disease (n=20), cyclin D1 
genotype was 45.0% for A/A, 40.0% for A/G, and 
15.0% for G/G. There was no correlation between 
CCND1 A870G polymorphism status and age, 
sex, and smoking rate both in metastatic and non-
metastatic groups. In non-metastatic group, median 
overall survival was 7.96 (1.13-21.47) months and 
there was no statistically signiÀcant correlation 
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P2.200 IGF-1, IGFBP-3 AND VEGF IN 
SMALL CELL LUNG CANCER PATIENTS.
Ewa Wojcik1, Beata Sas-Korczynska2, Jan Kanty 
Kulpa3 
1Clinical Biochemistry, Center Of Oncology 
- M.Sklodowska-Curie Memorial Institute, 
Cracow Division/Poland, 2Center Of Oncology 
- M.Sklodowska-Curie, Cracow Dision/Poland, 
3Center Of Oncology - M.Sklodowska-Curie 
Memorial Institute, Cracow Division/Poland
Background: The insulin-like growth factor system: 
two peptide ligands (IGF-1 and IGF-2), their cell 
surface receptors (IGF-1R and IGF-2R) and at least 
six speciÀc binding proteins (IGFBP1 – IGFBP-6), 
in the opinion of some investigators, plays important 
role in stimulation of proliferation and cell survival. 
Moreover, it is suggested that IGF-1 may participate 
in the development of angiogenesis in cancer, by 
regulation of VEGF expression and secretion via 
HIF-1-dependent and independent manner. The 
subject of the presented study was the evaluation 
of IGF-1, IGFBP3 and VEGF in respect to factors 
characterizing both insufÀcient supply and the 
developing of acute phase reaction in small cell lung 
cancer patients. 
Methods: The study of IGF-1, IGFBP3 and VRGF 
were studied in 49 small cell lung cancer patients ( 
LD-34, ED-19) before treatment and in the reference 
group of 29 healthy persons. For each investigated 
person Nutritional Risk Index (NRI). was evaluated 
The serum levels of IGF-1 and IGFBP-3 were 
determined using RIA and VEGF applyingg ELISA 
methods. 
Results: In SCLC patients as compared with the 
reference group, there were found signiÀcantly 
higher IGF-1 and VEGF levels and lower NRI 
value, at lack of signiÀcant differences for IGFBP-3. 
SigniÀcant positive correlations between IGF-1 
and IGFBP-3 (r = 0.623 p = 0.0001), and between 
IGFBP-3 and NRI (r = 0.386 p = 0.006) as well as 
negative correlation between IGFBP-3 and VEGF 
in small cell lung cancer group were observed. In 
the SCLC group no signiÀcant differences were 
found in the analyzed growth factors and binding 
protein in relation to stage of disease, probably due 
to low number of SCLC patients with extensive 
disease. However, the analysis of prognostic value of 
extent of disease, performance status, pretreatment 
and 22 age and gender matched healthy controls 
were included. Body composition was assessed by 
dual energy X-ray absorptiometry (DEXA) and 
biopsies were obtained from vastus lateralis muscle. 
IkappaBalpha (IƩBƠ) and Tumor Necrosis Factor 
alpha (TNF-Ơ) mRNA expression levels were 
determined as indirect indices of NF-ƩB activity. 
UPS activity was evaluated by mRNA expression of 
four E3 Ub-ligases: neural precursor cell expressed 
developmentally down-regulated 4 (NEDD4), 
Atrogin-1, Tripartite motif-containing protein 32 
(TRIM32) and Muscle RING-Ànger protein-1 
(MuRF1). 
Results: Mean weight loss was 13.1 ± 4.9% in 
cachectic patients compared with 2.1 ± 2.0% in 
the non-cachectic group. Cachectic patients had 
signiÀcantly decreased skeletal muscle mass content 
of upper and lower extremities compared with non-
cachectic patients (p=0.02) and healthy controls 
(p<0.001). Muscle IƩBƠ (p=0.04) and TNF-Ơ 
(p=0.03) mRNA expression and NEDD4 (p=0.03) 
were signiÀcantly increased in cachectic patients 
compared with healthy controls. No increase was 
observed in the other E3 Ub ligases. In contrast, 
TRIM32 (p<0.01) showed a signiÀcant decrease in 
non-cachectic patients compared to both cachectic 
patients and healthy controls, whereas MURF-1 
levels were unchanged. 
Conclusion: These results indicate that NF-ƩB 
activity is increased in lung cancer cachexia but 
show that E3 Ub-ligases are expressed differently. 
As all assessed E3 Ub-ligases have shown to 
be important regulators in experimental models 
of cachexia, the observed distinct regulation in 
cachectic patients with NSCLC has implications 
for understanding the mechanism of human lung 
cancer cachexia. Further research is required to 
investigate the potential contribution of individual 
E3 Ub-ligases to human cancer cachexia in order 
to develop therapeutic interventions to prevent or 
reverse cachexia and increase survival of lung cancer 
patients. 
Keywords: Non-small cell lung cancer, Cancer 
cachexia, Ubiquitin proteasome system, Skeletal 
muscle
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subset of patients with SCLC (n = 50) or NSCLC 
(n = 50) enrolled into the thalidomide studies, 
pre-treatment (C1) and / or before the fourth 
cycle of therapy (C4). Concentrations of vascular 
endothelial growth factor (VEGF), soluble vascular 
endothelial growth factor receptor-2 (sVEGFR-2) 
and interleukin-8 (IL-8) were determined using 
enzyme-linked immunosorbent assay and correlated 
with clinical data including stage, response rate and 
progression-free survival (PFS).
Results: Baseline values of angiogenic factors are 
summarised in Table 1. Table 1: Baseline levels of 
angiogenic factors 
Small cell lung cancer Non-small cell lung cancer
Angiogenic 
factor n Median (pg/mL) Range (pg/mL) n Median Range (pg/mL) 
VEGF 46 148 23.2 - 912 48 150 10.3 - 1361 
sVEGFR-2 46 7909 90 - 13711 48 8243 3302 - 14515 
IL-8 46 22.8 0 - 336 48 30.7 5.78 - 198 
Limited stage SCLC was associated with a below 
median level of VEGF at baseline (p = 0.041). 
Baseline VEGF signiÀcantly correlated with 
IL-8 (r = 0.496, p < 0.001). Univariate analysis 
demonstrated that patients with low VEGF or IL-8 
at baseline, had improved PFS compared to those 
with high values (median PFS 9.3 months versus 
6.3 months for both markers (p = 0.055 and 0.068, 
respectively)). SCLC patients demonstrating a partial 
response (PR) had a lower mean baseline VEGF 
than those with stable disease (SD) or progressive 
disease (PD) (117 versus 196 pg/mL (p = 0.047)). In 
both SCLC and NSCLC, patients demonstrating a 
PR had a greater mean reduction in IL-8 compared 
to those with PD or SD (35 pg/mL from C1 to C4 
versus 0.80 pg/mL (p = 0.018)). There were no 
signiÀcant associations between baseline sVEGFR-2 
levels and outcomes. Changes in biomarker levels 
in the thalidomide and placebo groups were similar; 
for VEGF from C1 to C4 there was an insigniÀcant 
mean reduction: 29.36 versus -32.93 pg/mL, 
respectively (p = 0.465).
Conclusion: Baseline serum VEGF is associated 
with disease stage in SCLC. InsufÀcient changes in 
serum VEGF levels may partially explain the lack 
of signiÀcant activity of thalidomide in the clinical 
trials. Our analysis supports the further study of IL-8 
and VEGF as potential biomarkers in lung cancer. 
Additional biomarkers are being analysed, including 
basic Àbroblast growth factor, soluble intracellular 
IFG-1, IGFBP-3, VEGF levels and NRI values 
revealed that presented worse prognosis patients 
with extensive disease as well as patients with low 
levels of IGFBP-3. The median survival of patients 
with limited and extensive disease was 23.0 and 6.5 
months respectively and for patients with IGFBP-3 
level higher than 3090 mg/L were 19.0 months, 
whereas with lower level of this binding protein - 
only 9.5 months (Àg.1). Fig. 1 
Conclusion: 
- In SCLC patients with worse nutritional status there 
seems to be a characteristic tendency to decrease of 
IGFBP-3 and growth of VEGF levels 
- Small cell lung cencer patients with low levels of 
IGFBP-3 have relatively increased risk of death. 
Keyword: SCLC, insulin-like growth factor, 
angiogenesis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.201 SERUM BIOMARKERS IN LUNG 
CANCER PATIENTS FROM TWO 
CLINICAL TRIALS OF CHEMOTHERAPY 
WITH OR WITHOUT THALIDOMIDE
Robin J. Young1, Aung Tin2, Nicola J. Brown1, 
Carolyn Staton1, Siow Ming Lee3, Mark Jital4, 
Penella Woll2 
1Academic Unit Of Surgical Oncology, University 
Of ShefÀeld/United Kingdom, 2Academic Unit Of 
Clinical Oncology, University Of ShefÀeld/United 
Kingdom, 3University College Hospital/United 
Kingdom, 4UCL Cancer Trials Centre, University 
College London/United Kingdom
Background: Thalidomide, a drug with immuno-
modulatory and anti-angiogenic activity was 
evaluated in combination with chemotherapy in two 
phase III, double-blind, randomized controlled trials 
in patients with advanced small cell lung cancer 
(SCLC) (n = 724) and non-small cell lung cancer 
(NSCLC) (n = 722). No survival beneÀt was found 
in either study.
Here, we investigate potential predictive and 
prognostic biomarkers in sera from a subset of the 
patients.
Methods: Serum samples were collected from a 
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years). In this analyzed group 72% were male, 28% 
women. Performance status was assessed as: Zubrod 
1-2: 78%, Zubrod 3-4: 22% of patients. All patients 
underwent radiotherapy for lung tumor and the 
regional lymph nodes, 82% of patients were treated 
with chemo-radiotherapy, 3% of patients underwent 
intrabronchial brachytherapy, 9% underwent surgery.
The concentration of OPN was determined in 
plasma of patients, before treatment, using ELISA 
test (Human Osteopontin Immunoassay, R&D 
Systems). Statistical analysis was performed 
using STATISTICA (version 7.1). InÁuence of 
concentration of OPN on overall survival was 
assessed using log-rank test. 
Results: The concentration of OPN in the analyzed 
group was within the range 14,9 – 619,1 ng/mL 
(median 101,7 ng/mL). OPN concentration values 
were signiÀcantly higher (p<0,0001) than in the 
reference group. The reference group consisted of 
114 healthy persons, with a median concentration of 
OPN 47,85 ng/mL.
Only 21 patients (12%) patients in the study group 
OPN levels did not exceed the designated cut-off 
value (68,4 ng/mL). The remaining patients OPN 
concentrations exceeded this value several times.
The present study demonstrated a statistically 
signiÀcant unfavorable impact of high initial 
concentration of OPN in the plasma on overall 
survival of the patients (p<0,0001). 
Conclusion: The analysis has shown that high OPN 
level negatively affects survival in non-small cell 
lung cancer patients treated with radio- and radio-
chemotherapy. This supports the studies that suggest 
the prospect of using OPN as prognostic marker in 
such therapy. 
Keywords: osteopontin, Radiotherapy, Non-small 
cell lung cancer
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P2.203 PROGNOSTIC IMPLICATIONS 
OF EPIDERMAL GROWTH FACTOR 
RECEPTOR, KRAS AND BRAF GENE 
MUTATIONS IN RESECTED NON-SMALL 
CELL LUNG CANCER PATIENTS.
Vienna Ludovini1, Fortunato Bianconi2, Lorenza 
Pistola1, Francesca romana Tofanetti1, Antonella 
Flacco1, Annamaria Siggillino1, Elisa Baldelli1, 
Vincenzo Minotti1, Mark Ragusa3, Jacopo Vannucci3, 
Stefano Treggiari4, Chiara Bennati1, Renato Colella5, 
adhesion molecule-1 and tumour necrosis factor-Ơ.
Keywords: angiogenesis, thalidomide, Biomarkers, 
Lung cancer
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P2.202 PROGNOSTIC SIGNIFICANCE 
OF OSTEOPONTIN LEVELS IN NON-
SMALL CELL LUNG CANCER PATIENTS 
TREATED WITH RADIO-AND RADIO-
CHEMOTHERAPY
Barbara Masãyk1, Regina Deja1, Anna Drosik2, 
Agata Gawryszuk3, Dorota Butkiewicz4, Monika 
Pietrowska4, Marzena Gawkowska-Suwinska5, 
Boŧena Jochymek3, Katarzyna Galwas-Kliber6, 
Sãawomir Blamek3, Rafaã Suwiĸski6, Piotr Widãak4 
1Department Of Analytics And Clinical Biochemistry, 
Maria Sklodowska-Curie Memorial Cancer Center 
And Institute Of Oncology, Gliwice Branch/Poland, 
2Clinical Oncology Clinic,, Maria Sklodowska-Curie 
Memorial Cancer Center And Institute Of Oncology, 
Gliwice Branch/Poland, 3Radiotherapy Department, 
Maria Sklodowska-Curie Memorial Cancer Center 
And Institute Of Oncology, Gliwice Branch/Poland, 
4Center For Translational Research And Molecular 
Biology Of Cancer, Maria Sklodowska-Curie 
Memorial Cancer Center And Institute Of Oncology, 
Gliwice Branch/Poland, 5Iii Radiotherapy Clinic, 
Maria Sklodowska-Curie Memorial Cancer Center 
And Institute Of Oncology, Gliwice Branch/Poland, 
6Ii Radiotherapy Clinic, Maria Sklodowska-Curie 
Memorial Cancer Center And Institute Of Oncology, 
Gliwice Branch/Poland
Background: Hypoxia impairs susceptibility of 
tumor cells to cytotoxic drugs and ionizing radiation, 
causing an increase resistance to chemotherapy and 
radiotherapy, thus inÁuences survival of patients. 
Osteopontin (OPN), multifunctional cytokine, is 
associated with tumor hypoxia and angiogenesis, 
and is related to more aggressive phenotype of tumor 
cells, metastasis and tumor progression.
The aim of this study was to evaluate prognostic 
importance of OPN non-small cell lung cancer 
patients treated with radio- and radio-chemotherapy.
Methods: The study included 173 patients treated in 
the Cancer Center and Institute of Oncology Gliwice 
Branch, between 2006 and 2010. Clinical stage was 
assessed (according to the TNM classiÀcation) as 
III-IV. The median age was 63 years (range 33 to 83 
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were more frequent in women (P =0.001) and in 
never-smokers (P =0.003) whereas patients with 
KRAS mutations were more likely to be former/
current smokers (92%). In the patients with ADC, 
EGFR exon 19 delections and L858R mutations were 
associated with better disease free survival (p=0.03). 
No difference in outcome was seen between patients 
harboring KRAS mutations.
Conclusion: Our Àndings suggest that the EGFR and 
KRAS mutations are frequent in adenocarcinomas 
while BRAF mutation is not present. KRAS is not 
a prognostic factor for survival. EGFR mutations 
could be used to identify patients with potential 
better outcome. 
Keywords: EGFR, KRAS, BRAF mutations, Early 
Stage NSCLC, prognostic factors
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P2.204 ANALYSIS OF THE EXPRESSION 
OF REGULATORY T-LYMPHOCYTE 
ASSOCIATED MARKERS IN 
PERIPHERAL BLOOD SAMPLES FROM 
ADVANCED NSCLC
Aida Artigot1, Elena Caballero1, Eloisa Jantus 
Lewintre1, Silvia Borrego2, Goitxane Marcaida2, 
Rafael Rosell3, Carlos Camps2, Rafael Sirera4 
1Molecular Oncology Laboratory, General 
University Hospital Research Foundation, Valencia/
Spain, 2Oncology, General University Hospital Of 
Valencia/Spain, 3Oncology, Catalan Institute Of 
Oncology, Hospital Germans Trias I Pujol/Spain, 
4Biotechnology, Polytechnic University Of Valencia/
Spain
Background: T-cell tolerance is an important 
mechanism for tumor escape. An imbalance of 
regulatory T-lymphocytes (Treg) could promote 
peripheral immune tolerance to tumor cells. Marker 
genes associated with the presence of Treg are 
CD127, CD8a, Foxp3, CD4, CD25 and TGF-ơ1. The 
aim of this study was to determine the expression 
level of these marker genes by qPCR in patients with 
non-small cell lung cancer (NSCLC) in advanced 
stages and to correlate them with clinic-pathological 
and prognostic variables. 
Methods: 54 control individuals and 50 patients 
with advanced-NSCLC (IIIB-IV) treated with 
cisplatin and docetaxel were studied. Blood samples 
were collected at baseline and after 3 cycles of 
Francesco Bigio5, Francesco Puma3, Lucio Crinò1 
1S. Maria Della Misericordia Hospital, Medical 
Oncology Department,s. Maria Della Misericordia 
Hospital/Italy, 2University Of Perugia, Department 
Of Electronic And Information Engineering, 
University Of Perugia/Italy, 3University Of Perugia, 
Department Of Thoracic Surgery, University Of 
Perugia/Italy, 4S. Camillo Forlanini Hospital, 
Thoracic Surgery,s. Camillo Forlanini Hospital/Italy, 
5University Of Perugia, Institute Of Pathological 
Anatomy And Histology, University Of Perugia/Italy
Background: Surgery is considered the treatment 
of choice for early stage non-small cell lung cancer 
(NSCLC). However Ì´ 30% of early stage (IA) 
patients die within 5 years. The identiÀcation of 
biomarkers that will predict patients with a poor 
outcome and who may beneÀt from adjuvant 
therapies is crucial to improve patient survival. The 
epidermal growth factor receptor (EGFR) and its 
downstream factors KRAS and BRAF are mutated 
with different frequencies in non small cell lung 
cancer and such mutations predict clinical response 
to EGFR inhibitors. Because the prognostic role 
of these mutations remain unclear we undertook 
this study to evaluate the incidence of EGFR 
and KRAS mutations and their correlation with 
clinicopathological parameters and outcome in 
resected stage I-III NSCLC.
Methods: A cohort of 232 patients were evaluated; 
median age was 67 (range 30–84), Male/Female: 
50/182; squamous/ADC/BAC/other: 98/100/4/30; 
smoker/never smoker:194/38, and stage I/II/III: 
141/49/49. EGFR (exons 18 to 21), KRAS (exons 
2 and 3) and BRAF (exons 11 and 15) genes were 
ampliÀed by nested PCR and sequenced in both 
sense and antisense direction using 3500 Genetic 
Analyzer (Applied Biosystems, Foster City, CA). 
Kaplan-Meier estimates of overall survival (OS) 
and disease free survival (DFS) were calculated for 
clinical and biologic variables using Cox model for 
multivariate analysis.
Results: EGFR mutations were present in 22 
patients (9.6 %): 12 delections in exon 19, 10 point 
mutations in exon 21 (L858R). KRAS mutations 
were present in 39 patients (19.3 %): the most 
common KRAS mutations were G12C (42.0 %), 
G12V(23.0%) and G12D (7.6%). BRAF gene was 
wild type in all patients. Both EGFR and KRAS 
mutations were associated with adenocarcinomas 
(19/22, 86.4% p<0.000 and 24/39, 61.5%, p=0.002, 
respectively). EGFR mutations in adenocarcinomas 
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Laboratorio De Dianas Terapéuticas, Hospital 
Universitario Madrid Sanchinarro/Spain
Background: EGFR mutation testing is rapidly 
becoming a part of the standard diagnostic workup of 
non-small cell lung carcinomas (NSCLC), although 
there is currently no standardised method to perform 
the mutational analysis. Direct sequencing is still a 
commonly used method despite its low sensitivity, 
long turn around time and labour requirements. 
Recent advancements in molecular technologies such 
as real-time PCR have enabled the design of rapid 
and sensitive detection assays for genetic alterations, 
but typically with a limited degree of mutation 
coverage. This is the Àrst report of the clinical testing 
of a novel real-time PCR assay with comprehensive 
EGFR mutation coverage. 
Methods: The cobas EGFR Mutation Test (Roche 
Molecular Systems Inc, Pleasanton, CA, USA) is 
an investigational real-time PCR assay which is 
designed to detect 43 mutations within exons 18, 
19, 20 and 21 of the EGFR gene. The assay can be 
performed on DNA isolated from a single 5 micron 
FFPET tissue section, and provides an automated 
test result. This assay was used to assess EGFR 
mutation status of 51 NSCLC samples, which 
had been previously tested by direct sequencing 
using published primers (Conde et al. Clin Cancer 
Res 2006), as part of clinical care (lung cancer 
specimens received at Laboratorio de Dianas 
Terapeúticas between 2007-2011). The tumor 
content of the samples ranged from 20 to 90%, 
and macrodissection was performed in eight cases. 
DNA extraction for the original sequencing was 
performed with the QIAamp DNA FFPE Tissue kit 
and automated on the QIAcube robot (QIAGEN, 
Valencia, CA). This previously isolated DNA was 
adjusted to the required volume for the cobas test 
prior to PCR ampliÀcation and detection. 
Results: The test gave valid test results in 50/51 
samples (98%), and detected 8 EGFR mutations 
(16%) including three E746-A750del, three 
L858R, one D770-N771insSVD, and one V769-
D770insASV, all of which were conÀrmed by the 
prior Sanger sequencing results. Sanger sequencing 
had also identiÀed a rare D770_N771insN, which the 
cobas test was not designed to detect. The analytical 
run time for the cobas test was < 2.5 hours, including 
PCR set-up, and the post-analytical phase was fully 
automated. The results of testing in a larger cohort 
of samples, together with a sensitivity study, will be 
presented. 
chemotherapy in PAXgene Blood RNA Tubes and 
stored at -80ºC until RNA isolation. mRNA was 
reverse transcribed and RT-PCR was performed to 
analyze the expression of CD127, CD8a, Foxp3, 
CD4, CD25 and TGF-ơ1. Relative expression 
was normalized by endogenous genes (GAPDH 
and ơ-actin) using the PfafÁ formulae. Statistical 
analyses were considered signiÀcant at p<0.05 
Results: The characteristics of the studied 
patients were: median age: 57.8 years [37.7-
75.1], 89% males, 55% adenocarcinomas. We 
found signiÀcant differences in the expression 
levels of CD4 (p<0.0001), CD8 (p=0.019), CD25 
(p=0.003), CD127 (p=0.031), Foxp3 (p< 0.0001) 
and TGF-ơ1 (p<0.0001) between patients and 
controls. Pair-matched samples comparing pre and 
post-treatment expression of TGF-ơ1 showed that 
it was signiÀcantly reduced after chemotherapy. 
Additionally, patients with higher ratios (baseline/
post-treatment) of CD4 and TGF-ơ1 were 
associated with local metastasis and progression, 
respectively. Survival analysis revealed that patients 
with combined high expression of CD25 and low 
expression of CD127 (reÁecting a Treg phenotype), 
had signiÀcantly reduced TTP (median 2,40 months 
vs 5,47 months, p=0.001) and a trend in OS (median 
3.87 months vs 9.80 months, p= 0.078). 
Conclusion: Based on gene expression analysis, 
it seems that the presence of a “Treg proÀle” in 
peripheral blood is associated with a poor prognosis 
in patients with advanced NSCLC. (This work was 
supported in part, by a grant [RD06/0020/1024] 
from Red Temática de Investigación Cooperativa 
en Cáncer, RTICC, Instituto de Salud Carlos III 
(ISCIII), Spanish Ministry of Science and Innovation 
& European Regional Development Fund (ERDF) 
“Una manera de hacer Europa”) 
Keywords: prognostic, regulatory T-lymphocytes, 
Advanced NSCLC, Treg
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P2.205 ANALYTIC PERFORMANCE OF A 
NOVEL REAL-TIME PCR METHOD FOR 
THE DETECTION OF MUTATIONS IN 
EGFR IN FORMALIN-FIXED PARAFFIN-
EMBEDDED TISSUE (FFPET) SAMPLES 
OF LUNG CANCER.
Barbara Angulo, Esther Conde, Rebeca Martinez, 
Belen Rubio-Viqueira, Fernando Lopez-Rios 
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expression was detected using TaqMan MicroRNA 
Assays (Applied Biosystems). 
Results: p characteristics: mean age, 67 (46-83); 
83% male; all p were PS 0-1; 44 (62.9%) stage 
I, 12 (17.1%) stage II, 14 (20%) stage III; 36 
(51.4%) adenocarcinoma, 28 (40%) squamous cell 
carcinoma; 18 (25.7%) received adjuvant treatment. 
With a mean follow-up of 17 months (m), 23 p 
(32.9%) had relapsed. miR-145 expression was 
downregulated (P<0.001), and miR-367 expression 
was upregulated (P<0.001) in tumor compared to 
normal tissue samples. Mean TTR for p with low 
miR-145 levels was 18.4 m vs 28.2 m for p with 
high miR-145 (P=0.015). Mean TTR for p with low 
miR-367 levels was 29.1 m vs 23.4 m for p with high 
miR-367 (P=0.048). In the multivariate analysis, 
high miR-145 expression (OR, 0.33; 95%CI, 0.13-
0.82; P=0.018), low miR-367 expression (OR, 0.297; 
95%CI, 0.09-0.94; P=0.038), and stage I disease 
(OR, 0.22; 95%CI, 0.07-0.73; P=0.013) emerged as 
independent markers for longer TTR. 
Conclusion: p with high miR-145 or low miR-367 
expression have a longer TTR. For the Àrst time, 
we show that miR-145 and miR-367 are involved 
in NSCLC and could be novel markers for tumor 
relapse in surgically treated NSCLC p. 
Keywords: miR-367, NSCLC, miR-145, SOX2
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P2.207 INSULIN-LIKE GROWTH FACTOR 
RECEPTOR 1(IGF1R) AND EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) 
AMPLIFICATION AND EXPRESSION IN 
SURGICALLY RESECTED NSCLC.
Vienna Ludovini1, Antonella Flacco1, Fortunato 
Bianconi2, Francesca Romana Tofanetti1, Mark 
Ragusa3, Jacopo Vannucci3, Guido Bellezza4, 
Rita Chiari1, Vincenzo Minotti1, Lorenza Pistola1, 
Annamaria Siggillino1, Elisa Baldelli1, Francesco 
Puma3, Lucio Crinò1 
1S. Maria Della Misericordia Hospital, Medical 
Oncology Department,s. Maria Della Misericordia 
Hospital/Italy, 2University Of Perugia, Department 
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University Of Perugia/Italy, 3University Of Perugia, 
Department Of Thoracic Surgery, University Of 
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Conclusion: Our preliminary study indicates that the 
test has a low failure rate and provides rapid results 
(< 2.5 hours). Furthermore the reagents in the test 
kit are conÀgured in a manner to reduce the need for 
batching samples. The rapid turnaround time and 
the ability to offer the test more frequently offers a 
signiÀcant improvement over current laboratory turn 
around times for direct sequencing of 7-10 days. 
Acknowledgment: Testing reagents were provided by 
Roche Molecular Systems. This work was partially 
funded by Fundación Mutua Madrileña. 
Keywords: lung carcinoma, EGFR, real-time 
quantitative PCR
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P2.206 SOX2-RELATED MICRORNAS 
AS PROGNOSTIC MARKERS OF 
RECURRENCE IN SURGICALLY 
TREATED NON-SMALL-CELL LUNG 
CANCER (NSCLC)
Alfons Navarro1, Marc Campayo2, Nuria Vinolas2, 
Victor Ciria1, Tania Diaz1, Ramon Marrades3, Jose 
Ramirez4, Jose M. Gimferrer5, Mariano Monzo1, 
Laureano Molins5 
1University Of Barcelona/Spain, 2Oncology, Hospital 
Clinic/Spain, 3Pneumology, Hospital Clinic/Spain, 
4Pathology, Hospital Clinic/Spain, 5Thoracic 
Surgery, Hospital Clinic/Spain
Background: SOX2 is a transcription factor essential 
for early mammalian development and for maintenance 
and regulation of stemness in human embryos and 
adult tissues. SOX2 overexpression has been observed 
in NSCLC and other solid tumors. miR-145 and the 
miR-302-367 cluster are involved in stemness through 
SOX2 regulation. miR-145 plays an important role in 
SOX2 translation, and SOX2 regulates the expression 
of the miR-302-367 cluster. We have analyzed the 
expression of miR-145 and the miR-302-367 cluster 
in tumor and paired normal tissue samples from 70 
surgically treated NSCLC patients (p) and correlated 
our Àndings with time to recurrence (TTR). 
Methods: We analyzed the expression of miR-
145 and miR-302-367 cluster (miR-302b*,b, c*,a, 
a*,d and 367) in 70 tumor and 70 paired normal 
tissue samples from NSCLC p who had undergone 
complete surgical resection from 2006 to 2009. RNA 
was obtained from fresh frozen tumor and normal 
tissue using the Trizol method and microRNA 
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P2.208 ERBB2 AND ERBB3 EXPRESSION 
IN RESECTED NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS (PTS)
Victor Freixinos, Maite Salcedo, Natalia Tallada, 
Nuria Murtra-Garrell, Alejandro Navarro, Pablo 
Martinez, Susana Cedrés, Cristina Teixido, Javier 
Hernandez-Losa, Eva Lopez, M. A. Montero, 
Vicente Peg, Esther Pallisa, Mercedes Canela, 
Enriqueta Felip, Santiago Ramón Y Cajal 
Medical Oncology, Vall D Hebron Hospital/Spain
Background: EGFR deregulation has been 
extensively studied in NSCLC, but less is known 
about the expression and role of other ErbB 
receptors. The aim of this study is to determine 
ErbB2 and ErbB3 expression in NSCLC and to 
explore their clinical and pathological features.
Methods: Tumor samples from 126 NSCLC pts who 
underwent complete resection in our institution from 
October 2007 to September 2010 were analyzed. 
Tissue microarrays were used to study ErbB2 
and ErbB3 expression by immunohistochemistry; 
expression was graded by two independent observers 
and tumors with a 2+/3+ score were classiÀed as 
“high
expression”. ErbB2 by FISH was analyzed in pts 
with high ErbB2 expression. EGFR-mutation (mut) 
status was determined in selected pts.
Results: Pts characteristics: median age 67 yrs, 
81% male, 6% never smokers, 40% adenocarcinoma 
(ADC)/ 39% squamous-cell (SCC)/ 21% others, 
p-stage 33% I/28% II/30% III/ 9% IV. High ErbB2 
expression was found in 5 (4%) pts: all 5 male, 1 
never smoker, 3 ADC/2 SCC. None of these pts 
was ErbB2 FISH+. High ErbB3 membranous and 
cytoplasmic expression was found in 27% and 
21% of samples, respectively, with 10% of samples 
having high expression at both sites. No correlation 
was found between ErbB3 expression and age and 
p-stage. High ErbB3 expression was more frequent 
in females than in males (membranous 46% vs 
22% p= .038; cytoplasmic 33% vs 18% p= .099, 
respectively), in ADC than in the other histologies 
(membranous 36% vs 21% p= .07; cytoplasmic 32% 
vs 13% p =.014, respectively). Five of 23 pts had 
EGFR-mut (2 del exon 19, 3 L858R exon 21): all 5 
female with ADC, 4 never smokers. No EGFR-mut 
pt had concomitant high ErbB2. Four EGFR-mut pts 
had high cytoplasmic ErbB3
Background: IGF1R represents a novel molecular 
target in non-small-cell lung cancer (NSCLC). 
IGF1R and EGFR activation is essential to mediate 
tumor cell survival, proliferation and invasion. This 
study investigates the prognostic role of IGF1R and 
EGFR copy number gain (CNG) by Áuorescence in 
situ hybridization (FISH) and protein overexpression 
by immunohistochemistry (IHC) in surgically 
resected NSCLC.
Methods: 114 NSCLC patients were evaluated; 
median age was 66y (range 40–84), Male/
Female:96/18; squamous (SCC)/adeno/BAC/
other:59/34/9/12; smoker/never smoker:105/9, and 
stage I/II/III:71/18/25. IGF1R and EGFR FISH 
were tested by customized and commercial probes, 
respectively; positive specimens showed gene 
ampliÀcation or polysomy (4 copies in 10% of 
tumor cells). IGF1R and EGFR protein expression 
were evaluated using mouse antibodies (clones 24-31 
and 3147, respectively); overexpression was deÀned 
by 10% positive cells. Kaplan-Meier estimates of 
survival and time to recurrence were calculated for 
clinical and biologic variables using Cox model for 
multivariate analysis.
Results: 46 tumors (40%) were IGF1R FISH+ 
and 76 (77%) were EGFR FISH+. IGF1R FISH+ 
was associated with EGFR FISH+ (p=0.03) and 
co-ampliÀcation was observed in 34 cases (30%). 
IGF1R and EGFR FISH+ were associated with 
SCC (p=0.01 and p=0.05, respectively). IGF1R and 
EGFR overexpression was detected in 36% and 
55% of NSCLC patients and co-expression was 
detected in 25%. Co-ampliÀcation and co-expression 
of both receptors were signiÀcantly associated 
(p=0.045). IGF1R and EGFR co-ampliÀcation and 
co-expression associated with shorter disease free 
survival (DFS; p=0.05, p=0.05 respectively), also at 
multivariate analysis adjusting for stage (p=0.0002).
Conclusion: IGF1R and EGFR are frequently 
co-ampliÀed in NSCLC and CNG correlates with 
protein overexpression. Both co-ampliÀcation 
and co-expression of IGF1R and EGFR predicts 
shorter DFS. These results provide a strong rational 
for targeting simultaneously EGFR and IGF1R 
in clinical trials for NSCLC. We thank Italian 
Association for Cancer Research (AIRC) for 
supporting the study (AF Fellowship) 
Keywords: IGF1R, EGFR, NSCLC, Early Stage, 
Prognosis
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differentiated histology (42%) and stage I disease 
(62%). The histological types included 51% squamous 
cell carcinoma (SCC), 30% adenocarcinoma, 
8% BAC, and 11% of other subtypes. CNG was 
determined when 4 gene copies were displayed 
in 40% of tumor cells. Kaplan-Meier estimates of 
survival and time to recurrence were calculated for 
clinical variables and biologic markers using the Cox 
model for multivariate analysis.
Results: Forty-one (36%) patients showed CNG for 
MYC and 41 (36%) for TERC. MYC and TERC 
gene ampliÀcation (GA) were found in 9 (8%) and 
15 (13%) cases, respectively. MYC and TERC 
contemporary CNG was observed in 12 cases (11%): 
2 (17%) cases with GA vs 10 (83%) high polysomy. 
TERC CNG was associated with SCC histology 
(80% vs 20% in non-SCC; p=0.001). In univariate 
analyses, both MYC CNG and GA were associated 
with shorter disease free survival (DFS, p=0.032 
and p=0.022, respectively) and overall survival (OS; 
p<0.032 and P<0.000, respectively) while TERC 
CNG or GA showed no association. In multivariate 
analysis including stage and age, MYC CNG and GA 
remained signiÀcantly associated with worse DFS 
(p=0.022; p= 0.011 respectively) and OS (p=0.026; 
p<0.000), respectively).
Conclusion: Our results indicate that MYC 
and TERC are frequently ampliÀed in NSCLC. 
TERC CNG shows phenotypic properties strongly 
associated with SCC and is not a prognostic factor. 
CNG for MYC is a strong predictor of worse 
survival. We thank Italian Association for Cancer 
Research AIRC (AF Fellowship).
Keywords: TERC, MYC, Early Stage NSCLC, 
Prognosis, FISH
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P2.210 INCREASED CD8+ T CELL 
PROLIFERATION FOLLOWING 
CHEMOTHERAPY PREDICTS 
IMPROVED SURVIVAL IN PATIENTS 
WITH THORACIC MALIGNANCIES
Melanie J. Mccoy, Anna K. Nowak, Robbert G. Van 
Der Most, Richard A. Lake 
Medicine And Pharmacology, The University Of 
Western Australia/Australia
Background: Chemotherapy and immunotherapy 
have historically been considered antagonistic, 
expression (80%), 3 (60%) had membranous 
expression. With a median follow up of 17 months 
there was no association between ErbB3 expression 
and disease-free or overall survival.
Conclusion: High ErbB2 expression is infrequent in 
NSCLC. Interestly, ErbB3 can be highly expressed 
in NSCLC and seems more frequent in females, 
ADC and EGFR-mut tumors. ErbB3 expression and 
its use as therapeutic target warrants further study in 
NSCLC.
Keywords: EGFR, NSCLC, ErbB2, ErbB3
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P2.209 MYC AND HUMAN TELOMERASE 
GENE (TERC) GENE COPY NUMBER 
GAIN IN RESECTED NON-SMALL CELL 
LUNG CANCER (NSCLC).
Antonella Flacco1, Vienna Ludovini1, Fortunato 
Bianconi2, Francesca Romana Tofanetti1, Lorenza 
Pistola1, Annamaria Siggillino1, Elisa Baldelli1, 
Guido Bellezza3, Maria Grazia Mameli3, Giulio 
Metro1, Mark Ragusa4, Jacopo Vannucci4, Francesco 
Puma4, Lucio Crinò1 
1S. Maria Della Misericordia Hospital, Medical 
Oncology Department,s. Maria Della Misericordia 
Hospital/Italy, 2University Of Perugia, Department 
Of Electronic And Information Engineering, 
University Of Perugia/Italy, 3University Of Perugia, 
Institute Of Pathological Anatomy And Histology, 
University Of Perugia/Italy, 4University Of Perugia, 
Department Of Thoracic Surgery, University Of 
Perugia/Italy
Background: Long-term survival of resected 
NSCLC is disappointing and the identiÀcation 
of biological prognostic factors is critical. 
Abnormalities in MYC are well known in lung 
cancer and TERC maps in chromosomal region 
with frequent copy number gain (CNG) in NSCLC. 
This study investigates the incidence of MYC and 
TERC CNG and evaluates their correlation with 
clinicopathological parameters and outcome in 
resected NSCLC
Methods: 113 NSCLC patients subjected to curative 
pulmonary resection were tested for TERC and 
MYC CNG by Áuorescence in situ hybridization 
(FISH) using commercial probes. Median age was 
66 years (range 40–84); most patients were male 
(84%), former/current smokers (92%), had poorly 
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survival in both univariate (p<0.05) and multivariate 
analysis including both immunological and clinical 
variables (p<0.05). Chemotherapy-induced change 
in CD8+ T cell proliferation was more predictive of 
outcome than any baseline clinical variable included 
in the model, including performance status. 
Conclusion: Lymphodepletion following 
chemotherapy was not found to be detrimental but 
instead appeared to reset the stage, temporarily 
removing Treg mediated suppression and enabling 
regeneration of the CD8+ T cell pool. This may 
represent a window of opportunity for manipulating 
these newly reconstituted T cells by combining 
chemotherapy with immunotherapy to skew the 
immune response in favour of effective anti tumour 
immunity.
Keywords: T cells, Chemotherapy, Non-small cell 
lung cancer, mesothelioma
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P2.211 SYSTEMATIC EVALUATION 
OF GENETIC VARIANTS IN THREE 
BIOLOGICAL PATHWAYS ON PATIENT 
SURVIVAL IN EARLY-STAGE NON-
SMALL CELL LUNG CANCER
V. S. Pankratz1, Zhifu Sun2, Jeremiah Aakre2, Yan 
Li2, Cassandra Johnson3, Yolanda I. Garces4, Marie 
Christine Aubry5, Julian R. Molina6, Dennis A. 
Wigle7, Ping Yang8 
1Health Sciences Research, Mayo Clinic/United 
States Of America, 2Biomedical Statistics And 
Informatics, Mayo Clinic/United States Of 
America, 3Division Of Epidemiology, Mayo Clinic/
United States Of America, 4Radiation Oncology, 
Mayo Clinic & Ncctg/United States Of America, 
5Anatomic Pathology, Mayo Clinic/United States Of 
America, 6Medical Oncology, Mayo Clinic & Ncctg/
United States Of America, 7Division Of Thoracic 
Surgery, Mayo Clinic/United States Of America, 
8Epidemiology, Mayo Clinic/United States Of 
America
Background: Studies from selected candidate genes 
suggest that single nucleotide polymorphisms (SNP) 
in genes involved with glutathione metabolism, DNA 
repair, or inÁammatory responses may affect survival in 
early-stage non-small cell lung cancer (NSCLC). In this 
study, we took a systematic pathway-based approach 
to evaluate the impact of genetic variation from these 
partly because lymphopaenia is a toxicity of most 
cytotoxic drugs. Recently, research in animal models 
has demonstrated that chemotherapy may actually 
enhance anti-tumour immunity by altering both the 
level and context of antigen presentation. However, 
despite increasing interest in combining chemo and 
immunotherapy, little is known of the effects of 
chemotherapy on the human anti-tumour immune 
response. This study investigated the longitudinal 
effects of standard chemotherapy regimens on T cell 
subsets in patients with malignant mesothelioma 
(MM) and advanced non-small cell lung cancer 
(NSCLC). CD8+ T cells, which drive anti-tumour 
immunity, and regulatory T cells (Treg), which play 
a suppressive role, were speciÀcally assessed.
Methods: 43 patients (27 MM and 16 NSCLC) 
were enrolled between 2007 and 2009. Serial blood 
samples were collected over four treatment cycles 
(baseline, cycle 1 day 8, post cycle 1, and post 
cycle 3) and analysed using multi-parameter Áow 
cytometry.
Results: Total lymphocyte numbers were 
signiÀcantly reduced one week following the Àrst 
dose of chemotherapy (mean 1.50 x 109/L (baseline) 
versus 1.30 (cycle 1 day 8); p<0.01) and then 
continued to decline at a slower rate throughout the 
course of treatment (1.23 (post cycle 1); 1.21 (post 
cycle 3); p<0.001 relative to baseline). Proliferating 
CD8+ T cells and Treg were almost entirely depleted 
at cycle 1 day 8, but rapidly recovered with higher 
than baseline levels of proliferating cells at the end 
of each treatment cycle (mean Ki67+ CD8+ T cells 
5.6% (baseline) versus 7.6% (post cycle 1); p<0.05 
and Ki67+ Treg, 17.8% versus 26.9%; p<0.001). 
Treg numbers were most profoundly affected, with 
a decline in the relative size of this population 
one week after chemotherapy (mean of CD4+ T 
cells 6.3% (baseline) versus 5.1% (cycle 1 day 
8); p<0.01). Activated effector CD8+ T cells were 
detected both before and after treatment, suggesting 
a degree of antigen-driven activation. Tumour 
antigen - speciÀc CD8+ T cells were identiÀed 
in 10% of patients but did not alter following 
chemotherapy. Higher proportions of proliferating 
CD8+ T cells and activated effector CD8+ T cells 
and Treg at baseline were predictive of poorer 
overall survival in univariate regression analyses 
(p<0.05, p<0.05 and p<0.01 respectively), suggesting 
that greater immune activity may be present in 
patients with more advanced disease. Conversely, 
increased CD8+ T cell proliferation following one 
cycle of chemotherapy was predictive of improved 
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crucial for non non-small lung cancer patients in 
selecting their therapy, because it is a predictor for 
the efÀcacy of EGFR tyrosine kinase inhibitors. 
Four EGFR gene mutation tests are commercially 
available in Japan. However differences in sensitivity 
between these tests have not been investigated. This 
study compared the peptide nucleic acid-locked 
nucleic acid polymerase chain reaction clamp 
assay (PNA-LNA PCR-Clamp) with the cycleave 
polymerase chain reaction assay (Cycleave-PCR) 
using formalin-Àxed parafÀn-embedded (FFPE) 
tissue samples of resected lung adenocarcinoma. 
Methods: We examined the EGFR gene mutation 
status in 42 lung adenocarcinoma patients who 
underwent curative operation at Tokushima 
University Hospital from 2004 to 2010. They 
included 15 males and 27 females and their mean age 
was 67 (range; 29 - 82). In these 42 patients, there 
were 15 smokers (35.7%). Pathologic staging was IA 
in 15, IB in 13, IIB in 5, and IIIA in 9. FFPE tissue 
was sliced at 10-ƫm thickness and Àve sections were 
used for each test (PNA-LNA PCR-Clamp assay and 
Cycleave-PCR assay). Fixation time was usually one 
week. Each sample was tested in a blinded manner 
by each laboratory
Results: PNA-LNA PCR-Clamp assay detected 25 
(61.0 %) EGFR gene mutation-positive samples 
and failed in 1 (2.4 %) case. Cycleave-PCR assay 
detected 28 (66.7 %) EGFR gene mutation-positive 
samples without failure. Concordance rate between 
the two methods was 95.1 % (39/41). Among the 
concordant cases, 14 (35.9 %) EGFR gene mutations 
were found at exon 19, and 11 (28.2 %) mutations 
were found at exon 21. According to the discordance, 
two samples with EGFR gene mutation-negative in 
PNA-LNA PCR-Clamp assay were revealed to have 
EGFR gene mutations at exon 19 in Cycleave-PCR 
assay. 
Conclusion: Cycleave-PCR assay demonstrated 
higher EGFR gene mutation-positive rate than 
PNA-LNA PCR-Clamp assay without failure. These 
discordances need conÀrmation by other EGFR gene 
mutation tests. 
Keywords: EGFR, Adenocarcinoma, EGFR gene 
mutation test
three pathways on survival for early-stage NSCLC.
Methods: DNA from 647 patients with Stage I and 
II NSCLC was genotyped for 480 SNPs (tagSNPs) 
tagging 57 genes from the three candidate pathways. 
Associations of tagSNPs with patient survival were 
assessed at the individual SNP and whole gene 
levels adjusting for age, tumor stage, surgery type 
and adjuvant therapy. The association of genotype 
combinations of the SNPs associated with post-
diagnosis survival was also estimated.
Results: Among the 412 tagSNPs that were 
successfully genotyped and passed all quality 
assessments, 28 showed association with survival 
(p<0.05). Two of the 28 were estimated to have 
less than a 20% chance of being false positive 
(rs3768490 in GSTM4 gene: p=1.32×10-4, q=0.06; 
rs1729786 in ABCC4 gene: p=9.25×10-4, q=0.20). 
Gene-based analysis suggested that, in addition to 
GSTM4 and ABCC4, variation in two other genes, 
PTGS2 and GSTA2, was also associated with 
survival following detection of early-stage NSCLC.
Conclusion: We describe further evidence that 
variation in genes involved in the glutathione and 
inÁammation pathways is associated with survival 
in early-stage NSCLC. Further study is warranted 
to verify our Àndings and elucidate the functional 
mechanisms of how these risk variants may inÁuence 
survival in NSCLC patients. 
Keywords: genetic polymorphisms, DNA repair, 
inÁammation response, glutathione metabolism
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P2.212 COMPARISON OF TWO 
DIFFERENT EGFR GENE MUTATION 
TESTS FOR RESECTED LUNG 
ADENOCARCINOMA
Mika Takashima1, Hiromitsu Takizawa1, Koichiro 
Kajiura1, Koh Uyama1, Hiroaki Toba1, Yasushi 
Nakagawa1, Yukikiyo Kawakami1, Koichiro 
Kenzaki1, Shoji Sakiyama1, Kazuya Kondo2, Akira 
Tangoku1 
1Department Of Thoracic, Endocrine Surgery And 
Oncology, The University Of Tokushima Graduate 
School/Japan, 2Department Of Oncological Medical 
Services, Institute Of Health Biosciences, The 
University Of Tokushima Graduate School/Japan
Background: Information of epidermal growth 
factor receptor (EGFR) gene mutation status is 
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relative standard curve method.
Results: The trial registered a total of 60 patients, 
of which 40 blood samples were available. Nineteen 
patients achieved a CR or PR to AMR according 
to the RECIST assessment and 21 did not. Patients 
with tumor response had a signiÀcantly lower Topo-
II level than those without (p=0.0465, Wilcoxon 
test), although there was no association between 
tumor response and the level of CBR-I (p=0.3229, 
Wilcoxon test). We did not Ànd any signiÀcant 
association between the levels of the two enzymes 
and toxicity.
Conclusion: Topo-II may be a potential predictor 
of response in the treatment of AMR for second-
line SCLC. Further investigations in larger patient 
materials are warranted.
Keywords: SCLC, amrubicin
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P2.214 EVALUATION OF VERISTRAT® 
SIGNATURE IN ADVANCED 
BRONCHIOLOALVEOLAR CARCINOMA 
(BAC): A POOLED ANALYSIS OF IFCT 
0401 AND 0504 TRIALS
Julia Grigorieva1, Elisabeth Quoix2, Marie Wislez3, 
Denis Moro-Sibilot4, Patrick Merle5, Radj Gervais6, 
Sylvie Friard7, Rébecca Rouveau8, Franck Morin8, 
Heinrich Roder1, Joanna Roder1, Jacques Cadranel3 
1R&D, Biodesix/United States Of America, 2Service 
De Pneumologie/France, 3Ap-hp Hopital Tenon/
France, 4Chest Medicine Department, Grenoble 
University Hospital/France, 5Pneumologie, Chu/
France, 6Oncology, Centre François Baclesse/
France, 7Pneumologie, Hôpital Foch/France, 
8Intergroupe Francophone De Cancérologie 
Thoracique (IFCT)/France
Background: Based on results from Phase II trials, 
it was suggested that EGFR-TKIs have reduced 
activity in mucinous BAC, while taxane-based 
chemotherapy could have some effect both in 
mucinous (M) and nonmucinous (NM) cytological 
subtypes. Two phase II trials conducted by French 
Intergroup of Thoracic Oncology (IFCT) evaluated 
Àrst-line geÀtinib (IFCT0401) and Àrst-line erlotinib 
or carboplatin/paclitaxel (C/P) (IFCT0504). VeriStrat 
is a pretreatment mass spectrometry-based test that 
assigns a “Good” or “Poor” classiÀcation, shown 
to correlate with survival on EGFR-TKIs therapies 
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P2.213 TOPOISOMERASE II, CARBONYL 
REDUCTASE I, CHEMOSENSITIVITY 
AND TOXICITY FOR AMRUBICIN IN 
THE SECOND-LINE TREATMENT OF 
PATIENTS WITH SMALL-CELL LUNG 
CANCER. THE RESEARCH FROM TORG 
0301
Takashi Seto1, Takeharu Yamanaka1, Noriyuki 
Masuda2, Kenji Eguchi3, Y. Takiguchi4, Hiroaki 
Okamoto5, Takashi Ogura6, Akira Yokoyama7, Seto 
Takashi1, Yukito Ichinose1, Koshiroh Watanabe8 
1Thoracic Oncology, National Kyushu Cancer 
Center/Japan, 2Department Of Respiratory 
Medicine, Kitasato University School Of Medicine/
Japan, 3Respirology Medicine, Teikyo University 
School Of Medicine/Japan, 4Respirology, Graduate 
School Of Medicine, Chiba University/Japan, 
5Department Of Respirology, Yokohama Municipal 
Citizens Hospital/Japan, 6Thoracic Oncology, 
Kanagawa Cardiovascular And Respiratory Center/
Japan, 7Department Of Internal Medicine, Niigata 
Cancer Center Hospital/Japan, 8Pulmonary 
Medicine, Yokohama Municipal Citizen’s Hospital/
Japan
Background: Amrubicin (AMR) has been 
suggested to provide a new effective therapeutic 
option for small-cell lung cancer (SCLC). It is a 
totally synthetic 9-aminoanthracyclin and converted 
by carbonyl reductase I (CBR-I) to its active 
form, amrubicinol, that has higher potent activity 
than the parent drug and inhibits puriÀed human 
topoisomerase II (topo-II). We previously reported 
the promising result of a prospective phase II trial 
for AMR monotherapy in patients with second-line 
SCLC (Thoracic Oncology Research Group Study 
0301). Using blood samples at enrollment in this 
trial, the clinical signiÀcance of topo-II and CBR-I 
expression levels on antitumor effect as well as 
toxicity has been examined.
Methods: Total RNA was extracted from the blood 
with an RNeasy Mini Kit (Qiagen Inc.) and DNase 
treatment was performed using the RNase-Free 
DNase Set (Qiagen Inc.). RT-PCR analysis was 
performed using TaqMan technology. QuantiÀcation 
of target cDNA (Top-II alpha, CBR-I and beta-actin 
gene) was conducted using an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems 
Inc.). QuantiÀcation was performed using the 
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patients derive similar beneÀt from both treatments; 
the predictive value of VeriStrat in BAC needs 
validation in larger studies. 
Keywords: bronchioloalveolar carcinoma, Mass 
spectrometry-based test VeriStrat, Mucinous 
cytological subtype, Nonmucinous cytological 
subtype
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P2.215 HIGHLY EXPRESSED ADAM9 
IN COMPLETELY RESECTED STAGE 
I NON-SMALL CELL LUNG CANCER 
CASES PREDICTS A SHORTENED 
SURVIVAL
Jun Zhang1, Juan Qi2, Ning Chen1, Yi Guo1, Weineng 
Fu1, Baosen Zhou1, Anguang He1 
1Department Of Molecular Targeted Therapeutics Of 
The First Hospital Of China Medical University, The 
First Hospital Of China Medical University Lung 
Cancer Center/China, 2Department Of Molecular 
Targeted Therapeutics Of The First Hospital Of 
China Medical University/China
Background: A disintegrin and metalloproteinase-9 
(ADAM9) was recently found highly expressed in 
some malignant solid tumors, correlates with cancer 
progression, metastasis, and predicts a shortened 
patients’ survival. However, the expression of 
ADAM9 in human resected lung cancer tissues, 
and its clinical signiÀcance are not clear. Here, we 
investigate the abnormal expression of ADAM9 on 
protein level in human resected non-small cell lung 
cancer (NSCLC) tissues, to evaluate the signiÀcance 
of ADAM9 expression in surgically resected 
NSCLC.
Methods: Sixty-four cases of completely resected 
stage I NSCLC with mediastinal N2 lymph node 
dissected were immunohistochemically analyzed 
for ADAM9 protein expression. Survival analysis, 
univariate and multivariate analysis were conducted 
to asses the signiÀcance of ADAM9 expression 
and the relationship with other clinicopathological 
characteristics.
Results: In 64 cases of completely resected stage 
I NSCLC, 53.1% (34/64) was found with ADAM9 
protein highly expressed (ADAM9+), signiÀcantly 
higher when compared with normal control lung 
tissues (P=0.001). In 48 adenocarcinoma cases, 
66.7% (32 cases) was found with ADAM9 protein 
in advanced NSCLC with a hazard ratio (HR) of 
approximately 0.5. This study aimed to evaluate the 
VeriStrat test in advanced BAC patients included in 
IFCT 0401 and 0504 trials. 
Methods: Pretreatment samples (64 from IFCT0401 
and 114 from IFCT 0504) were available for 
VeriStrat testing. The only population difference 
between the two trials was the proportion of men 
(45.5% vs. 60.9%); there was no difference in 
age, smoking status, or proportions of cytological 
subtypes.
Results: 175 samples were assigned VeriStrat 
classiÀcation; 148 were classiÀed as “Good”, 27 
as “Poor”. No signiÀcant correlation was found 
between VeriStrat classiÀcation and M and NM 
cytology, or other patient characteristics. In the 
combined population there was no signiÀcant 
difference in PFS between “Good” and “Poor” 
patients (p=0.26, median PFS: 100 days in “Good”, 
66 days in “Poor”) or between treatments (p = 
0.095, HR = 1.32; 95%CI 0.95-1.83; PFS 201 days 
in C/P, 90 days in EGFR-TKIs). Patients with M 
cytology had signiÀcantly longer PFS when treated 
with C/P than EGFR-TKIs (p = 0.0002, HR=0.39; 
95%CI 0.24-0.64; PFS 143 days in C/P, 64 days 
in EGFR-TKIs); no signiÀcant difference between 
“Good” and “Poor” was found in M patients treated 
with P/C or with EGFR-TKIs. Patients with M 
cytology identiÀed as “Good” beneÀted more from 
chemotherapy than from EGFR-TKIs (p = 0.0001; 
HR= 0.33, 95%CI 0.19-0.58; median PFS: 198 days 
in P/C, 81 in EGFR-TKIs); no difference in PFS 
between treatments was found in “Poor” M patients. 
In NM patients there was no signiÀcant difference 
between treatment arms; no comparison between 
VeriStrat groups was done in the NM subset treated 
with EGFR-TKIs due to an insufÀcient number of 
“Poor” subjects; PFS in the NM P/C-treated subset 
was signiÀcantly different between “Good” and 
“Poor” (p=0.039, HR= 0.17, 95%CI 0.03-0.91; 
median PFS: 269.5 days in “Good” and 70.5 days in 
“Poor”). There was no treatment-related difference in 
PFS in the NM “Good” group. 
Conclusion: In contrast to previous results, in non-
BAC NSCLC VeriStrat did not separate PFS in the 
EGFR-TKI-treated population of ADC-BAC, but 
did show signiÀcantly different PFS in NM patients 
treated with P/C. M and NM patients presented 
different susceptibilities to chemotherapy and 
EGFR-TKIs. Patients with M cytology classiÀed 
as VeriStrat “Good” may beneÀt more from 
chemotherapy than from EGFR-TKIs, while NM 
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P2.216 ESTROGEN HORMONE 
RECEPTOR EXPRESSION IN WOMEN 
WITH NON-SMALL CELL LUNG 
CANCER.
Bianca Tabajara1, Ana C.Z. Gelatti2, Sheila Calleari1, 
Fernanda B. Damian1, Cláudia S. Schavinski1, Maria 
Helena Sostruznik1, Carlos H. Barrios3 
1Hospital São Lucas Puc/rs/Brazil, 2Oncology, 
Hospital São Lucas Puc/rs/Brazil, 3Medicine, Pucrs 
School Of Medicine/Brazil
Background: Non-smal cel lung cancer (NSCLC) 
is the leading cause of cancer death in men and 
rates second among women in Brazil. It has been 
reported that women tend to develop NSCLC at an 
earlier age, have increased susceptibility to cancer 
and have better survival when compared with men. 
The biological reasons for these differences remain 
unknown. The aim of this study is to explore the 
expression of ER and its relationship with clinical 
factors in women with NSCLC. 
Methods: This is a descriptive analysis of 53 
consecutive female patients (pts) diagnosed with 
NSCLC at the Oncology Service, Hospital São 
Lucas, PUCRS, between January 2007 and April 
2010. ER was analyzed by Immunohistochemistry 
(Rabbit IGG, Biocare Medical). Positive ER 
expression was considered if >1% cells showed 
nuclear staining. 
Results: Mean age at diagnosis, 58.9y (35-89) and 
about 30% of pts were non-smokers. Nine records 
had no information on smoking. Adenocarcinoma 
(49,1%), squamous cell carcinoma (24,5%), 
adenosquamous carcinoma (1,9%) and NSCLC NOS 
(24,5%) were the reported histological subtypes. 
At baseline, 45,3% had stage IV and 60,4% 
performance status of 0-1. A total of 9/56 pts (17%) 
showed ER expression by IHC. Of the early stage 
pts (I-IIIA) ER positive pts represented 10% of 
cases while they were 19,4% of cases with advanced 
stage (IIIB-IV). The distribution of ER expression 
according to histology was equal in Adenocarcinoma 
and Squamous (15,4%). The 3 other positive pts had 
NSCLC-NOS. A total of 19,4% of smokers were ER 
positive while there were no positive cases among 
non-smokers. The distribution of ER positive cases 
according to age was 16,6% in pts <50y and 17% 
in pts >50%. Considering the whole group of pts, 
median survival was 7,5 months in ER positive cases 
highly expressed, however, in 16 cases of squamous 
cell carcinoma, only two cases (12.5%) showed 
ADAM9 highly expressed, the difference was 
statistically signiÀcant (P=0.000). There is no 
difference found between ADAM9 high expression 
rates in stage IA and IB group (P>0.05). The overall 
5-year survival rate was 71.8% for this group of 
64 completely resected stage I NSCLC cases with 
lobectomy and local hilar (N1) and mediastinal 
(N2) lymph nodes dissection performed. The 5-year 
survival rate in ADAM9 low expression (ADAM9-) 
group (30 cases) was as high as 88.9%, however, the 
5-year survival rate was sharply decreased to 56.9% 
in ADAM9 high expression (ADAM9+) group (34 
cases), the difference was statistically signiÀcant 
(P=0.012). There is no statistically signiÀcant effect 
of ADAM9 expression on the survival of patients 
found in different histological types, pathologic 
stages. In 24 stage IA cases, the 5-year survival rate 
for ADAM9 low expression group (8 cases) was 
100%, it sharply decreased to 55.0% for ADAM9 
high expression group (16 cases), the difference was 
statistically signiÀcant (P=0.049). In the 40 stage 
IB cases, the 5-year survival rate for ADAM9 low 
expression group (22 cases) was as high as 84.8%, 
but it decreased sharply to 55.6% for ADAM9 high 
expression group (18 cases), the difference was 
statistically signiÀcant (P=0.030). Cox regression 
model was used for multivariate survival analysis: 
patients’ gender, age, smoking status, histological 
types, pathologic stages (IA and IB) and ADAM9 
high/low expression, were entered into Cox 
proportional hazard regression model. The results 
showed that ADAM9 high/low expression was the 
independent predictor of prognosis for this group 
of completely resected stage I NSCLC (HR=3.385, 
95% CI: 1.224-9.360; P=0.019).
Conclusion: The results showed clearly for the Àrst 
time that ADAM9 is highly expressed in NSCLC and 
highly expressed ADAM9 correlates with shortened 
survival, suggesting that ADAM9 is a novel 
biomarker for predicting the prognosis in resected 
stage I NSCLC, and ADAM9 might become a 
useful predictive biomarker for selection of adjuvant 
chemotherapy treatment.
Keywords: immunohistochemistry, ADAM9, lung 
neoplasm, Prognosis
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Background: EGFR Tyrosine Kinase Inhibitors 
(TKIs), geÀtinib or erlotinib, is an effective 
treatment for patients with non-small cell lung 
cancer (NSCLC) tumors expressing EGFR-
sensitizing mutations. Molecular selection should 
be performed since clinical characteristics were 
shown to be insufÀcient to accurately select 
patients harboring EGFR mutations. After direct 
sequencing, various more sensitive and less time-
consuming molecular methods have been developed 
for EGFR detection because geÀtinib obtained 
restrictive EMA/FDA approval for Àrst line 
treatment of patients with EGFR mutated NSCLC. 
Methods: Three EGFR mutated NSCLC cell 
lines, SW48 (G179S), H1650 (DE746-A750), 
H1975 (T790M, L858R) and three wild-type 
DNA were blinded and simultaneously analyzed. 
DNA from each mutated cell line was diluted into 
wild-type DNA (100%, 20%, 10%, 5%). Twenty 
French molecular laboratories from ERMETIC-2 
(Evaluation of the EGFR Mutation status for the 
administration of EGFR-TKIs in non-small cell 
lung Carcinoma) and PREDICT.amm (Prediction of 
treatment of extended NSCLC – using of molecular 
markers) national studies used their current 
molecular sensitive techniques for EGFR mutation 
detection. 
Results: The table indicated by molecular 
technique, the number of centers which were able 
to detect the mutation related to the number of 
centers using the technique. 
vs 10,4 months in pts with no ER expression. Median 
survival of ER positive stage IV pts was 4,7 months 
while it was 6,0 months in ER negative patients. 
In the older women (>50y) median survival of ER 
positive pts was 6.8 months while it was 11,9 months 
in ER negative pts. In the younger cohort (<50y) 
median survival was 9,5 months in ER positive and 
5,7 months in ER negative cases. 
Conclusion: This retrospective analysis does 
not seem to identify a clear relationship of ER 
expression and survival in women with NSCLC. 
Small numbers in this subgroup of pts compromises 
deÀnitive conclusions. Larger prospective trials 
addressing clinical factors to ER expression in 
NSCLC are needed. 
Keywords: Estrogen Hormone Receptor, Lung 
cancer, Women
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Background: Protein level analysis has several 
beneÀts; proteins can be measured both in tissue 
and plasma and the majority of novel cancer 
drugs target proteins. Mass spectrometry (MS) 
is a powerful technology for the analysis of 
large numbers of endogenous proteins. We have 
developed methods to improve proteome analysis 
in lung cancer tissue1, plasma and pleural effusion 
samples2. We have previously used these methods 
to detect proteome changes in lung cancer cells3 
and further validated these in tumor tissue4. In this 
study we performed a proteomics anchored systems 
biology analysis of tumor tissue to elucidate the 
molecular proÀles of lung adenocarcinoma. In 
addition to comprehensive proteomics data, mRNA 
and miRNA expression and gene copy number 
alterations from same samples have been analyzed 
in relation to the proteomics data to elucidate the 
mechanisms behind tumor progression. The data 
has been correlated to clinical data on relapse and 
node invasion at time of surgery. 
Methods: Surgical samples (n=8 relapse free and 
8=relapse cases) were analyzed. Samples were 
fractionated by two dimensional fractionation using 
peptide isoelectric focusing followed by nLC-
MS/MS analysis. Quantitative proteomics data 
was generated using isotopic labelling (iTRAQ). 
Proteome was analysed by mass spectrometry 
based proteomics. Multivariate data analysis 
(PLS) was used to select signiÀcant protein level 
Cell line Direct 
sequencing 
Targeted 
techniques 
Fragment 
analysis 
HRM Pyrosequencing 
EGFR exon18, 
SW48, G719S 
(*) 
100% 10/10 4/4 NR 5/5 1/2 
20% 8/10 4/4 NR 4/5 2/2 
10% 2/10 4/4 NR 3/5 2/2 
5% 0/10 2/4 NR 1/5 0/2 
EGFR exon19, 
H1650, 
(DE746-A750) 
(**) 
100% 9/9 1/1 10/10 5/5 3/3 
20% 7/9 1/1 10/10 5/5 2/3 
10% 1/9 1/1 8/10 2/5 2/3 
5% 0/9 1/1 5/10 1/5 0/3 
EGFR exon20, 
H1975, T790M 
(***) NR 
100% 7/9 5/5 NR 4/5 2/3 
20% 3/9 4/5 NR 3/5 2/3 
10% 1/9 4/5 NR 0/5 2/3 
5% 0/9 3/5 NR 0/5 0/3 
EGFR exon21, 
H1975, L858R 
(****) NR 
100% 9/9 7/7 NR 5/5 2/3 
20% 3/9 5/7 NR 3/5 2/3 
10% 1/9 5/7 NR 1/5 1/3 
5% 0/9 4/7 NR 0/5 0/3 
NR: Not Relevant; (*) snap-shot analysis (1 center), 
real-time PCR (2 centers), short sequencing (1 
center); (**) real-time PCR (1 center); (***) snap-
shot analysis (1 center), real-time PCR (4 centers); 
(****) real-time PCR (5 centers), RFLP (1 center), 
snap-shot (1 center) For EGFR exon 18 analysis, 
one false positive result was observed with HRM 
analysis. For EGFR exon 19 analysis, one false 
positive result was observed with fragment analysis. 
For EGFR exon 20 T790M mutation analysis, 5 
false-positive results (one center) were observed with 
HRM. For EGFR exon 21 analysis, no false-positive 
result was detected. 
Conclusion: Conclusions and perspectives: In 
routine analysis of mutated cell lines, alternative 
molecular techniques for mutation detection 
in NSCLC cells are more sensitive than direct 
sequencing, but sensitivity could be different among 
techniques. Furthermore, some false-positive 
results could be observed. The next step is to use 
these techniques in the “real-life” on parafÀn-
embedded NSCLC samples, as in ERMETIC-2 and 
in PREDICT.amm studies in order to analyze these 
techniques in the context of poor tumor cells and 
lower DNA quality samples. 
Keyword: EGFR, mutation, molecular methods, 
ERMETIC-2, PREDICT.amm, NSCLC
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Background: Epidermal growth factor receptor 
(EGFR) is involved in cellular proliferation and 
differentiation. Increased expression of EGFR has 
been reported in squamous cell carcinomas of the 
lung. Serine/threonine kinase Akt is known to be 
a downstream mediator of phosphatidylinositol 
3-phosphate kinase (PI3K), a critical element in 
cancer development. Activity of AKT is mainly 
inhibited by phosphatase and tensin homologue 
(PTEN), a tumor suppressor gene that inhibits PI3K 
levels. The author hypothesizes that PTEN inhibition 
and subsequent PI3K-Akt signal transduction are 
major constituents in tumorigenesis. This study 
observes the expression patterns of EGFR and 
PTEN in non-small cell lung cancer patients by 
immunohistochemical stains, and analyzes the 
relationship between biological markers and clinical 
parameters. 
Methods: Lung cancer tissues obtained from 
surgical specimens of 178 patients who were 
diagnosed as non-small cell carcinoma and 
underwent curative operation were assessed by 
tissue microarray. The EGFR and PTEN expression 
patterns were examined by immunohistochemical 
stains and were statistically analyzed. 
Results: There was an inverse correlation between 
EGFR and PTEN expression patterns. With 
immunohistochemical stain, EGFR was expressed 
in 17% of adenocarcinoma and 44% of squamous 
cell carcinoma cases (p<0.001), while PTEN was 
expressed in 85% of adenocarcinoma and 23% 
of squamous cell carcinoma (p<0.001). Age, sex, 
degree of histological differentiation, lymph node 
invasion, and stage were not signiÀcantly different 
between positive and negative groups.
Conclusion: There is an inverse correlation between 
EGFR and PTEN expression patterns in non-small 
cell carcinoma patients.
alteration between the groups. Further, biological 
interpretation of data was performed by pathway 
analysis. Early validation of marker proÀles and 
altered pathways were performed using western 
blot and IHC. 
Results: We identiÀed and quantiÀed over 3500 
proteins. This is a one of the most comprehensive 
tumor proteomics data sets and to analyze it we 
used signiÀcance analysis between the groups but 
also characterized tumor speciÀc protein proÀle 
analysis to detect pathways driving tumor growth. 
The distribution of the GO terms is similar between 
the proteomics and the transcriptomics data. We 
identiÀed a substantial amount of membrane 
proteins, which are usually difÀcult to identify 
with global proteomics methods (36% of the 
proteins). Among the altered pathways, glucose 
and amino acid metabolism very commonly altered 
in all tumors. However, we could also detect 
tumor speciÀc cancer related pathways potentially 
powerful for molecular sub-typing of lung 
adenocarsinoma. Finally, the combined statistical 
and pathway analysis revealed ten potential markers 
for relapse in early stage adenocarsinoma with 
indications on MYC, HIF1a and metabolic switch 
related pathways.
Conclusion: Here we have performed 
comprehensive tumor proteomics comparing lung 
adenocarsinoma proteome between relapse free 
and relapsed cases. The proteomics data is related 
on genomics and transcriptomics data from same 
samples creating unique molecular landscape of 
altered pathways. This data can help to classify 
lung adenocarsinoma tumours based on pathway 
alteration and gain knowledge on proteome changes 
to direct the therapy. 1 De Petris, L. et al., Proteome 
Sci (2010) 2 Pernemalm, M. et al., Proteomics 
(2009). 3 Orre, L. M. et al., Mol Cell Proteomics 
(2007). 4 De Petris, L. et al., Lung Cancer (2009). 
Keywords: proteomics, Lung adenocarsinoma, 
Pathway analysis, Molecular systems biology
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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biosignature that differentiated NSCLC samples 
from control samples.
Results: A biosignature of 6 different proteins 
was found that differentiated patients with biopsy-
conÀrmed NSCLC (n=20) from individuals from 
the general population (n= 25) with a sensitivity of 
85% and speciÀcity of 92%. The NSCLC samples 
analyzed were comprised of AJCC/UICC stage 
IA/B (n=7), IIA (n=4), IIB (n=7) and IIIA (n=2). 
Half of these patients were positive for lymph node 
involvement. The biosignature found is composed of 
6 different surface membrane protein markers, which 
include both microvesicle and cancer-associated 
proteins. Three of the proteins are members of the 
tetraspanin transmembrane family (CD9, CD63 and 
CD81) that are found on microvesicles. Three other 
protein markers are DR3 (death receptor 3, a protein 
involved in apoptosis), PRB (progesterone receptor 
B) and MS4A (Membrane-spanning 4 domain 
subfamily A from the multigene family of proteins 
involved in signal transduction of which CD20 is one 
member).
Conclusion: In this small retrospective analysis, 
we have shown for the Àrst time that a unique cMV-
based biosignature derived from the blood is able to 
differentiate NSCLC patients from normals. These 
results may serve as the foundation to develop a 
diagnostic test for NSCLC.
Keywords: blood based diagnostics, circulating 
microvesicles, Non small cell lung cancer
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Background: 30% of patients (pts) affected by 
NSCLC presents with locally advanced stage for 
Keywords: EGFR, Non-Small-Cell Lung, PTEN
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Background: Early detection is one of the key 
elements to the successful treatment of NSCLC. 
In the past, individual biomarkers have failed to 
exhibit sufÀcient sensitivity or speciÀcity to allow 
for the detection of non-small cell lung cancer 
(NSCLC) at a stage that could be cured by surgical 
intervention. A multiplex approach with sub-
cellular vesicles secreted into the plasma by tumor 
cells offers an exciting potential solution to this 
dilemma. Circulating microvesicles (cMV) are lipid 
bilayer vesicles ranging in size from 40-1000nm 
in diameter. cMVs are secreted by most cell types, 
including tumor cells, through multiple mechanisms 
and contain membrane bound proteins that are 
characteristic of their cell of origin. This suggests 
that cMV surface protein composition and quantity 
can be used to evaluate the risk for the presence of 
disease and possibly to characterize disease sub-
types such as NSCLC. In this study, we demonstrate 
that a novel protein biomarker signature is associated 
with NSCLC by analysis of multiple protein markers 
found in circulating microvesicles in plasma of 
patients.
Methods: A novel multiplexed platform for 
quantifying and proÀling cMVs from plasma was 
used to develop a cMV-derived biosignature. We 
isolated cMVs from plasma of patients both with 
and without NSCLC, including both smokers 
and non-smokers. Beads coated with antibodies 
against surface proteins were used in a multiplex 
assay to capture and detect cMVs. QuantiÀcation 
of cMVs with signiÀcant concentrations of these 
surface proteins led to the development of a speciÀc 
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in NSCLC but a larger population is required to 
validate these preliminary results. 
Keywords: locally advanced NSCLC, combined 
modality, ERCC1
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Background: Activating mutations within the 
tyrosine kinase domain of Epidermal Growth Factor 
Receptor (EGFR) are found in approximately 10-
20% of non-small cell lung cancer (NSCLC) patients 
and are associated with response to EGFR tyrosine 
kinase inhibitors (TKIs). The aim of this study is 
to examine the prevalence of EGFR 18-21 among 
patients with histologically conÀrmed non-squamous 
NSCLC treated in our institution. 
Methods: We report the data of NSCLC patients of 
a single institution experience enrolled from April 
2010 to January 2011. We examined the mutation 
status of EGFR patients with newly diagnosed non-
squamous NSCLC. The formalin Àxed, parafÀn 
embedded tissue samples were obtained from tumor 
biopsy. These were sequenced to look for mutations 
in exons 18 - 21 of EGFR. 
Results: 67 patients were examined for EGFR 
mutations: 13 (19.4%) patients with stage IIIB and 
54 (80.6%) patients with stage IV. Age median 
was 63 years (range 34-80); male/female: 51/16; 
smokers/ex-smokers/never-smokers: 41/13/13; 
adenocarcinoma/large cell carcinoma/no otherwise 
speciÀed NSCLC: 44/19/4. The EGFR mutations 
(L858R in Exon21) were found in 5 patients 
(7.5%): female 12.5% (2/16), male 5.9% (3/51); 
adenocarcinoma 9.1% (3/44), large cell carcinoma 
10.5% (2/19); never-smokers 23.1% (3/13), smokers 
4.9% (2/41) (p>0.05). First-line treatment with 
EGFR-TKI was started for these patients. 
which a multidisciplinary therapeutic approach 
is recommended. Standard treatment is a neo-
adjuvant platinum-based chemotherapy followed 
by local treatment. When surgery is not feasible, 
due to comorbidity, compromised lung function, 
unresectable disease, integrated chemo-radiotherapy 
is the best approach. Several studies show a 
correlation between response to platinum and 
ERCC1 expression levels determined when an 
adequate tumor specimen is suitable. Data suggest 
low ERCC1 levels correlate with better response to 
treatments, while high levels link to resistance to 
platinum therapy. 
Methods: We enrolled 39 pts affected by NSCLC 
(18 pts with stage IIIA and 21 with stage IIIB), 
receiving neo-adjuvant chemotherapy with Cisplatin 
(CDDP) 75mg/m2 and Docetaxel (DOC) 75mg/m2 
day 1, q21. We evaluated objective response rate 
(ORR) and its correlation with ERCC1 expression, 
progression free survival (PFS) and overall survival 
(OS) at 24 months. ERCC1 mRNA levels were 
determined in peripheral blood cells samples using 
RT-PCR. 
Results: 38 pts completed planned chemotherapy. 
We observed partial response (PR) in 23 pts (60%), 
stable disease (SD) in 10 pts (26%) and progressive 
disease (PD) in 5 pts (13%). 11 pts underwent 
surgery (followed by adjuvant irradiation in 3 cases), 
17 received sequential radiotherapy; 7 patients 
stopped their treatments after chemotherapy. 2 years 
OS was 76% ; PFS was 46% for the whole cohort 
(75% for surgically treated patients, 42% for patients 
receiving sequential radiotherapy). In patients 
who didn’t received any local treatment 2 years 
OS was 20%, with PFS of 31% (OS p-value=0.02, 
PFS p-value<0.001). ERCC1 gene expression was 
collected in 24 patients, with the following Results: 
Partial Response (PR) Stable Disease (SD) Progression (PD) 
Low ERCC1 levels 
(expression 0.215) 10 (41.6%) 2 (8.4%) 0 (0%) 
High ERCC1 levels 
(expression >0.215) 5 (20.8%) 5 (20.8%) 2 (8.4%) 
OS and PFS were not statistically different in the two 
groups. 
Conclusion: Neo-adjuvant CDDP-DOC schedule 
obtains good response rate (60%) expecially in 
low ERCC1 level subgroup. At a 2 years follow 
up, surgery and radiotherapy show similar efÀcacy 
in terms of OS and PFS. Peripheral blood ERCC1 
expression seems to have a potential role in 
predicting response to platinum based chemotherapy 
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surgery compared with those who did not (10±8% vs. 
19±16%, all patients: 14±13%, p = 0.017). Patients 
whose tumor samples were categorized by low 
Ki67staining intensity ( 10% of Ki67 positivity) 
had signiÀcantly longer survival times than those 
with high staining intensity (median overall survival: 
470 vs. 197 days; log rank test: p = 0.004). The same 
was observed when the analysis was done within the 
pretreated patient subgroup (median overall survival: 
806 vs. 334 days; log rank test: p = 0.039). Finally, 
in the multivariate analyses, we could prove the 
prognostic power of Ki67, independent from sex, 
age, treatment, TNM-stage and histology. Treatment 
(p=0.009), histology (p=0.040) and Ki67 (p=0.012) 
were the remaining signiÀcant prognosticators in 
the Cox regression model. Data of an independent 
Hungarian collective will be available until June to 
validate our results.
Conclusion: This study reveals Ki67 as a novel, 
independent prognostic factor in MPM and warrants 
its further investigation in larger series of patients 
with this malignancy. 
Keywords: Ki67, malignant pleural mesothelioma, 
Biomarkers
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P2.224 THREE-MICRORNA EXPRESSION 
PROFILE IS RELATED TO THE RISK OF 
DISSEMINATION AND PROGNOSIS IN 
EARLY STAGE SQUAMOUS CELL LUNG 
CANCER (SQCLC)
Marcin T. Skrzypski1, Rafal Dziadziuszko1, Amelia 
Szymanowska1, Ewa Jassem1, Piotr Czapiewski1, 
Wojciech Biernat1, Ryszard Pawãowski1, Witold 
Rzyman2, Jacek Jassem1 
1Oncology And Radiotherapy, Medical University Of 
Gdansk/Poland, 2Department Of Thoracic Surgery, 
Medical University Of Gdansk/Poland
Background: About 50% of NSCLC patients (pts) 
will develop distant metastases following pulmonary 
resection. Currently, apart from clinical stage at 
diagnosis, there are no reliable clinical factors to 
select high risk pts for adjuvant chemotherapy. We 
previously demonstrated high prognostic value 
Conclusion: In comparison with literature data the 
frequency of EGFR gene mutations among non-
squamous NSCLC patients was very low. 
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P2.223 THE PROLIFERATION 
MARKER KI67 PREDICTS SURVIVAL 
IN MALIGNANT PLEURAL 
MESOTHELIOMA PATIENTS
Bahil Ghanim1, Mir Alireza Hoda1, Thomas 
Klikovits1, Clemens Aigner1, Martin Filipits2, Ulrike 
Setinek3, Michael Grusch2, Balazs Dome1, Balazs 
Hegedus1, Walter Berger2, Walter Klepetko1 
1Department Of Surgery, Division Of Thoracic 
Surgery, Medical University Of Vienna/Austria, 
2Institute Of Cancer Research, Department Of 
Internal Medicine I, Medical University Vienna/
Austria, 3Institute For Pathology And Bacteriology, 
Otto Wagner Hospital Baumgartner Höhe/Austria
Background: Malignant Pleural Mesothelioma 
(MPM) is an aggressive disease with increasing 
incidence and poor therapy response. The prognosis 
of patients suffering from MPM strongly depends 
on pathological variables including histological 
subtype and TNM stage. Despite of a wide panel 
of diagnostic immunohistochemical (IHC) markers 
used in MPM patients, none of them proved to have 
prognostic signiÀcance in the clinical practice.
Methods: The prognostic power of the routine IHC 
proliferation marker Ki67 was studied in parafÀn-
embedded tissue samples of 49 MPM patients who 
underwent tumor resection between 01/1994 and 
06/2009 at the Department of Thoracic Surgery of the 
Medical University of Vienna. Interpretation of the 
results was limited to proven tumor tissue. The results 
were documented as the percentage of Ki67 nuclear 
stained tumor cells and correlated with patients’ 
clinical data using the SPSS 17 software package.
Results: Of all 49 patients (mean age: 61±9 years; 10 
female, 39 male), 30 exhibited epithelial, 14 biphasic 
and 1 sarcomatous histology. Furthermore, in 4 
patients, pseudomesotheliomatous adenocarcinoma 
was found. Ki67 labeling was signiÀcantly decreased 
in the 25 patients who received chemotherapy before 
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Background: Biologic characterization of 
circulating tumor cells (CTCs) is becoming 
important in determining prognosis, monitoring 
response, and tailoring treatment strategies for lung 
cancer patients. The objectives of this study were to 
examine the CTC gene expression of cytokeratin-19 
(CK-19) throughout treatment of advanced cancer 
patients with extensive-small cell lung cancer 
(ES-SCLC; N0423) or advanced non-small cell 
lung cancer (NSCLC; N0426) and to investigate 
associations between baseline and post-treatment 
gene expression and patient outcome.
Methods: Blood was obtained at local sites 
(community-based sites that enroll patients) 
from advanced lung cancer patients before or 
during treatment with Àrst-line pemetrexed plus 
carboplatin (N0423) or second-line pemetrexed 
plus bevacizumab (N0426). CTC processing was 
performed at a central laboratory (Mayo Clinic, 
Rochester, MN). CTCs were enriched from 10mls 
of EDTA blood using CD45-depletion 24-30 hours 
after blood collection. CK-19 mRNA levels were 
determined using quantitative RT-PCR in CTC 
samples of 45 (N0423) and 42 (N0426) patients. 
The relative gene expressions were normalized to 
ơ
2
-microglobulin and calibrated to healthy blood 
using the 2-ƋƋCq algorithm. Cut points for CTC CK-
19mRNA positivity were explored. Cox proportional 
hazards models were used to compare the 
progression-free survival (PFS) and overall survival 
(OS) distributions for the baseline CTC subgroups. 
A landmark analysis was utilized for post-baseline 
CTC analyses.
Results: In ES-SCLC patients, at baseline, CK-
19mRNA was detected in 58% and 44% using 2 
and 5 cutpoints, respectively. On day 1 of cycle 
2, CK-19mRNA was detected in 54% and 41% 
of ES-SCLC patients using 2 and 5 cutpoints, 
respectively. ES-SCLC patients with higher CK-
of selected microRNAs (miRs) in frozen tissues 
of early stage SqCLC and the feasibility of their 
expression assessment in formalin Àxed parafÀn 
embedded (FFPE) samples (Skrzypski et. al. J Clin 
Oncol 28;521s:2010). In this study we validated 
the prognostic value of the 3-microRNA expression 
signature assessed in the FFPE samples in an 
independent patient population.
Methods: FFPE tumor tissue was obtained from 89 
stage I-II SqCLC pts. Of those, 40 pts developed 
distant metastases and 49 had no relapse after a 
median follow-up of 5.4 years (range, 3.4-8.2 years). 
MicroRNA was isolated from parafÀn blocks after 
macrodissection of tumor tissue, and extracted 
with RecoverAll kit (Ambion). Expression of miR-
10b, miR-532-3p and miR-192* was analyzed by 
RT-PCR assays (Applied Biosystems). Raw data 
were normalized vs. the expression of U6 RNA and 
calibrated by deltadeltaCt method. After z-score 
transformation, the risk score was calculated based 
on the expression of these 3 miRs.
Results: The median metastasis-free survival was 
not reached in the low risk group according to 
3-microRNA expression signature, whereas it was 26 
months in the high risk group. The three-microRNA 
(10b, 532-3p and 192*) expression signature was 
signiÀcantly related to the time to distant metastases 
(log-rank; p=0.013). With the median of the risk 
score as a cut-off value, the test sensitivity for 
distant relapse prediction was 66% at the speciÀcity 
of 64%. After exclusion of stage IA patients, the 
corresponding values were 73% and 69%.
Conclusion: Three-miRNA expression proÀle (10b, 
532-3p and 192*) has been successfully validated as 
a strong predictor of distant metastases in operable 
early stage squamous cell lung cancer.
Keywords: Prognosis, Adjuvant chemotherapy, 
microRNA, NSCLC
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P2.225 CIRCULATING TUMOR CELL 
CYTOKERATIN-19 GENE EXPRESSION 
AS A PROGNOSTIC FACTOR IN LUNG 
CANCER: ANALYSIS BASED ON NORTH 
CENTRAL CANCER TREATMENT 
GROUP (NCCTG) CLINICAL TRIALS 
(N0423/426)
Monica M. Reinholz1, Sumithra J. Mandrekar2, 
Nathan Foster2, Jeffery P. Meyers2, Kathleen A. 
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3Dept. Of Pneumology And Respiratory Critical Care 
Medicine, Thoraxklinik, University Of Heidelberg/
Germany, 4Institute Of Pathology, University 
Hospital Heidelberg/Germany
Background: Lung cancer is world-wide the leading 
cause of cancer related death. About 50% of lung 
cancer patients are diagnosed at late stages, when 
metastases have already been established, followed 
by a very bad outcome. Therefore, early detection of 
malignancies in the lung aims at achieving efÀcient 
intervention and subsequently a reduction of the high 
mortality rate. microRNAs have been searched in 
tissue and serum of cancer patients, and represent 
promising diagnostic and prognostic biomarkers. 
The aim of the study was to identify microRNAs in 
serum associated to early relapse in non-small cell 
lung cancer.
Methods: Serum samples and RNA extracts were 
collected from 232 patients including NSCLC 
disease and control samples (e.g. COPD and benign 
cases). We performed qRT-PCR based microRNA 
screening from a subset of 40 patients based on 
a low-density array including 667 microRNAs. 
microRNA candidates were further validated in 
serum samples of an independent patient cohort. For 
the statistical analyses, we used a modiÀed t-test 
(LIMMA) for the microarray analysis and Wilcox 
test in the validation experiment.
Results: The screening experiment revealed six 
potential microRNA biomarker to be associated 
with early relapse in NSCLC. One microRNA 
could be validated in an independent patient cohort. 
Furthermore, several microRNAs were deregulated 
in benign lung diseases like COPD, or associated to 
epidemiological parameters like gender and age. 
Conclusion: MicroRNAs may be promising 
prognostic biomarkers in early stage lung cancer. 
The combination of biomarker proÀles, clinical 
and epidemiological parameters may improve the 
diagnosis of severe cancer diseases and patient care. 
Keywords: microRNA, serum biomarker, Lung 
cancer, early relapse
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
19mRNA at baseline and at follow-up had worse 
prognosis, ie., patients with CK-19mRNA 5 at 
baseline had signiÀcantly worse PFS (HR=2.17; 
95%CI: 1.15-4.10; p=0.013) and OS (HR=4.23; 
95%CI: 2.05-8.72; p<0.001). Similarly, patients 
with follow-up (cycle 2, day 1) CK-19mRNA 5 
also had signiÀcantly worse OS (HR=2.81; 95%CI: 
1.30-6.08; p=0.0064) compared to those patients 
with CK-19mRNA <5. Patients that were positive 
(CK-19mRNA 5) at both baseline and follow-
up had signiÀcantly worse PFS (p=0.0071) and 
OS (p=0.0096) as compared to patients that were 
negative (CK-19mRNA <5) at baseline and follow-
up. In NSCLC patients, CK-19mRNA was detected 
in 45% using the 2 cutpoint. A signiÀcant increase 
in CK-19mRNA levels was observed from baseline 
to 24 hours post-treatment initiation (absolute 
change p=0.038; percent change p=0.002) in NSCLC 
patients. Although no signiÀcant associations were 
observed between baseline CK19mRNA 2 (or 
5) and PFS or OS, a borderline association was 
observed between baseline CK-19mRNA level, 
treated as a continuous variable, and OS (p=0.07) of 
NSCLC patients.
Conclusion: In ES-SCLC patients, higher levels 
of baseline and follow-up CK-19+mRNA CTCs 
were associated with poor prognosis. CTC gene 
expression analysis by a reference laboratory is 
feasible when blood is collected from community-
located, trial-enrolling sites.
Keywords: circulating tumor cells, Lung cancer, 
gene expression, prognostic factor
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P2.226 SERUM MICRORNAS AS 
BIOMARKER FOR EARLY RELAPSE IN 
NON-SMALL CELL LUNG CANCER
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who were treated with paclitaxel combined with 
platinum (91/92) as an induction treatment and 
who received vinorelbine combined with platinum 
for concomitant radiotherapy were retrospectively 
analyzed. Due to high homology between human and 
murine TUBB5 (97.7%), we used a murine TUBB5 
plasmid to produce the target protein in FNX cells, 
with which we established an antibody suitable for 
immunhistochemical staining. TUBB3/TUBB5 
protein expression levels in NSCLC were evaluated 
by immunohistochemistry using the H-Scoring 
system (ranging from 0 to 300), which is determined 
by the product of intensity of a speciÀc tumor cells 
immunoreactivity (range 0 to 3) and the percentage 
of positive tumor cells. Radiographic evaluation of 
response was performed according to RECIST.
Results: Median pre-treatment H-score for TUBB3 
was 110 (range: 0-290) and 150 for TUBB5 (range: 
0-280). Using the log-rank test and the median 
H-score as cut-off, we found a borderline signiÀcant 
association between improved overall survival (OS) 
and low TUBB3 protein expression (median OS of 
1,776 vs 642 days; hazard ratio [HR] 0.370, 95% CI, 
0.133 to 1.013; P=0.056). Surprisingly, prolonged 
progression-free survival (PFS) was associated with 
high TUBB5 protein expression (median PFS of 
539 vs 227 days; hazard ratio [HR] 2.139, 95% CI, 
1.144 to 4.001; P=0.017). Using a t-test we found an 
association between high TUBB5 protein expression 
and objective response to induction chemotherapy 
(mean H-score 160 for responders vs 113 for stable 
disease and progressive disease pts, P=0.005).
Conclusion: This is the Àrst report of TUBB5 
examination in NSCLC. Based on our retrospective 
study, base line determination of TUBB5 expression 
may be predictive for outcome of TBA-based 
therapy in NSCLC. TUBB5 expression might 
explain the inconsistency of results from studies 
evaluating the predictive value of TUBB3 protein 
expression. In contrast to TUBB3, protein expression 
of TUBB5 is a more signiÀcant predictor for 
response to TBA therapy. ConÀrmation of the 
prognostic and predictive value of combined 
TUBB3/TUBB5 expression in NSCLC by 
prospective studies is warranted.
Keywords: Non-small cell lung cancer (NSCLC), 
taxanes and vinca alkaloids, predictive biomarker for 
response and outcome, beta-tubulin isotypes III/V 
(TUBB3/5)
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PREDICTIVE BIOMARKER FOR 
CLINICAL BENEFIT FROM TREATMENT 
WITH TAXANES IN NON-SMALL CELL 
LUNG CANCER
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1Department Of Medicine, Division Of Medical 
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University Hospital Essen/Germany, 3Department 
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University Hospital Essen/Germany, 4Department Of 
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Background: Microtubule-binding agents (TBA) 
like taxanes and vinca alkaloids act to impair the 
normal function of mitotic spindles and are well 
established agents for treatment of non-small 
cell lung cancer (NSCLC). These drugs target 
microtubules, which are composed of Ơơ-dimers, 
form the Àbers of the mitotic spindle and change 
their polymerization or depolymerization dynamics, 
subsequently leading to mitotic arrest and cell death. 
Increased expression of the betaIII-tubulin isotype 
(TUBB3) has been inconsistently associated with 
a poor outcome in NSCLC patients (pts) treated 
with TBAs. Beta-tubulin isotypes (TUBBs) present 
a family of 8 members and are separated into 
biologically different subfamilies. In particular, the 
subfamily of TUBB3/TUBB5 leads to resistance 
against TBAs in vitro. Both of these isotypes are 
expressed in cancer cells and their patterns of 
expression seem to be complementary. Because of 
their similarities, it is conceivable that expression 
levels of TUBB5 would also alter the sensitivity 
of cancer cells to TBAs. We hypothesized that 
combined TUBB3/TUBB5 protein expression 
may predict outcome and response following TBA 
treatment of NSCLC pts.
Methods: Pre- and post-treatment samples from 
92 locally advanced or oligometastatic NSCLC pts 
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the rate of stage IA was only 13,8%. PTX3 and CRP 
serum levels did not correlate signiÀcantly with 
survival (p=0,08 and p=0,06 respectively) in the 
prospective group, while PTX3 expression in the 
tumour stroma signiÀcantly correlated with post-
treatment survival in both groups and in the whole 
series (p=0.0008). 
Conclusion: Our results show that PTX3 is 
often highly expressed intralesionally in NSCLC 
suggesting that inÁammatory signals produced by 
neoplastic cells induce the formation of a cellular 
inÀltrate responsible for PTX3 production. Serum 
levels were not signiÀcantly correlated with survival 
in this series (although there was a trend towards 
signiÀcance) while higher expression of PTX3 in the 
tumour stroma was shown to be a strong prognostic 
indicator, independent from the pathologic stage, 
in patients who had undergone potentially curative 
surgery. This is the Àrst study that investigates 
tumour stroma expression of Long Penthraxin 3 
and its relationships with treatment outcomes in 
patients with resectable lung cancer. These results, 
if conÀrmed, may represent a Àrst step toward new 
diagnostic and therapeutic strategies in NSCLC 
Keywords: Prognosis, Lung cancer, Surgery, PTX3
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P2.229 EXPRESSION OF MIR-497 IN 
CIRCULATING MICROVESICLES IS 
A POTENTIAL BIOMARKER FOR THE 
EARLY DETECTION OF NSCLC
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Meredith Millis1, Yuka Kojima1, Jason Zhong1, 
Christine Kuslich1 
1Research And Development, Caris Life Sciences/
United States Of America, 2Research And 
Development, Caris Life Sciences/Switzerland
Background: Currently, early detection facilitating 
complete surgical resection remains the best hope 
for a cure for NSCLC. Therefore, Ànding biomarkers 
for the early detection of NSCLC has become an 
important goal in lung cancer research. Recent 
research with micro RNAs (miRs) has suggested 
that quantiÀcation of miRs in blood may be an 
attractive avenue for discovering such biomarkers. 
In recent years, microRNAs and circulating 
microvesicles (cMVs) have shown promise for 
detecting and classifying a variety of cancer types. 
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PROGNOSTIC ROLE OF THE LONG 
PENTHRAXIN PTX3 IN RESECTABLE 
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Background: C-Reactive Protein (CRP) and other 
acute phase proteins are elevated in patients with 
lung cancer and high levels correlate with more 
aggressive disease suggesting a potential role as 
prognostic markers. Both malignant and normal cells 
express a wide array of inÁammatory mediators. 
Penthraxin 3 (PTX3) is an acute phase protein 
produced mainly by endothelial cells, Àbroblasts, 
macrophages and granulocytes. Its prognostic role in 
lung cancer has never been investigated before. The 
purpose of this study was to evaluate the role of CRP 
and PTX3 as diagnostic and prognostic markers in 
resectable non-small cell lung carcinoma (NSCLC). 
Methods: Patients with completely resected 
NSCLC were identiÀed from two groups: a 
retrospective one derived from a randomized trial 
of lung cancer screening with spiral-CT (DANTE 
Trial), and a prospective group of consecutive 
patients who underwent resection for lung cancer 
between February and July 2009 in our institution. 
Intratumour expression of PTX3 was assessed by 
immunohistochemistry with a speciÀc antibody and 
evaluated semiquantitatively. In the prospective 
cases, serum samples were collected immediately 
before surgery and levels of CRP and PTX3 were 
determined by speciÀc and validated assays. 
Relationships between PTX3 and CRP serum levels, 
intratumour PTX3 expression and survival were 
analyzed by the Cox proportional-hazards model. 
Results: Seventy cases (34 retrospective and 36 
prospective, average age 69,6) were analyzed. The 
screening-detected group showed a higher rate of 
IA stage (44,1%), while among prospective patients 
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mutation, (b) there are minor clones with such 
alterations even before EGFR-TKI treatment, (c) 
only 4-fold MET ampliÀcation is clinically relevant 
and (d) the alteration may depend on the lesion site 
within each patient. With the above facts in mind 
it is obvious that targeting MET necessitates the 
development of companion diagnostics that optimize 
the tissue sample and are rapid. Although MET gene 
ampliÀcation has been studied with various assays, 
all of which have yet to be standardized, there are 
no publications using SISH. We sought to evaluate 
a novel dual-color brightÀeld approach (SISH) 
in a series of early stage untreated NSCLCs and 
to correlate this alteration with EGFR and KRAS 
mutations. 
Methods: MET gene ampliÀcation was analyzed in 
108 surgically resected untreated NSCLCs, including 
60 SCCs and 48 adenocarcinomas (ACs). Automated 
SISH was performed on Ventana Benchmark XT 
(Ventana Medical Systems, Tucson, AZ), following 
manufacturer´s protocols with few variations. 
The entire assay procedure was fully automated 
and was performed on a single 5 micron slide. 
AmpliÀed cases were conÀrmed by FISH (Kreatech, 
Amsterdam, The Netherlands). EGFR and KRAS 
mutations were studied by direct sequencing in ACs. 
Results: SISH was successfully performed on 
all samples. The turnaround time was ~14 hours. 
The median mean MET gene copy number was 
3.075. Using this cutoff, a total of 54 cases (50%) 
were MET SISH positive, including Àve cases 
(4.6%) with true gene ampliÀcation. Among those 
ampliÀed cases, three ACs (EGFR and KRAS wild 
type) exhibited high ampliÀcation (ratio > 3) and 
two SCCs showed low ampliÀcation (ratio  3). 
Interestingly, two of the three EGFR mutant ACs 
were non-ampliÀed positive as were four of the 
seven KRAS mutant ACs. 
Conclusion: In early stage untreated NSCLCs, true 
MET gene ampliÀcation is an uncommon event 
and our study suggests that it is mutually exclusive 
with EGFR and KRAS mutations in ACs. MET 
ampliÀcation in SCCs should also be considered. 
Dual color SISH represents a robust method for 
the determination of MET status in NSCLC. This 
rapid test helps in the strategic time management 
when dealing with NSCLC targeted therapies. 
Acknowledgements: This study was funded by 
Fundación Mutua Madrileña and Ventana Medical 
Systems. 
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A proprietary method for isolating cMVs from 
plasma and extracting microRNAs from cMVs was 
used to explore microRNA expression differences 
between healthy individuals and those with NSCLC. 
In particular, we found signiÀcant differential 
expression of miR-497.
Methods: cMVs from 24 NSCLC patients of 
primarily early stage disease (IA = 9, IB = 9, IIA = 
1, IIB = 2, III = 1, IV = 2) and 26 healthy individuals 
were isolated from 1 ml of frozen plasma. RNA was 
then extracted from the cMVs using a Trizol and 
afÀnity bead based extraction method. A quantitative 
Taqman® assay was constructed with a calibration 
curve for the determination of the number of copies 
per ml of mir-497 in each sample.
Results: Median normalized copy number for 
normal individuals was 9000±307 copies per ml 
(±95% CIM) and 27,500±1298 copies per ml (±95% 
CIM) for patients with NSCLC. Expression levels 
did not correlate to disease stage. Setting a threshold 
of 15,700 copies per ml, this assay had a sensitivity 
of 79% and speciÀcity of 81% and an AUC of 0.89.
Conclusion: While further study is warranted due 
to the small sample size in this exploratory analysis, 
it demonstrates the promise of using cMVs in 
combination with microRNA expression for the early 
diagnosis of NSCLC.
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AMPLIFICATION IN NON-SMALL 
CELL LUNG CARCINOMAS BY SISH: 
CORRELATION WITH EGFR AND KRAS 
MUTATIONS IN EARLY STAGES
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1Laboratorio De Dianas Terapéuticas, Hospital 
Universitario Madrid Sanchinarro/Spain, 2Hospital 
Universitario 12 De Octubre/Spain, 3Hospital 
Universitario Virgen Del Rocío/Spain
Background: The ampliÀcation of the MET gene 
is one of the main mechanisms responsible for 
resistance to EGFR-tyrosine kinase inhibitors (TKIs) 
in patients with non-small cell lung carcinoma 
(NSCLC). Some authors have suggested that: (a) 
there is a reciprocal and complementary relationship 
between MET ampliÀcation and the T790M EGFR 
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cancer line cells, 4 (15%) display over of six copies 
number of ALK and 20 (75%) presented a gain of 
over three ALK copy number. 
Conclusion: The increased ALK copy number was 
close to a polysomy of the chromosome 2 and seem 
to be not exclusively to EGFR wild type. ALK 
ampliÀcation in preclinical models of neuroblastoma 
harbour a good sensitivity to ALK inhibitors. Further 
preclinical studies in lung cancer models are ongoing 
to determine the prognostic and predictive value of 
this event.
Keywords: anaplastic lymphoma kinase, Lung 
cancer, new predictive marker, high gene copy 
number
A revised/updated abstract may be included in 
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P2.232 THE EXPRESSION OF RCAS1 
MOLECULE IN LUNG CANCER AND ITS 
CLINICAL SIGNIFICANCE
Nikolaos Tsoukalas1, Evangelos Tsiambas2, 
Theodora Economaki3, Andreas Karameris2, Maria 
Tolia4, Ioannis SÀniadakis5, Alexandros Tzovaras4, 
Evangelos Manolis3, Stamatios Theocharis3, Christos 
Kittas3 
1Medical Oncology, 401 General Army Hospital/
Greece, 2Pathology, 417 Nimts Army Hospital/
Greece, 3Medical School, National-kapodistrian 
University/Greece, 4Medical Oncology, Aghios 
Savvas Anticancer Hospital/Greece, 5Pathology, 
Navy Hospital/Greece
Background: RCAS1 (Receptor-binding Cancer 
Antigen expressed on SiSo cells) is a membrane 
protein that is expressed in different types of cancer. 
It halts the cell cycle and/or induces the apoptosis 
of the immune system cells within the tumour 
microenvironment. Hence, it is possible that this 
molecule is involved in the mechanism of the tumour 
cells’ escape from the immune system surveillance 
(immunoescape).The aim of this study is the 
measurement the RCAS1 molecule’s expression in 
primary lung cancer and the evaluation of its clinical 
signiÀcance.
Methods: Patients with primary lung cancer, eligible 
for surgical treatment, were included in the study. 
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P2.231 HIGH ALK GENE COPY NUMBER 
IS A FREQUENT EVENT IN NON-SMALL 
CELL TUMORS AND CELL LINES OF 
LUNG CANCER
Khadija Kalai1, Nathalie Auger2, Ludovic Lacroix3, 
Nicolas Dorvault3, Ken Olaussen3, Alexander 
Valent3, David Planchard3, Jean Charles Soria3, 
Benjamin Besse3 
1Medicine, Institut Gustave Roussy/France, 
2Cytogenetic, Institut Gustave Roussy/France, 
3Institut Gustave Roussy/France
Background: The anaplastic large cell kinase gene 
(ALK) rearrangement is a rare event, described in 
approximately 4-6% of lung adenocarcinoma. ALK 
translocation is described as mutually exclusive with 
EGFR and KRAS mutations. ALK activation may 
depend however, on alternative mechanisms, such as 
an increase in gene copy number (GCN). We propose 
in this study to describe ALK GCN among non small 
cell lung cancer (NSCLC) cell lines and patients with 
advanced disease. 
Methods: ALK status was evaluated by Áuorescence 
in situ hybridization (FISH) in parafÀn embedded 
specimens from advanced NSCLC patients. Lung 
cancer cell lines were screened by FISH-ALK after 
cytospin. ALK scoring was performed following 
Cappuzzo criteria established for EGFR and HER2 
in lung cancer. High GCN was deÀned as the 
presence of  6 copies of ALK per cell in  10% 
of analyzed cells. FISH with CEP2 was performed 
to determine the ploïdy status in samples with high 
GCN. EGFR and KRAS mutational status were 
determined on DNA extracted from the parafÀn 
embedded tumor specimens. All coding sequences 
of exon 18 to 21 of EGFR , exon 2 and 3 of 
KRAS were analyzed by Sanger direct sequencing 
performed after Polymerase Chain Reaction 
ampliÀcation of targeted exons. 
Results: Among 96 NSCLC tumors, FISH ALK 
was contributive in 75. There were ten cases (13%) 
of EML4-ALK translocation which were EGFR 
and KRAS wild type. Eleven cases (15%) exhibited 
high ALK GCN and 38 (51%) copy number gains, 
whereas two exhibited monosomy. The ALK high 
GCN were associated with polysomic status as 
revealed the FISH with CEP2.EGFR was mutated in 
seven cases, two exhibiting high ALK GCN and Àve 
with unless 3 gains ALK copy number.Among lung 
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M1a or M1b for the occurrence of these molecular 
alterations. 
Methods: Archived formalin Àxed parafÀn 
embedded tumor material was microdissected and 
studied for activating mutations in EGFR exons 
18-21 using Sanger sequencing. Direct sequencing 
(Sanger method) was also used to evaluate codons 
13, 13, and 61 of the KRAS gene for mutations. The 
BRAF mutation V600E was detected using a PCR 
based allelic discrimination assay and screening for 
EML4-ALK translocation was done by RT-PCR 
assays spanning all 12 relevant exons of EML4 
and exon 20 of ALK. Smoking status was deÀned 
according to the criteria in the IPASS trial (Mok et 
al., NEJM 2009). 
Results: 88 patients were screened for the genetic 
alterations. Patient characteristics were: male/female: 
42/46, median age: 62, non-squamous/squamous: 
80/8, never smoker/light smoker vs. smoker:37/42 
. In 8 patients, the amount of tumor material was 
not sufÀcient to carry out the molecular analyses. In 
18/80 patients, EGFR mutations were found, in 5/80 
patients, EML4-ALK inversions were detected, in 
0/59 patients, B-RAF mutations and in 5/53 patients, 
k-ras mutations were found. Patient characteristics of 
the EGFR mutated patients were: male/female:4/14, 
non-squamous vs. squamous: 17/1, never/light 
smoker vs. smoker:14/4. Median age of the EGFR-
MT group was 66, the distribution of e19 mutations/ 
L858R mutations/vs. other mutations was: 8/7/3. 
Median time to progression in e19/e21 EGFR-
MT pts was 14 months (6-24 months). Patient 
characteristics in the EML4-ALK positive group 
were: male/female 1/4, median age 77 years (33-
80) and never/light smoker vs. smoker: 4/1. Patient 
characteristics of the KRAS mt patients were male/
female 3/2, never/light smoker vs smoker: 2/2, and 
median age was 66 years. EGFR mutations did not 
occur in combination with k-ras, BRAF or EML4-
ALK alterations. Within the group of 35 never/light 
smokers, successfully analyzed for the molecular 
targets, the incidence of EGFR mutations was 14/35 
(40%), of EML4-ALK 4/35 (16%) and KRAS 2/35 
(8%).
Conclusion: Recurrent mutations were detected in 
this screened population diagnosed and treated at a 
certiÀed lung cancer center with an incidence of 23% 
(EGFR-MT), 6% (EML4-ALK) and 9% (KRAS). 
An association with smoking status, gender and 
histology was found for EGFR and EML4-ALK 
alterations. The EML4-ALK population had a higher 
median age than the EGFR-MT group and seemed 
The tissue samples (parafÀn cubes) were processed 
using the Tissue Micro-arrays Method. Then, an 
immunohistochemical study followed, speciÀc 
for the RCAS1 and the Ki-67 (a cell proliferation 
marker). The image analysis was feasible due to 
a special program. In addition, a database was 
created that included the clinical and pathological 
characteristics of the patients.
Results: In total, 108 patients were examined (81 
men and 27 women), mean age 62 years old. Almost 
44% of the cases were adenocarcinoma, 31% 
squamous cell, 9% large cell, and 16% other types of 
lung cancer. The results of the immunohistochemical 
and statistical analysis that followed will be ready 
shortly.
Conclusion: The conclusions according to the 
results of the study will be ready to announce shortly.
Keywords: RCAS1, Lung cancer, Tissue 
microarrays, Biomarkers
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.233 INCIDENCE OF MOLECULAR 
TARGETS (EGFR-MUTATION, EML4-
ALK, BRAF AND KRAS) IN METASTATIC 
NSCLC IN A CERTIFIED LUNG CANCER 
HOSPITAL.
Volker Halbfass1, Markus Falk2, Regina Prenzel3, 
Hans G. Dercken3, Douglas Scriba4, Markus 
Tiemann2, Frank Griesinger5 
1Hematology And Oncology, Pius-Hospital 
Oldenburg/Germany, 2Molecular Biology, 
Hematopathology/ Germany, 3Pneumology, Pius-
hospital/Germany, 4Thoracic Surgery, Pius-Hospital/
Germany, 5Hematology And Oncology, Pius-
Hospital/Germany
Background: NSCLC has become a molecularly 
deÀned disease with the discovery of activating 
mutations within the EGFR gene, inversions of 
EML4 –ALK as well as the description of B-RAF 
and k-ras mutations. The incidence of these targets 
is not well known in the Caucasian population. 
Therefore, we have in part retrospectively, in part 
prospectively screened patients with predominantly 
non-squamous cell NSLCLC with a tumor stage 
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cancer and its precursor lesions from 109 formalin-
Àxed, parafÀn-embedded blocks of bronchial 
biopsies and lung resection specimens. We stained 
for the epithelial markers E-cadherin and MNF116 
(pancytokeratin), the mesenchymal marker S100A4, 
and beta-catenin (which translocates from the cell 
membrane to the nucleus during EMT). Up to three 
representative areas from each lesion were scored 
using an aggregate scoring system based on extent 
and intensity of staining. Where expression was 
expected to shift from membranous to nuclear, one 
hundred cells per high power Àeld were counted 
and the proportion of membranous, cytoplasmic 
and nuclear staining noted. The majority of lesions 
were scored jointly by two investigators, one an 
experienced Thoracic Pathologist.
Results: The 109 blocks came from 70 patients 
(55 men, 15 women; average age 66.4 years). 
There was a progressive loss of E-cadherin and 
MNF116 with increasing grade of dysplasia and a 
concurrent gain of S100A4 expression. Similarly, 
beta-catenin showed exclusively membranous 
expression in normal respiratory epithelium and 
basal cell hyperplasia but showed progressively more 
cytoplasmic and nuclear expression as dysplastic 
grade increased. These changes began as early as 
squamous metaplasia and consistently reached 
signiÀcance across all markers between low- and 
high-grade dysplasia.
Conclusion: Our results suggest that EMT may be 
beginning earlier than previously thought during the 
development of squamous cell lung cancer. This has 
implications for future research examining processes 
determining the temporal behaviour of dysplastic lesions.
Keywords: squamous cell lung cancer, epithelial 
mesenchymal transition, squamous dysplasia
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P2.235 CLINICAL STUDY BY THE DUTCH 
ASSOCIATION OF PULMONOLOGISTS 
(NVALT) INVESTIGATING THE EARLY 
IMMUNE TUMOR INTERPLAY DURING 
CHEMOTHERAPY IN STAGE IV NON-
SQUAMOUS NSCLC PATIENTS
Marlies E. Heuvers1, Robin Cornelissen1, Femke 
Muskens1, Margaretha Lambers1, Fahdil Ahsan1, 
Anne-Marie Dingemans2, Harry J.M. Groen3, Egbert 
F. Smit4, Henk Hoogsteden1, Joost Hegmans1, 
Joachim Aerts5 
to be more frequently detected than in most reported 
series. 
Keywords: EGFR mutation, EML4-ALK fusion 
gene, KRAS mutation, BRAF mutation
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P2.234 EPITHELIAL MESENCHYMAL 
TRANSITION OCCURS EARLY IN 
SQUAMOUS CELL LUNG CANCER 
DEVELOPMENT
Natalie M. Cummings1, Doris M. Rassl2, Helen C. 
Boobier2, John Gosney3, Andrew G. Nicholson4, 
Ute Oltmanns1, Stuart Ruthven5, Marianne Mason4, 
Xinxue Liu6, Linda D. Sharples7, Rebecca C. 
Fitzgerald6, Robert C. Rintoul1 
1Thoracic Oncology, Papworth Hospital/United 
Kingdom, 2Histopathology, Papworth Hospital/
United Kingdom, 3Liverpool Heart & Chest 
Hospital; Royal Liverpool University Hospital/
United Kingdom, 4Histopathology, Royal Brompton 
Hospital/United Kingdom, 5Histopathology, Royal 
Liverpool University Hospital/United Kingdom, 
6Cancer Cell Unit, Hutchison-mrc Research Centre/
United Kingdom, 7MRC Biostatistics Unit, Institute 
Of Public Health/United Kingdom
Background: Lung cancer is the commonest cause 
of cancer death worldwide; there is increasing 
interest in identifying disease as early as possible 
in an attempt to improve survival. Squamous cell 
carcinoma accounts for approximately 35% of 
all lung cancer and has a well deÀned pathway of 
development from basal cell hyperplasia through 
squamous metaplasia, low- and high-grade dysplasia 
to invasive disease. Preneoplastic lesions may be 
detected using autoÁuorescence bronchoscopy; 
previous work suggests that some lesions may 
remain static or even regress rather than proceeding 
to invasive disease. However, it is unclear what 
drives these changes. Epithelial mesenchymal 
transition (EMT) is increasingly recognised as being 
a key sequence of events in cancer development. 
It is the process whereby cells lose their epithelial 
characteristics and dedifferentiate into a more motile, 
invasive phenotype. Previously this was not thought 
to occur until carcinoma in situ became invasive 
disease. We examined EMT during squamous cell 
lung cancer development.
Methods: We identiÀed areas of squamous cell lung 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1083
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
level. First results indicate that high levels of MDSC 
correlate with early tumor progression and poor 
prognosis. This is in line with our pre-study results. 
We anticipate that results on NTG patches are 
available at the time of the conference. 
Conclusion: Clear shifts of immunoregulatory 
cells are observed between patients at the start of 
treatment and during treatment. This may indicate 
that immunoregulatory cells in the peripheral blood 
may be suggestive for response to treatment and for 
disease progression.
Keyword: Myeloid Derived Suppressor Cells
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P2.236 CORRELATION OF 
THYMIDYLATE SYNTHASE GENOTYPE 
AND PROTEIN EXPRESSION AND 
ASSOCIATION WITH LUNG CANCER 
SURVIVAL
Theresa Boyle1, Jerry Haney2, Patricia Lenhart1, 
Rosita Montoya1, Patrick Chesnut1, Daniel Merrick3, 
Ross D. Camidge4, Wilbur Franklin1 
1Pathology, University Of Colorado Denver/United 
States Of America, 2University Of Colorado Denver/
United States Of America, 3Pathology, Denver 
Veterans Affairs Medical Ctr/United States Of 
America, 4Medicine, University Of Colorado Denver/
United States Of America
Background: Thymidylate synthase (TS) catalyzes 
DNA synthesis and is directly inhibited by 
pemetrexed, a drug used for treatment of lung cancer. 
The aim of this study is to analyze the association of a 
TS genetic polymorphism and protein expression with 
survival in patients with non-small cell lung cancer. 
Methods: We performed a retrospective study of 
1Respiratory Medicine, Erasmus Medical University 
Center/Netherlands, 2Pulmonology, Maastricht 
University Medical Center/Netherlands, 3Respiratory 
Medicine, University Medical Center Groningen/
Netherlands, 4Pulmonary Diseases, Vrije Universiteit 
Medical Centre/Netherlands, 5Pulmonary Diseases, 
Amphia Hospital/Netherlands
Background: Standard treatment for non-small 
cell lung cancer (NSCLC) consists of platinum-
containing chemotherapy. It has been shown that the 
addition of bevacizumab to carboplatin-paclitaxel 
(bevCaTAX) combination chemotherapy improves 
overall survival in patients with non-squamous 
NSCLC. BeneÀt from this treatment is still limited, 
and therefore a need for better treatments exists. 
Tumor hypoxia is a common phenomenon in lung 
cancer; it is a known poor prognostic marker and is 
related to treatment resistance. Pre-clinical studies 
have shown that nitric oxide (NO) donating drugs 
may decrease hypoxia related drug resistance. 
Nitroglycerin (NTG) is one of those NO donating 
drugs. Hypothetically NTG increases tumor blood 
Áow, augments antitumor drug delivery and inhibits 
hypoxia inducible factor (HIF) -1a. HIF-1a is the 
major factor regulating the response to hypoxia. 
It has recently been shown in mouse models that 
the addition of HIF-1 inhibitors to bevacizumab 
signiÀcantly inhibits tumor growth by inducing 
apoptosis. In vitro testing has also showed an effect 
of HIF-1a on immune regulatory cells. Our aim is 
to determine the effect of bevCaTAX chemotherapy 
±NTG on immunoregulatory cells (regulatory T-cells 
and myeloid derived suppressor cells (MDSCs)) and 
to establish the value of these cells as a predictive 
marker to bevCaTAX.
Methods: A randomized multi-centre open label 
phase II study investigating bevCaTAX +/-NTG 
patches in patients with stage IV non-squamous-
NSCLC: “NVALT 12” is open for accrual. Expected 
enrollment is 222 patients. Immunoregulatory cells 
blood samples are taken at the start of chemotherapy, 
in week 3 and week 6 (Àgure 1). All patients undergo 
a FDG-PET scan in week 3 and a CT scan in week 6 
to determine response to treatment.
Results: Mononuclear cells were puriÀed from 
peripheral blood by density gradient centrifugation 
and analysed by Áowcytometry. All patients have 
a signiÀcantly increased percentage and number of 
CD11b+ CD15+ CD33+ HLA-DR- MDSC in their 
blood compared to healthy controls. These cells 
produced reactive oxygen species (ROS) at a high 
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P2.237 LUNG CANCER: CORRELATION 
OF CRP AND SERUM ALBUMIN AT 
DIAGNOSIS WITH CLINICAL AND 
PATHOLOGICAL PARAMETERS
Nikolaos Tsoukalas1, Konstantinos Liaskonis2, 
Theodora Economaki3, Maria Tolia4, Alexandros 
Tzovaras4, Aristoula Papakostidi4, Nikolaos 
Pistamaltzian4, Alexandros Ardavanis4, Vasilios 
Barbounis4, Stamatios Theocharis3 
1Medical Oncology, 401 General Army Hospital/
Greece, 2Biochemistry-immunology Laboratory, 401 
General Army Hospital/Greece, 3Medical School, 
National-kapodistrian University/Greece, 4Medical 
Oncology, Aghios Savvas Anticancer Hospital/
Greece
Background: CRP and serum albumin are indicators 
of systemic inÁammatory reaction and the status 
of patient’s nutritional condition respectively. It 
has been found that CRP has a prognostic value 
in advanced neoplasms of various types while its 
combination with serum albumin has additional 
prognostic value in certain tumours. The aim of 
this study is to assess the values of CRP and serum 
albumin in primary lung neoplasms and to evaluate 
their clinical signiÀcance.
Methods: Patients with primary lung cancer and 
no active infection were included in the study. The 
diagnosis of the neoplasm was made by means of 
histology or cytology. A blood sample was taken 
prior to any therapeutic intervention. The samples 
were centrifuged and the serum was stored in deep 
freezer until the measurement. CRP and albumin 
were assessed using nephelometry and photometry 
respectively. Finally, a database was created with all 
the clinical and histological data of the patients.
Results: Overall, 129 patients (114 men and 15 
women) with a mean age of 64 years were assessed. 
The histology types were: 79% non small cell and 
21% small cell neoplasms. The results and the 
respective statistical analysis will be available shortly.
Conclusion: The conclusions of the study will be 
announced shortly.
Keywords: Biomarkers, Lung cancer, CRP, serum 
albumin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
114 patients with NSCLC using parafÀn embedded 
tumor tissue at the University of Colorado. DNA was 
extracted from each tumor specimen and assessed by 
fragment analysis for genotype in the TS promoter 
variable tandem repeat region (VNTR). Thymidylate 
synthase protein expression was evaluated with 
immunohistochemistry and percent nuclear positivity 
was assessed. Survival analysis with the log rank 
test statistic was performed to compare survival 
time based on TS genotype and protein expression. 
The association between TS genotype and protein 
expression was evaluated by Pearson correlation 
analysis. 
Results: Of the 114 lung tumor specimens, 32 were 
homozygous for three repeats (3R/3R), 49 were 
heterozygous (2R/3R) and 33 were homozygous 
for two repeats (2R/2R). Patients with lung cancer 
who were homozygous or heterozygous for three 
repeats in the TS VNTR survived signiÀcantly longer 
than patients homozygous for two repeats (N=114, 
p=0.007) with death due to lung cancer as an 
endpoint. Lower than average thymidylate synthase 
protein expression (<=12% nuclear positivity) was 
signiÀcantly associated with longer survival (N=94, 
p=0.001). The TS genotype was correlated with TS 
protein expression (N=94, p=0.03). 
Conclusion: This work suggests that TS VNTR may 
be an important prognostic marker in NSCLC. The 
TS VNTR genotype and TS protein expression are 
associated with a signiÀcant difference in mortality 
from lung cancer. The TS VNTR genotype may be 
associated with survival because of its association 
with a differential expression of TS protein. Tumors 
homozygous or heterozygous for three repeats in the 
TS VNTR are associated with lower TS expression 
and have a better prognosis than tumors homozygous 
for two repeats in the TS VNTR. Whether TS VNTR 
predicts response to pemetrexed is a question that 
warrants further study.
Keyword: thymidylate synthase, genotype, protein, 
NSCLC, polymorphism, VNTR
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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survival of patients whose tumors were suitable 
for TMA generation was similar to the general 
cohort. Automated IHC for CXCR4 and ERs was 
successfully completed on all samples. CXCR4 
expression was seen in the cytomembranous 
compartment of almost all samples tested. High 
expressors had a signiÀcantly poorer median overall 
survival (MOS) of 2.7 months vs 5.6 months for 
the low expressors (p = 0.0468). This difference 
was driven by high expressing females who had a 
MOS of 1.6 months versus 6.4 months for the low 
expressors (p = 0.006). No signiÀcant difference in 
survival was seen in the males. ERs were expressed 
in the nucleus in approximately 15-20% of tumor 
samples. There appears to be more females with 
expression of ERs than males which may be 
inÁuencing the observed gender discrepancy in 
outcome seen in CXCR4 high expressors. 
Conclusion: Estrogen receptors (ERs) are expressed 
in a signiÀcant number of NSCLC tumors and are 
localized to the nucleus while CXCR4 is limited 
to the non nuclear compartment of tumor cells. We 
describe a gender dependent effect on the association 
between CXCR4 and clinical outcome which may be 
inÁuenced by ER co-expression in stage IV NSCLC. 
Detailed analysis of the relationship between ER 
expression, ER/CXCR4 co-expression and outcome 
is ongoing and will be presented. 
Keywords: Non small cell lung cancer, estrogen 
receptors, outcome, CXCR4
Poster Session 2 – Prognostic and Predictive Markers Tuesday, 5 July 
2011 12:15-14:00
P2.239 PREDICTIVE AND PROGNOSTIC 
ROLE OF GEMCITABINE-RELATED 
GENES IN ADVANCED NON-SMALL 
CELL LUNG CANCER
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P2.238 INFLUENCE OF CXCR4 AND 
ER CO-EXPRESSION IN METASTATIC 
NSCLC AND ASSOCIATION WITH 
OUTCOME
Shannon Otsuka, Alexander C. Klimowicz, 
Stephanie Petrillo, Mie Konno, Don Morris, Anthony 
M. Magliocco, Dafydd G. Bebb 
Medicine, University Of Calgary/Tom Baker Cancer 
Centre/Canada
Background: CXCR4, a G protein coupled 
chemokine receptor, and its ligand, stromal cell 
derived factor-1 (SDF-1), play a critical role in 
organ speciÀc tumor metastasis. Increasing evidence 
suggests that it contributes to metastasis in Non 
Small Cell Lung Cancer (NSCLC) and that its 
expression may be associated with poor outcome. It 
was recently demonstrated that a positive regulatory 
loop exists between the CXCR4/SDF-1 chemokine 
axis and estrogen receptor (ER) signaling pathways 
which inÁuences both ER and CXCR4 dependent 
gene expression and ultimately tumor cell growth in 
vitro. It is also known that a signiÀcant proportion of 
NSCLC tumors express ERs and that there may be 
a gender dependent difference in ER expression. We 
set out to assess the expression of CXCR4 and ERs 
in stage IV NSCLC diagnostic biopsies to determine 
if either receptor alone, or co-expression of both 
CXCR4 and ER is associated with clinical outcome. 
Methods: After ethical approval was obtained, 
demographic details, clinical variables and outcome 
data were gathered on NSCLC patients diagnosed 
at the Tom Baker Cancer Centre (TBCC) from 
2003 to 2006 (Glans-Look Lung Cancer Database). 
Formalin-Àxed parafÀn embedded tumor specimens 
were obtained from patients diagnosed with 
stage IV disease and tissue micro arrays (TMAs) 
were generated. Protein expression of the target 
biomarkers was analyzed by quantitative Áuorescent 
immunohistochemistry (IHC) using the HistoRx 
PM-2000 platform. A quantitative AQUA expression 
score for ERs and CXCR4 was obtained. CXCR4 
and ER expression, and co-expression of both 
receptors was then correlated with clinical outcome. 
Survival analyses were performed using the Kaplan-
Meier method and tested using a log rank test. 
Results: 832 patients were diagnosed with stage 
IV NSCLC, 170 of which had suitable samples 
for incorporation into TMAs. The overall 
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for shorter TTP in patients with high versus low/
intermediate RRM2 mRNA levels (2.8 versus 4.17 
months, P =0.063). Furthermore, patients with 
combined overexpression of the genes disfavouring 
gemcitabine activity, i.e RRM1, RRM2 and CDA, 
had signiÀcantly shorter TTP compared with those 
with combined low levels of the corresponding 
genes (0.3 versus 1.82 months; P =0.045). Similarly, 
OS was signiÀcantly shorter in the former group of 
patients compared with those combining high and 
low levels (0.6 versus 3.16 months; P =0.027).
Conclusion: The combination of tumour RRM1, 
RRM2 and CDA expression is a potential biomarker 
tool for tailoring gemcitabine-based chemotherapy 
in advanced NSCLC. Prospective cross-validation is 
required.
Keywords: NSCLC, gemcitabine, tumor biomarkers, 
clinical outcome
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P2.240 CONCURRENT TP53 AND 
TYROSINE KINASE SIGNALING 
PATHWAY MUTATIONS IN 
ADENOCARCINOMA OF LUNG
Wilbur Franklin1, Jerry Haney1, Christopher Korch1, 
Dara L. Aisner1, Paul Bunn2 
1Pathology, University Of Colorado Anschutz 
Medical Campus/United States Of America, 
2Medicine, University Of Colorado Anschutz Medical 
Campus/United States Of America
Background: Emerging data suggests that 
adenocarcinomas of lung appear to be driven by 
a small number of mutations that affect tumor 
behavior and response to treatment. The effect 
of combinations of mutations is currently being 
assessed by a consortium of centers in the US, the 
Lung Cancer Mutation Consortium. It is assessing 
1000 adenocarcinomas for the presence of mutations 
in 15 or more genes by high throughput allele 
speciÀc technologies including Sequenom and 
SNaPshot or by direct sequencing. 
Methods: In this abstract we report the frequency 
of TP53 mutation determined by direct sequencing 
of exons 5, 6, 7, and 8 and their associations with 
mutations detected in 13 other genes including APC, 
AKT1, BRAF, CTTBN1, EGFR, FLT3, JAK2, KIT, 
MAP2K1 (MEK1), Notch1, NRAS, PIK3C,and 
PTEN by SNaPshot in 44 tumor cases. 
Background: Gemcitabine is widely used in the 
Àrst-line treatment of advanced non-small cell lung 
cancer (NSCLC), either as a single agent or in 
combination regimens. Tumour mRNA expression 
levels of breast cancer susceptibility gene-1 
(BRCA1) and ribonucleotide reductase subunits M1 
and M2 (RRM1 and RRM2) were recently indicated 
as useful tools for customising gemcitabine-based 
chemotherapy in this setting. Furthermore, human 
equilibrative nucleoside transporter-1 (hENT1), 
deoxycytidine kinase (dCK) and cytidine deaminase 
(CDA) have a key role in the cellular transport and 
metabolism of gemcitabine, thus being implicated 
in the drug’s antitumour activity. We investigated 
the potential role of tumour expression of the 
six aforementioned genes in clinical outcome to 
gemcitabine-based chemotherapy in advanced 
NSCLC.
Methods: BRCA1, RRM1, RRM2, hENT1, dCK 
and CDA mRNA expression was retrospectively 
analysed by RT-qPCR in microdissected, FFPE 
primary tumour specimens from 138 patients with 
stage wet-IIIB and IV NSCLC (UICC 6th TNM 
edition) or recurrent, locally-advanced disease 
not amenable to surgery or radiation. Patients 
had participated in clinical trials of the Hellenic 
Oncology Research Group and received Àrst-line 
gemcitabine, either as monotherapy (G) or combined 
with platinum (GC), taxane (GT), vinorelbine (GV) 
or pemetrexed (GP). Relative gene-expression 
quantiÀcation was performed with the comparative 
Ct method, using ơ-actin and 3-phosphoglycerate 
kinase as endogenous controls. The individual and 
combined gene expression patterns were statistically 
evaluated for association with clinicopathological 
features and outcome endpoints, including overall 
response rate (ORR), time to progression (TTP) and 
overall survival (OS).
Results: Patients’ and tumour characteristics were 
as follows: median age 64 years; males 86%; 
ECOG performance status 0-1 88%; stage IIIB 
28% and stage IV 68%; adenocarcinomas 56% and 
squamous-cell carcinomas (SCC) 30%; treatment 
with GT and GV 75%, GC 14%, and G 9%. All 
six target genes were successfully ampliÀed in 
78% of the specimens. BRCA1, RRM2, and dCK 
expression levels were signiÀcantly higher in SCC 
compared with non-SCC (P <0.05). A signiÀcant 
intermediate to strong coexpression was observed 
between BRCA1/RRM1, BRCA1/RRM2 and dCK/
RRM2 (Spearman’s coefÀcient >0.55, P <0.001). 
In univariate analysis, there was a statistical trend 
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Background: Despite signiÀcant advances in non-
small cell lung cancer (NSCLC) therapy during 
the past decade, platinum compounds remain the 
cornerstone for both early and advanced stages 
NSCLC management. However, the mechanisms 
underlying platinum resistance/sensitivity are poorly 
understood and no major impact in patient selection 
or treatment modulation has been achieved to date. 
Anti-apoptotic proteins and platinum-efÁux pumps 
are known mechanisms, therefore we decided to 
evaluate the role of XIAP and pAkt anti-apoptotic 
proteins, and ATP7A, a cisplatin-efÁux pump, 
correlating its expression with cisplatin sensitivity in 
either cell lines or patients.
Methods: We analyzed three human tumor cell 
lines, ACC-LC94, ACC-LC319 and A549, all 
comprising adenocarcinoma histology and harboring 
KRAS mutations. The cisplatin IC50 was assessed 
using MTT assay after 48 hours incubation. mRNA 
expression was evaluated by Real-time PCR, while 
Western blotting was performed to evaluate protein 
expression. For correlative studies, two distinct 
cohorts of NSCLC patients were evaluated. The Àrst 
cohort comprised 39 patients diagnosed at early-
stage NSCLC, whereas the second included patients 
with metastatic disease. In the latter, patients were 
clinically classiÀed as platinum-sensitive (more than 
6-months progression-free interval after platinum-
based therapy) and platinum-non-sensitive group 
(less than 6-months interval). In these two cohorts, 
we have either analyzed mRNA or protein expression 
by immunohistochemistry.
Results: The studied cell lines exhibited distinct 
proÀles regarding cisplatin sensitivity. LC94 was 
especially sensitive to cisplatin (IC50 11.2 mM), 
in contrast to LC319 (IC50 47.4 mM) and A549 
(IC50 63.7 mM). Notably, resistant cell lines 
(LC319 and A549) showed a positive correlation 
of high XIAP and ATP7A mRNA expression when 
compared to LC94. These data was corroborated by 
XIAP and ATP7A mRNA expression, which also 
showed a signiÀcant positive correlation (R2=0,88) 
among early-diagnosed patients. Unfortunately, we 
were not able to correlate these data to treatment, 
since only few patients received adjuvant therapy. 
Results: SNaPshot detected mutations is 5 genes 
in this cohort of adenocarcinomas for which data 
is currently available as shown in the table at the 
left (n=44). A total of 6 cases with TP53 mutations 
were identiÀed by direct sequencing in the subset 
of tumor so far evaluated by both methods. TP53 
mutation occurred in approximately 1/6 of the cases, 
regardless of the presence or type of an associated 
additional mutation. The single tumor with both 
EGFR and TP53 mutations had an EGFR exon 19 
deletion and a second erlotoinib resistance-associated 
mutation in EGFR exon 20 (T790M) together with 
a point mutation at TP53 codon 248 on exon 7 
(742 CAG). In 4 of 6 cases with TP53 mutation 
no additional mutations were found in any of the 
evaluated targets. Association Between TP53 status 
And Additional Mutations in Adenocarcinoma 
TP53+ TP53- Totals 
EGFR 1 5 6 
KRAS 0 6 6 
BRAF 0 3 3 
PIK3CA 1 1 2 
CTNNB1 0 1 1 
Wild 4 22 26 
Totals 6 38 44 
Conclusion: These data suggest that TP53 may 
be the only identiÀable driver mutation among 
the 14 genes evaluated in a signiÀcant proportion 
of cases. Further investigation as to the impact of 
TP53 mutation alone or in combination with other 
mutations on prognosis and response to therapy is 
warranted. 
Keyword: Adenocarcinoma, mutation, TP53, 
SNaPshot, sequencing
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P2.241 CORRELATION BETWEEN 
ATP7A, XIAP AND PAKT EXPRESSION 
AND CISPLATIN RESISTANCE IN NON-
SMALL CELL LUNG CANCER.
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vitamin D receptor (VDR), which has been identiÀed in 
a variety of tissues. Certain polymorphisms in the VDR 
gene have been associated with various neoplasms. 
The purpose of this study was to determine whether 
polymorphism in the VDR gene might also inÁuence 
non-small cell lung cancer (NSCLC) risk.
Methods: Polymerase chain reaction (PCR) and 
restriction fragment length polymorphism (RFLP), 
and agarose gel electrophoresis techniques were 
used to detect VDR TaqI and Fok I polymorphisms. 
Sixtytwo NSCLC patients and 74 healthy controls 
were genotyped for the TaqI and FokI .The survival 
and staging data of operated NSCLC patients were 
also recorded. Kaplan Meier analysis, log-rank and 
Cox-proportional hazard risk test were also used.
Results: The frequencies of the TT, Tt and tt 
genotypes were 32.0%, 48.0%, 20% in NSCLC 
cancer patients and 54.8%, 37.1%, 8.1% in healthy 
controls, respectively. The genotype distribution 
for TaqI polymorphism was different between 
NSCLC patients and controls (p =0.015). VDR Taq 
I TT genotype was signiÀcantly associated with 
a increased risk of NSCLC in our study groups 
(OR=1.893; 95%CI 1.122-3.192; P = 0.032). On 
combined genotype analysis, the TTFF combined 
genotype was associated with NSCLC risk compared 
with other genotypes (OR=1.788; 95%CI 1.189-
2.690; P = 0.004). VDR Taq genotype was also 
found to be associated with survival (p=0.02) and 
lymph node involvement (p=0.03).
Conclusion: Our Àndings suggest that the TT 
genotype of the VDR TaqI variant was signiÀcantly 
associated with a increased risk of NSCLC. VDR taqI 
genotype also seemed to be associated with survival.
Keywords: vitamin D receptor, polymorphism, 
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P2.243 STUDY OF MORPHOLOGICAL 
AND IMMUNOHISTOCHEMICAL 
FEATURES, AND EGFR AND 
KRAS STATUS OF PULMONARY 
ADENOCARCINOMAS WHEN 
DIAGNOSED ON CYTOLOGY
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Subsequently, the XIAP protein expression was 
evaluated in cell lines and in the cohort of metastatic 
patients. XIAP had higher expression in the resistant 
cell lines when compared to the sensitive cell line. 
Among metastatic patients, XIAP was expressed in 
45% (21/47) in the platinum-non-sensitive group, 
while no expression was observed in the platinum-
sensitive (0/4). Knowing that XIAP is regulated 
by PI3K/Akt pathway through phosphorylation 
at the serine-87 residue, which increases XIAP 
stability and accumulation, we further analyzed 
the Akt phosphorylation on cell lines. In LC319 
and A549, with high XIAP expression, we also 
observed increased Akt phosporylation, in contrast 
to LC 94. We also assessed the Akt activation after 
cisplatin exposure. In fact, cisplatin induced Akt 
phosphorylation in resistant cell line (A549), but not 
in the sensitive (LC 94).
Conclusion: XIAP and ATP7A mRNA expression 
were positively correlated to cisplatin resistance/
sensitivity in NSCLC patients and cell lines. Also, 
we observed a correlation of high XIAP mRNA 
and protein expression and Akt phosphorylation 
with cisplatin resistance in the studied cell lines. 
While further analyses are warranted to validate 
these Àndings in larger cohorts, these proteins are 
putative targets for drug development, since they 
seem promising for combined therapies directed to 
overcome cisplatin resistance.
Keywords: Lung neoplasms, Biomarkers, Cisplatin, 
Predictive
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P2.242 ASSOCIATION BETWEEN 
VITAMIN D RECEPTOR GENE 
POLYMORPHISM AND NON-SMALL 
CELL LUNG CANCER RISK AND 
SURVIVAL.
Akif Turna1, Canan Cacina2, Kamil Kaynak1, 
Yemliha Yildiz2, Arzu Ergen2, Zelal Erkisi2, Ilhan 
Yaylim Eraltan2 
1Department Of Thoracic Surgery, Istanbul 
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2Department Of Molecular Medicine, Istanbul 
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Background: The effects of 1,25-dihydroxyvitamin 
D3 are mediated by binding to a speciÀc intracellular 
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papillary fragments on cytology was associated 
with EGFR mutations. Tumors with KRAS 
mutations frequently had necrosis and squamoid 
features on cytologic material and were almost all 
poorly differentiated. Tumors with either mutation 
was immunohistochemically positive with TTF-
1 stain. These morphological features may help 
cytopathologists better triage specimens for 
molecular studies. 
Keyword: Cytology, pulmonary adenocarcinoma, 
EGFR, KRAS
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P2.244 TECHNICAL VALIDATION STUDY 
OF A MULTI-ANALYTE SERUM PANEL 
FOR LUNG CANCER DETECTION
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Basu4, Edward Hong5, PenÀeld L. Faber5, William H. 
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Background: Lung cancer is the leading cause 
of cancer death worldwide primarily due to late 
stage presentation and no accepted early detection 
protocol. Preliminary National Lung Cancer 
Screening results using computed tomography 
(CT) have shown enhanced detection of early 
stage disease with better survival. However, a large 
number of incidentally found benign nodules lead to 
costly further workups and non-therapeutic invasive 
procedures. A simple, cost-effective serum test 
for early detection could improve falsely positive 
Àndings on imaging to accurately identify early stage 
lung cancer patients.
Methods: We reported two individual serum tests 
for non-small cell lung cancer (NSCLC) using 
immunobead (Luminex) assays, including one 
comprised of circulating biomarkers (tumor necrosis 
factor-Ơ, CYFRA 21-1, interleukin-1ra, matrix 
metalloproteinase-2, monocyte chemotactic protein-1 
and sE-selectin) and one comprised of autoantibodies 
Background: Bronchioloalveolar carcinoma (BAC) 
and mixed-type adenocarcinomas with BAC features 
are associated with EGFR mutations and a clinical 
response to tyrosine kinase inhibitors. Tumors 
that contain KRAS mutations and lack EGFR 
mutations have different therapeutic implications. 
In this study we present the cytomorphological 
and immunohistochemical features of lung 
adenocarcinomas, that were diagnosed by cytologic 
methods and their relationship to both EGFR and 
KRAS mutational status.
Methods: We retrospectively reviewed 50 lung 
adenocarcinomas that were diagnosed cytologically 
for cell size, architectural pattern, nucleoli, 
intranuclear cytoplasmic inclusions (INCI), mucin, 
necrosis, squamoid features, lymphocytic response, 
and histologic features of BAC differentiation on 
FNA and/ or touch imprint of needle core biopsies 
(NCB) and tested for both EGFR and KRAS 
mutations. Immunohistochemistry was performed 
on the cell block or NCB using CK7, CK20, TTF-1 
and P63. DNA extracted from parafÀn embedded 
cell block or frozen needle core fragments was 
studied for exon 19 deletions and the L858R 
mutation in exon 21 of EGFR (using PCR followed 
by capillary electrophoresis for fragment sizing). 
KRAS mutational analysis was performed by real-
time PCR using a set of 7 different Taqman(r) allelic 
discrimination assays to detect 6 mutations in codon 
12 and 1 mutation in codon 13. 
Results: KRAS mutations were seen in 12 (24%) 
and EGFR mutations in 6 (12%) patients. Thirty 
eight (62%) patients were negative for both EGFR 
and KRAS mutations. Tumors with EGFR mutations 
were more likely to be well differentiated (P=0.016) 
and tumors with KRAS mutations were more 
poorly differentiated adenocarcinomas (P=0.025). 
Presence of prominent INCI (P=0.036), papillary 
fragments (P=0.041), and histologic features of BAC 
on parafÀn block (P= 0.039) correlated with EGFR 
mutations while necrosis (P=0.030), squamoid 
features (P=0.048), and poorly differentiated tumors 
(P=0.025) with KRAS mutations. Tumors with 
EGFR or KRAS mutations were positive with TTF-
1 and CK7 immunostains. There was no signiÀcant 
association between lymphocytic response and 
EGFR or KRAS mutational status. 
Conclusion: The distribution of EGFR and KRAS 
mutations in lung adenocarcinomas when diagnosed 
on cytology was similar to that reported in prior 
studies on surgical material. Features of BAC 
including the presence of INCI, Áat sheets and 
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Background: The detection of activating mutations 
in exons 19 and 21 of the epidermal growth factor 
receptor (EGFR) gene, which predict sensitivity to 
treatment with EGFR tyrosine kinase inhibitors, 
represents a major advance in the treatment of lung 
adenocarcinoma. The prevalence of these mutations 
in Colombian patients has not been thoroughly 
investigated.
Methods: We collected formalin-Àxed, 
parafÀn-embedded material from resected lung 
adenocarcinomas from patients in Cali (Southwest 
Colombia) for DNA extraction, PCR ampliÀcation 
and subsequent automated sequencing. The 
frequencies of EGFR exon 19 deletions and exon 
21 L858R substitutions in tumor specimens from 
southwest Colombia patients were compared with 
data from America and Asian populations.
Results: EGFR mutations were detected in 6 out 
of the 37 specimens tested from Cali (southwest 
Colombia) for a frequency of 16,2% (95%IC: 
0,86 – 19,03, P=0,0002). All detected mutations 
were deletions in exon 19. The detected activating 
mutations were present in non-smoker women. 
Besides, there was no signiÀcant difference between 
frequencies of EGFR mutations comparing to 
African American (P=0,8868) or White American 
(P=0,7630) patients; However, there was a tendency 
to lower frequencies than in Japanese (P=0,0474) or 
Korean patients (P=0,0610).
Conclusion: This is the Àrst study to date examining 
the frequency of mutations in lung adenocarcinomas 
in patients from southwest Colombia. There was 
no difference between the frequencies of EGFR 
mutations in patients outside Asia. These results 
suggest that, as suggested elsewhere, all Colombian 
patients with advanced lung adenocarcinomas should 
undergo mutational analysis before initiation of 
therapy.
Keywords: EGFR mutations, lung adenocarcinoma, 
Sothwest Colombia
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
(inosine monophosphate dehydrogenase, 
phosphoglycerate mutase, ubiquillin, annexin I, 
annexin II, and heat shock protein 70-9B). Each test 
was validated against separate patient cohorts; the 
biomarkers were tested against 92 NSCLC and 43 
non-cancer controls, and the autoantibodies were 
tested against 117 NSCLC, 43 non-cancer, and 31 
normal controls. The misclassiÀcation rate for these 
independently published panels was 15% and 7%, 
respectively. Multivariate statistical methods were 
used to condense these algorithms into a single 
multi-analyte panel for detecting NSCLC.
Results: Two published serum panels were 
combined into a single panel for classifying 
patient disease status, which consists of tumor 
necrosis factor-Ơ (TNF-Ơ), cytokeratin 19 fragment 
(CYFRA 21-1), and autoantibodies against 
endoplasmic reticulum protein-29 (ERP29), 
inosine monophosphate dehydrogenase (IMPDH), 
monocyte chemotactic protein-1 (MCP1), ubiquillin, 
and annexin A2 (ANXA2). Performance of this 
combined serum panel against our original discovery 
and validation cohorts revealed a 3.2% (3/94) overall 
misclassiÀcation rate.
Conclusion: Here we report the development of a 
7-target panel for the detection of NSCLC that was 
found to be highly accurate against all cohorts tested 
except those with inÁammatory, benign lesions. 
Further reÀnement of this detection algorithm 
has potential to provide a useful Àrst-line serum 
screening test for early NSCLC.
Keywords: NSCLC, Early Detection, biomarker, 
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P2.245 FREQUENCY OF EGFR 
ACTIVATING MUTATIONS IN LUNG 
ADENOCARCINOMA PATIENTS 
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proportional hazards modeling employing h-fold 
cross-validation was used to select and validate a 
prognostic model. Risk scores were assigned using 
model coefÀcients and dichotomized. Survival of 
low- and high-risk category patients was analyzed 
using the Kaplan-Meier method.
Results: Expression of target genes was reliably 
measured in 413 FFPE specimens. 5-year overall 
survival was 41% among high-risk patients and 
69% among low-risk patients (p<0.0005). Among 
stage I patients, 5-year overall survival was 46% 
among high-risk patients and 73% among low-risk 
patients (p<0.0005). After adjusting for patient age, 
sex, and stage, the hazard ratio of the risk score as 
a continuous variable was 2.6 (95%CI 1.97-3.43, 
p<0.0005).
Conclusion: We have begun large-scale validation 
of a practical multi-gene qPCR-based assay that 
is prognostic of survival in patients with resected 
NSCLC. Further validation of this assay on a large, 
independent cohort of patients who have undergone 
resection for early-stage NSCLC at Kaiser 
Permanente Northern California is ongoing. This 
practical genetic assay provides additional prognostic 
information beyond the traditional TNM staging 
system that may impact both the use of adjuvant 
therapy as well as the choice of surgical procedures 
in patients with NSCLC.
Keywords: genetic, Non-small cell lung cancer, 
prognostic, biomarker
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P2.247 PREDICTIVE VALUE OF 
THYMIDYLATE SYNTHASE 
AND FOLYLPOLY-GLUTAMATE 
SYNTHETASE FOR CLINICAL BENEFIT 
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PLEURAL MESOTHELIOMA
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P2.246 VALIDATION OF A QPCR-BASED 
GENETIC ASSAY PROGNOSTIC OF 
SURVIVAL IN RESECTED NON-SMALL 
CELL LUNG CANCER
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R. Segal2, Kirk D. Jones3, Thierry M. Jahan4, Biao 
He1, Michael J. Mann1, David M. Jablons1 
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Background: The large scale validation of genetic 
assays that provide more accurate prognosis than 
traditional staging has altered the standard of care 
for early-stage breast cancer patients. By comparison 
to most cancers, the Àve-year survival of patients 
undergoing an attempt at curative resection for 
non-small cell lung cancer (NSCLC) is poor. Most 
treatment failures are due to distant disease, often 
indicating an inaccurate post-operative staging and 
a resultant failure to consider adjuvant therapies 
that might have improved survival. Although 
numerous studies have established the feasibility of 
using genetic parameters to differentiate between 
patients with good and poor prognosis after resection 
of NSCLC, these studies have generally utilized 
microarray-based proÀling and/or fresh frozen 
tissues, methods that are difÀcult to reproduce in 
a community-practice setting. None have been 
validated on a large scale. We report the development 
and initial large scale validation of a straightforward, 
quantitative PCR-based multi-gene assay using 
formalin-Àxed, parafÀn embedded (FFPE) specimens 
that identiÀes patients at high risk for treatment 
failure after resection of NSCLC.
Methods: Specimens were studied from 468 
patients who underwent resection and complete 
surgical staging of stage I-IV NSCLC at University 
of California, San Francisco. RNA was extracted 
from FFPE tumor specimens using modiÀcations 
of previously published methods. Expression of 11 
target genes previously identiÀed in a study using 
frozen tissues was measured using custom-designed 
TaqMan quantitative PCR assays. Multivariable Cox 
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specimens from pemetrexed-treated MPM pts to 
date. Based on our retrospective study, base line 
determination of TS and FPGS expression may 
be predictive for clinical beneÀt of PMX-based 
therapy in MPM. ConÀrmation of the prognostic and 
predictive value of TS and FPGS expression in MPM 
by prospective studies is warranted.
Keywords: thymidylate synthase (TS) and 
folylpoly-glutamate synthetase (FPGS), malignant 
pleural mesothelioma (MPM), predictive biomarker 
for response and outcome, Pemetrexed
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P2.248 ROUTINE IMAGE-GUIDED 
DIAGNOSTIC BRONCHOSCOPIES 
CAN YIELD TUMOR SPECIMEN 
SUITABLE FOR BROAD PANEL 
OF IMMUNE AND PREDICTIVE 
MOLECULAR MARKERS STUDIES IN 
THORACIC MALIGNANCIES. ROLE OF 
COORDINATED MULTIDISCIPLINARY 
THORACIC ONCOLOGY PATHOLOGY 
TEAMWORK.
Rex C. Yung1, Peter Illei2, Qing Kay Li3 
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Johns Hopkins University/United States Of America, 
2Pathology, Johns Hopkins University/United States 
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Background: Lung Cancer(LC) fatality remains 
high, previously prognosis is linked to patients’ 
disease stage and functional status. Recent studies 
with have highlighted importance of accurately 
characterizating NSCLC celltypes: distinguishing 
between squamous and non-squamous carcinomas. 
Introduction of molecular “targeted” agents (EGFR-
TKIs, EML4-ALK antagonists) and proliferation 
of other prognostic and predictive markers 
(PIK3CA,BRAF, AKT,etc) requires more tumor tissue 
for immunohistochemical(IHC) and genetic testing 
than simple cytologic diagnosis of “lung cancer”. 
Coincidentally, there’s a drive to reduce more invasive 
initial surgical procedures (medianstinoscopies, open 
lung biopsies) as patients receiving induction-therapy 
may require re-staging prior to resections. Minimally 
invasive bronchoscopies have heretofore provided 
limited diagnostic material. We describe the routine 
use of Endobronchial Ultrasound (EBUS) Image 
Oncology, University Of Colorado Denver/United 
States Of America, 2Department Of Pathology 
And Neuropathology, University Hospital Essen/
Germany, 3Department Of Medical Oncology, West 
German Cancer Center, University Hospital Essen/
Germany, 4Institute Of Pathology, Ruhr-university 
Bochum/Germany, 5Department Of Radiotherapy, 
West German Cancer Center, University Hospital 
Essen/Germany
Background: The antifolate pemetrexed (PMX) 
targets multiple enzymes involved in pyrimidine 
and purine synthesis including thymidylate synthase 
(TS). After entry into cells, PMX is converted to 
more potent polyglutamated forms by folylpoly-
Ƣ-glutamate synthetase (FPGS), a critical step to 
achieve full target inhibition. We hypothesized 
that FPGS and TS protein expression may predict 
response and outcome following PMX treatment of 
patients (pts) with malignant pleural mesothelioma 
(MPM).
Methods: Pre-treatment tumor samples from 
69 pts with MPM, treated with PMX combined 
with platinum (64/69) or as single agent (5/69), 
were retrospectively analyzed. TS and FPGS 
protein expression levels were evaluated by 
immunohistochemistry using the H-Scoring system 
(ranging from 0 to 300), which relies on the product 
of intensity of speciÀc tumor cell immunoreactivity 
(range 0 to 3) and the percentage of positive tumor 
cells. Radiographic evaluation of response was 
performed according to RECIST.
Results: Median pre-treatment H-scores were 230 
(range: 50-300) for TS and 240 for FPGS (range: 
110-300). Using the log-rank test and the median 
H-score as cut-off, we found a signiÀcant association 
between improved progression-free survival (PFS) 
and low TS protein expression (median PFS of 
225 vs 190 days; hazard ratio [HR] 0.516, 95% 
CI, 0.295 to 0.908; P=0.022). High FPGS protein 
expression was associated with objective response 
(mean H-score 251 for responders vs 230 for non-
responders, P=0.016) as well with absolute clinical 
beneÀt including objective response and disease 
control (mean H-score 244 for responders and 
stable disease pts vs 215 for progressive disease pts, 
P=0.009). Moreover, we found an association of 
high FPGS protein expression with prolonged PFS 
(median PFS of 218 vs 185 days; HR 0.847, 95% CI, 
0.268 to 1.430; P=0.019). 
Conclusion: Here we report the most thorough 
investigation of TS and FPGS expression in tumor 
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Conclusion: Tumor specimen from routine EBUS-
guided diagnostic bronchoscopies can generate 
information about cancer-origin, cell-type, and 
mutation-status to provide guidance for personalized 
cancer therapy; successful implementation requires 
close collaborative teamwork between diagnostic-
pathology services. 
Keywords: Endobronchial Ultrasound (EBUS), 
Bronchoscopic Image Guided Interventions 
(BIGI), Prognostic/predictive Markers; 
Immunohistochemistry (IHC), Molecular Targeted 
Therapies
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P2.249 KRAS MUTATION STATUS 
PREDICTS SENSITIVITY TO ANTI-DHFR 
THERAPY (METHOTREXATE) IN NON 
SMALL CELL LUNG CANCER CELL 
LINES
Patricia Trusk, Diarmuid M. Moran, Scott A. Shell, 
Sarah Bacus 
R&D Translational Oncology, Quintiles/United 
States Of America
Background: Somatic genetic mutation in the 
V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) gene has been linked to resistance 
to various targeted therapeutics (e.g.Erlotinib, 
GeÀtinib) in Non Small Cell Lung Cancer (NSCLC). 
Therapeutic strategies that target tumors harboring 
these mutations represent an unmet medical need. 
In this study, we have identiÀed higher sensitivity 
to a dihydrofolate reductase (DHFR) inhibitor, 
methothrexate (MTX), in KRAS mutant (mut) versus 
wild type (wt) NSCLC cell lines. 
Methods: The NCI Developmental Therapeutics 
Progam cancer drug screen database was 
interrogated for association between KRAS mutation 
status and drug efÀcacy in NCI60 NSCLC cell 
lines. Furthermore, ten human NSCLC cell lines (4 
KRASwt / 6 KRASmut) were treated with MTX 
and assayed for proliferation after 72h. Microarray 
gene expression data from the NCI-60 NSCLC 
cell lines using Ingenuity pathway analysis was 
also performed. Finally, expression of genes/
Guidance and a coordinated pathology-diagnostic 
team approach to provide material necessary to guide 
personalized therapy in thoracic malignancies. 
Methods: Retrospective review of database developed 
to assess impact of bronchoscopic real-team image-
guided interventions (BIGI) in improving diagnostic 
yield. From 2-2008 through 2-2011, 80 cases of 
suspected thoracic malignancies included. EBUS used 
as the primary mode of BIGI, plus Áuoroscopy for 
peripheral lesions; bedside cytopathology to provide 
on-site evaluation available in all cases. Male:female 
ratio 49:31; age range 17-95, median 6th decade. 34 
suspected of primary lung cancers (risk factors); 46 
suspected recurrent cancers or new primary lung with 
prior non-lung cancers: 16lung, 7H&N, 7colorectal, 
3RCC, 3pancreatic, 3hematologic malignancies, 
2breast, 2melanoma, 1 each bladder, prostate, 
osteosarcomas. Tissue sample by EBUS guided 
transbronchial needle aspiration (TBNA) 90 lymph 
node stations sampled in 76/80 patients, (4/80 without 
lymphadenopathy); 33 patients have parechymal(29) 
or central airway masses(4). Transbronchial biopsies 
(forcep and needle) of peripheral lesions guided by 
EBUS probe and Áuoroscopy. 
Results: Diagnosis: Cancer 61/80, 17 
benign(granulomatous) 2 false-negative (NSCLC). 
Malignancies include 49 LCs in 47 patients: 38 
new, 9 recurrences; synchronous primaries in 2. 
15 thoracic metastases in 30 patients with prior 
non-lung primaries; other 15 with new primary 
lung or granulomas (Table). A broad panel of 
immunohistochemical stains geared to determine 
cancer origin ordered per pathology staff based on 
detailed history, additional molecular biomarkers 
included KRAS 10+/33(30%); EGFR 8+/30(27%); 
EML4-ALK 2+/4(3.4%,3.5% fusion); BRAF ordered 
on 1 each lung, melanoma and colon 2+/3(66%); 
ERCC1/RRM1 high expression in one specimen sent 
for analysis. HPV16/18+ in two H&N metastases. 
LN Station # attempt Cancer Dx Lymphs Inadequate Final Diagnosis IHC /Marker 
4R 41 26 15 1 Primary Lung: 49 SCLC 9 Chromogranin 
Synaptophysin 
4L 5 2 2 1 New 38 NSCLC 42 
Adenocarcinoma 
NapsinA,TTF1 
KRAS,EGFR, EML4-
ALK,ERCC1,RRM1 
7 23 8 14 1 Recurrent 9 >1 primary 2 pts 
11R 27 10 12 5 Metastatic Cancers #15 
11L 7 2 5 0 Head & Neck 
squamous cell 
P16, HPV16, 18 KRAS, 
EGFR 
9L/10L 2 2 0 0 Colorectal CDX2, CK20 KRAS 
12R/13R 4 1 1 2 Melanoma S100, HMB45 
Extra-
thoracic 
2 2 0 0 Breast ER, PR, HER-2 Gross 
Cystic Dis protein 
Lung nodule 
Endo-
bronchial 
30 4 26 4 0 0 4 0 Pancreas Renal 
Cell (RCC) 
DPC4 loss PAX8 
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P2.250 N-NITROSO-TRIS-
CHLOROETHYLUREA INDUCES PRE-
MALIGNANT SQUAMOUS DYSPLASIA 
IN MICE
Tyler M. Hudish1, Laura I. Opincariu1, Anthony B. 
Mozer1, Micah S. Johnson1, Timothy G. Cleaver2, 
Stephen P. Malkoski2, Daniel T. Merrick3, Robert L. 
Keith4 
1Research, Denver VA Medical Center/United States 
Of America, 2Medicine, University Of Colorado 
Denver/United States Of America, 3Pathology 
113, Denver VA Medical Center/United States Of 
America, 4Division Of Pulmonary Sciences And 
Critical Care Medicine, Denver VA Medical Center/
United States Of America
Background: Squamous cell carcinoma (SCC) is the 
second-most common form of non-small cell lung 
cancer, and SCC tumor models have been difÀcult 
to develop. Herein, we propose a murine SCC (and 
pre-malignant precursor lesions) model using topical 
N-nitroso-tris-chloroethylurea (NTCU) application, 
and determine the extent to which airway dysplasias 
develops, and compare immunohistochemical 
staining patterns to dysplastic lesions from human 
smokers. 
Methods: FVB/N mice were given biweekly 
topical applications of NTCU for 32 weeks at 
concentrations of 4mM, 8mM and 40mM, diluted 
with acetone. Following dorsal coat shaving a 25ƫl 
volume was applied to exposed skin. Afterward, 
formalin-Àxed lung was thoroughly examined under 
bright Àeld microscopy. Three separate H&E slides 
were examined per animal, taken from a single 
parafÀn block, spaced 50ƫm apart. Squamous 
cell lesions were enumerated and categorized as 
one of the following: Áat atypia (FA), low-grade 
dysplasia (LGD), high-grade dysplasia (HGD), 
and invasive SCC (iSCC). Squamous origin of 
the range of observed lesions was conÀrmed with 
immunohistochemical staining for cytokeratin 5/6, 
p63, thyroid transcription factor-1, and napsin-A. 
As prostaglandins play a prominent role in lung 
carcinogenesis, we chose to measure changes in 
prostaglandin E
2
 (PGE
2
) and prostaglandin I
2
 (PGI
2
) 
levels. 
Results: Despite the intolerability of 64 total NTCU 
applications over 32 weeks to the 40mM group, 
this concentration produced the entire spectrum 
proteins related to folate metabolism and cell cycle 
progression were examined in KRASmut and 
KRASwt NSCLC cells with methotrexate treatment 
and KRAS overexpression or knockdown.
Results: Interrogation of the NCI Developmental 
Therapeutics Progam cancer drug screen database 
revealed increased efÀcacy of MTX in KRASmut 
versus KRASwt NCI-60 NSCLC cell lines. 
Furthermore, a similar speciÀcity was revealed for 
other anti-folate therapies in the NCI cell screen. 
In our proliferation assays, KRASwt cells did 
not show response to MTX treatment, however, 
growth of 4 out of 6 KRASmut cell lines was 
signiÀcantly inhibited. Examination of microarray 
gene expression data from the NCI-60 NSCLC cell 
lines demonstrates increased expression of folate 
metabolism associated genes in KRASmut versus 
KRASwt cells. Furthermore, we determined that 
expression of DHFR, TS, E2F-1, phosphorylated Rb 
and mutant KRAS were decreased by methotrexate 
treatment in KRASmut but not in KRASwt cells. We 
also demonstrate that expression of DHFR, TS, E2F-
1 and phosphorylated Rb are increased upon KRAS 
transfection and decreased upon siRNA knockdown 
of mutant KRAS. 
Conclusion: Collectively, these studies highlight 
increased sensitivity to MTX in KRASmut NSCLC 
cells. We propose that mutant KRAS drives 
expression and release of E2F-1 which may in 
turn lead to increased expression of DHFR / TS 
and potential dependency on these pathways. The 
remainder of this study aims to characterize the 
underlying molecular mechanisms leading to this 
dependency on folate metabolism. Pemetrexed 
(Alimta) is a MTX derivative that is currently 
approved for the treatment of advanced or metastic 
nonsquamous NSCLC. Surprisingly this is one of 
the few antifolates from our analysis that do not 
show a similar enhanced efÀcacy in KRASmut 
versus KRASwt NSCLC cell lines which may be 
due to lower speciÀcity of this drug for DHFR. 
While Pemetrexed has shown good efÀcacy in 
NSCLC treatment, our data suggests that the parental 
molecule MTX, should be revisited as a potential 
candidate for the treatment of NSCLC harboring 
KRAS mutation. 
Keywords: Kras, Methotrexate, DHFR
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P2.251 BRONCHIAL DYSPLASIA 
IS MORE FREQUENT AND MORE 
ATYPICAL IN BIOPSY AND SPUTUM 
MATERIAL FROM HIV INFECTED 
SUBJECTS: A PRELIMINARY REPORT 
FROM AN ONGOING STUDY.
Daniel T. Merrick1, Mary Bessessen1, Steven C. 
Johnson2, Thomas A. Clagett3, Mary K. Jackson3, 
Robert L. Keith4, Tim E. Byers3, William J. Feser5, 
Wilbur Franklin6, Paul Bunn7, York E. Miller4 
1Pathology 113, Denver VAMC/United States 
Of America, 2Infectious Diseases, University Of 
Colorado/United States Of America, 3University Of 
Colorado Cancer Center/United States Of America, 
4Division Of Pulmonary Sciences And Critical 
Care Medicine, Veterans Administration Medical 
Center/United States Of America, 5Biostatistics And 
Informatics, Colorado School Of Public Health/
United States Of America, 6Pathology, University Of 
Colorado/United States Of America, 7Cancer Center, 
University Of Colorado School Of Medicine/United 
States Of America
Background: While the era of highly active 
antiretroviral therapy (HAART) has brought about 
dramatic improvements in overall life expectancy, 
the relative importance of non-AIDS-deÀning 
malignancies as a contributor to HIV-related 
morbidity and mortality has grown. Previous studies 
have demonstrated that carcinoma of the lung occurs 
in HIV infected individuals with higher frequency 
and at younger age than is typically observed in the 
HIV negative population. It has been noted that lung 
cancer in HIV infected patients is often associated 
with no observable radiographic abnormality even 
within the year prior to diagnosis, and HIV infected 
lung cancer is associated with signiÀcantly shorter 
survival. We have hypothesized that increased 
development and progression of bronchial dysplasia 
may have an important role in the observed increase 
of lung cancer incidence in the HIV infected 
population.
Methods: HIV infected subjects were recruited 
to an ongoing study of lung cancer biomarkers in 
a Colorado Lung SPORE approved protocol for 
sputum evaluation and potential bronchoscopy. A 
Ànding of moderate or worse sputum atypia was an 
indication for bronchoscopy. Sputum and bronchial 
biopsy specimens were read by either of two SPORE 
of premalignant dysplasias and squamous cell 
carcinomas. Survival rates were 45.0% (18/40) in 
40mM NTCU-treated animals, 77.8% (21/27) in 
8mM, 92.3% (24/26) in 4mM, and 84.6% (22/26) in 
acetone control animals. Lesions detected per square 
centimeter of lung tissue (±SE) were as follows: 
FA, 2.96 (±0.63), 2.99 (±0.67), 1.12 (±0.39); LGD, 
0.08 (±0.05), 0.15 (±0.06), 1.70 (±0.29); HGD, 0, 
0.03 (±0.03), 0.98 (±0.40); iSCC, 0, 0, 0.49 (±0.22), 
respectively for the 4mM, 8mM, and 40mM groups. 
Control animals did not develop SCC lesions of any 
type. Interestingly, animals of the 40mM group that 
received 33 applications of NTCU over 32 weeks 
developed more SCC than those of the same group 
that received 46 applications (0.63±0.36, 0.35±0.36, 
p=0.39, n=14). Immunohistochemical staining 
patterns of cytokeratin 5/6, p63, thyroid transcription 
factor-1, and napsin-A revealed distinct similarities 
to human predysplastic lesions and SCC. Selected 
prostaglandin levels of the 8mM group were 
signiÀcantly higher than the 4mM group (p<0.05). 
Conclusion: Concentrations of 4mM and 8mM 
NTCU were better tolerated and produced signiÀcant 
levels of FA but not HGD or iSCC. Data from 
selected prostaglandin levels is suggestive of an 
integral relationship between aberrant inÁammation 
involving the COX-2/PGE
2
 pathway and cancer-
mediated immunosuppression. Alterations in 
prostaglandin production may be associated with 
alterations in chemoprotection in lung cancer 
incidence and progression. Although more data is 
needed to improve the applicability of this model 
in the FVB/N mouse, it seems an equivalent degree 
of SCC development may be possible through 
fewer NTCU doses over a longer period of time. 
This study demonstrates that topical application 
of NTCU produces endobronchial pre-malignant 
lesions with clear squamous characteristics 
immunohistochemically comparable to those seen 
in human smokers and is a useful model in the pre-
clinical evaluation of chemopreventive agents. 
Keywords: NTCU, squamous cell carcinoma, Lung 
cancer, prostaglandin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: Bronchial dysplasia (BD) is believed 
to be a precursor lesion for the development of 
squamous cell carcinoma (SCC) of the lung. 
However, the majority of these lesions do not 
progress to invasive cancer. IdentiÀcation of features 
of BD that are associated with risk for progression 
is essential for effective management of these 
lesions. Persistence of BD is a characteristic that 
may indicate increased malignant potential. We 
have previously found a direct correlation between 
the degree of atypia at baseline and higher levels 
of atypia on re-biopsy. Furthermore, in subjects 
with SCC, follow-up diagnoses are higher than 
equivalent sites in subjects without cancer. Thus, 
we hypothesized that differences in gene expression 
will distinguish persistent from regressive BD and 
identify markers of malignant potential and targets 
for therapeutic intervention in these lesions. 
Methods: 111 biopsies snap frozen in liquid N2 
immediately after collection were chosen for 
analysis. Expected baseline histology was based 
on diagnoses in immediately adjacent formalin 
Àxed parafÀn embedded (FFPE) biopsies. Gene 
expression analysis was performed on 64 specimens; 
47 were excluded (22 for discrepant frozen and 
FFPE diagnoses, and 25 for inadequate RNA). 
Biopsies were classiÀed into four groups based 
on the diagnosis at baseline and on follow-up at 
the site: Group 1 – Persistent Dysplasia (follow-
up > mild dysplasia; n=24) Group 2 – Regressive 
Dysplasia (follow-up < hyperplasia; n=15) Group 
3 – Progressive Non-dysplasia (follow-up > mild 
dysplasia; n=9) Group 4 – Stable Non-dysplasia 
(follow-up < hyperplasia; n=16) Total RNA was 
extracted from the portion of the biopsy remaining 
after frozen sectioning. Gene expression proÀling 
was conducted using Affymetrix Human Gene 
1.0 ST microarrays, and analyzed using RMA 
and ANOVA methods. SigniÀcant differences in 
expression were deÀned using a false discovery rate 
cutoff of 0.05% based on a corrected t-test. 
Results: Groups 1 and 2 were not signiÀcantly 
different in respect to baseline diagnoses (5.08 vs. 
4.73, group 1 vs. 2 respectively), gender (67.7% 
vs. 73.3% male), age (58.9 vs. 63.2 years), tobacco 
status (50.0% vs. 40.0% current smokers) or 
history of lung cancer (33.3% vs. 20.0%). The gene 
pathologists (DTM, WAF) who were blinded to the 
HIV status of the subject. The frequency of atypical 
Àndings in sputum and bronchial biopsies in HIV 
infected subjects were compared to the frequency of 
these Àndings in subjects without a known history 
of HIV infection that were matched by age, gender 
and smoking status. In bronchoscopically evaluated 
subjects, frequencies of atypia were calculated by 
number of atypical biopsies per total number of 
biopsies.
Results: 30.8% (4/13) HIV infected subjects 
screened by sputum cytology showed moderate or 
higher degrees of dysplasia as compared to 21.7% 
(97/448) of HIV negative individuals. In addition, 
the frequency of severe sputum atypia was markedly 
higher in HIV infected than in HIV negative subjects 
[15.4% (2/13) vs. 0.9% (4/448)]. Four HIV infected 
subjects have been evaluated by bronchoscopy to 
date. The frequency of moderate or higher degrees 
of dysplasia for these respiratory epithelial biopsies 
in HIV infected patients was 38.9% (7/18) versus 
24.9% (64/257) in age, gender and tobacco status 
matched non-HIV subjects.
Conclusion: The Àndings from this small number 
of HIV positive subjects studied to date supports our 
hypothesis that there may be more frequent and more 
atypical bronchial lesions in HIV infected subjects. 
If these Àndings are conÀrmed on extended analyses, 
it suggests that altered surveillance guidelines may 
be needed for early lung cancer detection in HIV 
infected patients and that these patients may beneÀt 
from chemopreventive therapy beyond smoking 
cessation. Recruitment of additional study subjects is 
continuing to conÀrm these preliminary Àndings.
Keywords: HIV infection, Sputum, bronchial 
biopsy, Bronchial dysplasia
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P2.252 IDENTIFICATION OF 
ALTERATIONS IN GENE EXPRESSION 
THAT DISTINGUISH PERSISTENT FROM 
REGRESSIVE BRONCHIAL DYSPLASIA
Daniel T. Merrick1, Chris D. Coldren2, Wilbur 
Franklin3, Michio Sugita4, York E. Miller3, Robert 
L. Keith3, Timothy C. Kennedy3, Patrick Chesnut3, 
Céline Mascaux3, Fred R. Hirsch3, Mark W. Geraci3, 
Raphael Nemenoff2 
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(AD) and 21 lung squamous cell carcinoma (SCC) 
patients who were operated on Nara Medical 
University (stage I: 42, stage II: 8, stage III: 18). 
RNA was extracted from tumor and corresponding 
normal lung tissue, and used for real-time RT-PCR 
to measure REG family genes expressions. We set 
the cutoff levels from the expressions of the normal 
lung tissues and then correlated these expressions 
of tumors with prognosis of patients. In vitro, we 
obtained lung adenocarcinoma (HLC-1) and lung 
squamous cell carcinoma (EBC-1) cell lines and 
established HLC-1 and EBC-1 expressing REG IƠ 
(HLC-1 REG IƠ and EBC-1 REG IƠ). Cell growth, 
cell proliferation, and anchorage independent cell 
growth of HLC-1 REG IƠ and EBC-1 REG IƠ were 
compared with those of control HLC-1 and EBC-1 
(HLC-1 mock and EBC-1 mock), respectively.
Results: REG IƠ and REG VI genes expressed 
high rate in tumors than in normal lung tissues. 
Especially, the survival rate among the stage I 
patients of AD and SCC expressing higher levels of 
REG IƠ was signiÀcantly worse than among those 
expressing lower levels of REG IƠ (P<0.01, Kaplan-
Meier survival curve). In contrast, the characteristics 
of expressions of REG Iß, REG III, and HIP/PAP 
had no difference in normal lung tissues and tumors. 
In vitro, HLC-1 REG IƠ showed signiÀcant increases 
in cell growth, cell proliferation, and anchorage 
independent cell growth compared with HLC-1 
mock. On the other hand, EBC-1 REG IƠ showed 
signiÀcant increase only in anchorage independent 
cell growth compared with EBC-1 mock. 
Conclusion: The present results demonstrated 
that REG IƠ expression was correlated with poor 
prognosis of early stage non-small cell lung cancer 
because of enhancement of cancer cell progression. 
REG IƠ may be a useful target for anticancer 
treatment to patients of non-small cell lung cancer.
Keyword: Regenerating gene (REG)
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P2.254 HISTOLOGIC SUBTYPING AND 
TUMOR STROMAL RESPONSES IN 
LUNG ADENOCARCINOMA AND THEIR 
RELATIONSHIP TO SURVIVAL
Mark Pool1, Mary J. Fidler2, Kelly Kaiser1, Sanjib 
Basu2, Jeffrey A. Borgia3, Eduardo Braun2, Thomas 
A. Hensing4, Philip Bonomi2 
1Pathology, Rush University Medical Center/United 
expression analysis comparing group 1 to group 
2 revealed 66 genes with statistically signiÀcant 
differential expression of greater than two-fold 
change. Many genes encode proteins with activities 
related to known cellular processes including 
squamous differentiation (13 genes), cellular 
proliferation (10), invasion (7), inÁammation (6), 
cell-cell adhesion (5), angiogenesis (3) and apoptosis 
(2). Although 3 of the 5 upregulated genes in 
the adhesion group promote cell-cell interaction, 
within the rest of these groups the majority or all 
of the genes are modulated in a manner that would 
be expected to promote malignant progression. 
Group 1 also showed 896 differentially expressed 
genes compared to group 4. Except for 3 genes 
differentially expressed when comparing groups 
3 and 4, no signiÀcant changes were seen in other 
comparisons. 
Conclusion: Gene expression analyses identiÀed 
several alterations that distinguish persistent BD 
from regressive lesions. The genes identiÀed in this 
analysis could provide needed prognostic markers of 
risk for progression and indicate potential targets for 
chemoprevention in high risk patients. 
Keywords: Bronchial dysplasia, Persistence, gene 
expression
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P2.253 REG FAMILY GENES 
EXPRESSION IN LUNG CANCER
Takashi Tojo1, Hiroshi Naito1, Michitaka Kimura1, 
Takeshi Kawaguchi1, Shin Takasawa2, Asako Itaya-
Hironaka2, Yoshiko Dohi2, Shigeki Taniguchi1 
1Department Of Thoracic And Cardiovascular 
Surgery, Nara Medical University School Of 
Medicine/Japan, 2Department Of Biochemistry, Nara 
Medical University School Of Medicine/Japan
Background: Regenerating gene (REG) was 
originally discovered as a gene which related in 
regeneration of pancreatic ß-cells. REG family genes 
(REG IƠ, REG Iß, REG III, HIP/PAP, and REG IV) 
encode growth factor family, and they are involved 
not only in regeneration of damaged tissues but also 
in tumor growth of gastrointestinal cancer cells. In 
the present study, we investigated expressions and 
effects of REG family genes in non-small cell lung 
cancer in vivo and in vitro.
Methods: We enrolled 47 lung adenocarcinoma 
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ADC, measurement of FF, identiÀcation of EMT 
markers, and qualitative and quantitative assessment 
of tumor immune responses need to be examined 
further in a larger group of resected early stage ADC 
for possible prognostic signiÀcance.
Keywords: Àbrotic focus, Adenocarcinoma, 
morphologic subtyping
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P2.255 USE OF A CONTINUOUS 
EGFR IHC SCORING METHOD IN 
NSCLC: FEASIBILITY IN A GENERAL 
PATHOLOGY DEPARTMENT AND 
RELATIONSHIP TO EGFR FISH
Paul Mitchell1, Carmel Murone2, Simon Knight3, 
Thomas John4, Faye Putt1, Adrienne Morey5 
1Joint Austin-ludwig Medical Oncology Unit, 
Austin Health/Australia, 2Pathology, Austin Health/
Australia, 3Thoracic Surgery Dept, Austin Health/
Australia, 4Melbourne Centre For Clinical Sciences, 
Ludwig Institute For Cancer Research/Australia, 5St 
Vincent’s Hospital/Australia
Background: Using a continuous Epidermal Growth 
Factor Receptor (EGFR) immunohistochemistry 
(IHC) scoring method, high EGFR expression 
levels were predictive of high response rate and 
patient beneÀt from the addition of cetuximab to 
chemotherapy in the FLEX trial (O’Byrne K et al. 
JTO 2010; 5(12), LBOA1). We investigated whether 
this scoring method was feasible in a general 
pathology department and related IHC scores to 
patient and tumour characteristics and EGFR FISH 
analysis. 
Methods: Triplicate FFPE samples of resected 
primary NSCLC tumours were prepared as tissue 
arrays. The FDA approved Dako PharmDX kit was 
used for IHC detection of EGFR expression by a 
senior laboratory scientist skilled in IHC. Expression 
levels were determined via a continuous scoring 
system based on membrane staining intensity (0, 1+, 
2+, 3+) and percentage of positive tumour cells. The 
score was calculated as (% 1+ x 1) + (% 2+ x 2) + 
(% 3+ x 3), with possible scores of 0 (no staining) to 
300 (strong staining all cells). The mean of triplicate 
States Of America, 2Hematolog/oncology/bmt, 
Rush University Medical Center/United States Of 
America, 3Biochemistry, Rush University Medical 
Center/United States Of America, 4Medicine, 
Northshore University Healthsystem/university Of 
Chicago/United States Of America
Background: Lung adenocarcinoma (ADC) has 
variegated histology and diverse clinical behavior. 
The 2011 IASLC classiÀcation of lung ADC 
recognizes distinctive architectural subtypes but 
cytological features and tumor stromal responses 
may be particularly useful for prognosis. The 
predictive value of these features in relation to 
erlotinib treatment is unknown. The objectives were 
to develop a tool for detailed morphologic proÀling 
of ADC and to identify potential features related 
to outcome in a cohort of patients (pts) with ADC 
treated with erlotinib following progression.
Methods: This was a retrospective study of ADC 
from pts who initially underwent resection and 
then were treated with erlotinib following disease 
progression (N=51). Subtyping of resected ADC 
using morphometric proÀling (Okudela 2008). 
Tumor-associated Àbrotic focus (FF) and lymphoid 
responses (TALR) were graded on H&E sections 
as prominent vs mild/none. The log-rank test was 
used to compare selected morphologic parameters 
for their effects on overall (OS) and progression-free 
survival (PFS).
Results: 51 pts included 29 females, 8 never 
smokers. ADC with prominent FF (N=33) showed 
a signiÀcant difference for improved PFS (p=0.002) 
compared with those without (N=5), but there was 
no difference in OS. No signiÀcant differences in 
survival were found between mixed vs pure ADC 
types, mixed type with solid pattern vs without, 
mixed subtype with high columnar cell type vs 
without, and prominent TALR vs. none.
Conclusion: This is a small, retrospective study 
but our data show that prominent FF is related to 
improved PFS in resected ADC pts treated with 
erlotinib upon progression. This was unexpected 
given the association of FF with poor outcomes in 
breast cancer. This suggests that FF in lung ADC 
may identify tumors with a favorable prognosis 
but does not appear to be associated with response 
to erlotinib following progression. These data also 
suggest that mixed subtype ADC, solid pattern 
component, variations in tumor cytology and TIR 
may not be signiÀcant for PFS or OS in early stage 
resectable pts. Detailed morphologic subtyping of 
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P2.256 EGFR AND KRAS MUTATIONAL 
PROFILING IN FRESH NSCLC CELLS
Giulia M. Stella1, Simona Inghilleri1, Roberta 
Scabini1, Francesca Cemmi1, Patrizia Morbini2, 
Ernesto Pozzi1, Roberto Dore3, Maurizio Luisetti1, 
Michele Zorzetto1 
1Pneumology, Irccs Policlinico San Matteo/Italy, 
2Pathology Unit, Irccs Policlinico San Matteo/Italy, 
3Radiology, Irccs Policlinico San Matteo/Italy
Background: Correlation between mutations in 
cancer alleles and drug response is a crucial point 
to identify drugs or drug combinations that match 
the genetic proÀle of individual tumors. In NSCLC 
genetic lesions affecting EGFR pathway act as 
predictive markers of response to EGFR inhibitors. 
Inappropriate EGFR phosphorylation is mainly 
consequent to somatic mutations in receptor tyrosine 
kinase (TK) domain. Incidence of EGFR mutations 
is about 77% among erlotinib/geÀtinb responders 
while it is < 7% in unsensitive cases; mutations are 
more frequent in adenocarcinomas (ADK) aroused 
in not smokers and females. Downstream KRAS 
mutations are highly speciÀc negative predictors of 
response to single agent EGFR inhibitors
Methods: We planned to evaluate in a cohort of 
NSCLC patients the EGFR and KRAS mutations 
prevalence by analyzing tumor cells directly obtained 
through CT-guided trans-thoracic biopsy, which 
represents a proper diagnostic tool for peripheral 
lesions, such as ADKs - actually accounting for 40% 
of all NSCLC diagnosis. Importantly this procedure 
allows acquisition of samples enriched by cancer 
cells captured through CT Áuoroscopic guidance. 
Results: In an ongoing study we have till now 
evaluated 134 cases, 88 males and 46 females 
(mean age = 67 years). 62.9% of them are smokers. 
We found EGFR somatic mutations in 13 (9.7%) 
patients affected by ADK, of them 7 were females 
and 11 never or former smokers. KRAS mutations 
occurred in 20 (5,95%) patients (F:M=3:2), 3 
affected by ADK and 2 by squamous cell (SCC) 
cancer. As expected EGFR and KRAS mutations 
are mutually exclusive. Results have been validated 
by performing the same analysis on corresponding 
parafÀn-embedded samples and obtaining the same 
mutational results. Clinical response of patients 
treated with erlotinib will be also presented. 
Conclusion: Mutational screening on fresh cancer 
specimens was calculated. EGFR FISH was carried 
out on the same tissue array samples. 
Results: Tissue arrays were from tumours resected 
from 403 patients over the period 1992-2008. Patient 
and disease characteristics were: median age 68 yrs 
(range 22 - 102); male 282 pts (70%); TNM – T
1-2
N
0
 
344 pts (85.4%), T
1-3
N
1
 56 pts (13.9%) and T
1-2
N
2
 
3 pts; smoking – never smoked 26 pts (6.5%), light 
smoking (10 pack years ceased  10 yrs) 9 pts 
(2.2%); histology included adenocarcinoma 181 pts 
(44.9%), squamous cell 142 pts (35.2%) and large 
cell / LC neuroendocrine 36 pts (8.9%); 5yr survival 
was 53% (Kaplan-Meier). Low EGFR expression 
(0-199) was scored for 264 patients and high (200-
300) for 139 patients (34.5%), similar to the 31% 
high EGFR expression for FLEX trial patients 
(O’Byrne et al). High EGFR expression was more 
frequent with squamous cell than adenocarcinoma 
tumours (54% vs 23% respectively, p<0.001), 
and trended more frequent in heavy smokers than 
never or light smokers (35% vs 20%, p=0.14 NS). 
Survival over the 5 years following resection was 
worse for patients with high EGFR expression 
(further analysis will be presented). Overall 87 
cases (21.5%) were positive on EGFR FISH: 11 
and 15 patients showed high and low ampliÀcation 
respectively, 15 polysomy and 46 ‘Colorado criteria’ 
(4 copies in  40% cells). Nine cases (6.5%) of 
EGFR high ampliÀcation were seen with high EGFR 
IHC scores compared with 2 cases (0.8%) with low 
scores. Overall there were 41 FISH positive (15.8%) 
amongst low IHC score cases and 41 positive 
(29.9%) amongst high IHC score cases (p=0.0015). 
Conclusion: This EGFR IHC scoring system was 
feasible in a general pathology department. The 
proportion with high expression was similar in our 
early stage patients to that seen for patients in the 
FLEX trial, who were treated for advanced disease. 
As expected, high expression was more frequent in 
squamous cell carcinomas. Positive EGFR FISH 
was signiÀcantly associated with high EGFR IHC 
expression although the overall proportion of cases 
with FISH positive tumours was low. 
Keywords: predictive factors, EGFR IHC, EGFR 
FISH, NSCLC 
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partial response for 8 months, including complete 
resolution of his liver disease. Nine pts had disease 
stabilization (SD) over multiple cycles, including 
2 patients with SD for 14 months and 16 months 
respectively. Of 45 detectable methylation events, 30 
(66%) showed decreasing methylation detectablity. 
No patient (0%) responded to therapy if methylation 
was unable to be detected at baseline. Of the 17 
patients with two or more methylated genes, 8/17 
(47%) showed demethylation at all detectable loci 
on day 29. Of these 8 patients, 6 (75%) met RECIST 
criteria of SD (n=6), PR (n=1), or CR (n=1).
Conclusion: The combination of 5AC and entinostat 
is safe and well tolerated in advanced NSCLC 
patients. Durable patient beneÀt was observed in this 
extensively pretreated population, including major 
objective responses. qMSP of plasma CNAs show 
that patients with more methylated alleles and who 
show decreasing methylation have a high probability 
of clinical beneÀt, while patients without detectable 
methylation in plasma samples derived no clinical 
advantage. Overall decreasing levels of methylation 
and lack of beneÀt to any with no detectable 
methylation support the putative pharmacodynamic 
mechanism of action of epigenetic therapy.
Keywords: Biomarkers, epigenetics, methylation, 
Lung cancer
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P2.258 SERUM BIOMARKERS FOR 
APOPTOSIS HAVE VALUE FOR 
PROGNOSTICATING PROGRESSION-
FREE AND OVERALL OUTCOMES IN 
ADVANCED NSCLC.
Jeffrey A. Borgia1, Reem Karmali2, Mary J. Fidler3, 
Sanjib Basu4, Brett Mahon5, Omid Rouhi1, David D. 
Shersher6, Cristina Fhied7, Philip Bonomi3 
cells is an achievable, safe and cost-effective 
procedure that could be easily integrated to 
conventional histopathological
Keyword: mutations, fresh cancer cells
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P2.257 BIOMARKER DEVELOPMENT 
FOR A PHASE II STUDY OF 
COMBINATION EPIGENETIC THERAPY 
IN ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
John M. Wrangle1, Rosalyn A. Juergens1, Frank 
Vendetti1, Barbara Coleman1, Rosa Sebree1, Michelle 
Rudek1, James Herman1, Charles Rudin1, Malcolm V. 
Brock2 
1Medical Oncology, Johns Hopkins School Of 
Medicine/United States Of America, 2Surgery, Johns 
Hopkins University/United States Of America
Background: Epigenetic gene silencing is an 
important contributor to carcinogenesis. Pre-clinical 
studies suggest that combined inhibition of DNA 
methyltransferase and histone deacetylase activity can 
synergistically re-express aberrantly silenced genes. 
A trial employing the combination of 5-azacitidine 
(5AC) and entinostat was performed for patients with 
advanced non-small-cell lung cancer (NSCLC). DNA 
in circulation was analyzed for hypermethylation of 
genes known to be critical in NSCLC tumorigenesis.
Methods: Patients with recurrent, metastatic NSCLC 
having received at least 1 prior chemotherapy 
regimen were given 5AC 40 mg/m2 SQ days 1-6 
and 8-10, and entinostat 7 mg days 3 and 10, on 
a 28 day cycle. Plasma samples were collected 
prior to treatment and 28 days later. Single-stage, 
quantitative-methylation-speciÀc PCR (qMSP) 
was performed on circulating nucleic acids (CNA) 
extracted from plasma for the promoter regions of 
APC, HCAD, and RASSF1A and normalized to 
circulating Beta-Actin. Patients were considered to 
have a positive methylation signature if at least 2 of 
the 3 genes assayed were methylated and showed 
decreasing detectability at day 29.
Results: 27 patients with a median of 3 prior 
therapies had both pretreatment and posttreatment 
plasma available. Median overall survival was 8 
months. A complete response was observed in a 
patient with 3 prior therapies. A second patient with 
3 prior therapies and metastases to the liver had a 
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associated with improved outcome (e.g. IL-6: PFS 
- 3.91 vs. 1.74 months, p=0.00048; OS - 10.78 vs. 
4.44 months, p=0.00012). Interestingly, although 
insulin-like growth factors 1 and 2 (IGF-I, IGF-II) 
are classically protective against apoptosis, here 
increased levels of these factors strongly-correlated 
with better survival outcomes. One possible 
explanation for these Àndings is the sequestration 
of circulating IGFs through speciÀc IGF-binding 
proteins, which high circulating levels were also 
observed to be positively-associated with outcome 
(e.g. high IGFBP-3: PFS – 3.68 vs. 5.82 months, 
p=0.0087; OS – 10.5 vs. 32.8 months, p=0.0012). 
Increased expression of the anti-apoptotic tumor 
growth factor–alpha (TGF-Ơ), vascular endothelial 
growth factor (VEGF) and receptors (VEGFRs 
1-3) and Àbroblast growth factor-2 (FGF-2) had 
no survival correlation, but low levels of FasL 
predicted poor OS in the erlotinib group alone. 
Matrix metalloproteinases (MMPs) -7 and -10 
strongly-correlated with improved PFS and OS; low-
levels of MMP-9 were associated with improved 
OS (p=0.0026). Surprisingly, MMP-2, the MMP 
commonly associated with increased metastatic 
potential, was expressed at higher levels in patients 
with favorable clinical outcomes. 
Conclusion: This study used a functional pathway 
strategy to identify candidate apoptosis-related 
biomarkers for classifying advanced NSCLC patients 
according to outcome. Statistical signiÀcance for 
prognosticating outcome was observed by several 
candidate biomarker families, which include 
biomarkers related to TNF-Ơ, IL-6, IGF-I, and 
MMPs, to name a few. Our efforts are currently 
focused on further examinations of the biological 
and clinical signiÀcance of these Àndings in relation 
to our goal of developing a serum ‘EMT-biomarker’ 
panel to help individualize treatment selection for 
advanced NSCLC. 
Keywords: apoptosis, EMT, Serum Biomarkers, 
NSCLC
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Background: Dysregulation of programmed cell 
death, or apoptosis, is implicated in the progression 
of an epithelial-to-mesenchymal transition (EMT) in 
NSCLC and other carcinomas, creating a permissive 
environment for uncontrolled cellular proliferation 
and genetic instability. Despite advancements 
in therapeutic options, this process may confer 
resistance to cytotoxic therapy and/or radiation, 
potentially impacting cancer survival outcomes. In 
this study we examine whether serum biomarkers 
of the apoptosis functional pathway correlate with 
clinical outcome in advanced NSCLC. 
Methods: Luminex-based immunoassays were 
used to evaluate circulating levels of 27 circulating 
protein biomarkers implicated in the regulation 
of apoptosis by the KEGG (Kyoto Encyclopedia 
of Genes and Genomes) pathways database. Sera 
were collected from 146 patients with stage III or 
IV NSCLC patients immediately prior to treatment 
initiation. Treatment groups consist of front-line 
platinum-based chemotherapy (n=43), second-line or 
greater cytotoxic chemotherapy (n=30), or erlotinib 
(n=73). Disease progression was measured using 
RECIST criteria. Differences in progression-free- 
(PFS) and overall-survival (OS) was assessed by 
log-rank test and Kaplan-Meier estimates using the 
R statistical software package. The p-values reported 
are two-sided with p-values  0.01, 0.01-0.05, and 
0.05-0.10 reported as strongly-signiÀcant, signiÀcant 
and marginally-signiÀcant (respectively). 
Results: Low levels of the pro-apoptotic ‘tumor-
necrosis factor’ family of proteins, including 
sFas, tumor necrosis factor–alpha (TNF-Ơ) and its 
receptors (sTNF-RI, sTNF-RII), and high levels of 
TNF-related apoptosis inducing ligand (TRAIL) 
were all strongly associated with favorable PFS 
and OS in all patients. As expected, low levels 
of anti-apoptotic interleukin-6 (IL-6) and soluble 
IL-6 receptors (sIL-6R and sgp130) were also 
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these two molecular features will be presented.
Conclusion: There is a signiÀcant correlation 
between MET protein expression and MET gene 
copy number in NSCLC, but neither are associated 
with clinical variables or prognosis. Both markers 
may be considered for patient selection to MET 
inhibitors and their predictive value for this therapy 
should be assessed in prospective clinical studies.
Keywords: MET, gene copy number, 
immunohistochemistry, silver in-situ hybridization
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P2.260 STUDY OF PHARMACOKINETIC 
AND PHARMACOGENOMIC 
CHARACTERISTICS IN PATIENTS WITH 
ADVANCED NSCLC TREATED WITH 
ERLOTINIB
Marcello Tiseo1, Roberta Andreoli2, Francesco 
Gelsomino1, Paola Mozzoni2, Cinzia Azzoni3, Marco 
Bartolotti1, Beatrice Bortesi1, Enrico Maria Silini3, 
Antonio Mutti2, Andrea Ardizzoni1 
1Medical Oncology Unit, University Hospital Of 
Parma/Italy, 2Laboratory Of Industrial Toxicology, 
Department Of Clinical Medicine, Nephrology 
And Health Sciences, University Of Parma/Italy, 
3Anatomia Patologica, University Hospital Of 
Parma/Italy
Background: A strong but unexplained association 
between toxicity and outcome has been noted for 
patients given Erlotinib in lung cancer. Several 
potential explanations have been suggested, 
including pharmacokinetic and pharmacogenomic 
variability.The purpose of this study was to better 
characterize Erlotinib pharmacokinetics in patients 
with advanced NSCLC and to relate Erlotinib 
plasma and urine concentrations to toxicity, 
activity and clinical and molecular (i.e speciÀc 
DNA polymorphisms and EGFR gene mutations) 
characteristics. 
Methods: Pre-treated patients with advanced 
NSCLC consecutively treated with Erlotinib in 
Medical Oncology Unit of Parma from 2008 to 
2010 were enrolled. Relative biological materials 
(blood, urine and cytological/tissue specimens) 
were collected. Erlotinib levels in spot serum and 
urine samples of all the patients after 7 (T1) and 30 
(T2) days of treatment were quantiÀed by LC-MS/
MS analysis, carried out on an AB-Sciex API 4000 
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P2.259 CORRELATION BETWEEN 
MET GENE COPY NUMBER BY 
SILVER IN SITU HYBRIDIZATION 
AND PROTEIN EXPRESSION BY 
IMMUNOHISTOCHEMISTRY IN NON-
SMALL-CELL LUNG CANCER
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Singh3, Bernadette G. Reyna Asuncion2, James 
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Hirsch2 
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Denver/United States Of America, 3Ventana Medical 
Systems/United States Of America, 4Department Of 
Thoracic Surgery, Medical University Of Gdansk/
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Background: MET is a receptor implicated in the 
pathogenesis and progression of non-small-cell lung 
cancer (NSCLC). Clinical trials with MET inhibitors 
in NSCLC are ongoing or planned with patient 
selection based on immunohistochemistry (IHC) 
and/or gene copy number assessment, therefore 
detailed understanding of relationship between these 
markers is essential.
Methods: Primary tumors from 189 NSCLC 
patients who underwent pulmonary resection 
(median follow-up of 5.3 years) were included in 
this study. MET expression was evaluated by IHC 
on tissue microarray and scored according to hybrid 
(H) score (range: 0-400). MET gene copy number 
was assessed by silver in-situ hybridization (SISH, 
N=140 patients).
Results: Median MET IHC score was 60 (range: 
0-400; N=174). There were no associations between 
clinical and pathological characteristics, disease-
free or overall survival according to median value 
(P=0.36 and P=0.38, respectively) or other cut-off 
points. Of the 140 tumors evaluable for MET copy 
number, three (2.1%) showed gene ampliÀcation and 
14 (10%) had an average of 5 or more copies per 
nucleus. There were no associations of MET copy 
number with clinico-pathological features, disease-
free or overall survival with any analyzed cut-off 
points. Correlation between MET copy number and 
protein expression was signiÀcant (Pearson’s r=0.42, 
P<0.0001) and detailed analysis of the distribution of 
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P2.261 ERBB3 EXPRESSION ASSESSED 
BY IMMUNOHISTOCHEMISTRY (IHC) 
IN NON-SMALL CELL LUNG CANCER 
(NSCLC) TUMORS WITH EGFR 
MUTATION, BEFORE EGFR-TYROSINE-
KINASE INHIBITOR (EGFR-TKI) 
EXPOSURE
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Murtra-Garrell1, Victor Freixinos1, Maite Salcedo2, 
Natalia Tallada2, Cristina Teixido2, Pablo Martinez1, 
Susana Cedrés1, Eva Lopez3, Anastasio Pandiella4, 
Santiago Ramón Y. Cajal2 
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Background: Although most NSCLC patients (p) 
with EGFR mutation initially respond to EGFR-
TKIs, the vast majority of these tumors ultimately 
become resistant to this treatment. One of the 
resistance mechanisms is the MET ampliÀcation by 
activating ErbB3 signaling. The aim of this study is 
to determine baseline ErbB3 expression in EGFR-
mutated tumors before EGFR-TKI exposure. 
Methods: We assessed ErbB3 expression by IHC 
in the pre-treatment samples from p with activating 
EGFR mutation screened in our center; expression 
was graded by two independent observers and 
tumors with a 2+/3+ score were classiÀed as “high 
expression”. 
Results: 31 p with EGFR mutation were identiÀed: 
median age 63 yrs, 25 female, 15 PS 0, 21 never-
smoker, 30 ADC/ 1 NOS, 14 del exon 19/ 17 L858R 
exon 21, 18 stage IIIB-IV. 22 p received erlotinib 
for advanced disease, 16 as 1st line and 6 as 2nd line. 
Survival outcomes for p receiving erlotinib were: 
median progression-free survival (PFS) 9 months 
(mo) and median overall survival (OS) 26 mo. 
Survival outcomes were similar in patients receiving 
erlotinib as 1st line or as 2nd line. In 21 of 31 EGFR-
mutated p, determination of ErbB3 expression was 
feasible. High ErbB3 membranous and cytoplasmic 
expression was found in 9 (29%), and 11 (35%) 
samples, respectively, with 6 (19%) of samples 
having high expression at both sites. No correlation 
was found between ErbB3 expression and age, sex, 
PS, smoking history, type of mutation or stage. 
triple quadrupole mass spectrometer. Moreover, 
the metabolic phenotype of the main enzymes 
involved in Erlotinib metabolism (CYP3A4, 
CYP1A2 and CYP1A1), by the determination of the 
6ơ-hydroxycortisol/cortisol ratio, and EGFR gene 
status were determined.
Results: 56 patients with stage IV NSCLC who 
received Erlotinib (orally 150 mg/day) in 2nd- or 
3rd-line treatment were recruited. The main patient 
characteristics were: 21 (37%) males, with age mean 
65.6 ± 9.20; 24 (43%) patients were non-smokers, 
21 (37%) ex-smokers and 11 (20%) still smokers. 
43 (78%) had adenocarcinoma, 6 (10%) squamous 
cell carcinoma and 7 (12%) not-otherwise speciÀed 
NSCLC histotype. At T1 and in all the patients, 
Erlotinib levels, expressed as geometric means 
and geometric standard deviation, were 3.66 [2.17] 
ƫmol/l e 0.39 [3.07] ƫmol/mol creat in serum and 
urinary samples, respectively. At T2 the serum and 
urine amounts were signiÀcantly lower, 2.02 [4.05] 
ƫmol/l e 0.23 [4.47] ƫmol/mol creat, respectively. 
Serum and urinary drug concentrations were 
signiÀcant correlated both at T1 (r Pearson = 0.317, 
p = 0.017) and at T2 (r Pearson = 0.659, p < 0.0001). 
Patients who showed Grade 3-4 toxicity, received a 
dose reduction (from 150 to 100 mg/day) after T1. 
Higher Erlotinib levels were detected in patients 
with drug reduction, both in serum and urinary 
samples, and at each sampling times. Even if the 
urinary 6ơ-hydroxycortisol/cortisol ratio, metabolic 
phenotype of CYP3A4 activity, was not statistically 
different at T1 and T2, it was interesting to note 
that a negative correlation between serum Erlotinib 
levels and the 6ơ-hydroxycortisol/cortisol ratio was 
observed, only in the patients with dose reduction. In 
particular, at T1 the Pearson correlation coefÀcient 
was - 0.67 (p = 0.012) and at T2 was -0.76 (p = 
0.011), respectively. 
Conclusion: Our preliminary Àndings suggest that 
the pharmacokinetic and the metabolism of Erlotinib 
may be involved in its toxicity. The correlations with 
activity and clinical/molecular characteristics will be 
presented at the meeting. 
Keywords: pharmacokinetic, pharmacogenomic, 
erlotinib, NSCLC
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with response measured by RECIST in patients with 
advanced NSCLC receiving only Àrst or second 
line chemotherapy was performed. CEA levels were 
measured at baseline and after every two treatment 
cycles; comparison with objective response and its 
correlation to both progression free-survival (PFS) 
and overall survival (OS) was made. Protocol was 
approved by Institutional Boards.
Results: 183 (42.9%) of 426 patients had a baseline 
CEA serum level >10ng/ml (Median 60 ng/ml; 
range 10-7,440ng/ml). Treatment was platinum-
based chemotherapy in 123 (67.2%) patients, single 
agent chemotherapy in 48 (26.2) and a tyrosine 
kinase inhibitor (TKI) in 12 patients (6.6%). 
The mean follow-up time was 11.8 ±8.4 months. 
Objective global response, stable disease and disease 
progression were 28.3, 49.4 and 22.2%; respectively. 
Patients with global response had a reduction of CEA 
levels of 55.6% approximately (95%CI 64.3 to 46.8); 
while patients with stable disease or progressive 
disease had an increase of 9.4% (95%CI 1.5 to 
17.3) and 87.5% (95%CI 60.9-114); respectively 
(p<0.001). The ROC curve analysis for the changes 
in CEA levels in responsive patients, had an area 
under the curve (AUC) of 0.945 (95%CI 0.91-.0.99) 
Sensitivity and speciÀcity were of 90.2 and 89.9%, 
respectively, for a CEA level reduction of 14% 
or greater. AUC in progressive disease was 0.911 
(95%CI 0.86-.0.961) with sensitivity and speciÀcity 
of 85 and 15% - respectively - for a CEA level 
increase of 18% from baseline. PFS was longer in 
patients with a 14% reduction in CEA (8.7 months 
[CI 95% 8.4-9] vs 5.1 months [4.5-5.8], p<0.001). 
Neither reduction of CEA (p=0.48) nor objective 
response measured by RECIST (p=0.28) were 
predictive of OS.
 
Conclusion: A CEA level reduction is both a 
sensitive and speciÀc marker of objective response; 
as well as a sensitive marker for progression to 
chemotherapy in advanced NSCLC. A decrease of 
14% in CEA levels is associated to better PFS but 
not OS in advanced NSCLC.
Keywords: NSCLC, carcinoembryonic antigen, 
Response, progression free survival
When we analyzed the group of 14 p with advanced 
disease treated with erlotinib for whom we also had 
the ErbB3 expression determination, we found no 
association between ErbB3 expression and PFS or 
OS. 
Conclusion: In our experience, high ErbB3 
expression assessed by IHC in EGFR-mutated 
tumors previous to EGFR-TKI exposure is frequent. 
ErbB3 warrants further study in pre-treatment 
biopsies from EGFR-mutated tumors to clarify its 
role and its potential use as therapeutic target. 
Keywords: EGFR mutation, ErbB3
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P2.262 USEFULNESS OF SERUM 
CARCINOEMBRYONIC ANTIGEN 
(CEA) MONITORING TO DEFINE 
RESPONSE OR PROGRESSION 
TO CHEMOTHERAPY AND ITS 
CORRELATION WITH SURVIVAL IN 
PATIENTS WITH ADVANCED NON 
SMALL-CELL LUNG CANCER: A 
PROSPECTIVE COHORT STUDY
Oscar Arrieta1, Marcelino Morales1, Yuzmiren 
Dorantes-Gallareta2, Omar Peña2, Luis Martínez-
Barrera3, Daniela Morales-Espinosa4, Jaime De La 
Garza5 
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De Enfermedades Respiratorias/Mexico, 4Cancer 
Center, Medica Sur Foundation And Clinic/Mexico, 
5Clinical Research Department, Instituto Nacional 
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Background: Nowadays, there are no 
satisfactory markers to predict objective response 
to chemotherapy in Non Small-Cell Lung 
Cancer (NSCLC). Carcinoembryonic antigen 
(CEA) is an oncofetal protein attached to the 
epithelial-cell apical membrane via its c-terminal 
glycosyphospatidylinositol anchor; it is often over-
expressed in NSCLC. High serum CEA levels are 
an independent prognostic factor for recurrence 
and survival in patients with NSCLC. Its role as a 
predictive marker has not been widely characterized.
Methods: A prospective evaluation of the 
relationship between changes in serum CEA levels 
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Results: 95 patients (WCMC: 70, AH: 25) were 
studied. Staining for one or more CTAgs was 
positive in 50% of samples regardless of histology. 
NY-ESO-1 was expressed in 32 (33%) samples. 
DNA was successfully isolated from 88 samples. 
Mutations were seen predominantly in the EGFR 
(5/95) and KRAS (10/95) genes, although P53, 
BRAF and NRAS mutations were also seen. CTAg 
expression occurred independent to KRAS mutant 
tumors. NY-ESO-1 expression occurred independent 
to EGFR and KRAS mutations and was signiÀcantly 
associated with chemosensitivity in both datasets 
(Chi square p=0.010). Improved OS was only seen 
in the AH dataset (HR 0.36; 95% CI 0.14-0.96, 
p=0.04).
Conclusion: Expression of NY-ESO-1 predicts 
response to neoadjuvant chemotherapy in stage 
3A NSCLC. Expression was independent to 
common mutations and in both adenocarcinoma 
and squamous cell carcinoma, suggesting that 
these antigens may represent molecules in alternate 
oncogenic pathways. Given the immunogenicity of 
these antigens, chemotherapy induced cellular lysis 
may have triggered an immunological response to 
the tumor. Mechanisms for these Àndings are being 
investigated in the pre and post-operative sera taken 
from these patients.
Keywords: NY-ESO-1, CT antigens, neoadjuvant 
chemotherapy, chemosensitivity
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P2.264 UNIQUE BRCA1, ERCC1 
AND TYMS MRNA PROFILES MAY 
BE RELATED TO NSCLC PATIENT 
OUTCOME ACCORDING TO DISEASE 
STAGE.
Vassiliki Kotoula, V. Karavasilis, A. G. Eleftheraki, 
D. Televantou, K. Papadopoulou, E. Charalambous, 
I. Korantzis, S. Dimoudis, D. Dionysopoulos, 
Epaminondas Samantas, G. Papaxoinis, 
Dimosthenis-Vassilios Skarlos, D. Pectasides, Paris 
A. Kosmidis, G. Fountzilas 
Data OfÀce, Hellenic Cooperative Oncology Group/
Greece
Background: BRCA1, ERCC1 and TYMS 
expression has been individually associated with 
patient outcome upon single chemotherapeutic 
agents; the fact is, however, that these agents are 
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P2.263 NY-ESO-1 AS A PREDICTIVE 
MARKER IN STAGE 3A PATIENTS 
UNDERGOING NEOADJUVANT 
CHEMOTHERAPY FOR NON SMALL 
CELL LUNG CANCER (NSCLC)
Thomas John1, Yao-Tseng Chen2, Maud H. 
Starmans3, Marzena Walkiewicz4, Prudence A. 
Russell5, Arun Azad4, Siddhartha Deb4, Paul C. 
Boutros6, Nasser Altorki7, Jonathan S. Cebon4, Paul 
Mitchell1 
1Medical Oncology, Austin Health/ludwig Institute 
For Cancer Research/Australia, 2Weill Cornell 
Medical Center/United States Of America, 
3Maastricht University/Netherlands, 4Cancer Vaccine 
Laboratory, Ludwig Institute For Cancer Research/
Australia, 5Department Of Anatomical Pathology, St 
Vincent’s Hospital/Australia, 6Ontario Institute For 
Cancer Research/Canada, 7Cardiothoracic Surgery, 
Weill Cornell Medical Center/United States Of 
America
Background: The use of neoadjuvant chemotherapy 
in Stage 3A NSCLC is controversial with trials 
consistently failing to demonstrate a signiÀcant 
beneÀt. The ability to identify patients with 
chemoresponsive disease should aid clinical trial 
design and outcome. Cancer-Testis antigens (CTAg), 
such as MAGE A3, are currently being investigated 
as immunotherapeutic targets in the adjuvant 
setting. CTAgs are expressed in over 50% of both 
squamous cell and adenocarcinomas but restricted 
to testis in normal tissues. Since CTAgs have been 
proposed as markers of drug-resistant stem-like 
cells, we investigated the relationship between their 
expression and chemosensitivity.
Methods: Stage 3A patients treated with 
neoadjuvant chemotherapy at the Austin Hospital 
(AH), Melbourne and Weill Cornell Medical 
College (WCMC) New York were investigated. 
Preoperative mediastinal lymphadenectomy tissues 
were stained for a panel of CTAgs including NY-
ESO-1, MAGE-A, MAGE-C1/CT7, GAGE and 
CT45 by immunohistochemistry. DNA was isolated 
from parafÀn sections and subjected to mutation 
proÀling using Sequenom’s MassArray platform. 
Molecular results were correlated to baseline clinical 
characteristics, chemoresponsiveness (deÀned 
as pathological down-staging of TNM status), 
progression free and overall survival (OS).
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combinations (PFS, p=0.001; OS, p=0.033). 
However, in the adjuvant setting, where practically 
all patients had received platinum/taxanes, the same 
proÀle was again associated with shorter DFS and 
OS (p=0.021 and p=0.008, respectively). 
Conclusion: This study shows that, when assessed 
in combination, BRCA1/ERCC1/TYMS mRNA 
expression in tumors, as compared to non-cancerous 
lung tissues, is related to NSCLC patient outcome 
and to the effect of platinum/taxane treatment, in the 
case of ERCC1/TYMS. The impact of such proÀles 
seems to be disease stage speciÀc, since it appears 
inversed in the adjuvant and in the 1st line setting, 
even for the same chemotherapeutic combination. 
Keywords: platinum, taxanes, gene expression 
proÀling, NSCLC
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P2.265 IN VIVO ISOLATION OF 
CIRCULATING LUNG CANCER CELLS 
- A PRELIMINARY REPORT -
Tatiana Tomasi1, Nadia Zeni1, Lukasz Gasiorowski2, 
Phillip Kim3, Sharat Singh3, Arndt Schmitz4, 
Thomas Krahn4, Grzegorz Dworacki2, Wojciech 
Dyszkiewicz2, Klaus Luecke5 
1Gilupi Gmbh/Germany, 2Poznan University Of 
Medical Science/Poland, 3Prometheus Therapeutics 
& Diagnostics/United States Of America, 4Bayer 
Schering Pharma AG/Germany, 5Cancer, Gilupi 
GmbH/Germany
Background: Circulating tumor cells (CTCs) in 
the bloodstream of lung cancer patients provide a 
source for early detection, prognosis, and therapy 
monitoring. Currently, CTCs are mostly isolated in 
vitro from small volumes of patient blood samples. 
In order to increase the sensitivity of the CTCs 
detection in the peripheral blood GILUPI has 
developed a novel in vivo method, the functionalized 
and structured medical wire (FSMW) for an in vivo 
application, which enables the capture of CTCs from 
the patient´s blood stream with a higher sensitivity 
and efÀcacy than existing methods. Enumeration and 
characterization of those CTC will serve to improve 
and monitor clinical cancer early detection and 
treatment.
Methods: The interaction of target CTC with the 
FSMW is mediated by an antibody directed against 
the epithelial cell adhesion molecule (EpCAM). 
usually given in combination. The aim of this study 
was to (a) understand variations in the expression 
of BRCA1, ERCC1 and TYMS in tumors in 
comparison to the non-cancerous lung, and (b) to 
develop mRNA expression proÀles that might be 
applicable for the assessment of NSCLC patients in 
all stages of disease. 
Methods: Relative mRNA expression of BRCA1, 
ERCC1 and TYMS was evaluated with qRT-PCR in 
a group of matched NSCLC tumor/non-cancerous 
lung samples (N=35) prepared from formalin-Àxed 
parafÀn-embedded tissues (FFPE), (test group 1). 
Samples were characterized as expressing normal 
(within a range of relative quantiÀcation [RQ] values 
allowing for a 10-fold difference of gene expression 
in non-cancerous lung samples) or deviating from 
normal transcript levels (RQ values outside this 
range) of BRCA1, ERCC1, RRM1 and TYMS. This 
classiÀcation of gene expression was considered 
necessary because in the majority of cases all genes 
deviating from normal appeared upregulated; the 
same classiÀcation was then applied on 232 FFPE 
samples from routinely processed NSCLC tissues 
(test group 2, to validate gene expression patterns 
in tumor vs non-cancerous tissues). Out of these, 
registered clinical data existed for 155 patients who 
had been treated in the adjuvant (N=39, 36 treated 
with platinum/taxane combinations), neoadjuvant 
(N=11) and chemo-naïve 1st line (N=105, 40 treated 
with platinum/taxane combinations) settings (clinical 
study group, to evaluate the effect of gene expression 
on patient outcome). 
Results: ERCC1 expression deviated from normal 
in 30.2%, TYMS in 51.3% and BRCA1 in 83.3% 
of NSCLC tissues; these results from test group 2 
applied with comparable percentages to all groups 
employed in this study. ProÀling of all three genes 
revealed a favorable effect of deviating BRCA1 / 
normal ERCC1 / deviating TYMS in 1st line treated 
patients (log-rank p=0.019 [PFS] and p=0.044 [OS]); 
the same proÀle was, however, strongly associated 
with unfavorable outcome of patients treated in 
the adjuvant setting (log-rank p=0.002 [DFS] 
and p<0.001 [OS]). This proÀle was not drug- or 
regimen-speciÀc. When reducing the proÀle to two 
genes, normal ERCC1 / deviating TYMS, a proÀle 
observed in 31% of the 1st line treated patients, was 
strongly associated with prolonged PFS and OS in 
this patient group irrespectively of treatment regimen 
(log-rank p=0.001 and p=0.016, respectively); for 
this proÀle, the same favorable effect was observed 
in the patient group treated with platinum/taxane 
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Background: ATM, a serine/threonine protein 
kinase and a member of the phosphatidyl inositol-3 
kinase like kinase family, is activated in response to 
DNA double strand breaks (DSBs). It phosphorylates 
multiple downstream proteins involved in cell 
cycle checkpoint arrest, DNA repair, and apoptosis. 
Aberrant ATM function has been implicated in 
several malignancies including lung cancer. In an 
analysis of listed mutations in 500 human protein 
kinases in 169 primary tumors and 40 cell lines, 
ATM mutations emerged at number 3 in terms of 
frequency, with a large proportion being found in 
lung cancers. However ATM’s role and inÁuence 
on outcome in NSCLC has not been extensively 
explored. We set out to assess the frequency with 
which ATM deÀciency occurs in NSCLC and 
correlate such deÀciency with outcome. 
Methods: After ethical approval was obtained, 
demographic details, clinical variables and outcome 
data were gathered on patients with resected NSCLC 
at the Tom Baker Cancer Centre (TBCC) between 
2003 to 2006 using the Glans-Look lung cancer 
database. Formalin-Àxed parafÀn embedded resected 
NSCLC tumors were obtained and tissue micro 
arrays (TMAs) generated. Expression was analyzed 
by quantitative immunoÁuorescent histochemistry 
using a rabbit anti-ATM monoclonal antibody 
(Epitomics) and the HistoRx AQUA® platform. 
ATM expression was quantiÀed in both pan-
cytokeratin positive tumor cells, as well as vimentin 
positive tumor-associated stromal cells. ATM 
proÀcient (BT) and deÀcient (UPN2) cell lines were 
used as controls. ATM deÀciency was determined 
by assessing the ratio of maximum ATM expression 
in the malignant component with that seen in the 
stromal component. A cutpoint to identify two 
groups from the ATM maximum expression ratio was 
found using a method based on the log rank statistic. 
AQUA scores were correlated with clinical outcome 
using the Kaplan-Meier method, multivariate 
analysis and Spearman’s rank correlation. 
Results: 165 cases of resected NSCLC (113 stage 
I, 52 stage II, 16 stage III) were identiÀed and 
their tumors incorporated into TMAs. Histology 
distribution, gender make up and median overall 
survival of the cohort were compatible with 
historical controls. The cutpoint for ATM tumour/
stromal expression ratio was identiÀed as 0.71. 
Patients with a low ATM expression ratio had a 
poorer progression free survival (P=0.004) and 
worse overall survival (P=0.0056) compared with 
those with a high ratio. Further analysis showed that 
CTCs were isolated from non small lung cancer 
patients (n=40). In order to catch CTCs, the medical 
wire is inserted in a patient’s vein for thirty minutes. 
An identiÀcation of epithelial origin of bound to the 
FSMW cells was performed by immunocytochemical 
staining against commonly used tumor markers of 
epithelial origin (cytokeratin, EGFR) as well as for 
negative selection with an CD45 antigen.
Results: In clinical studies, we successfully isolated 
EpCAM-positive tumor cells in the peripheral blood 
originating from non small lung cancer patients. First 
clinical results from 40 lung cancer patients indicate 
a sensitivity of 80% and a higher CTC capturing rate 
compared to existing in vitro methods. We could also 
conÀrm very good biocompatibility of the FSMW 
and did not report any side effects.
Conclusion: In vivo detection of the CTCs 
provides higher sensitivity, is safe for the patients 
and in an elaborated protocol speciÀc for cells of 
epithelial origin. Subsequent the FSMW technology 
for isolating circulating tumor cells (CTCs) will 
be evaluated as an upstream circulating tumor 
cell (CTC) enrichment method for subsequent 
downstream analysis of tumor cells. In collaboration 
with Bayer Healthcare, Prometheus developed, 
a proximity mediated immune-assay platform, 
CEER (Collaborative Enzyme Enhanced Reactive 
ImmunoAssay) which provides valuable insight into 
the tumor cells. A clinical trial with downstream 
CEER analysis of CTCs obtained in vivo from 12 
cancer patients using FSMW was initiated.
Keywords: NSCLC, circulating tumor cells
A revised/updated abstract may be included in 
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P2.266 ATM DEFICIENCY IS 
ASSOCIATED WITH WORSE OUTCOME 
IN RESECTED NON-SMALL CELL LUNG 
CANCER
Gwyn Bebb1, Alexander C. Klimowicz1, Tyler 
Williamson2, Stephanie Petrillo1, John Fralick3, 
Shannon Otsuka1, Chris Williamson3, Susan Lees-
Miller3, Don Morris1, Anthony M. Magliocco1 
1Tom Baker Cancer Centre, University Of Calgary/
Canada, 2Tom Baker Cancer Centre/Canada, 
3University Of Calgary/Canada
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the context of TNM 7th edition.
Methods: Retrospective analysis was performed 
on a prospective database of patients, undergoing 
curative resection of NSCLC, from November 
2006-November 2008. All patients underwent 
complete (pre)surgical staging including FDG-
PET acquisition based on Netherlands protocol 
for multi-center trial standardization (NEDPAS). 
Immuno-histochemistry for Ki67 and PAS staining 
was performed following international guidelines. 
Patients with a history of malignancy, (neo) 
adjuvant treatment and/or diabetes were excluded. 
Postoperative staging was performed using TNM 
7th edition. Follow up 24 months.
Results: A total of 35 patients met inclusion criteria 
for PET, 32 for pathological evaluation. Stage IA 
(n=23/21), 1B (n=5), 2A (n=3), 2B (n=3) and 3A 
(n=1). Disease recurrence was determined within 
2 years in 5/35 patients, 3 disease related deaths 
during follow up. Both staging and FDG uptake 
were of signiÀcant prognostic value (resp. p=0,034 
and p=0,021) for disease recurrence and disease 
related death. Multivariate non-signiÀcant (resp. 
p=0,155 and 0,151). Mean GC-SUVmax is different 
for postoperative determined stage I-II (p=0,006). 
FDG-uptake is suitable to identify patients at risk 
for recurrent disease (p=0,001) and of prognostic 
value for poor survival (p=0,004). Ki67 and PAS 
expression showed no signiÀcant correlation with 
disease recurrence and/or poor survival. We found 
no signiÀcant correlation for Ki67, PAS and FDG 
uptake.
Conclusion: PET is a useful tool to identify 
patients at risk of early disease recurrence and 
death within 2 years after complete resection of 
early stage NSCLC in addition to recently revised 
staging method. Prospective trials, performing 
FDG-PET following standardized protocol, are 
needed to identify clinically useful cut off values 
of GC-SUVmax, in order to produce stratiÀcation 
models applicable in future guidelines.
Keywords: FDG uptake, Early Stage NSCLC, 
curative resected
this effect was driven by the stage II and III patients 
with low ATM expression (HR: 4.86, 95% CI: 2.16 
to 10.95, P=0.027) with no effect seen in the stage I 
cases. 
Conclusion: Reduced ATM expression is associated 
with worse outcome in resected stage II and III 
NSCLC. Since many therapeutic interventions used 
in NSCLC rely on DNA damage for their effect, 
ATM deÀciency is likely to inÁuence response to 
speciÀc cytotoxic and targeted agents. We recently 
demonstrated that loss of ATM function in mantle 
cell lymphoma sensitizes tumors to PARP-1 
inhibition. Taken together, our results suggest that 
ATM deÀciency in NSCLC may be a predictive as 
well as a prognostic marker. 
Keywords: ATM, DNA repair, resected non small 
cell lung cancer, Prognosis
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P2.267 PROGNOSTIC VALUE OF KI67 
AND FDG-PET UPTAKE IN EARLY 
RECURRENCE OF NON-SMALL CELL 
LUNG CANCER AFTER COMPLETE 
RESECTION.
Renske Konings1, Erik Thunnissen2, Herman Bril3, 
Herman Rijna1 
1Surgery, Kennemer Hospital/Netherlands, 
2Pathology, VU Medical Center/Netherlands, 
3Pathology, Kennemer Hospital/Netherlands
Background: Treatment stratiÀcation in NSCLC is 
based on staging, which has been recently revised. 
Following current treatment guidelines half of 
the patients will have disease recurrence within 5 
years after complete resection. This highlights the 
necessity for identifying tumour speciÀc factors 
to identify patients at risk. Several heterogeneous 
studies have been reporting the prognostic value 
of both FDG-PET CT and Ki67 expression. Few 
studies however, describe FDG-PET acquisition 
based on standardized protocol and / or correct 
for glucose levels. The aim of this study was 
to determine whether these factors could be of 
additional prognostic value for early recurrence and 
survival, in primarily surgical treated NSCLC, in 
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Gene expression proÀling of total RNA isolated 
from bronchial brushings was performed using the 
Affymetrix Human Gene 1.0 ST platform. Analysis 
began by construction of a mixed-effects model 
that incorporated information on the site and time 
(continuous) the bronchial brushing was obtained 
as Àxed effects. Time and site-dependent Àeld of 
cancerization differential expression proÀles were 
identiÀed based on a false discovery rate (FDR) cut-
off of 5% and 1% based on p-value distributions, 
respectively, studied by hierarchical clustering and 
functionally analyzed using network analysis.
Results: 1395 genes were determined to 
be differentially expressed with time in the 
cancerization Àelds. Hierarchical clustering analysis 
using these genes demonstrated that samples (n=391) 
were divided into two clusters or branches which 
were signiÀcantly unbalanced with respect to time 
with the majority of the baseline and 36 months 
samples separated (p<0.001 of the Fisher’s Exact 
test). Moreover, functional analysis of the genes 
showed that a nuclear factor-kB (NF-kB)-mediated 
gene-network was most signiÀcantly elevated 
(p<0.001) with time. 1165 gene features were 
differentially expressed by site. Two-dimensional 
clustering of these genes and samples showed 
distinct classes of differential expression and 
revealed two main sample clusters with signiÀcant 
separation of ADJ samples from MCs and non-
adjacent CONTRA airway samples (p=0.003). 
Pathways analysis of the genes revealed that gene-
networks mediated by NF-kB, PI3K and ERK1/2 
were signiÀcantly elevated (p<0.001) in function 
in ADJ airway samples. Furthermore, hierarchical 
clustering analysis of patients (n=19) based on 
differences of expression (ADJ/NON-ADJ) of 
genes differentially expressed by paired t-tests 
between ADJ and NON-ADJ samples revealed 
two main clusters with all relapses located in one 
branch suggesting associations between Àeld of 
cancerization expression proÀles and lung cancer 
relapse.
Conclusion: Our Àndings highlight expression 
signatures and pathways in a “cancerization Àeld” 
that may drive lung cancer pathogenesis and be 
associated with recurrence or SPT development 
in ES NSCLC patients and thus useful for 
derivation of biomarkers to guide personalized 
prevention strategies. Supported by DoD grants 
W81XWH-04-1-0142 and W81XWH-10-1-1007.
Keywords: Prevention, gene expression proÀling, 
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P2.268 FIELD OF CANCERIZATION 
MOLECULAR PROFILING IN EARLY 
STAGE NSCLC PATIENTS TOWARDS 
DEVELOPMENT OF BIOMARKERS FOR 
PERSONALIZED PREVENTION
Humam Kadara1, Pierre Saintigny1, Li Shen2, 
Chi-Wan Chow1, Zuoming Chu1, Wenhua Lang3, 
Mohamed Kabbout3, You-Hong Fan1, Carmen 
Behrens1, Kathryn Gold3, Diane Liu4, J. J. Lee4, Li 
Mao5, Jing Wang2, Kevin R. Coombes2, Edward 
Kim3, Waun K. Hong3, Ignacio I. Wistuba6 
1Thoracic/head And Neck Medical Oncology, 
University Of Texas MD Anderson Cancer Center/
United States Of America, 2Bioinformatics And 
Computational Biology, University Of Texas MD 
Anderson Cancer Center/United States Of America, 
3Thoracic And Head & Neck Medical Oncology, 
University Of Texas MD Anderson Cancer Center/
United States Of America, 4Biostatistics, University 
Of Texas MD Anderson Cancer Center/United States 
Of America, 5University Of Maryland/United States 
Of America, 6Pathology And Thoracic/head And 
Neck Medical Oncology, University Of Texas MD 
Anderson Cancer Center/United States Of America
Background: Increasing our understanding of lung 
cancer pathogenesis will aid in the identiÀcation 
of early stage (ES) non-small cell lung cancer 
(NSCLC) patients at higher risk for recurrence or 
second primary tumor (SPT) development which in 
turn is vital to personalizing prevention and therapy. 
We sought to perform global gene expression 
analysis of the Àeld of cancerization in ever-smoker 
ES NSCLC patients to better understand lung 
cancer pathogenesis and predict recurrence or SPT 
development.
Methods: Patients on the prospective Vanguard 
study had deÀnitively treated ES (I/II) NSCLC 
and were current or former smokers. Patients had 
bronchoscopies with brushings obtained from the 
main carina (MC), airways adjacent (ADJ) to the 
previously resected tumor and from airways distant 
from the tumor in the ipsilateral (NON-ADJ) and 
contralateral (CONTRA) lung at baseline, 12, 24 
and 36 months following resective surgery. Nineteen 
patients were selected for the study based on airway 
sampling of at least Àve different regions per time 
point and continuously up to 24 or 36 months 
(391 airway samples from nineteen patients). 
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approach to lung cancer risk assessment, and/or early 
detection of lung cancer itself. Supported by NCI 
Grants CA 1RC1145422; 1K24139054; 1R21 CA 
121068. 
Keywords: MicroRNAs, Early Detection, risk 
assessment, exhaled breath
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P2.270 BIOMARKER PATTERN IN 
NEVER SMOKER PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC).
Edgardo S. Santos1, Roberto E. Ochoa2, Jose 
Villasboas Bisneto2, Jorge E. Gomez1, Kathleen 
Danenberg3, Luis E. Raez4 
1Hematology/oncology, University Of Miami Miller 
School Of Medicine/United States Of America, 
2Medicine, Jackson Memorial Hospital/university 
Of Miami/United States Of America, 3Response 
Genetics/United States Of America, 4University Of 
Miami Miller School Of Medicine/United States Of 
America
Background: It is recognized that tumor biomarker 
(BM) expression plays an important role in 
personalized therapy in cancer patients (pts). Never 
smoker NSCLC pts represent 15% of all NSCLC, 
and their prognosis differs from former or current 
smokers. Two gene mutations are frequently seen in 
this population: EGFR and EML4/ALK mutations. 
These gene abnormalities are suitable for targeted 
therapy. However, their association with other 
potential BMs has not been well elucidated. 
Methods: Tumor samples from 80 advanced NSCLC 
pts were analyzed for BM expression; 25 were never 
smokers. BMs were tested by using ResponseDx 
test: RNA expression of ERCC1, TS, and RRM1 was 
analyzed by RT-PCR and PCR analysis of DNA was 
used to determine K-ras, EGFR, and EML4/ALK 
mutation status.
Results: 25 pts out of 80 (31%) were never smokers; 
median age was 61 (range 40-79 years), 16 pts 
were female; 15 pts (60%) were Hispanic, 7 pts 
Caucasian, 2 pts Asian, and 1 pt African American. 
In 10 cases (40%), there was either no enough tissue 
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P2.269 EXHALED MICRORNAS AS 
POTENTIAL BIOMARKERS IN LUNG 
CANCER
Miao Shi, Weiguo Han, Simon Spivack 
Pulmonary Medicine, Albert Einstein College Of 
Medicine/United States Of America
Background: There is a need for non-invasive 
airway-based biomarkers in lung carcinogenesis 
for both risk assessment of the ex-smoker, and 
earlier diagnosis. MicroRNAs are small, stable, 
noncoding RNAs that function in gene regulation. 
Recent studies have revealed that microRNAs play 
important regulatory roles in carcinogenesis. Exhaled 
breath condensate (EBC) contains airway lining 
Áuid molecules, including nucleic acids, presumably 
inpart from epithelial cellular origins, as we’ve 
previously reported for DNA methylation. Here we 
pilot the detection of microRNAs in EBC from lung 
cancer patients and controls.
Methods: MicroRNA expression proÀling using 
RNA-speciÀc RT-qPCR was performed in EBC 
from 29 subjects, choosing literature-derived 
microRNAs segregating with case-control status, 
combined with an ongoing discovery effort we 
have commenced using microRNA-seq on lung 
tumors and surrounding non-tumor tissue. As of 
abstract deadline, the top three tumor-non-tumor 
differentiating microRNAs (miR-21, 126, and 200c) 
were chosen by consensus between the literature 
and our own discovery data. The qPCR primers 
were designed using our previously published RNA-
speciÀc realtime RT-PCR technique. All samples 
were run with positive and negative controls. 
Results: We have detected varying combinations of 
microRNAs in EBC for all three microRNAs (miR-
21, 126, and 200c) in most (>16 each) subjects. 
Case-control comparisons have not yet been made, 
pending generation of a more complete microRNA 
panel, and sampling from higher numbers of 
subjects. 
Conclusion: Technically, we are able to detect 
microRNAs in the breath. We will validate this 
evolving miR panel both anatomically, as to airway 
topographic site of origin, and to the cells of origin, 
using banked lung specimens from these same 
donors. This potential biomarker class will be 
correlated to case-control phenotype. Once validated, 
our goal is to apply this non-invasive biomarker 
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Background: Lung cancer is the leading cause 
of cancer mortality worldwide despite efforts to 
enhance early detection and improvements in 
therapeutic options. The recent National Lung 
Screening Trial results, which preliminarily propose 
a 20% mortality reduction using CT imaging to 
screen patients for NSCLC, are promising but cannot 
differentiate aggressive from more indolent early-
stage tumors. Surgery alone is curative for 60–70% 
of the pathologic stage I NSCLC patients. Molecular 
diagnostics which could identify stage I patients 
who have a high chance of tumor recurrence would 
have practical implications for developing node 
negative adjuvant trials. The objective of this study 
was to evaluate potential relationships between the 
preoperative levels of selected serum biomarkers 
with recurrence-free survival and overall survival in 
node negative NSCLC patients. 
Methods: Immunobead assays based on the 
Luminex platform were used to measure 
pre-treatment serum levels of 74 circulating 
immunomodulatory biomarkers, growth factors, and 
autoantibodies that we previously correlated with 
preoperative nodal status. Pre-treatment sera of 80 
surgically-resected NSCLC patients treated with at 
least 2 years clinical follow-up data were evaluated. 
49 patients had no nodal disease (T
1-4
N
0
M
0
), whereas 
31 had progression to the locoregional lymph nodes 
(T
1-4
N
1-3
M
0
). Mann-Whitney rank-sum tests were 
used to assess difference in biomarker concentrations 
with respect to sex, race, smoking history, and 
histology. For each biomarker, the difference in 
recurrence-free survivals were assessed by the 
log-rank PH test, and Kaplan-Meier estimates of 
recurrence-free survival curves were obtained using 
the R statistical software package. 
Results: A Kaplan-Meier evaluation of recurrence-
free survival revealed 11 serum biomarkers which 
were related to survival (p0.05). Using the Random 
Forest algorithm, we performed a multivariate 
biomarker selection analysis of these 11 biomarkers 
to deÀne a classiÀcation scheme of 4 biomarkers, 
consisting of: tissue inhibitor of metalloproteinases-1 
(TIMP-1), osteopontin, CA15-3, and an autoantibody 
to develop the BM panel or tissue available at all. 
Relatively, Caucasian had a higher incidence of 
EGFR mutation (5 [71%] Caucasian and 4 Hispanic). 
Eleven pts (44%) had EGFR mutation, 1 pt had 
EML4/ALK, and 1 pt K-ras mutation. High EGFR 
expression correlates in 10 pts (91%) with EGFR 
mutation; EGFR mutations were found in 7 Adeno, 
2 BAC, 1 large cell, and 1 undetermined. Most of 
the EGFR mutated pts (n=7) had low ERCC1 and 
RRM1 levels; 3 pts had high level expressions of 
these BMs. TS expression in EGRF mutated pts was 
equal (4 pts with high- and low-level each; 3 pts had 
no enough tissue for analysis). Both patients K-ras 
and EML4/ALK mutated had high levels of ERCC1, 
RRM1 and TS.
Conclusion: This report includes only never smoker. 
Our group continues screening pts for EGFR and 
other BMs as we have a special interest in analyzing 
these BMs in the Hispanic population. Although our 
cohort is small, we found similar patterns of BM 
expression (ERCC1, RRM1, TS) and a histology-
preferred type in those pts who had EGFR mutated 
as it has been described by others (Gandara et al. 
ASCO 2010). Both patients who had poor prognosis 
by gene mutation analysis also expressed high 
levels of ERCC1, RRM1 and TS which may confer 
resistance to different chemotherapeutic agents. This 
cohort of pts is part of a larger study group where 
we were able to Ànd that only ERCC1 and RRM1 
indicate association with ethnicity. Hence, our group 
will continue enriching this important biologic data 
in NSCLC. 
Keywords: Lung cancer, biomarker, ethnicity, never 
smoker
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P2.271 A MULTI-ANALYTE SERUM 
PANEL CAPABLE OF STRATIFYING 
NODE-NEGATIVE NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS 
BASED ON RECURRENCE-FREE 
SURVIVAL
Jeffrey A. Borgia1, David D. Shersher2, Sanjib Basu3, 
Omid Rouhi1, Cristina Fhied4, PenÀeld L. Faber5, 
Edward Hong5, William H. Warren5, Mary J. Fidler6, 
Philip Bonomi6, Michael J. Liptay5 
1Biochemistry And Pathology, Rush University 
Medical Center/United States Of America, 2General 
Surgery, Rush University Medical Center/United 
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approved in the second line setting. EGFR mutations 
have predictive value for PFS in the Àrst and 
second line settings, but there are no other reliable 
ways to select an EGFR-TKI versus cytotoxic 
agents. The objective of this study was to examine 
whether circulating upstream members of the EGFR 
signaling pathway correlate with clinical outcome in 
previously-treated advanced NSCLC patients. 
Methods: Luminex-based immunoassays were 
used to evaluate pre-treatment serum levels of 7 
circulating protein biomarkers implicated EGFR 
signaling by the KEGG (Kyoto Encyclopedia of 
Genes and Genomes) pathways database. All patients 
(n=102) were previously treated with platinum-based 
chemotherapy and grouped for this study according 
to treatment containing either erlotinib (n=73) or 
cytotoxic chemotherapy (n=30). Whole blood was 
collected before treatment initiation and processed 
to serum using standard phlebotomy techniques 
with full institutional IRB approval and with written 
patient consent. For each biomarker, the difference 
in progression-free- (PFS) and overall-survival (OS) 
was assessed by the log-rank test and Kaplan-Meier 
estimates using the R statistical software package. 
The p-values reported are two-sided with p-values  
0.01, 0.01-0.05, and 0.05-0.10 reported as strongly-
signiÀcant, signiÀcant and marginally-signiÀcant 
(respectively). 
Results: High serum levels of EGF were found to 
signiÀcantly associated with a favorable OS (7.5 
vs. 24.3 months; p=0.028) for all previously-treated 
patients examined, whereas high levels of the 
heparin-binding EGF (HB-EGF) isoform was found 
to be strongly signiÀcant for predicting a favorable 
PFS (1.32 vs. 3.44 months; p=0.0018) and OS (5.1 
vs. 11.6 months; p=0.0011) in the chemotherapy 
group alone. Similarly, high levels of betacellulin 
and epiregulin were strongly signiÀcant for 
favorable outcome in chemotherapy treated patients; 
betacellulin – PFS (4.0 vs. 1.3 months, p=.0015); 
Epiregulin - PFS (1.78 vs. 3.91, p=0.0029) and OS 
(6.67 vs. 19.43, p<0.001). In contrast to these results, 
low serum levels of transforming growth factor-
alpha (TGF-Ơ) and amphiregulin were strongly 
associated with prolonged PFS (e.g. TGF-Ơ: 2.66 vs. 
1.02 months, p=0.00027) and OS (e.g. TGF-Ơ: 9.57 
vs. 3.42 months, p=0.0033) regardless of treatment 
type. In all patients low levels of soluble EGFR was 
strongly signiÀcantly associated with shortened PFS 
and OS.
Conclusion: Although further validation is required 
to substantiate our Àndings, this preliminary work 
directed against phosphoglycerate mutase (PGAM). 
Performance of this panel to predict recurrence free 
survival in node negative patients treated by surgery 
revealed a 12% overall misclassiÀcation rate. 
Conclusion: Here we report the development of 
a 4-target serum panel for prognosticating nodal 
involvement of early stage NSCLC with the potential 
to predict “micrometastatic” disease previously 
undetected by standard imaging and pathology. 
Further reÀnement of this panel has potential to 
better deÀne patients for adjuvant systemic therapy 
who would otherwise receive surgery alone. 
Keywords: NSCLC, disease recurrence, serum 
biomarker, Stage I
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P2.272 SERUM PROTEIN LEVELS 
MAY BE USEFUL IN SELECTING 
TREATMENT WITH AN EPIDERMAL 
GROWTH FACTOR RECEPTOR 
TYROSINE KINASE INHIBITOR (EGFR 
TKI) VERSUS CHEMOTHERAPY IN 
PREVIOUSLY TREATED NON-SMALL 
CELL LUNG CANCER (NSCLC) 
PATIENTS.
Mary J. Fidler1, Reem Karmali1, Marta Batus1, Brett 
Mahon2, Omid Rouhi3, David D. Shersher4, Cristina 
Fhied5, Kelly Walters2, Philip Bonomi1, Jeffrey A. 
Borgia3 
1Hematology/oncology/bmt, Rush University Medical 
Center/United States Of America, 2Pathology, Rush 
University Medical Center/United States Of America, 
3Biochemistry And Pathology, Rush University 
Medical Center/United States Of America, 4General 
Surgery, Rush University Medical Center/United 
States Of America, 5Biochemistry, Rush University 
Medical Center/United States Of America
Background: A phase III trial comparing geÀtinib 
to docetaxel in previously treated stage IV/IIIB 
NSCLC patients showed no signiÀcant differences 
in progression-free survival (PFS) or overall 
survival (OS). Subset analyses based on clinical 
characteristics and molecular analyses (<30% 
patients had analyzable samples) failed to show 
signiÀcant differences in PFS or OS with the 
exception of superior PFS in geÀtinib treated patients 
whose tumors contained EGFR exon 19 and 21 
mutations. Erlotinib, docetaxel, and pemetrexed are 
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RECIST. PB mononuclear cells were enriched using 
buoyant density gradient centrifugation. Following 
immunomagnetic negative selection with anti-CD15 
and anti-CD45 antibody-beads, CTC were positively 
selected using the bead-coupled monoclonal 
antibody BerEP4, that is directed against the human 
epithelial antigen EpCAM. For quantitation of 
CTC, cytospins of CTC-enriched samples were 
analyzed by immunocytochemistry using a panel of 
cytokeratin (CK) antibodies.
Results: CTC were identiÀed prior to chemotherapy 
in 15/16 patients (6/6 SCLC, 9/10 NSCLC). 
Following one course of chemotherapy, a second 
NSCLC patient converted to CTC negativity. Only 
one of 6 SCLC patients patient showed decreasing 
CTC counts following chemotherapy. This patient 
achieved a CR. Five of 6 SCLC patients achieved a 
PR, which was associated with a signiÀcant increase 
of CTC counts following treatment (p less than 
0.05). Seven of 10 NSCLC patients (70%) achieved 
a PR. Clinical response was signiÀcantly associated 
with changes in CTC count after one course of 
chemotherapy (p=0.006; r=0.8).
Conclusion: Detection of CTC enriched by a 
combined negative/positive selection strategy and 
immunocytochemistry is feasible in lung cancer 
patients. Changes in CTC counts after one course 
of chemotherapy may be predictive of treatment 
response in NSCLC. Further studies are warranted.
Keywords: Lung cancer, circulating tumor cells, 
platinum-based chemotherapy
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P2.274 SERUM BIOMARKERS FOR 
ANGIOGENESIS HAVE VALUE FOR 
PROGNOSTICATING PROGRESSION-
FREE AND OVERALL OUTCOMES IN 
ADVANCED NSCLC
Reem Karmali1, Mary J. Fidler1, Sanjib Basu2, 
Brett Mahon3, Omid Rouhi4, Cristina Fhied5, Kelly 
Walters3, Gabriela C. Lobato5, Philip Bonomi1, 
Jeffrey A. Borgia4 
1Hematology/oncology/bmt, Rush University Medical 
Center/United States Of America, 2Preventative 
Medicine, Rush University Medical Center/United 
States Of America, 3Pathology, Rush University 
Medical Center/United States Of America, 
4Biochemistry And Pathology, Rush University 
Medical Center/United States Of America, 
demonstrates that upstream members of the EGFR 
signaling pathway show great promise as serum 
biomarker panel to help individualize treatment 
selection (chemotherapy vs. erlotinib) in patients 
with advanced NSCLC that fail Àrst line therapy. Our 
efforts are currently focused on further examinations 
of this and other biological pathways in relation to 
our goal of developing a serum biomarker panel to 
help individualize treatment selection for advanced 
NSCLC. 
Keywords: EGFR, serum biomarker, NSCLC, 
patient stratiÀcation
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P2.273 DECREASE OF CIRCULATING 
TUMOR CELLS ASSOCIATES WITH 
RESPONSE TO PLATINUM-BASED 
CHEMOTHERAPY IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER, 
BUT NOT WITH SMALL CELL LUNG 
CANCER
Thomas C. Gauler1, Dirk Theegarten2, Annette 
Parr1, Ivonne Schuhr1, Kurt W. Schmid2, Wilfried 
Eberhardt1, Martin Schuler1, Andreas-Claudius 
Hoffmann1 
1Department Of Medical Oncology, West German 
Cancer Center, University Duisburg-Essen/Germany, 
2Department Of Pathology And Neuropathology, 
West German Cancer Center, University Duisburg-
Essen/Germany
Background: Circulating tumor cells (CTC) have 
been detected in peripheral blood (PB) of patients 
with several malignant diseases. CTC are implied in 
metastasis and relapse and may serve as diagnostic 
parameter. The association of CTC with patient 
outcome and treatment response in lung cancer is 
still unclear. In this pilot study we aimed to elucidate 
whether quantiÀcation of CTC is technically feasible 
in lung cancer patients, and whether changes in CTC 
counts correlate with response to systemic platinum-
based chemotherapy. Furthermore, we examined 
whether histology (SCLC vs. NSCLC) or tumor 
stage inÁuenced CTC counts.
Methods: We analyzed 16 consecutive, untreated 
lung cancer patients treated at our institution. PB was 
drawn 1 hour before platinum-based chemotherapy 
on days 1 and 22 of 21 day cycles. Clinical 
response to chemotherapy was assessed following 
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high levels of expression of platelet-derived 
growth factor-BB (PDGF-BB) were associated 
with improved PFS and OS (p=0.024 and p=0.023, 
respectively). The collective impact of pro-
angiogenic matrix metalloproteinases (MMPs) 
remains less clear in this functional pathway, 
arguably confounded by parallel roles in other 
functional pathways that correlate with clinical 
outcome. An exploratory analysis comparing 
biomarkers in bevacizumab treated patients (n=25) 
versus patients that did not receive bevacizumab 
showed that increased VEGF in bevacizumab treated 
patients correlated with both prolonged PFS and 
OS (p=0.000957, p=0.036611, respectively) while 
increased levels of VEGF patients not treated with 
bevacizumab was associated with shortened PFS and 
OS survival (p=0.041223, p=0.009831, respectively). 
The only other biomarkers with signiÀcance for 
OS in bevacizumab treated patients were MMP-
2, sVEGFR1 and sVEGFR3, with sVEGFR1 also 
correlating with longer PFS. 
Conclusion: An examination of circulating 
biomarkers associated with the KEGG-deÀned 
angiogenesis functional pathway has yielded a 
range of serum biomarkers with apparent value for 
prognosticating outcome in advanced NSCLC. If 
serum were available from phase III bevacizumab 
trials, it might be reasonable to further evaluate/ 
validate these and other pathway members as a 
means to potentially identify NSCLC patients most 
likely to beneÀt from this treatment. 
Keywords: angiogenesis, patient outcome, EMT, 
Serum Biomarkers
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P2.275 PREDICTING RECURRENCE 
IN EARLY STAGE, RESECTED NON- 
SMALL CELL LUNG CANCER USING 
MUTATIONAL AND METHYLATION 
BIOMARKERS
Amir Onn1, John Wrangle2, Goni Hout Siloni1, Maya 
Damianovich1, Yoram Cohen1, Oranit Zadok1, Ronit 
Yarden1, Marina Perelman1, Ninette Amariglio1, 
Craig Hooker2, Malcolm V. Brock2, Gideon 
Rechavi1, Charles Rudin3 
1Pulmonary Oncology, Sheba Medical Center/Israel, 
2Oncology, John Hopkins University/United States 
Of America, 3The Sidney Kimmel Comprehensive 
Cancer Center At Johns Hopkins, Johns Hopkins 
5Biochemistry, Rush University Medical Center/
United States Of America
Background: Angiogenesis is a key component 
of the epithelial-to-mesenchymal transition 
(EMT) and is believed to be important in the 
development and progression of NSCLC. Combining 
bevacizumab with chemotherapy or erlotilnib has 
resulted in superior progression-free survival in 
three randomized studies, but overall survival was 
improved with bevacizumab in only one trial. It 
seems likely that bevacizumab has a modest biologic 
effect in NSCLC. Validation of a biomarker which 
would identify patients who are most likely to 
beneÀt from bevacizumab would have practical 
therapeutic and economic implications. Here, we 
examine a series of serum biomarkers implicated in 
the angiogenesis functional pathway in an effort to 
delineate the impact of these proteins on survival 
outcomes in advanced NSCLC patients. 
Methods: Luminex-based immunoassays were 
used to evaluate pre-treatment serum levels of 12 
circulating protein biomarkers implicated in the 
regulation of angiogenesis by the KEGG (Kyoto 
Encyclopedia of Genes and Genomes) pathways 
database. Pre-treatment sera were prospectively 
collected from advanced NSCLC patients with 
full institutional IRB approval and written patient 
consent. Treatment groups evaluated include: front 
line platinum-based chemotherapy (n=42), second 
line or greater platinum-based chemotherapy 
(n=31), or erlotinib (after failing previous platinum-
based chemotherapy)(n=73). Disease progression 
was measured using RECIST criteria. For each 
biomarker, the difference in progression-free- (PFS) 
and overall-survival (OS) was assessed by the log-
rank test and Kaplan-Meier estimates using the R 
statistical software package. 
Results: Low levels of expression of VEGF, 
macrophage migration inhibitory factor (MIF), 
hepatocyte growth factor (HGF), transforming 
growth factor-alpha (TGF-Ơ), and placenta growth 
factor (PIGF) were all strongly-signiÀcant with 
respect to improved PFS (log rank p=0.0142, 
p=0.021, p=0.0097, p=0.00004, p=0.033; 
respectively) and OS (log rank p=0.0125, p=0.034, 
p=0.00005, p=0.004; respectively). High expression 
of VEGF receptors 1-3 were also associated 
with improved PFS though only VEGF-R2 was 
signiÀcantly correlated on OS (10.55 vs. 2.43 
months, p=0.000002). Despite its reported role 
in promoting angiogenesis in tumor progression, 
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Conclusion: Mutational and epigenetic analysis of 
parafÀn-embedded tumors from patients with stage 
I NSCLC may be prognostic of cancer recurrence. A 
larger cohort is needed to identify a speciÀc genetic 
proÀle of clinical outcome. MSP analyses suggest a 
test which increases a patient’s odds of recurrence 
but must be examined in a larger cohort. A 
prospective validation of these results will be needed 
prior to clinical use. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.276 CHARACTERISATION OF 
CIRCULATING TUMOUR CELLS AND 
MICROEMBOLI IN LUNG CANCER 
PATIENTS: BEYOND THE NUMBERS.
Tim Ward1, Matt Krebs1, Karen Morris2, Jessica 
Booth2, Mathew Lancashire2, Rajeeb Swain2, 
Mathew Krebs2, Jian Mei Hou1, Lynsey Priest2, 
Fiona Blackhall3, Caroline Dive2 
1Clinical & Experimental Pharmacology, Paterson 
Institute For Cancer Research/United Kingdom, 
2Clinical And Experimental Pharmacology, Paterson 
Institute/United Kingdom, 3Medical Oncology, 
Christie Hospital/United Kingdom
Background: Circulating tumour cells and 
circulating tumour microemboli (CTC/CTM) 
can be already detected at early stages of tumour 
progression in regional lymph nodes, peripheral 
blood, and bone marrow of cancer patients. CTCs in 
the peripheral blood have as yet unknown molecular 
characteristics and the clinical impact of detecting 
CTC/CTM is under intense debate. 
Methods: We have utilised and developed several 
different technology platforms (Cell Search, ISET, 
Ariol Image analysis) in order to maximise our 
ability to detect and molecularly characterise CTCs/
CTMs. We have successfully undertaken rare 
cell detection by all of these methods in addition 
University/United States Of America
Background: Despite appropriate surgical 
intervention, approximately 30%-40% of patients 
with node negative non-small-cell lung cancer 
(NSCLC) have recurrent disease. Although 
clincopathological criteria fail to identify those at 
higher risk of relapse, recent evidence suggests that 
molecular biomarkers, such as oncogenic mutations 
and DNA hypermethylation, may hold prognostic 
value. Our objective was to determine if mutations 
or promoter hypermethylation of candidate genes 
predict disease recurrence after curative resection. 
Methods: ParafÀn embedded, surgically resected 
specimens from patients with stage I NSCLC were 
utilized. Mutational analysis was performed on 
NSCLC adenocarcinomas (n=35) and squamous cell 
carcinomas (n=5). A high-throughput genotyping 
method (SEQUENOM MassARRAY) and a 
multi base extension (MBE) matrix-assisted laser 
desorption/ionization time-of–Áight (MALDI-TOF) 
mass spectrometry were employed to study 322 
known somatic mutations involving 23 genes. After 
genetic mutations were detected, identiÀcation and 
validation of mutations were analyzed in duplicate. 
For methylation analysis, single-stage, methylation-
speciÀc PCR for APC, CDH13, RASSF1A, and 
CDKN2A was performed on bisulÀte treated DNA 
from paired primary tumor and mediastinal lymph 
node samples from NSCLC adenocarcinomas 
(n=35) squamous cell carcinomas (n=15) and was 
considered to have methylation concordance if a 
gene methylated in the tumor was also detected as 
methylated in the lymph node. 
Results: Patients whose primary tumors had 
EGFR gene mutations had a longer survival time, 
while patients with KRAS mutations had a poorer 
outcome. P53 mutations were seen only in the non-
recurrence group. Overall, patients with longer 
survival times had more mutations compared to those 
with shorter survival times. Patients with NSCLC 
other than squamous cell histology with methylation 
concordance of primary tumor and lymph nodes have 
78% increased odds for recurrence within 5 years 
compared to patients that test negative (OR=1.78; 
95% CI 0.45; 6.97, p=0.409). Importantly, this test 
detected those aggressive NSCLCs that recurred in 
the Àrst 2 years with an odds of recurrence of 2.22 
(95% CI 0.379; 13.18, p=0.379). 
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P2.277 DEVELOP AND VALIDATE 
CLINICAL PREDICTION MODEL 
TO ESTIMATE THE PROBABILITY 
OF MALIGNANCY IN SOLITARY 
PULMONARY NODULES FOR CHINESE 
PEOPLE
Yun Li 
Dapertment Of Thoracic Surgery, People’s Hoapital, 
Peking University/China
Background: The Character of SPN were important 
for clinical decision-making and prognosis 
signiÀcance. But it was difÀcult and was a hot-spot 
for Clinicians. Mathematical model is based on the 
experience of Experimental Medicine, and is the 
advanced form of medical research. In judging the 
character of the SPN, the capability of mathematical 
model is similar to experienced clinicians . Studies 
on mathematical model for properties of SPN 
currently have been carried out abroad, but in China, 
there was not yet a mathematical model for Chinese 
people.So we collected data of Chinese people 
with SPN, Retrospective analysis informations and 
try to To evaluate the clinical factors affecting the 
probability of malignancy of solitary pulmonary 
nodules(SPN) with multivariate logistic regression 
analysis.Develop a clinical prediction model to 
estimate the probability of malignancy, and validate 
the value of the model. 
Methods: from Jan 2000 to Sep 2009, 371 patients 
(197 male, 174 female) with SPN got deÀnite 
pathological diagnosis in our institute. Clinical 
data of these patients included age,gender,course of 
disease,symptoms,history and quantity of Cigarette 
smoking, history of other tumor,Œ family history 
of tumor,site of tumor,diameter, calciÀcation,specu
lation,border,lobulation,traction of pleural,vascular 
convergence sign,cavity. To estimate the independent 
predictors of malignancy of SPN with multivariate 
analysis and then develop a . from Oct 2009 to 
Mar 2010, Other 62 patients with SPN got deÀnite 
pathological diagnosis in our institute was used to 
validate value of this clinical prediction model, and 
compared our model with other two models.
Results: The median age of the patients was 57.1 
years. Fifty three percent of the nodules were 
malignant, and forty six percent were benign. 
Logistic regression analysis show six clinical 
characteristics (age of patient(OR:1.073), diamete
r(OR:1.966),border(OR:0.245),calciÀcation(OR:0
to Áuorescence in situ hybridization (FISH) 
analysis, custom marker labelling and molecular 
characterisation by qtPCR. To further characterise 
the heterogeneous nature of these populations 
we have developed 4 colour mutiplex Áuorescent 
staining techniques. Using these techniques we have 
successfully captured and enumerated both CTCs 
and CTMs. We have been able to stain cells for 
EMT, proliferation and tumour speciÀc markers.
Results: The substantial data collected by this 
group suggest there is vast potential in CTC/CTM 
detection as a predictive/pharmacodynamic marker 
in early clinical trials. A particularly confounding 
problem is that invasive tumour cells often lose 
their epithelial antigens due to an epithelial to 
mesenchymal transition process. Considerable 
heterogeneity in the expression of EMT and other 
markers was observed within populations of CTC/
CTM cells from individual patients. Furthermore, 
non-tumour epithelial cells were often also present 
in blood. Thus, it appears that a reliable diagnostic 
identiÀcation of CTC and CTM cannot be based 
simply on the expression of epithelial-speciÀc 
transcripts or antigens. 
Conclusion: All of these technologies have now 
become key applications in much of the clinical 
translational trial work undertaken by our group. 
Our multifaceted approach to rare cell detection 
and analysis enables us to further gain insight into 
possible mechanisms involved in metastasis. We are 
now routinely deploying these techniques in Àrst into 
man trials of novel therapeutics agents. 
Keywords: Circulating tumour cells, Biomarkers, 
Clinical Trials, EMT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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diaphragm top, skin markers were measured and 
their correlation were analyzed, and the same for 
the volume variation of GTVs and lungs by 4D-CT 
images of 10 respiratory phases. 
Results: Movement range of lung cancer in different 
lobe differed extinctly: 0.8mm–5.0mm in upper lobe, 
5.7mm–5.9mm in middle lobe and 10.2mm–13.7mm 
in lower lobe. Movement range of lung cancer in 
three dimensional direction was different: Z-axis 
4.31±4.34mmï¹¥Y-axis 2.19±1.04mmï¹¥X-axis 
1.73±1.5mm. For individual patients, the range of 
maximum three-dimensional centroid movement 
was 0.75–13.65 mm for GTVs, 2.83–9.70 mm for 
tracheal bifurcation, 2.24–9.11 mm for hilum of 
lung, 6.21–25.40 mm for diaphragm top, and 0 
–5.5 mm for skin markers. Mean volume of GTV 
was 20.90cm3 range 20.25cm3– 21.66 cm3 ŒMean 
volume of lung was 2800.55cm3 range 2657.58cm3– 
2968.54cm3 . There was no statistical signiÀcance for 
volume variation of tumor and lung(r=0.23, p=0.52).
Conclusion: Based on 4D-CT, statistically 
signiÀcant differences of GTVs centroid movement 
were observed at different pulmonary lobes, and 
the differences of centroid movement in three 
dimensional directions were signiÀcant, but no 
signiÀcant correlation between three dimensional 
vector of GTVs and that of normal tissue structures 
or skin markers were observed. So individual 4D-
CT measurement is necessary for deÀnition of ITV 
margin for lung cancer.
Keywords: Cancer; non-small cell lung /
radiotherapy, four-dimensional computed 
tomography, structures of interest
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.279 THE PLEURAL TAGGING ON 
HIGH RESOLUTION COMPUTED 
TOMOGRAPHY IN PREDICTING 
VISCERAL PLEURA INVOLVEMENT 
IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
Shu-Lan Hsu1, Nai-Chuan Chien2, Shih-Liang Yu3, 
Chun-Liang Lai1, Kuo-Sheng Fan1, Yen-Hsien Lee1, 
Hsing-Chun Chen1 
1Division Of Pulmonology And Critical Care, 
Department Of Internal Medicine, Buddhist Dalin 
.199),spiculation(OR:2.088)and the family history 
of tumor(OR:3.550) were independent predictors of 
malignancy in patients with SPN(P<0.05). The area 
under the ROC curve for our model (0.89; 50% CI 
0.78 to 0.99) was higher than the other two foreign 
models(Sensitivity:92.5%,SpeciÀcity:81.8%,Pos
itive predictive value:90.2%, Negative predictive 
value:85.7%). 
Conclusion: Age of patient, diameter,border,calcif
ication,spiculation and the family history of tumor 
were independent predictors of malignancy in 
patients with SPN. Our prediction model was more 
accurate than the other two foreign models, and was 
sufÀciently to estimate the malignancy of patients 
with SPN. 
Keywords: Prediction model, Solitary pulmonary 
nodule, Logistic regression analysis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P2.278 A CORRELATION STUDY ON 
POSITION AND VOLUME VARIATION 
OF PRIMARY LUNG CANCER DURING 
RESPIRATION BY 4D-CT.
Ying-Jie Zhang1, Jianbin Li2 
1Department Of Radiation Oncology, Shhospitalandong 
Cancer/China, 2Radiation Oncology Department, 
Shandong Cancer Hospital/China
Background: By 4D-CT simulation ,the correlation 
of position movement of primary tumor with 
interested organs and the correlation of volume 
variation of primary tumors and lungs during different 
respiration phases for patients with lung cancer at free 
breath condition scanned could be investigated.
Methods: Based on simulation 4D-CT images which 
binned in 10 respiratory phases, 16 patients with 
lung cancer were scanned at free breath condition by 
simulation 4D-CT which connected to a respiration-
monitoring system (RPM ). A coordinate system 
was created based on image of T5 phase, which was 
registered by other images of 9 phases. Gross tumor 
volumes (GTV) and normal tissue structures (lungs, 
hilum of lungs, tracheal bifurcation, diaphragm top 
and skin markers ) of 10 phases were contoured. 
The three dimensional position variation of GTVs 
centroid, hilum of lungs, tracheal bifurcation, 
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level, the sensitivity of pleural tag sign was 93% and 
speciÀcity was 52%, the positive predictive value 
of pleural tag sign was 60% and negative predictive 
values was 91%. Pleural involvement reported by 
chest surgeon during operation had no correlation 
with true pathologic pleural involvement. 
Conclusion: Tumor with a diameter smaller than 22 
mm and pleural tagging on HRCT is less likely to 
have true visceral pleura involvement.
Keywords: Lung Cancer Staging, Pleural tag sign, 
Elastica-Van Gieson stain, High resolution computed 
tomography
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P2.280 USEFULNESS OF PREOPERATIVE 
3D-CT ANGIOGRAPHY FOR PRIMARY 
LUNG CANCER
Masashi Yanada1, Junichi Shimada2, Kazuhiro Ito3 
1Thoracic Surgery, Ayabe City Hospital/Japan, 
2Thoracic Surgery, Kyoto Prefectural University Of 
Medicine/Japan, 3Department Of General Thoracic 
Surgery, Kyoto Prefectural University Of Medicine/
Japan
Background: In recent years, a breakthrough in 
diagnostic technology in radiographical image is 
superimpressive. Three dimensional computed 
tomography (3D-CT) has often been used as a useful 
method of investigation before surgery. So 3D-CT 
enables surgeons to be able to operate more safety. 
In our hospital, 64-row multi-detector computed 
tomography (MDCT) was Àrst introduced in 
November 2009. This study investigated utility of 
preoperative 3D-CT for primary lung cancer.
Methods: Thirty-eight patients who underwent 
either a lobectomy or a segmentectomy for lung 
cancer between January 2009 and December 
2010 at Ayabe City Hospital were included in this 
study. Video assisted thoracic surgery (VATS) was 
performed in all 38 patients. Fourteen of all patients 
between January and October 2009 had been 
examined by CT (Asteion Multi 4-row, 0.75 s/rot, 
Toshiba), and an iodinated contrast medium had been 
administered intravenously by a mechanical injector 
into their upper limbs (Group A). The remaining 
twenty-four patients between November 2009 and 
December 2010 had been examined by CT (Light 
Speed VCT 64-row, 0.4 s/rot, GE Healthcare), and 
an iodinated contrast medium had been administered 
intravenously by a mechanical injector into their 
Tzu Chi General Hospital/Taiwan, 2Division 
Of Thoracic Surgery, Department Of Surgery, 
Buddhist Dalin Tzu Chi General Hospital/Taiwan, 
3Department Of Pathology, Buddhist Dalin Tzu Chi 
General Hospital/Taiwan
Background: A pleural tag is deÀned as a linear 
area of high attenuation surrounded by aerated 
lung, originating from the edge of the mass and 
extending peripherally to contact the pleural surface. 
It could be seen both in benign and malignant 
diseases. According to the 7th edition of the TNM 
classiÀcation for lung cancer from the IASLC 
Staging Project, pleural involvement should be 
conÀrmed and documented since the diagnosis of 
pleural invasion would inÁuence the T staging and 
subsequent treatment strategy. The purpose of this 
study is to correlate the pleural tagging on high 
resolution computed tomography (HRCT) of chest 
with the operative Àndings, and histopathology in 
non-small cell lung cancer (NSCLC). 
Methods: We analyzed 102 consecutive adult 
patients with NSCLC and received thoracotomy 
between January 2008 and October 2010 from the 
medical record registry and cross index system of a 
referral teaching hospital. HRCT before operation 
were interpreted by 2 experienced pulmonologists 
to identify tumors with pleural tag sign. Operative 
Àndings were reconÀrmed by the chest surgeon. 
Pleural invasion was deÀned by Elastica-Van 
Gieson stain according to the criteria of IASLC 
and reviewed by a lung pathologist. Associations 
between the imaging and pathological Àndings were 
examined using a chi-square test. The correlation 
of operation Ànding and true pathologic pleural 
involvement were examined using Pearson’s 
correlation. A p-value of less than 0.05 denotes a 
statistically signiÀcant difference. 
Results: There are 43 NSCLC patients identiÀed 
to have pleural tag sign. Six patients were excluded 
due to multiple nodules in the lung. Pathologically 
pleural involvement was found in 16 of 37 patients 
(43.2%). Tumor size is the only image predictive 
factor to correlate the pleural tagging and true pleural 
invasion with a mean tumor size of 38 mm ± 13 mm 
in invasion group and 23 mm ± 9 mm in noninvasion 
group (P< 0.001). Other factors including the mean 
tag length, location, cell type, and gender did not 
show signiÀcant difference between invasion and 
non-invasion groups. The CT pattern of tumor 
such as ground-glass opacity or solid type was not 
informative. Using tumor size of 22 mm as a cut 
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United States Of America, 2Surgery, University Of 
Washington/United States Of America, 3Hematology/
oncology, University Of New Mexico/United States 
Of America, 4Radiation Oncology, University Of 
Washington/United States Of America, 5Radiology, 
University Of Washington/United States Of America
Background: Chemotherapy has become an 
important component of the therapy of stages II and 
IIIA NSCLC, treated with surgery. FDG-PET scan 
may have prognostic or predictive value after one 
cycle of induction chemotherapy.
Methods: Patients with stage IB to IIIB (T4 
considered operable at our institution) NSCLC were 
treated with 3 cycles of neoadjuvant chemotherapy 
using cisplatin and pemetrexed. Between days 18 
and 21 after the Àrst cycle of chemotherapy, patients 
underwent FDG-PET scan. Investigators caring for 
patients were blinded to results unless they showed 
progression. FDG-PET response was deÀned as 
decrease of the SUV of the dominant lesion  20%. 
Results: Between 10/05 and 02/10, 25 patients were 
enrolled. One patient was excluded from the efÀcacy 
analysis because she had a carcinoid tumor (despite 
two independent reviews indicating NSCLC in the 
initial biopsy). Fifty two percent were female, 88% 
white, and median age was 62 years. Histology was 
divided into squamous cell 12%, NOS 16%, large 
cell 4% and adenocarcinoma 66%. Stage distribution 
was: 16% IB, 4% IIB and 79% IIIA (58% conÀrmed 
by mediastinoscopy). Treatment was well tolerated 
and only one patient had a grade 4 toxicity. Three 
patients did not have surgery: one had a stroke, 
one had disease progression and one had a drop 
in performance status. The median follow-up of 
surviving patients is 30 months. The 4 year PFS 
and OS for the entire population were 52 and 68%, 
respectively . Nineteen patients had a baseline FDG-
PET scan and a day 18-21 available for comparison. 
Eleven patients (57%) were considered responders 
on day 18-21 FDG-PET scan. Responders had an 
OS at 3 years of 45% , while the percentage for non-
responders was 88% (P= 0.45). Between years 2 and 
4 of follow-up, both the PFS and OS curves for non-
responders were consistently above the curves for 
responders.
Conclusion: The outcome of patients in this trial 
was better than predicted based on the initial staging. 
Treatment with cisplatin and pemetrexed was well 
tolerated in the neoadjuvant setting. This pilot 
trial showed no evidence that a PET scan after one 
cycle of chemotherapy can predict the outcome 
upper limbs (Group B). In all cases of group B 
coronal, sagittal and 3D-CT angiography images 
were constructed. One surgeon performed all 
operations, and analyzed these images. 
Results: There was no statistically signiÀcant 
difference of sex, respiratory functions, operative 
duration, and duration of the chest tube placement 
between both groups. However, operative duration 
tended to be longer in the cases of group A than that 
of group B (291 vs 245 ; p=0.08). The amount of 
blood loss (p=0.02) and the length of postoperative 
hospital stay (p=0.04) was less in group B than in 
group A. There was no postoperative death and there 
were no serious complications in both groups.
Conclusion: Coronal, sagittal and 3D- CT angiography 
images using MDCT quickly provides important 
preoperative information to surgeons and could play 
an important role in facilitating VATS lobectomy 
procedure more safety. We therefore recommend using 
these images for thoracic operations, especially before 
performing VATS lobectomy.
Keywords: VATS lobectomy, 3D-CT angiography, 
Lung cancer
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P2.281 EARLY POSITRON EMISSION 
TOMOGRAPHY (PET) SCAN AFTER 
ONE CYCLE OF NEOADJUVANT 
CHEMOTHERAPY FOR NON-SMALL-
CELL LUNG CANCER(NSCLC): A PILOT 
TRIAL.
Renato G. Martins1, Keith Eaton1, Douglas E. 
Wood1, Sanaz Behnia1, Bernardo Goulart1, Michael 
Mulligan2, Sarah Wallace1, Julie E. Bauman3, Shilpen 
Patel4, Hubert Vasselle5 
1Medical Oncology, University Of Washington/
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signiÀcant in pathological responders (84% vs 54% for 
Àxed threshold, p=0.035; 90% vs 47% for adaptive-
threshold method, p=0.043). In partial pathological 
responders, EORTC criteria misclassiÀed 4/8 patients as 
stable or progressive disease. In these 4 patients, MTV 
decreased (median percentage decrease: 59% for Àxed 
threshold method, 40% for adaptive-threshold method) 
and inÁammatory cell accumulation was noted within the 
tumor: moderate (n=3) or low (n=1). 
Conclusion: SUVmax measurement seems to 
be insufÀcient as a criteria of assessment of the 
therapeutic response, probably because of post-
chemotherapy inÁammatory changes. MTV could 
be a complementary parameter in the assessment 
of pathological response after neoadjuvant 
chemotherapy in NSCLC. 
Keywords: metabolic tumor volume, neoadjuvant 
chemotherapy, Non-Small-Cell Lung Cancer
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P2.283 CAN METABOLIC IMAGING 
OBVIATE THE NEED FOR 
MEDIASTINOSCOPY IN NON-
SMALL CELL LUNG CANCER IN A 
TUBERCULOUS-ENDEMIC COUNTRY?
C S. Pramesh1, Venkatesh Rangarajan2, George 
Karimundackal1, Nilendu Purandare2, Marzi Mehta1, 
Sabita Jiwnani1, Nirmala Jambhekar3 
1Thoracic Surgery, Tata Memorial Hospital/
India, 2Bioimaging, Tata Memorial Hospital/India, 
3Pathology, Tata Memorial Hospital/India
Background: Metabolic imaging with 18-F Fluoro 
Deoxy Glucose (FDG)Positron Emission Tomography-
Computed Tomography (PET-CT) scanning has 
revolutionized the preoperative diagnostic workup 
in patients with localized non-small call lung cancer 
(NSCLC). In addition to diagnosing occult distant 
metastases, PET-CT scanning has been advocated as 
an important diagnostic tool for accurate diagnosis of 
mediastinal lymph node involvement. Tuberculosis is 
a known confounder and can detract from the utility 
of PET-CT especially in endemic countries. Very few 
studies have compared the accuracy of mediastinal 
lymph node involvement by PET-CT scanning 
with mediastinoscopy against the gold standard of 
histopathology in a tuberculous endemic country.
Methods: We retrospectively reviewed patients 
with non-small cell lung cancer who underwent 
mediastinoscopy or systematic mediastinal lymph 
of patients with NSCLC treated with neoadjuvant 
chemotherapy.
Keywords: neoadjuvant, Chemotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.282 ASSESSMENT OF 
PATHOLOGICAL RESPONSE TO 
NEOADJUVANT CHEMOTHERAPY IN 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER USING 18F-FDG 
PET/CT: SUVMAX VS METABOLIC 
TUMOR VOLUME
Michael Soussan1, Kader Chouahnia2, Mariane 
Kambouchner3, A Khafagy1, Gaetan Des Guetz2, 
Emmanuel Martinod4, Jean-Fraonçois Morère2 
1Medecine Nucleaire, Chu Avicenne. Ap-hp. Paris 
Xiii/France, 2Oncologie Medicale, Chu Avicenne. 
Ap-hp. Paris Xiii/France, 3Anatomopathologie, 
Chu Avicenne. Ap-hp. Paris Xiii/France, 4Chirurgie 
Thoracique, Chu Avicenne. Ap-hp. Paris Xiii/France
Background: We aimed to evaluate metabolic tumor 
volume (MTV) compared to SUVmax measurement as 
markers of histopathological response to neoadjuvant 
chemotherapy in locally advanced NSCLC. 
Methods: Twenty-two patients (18 men; median 
age:64 years) with locally advanced NSCLC 
received neoadjuvant platinum-based chemotherapy 
and, if considered resectable, proceeded to surgery 
(14/22). Patients had FDG-PET/CT scans before and 
after 3 cycles of chemotherapy. SUVmax and MTV 
(40%-SUVmax and adaptive-threshold methods) 
of the primary tumor was recorded (DOSIsoft 
Software). SUVmax was graded using EORTC 
criteria. Pathological response was deÀned as: non-
responders, partial responders (>10% residual tumor 
cells) and pathological responders (<10% residual 
tumor cells). InÁammatory cell presence within 
the tumor was graded as low, moderate or high. 
Changes in SUVmax and MTV were correlated with 
pathological response (Wilcoxon test). 
Results: There were 8 partial responders, 3 pathological 
responders 3 non responders. The median decrease of 
tumor SUVmax was higher in pathological responders 
than non and partial responders (79% vs 24%, p=0.086). 
A median percentage decrease in MTV was more 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1121
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Sensing Laboratory (TELE), Université Catholique 
De Louvain/Belgium, 3Department Of Radiation 
Oncology, Erasmus MC - Daniel Den Hoed Cancer 
Center/Netherlands
Background: Pre-treatment FDG uptake levels in 
the lungs are prognostic for radiation induced lung 
toxicity (RILT) in NSCLC patients. In this study, 
we investigated if FDG uptake in speciÀc normal-
lung regions is correlated to the development of 
RILT after radiotherapy. To this end, we use a 
novel approach based on non-rigid registration for 
transforming and fusing data from multiple lung 
cancer patients into a common spatial reference 
(“Virtual Patient”) in order to perform spatial-
based statistics. This allows us to study the effects 
of radiotherapy by comparing CT, PET and dose 
distribution for multiple patients having of not 
having a complication.
Methods: An intensity-based afÀne alignment 
followed by a log-domain phase-based non-rigid 
registration were applied, producing for each patient 
a deformation Àeld representing the transformation 
from the reference to the patient. For each patient, 
the tumor was delineated and ignored. In this 
study we considered two distinct locations: the 
lower and the middle/upper lung lobes. The lobes 
were delineated only on the reference patient. 
We performed non-rigid registration of patients 
to map corresponding lung regions between 
them. To achieve higher-quality deformation, the 
virtual patient was chosen such that the amount of 
deformation needed to deform to the other patients 
is smallest. For this study we included 20 patients 
with relatively high mean SUV uptake value, 10 with 
increased RILT score during treatment (change in 
dyspnea grade > =1) and 10 without an increase.
Results: 
CT and PET images were successfully deformed 
node dissection after an 18-F FDG PET-CT scan. 
Patients who underwent PET-CT but did not have 
histopathological evaluation of the mediastinal lymph 
nodes were excluded. Sensitivity, speciÀcity, positive 
and negative predictive values (PPV, NPV) and 
accuracy of PET-CT scanning was compared with that 
of mediastinoscopy and formal mediastinal lymph node 
dissection. False positive lymph nodes on PET-CT were 
examined for involvement by tuberculosis.
Results: Seventy three consecutive patients who had 
an 18-F FDG PET-CT scan prior to mediastinoscopy 
were evaluated. Twenty two of 73 (30.1%) patients 
had mediastinal lymph node involvement on 
histopathology. The sensitivity, speciÀcity, PPV, 
NPV and accuracy of 18-F FDG PET-CT scanning 
vs mediastinoscopy was 77.3 vs 80%, 72.5 vs 100%, 
54.8 vs 100% and 88.1 vs 92.9% respectively. False 
positivity with PET-CT scanning was seen much more 
with reactive inÁammatory (79%) than tuberculous 
(21%) lymphadenopathy. Station-wise evaluation of 
359 lymph node stations yielded similar results. 
Conclusion: PET-CT scanning might obviate the need 
for mediastinoscopy in patients with no FDG uptake in 
mediastinal lymph nodes but has a high false positivity. 
Surprisingly, non-speciÀc inÁammatory pathology 
was a bigger confounder than tuberculosis even in an 
endemic country like ours. Further studies are required 
to identify PET-CT uptake characteristics which could 
reliably distinguish inÁammatory from metastatic 
involvement of mediastinal lymph nodes.
Keywords: Lung cancer, Metabolic imaging, PET-CT
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P2.284 IS HIGH PRE-TREATMENT FDG 
UPTAKE IN CERTAIN REGIONS OF 
THE NORMAL LUNG CORRELATED TO 
THE DEVELOPMENT OF RADIATION 
INDUCED LUNG TOXICITY AFTER 
RADIOTHERAPY? AN IN-SILICO TRIAL 
WITH A NOVEL APPROACH: THE 
“VIRTUAL PATIENT”: FUSING DATA 
FROM MULTIPLE LUNG CANCER 
PATIENTS INTO A COMMON SPATIAL 
REFERENCE
Georgi Nalbantov1, Wouter Van Elmpt1, André L.A.J. 
Dekker1, Bianca Hanbeukers1, Guillaume Janssens2, 
Dirk De Ruysscher1, Steven Petit3, Philippe Lambin1 
1Dept. Of Radiation Oncology (MAASTRO), 
Grow - School For Oncology And Developmental 
Biology/Netherlands, 2Communications And Remote 
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computed tomography (PET/CT) scanning is 
becoming widely used for MLN staging in patients 
with non-small cell lung cancer. We performed a 
bivariate meta-analysis to determine the pooled 
sensitivity and speciÀcity of this imaging modality.
Methods: The PUBMED/MEDLINE, EMBASE 
and SPRINGERLINK databases were searched for 
the related articles on PET/CT for MLN staging in 
patients with NSCLC. Sensitivity and speciÀcity 
were calculated for every study. Hierarchical 
summary receiver operating characteristic curves 
were used to summarize overall test performance, 
and study quality was assessed. Potential between-
study heterogeneity was explored by subgroup 
analysis.
Results: Fourteen of 320 initially identiÀed reports 
were included in the meta-analysis. When we 
did not consider the analysis unite, the pooled 
weighted sensitivity (SEN) and speciÀcity (SPE) 
were 0.73(95%CI 0.65~0.79) and 0.92(95% CI 
0.88~0.94), respectively. In patient-based data 
analysis, the pooled weighted SEN was 0.76(95%CI 
0.65~0.84) and the pooled weighted SPE was 
0.88(95%CI 0.82~0.92). In node-based data analysis, 
the pooled SEN was 0.68(95%CI 0.56~0.78) and the 
pooled SPE was 0.95(95%CI 0.91~0.97).
Conclusion: Integrated PET/CT is an accurate 
noninvasive imaging test and has excellent 
diagnostic performance, and speciÀcity for MLN 
staging in patients with NSCLC.
Keywords: integrated positron emission tomography 
and computed tomography, mediastinal lymph nodes 
staging, Non-small cell lung cancer, meta-analysis
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P2.286 AUTOMATIC IMAGE 
REGISTRATION OF LUNG CT WITH 
SYNCHRONOUSLY ACQUIRED 
HYPERPOLARIZED HELIUM-3 MRI AND 
PROTON MRI FOR PATIENTS WITH 
NSCLC
Matthew Hatton1, Rob H. Ireland1, James A. 
Swincoe1, Helen Marshall2, Salma Ajraoui2, Juan 
Parra-Roubles2, Jim Wild2 
1Dept Of Clinical Oncology, Weston Park Hospital/
United Kingdom, 2Acadamic Dept Of Radiology, 
ShefÀeld University/United Kingdom
Background: Same breath-hold hyperpolarized 3He 
MRI and 1H MRI lung image acquisition has recently 
towards the reference “virtual patient” (see Figure 
1) using the deformation Àelds resulting from 
registration. Patients with higher FDG uptake in the 
lower lung lobes prior to radiation treatment were 
found to be more likely to develop RILT. The mean 
SUV level for the lower lung lobes of the virtual 
patient was 0.90(±0.06) for the group whose RILT 
score increased, and 0.73(±0.05) for the no-increase-
in-RILT group.
Conclusion: Our conclusion is twofold: a) These 
results showed that non-rigid registration was able to 
match accurately the lung contours of the reference 
with the lung contours of the patients; b) Thanks to 
the novel, virtual-patient approach we showed that 
location of the pre-treatment FDG uptake in the 
lungs is an indicator for a potential development 
of dyspnea after radiation treatment of NSCLC 
patients. The result suggests treatment planning 
may be improved if certain anatomic sub-regions 
are avoided. These results should be conÀrmed in a 
larger dataset. 
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P2.285 DIAGNOSTIC PERFORMANCE 
OF INTEGRATED POSITRON 
EMISSION TOMOGRAPHY/COMPUTER 
TOMOGRAPHY FOR MEDIASTINAL 
LYMPH NODES STAGING IN NON-
SMALL CELL LUNG CANCER: A 
BIVARIATE SYSTEMATIC REVIEW AND 
META-ANALYSIS
Yanling Lv1, Dongmei Yuan2, Ke Wang3, Xiaohui 
Miao4, Qian Qian5, Shuzhen Wei4, Xixu Zhu6, Yong 
Song2 
1Department Of Respiratory Medicine, Clinical 
School Of Southern Medical University/China, 
2Department Of Respiratory Medicine, Nanjing 
University, Jinling Hospital/China, 3Institute Of 
Respiratory Diseases, First AfÀliated Hospital, 
Guangxi Medical University/China, 4Nanjing 
University, Jinling Hospital/China, 5Department 
Of Respiratory Medicine, Nanjing Chest Hospital/
China, 6Department Of Radiotherapy Center, Jinling 
Hospital/China
Background: Accurate clinical staging of 
mediastinal lymph nodes (MLN) for patients with 
non-small cell lung cancer (NSCLC) is important 
in determining therapeutic options and prognoses. 
Integrated positron emission tomography and 
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radiotherapy and its side effects [3,4]. [1] Wild JM 
et al. NMR Biomed (DOI: 10.1002/nbm.1565), 2010 
[2] Ireland RH et al. Phys Med Biol 53(21):6055-
6063, 2008 [3] Ireland RH et al. Int J Radiat Oncol 
Biol Phys 68(1):273-281, 2007 [4] Ireland RH et al. 
Radiother Oncol 97(2):244-248, 2010 
Keywords: Radiotherapy Planning, NSCLC, 
Hyperpolised Helium MRI, Proton MRI
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P2.287 ERLOTINIB ACCUMULATION 
IN BRAIN METASTASES FROM 
NON-SMALL CELL LUNG CANCER 
-VISUALIZATION BY PET IN A PATIENT 
HARBORING A MUTATION IN THE 
EPIDERMAL GROWTH FACTOR 
RECEPTOR
Britta Weber1, Michael Winterdahl2, Ashfaque 
Memon3, Boe S. Sorensen3, Susanne Keiding2, Leif 
Sorensen4, Ebba Nexo3, Peter Meldgaard1 
1Department Of Oncology, University Hospital 
Of Aarhus/Denmark, 2Pet Center, University 
Hospital Of Aarhus/Denmark, 3Department Of 
Clinical Biochemistry, University Hospital Of 
Aarhus/Denmark, 4Department Of Neuroradiology, 
University Hospital Of Aarhus/Denmark
Background: Drugs directed towards the epidermal 
growth factor receptor (EGFR), such as erlotinib 
(Tarceva®) and geÀtinib (Iressa®), are used for the 
treatment of patients with advanced non-small cell 
lung cancer (NSCLC), including patients with brain 
metastases. However, whether erlotinib actually 
enters into brain metastases has not been adequately 
elucidated. In this study, we investigated the 
accumulation of [11C]-erlotinib by positron emission 
tomography (PET) and magnetic resonance imaging 
(MRI). 
Methods: A 32-year-old patient with NSCLC and 
multiple brain metastases was treated with Àrst-
line erlotinib. EGFR mutations were determined 
by analyzing a Àne-needle lung tumor biopsy taken 
prior to treatment. A PET scan of the brain with 
[11C]-erlotinib was performed during treatment, and 
a MRI of the head and a computed tomography (CT) 
of the chest were performed pre- and posttreatment. 
Results: The primary lung tumor displayed an 
erlotinib-sensitizing exon 19 deletion in the EGFR 
gene and [11C]-erlotinib PET showed accumulation 
in the brain metastases. Post-treatment MRI and CT 
been developed [1]. The aim of this study was to 
test the feasibility of synchronous 1H-3He MRI 
acquisition in lung cancer patients and to register the 
MRI to radiotherapy planning CT. 
Methods: Before radiotherapy, 4 patients underwent 
MRI. 3He gas was polarized on site and ventilation 
images were acquired during a single breath-hold 
of 1L 3He / N
2
 mix. With patients in the treatment 
position, 3He MRI was acquired on a 3T system 
Àtted with a second radiofrequency ampliÀer using 
prototype transmit–receive (T-R) coils. During 
the same breath-hold, the coil was detuned during 
1H transmit and 1H T–R was performed with the 
scanner’s 1H body coil, which itself was actively 
detuned during 3He T–R [1]. On the same day, 
radiotherapy planning CT was acquired using an 
inspiration breath-hold technique to simulate the 
MRI breath-hold [2]. The required 3He MRI to CT 
image registration was performed in two automatic 
steps. Firstly, 1H MRI was rigidly registered to 
planning CT using mutual information. Secondly, as 
3He and 1H MRI are acquired in a single breath-hold 
the calculated transformation for 1H MRI to CT was 
directly applicable to 3He MRI. 
Results: The 4 patients completed the imaging 
procedure and held their breath sufÀciently for 
all sets of images to be acquired without any 
detrimental clinical effects. All ventilation images 
were successfully fused with radiotherapy planning 
CT. The registration procedure is demonstrated in 
Fig 1. a) 3He MRI (blue) and 1H MRI are inherently 
registered due to the single breath-hold acquisition 
sequence. b) 1H MRI (red) is registered to the 
radiotherapy planning CT (green). c) The same 
image transformation is applied to the 3He MRI to 
generate the registered ventilation and CT images. 
Conclusion: This preliminary work demonstrates 
that synchronous acquisition of 3He and 1H lung 
MRI is possible for NSCLC patients, and that the 
ventilation images can be registered to CT via mutual 
information of the 1H MRI. The automatic method 
of registration may be a useful supplementary tool 
for the planning and evaluation of lung cancer 
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both groups was recorded from the PET/CT scan 
date. 
Results: We recruited 76 eligible patients, of whom 
50 were deemed suitable for RT to 60 Gy after 
PET/CT imaging and 26 (34%) received palliative 
therapies because of distant metastasis (n=12) or 
extensive locoregional disease seen on PET/CT 
(n=14). Approximately 1/3 of radical RT patients 
would have had a grade I geographic miss (FDG-
avid tumor outside PTV) if RT was planned without 
PET. Overall survival (OS) for all 76 patients was 
56.8% (46.5% - 69.3%) at one year and 24.9% 
(16.7% - 37.2%) at 4 years respectively. OS for the 
50 patients treated radically was 77.5% (66.6% - 
90.2%) and 35.6% (24.3% - 52.1%) at one and four 
years respectively. OS for the 26 patients treated 
palliatively was signiÀcantly worse at 16.3% (6.7% 
- 39.8%) and 4.1% (0.6% - 27.7%) at one and four 
years respectively (P<0.001). 
Conclusion: Without PET/CT, all patients would 
have received radical RT. Although >1/3 received 
palliative therapies, survival for the entire cohort 
comprising both radically and palliatively-treated 
patients was good. Survival for patients actually 
treated with radical chemoRT/RT after selection 
with PET/CT was exceptionally good, suggesting a 
possible survival beneÀt from timely PET/CT-based 
patient selection and RT planning. 
Keywords: Non-small cell lung cancer, Positron 
Emission tomography, Radiation Therapy, 
Chemotherapy
demonstrated regression of both the brain metastases 
and the primary lung tumor. 
Conclusion: Our data demonstrated that erlotinib 
accumulated in brain metastases in a NSCLC patient 
who responded to the treatment. 
Keywords: NSCLC, EGFR mutation, erlotinib, PET
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P2.288 EXCEPTIONAL LONG-TERM 
SURVIVAL FOR PATIENTS WITH 
UNRESECTABLE NON-SMALL CELL 
LUNG CANCER TREATED WITH 
RADICAL RADIATION THERAPY ON 
A PROSPECTIVE CLINICAL TRIAL OF 
FDG-PET/CT SCANNING FOR STAGING 
AND TREATMENT PLANNING
Michael P. Macmanus1, Alan Herschtal2, Rod Hicks2, 
Michael Bayne3, Eddie Lau2, David Ball1, Deborah 
Cruickshank2, David Binns2, Nikki Plumridge1, 
Mathias Bressel2, Sarah Everitt2 
1Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia, 2Peter MacCallum Cancer Centre/
Australia, 3Poole Hospital/United Kingdom
Background: We recently reported that combined 
FDG-PET/CT profoundly inÁuences patient 
selection and radiation therapy (RT) planning in 
patients with non-small cell lung cancer (NSCLC) 
considered suitable for radical chemoRT/RT after 
conventional staging (CS). In this report, for the 
Àrst time, we document survival of patients treated 
on that study. 
Methods: Consecutive consenting candidates 
for radical RT with stage I-IIIB NSCLC who had 
undergone CS were enrolled. Those who remained 
candidates for radical RT after CS underwent a 
dedicated PET/CT scan in the RT planning position 
for both staging and RT target volume deÀnition 
(according to a detailed visual protocol). We aimed 
to recruit 50 patients who could safely undergo 
radical chemoradiation to 60 Gy in 30 fractions 
over 6 weeks after PET/CT imaging and planning. 
It was expected that > 50 patients would need to 
be enrolled because of stage migration after PET/
CT. Patients who had a previous PET/CT >30 days 
previously or performed in a position unsuitable 
for RT planning had a further PET/CT scan. After 
PET/CT, patients still eligible received radical RT/
chemoRT and patients with PET-detected advanced 
disease received palliative therapies. Survival for 
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Results: Mediastinal lymph nodes enlargement 
( short axis>1 cm) was observed in 93% of pts 
with npe and in 30% of pts with bpe (p<0.00001). 
Median Cyfra 21-1 values in npe and in bpe were 
62,9 ng/ml and 13,4 ng/ml respectively (p<0.0001). 
Median CEA values in npe and in bpe were 22,9 ng/
ml and 0,9 ng/ml respectively (p<0.0001). Optimal 
cut off values calculated by ROC analysis were: 
95 ng/ml for Cyfra 21-1 and 5 ng/ml for CEA. 
Diagnostic utility of examined variables is presented 
below. Parameter Sensitivity SpeciÀcity PPV NPV 
Lymphadenopathy 0.93 0.7 0.66 0.94 Cyfra 21-1>95 
ng/ml 0.64 0.95 0.93 0.71 CEA >5 ng/ml 0.63 0.94 
0.91 0.71 
Conclusion: Mediastinal lymph nodes enlargement 
and increased Cyfra 21-1> 95 ng/ml and CEA > 5 
ng/ml in pe are of high diagnostic signiÀcance in 
assessing the probability of npe. The diagnostic 
algorithm combining these variables is presently 
under evaluation. 
Keywords: pericardial effusion, Lung cancer, 
mediastinal lymphadenopathy, tumor markers
Poster Session 2 - Imaging Tuesday, 5 July 2011 12:15-14:00
P2.290 DUAL-ENERGY CT IN THE 
PATIENTS TREATED WITH ANTI-
ANGIOGENIC AGENT FOR NON-SMALL 
CELL LUNG CANCER: A NEW METHOD 
OF MONITORING TREATMENT?
Ho Yun Lee1, Yoo Na Kim1, Myung Jin Chung1, Joon 
Beom Seo2, Myung-Ju Ahn3, Keunchil Park4, Kyung 
Soo Lee1 
1Radiology, Samsung Medical Center, Sungkyunkwan 
University School Of Medicine/Korea, 2Radiology, 
Asan Medical Center, University Of Ulsan College 
Of Medicine/Korea, 3Division Of Hemato-Oncology 
Of The Department Of Internal Medicine, Samsung 
Medical Center, Sungkyunkwan University School 
Of Medicine/Korea, 4Div Of Hem/onc, Dept Of 
Medicine, Samsung Med Ctr, Sungkyunkwan 
University School Of Medicine/Korea
Background: Regarding to anti-angiogenic 
treatment of non–small-cell lung cancer (NSCLC), 
intratumoral hemorrhage related to the anti-
angiogenic action of the drug can lead to increase 
in size of the tumor and be misinterpreted to 
progressive disease. Recent a few studies showed the 
iodine component in lung nodules is measurable on 
iodine enhanced image of dual-energy CT (DECT) 
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P2.289 METASTATIC PERICARDIAL 
INVOLVEMENT AS THE FIRST SIGN OF 
NEOPLASTIC DISEASE – DIAGNOSTIC 
SIGNIFICANCE OF MEDIASTINAL 
LYMPH NODES ENLARGEMENT ON 
CHEST CT AND INCREASED TUMOR 
MARKERS CONCENTRATION IN 
PERICARDIAL FLUID.
Monika Szturmowicz1, Anna Pawlak-Cieŋlik1, Anna 
Fijaãkowska1, Wãodzimierz Kupis2, Renata Langfort3, 
Katarzyna Bãasiĸska4, Beata Broniarek-Samson5, 
Renata Gralec6, Agnieszka Skoczylas7, Witold 
Tomkowski6 
1Dept. Of Chest Medicine, National Institute Of 
Tuberculosis And Lung Diseases/Poland, 2Dept. Of 
Thoracic Surgery, National Institute Of Tuberculosis 
And Lung Diseases/Poland, 3Dept. Of Pathology, 
National Institute Of Tuberculosis And Lung 
Diseases/Poland, 4Dept. Of Radiology, National 
Institute Of Tuberculosis And Lung Diseases/
Poland, 5Dept. Of Clinical Biochemistry, National 
Institute Of Tuberculosis And Lung Diseases/Poland, 
6Dept. Of Intensive Cardio-thoracic Care, National 
Institute Of Tuberculosis And Lung Diseases/Poland, 
7Outpatients Clinic/Poland
Background: Large pericardial effusion (pe) is a life 
threatening pathology requiring prompt diagnosis 
and effective local treatment. Malignancy and 
especially lung cancer, is one of the leading causes. 
The aim of the present study was to Ànd the optimal 
diagnostic algorithm for assessing the probability of 
neoplastic pericardial involvement. 
Methods: 146 patients (pts) treated in the National 
Institute of Tuberculosis and Lung Diseases with 
pericardiocenthesis or pericardioscopy in the period 
of 1989-2006 entered the study. Neoplastic pericardial 
effusion (npe) was recognized in 66 pts, based on 
positive pe cytology and/or neoplastic pericardial 
inÀltration in pericardial biopsy specimen. Primary 
site of disease was: lung – in 46 pts, breast – in 
10, mesothelioma – in 3, others – in 7 pts. Benign 
pericardial effusion (bpe) was recognized in 80 pts 
with negative results of pe cytology and/or pericardial 
biopsy specimen, and no signs of neoplastic disease 
at the time of hospitalization and during 12 months 
of subsequent observation time. Chest CT scan 
was performed with Somatom Sensation 16, tumor 
markers ( Cyfra 21-1 and CEA) concentrations in pf 
were measured with Elecsys- Roche assay. 
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Background: [F-18]Fluorothymidine (FLT), a 
radiotracer probing proliferation, holds promise as an 
early response biomarker. There is limited literature 
on FLT PET in the evaluation of response to radical 
RT for lung cancer (Everitt 2009, Vera 2011). Most 
patients studied received concurrent chemo-RT, 
rather than RT alone. Questions also remain about 
the baseline variation and optimal methodology for 
tumour delineation and analysis.
Methods: FLT-PET imaging is performed in patients 
with non-small cell lung cancer (NSCLC) scheduled 
for radical RT twice at baseline (scan 1 and 2) 
with the objective to assess reproducibility and 
after 3-10 fractions of treatment (scan 3), to assess 
early response. All patients consent to an ethically 
approved protocol also including serial blood 
sampling for analysis of circulating biomarkers of 
cell death (M30/65), aiming to recruit at least 12 
patients. Data are dynamically acquired for 60min 
on the TrueV PET/CT scanner. 45-60 minute images 
are reconstructed using 3D-OSEM, smoothed with 
a 4mm Gaussian Àlter. Tumours are manually 
delineated on PET-CT images by two thoracic 
radiology experts and functional volumes are deÀned 
using a region-growing Àxed-threshold algorithm 
set at 41% of SUVmax. SUV reproducibility is 
measured as (SUV2-SUV1)/(SUV1+SUV2)*200. RT 
response is calculated as % change relative to single 
or average baseline value.
Results: To date, six patients undergoing radical RT 
(5 sequential after chemotherapy, 1 RT alone) had a 
total of 12 scans: All were male, aged 66-77 years 
with inoperable Stage II/III NSCLC treated with an 
accelerated RT regimen of 55Gy in 20 fractions. Two 
patients underwent scans 1 and 2, two had scans 1 
and 3, one completed scans 1, 2 and 3 and one had 
scan 1 only (not reported). Pre-treatment scans were 
done within 2-5 days and on-treatment scans 7-16 
days after RT initiation. Average tumour SUVmean 
reproducibility was 7.3%. After 6, 8 and 11 2.75Gy 
fractions, tumour SUVmean decreased by 23%, 21% 
and 30% respectively. SUVmax reproducibility and 
response were similar. 
and is comparable to the real value of the degree 
of enhancement. This study aimed to determine 
the clinical feasibility of dual-energy CT in the 
evaluation of response after anti-angiogenic therapy 
of NSCLC.
Methods: Ten NSCLC patients treated with 
bevacizumab underwent CT scans were obtained 
before and 3 minutes after contrast material injection 
by using a scanner with a dual-energy technique. 
Image sets that included nonenhanced weighted 
average, enhanced weighted average, virtual 
nonenhanced (VNC), and iodine-enhanced images 
were reconstructed. CT numbers of NSCLCs on 
virtual nonenhanced and nonenhanced weighted 
average images were compared, and CT numbers 
on iodine-enhanced image and the degree of 
enhancement on average images (subtraction of 
CT number of a tumor on a nonenhanced weighted 
average image from its CT number on an enhanced 
weighted average image) were compared.
Results: CT numbers showed no signiÀcant 
difference between virtual nonenhanced and 
nonenhanced weighted average images (37.7 ± 6.5 
vs. 40.4 ± 6.3, respectively, P = .195, Wilcoxon test). 
CT numbers between iodine enhanced image and the 
degree of enhancement also showed no signiÀcant 
difference (33.7 ± 24.4 vs. 35.4 ± 24.6, respectively, 
P = .652).
Conclusion: Dual-energy CT may serve as useful tool 
for response evaluation after anti-angiogenic treatment 
in NSCLC, providing the degree of enhancement of 
NSCLC without additional radiation dose.
Keywords: non–small-cell lung cancer, Response 
evaluation, antiangiogenic therapy, dual-energy CT 
technique
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P2.291 EVALUATION OF FLT-PET AS 
EARLY PREDICTOR OF RESPONSE TO 
RADICAL RT IN PATIENT WITH NON-
SMALL CELL LUNG CANCER
Ioannis Trigonis1, Pek Koh2, Marie-Claude 
Asselin1, Mahbubunnabi Tamal1, Ben Taylor2, Tony 
Goldstone2, Emma Dean3, Ozlem Ataman4, Alan 
Jackson1, Corinne Faivre-Finn2, Fiona H. Blackhall2 
1Wolfson Molecular Imaging Centre, The University 
Of Manchester/United Kingdom, 2The Christie 
NHS Foundation Trust/United Kingdom, 3Paterson 
Institute For Cancer Research/United Kingdom, 
4Astrazeneca/United Kingdom
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evidence that these models have been validated in 
the UK population, in particular in patients who are 
managed by a Lung MDT Objective: To validate two 
existing clinical prediction models in patients with 
SPNs managed by the Lung MDT at a large teaching 
hospital in Northern England 
Methods: 175 patients (age range 32-92 years, 91 
females) with SPNs measuring 8–30 mm managed 
by the Lung MDT over a 3 year period (1st January 
2007 - 31st December 2009) were identiÀed 
retrospectively through the institutional Lung Cancer 
database. Data on age, smoking, cancer history, 
nodule size, location, spiculation, and Ànal diagnosis 
were collected. Each patient’s Ànal diagnosis was 
compared with the probability of malignancy 
predicted by two models: one developed at the 
Mayo Clinic and the other developed from patients 
enrolled in a Veteran Affairs (VA) Cooperative 
Study. The accuracy of each model was assessed 
by calculating areas under the receiver operating 
characteristic (ROC) curve and the models were 
calibrated by comparing predicted and observed rates 
of malignancy 
Results: The area under the ROC curve for the 
Mayo Clinic model (0.832; 95% CI 0.753-0.911) 
was higher than that of the VA model (0.739; 95% CI 
0.641-0.838) but this difference was not statistically 
signiÀcant. Calibration curves showed that both 
models slightly underestimated the probability 
of malignancy for patients across all deciles of 
predicted probabilities, except for those with highest 
probability of malignancy, where the VA model 
slightly overestimated the probability of malignancy
Conclusion: The two existing prediction models 
are sufÀciently accurate to guide decisions about 
management of patients with SPNs managed by the 
Lung MDT at a large teaching hospital in the UK
Keywords: Solitary pulmonary nodule, Cancer, 
Prediction model, CT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Conclusion: In agreement to previous studies (de 
Langen, 2009), our preliminary results demonstrate 
little baseline variation suggesting that one 
baseline scan is sufÀcient for comparison to an 
on- or post-treatment scan. To date, we observed 
less average decrease in primary tumour uptake 
(SUVmax, 26.6%, SUVmean 24.8%) compared 
to previous reports using comparable RT dose but 
with concomitant chemotherapy (SUVmax >40%) 
(Everitt, 2009). Recruitment is ongoing and results 
from analysis of blood borne cell death biomarkers 
in addition to updated results on FLT-PET will be 
reported.
Keywords: [F-18]Fluorothymidine PET, Non-small 
cell lung cancer, Radiotherapy
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P2.292 VALIDATION OF EXISTING 
CLINICAL PREDICTION MODELS 
FOR PATIENTS WITH SOLITARY 
PULMONARY NODULES (SPN) 
MANAGED BY A LUNG MULTI-
DISCIPLINARY TEAM (MDT).
Puneet Malhotra1, Natasha Lovell1, Paul K. Plant1, 
Shishir Karthik2, Andrew Scarsbrook2, Matthew E.J. 
Callister1 
1Respiratory Medicine, Leeds Teaching Hospitals 
NHS Trust/United Kingdom, 2Nuclear Medicine And 
Radiology, Leeds Teaching Hospitals Nhs Trust/
United Kingdom
Background: The management of patients with 
SPNs depends critically on the pre-test probability 
of malignancy. There are currently two clinical 
predictions models for SPNs based on data from 
North America. However, there is no published 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.294 A RADIOGRAPHIC AND 
PATHOLOGICAL ANALYSIS OF SMALL 
LUNG ADENOCARCINOMAS WITH AIR-
CONTAINING TYPE LESIONS BY USING 
COMPUTED TOMOGRAPHY
Takeshi Honda1, Tetsuro Kondo1, Miki Ohe1, 
Shuji Murakami1, Haruhiro Saito1, Funihiro 
Oshita1, Hiroyuki Ito1, Masahiro Tsuboi1, Haruhiko 
Nakayama1, Tomoyuki Yokose2, Yoichi Kameda2, 
Kouzo Yamada1 
1Department Of Thoracic Oncology, Kanagawa 
Cancer Center/Japan, 2Department Of Pathology, 
Kanagawa Cancer Center/Japan
Background: Cases of solitary small noninvasive 
peripheral lung tumors (adenocarcinoma in situ, 
AIS) with a 100% 5-year survival and minimally 
invasive adenocarcinoma (MIA, invasion diameter 
<= 5 mm) with approximately 100% 5-year 
survival have been reported. Based on thin-section 
computed tomography (TS-CT) Àndings, small 
lung adenocarcinomas are classiÀed as either air-
containing or solid-density type. Therefore, we 
analyzed the relationship between air-containing type 
and International Association for the Study of Lung 
Cancer classiÀcation of lung adenocarcinoma.
Methods: Of 308 consecutive patients with 316 
lesions who underwent surgical resection for 
peripheral lung adenocarcinomas (diameter, <=20 
mm) between April 2004 and October 2010, the 
TS-CT Àndings and pathologic specimens of 137 
patients with 142 air-containing lesions were 
reviewed.
By using TS-CT scan images, a tumor was classiÀed 
as an “air-containing” type if the maximum diameter 
of tumor opacity on the mediastinal window image 
was less than or equal to half of that seen on the 
lung window image and as a “solid-density” type if 
the maximum diameter on the mediastinal window 
image was more than half of that on the lung window 
image. “Disappearance rate” was deÀned as the 
percentage loss in the mediastinal window. Then, 
the invasion diameter of air-containing type was 
measured. The correlation between TS-CT scan 
Àndings (air bronchogram, pulmonary vascular 
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P2.293 CORRELATION OF THE 
STANDARDIZED UPTAKE VALUE IN 
FDG-PET WITH THE BIOLOGICAL 
MARKER IN LUNG ADENOCARCINOMA 
LESS THAN 3CM
Takuro Yukawa, Katsuhiko Shimizu, Yuji Hirami, Ai 
Maeda, Koichiro Yasuda, Masao Nakata 
General Thoracic Surgery, Kawasaki Medical 
School/Japan
Background: Fluorodeoxyglucose positron 
emission tomography (FDG-PET) has become an 
important tool for the diagnosis and the staging 
of non-small cell lung cancer. FDG-PET maximal 
standardized uptake values (SUV
max
) of primary 
lesion have been shown to have the correlation with 
some clinicopathological factors, but its biological 
mechanism is unclear. 
Methods: We conducted a retrospective review of 
60 patients who underwent preoperative FDG-PET 
and complete resection of lung adenocarcinoma 
less than 3cm. Immunohistochemical study 
for cyclooxygenase-2 (Cox-2), Ki-67, vascular 
endothelial growth factor (VEGF), thyroid 
transcription factor-1(TTF-1), phosphorylated 
epidermal growth factor receptor (pEGFR), insulin-
like growth factor 1 receptor (IGFR), and platelet-
derived growth factor receptor Ơ (PDGFRƠ) 
was performed, and the correlation between the 
expression of these biological markers and SUV
max
 
was evaluated. 
Results: A signiÀcant correlation was observed 
between the SUV
max
 and Cox-2, Ki-67, and VEGF 
expression. Cases which expressed the growth 
factor receptors tended to have higher SUV
max
, 
but it’s not signiÀcant. The expression of Cox-
2 was signiÀcantly associated with Ki-67 and 
VEGF expression, and the expression of VEGF 
was signiÀcantly associated with Cox-2, Ki-67, 
PDGFRƠ, and TTF-1 expression. EGFR mutation 
did not correlate with SUV
max
. 
Conclusion: The expression of Cox-2, Ki-67 
and VEGF is associated with the SUV
max
 in lung 
adenocarcinoma less than 3cm. These results 
showed that the SUV
max
 might reÁect the cellular 
proliferation and aggressiveness even in the small 
lung adenocarcinoma. 
Keywords: lung adenocarcinoma, FDG-PET, VEGF, 
COX2
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therapeutic responses in patients with non-small cell 
lung cancer (NSCLC). On the other hands, epidermal 
growth factor receptor (EGFR) mutation is the most 
important therapeutic predict factor to tyrosine 
kinase inhibitors (TKIs) in NSCLC, especially 
adenocarcinoma. The purpose of this study is to 
identify any particular imaging features on CT and 
SUV max of FDG-PET in patients with advanced 
NSCLC conÀrmed adenocarcinoma and known 
EGFR mutations, and to assess the relationship 
between the radiological features and the therapeutic 
response for EGFR TKIs.
Methods: Institutional review board approval 
was obtained for this retrospective study. For 
subsequent 49 patients with a histologic diagnosis 
of adenocarcinoma of advanced NSCLC and known 
EGFR mutation status between May and September 
2009, lesion density (part-solid versus solid) on thin-
section CT, SUV max of primary lesion and sites of 
metastases were assessed. And the imaging Àndings 
were compared with the therapeutic response (PD 
versus SD/PR).
Results: Thirty-one of the patients were female 
and eighteen were male. The majority of patients 
had stage IV disease. FDG-PET was performed in 
thirty-three patients. There were eight with part-solid 
and the other 41 with solid appearance of primary 
tumor on thin-section CT. The SUV max of primary 
tumor was ranged from 2.5 to 17.1 (mean; 9.3). Most 
of patients had multiple distant metastases, high 
frequent metastatic site were pleural dissemination, 
intrapulmonary and bone, respectively. 32 patients 
had exon 19 deletion type and 17 had L858R 
within exon 21 for EGFR mutation. Forty patients 
were administrated TKIs, geÀtinib for 36 patients 
and erlotinib for four. The mean duration of these 
medication was 244 days, ranged from 20 to 689. 
Therapeutic responses were evaluated as PR in 24, 
SD in 10 and PD in 6. The SUV max of primary 
tumor was not correlated with the duration of 
oral TKIs (Ƣ=-0.1266, p=0.5081 at Spearman’s 
coefÀcient). And CT Àndings of primary tumor 
did not also have a correlation with the duration of 
oral TKIs (solid vs. part solid, p=0.1043 at t-test). 
Furthermore, the SUV max of primary tumor had 
no relationship for therapeutic effect (p=1.000). But 
liver metastases were signiÀcantly lower than pleural 
dissemination (p<0.001), intrapulmonary (p<0.001), 
brain (p=0.0022) and bone metastases (p<0.001), 
respectively.
Conclusion: There was no speciÀc CT appearance 
of primary tumor in advanced lung adenocarcinoma 
convergent, pulmonary vascular involvement, 
indentation, notch, and disappearance rate) and 
pathological Àndings (subclassiÀcation) were 
investigated.
Results: Of the 142 air-containing lesions, 114 had 
AIS and 28 had MIA. The average diameter of tumor 
invasion in MIA was 2.3 mm (range, 0.5-5.0 mm). 
Invasive adenocarcinoma with invasion diameter of 
>5 mm, vascular invasion, and lymphatic invasion 
were not observed in air-containing lesions, and 
none of the patients has a recurrence. Both AIS and 
MIA showed air bronchogram, pulmonary vascular 
convergent, pulmonary vascular involvement, 
indentation, and notching. There was no signiÀcant 
difference in the correlation of TS-CT scan Àndings 
and the pathological Àndings.
Conclusion: Both AIS and MIA showed TS-
CT Àndings of lung adenocarcinoma, such as air 
bronchogram, pulmonary vascular convergent, 
pulmonary vascular involvement, indentation, and 
notching; therefore, TS-CT Àndings made nothing 
for diagnostic imaging of AIS and MIA.
Invasive adenocarcinoma with invasion diameter 
of >5 mm were not observed in air-containing type 
with diameters of <20 mm. In conclusion, small lung 
adenocarcinoma with air-containing type was AIS or 
MIA.
Keywords: minimally invasive adenocarcinoma, air-
containing type, thin-section computed tomography, 
adenocarcinoma in situ
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P2.295 RADIOLOGICAL FEATURES OF 
ADVANCED NON-SMALL CELL LUNG 
CANCER WITH THE PRESENCE OF 
EGFR MUTATION COMPARED WITH 
THERAPEUTIC RESPONSE FOR TKIS
Masahiro Endo1, Rieko Kaira2, Madoka Kimura2, 
Sakae Fujiwara2, Hiroaki Akamatsu2, Akira Ono2, 
Takehito Shukuya2, Tateaki Naito2, Hirotsugu 
Kenmotsu2, Asuka Tsuya3, Haruyasu Murakami2, 
Toshiaki Takahashi2, Nobuyuki Yamamoto2 
1Diagnostic Radiology, Shizuoka Cancer Center/
Japan, 2Thoracic Oncology, Shizuoka Cancer 
Center/Japan, 3Division Of Thoracic Oncology, 
Shizuoka Cancer Center/Japan
Background: Primary tumor maximum standardized 
uptake value (SUV max) of FDG PET has been 
studied as a potential factor for overall survival or 
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Conclusion: Good repeatability was found for all 
18F-FDG uptake measures with SUV
mean
 performing 
best. Because percentage repeatability was a function 
of the uptake level, we propose to use absolute- 
instead of percentage change for lesions with low 
uptake. 
Keywords: 18F-FDG PET, Repeatability, Cancer
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P2.297 REDUCTION OF STANDARDIZED 
UPTAKE VALUE IN 18F-FDG PET MIGHT 
REVEAL THE SIMILAR SURVIVAL 
BENEFIT OF STABLE DISEASE AND 
PARTIAL RESPONSE TO PLATINUM-
BASED CHEMOTHERAPY IN 
UNTREATED ADVANCED NON-SMALL 
CELL LUNG CANCER
Jinji Yang1, Shu-Xia Wang2, Ri-Qiang Liao2, Yi-
Sheng Huang3, Qing Zhou3, Hong-Hong Yan4, 
Chong-Rui Xu4, Yi-Long Wu4 
1Division Of Pulmonary Oncology, Guangdong 
General Hospital, Guangdong Academy Of Medical 
Sciences/China, 2Pet Center, Department Of 
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Background: 18F- Áuorodeoxyglucose positron 
emission tomography (18F-FDG PET) appears 
with the presence of an EGFR mutation, and no 
relationship between radiological features and tumor 
response for EGFR TKIs. 
Keywords: Non small cell lung cancer, 
Adenocarcinoma, EGFR mutation, FDG PET
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P2.296 REPEATABILITY OF SERIAL 
18F-FDG UPTAKE MEASUREMENTS 
IN TUMORS USING PET: A META-
ANALYSIS
Adrianus Johannes De Langen1, A. Vincent2, Ronald 
Boellaard3, Harm Van Tinteren2, Egbert F. Smit1, 
Otto S. Hoekstra3 
1Pulmonary Diseases, VU University Medical 
Center/Netherlands, 2National Cancer Institute/
Netherlands, 3VU University Medical Center/
Netherlands
Background: Although guidelines are yet based on 
anatomic size measurements (RECIST) these criteria 
have limitations, particularly with newer anti-cancer 
therapies that stabilize disease. Metabolic response, 
assessed by PET, might add to size measurements. 
To discriminate true signal changes from noise the 
repeatability needs to be known. 
Methods: A systematic literature search was 
performed to identify studies addressing 18F-FDG 
repeatability in malignant tumors. For each of four 
PET uptake measures, SUV
max
, SUV
mean
, K
i
 and 
MR
glu
, the level of agreement between test and retest 
values was assessed with the CR95. The relation 
between the test-retest ratio and the level of uptake 
and tumor volume was evaluated with generalized 
linear mixed effects models. Principle component 
transformation was used to compare the repeatability 
of the four different uptake measures. 
Results: Seven repeatability studies were identiÀed. 
Percentage repeatability was a function of the level 
of uptake (Figure). Therefore, a binary model was 
developed in which the absolute change between the 
test and retest scan was used for tumors with low 
uptake values and the percentage change for tumors 
with high uptake values (Table). Tumor volume did 
not affect SUV
mean
 repeatability, but K
i
 and MR
glu
 had 
poor repeatability at tumor volumes below 4.5 cm3. 
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types of effusion. FDG PET-Ct is an noninvasive 
imaging method which is widely used to staging lung 
cancer. 
Methods: For two years period, 52 of patients 
histological proven nonsmall cell lung cancer 
patients with pleural effusion who were performed 
FDG PET-CT for staging prosedure lung cancer was 
evaluated
Results: Patients pleural Áuid volume (Min-
modarate-massive), FDG PET-CT Àndings, pleural 
Áuid pathological and biochemical parameters 
(transudate/exudate) were determined. Results 
of FDG PET-CT Àndings were coraleted with 
pathologica diagnosis of pleural Áuid or pleural 
biopsy. Senstivity, spesiÀty, accuracy, PPV and NPV 
of FDG PET_CT for detecting malignant pleural 
effusion were calculated. 
Conclusion: FDG PET_CT may be useful in 
differantiation malignant or benign pleural effusion 
in patients with NSCLC 
Keywords: pleural effusions, malignant/ benign, 
FDG PET_CT, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.299 CAN PET-CT BE A PROGNOSTIC 
FACTOR IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER?
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1Oncology Clinic, Yedikule Chest Disease And 
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Background: Although advanced diagnostic and 
theraphautic development are achieved, lung cancer 
is the most leading cause of death in both gender 
around the world. The stage of tumor is stil the most 
important factor in determining the prognosis of 
lung cancer. Since even at the same stage, survival 
rates are different and additional factors are needed 
for determining the prognosis. In this study, in order 
to determine the role of FDG-PET([18F]-Áuoro-2-
deoxy-D-glucose Positron Emission Tomography) 
particularly valuable in stable disease (SD). This 
prospective study was undertaken to evaluate the 
impact of SD and partial response (PR) to platinum-
based chemotherapy in advanced non-small cell lung 
cancer (NSCLC) on survival in terms of maximum 
standardized uptake value (SUV
max
) reduction in 
18F-FDG PET after two cycles of chemotherapy. 
Methods: Untreated patients with advanced 
NSCLC recommended to undergo platinum-based 
chemotherapy were eligible for this study. They did 
18F-FDG PET at the baseline and after two cycles of 
chemotherapy.
Results: 43 patients were enrolled from August 
2003 to May 2007. Median progression-free survival 
(PFS) was 6.0 months (95%CI, 4.8 7.2) for 16 
achieving SD and 6.2 months (95%CI, 4.3 8.1) 
for 18 achieving PR, p = 0.965. Median overall 
survival OS was 20.0 months (95%CI, 2.0 38.0) 
and 15.0 months (95%CI, 6.7 23.3) respectively, p 
= 0.194. PFS was signiÀcantly correlated with Àrst-
line response (p = 0.013), but OS was signiÀcantly 
correlated with Àrst-line response (p = 0.009) and 
epidermal growth factor receptor tyrosine kinase 
inhibitors in the 2nd or 3rd-line setting (p = 0.010). 
Mean SUV
max
 at the baseline was signiÀcantly 
correlated with that after two cycles of chemotherapy 
for SD patients (r = 0.853, p = 0.000) and PR 
patients (r = 0.658, p = 0.003) respectively, and mean 
SUV
max
 reduction was of signiÀcant difference for 
SD patients (p = 0.014) and PR patients (p = 0.000) 
respectively. 
Conclusion: A signiÀcant SUV
max
 reduction 
in 18F-FDG PET might reveal the similar 
survival beneÀt of SD and PR to platinum-based 
chemotherapy in untreated advanced NSCLC.
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P2.298 EVALUATION OF PLEURAL 
EFFUSION IN PATIENTS WITH 
NONSMALL CELL LUNG CANCER 
USING FDG PET-CT
Berna E. Kömürcüoùlu, A kadri Cirak, Hakan 
Koparal, Serpil Tekgul 
Pulmonology, Dr. Suat Seren Education And Traning 
Hospital For Chest Disease And Surgery/Turkey
Background: Pleural effusions frequently seen 
in patients with lung cancer. Many of them are 
malignant but some of them are benign, reactive 
Áuid. Sometimes it can be difÀcult to differentiate 
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P2.300 MULTICENTER EXPERT 
PANEL REVIEW OF FDG-PET/CT 
FOR RADIOTHERAPY PLANNING 
IN LOCALLY ADVANCED NSCLC: 
ADRESSING THE CHALLENGE OF 
INTER-OBSERVER VARIABILITY
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Vach10, Wolfgang Weber11, Anca-Ligia Grosu1 
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Mainz/Germany, 10Institut Für Medizinische 
Biometrie Und Medizinische Informatik Der 
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Universitätsklinikum Freiburg/Germany
Background: To guarantee quality assurance in 
a randomized multicenter study on PET-based 
radiotherapy planning in locally advanced lung cancer 
(PET-Plan*), mediastinal and hilar lymph nodes 
(LN) of study patients are reviewed for visual FDG-
positivity and anatomical localisation by an online 
panel of 9 experts via an electronic Case Report 
Form (eCRF; Alcedis, Giessen). During the review 
process, two blinded observers independently evaluate 
PET/CT datasets of each study patient. In case of 
discrepancies an additional review by a third non-
blinded observer is performed. In order to minimize 
the interobserver variability within this panel, we 
initiated a harmonisation process to establish detailed 
criteria of PET-reading and reporting. 
as a prognostic factor in patients with non-small 
cell lung cancer, the relationship between SUVmax 
(maximum Standardized Uptake Value) and 
histological and TMN characteristics of the tumor 
were evaluated.
Methods: The data of 77 lung cancer patients, 
pathologically diagnosed as NSCLC, admitted to the 
Department of Chest Disease, School of Medicine, 
University of Çukurova between June 2006 and 
August 2009 were retrospectively analyzed.The 
patients were followed up till August 2010. 
Results: The mean age of the patients included into 
the study were 77 (5 female (6,5%) mean age was 
57 years (range 32-81). Histological distribution of 
patients was as follows 34(44,2%) adenocarcinoma, 
29(37,7%) squamous carcinoma, 14 (18,2%) 
undetermined NSCLC. While 24 (31,2%) patients 
were at stage I-III, 53 (68,8%) patients were at stage 
IV. We found no signÀcant correlation between 
SUV max value and TNM stages, N values, and 
histological types were detected. But, in case of 
tumor size, SUV max was found to be higher in 
tumors larger that 3 cm (n=57, 13,11 ± 6,46; p=0.02). 
No signiÀcant correlation between the SUV max 
value and the histological types of the tumor except 
in the undetermined group of NSCLC in which 
weak positive correlation with SUV max value was 
determined in this group when the cut off value 
of the SUV max was taken as 7 (n=14, p=0.052). 
Also, patients with SUV max greater than 7 were 
signiÀcantly more in the group having a tumor size 
greater than 3 cm (p=0.002). However none of the 
parameters including histological subtype, TNM 
stage, N value, and SUV max value of tumor were 
found to be correlated with the survival. On the other 
hand, by cox regression analyses, it was seen that each 
one milimeter increase of the tumor size, increases 
the percentage of death by 1,6%. (95% CI, 1.0011-
1.0309) and tumor size was found to be statistically 
signiÀcantly correlated with the survival (p=0,049). 
Conclusion: In our study, tumor size found to be the 
only signiÀcant determinate of the survival, patients 
with SUV max greater than 7 were signiÀcantly 
more in the group having a tumor size greater than 3 
cm.But,no signiÀcant correlation was found between 
survival and histological subtype, TNM stage, N 
value, and SUV max value of tumor in NSCLC. We 
conclude that further prospective and multicentric 
studies with larger patients groups are needed to 
identify parameters effecting FDG uptake and the 
relation of SUV with prognosis in NSCLC. 
Keywords: Prognosis, NSCLC, FDG PET
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P2.301 NON-INVASIVE 
BIOCONDUCTANCE MEASUREMENT 
AS ADJUNCTIVE DIAGNOSTIC 
TECHNIQUE OF LUNG CANCERS IN 
SUBJECTS WITH ABNORMAL CHEST 
CT.
Rex C. Yung1, Mingying Zeng2, Greg Stoddard3, 
Karleen Callahan4 
1Medicine, Oncology, Pulmonary & Critical Care, 
Johns Hopkins University/United States Of America, 
2Pulmonary And Critical Care Medicine, Johns 
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4Clinical Affairs, Freshmedx/United States Of 
America
Background: Recent Àndings conÀrm utility of 
chest CT screening in reducing lung cancer (LC) 
mortality in high-risk populations. While the 
majority of CT-detected lung nodules (85 – 95%) 
are benign, a clinical decision is necessary. The 
bioelectrical properties of cancerous tissue vary 
signiÀcantly from benign tissue. We hypothesize 
that cutaneous bioconductance could help in 
distinguishing benign from malignant CT-detected 
chest lesions. Having an adjunctive diagnostic 
technology that’s non-invasive and discriminates 
between the need for more ionizing radiation studies 
or biopsies versus observation would be valuable. 
Methods: Forty-one subjects, 22 male, 19 female 
(ages 34-80) were evaluated for possible LC based 
on at least one suspicious radiological Ànding, a non-
calciÀed nodule. Subjects were measured with the 
trans-thoracic Bioconductance Scan Platform (BSP). 
The BSP device collects measurements at several 
anatomical locations across the thorax and other sites 
providing conductivity data. Measurement sessions 
were completed prior to tissue diagnosis. 
Results: 29 subjects had conÀrmed LC by pathology 
(26 NSCLC, 2 SCLC, 1 carcinoid) with mass sizes 
ranging from 0.4 cm to 14.6 cm, median 2.8 cm. 12 
subjects had a benign outcome based on pathology 
(9) or by stable follow-up CT scans (3) at 2, 4 and 
8 months. For each subject a composite score from 
the collected data was calculated and an optimal cut-
point set for discriminating between the malignant 
and benign outcomes chosen. BSP data for malignant 
cases resulted in 26 true positives (including 2 
with small masses of 0.8 cm) and 3 false negatives 
Methods: For the harmonisation process ten 
discrepantly reported study cases during the early 
(oder initial) stage of the panel were re-evaluated 
in a blinded manner by all panel members for 
FDG-positive lymph nodes and their anatomical 
localisation according to an atlas. As a result of this 
process detailed criteria for reading and reporting 
FDG-PET within the context of the study could be 
elaborated . These criteria were applied to image data 
of 13 non-study patients with 42 mediastinal lymph 
nodes, for which biopsy results were available. 
Results: Before the harmonisation process, inter-
observer variability among the observers was in the 
range of literature (kappa around 0,6 for detecting 
positive mediastinal and hilar lymph nodes in FDG-
PET). Inter-observer agreement was particularly poor 
for the conjoint evaluation of hilar lymph nodes and 
of rarely affected lymph node stations. Therefore, 
the criteria for reading and reporting PET elaborated 
by the panel tackled the following issues: conjoint 
evaluation of nodal stations 1/ 2 and 10/11, positive 
reporting of node stations in direct neighborhood 
of the primary tumour, reporting only the primarily 
affected positive lymph node station in the case of 
a LN < 15 mm in equivocal anatomical location 
while positively reporting all affected stations in 
case of larger or bulky lymph nodes Furthermore, 
the pre-test probability is taken into account in cases 
of equivocal FDG-accumulation. In comparison to 
biopsy results, none of the tumor affected nodes was 
read negative by the panel in consensus, while a 
relevant but acceptable rate of nodes were reported 
falsely positive. 
Conclusion: Despite a relevant inter-observer 
variability, whose improvement will be subject to 
further studies, there was an encouraging agreement 
of the expert panel concerning the detection of tumor 
affected nodes. This is an important Ànding in the 
context of the use of FDG-PET for radiotherapy 
planning, supporting the restriction of target volumes 
to FDG-positive lymph node regions only. * 
Supported by Deutsche Krebshilfe 
Keywords: Interobserver Variability, FDG-PET/ CT, 
Expert Panel
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of decision making in patients with SPN. 
Methods: A total of 36 SPN in 36 patients (15 
female; 21 male; age range, 32-83 years) were 
included in this retrospective study. The Ànal 
diagnosis was conÀrmed by histopathologically 
or follow-up by CT. Two PET/CT scans were 
performed one (early) and two hours (delayed) 
after injection of F-18 FDG. SUV values (early and 
delayed SUVmax and SUVmean adjusted to body 
weight; SUVmax and SUVmean adjusted to BSA, 
LBM and GLC); retention index (RI); nodule to 
mediastinum (nodule activity/subcarinal roi activity) 
ratios (nod/med) were calculated. The sensitivity, 
speciÀcity, negative (NPV) and positive predictive 
values (PPV) and accuracy of early and delayed 
F-18 FDG PET/CT (both visual and semiquantitative 
assessments) and low dose non-enhanced CT were 
calculated. ROC curves were obtained for each SUV 
parameter, nod/med ratio and RI. The threshold 
values were calculated in the terms of highest 
sensitivity and speciÀcity points. 
Results: Histopathological evaluations and 
follow up of the patients revealed 16 patients had 
malignant tumour whereas 20 patients had benign 
lesions. There was no statistical difference between 
malign and benign SPN patients in the terms of 
height, injection dose of F18 FDG, weight, blood 
glucose, BSA and LBM values. The median (min-
max) SUVmax values were 1.5 (0.5-4.1) in benign 
group and 4 (1.3-38) in malign SPN group. Early 
and delayed SUVmax, SUVmean, BSA-SUVmax, 
BSA-SUVmean, LBM-SUVmax, LBM-SUVmean, 
GLC-SUVmax, GLC-SUVmean ve nod/med values 
were statistically higher in malign SPN group than 
benign group. The sensitivity, speciÀcity, NPV, 
PPV and accuracy of low dose non-enhanced CT 
was 88%, 50% and 67% respectively. With the 
threshold value of early SUVmax as 2.5 and 3.05 
that is obtained from our population using ROC 
curve, 94-75% sensitivity, 75-80% speciÀcity and 
83-78% accuracy were calculated respectively. With 
the same threshold values for delayed scan, 100-
88% sensitivity, 75-85% speciÀcity and 86-86% 
accuracy were obtained respectively. The delayed 
BSA-SUVmax and LBM-SUVmax had 100% 
sensitivity, 80% speciÀcity in the determining SPN 
characterization. 
Conclusion: The study showed that dual Phase PET/
CT might increase the diagnostic potential of F-18 
FDG PET in the characterization of SPN. BSA, 
LBM and glucose corrected SUV values did not have 
better diagnostic performance compared to routine 
(including the carcinoid case), for a 90% sensitivity. 
For 12 benign cases, 1 false positive and 11 true 
negatives yield a speciÀcity of 92%. Thus, the 
overall ROC from BSP analysis was 91%. 
Conclusion: A high-precision transthoracic 
BSP can non-invasively provide bioconductance 
measurements that are scored to have a strong 
association with an in-vivo thoracic malignancy. It’s 
simple to perform, involves no ionizing radiation, 
and differs from other LC “biomarkers” by focusing 
strictly upon characterization of an already identiÀed 
indeterminate lung mass. A technology that will 
provide adjunctive information to CT scanning to 
determine the most appropriate diagnostic pathway, 
either biopsy or further follow-up, would be an 
important advance for the clinician. 
Keywords: Bioconductance, Adjunctive Diagnostic 
Technique, BSP - Bioconductance Scan Platform
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P2.302 THE DIAGNOSTIC ROLE OF 
DUAL PHASE F-18 FDG PET/CT IN 
CHARACTERIZATION OF SOLITARY 
PULMONARY NODULES
Yusuf Demir1, Berna Degirmenci Polack1, Sinan 
Genç2, Canan Karaman3, Duygu Gurel4, Sadet 
Ayhan1, Nezih Ozdemir5, Emine Osma2, Atila 
Akkoclu3 
1Nuclear Medicine, Dokuz Eylul University School 
Of Medicine/Turkey, 2Radiology, Dokuz Eylul 
University School Of Medicine/Turkey, 3Department 
Of Chest Diseases, Dokuz Eylul University School Of 
Medicine/Turkey, 4Pathology, Dokuz Eylul University 
School Of Medicine/Turkey, 5Chest Surgery, Dokuz 
Eylul University School Of Medicine/Turkey
Background: Our objective was to evaluate the 
diagnostic role of dual phase F-18 FDG PET/CT 
in the characterization of the solitary pulmonary 
nodules (SPN). We also compared the SUV variables 
adjusted to body surface area (BSA), lean body mass 
(LBM) and blood glucose level (GLC) in the terms 
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medicine physician. Eligible patients were 
treated with a therapy activity of 7.9GBq 177Lu-
octreotate administered with as a day patient at 
Fremantle Hospital with concomitant amino acid 
nephroprotection and tropisetron emesis prophylaxis. 
Whole body gamma imaging at 4hrs and 24hrs was 
performed.
Results: Since January 2010, X eligible patients 
with bronchial carcinoid have been identiÀed with 
68Ga-DOTATATE and treated with Lu-177 tagged 
Octreotate combined with Capecitabine. Our 
preliminary results are positive with a symptomatic 
improvement observed in most patients and possibly 
a survivial beneÀt. No serious side effects have been 
observed to date. FIGURE - 68Ga-DOTATATE 
PET/CT demonstrating uptake in right upper lobe 
bronchial carcinoid (UNABLE TO ATTACH 
FIGURE)
Conclusion: Early experience in Western 
Australia has conÀrmed 68Ga-DOTATATE is a 
good alternative to FDG18-PET/CT in imaging of 
bronchial carcinoids and assessment of suitability 
for treatment including 177Lu-octreotate with 
oral capecitabine. Initial results in our pilot group 
indicate symptomatic improvement and possibly a 
survival beneÀt.
Keywords: Neuroendocrine, PET/CT, Ga-
DOTATATE
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.304 18F-FDG PET/CT SCAN AND 
ULTRASOUND GUIDED TRANS-
BRONCHIAL/TRANS-TRACHEAL 
LYMPH NODE NEEDLE ASPIRATION 
(EBUS/EUS) IN RESTAGING OF 
LOCALLY-ADVANCED (LA) NON-
SMALL CELL LUNG CANCER 
(NSCLC) TREATED WITH INDUCTION 
CHEMOTHERAPY FOLLOWED BY 
3-DIMENSIONAL-HYPOFRACTIONATED 
ACCELERATED RADIOTHERAPY 
(3D-HAR): OUR EXPERIENCE.
Giovenzio Genestreti1, Sara Piciucchi2, Giampaolo 
Gavelli2, Federica Matteucci3, Riccardo Galassi3, 
Elisabetta Parisi4, Rolando Polico4, Emanuela 
Scarpi5, Venerino Poletti6, Carlo Gurioli6 
body weight adjusted SUVmax values. SUVmax 
as 2.5 for early images and SUVmax as 3.05 for 
delayed images were acceptable threshold values 
in the characterization of SPN by F-18 FDG PET/
CT. In this particular study group, a threshold value 
cannot be determined for retention index, but higher 
retention index values may show higher malignant 
potential in solitary pulmonary nodules. 
Keyword: F-18 FDG PET/CT, SUV, Solitary 
pulmonary nodule, dual phase PET/CT
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P2.303 A NOVEL APPROACH TO 
IMAGING AND TREATMENT 
OF BRONCHIAL CARCINOIDS - 
EXPERIENCE IN WESTERN AUSTRALIA
Liesl Celliers 
Radiology, Fremantle Hospital/Australia
Background: Treatment options in advanced-
stage neuroendocrine tumors are limited. There 
is a promising new therapy in which radioactive 
atoms are attached to molecules that target and 
bind to neuroendocrine cancer cells. In Western 
Australia several patients with bronchogenic 
carcinoid tumours have received Lutetium-177 
(Lu-177) Peptide Receptor Radionuclide Therapy 
(PRRT). Lu-177 tagged Octreotate (a somatostatin 
analogue) is combined with a radiosensitizing 
chemotherapy agent (Capecitabine). To identify 
eligible patients, imaging has been performed using 
68Ga-1,4,7,10-tetraazacyclododecane-tetraacetic 
acid-D-Phe1,Tyr3-octreotate (DOTATATE), a 
novel selective somatostatin receptor PET ligand. 
Bronchial carcinoids typically have low glucose 
turnover, and 18F- FDG is thought to be of limited 
use in these patients. Compared with18F-FDG in 
the detection of pulmonary neuroendocrine tumors 
68Ga-DOTATATE is more speciÀc and has been 
shown to be superior in discriminating endobronchial 
tumor from distal collapsed lung.
Methods: Images were acquired 60 min after 
injection of 120MBq of 68Ga- DOTATATE. Imaging 
was performed using a dedicated GE Discovery 
ST camera combining a PET unit and a 16-slice 
CT unit; whole-body examinations (brain to mid 
thigh) were performed with the patient supine. 
The 68Ga-DOTATATE and 18F-FDG PET/CT 
studies were reviewed for areas of abnormally 
increased tracer uptake by an experienced nuclear 
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restaging with 18F-FDG PET/CT scan in order to 
distinguish sensitive from resistant disease for the 
different prognosis in these two groups of patients. 
The major beneÀt of this modality is the possibility 
to distinguish Áogosis to pathological involvement of 
mediastinum. Supported by GIPO. 
Keywords: EBUS, EUS
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.305 POSITRON EMISSION 
TOMOGRAPHY CAN DETECT 
POSTOPERATIVE RECURRENCE OF 
THE LUNG CANCER ANTECEDENT 
TO THE ELEVATION OF SERUM 
CARCINOEMBRYONIC ANTIGEN
Daishiro Kato, Junichi Shimada, Kunihiko Terauchi, 
Kazuhiro Ito, Masanori Shimomura, Hiroaki 
Tsunezuka, Kaori Ichise 
Department Of General Thoracic Surgery, Kyoto 
Prefectural University Of Medicine/Japan
Background: Lung cancer very often recurs even 
though curative surgical resection has performed. 
It is important to manage the patients with 
postoperative state for lung cancer, but it is still 
controversial. In this study, we show the usefulness 
for postoperative screening of lung cancer with 
positron emission tomography (PET) or PET-
computed tomography (PET-CT).
Methods: Forty-eight patients who had shown 
postoperative relapse of lung cancer were enrolled 
in this study. They were 32 male and 16 female, 
and their mean age at surgery was 67.7 years. The 
pathological tumor stage at surgery was IA in 10 
patients, IB in 19, IIA in 1, IIB in 8 and IIIA in 10. 
They received postoperative surveillance with serum 
carcinoembryonic antigen (CEA) and PET/PET-CT
at 6, 12, 18, 24, 36, 48, 60 months after operation.
Results: Forty-three of 48 patients were pointed out 
the tumor relapse on scheduled screening, whereas 
the others were at unscheduled time.
The recurrent site was as follows; 18 of local 
recurrences (tumor relapse at surgical stump in 4 
patients, intra-thoracic lymph node metastasis in 9 
and pleural dissemination in 6), and 30 of distant 
metastases to lung (n=14), bone (n=7), brain (n=4), 
1Oncology, Irst Meldola/Italy, 2Radiology, Irst/Italy, 
3Nuclear Medicine, Irst/Italy, 4Radiotherapy, Irst/
Italy, 5Unit Of Biostatistics, Irst/Italy, 6Pneumology, 
Hospital Morgagni/Italy
Background: Accurate restaging in patients 
with LA-NSCLC treated with chemotherapy and 
radiotherapy plays an important role in determining 
the patient outcome, because it is well known that 
lymph node down staging after treatment completion 
is the most indicator of better survival in this setting. 
However invasive restaging after multimodality 
therapy may be very difÀcult. 18F-FDG PET/CT 
scan is a non-invasive exam allows the monitoring 
of clinical result obtained by treatment. EBUS/EUS 
allows a cito- histological sample of mediastinal 
suspected masses and/or lymph nodes to distinguish 
benign Áogosis to malignant involvement. We 
investigated the concordance of EBUS/EUS and 
18F-FDG PET/CT scan in mediastinal restaging.
Methods: We collected all clinical data about 
all consecutive patients with LA-NSCLC which 
performed a 18F-FDG PET/CT scan before 
induction chemotherapy containing platin followed 
by 3D-HAR. At treatment completion patients 
performed a restaging with 18F-FDG PET/CT scan 
and EBUS/EUS. We matched the 18F-FDG PET/CT 
scan results with those reported by EBUS/EUS and 
cito- histological specimens. 
Results: From May 2007 to December 2010, overall 
12 consecutive patients have been analyzed: there 
were 10 (83%) males and 2 (17%) females, with a 
median age of 62 (range: 50 – 74) years. There were: 
5 (42%) adenocarcinoma, 4 (33%) squamous cell 
carcinoma, 1 (8%) great cell carcinoma and Ànally 
2 (17%) NSCLC not other speciÀed. Pathological 
mediastinal lymph node involvement was reported 
in 6 (50%) patients. In 5(42 patients, pathological 
involvement was absent and in one case was not-
diagnostic (8%) . Overall there were 11 (92%) 
stage IIIA and 1 (8%) stage IIIB disease with a left 
emithorax involvement in 6 (50%) patients, right 
emithorax involvement in 5 (42%) patients and 
Ànally unknown side in 1 (8%) patients. Overall 
positive EBUS/EUS procedures had similar positive 
18F-FDG PET/CT scan. However in 5 (42%) patients 
EBUS/EUS didn’t show a lymph node involvement, 
as PET had pointed probably due to the false positive 
related to Áogosis. 
Conclusion: In LA-NSCLC treated with 
multimodality therapy, it seems reasonable to 
perform EBUS/EUS already done to complete the 
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Methods: Between July 2010 and January 2011, 
42 patients with primary and metastatic lung cancer 
underwent radical surgical resection of the lungs 
at Ehime University Hospital. The imaging sets of 
34 of these patients undergoing FDG-PET/CT and 
multidetector CT at our institute were included in 
the present study. All patients underwent FDG-
PET/CT with a GE Discovery 600 (GE Healthcare, 
Milwaukee, WI) for clinical indications. Images 
were analyzed using a GE Advantage Workstation 
VolumeShare 4 (GE Healthcare, Milwaukee, 
WI), capable of advanced image processing and 
manipulation. ModiÀed average SUV was evaluated 
using the following formula: modiÀed average SUV 
= average SUV/tumor volume × (CT number + 
1000). We considered a lung tumor as an ellipsoid 
body and calculated the volume of these tumors 
using the following formula: (4 ×  × r1 × r2 × 
r3)/3 (r1 is the width axis radius, r2 is the length 
axis radius, r3 is the height axis radius). Data were 
analyzed using Student’s t test. 
Results: In this patient population, 20 showed 
pathological Stage I NSCLC, 4 showed Stage II, 4 
showed Stage III, and 6 showed lung metastases. 
Histological diagnosis revealed adenocarcinoma 
(ad) in 20, squamous cell carcinoma (sq) in 7, 
pleomorphic carcinoma in 1, and lung metastases in 
6. The modiÀed average SUV of pathological Stage 
I, II, III NSCLC, and lung metastasis was 0.96, 0.11, 
1.61, and 3.17, respectively. The modiÀed average 
SUV of pathological Stage I was signiÀcantly higher 
than that of Stage II (p = 0.037) and lower than that of 
metastasis (p = 0.002). However, the modiÀed average 
SUV of pathological Stage II was signiÀcantly lower 
than that of metastasis (p = 0.031). Furthermore, the 
modiÀed average SUV of ad, sq, and lung metastasis 
was 1.47, 1.04, and 3.17, respectively. No signiÀcant 
difference was observed between the modiÀed 
average SUV of ad and sq (p = 0.414). However, the 
modiÀed average SUV of ad was signiÀcantly lower 
than that of metastasis (p = 0.001). 
Conclusion: SUV is calculated as a ratio of tissue 
radioactivity concentration at time and injected dose 
at the time of injection divided by body weight. 
Therefore, it is necessary to consider tumor volume 
and density in order to characterize malignant 
tumors. Studies with a larger number of patients and 
modalities to estimate tumor volume and density 
are required to acquire more information regarding 
tumors detected with FDG-PET/CT. 
Keywords: Lung cancer, Positron Emission 
tomography
liver (n=1) etc.). Recurrent tumors were mainly 
detected with PET or PET-CT. Only 4 cases elevated 
serum CEA level prior to detection of PET-CT 
imaging. Most of the patients whose relapsed tumor 
was detected by PET/PET-CT still showed normal 
serum CEA level. The patients without PET/PET-CT 
abnormalities recurred with pleural dissemination or 
brain metastasis.
Conclusion: Regular screening with PET/PET-CT 
could spend less time and cost. It could tell us not 
only possibility of recurrence like serum CEA level 
do, but also it’s location and spread. Then we can 
treat patients immediately.
We herein show that detection of tumor recurrence 
by PET/PET-CT is earlier than by serum tumor 
marker examination. Whole-body PET/PET-CT and 
brain MRI are recommended for tumor screening. 
Postoperative PET/PET-CT screening could lead us 
earlier detection and treatment for recurrent tumor.
Keywords: outpatient, Non small cell lung cancer, 
Positron Emission tomography
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P2.306 PRELIMINARY STUDY ON 
THE CORRELATION BETWEEN 
TUMOR CHARACTERISTICS 
AND THE FLUORINE-18-
FLUORODEOXYGLUCOSE UPTAKE 
VALUE, CONSIDERING THE VOLUME 
AND DENSITY OF LUNG TUMORS
Yoshifumi Sano, Mikio Okazaki, Hitoshi Katayama, 
Kazunori Irifune, Ryoji Ito 
Center Of Chest Medicine And Surgery, Ehime 
University School Of Medicine/Japan
Background: Fluorine-18-Áuorodeoxyglucose 
(FDG)–positron emission tomography (PET)/
computed tomography (CT) has been recognized as 
a useful tool for characterizing pulmonary lesions. 
Furthermore, the maximum standardized uptake value 
(SUVmax) on FDG-PET/CT can help in prognosis of 
non-small cell lung cancer (NSCLC); however, the 
volume or density of these lesions must be known. 
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angiogenesis
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P2.308 AT PERIPHERAL AND CENTRAL 
LUNG TUMORS, THE IMPORTANCE 
OF SUV MAX VALUE OF PET-CT AND 
TUMOR NECROSIS IN SELECTION OF 
DIAGNOSTIC METHODS
Pinar Mutlu1, Hakan Cayvarli2, Atila Akkoclu1, 
Berna Degirmenci Polack3 
1Chest Diseases, Dokuz Eylul Universty/Turkey, 
2Nuclear Medicine, Dokuz Eylul Universty, Izmir, 
Turkey/Turkey, 3Nuclear Medicine, Dokuz Eylul 
University School Of Medicine/Turkey
Background: At Peripheral And Central Lung 
Tumors, The Importance Of Suv Max Value Of Pet-
Ct And Tumor Necrosis In Selection Of Diagnostic 
Methods 
Methods: In this study,we wanted to compare , 
tissue necrosis and the intensity with the SUV max 
values at PET-CT in the diagnosis of central and 
peripheral lung tumors. 45 (88.3%) were male and 
6 (11.7%) were female, mean age of 66.59 ± 10.05, 
34 (66.7%) peripheral and 17 (33, 3%) central , 
total of 51 cases with lung tumors , the presence of 
necrosis and the intensity were compared with SUV 
max values at PET-CT for the selection of diagnostic 
methods. 
Results: In peripheral tumors ten of them were 
diagnosed with transthoracic Àne-needle aspiration 
biopsy, 7 cases with bronchial biopsy, 6 cases with 
bronchial brushing,two cases with bronchial lavage, 
two cases with mediastinoscopy, three cases with 
endobronchial biopsy and 4 cases with thoracotomy.
In central tumors eight of them were diagnosed with 
endobronchial biopsy, three cases with bronchial 
biopsy, one case with bronchial brushing, one case 
with transbronchial Àne needle aspiration biopsy, 
one case with mediastinoscopy and three cases with 
thoracotomy. Tumors were evaluated with PET-
CT SUV max values and necrosis; in peripheral 
tumors, 11 of them with central necrosis, 6 of them 
peripheral necrosis and 3 cases had both central and 
peripheral necrosis. There was no necrosis in 14 
cases and the mean SUV max values of 13.02 ± 6.43.
In central tumors, one of them with central necrosis, 
two of them with peripheral necrosis, and 2 of them 
had both central and peripheral necrosis, therefore 12 
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P2.307 FUNCTIONAL IMAGING OF 
LUNG CANCER USING DUAL ENERGY 
CT: HOW DOES IODINE RELATED 
ATTENUATION CORRELATE WITH 
STANDARDIZED UPTAKE VLAUE OF 
18FDG-PET-CT?
Christian Fink1, Thomas Henzler1, Tian Qing Chu1, 
Mathias Meyer1, Paul Apfaltrer1, Radko Krissak1, 
Dietmar Dinter1, Stefan O. Schoenberg1, Christian 
Manegold2, Gerald Schmid-Bindert2 
1Institute Of Clinical Radiology And Nuclear 
Medicine, University Medical Center Mannheim/
Germany, 2Interdisciplinary Thoracic Oncology, 
University Medical Center Mannheim/Germany
Background: Functional imaging is a promising 
approach to improve the response assessment of lung 
cancer after therapy. Dual energy CT is a new CT 
technique which allows a selective visualization of 
intravenously injected iodinated contrast media as a 
surrogate for blood volume in tumor. The purpose of 
this study was to investigate the correlation between 
maximum standardized uptake value (SUV
max
) of 
18FDG PET-CT and iodine-related attenuation (IRA) 
of dual energy CT in patients with lung cancer. 
Methods: In a retrospective study 37 patients with 
lung cancer (27 NSCLC, 10 SCLC, 86 PET-CT 
positive thoracic lymph nodes (LN)) who underwent 
both 18FDG PET-CT and DECT were analyzed. While 
the mean study intervals between 18FDG PET-CT and 
DECT was 27±31 days, it was 21 days in 17 patients. 
The mean and maximum IRA of DECT was analyzed 
and correlated to the SUV
max
 of 18FDG PET-CT. 
Results: A moderate correlation was found 
between SUV
max
 and maximum IRA in all tumors 
(n=37;r=0.507;p=0.025) . A strong correlation 
wasfound in patients with study intervals 21 days 
(n=17;r=0.768;p=0.017). Analysis of histological 
subtypes of lung cancer showed a strong correlation 
between SUV
max
 and maximum IRA in the analysis 
of all patients with NSCLC (r=0.785;p=0.001) and in 
patients with NSCLC and study intervals 21 days 
(r=0.876;p=0.024). Thoracic LN showed a moderate 
correlation between SUV
max
 and maximum IRA in 
all LN (r=0.570;p=0.047) and those of patients with 
study intervals 21 days (r=0.654;p=0.010). 
Conclusion: DECT could serve as a valuable 
functional imaging test for patients with NSCLC as 
the IRA of DECTcorrelates with SUV
max
 of 18FDG 
PET-CT. 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1139
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: Auto Áuorescence bronchoscopy 
(AFB) is a new endoscopic tool that improves 
visualization of neoplastic changes in the bronchial 
mucosa. . In this study, we examined the usefulness 
of autoÁuorescence bronchoscopy (SAFE-3000) 
during follow-up of photodynamic therapy (PDT) 
- treated early central lung cancer by precise 
histological analysis of the photodynamic therapy 
(PDT) treated lesions. . 
Methods: Between December 1999 and August 
2010, 13 patients with 16 centrally located early 
lung cancer (CLELC) lesions, have been treated by 
PDT and also been followed - up after the PDT by 
the auto Áuorescence bronchoscopy (SAFE-3000). 
Fluorescence bronchoscopy was performed between 
1 and 60 months after photodynamic therapy. 
PDT procedures were performed using porÀmer 
sodium or talaporÀn sodium and an Excimer Dye 
Laser or a diode laser system.The total energy of 
the laser irradiation was 100 J/cm2, 150 mW/cm2, 
and the duration of irradiation was usually 10 to 20 
min. Before the PDT, we performed SAFE-3000 
with a diode laser (408 nm) to deÀne the base line 
Áuorescence intensity emitted from the tumor. After 
the PDT, we performed SAFE-3000 to determine the 
change in the intensity of Áuorescence emitted from 
the tumor as compared with that observed before 
the PDT. Cytological and histological examinations 
via Àber optic bronchoscope were performed at 1, 2 
and 3 months and thereafter at 3-month intervals in 
the Àrst year and 6-month intervals after the second 
years after PDT. The antitumor effect of the initial 
treatment was evaluated on the basis of the change 
in the intensity of the Áuorescence emitted from the 
tumor after PDT compared with that observed before 
the PDT, morphologic appearance, and the Àndings 
on histopathologic examination of biopsy specimens. 
Biopsy specimens were taken from all suspicious 
and abnormal lesions detected by AF bronchoscopy 
and WL bronchoscopy. 
Results: Of the 16 early carcinomas treated, 14 
(87.5%) had complete response (CR), 2 (12.5%) 
had no response (NR) after initial PDT. Among the 
14 carcinomas achieving a CR, 4 (29%) recurred 
locally from 6 to 12 months after initial PDT. A total 
of 62 surveillance auto Áuorescence bronchoscopies 
(average; 4.5/ patient) and 47 biopsies (average; 4/ 
patient) were performed after PDT. The addition 
of the SAFE-3000 examination to conventional 
bronchoscopy increased the sensitivity of screening 
from 69 % to 100%, which yielded a relative 
sensitivity of 145% with a negative predictive value 
cases had no necrosis and the mean SUV max values 
of 12.81 ± 5.58. The patients were evaluated in terms 
of FDG uptake, involvement in 21 cases (41.2%) 
diffuse, 9 cases (17.6%) non-homogeneous lateral 
and in 21 cases (41.2%) medial active. There was no 
statistically signiÀcant difference with FDG uptake 
of tumor type, tumor location and how the diagnosis 
had demonstrated . (P = 0.078) In peripheral tumors 
have diagnosed with transthoracic Àne-needle 
aspiration biopsy, if in PET-CT the rates of necrosis 
were between 25-75%, we can say that the SUV max 
values were high. 
Conclusion: At Lung tumors, tumor localization, is 
important in obtaining tissue diagnosis. Currently 
bronchoscopy is preferred as a priority. But the 
diagnostic rate of bronchoscopy in peripheral tumors, 
not at the desired level despite new technologies, 
such as EBUS and superdimension. In addition, the 
presence of necrosis in tumors by the pathologist 
makes it difÀcult to diagnose correctly. For this 
purpose, we compared taking into account tumor 
localisations, diagnostic methods, tumor necrosis 
and tumor the PET-CT SUV max values, and we 
would like to contribute to the pathologist obtain a 
more suitable material for the diagnosis. As a result, 
at peripheral tumors, necrosis was found with a high 
SUV max values are important. At central tumors, 
we found that a high SUV max values guiding the 
diagnosis. 
Keywords: necrosis, SUV max, PET-CT
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P2.309 FOLLOW- UP USING 
FLUORESCENCE BRONCHOSCOPY FOR 
THE PATIENTS WITH PHOTODYNAMIC 
THERAPY TREATED EARLY LUNG 
CANCER
Abdellah H.K. Ali1, Hiromitsu Takizawa2, Kazuya 
Kondo3, Yasushi Nakagawa2, Hiroaki Toba2, 
Narmisheekh Khasag2, Koichiro Kenzaki2, Shoji 
Sakiyama2, Akira Tangoku2 
1Respiratory Medicine, Sohag University, Faculty 
Of Medicine/Egypt, 2Department Of Thoracic, 
Endocrine And Oncological Surgery, Institute Of 
Health Biosciences, The University Of Tokushima 
Graduate School/Japan, 3Department Of 
Oncological Medical Services,, Institute Of Health 
Biosciences, The University Of Tokushima Graduate 
School/Japan
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lung cancer, and 6 other diseases) and 17 benign 
lesions (6 nontuberculous mycobacteriosis, and 2 
tuberculosis ,and 9 other diseases), and 2 lesions 
without diagnosis. A deÀnitive diagnosis was 
established by TBB using EBUS-GS in 39 lesions 
(66.1%) malignant lesions,26/40 (65.0%) and benign 
lesions,13/17 (76.5%). Forty-one cases in which 
the EBUS probe was positioned within the lesions 
had a higher diagnostic yield (82.9%) than 9 cases 
in which the probe was positioned adjacent to the 
lesions (55.6%) or 9 cases in which the probe was 
outside of the lesions (0%) There were no major 
complications ,including dissemination of the 
pathogens or tumor cells. 
Conclusion: EBUS-GS is a reliable and safety 
method for the diagnosis of PPLs with cavitation. 
Keywords: bronchoscopy, cavitary lesion
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.311 NARROW BAND IMAGINING 
(NBI) VCIDEOBRONCHOSCOPY IN 
DETECTION OF PREMALIGNANT 
BRONCHIAL LESIONS
Bojan Zaric, Branislav Perin, Goran Stojanovic, 
Svetlana Jovanovic, Evica Budisin, Nensi Lalic, 
Milan Antonic 
Clinic For Pulmonary Oncology, Institute For 
Pulmonary Diseases Of Vojvodina, Faculty Of 
Medicine, University Of Novi Sad/Serbia
Background: Narrow band imaging (NBI) is one 
of the newest image enhancement technologies 
investigated for the use in diagnostic bronchoscopy. 
It is designed for detection of abnormal submucosal 
blood vessels. The major aim of this study was to 
investigate sensitivity, speciÀcity, positive predictive 
value (PPV) and negative predictive value (NPV) 
of WLB and NBI in detection of premalignant 
bronchial lesions. 
Methods: This was a prospective, randomized 
trial that included 88 patients scheduled for 
routine bronchoscopy. Major indications included: 
radiological suspicion for lung cancer, additional 
evaluation of known lung cancer, follow up after 
surgical treatment, positive sputum cytology, and 
prolonged cough. Patients were randomized in two 
of 100%. Out of 14 CR lesions, 9 lesions Ànally 
reverted to normal Áuorescence. CR cases that 
did not show normal Áuorescence were relapsed 
cases or a patient with complete response whose 
treated lesion showed Àbrosis in the sub mucosa. 
Histopathological Ànding of the complete response 
sites which demonstrated temporal Áuorescent 
defect consisted of inÁammatory lesions, goblet 
cell hyperplasia, basal cell hyperplasia, squamous 
metaplasia or dysplasia. 
Conclusion: Our results conÀrm that SAFE-3000 
allows accurate assessment of the quality and 
efÀcacy of PDT. 
Keywords: photodynamic therapy, Fluorescence 
bronchoscopy, Lung cancer
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P2.310 ENDOBRONCHIAL 
ULTRASONOGRAPHY WITH A 
GUIDE SHEATH (EBUS-GS) FOR 
THE DIAGNOSIS OF PERIPHERAL 
PULMONARY LESIONS WITH 
CAVITATION.
Taichi Takashina, Naofumi Shinagawa, Hajime 
Asahina, Yasumoto Ikezawa, Iki Y. Ogura, Yutaka 
Takeuchi, Hidenori Mizugaki, Noriyuki Yamada, 
Eiki Kikuchi, Junko O. Kikuchi, Jun K. Sakakibara, 
Satoshi Oizumi, Masaharu Nishimura 
First Department Of Medicine, Hokkaido University 
School Of Medicine/Japan
Background: Transbronchial biopsy (TBB) from 
cavitary lesions may induce the dissemination of 
the pathogens or tumor cells, which is generally 
regarded as contraindication. It is important to 
diagnose cavitary lesions safely and less invasively. 
TBB using endobronchial ultrasonography with a 
guide sheath (EBUS-GS) may be one of promising 
methods to overcome this problem, because of less 
bleeding by wedging the GS in the target bronchus. 
The aim of this study was to assess the usefulness of 
EBUS-GS for the diagnosis of peripheral pulmonary 
lesions (PPLs) with cavitation. 
Methods: We retrospectively reviewed 57 
consecutive patients with 59 cavitary PPLs who 
underwent TBB using EBUS-GS between August 
2003 and January 2011 at our institute. 
Results: The mean diameter of cavitary lesions 
was 28 mm. Fifty-nine PPLs with cavitation 
consisted of 40 malignant lesions (34 primary 
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P2.312 CLINICAL PROGNOSTIC 
FACTORS FOR COMPLICATIONS 
FOLLOWING ND:YAG LASER 
RESECTION OF CENTRAL, ADVANCED 
STAGE LUNG CANCER
Bojan Zaric, Branislav Perin, Svetlana Jovanovic, 
Evica Budisin, Goran Stojanovic, Nensi Lalic, 
Vladimir Carapic, Vladimir Stojsic, Milan Antonic 
Clinic For Pulmonary Oncology, Institute For 
Pulmonary Diseases Of Vojvodina, Faculty Of 
Medicine, University Of Novi Sad/Serbia
Background: Nd:YAG laser resection is one of 
the most established interventional pulmonology 
techniques for immediate desobstruction of 
malignant central airway obstruction (CAO). Major 
aim of this study was to investigate complications 
rate and identify clinical risk factors for 
complications in patients with advanced lung cancer. 
Methods: This was a retrospective analysis of 464 
laser resections performed at our institution from 
January 2005 to December 2009. Complications 
after laser resection were deÀned as: severe 
hypoxemia, global respiratory failure, arrhythmia 
requiring treatment, haemoptysis, pneumothorax, 
pneumomediastinum, pulmonary edema, trachea-
esophageal Àstulae and death. Risk factors were 
deÀned as: acute myocardial infarction within 6 
months before treatment, hypertension, chronic 
arrhythmia, chronic obstructive pulmonary disease 
(COPD), stabilized cardiomyopathy, previous 
external beam radiotherapy, previous chemotherapy 
and previous interventional pulmonology treatment. 
Results: There was 76.1% male and 23.9% female 
patients in the study, 76.5% were current smokers, 
17.2 former smokers and 6.3% of non smokers. 
Majority of patients had squamous cell lung cancer 
(70%), small cell lung cancer was identiÀed in 
18.3%, adenocarcinoma in 3.4% and metastases from 
lung primary in 8.2%. Overall complication rate 
was 8.4%. Statistically signiÀcant risk factors were: 
age (p=0.001), current smoking status (p=0.012), 
arterial hypertension (p<0.000), chronic arrhythmia 
(p=0.034), COPD (p<0.000), and stabilized 
cardiomyopathy (p<0.000). Independent clinical risk 
factors were age over 60 years (p=0.026), arterial 
hypertension (p<0.000), COPD (p<0.000) and 
smoking over 60 pack years (p=0.012).
Conclusion: Closer monitoring of patients with 
identiÀed risk factors is advisable prior and 
groups, Àrst group was examined by white light 
videobronchoscopy (WLB) alone, and group two 
was examined by combination of WLB and NBI. 
Squamous metaplasia, mild, moderate, severe 
dysplasia and CIS were regarded as positive results 
(premalignant lesions). In each patient at least one, 
but no more than three biopsies were taken from 
places designated as visually pathological, and at 
least one biopsy was taken from normal mucosa. 
We were using EVIS LUCERA SPECTRUM 
video processor, and BF T160 (Olympus Co.) 
videobronchoscope. 
Results: There were 34 males and 9 females 
in group one. Average age was 54 ±14 years. 
Sensitivity, speciÀcity, PPV and NPV of WLB 
(group I) in detection of precancerous lesions 
were 55.6%, 55%, 41.7% and 68.2%, respectively. 
Corresponding values for metaplasia were 33.3%, 
55%, 39% and 93.8%; for mild dysplasia 53.3%, 
55%, 14%, 89.6%, respectively. Corresponding 
values for moderate dysplasia were 58.3%, 55%, 
12.5%, 92.3%, respectively, and for severe dysplasia 
60%, 55%, 26.9% and 83.3%, respectively. In group 
two there was 35 males and 10 female patients, 
average age 57±12. Sensitivity, speciÀcity, PPV and 
NPV for WLB+NBI in detection of premalignant 
lesions were 75%, 85.9%, 86.7% and 73.7% 
respectively. Corresponding values for sensitivity, 
speciÀcity, PPV and NPV of NBI in detection of 
each premalignant lesion were given in table 1. 
Sensitivity (%) Speci¿city (%) PPV (%) NPV (%) 
Metaplasia 75 85.9 42.9 96.1 
Mild dysplasia 52.2 85.9 50 86.9 
Moderate dysplasia 78.4 85.9 70.7 90.1 
Severe dysplasia 87.5 85.9 70 94.8 
Conclusion: NBI showed higher sensitivity and 
speciÀcity for detection of premalignant lesions 
than WLB alone. Further studies are necessary to 
investigate the role and potential of this technology 
in detection of premalignant bronchial lesions. 
Keywords: narrow band imaging, Lung cancer, 
interventional pulmonology, bronchoscopy
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100%. Twenty-four (34%) patients predicted with 
mediastinal involvement in the PET-CT were 
actually without mediastinal metastatic nodes. 
Evaluated average lymph node size was 10mm. 
Conclusion: Endobronchial unltrasound can 
effectively be used to evaluate mediastinal lymph 
node involvement in patients with lung cancer and 
PET-CT positive Àndings. However, in this early 
experience more than 30% of patients with predicted 
mediastinal lymph node involevement in the PET-CT 
were pathologically negative in the EBUS-TBNA 
for position N2/3 challenging the exclusive use of 
the PET-CT and demanding cytological/histological 
evaluation of the mediastial nodes to ensure 
appropriate therapy. 
Keywords: PET-CT, EBUS-TBNA, NSCLC, 
Staging
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.314 SAFE BRNO EXPERIENCE
Horvath Teodor1, Martin Sobotka1, Ladislav Mitáš1, 
Marta ÿíhalová2, Mojmír Moulis2, Stanislav Špelda3, 
Jindŉich Vomela1, Marie Horváthová4 
1Department Of Surgery, Faculty Hospital Masaryk 
University Brno/Czech Republic, 2Dept. Of 
Pathology Faculty Hospital Bohunice, Faculty Of 
Medicine Masaryk University/Czech Republic, 3Dept. 
Of Comprehensive Oncological Care, Masaryk 
Memorial Cancer Institute/Czech Republic, 4Early 
Diagnosis, Czech B Concept/Czech Republic
Background: Description of the morphological 
features of bronchial carcinogenesis (Scheme 1) in 
vivo by use of autoÁuorescence bronchoscopy. 
Methods: Yearly repeated bronchoscopy in 
persons (n=361) with high risk of lung cancer by 
AutoÁuorescence endoscopy SAFE-1000 Pentax 
immediately after laser resection. In order to avoid 
or minimize complications special attention should 
be directed towards patients who are current smokers 
(over 60 pack years), over 60 years of age, with 
arterial hypertension or COPD. 
Keywords: Lung cancer, Nd:YAG laser resection, 
interventional pulmonology, bronchoscopy
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P2.313 IMPACT OF COMBINED PET-
CT AND EBUS-TBNA ON STAGING OF 
PATIENTS WITH SUSPECTED LUNG 
CANCER
Sebastian Dango1, Jutta Günter2, Mirjam Elze2, 
Nico Freudenberg3, Christian Stremmel2, Bernward 
Passlick3 
1Thoracic Surgery, University Medical Center 
Freiburg/Germany, 2Thoracic Surgery, University 
Medical Center/Germany, 3Pathology, University 
Medical Center/Germany
Background: Endobronchial unltrasound with 
transbronchial needle aspiration (EBUS-TBNA) has 
been proposed as a safe, less-invasive approach to 
mediastinoscopy to evaluate possible mediastinal 
lymph node involvement in patients with lung 
cancer. Herein, we evaluated the impact and 
predictive value of EBUS-TBNA in lung cancer 
patients with radiologically suspected mediastinal 
metastatic lymph nodes in the Positron-Emission-
Tomograpgie combined with CT scan (PET-CT). 
Methods: This study is a single-institutional 
retrospective review of cases with suspected or 
conÀrmed lung cancer undergoing mediastinal 
staging with PET-CT followed by mediastinoscopy/
surgery after negative evaluation via EBUS-TBNA 
in the year 2010. 
Results: A total of 118 patients underwent EBUS-
TBNA after PET-CT during the study period. 
Seventy (59.4%) patients were radiologically 
N2/3 positive in the PET-CT, in 32 (46%) cases 
radiologically positive Àndings were conÀrmed via 
EBUS-TBNA. Thirty-eight (55%) EBUS-TBNA 
negative patients were further investigated either 
by subsequent mediastinoscopy (n=20) or primary 
surgery (n=17). Mediastinoscopy or surgery found 
metastatic nodes in 5 and 4 patients, respectively, 
for a patient-speciÀc negative predictive value 
of EBUS-TBNA of 73% (95% CI, 56% to 89%) 
with a sensitivity of 77.5% and a speciÀcity of 
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P2.315 NAVIGATED BRONCHOSCOPY 
– A RESEARCH PLATFORM USING 
INTRAOPERATIVE CONE BEAM CT
Tore Amundsen1, Håkon O. Leira1, Geir Arne 
Tangen2, Frode Manstad-Hulaas3, Thomas Lang2 
1Dept. Thoracic Medicine, St. Olavs Hospital/
Norway, 2Medical Technology, Sintef/Norway, 
3Radiology, St. Olavs Hospital/Norway
Background: Bronchoscopy has limitations 
in diagnosing pulmonary lesions, and the 
bronchoscopist must rely on preoperative x-ray 
or CT evaluations, and inadequate peroperative 
Áuoroscopy guided maneuvers (small, sparse, 
peripheral opacities often visible only in one plane). 
Preoperative imaging based navigation systems also 
have limitations due to lung movement caused by 
endobronchial instruments and respiration. Thus, 
we are developing a navigation system to improve 
targeting of lung lesions and to reduce repeated 
examinations.
Methods: The navigation system is based on 
electromagnetic (EM) tracking, navigation and 
visualization software, and intraoperative cone beam 
CT (CBCT) images, in which the position of the 
bronchoscope, biopsy equipment and lung lesions 
are presented in real-time to the bronchoscopist. 
The bronchoscopic track is displayed in volume 
rendering view or orthogonal slices selected from 
the images by the position and orientation of the 
bronchoscope tip. The set-up was designed to 
evaluate feasibility and accuracy in a pig model that 
closely resembles the human lung anatomy. Three 
different experiments were performed: 1) Evaluating 
the ability of CBCT to detect foreign bodies of 
different x-ray opacity, and act as basis for navigated 
bronchoscopy. Four foreign objects of different 
materials were placed in different lung segments; 
a plastic tube, a glass ball, a wooden ball and a 
metal ring; 2) Pinpointing the foreign bodies with a 
tracked catheter advanced all the way to the foreign 
objects; and 3) InÁuence of CBCT equipment on the 
EM tracking Àeld. In experiment 3, the C-arm was 
moved continuously, from a position approximately 
1 m outside the electromagnetic Àeld towards its 
center.
Results: Experiment 1 showed that CBCT was 
superior to Áuoroscopy, providing more detailed 
anatomical information. The plastic tube and wood 
ball were not recognizable in Áuoroscopy or the 
during dozen years (1999-2010). Both white 
light bronchoscopy (WLB) and autoÁuorescence 
(AFB) mode are feasible at the same investigation. 
Hematoxylin-and-eosin histopathology and 
immunohistochemistry p21 and ki67 were used. 
Results: Eleven morphological units of bronchial 
premalignancy are deÀned. They are divided into 
two classes: SuperÀcial Spreading Lesion – 1/ 
invisible islet and 2/ spot, 3/ redness islet and 4/ 
spot, 5/ spider, 6/ swollen and thickened mucosal 
fold, 7/ granular, 8/ mixed lesion; and Protruding 
Lesion – 9/ nodular, 10/ wart-like 11/ polypoid. 
SuperÀcial spreading lesions are of high variability. 
Roughening in WLB and arenaceous depiction at 
AFB mode of the surface of the lesion represent 
evolving risk of malignant transformation. 
Irregular margin of the lesion (star shaped; spider) 
is important sign of advanced lesion. SuperÀcial 
spreading lesions with distinct limitation (border) 
represent by histopathology early premalignant 
processes. Protruding lesion with smooth surface 
in WLB and low decreased autoÁuorescence signal 
output is not risky; Protruding lesion with smooth 
surface and deep decreased autoÁuorescence 
characteristic is at risk of malignant development or 
it is malignant. Wart-like surface of the protruding 
lesion represents advanced lesion at risk. The 
cogency of overdiagnosis and underdiagnosis issue 
of every particular lesion in the course of time were 
studied. There are deÀned three classes of the lesions 
regardless of their superÀcial spreading or protruding 
nature in general: 1/ Quiet – oncologically 
unimportant, in the course of time disappearing 
lesion 2/ Ambiguous – representing biologically 
uncertain unit inviting follow-up endeavour, and 
3/ Persistent – proliferative lesion at risk needed 
particular attention from the clinical point of view. 
Conclusion: To detect early bronchial 
premalignancy low output ilumination intensity 
and mild autoÁuorescence signal ampliÀcation are 
needed. A part of advanced premalignant bronchial 
lesions at risk is recognizable by naked eye. 
Keyword: AutoÁuorescence; Bronchoscopy; 
Carcinogenesis; Morphology
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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which could be diagnosed and the cases which 
couldn’t be diagnosed. Then we considered the 
factors which provided difÀculties in diagnosis by 
EBUS. 
Methods: From January 2009 to November 2010, 
45 patients had undergone EBUS in our hospital. 
VBN was used for 33 of the 45 patients. EBUS and 
virtual bronchoscopic navigation (VBN) were used 
at physicians’ discretion. An ultrasound probe (UM-
S20-17S; OLYMPUS), a bronchoscopy (BF-P260F; 
OLYMPUS), a VBN software (Bf-Navi; OLYMPUS) 
were used. Statistical software (SPSS version 16) 
was used for statistical analysis, and p < 0.05 was 
considered statistically signiÀcant. 
Results: Twenty-four of the 45 patients were 
diagnosed malignancies (21; primary lung cancer, 2; 
metastatic lung cancer, 1; malignant lymphoma), two 
were diagnosed benign disease (1; non-tuberculous 
mycobacteriosis, 1; organizing pneumonia) and 
remained 19 weren’t diagnosed with this procedure. 
Finally, 36 were diagnosed malignancies and nine 
were diagnosed benign disease by this or other 
procedures. We analyzed the 36 patients who 
diagnosed malignancies to assess the diagnostic 
yield for peripheral lung malignancies. Diagnostic 
yield of malignancy was 66.7% (24/36). Diagnostic 
yields according to the location of the ultrasound 
probe were 87% (20/23) of “within”, 36.4% (4/10) 
of “adjacent to”, and 0% (0/3) of undetectable 
lesions by EBUS. Diagnostic yields according to 
diameter of the lesion were 0%(0/1) of <10mm, 
61.5%(8/13) of >=10mm to <20mm, 66.7%(10/15) 
of >=20mm to <30mm, 85.7%(6/7) of >=30mm. 
According to the location of the lesion, diagnostic 
yield was 14.3% (1/7) of lower lobe superior 
segment and 79.3% (23/29) of other locations. 
By multiple logistic regression analysis including 
the location of the ultrasound probe, diameter 
of the lesion and the anatomical location of the 
lesion, the location of the ultrasound probe was the 
independent determinant of successful diagnosis (P 
= 0.002). Twenty of the 23 patients whose lesions 
in which the probe was located “within” could be 
diagnosed but remained three patients could not be 
diagnosed. These three lesions located lower lobe 
basal segment. We considered it was attributed 
to respiratory displacement. Diagnostic yields of 
lesions undetectable by X-ray Áuoroscopy was 50% 
(4/8). There were no complications with the patients 
who had undergone EBUS. 
Conclusion: EBUS provided the diagnosis to the 
peripheral lung lesions which were difÀcult to be 
initial CBCT images, but unlike Áuoroscopy later 
CBTC scans could locate them on indirect signs 
as they caused atelectasis (lung segment collapse). 
In experiment 2, CBCT conÀrmed the position of 
the tracked catheter tip next to the foreign objects 
in correspondence with the navigation system and 
visual bronchoscopic inspection. In experiment 
3, with the C-arm turned on and approximately 1 
m away from the target, we observed an accuracy 
comparable to those stated by the vendor of the 
tracking system, i.e. less than 0.5 mm. We saw 
an increasing error as the C-arm approached the 
tracking Àeld, and the positions started to drift in a 
sine-wave fashion. The jitter did not increase, and 
the readings where not randomly distributed, as one 
maybe would have expected if the EM Àeld was 
corrupted. We measured a range of drift up to ~13 
mm in one of the sensors. We also noticed that the 
positional readings did not drift around their “true” 
position, but were shifted in all three planes.
Conclusion: The live animal navigated 
bronchoscopy platform yielded a high diagnostic 
accuracy and feasibility, serving as a valuable tool 
for accurate diagnostic investigation and research 
purposes. But care must be taken when performing 
navigation with the C-arm in the Àeld.
Keywords: navigation, bronchoscopy, tracking, cone 
beam CT
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P2.316 ENDOBRONCHIAL 
ULTRASONOGRAPHY FOR 
PERIPHERAL LUNG MALIGNANCIES; 
ANALYSIS FOR THE DETERMINANT OF 
SUCCESSFUL DIAGNOSIS
Kosuke Yamaguchi1, Satoshi Terashita1, Tetsuhiro 
Shiota1, Yasuyuki Mizumori2, Miki Yamamura3, 
Tatsuya Hayabuchi3, Haruhiko Makino3, Yuji 
Kawasaki3, Tadashi Igishi3, Eiji Shimizu3 
1Respirology, Yoka Hospital/Japan, 2Respiratory 
Medicine, National Hospital Organization Himeji 
Medical Center/Japan, 3Medical Oncology And 
Molecular Respirology, Tottori University/Japan
Background: We use endobronchial 
ultrasonography (EBUS) for the cases anticipated 
difÀculties in the diagnosis by usual X-ray 
Áuoroscopy guided bronchoscopic examinations. 
We evaluated the ability of EBUS to diagnose the 
peripheral lung malignancies and analyzed the cases 
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series. In the H&N region there were 27 known 
primary squamous cell carcinomas detected and 
these were excluded from Ànal analysis.
In the H&N there were 22 signiÀcant lesions 
detected, and in the bronchus there were 17 
signiÀcant lesions. The relatives sensitivities 
and speciÀcities of white light, autoÁuorescence 
and narrow band imaging are summarized in the 
attached table. 11/74 (15%) patients had additional 
Àndings detected by AF and NBI which impacted 
on deÀnitive management. The 17 endobronchial 
lesions of moderate dysplasia or worse are currently 
undergoing bronchoscopic surveillance. 
Head and neck 
region 
White light AutoÀuorescence Narrow band imaging 
True Positive 7/22 (32%) 21/22 (95%) 21/22 (95%) 
False Positive 1/13 (8%) 11/13 (85%) 3/13 (23%) 
Sensitivity 32% (95% CI, 0.16-0.53) 95% (95% CI, 0.78-0.99) 95% (95% CI, 0.78-0.99) 
Speci¿city 92% (95% CI 0.67-0.98) 15% (95% CI, 0.04-0.42) 77% (95% CI, 0.45-0.88) 
Bronchus White light AutoÀuorescence Narrow band imaging 
True positive 2/17 (12%) 13/17 (76%) 15/17 (88%) 
False Positive 2/41 (5%) 20/41 (49%) 7/41 (17%) 
Sensitivity 12% (95% CI, 0.03-34%) 76% (95% CI, 41%-83%) 88% (95% CI, 66%-97%) 
Speci¿city 95% (95% CI, 0.84-0.99) 51% (95% CI, 0.36-0.66) 83% (95% CI, 0.69-0.91) 
Conclusion: AF and NBI inspection adds to WL 
evaluation in these patients. NBI improves speciÀcity 
in both regions and can inÁuence deÀnitive 
management.
Keywords: AutoÁuorescence, narrow band imaging, 
Preneoplasia, Early central lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.318 MAJOR PULMONARY 
RESECTION AFTER INDUCTION 
CHEMOTHERAPY IN PATIENTS WITH 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CARCINOMA.
Michael Papiashvilli1, Henri Hayat2, Letisia 
Schreiber2, Lior Sasson2, Israel E. Priel2 
1Cardio-thoracic Surgery Department, Edith Wolfson 
Medical Center/Israel, 2Edith Wolfson Medical 
Center/Israel
Background: Locally advanced Non-Small-
Cell Lung Cancer is a heterogeneous group of 
disease with stages IIIA and IIIB. The optimal 
diagnosed by usual X-ray Áuoroscopy and expanded 
indication of bronchoscopic examinations. The 
location of the ultrasound probe was the independent 
determinant of successful diagnosis. 
Keywords: EBUS, bronchoscopy, peripheral lung 
lesion, Lung cancer
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P2.317 NARROW BAND IMAGING 
IMPROVES PREOPERATIVE 
FLUORESCENCE ASSESSMENT OF 
UPPER AND LOWER AIRWAYS IN HEAD 
AND NECK CANCER PATIENTS
Phan Nguyen1, Farzad Bashirzadeh1, Julie Agnew2, 
Robert Hodge2, Ian Brent Masters3, Camile Farah4, 
Edwina Duhig5, Belinda Clarke5, David Fielding1 
1Thoracic Medicine, The Royal Brisbane And 
Women’s Hospital/Australia, 2Ear Nose And 
Throat Surgery, The Royal Brisbane And Women’s 
Hospital/Australia, 3Respiratory Medicine, The 
Royal Children’s Hospital/Australia, 4Oral Cancer 
Research Program, University Of Queensland 
Centre For Clinical Research/Australia, 5Anatomical 
Pathology, The Prince Charles Hospital/Australia
Background: AutoÁuorescence (AF) has been used 
to improve the detection of preneoplastic lesions 
of the bronchus and the head and neck (H&N). It 
is known to have a high false positive rate. Narrow 
band imaging (NBI) has better speciÀcity but 
reportedly a poorer sensitivity. We hypothesised that 
combined AF and NBI inspection would improve 
overall speciÀcity without impacting sensitivity. 
Aim: To detect additional lesions to the primary 
head and neck cancer and to determine how these 
impacted on overall management. 
Methods: H&N cancer patients had white light 
(WL), AF and NBI inspection of the upper 
aerodigestive tract and tracheobronchial tree at 
panendoscopy. In the H&N region, AF and NBI 
inspection was performed unblinded. AF and NBI 
bronchoscopy of the tracheobronchial tree were 
done by two different bronchoscopists with Àndings 
reported independently. Detected lesions were 
graded as per established scoring systems and lesions 
considered abnormal by any imaging modality were 
biopsied. For statistical analysis, histological Àndings 
of moderate dysplasia or worse were considered 
signiÀcant. Results are reported on a per lesion basis. 
Results: There were a total of 74 patients in this 
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were downstaged to: T1N0 – 3 patients, T2N0 – 2 
patients, T3N0 – 1 patient and in 1 were not found 
residual tumor. Eighth patient not changed the stage 
and stayed T3N2. The postoperative complications 
were: broncho-pleural Àstula with empyema – 1 
patient, empyema – 1 patient, air leak – 2 patients, 
chylothorax - 1 patient, lobar atelectasis – 1 patient. 
Mean hospital stay was 21.1 days (range 6-107 
days). 
Conclusion: The treatment strategy for stage IIIA/
IIIB Non-Small Cell Lung Carcinoma should involve 
a multimodality approach. Combined modality 
therapy by induction chemotherapy and surgery may 
be beneÀcial in selected cases, with low morbidity 
in patients that underwent only lobectomy and 
high morbidity in patients after pneumonectomy 
and lobectomies or bilobectomies with chest wall 
resection or reconstraction.
Keywords: Non-Small Cell Lung Carcinoma, 
Induction Chemotherapy, Lobectomy, Chest Wall 
Resection, Pneumonectomy, Reconstraction, 
Neoadjuvant
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P2.319 ENDOBRONCHIAL ULTRASOUND 
(EBUS) GUIDED BRONCHOSCOPY FOR 
THE DIAGNOSIS OF PERIPHERAL LUNG 
CANCER LESIONS
Nensi Lalic, Bojan Zaric, Branislav Perin, Evica 
Budisin, Svetlana Jovanovic, Goran Stojanovic, 
Milan Antonic 
Clinic For Pulmonary Oncology, Institute For 
Pulmonary Diseases Of Vojvodina, Faculty Of 
Medicine, University Of Novi Sad/Serbia
Background: Lung cancer presents as peripheral 
lesions in 25-30% of the cases. Endoscopic diagnosis 
is essential for the prevention of futile thoracotomies. 
Chest physicians usually perform bronchoscopy 
under Áuoroscopy guidance in an attempt to sample 
a peripheral solitary pulmonary nodule (SPN). Yields 
range from 25 to 58% for lesions <2 cm, and 60 to 
83% for lesions > 2 cm. For a successful biopsy, 
therefore, knowledge of the relationship of the 
target lesion to the airway is essential. Conventional 
diagnostic procedures have limitations in availability 
and results. The major aim of this study was to 
determine sensitivity of EBUS guided transbronchial 
biopsy (TBB), catheter biopsy (CB) and brush-
biopsy. 
treatment for stages IIIA/B (N2/3) NSCLC remains 
controversial. Previous trials have shown efÀcacy 
of various treatments for different stages. Induction 
chemotherapy or chemoradiotherapy trials show 
that both approaches in the neoadjuvant setting 
are feasible. An outcome following induction 
therapy depends on residual mediastinal lymph 
nodes involvement by carcinoma. Surgery as initial 
therapy is beneÀcial for patients with T3, N1 or T3-
4, N0-1 disease (T4 due to satellite lesion/s within 
the same lobe/lung). Lobectomy may be generally 
safely performed following induction therapy, while 
pneumonectomy or lobectomy/bilobectomy with 
chest wall resection/reconstraction may carry a high 
and possibly unacceptable rate of perioperative 
mortality. 
Methods: 9 patients (mean age - 71.9 years; 8 
male and 1 female), all smokers, with stages IIIA/B 
Lung Carcinoma were treated at our Hospital. 
All patients were preoperatively diagnosed ( 5 
adenocarcinomas, 4 squamous cell carcinomas); 
6 of them by TTNA, 2 by Bronchoscopy and 1 by 
Mediastinoscopy and staged by CT of the chest, 
PET-CT and/or Mediastinoscopy. Patients with T3/
N0/1 disease (stages IIB/IIIA) were considered for 
curative resection. Patients with T3/T4,N2/3 disease 
(stages IIIA/IIIB) were considered for neoadjuvant 
chemotherapy according to tumor pathology. 
Postchemotherapy the patients restaged by CT of the 
chest and/or PET-CT or mediastinoscopy (in IIIB 
disease) and considered for curative resections. 
Results: One patient with T3N0 adenocarcinoma 
underwent Mediastinoscopy, that was negative, 
and curative RUL with En-Block Chest Wall (2-5 
ribs) & T3-T5 transverse processes resection. 
Other 8 patients preoperative stages were: 
T1N2 – 1 patient, T2N2 – 2 patients, T2N3 – 1 
patient, T3N2 – 2 patients, T4N1 – 1 patient and 
T4N2 – 1 patient. They underwent neoadjuvant 
chemotherapy according to the Institutional 
protocol (4 patients with adenocarcinoma received 
course of Olimpta and Platinum and 4 patients 
with squamous cell carcinoma - Gemzar with 
Platinum). Curative resections that done after 
chemotherapy were: 1 Right Pneumonectomy, 1 
RML/RLL Bilobectomy with Chest Wall (7-9 ribs) 
resection and reconstruction , 1 LUL Lobectomy 
with En-Block Chest Wall (4-6 ribs) resection, 2 
LLL and LUL Lobectomies with segmentectomies 
of adjacent lobe (superior segment of LUL and 
posterior segment of LLL) and 3 Lobectomies 
(RUL,RLL,LLL). Postoperatively 7 from 8 patients 
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efÀcacy of the larger gauge needle has been reported 
in a study from Nakajima (Respirology (2011) 16, 
90-94). This trial compared the diagnostic yield 
from both needles in same lymph notes. The study 
presented was designed as prospective comparison 
of both 22G and 21G biopsy needles in two 
independent groups.
Methods: Between July and October 2010, 60 
patients randomly divided in 2 groups underwent 
EBUS-TBNA in our clinic. 31 patients obtained 
diagnostic assignment with a 21 G needle and 29 
patients using a 22 G needle. The dedicated 22 
G and 21 G needles (Olympus, NA-201SX-4021 
and N-201SX-4022) where used for the complete 
diagnostic assay of each patient. The histological 
and cytological Àndings where obtained by the same 
experienced pathologist without any knowledge 
about the type of needle used. Data was analysed 
by descriptive statistics with respect to quality of 
histologic/cytologic material in tumour tissue and/or 
lymph-node-tissue.
Results: The distribution of diagnoses was 
comparable in both groups (21 G needle/22 G 
needle) with respect to lung cancer (23/19), other 
malignant tumors (2/6), Sarcoidosis and Tbc (2/2). 
InÁammatory changes were distributed evenly 
(3/3). In both groups we found coequal statements 
of all sample portions (1,2 or 3 per stage). In the 
21G-needle group a diagnosis could be obtained 
in all cases (31/31) either by histology or cytology. 
In the 22G-needle group the material obtained was 
not sufÀcient for a pathology diagnosis in 5 of 29 
cases (p=0,022 in Àshers exact test). Including only 
the cytological Àndings, in the performance of both 
needles in specimen quality no difference could be 
found. Blood contamination was present in both 
groups coequally without signiÀcant differences: 
21G/22G: 35%/28% in cytological and 33%/30% in 
histological Àndings.
Conclusion: We evaluated the difference of the 
cytopathological sample quality of the samples 
between the use of 21G and 22G EBUS-TBNA 
needles in two randomised groups (31/29 patients). 
Our data suggest that the cytological and histological 
structure of the samples obtained by a 21G needle 
may produce better results. Due to the potential 
impact on the diagnostic yield of EBUS depending 
on the needle used our results should be conÀrmed in 
a larger series.
Keywords: histology/cytology, bronchoscopy, 
untrasound-guided transbronchial needle aspiration, 
Lung cancer
Methods: In this study we prospectively evaluated 
sensitivity of EBUS guided TBB, CB and brush-
biopsy in diagnosis of peripheral lung lesions. We 
evaluated 48 patients, who met all of the inclusion 
criteria, not having any exclusion. The radial EBUS 
was carried out via 20 MHz probe (Km-BS20-26R). 
After identiÀcation and localization of peripheral 
lesion, TBB, CB or brush-biopsy were carried out in 
order to establish patohistological diagnosis. 
Results: Radial EBUS guided sampling was performed 
in 48 patients with peripheral lesions (14-58 mm 
measured on CT Àndings). In 32 patients lesion was 
visualized by radial probe. The histopathological and 
cytological diagnosis was established in 23 patients 
(malignancy in 15 pts, benign tumor in 1 pts or 
inÁammation in 6 pts). Transbronchial biopsy shows 
the highest sensitivity (0.77) when compared to the 
other two sampling procedures - catheter biopsy (0.27) 
and brush biopsy (0.36). 
Conclusion: Peripheral lung cancer lesions can be 
successfully diagnosed using radial ultrasound probe 
without need for Áuoroscopy or CT guidance. TBB 
exceeds in sensitivity the other sampling procedures. 
Keywords: Endobronchial Ultrasound, 
bronchoscopy, interventional pulmonology, Solitary 
pulmonary nodules (SPN)
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P2.320 COMPARISON OF 21 GAUGE 
AND 22-GAUGE ASPIRATION 
NEEDLE DURING ENDOBRONCHIAL 
ULTRASOUND-GUIDED 
TRANSBRONCHIAL NEEDLE 
ASPIRATION: A RANDOMISED TRIAL
Christian Grah1, Sergej Griff2, Thomas Mairinger2, 
Lutz Bollmann1, Hilke Temme1, Rose Seiberth3, 
Mirijam Vogelbusch1 
1Berlin, Pulmonology Havelhoehe/Germany, 2Berlin, 
Center Of Pathologie/Germany, 3Berlin, Center Of 
Clinical Research/Germany
Background: Endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) is 
a safe minimally invasive diagnostic modality. The 
quality and the quantity of EBUS-TBNA aspirates 
depends on puncture technique and size of the needle 
used. A dedicated 22-gauge (G) needle is typically 
used for EBUS-TBNA. A new EBUS-TBNA 21 
G needle has recently been introduced to improve 
the quantity and quality of the biopsy sample. The 
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centre was comparable with the existing evidence. 
TIPC is cost effective in the short term. TIPC is 
a good alternative to repeated chest drainage and 
should be considered as Àrst line management in 
cases of recurrent MPE. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.322 FACTORS ASSOCIATED 
TO INFORMATIVE EBUS TBNA 
PROCEDURES. RESULTS OF A 
PROSPECTIVE MULTICENTER STUDY 
ON 198 PATIENTS (EVIEPEB STUDY)
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1Clinique Pneumologique, Rouen University 
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Tenon University Hospital/France, 3Service De 
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4Department Of Pneumology, Ch Saint-quentin/
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University Hospital/France, 6Department Of 
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7Department Of Pneumology, Lille University 
Hospital/France, 8Department Of Pneumology, 
Lyon University Hospital/France, 9Department 
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P2.321 SINGLE CENTRE EXPERIENCE 
IN TUNNELLED PLEURAL AND 
ABDOMINAL CHEST DRAIN INSERTION
Aparna Deshpande1, Samreen Ahmed2, Amrita 
Bajaj1, Vimal Raj1, Mini Pakkal1 
1Imaging, GlenÀeld Hospital/United Kingdom, 
2Oncology, Leicester Royal InÀrmary/United 
Kingdom
Background: BTS guideline 2010 outlines use 
of tunnelled indwelling pleural catheter (TIPC) as 
second line management in recurrent malignant 
pleural effusion (MPE) and Àrst line management 
in MPE with an underlying trapped lung in patients 
with an expected life expectancy of more than one 
month. To assess the indications, practice of TIPC 
insertions in our institute and compare with previous 
studies. 
Methods: Retrospective study of 50 patients. Data 
collected from the Radiology Information System 
(RIS), case notes, questionnaires and telephonically. 
Results: Divided into demographic data, economic 
analysis and quality of life analysis. A) Demographic 
data: 50 patients (29 female, 21 male) Average age 
62.5years, range 35-89years 28 for pleural effusion, 
22 for ascites, 27 of 28 procedures for pleural 
effusion were under ultrasound guidance, 1 under 
CT guidance 11 complications. The most common 
complication was asymptomatic pneumothorax in 7 
patients. Other complications included displacement/
migration of drain, loculation, infection and 
pyopneumothorax. TIPC removed in 5 patients due 
to successful complete drainage of Áuid Average 
lifespan following drain insertion 52.6 days. 5 
patients were alive with drain in situ at the time of 
data collection. B) Economic analysis: Cost of TIPC 
insertion including that of the kit was calculated 
at £262 and compared with repeated routine chest 
drain insertions. 15 patients had a total of 22 drains, 
costing £774. 9 patients had failed pleurodesis. 7 
patients had a total of 9 aspirations. TIPC found to be 
more cost effective in the short term. However, long 
term economics needs to be considered in view of 
requirement for home care support. C) Quality of life 
issues: DifÀculties in obtaining the data outlined. Of 
the notes available, 15 patients improved following 
the tunnelled drain. 8 patients did not show 
improvement and were readmitted for other reasons. 
1 patient died the day after TIPC insertion. 
Conclusion: Post TIPC complication rate in our 
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P2.323 DIAGNOSIS ACCURACY OF 
EBUS-FNA IN THE RESTAGING OF 
MEDIASTINAL DISEASE OF THE 
PATIENTS WITH NOT SMALL CELL 
LUNG CANCER (NSCLC).
Susana Padrones1, Samantha Aso Gonzalez1, José 
Ignacio Martínez Ballarin1, Roger Llatjós2, Noelia 
Cubero1, Ivan Macia Vidueira3, Maria Dolores 
Arnaiz Fernandez4, Ramon Palmero5, Jordi Dorca1, 
Antoni Rosell1 
1Pulmonology, Hospital Universitari De Bellvitge/
Spain, 2Pathologic Anatomy., Hospital Universitari 
De Bellvitge/Spain, 3Thoracic Surgery, Hospital 
Universitari De Bellvitge/Spain, 4Radiotherapic 
Oncology, Institut Català D’Oncologia/Spain, 
5Medical Oncology, Institut Català D’Oncologia/
Spain
Background: Nodal down-staging after induction 
treatment in patients with resecable stageIII-N2 
NSCLC is the best prognostic factor for proceeding 
with surgery. The EBUS is expected to be a good 
test used to study the mediastinal nodal disease 
after the induction treatment. AIM: To compare 
the diagnostic yield of EBUS and PET-CT in the 
mediastinal restaging of patients with stage IIIA-N2 
NSCLC.
Methods: 
We reviewed all the patients stage IIIA NSCLC 
with involvement of one mediastinal lymph node 
station, who had made neoadjuvant therapy between 
July 2009 and September 2010. From six patients 
who met these criteria, we selected the ones in 
which staging and restaging of the mediastinum was 
performed using both, PET-CT and EBUS, with 
subsequent histological conÀrmation for those who 
were conÀrmed negative. Data were collected from 
the PET-CT and the EBUS, performed for initial 
staging and response assessment. 
Results: Four male smokers with NSCLC were 
selected for this study. They had a mean age of 62.2 
years old. The cytological diagnosis in three of 
them was adenocarcinoma and for the other one was 
squamous cell carcinoma. All of them were treated 
with chemotherapy (2 cycles of cisplatin/etoposide) 
and 50 Gy of radiotherapy. Five nodal stations were 
studied, being two of them from the same patient. 
The attached table shows the nodal stations studied, 
the SUV values after the neoadjuvant treatment, 
the degree of metabolic response according to the 
Pneumology, Clinique Pasteur/France, 19Department 
Of Pneumology, Saint-etienne University Hospital/
France
Background: Endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) is 
increasingly being performed for the evaluation of 
the mediastinal staging in NSCLC.
The objective of this study is to identify the factors 
associated to the informative procedures in a 
multicenter prospective French study (EVIEPEB; 
ClinicalTrial.gov identiÀer NCT00960271).
Methods: Patients with mediastinal lymph nodes 
underwent EBUS-TBNA in 19 French centers 
as part of a prospective study. All the procedures 
were performed by the same operator in each 
center. The procedure was considered informative 
if lymphocytes were observed on the cytological 
preparation. A minimum of 9 out of 10 consecutive 
procedures were required to be informative in each 
center to meet the quality criteria of the study. The 
size and location of the lymph node, the number 
of needle aspirations per node, and the anesthesia 
procedure were compared between informative and 
non-informative cases.
Results: 18 of the 19 centers met the quality criteria 
over a one-year period, and 198 patients were 
included. No serious adverse event was reported. 325 
cytological samples were analyzed. The endoscopic 
procedures were informative in 88% of the patients 
[min: 40% - max: 100%] and in 80% of the sampled 
stations (262 out of 325). Informative EBUS-TBNA 
were associated to a larger diameter of the lymph 
node (mean: 15.7 vs. 13.6 mm; p=0.0012), and to 
a greater number of needle aspirations per node 
(median: 3 vs. 2; p<0.001). The station site and the 
anesthesia procedure were not different between 
informative and non-informative procedures.
Conclusion: Learning curve of EBUS-TBNA to 
access a 90% rentability can be reached shortly. 
High rate of informative procedures is associated 
to a mean lymph node size of 15 mm and to a 
minimal number of 3 punctures per site. Rentability 
of the method does not seem to be dependent on the 
anesthesia procedure or on the node location.
Supported by a grant from INCa (Institut National du 
Cancer).
Keywords: EBUS-TBNA, Endoscopy, Diagnostic 
procedure, Mediastinal staging
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with electromagnetic sensors were placed in the 
right lung of a mechanically ventilated live pig, 
in the periphery of the lower, middle (RML) and 
accessory upper lobe. The movement of the lung 
was recorded while the bronchoscope was advanced 
stepwise towards the sensor in the middle lobe, 
ending in a “wedge” position, where it Àlls out the 
diameter and jams. The sensors sense their position 
in an electromagnetic Àeld set up by an external 
transmitter, with a precision of ~0.5 mm.
Results: The bronchoscope did not affect lung 
segment movement signiÀcantly while positioned 
in trachea, main bronchus or lobe bronchus. When 
placed in a wedge position, the bronchoscope 
caused the following, more pronounced in the 
nearest segment : 1) the adjacent lung segments 
were displaced; 2) Àrst displaced, the respiratory 
movement decreased, and 3) the direction of 
respiratory movement changed (see Àgure).
Conclusion: Using our novel live animal model, 
we succeeded demonstrating that the bronchoscope 
caused major changes in lung segment movement 
when it was moved as close to the target as possible. 
All changes appeared in a pattern and with a 
magnitude implicating clinical signiÀcance for 
navigated bronchoscopy. Care must be taken when 
navigating based on preoperative images.
Keywords: lung movement, tracking, bronchoscopy, 
navi
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P2.325 ACCURACY OF 
ELECTROMAGNETIC TRACKING IN 
NAVIGATED BRONCHOSCOPY WITH A 
PROTOTYPE FIELD GENERATOR IN AN 
INTERVENTIONAL OR SETTING
Erlend F. Hofstad1, Lars-Eirik Bø1, Geir Arne Tangen1, 
Håkon O. Leira2, Tore Amundsen2, Thomas Lang1 
EORTC and the treatment after the restaging. PET-CT 
from one of the patients showed complete metabolic 
response (CMR), which was later conÀrmed by 
surgery (lobectomy). PET-CT from two of the patients 
showed partial metabolic response (PMR), which was 
conÀrmed by EBUS (positive cytology) only in one of 
them, the other one had a negative cytology result not 
conÀrmed surgically. PET-CT from one of the patients 
showed stable metabolic disease (SMD) which was 
conÀrmed by EBUS. PET-CT showed progressive 
metabolic disease (PMD) in one of the patients, which 
was conÀrmed by EBUS. All the patients who had 
persistent disease, completed afterwards a total dose 
of radiotherapy of 70 Gy and received 2 cycles of 
chemotherapy. 
Conclusion: Although changes in mediastinal PET-
CT uptake show high concordance with EBUS, 
pathological conÀrmation is still superior and 
therefore necessary. Echoendoscopy (EBUS and/or 
EUS) is the choice test for mediastinal restaging.
Keywords: Lung cancer, Mediastinal restaging, 
EBUS-FNA
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P2.324 THE INFLUENCE ON LUNG 
SEGMENT AND TUMOR MOVEMENT 
BY BRONCHOSCOPIC INSTRUMENTS 
– IMPACT ON NAVIGATED 
BRONCHOSCOPY
Håkon O. Leira1, Thomas Lang2, Erlend F. Hofstad2, 
Geir Arne Tangen2, Lars-Eirik Bø2, Tore Amundsen1 
1Dept. Thoracic Medicine, St. Olavs Hospital/
Norway, 2Medical Technology, Sintef/Norway
Background: Developing a platform for navigated 
bronchoscopy, we have suspected that the 
bronchoscope inÁuences the movement of the lung, 
especially the adjacent segments, changing the position 
and movement pattern. We therefore wanted to measure 
to what extent instruments like the bronchoscope 
inÁuences the target movement during respiration.
Methods: Using a novel method, balloon catheters 
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inÁuence is constant at a given position in the Àeld, 
but not constant throughout the Àeld. The inÁuence 
from the C-arm is negligible once it is moved out 
of the Àeld. Care should be taken if one wants to 
perform navigation and imaging with a C-arm 
system simultaneously.
Keywords: accuracy, navigation, bronchoscopy, 
cone beam CT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.326 A NEW METHOD FOR IN-VIVO 
LUNG MOVEMENT TRACKING – FOR 
DIAGNOSIS AND THERAPY IN LUNG 
MEDICINE
Håkon O. Leira1, Thomas Lang2, Erlend F. Hofstad2, 
Geir Arne Tangen2, Lars-Eirik Bø2, Tore Amundsen1 
1Dept. Thoracic Medicine, St. Olavs Hospital/
Norway, 2Medical Technology, Sintef/Norway
Background: Respiratory lung movement is a major 
challenge in bronchoscopic lung cancer diagnostics 
and radiation therapy. The current methods for 
evaluating lung segment and tumor movement (CT 
/ MRI / Áuoroscopy / internal and external markers) 
have important limitations. CT involves a high 
radiation dose, MRI is incompatible with metallic 
equipment, and both have poor temporal resolution. 
External evaluation is not precise enough. To study 
the impact of respiratory movement for image 
guided tumor diagnostics, we needed a method that 
overcomes these limitations.
Methods: Three electromagnetic sensors mounted 
inside balloon catheters were placed using a 
bronchoscopy-Áuoroscopy procedure, in the right 
lung of a mechanically ventilated live pig; in the 
periphery of the lower (RLL), middle (RML) 
and accessory upper lobe (AL). The movement 
of the sensors was recorded in different animal 
positions on the OR table and at different tidal 
volumes. The sensors sensed their position at 40 
Hz in an electromagnetic Àeld set up by an external 
transmitter, with a precision of ~0.5 mm. The 
validity and reliability of the method were evaluated 
in terms of precision and functionality.
Results: As expected, increasing the ventilation 
volume increased the respiratory movement (see 
1Medical Technology, Sintef/Norway, 2Dept. Thoracic 
Medicine, St. Olavs Hospital/Norway
Background: We have studied the accuracy 
and robustness of a new prototype window Àeld 
generator (WFG), in an interventional radiology 
suite with a robot cone beam CT (rCBCT). The 
goal was to compare the performance the WFG 
to a standard Àeld generator (SFG), both part of 
the Aurora electromagnetic tracking (EM) system 
(NDI, Waterloo, Ontario, Canada), and to study the 
inÁuence of the rCBCT on both tracking systems. 
The main purpose is development of a one-stop 
solution for navigated bronchoscopy and improved 
success rate in targeting peripheral lung lesions, and 
the WFG allows for simultaneous X-ray imaging and 
position tracking.
Methods: The Àeld generators was mounted 
under the OR table, imposing no restrictions to the 
movement of the rCBCT. An accuracy phantom was 
used, a Plexiglas cube with 225 predeÀned positions 
( bottom of drilled holes). The phantom was placed 
on the OR table in the center of the tracking system’s 
measurement volume. In this way, our experimental 
setup represented a navigation volume relevant for a 
bronchoscopy. A 6DOF sensor catheter was used to 
sample the phantom’s 225 positions (100 samples). 
This was repeated with the C-arm inside and outside 
the tracking system’s measurement volume, for both 
Àeld generators. For the robustness measurements 
we performed similar measurements with 4 tracked 
tools inside the phantom with the C-arm in different 
positions and rotations.
Results: The SFG appears to provide a smaller RMS 
position error, while the WFG has less maximum 
and variance of the error. The C-arm caused a 
strong disturbance on the EM tracking systems. 
The inÁuence is greater on the SFG, increasing the 
RMS error with about 7 mm, compared to 4 mm for 
the WFG. The results when using the SFG have a 
larger spread of the error as well. Moving the C-arm 
into the EM Àeld, along or perpendicular to the 
operating table, caused a decrease in the distance 
between two sensors of up to 13 mm. The measured 
sensor distance was close to constant as a function 
of the C-arm position when the C-arm was at a large 
distance (> 0.5 m) from the EM Àeld.
Conclusion: The WFG outperformed the SFG, with 
and without the inÁuence of the C-arm, with respect 
to RMS error and spread of the angle of the tracked 
catheter. The EM Àeld was strongly affected by the 
rCBCT. When the C-arm is in a Àxed position, the 
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are some problems after stenting such as restenosis 
by granulations and tumor growth, moving of the 
stent and difÀculty in mucus expectoration. In this 
study, we evaluated the efÀcacy and feasibility of 
combination therapy, which is inserting clear type 
stent following photodynamic therapy using NPe6.
Methods: We inserted the clear type stent(Dumon 
Gold Studded Stent: NOVATECH) in the central 
airway of pigs and then we performed the NPe6-
PDT. One week later, we examined the pathological 
changes and evaluated the efÀcacy of NPe6-PDT 
through the clear type stent.
Results: The laser output decreased 22.2% by 
passing by the clear type stent. Normal part of 
trachea was irradiated with a 664nm laser at the 
dose of 100J/cm2 (power output: 180mW, irradiation 
time: 9 min 16 sec) and the part of trachea covered 
by stent was irradiated with a 664nm laser at the 
dose of 100J/cm2 (power output: 180mW, irradiation 
time: 11min 55 sec). We were able to obtain the same 
effect of NPe6-PDT at the part of trachea covered by 
stent compared with the normal part of trachea.
Conclusion: We can conclude that PDT after 
inserting the clear type stent is effective and feasible. 
This treatment may contribute the maintenance of 
the patients with the advanced lung cancer in the 
central airway.
Keywords: stent, airway stenosis, photodynamic 
therapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.328 PATIENT SELF-REFERRAL FOR 
CHEST X-RAY TO INCREASE EARLY 
DETECTION OF LUNG CANCER IN 
LEEDS, UNITED KINGDOM.
Matthew E.J. Callister1, Richard Milton2, Michael 
Darby3, Roderick J. Robertson3, Paul K. Plant1, 
Puneet Malhotra1, Mohammed Alhajji1, Akshay 
Dwarakanath1, Victoria Ashford-Turner1, Veronica 
Lovatt4, Francesca Hewitt4, Norma Thompson4, 
Catherine Foster4, Jon Fear5 
1Department Of Respiratory Medicine, Leeds 
Teaching Hospitals NHS Trust/United Kingdom, 
2Department Of Thoracic Surgery, Leeds Teaching 
Hospitals NHS Trust/United Kingdom, 3Department 
Of Radiology, Leeds Teaching Hospitals Nhs Trust/
Àgure), and the right lung moved signiÀcantly less in 
a right lateral than a left lateral position. The RML 
and AL sensors showed only a small reduction of 
movement in the lateral position. The supine position 
allowed the right lung to move signiÀcantly more 
than any lateral position. The sensors were easily 
placed and removed. No systematic position drift in 
tracking or Áuoroscopy was registered, indicating 
that sensors remained in the chosen location 
throughout the experiment (~5 hours). The method 
was highly valid, reliable and accurate.
Conclusion: The novel method for tracking lung 
segment movements during respiration was stable, 
accurate, the equipment was reusable and fulÀlled 
the purpose. We found a high spatial and temporal 
resolution and the method will be easy to implement 
in a bronchoscopic suite as a research tool for 
navigated bronchoscopy, radiation therapy and the 
study of lung physiology.
Keywords: tracking, navigation, lung movement, 
bronchoscopy
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P2.327 THE STUDY OF STENT AND 
PDT COMBINATION THERAPY FOR 
MALIGNANT AIRWAY STENOSIS
Keishi Ohtani, Jitsuo Usuda, Shuji Ichinose, Tatsuya 
Inoue, Taichiro Ishizumi, Yujin Kudo, Naohiro 
Kajiwara, Hidemitsu Tsutsui, Tatsuo Ohira, Norihiko 
Ikeda 
Surgery, Tokyo Medical University/Japan
Background: Centrally located early lung cancers 
can be treated with photodynamic therapy(PDT) 
for the curative intent. On the other hand, airway 
symptom due to advanced or end-stage lung 
cancer can be relieved immediately by means of 
bronchoscopic procedure. Moreover airway stent 
maintains symptom free and quality of life. But there 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1153
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
in making an GP appointment, and reluctance to 
waste doctor’s time were two of the most common 
reasons for failure to consult regarding symptoms. 
The marketing communication campaign, healthcare 
professional campaign and self-referral CXR service 
all initiated in January 2011. During the Àrst seven 
weeks 95 patients had presented for self-referral 
CXR, of which 3 patients had conÀrmed lung cancer. 
There was a 30% increase in the number of GP-
ordered CXRs compared to the same period in 2010 
(557 ± 65 per week vs 428 ± 55 respectively, mean ± 
SD, p<0.001), and a 70% increase in fast-track lung 
cancer clinic referrals compared to 2010 as a whole 
(16.0 ± 6.0 per week vs 9.4 ± 3.1 respectively, mean 
± SD, p<0.05). Further data on CXR numbers and 
lung cancer diagnoses and stage will be available by 
the late-breaking deadline. 
Conclusion: Review of CXR rates and lung cancer 
diagnoses, stage, treatment and outcome during the 
campaign will allow evaluation of the success of 
such an approach.
Keywords: Early Detection, Chest X-ray, Social 
marketing
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P2.329 DOES ROUTINE USE OF EBUS-
TBNA AND EUS-FNA IMPROVE THE 
ACCURACY OF STAGING OF NON 
SMALL CELL LUNG CANCER PATIENTS 
– A NATIONAL TUMOR REGISTRY 
BASED STUDY
Mark Krasnik1, Anders Mellemgaard2, Erik 
Jakobsen3 
1Thoracic And Cardiovasc.Surg, Rigshospitalet 
Copenhagen University/Denmark, 2Oncology, 
Herlev University Hospital/Denmark, 3Thoracic 
And Cardiovasc. Surg, Odense University Hospital/
Denmark
Background: Evaluation of the extend of disease or 
stage (TNM) is a prerequisite for correct treatment 
of lung cancer. Several studies have showed that 
biopsies and Àne needle aspirations obtained by 
EBUS-TBNA and EUS-FNA yield similar results as 
mediascopy, which previously have been considered 
the gold standard for evaluation of mediastinal nodal 
United Kingdom, 4NHS Leeds Primary Care Trust/
United Kingdom, 5Department Of Public Health 
Medicine, NHS Leeds Primary Care Trust/United 
Kingdom
Background: Lung cancer is responsible for 22% 
of all UK cancer deaths. 5 year survival rates in the 
UK lag behind other European and North American 
nations, and recent evidence has suggested that 
this may relate to later diagnosis. Leeds Teaching 
Hospitals NHS Trust (LTHT) serves a local 
population of 770,000 and diagnoses the largest 
number of new cases of lung cancer in any hospital 
nationwide (553 in 2009). The majority of patients 
present with late stage disease (72% stage III/IV). 
There is wide variation in rates of referral for chest 
X-ray (CXR) by general practitioners (GPs - primary 
care clinicians) across Leeds. Median CXRs per 
1,000 population per year (2008-2009) were 30 (IQR 
25-40, Range 7-101). Local audit revealed signiÀcant 
delay in referral for CXR and variable adherence to 
recommendations for CXR referral criteria issued by 
the National Institute for Clinical Excellence (NICE).
Methods: NHS Leeds and LTHT undertook a joint 
campaign to improve awareness of early symptoms 
of lung cancer to promote early referral for CXR, 
funded by the National Awareness and Early 
Diagnosis Initiative. Public awareness was assessed 
at the project outset using the validated Cancer 
Awareness Measure. A social marketing approach 
was used to promote the NICE recommendation for 
CXR referral (3 weeks of persistent and unexplained 
respiratory symptoms - predominantly cough, 
haemoptysis, breathlessness and chest/shoulder 
pain). 12 talks were given to healthcare professionals 
(GPs, community health educators, community 
matrons, respiratory nurses and pharmacists). A 
variety of marketing communication tools were 
used including bus adverts, posters, postcards and 
beer mats. Self-referral CXR was established where 
patients 50yrs or over could self-present for CXR 
after 3 weeks of cough or other chest symptom 
without medical referral. All community healthcare 
professionals were encouraged to direct symptomatic 
patients to the self-referral service. Outcome 
measures were numbers of CXRs ordered, numbers 
and stages of lung cancers diagnosed, proportions 
of patients undergoing radical therapy and 1 year 
survival rates. 
Results: Pre-campaign market research of 630 
members of the public revealed poor knowledge of 
early lung cancer symptoms. Perceived difÀculty 
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we integrated endobronchial ultrasound with Àne 
needle aspiration (EBUS-FNA) in the evaluation of 
thoracic lymphadenopathy. 
Methods: We report our single institution’s results 
over a two year period from September 2008 to 
September 2010. We identiÀed 173 patients with 
thoracic lymph nodes suspicious for malignancy, 
namely greater than one cm in short axis or PET-
positive. 
Results: We performed 180 EBUS-FNA of thoracic 
lymph nodes on these 173 patients with no major 
complications. EBUS-FNA of thoracic lymph nodes 
provided adequate tissue for pathologic evaluation 
in 159 (92%) of 173 patients. We found malignancy 
in 104 patients (60%), benign lymph node tissue in 
41 patients (24%) and granulomatous lymph node 
tissue in 14 patients (8%). We found lung cancer in 
86 patients (50%) including 41 with adenocarcinoma 
(24%), 21 (12%) with small cell lung cancer, 18 
(10%) with squamous cell carcinoma, 5 (3%) with 
poorly differentiated non-small cell lung cancer 
and one with large cell cancer (<1%). Ten patients 
(6%) had extrathoracic malignancies metastatic 
to mediastinal lymph nodes. Eight patients (5%) 
had recurrent lung cancer. Eight patients (5%) 
had non-diagnostic samples, 6 patients (4%) had 
atypical lymph nodes and 4 patients (2%) had 
benign pathology that conÁicted with a high clinical 
suspicion of malignancy. Of these 18 patients with 
unclear pathology, seven (40%) had repeat EBUS-
FNA. Only one of these revealed malignancy with 
the second EBUS-FNA. The remaining 17 patients 
underwent mediastinoscopy, thoracoscopy or CT-
guided Àne needle aspiration which provided a tissue 
diagnosis of malignancy in 14 patients. Of the 65 
patients found to have non-small cell lung cancer, 8 
(12%) had stage II disease (by N1 involvement), 25 
(38%) had stage IIIA disease, one (2%) had stage 
IIIB disease, 26 had stage IV disease (40%) and 5 
(8%) did not complete staging. Only one of these 
patients received an additional invasive procedure to 
conÀrm distant metastasis. Of the 21 patients with 
small cell cancer, 14 (66%) had limited disease and 7 
(33%) had extensive disease. Samples from EBUS-
FNA were analyzed for molecular analysis in 22 of 
our 41 adenocarcinoma patients (52%). Only 2 of 
these (9%) were inadequate sample size for analysis. 
Of the 20 patients who did have molecular analysis, 
2 (10%) had KRAS mutations and 1 (5%) had an 
EGFR mutation. 
Conclusion: EBUS-FNA is a powerful, safe and 
accurate diagnostic procedure in the evaluation 
involvement in NSCLC. Thus EBUS-TBNA and 
EUS-FNA should now be considered as procedures 
which are equally effective as mediastinoscopy in 
staging while at the same time being more gentle to 
the patient. 
Methods: We therefore used data from a population 
based lung cancer registry to evaluate the association 
between frequency of use of EBUS-TBNA/ EUS-
FNA and precision of mediastinal diagnostic work-
up. EUS in diagnostics and staging of lung cancer 
have been used in several centres for more than a 
decade and since 2005 several centres have inter 
grated EBUS TBNA in their procedures
Results: The material consisted of 7000 operated 
patients since 2003. The use of endoscopic 
ultrasound (EBUS-TBNA/EUS-FNA were 
mostly used in one region and mediastinoscopy 
in another. The concordance between cN and pN 
were higest and equal in the regionswhere mainly 
mediastinoscopy were used and the reion where 
Endoscopic Ultrasound were used 
Conclusion: For the Àrst time it is possible to get an 
impression of the impact of the use of EBUS-TBNA 
and EUS-FNA in a national populationof lung cancer 
patients. The were no difference in the cN/pN ratio 
in the areas where they used mediastinoscopy and 
where they used endoscopic Ultrasound 
Keywords: Lung cancer, Endoscpic Ultrasound, 
National results
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P2.330 ACHIEVING TISSUE DIAGNOSIS, 
STAGING AND MOLECULAR 
ANALYSIS OF LUNG CANCER WITH 
ENDOBRONCHIAL ULTRASOUND- FINE 
NEEDLE ASPIRATION (EBUS-FNA)
Cherie P. Erkmen1, Bryan P. Stanifer2, Vijayalakshmi 
Padmanabhan3, Piroska K. Kopar1, Anne K. 
Mcgowan1, Lisa O. Tilluckdharry4, James R. Rigas4, 
Konstantin H. Dragnev4, Peter A. Delong4 
1Surgery, Dartmouth-Hitchcock Medical Center/
United States Of America, 2Dartmouth-Hitchcock 
Medical Center/United States Of America, 
3Pathology, DHMC/United States Of America, 
4Thoracic Oncology, Dartmouth Hitchcock Medical 
Center/United States Of America
Background: Lymph node involvement has both 
prognostic and therapeutic implications in lung 
cancer. To limit inherent risks of mediastinoscopy, 
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less than 20mm lesions. Diagnostic rate was 100% 
(14/14 cases) in more than 21mm lesions. We studied 
relationship between the location of responsible 
bronchial branch and the properties of pulmonary 
lesions in less than 20mm lesions(table). 
Conclusion: We could identify about 6th responsible 
bronchial branch and reach that branch selectively 
with 2.8mm bronchoscopy. It was important that 
the responsible bronchial branch cut into central or 
solid part of lesion, needless to say tumor size, for 
increasing diagnostic rate. 
Keyword: VBN
Session P3: Poster Session 3
Wednesday, 6 July 2011
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.001 MATURE CIRCULATING 
ENDOTHELIAL CELLS IN THE 
PERIPHERAL BLOOD AS A MARKER OF 
CLINICAL EFFICACY IN NON-SMALL 
CELL LUNG CANCER THERAPY
Cao L. Jie 
Department Of Respiratory Medicine, Provincial 
AfÀliated Hospital Of Anhui Medical University/
China
Background: Medical oncologists are increasingly 
using anti-angiogenic drugs, but identifying the best-
suited drug and the optimal dosage and schedule 
for treatment of patients with lung cancer remain 
challenging issues. Circulating endothelial cells 
(CECs) and circulating endothelial progenitors 
(CEPs) are modulated in a variety of diseases 
including lung cancer, and are promising surrogate 
biomarkers in oncology. Here, we investigate the 
changing pattern of mature circulating endothelial 
cells (CECs) in non-small cell lung cancer (NSCLC) 
of patients with suspected lung cancer and 
lymphadenopathy. EBUS-FNA is capable of 
detecting a wide array of tissue pathologies including 
recurrent lung cancer and extrathoracic malignancies 
metastatic to thoracic lymph nodes. EBUS-FNA can 
reÀne clinical staging by CT or PET by providing 
samples from hilar and mediastinal lymph nodes. 
EBUS-FNA samples are also sufÀcient in quantity to 
analyze molecular markers. In summary, EBUS-FNA 
can provide a tissue diagnosis, accurate staging and 
mutational analysis for gene-targeted treatment of 
lung cancer. 
Keywords: molecular analysis, Tissue Diagnosis, 
Lung Cancer Staging, Endobronchial Ultrasound
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P2.331 EXPERIENCE OF TBLB USING 
THIN BRONCHOSCOPY WITH VBN
Koichiro Kajiura, Hiroaki Toba, Shoji Sakiyama, 
Mika Takashima, Koh Uyama, Yasushi Nakagawa, 
Hiromitsu Takizawa, Yukikiyo Kawakami, Koichiro 
Kenzaki, Kazuya Kondo, Akira Tangoku 
Department Of Thoracic, Endocrine Surgery And 
Oncology, The University Of Tokushima Graduate 
School/Japan
Background: It is said that diagnostic yield for 
small peripheral pulmonary lesion is increased 
with virtual bronchoscopic navigation(VBN). We 
reviewed utility of VBN on Transbronchial lung 
biopsy (TBLB) with thin bronchoscopy. 
Methods: We had 41 cases TBLB examinations by 
2.8mm bronchoscopy with VBN from Oct. 2008 to 
Dec. 2010. VBN images were created by Bf-Navi of 
Olympus company, using 1mm thin slice CT. 
Results: VBN images showed 5.2±0.7th bronchial 
branches automatically. VBN images, added 
bronchial branches to pulmonary lesion manually, 
expressed 5.8±0.7th bronchial branches Ànally. 
We reached the object while recognizing 5.8±0.7th 
bronchial branches on TBLB examination. Object 
persons were 26 men and 15women, average 
age was 68.8±7.2 years old. The average size of 
pulmonary lesions were 18.1±6.0mm. (4cases in less 
than 10mm, 23 cases in from 11 to 20mm, 10cases in 
from 21 to 30mm, 4cases in more than 31mm). The 
characteristics of lesions was 2cases in pure GGO, 
9cases in partial solid lesion , 30cases in solid lesion. 
Total diagnostic yield was 80.5% (33/41 cases). 
That was, especially, 70.4% (19/27 cases),limited in 
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Background: Fertility is a major concern in 
cancer patients of reproductive age who are 
undergoing chemotherapy. Few studies regarding 
the gonadotoxic effects of taxanes have been 
performed, mostly on experimental animals. Inhibin 
B, a hormone primarily secreted by Sertoli cells, 
can be used as a direct marker of spermatogenesis in 
adult males. Loss of germ cells in men is known to 
cause a decrease in levels of inhibin B and increased 
levels of follicle-stimulating hormone (FSH). We 
conducted this study in order to assess the impact of 
taxane-based chemotherapy on fertility of non-small 
cell lung cancer (NSCLC) male patients by studying 
its effect on the male reproductive axis.
Methods: Forty male NSCLC patients aged 20-60 
years old were included in the study. All of them 
had been scheduled to receive chemotherapy with 
a taxane (docetaxel or paclitaxel) in combination 
with gemcitabine or carboplatin. Serum levels 
of inhibin B, FSH and luteinizing hormone (LH) 
were measured before and after completion of 
chemotherapy. In half of the patients, bilateral 
testicular volume (BTV) was measured through 
testicular ultrasonography at these stages.
Results: The mean age of the patients was 53.05 
years. Twenty-four patients received docetaxel-
based doublets, whereas 16 patients were 
administered paclitaxel doublets. The median 
number of chemotherapy cycles received was three. 
The median levels of serum inhibin B before and 
after chemotherapy were 97.7 (range 1.04–1,753 
pg/mL) and 40.1 pg/mL (range 0–668 pg/mL), 
respectively, and this reduction was statistically 
signiÀcant (p<0.01). On the contrary, median 
serum FSH levels showed a statistically signiÀcant 
increase from 6.65 (range 0.5–26.2 IU/L) to 10.3 
IU/L (range: 2.6–32.3 IU/L), p0.001. The above 
differences were found statistically signiÀcant when 
each of the docetaxel and paclitaxel were examined 
separately as well. The median inhibin B/FSH ratio 
showed a statistically signiÀcant decrease (15.6 to 
4.72), p0.001. The increase in median LH levels 
from 4.80 IU/L (range 0.9–13.6 IU/L) to 5.04 IU/L 
(range 2–13.7 IU/L) was not statistically signiÀcant 
(p>0.05). The BTV decreased from a median of 
27.6 mL (range 13.8–37.3 mL) to 23.5 mL (range 
9.2–32.8 mL). This difference was statistically 
signiÀcant (p0.001), as was the decrease in each of 
the taxane groups separately. There was a signiÀcant 
inverse correlation between inhibin B and FSH 
concentrations as well as between FSH and BTV. 
Inhibin B and LH were not correlated to BTV.
patients before and after therapy and analyze its 
clinical implication in NSCLC therapy. 
Methods: Fifty-seven NSCLC patients were divided 
into three groups according to their treatment 
modality; surgical operation, chemotherapy alone, 
and chemotherapy plus Endostar. The mature CECs 
were measured by Áow cytometry in the peripheral 
blood of NSCLC patients and 18 healthy subjects. 
Results: The number of mature CECs (mean ± SD) 
in NSCLC patients (n=57, 0.33357±0.20060%) 
were signiÀcantly higher than the number in 
healthy volunteers (n=18, 0.16923±0.13488%) 
(P=0.003). After treatment, the number of mature 
CECs decreased signiÀcantly in the surgical 
operation group (P=0.002) and in the chemotherapy 
plus Endostar group (P=0.004), but not in the 
chemotherapy alone group [If the difference is not 
signiÀcant, than you do not need to show a P-value]. 
After therapy, a statistically signiÀcant decrease of 
CECs was observed in patients with early NSCLC 
(P=0.04), but not in patients with advanced-stage 
NSCLC. A positive correlation between mature 
CECs and WBC was found before treatment 
of NSCLC (r=0.911, P<0.001).[P=0.000 is not 
possible.] 
Conclusion: Surgical operation and chemotherapy 
plus Endostar is superior to chemotherapy alone in 
the treatment of NSCLC. Monitoring the number of 
mature CECs may be a promising predictive marker 
of the clinical efÀcacy in NSCLC therapy. 
Keyword: non-small cell lung cancer; circulating 
endothelial cell; Endostar
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.002 TAXANE-BASED 
CHEMOTHERAPY IS ASSOCIATED 
WITH GONADAL DAMAGE IN NSCLC 
MALE PATIENTS
Eleftherios Chatzidarellis1, Nektaria Makrilia1, Laura 
Giza2, Efstratios Georgiadis2, Antonios Vassias1, 
Christina Alamara1, Kostas N. Syrigos1 
1Oncology Unit, 3rd Department Of Medicine, 
Sotiria General Hospital, Athens School Of 
Medicine/Greece, 2Radiology Department, Ygeias 
Melathron Hospital/Greece
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patients complained grade 3 general weakness and 
one grade 4 pneumonia. 
Conclusion: The addition of bevacizumab in 
combination of gemcitabine and carboplatin is active 
in terms of response rate. We need more enrollment 
and longer follow-up. 
Keywords: Non-small cell lung cancer, gemcitabine, 
Carboplatin, bevacizumab
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P3.004 IMPROVEMENT IN SURVIVAL 
BUT NOT SKELETAL MORBIDITY IN 
STAGE IV NON-SMALL CELL LUNG 
CANCER PATIENTS WITH BONE 
METASTASES: TIME TO CONSIDER 
BONE TARGETED THERAPY?
Joanne L. Yu1, Sunil Verma1, Charles Victor2, Dolly 
Han3, Sophie Hogeveen3, Natasha Leighl4, Christine 
Simmons3 
1Division Of Medical Oncology, University Of 
Toronto/Canada, 2Dalla Lana School Of Public 
Health, University Of Toronto/Canada, 3St. Michael’s 
Hospital/Canada, 4Princess Margaret Hospital/
Canada
Background: Bone metastases are common in 
non-small cell lung cancer (NSCLC) and cause 
signiÀcant morbidity in the form of pain, skeletal-
related events, and decreased quality of life. 
Because stage IV NSCLC is associated with poor 
survival, therapy directed at skeletal disease (e.g. 
bisphosphonates) is generally not currently the 
standard of care. However, with signiÀcant advances 
in the systemic management of metastatic lung 
cancer over the last decade, we propose that patients 
with bone metastases will have improved survival, 
and as such may now be candidates for bone targeted 
therapies.
Methods: This was a retrospective cohort study 
of 987 patients diagnosed with stage IV NSCLC 
at 2 institutions. Demographic data, as well as the 
frequency of bone metastases, speciÀc treatments 
received, overall survival, and frequency of skeletal-
related events were collected from patients who 
presented to these centres in 1998, 2003, and 2008. 
Results were then compared across the three time 
periods.
Results: Bone was the most common site of 
metastasis, occurring in approximately half of all 
Conclusion: Taxane-based chemotherapy causes 
a decrease in inhibin B levels, elevation of FSH 
levels and reduction of bilateral testicular volume, 
all of which indicate a signiÀcant gonadal damage 
immediately after completion of chemotherapy. 
Keywords: Chemotherapy, gonadal damage, Non-
small cell lung cancer, taxanes
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P3.003 THE COMBINATION 
CHEMOTHERAPY OF GEMCITABINE, 
CARBOPLATIN AND BEVACIZUMAB 
IN PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER
Bong Seog Kim, Young Mi Ahn, Moon Hyung Lee, 
Kang Heum Suh, Seung-Hyun Nam 
Internal Medicine, Seoul Veterans Hospital/Korea
Background: The addition of bevacizumab in 
combination of paclitaxel and carboplatin showed 
signiÀcant beneÀts in progression-free survival 
and overall survival in patients with advanced non-
small cell carcinoma. We are conducting a phase II 
clinical study of combination chemotherapy with 
gemcitabine, carboplatin and bevacizumab in same 
patients population. 
Methods: The regimen consists of gemcitabine of 
1,000mg/m2 on D1 and D8, carboplatin of AUC 
5 and bevacizumab of 15mg/kg on D1. Treatment 
repeats every 3 weeks. The tumor response was 
checked every 2 cycles according to RECIST 1.1 
criteria. 
Results: Twenty-four patients enrolled in this study 
till now. 23 patients were male. The median age of 
patients was 68 (55~79) Years. Thirteen patients 
were stage IV or recurrent disesase, 7 were IIIB 
and 4 were IIIA. Ten patients were squamous cell 
carcinoma, 11 were adenocarcinoma and 3 were 
unclassiÀed non-small cell carninoma. Fifteen 
patients had ECOG performance status of 1 and 9 
had 2. Total 93 cycles of therapy were administered 
and median cycles of therapy were 4 (1~8). Eleven 
of 21 evaluable patients showed partial responses, 
6 had stable disease. The overall response rate was 
52%, disease control rate was 76%. In total 93 
cycles grade 3 and 4 neutropenia were 14% and 
1%, respectively. Grade 4 thrombocytopenia were 
1% and grade 3 anemia were 7%. Non-hematologic 
toxicities were mild and manageable, but two 
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translational Oncology Research International 
Network/United States Of America, 5Alamance 
Regional Medical Center/United States Of America, 
6Washington University/United States Of America, 
7Eli Lilly And Company/United States Of America
Background: There is no consensus chemotherapy 
regimen with concurrent radiation therapy (CRT) 
for inoperable Stage IIIA/B non-small cell lung 
cancer (NSCLC). Pemetrexed (P) synergizes with 
ionizing radiation, as well as carboplatin (Cb) and 
cisplatin (C) in preclinical models. These doublets 
have shown efÀcacy and favorable toxicity proÀles 
in Phase II/III trials. 
Methods: In this open-label randomized non 
comparison Phase II trial, 98 patients with inoperable 
Stage IIIA/B NSCLC were randomized (1:1) to P 
plus Cb (PCb) or P plus C (PC) intravenously (IV) 
every 21 days for 3 cycles. All patients received 
CRT 64–68 Gy (2 Gy/day, 5 days/week, Days 1–45). 
Consolidation P 500 mg/m2 IV every 21 days for 
3 cycles began 3 weeks after completion of CRT. 
The primary endpoint of this ongoing trial is 2-year 
overall survival (OS); secondary endpoints include 
toxicity, overall response rate (ORR), time to 
progression (TTP), and median survival. 
Results: Since June 2007, 98 patients have been 
enrolled (PCb: 46; PC: 52). Mean dose compliance 
was PCb: 94.9% P, 94.9% Cb; PC: 89.7% P, 87.2% 
C. Mean dose compliance for CRT was PCb: 95.7%; 
PC: 86.7%. Dose interruptions occurred with 39 
patients. The ORR rates were PCb: 56.5% (complete 
response [CR], 6.5%; partial response [PR], 50.0%); 
PC: 46.2% (CR, 1.9%; PR, 44.2%). One-year OS 
was PCb: 68.1% (95% conÀdence interval [CI], 
51.2-80.2); PC: 71.9% (95% CI, 56.4-82.7); 2-year 
OS was PCb: 32.4% (95% CI, 13.8-52.7); PC: 56.1% 
(95% CI, 36.9-71.5). Median OS was PCb: 18.7 
(95% CI, 12.9-not assessable [N/A]) months; PC: 
25.9 (95% CI, 23.2-N/A) months. Selected toxicities 
are shown in Table 1. Table 1. Select Treatment-
Related Toxicities, %* 
Grade 3 Grade 4 
PCb PC PCb PC 
Anemia 10.9 3.8 0 1.9 
Neutropenia 15.2 9.6 6.5 3.8 
Febrile neutropenia 4.3 0 0 0 
Thrombocytopenia 2.2 3.8 4.3 1.9 
Dehydration 6.5 9.6 0 0 
Dysphagia 2.2 0 0 0 
Esophagitis 4.3 3.8 0 1.9 
Fatigue 6.5 1.9 0 0 
patients, a proportion that was stable over time (49% 
in 1998, 54% in 2003, 54% in 2008). While the use 
of systemic therapy increased signiÀcantly over 
time, very few patients received IV bisphosphonate 
therapy. Overall survival from the time of diagnosis 
of bone metastases improved signiÀcantly across 
cohorts (P <0.001), with an actuarial probability 
of survival of 10.0% at 2 years among patients 
diagnosed in 2008, compared with a probability 
of only 0.6% among those diagnosed in 1998, 
and 3.6% in 2003. However, the proportion of 
patients experiencing skeletal-related events did not 
differ signiÀcantly between time cohorts, with no 
improvement over time in the frequency of radiation 
to bone (71% in 1998, 74% in 2003, 70% in 2008; P 
= 0.714), surgery to bone (8% in 1998, 10% in 2003, 
10% in 2008; P = 0.616), or spinal cord compression 
(8% in 1998, 4% in 2003, 10% in 2008; P = 0.091).
Conclusion: While the overall survival of patients 
with bone metastases from NSCLC has improved 
over the past decade, the use of bisphosphonates is 
not standard practice, and the frequency of skeletal-
related events remains unchanged. These results 
support further investigation into the use of bone 
targeted therapies in the setting of metastatic lung 
cancer, to reduce skeletal morbidity and improve 
quality of life in these patients, who are now living 
longer.
Keywords: NSCLC, stage IV, bone metastases, 
bisphosponates
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P3.005 ONGOING PHASE II STUDY OF 
PEMETREXED PLUS CARBOPLATIN 
OR CISPLATIN WITH CONCURRENT 
RADIATION THERAPY FOLLOWED 
BY PEMETREXED CONSOLIDATION 
IN PATIENTS WITH FAVORABLE-
PROGNOSIS INOPERABLE STAGE IIIA/B 
NON-SMALL-CELL LUNG CANCER: 
UPDATE
Hak Choy1, Lee Schwartzberg2, Shaker R. Dakhil3, 
Edward B. Garon4, Janak K. Choksi5, Ramaswamy 
Govindan6, Guangbin Peng7, Andrew Koustenis7, 
Joseph Treat7, Coleman Obasaju7 
1Medical Center, University Of Texas Southwestern/
United States Of America, 2Acorn And West 
Clinic/United States Of America, 3Cancer Center 
Of Kansas/United States Of America, 4Ucla/
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line treatment. This treatment shows an encouraging 
median survival on second line chemotherapy for 
patients with advanced or metastatic NSCLC on 
recurrent disease. 
Keywords: NSCLC, second line chemotherapie, 
Pemetrexed
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P3.007 FIRST LINE CHEMOTHERAPY 
WITH PEMETREXED PLUS CISPLATIN 
IN ADVANCED NONSQUAMOUS NON-
SMALL CELL LUNG CANCER (NSCLC): 
A COMPARISON OF TWO PHASE III 
TRIALS
Giorgio Scagliotti1, Cesare Gridelli2, Filippo De 
Marinis3, Michael Thomas4, Mircea Dedui5, Jean-
Louis Pujol6, Christian Manegold7, Symantha 
Melemed8, William John8, Annamaria H. 
Zimmermann8, Nadia Chouaki9, Allen Melemed8, 
Carla Visseren-Grul10, Luis Paz Ares11 
1Thoracic Oncology Unit, University Of Turin/
Italy, 2S. Giuseppe Moscati Hospital/Italy, 3Medical 
Oncology, San Camillo-forlanini Hospital/Italy, 
4Thoraxklinik, University Of Heidelberg/Germany, 
5Institute Of Oncology, Bucharest/Romania, 
6Montpellier Academic Hospital/France, 7Heidelberg 
University Medical Center/Germany, 8Eli Lilly 
And Company/United States Of America, 9Eli Lilly 
And Company, Suresnes/France, 10Eli Lilly And 
Company, The Netherlands/Netherlands, 11University 
Hospital - Virgen Del Rocio/Spain
Background: In a recent phase III trial (JMDB), 
patients with stage IIIB/IV NSCLC treated with 
pemetrexed/cisplatin had similar outcomes compared 
with those treated with gemcitabine/cisplatin 
(Scagliotti et al 2008). However, a preplanned 
subgroup analysis showed a signiÀcant improvement 
in survival for patients with nonsquamous histology 
treated with pemetrexed/cisplatin (Scagliotti 
et al 2009). The phase III PARAMOUNT trial 
investigated the efÀcacy/safety of pemetrexed 
continuation maintenance therapy after pemetrexed/
cisplatin induction therapy in patients with advanced 
nonsquamous NSCLC. We evaluated whether results 
of the pemetrexed/cisplatin induction regimen of 
PARAMOUNT were conÀrmatory of results of the 
pemetrexed/cisplatin-treated nonsquamous patient 
subpopulation of JMDB. 
PC, pemetrexed plus cisplatin; PCb, pemetrexed 
plus carboplatin * No grade 5 toxicities have been 
reported 
Conclusion: Overall, P plus either Cb or C in 
combination with CRT appear well tolerated in 
treatment of locally advanced NSCLC. EfÀcacy data 
will be updated at the meeting. 
Keywords: NSCLC, Pemetrexed, concurrent 
radiotherapy, chemoradiotherapy
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P3.006 SECOND LINE CHEMOTHERAPY 
WITH PEMETREXED (P) FOR PATIENTS 
IN STAGE IIIB/IV NON SMALL CELL 
LUNG CANCER (NSCLC).
Malika Gamaz Bensaou, Nawel Mehenni, Kamel 
Bouzid 
Medical Oncology, Pierre And Marie Curie Center 
Algiers/Algeria
Background: Pemetrexed is recommended as 
second line treatment for stage IIIB / IV NSCLC 
after failure of Àrst line chemotherapy. The aim 
of our study is to analyze activity and toxicity of 
pemetrexed in second line treatment of advanced and 
metastatic lung cancer. 
Methods: Since october 2007 to december 2009, 27 
patients with advanced and metastatic NSCLC were 
treated with second line chemotherapy and received 
pemetrexed 500 mg/m2 10 minutes infusion day 1. 
All patients received full vitamin supplementation. 
Response and toxicity were assessed using WHO 
criteria.
Results: 27 (1 F and 26 M) patients were enrolled, 
and all are evaluable for response and toxicity. 
Median age was 60.4 years (range m 47years – M 
76years). Histology was adenocarcinoma in 12 
patients, squamous cell cancer in 13 patients and 
carcinoma with large cell in 2 patients. Fifteen (15) 
patients had IV stage and twelve (12) patients had 
IIIB stage disease. The main reported grade III / IV 
events are: neutropenia 4 %, anemia 16 %. Common 
non hematologic grade III / IV toxicities include 
nausea 48 %, and asthenia in 24 % of patients. 
Response rate was (CR + PR) 12 %. Stable disease 
was achieved in 28 % of patients. Median survival 
was 11 months. 
Conclusion: Pemetrexed is well tolerated in second 
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the incidence is higher in JMDB, possibly due to 
the increased number of cycles given. The toxicity 
proÀles in both trials are consistent with the known 
safety proÀle of pemetrexed/cisplatin. 
Keywords: Cisplatin, nonsquamous, Àrst-line, 
Pemetrexed
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P3.008 HOW DO ADVANCED NON 
SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS OVER 70 FARE 
ON FIRST LINE PLATINUM DOUBLET 
CHEMOTHERAPY?
Pooja Jain, Noorulain Mughal, Marie Mckay, 
Helen Wong, Farida Alam, John A.H. Littler, 
Vidhyasagar Ramani, Catherine P. SchoÀeld, Asha 
Sivapalasuntharam, Karen Whitmarsh 
Clinical Oncology, Clatterbridge Centre For 
Oncology/United Kingdom
Background: Platinum doublet chemotherapy 
is standard of care in good performance status, 
advanced stage (IIIb/IV) NSCLC with a 1 year 
survival advantage of 9% and an absolute increase in 
median survival of 6 weeks (Cochrane Database of 
Systematic Reviews 2010). Data on chemotherapy 
in an elderly population (70) is limited in trials. 
Ironically the median age of  Stage III NSCLC 
patients is 70 in our catchment area of 2.3 million. A 
small (n=76) Japanese trial in >75 years old did not 
Ànd any difference in efÀcacy between single agent 
and platinum doublet chemotherapy [1]. 
Methods: A retrospective case note audit was 
carried of patients aged  70 with stage III/IV 
disease. 200 patients received Àrst line chemotherapy 
between 1/1/2004 and 31/12/2008. Data recorded 
was: age, gender, performance status, co-morbidities, 
stage, histology, chemotherapy regimen (cycle 
number, dose intensity/delays/reductions), toxicity 
(CTCVAE4.0), response rates and date of death. 
Results: Results are presented from the analysis of 
the 1st 100 patients. The median age of the audit 
population was 74 (70-84), 63% were male; 62% 
had an ECOG PS 0-1 and 36% had a PS 2. 61% 
had stage IV, 23% stage IIIb and 16% stage IIIa 
disease. 98% of the patients had platinum doublet 
chemotherapy, commonest being gemcitabine/
carboplatin (81%). Approximately 75% of the 
patients had at least 3 cycles of chemotherapy with 
Methods: The JMDB trial randomized 1725 
chemonaive patients with advanced NSCLC of 
all histologies and an ECOG performance status 
of 0/1. Of 1252 nonsquamous patients, 618 were 
randomized to pemetrexed/cisplatin. Patients 
received cisplatin 75 mg/m2 (day 1) with either 
gemcitabine 1250 mg/m2 (days 1, 8) or pemetrexed 
500 mg/m2 (day 1), every 21 days, for a maximum 
of 6 cycles. PARAMOUNT was a double-
blind, placebo-controlled trial that enrolled 939 
chemonaive patients with advanced nonsquamous 
NSCLC and a performance status 0/1 to receive 4 
cycles of induction pemetrexed (500 mg/m2) and 
cisplatin (75 mg/m2) on day 1 of a 21-day cycle. 
Patients who did not progress on induction therapy 
randomly received maintenance therapy with 
pemetrexed or placebo. This comparison examines 
the response and safety data of the nonsquamous 
patients treated with pemetrexed/cisplatin in JMDB 
and the patients treated with induction pemetrexed/
cisplatin in PARAMOUNT. 
Results: In the JMDB trial, among 618 
nonsquamous patients randomized to pemetrexed/
cisplatin, 604 were treated, with 71% completing 4 
treatment cycles, and 47% completing all 6 cycles 
(median=5 cycles). In PARAMOUNT, among the 
939 enrolled patients, 68% completed 4 cycles of 
induction pemetrexed/cisplatin (median=4 cycles). 
The tumor response rates (30.1% and 28.6%) and 
disease control (response plus stable disease) rates 
(74.5% and 63.8%) were similar for PARAMOUNT 
and JMDB. Among the patients who had a response 
(CR/PR) in the JMDB trial, 90.5% achieved the 
response within the Àrst 4 cycles. The pattern of 
grade 3-4 treatment-related toxicities (neutropenia, 
anemia, nausea/vomiting, fatigue) was similar in 
PARAMOUNT and JMDB nonsquamous treated 
patients, but the incidence of laboratory (13.7% and 
21.4%) and nonlaboratory toxicities (14.8% and 
21.9%) was higher in JMDB. The percentage of 
possible treatment-related deaths (1.2% and 1.0%) 
and serious adverse events (14.2% and 16.4%) were 
comparable between PARAMOUNT and JMDB. 
Conclusion: The PARAMOUNT results for patients 
treated with induction pemetrexed/cisplatin conÀrm 
the Àndings for nonsquamous patients treated with 
pemetrexed/cisplatin in JMDB. The two trials 
demonstrate consistent response and disease control 
rates for the pemetrexed/cisplatin combination 
as Àrst-line treatment for patients with advanced 
nonsquamous NSCLC. In addition, the types of 
toxicities reported in the two trials are similar, but 
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Background: Clinicians’ views on EGFR testing: 
Getting the process right for New Zealand 
Background This paper reports the preliminary 
Àndings of a survey to ascertain clinicians’ views 
on introducing Epidermal Growth Factor Receptor 
(EGFR) testing in New Zealand. In advanced non 
small cell lung cancer (NSCLC) tyrosine kinase 
inhibitors (TKIs) and EGFR testing offer new 
hope to many patients. In New Zealand, Maori, 
the indigenous population, have the poorest 
outcomes from advanced NSCLC, and therefore 
treatment options that beneÀt this population are of 
considerable importance. Funding for second line 
erlotinib therapy was introduced in late 2010, with 
no funding for Àrst line therapy in New Zealand. 
Currently no EGFR testing is undertaken in New 
Zealand; patients can pay privately for sample testing 
in Australia. The EGFR mutation rates of New 
Zealand ethnic populations with NSCLC, including 
Maori, have not been tested. International research 
demonstrates TKI response rates vary from 15% 
when EGFR status is unknown to 80% when EGFR 
mutation is positive. Therefore, introducing EGFR 
testing here may enable more effective targeted 
therapy with improved patient outcomes, with the 
potential for a reduction in health inequalities. 
Methods: Following ethical approval, an anonymous 
electronic survey was sent to a range of clinicians 
involved in diagnosing and managing NSCLC in 
New Zealand, including radiation and medical 
oncologists, respiratory physicians, pathologists, 
and advanced trainees in these specialties. Questions 
included who should be tested, wait times for 
results, costs, speciÀc test type, and preferences for 
a centralized or localized service. The preliminary 
results are discussed in this paper. 
Results: 41 clinicians, representing all disciplines 
and from 9 of the 20 District Health Boards, 
responded. Findings included that 67% strongly 
agreed that treating NSCLC with targeted therapy 
was an important health issue. However, opinions 
differed on who should be tested; from only patients 
in research studies to everyone for whom active 
therapy was considered. 71% of clinicians had not 
arranged EGFR tests for any patients, and only 
one clinician had tested more than 10% of their 
Maori NSCLC patients for the EGFR mutation. 
Most clinicians were in favour of a centralized 
64% completing all 4 cycles. Drop out rate was 26% 
due to falling PS or toxicity of which the majority, 
18%, stopped after one cycle of chemotherapy. There 
was a 43% overall response rate with a further 25% 
disease stabilisation. 11% of patients progressed 
on treatment and in a further 18% response was 
not assessed as treatment was stopped early after 
1-2 cycles. Majority of  Grade 3 toxicity was 
haematological. 38% of the patients had  20% 
dose reduction of either one or both chemotherapy 
agents in cycle 1, this increased to 44% by the end 
of second cycle of chemotherapy. 33% patients 
were admitted with pyrexia on chemotherapy. 
Further details are limited as most patients were 
admitted to referring hospitals. Median length of 
hospital stay was 4 days (range 1-15). Chemotherapy 
related mortality, death within 30 days of receiving 
last cycle of chemotherapy was 9%, 4 of these 
patients had progressed on chemotherapy. Median 
progression free survival from date of diagnosis of 
14 months and 1 year overall survival was 45%. 
Conclusion: Our results from an unselected 
population show a better median progression free 
survival (14.0 vs. 6.3 months) from platinum 
doublet chemotherapy than seen in a recent trial 
comparing platinum doublet chemotherapy to 
single agent chemotherapy (Quiox et al, ASCO 
2010). As expected patients with a PS 0-1 had a 
signiÀcantly better survival 13 vs. 9 months for PS 
2 patients (p=0.01). Elderly patients if carefully 
selected do appear to beneÀt from platinum doublet 
chemotherapy despite the reduced dose intensity. 
The full analysis will be submitted before the late 
breaking abstract deadline. References
1. Tamya, A., T. Naito, T. Takahashi, et al. Gan To 
Kagaku Ryoho, 2010. 37(10): p. 1897-1901.
Keywords: Advanced NSCLC, Elderly, 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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after cycle 2 and after conclusion of chemotherapy 
if required or clinically indicated. Chemotherapy 
was stopped if progressive disease was noted or 
due to patient intolerance. Eligible patients for 
this retrospective analysis was required to have 
histological proven non-small cell lung cancer, 
stage IV and not previously treated. Patients were 
required to have a WHO Performance Status of 0 to 
1, adequate bone marrow reserve and renal function 
and no previous malignancy. 
Results: There were 34 males and 15 females. The 
median age at presentation was 67.5 years (53 -82). 
Toxicity was predominantly haematological. Grade 
3-4 neutropenia was noted in 25 patients during 
chemotherapy (52%). No grade 3-4 thombocitopenia 
occurred and 1 patient died within 30 days of 
receiving chemotherapy. Twenty patients needed one 
or more blood transfusions (48%). There were 31.5 
% partial response, 30 % stable disease and 38.5 % 
progressive disease in response to chemotherapy. No 
complete response was recorded. The median overall 
survival was 8.8 months (3-44). The 1,2 and 3 year 
OS were 23%, and 14.5% and 6.5 % respectively. 
The estimated time to progression was 3.5 months 
and only one patient is still alive after 40 months 
follow-up. 
Conclusion: Using the same inclusion criteria as 
described in the Sandler and other phase III studies, 
the results in our institution are in keeping with the 
published data. It is encouraging that the results of 
the randomised controlled trial using a doublet with 
platinum agent and Gemcitabine are applicable to 
a standard population. However we have noticed 
increased incidence of neutopenia and blood 
transfusion rate compared with published data from 
phase III trials. 
Keywords: stage IV, Chemotherapy, survival, 
gemcitabine and carboplatin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
service, with uncertainty regarding test method. 
45% felt there were no drawbacks to introducing 
EGFR testing here, however others had concerns 
including costs (34%), the lack of expertise (24%), 
and potential clinical implications (10%). Over 60% 
were prepared to arrange additional biopsies for 
EGFR testing and 80% wanted a turnaround of less 
than two weeks. Fewer than 50% of clinicians were 
very familiar with other NSCLC molecular tests, 
including ALK fusion gene. 
Conclusion: Whilst most clinicians who responded 
had little experience with EGFR testing, they 
supported the introduction of EGFR testing into New 
Zealand. However, clinicians also identiÀed issues, 
such as expertise, that need to be dealt with while 
work to introduce the testing is undertaken
Keywords: EGFR, NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.010 CHEMOTHERAPY IN PATIENTS 
WITH STAGE IV NON-SMALL CELL 
LUNG CANCER.THE WREXHAM 
MAELOR HOSPITAL EXPERIENCE.
Angel Garcia-Alonso1, M. Wilczynska2, C. F. Smith1, 
N. Smith3, N. Ghosal1, G. Drury1, A. Gostage1 
1Oncology, Bcuhlb/United Kingdom, 2Respiratoty 
Medicine, BCULHB/United Kingdom, 3Oncology, 
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Background: Wrexham Maelor Hospital in North 
Wales serves approximately 250,000 people. 
The lung cancer multi disciplinary team sees 
approximately 100 newly diagnosed non-small-cell 
lung cancer (NSCLC) patients a year. Of these 40 % 
are stage IV on presentation. We present the outcome 
data of our stage IV lung cancer patients. 
Methods: The study period was January 2007 
to December 2008. Total 48 stage IV (TNM 
6th Edition) were treated with platinum doublet 
chemotherapy with the commonest regimen being 
Gemcitabine 1250mg/m2 and Carboplatin AUC 
5 given every 3 weeks for 4 cycles. The patients 
treated with chemotherapy represented 60% of 
the total referred stage IV Non Small Cell Lung 
Cancer during this period. CT staging was repeated 
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P3.012 ERLOTINIB (TARCEVA®) IN THE 
TREATMENT OF A NON-SELECTED 
POPULATION OF 1735 PATIENTS (PTS) 
WITH ADVANCED NON-SMALL-CELL 
LUNG CANCER (NSCLC) FROM THE 
CZECH REPUBLIC
Jana Skrickova1, Milos Pesek2, Petr Zatloukal3, 
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Koubkova6, Milana Zemanova7, Dimka Sixtova8, 
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University Hospital Olomouc/Czech Republic, 
5Department Of Respiratory Diseases, University 
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Republic, 10Department Of Oncology, Masaryk 
Memorial Institute/Czech Republic, 11Institute Of 
Biostatistics And Analyses, Masaryk University/
Czech Republic
Background: The human epidermal growth factor 
receptor (EGFR) tyrosine-kinase inhibitor (TKI) 
erlotinib (Tarceva®) is approved for use in advanced, 
pretreated NSCLC. This analysis presented examines 
data obtained from the Czech population of NSCLC 
pts who received erlotinib. 
Methods: Data of all 1735 NSCLC pts treated 
with erlotinib between 12/2005 and 12/2010 in the 
Czech Republic are summarised. We evaluated 
efÀcacy and toxicity. Retrospective analyses were 
carried out to determine if any associations were 
seen between speciÀc characteristics and either 
median Progression Free Survival (mPFS) or median 
Overall Survival (mOS), PS, gender, smoking status, 
histology and toxicity were also assed. Erlotinib 
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P3.011 PEMETREXED PLUS PLATINE 
IN FIRST LINE FOR TREATMENT OF 
ADVANCED AND METASTATIC NON-
SQUAMOUS CELL LUNG CANCER.
Nawel Mehenni1, Malika Gamaz Bensaou2, Kamel 
Bouzid1 
1Medical Oncology, Centre Pierre And Marie Curie/
Algeria, 2Medical Oncology, Pierre And Marie Curie 
Center Algiers/Algeria
Background: Pemetrexed was initially approved as 
second-line monotherapy in advanced NSCLC, and 
then in Àrst line of non-squamous cell lung cancer in 
association with platine. In this study, we evaluate 
the efÀcacy and toxicity of pemetrexed plus platine 
in patients with advanced non-squamous cell lung 
cancer in chemo naive patients. 
Methods and Patients: From October 2009 to 
December 2010, twenty two (22) patients with non 
squamous cell lung cancer stage IIIB or IV were 
treated in Àrst line with pemetrexed 500 mg/m2 day 
1 plus cisplatine 70 mg/m2 on day 1 or carboplatine 
AUC6 (for patients more than 60 years. All patients 
received full vitamin supplementation and the 
response and toxicity were assessed using Recist 
criteria. Twenty two patients were enrolled, and all 
are evaluable for response and toxicity. Eighteen 
(18) male and 4 female, and the median age was 
61,8 (range 46 -69) years. Six (6) patients had IIIB 
stage and 16 patients had IV stage disease. Large cell 
cancer was found in 5 patients, adenocarcinoma in 
17 patients. 
Results: No complete response were observed, 
partial response was observed in 8 (36%) patients, 
stable disease was achieved in 4 (18%) patients, 
and disease progression was observed in 10 (45%) 
patients. Toxicities grade 3 and 4 was 17 %, mainly 
hematological (leucopenia and anemia). 
Conclusion: Pemetrexed plus platine is well 
tolerated and active. Larger and longer follow-up 
studies may be needed to determine the real impact 
in survival of the association pemetrexed plus platine 
in non squamous cell lung cancer.
Keywords: Pemetrexed, Adenocarcinoma, advanced 
stage
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.013 A PHASE II STUDY OF 
INTERMITTENT IMATINIB MESYLATE 
AND WEEKLY PACLITAXEL IN 
PATIENTS AGED 70 OR OLDER WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER
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Background: In epithelial tumors including 
non-small cell lung cancer (NSCLC), interstitial 
hypertension is a barrier to chemotherapy delivery, 
and is mediated by platelet derived growth factor 
receptor (PDGFR) expressed by matrix Àbroblasts. 
Antagonizing PDGFR with imatinib may improve 
intra-tumoral delivery of paclitaxel, thereby 
increasing response rate (RR).
Methods: This single-stage, open-label, multicenter 
phase II study evaluated the efÀcacy of weekly 
paclitaxel (90 mg/m2 on day 3, 10, 17 of 28-day cycle) 
and imatinib pulses (600 mg daily on day 1-4, 8-11, 
15-18) in elderly patients with advanced NSCLC. 
Eligible patients were aged  70 with untreated 
stage IIIB-IV NSCLC and ECOG performance 
status 0-2. Primary endpoint was RR (RECIST 1.0). 
Secondary endpoints included median progression 
free and overall survival (PFS, OS), toxicity, and 
tissue correlatives of PDGFR pathway activation. The 
Charlson Comorbidity Index (CCI) and Vulnerable 
Elder Survey-13 (VES-13) were measured at baseline 
for correlation with RR, PFS and OS.
Results: Between 9/1/2006 and 4/15/2010, 34 
patients enrolled. Median age was 75, 91% were 
non-Hispanic white, and 68% were male. Eleven 
of 29 (38%) patients were frail by VES-13 score. 
Histology was 47% adenocarcinoma, 29% squamous 
cell, 18% poorly differentiated, and 6% other. 
Patients who withdrew or died before response 
assessment were considered non-responders. Overall 
RR was 11/34 (32% with 95% CI 17%-51%), all 
partial responses, which met the primary endpoint. 
Median PFS and OS were 3.6 and 7.3 months, 
was administered orally 150 mg/day until disease 
progression. The difference in response relative 
to baseline characteristics was determined using 
Pearson Chi-square test. Differences in OS and PFS 
relative to baseline characteristics were evaluated for 
signiÀcance using log-rank test. 
Results: Of the 1735 patients with advanced 
NSCLC, 617 (35.6 %) were female and 1118 
(64.4%) male, 374 (21.6%), non-smokers, 686 
(39.5%) former smokers and 675 (38.9%) current 
smokers. Median age was 65 years. Erlotinib was 
used as 1st line therapy in 14.4%, as 2nd line in 
47.3% and as 3rd line in 38,3% patients. At the 
time of indication for erlotinib, disease states were 
ECOG PS 0 in 132 (7.6%), PS 1 in 976 (56.3%), 
PS 2 in 382 (33.5%) and PS 3 in 45 (2.6%) pts. The 
most patients were stage IIIB (32.0%) and stage IV 
(58.0%). Adenocarcinoma was conÀrmed in 45.9%, 
squamous-cell carcinoma in 39.2%, large–cell 
carcinoma in 4.0% and non speciÀed carcinoma 
in 9.4% pts. CR was conÀrmed in 0.6%, PR in 
123 7.1% pts, SD in 44.1% of pts; 23.0% of pts 
progressed and 25.2% pts were not evaluated. Major 
toxicities were skin toxicity in 56.7% and diarrhoea 
in 24.3 pts, but the therapy was Ànished due to 
toxicity grade 3-4 only in 5.0%. Median survival 
(95% CI) was 7.5 months (6.9; 8.1). Probability of 
3-months survival was 74.8%, of 6-month survival 
was 56.7% and of one-year survival was 16.7%. 
PFS (95% CI) was 2.9 months. The probability 
of 3-months PFS was 51.2%, of 6-month survival 
30.4% and of one-year PFS 16.7%. The differences 
between the lines of treatment were not statistically 
signiÀcant (p = 0.744). The differences between 
groups of pts according to PS (0+1 vs. 2+3) were 
statistically signiÀcant (p < 0.001). The best median 
survival (17.6 month) was in the group of pts with 
PS 0. Statistically signiÀcantly longer (p< 0.001) 
was mOS and mPFS survival in patients with skin 
toxicity, in female pts, in non-smokers and in pts 
with adenocarcinoma. 
Conclusion: Erlotinib (Tarceva ®) in this non-selected 
group of pts with advanced NCCLC was well tolerated, 
with evidence of antitumor activity in 1st, 2nd and 3rd 
line of therapy. The statistically signiÀcant best (p < 
0.001) outcomes were seen the results in patients who 
had PS 0+1, skin toxicity, or were female, non-smokers, 
or had adenocarcinoma. The results from the Czech 
Republic are better then the data from BR.21 study and 
comparable with the results of TRUST. 
Keywords: performans status, Advanced NSCLC, 
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Background: Epidermal growth factor receptor 
(EGFR) mutation is suggested to be associated 
with radiosensitivity of non-small cell lung cancer 
(NSCLC) in vitro. We attempted to analyze the 
clinical impact of EGFR mutation on the response 
to platinum-based neoadjuvant chemoradiotherapy 
(CCRT) in N2(+) NSCLC patients. 
Methods: 161 patients with mediastinoscopy-proven 
N2(+) NSCLC received platinum-based neoadjuvant 
CCRT at Samsung Medical Center between 1998 
and 2006. EGFR mutation was assessed by Peptide 
Nucleic Acid(PNA)-mediated PCR clamping 
method in 98 patients with available remained tumor 
tissue. 88 patients were Ànally included in analysis, 
excluding patients with indeterminate EGFR 
mutation results or patients who were lost to follow 
up during CCRT
Results: Among 88 patients, adenocarcinoma 
was 55.7% (n=49) and squamous carcinoma was 
37.5% (n=33). EGFR mutation (exon 19 deletions 
or L858R) was detected in 13 patients (14.8%), 
and KRAS mutation in 2 patients (2.3%). After 
neoadjuvant CCRT, 5 patients showed progressive 
disease, pathologic downstaging of lymph 
nodes(LN) to N0 or N1 was achieved in 44 patients 
(50%), and pathologic CR in 13 patients (14.8%). 
Achievement of pathologic CR or pathologic 
downstaging of LNs were not associated with EGFR 
mutation status. With a median follow-up of 73.8 
months, no signiÀcant differences were observed 
in overall survival (OS) or progession free survival 
(PFS) according to EGFR mutation status (OS 28.2 
months vs 33.6 months in EGFR mutation positive 
vs. negative patients, p=0.125; PFS 15.2 months vs. 
18.0 months in EGFR mutation positive vs. negative 
patients,p=0.631), respectively. 
Conclusion: In N2-positive NSCLC patient, EGFR 
mutation status was not associated with cinical outcome 
in response to neoadjuvant CCRT, in terms of response 
rate, PFS or OS. Further study should be needed to 
conÀrm the association between EGFR mutation status 
and radiosensitivity in NSCLC patients. 
respectively. Fourteen patients experienced 18 
serious adverse events (SAE), including 4 deaths 
on treatment (1 infection, 1 pneumonitis, 2 cardiac). 
Neuropathy  grade 2 occurred in 8 (24%), and 
myelosuppression  grade 3 in 7 (21%). The CCI 
did not predict RR, PFS or OS. VES-13 score 
was a signiÀcant predictor of PFS and OS. Frail 
patients had signiÀcantly worse median PFS (3.2 
vs. 4.5 months; p=0.02) and OS (4.8 vs. 12 months; 
p=0.02) than non-frail. Biomarkers of PDGFR 
pathway activation will be presented at the meeting. 
Conclusion: The combination of imatinib and 
paclitaxel had excellent activity as measured by 
RR, however PFS and OS were typical for elderly 
patients with advanced NSCLC. Toxicity was 
acceptable. Further evaluation of this combination 
may be justiÀed in patients selected for PDGFR 
pathway activation. The VES-13 was a powerful 
predictor of survival outcomes in this population.
Keywords: Non-small cell lung cancer, Elderly, 
VES-13, PDGFR
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P3.014 CLINICAL IMPACT OF 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION IN N2(+) 
NON-SMALL CELL LUNG CANCER 
PATIENTS TREATED WITH PLATINUM-
BASED NEOADJUVANT CONCURRENT 
CHEMORADIOTHERAPY
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of response only 8/32 pts (25%) progressed, and 
for Overall Survival only 12/131 pts (9.2%) died 
: 8/66 arm A and 4/65 arm B (median follow-up 
3.2 months). Median dose intensity for NVBo was 
44.7 mg/m²/week, 15.6 mg/m²/week for NVBiv, 
with a relative dose intensity (RDI) of 89.3% for 
NVBo and 81.5% for NVBiv. The CDDP median 
dose intensity was 24.6 mg/m2/week in arm A and 
24.5 mg/m2/week in arm B, with a RDI of 92.1% 
and 91.6% respectively. Grade 3/4 neutropenia : 29 
pts and 43 cycles in arm A, 56 pts and 106 cycles 
in Arm B. Febrile neutropenia : 4 (6.1%) pts in arm 
A and 6 patients (9.2%) in arm B. Grade 3 anaemia 
: 6 (9.1%) pts and 10 cycles in arm A and 13 pts 
(20%) and 18 cycles in arm B, with grade 4 anaemia 
in 3 pts (4.6%) only in arm B. The most frequent 
non haematological disorders were nausea (8 pts 
Grade 3 - 12.1% arm A; 6 pts Grade 3 - 9.2% arm 
B) and vomiting (10 pts Grade 3 -15.2%, 1 pt Grade 
4 - 1.5% arm A; 9 pts Grade 3- 13.8%, 1 pt Grade 4 
- 1.5% arm B). Diarrhea was reported in 16 (24.2%) 
and 12 (18.5%) pts in arm A and arm B, respectively. 
Conclusion: Both arms testing NVBo and NVBiv 
with CDDP reported similar efÀcacy results. The 
recommended NVBo dose titration from 60 to 
80 mg/m² allowed to improve the haematological 
tolerance by keeping the same efÀcacy. NVBo is 
a step forward in the treatment of NSCLC since 
it optimises treatment convenience thanks to its 
oral formulation while maintaining a high level of 
efÀcacy. 
Keywords: Advanced Lung Cancer, Chemotherapy, 
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P3.016 IMPACT OF THE 7TH EDITION OF 
TNM CLASSIFICATION (UICC7) IN NON-
SURGICAL CASES OF ADVANCED NON-
SMALL CELL LUNG CANCER
Noriko Yanagitani, Toshio Sakatani, Ryota Saito, 
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Background: The 7th edition of the TNM 
classiÀcation (UICC7) in lung cancer has recently 
Keywords: Epidermal growth factor receptor, Non 
small cell lung cancer, Radiotherapy
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P3.015 OPEN-LABEL, RANDOMISED 
MULTICENTRE, PHASE II TRIAL OF 
ORAL VINORELBINE (NVBO) OR 
INTRAVENOUS VINORELBINE (NVBIV) 
WITH CISPLATIN (CDDP) IN PATIENTS 
(PTS) WITH ADVANCED NON SMALL 
CELL LUNG CANCER (NSCLC): A 
CHINESE EXPERIENCE
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Médicament/France
Background: Aim of the study : to evaluate efÀcacy 
(CR, PR) of the two formulations with CDDP in 
advanced NSCLC. Progression-free survival (PFS), 
overall survival (OS) and safety were secondary 
objectives. 
Methods: NVBo, 60 mg/m² (arm A) and NVBiv, 25 
mg/m² (arm B) were delivered on D1, D8, repeated 
every 3 weeks. Doses were increased at cycle-2 
(NVBo 80 mg/m2 - NVBiv 30 mg/m2) according to 
haematological tolerance. CDDP doses were 80 mg/
m2 D1 every 3 weeks in both arms. Pts received a 
maximum of 4 cycles in the absence of progression. 
Results: Between 1/2008 and 6/2009, 132 pts were 
randomised at 6 investigational centres (cut-off date 
for Ànal analysis : January, 15th 2010 - arm A 67 pts, 
arm B 65 pts). One patient in arm A was not treated. 
Among the 131 treated patients, 92 (71.9%) pts (54 
- 84.4% arm A, 38 - 59.4% arm B), escalated NVBo 
and NVBiv doses and 36 did not (10 arm A, 26 arm 
B). Among the 131 pts analysed by an independent 
panel review, PR was 25.8% (95% CI [15.8-38.0]) 
in arm A and 23.1% (95% CI [13.5-35.2]) in arm 
B, with a disease control (PR+SD) of 72.7% (95% 
CI [60.4-83.0]) in arm A and 72.3% (95% CI [59.8-
82.8]) in arm B. Other secondary endpoints were 
not yet reached at the cut-off date : for duration 
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P3.017 CURATIVE TREATMENT VS. 
BEST SUPPORTIVE CARE IN ADVANCED 
NON-SMALL CELL LUNG CANCER 
OVER AGE 70
Junghyun Chang1, Yon Ju Ryu2, Ji Hye Kim1, Jin 
Hwa Lee2 
1Pulmonology And Critical Care Medicine, Ewha 
Womans University Mokdong Hospital/Korea, 
2Pulmonology, Ewha Womans University Mokdong 
Hospital/Korea
Background: With the introduction of new 
chemotherapeutics showing better efÀcacy and 
low side effects, curative treatment (CT) in lung 
cancer has been extended to over aged patients in 
recent years. However, the patients and their family 
provide negative minds for the deÀnitive treatment 
of curative aim in aged person. It was reevaluated 
whether the curative anticancer treatment including 
chemotherapy and/or radiation therapy of curative 
aim had a survival beneÀt comparing to best 
supportive care(BSC) especially in aged advanced 
lung cancer subjects.
Methods: The data was retrieved retrospectively 
from medical records of 618 patients who had been 
diagnosed as non-small cell lung cancer (NSCLC) 
in tertiary university hospital from 2000 through 
2007. The analysis was conÀned to 146 subjects of 
stage IIIb or IV NSCLC over 70 years old, excluding 
cases of insufÀcient data, chemotherapy less than 
two times, or follow up loss after diagnosis. For the 
staging, 7th edition of TNM staging was applied.
Results: The mean age at diagnosis was 77 years old 
(range: 70-95). In good performance group (ECOG, 
0-1) was 109 patients(75%) and bad performance 
group(ECOG, 2-3) was 37(25%). The mean 
survival time following the diagnosis was 10.0± 
12.8 months(m). As compared to BSC(n=92), the 
curative treatment group(n=54) showed the better 
survival rate (CT median 7± 0.9 m, 95% conÀdence 
interval [CI]: 5.2-8.8 vs. BSC median 4± 0.8 m, 95% 
CI: 2.3-5.7, p= 0.008). Within good performance 
group, the better survival rate was also shown in 
curative treatment group than BSC (CT median 7 ± 
0.9 m, 95% CI: 5.2-8.8 vs. BSC median 4 ± 1.1 m, 
95% CI: 1.8-6.2, p= 0.036). Contrarily, within bad 
performance group, there was no signiÀcant survival 
gain in curative treatment over BSC(CT median 10 
± 5.0m, 95% CI: 0.3-19.7 vs. BSC median 3 ± 1.5m, 
been published. However, the impact of this new 
staging system has not yet been well examined in 
advanced non-small cell lung cancer (NSCLC), 
especially in non-surgical cases. In this study, we 
validated the prognostic value of this new staging 
system in advanced NSCLC patients who did not 
undergo surgery.
Methods: A total of 511 patients who were newly 
diagnosed to have NSCLC and were treated without 
surgery at our hospital between January 2005 
and January 2010 were identiÀed and reclassiÀed 
according to the UICC7 criteria. All patients had 
either histologically or cytologically conÀrmed 
NSCLC and were clinically staged as either IIIA, 
IIIB or IV according to the 6th TNM classiÀcation 
(UICC6) criteria. The primary outcome measure was 
to compare the stage-speciÀc overall survival (OS) of 
advanced NSCLC using both the UICC6 and UICC7. 
Results: The patient characteristics were as follows: 
male/female: 338/ 173; median age: 66 years (30- 
81); histology, adeno/ squamous/ large/ other: 330/ 
91/ 35/55; PS, 0/1/2/3/4/unknown: 264/ 194/ 30/ 
13/ 5/ 5. Based on UICC6, 511 patients were staged 
as 69 IIIA/ 136 IIIB/ 306 IV. After reclassifying the 
case according to UICC7, 90 patients (17.6%) were 
differently staged (IIIA/IIIB/IV: 77/ 74/ 360). In 
addition, 9 IIIA, 17 IIIB, 59 IIIB and 5 IV cases were 
restaged to IIIB, IIIA, IV and IIIB, respectively. The 
reasons for these differences were due to malignant 
effusion being classiÀed as M1 instead of T4 (59 
cases), ipsilateral same-lobe nodules as T3 instead 
of T4 (6 cases), ipsilateral different-lobe nodules as 
T4 instead of M1 (5 cases) , peribronchial lymph 
node as the no.4 R node instead of the no.3 node 
(9 cases) and extension as T4; stage IIIB instead 
of T4N1; stage IIIA (11 cases). The median OS of 
stage IIIA, IIIB and IV of UICC6 were 23.8 months, 
26.1 months and 13.3 months, respectively and the 
median OS of stage IIIA, IIIB and IV of UICC7 
were 29.0 months, 22.8 months and 14.3 months, 
respectively. The OS curves of stage IIIA and IIIB of 
UICC6 were substantially overlapped, whereas the 
OS curves of stage IIIA, IIIB and IV cases according 
to UICC7 could be clearly distinguished.
Conclusion: The UICC7 staging system is therefore 
considered to be able to better predict advanced 
NSCLC than UICC6, even in non-surgical cases. 
Keywords: UICC7, TNM classiÀcation, Advanced 
NSCLC
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Background: Based on self-adjuvanted mRNA 
molecules we developed a novel vaccination 
technology using a therapeutic cancer vaccine for 
non small cell lung cancer (NSCLC). CV9201 
contains Àve mRNAs encoding NSCLC associated 
tumor antigens (NY-ESO1, Mage-C1, Mage-C2, 
Survivin, 5T4). Here, we report preliminary results 
of a phase I/IIa trial. Stage IIIb/IV NSCLC patients 
that showed no tumor progression after Àrst line 
chemo- or chemo-radiotherapy were treated with 
CV9201. Primary endpoint was assessment of safety 
and tolerability of CV9201 and secondary endpoints 
were evaluation of induction of immune response 
and assessment of anti-tumor activity.
Methods: Patients were vaccinated intra-dermally up 
to Àve times in max. 15 weeks. A total of 9 patients 
were vaccinated in the phase I part of the study, 3 
patients each at three different dose levels (400g, 
800g and 1600g total mRNA administered). The 
highest dose level was then continued within the 
phase IIa part. Blood samples were taken before 
the Àrst vaccination and two weeks after the 3rd and 
5th vaccination respectively, and peripheral blood 
mononuclear cells (PBMCs) were isolated. PBMCs 
were later on analyzed for induction of effector and 
memory T-cell subsets, B-cells and CD4+CD25++ T 
regulatory cells. Antibody production was analyzed 
by IgM and IgG ELISA against the vaccination 
antigens used and antigen-speciÀc T-cell responses 
were analyzed by IFN-g ELISPOT, ICS and tetramer 
analysis. 
Results: Phase I safety analysis showed neither 
vaccine-related serious adverse events nor dose-
limiting toxicity. Most notably treatment related 
grade 1 injection site reactions and grade 2 fever 
were reported. After 3 vaccinations, frequency 
of B-cells increased. In 41% of the 17 patients 
analyzed so far a signiÀcant (P< 0.01) shift from 
IgD+CD38+/- naïve B-cells towards IgD+CD38++ 
germinal center founder B-cells by > 2 fold was 
observed. T-cell population tends to shift from 
effector to memory subtype 2 weeks after the Ànal 
vaccination. Antigen-speciÀc antibodies, CD4+ 
and CD8+ T-cell responses were detected after 
vaccination with CV9201. 
Conclusion: The interim analysis indicates that 
vaccination with CV9201 induces an adaptive 
immune activation and detectable antigen-speciÀc 
humoral and cellular immune responses. Further, this 
novel class of vaccines appears to be safe and well 
tolerated by patients with advanced NSCLC. 
Keywords: GC-founder B-cells, antigen-speciÀc 
95% CI: 0.2-5.8, p= 0.076).
Conclusion: The survival beneÀt was observed in 
curative treatment, especially in good performance 
status, compared to best supportive care. In 
relatively poor performance status over ECOG 1, 
although the outcome of survival time had a little 
superior tendency in curative treatment comparing 
to supportive care without statistical signiÀcance, 
meticulous attention should be given in treatment 
decision. In over 70 years old, advanced NSCLC, 
we recommend that treatment of curative aim has to 
try in good performance status and in relatively bad 
performance, the decision should be individualized 
carefully.
Keywords: Lung cancer, survival, curative 
treatment, best supportive care
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P3.018 MESSENGER RNA VACCINATION 
IN NSCLC- FINDINGS FROM A PHASE I/
IIA CLINICAL TRIAL
Martin Sebastian1, Lotta Von Böhmer2, Alfred 
Zippelius3, Frank Mayer4, Martin Reck5, Djordje 
Atanackovic6, Michael Thomas7, Folker Schneller8, 
Jan Stoehlmacher9, Eray Goekkurt10, Helga 
Bernhard11, Andreas Gröschel12, Robert Bals12, 
Susanne Rittig4, Birgit Scheel13, Sven D. Koch13, 
Thomas Lander14, Karl-Josef Kallen14, Alexander 
Knuth2 
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Medical Center Of The Johannes Gutenberg-
university/Germany, 2Universitätsspital Zürich/
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stable until the end of July 2010 when multiple brain 
metastases were found. Case 3 A Àfty-four-year-
old female started the study from November 2009. 
A PET scan demonstrated complete disappearance 
of the primary tumor as well as all the metastases 
except for a bone metastasis to the right 8th rib. 
Control of the tumor was observed until Des 2010 
when she complained dyspnea with local recurrence 
and both side pleural effusion. Initial response 
was encouraging but all three cases had recurrence 
within 12 months. Two cases in distant metastasis to 
brain and one in local recurrence. ALK fusion gene 
expression in the recurrences of brain or pleural 
effusion by immunohistochemical methods was 
negative in case 1 and positive in case 2 and 3. 
Conclusion: ALK kinase inhibitor, Crizotinib, is 
effective in ALK fusion gene positive lung cancer 
patients but further analysis is necessary for the 
prevention of recurrences . . 
Keywords: Crizotinib, Lung cancer, recurrence, 
EML4-ALK
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P3.020 TWO NSCLC PATIENTS 
ACHIEVED PR BY ARQ 197 
MONOTHERAPY - FINAL RESULT OF 
THE FIRST ASIAN PHASE I TRIAL OF 
SELECTIVE C-MET INHIBITOR ARQ 197
Nobuyuki Yamamoto1, Tomohiro Nishina2, Kenji 
Sugio3, Kei Muro4, Shiro Akinaga5, Hiroshi Maeda6, 
Toshiaki Takahashi1, Tateaki Naito1, Haruyasu 
Murakami1, Hirofumi Yasui7, Narikazu Boku7, 
Tomonori Hirashima8 
1Division Of Thoracic Oncology, Shizuoka Cancer 
Center/Japan, 2Shikoku Cancer Center/Japan, 
3Kyushu Cancer Center/Japan, 4Aichi Cancer 
Center/Japan, 5Clinical Development Department 1, 
Kyowa Hakko Kirin Co., Ltd./Japan, 6Kyowa Hakko 
Kirin Co., Ltd./Japan, 7Division Of Gastrointestinal 
Oncology, Shizuoka Cancer Center/Japan, 8Thoracic 
Malignancy, Osaka Prefectural Medical Center For 
Respiratory And Allergic Diseases/Japan
Background: Tivantinib (ARQ 197) is a selective, 
non-ATP competitive inhibitor of c-MET, a receptor 
T-cell responses, mRNA vaccination, immune 
therapy
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P3.019 EFFECT OF ALK KINASE 
INHIBITOR (CRIZOTINIB)AGAINST 
ALK FUSION GENE POSITIVE LUNG 
CANCER PATIENTS AND THE PATTERN 
OF RECURRENCES
Hideki Kimura1, Toshihiko Iizasa1, Yukiko Matsui1, 
Mitsuru Yoshino1, Masato Shingyoji1, Meiji Itakura1, 
Sana Yokoi2, Makiko Itami3 
1Department Of Thoracic Diseases, Chiba Cancer 
Center/Japan, 2Cancer Genome Center, Research 
Institute, Chiba Cancer Center/Japan, 3Department 
Of Pathology, Chiba Cancer Center/Japan
Background: Anaplastic lymphoma kinase (ALK) 
fusion gene-positive lung cancer accounts for 4-5% 
of non-small cell lung carcinoma. A clinical trial of 
the speciÀc inhibitor of ALK fusion-type tyrosine 
kinase(Crizotinib) is currently under way. 
Methods: ALK fusion gene products were analyzed 
immunohistochemically with the materials obtained 
by endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA) from mediastinal 
lymphnodes of lung cancer patients. After we 
obtained informed consent and eligibility criteria, 
3 patients were enrolled for the PÀzer Study of 
Crizotinib (PF02341066), Clinical Trial A8081001, 
conducted at Seoul National University. 
Results: Case 1 A 48-year-old male patient had ALK 
fusion gene positive lung adenocarcinoma (T3N2M1 
stage IV). was enrolled in a trial of crizotinib 
(PF02341066) at Seoul National University. 
Almost all the bone and lymph node metastases 
disappeared except for those at the left vertebral arch 
of L5. The control of the primary and metastatic 
tumors continued for 11 months until multiple 
brain metastases were found. Case 2 A 49-year-
old female, with T1N3M1 stage IV ALK positive 
adenocarcinoma was enrolled to the study from 
July 2009. A PET scan performed 5 weeks after the 
initiation of the therapy showed marked reduction of 
bone and lymph node metastases. The response was 
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P3.021 3D-CT GUIDED PERCUTANEOUS 
RADIOFREQUENCY ABLATION 
AGAINST ADVANCED NON-SMALL 
CELL LUNG CANCER：SHORT TERM 
EFFECT ASSESSMENT
Hu Mu1, Zhi X. Yi2, Liu B. Dong2, Liu Lei2 
1Thoracic Surgery Department, Bejing Lung Cancer 
Center,capital Medical University/China, 2Thoracic 
Surgery, Beijing Lung Cancer Center Cmu/China
Background: Although the most effective 
treatment for lung cancer is surgery at present, 
70% of lung tumors are not suitable for potentially 
curative resection. There are two main reasons 
that account for the unsuitability of surgery as the 
prime treatment modality: advanced stage due to 
lack of effective early diagnostic method and poor 
operation tolerance due to advanced age or co-
morbid medical conditions. In recent years, Radio 
Frequency Ablation (RFA), a newly-developed local 
physiotherapy, has been applied as an alternative 
therapeutic strategy for lung cancer, receiving 
remarkable clinical effect. 
Methods: After 2007,2, we used RITA 
radiofrequency therapeutic equipment to treat 
advanced non-small cell lung cancer under 
the guidance of spiral CT (Siemens) and three 
dimensional reconstruction of the image. The 
target temperature is 90 centidegree. We inserted 
the electrode needle into tumor, opened anchor 
electrodes and ablated according to tumor size and 
shape. Insertion of electrodes was similar as in 
percutaneous pneumocentesis biopsy. By virtue of 
CT scan, which revealed tumor size, position and its 
anatomical relation with neighboring organs, such 
as diaphragm, heart, great vessels and pleural wall, 
we chose the nearest position to tumor, measured 
and Àgured out the inserting angle and depth, 
making sure that the vital part would not be injured 
by mistake and all the tumor should be covered by 
ablation. With local anesthesia, electrode needle was 
inserted into tumor and the insertion was checked 
by CT. Afterwards, we opened anchor electrodes 
to maximum diameter as planned and scanned CT 
to locate the main needle and every anchor needle. 
Finally we ablated when all the steps above met 
requirements. After lesion ablation, we closed the 
anchor electrodes and ablated Needle-tract. Chest 
CT was then re-checked to observe pneumothorax 
tyrosine kinase implicated in tumor cell migration, 
invasion and proliferation. In this Àrst Asian phase I 
study that was conducted in Japan, we examined the 
drug’s safety proÀle, pharmacokinetics, biomarkers 
and preliminary antitumor activity and determined 
Recommended-phase-2 dose (RP2D) in patients (pts) 
with metastatic solid tumors. ARQ 197 is mainly 
metabolized by CYP2C19 of which is known; it is 
reported that the ratio of the poor metabolizer (PM) 
of CYP2C19 in Asian countries is around 20 % and 
much higher than Western countries. We established 
RP2D of ARQ 197 for extensive metabolizer (EM) 
and PM pts separately while RP2D in western 
countries was determined to be 360 mg bid.
Methods: ARQ 197 was administered orally at 8 
dose levels from 70 to 360 mg bid in a standard 
3+3 dose escalation design. We tested CYP2C19 
genotype in advance and enrolled EM and PM pts 
separately from 120 mg bid.
Results: Forty-seven pts consisted of 33 EM pts 
(median age: 61.0 yrs; ECOG PS 0/1: 15/18; median 
prior therapies: 4) and 14 PM pts (median age: 59.5 
yrs; ECOG PS 0/1: 6/8; median prior therapies: 
4) were treated. The most common drug-related 
adverse events (AEs) were fatigue, leukopenia, 
anemia, neutropenia and anorexia. The severe AEs 
were hematologic toxicities such as neutropenia. 
Gr.4 neutropenia occurred in 1 of 6 EM pts at 360 
mg bid and 3 of 7 PM pts at 240 mg bid, which 
identiÀed each dosage as RP2D for EM and PM 
respectively. At 240 mg bid, the ARQ 197 C
max
 and 
AUC
0-12
 of PM pts were respectively, which might 
lead higher incidence of severe neutropenia at lower 
dose in PM pts. Two NSCLC pts, both of whom 
were PM at 240 mg bid and treated 4 or more prior 
systemic chemotherapies including EGFR-TKI, 
achieved partial response and 16 pts (34.0%) had 
stable disease (SD) for >= 16 weeks, especially 6 
of 25 pts (24.0 %) in NSCLC had SD for >= 28 
weeks. Findings from biomarker study will be also 
presented.
Conclusion: ARQ 197 was well tolerated. The 
most common adverse events were hematologic 
toxicities. CYP2C19 polymorphism clearly affected 
the exposure to ARQ 197 which led different RP2Ds, 
360 mg bid for EM pts and 240 mg bid for PM 
pts. ARQ 197 monotherapy showed a clear sign of 
activity against NSCLC. Further study for NSCLC is 
warranted.
Keywords: ARQ 197, Tivantinib, c-Met tyrosine 
kinase inhibitor, CYP2C19 polymorphism
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Results: A distinct and interpretable three-cluster 
solution was identiÀed by an order of magnitude 
of the four most prevalent symptoms. The three 
subgroups were called as: Mild Symptom Group 
(n=30; 60%); Moderate Symptom Group (n=14, 
28%); Severe Symptom Group (n=6, 12%). To 
evaluate quality of life, the average score values for 
each scale of EORTC QLQ-C30, FACT-L e SF-36 
were stratiÀed by the cluster solution. The Severe 
Symptoms Group had the worst quality of life based 
not on total scores alone, but rather on integrated 
dimensions, in all three instruments studied. 
Conclusion: Increasing in the magnitude of 
symptoms had a negative impact on quality of life of 
lung cancer patients. We highlight the importance of 
evaluation by cluster of symptoms as an important 
issue to assess quality of life in patients with chronic 
diseases such as lung cancer. 
Keywords: symptom cluster, Lung cancer, Quality 
of Life
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P3.023 FIRST-LINE MODIFIED 
SCHEDULE OF GEMCITABINE WITH 
A LOWER DOSE THAN STANDARD IN 
VERY ELDERLY OR PS 2 PATIENTS 
WITH ADVANCED NSCLC
Angelo Nacci, Pietro Rizzo, Saverio Cinieri 
U.O.C. Oncology And Breast Unit, Brindisi Hospital/
Italy
Background: Monochemotherapy with gemcitabine 
(Gem) is often the treatment of choice in elderly or 
poor performance status (PS) patients with advanced 
non-small cell lung cancer (NSCLC). Our study 
was aimed to assess the efÀcacy and tolerability of a 
modiÀed schedule of Gem using a lower dose than 
standard. 
Methods: From May 2009 through December 2010, 
Àfty patients (43 males and 7 females with a median 
age of 76 years (64 to 85) with advanced NSCLC 
(stage IIIB 34,0% and IV 66,0%) were enrolled. 
Histology were: squamous 39,6%, adenocarcinoma 
31,2%, large cell 6,2 %, undifferentiated 4,2 %, 
undetermined 18,8%. Only eight patients (16,0%) 
had a WHO PS 0 whereas nineteen (38,0%) were 
PS 1 and eleven (46,0%) PS 2. All patients received 
Àrst-line chemotherapy with 6 cycles of Gem 1000 
mg/sq on days 1 and 8 every 4 weeks. 
and bleeding, which may be managed immediately if 
necessary. 
Results: We performed 29 RFAs on 25 patients. In 
the follow-up, 10 of them showed tumor shrinkage 
by CT scan . There were 23 showed lack of tumor-
uptake value by SPECT scan and 2 showed lower 
tumor-uptake value. There were 5 cases of fever, 7 
pneumothorax, and 5 bleeding. Among the 7 cases 
of pneumothorax, 2 were relieved by drainage and 
the other 5 were not treated because their conditions 
were self-limited. No serious complications or 
perioperational death occurred. 
Conclusion: CT-guided percutaneous RFA is safe 
and practical for lung cancer. It has satisfactory 
short-term effect to reduce tumor burden. 
Keywords: Advanced Non-Small Cell Lung Cancer, 
radiofrequency ablation
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P3.022 PONDERING SYMPTOMS 
MAGNITUDE IN QUALITY OF LIFE FOR 
BRAZILIAN LUNG CANCER PATIENTS: 
A CLUSTER ANALYSIS
Ilka L. Santoro1, Juliana Franceschini1, Sérgio 
Jamnik1, Hakaru Tadokoro2, José R. Jardim1, Ana 
Luisa G. Fernandes1 
1Respiratory Division, Federal University Of 
São Paulo/Brazil, 2Oncology Division, Federal 
University Of São Paulo/Brazil
Background: Patients with lung cancer have 
more symptoms distress than patients with other 
type of cancer, especially near the end of life. The 
aim of this study was to examine the prevalence 
of symptoms in lung cancer patients; to identify 
subgroups (cluster solutions) according to symptoms 
magnitude; and to compare the quality of life among 
the identiÀed symptoms subgroups. 
Methods: This is a cross sectional study using a 
hierarchical agglomerative cluster analysis. Subject 
characteristics and the scores of the Quality of Life 
Questionnaires (EORTC QLQ-C30, FACT-L and 
SF-36) were obtained from all included lung cancer 
patients. The cluster analysis took into account a set 
of symptom magnitude measure from the EORTC 
QLQ-C30 symptom scales (higher prevalence): 
fatigue, pain, dyspnea and insomnia, which are not 
standardized assessment for functioning and global 
quality of life. 
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Methods: RNA was isolated from fresh tumor tissue. 
The chemotherapy regimen that patients received 
was based on their BRCA1 and RRM1 mRNA 
levels: both low, cisplatin plus gemcitabine(GP); 
both high novelbine plus cisplatin(NP); BRCA1 
low and RRM1 high, cisplatin plus docetaxel(DP); 
BRCA1 high and RRM1 low, novelbine plus 
gemcitabine(GN).
Results: From Dec 2005 to Nov 2008, 94 metastatic 
or local advanced NSCLC patients in our institute 
were enrolled into this study. The median age was 
58 years old and 76% were male. Among them, 21 
patients received GP, 30 patients received TP, 43 
patients received NP and no patient received NP 
chemotherapy. GP group got a numerically higher 
response rate, longer median time to progression and 
median overall survival time than the other 2 group. 
The response rate in the GP,TP and NP group were 
42.9%, 36.7% and 27.9% respectively(P=0.568), 
Median time to progression was 5.6,5.0,4.8 
months (P=0.975)and median overall survival was 
12.5,11,9.7 months(P=0.808) respectively(Seen in 
Table 1). Table 1, EfÀcacy of patients according to 
the treatment group 
Regimen N Response TTP OS 
PR SD PD 
GP 21 9 9 3 5.6 12.5 
TP 30 11 10 9 5.0 11 
NP 43 12 19 12 4.8 9.7 
Total 94 32 38 24 5 11 
PR: partial response, SD: stable disease, PD: 
progression disease 
Conclusion: Chemotherapy customized according to 
BRCA1 and RRM1 expression levels is associated 
with numerically higher response rate and longer 
TTP and OS time in the GP group, which may be 
caused the controversial function of the BRCA1 and 
RRM1 mRNA at the initiation period of this trial, 
and suggested that BRCA1 and RRM1 mRNA levels 
could be used as biomarker in individual therapy in 
NSCLC. 
Keywords: Non small cell lung cancer, 
Individualized chemotherapy, BRCA1, RRM1
Results: At the time of analysis 35 patients were 
evaluable for response. Partial response (PR) was 
achieved in 7 patients (20,0%), stable disease > 
12 weeks (SD) in 16 (45,7%) whereas 12 had 
progressive disease (34,3%). Importantly, the clinical 
beneÀt rate (PR + SD) was 65,7%. Quality of life 
was mesured with EORTC QoL 3.0 Questionary. 
Both pain and PS improved in 6 patients (17,1%) 
whereas 19 (54,2%) had an improvement in pain 
with no worsening of PS. We observed only grade 
2 NCCTs version 3 haematological toxicities 
including anemia, leucopenia, neutropenia and 
trombocytopenia. Not febrile neutropenia occurred in 
4 patients (11,4%). Overall, we did not observe any 
not-haematological treatment-related event. 
Conclusion: Our data show that a modiÀed schedule 
of Gem with a lower dose intensity than standard 
may be beneÀcial in terms of both disease control 
and tolerability when employed in elderly or PS 
2 patients with advanced NSCLC. These data 
are similar to published data in elderly. At ASCO 
meeting we present all data about 50 pts enrolled. 
Keywords: Lung cancer, PS 2
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P3.024 INDIVIDUALIZED 
CHEMOTHERAPY IN THE ADVANCED 
NSCLC PATIENTS BASED ON THE 
MRNA LEVEL OF BRCA1 AND RRM1
Shengxiang Ren1, Caicun Zhou2, Songwen Zhou2, 
Ling Zhang2, Xiaoxia Chen2 
1Medical Oncology, Tongji University AfÀliated 
Shanghai Pulmonary Hospital/China, 2Tongji 
University AfÀliated Shanghai Pulmonary Hospital/
China
Background: Experimental evidence suggests 
that BRCA1 overexpression enhances sensitivity 
to docetaxel and resistance to cisplatin and RRM1 
overexpression enhances resistance to gemcitabine. 
In order to further investigate the effect of BRCA1 
and RRM1 mRNA levels on outcome in advanced 
NSCLC, we performed this phase II clinical trial, 
testing the hypothesis that customized therapy would 
confer improved outcome over non-customized 
therapy.
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Results: In Phase Ib, 15 patients (median age, 
53.5 years; 10 male) were enrolled; a median of 
two cycles (range, 1–8) were delivered. In Arm 
1, 10 patients were escalated from 0.9 to 1.4 mg/
m2 eribulin with pemetrexed (500 mg/m2) on Day 
1 of each 21-day cycle. In Arm 2, 5 patients were 
dosed with 0.7 mg/m2 eribulin on Days 1 and 8, with 
pemetrexed (500 mg/m2) on Day 1 of each 21-day 
cycle. DLTs are summarized below. 
Arm 
Eribulin
dose
(mg/m2) 
n # DLTs DLTs 
1
(Day 1 eribulin/Day 1 
pemetrexed) 
0.9 4 0 
1.4 6 3 
Grade 3 transaminitis
Grade 4 febrile neutropenia
Grade 4 thrombocytopenia 
2
(Day 1 and 8 eribulin/
Day 1 pemetrexed) 
0.7 5 2 Grade 3 transaminitisGrade 4 pneumonia 
The MTD for Arm 1 was 0.9 mg/m2, but was 
not determined for Arm 2 as the acceptable DLT 
frequency was exceeded at the initial dose level. 
The most common adverse events at the MTD in 
Arm 1 were neutropenia (4 patients), leukopenia (3 
patients), anemia (3 patients), fatigue, rash, cellulitis, 
hypokalemia, asthenia, nausea, diarrhea, and 
anorexia (2 patients each). The best response at the 
MTD in Arm 1 was PR (2 patients). Median PFS at 
the MTD in Arm 1 was 5.25 months.
Conclusion: The recommended Phase II dose of 0.9 
mg/m2 with pemetrexed 500 mg/m2 was generally 
well tolerated with an expected toxicity proÀle. 
Encouraging clinical activity was noted on this 
schedule. Owing to lack of determination of an MTD 
in Arm 2, the Phase II portion of the study will be 
amended to a 1:1 randomization of Arm 1 (Day 1 
eribulin plus Day 1 pemetrexed) versus Arm 2 (Day 
1 pemetrexed alone).
Keywords: Eribulin, E7389, NSCLC, lung
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P3.025 AN OPEN-LABEL, MULTICENTER, 
RANDOMIZED PHASE IB/II STUDY OF 
ERIBULIN MESYLATE ADMINISTERED 
IN COMBINATION WITH PEMETREXED 
VERSUS PEMETREXED ALONE AS 
SECOND-LINE THERAPY IN PATIENTS 
WITH STAGE IIIB OR IV NON-
SQUAMOUS NSCLC: PRELIMINARY 
PHASE IB RESULTS
Vanesa Gregorc1, M. R. Modiano2, M. R. Oliveira3, 
Petr Zatloukal4, J. W. Lee5, Filippo De Marinis6, 
B. Huber7, H. P. Dave7, Jeffrey P. Hodge8, R 
Lieberman7, L. J. Arvay7, S Saint9, P. De Leonardis10, 
.C Taylor7, J. Wanders11, A. B. Kremer12 
1Department Of Oncology, Istituto ScientiÀco San 
Raffaele/Italy, 2Arizona Clinical Research Center 
Inc/United States Of America, 3Northwest Medical 
Specialties/United States Of America, 4University 
Hospital Bulovka/Czech Republic, 5Hematology 
Oncology Associates/United States Of America, 
6Medical Oncology, San Camillo-forlanini Hospital/
Italy, 7Quintiles/United States Of America, 
8Innovation Oncology, Quintiles/United States Of 
America, 9Quintiles/United Kingdom, 10Quintiles/
Italy, 11Eisai Ltd/United Kingdom, 12Eisai Inc/United 
States Of America
Background: Eribulin mesylate (E7389, HalavenTM) 
is a fully synthetic analog of the marine sponge 
natural product halichondrin B that inhibits 
microtubule dynamics, triggering apoptosis of cancer 
cells following prolonged mitotic blockade in vitro. 
In a previous Phase II study in NSCLC patients 
treated with a median of two prior therapies, eribulin 
had an overall PR rate of 9.7% and median OS 
was 9.6 months. Treatment options in second-line 
NSCLC have demonstrated modest clinical beneÀt. 
Pemetrexed, as monotherapy, has demonstrated a 
median PFS of 2.9 months in this disease setting.
Methods: The current trial is an open-label, 
multicenter, randomized study consisting of Phase 
Ib (three ascending doses of eribulin in each of 
two parallel dosing schedule arms to determine the 
MTD) and Phase II (randomized design to determine 
safety and preliminary efÀcacy) in patients with 
measurable, non-squamous NSCLC, previously 
treated with one cytotoxic chemotherapy regimen for 
stage IIIB with malignant pleural effusion or stage 
IV disease.
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P3.027 PHASE II TRIAL OF ERLOTINIB 
IN PREVIOUSLY TREATED PATIENTS 
WITH NON-SMALL CELL LUNG 
CANCER
Yoshio Okano1, Tsutomu Shinohara1, Hisanori 
Machida1, Nobuo Hatakeyama1, Eiji Takeuchi2, 
Hiroyuki Doi3, Tetsuya Kubota4, Akihito Yokoyama4, 
Fumitaka Ogushi1 
1Respiratory Medicine, National Hospital 
Organization, Kochi Hospital/Japan, 2Respiratory 
Medicine, Kochi Red Cross Hospital/Japan, 
3Respiratory Medicine, Kochi Medical Center/Japan, 
4Hematology And Respiratory Medicine, Kochi 
University/Japan
Background: Erlotinib has been shown to have 
an antitumor activity as a single agent against 
previously treated NSCLC. The objective of this 
study was to assess the efÀcacy and safety of 
erlotinib in patients with relapsed NSCLC.
Methods: Patients with histologically or 
cytologically conÀrmed NSCLC, more than 20 
years in age, performance status 0-2, with a history 
of receiving one or two chemotherapy regimen(s) 
were eligible for the study. Treatment was consisted 
of erlotinib (150 mg/day) on everyday. The primary 
endpoint was the response rate (RR), and planned 
sample size for this phase II study was 38 patients 
(Simon’s two-stage minimax design).
Results: Thirty-three patients were enrolled and 
33 patients (22 males/11 females, median age, 69 
years) receive protocol treatment in this phase II 
trial. The histological diagnosis was adenocarcinoma 
in 24 patients (72.7%), squamous cell carcinoma 
in 5 patients (15.2%), and unclassiÀed in 4 patients 
(12.1%). Twelve patients (36.4%) were PS0, 16 
patients (48.5%) were PS1, and 5 patients (15.1%) 
were PS2. The progression free survival time was 
131 days. The overall response rate was obtained 
in 27.3% of the patients. Ten patients (30.3%) had 
EGFR mutation-positive tumors and 12 patients 
(36.4%) had EGFR mutation-negative tumors. EGFR 
mutations in 11 patients (33.3%) were not analyzed. 
Disease control rate was 51.5%. The response rates 
of EGFR mutation-positive/negative/unknown 
patients were 50.0%/16.7%/18.1%, respectively. The 
progression free survival time of EGFR mutation-
positive/negative/unknown patients were 418 
days/52 days/115 days, respectively.
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P3.026 SURVIVAL AFTER 
RADIOFREQUENCY ABLATION （RFA） 
FOR 100 CASES OF LUNG NEOPLASMS
Liu Baodong 
Department Of Thoracic Surgery, Xuanwu 
Hospital,capital Medical University/China
Background: Surgical resection is the preferred 
treatment in selected patients with pulmonary 
neoplasms. In older than 70 years or have 
compromised cardiopulmonary status or coexistent 
medical problems patients, radiofrequency ablation 
(RFA) may offer an alternative option. Our 
objectives were to evaluate the long-term outcomes 
after RFA in 100 patients with pulmonary neoplasms.
Methods: One handred cases of unresectable lung 
tumors with 106 lesions were underwent RFA 
therapy.To evaluate the long-term therapeutic effect 
and complications of lung tumors using spiral CT 
scanning and SPECT in 1-3 months after RFA.
Results: One hundred patients underwent RFA 
for lung neoplasms (62 men,38 women;median 
age, 66.6 years; range, 36 to 91 years).Eighty-
six patients with primary lung neoplasms and 14 
patients with pulmonary metastases underwent RFA. 
Treatment was complete in all cases,no procedure-
related deaths occurred in all of the 106 ablation 
procedures and serious morbidity associated with 
the procedures. The median overall survival for 
the entire group of patients was 13.0 months, the 1 
and 2 years overall survival for total of were 51% 
and 32.5% respectively. No differences in overall 
survival noted between patients with primary lung 
neoplasms or lung metastases (p=0.922). The median 
overall survival for the early stage of patients was 
28.0 months, 2-year overall survival for early stage 
primary lung cancer patients were 57.7%.
Conclusion: RFA is a safe and effective procedure in 
unresectable lung tumors. CT-guided radiofrequency 
ablation is a minimally invasive treatment option. 
RFA could act as an alternative treatment to 
inoperable early stage lung cancer and cytoreductive 
treatment for advanced lung cancer. 
Keywords: radiofrequency ablation, survival, Lung 
neoplasms
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preliminary antitumor activity of ACE-041 in 
patients with advanced cancer who had previously 
progressed on chemotherapy and/or anti-VEGF 
therapy. A total of 37 patients were enrolled; the 
Àrst 25 patients were enrolled in 7 dose-escalating 
cohorts (0.1 to 4.8 mg/kg SC; treatment cycle 3 
weeks) and an expansion cohort of 12 patients was 
enrolled at either 0.8 or 1.6 mg/kg.
Results: ACE-041 was generally well-tolerated. 
Common AEs included fatigue, peripheral 
edema, nausea, anemia, headache, anorexia, and 
dyspnea. Possibly or probably related SAEs in 4 
patients included Áuid overload (2), CHF, and LV 
dysfunction. Edema and Áuid overload were dose-
dependent and responded to diuretic therapy. Due 
to DLT of Áuid overload seen at higher dose levels, 
dose expansion was performed at intermediate 
dose levels. Of the 37 patients enrolled, six were 
NSCLC patients, (3 with squamous and and 3 with 
non-squamous histology). Three of the six NSCLC 
patients had periods of stable disease, including a 
non-squamous NSCLC patient who had 8 cycles 
(24 weeks) of ACE-041 at 0.4 mg/kg, a squamous 
NSCLC patient who has had 6 cycles (18 weeks) 
of ACE-041 at 1.6 mg/kg, and a squamous NSCLC 
patient who has had 12 cycles (36 weeks) of ACE-
041 at 3.2/1.6 mg/kg (still on study at time of 
abstract submission). The preliminary estimate of 
median progression-free survival for the NSCLC 
patients in this study was 17.5 weeks (95% CI: 
8.6 - 22.0 weeks). Of the 5 NSCLC patients with 
FDG-PET scans available, the mean maximal 
change in SUV was -34% (range: -14%, -62%). The 
one NSCLC patient (squamous histology, stable 
disease, 6 cycles of ACE-041) with DCE-MRI scans 
available had a 30% and 37% decrease in Ktrans 
from baseline to days 15 and 43, respectively, 
indicating a reduction in tumor blood Áow.
Conclusion: ACE-041 is a Àrst-in-class 
angiogenesis inhibitor that targets the ALK1 receptor 
pathway. Preliminary results for this Phase 1 data 
show that ACE-041 was generally well-tolerated 
and demonstrated antitumor activity in patients 
with NSCLC refractory to other therapies. A Phase 
2 study of ACE-041 in NSCLC patients is being 
planned.
Keywords: ACE-041, ALK1, activin receptor-like 
kinase-1, angiogenesis inhibitor
Conclusion: Erlotinib is an active regimen for 
EGFR mutation-positive patients with NSCLC: 
Keywords: erlotinib, Non-small cell lung cancer, 
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P3.028 PRELIMINARY EVIDENCE 
OF ACTIVITY OF ACE-041, A NOVEL 
INHIBITOR OF ALK1-MEDIATED 
ANGIOGENESIS, IN PATIENTS WITH 
REFRACTORY NSCLC TREATED IN A 
PHASE 1 DOSE-ESCALATION STUDY
Johanna Bendell1, Michael S. Gordon2, Herbert 
Hurwitz3, Nicolas Solban4, R. S. Pearsall4, Ravindra 
Kumar4, Carolyn H. Condon4, Yijun Yang4, Dawn 
Wilson4, Kenneth M. Attie4, Matthew L. Sherman4, 
Sunil Sharma5 
1Gi Oncology Research, Sarah Cannon Research 
Institute/United States Of America, 2Pinnacle 
Oncology/United States Of America, 3Duke 
University Medical Center/United States Of 
America, 4Acceleron Pharma/United States Of 
America, 5Huntsman Cancer Institute/United States 
Of America
Background: Activin receptor-like kinase-1 
(ALK1), a type I receptor in the TGF-beta 
superfamily, is selectively expressed on activated 
endothelial cells and is required for vascular 
maturation and the development of capillary 
beds. ALK1 is widely expressed on human tumor 
endothelium, including approximately 25% and 
35% of non-squamous and squamous NSCLC tumor 
biopsy samples tested. ACE-041 is an ALK1 ligand 
trap, which binds with high afÀnity to BMP9 and 
BMP10, and prevents activation of ALK1 receptors. 
In xenograft studies using mice implanted with Calu-
6 lung tumors, treatment with ACE-041 signiÀcantly 
decreased tumor vascularization and burden 
compared to vehicle-treated mice. A Phase 1 clinical 
study of ACE-041 in advanced, heavily pre-treated 
cancer patients was recently fully enrolled and 
results for patients with NSCLC are presented here.
Methods: This was a multi-center Phase 1 study 
to evaluate the safety, tolerability, PK, PD and 
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P3.030 CLINICAL BENEFITS OF 
SEQUENTIAL ADMINISTRATION OF 
DOCETAXEL AND INTERMITTENT 
ERLOTINIB AS A SECOND-LINE 
THERAPY FOR ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC), A PHASE 
II RANDOMIZED STUDY
Oscar Juan Vidal1, Jose García Sánchez2, Alfredo 
Sánchez3, Vicente Giner4, Jose Munoz Langa5, 
Gaspar Esquerdo6, Antonio López7, Javier Garde8, 
Francisco de Asis Aparisi9 
1Oncology Department, Hospital Arnau De Vilanova 
De Valencia/Spain, 2Hospital Arnau De Vilanova/
Spain, 3Hospital Provincial De Castellon/Spain, 
4Oncology, Hospital De Sagunto/Spain, 5Hospital 
Universitario Dr Peset/Spain, 6Itc-clínica Benidorm/
Spain, 7Hospital Clínico San Juan/Spain, 8Hospital 
De Denia/Spain, 9Hospital Virgen De Los Lirios/
Spain
Background: Erlotinib (E) has shown efÀcacy 
in 2nd line treatment in patients with advanced 
NSCLC; however, the combination of E and 
chemotherapy (CT) in Àrst line therapy has not 
demonstrate to be superior to CT alone, probably due 
to an antagonism between CT and E concurrently 
administered. Several preclinical and phase I studies 
have suggested that sequential administration of E 
and docetaxel could avoid the suggested negative 
interaction and hence optimize the beneÀt in patients 
(P) with advanced NSCLC. This randomized phase 
II was designed to address the clinical beneÀt 
obtained with the use of sequential administration of 
docetaxel and intermittent E. 
Methods: 70 p with advanced NSCLC progressing 
to previous platinum based chemotherapy for 
advanced disease were randomized (1:1): 
Group A (n = 34): Docetaxel 75 mg/m• 2 day 1 and 
intermittent E (day 2-16), up to 4 cycles, followed by 
E in monotherapy 
Group B (n = 36): E in monotherapy. • 
Treatment was administered until unacceptable 
toxicity or disease progression. Primary endpoint: 
rate of p free of progression at 6 months; secondary 
endpoints: progression-free survival (PFS), overall 
survival (OS), disease control rate (DCR) and safety. 
The study has completed enrolment. Data from 32 p 
included are shown: 15 in Group A/17 in Group B. 
Results: Baseline characteristics: non-
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P3.029 PEMETREXED + GEMCITABINE 
VS CARBOPLATIN+GEMCITABINE: 
A RANDOMIZED NON-INFERIORITY 
PHASE II STUDY IN ONE CENTER
Gunnar Hillerdal, Eva Brandén, Hirsh Koyi, Karl 
Kolbeck 
Lung Medicine, Karolinska Hospital And Institute/
Sweden
Background: The standard treatment for inoperable 
non-small cell lung cancer is a combination of 
cytostatics, one of which should be a platinum 
compound. We questioned whether the platinum 
could be replaced with a modern cytostatic.
Methods: From January,2006 to October,2009, 
patients in PS WHO 0-2 and Stage III Bwet or IV 
according to the then used TNM classiÀcation were 
randomized to either Gemcitabine 1250 mg/m2 day 
1 and 8 + Carboplatin 5 AUC day 1 (GC arm), or 
Pemetrexed 500 mg/m2 + Gemcitabine 1500 mg/m2 
every third week (PG), after informed consent. In 
this way the length of treatment was the same and 
the total dose of Gemcitabine almost the same. 
Results: Forty-six patients were randomized to the 
PG group, and 50 to the GC. At least one course 
was given to 43 PG and 48 GC. There groups were 
well matched in smoking habits, type of cancer, age 
etc. Mean age was 69 years. In the GC group, dose 
adjustment was necessary in 58%, and in the PG 
27% of the patients. The side effects were similar 
with grade 3 (mainly hematological) in 31% of AC 
and 33 in the PG groups, respectively. The mean TTP 
in both groups was 5 months. Mean survival was 10 
months in GC and 15 months in the PG group.
Conclusion: Replacing Carboplatin with Pemetrexed 
in the Àrst-line treatment of NSCLC will not 
increase side effects. There was a tendency to better 
survival in the Pemetrexed group, but the study 
was not powered to show this. Further studies with 
the combination Pemetrexed + Gemcitabine seem 
warranted.
Keywords: NSCLC, Cytostatics, gemcitabine, 
Pemetrexed
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as a phase I/II clinical trial to explore the effects 
of combining a novel microtubule-interfering 
drug (ABT-751) and the US FDA-approved drug 
carboplatin, as both drugs were previously shown 
to have anti-neoplastic effects against lung cancer 
based on preclinical or clinical evidence. 
Methods: For in vitro studies, the human lung 
cancer cell lines HOP62, A549 and U1571 were each 
studied to determine the single agent anti-neoplastic 
effects of ABT-751 as well as the combined effects 
of ABT-751 with carboplatin. The primary endpoint 
of the in vitro studies were induced growth inhibitory 
response in these lung cancer cells, the secondary 
endpoints were induction of apoptosis and the 
repressed expression of the cell cycle regulator 
cyclin D1. We conducted a phase I/II clinical trial 
of the combination of ABT-751 and carboplatin in 
patients with advanced previously treated NSCLC. 
The primary endpoint for the phase I portion of the 
trial was determination of the maximum tolerated 
dose (MTD) of the combination, the secondary 
endpoints were dose-limiting toxicity (DLT) and side 
effects proÀle. For the phase II portion of the trial, 
the primary efÀcacy endpoint was objective response 
rate after two cycles of treatment, the secondary 
endpoints were median survival, time to progression, 
and evaluation of pharmacodynamic markers in pre-
treatment versus post-treatment buccal swabs.
Results: In vitro studies of the combination of ABT-
751 and carboplatin showed cooperative growth 
inhibitory effects associated with increased apoptosis 
in HOP62 and A549 cells and decreased cyclin D1 
expression in HOP62 cells. These Àndings were 
translated into the clinic with the enrollment of 20 
patients with advanced NSCLC previously treated 
with a carboplatin-containing regimen. Nineteen 
patients received study treatment. The MTD for 
ABT-751 was 125mg twice daily for 7 days with 
carboplatin AUC of 6 given every 21 days. DLTs 
included fatigue, neutropenia and ileus. The most 
common side effects were constipation, anemia, 
thrombocytopenia, nausea and fatigue. These doses 
of ABT-751 and carboplatin were used in the phase 
II portion of this trial. Two patients (11%) had 
a partial response after two cycles. The median 
survival was 11.7 months (95% CI 5.9-27.0) and the 
time to progression was 2.8 months (95% CI 2.0-
2.7). Four of the six paired pre-treatment versus post-
treatment buccal swab samples showed a decrease 
in cyclin D1 expression in the post-treatment as 
compared to the pre-treatment swabs. 
Conclusion: The combination of ABT-751 and 
adenocarcinoma (71%), current/former smokers 
(93.7%), male (90.6%) and stage IV (83.9%). 6 
months PFS: 14.3% in the sequential arm. Median 
PFS: 2.3 months (m) in Group A (95% CI 1.9 – 3.1) 
and 3.1 m in Group B (95% CI 2.0 – 4.5). Median 
OS: 4.9 m (95% CI 2.7 - -) in group A, slightly 
different than in Group B (6.0 m; 95% CI 2.5 – 6.0). 
DCR: 25% in the experimental group (95% CI 
0.5 – 49.5) and 50% (95% CI 23.8 – 76.2) in group 
B. Adverse events (AEs), including skin rash and 
diarrhea, were all generally tolerable. Although the 
incidence of treatment-related AEs was higher in 
Group A than in B, AEs leading to dose reduction 
were more frequent in the E arm (11.8% vs. 6.7%). 
Conclusion: Data from 6 months PFS of the 
sequential arm may suggest a potential beneÀt 
of the combination, although this preliminary 
analysis shows no impact in the PFS and OS of this 
sequential treatment. Final analysis of the study will 
be reported. 
Keywords: erlotinib, Docetaxel, Sequential erlotinib
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P3.031 A PRECLINICAL AND CLINICAL 
PHASE I/II STUDY OF ABT-751 IN 
COMBINATION WITH CARBOPLATIN 
IN PATIENTS WITH PREVIOUSLY 
TREATED ADVANCED LUNG CANCER
Tian Ma1, Alexander D. Fuld2, James R. Rigas2, Anne 
E. Hagey3, Gary B. Gordon3, Ethan Dmitrovsky1, 
Konstantin H. Dragnev2 
1Pharmacology And Toxicology, Dartmouth Medical 
School/United States Of America, 2Medicine, 
Dartmouth Medical School/United States Of 
America, 3Abbott Laboratories/United States Of 
America
Background: Lung cancer is the leading cause 
of cancer-related death in the United States. New 
effective treatments for advanced stage non-
small cell lung cancer (NSCLC) are needed. 
Combination chemotherapy using drugs that could 
act cooperatively at different targets are appealing 
to consider for the treatment of advanced NSCLC. 
In this study, we conducted in vitro studies as well 
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adverse events. All costs and incremental cost-
effectiveness ratios (ICER) were expressed in 2010 
Singapore Dollars (S$) or 2010 Euros. A secondary 
analysis compared 1st line geÀtinib with 1st line 
chemotherapy in patients with activating EGFR 
mutations. Sensitivity analyses were conducted to 
assess the robustness of the results.
Results: EGFR testing and Àrst line treatment with 
geÀtinib is a dominant strategy (i.e., it has lower 
costs and greater effectiveness) compared to no 
testing, 1st line chemotherapy and 2nd line geÀtinib 
in unselected patients in Singapore and Italy. 
Because the main savings in the testing arm result 
from not providing geÀtinib to those patients who are 
less likely to beneÀt, these Àndings hold regardless 
of the prevalence of patients with activating 
mutations. In the secondary analysis, 1st line 
geÀtinib was also dominant when compared to 1st 
line chemotherapy in patients with activating EGFR 
mutations, primarily due to better QOL.
Conclusion: Based on these data, EGFR testing 
and Àrst line treatment with geÀtinib for patients 
with activating mutations should become the 
standard treatment in advanced NSLC. In this era of 
exponentially increasing costs the use of biomarkers 
may improve patient selection and the CE of new 
therapies
Keywords: geÀtinib, Epidermal growth factor 
receptor, Cost-effectiveness
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P3.033 EFFICACY OF CARBOPLATIN, 
PEMETREXED AND BEVACIZUMAB 
FOLLOWED BY MAINTENANCE 
GEFITINIB IN ADVANCED NON-
SQUAMOUS NON SMALL CELL LUNG 
CANCER - A STUDY FROM NORTH 
INDIA
Shyam Aggarwal, A. Basu, S. Bhalla, Y. Shokeen, A. 
Negi, S. Kohli, N. Jain 
Oncology, Sir Ganga Ram Hospital/India
Background: Platinum based doublet is the Àrst 
line treatment for advanced NSCLC. Apparently 
pemetrexed and bevacizumab are approved for their 
use in Àrst line non-squamous NSCLC. We have 
tried the combination of carboplatin with pemetrexed 
and bevacizumab in advanced non-squamous 
NSCLC
carboplatin induces apoptosis in lung cancer cell 
lines but has moderate activity in advanced NSCLC 
previously treated with carboplatin. Further studies 
in chemotherapy-naïve patients are warranted.
Keywords: ABT-751, Carboplatin, Phase I/II 
clinical trial, Advanced stage NSCLC
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P3.032 EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION 
TESTING AND FIRST LINE TREATMENT 
WITH GEFITINIB IS A DOMINANT 
STRATEGY IN THE TREATMENT OF 
ASIAN AND EUROPEAN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC)
Gilberto D.L. Lopes, Jr.1, Joel Segel2, Daniel Tan3, 
Young Do2, Silvia Novello4, Tony Mok5, Giorgio 
Scagliotti4, Eric Finkelstein2 
1Johns Hopkins Singapore International Medical 
Centre, Johns Hopkins University School Of 
Medicine/Singapore, 2Health Services And Outcomes 
Research, Duke-NUSs/Singapore, 3National Cancer 
Centre Singapore/Singapore, 4Thoracic Oncology 
Unit, University Of Turin/Italy, 5Department Of 
Clinical Oncology,, The Chinese University Of Hong 
Kong/Hong Kong
Background: GeÀtinib improves response rates, 
progression-free survival and quality of life (QOL) 
when compared to chemotherapy in patients with 
advanced NSCLC who have activating EGFR 
mutations. Yet, little is known about the cost-
effectiveness (CE) of EGFR mutation testing 
followed by therapy guided by mutational status.
Methods: A decision-analytic model was 
developed to determine the CE of EGFR testing 
and guided therapy with 1st line geÀtinib and 2nd 
line chemotherapy for patients with activating 
mutations (and 1st line chemotherapy and no 
geÀtinib for patients without) vs. standard care: 
Àrst line chemotherapy and geÀtinib at progression 
in unselected patients. Clinical data are derived 
from three published randomized clinical trials and 
societal costs from three cancer centers in Singapore 
and one in Italy. Health effects were expressed as 
quality-adjusted life years (QALY) gained. Costs 
include medications, physician visits, laboratory 
tests, scans, hospitalizations and treatment of 
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guidance recommending Erlotinib as an alternative 
to Docetaxol as second-line treatment for patients 
with non-small cell lung cancer (NSCLC) [1]. This 
guidance was based on evidence from the TAX 317 
trial [2] and BR21 [3] trials respectively. In addition 
it took into account the clinical and cost effectiveness 
(within NHS resources) of Erlotinib, having 
considered evidence regarding the nature of the 
condition and the beneÀts of Erlotinib, as presented 
by NSCLC patients, their representatives and clinical 
specialists [1, 2, 3]. Second-line Erlotinib is now 
widely used in the North Wales Cancer Treatment 
Centre and we thus decided to review our local use 
of the drug. 
Methods: Data was collected retrospectively on 26 
patients commenced on second-line Erlotinib for 
progressive NSCLC having previously received 1st 
line platinum doublet chemotherapy (Carboplatin/ 
Gemcitibine). Demographic data included the 
patient’s age and sex, as well as the histological sub-
type. The dates of commencing and discontinuing 
treatment, in addition to date of patient’s death 
were all recorded, enabling us to calculate length 
of treatment and time from discontinuation until 
death. We also assessed the length of treatment per 
histological sub-type. The presence and grade of 
side-effects from Erlotinib were recorded as well 
as any dose adjustments. Clinical and radiological 
progression was assessed, where formally 
documented. 
Results: Twenty-six patients (14 female, 12 male) 
commenced treatment between August 2009 
and December 2010.The average age was 67 
(range 44-82). Histological sub-type stratiÀcation 
showed 4 squamous cell, 2 broncho-alveolar, 9 
adenocarcinoma and 11 patients with histology 
of NSCLC not otherwise speciÀed. The average 
number of weeks on Erlotinib treatment was 19.7 
(range 3-80). The average time from discontinuing 
treatment until death was 10.2 weeks. According 
to histological sub-type the mean number of 
weeks on erlotinib was calculated as 32.5 for 
squamous cell, 53 for broncho-alveolar, 7.2 for 
adenocarcinoma and 19.1 for NSCLC nos. Fifteen 
patients had documented radiological progression, 
associated with a clinical decline in 5. Eleven of 
these patients did not demonstrate clinical decline 
despite progression on radiology. Six patients 
had documented clinical decline not conÀrmed 
radiologically. Rash was the most commonly 
experienced side-effect with 14 patients developing 
it notably (n=7 grade 1, n=4 grade 2 and n=3 grade 
Methods: Fifteen patients were treated at Sir Ganga 
Ram Hospital during the last two years for non 
squamous NSCLC with three drug combination 
using carboplatin, pemetrexed and bevacizumab. 
There were twelve males and three females. Median 
age was 55 years. There were nine smokers and six 
non smokers. The sites of metastasis were as follows 
: pleural effusion – 7 pts., bones – 3 pts., liver – 2 
patients, adrenal 3 pts., CNS – 3 patients, lymph 
nodes -7 pts., contralateral lung – 5 pts. ECOG status 
was 0 in 10 cases, 1 in 2 cases and 2 in 3 cases. 4 out 
of 15 cases underwent pleurodesis. Histopathology 
was large cell type in 2, adenocarcinoma in 10 and 
poorly differentiated carcinoma in 3 cases. Doses 
of the drugs were as follows : carboplatin AUC 6, 
pemetrexed 500mg/sq. mt, and bevacizumab 500mg/
sq.mt given every three weeks. Premedication with 
folic acid, vitamin B12 and dexamethasone was 
given.
Results: Median number of cycles used were 
six. Four patients received less than Àve cycles. 
The chemo-protocol was well tolerated, only 
three patients had delay in their doses and two 
patients required G-CSF. There was mild epistaxis 
in four cases. Eight patients achieved partial 
response (53%), four stable disease and three 
progressive disease. Three patients progressed in 
the CNS. All the patents were given geÀtinb 250 
mg as maintenance therapy after completion of 
chemotherapy. Five ( two smokers and three non 
smokers )out of these patients have sustained their 
responses beyond 18 months and three are still alive. 
Median overall survival is not reached at 11 months 
follow up
Conclusion: Carboplatin, pemetrexed and 
bevacizumab combination is effective and safe for 
management of advanced non-squamous NSCLC. 
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P3.034 SECOND LINE ERLOTINIB IN 
NON-SMALL CELL LUNG CANCER: A 
LOCAL EXPERIENCE
C F. Smith, Angel Garcia-Alonso, G. Drury, A. 
Gostage, N. Smith 
Oncology, Betsi Cadwaladr University Health 
Board: North Wales Cancer Treatment Centre/United 
Kingdom
Background: In November 2008 NICE issued 
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thrombosis. One patient had both. The most 
common underlying disease was hypertension 
with 18 cases. By type of disease, there were 27 
cases of deep vein thrombosis (60%) and 7 cases 
of pulmonary thromboembolism (16%, of whom 
6 were complicated with venous thrombosis of 
legs). Other cases, such as arterial mural thrombus 
(aorta and superior mesenteric artery etc.), stroke, 
renal infarction, and splenic infarction were 
observed. By histology of lung cancer, 23 cases 
were adenocarcinoma, 10 cases were squamous cell 
carcinoma, 7 cases were small cell carcinoma, and 
there were 5 other cases (including unknown): by 
stage, many were StageIIIA or more advanced. On 
the other hand, Performance statuses (PS) at the 
time of detection of thrombus were as follows: “0” 7 
cases (16%). “1” 14 cases(30%), “2” 12 cases(27%), 
“3” 8 cases (18%), and “4” 4 cases (9%), thus 
comparatively good PS patients accounted for the 
majority. By clinical symptoms, 30 cases (67%) had 
no symptoms. Chemotherapy was performed before 
thrombus found in 27 cases(60%).
Conclusion: Among patients with advanced 
lung cancer, regardless of clinical symptoms, 
general condition, and histological type, many 
had thrombosis. In addition, onset of thrombosis 
seriously affected many patients’ QOL and 
prognosis. In advanced lung cancer, it is necessary 
to bear in mind the presence of thrombosis, 
immediately after diagnosis, especially before 
starting chemotherapy. In addition, attention to 
thrombosis as a paraneoplastic syndrome and 
increased use of bevacizumab require further study.
Keywords: thrombosis, pulmonary 
thromboembolism, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.036 ERLOTINIB VS DOCETAXEL 
AS SECOND-LINE TREATMENT OF 
ADVANCED NSCLC: A REAL-WORLD 
COST-EFFECTIVENESS STUDY
Ian Cromwell1, Kimberly Van Der Hoek1, Barbara 
Melosky2, Stuart Peacock1 
1Canadian Centre For Applied Research In Cancer 
Control (arcc), British Columbia Cancer Agency/
3). Fatigue was experienced by 12 patients (n=5 
grade 1 and n=7 grade 2). Diarrhoea occurred in 6 
patients (n=4 at grade 1 and n=1 each of grade 2 and 
3). No grade 4 side effects were noted. The majority 
of patients (n=22) stayed on the full dose (150 mg 
daily) with only 4 having a dose reduction (100mg 
daily). 
Conclusion: This data gives us an overview of a 
local cancer unit’s experiences of the use of second-
line Erlotinib. As numbers are small no conclusions 
can be drawn but on the whole the treatment 
was tolerated well with manageable side-effects 
most commonly rash and fatigue. Mean length of 
treatment compares favourably with current data (1, 
2, 3). Second-line Erlotinib thus provides us with a 
well tolerated and effective alternative to Docetaxol. 
Keywords: erlotinib, second line, NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.035 CLINICAL FEATURES OF 
PATIENTS WITH THROMBOSIS 
ASSOCIATED WITH LUNG CANCER
Keisuke Imasaka, Hiroki Takakura, Akio Komuro, 
Nobuyuki Hamanaka, Miki Takahashi, Kunihiko 
Shimizu 
Respiratory Medicine, Saiseikai Yokohamashi Tobu 
Hospital/Japan
Background: It has been known that cancer patients 
are often complicated with thrombosis. This has 
sometimes had a signiÀcant impact on treatment 
and prognosis. However, backgrounds are diverse, 
so at present standardized treatment is not possible. 
Therefore, we studied the clinical features of 
thrombosis associated with lung cancer.
Methods: A total of 307 lung cancer patients had 
visited our hospital in the previous three years (April 
2007-March 2010). We extracted 45 patients in 
whom the presence of thrombosis was conÀrmed 
by diagnostic imaging such as ultrasound or CT, 
regardless of symptoms. A retrospective study was 
carried out based on medical records.
Results: Thirtyfour male cases (75.5%) and 11 
female cases (24.5%), mean age 69.5 years, 17 
cases of arterial thrombosis and 27 cases of venous 
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P3.037 LOW FEASIBILITY OF SECOND-
LINE CHEMOTHERAPY IN PATIENTS 
WITH DIABETES MELLITUS IN 
ADVANCED NON-SMALL CELL LUNG 
CANCER
Yoshihito Kogure, Kazumi Hori, Yoriko Funahashi, 
Saori Oka, Rie Tsuboi, Takashi Adachi, Misaki 
Ryuge, Naohiko Murata, Chiyoe Kitagawa, 
Masahide Oki, Hideo Saka 
Respiratory Medicine, Nagoya Medical Center/
Japan
Background: Non-small cell lung cancer (NSCLC) 
is mostly diagnosed in the advanced stage, and 
chemotherapy is the treatment of choice. In 
patients with diabetes mellitus (DM) in NSCLC, 
chemotherapy could be insufÀcient for the following 
reasons: 1) uncontrollable glucose level due to 
corticosteroid use as an antiemetic drug, 2) renal 
deÀciency, and 3) complication of DM such as 
peripheral neuropathy. We aim to investigate the 
feasibility of second-line chemotherapy with DM in 
advanced NSCLC.
Methods: Clinical information was retrospectively 
gathered for stage IIIB or IV NSCLC patients who 
started Àrst-line systematic chemotherapy at our 
institution between January 1, 2004 and December 
31, 2009. Patients who relapsed after surgery were 
excluded. Patients were assigned to the DM or non-
DM (NDM) arm. Primary endpoint was to assess the 
feasibility of second-line chemotherapy. Secondary 
endpoint was overall survival (OS). Kaplan Meier 
and log-rank analyses were used for OS. 
Results: Overall, 211 consecutively treated patients 
were collected at our institution. 33 patients were 
treated with DM and 178 with NDM. Patient 
characteristics of DM were: median age, 70 years 
(range: 49 -88); male/female, 28/5; Ad/Sq/others, 
20/9/4; IIIB/IV, 16/17; ECOG Performance Status 
(PS), 0/1/2/3<=5/27/1/0; and platinum doublet/
others, 25/8. Those of NDM patients were: median 
age 67 years (range: 36-88); male/female, 114/64; 
Ad/Sq/others, 113/35/30; IIIB/IV, 50/128; PS, 
0/1/2/3<=30/118/25/5; and platinum doublet/others, 
129/49. The feasibility of second-line chemotherapy 
was slightly worse in DM than in NDM (51.5% vs. 
57.9%, respectively). Patients who received third-
line or more were also worse in DM than in NDM 
(18.2% vs. 29.2%, respectively). The median OS of 
Canada, 2Medical Oncology, British Columbia 
Cancer Agency/Canada
Background: The British Columbia Cancer Agency 
(BCCA) began funding erlotinib as a second-line 
treatment for advanced NSCLC in 2005. While 
the efÀcacy of the drug has been shown in clinical 
trials, real-world cost-effectiveness has not been 
shown. This study investigated the real-world cost-
effectiveness of second-line erlotinib in patients 
treated across British Columbia, Canada.
Methods: This was a retrospective study of all 
patients who had been treated with second-line 
chemotherapy for advanced NSCLC at the BCCA 
since September, 2005. As pemetrexed is now 
frequently being used as a front line therapy with 
cisplatin, a comparison of second-line erlotinib to 
doctexal is relevant. The primary endpoint was cost-
effectiveness, measured in terms of cost per years 
of life gained. The calculation of life years gained 
was based on the area under the Kaplan-Meier curve 
of overall survival, deÀned as days between start of 
second line chemotherapy and death or censoring. 
Analysis was performed from the perspective of the 
British Columbia Ministry of Health Services, and 
included the costs of drugs, radiation, hospitalization, 
appointments, tests, and home/community care.
Results: A total of 133 erlotinib patients and 68 
docetaxel patients were identiÀed. There were no 
signiÀcant differences in either survival or cost 
between the two groups in the real-world setting. 
Results are presented in the table. As costs and 
outcomes in the docetaxel arm were not signiÀcantly 
different from costs and outcomes in the erlotinib 
arm (incremental costs and effectiveness were both 
near zero), no ICER could be calculated.
Conclusion: Our analysis found that in terms of 
both costs and effectiveness (overall survival and 
progression-free survival), erlotinib and docetaxel 
are equivalent. This Ànding suggests that patients 
and physicians should make the decision of 
treatment modality based on patient preferences and 
other concerns, rather than on the basis of survival 
and cost. 
Keywords: health economics, erlotinib, 
retrospective trial, Cost-effectiveness
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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mutations and 10 patients had 2 mutations. Mutated 
patients are mainly women (63%) and 97.5% have an 
adenocarcinoma. 60.3% are never smokers, 28.1% are 
former smokers and 11.6% are current smokers (mean 
pack-year is 27.49 (1-100) for former and current 
smokers). Mean age is 66.43 (+/- 23.25 years). 5 
patients present at least one EGFR resistance mutation 
mainly on exon 20 (2 undergo TKI: one in Àrst line 
and one in second line). Among all, 85 patients 
(70.2%) received a TKI, mainly those with stage IIIb 
or IV disease (96.4%). Before TKI, 58.8% underwent 
chemotherapy, 14% thoracic radiotherapy and 23% 
thoracic surgery. TKI was Àrst line treatment in 41% 
(71% geÀtinib) and second or third line in 59% (56% 
erlotinib). Among patients who underwent TKI, the 
mean progression free survival (PFS) was 13 months 
(10.5-15.5). There were no signiÀcant differences in 
PFS between the “Àrst line” and the “second line” 
groups (14 [2,012-25,988] months vs 13 [9.240-
16.760] respectively; p=0.843). Responses observed 
were: complete in 4%, partial in 56% and stable in 
19%. 21% had immediate progressive disease. There 
is no signiÀcant difference in mutated exon type and 
survival according to sex, age, smoking history or 
prior treatment by chemotherapy. Overall response 
observed is higher in case of exon 19 mutations (66% 
vs 33%; p=0.022) and lower in case of mutations 
in exon 20 that contains most of the resistance 
mutations (1.6% vs 98.4%; p<0.0001). Concordantly 
a signiÀcant difference in PFS is observed according 
to the location of sensitizing mutations. Exon 19 
sensitizing mutations show better survival (15.0 
[6.72-23.27] months) than exon 21 (13.0 [7.34-18.65] 
months) and 18 (4.0 [0-8.0] months) respectively 
(p=0.002). Advert effects are more frequent when 
patients are treated with erlotinib than with geÀtinib 
as shown by dose reduction observed only in the 
erlotinib group (27.8% of patients). 
Conclusion: This retrospective study highlights that 
survival is not affected by prior chemotherapy in case 
of activating EGFR mutation. Moreover sensitizing 
mutations on exon 19 show signiÀcant better survival 
than exon 21 and exon 18 respectively. Finally, 
geÀtinib has a better tolerance proÀle than erlotinib. 
Further data will be available on meeting. 
Keywords: EGFR mutations, Non small cell lung 
cancer, tyrosine kinase inhibitors, clinical outcome
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
DM was shorter than that of NDM (366 days vs. 423 
days, p=0.572).
Conclusion: The feasibility of second-line 
chemotherapy with DM in advanced NSCLC tended 
to be worse, but there was no signiÀcant difference 
between DM and NDM. Median OS of DM was 
similar to that of NDM. This study was retrospective 
and the clinical background was not well balanced. 
To conÀrm this study, a prospective cohort study is 
needed.
Keywords: NSCLC, Chemotherapy, diabetes 
mellitus
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P3.038 CLINICAL OUTCOMES AFTER 
ROUTINE DIAGNOSIS OF EGFR 
MUTATION: A MULTICENTRIC 
RETROSPECTIVE STUDY ABOUT 121 
PATIENTS.
Myriam Locatelli Sanchez1, Sebastien Couraud1, 
Pierre Paul Bringuier2, Jean Yves Scoazec2, Pierre 
Jean Souquet1 
1Service De Pneumologie Dr Souquet, Hôpital Lyon 
Sud, Hospices Civils De Lyon/France, 2Service 
D’Anatomie Et Cytologie Pathologiques, Hôpital 
Edouard Herrriot, Hospices Civils De Lyon/France
Background: Epidermal growth factor receptor 
(EGFR) mutations in non small-cell lung cancer 
(NSCLC) were described seven years ago. When 
tumors harbour sensitizing mutations, patients are 
more likely to respond to tyrosine kinase inhibitors 
(TKI). Conversely some mutations are associated 
with drug resistance and some, less frequent, are 
not yet evaluated. GeÀtinib can be delivered in 
Àrst line therapy for mutated patients with stage IV 
NSCLC. In France, EGFR mutations detection is 
routinely performed in molecular genetic platforms. 
This retrospective study aims to determine clinical 
outcomes of mutated patients.
Methods: Medical Àles from patients with EGFR 
mutation diagnosed on the Rhône platform between 
09/09 and 09/10 were retrospectively reviewed. Data 
including histologic type, TNM status, smoking 
history, sample origin, treatment administered and 
response to treatment were collected in all health 
centres that sent samples (University hospital 34%; 
secondary hospitals 36%; private clinics 30%). 
Results: 133 mutations were found: 1 patient had 3 
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AGE 
(CHARLSON) 
IADL
(dependence) 
ADL
(dependence 
Geriatric 
syndrom 
Charlson 
Comorbidity PS Treatment 
65-69y(2) 1 0 0 0-2 2 eligible 
65-69y (2) <2 0 0 3-4 0-1 eligible 
65-69y (2) <2 0 0 3-4 2 eligible 
70-79y (3) 1 0 0 0-1 0-1 eligible 
70-79y (3) <2 0 0 0-1 2 eligible 
70-79y (3) <2 0 0 2-4 0-2 eligible 
80-89 y (4) 1 0 0 0 0-1 eligible 
80-89y (4) <2 0 0 2-4 0-2 eligible 
Results: 100 pts (94 available) were enrolled from 
aug 2006 to dec 2009 Patients: Male/Female 76/18, 
median age 78.2(44%>79 years); PS 0/1/2:30/47/14, 
median co-morbidity (CS) 1.74 (1-3), median 
IADL score 3.35 (1-4), median global geriatric 
index: 17.8/20 .Respectively for arm A and B, 
partial response was 13% and 14%,stable disease 
26 % and 23%,progressive disease 61% and 63%( 
Àrst line),TTP2 4.3 and 3.5 months, TTP1 2.5 and 
2.2 months, median survival 4.4 and 4 months(no 
signiÀcant difference between 2 arms),1 year 
survival 27% arm A and 20% arm B. The main WHO 
Grade3/4 toxicity was fatigue 11% and anemia 9.% 
in arm A and in arm B fatigue 18% and diarrhea 
6%.There was no decrease in QOL.
Conclusion: Preliminary analysis suggests that 
either the G followed by E or E followed by G 
appears to have acceptable toxicity but moderate 
activity ,comparable in term of efÀcacy to prior data 
in this vulnerable elderly NSCLC pts population 
with signiÀcant co-morbidities. Our trial conÀrms 
the necessity to identify the better tools in CGA to 
distinguish frail pts.
Keywords: Non small cell lung cancer, elderly 
patients, geriatric assessment, Chemotherapy
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P3.040 GASTROINTESTINAL TOXICITY 
OF THE PAN-HER TYROSINE 
KINASE INHIBITOR (TKI) PF299804: 
ASSESSMENT BY PATIENT-REPORTED 
OUTCOMES IN 2ND/3RD-LINE AND 
REFRACTORY NON-SMALL CELL LUNG 
CANCER (NSCLC)
Alicyn K. Campbell1, Fiona H. Blackhall2, Shirish 
M. Gadgeel3, Pasi A. Janne4, Keunchil Park5, Rajiv 
Mundayat6, Stephen P. Letrent1, Michael Boyer7, 
Joseph O’Connell8, Suresh Ramalingam9 
1Clinical Development And Medical Affairs, PÀzer 
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P3.039 A MULTICENTER PHASE 
II RANDOMIZED STUDY OF 
GEMCITABINE(G) WEEKLY 
FOLLOWED BY ERLOTINIB(E) AFTER 
PROGRESSION VERSUS E FOLLOWED 
BY G AFTER PROGRESSION IN 
ADVANCED NON SMALL CELL LUNG 
CANCER(NSCLC)IN VULNERABLE 
ELDERLY PATIENTS SELECTED WITH 
A COMPREHENSIVE GERIATRIC 
ASSESSMENT (CGA) (GFPC*0505)
Hervé Jullian1, Herve Le Caer2, Laurent Greillier3, 
Romain Corre4, Jacky Crequit1, Lionel Falchero1, 
Celine Dujon1, Henri Berard5, Jean B. Auliac1, 
Christos Chouaid6 
1Pneumologie, Centre Hospitalier/France, 
2Oncology, Centre Hospitalier Dracenie/
France, 3Service D’oncologie Multidisciplinaire 
Et Innovations Thérapeutiques, Hôpital Nord, 
Assistance Publique- Hôpitaux De Marseille/France, 
4Pneumologie, Chu Rennes/France, 5Hia Sainte 
Anne/France, 6Chu Saint Antoine/France
Background: Elderly patients (pts) is an 
heterogeneous population in which anticancer 
therapeutic decision is often difÀcult. The objective 
of this study was to evaluate the feasibility and 
activity of weekly G followed by E after progression 
versus E following by G after progression in 
vulnerable elderly advanced NSCLC patients 
selected on the basis of a CGA and Charlson score 
(CS)
Methods: This multicenter phase 2 study 
randomized chemonaive pts with stage IV and IIIB 
with pleural effusion received G1250mg/m² days 
1,8, for a maximum of 18 weeks or until progression, 
followed by E until second progression (arm A)
versus E in Àrst line followed by G until second 
progression(arm B).Only vulnerable pts(without 
dependence for ADL and geriatric syndrom like falls, 
dementia , incontinence)(Table 1)were selected by 
CGA using a software (EGSK) included in a palm 
assistant with 10 items: socio-economic conditions, 
cognitive assessment, depression scale, nutritional 
risk, quality of life(QOL), ADL,IADL(Lawton), 
incontinence, falls, pain. Major endpoint was time 
to second progression (TTP2), secondary endpoints 
were response, time to Àrst progression (TTP1), 
survival, safety, QOL. Table1 
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assessment timepoint for refractory and 2nd/3rd-line 
NSCLC (scored on a 0–100 scale with higher scores 
indicating higher levels of symptoms).* 
Refractory 
Day 1 Cycle 1 
(n=65) 
Week 3 
(n=56) 
Week 6 
(n=51) 
Week 9 
(n=33) 
Week 12 
(n=33) 
Diarrhea† 7.18 50.88 50.64 48.04 44.44 
Sore mouth 4.1 34.52 26.8 19.19 20.2 
Dif¿culty swallowing 2.05 8.33 11.76 9.09 9.09 
2nd/3rd-line 
Day 1 Cycle 1 
(n=90) 
Week 2 
(n=80) 
Week 4 
(n=82) 
Week 8 
(n=64) 
Week 12 
(n=45) 
Week 16 
(n=38) 
Diarrhea‡ 9.26 40.0 48.56 41.8 36.36 38.6 
Sore mouth 6.67 39.17 36.59 28.12 22.96 21.93 
Dif¿culty swallowing 5.93 22.5 20.33 16.67 8.89 7.89 
n= number of patients answering each item at each assessment timepoint *A change 5 points is 
considered to be clinically meaningful when assessing these data †For diarrhea in refractory population, 
n=57, n=52, n=34 for weeks 3, 6 and 9, respectively ‡For diarrhea in 2nd/3rd-line population n= 81, n=63, 
n=44 for weeks 4, 8 and 12, respectively. 
Conclusion: In clinical trials of PF299804 in 
refractory and 2nd/3rd-line NSCLC, the most common 
gastrointestinal TRAE were diarrhea, stomatitis and 
mucositis. Though these were relatively common, 
they were rarely a reason for discontinuation, and 
PRO for these TRAE peaked early in therapy and 
stabilized over time. PRO measures can provide 
insight into patient experience that is not captured 
by CTCAE grading. Furthermore, understanding 
the time course and patient impact of common 
gastrointestinal TRAE may better prepare 
patients and enable providers to anticipate when 
intervention can best be targeted in the course of 
care. 1. Campbell A et al. ASCO 2010; abstr 7596. 2. 
Ramalingam SS et al. ESMO 2010; abstr 365PD. 
Keywords: EGFR TKI, Patient Reported Outcomes, 
Gastrointestinal Toxicity, PF-00299804
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.041 DERMATOLOGIC ADVERSE 
EVENTS OF THE PAN-HER TYROSINE 
KINASE INHIBITOR (TKI) PF299804: 
ASSESSMENT BY PATIENT-REPORTED 
OUTCOMES IN 2ND/3RD-LINE AND 
REFRACTORY NON-SMALL CELL LUNG 
CANCER (NSCLC)
Alicyn K. Campbell1, Michael Boyer2, Giuseppe 
Giaccone3, Pasi A. Janne4, Dong-Wan Kim5, 
Keunchil Park6, Suresh Ramalingam7, Karen L. 
Oncology/United States Of America, 2Medical 
Oncology, The Christie NHS Foundation Trust/
United Kingdom, 3Oncology, Karmanos Cancer 
Institute/wayne State University/United States Of 
America, 4Lowe Center For Thoracic Oncology, 
Dana Farber Cancer Institute/United States Of 
America, 5Div Of Hem/onc, Dept Of Medicine, 
Samsung Med Ctr, Sungkyunkwan University School 
Of Medicine/Korea, 6Statistics, Specialty Care 
Business Unit, PÀzer Oncology/United States Of 
America, 7Medical Oncology, Sydney Cancer Centre/
Australia, 8Oncology, PÀzer Oncology/United States 
Of America, 9Hematology And Medical Oncology, 
Winship Cancer Institute Of Emory University/
United States Of America
Background: PF299804, a potent, irreversible 
inhibitor of human epidermal growth factor receptor 
(EGFR)/HER-1, -2, and -4 tyrosine kinases, is active 
in erlotinib-sensitive and -resistant preclinical models. 
PF299804 had clinical activity in phase 2 trials of 
chemotherapy and EGFR TKI-refractory KRAS 
wild-type NSCLC1 and compared with erlotinib in 
2nd/3rd-line NSCLC.2 Phase 3 trials are ongoing in 
both NSCLC settings. Gastrointestinal toxicities of 
diarrhea, stomatitis and mucositis are known class 
effects of EGFR targeted therapy, but Common 
Terminology Criteria (CTC) for AE grading does not 
fully characterize the patient’s experience. Qualitative 
assessment from the patient’s perspective of the burden 
of toxicity and changes over time further characterizes 
the impact of AEs. As current therapies are not curative, 
it is important to understand the impact of side effects 
when making treatment decisions. 
Methods: In refractory (n=66, KRAS wild type) and 
2nd/3rd-line (n=94) advanced NSCLC, ECOG PS 0–2, 
patients received oral PF299804 with assessments 
every 3 (refractory) or 4 (2nd/3rd-line) weeks. Patient-
reported outcomes (PRO) were assessed by the 
EORTC Quality of Life Questionnaire [QLQ-C30], 
and its lung cancer module [QLQ-LC13).
Results: The most common (>10% incidence) 
gastrointestinal treatment-related (TR) AE in 
refractory/2nd/3rd-line were: diarrhea (85%/73%), 
stomatitis (24%/29%), and mucositis (11%/25%), all 
predominantly of Grade 1 severity; discontinuations 
were: refractory = 0, 2nd/3rd-line = 1 (diarrhea). 
EORTC QLQ-C30/LC13 data indicated that these 
AEs peaked early in therapy, between Weeks 2–6, 
in both refractory and 2nd/3rd-line and stabilized 
over the course of treatment. EORTC QLQ-C30 
symptom scores: mean patient score at each 
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(34.8% Grade (G) 1) and 2nd/3rd-line = 78.5% (38.7% 
G1), appearing initially on head and chest with later 
involvement of limbs and back. Other AEs (overall 
incidence, refractory; 2nd/3rd-line) were dry skin 
(37.9%; 23.7%), exfoliative rash (24.2%; 17.2%), 
pruritus (22.7%; 15.1%) and paronychia (9.1%; 
25.8%). Late-emerging AEs (incidence in cycle 1 vs. 
later cycles), included dry skin (refractory: 19.7% vs. 
30.5%; 2nd/3rd-line: 9.7% vs. 20.8%) and paronychia 
(refractory: 0 vs. 10.2%; 2nd/3rd-line: 10.8% vs. 
20.8%). Mean patient DLQI Symptoms and Feelings 
subscale scores* and DLQI Total score** for 
refractory and 2nd/3rd-line NSCLC patients treated 
with PF299804 
Refractory 
Day 1 Cycle 1 (n=65) Week 6 (n=52) Week 12 (n=34) 
DLQI Symptoms and Feelings subscale* 0.28/6 1.69/6 2/6 
DLQI Total score** 0.48/30 3.81/30 4.94/30 
2nd/3rd-line 
Day 1 Cycle 1 (n=91) Week 4 (n=82) Week 12 (n=44) 
DLQI Symptoms and Feelings subscale* 0.56/6 1.9/6 2.14/6 
DLQI Total score** 0.88/30 3.91/30 5.82/30 
*DLQI Symptoms and Feelings subscale: 0–6 where higher score = higher level of impairment; **DLQI 
Total score: 0–1 = ‘no effect’; 2–5 = ‘small effect’; 6–10 = ‘moderate effect’; 11–20 = ‘very large effect’; 
21–30 = ‘extremely large effect’ on patient’s life 
Conclusion: In studies showing clinical activity 
of PF299804, dermatologic AEs were consistent 
with other EGFR inhibitors. As measured by DLQI, 
PF299804 dermatologic AEs had a small impact on 
patients’ DRQoL. Understanding the time course and 
patient impact of dermatologic treatment-related AEs 
may enable providers to anticipate when intervention 
can best be targeted in the course of patient 
management. 1. Campbell A et al. ASCO 2010;abstr 
7596. 2. Ramalingam SS et al. ESMO 2010;abstr 
365PD. 3. Joshi SS et al. Cancer 116:3916-3923. 
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Background: PF299804, a potent, irreversible 
inhibitor of human epidermal growth factor 
receptor (EGFR)/HER-1, -2, and -4 TKs, is active 
in erlotinib-sensitive and -resistant preclinical 
models. PF299804 had clinical activity in phase 2 
trials of chemotherapy and EGFR TKI-refractory 
KRAS wild-type NSCLC1 and versus erlotinib in 
2nd/3rd-line NSCLC;2 phase 3 trials are ongoing in 
both settings. A profound impact on Dermatologic 
Related Quality of Life (DRQoL) has been described 
with the EGFR inhibitor erlotinib3 but Common 
Terminology Criteria (CTC) for AE grading may not 
fully characterize the patient’s experience of side 
effects from therapy. Assessment of the AE burden 
qualitatively from the patient’s perspective further 
characterizes the impact of AEs related to EGFR 
TKIs. As current therapies are not curative, it is 
important to understand the impact of side effects 
when making treatment decisions. 
Methods: In refractory (n=66) and 2nd/3rd-line 
(n=94) advanced NSCLC, ECOG PS 0–2, patients 
received oral PF299804 with assessments every 
3 (refractory) or 4 (2nd/3rd-line) weeks. The 10 
question Dermatology Life Quality Index (DLQI) 
questionnaire was used to assess the impact of anti-
cancer treatment on patients’ DRQoL on Day 1 of 
each cycle. Total scores range from 0–30; subscale 
scores range from 0–6, with higher scores indicating 
a higher level of impairment. 
Results: The most common dermatologic AE was 
acne; overall frequency in refractory = 66.7% 
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addition, 20.2% of pts needed dose reductions and 
67.9% dose delays. The relative dose intensities 
for pemetrexed and carboplatin were 88.8% and 
89.5%, respectively. Red blood cells transfusion, 
platelet transfusion and G-CSF administration were 
required in 10%, 7% and 9 % of the patients. Rash 
(26%) and fever (17%) were relatively common 
non-hematological toxicity. There were no study 
related deaths. Serious adverse reactions including 
thrombocytopenia, anemia, and gastric ulcer were 
reported in 8 patients (7%). Of 109 pts evaluable for 
response (RECIST criteria), 42 pts (38.5%) achieved 
a partial response (either conÀrmed or unconÀrmed) 
and 47 pts (43.1%) had stable disease in induction 
period. Seventy-Àve pts (68.8%) were completed 
induction period, and 60 pts (55.0%) entered into the 
maintenance period.
Conclusion: This prospective, nonrandomized, 
multicenter study suggested that pemetrexed plus 
carboplatin combination chemotherapy would be 
well tolerated and effective as a Àrst-line therapy for 
advanced nonsquamous NSCLC.
Keywords: Pemetrexed, Carboplatin, NSCLC
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.043 DIFFERENT OUTCOMES IN 
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Background: Prognosis for advanced NSCLC is 
still unsatisfying despite a large number of clinical 
trials are enrolling patients (pts) to evaluate new 
therapeutic approaches and anticancer drugs. 
Independently from the Ànal results of each clinical 
trial, the common perception is that the inclusion in 
clinical trials leads to improved outcomes in patients 
with cancer, even if there aren’t clear data to make 
a statement about this issue. In any case, pts with 
cancer should be encouraged to be part of clinical 
trials on the basis of trials’ unquestioned role in 
improving treatment for future pts. We conducted 
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Background: Platinum-based chemotherapy is the 
standard Àrst-line treatment for advanced non-small 
cell lung cancer (NSCLC); furthermore, recent 
phase III studies have shown a beneÀcial role of 
pemetrexed as a maintenance therapy. This is an 
ongoing clinical study of pemetrexed combined with 
carboplatin during an induction period followed by 
pemetrexed maintenance.
Methods: Eligible patients (pts) were previously 
untreated, unresectable stage IIIB, IV or 
postoperative recurrent nonsquamous NSCLC, 
ECOG Performance Status (PS) was 0–1 at 
study entry. Pts received carboplatin AUC 6 and 
pemetrexed 500 mg/m2 on Day 1 of each of 4 
three-week cycles as induction therapy. Pts with 
objective response and stable disease at the end of 
the induction period could continue on pemetrexed 
as maintenance therapy until disease progression or 
unacceptable toxicity. We report preliminary results 
of the induction period.
Results: Pemetrexed and carboplatin were 
administered as induction therapy to 109 pts. Median 
age was 63 years (range 38–78); 63.3% were male, 
36.7% female. Other patient backgrounds: PS 0/1 
( 33.9%/66.1%), stage IIIB/IV/recurrent disease 
(30.3%/66.1%/3.7%), current/former smoker 
(8.3%/61.5%). The most frequently reported Grade 
3 toxicity was neutropenia (54%). Other Grade 
3 toxicities were also hematologic, including 
thrombocytopenia (41%) and anemia (28%). In 
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Background: Clinical trials and meta-analyses 
have demonstrated survival beneÀts of cytotoxic 
chemotherapy in advanced stage (stage 3 and 4) 
non-small cell lung cancer (NSCLC). To determine 
whether these controlled trial results translate into 
survival beneÀts in an unselected population, the 
database of the Cancer Registry at The Queen 
Elizabeth Hospital was analysed for all patients with 
stage 3 and 4 NSCLC to determine if changes in 
patterns of care in two completely separate 5 year 
time cohorts (1988 – 1992, cohort A and 2003 – 
2007, cohort B) resulted in any overall improvement 
in survival. 
Methods: Demographic, management and outcome 
data was determined from clinical records. Stage 
wise survival analysis was undertaken using the 
Kaplan-Meier product-limit method and the log-
rank test. Factors inÁuencing survival outcome were 
assessed using Cox proportional hazards regression. 
Results: Data for 516 patients identiÀed in the 2 
cohorts are shown in Table 1. 
Cohort A (1988-1992) 
Total 210 
Cohort B (2003-2007) 
Total 306 
Males/Females 68%/32% 65%/35% 
Predom histol squamous/adeno 33%/38% 30%/30% 
Stage3/Stage 4 34%/66% 42%/58% 
Never smokers 6% 11% 
Median age 68 yrs 69yrs 
Age 65 yrs or older 65% 63% 
EGOG PS 0-2/3-4 75%/25% 75%/25% 
Received chemotherapy* 4% 41% 
Received radiotherapy 51% 50% 
Table 1. * 60% chemotherapy regimens were 
gemcitabine/platinum combinations Median survival 
for all patients was signiÀcantly increased in cohort 
B compared with cohort A (HR 0.74, 95% CI 0.60-
a retrospective analysis in a single institution 
evaluating survival data and toxicity proÀle in 
advanced NSCLC pts treated with standard therapy 
or within controlled clinical trials.
Methods: We analysed 300 consecutive pts 
treated at the Thoracic Oncology Unit of San Luigi 
Gonzaga Hospital from 2004, January the 1st to 
2010, December the 31st having these characteristics: 
histo/cytological diagnosis of NCSLC, stage IV 
who received at least 3 chemotherapy cycles, with 
a minimum follow-up of six months. In this pts 
population 178 (59%) were enrolled in controlled 
clinical trials (T) while 122 (41%) were treated with 
standard therapy (S) . 
Results: the most important differences between 
the two groups were about median age at the time 
of starting Àrst line treatment (61.2 in group T vs 64 
years in group S), pts older than 70 years old (19% 
vs 27%, respectively) and ECOG/PS distribution 
(PS=2: 0 vs 9 pts, PS=1: 33 vs 53 pts, PS=0: 145 vs 
60 pts in T and S group, respectively). Distinguishing 
different lines of therapy in T population: in pts 
enrolled in Àrst line clinical trials only, median OS 
was 9.2 months, 18.1 months in pts enrolled in Àrst 
and second line clinical trials, 15.3 months in pts 
enrolled only in second line clinical trials and 26.4 
months in pts enrolled in Àrst, second and third line 
studies. Any relevant differences was seen between 
group T and S in terms of toxicity. 
Group S Group T 
Pts eligible for second line treatment 43 (35%) 105 (59%) 
Pts eligible for third line treatment 18 (15%) 45 (25%) 
OS (months) 9.5 13.5 
PFS (months) 6.3 7.1 
Conclusion: This retrospective analysis done in 
a single institution documented a better outcome 
for pts enrolled in clinical trials compared to those 
treated with standard therapy (even without a 
statistical signiÀcance) with an higher percentage 
of pts reaching a second and third line therapies. 
This kind of analysis is burdened by a series of 
possible biases, which can be solved only with larger 
multicenter prospective dedicated studies.
Keywords: Advanced NSCLC, Clinical Trials
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to over 70%, to Àrst line treatment with geÀtinib 
in advanced NSCLC patients harboring mutations 
in the epidermal growth factor receptor (EGF-R). 
Based on these works, geÀtinib was included in 
the Israeli Health Scheme for this select population 
since the beginning of 2010. The primary goal of this 
retrospective analysis was to study the efÀcacy of 
geÀtinib in the Àrst line treatment of EGFR-mutated 
advanced NSCLC patients in two Israeli tertiary 
hospitals. 
Methods: The clinical data of patients tested positive 
for EGFR mutations from the Sheba Medical Center 
and the Meir Hospital since the beginning of 2010 
were included in the current retrospective analysis. 
Analyses were based on demographic, clinical and 
molecular data. 
Results: Since the beginning of 2010, EGFR 
mutations were identiÀed in 20% of all patients 
evaluated, with a total of 38 patients testing positive 
for mutations. EGFR mutations were primarily 
exon 19 deletions (55%) and exon 21 L858R point 
mutations (26%), with the remaining mutations 
identiÀed in exon 21 Leu861Gln (11%) and exon 18 
Ala719Gly (5%). One patient’s mutation status was 
not recorded in the chart. The median age of this 
cohort was 69 (range 45-85) with 24 of these females 
(63%). 23 were never smokers (61%) with 31 
adenocarcinomas (81%), 2 patients with squamous 
cell carcinoma (5%) and the remaining diagnosed 
as of non-squamous origin. Of these 38 patients, 24 
were treated with Àrst line geÀtinib for advanced 
disease. The majority of these patients (89%) had 
an ECOG performance status of 0-2. By the date of 
abstract submission, 19 of these patients have been 
evaluated for treatment response. Adverse events 
were generally mild and similar to published reports 
– 9 experienced grade 1-2 rash (47%), 6 experienced 
grade 1-2 diarrhea (32%) and one patient had grade 
3 hypomagnesemia. 2 patients achieved a partial 
response (10.5%) as deÀned by the RECIST criteria, 
12 had a documented best response of stable disease 
by RECIST criteria (63%), and 5 had progressive 
disease (26.5%). Of the 19 patients, 4 have died 
within 4 months of starting geÀtinib. Thus, in this 
current retrospective study of the Israeli population, 
our response rate is signiÀcantly lower than 
expected. The null-hypothesis of a minimal 50% 
response rate (as seen for other western populations) 
is rejected with a P value of 0.02 using a two-tailed 
chi-square test. 
Conclusion: Albeit the very small number of 
patients in this current retrospective study, the 
0.89, p = 0.0018). Univariate analysis of outcomes in 
cohort B suggested that the majority of improvement 
in survival in cohort B appeared to be dependent 
on the use of chemotherapy (p = 0.0003), better 
performance status (PS)(p < 0.0001), stage 3 disease 
(p = 0.0004) and female gender (p = 0.004). Age 
over 65 and use of radiotherapy alone did not appear 
to affect outcome for either cohort. 
Conclusion: In an unselected population, the median 
overall survival for patients with advanced stage 
NSCLC has improved signiÀcantly over a 15 year 
period. The most signiÀcant factor contributing to 
the improvement in survival appears to be the use of 
chemotherapy, which was 10 times more likely to 
occur in the more recent cohort and probably reÁects 
the more general acceptance of chemotherapy as 
part of standard therapy that occurred over the same 
time period. The increased magnitude of difference 
in survival for stage 3 patients in the latter cohort of 
patients is likely to reÁect the improved co-ordinated 
use of synchronous chemo-radiotherapy programs. A 
greater improvement in survival observed for females 
between the 2 cohorts may be related to gender 
differences in tumour biology resulting in variations 
in response to chemotherapy. A signiÀcant proportion 
of good PS patients still did not receive chemotherapy 
and reasons why such patients don’t ever receive 
potentially beneÀcial therapy need to be explored. 
Keywords: Chemotherapy, outcomes, Advanced 
stage NSCLC
A revised/updated abstract may be included in 
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Background: Recent clinical trials have shown 
extremely high response rates, ranging from 55% 
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subgroup(14.0m vs 9.3m,P=0.042)and the taxanes 
subgroup (18.5m vs 7m,P=0.01).
Conclusion: XRCC3 gene Polymorphisms may play 
different roles in predicting the efÀcacy of platinum-
based doublet chemotherapy according to different 
chemotherapy regimen, which warrant further 
prospective large-scale study. 
Keywords: X-ray repair cross-complementing 
group 3, Polymorphisms, Xeroderma pigmentosum 
group D, Non-small cell lung cancer, Chemotherapy, 
Polymorphisms
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: Monotherapy with a third generation 
anticancer agent has been regarded as the standard 
therapy for elderly patients with advanced non-
small-cell lung cancer (NSCLC). However, it 
is unclear whether elderly patients with a good 
performance status can tolerate platinum-doublet 
chemotherapy like younger patients. 
Methods: A combination phase I/II study was 
conducted in chemo-naive elderly patients with 
NSCLC to establish the toxicity and maximum 
tolerated dose (MTD) and to investigate the 
antitumor activity of carboplatin (CBDCA) plus 
gemcitabine (GEM). GEM was infused on days 1 
and 8, and CBDCA on day 1 every 3 weeks. 
Results: Seventy-Àve patients (phase I study; 26 
patients) were enrolled. The most frequent toxicities 
were hematological, especially thrombocytopenia. 
Three of three patients experienced a dose-limiting 
low rate of radiological response suggests that in 
our tested population, the actual response rate is 
signiÀcantly lower than reported in the literature. 
Epidemiologic, pharmacogenetic and/or molecular 
mechanisms of resistance need to be explored to 
explain these differences. 
Keywords: Advanced NSCLC, EGFR mutation, 
geÀtinib
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.046 ASSOCIATION OF XRCC3 AND 
XPD751 SNP WITH RESPONSE TO 
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Background: The purpose of this study was 
to investigate whether X-ray repair cross-
complementing group 3 alleles Thr241Met, 
xeroderma pigmentosum group D variant alleles 
Lys751Gln affected clinical outcomes of 1st line 
platinum-based chemotherapy in advanced non-small 
cell lung cancer patients.
Methods: 355 patients were enrolled into this 
study and their genotyping of X-ray repair cross-
complementing group 3 Thr241Met,xeroderma 
pigmentosum group D Lys751Gln were detected by 
the TaqMan assay plus the real time PCR method in 
theri peripheral blood lymphocytes. SPSS version 
17.0 was used to do the Ƶ2 and Kaplan-Meier 
survival analysis.
Results: The median age was 59.5 years old and 
68.5% of the patients were male. No relationship 
was found between the wild-type, heterozygous and 
homozygous polymorphic variants SNPs of XRCC3 
241, XPD751 and genders, ages, histology, smoking 
status. Progression free survival(PFS) and overall 
survival(OS) were similar between the patients 
with wild-type, heterozygous and homozygous 
polymorphic variants of XRCC3 and XPD751. 
However, in the subgroup analysis, OS of the 
patients with XRCC3 C/C was signiÀcantly longer 
than the patients with C/T or T/T in the vinorelbine 
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Methods: We reviewed records for 70 consecutive 
patients age 70 or older with metastatic NSCLC 
treated at our center from January 2008 through 
December 2009 with Àrst-line cytotoxic 
chemotherapy. The CGA-derived 11-item metric was 
modiÀed to 9 items (age >72, pre-existing anemia, 
creatinine clearance <34, full dose chemotherapy 
planned, combination chemotherapy planned, falls, 
needing assistance with medications, impaired 
hearing, and difÀculty walking) for which most data 
were available for our cohort. Scores were generated 
and risk categories were recalibrated based on our 
modiÀcations. 
Results: Patient characteristics: median age 75 (range 
70-92); median Karnofsky performance status (KPS) 
80% (range 60-90%); dependent in activities of daily 
living (ADLs) 6% and instrumental ADLs (iADLs) 
9%. Treatment: 80% doublet therapy (64% platinum 
doublet); 40% completed 4 cycles without dose 
reduction. Toxicity: 44% hospitalized; 6% grade 4 
hematologic toxicity; 39% grade 3/4 non-hematologic 
toxicity. KPS was not associated with toxicity or 
hospitalization. Dependence in ADLs and dependence 
in iADLS were associated with shorter survival 
(p<0.001, p=0.02). Doublet therapy had a higher risk 
of hospitalization (p=0.02) while platinum doublets 
had improved median survival (11 vs 8 months, 
p=0.005), but this is confounded by patient selection. 
Metric scores designated 22 low-, 35 intermediate-, 
and 13 high-risk patients. The incidence of grade 
3 hematologic toxicity (18%, 31%, 46%), grade 4 
hematologic toxicity (5%, 6%, 8%), and grade 4 
non-hematologic toxicity (0%, 6%, 15%) increased 
across the risk groups, although non-signiÀcantly. 
Hospitalization (55%, 34%, 38%) and the inability to 
complete 4 cycles of treatment without dose reduction 
did not (59%, 57%, 69%). 
Conclusion: Many in this cohort experienced 
signiÀcant toxicity and 44% required hospitalization, 
but others tolerated therapy well and possibly derived 
beneÀt from platinum treatment. The modiÀed CGA-
derived metric used in this analysis showed trends 
towards a predictive effect for some relative rates 
of toxicities but not for others in this retrospective 
cohort. This is likely because the metric was derived 
from patients with a wide spectrum of malignancies in 
various stages of their treatment and, therefore, may 
not be as accurate for this speciÀc group of patients. 
Therefore, we plan to prospectively assess a version of 
the CGA in metastatic lung cancer patients to identify 
the factors most predictive of chemotherapy doublet 
tolerance in this population. 
toxicity at dose level 3:1000 mg/m2 GEM with AUC 
5 CBDCA (MTD), three of eight at dose level 2b: 
800 mg/m2 GEM with AUC 5 CBDCA, and one of 
seven patients at level 2a: 1000 mg/m2 GEM with 
AUC 4 CBDCA (recommended dose). In the phase 
II study, the overall response rate was 22.2% and the 
median overall survival time was 14.2months. 
Conclusion: Although the recommended dosage 
is restricted to a lower level compared to younger 
patients, combination therapy using CBDCA with 
GEM is tolerable and promising for elderly patients 
with advanced NSCLC. 
Keywords: phase I/II study, Carboplatin, 
gemcitabine, elderly patients
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P3.048 CAN WE PREDICT TOXICITY 
IN PATIENTS OVER 70 YEARS OLD 
TREATED WITH CHEMOTHERAPY FOR 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)?
Marjorie G. Zauderer1, Camelia S. Sima2, Beatriz 
Korc-Grodzicki3, Mark G. Kris3, Lee M. Krug4 
1Thoracic Oncology Service, Memorial Sloan-
kettering Cancer Center/United States Of America, 
2Epidemiology And Biostatistics, Memorial Sloan-
kettering Cancer Center/United States Of America, 
3Medicine, Memorial Sloan-kettering Cancer Center/
United States Of America, 4Thoracic Oncology, 
Memorial Sloan-kettering Cancer Center/United 
States Of America
Background: A recent randomized trial showed 
that patients over 70 years old with advanced lung 
cancer achieved superior survival but experienced 
more hematologic toxicity with platinum doublet 
therapy compared to single-agent therapy (Quoix et 
al., ASCO 2010). Clearly, not all elderly can tolerate 
this treatment. We need metrics to identify appropriate 
patients for doublet chemotherapy. A cancer-speciÀc 
geriatric assessment (CGA) is in development (Hurria 
et al., ASCO 2010), but no deÀnitive predictive metric 
has been established and none has been studied in 
speciÀc sub-populations. To help reÀne and tailor 
a metric for prospective study in lung cancer, we 
retrospectively evaluated the ability of a modiÀed 
version of the CGA derived metric to predict toxicities 
among elderly patients who received Àrst-line 
chemotherapy for metastatic NSCLC. 
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good performance status (KPS >70), and 39% had 
a solitary brain metastasis on a CT or MRI scan. 
At baseline, whilst 22% of patients reported no 
moderate or severe problems, the remaining 78% 
reported a wide range of problems, most commonly 
tiredness (47%). 80% of patients received the 
full course of WBRT, though 11 (15%) patients 
experienced rapid progression and did not begin 
WBRT. The average daily dose of dexamethasone 
throughout the study was 6 mg in both arms. The 
average QALY was 30 days in the OSC alone group, 
and 31 days in the OSC+WBRT group. Median 
survival was 7.3 weeks for patients receiving OSC 
alone, compared to 7.0 weeks for those receiving 
OSC+WBRT. Treatment with WBRT did not appear 
to have an obvious effect on QoL. 
Conclusion: These data provide preliminary 
evidence that omitting WBRT is not detrimental to 
this group of patients. They are not deÀnitive results 
but provide a strong rationale for the trial continuing, 
to answer this longstanding clinical question. 
Recruitment is improving since the data release. 
Keywords: supportive care, Non-small cell lung 
cancer, Whole Brain radiotherapy, Quality Adjusted 
Life Years
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P3.050 DO BETA-BLOCKERS ALTER 
DYSPNEA AND FATIGUE IN ADVANCED 
LUNG CANCER? A RETROSPECTIVE 
ANALYSIS.
Paul Cameron1, Peter M. Ellis2, Greg R. Pond2, John 
R. GofÀn2 
1School Of Medicine, Queen’s University/Canada, 
2Faculty Of Health Sciences, Mcmaster University/
Canada
Background: Most patients with advanced lung 
cancer will suffer from dyspnea but there are 
multiple causes and the treatment options are limited. 
Cachexia, muscle weakness, and increased muscle 
receptor (ergoreceptor) feedback could increase 
ventilatory drive and thus contribute to both dyspnea 
and fatigue. The sympathetic component of this 
ventilatory pathway might be usefully interrupted by 
Keywords: Non-small cell lung cancer, geriatric, 
Chemotherapy
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P3.049 QUALITY OF LIFE AFTER 
TREATMENT FOR BRAIN METASTASES: 
INTERIM DATA FROM THE MRC 
QUARTZ CLINICAL TRIAL.
Rachael Barton1, Paula Mulvenna2, Corinne Faivre-
Finn3, Paula Wilson4, Cheryl Pugh5, Matthew 
Nankivell6, Ruth Langley6 
1Queens Centre For Oncology & Haematology, 
Castle Hill Hospital/United Kingdom, 2Oncology, 
Northern Centre For Cancer Care/United Kingdom, 
3The Christie NHS Foundation Trust/United 
Kingdom, 4Bristol Oncology And Haematology 
Centre/United Kingdom, 5Cancer Division, MRC 
Clinical Trials Unit/United Kingdom, 6MRC Clinical 
Trials Unit/United Kingdom
Background: QUARTZ addresses the longstanding 
clinical question; what is the role of whole brain 
radiotherapy (WBRT) in the treatment of patients 
with non-small cell lung cancer (NSCLC) and 
inoperable brain metastases. All patients receive 
steroids and optimal supportive care (OSC), and are 
randomised to WBRT or not. The trial’s primary 
endpoint is quality adjusted life years (QALYS), 
reÁecting the importance of quality of life (QoL) as 
well as survival in this very poor prognosis patient 
group. It is designed to assess whether OSC alone is 
non-inferior to OSC+WBRT, with a non-inferiority 
margin of 1 week in QALYS seen as clinically 
important. Recruitment started in March 2007 with 
a target of 534 patients. Despite widespread support 
from 76 UK and Australian centres, recruitment 
was slower than anticipated and the trial was under 
threat of closure. An issue contributing to the poor 
recruitment was thought to be the lack of preliminary 
data supporting the question being evaluated. 
Methods: The Trial Steering Committee agreed to 
a data release relating to the Àrst 151 randomised 
patients. They were unaware of the results at 
the time, Data were analysed and presented 
to participating centres, in order to provide 
investigators with further information upon which to 
base trial decisions and discussions. 
Results: 60% of patients were male, the median age 
was 67 years (range 38 years - 85 years), 50% had 
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P3.051 PATTERS AND COST OF 
MANGEMENT OF METASTATIC 
NON-SMALL CELL LUNG CANCER 
(NSCLC) AFTER COMPLETION 
OF CHEMOTHERAPY WITH THE 
INTRODUCTION OF ERLOTINIB.
Sri Navaratnam1, Bosu Seo2, Grace Musto3, Ricardo 
Prayag4, Ketan Badiani5, Julia Witt6 
1Medical Oncology And Haematolgoy, Cancercare 
Manitoba/university Of Manitoba/Canada, 
2Division Of Continuing Medical Education, 
University Of Manitoba/Canada, 3Epidemiology & 
Cancer Registry, Cancercare Manitoba/Canada, 
4Cancercare Manitoba/Canada, 5Manitoba Insitutie 
Of Cell Biology, Cancercare Manitoba/Canada, 
6University Of Manitoba/Canada
Background: We previously published the 
population- based patterns and cost of management 
of metastatic NSCLC after completion of 
chemotherapy until death, prior to the introduction 
of erlotinib in the treatment of NSCLC (Lung cancer 
2010, 70; 110). The current study was undertaken to 
investigate the above in patients who also received 
erlotinib. 
Methods: Metastatic NSCLC patients, who were 
approved for erlotinib in Manitoba between June 
2006 and March 2009, were selected. Manitoba 
cancer registry (MCR) and chart review were used 
to capture the information on treatment and clinical 
outcome. Service utilization information and direct 
cost information were extracted from the MCR, the 
Physicians Claims, the Hospital Discharge database, 
and the Drug Program Information Network. 
Results: We identiÀed 71 NSCLC patients treated 
with erlotinib in the study period. Of these patients, 
54% were male, 14% were Asian, and 70% were 
either current or ex-smoker. Most of the patients 
received erlotinib as either second line (42%) or 
as third line (48%) treatment. The median survival 
was 40.1 weeks from the last date of the last cycle 
of chemotherapy (39.3 for males; 52.1 for females). 
Each person on average had 33.2 medical claims 
(29.8 for males; 36.2 for females) or 90 medical 
claims per 100 person week. Among males, those 
aged 65 years and older had the most claims (38.9), 
while among females, the most claims were observed 
in the age group less than 55 years old (40.0). The 
patient cohort had a total of 100 hospitalizations 
beta-blockers. This retrospective review assessed the 
association between beta-blocker use and dyspnea 
and fatigue in a regional tertiary cancer centre. 
Methods: An ethics approved review was 
conducted of new patients with stage III-IV non-
small lung cancer (NSCLC) or any small cell lung 
cancer (SCLC) seen from July 2007 to June 2008. 
Data were abstracted for clinical characteristics, 
comorbidity, beta-blocker use, and pre-treatment 
Edmonton Symptom Assessment System (ESAS) 
dyspnea and fatigue scores. Sample size was 
calculated to have an 80% power to detect a 1.5 point 
difference (0.5 standard deviations) on the 10 point 
ESAS scale using a two-sided, two-sample t-test. 
Results: There were 348 patients screened and 
202 eligible for inclusion. Reasons for ineligibility 
included: stage I-II NSCLC (n=52) and not having 
completed ESAS (n=94). Median age was 67, 
55.4% of patients were female, 18.8% had chronic 
obstructive pulmonary disease (COPD), and 
5.9% had active coronary artery disease. Median 
hemoglobin was 129. Thirty-eight patients (18.8%) 
were taking beta-blockers. Over 60% of patients 
scored 4/10 or higher on their dyspnea and fatigue 
scores. Mean dyspnea / fatigue scores were 5.05 
/ 5.24 for patients taking beta-blockers and 4.94 / 
5.11 for patients not taking beta-blockers, which 
was not statistically different (p-value = 0.89 for 
dyspnea, 0.93 for fatigue). Dyspnea and fatigue were 
moderately associated (Spearman rho=0.38, p < 
0.001). Multivariate models showed that COPD was 
associated with increased dyspnea and fatigue and 
anemia was associated with increased fatigue, but 
beta-blockers did not alter ESAS scores. Recorded 
dosages of beta-blockers were low; 29 of 38 patients 
taking a beta-blocker had their dosage recorded, and 
28 of these were taking a dose representing less than 
half of the daily maximal dose. 
Conclusion: Dyspnea and fatigue are common in our 
patient population at the time of Àrst consultation. 
COPD and anemia appear to contribute to these 
symptoms. No association between beta-blocker 
use and dyspnea or fatigue scores was observed. 
Given the limitations of this retrospective study, 
prospective research into the impact of beta-blocker 
use is warranted. 
Keywords: Lung cancer, dyspnea, fatigue, beta-
blockers
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Results: 40 patients were enrolled. M:F 12:28, 
mean age was 60+/-12 years; ECOG PS for 35 
patients was 1. All patients were staged 3B/4. All 
40 patients had been treated with a TKI: 5 patients 
received geÀtinib and 35 received erlotinib. 8 
received TKI 1st line, 19 2nd line, and 13 3rd/4th 
line. There was no difference in CRP when stratiÀed 
by line. Best response to TKI was NP in 21 patients 
and PD in 16 patients. The mean CRP value was 
22.25 (SEM 5.96) among those who were NP and 
56.6 (SEM 20) in those who had PD. Of the 21 
patients who were NP, 11 had CRP 10mg/L and 10 
had CRP >10mg//L. Of the 16 patients who had PD, 
6 had CRP 10mg/L and 10 had CRP >10mg//L. 
Median time to progression on TKI was 13.2 mo for 
CRP 10mg/L, 2.1 mo for CRP >10 mg/L (p=0.006). 
CRP: n=40 Median Survival (months) ±SE 95% CI p-value 
10mg/L (n=17) 30.9±6.5 18.3-43.6 0.005 
>10 mg/L (n=23) 4.9.±3.5 0.0-11.7 
Overall 12.4±5.3 2.0-22.8 
Conclusion: In our retrospective analysis of patients 
with an EGFR mutation treated with TKI, elevated 
CRP was associated with a worse outcome in terms 
of median time to progression and median survival. 
Large prospective studies are required to conÀrm 
these results.
Supported by: The Mona Zavalkoff Fund for 
Pulmonary Oncology
Keywords: Response, NSCLC and EGFR, CRP, TKI
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P3.053 A PHASE I STUDY OF 
PACLITAXEL, CARBOPLATIN AND 
YM155 (SURVIVIN SUPPRESSOR) IN 
SUBJECTS WITH SOLID TUMORS
Ronan J. Kelly1, Arun Rajan2, Guinevere Chun2, 
Ariel Lopez-Chavez2, Giuseppe Giaccone2 
1Thoracic Oncology Branch, National Cancer 
Institute/United States Of America, 2National Cancer 
Institute/United States Of America
Background: To determine the maximum-
tolerated dose (MTD) and to assess the safety, 
pharmacokinetics, and preliminary evidence of 
antitumor activity of YM155 (Y), a small-molecule 
selective survivin suppressant, administered in 
and 2.7 hospitalizations per 100 person weeks as 
compared to 207 and 7.0 before the introduction of 
erlotinib respectively. 
Conclusion: Patients who were treated with erlotinib 
utilized less medical services including hospital 
admission, which has major impact on the overall 
management cost as compared to our previous 
published study population (80% of $10, 805). This 
may offset the cost of erlotinib and may possibly 
lead to cost saving. 
Keywords: erlotinib, targeted therapy, Lung cancer, 
Cost
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.052 INFLUENCE OF BASELINE 
INFLAMMATORY MARKERS ON THE 
RESPONSE TO TKI AND OVERALL 
SURVIVAL IN NSCLC
Andrew Rabinovitch1, Goulnar Kasymjanova1, 
Chantal Robitaille1, Jason Agulnik1, Carmela Pepe1, 
David Small1, Victor Cohen2 
1Pulmonary Oncology, Jewish General Hospital/
Canada, 2Oncology, Jewish General Hospital/
Canada
Background: Mutations of the epidermal growth 
factor receptor (EGFR) gene have been identiÀed in 
non-small cell lung cancer specimens from patients 
responding to EGFR tyrosine kinase inhibitors 
(TKI). However, clinical resistance to TKI is 
commonly observed regardless of mutation status. 
There is evidence that resistance can be caused by 
secondary mutations (EGFR T790M) and MET 
ampliÀcation. A more recently described mechanism 
involves inÁammation-driven IL-6 overproduction. 
We hypothesize that CRP is a marker of impaired 
TKI sensitivity possibly through the TGF-ơ IL-6 axis 
pathway in EGFR mutation positive patients.
Methods: We retrospectively reviewed the charts of 
all NSCLC patients with an EGFR mutation newly 
diagnosed between December 2003 and June 2010. 
Patients with CRP measurements prior to treatment 
with TKI therapy in any line were included. Response 
was evaluated by chest CT using Recist 1.1 and 
categorized as progression (PD) or non-progression 
(NP). Patients were categorized based on CRP value 
as 10mg/L and >10mg/L. We investigated the 
association between baseline CRP and response to 
TKI, time to progression, and survival.
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General Hospital/Japan, 3Respiratory Medicine, 
Ashikaga Red Cross Hospital/Japan, 4Sanokousei 
General Hospital/Japan, 5Saitama Social Insurance 
Hospital/Japan
Background: Incidence of elderly patients with 
advanced non-small cell lung cancer (NSCLC) 
is increasing, however the treatment for elderly 
patients is still waiting for the best answer. Although 
several studies had suggested the advantage of 
chemotherapy with platinum doublet for elderly 
patients with advanced NSCLC (e.g. Asco2010 
abstract 2), the application of platinum doublet to the 
elderly is still controversial. To evaluate the efÀcacy 
and tolerability of combination chemotherapy with 
biweekly carboplatin (CBDCA) and paclitaxel 
(PTX) for elderly patients with advanced NSCLC, 
we conducted a multicenter non-randomized open 
label phase II trial. 
Methods: Eligibility criteria were as follows; 
histologically or cytologically proven NSCLC, aged 
70 years and older, ECOG performance status (PS) 
of 0 to 2, clinical stage IIIB and IV, chemotherapy 
naïve, and adequate organ function. Symptomatic 
brain metastases were not allowed. Patients received 
CBDCA (AUC=2.5) and PTX (90 mg/m2) on day 1 
and 15 every 4 weeks for up to 6 cycles, until disease 
progression or intolerable toxicity. The primary 
endpoint was overall response rate (ORR), and the 
secondary endpoints were overall survival (OS), 
progression-free survival (PFS) and tolerability.
Results: 47 patients (median age 77 years old, range 
70-85) were enrolled. 36 were male and 36 patients 
were stage IIIB. PS 0/1/2 were 19/26/2, respectively. 
The median number of treatment cycle was 3 (1-
6). No complete response and 10 partial responses 
were observed, giving an ORR of 21.3% (95% CI: 
9.6-33.0%). Twelve patients (25.5%) had stable 
disease and 14 (23.4%) had progressive disease as 
the best response and 11 had not evaluable (2 due to 
death, 3 due to adverse event, 5 due to withdrawal 
/ missing). The overall disease control rate was 
46.8% (95% CI: 32.5-61.1). Median PFS was 4.17 
month (95% CI: 2.18-6.16). Grade 3/4 hematological 
toxicities were neutropenia (28%), leucopenia 
(19%), anemia (11%) and no thrombocytopenia. 
Grade 3 non-hematological toxicities were infusion 
reaction (2%), anorexia (2%), infection (13%), 
thrombosis (2%), fatigue (2%), diarrhea (2%) and 
gastrointestinal bleeding (2%). Although no grade 4 
non-hematological toxicity was observed, one patient 
died probably due to treatment-related interstitial 
combination with carboplatin (C) and paclitaxel (P). 
Methods: Patients with advanced malignancies who 
had received no more than one prior chemotherapy 
regimen received C (AUC6) and P (200mg/m2) 
followed by escalating doses of Y administered as 
a continuous intravenous infusion (CIVI) over 72 
hours in 21-day treatment cycles. 
Results: Twenty two patients (19 lung, 1 adenoid 
cystic, 1 angiosarcoma, 1 carcinoma of unknown 
origin) received 98 cycles of Y at six different dose 
levels from 3.6 to 12mg/m2 with standard doses of C 
and P. Treatment with Y was well tolerated, grade 3/4 
toxicities consisted of grade 3 neutropenia (41%) and 
thrombocytopenia (14%) and grade 4 neutropenia 
(41%). Non hematological toxicities consisted of 
grade 3 hypophosphatemia (18%), hyponatremia 
(14%), hypokalemia (9%) and grade 4 hyponatremia 
(9%). Grade 3 amylase and grade 3 pneumonitis 
during cycle 1 were considered dose limiting at 
the 12mg/m2 dose. The MTD was determined as 
10mg/m2 and the median steady-state concentration, 
clearance, volume of distribution, and terminal 
elimination half-life of YM155 were 16.2 ng/mL, 
8.6 L/h/m2, 226 L/m2, and 17 hours, respectively. 
Of 16 evaluable patients, 5 (31%) achieved a partial 
response and 11 (69%) achieved stable disease. 
Conclusion: The combination of Y (10mg/m2/d 
72 hours CIVI) administered with C and P every 3 
weeks exhibited a favorable safety proÀle. A phase II 
trial as Àrst line therapy in patients with stage IV non 
small cell lung cancer is ongoing. 
Keyword: survivin
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P3.054 BIWEEKLY AND 
CARBOPLATIN(CBDCA) AND 
PACLITAXEL(PTX) AS FIRST-LINE 
IS HOPEFUL THERAPY IN ELDERLY 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER: 
PRELIMINARY RESULTS OF A PHASE II 
STUDY
Hideki Terai1, Kenzo Soejima1, Morio Nakamura2, 
Katsuhiko Naoki1, Hideo Watanabe1, Ichiro 
Kawada1, Ichiro Nakachi1, Hiroyuki Yasuda1, Souhei 
Nakayama3, Ryousuke Satomi4, Satoshi Yoda5, 
Shinnosuke Ikemura1, Takashi Sato1, Kouichirou 
Asano1 
1Pumonary Medicine, Keio University/Japan, 2Eiju 
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February 2008 and October 2010. Median age was 
61 years (range 42-75) with 26% >65 years. M:F 
ratio was 23:12 and ECOG performance status 
was 0 (n=11) or 1 (n=24). Median predicted FEV
1
 
was 81% (41-94%). Tumour histologies comprised 
adenocarcinoma (n=7), squamous cell carcinoma 
(n=21), undifferentiated carcinoma (n=4) or was 
not speciÀed (n=3). TNM staging (6th edition) at 
presentation was: T2N2=3 (9%), T2N3=2 (6%), 
T3N2=6 (17%), T4N0=12 (33%), T4N2=10 (29%), 
T4N3=2 (6%). Median planning target volume 
was 464.3 cm3 (284.1-1064.3) and median V
20
 was 
30% (10.5-35.3). All 35 patients received cCTRT: 
33 patients (94%) received full dose concurrent 
chemotherapy and 32 patients (91%) received the 
planned dose of 66Gy (range 56-66 Gy). Number 
of patients who received pemetrexed: cycle 1=25 
(71%), cycle 2=21 (60%), cycle 3=16 (46%). 
Reasons for omitting cycle 1 pemetrexed were as 
follows: 7 patients had not recovered from cCTRT-
related adverse events, 2 patients withdrew and 
1 patient died on study. Median duration from 
completion of cCTRT to cycle 1 pemetrexed was 
32 days (19-41). Oesophagitis and pneumonitis 
were not assessable for one patient. 10 patients 
experienced grade 3 oesophagitis (29%) and 1 
patient grade 4 (3%). Median duration grade 3/4 
oesophagitis was 10 days (2-24). Median time from 
treatment commencement to onset of maximum 
grade oesophagitis was 36 days (8-82). 1 patient 
experienced grade 3 pneumonitis (3%), no grade 
4. 8 patients experienced grade 3 fatigue (23%), 
no grade 4. Two patients suffered grade 4 venous 
thromboembolic events. 2 patients with central 
disease suffered grade 5 haemoptysis. The results of 
1 year survival, progression-free survival and late 
toxicity are awaited. 
Conclusion: The addition of consolidation 
pemetrexed following cCTRT for stage III lung 
cancer does not appear to worsen the incidence 
or severity of treatment-related pneumonitis or 
oesophagitis in a population of patients with large 
planning target volumes. However, the full dose of 
consolidation therapy was not feasible in half (54%) 
of the patients. This study highlights the challenges 
of adding further systemic therapy to cCTRT in 
locally advanced NSCLC, and will be of value to 
inform the design of future trials of consolidation 
treatment in this population. 
Keywords: chemoradiotherapy, Non small cell lung 
cancer, Concurrent, NSCLC
pneumonitis. The adverse events were relatively mild 
and manageable. 
Conclusion: The combination of biweekly CBDCA 
(AUC=2.5) and PTX (90 mg/m2) was well tolerated 
and was effective for elderly patients with advanced 
NSCLC. (This study was registered at UMIN 
000001328)
Keywords: paclitaxel, biweekly, elderly people, 
Carboplatin
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P3.055 INITIAL TOXICITY AND 
COMPLIANCE EVALUATION FOR 
CONSOLIDATION PEMETREXED 
FOLLOWING CONCURRENT 
CHEMORADIOTHERAPY (CCTRT) IN 
STAGE III NON-SMALL CELL LUNG 
CANCER (NSCLC): A PHASE II TRIAL.
Jonathan Helbrow1, Corinne Faivre-Finn1, Neil 
Bayman1, Paul A. Burt1, Abbas Chittalia1, Maggie 
A. Harris1, Helen Lander1, Lip W. Lee1, Laura 
Pemberton1, Hamid Sheikh1, Paul Taylor2, Linda 
Ashcroft3, Fiona Blackhall4 
1Clinical Oncology, The Christie NHS Foundation 
Trust/United Kingdom, 2Medical Oncology, The 
Christie NHS Foundation Trust/United Kingdom, 
3The Christie NHS Foundation Trust/United 
Kingdom, 4Department Of Medical Oncology, The 
Christie NHS Foundation Trust/United Kingdom
Background: cCTRT is the standard treatment 
for good performance status stage III NSCLC 
and is associated with 5 year survival of 20-25% 
. Strategies to improve on the efÀcacy of cCTRT 
with cisplatin/etoposide are required. Here we 
evaluate the compliance and acute toxicity of cCTRT 
followed by consolidation pemetrexed. 
Methods: This was a single-institution phase II 
study. Treatment comprised cisplatin (50 mg/m2 days 
1, 8, 29, 36), etoposide (50 mg/m2 days 1-5 and 29-
33) and concurrent thoracic radiotherapy starting on 
day 1 chemotherapy (66 Gy in 33 daily fractions; 
3D conformal radiotherapy or IMRT) followed by 
consolidation pemetrexed (500 mg/m2 on days 71, 92 
and 133). The primary endpoint was 1 year survival. 
Secondary endpoints were progression-free survival, 
acute/late toxicity (CTCAE v3.0), compliance and 
response to treatment. 
Results: 35 patients were recruited between 
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and 12.00±1.98 nmoL. The mean levels of BAP 
before and after treatment were 21.88±8.37 U/L 
and 20.95±6.58U/L. Chemotherapy had tendency 
to decrease serum NTX levels and did not reduce 
BMD. The early increases of NTX are reported in 
the glucocorticoid induced osteoporosis, however 
glucocorticoids used with chemotherapy for the 
purpose of anti-emesis and anti-allergy did not 
increase NTX levels in our study. 
Conclusion: In this study, there was no correlation 
between the use of G-CSF with NSCLC 
chemotherapy, and bone density or bone metabolism 
markers. However, there was no increase in the 
risk of loss of BMD in NSCLC patients even if we 
repeated chemotherapy in a lung cancer patient. 
Keyword: G-CSF BMD
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P3.057 PALLIATIVE MANAGEMENT IN 
LOCALLY ADVANCED/METASTATIC 
NON SMALL CELL LUNG CANCER IN 
NON SMOKER INDIANS.
Neeraj Jain, Meena Sudan 
Radiation Oncology, Sri Guru Ram Das Institute Of 
Medical Sciences/India
Background: Non small cell Lung cancer is a 
rare disease in Punjab state of North India. This 
is attributable to smoking constraints because of 
religious restrictions among Sikh community which 
accounts for Àfty percent of state population. The 
prime occupation in the state is agriculture and the 
industries are few. Most of the patients belong to 
poor socioeconomic status and present at locally 
advanced and even metastatic stage. 
Methods: 22 patients were treated during January 
2009 to July 2010. All were non smokers with non 
squamous histopathology. 17 were male and 5 female 
in age group of 55-75 years. All had EGFR mutation 
. 16were locally advanced and 6 had metastatic 
disease at presentation. Palliative Radiotherapy for 
Haemoptysis, SVC obstruction and Pain in case of 
Pancoast tumors was given to 19 patients. 30Gy in 
10 fractions @ Àve fractions per week. Oral geÀtinib 
250 mg OD was given to all patients. 
Results: Results were evaluated at 3 months and 6 
months. There was Partial response in 8 patients. 8 
had stable disease. 6 patients had progression out 
of which 2 progressed at Ist evaluation and 4 at 2nd 
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P3.056 RELATIONSHIP BETWEEN THE 
G-CSF AND BONE METABOLISM IN 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER PATIENTS
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Norihiko Funaguchi1, Junki Endo3, Hirotoshi Iihara4, 
Takuma Aoyama4, Shinya Minatoguchi2 
1Second Department Of Internal Medicine, Gifu 
Univarsity School Of Medicine/Japan, 2Second 
Department Of Internal Medicine, Gifu University 
School Of Medicine/Japan, 3Gifu University 
Sclool Of Medicine, Seconddepartment Of Internal 
Medicine/Japan, 4Department Of Phamacy, Gifu 
University Hospital/Japan
Background: Although the granulocyte colony-
stimulating factor (G-CSF) is widely used for 
neutropenia with cancer chemotherapy, the 
reaction of the neutrophil at the time of G-CSF 
medication, has large individual difference, and we 
cannot predict the reaction. The relation between 
myelosuppression with chemotherapy and bone 
density or bone metabolism is also unclear. 
Methods: Stage IIIB or IV chemo-naive non-
small cell lung cancer (NSCLC) patients were 
eligible. Patients received chemotherapy with 
platinum-based doublets. We measured serum bone 
metabolism markers (N-terminal telopeptide of type 
I collagen:NTx, bone alkaline phosphatase:BAP) 
before treatment and after each course of the 
chemotherapy. We measured lumbar-vertebrae 
bone mineral density (BMD) by dual-energy 
x-ray absorptiometry before treatment and after 
3 courses of the chemotherapy. We evaluated 
the relation between BMD or bone metabolism 
markers, neutropenia with chemotherapy and 
G-CSF. Furthermore, the relation of glucocorticoids 
used with chemotherapy, and bone density or bone 
metabolism markers was also considered. At the time 
of neutropenia , G-CSF (Àlgrastim) was administered 
until recovering from myelosuppression . The cases 
required the radiotherapy to bone metastasis and 
treatment with bisphosphonates were excepted. 
Results: Ten patients were enrolled in this study 
. Seven patients completed the treatment. The 
average of BMD before and after treatment were 
both 1.04±0.14 g/cm2. The mean levels of NTX 
before and after treatment were 17.15±6.41 nmoL 
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preserved functional status, the standard therapy 
is a double agent platinum-based chemotherapy. 
Most patients who receive Àrst-line chemotherapy 
experience disease progression within 3 to 6 months 
of initiating therapy and the median survival time 
observed is 8 to 10 months. In this situation, there 
is a need to Ànd effective therapeutic regimen with 
an administration as simple as possible and the 
most favorable toxicity proÀle. The purpose of this 
trial was to evaluate the activity and feasibility of 
CBDCA together with NVBiv and NVBo. 
Methods: Patients with advanced NSCLC received 
NVBiv 25 mg/m² on D1 and NVBo 60 mg/m² on D8 
combined with CBDCA AUC5 on D1 every three 
weeks. In stage III, chemotherapy was followed 
by external radiotherapy. The outcomes include 
following: response, median overall survival (mOS) 
and median progression free survival (mPFS). 
Response was assessed by imaging techniques after 
4-6 weeks of treatment and was conÀrmed one 
month later by chest X-ray and/or CT scanning. 
The difference in response relative to baseline 
characteristics was determined using Pearson Chi-
square test. Differences in OS and PFS relative 
to baseline characteristics were evaluated for 
signiÀcance using Log-rank test. 
Results: 144 patients were treated: 117 men (81.2%) 
and 27 women (18.8%), median age 65 years. 
ECOG performance status at inclusion was PS 0 in 
33 (22.9%) patients, PS 1 in 99 (68.8%) and PS 2 
in 12 (8.3%) and patients. Most patients had stage 
IIIB 64 (44.4%) and stage IV NSCLC 76 (52.78%), 
only 4 (2.78%)pts were IIIA. Adenocarcinoma was 
conÀrmed in 32 patients (22.2%), squamous-cell 
carcinoma in 86 (59.7%) and other in 26 (18.1%). 
Complete response was conÀrmed in 1 (0.7%) 
patient, partial response in 68 (47.5%), stable disease 
in 47 (32.9%), 27 (18.9%) patients progressed, one 
patient (0.7%) was not evaluated. The regimen was 
well tolerated. Median cycles was 6, the dosage of 
NVB was without changes in 126 (87.5%) patients, 
the dosage of NVB was reduced in 14 (9.7%) and 
escalated in 4 (2.8%) patients. Major toxicities 
(Grade 3-4) were neutropenia in 45 (31.2%%), 
leucopenia in 22 (15.9%), anemia in 5 (3.5%), and 
thrombocytopenia in 3 (2.1%) patients. Febrile 
neutropenia was observed in 3 (12.1%) patients. The 
mOS was 14.2 moths and the mPFS 10.5 months. 
The differences between groups of pts according 
to PS (0+1 vs. 2) were statistically signiÀcant (p < 
0.001) better for patiens with PS 0+1. 
Conclusion: In this group of 144 non-selected 
evaluation. These were patients who presented with 
Metastatic disease. All the patients who had PR have 
had received palliative Radiotherapy. 
Conclusion: Radiotherapy followed by Oral 
GeÀtinib is an effective mode of palliation in locally 
advanced/ metastatic non squamous ,non smokers 
NSCLC . 
Keyword: GeÀtinib, Radiotherapy
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P3.058 INTRAVENOUS VINORELBINE 
(NVBIV) ON D1 SWITCH TO ORAL 
VINORELBINE (NVBO) ON D8 IN 
COMBINATION WITH CARBOPLATIN 
(CBDCA) AS FIRST LINE TREATMENT 
IN ADVANCED NON-SMALL LUNG 
CANCER (NSCLC) PATIENTS: FINAL 
RESULTS OF A PROSPECTIVE STUDY IN 
NONRANDOMIZED POPULATION
Jana Skrickova1, Jana Keilova2, Tereza Janaskova3, 
Vitezslav Kolek4, Marcela Tomiskova5, Lenka 
Babickova5, Bohdan Kadlec5, Yvona Grygarkova6, 
Jiri Bartos7, Jan Chalupa7, Jaromir Roubec8, Tomas 
Trason9, Jiri Gruna10, Jana Svecova11, Helena 
Coupkova12 
1Department Of Respiratory Diseases And 
Tb, University Hospital Brno/Czech Republic, 
2Department Of Respiratory Diseases, Kladno 
Hospital/Czech Republic, 3Department Of 
Respiratory Diseases, Vitkovice Hospital/Czech 
Republic, 4University Hospital Ostrava/Czech 
Republic, 5Department Od Respiratory Diseases 
And Tb, University Hospital Brno/Czech Republic, 
6Depratment Of Respiratory Diseases And Tb, 
University Hospital Olomouc/Czech Republic, 
7Liberec Hospital/Czech Republic, 8Department 
Od Respiratory Diseases And Tb, University 
Hospital Ostrava/Czech Republic, 9Department Od 
Oncology Kromeriz/Czech Republic, 10Departmen Of 
Oncology Novy Jicin/Czech Republic, 11Department 
Of Oncology Tabor/Czech Republic, 12Department 
Of Oncology, Masaryk Memorial Institute/Czech 
Republic
Background: Lung cancer is the leading cause 
of cancer mortality in the Czech Republic. 
Approximately 80% of cases are NSCLC and 65% 
of patients have advanced disease at the time of 
diagnosis. For patients with advanced NSCLC and 
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pts, paclitaxel 11(18.0%) pts, vinorelbin 6 (9.8%) 
pts, pemetrexed 3 (4.9%) pts, and docetaxel 1 
(1.6%). Bevacizumab dose was 7.5mg/kg in 37 
(60.7%) pts and 15mg/kg in 24(39.3%) pts. The 
median of administered cycles of bevacizumab was 
8 (1-30). Median OS was 18.3 months (11.1-24.3 
months 95% CI), median TTP was 8.4 months (6.6 
– 11.2 months 95% CI). Objective response rate: 
CR 2(3%), PR 31 (53%), SD 23 (39%), PD 3 (5%). 
Grade 3/4 adverse events included neutropenia 
in 13 (21.3%) pts, leukopenia in 7 (11.5%) pts, 
thrombocytopenia in 6 (9.8%) pts and anemia in 
9 (14.8%). Grade 3/4 non hematologic adverse 
events included hypertension in 14 (23%) pts, 
gastrointestinal perforation in 1 (1.6%) pt, cardiac 
ischemia after 24 cycles of B which required 
surgical bypass in 1 (1.6%) pt, arterial thrombosis in 
1(1.6%) pt. In one patient pneumothorax grade 3 was 
observed due to cavitation of tumor after carboplatin, 
paclitaxel and B 15mg/kg. Cerebrovascular ischemia 
(stroke) was suspected in one patient, which died 
after Àrst cycle with disease progression. Common 
grade 1/2 adverse events included leukopenia, 
neutropenia, anemia, fatigue, hypertension, and 
epistaxis. We brieÁy refer a case of two subsequent 
gastrointestinal perforation in patient treated with 
cisplatin/carboplatin + docetaxel + B 7.5mg/kg and 
discuss the possible reasons. 
Conclusion: Adverse events in our local 
retrospective study were acceptable, the proÀle was 
similar to that in large studies E 4599 and AVAIL. 
From the more rare adverse events we have observed 
two subsequent GI perforations in one patient, 
cardiac ischemia after 24 cycles of B which required 
surgical bypass in one patient and pneumothorax due 
to tumor cavitation in one patient.
Keywords: gastrointestinal perforation, adverse 
events, bevacizumab
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P3.060 BRAIN METASTASIS REVEALING 
LUNG CANCER
Hanène L. Ben Salah1, Zaher Boudawara2, Mounir 
Frikha3, Ilhem Yengui3, Tahia Boudawara4, Jamel 
Daoud1 
1Radiotherapy, Habib Bourguiba’s Universital 
Hospital/Tunisia, 2Surgery, Habib Bourguiba’s 
Universital Hospital/Tunisia, 3Medical Carninology, 
Habib Bourguiba’s Universital Hospital/Tunisia, 
patients with advanced NSCLC treated with NVB-
CBDCA in Àrst line, switching from NVBiv to 
NVBo allows a more convenient and well tolerated 
treatment with evidence of high antitumour activity. 
This combination was active in all groups patients 
according histology (mOS 14,2 and mDFS 10,5 
months). Statistically signiÀcant better were the 
results in patients with PS 0+1. 
Keywords: vinorelbin, Advanced NSCLC, First line 
treatment
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.059 ADVERSE EFFECTS IN 
COMBINATION THERAPY WITH 
BEVACIZUMAB IN ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG 
CANCER – RETROSPECTIVE STUDY
Maria Cerna1, Peter Berzinec2, Peter Kasan3, 
Gabriela Chowaniecova2, Marian Martak3, Milada 
Vesela3, Iveta Jancokova4, Iveta Kuliskova5, Juraj 
Mazal6, Elena Kavcova5 
1Dept. Of Pneumology And Phtiseology, Slovak 
Medical University, University Hospital, Bratislava/
Slovak Republic, 2Specialized Hospital Of St 
Zoerardus Zobor, Nitra/Slovak Republic, 3University 
Hospital, Bratislava/Slovak Republic, 4Hospital, 
Bojnice/Slovak Republic, 5University Hospital, 
Martin/Slovak Republic, 6Faculty Hospital, Banska 
Bystrica/Slovak Republic
Background: Bevacizumab improves response rate 
(RR) , progression free survival (PFS) and overall 
survival (OS) when added to Àrst line paclitaxel/
carboplatin and RR and PFS when added to Àrst line 
cisplatin/gemcitabin for patients with advanced non 
squamous non-small cell lung cancer.
Methods: Retrospective analysis of data of patients 
treated for newly diagnosed advanced non-squamous 
non-small cell lung cancer with chemotherapy and 
bevacizumab at Àve institutions in Slovakia. Patients 
which began the treatment between 06/2007 and 
03/2010 were considered for this analysis.
Results: Included in the study were sixty one 
patients, median of age was 58(33-77) years, male 
were 34 (55.7%) female 27 (44.3%). Chemotherapy 
consisted of platinum (cisplatin or carboplatin) and 
another agent (gemcitabin, paclitaxel, pemetrexed, 
vinorelbin or docetaxel): cisplatin 37 (60.7%) pts, 
carboplatin 24 (39.3%) pts, gemcitabin 40 (65.6%) 
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P3.061 INDUCTION PEMETREXED 
AND CISPLATIN FOLLOWED BY 
MAINTENANCE PEMETREXED VS 
CARBOPLATIN-PACLITAXEL PLUS 
BEVACIZUMAB FOLLOWED BY 
MAINTENANCE BEVACIZUMAB: 
MULTICENTER RANDOMIZED 
PHASE III STUDY IN PATIENTS WITH 
ADVANCED NON-SQUAMOUS NON 
SMALL-CELL LUNG CANCER (NSCLC). 
PRELIMINARY DATA OF A QUALITY 
OF LIFE ORIENTED PHASE III TRIAL 
OF THE GOIM (GRUPPO ONCOLOGICO 
ITALIA MERIDIONALE)
Domenico Galetta1, Salvatore Pisconti2, Saverio 
Cinieri3, Vittorio Gebbia4, Giovanni Luigi 
Pappagallo5, Nicola Borsellino6, Angelo Nacci3, 
Michele Montrone2, Giuseppe Palomba7, Alessandro 
Morabito8, Giampiero Romano9, Daniele Rizzi1, 
Antonio Febbraro10, Giuseppe Colucci1 
1Medical Oncology, Giovanni Paolo Ii Oncology 
Institute/Italy, 2Medical Oncology, San Giuseppe 
Moscati Hospital/Italy, 3U.o.c. Oncology And Breast 
Unit, Perrino Hospital/Italy, 4Medical Oncology, 
“la Maddalena” Hospital/Italy, 5Biomedical 
Sciences Departement, Azienda Ulss 13/Italy, 
6Medical Oncology, Buccheri-la Ferla Hospital/Italy, 
7Medical Oncology, Casa Sollievo Della Sofferenza/
Italy, 8Thoracic Oncology, Pascale Cancer Center/
Italy, 9Medical Oncology, Vito Fazzi Hospital/Italy, 
10Medical Oncology, Fatebenefratelli Hospital/Italy
Background: In metastatic NSCLC, the role of 
chemotherapy has essentially a palliative approach 
with substantial similarities in terms of treatment 
efÀcacy and survival emerging over the years 
between the different systemic chemotherapy 
regimens used. More recently, other topics such 
as histotype, maintenance therapy and quality of 
life (QoL) have been explored to ameliorate this 
plateau. Cisplatin (C) plus Pemetrexed (P) and 
Carboplatin (Cb) in combination with Paclitaxel 
(T) and Bevacizumab (Be) represent two standards 
of care in patients (pts) with advanced Non Small-
Cell Lung Cancer (NSCLC) and Non-Squamous 
histotype (NS). P maintenance after chemotherapy 
(CT) confers further advantage in NS-NSCLC 
with respect to placebo. Quality of Life (QoL) 
may inÁuence the therapeutic choice if one of the 
4Anatomo-Pathology, Habib Bourguiba’s Universital 
Hospital/Tunisia
Background: To study epidemiological, clinical and 
therapeutic proÀle of lung cancer revealed with brain 
metastasis. 
Methods: During the period 1993-2006, twenty 
two patients having lung cancer revealed with 
brain metastasis were treated in Habib Bourguiba’s 
Universital Hospital of Sfax (Tunisia). The discovery 
of brain metastasis had incited to check up the 
disease extension and to start cerebral radiotherapy 
and chemotherapy. 
Results: The age of patients varied from 34 
to 73 years with a median age of 57.4 years. 
The sex ratio was 10. Symptoms revealing the 
disease were headache (20.5%), epileptic crisis 
(23.07%), hypertension syndroma (12.8%) and 
neurologic deÀcit (23.07%). All patients had 
radiological exploration (CT or MRI). Described 
lesions were numerous in 13 cases and single in 9 
cases The diagnosis of lung cancer was based on 
anatomopathologic exam after metastasectomy 
(50%), radiological appearance of brain lesions 
(36.3%) and on chest radiography before anesthesia 
(13.6%). Lung cancer was adenocarcinoma in 41% 
and epidermoid in 32% of cases. Metastasectomy 
followed by radiotherapy have been realized in 
54.5% of patients, 46.5% of patients had radiation 
alone Radiotherapy protocol was 30 Gy in 10 
fractions (59%) or 18 Gy in 6 fractions (40.9%) 
Chemotherapy was administrated in 9 cases Average 
survival was 5 months after diagnosis (1 to 29 
months) 
Conclusion: Brain metastasis constitutes a 
frequent circumstance of discovery of the lung 
cancer. Therapeutic decision must be taken 
within a multidisciplinary committee considering 
performance statute of the patient, his co morbidities 
and disease prognostic. Brain radiotherapy is 
standard treatment chemotherapy is controversial. 
Metastasectomy is reserved to single metastasis. 
The best survivals are observed in cases of single 
metastasis and using metastasectomy, brain 
radiotherapy and chemotherapy. In other cases the 
prognostic is very poor. 
Keyword: brain metastasis,lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.062 RANDOMISED EVALUATION 
OF STENTS TO OPEN RESTRICTED 
AIRWAYS IN PATIENTS WITH 
CENTRALLY PLACED NON-SMALL 
CELL LUNG CANCER (RESTORE - AIR)
James S. Myerson1, KoÀ Nimako1, Harpreet Ranu2, 
Brendan Madden2, Sanjay Popat3, Mary O’Brien1 
1The Lung Unit, Royal Marsden Hospital/United 
Kingdom, 2Cardiothoracic Medicine, St George’s 
Hospital/United Kingdom, 3National Heart And Lung 
Institute, Imperial College/United Kingdom
Background: A common cause of breathlessness in 
patients with lung cancer is malignant central airway 
obstruction. The deployment of an endobronchial 
stent can restore airway patency and improve 
breathlessness. This pilot RCT aimed to determine 
whether the deployment of a stent improves 
breathlessness and functional ability compared 
with standard palliative anticancer therapy alone in 
patients with advanced NSCLC. 
Methods: Patients with central airway obstruction 
were randomised to either an intervention group 
(rigid bronchoscopy and endobronchial stent 
insertion plus palliative anticancer therapy) or 
to a control group (palliative anticancer therapy 
alone). The primary endpoint of the study was the 
proportion of patients achieving a 50% improvement 
in the 6-minute walk distance (6MWD) at 2 weeks 
compared to their baseline assessment. Exploratory 
endpoints included change in 6MWD at day 15 and 
3 months, change in visual analogue scale (VAS) for 
breathlessness at day 15 and median survival. For 
the primary endpoint a 5% level of signiÀcance was 
used. For the exploratory end points a 1% level of 
signiÀcance was used. 
Results: See Tables 1 and 2 for the clinical 
characteristics and results of the patients in the two 
treatment groups. Table 1: Clinical Characteristics in 
Treatment Groups 
Characteristic Intervention arm N=10 Control arm N=11
Age
Mean (Range) 66 (58,73) 66 (57, 75)
Sex
M:F 7:3 6:5
Histology 
Adenocarcinoma 1 (10%) 3 (27%) 
Squamous cell 7 (70%) 6 (55%) 
Undifferentiated carcinoma 2 (20%) 2 (18%)
associations showed to be better tolerated and 
favoured an amelioration of QoL. its effect on 
symptom relief and QoL is of the utmost importance 
Thus, we propose a study comparing CP followed 
by P maintenance versus CbTBe followed by Be 
maintenance. 
Methods: Since January 2010 chemonaive pts with 
NS advanced NSCLC, age < 70 years, stage IIIB/IV 
according 7th TNM Edition, ECOG PS 0-1, adequate 
bone marrow reserve, renal , hepatic and coagulative 
function and at least 1 uni-dimensionally measurable 
lesion according RECIST criteria were enrolled. 
Pts were allocated 1/1 to the following arms: (A) C 
75 mg / m2 d1 plus P 500 mg / m2 d1 q3 wks for 6 
cycles followed by P 500 mg / m2 q3 wks, until PD 
or unacceptable toxicity if SD or PR, (B) Cb AUC 
6 d1 plus T 200 mg / m2 d1 plus Be 15 mg / kg q3 
wks for 6 cycles followed by Be 15 mg / kg q3 wks, 
until PD or unacceptable toxicity in SD/PR pts. The 
primary objective of the study is to evaluate the 
difference in terms of QoL between treatment arms. 
together with Co-primary endpoints represented 
by the EQ5D questionnaire total score and the 
EQ5D visual analog scale. Secondary objectives: 
evaluation of QOL across time, treatment activity 
and tolerability. 
Results: Sample size and statistical design: Null 
hypothesis (H0): no minimal interesting difference 
(MID) (i.e. a difference of clinical interest) between 
arms at 12 weeks of maintenance. A sample of 49 
patients per arm (not progressing during initial 
CT and having undergone maintenance therapy 
for at least 12 weeks) will have a 91% chance 
to demonstrate a MID in terms of EQ5D and 
VAS when H0 is not-true, and a 87% chance to 
demonstrate a MID in terms of EQ5D total score, 
when H0 is not-true. It is assumed that about 20% 
of randomized patients experienced a PD before the 
time of evaluation of the primary endpoint, with no 
signiÀcantly difference between arms. The study 
sample will then be increased to 118 patients [(49 
+49) +20%)]. From january 2010 sixty six patients 
were recorded. Median age 49 years (range 39-70), 
M/F: 75%/25%, PS 0/1: 76%/24%, stage IIB/IV: 
16%/84%. 
Conclusion: The trial is actually recruiting and 
results are eagerly awaited. 
Keywords: Chemotherapy, non-squamous advanced 
NSCLC, EQ5D questionnaire, Quality of Life
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Kohei2, Yasuto Yoneshima2, Yoichi Nakanishi1 
1Research Institute For Diseases Of The Chest, 
Graduate School Of Medical Sciences, Kyushu 
University/Japan, 2Kyushu University/Japan
Background: In patients with lung cancer, weight 
loss is common at presentation and a frequent cause 
of patient concern. The prognostic effect of weight 
loss has been reported repeatedly and conÀrmed 
by several retrospective studies. Weight loss is 
considered to be a speciÀc symptom of cancer 
cahexia, which may be a new treatment target in 
combination with the apetite enhancer development 
like a ghrelin. In this study, we analyzed the 
relationship of weight loss and prognosis in 
advanced lung cancer patients in recent years.
Methods: A total of 206 patients conÀremd as 
advanced lung cancer between 2002 and 2008 were 
reviewed retrospectively. The prognostic effect of 
weight loss on the overall survival was analyzed 
using logrank test statistically.
Results: Demographic characteristics of patients 
were: median age 67 years (33 to 86 years); M/F 
148/58, Histology Ad/Sq/Sm/Others 101/41/47/17 
Stage III/IV/Recurrence 55/143/8 Patient >5%weight 
loss/>10% weight loss 58%/36%; Timing of the 
weight loss after admission to the hospital <6m/6-
12m/12-18m 37%/10%/4% MST in the patients with 
<5% or >=5% weight loss were 370 and 314 days, 
respectively (p=0.3234) MST in the patients with 
<10% or >=10% weight loss is 370 days and 289 
days, respectively (p=0.0026).
Conclusion: Body weight loss (>5%) in the 
advanced lung cancer are observed in 58% during 
the entire cinical course, and associated with a 
marginal effect on worse prognosis. Weight loss 
>10% is correlated with shorter survival, and is a 
prognositic factor clearly. The body weight loss start 
during 6 months after Àrst admission to the hospital.
Keywords: weight loss, Lung cancer, cahexia
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P3.064 EVALUATION OF THE EFFICACY 
AND SAFETY OF BEVACIZUMAB IN 
COMBINATION WITH PLATINUM 
-BASED CHEMOTHERAPY FOR 
ADVANCED NONSQUAMOUS NON-
SMALL CELL LUNG CANCER.
Asuka Okada1, Kazuya Fukuoka2, Hisaya Okuwa1, 
Performance status
1 6 (60%) 7 (64%) 
2 4 (40%) 4 (36%)
Treatment 
Lines of anti-cancer therapy prior to 
randomisation. Mean (Range) 
1 (0,3) 0.8 (0,2) 
Line of anti-cancer therapy post 
randomisation. Mean (Range) 
0.9 (0, 2) 1.4 (1,2) 
Serious Adverse Events (adverse event 
requiring hospital admission or death 
within 30 days of admission) 
6 1 
Table 2: Change in 6MWD, VAS and Survival in 
Treatment Groups 
Characteristics Intervention arm N=10 Control arm N=11 p value 
6MWD 
50% improvement 
from baseline 0/10 0/11 
Change from 
baseline at day 15 
Median (Range) 
36 (-203.5 to 156) 
n=8/10 
10.25 (-109 to 65) 
n=8/11 
p=0.372 (Mann-
Whitney test) 
Change from 
baseline at 3 months 
Median (range) 
98.5 (45 to 139) 
n=4/10 
-90 (-149.5 to -39) 
n=4/11 
p=0.021 (Mann-
Whitney test) 
VAS 
1.5 point fall in VAS 
at day 15 40% (4/10) 18% (2/11) 
p=0.234 (Fisher’s 
exact test) 
SURVIVAL 
Median survival 
(95% CI) 4.1 (1.1, 7.1) 6.2 (0, 18.6) p=0.05 (Log Rank) 
Conclusion: There was a trend toward towards 
improvement in 6MWD. This was most marked at 
3 months (p=0.021, 1% signiÀcance). The number 
of patients in the study was small and only 3 out the 
10 patients in the intervention arm actually received 
a stent, 4 others received laser therapy, dilatation 
or debulking procedures. Three patients received 
no procedures. Median survival was shorter for the 
intervention group than for the control group. This 
may be explained by two early (within 30 days) 
deaths in the intervention group. Further studies on 
the beneÀt of endobronchial stenting should select 
patients with a predicted life expectancy of 3 months. 
Keywords: NSCLC, Bronchial Stents, 6 Minute 
Walking Distance, Airway Obstruction
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P3.063 THE EFFECT OF BODY WEIGHT 
LOSS ON THE PROGNOSIS OF 
ADVANCED LUNG CANCER PATIENTS
Koichi Takayama1, Miiru Izumi2, Kentaro Tanaka2, 
Taishi Harada2, Kazuhito Furuyama2, Ootsubo 
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P3.065 A RANDOMIZED TRIAL OF 1ST 
LINE DOCETAXEL AND CISPLATIN AT 
75/60 VS 60/60 MG/M2 FOR PATIENTS 
WITH STAGE IIIB OR IV NON-SMALL 
CELL LUNG CANCER AND CYP3A5 
GENOTYPE
Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Hee-
Jung Ban, Su-Young Chi, Hyun-Ju Cho, Kook-Joo 
Na, Sang-Yun Song, Song Choi, Yoo Duk Choi, 
Sung-Ja Ahn, Yun-Hyeon Kim 
Lung Cancer Clinic, Chonnam National University 
Hwasun Hospital/Korea
Background: Combinations of Docetaxel(D) and 
Cisplatin(P) are one of the standard regimens for the 
treatment of advanced non-small cell lung cancer 
(NSCLC). However, there have been concerns about 
toxicity of using a D regimen at 75mg/m2 3-weekly 
dosage in an Asian population. The primary 
objective of this study was to prove non-inferiority 
of response rate of 60mg/m2 dose of docetaxel with 
60mg/m2 cisplatin compared to 75mg/m2 dose of 
docetaxel with 60mg/m2 cisplatin as a Àrst line 
treatment for NSCLC.
Methods: In this randomized, phase III clinical trial, 
we compared response rates and toxicity proÀle of 
two combination regimens of DP - 75/60 vs 60/60 
mg/m2/3week in patients with stage IIIB or IV 
NSCLC. Patients were stratiÀed according to ECOG 
PS 0,1 vs 2, weight loss in the previous 6 months 
< 5% vs > 5% and Stage IIIB vs IV or Relapsed. 
The non-inferiority margin was set at -15%. A total 
of 264 patients were required to provide the study 
with 80% power with a 5% type 1 one-sided error 
rate. Secondary objectives included progression 
free survival and safety. Genotyping of CYP3A4, 
CYP3A5 and ABCB1 were performed and correlated 
with toxicities.
Results: From September 2007 to September 2009, 
132 patients were enrolled. After a pre-planned 
interim analysis, this study was closed early as it 
met primary end point. The patients were randomly 
assigned to 75/60 (n=65) or to 60/60 (n=67). 
Response rates were 38.5% in 75/60 group and 
40.3% in 60/60 group. The 95% CI for the difference 
in response rate was -14.9%~18.5%. There was no 
signiÀcant difference in number of cycles (3.42 vs. 
3.57), time to progression (4.9 vs. 4.7m) between 
the two groups. However, the dose reduction rate 
Hitomi Kamiya1, Miki Honda1, Eriko Masachika1, 
Taiichiro Otsuki1, Risa Maeda1, Noriko Hirayama1, 
Takayuki Terada1, Aki Murakami1, Syusai Yamada1, 
Kuninobu Tamura1, Chiharu Tabata1, Takashi 
Nakano1 
1Division Of Respiratory Medicine, Department Of 
Internal Medicine, Hyogo College Of Medicine/
Japan, 2Cancer Center, Hyogo College Of Medicine/
Japan
Background: Bevacizumab, a monoclonal antibody 
against the vascular endothelial growth factor 
(VEGF), has been associated with improved survival 
and response rates when combined with platinum-
based chemotherapy in patients with non-small cell 
lung cancer (NSCLC). The aim of this retrospective 
study was to evaluate the efÀcacy and safety of 
platinum-based chemotherapy plus bevacizumab in 
patients with advanced nonsquamous NSCLC in our 
hospital. 
Methods: Patients received platinum-based 
chemotherapy, including cisplatin (75mg/m2) 
plus pemetrexed (500mg/m2), carboplatin (area 
under the curve of 5) plus pemetrexed (500mg/
m2), and carboplatin (area under the curve of 5) 
plus paclitaxel (200mg/m2) in combination with 
bevaciuzmab (15mg/kg) every 3 weeks. After 4-7 
courses of chemotherapy, maintenance bevacizumab 
was continued until disease progression or 
intolerance to treatment.
Results: A total of 17 patients received this 
treatment. Base line characteristics : male/female 
12/5, all patients are stage4 adenocarcinoma, ECOG 
PS0/1:13/4; median age:62.8yr. Of the patients 
evaluated for efÀcacy(n=14), the overall response 
rate was 71.4%; stable disease was observed in 
another 21.4%. Hematological toxicities of grade 
3 included leucopenia in 23.5%, neutropenia in 
35.3%, anemia in 5.9%, and thrombocytopenia in 
17.6%, respectively. Neither febrile neutropenia 
nor neutropenic infection was observed. Common 
non-hematological toxicities were gastrointestinal 
toxicities, such as nausea, constipation, anorexia, and 
vomiting, although toxicities of grade 3 were not 
observed. There were no treatment-related deaths.
Conclusion: This combination treatment followed 
by maintenance therapy with bevacizumab was 
effective with acceptable toxicity in patients with 
advanced nonsquamous NSCLC.
Keywords: nonsquamous, bevacizumab, NSCLC
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received Pemetrexed as a Àrst-line agent. The median 
cycles of chemotherapy was 3 (range 1-7 cycles). 
No severe side effect was observed. Local cerebral 
response assessment showed that 17 patients (37.8%) 
got a partial response (PR), 20 (44.4%) had a stable 
disease (SD) and 8 (17.8%) were disease progressed 
(PD). General lesions assessment presented that 
5(11.1%), 16(35.5%) and 24(55.6%) patients got 
a PR, SD and PD respectively. The disease control 
rate (DCR) was 82.2% in local cerebral disease, 
which was signiÀcantly higher than 46.6% in 
general lesions (P=0.004). As for patients who didn’t 
previously receive radiotherapy, the ORR was 46.2% 
and DCR was 84.6% in local cerebral disease, while 
in general disease, 7.6% and 61.5% only.
Conclusion: Pemetrexed demonstrated a higher 
efÀcacy on cerebral metastases than general lesions 
in NSCLC, which could warrant further investigation 
to guide the clinical practice.
Keywords: asymptomatic brain metastases, Non 
small cell lung cancer, Pemetrexed
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.067 THE IMPACT OF EPIDERMAL 
GROWTH FACTOR RECEPTOR GENE 
MUTATIONS ON SKELETAL-RELATED 
EVENTS IN PATIENTS WITH ADVANCED 
LUNG ADENOCARCINOMA
Haruyasu Murakami1, Takehito Shukuya1, Akira 
Ono1, Asuka Tsuya1, Yukiko Nakamura1, Hirotsugu 
Kenmotsu1, Tateaki Naito1, Toshiaki Takahashi1, 
Masahiro Endo2, Nobuyuki Yamamoto1 
1Division Of Thoracic Oncology, Shizuoka Cancer 
Center/Japan, 2Diagnostic Radiology, Shizuoka 
Cancer Center/Japan
Background: Bone metastases cause signiÀcant 
pain and morbidity leading to skeletal-related events 
(SREs), including a requirement for radiation or 
surgery of the bone, pathologic fractures and spinal 
cord compression. Recent reports suggested non-small 
cell lung cancer (NSCLC) patients with characteristics 
such as male sex, poor performance status and ever-
smoking were more likely to have SREs. However, 
the relationship between EGFR gene mutation status 
(53.8% vs 22.4% p<0.01), incidences of grade 3-4 
leukopenia and neutropenia were signiÀcantly higher 
in 75/60 compared to 60/60 group. The incidence 
of neutropenia was signiÀcantly higher in non-
expressing genotype (GG) compared to AG or AA 
genotypes of CYP3A5.
Conclusion: We conclude that D 60mg/m2 in 
combination with P 60mg/m2 was non-inferior to D 
75mg/m2 with P 60mg/m2 in response rate and time 
to progression, while providing patients with a better 
safety proÀle in Asian population.
Keywords: Docetaxel, Cisplatin, Non-small cell 
lung cancer, CYP3A5
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P3.066 EFFECT OF PEMETREXED ON 
BRAIN METASTASES IN 45 PATIENTS 
WITH ADVANCED NON SMALL CELL 
LUNG CANCER
Qiong Hu1, Shengxiang Ren2, Shu Y. Men3, Ai W. 
Li3, Xiao X. Chen3, Jia Y. Chen3, Yong S. Wang3, 
Caicun Zhou3 
1Medical Oncology, Tongji University AfÀliated 
Shanghai Pulmonary Hospital, Shanghai, China/
China, 2Medical Oncology, Tongji University 
AfÀliated Shanghai Pulmonary Hospital/China, 
3Oncology, Tongji University AfÀliated Shanghai 
Pulmonary Hospital/China
Background: Pemetrexed is a multitargeted 
antifolate inhibitor used as a standard agent in 
patients with advanced non squamous cell non small 
cell lung cancer (NSCLC). Some cases reported in 
the literature showed that it was effective on the 
brain metestasis in NSCLC. The purpose of this 
study was to evaluate the efÀcacy of Pemetrexed in 
the treatment of NSCLC patients with asymptomatic 
brain metastases.
Methods: NSCLC Patients with brain metastases 
from Nov 2007 to Dec 2010 in our department who 
received Pemetrexed were analyzed. SPSS version 
12.0 software was applied to perform the statistical 
analysis.
Results: A total of 45 NSCLC patients were enrolled 
into this study with a median age of 57 years (range 
35-76), M/F: 25/20, Smoker/ Nonsmoker: 19/26, 
single/ multiple lesion: 12/33, adenocarcinoma: 
42. 32 patients received whole brain radiotherapy 
(WBRT) before the chemotherapy and 6 patients 
S1204 Copyright © 2011 by the International Association for the Study of Lung Cancer
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1Departments Of Internal Medicine, Seoul National 
University Bundang Hospital/Korea, 2Pathology, 
Seoul National University Bundang Hospital/Korea, 
3Department Of Radiation Oncology, Seoul National 
University Bundang Hospital/Korea
Background: We intended to analyze the patterns of 
treatment and clinical outcomes of leptomeningeal 
metastasis (LM) in patients with non-small cell lung 
cancer (NSCLC) in the modern chemotherapy era.
Methods: We retrospectively reviewed the data of 
NSCLC patients who were diagnosed with LM from 
2003 to 2009 in Seoul National University Bundang 
Hospital.
Results: Of the 50 patients with cytologically proven 
LM, 25 were male (50%), 14 (28%) had ECOG 
performance status (PS) 3, and the median age was 
62.5 years (34-81). The patients were diagnosed 
with LM after median 10.4 month (0-86.8) from the 
initial diagnosis of metastatic NSCLC. LM presented 
in 11 patients at the time of initial diagnosis. The 
median overall survival (OS) after the diagnosis of 
LM was 4.3 months (95% CI 1.5-6.7). Forty-eight 
patients (96%) received intrathecal chemotherapy 
and cytological response rate was 52%. The median 
survival was 5.5 months in cytologic responders and 
1.4 months in nonresponders (p=0.075). The median 
OS in patients with ECOG PS 1-2 was longer than 
in those with ECOG PS 3-4 (5.5 vs. 0.7 months, 
p<0.001). Twenty-two patients (44%) underwent 
systemic cytotoxic chemotherapy or EGFR tyrosine 
kinase inhibitor (TKI) after being diagnosed with 
LM. These patients showed prolonged survival (11.5 
vs. 1.4 months, p<0.001), and in 15 patients (30%) 
who received EGFR TKI, the median OS was 19.2 
months. In patients with ECOG PS 1-2, patients who 
received further systemic chemotherapy showed 
improved survival (11.5 vs. 2.1 months, p<0.001). 
Conclusion: NSCLC patients with LM showed 
diverse clinical outcomes rather than uniformly poor 
prognosis. Systemic chemotherapy, especially EGFR 
TKIs, in addition to intrathecal chemotherapy might 
confer survival beneÀt.
Keywords: systemic chemotherapy, NSCLC, 
leptomeningeal metastasis, EGFR TKI
and SREs has not yet been assessed. 
Methods: To assess the impact of EGFR gene 
mutations on SREs, we retrospectively examined 
the clinical records of patients with advanced lung 
adenocarcinoma who were evaluated EGFR mutation 
status and treated with GeÀtinib or platinum-based 
chemotherapy as initial systemic treatment at Shizuoka 
Cancer Center between January 2008 and March 2010.
Results: A total of 138 patients were included in 
this study. The median age was 64 years (range, 33-
80 years). Fifty patients (36%) were female, and 50 
patients (36%) were never-smokers. The PS and EGFR 
mutation status were as follows: 41 patients with PS 
0, 73 patients with PS 1, 24 patients with PS 2-4; 91 
patients (66%) with wild type EGFR, 47 patients (34%) 
with EGFR mutations. Most patients had exon 19 
deletions or the exon 21 point mutation termed L858R. 
The median follow-up time was 19.4 months (range, 
10.3-36.8 months). The median overall survival for 
patients with wild type EGFR and EGFR mutations 
were 10.8 and 25.8 months, respectively (p<0.01). A 
total of 72 patients (52%) were diagnosed with bone 
metastases at the time of diagnosis, and 82 patients 
(59%) were found to have bone metastases during their 
clinical course; 52 patients (57%) of the 91 patients 
with wild type EGFR and 30 patients (64%) of the 47 
patients with EGFR mutations. Among the 82 patients 
with bone metastases, 52 patients (63%) developed 
at least one SRE and 17 patients (21%) had multiple 
SREs. In patients with wild type EGFR, 33 patients 
(63%) developed at least one SRE and 8 patients (15%) 
had multiple SREs. In patients with EGFR mutations, 
19 patients (63%) developed at least one SRE and 9 
patients (30%) had multiple SREs.
Conclusion: Advanced lung adenocarcinoma 
patients with EGFR gene mutations have a longer 
survival, and are more likely to have multiple SREs.
Keywords: bone metastases, EGFR mutation, 
Adenocarcinoma
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P3.068 CLINICAL OUTCOMES OF 
LEPTOMENINGEAL METASTASIS IN 
PATIENTS WITH NON-SMALL CELL 
LUNG CANCER IN THE MODERN 
CHEMOTHERAPY ERA
Jin Hyun Park1, Yu Jung Kim1, Jeong-Ok Lee1, 
Keun-Wook Lee1, Jee Hyun Kim1, Soo-Mee Bang1, 
Jin-Haeng Chung2, Jae Sung Kim3, Jong Seok Lee1 
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demographic variables including stage, age, race, sex 
and PS etc. 
Conclusion: Our institution is the only oncology 
department in Denmark, who rutinely has been 
using bevacicumab for patients with advanced 
adenocarcinoma of the lung. This study evaluates 
the exact proportion of patients, who were eligible 
for treatment with bevacicumab and characterize 
the reasons for exclusion or inappropriate usage of 
bevacicumab. References cited:
1) Sandler A, Gray R, Perry MC, et al. Paclitaxel-
carboplatin alone or with bevacizumab for non-
small-cell lung cancer. N Engl J Med 2006; 355: 
2542–50. 2) Reck M, von Pawel J, Zatloukal P, et 
al. Phase III trial of cisplatin plus gemcitabine with 
either placebo or bevacizumab as Àrst-line therapy 
for nonsquamous non–small-cell lung cancer: 
AVAiL. J Clin Oncol 2009; 27: 1227–34. 3) Crinó 
L, Dansin E, Garrido P, Zhou, C Safety, et al. Safety 
and efÀcacy of Àrst-line bevacizumab-based therapy 
in advanced non-squamous non-small-cell lung 
cancer (SAiL, MO19390): a phase 4 study: Lancet 
Oncol 2010; 11: 733–40 
Keywords: Bevacicumab, eligibility, advanced 
adenocarcinomas of the lung
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P3.070 QUALITY OF LIFE 
ASSESSMENTS IN LUNG CANCER AND 
MESOTHELIOMA. A COMPARISON OF 
QUESTIONNAIRES AND PHYSICIAN 
CONSULTATION – A POOR WORKMAN 
ALWAYS BLAMES HIS TOOLS?
James S. Myerson1, KoÀ Nimako1, Sally Moore1, 
Anna Karpathakis1, Rosella Calderone1, Sanjay 
Popat2, Mary O’Brien1 
1The Lung Unit, Royal Marsden Hospital/United 
Kingdom, 2National Heart And Lung Institute, 
Imperial College/United Kingdom
Background: Lung cancer and mesothelioma 
patients often have poor Quality of Life (QoL). 
Validated QoL questionnaires are used in clinical 
trials, and should be useful in routine practice. 
This study aimed to identify the most effective 
questionnaire as a QoL tool for routine clinical use in 
thoracic malignancies.
Methods: Three QoL questionnaires were evaluated 
(EORTC QLQ C30+LC13, FACT-L, and PSALC) 
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P3.069 THE USE OF BEVACICUMAB 
IN ADVANCED NON-SMALL CELL 
LUNG CANCER, EXPERIENCE FROM A 
SINGLE INSTITUTION IN DENMARK
Jon L. Andersen, Henrik A. Nielsen 
Oncology, University Hospital Of Hilleroed/
Denmark
Background: Bevacizumab, a humanized 
monoclonal anti-VEGF antibody, has demonstrated 
signiÀcant clinical beneÀt in the Àrst-line treatment 
of advanced nonsquamous non-small cell lung 
cancer [1,2]. However there are several exclusion 
factors limiting the proportion of patients eligible 
for bevacizumab. The department of oncology 
Hillerød Hospital is to our knowledge the only 
institution in Denmark who routinely has treated 
patients with advanced NSCLC with bevacicumab 
since 2008. In the following study we will evaluate 
the exact proportion of patients with advanced 
adenocarcinoma of the lung, who were eligible 
for treatment with bevacicumab and characterize 
the reasons for exclusion or inappropriate usage of 
bevacizumab. 
Methods: A retrospective review of all new patients 
with advanced non-small cell lung cancer at the 
department of oncology Hillerød Hospital from 
January 2009 through December 2010 will be 
conducted. Only adenocarcinomas will be recorded. 
With permission from the Danish Data Protection 
Agency and the National Board of Health, data will 
be abstracted from the patients electronic medical 
records. Bevacizumab eligibility criterias, at our 
instition, are in accordance with the SAIL study 
MO19390 [3] . Exclusion criterias are squamous 
or mixed adenosquamous histology, a history of 
signiÀcant haemoptysis (2·5 mL red blood per 
episode), uncontrolled hypertension, a history of 
thrombotic or haemorrhagic disorders. Radiological 
evidence of tumour invading or abutting major blood 
vessels and major surgery within 28 days before start 
of treatment. Patients with untreated brain metastasis 
are, in accordance with the European Medicines 
Agency, considered eligible for treatment with 
bevacicumab since march 2009. 
Results: At the World conference 2011 we will 
be presenting results of the study of bevacicumab 
eligibility in above mentioned population. 
The results will be correlated to a number of 
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FACT-L. Discrepancies between the 2 modes of 
information gathering were greatest for non-physical 
symptoms and, therefore, questionnaires would serve 
as a tool for further discussion. However, all three 
questionnaires showed discrepancies in physical 
symptoms detection, potentially affecting assessment 
of a patient’s true performance status (PS). Use of 
routine QoL tools can help focus questioning. 
Keywords: Quality of Life, NSCLC, SCLC, 
mesothelioma
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P3.071 PHASE I STUDY OF E7080, A 
MULTI-TARGETED TYROSINE KINASE 
INHIBITOR, IN COMBINATION WITH 
CARBOPLATIN PLUS PACLITAXEL 
IN PATIENTS WITH ADVANCED NON-
SMALL-CELL LUNG CANCER (NSCLC)
Hiroshi Nokihara1, Noboru Yamamoto1, Makoto 
Nishio2, Atsushi Horiike2, Takeshi Horai2, Toshiaki 
Takahashi3, Haruyasu Murakami3, Nobuyuki 
Yamamoto3, Wataru Yusa4, Tomohide Tamura5 
1Department Of Thoracic Oncology, National 
Cancer Center Hospital/Japan, 2Department Of 
Thoracic Medical Oncology, Cancer Institute 
Hospital/Japan, 3Department Of Thoracic Oncology, 
Shizuoka Cancer Center/Japan, 4Eisai Co., Ltd/
Japan, 5National Cancer Center Hospital/Japan
Background: E7080 is an orally administered 
receptor tyrosine kinase inhibitor of VEGFR1-3, 
FGFR1-4, PDGFR and KIT. In Phase I studies of 
E7080 monotherapy, a manageable toxicity proÀle 
and anti-tumor activity have been observed in 
patients with advanced solid tumors. 
Methods: This was an open-label, dose-escalation 
study of E7080 administered twice daily (bid) in 
combination with carboplatin (C) (AUC 6 mg/
mL/min, Day 1) and paclitaxel (P) (200 mg/
m2, Day 1) in chemotherapy-naïve patients with 
advanced NSCLC. After the initial 7-day run-in 
phase of E7080 monotherapy, patients received 
E7080 with CP every 3 weeks for a maximum 
of 6 cycles. Patients were allowed to continue 
E7080 monotherapy after the completion of CP. 
The initial dose level of E7080 was 6 mg bid in 
the dose-escalation cohort. Primary endpoint was 
the maximum tolerated dose (MTD) of E7080 in 
combination with CP. Patient accrual was expanded 
in 3 separate time periods over the course of 3 years 
(April 2006-April 2009) in Oncology outpatients, 
Royal Marsden Hospital, Sutton. Newly diagnosed 
NSCLC, SCLC or mesothelioma patients completed 
a paper-based questionnaire before seeing the 
doctor; this was collected but not used during the 
consultation. The consultation continued as normal 
with a clinic letter dictated onto the Electronic 
Patient Record (EPR). Only questionnaire items 
reported as signiÀcant or important (‘Quite a bit’ 
or ‘Very much’ on each questionnaire scale) by 
>25% of patients were included in the analysis. 
For each questionnaire item, we assessed whether 
it was identiÀed during the consultation or on the 
completed questionnaire. Questionnaire completion 
rate and number of missing responses were 
documented.
Results: The study patient population consisted of 
33 NSCLC, 34 SCLC, and 31 Mesothelioma. The 
median age was 65.9 (45 – 84 yrs) with 58 male and 
40 female patients. EORTC, FACT-L, and PSALC 
were completed by 36, 31, and 31 lung cancer and 
mesothelioma patients respectively. The number 
of symptoms/issues identiÀed as signiÀcant or 
important by >25% of patients were as follows: 15 
/ 45 for EORTC, 19 / 37 for FACT-L, and 5 / 9 for 
PSALC questionnaires. The table shows cumulative 
percentage scores for each domain, comparing issues 
reported by: i) questionnaire alone and ii) within the 
consultation. 
EORTC FACT-L 
Effect on: 
Occasions 
signi¿cant issue 
reported in 
questionnaire 
alone 
Occasions issue 
reported in 
consultation 
Effect on: 
Occasions 
signi¿cant issue 
reported in 
questionnaire 
alone 
Occasions 
issue reported 
in consultation 
Physical 
function 16 (44%) 11 (31%) 
Physical 
wellbeing 55 (25%) 29 (13%) 
Role function 26 (72%) 4 (11%) Functional wellbeing 80 (37%) 10 (5%) 
Cognitive 
function 20 (56%) 1 (3%) 
Lung Cancer 
Subscale 20 (56%) 1 (3%) 
Emotional 
function 28 (78%) 5 (14%) 
Emotional 
wellbeing 51 (27%) 2 (1%) 
Social 
function 26 (72%) 2 (6%) 
Social 
wellbeing 23 (11%) 0 (0%) 
No patient refused to complete a questionnaire. With 
the EORTC, 18/540 responses were missing (3%). 
With the FACT-L, 34/589 responses were missing 
(6%). The PSALC questionnaire had no missing 
responses.
Conclusion: This study has shown the EORTC 
questionnaire to be the most effective QoL 
instrument to use during our routine clinical 
practice to improve QoL issues identiÀcation, and 
was associated with fewer missing responses than 
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P3.072 PROGNOSTIC SCORE FOR 
SECOND-LINE CHEMOTHERAPY 
OF ADVANCED NON-SMALL-CELL 
LUNG CANCER (NSCLC): EXTERNAL 
VALIDATION IN A PHASE III TRIAL 
COMPARING VINFLUNINE WITH 
DOCETAXEL
Maciej Krzakowski1, Massimo Di Maio2, Kevin 
Perraud3, Dariusz M. Kowalski1, Cesare Gridelli4 
1Medical Oncology, The Maria Sklodowska-curie 
Institute Of Oncology/Poland, 2Clinical Trials 
Unit, National Cancer Institute/Italy, 3Institut De 
Recherche Pierre Fabre/France, 4S. Giuseppe 
Moscati Hospital/Italy
Background: Prognostic index for patients eligible 
for second-line chemotherapy of NSCLC was 
previously developed, based on individual patient 
data (IPD) of 9 randomized trials (Table 1) [Di Maio 
et al, Eur J Cancer 2010; 46: 735-743]. In this study, 
we aimed to validate the prognostic score, with the 
use of an external dataset.
Methods: We analyzed IPD of patients enrolled 
in a non-inferiority phase III trial comparing 
vinÁunine vs. docetaxel in second-line treatment 
of advanced NSCLC. Primary endpoint of this 
validation was overall survival (OS). The following 
variables were considered for survival analysis and 
score calculation: gender, performance status (PS), 
extent of disease, tumor histotype, type of Àrst-
line treatment, response to Àrst-line treatment. Cox 
model, stratiÀed by treatment arm, was used for 
multivariate analysis. Individual prognostic scores 
were derived according to our scoring system, and 
patients were divided into 3 categories according to 
the score: <5 (best), 5-9 (intermediate), >9 (worst). 
Results: All 551 patients enrolled in the trial 
had complete information for prognostic score 
calculation. Median OS in the whole study 
population was 6.9 months, with similar efÀcacy 
in the two study arms. At the multivariate survival 
analysis, there was no heterogeneity between the 
results obtained in the validation dataset and the 
results obtained in the previous dataset where the 
score was produced. Sixty patients (11%) were in the 
best category, 427 (77%) were in the intermediate 
category and 64 (12%) were in the worst category. 
Median OS was 12.9, 6.9 and 3.8 months for the 
best, intermediate and worst categories, respectively. 
to 22 patients at the MTD level in the expansion 
cohort to further evaluate safety and efÀcacy. 
Results: Twenty-eight patients were enrolled. 
Patient backgrounds were: median age 58 
years (range 38-73); males 75% / females 25%; 
performance status (PS) 0=68% / 1=32%; stage 
IIIB 29% / IV 71%; and histology subtype, 
adenocarcinoma 82% / squamous 7% / others 11%. 
In the dose-escalation cohort, 6 patients received 
6 mg bid of E7080 with CP. Two dose-limiting 
toxicities (DLTs) were observed in 2 patients 
(febrile neutropenia and infection each) in the 
Àrst cycle. Another patient discontinued E7080 
monotherapy during the 7-day run-in phase due to 
deterioration of PS. In the next cohort, the dose of 
E7080 with CP was decreased to 4 mg bid and no 
DLT was observed in 6 patients. In the expansion 
cohort, 16 patients were enrolled at the MTD level 
of 4 mg bid. In 22 patients at the 4 mg level, the 
common toxicities included thrombocytopenia 
(100%), leukopenia (95%), neutropenia (95%), 
arthralgia (95%), peripheral sensory neuropathy 
(95%) and alopecia (95%). The common grade 
3/4 toxicities were neutropenia (95%), leukopenia 
(50%), hypertension (36%), thrombocytopenia 
(27%) and febrile neutropenia (23%). The 
pharmacokinetic analyses of E7080 with C and P 
suggested no apparent interaction among the three 
drugs. In all 28 patients, the response rate (RR) was 
60.7 % with 1 complete response and 16 partial 
responses, and the median progression-free survival 
(PFS) was 9.0 months. The RR and median PFS for 
22 patients at the 4 mg level were 68.2% and 9.0 
months, respectively. Biomarker analysis indicated 
that longer PFS in the 4 mg level was correlated 
with lower baseline levels of plasma stromal cell-
derived factor (p=0.011). 
Conclusion: The MTD of E7080 in combination 
with CP is 4 mg bid. Combination therapy shows an 
encouraging anti-tumor activity with manageable 
toxicity proÀle in patients with advanced NSCLC 
and warrants further evaluation. 
Keywords: E7080, Non-Small-Cell Lung Cancer, 
Carboplatin, paclitaxel
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promising result in advanced cases of NSCLC in 
Phase I and II studies. Earlier, we have presented our 
experience of using this combination, particularly, 
keeping in view the cost factor. This study was 
undertaken to evaluate the efÀcacy and safety proÀle 
of a combination of our weekly CPT-II and Cisplatin 
in patients with advanced NSCLC attending to a TB 
hospital. 
Methods: Patients with chemotherapy naÏve stage 
III B or IV NSCLC were treated with repeated cycles 
of therapy comprising four weekly treatments with 
both Cisplatin and CPT-II for 6 cycles. The starting 
doses of CPT-II and cisplatin were 70 and 50 mg/
m2, respectively. Treatment was continued until the 
occurrence of disease progression, unacceptable 
toxicity, or the completion of sic chemotherapy 
cycles. Solid tumour response evaluation was 
determined using ModiÀed Response Evaluation 
Criteria in Solid Tumour (RECIST) Criteria. 8 
patients received external radiotherapy in addition.
Results: Of 137 patients registered at Lung 
Cancer Clinic 121 (88.32%) had NSCLC. Of these 
40 (33.1%) met the eligibility criteria and were 
enrolled into study after taking consent (study 
group, n-40). Of these 40 patients, 5 (12.5%) were 
lost in follow up after one cycle and thus excluded 
from Ànal analysis. Of 68 (56.2%) patients not 
given any chemotherapy, 49 did not meet the 
inclusion criteria. Remaining 19 (15.7%) patients, 
meeting th3 enrolment criteria, but refusing for 
any chemotherapy served as our control group 
to whom best supportive care (BSC) was offered 
and subsequently followed up. The median age of 
enrolled group (40 patients) was 59 years (range, 44-
79). Eastern cooperative Oncology Group (ECOG) 
performance status was 0, 1 and 2 in 4 (10%), 25 
(62.5%) and 11 (27.5%) patients respectively. Stage 
IIIB and IV disease was found in 27 (67.5%) and 
13 (32.5%) respectively. The objective tumour 
response was seen in seven (26%) patients of whom 
1(3.7%) had complete response (CR) and 6 (22.2%) 
had partial response (PR) while 15 (55.6%) had 
stable disease (SD). Five (18.51%) patients had 
progressive disease (PD). The median survival, the 
1- year survival rate and the median progression free 
survival were 57 weeks (95% CI, 49.52 to 64.48 
weeks), 53% and 27 weeks (range of 5 to 54 weeks) 
respectively, in 27 patients who completed six cycles 
of chemotherapy. The median survival for control 
group was 11 weeks (95% ConÀdence interval, 
5.96 – 16.04 weeks) [log ran test, P<0.001] while all 
patients of this group expired by end of 35 weeks. 
Cox model analysis showed a signiÀcant effect for 
intermediate vs. best category comparison (Hazard 
Ratio 1.79, 95%CI 1.31-2.47, p=0.0003) and for 
worst vs. best category comparison (Hazard Ratio 
3.25, 95%CI 2.18-4.83, p<0.0001). The C-index 
of the model was high (0.926), indicating a good 
discrimination according to the proposed risk 
categories. 
Conclusion: Prognostic ability of our score for 
candidates to second-line treatment in advanced 
NSCLC was successfully validated. Subgroups 
of patients with more vs. less favorable prognosis 
were identiÀed. Prognostic score could be useful in 
clinical practice. 
Table 1. Scoring system 
Points 
0 1 2 7 
Gender Female Male 
ECOG PS PS 0 PS 1 PS 2 
Tumor stage IIIb (locally advanced) IV (metastatic) 
Histologic type Adenocarcinoma Squamous Other 
Type of ¿rst-line Without platinum Platin-based 
Objective response 
to ¿rst –line Yes No 
Keywords: Prognostic score, second-line 
chemotherapy, Advanced NSCLC, phase III 
randomized trial
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P3.073 CISPLATIN AND IRINOTECAN 
COMBINATION CHEMOTHERAPY IN 
NON-SMALL CELL LUNG CANCER 
PATIENTS ATTENDING A TB HOSPITAL 
IN INDIA
Digambar Behera1, Anand Jaiswal2, Jitender Saini2, 
Deepak Nagar2, Ashish Jaiswal2, Bidhu K. Mohanty3 
1Pulmonary Medicine, Lrs Institute Of Tuberculosis 
And Respiratory Diseaes And Postgraduate Institute 
Of Medical Education And Research/India, 2Chest 
And Tb, Lrs Institute Of Tb And Respiratory Diseaes/
India, 3All India Institute Of Medical Sciences/India
Background: Lung cancer is the most commonly 
diagnosed malignancy and the leading cause of 
cancer related death. In absolute numbers, non small 
cell lung cancer (NSCLC) accounts for about 80% 
of all lung cancer cases. The combination of weekly 
Irinotecan (CPT-II) and monthly Cisplatin has shown 
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or partial response. 7/39 (17.9%) achieved stable 
disease and 9/39 (23.0%) had progressive disease 
or unacceptable toxicity. The commonest toxicity 
reported was anaemia requiring transfusion 7/39 
(17.9%) followed by fatigue 5/39 (12.9%). Febrile 
neutropenia occurred in 3/39 (7%) and platelet 
transfusion was needed in 2/39 (5%). 
Conclusion: The use of carboplatin as a platinum 
agent in patients with non-small cell lung cancer 
is relatively controversial. It is believed by many 
people that response rates and survival are less 
with carboplatin compared to cisplatin and this is 
the subject of a large clinical trial which is due to 
report later this year (the BTOG2 trial). Additionally, 
carboplatin is more myelosuppressive than cisplatin, 
leading to concerns when given in combination with 
other myelotoxic drugs. Cisplatin is nephrotoxic 
and requires long pre and post treatment hydration 
schedules leading to difÀculties in delivery of this 
treatment in the outpatient setting. Cisplatin is 
contra-indicated in patients with impaired renal 
function, and carboplatin has been safely used 
in this group as dose is adjusted according to 
renal function. We have found in our centre that 
patients prefer carboplatin over cisplatin and this 
audit shows that the toxicity of carboplatin in 
combination with pemetrexed is manageable. The 
response rate was very high compared to trial data, 
suggesting signiÀcant activity of this combination of 
chemotherapy, although our population was highly 
selected, non-randomised and tumour assessments 
were subjective. Our results suggest that further 
research is warranted to investigate whether 
carboplatin has superiority over cisplatin when given 
in combination with pemetrexed.
Keywords: Non-small cell lung cancer, 
Chemotherapy, Carboplatin, Pemetrexed
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P3.075 ERLOTINIB AFTER FAILURE 
OF GEFITINIB THERAPY IN PATIENTS 
WITH NON-SMALL CELL LUNG 
CANCER (NSCLC) WITH OR WITHOUT 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION
Hiroshi Saito1, Tomoki Kimura2, Takashi Abe3, 
Masashi Kondo4, Tomohiko Ogasawara5, Yoshimasa 
Tanikawa6, Toshihiko Yokoyama7, Eiji Kojima8, 
Masashi Yamamoto9, Ryujiro Suzuki10 
Grade ¾ non haematological toxicities included 
vomiting (12%) and diarrhoea (26%) where as grade 
3/4hematological toxicities comprised of anaemia 
(14%), neutropenia (26%), and thrombocytopenia 
(14%). 
Conclusion: Four weekly combined administrations 
of CPT-II and cisplatin achieved a promising overall 
response rate, median time to tumour progression, 
and median survival in patients with stage IIIB/IV 
NSCLC.
Keyword: RECIST Criteria, ECOG, BSC, NSCLC, 
Irinotecan (CPT-II) and Cisplatin
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P3.074 RESPONSE RATES TO 
CARBOPLATIN AND PEMETREXED IN 
NON-SQUAMOUS NON-SMALL CELL 
LUNG CANCER – A SINGLE CENTRE 
AUDIT
Toby L.J. Talbot, Matthew P. Collinson, Charlotte 
Buscombe, Susan Pascoe 
Clinical Oncology, Royal Cornwall Hospital/United 
Kingdom
Background: Cisplatin and Pemetrexed has become 
standard chemotherapy in the management of 
advanced non-squamous non-small cell lung cancer. 
For logistical reasons, including lack of capacity 
and long infusion times with Cisplatin, the preferred 
combination of chemotherapy in our centre is 
Carboplatin and Pemetrexed. This audit examines 
response rates and toxicity proÀle in our patient 
population. 
Methods: All patients with non-squamous non-small 
cell lung cancer who received chemotherapy using 
Carboplatin and Pemetrexed between August 2009 
and August 2010 were included. A total thirty nine 
patients underwent treatment and data were analysed 
from the patient notes and chemotherapy record. 
Patients received Carboplatin AUC5 and Pemetrexed 
500mg/m2 every 21 days with a CT scan after 3 
cycles and a further 3 cycles given if response or 
stable disease was seen. Responses were taken from 
CT scan assessments and were divided into Good or 
Partial response, Stable disease, Disease progression 
or treatment discontinued due to toxicity. Formal 
tumour measurements such as RECIST were not 
taken. 
Results: 23/39 (59.0%) of patients achieved a good 
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start of erlotinib therapy) were 13.7 weeks and 54.3 
weeks, respectively. The response rate, disease 
control rate and progression-free survival time 
were 12%, 76% and 13.3 weeks, respectively, for 
the EGFR mutant group (N=17) and 0%, 67% and 
24.3 weeks, respectively, for the EGFR wild type 
group (N=3). The response rate, disease control rate 
and progression-free survival time were 14%, 79% 
and 19.3 weeks, respectively, for patients who had 
achieved PR with geÀtinib (N=14) and 0%, 80% and 
11.9 weeks, respectively, for patients who had had 
SD with geÀtinib (N=5).
Conclusion: Erlotinib appears to have some clinical 
beneÀt after failure of geÀtinib therapy. There was 
no signiÀcant difference in disease control rate 
according to EGFR mutational status and response 
to prior geÀtinib therapy. Patients who had achieved 
partial response with geÀtinib tended to have longer 
PFS with erlotinib.
Keywords: EGFR mutation, geÀtinib, erlotinib, 
Non-small cell lung cancer
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P3.076 PHASE Ⅰ/Ⅱ TRIAL OF S-1 PLUS 
DOCETAXEL (DTX) FOR PREVIOUSLY 
TREATED ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC): KANTO 
RESPIRATORY DISEASE STUDY GROUP.
Takashi Kasai1, Kiyoshi Mori1, Kunihiko 
Kobayashi2, Kenichiro Komiyama2, Syohei 
Minezaki2, Yuka Uchida2, Eishin Hoshi3, Shinichiro 
Koyama4, Keisuke Eguchi5, Mitsuo Nakayama5, Koji 
Kikuchi5 
1Department Of Medical Oncology, Tochigi Cancer 
Center/Japan, 2Saitama Medical University 
International Medical Center/Japan, 3Saitama 
Cardiovascular And Respiratory Center/Japan, 
4Saitama Medical Center, Jichi Medical University/
Japan, 5Saitama Medical University Saitama 
Medical Center/Japan
Background: S-1, a novel oral Áuoropyrimidine, is 
active in the treatment of NSCLC. Previous studies 
investigating a combination of S-1 plus DTX showed 
promising efÀcacy but clinically problematic emesis. 
We conducted a phase I study to Ànd the maximum 
tolerated doses (MTD) of bi-weekly administered 
DTX with oral S-1 for one week, and a phase II 
study to evaluate the efÀcacy and toxicity.
1Department Of Respiratory Medicine, Aichi Cancer 
Center Aichi Hospital/Japan, 2Tosei General 
Hospital/Japan, 3Ogaki Municipal Hospital/Japan, 
4Nagoya University Graduate School Of Medicine/
Japan, 5Nagoya Daini Red Cross Hospital/Japan, 
6Toyota Kosei Hospital/Japan, 7Japanese Red Cross 
Nagoya Daiichi Hospital/Japan, 8Komaki Municipal 
Hospital/Japan, 9Nagoya Ekisaikai Hospital/Japan, 
10Toyohashi Municipal Hospital/Japan
Background: EGFR tyrosine kinase inhibitors 
(EGFR-TKI), geÀtinib and erlotinib, are effective 
in the treatment of patients with advanced NSCLC, 
especially those harboring EGFR mutations. 
Although both EGFR-TKIs may be affected by the 
same resistance mechanism, erlotinib is given at a 
higher biological dose than geÀtinib and may confer 
some clinical beneÀt after failure of geÀtinib therapy. 
Several studies evaluated the effects of erlotinib 
after geÀtinib failure in patients with advanced 
NSCLC. However, the numbers of patients were 
small and EGFR mutational status was not examined 
in all patients. To clarify the role of erlotinib after 
geÀtinib failure in patients with advanced NSCLC 
in association with EGFR mutational status and 
response to prior geÀtinib treatment, we conducted 
this retrospective analysis.
Methods: Patients with advanced NSCLC with 
or without EGFR mutation who were treated 
with erlotinib after geÀtinib failure and had the 
presence of measurable or evaluable lesion(s) were 
eligible. Erlotinib was started at the dose of 150 mg 
daily and was given until disease progression or 
unacceptable toxicity. Tumor response was evaluated 
with computed tomography of the chest or chest 
radiography.
Results: Twenty Japanese patients were collected 
from 9 institutions. Thirteen patients (65%) were 
female and 15 patients (75%) were non-smokers. 
Eighteen patients (90%) had adenocarcinoma and 
one patient each had squamous cell carcinoma and 
NSCLC not otherwise speciÀed. Seventeen patients 
(85%) harbored sensitive EGFR mutations (exon 
19 deletions in 7, the L858R substitution in 10). 
In geÀtinib therapy, 14 patients achieved partial 
response (PR) and Àve had stable disease (SD) with 
a response rate of 70% and disease control rate of 
95%. In erlotinib therapy after failure of geÀtinib 
therapy, two patients achieved PR and 13 had SD 
with a response rate of 10% and disease control 
rate of 75%. The median progression-free survival 
time and median overall survival time (both from 
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Of Medical Sciences, Kyushu University/Japan, 
3Department Of Respiratory Medicine, National 
Hospital Organization Kyushu Medical Center/
Japan, 4Department Of Respiratory Medicine, 
Kitakyushu Municipal Medical Center/Japan, 
5Internal Medicine, National Hospital Organization 
Okinawa Hospital/Japan, 6Department Of 
Respiratory Disease, Fukuoka-higashi Medical 
Center/Japan, 7Department Of Internal Medicine, 
Saiseikai Fukuoka General Hospital/Japan, 
8Department Of Respiratory Medicine, Fukuoka 
University Hospital/Japan, 9Department Of Internal 
Medicine Of Tropical Medicine, Nagasaki University 
Hospital/Japan, 10Department Of Respiratory 
Medicine, Kumamoto City Hospital/Japan, 11Division 
Of Respiratory Disease, Nippon Steel Yawata 
Memorial Hospital/Japan, 12Department Of Thoracic 
Oncology, National Kyushu Cancer Center/Japan
Background: Anemia is frequently observed 
in cancer patients undergoing chemotherapy. 
No large-scale epidemiologic study evaluating 
the incidence of chemotherapy-induced anemia 
in cancer patients has been conducted in Japan. 
The LOGIK0403 was a phase II randomized trial 
comparing biweekly and weekly administration of 
paclitaxel-carboplatin therapy in advanced non-
small-cell lung cancer (NSCLC). We retrospectively 
determined the prevalence and incidence of anemia 
throughout treatment for each group, risk factors 
for the development of anemia, and the impact of 
anemia during chemotherapy on treatment outcome 
including overall survival (OS) using these data.
Methods: Previously untreated NSCLC patients 
enrolled in the LOGIK0403 trial (n=140) and 
having at least one hemoglobin value recorded 
during chemotherapy were included in the analysis. 
The Wilcoxon rank-sum test was used to examine 
the association between baseline variables and 
hemoglobin grades. Median survival times for 
the different worst grades of hemoglobin during 
chemotherapy were calculated using the Kaplan-
Meier method. Univariable and multivariable Cox 
proportional hazards regression analyses were 
performed to assess the impact of anemia during 
chemotherapy on OS.
Results: A total of 135 patients were included in 
this analysis. Fifty-six percent of the patients had 
hemoglobin of grade 1 (between the lower limit of 
normal and 10 g/dL) and 4% had grade 2 (10-8 g/
dL) prior to chemotherapy. Patients in the weekly 
group had more severe anemia during chemotherapy 
Methods: Previously treated pts with NSCLC were 
included. Other eligibility criteria were performance 
status of 0-1, measurable lesions, age < 75 years, 
and adequate organic functions were eligible. Pts 
received S-1 on days 1-7 and DTX on day 1 of each 
14-day cycle.
Results: Doses of S-1/DTX (mg/m2) in the phase 
I study portion were escalated as follows: 80/30, 
80/35, and 80/40. In the phase I, MTD among 13 
patients were S-1 80 mg/m2 with DTX 40 mg/
m2. The dose limiting toxicity (DLT) was febrile 
neutropenia. The recommended doses for the phase 
II study were S-1 80mg/m2 and DTX 35 mg/m2. A 
total of 34 pts from 5 institutions were enrolled from 
Oct. 2009 to Nov. 2010. The overall responses were 
CR 0; PR 9; SD 12; PD 10 and NE 3, resulting in 
a response rate of 26.5% (95% conÀdence interval 
[CI], 11.6-41.3%). The overall disease control rate 
was 61.8% (95% CI, 45.4-78.1%). Hematologic 
grade 3/4 toxicities were neutropenia (29.4%), 
febrile neutropenia (2.9%) and thrombocytopenia 
(2.9%). In non-haematologic toxicities, 4 patients 
with grade 2 interstitial pneumonitis were observed. 
Nine patients experienced grade 1 nausea only for 
short durations, and there were no grade 2 nausea.
Conclusion: The combination of one week S-1 with 
biweekly DTX is an active regimen with low-emesis 
and low myelotoxicities for previously treated 
advanced NSCLC. 
Keywords: Non-small cell lung cancer, phase I/II 
study, Docetaxel, S-1
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P3.077 IMPACT OF ANEMIA DURING 
PACLITAXEL-CARBOPLATIN THERAPY 
ON SURVIVAL OF PATIENTS WITH 
ADVANCED NON-SMALL- CELL LUNG 
CANCER: A RETROSPECTIVE ANALYSIS 
OF A PHASE II TRIAL (LOGIK0403) BY 
THE LUNG ONCOLOGY GROUP IN 
KYUSHU, JAPAN
Shoji Tokunaga1, Koichi Takayama2, Masao Ichiki3, 
Miiru Izumi2, Koji Inoue4, Mutsuo Kuba5, Masayuki 
Kawasaki6, Hiroshi Wataya7, Kentaro Watanabe8, 
Masayuki Ishida9, Koichiro Fukuda10, Tomotoshi 
Imanaga11, Yoichi Nakanishi2, Yukito Ichinose12 
1Department Of Medical Informatics, Kyushu 
University Hospital/Japan, 2Research Institute 
For Diseases Of The Chest, Graduate School 
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P3.078 PEMETREXED MONOTHERAPY 
FOR JAPANESE PATIENTS WITH 
PREVIOUSLY TREATED NON-SMALL 
CELL LUNG CANCER (NSCLC).
Akira Sato, Yuki Misumi, Fumihiro Kashizaki, Mari 
Ishii, Tsuneo Shimokawa, Naoya Hida, Hiroaki 
Okamoto 
Department Of Respiratory Medicine, Yokohama 
Municipal Citizen’s Hospital/Japan
Background: Pemetrexed monotherapy would 
be considered one of the standard second-line 
treatments for pretreated and relapsed NSCLC. 
Since pemetrexed was approved for NSCLC in 
May 2009 in Japan, there has been little evidence 
in clinical practice to assess the efÀcacy and safety 
of pemetrexed in Japanese patients with advanced 
NSCLC. Our objects are to assess the outcome 
and adverse events of pemetrexed monotherapy 
for Japanese patients with advanced NSCLC at the 
Yokohama Municipal Citizen’s Hospital.
Methods: We retrospectively reviewed advanced 
NSCLC patients who received pemetrexed 
monotherapy at our hospital. Pemetrexed 500 mg/
m2 was administered every 3 weeks with oral folic 
acid and vitamin B12 i.m. supplementation. Patients 
also received dexamethasone i.v. day 1 to reduce 
toxicity. Chemotherapy was repeated unless disease 
progression, unacceptable toxicities or patient refusal 
was occurred.
Results: From May 2009 to December 2010, a 
total of 53 Japanese patients with stage III and 
stage IV disease were evaluable for the analysis. 
Patients characteristics were as follows: median 
age 68 years, 32% (n=17) female, ECOG PS 
0-1/2 were 49 (92%)/4 (7.5%), Stage III/IV were 
16 (30%)/ 37 (70%), adenocarcinoma histology/
others were 49 (93%)/4 (7%), and EGFR mutation 
positive/negative/unknown were 9/28/16. Second 
line chemotherapy/3rd/>4th were 18/17/18 and 
median administered cycles was 3 (range 1-19). 
Previous use of platinum were given in 42 (79%). 
Gr 3/4 hematologic toxicities were neutropenia 8/1 
patients, thrombocytopenia 0/0, anemia 3/0 and 
febrile neutropenia 2/0. Gr 3/4 non-hematologic 
toxicities were pneumonitis 4/0 patients and 
syncope 1/0. All four patients (7.5%) with Gr 3 
pneumonitis were male and ex or current smokers. 
Although all pneumonitis were recovered by steroid 
compared to the biweekly group. More than 50% 
of the patients in the weekly group had hemoglobin 
of grade 2-4 (< 6.5 g/dL) as the worst grade. Pre-
chemotherapy hemoglobin grade and treatment 
regimen were associated with the worst grade of 
hemoglobin during chemotherapy (P < 0.001). A 
statistically signiÀcant difference was seen in terms 
of OS among the worst grades of hemoglobin (P = 
0.02), whereas no signiÀcant differences were seen 
in relative dose intensity, objective response rate, 
or progression-free survival. Multivariable Cox 
regression analysis demonstrated that the worst grade 
of hemoglobin was an independent prognostic factor 
after adjustment for relevant variables such as sex, 
performance status, and histology (anemia during 
chemotherapy was associated with poorer survival).
Table. Cox regression analysis for the association 
between overall survival and worst grade of 
hemoglobin during chemotherapy. 
Univariable Analysis Multivariable Analysis
Variable Hazard Ratio(95% CI) P 
Hazard Ratio
(95% CI) P 
Hemoglobin Grade
Grade 0/1 1 (Referent) 1 (Referent) 
Grade 2 1.50 (0.98, 2.28) 0.06 2.04 (1.31, 3.17) 0.002 
Grade 3/4 2.08 (1.21, 3.56) 0.008 2.38 (1.31, 4.32) 0.004 
Sex
Male 1 (Referent) 1 (Referent) 
Female 0.36 (0.23, 0.56) <0.001 0.29 (0.18, 0.48) <0.001 
Performance Status
0 1 (Referent) 1 (Referent) 
1 2.33 (1.59, 3.44) <0.001 2.26 (1.51, 3.38) <0.001 
Histology
Adenocarcinoma 1 (Referent) 1 (Referent) 
Others 1.36 (1.10, 1.68) 0.004 0.99 (0.78, 1.25) 0.90 
Conclusion: Anemia that occurred during paclitaxel-
carboplatin therapy was associated with poorer 
survival of patients with advanced NSCLC. Further 
studies are required to investigate the detailed role of 
anemia during chemotherapy in a prospective study 
design.
Keywords: Lung cancer, survival, anemia, 
Chemotherapy
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chemotherapy for the treatment of Àrst-line advanced 
Non-Small Cell Lung Cancer (NSCLC). This study 
contributes to the discussion and debate about the 
role of EGFR mutation testing as part of the standard 
clinical work-up for patients presenting with NSCLC.
Methods: Of the 13 patients examined with a 
diagnosis of non small cell lung cancer, 8 patients 
had histology: adenocarcinoma. 4 of them were 
identiÀed a mutation in 19 exon EGFR. All patients 
were women, Ñaucasians, never smokers, aged 59, 
65, 65 and 70 years with comorbidity . All patients at 
the time of initiation of therapy were 4 stages of the 
disease with lung metastasis (4 pts) and bones (1 pts) 
, the overall state ECOG 1-3. All patients received 
geÀtinib as Àrst-line therapy at a dose of 250 mg. 
Duration of therapy from 1 month to 14 months.
Results: One patient a month later, while taking geÀtinib, 
marked progression of the disease. One patient died of 
a heart attack after 4 month. Two patients continued to 
receive geÀtinib between 3 and 14 months. They noted 
the stabilization process. All patients noted diarrhea 1-2 
degrees, pustular rash of 1 degree, does not require a 
dose reduction and withdrawal of therapy.
Conclusion: All patients with non-small cell lung 
cancer should be tested for EGFR mutation for 
the correct choice of therapy. GeÀtinib was well 
tolerated and can be assigned to elderly patients with 
comorbidity and performance status greater than 2.
Keyword: geÀtinib, NSCLC,
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.080 CLINICAL SIGNIFICANCE 
OF EPIDERMAL GROWTH FACTOR 
RECEPTOR GENE MUTATIONS ON 
PROGRESSION OF BRAIN METASTASES 
IN PATIENTS WITH ADVANCED LUNG 
ADENOCARCINOMA
Sakae Fujiwara1, Haruyasu Murakami1, Takehito 
Shukuya1, Akira Ono1, Asuka Tsuya1, Yukiko 
Nakamura1, Hirotsugu Kenmotsu1, Tateaki Naito1, 
Toshiaki Takahashi1, Masahiro Endo2, Nobuyuki 
Yamamoto1 
1Division Of Thoracic Oncology, Shizuoka Cancer 
Center/Japan, 2Diagnostic Radiology, Shizuoka 
Cancer Center/Japan
therapy, two of four patients needed home oxygen 
therapy at discharge. All other hematologic and 
non-hematologic toxicities showed Gr 2 or less and 
no treatment-related deaths occurred. The overall 
response rate was 5.7% and disease control rate 
was 60% (PR/SD/PD/NE: 3/29/19/2). The median 
progression free survival time was 3.4 months 
(95% CI 2.52~4.28): female 6.1 months (95% 
CI 3.11~9.02), male 2.6 (95% CI 1.28~3.92) and 
median overall survival time was 13.6 months (95% 
CI 8.49~18.78). Based on the multivariate analysis 
using Cox proportional hazard model, only poor 
prognostic factor was PS 2 (HR: 4.65, 95%CI: 1.25-
17.3, p=0.022).
Conclusion: Results of this retrospective study 
suggest that pemetrexed monotherapy in Japanese 
patients with previously treated NSCLC has 
promising efÀcacy, especially in disease control 
rate and overall survival. However, because our 
study was reported by single institution and had 
small sample size, it is unclear whether pneumonitis 
is more eventful in Asian peoples, especially in 
Japanese. Since it is expected to increase in use of 
pemetrexed worldwide, further investigations are 
warranted
Keywords: NSCLC, Pemetrexed, monotherapy, 
single agent
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.079 CLINICAL EXPERIENCE USE 
GEFITINIB IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER WITH A 
MUTATION EGFR.
Eduard Vozniy1, Anatoly Popov2, Michail Galkin3, 
Tamara Astrakhankina3 
1Chemotherapy, Municipal Hospital 57 Moscow/
Russian Federation, 2Municipal Hospital 57/Russian 
Federation, 3Chemotherapy, Municipal Hospital 57/
Russian Federation
Background: 35th Congress of the European Society 
of Medical Oncology (ESMO) in Milan, Italy, a late-
breaking abstract provided Ànal overall survival (OS) 
results from the IPASS study (IRESSA Pan-Asia 
Study), which compared geÀtinib to platinum-based 
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the EGFR gene mutations in patients with advanced 
lung adenocarcinoma.
Keywords: EGFR mutation, Brain Metastasis, 
Adenocarcinoma
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P3.081 EGFR TYROSINE KINASE 
INHIBITOR : CLINICAL EFFICACY IN 
ADVANCED NON SMALL CELL LUNG 
CANCER IN OUR SETUP
Aseem R. Bhatnagar, Rameshwaram Sharma, 
Dharam P. Singh, Om P. Sharma, Shantanu Sharma 
Radiotherapy & Oncology, S.M.S. Medical College 
& Attached Hospitals/India
Background: To evaluate Progression Free Survival 
(PFS), efÀcacy and tolerance of single agent 
GeÀtinib, an oral epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor, as up-front therapy 
for advanced non-small cell lung cancer (NSCLC) in 
elderly patients.
Methods: 30 patients, aged between 65 and 80 
years, smokers or non-smokers, who were unÀt 
for chemotherapy, received oral GeÀtinib 250 mg 
daily as Àrst-line up-front therapy for the treatment 
of advanced NSCLC at our institution. Patients 
had stage IIIB or stage IV NSCLC and Eastern 
Cooperative Oncology Group (ECOG) performance 
status 0-2 and adequate hematologic, renal, and 
hepatic functions. Measurable disease as assessed 
by Response Evaluation Criteria in Solid Tumors 
(RECIST v1.1). Palliative local radiotherapy was 
used in those patients who had painful metastasis.
Results: Out of 29 evaluable patients, 14 
had adenocarcinoma, 12 had squamous cell 
carcinoma, 2 had large cell carcinoma and 1 had 
bronchioloalveolar carcinoma. There was signiÀcant 
increase in PFS with 1-year survival over 60%. The 
partial response (PR) plus stable disease (SD) rate 
by ECOG performance status (PS) was 8/9 for PS 
0 patients; 9/18 for PS 1-2 patients. Two patients 
discontinued therapy due to toxicities; both had 
severe liver dysfunction. A correlation between rash 
and antitumor activity was noted.
Conclusion: We found encouraging response and 
PFS results with GeÀtinib as Àrst-line up-front 
treatment in selected patients with advanced NSCLC. 
The treatment is also cost effective, with oral 
therapies scoring over cost of hospitalization and 
Background: Recent reports suggested a lower 
risk of central nervous system (CNS) progression in 
patients with advanced non-small cell lung cancer 
(NSCLC) harboring mutations of the epidermal 
growth factor receptor (EGFR) initially treated 
with EGFR-targeted agents (geÀtinib or erlotinib). 
However, the relationship between EGFR gene 
mutation status and development of CNS progression 
has not yet been fully assessed.
Methods: To assess the impact of EGFR gene 
mutations on progression of brain metastases (BM), 
we reviewed the clinical records of patients with 
advanced lung adenocarcinoma who were evaluated 
EGFR mutation status at Shizuoka Cancer Center 
between January 2008 and January 2010.
Results: A total of 141 patients were included in 
this retrospective study, and 47 patients (33%) 
were positive for EGFR gene mutations. The most 
common mutations observed were exon 19 deletions 
(28 patients) and the exon 21 point mutation termed 
L858R (19 patients). Two patients had both an exon 
19 deletion and L858R. Fifteen (32%) of the 47 
patients with EGFR mutations, and 25 (27%) of 
the 94 patients with wild type EGFR had BM at the 
time of diagnosis. The median follow-up time was 
14 months. The median progression-free survival 
for patients with EGFR mutations and wild type 
EGFR were 8.3 and 5.9 months, respectively (p = 
0.048). The median overall survival for patients with 
EGFR mutations and wild type EGFR were 25.3 
and 10.1 months, respectively (p<0.001). The 1- and 
2-year actuarial rates of BM progression in patients 
with EGFR mutations were 30% [95% conÀdence 
interval (95% CI), 18-45] and 58% (95% CI, 39-
75), respectively, compared with corresponding 
rates of 30% (95% CI, 20-42) and 37% (95% CI, 
25-51) in patients with wild type EGFR (p = 0.403). 
BM at the time of diagnosis was associated with an 
increased risk of BM progression in both patients 
with EGFR mutations (p = 0.022) and wild type 
EGFR (p<0.001). Of the patients with BM at the 
time of diagnosis, the median BM progression-free 
survival for patients with EGFR mutations and wild 
type EGFR were 15.9 and 10.0 months, respectively 
(p = 0.203). Of the 47 patients with EGFR 
mutations, 13 patients (28%) were initially treated 
with EGFR-targeted agents (geÀtinib or erlotinib). 
Initial treatment with EGFR-targeted agents was not 
associated with a decreased risk of BM progression 
in patients with EGFR mutations (p = 0.923).
Conclusion: There was not a signiÀcant relationship 
between the cumulative risk of BM progression and 
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existent polyneuropathy or uncontrolled metastasis 
in the central or peripheral nervous system were 
excluded. Before start of the treatment, after the 3rd 
cycle and 2 months after the last cycle, neurotoxicity 
was assessed by EMG including clinical examination 
and/or audiometry. Primary endpoints consisted 
of the modiÀed Total Neuropathy (TNP) score for 
peripheral neuropathy. For ototoxicity CTCAE 
criteria and the intergroup AR medulloblastoma 
protocol (A9961) were used. 
Results: Until September 2010 45 patients had been 
included. A pre-deÀned safety-analysis was then 
performed. Assessment of peripheral neurotoxicity, 
using the modiÀed TNP score, could be done for 
26 patients who had undergone measurements at 
baseline and after the 3rd cycle, and for 13 patients 
who had completed the whole study. Disease 
progression was the mean reason patients couldn’t 
complete the study. No signiÀcant changes between 
the groups concerning modiÀed TNP score were 
found so far. Mean modiÀed TNP scores increased in 
the placebo group from 5.3 (baseline) to 7.0 (after 3rd 
cycle) to 8.0 (end of study). The intervention group 
showed increase from 2.7 (baseline) to 4.0 (after 3rd 
cycle) to 6.9 (end of study). The incidence of any 
ototoxicity after the 3rd cycle showed no signiÀcant 
difference between the groups. No difference in 
tumour response was observed. 
Ototoxicity CTCAE (after 3rd course) 
incidence n(%) grade 1 grade 2 grade 3 grade 4 
Placebo 3(27) 1 2 0 0 
NAC 5(42) 5 0 0 0 
Ototoxicity AR medullablastoma protocol (after 3rd course) 
incidence n(%) grade 1 grade 2 grade 3 grade 4 
Placebo 2(18) 0 2 0 0 
NAC 3(25) 2 0 0 1 
Conclusion: This interim analysis shows that 
application of N-acetylcysteine seems safe in 
patients receiving cisplatin based chemotherapy as 
no negative effect on tumour response was observed. 
However NAC hasn’t shown a protective effect in 
cisplatin induced neurotoxicity so far.
Keywords: Lung cancer, Cisplatin, N-acetylcysteine, 
neurotoxicity
IV drug administration. Moreover, the compliance 
is more because of convenience of being on a pill. 
GeÀtinib monotherapy should undergo further 
evaluation as Àrst-line therapy in advanced NSCLC.
Keywords: geÀtinib, EGFR Tyrosine Kinase 
Inhibitor, Advanced Non-Small Cell Lung Cancer
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P3.082 A RANDOMIZED DOUBLE-
BLIND STUDY OF N-ACETYLCYSTEINE 
TO PREVENT NEUROTOXICITY 
INDUCED BY PLATINUM CONTAINING 
CHEMOTHERAPY IN PATIENTS 
TREATED FOR (NON) SMALL CELL 
LUNG CANCER AND MALIGNANT 
MESOTHELIOMA. A PRE-LIMINARY 
REPORT.
Egidius C.J. Smolders1, R. H. Boerman2, Idris 
Bahce3, Q. H. Leijten2, P. M.G. Filius4, Y. P. De 
Jong1, Hans J.M. Smit1 
1Pulmonology, Rijnstate/Netherlands, 2Neurology, 
Rijnstate/Netherlands, 3Pulmonology Department, 
Vrije Universiteit Medical Centre/Netherlands, 
4Pharmacy, Rijnstate/Netherlands
Background: Neurotoxicity is a common side 
effect of cisplatin. Peripheral neuropathy occurs 
in the majority of patients receiving cumulative 
doses of cisplatin. Another frequently occurring 
dose-dependent side effect is ototoxicity, affecting 
30-70% of patients. These side effects pose an 
important clinical problem as they can be dose-
limiting and reduce quality of life. Both peripheral 
neuropathy and ototoxicity are caused by cisplatin 
induced formation of reactive oxygen species. 
N-acetylcysteine (NAC), a cysteine-analog with 
strong anti-oxidant capacity, has shown a protective 
effect against cisplatin induced neurotoxicity in 
animal studies. In patients antioxidants have also 
demonstrated protective effects in studies with 
oxaliplatin (NAC) and cisplatin (vitamin E). This 
study investigated whether NAC can prevent 
cisplatin induced neurotoxicity. 
Methods: Patients receiving at least four cycles of 
cisplatin (80 mg/m2 per cycle) in the treatment of 
(non) small lung cancer or malignant mesothelioma 
were randomly assigned to receive either intravenous 
NAC 40 mg/kg 6 hours after completion of the 
cisplatin infusion or placebo. Patient with pre-
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P3.084 EARLY CLOSURE OF A CLINICAL 
TRIAL OF DICHLOROACETATE 
IN PATIENTS WITH PREVIOUSLY 
TREATED, ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) AND 
BREAST CANCER
Edward B. Garon1, Wylie Hosmer2, Carolyn Britten3, 
Fairooz Kabbinavar3, Evangelos D. Michelakis4 
1Medicine; Division Of Hematology/oncology, David 
Geffen School Of Medicine At Ucla/United States Of 
America, 2Cancer Center Of Central Connecticut/
United States Of America, 3David Geffen School 
Of Medicine At Ucla/United States Of America, 
4Medicine, University Of Alberta/Canada
Background: Dichloroacetate (DCA) is a highly 
bioavailable, small molecule that inhibits pyruvate 
dehydrogenase kinase, promoting glucose oxidation 
and reversing the glucolytic phenotype in cancer 
tissues in preclinical studies. DCA has been used 
for decades in the symptomatic treatment of 
mitochondrial disorders and lactic acidosis. DCA is 
undergoing evaluation in early phase trials in solid 
tumors and a recently completed phase Ib trial in 
glioblastoma multiforme.
Methods: A clinical trial was conducted at UCLA 
with collaborators at the University of Alberta. The 
study was an open label trial of DCA 6.25 mg/kg 
orally twice daily in patients with previously treated 
stage IIIB/IV NSCLC or stage IV breast cancer. 
The NSCLC cohort was to enroll 29 patients. The 
breast cancer cohort was to enroll 18 patients with 
expansion to 43 patients if 3 responses were seen 
among the 18 patients. Normal organ function was 
required. ECOG PS 0-2 was initially allowed, but 
this was restricted to 0-1 during the study. 
Results: Seven patients were enrolled, six had 
NSCLC and one had breast cancer. All patients 
had been previously treated, most with multiple 
previous therapies. The breast cancer patient, who 
had known brain metastases, had stable disease 
after eight weeks, but then developed progressive 
brain metastases shortly thereafter. Two patients 
had disease progression after approximately six 
to eight weeks. Two patients withdrew within a 
week of enrollment, one after an unrelated grade IV 
pulmonary embolism (PE) and the other enrolled 
in a hospice program and died within 30 days 
of study enrollment. One patient died suddenly 
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P3.083 CLINICAL OBSERVATION OF 
COMPOUND MATRINE INJECTION IN 
COMBINATION WITH CHEMOTHERAPY 
FOR ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC)
You B. Cui, Chang Y. Li, Shi Y. Feng, Hong Y. Li, 
Yang Li 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: Compound Matrine Injection is an 
effective anti-cancer drug. Recent clinical study 
shows that it can alleviate the symptoms, improve 
the quality of life, and reduce adverse effects of 
chemotherapy in patients with advanced NSCLC. 
The purpose of this study was to evaluate the 
therapeutic effect and safety of Compound Matrine 
Injection in combination with chemotherapy in the 
treatment of advanced (NSCLC).
Methods: A total of 60 patients with lung cancer 
in our hospital were randomly assigned to 2 
groups,30 people in each group. The trial group 
received common chemotherapy for 6 weeks plan 
in combination with Compound Matrine Injection 
for the Àrst 10 to 14 days, while the control 
group received common chemotherapy only. The 
therapeutic efÀcacy on solid tumor, immunological 
function, improvement of life quality and the adverse 
reaction were compared between the two groups.
Results: The short term therapeutic efÀcacy on 
solid tumor , improves patients’immune function, 
improvement of life quality and the adverse reaction 
and side effects of the treatment group was much 
better than that of the control group. There were 
signiÀcant difference in theses indexes compared 
with control group (P<0.05).
Conclusion: Compound Matrine Injection has 
synergism and attenuation action on chemotherapy in 
patients with advanced lung cancer, enhance cellular 
immune function, improving quality of life, which 
is thus worthy of being recommended in clinical 
practice.
Keyword: Compound Matrine Injection; NSCLC; 
Chemotherapy
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Background: PF-3512676 is a TLR9 agonist that 
can activate innate and adaptive immune responses. 
This phase II study was conducted to assess the 
efÀcacy and safety of PF-3512676 in combination 
with EGFR tyrosine kinase inhibitor erlotinib in 
patients with EGFR-positive advanced NSCLC after 
failure of at least 1 prior chemotherapy regimen.
Methods: Patients were randomized 1:1 to 
treatment with PF-3512676 (0.20 mg/kg injected 
subcutaneously once weekly) plus erlotinib (150 
mg daily) or erlotinib alone. Randomization was 
stratiÀed by Eastern Cooperative Oncology Group 
performance status and smoking history. EfÀcacy 
was evaluated every 6 weeks. The primary endpoint 
was progression-free survival (PFS); secondary 
endpoints included objective response rate, overall 
survival (OS), safety, and detection of speciÀc 
immune activation biomarkers.
Results: A total of 43 patients were randomized to 
the study, but only 39 patients received treatment 
with PF-3512676 and erlotinib (n=18) or erlotinib 
alone (n=21). Patient characteristics were well 
balanced between the 2 arms. Median duration 
of erlotinib treatment was 6 weeks (range, 1 - 81 
weeks) in combination with PF-3512676 and 
7 weeks (range, 0 - 29 weeks) when used as 
monotherapy. The study was halted because of 
slow enrollment and an unplanned interim analysis 
indicating that a large improvement in PFS with the 
addition of PF-3512676 would be unlikely even if 
additional patients were enrolled. In the PF-3512676 
plus erlotinib and the erlotinib alone arms, median 
PFS was 1.6 and 1.7 months (HR 1.00; 95% CI: 
[0.49, 2.01]; P=.934), respectively; median OS 
was 6.4 months and 4.7 months (HR 1.30; 95% CI: 
[0.61, 2.79]; P=.493), respectively. There were 2 
partial responses (PRs, 10%) and 2 patients with 
stable disease (SD) in the PF-3512676 plus erlotinib 
arm; there was 1 PR (5%) and 3 with SD in the 
erlotinib alone arm. Levels of immune activation 
biomarkers measured in patients treated with PF-
3512676 and erlotinib demonstrated an increase in 
serum interferon-inducible protein 10 (IP-10) from 
mean 173 pg/mL to 841 pg/mL at 24 hours postdose 
after approximately one week on study. The 
cause of death was not identiÀed, as the family 
refused further investigation. A cerebrovascular 
accident was suspected based on symptoms. One 
patient developed lethal PE after one week on 
study. Although the relation of these deaths to 
DCA was uncertain, the UCLA Data Safety and 
Monitoring Board decided to close the study. This 
decision is supported by recent evidence that oral 
DCA therapy requires several months to reach 
sustained therapeutic serum levels; suggesting that 
during this time, patients are vulnerable to early 
disease progression. Grade III or higher peripheral 
neuropathy was not observed. Although this is a 
potential adverse effect of DCA, it typically appears 
a few months into therapy. 
Conclusion: Patients with previously treated 
advanced NSCLC are likely to develop disease 
progression before therapeutic serum levels can 
be achieved with oral DCA therapy. Further 
development of DCA should be in alternate settings, 
including less advanced disease or in combination 
with standard therapies in advanced disease. This 
study generated insufÀcient data to draw conclusions 
regarding the role of DCA in previously treated 
metastatic breast cancer patients. This study was 
supported by the Lincy Foundation, the Aljian 
Family Trust in Memory of James Aljian and the 
Hecht Foundation. 
Keyword: Dichloroacetate
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P3.085 RANDOMIZED PHASE II TRIAL 
OF ERLOTINIB WITH OR WITHOUT 
PF-3512676 (CPG 7909, A TOLL-LIKE 
RECEPTOR 9 [TLR9] AGONIST) 
IN PATIENTS WITH ADVANCED 
RECURRENT EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR)-POSITIVE 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
Chandra P. Belani1, John J. Nemunaitis2, Abraham 
Chachoua3, Peter D. Eisenberg4, Luis E. Raez5, Juan 
D. Cuevas6, Cecile B. Mather7, Rebecca J. Benner7, 
Sandra J. Meech7 
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United States Of America, 2Mary Crowley Medical 
Research Center/United States Of America, 3New 
York University School Of Medicine And National 
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Methods: A literature search for all phase III 
randomized controlled trials of systemic therapy for 
advanced NSCLC between 1980 and the present was 
performed using Pubmed. The 100 most highly cited 
trials were then determined using the Web of Science 
application. The exclusion criteria and results of each 
of these studies were examined for the exclusion of 
elderly patients, median patient age and age range. 
Results: A total of 238 trials were reviewed. Among 
the 100 most cited trials, 31% speciÀcally excluded 
elderly patients in their trial design (age exclusion 
ranged from >65 to >75 years of age). The mean 
patient age in these trials was 60.8 years. The 
average age for trials that did not speciÀcally exclude 
elderly patients was not signiÀcantly different at 62.2 
(p=0.37). 
Conclusion: Elderly patients are signiÀcantly 
underrepresented in key phase III clinical trials 
in advanced NSCLC. A signiÀcant percentage of 
these trials speciÀcally excluded elderly patients. 
However, the median patient age in trials which 
allowed elderly patients is not dissimilar, and the 
mean patient age in all these trials is lower than that 
of the general advanced NSCLC population. Greater 
representation of elderly patients in phase III trials 
is required to better inform the optimal treatment of 
advanced NSCLC in the general population. 
Keywords: NSCLC, Elderly, systemic therapy
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P3.087 PEMETREXED COMBINED 
WITH PLATINUM AS FRONT LINE 
TREATMENT IN NON SQUAMOUS 
NSCLC: AN INDIAN PERSPECTIVE
Sumit Goyal, Ullas Batra, Dinesh C. Doval 
Medical Oncology, Rajiv Gandhi Cancer Institute & 
Research Centre/India
Background: The management of NSCLC has seen 
a paradigm change in the last two years. In particular, 
there is plethora of options available in the treatment 
of Non squamous NSCLC. In 2009, Pemetrexed 
Platinum combination became the standard of care 
in the Àrst line treatment of adenocarcinoma. We 
undertook this study to evaluate the efÀcacy of this 
regimen in the Àrst line treatment of non squamous 
NSCLC.
Aim: 1) To evaluate the efÀcacy & safety 
cycle 1 and remained elevated (mean, 445 pg/mL) 
through day 8; however, there were no detectable 
increases in interferon-alfa (IFN-Ơ). Among 13 
patients in the PF-3512676 plus erlotinib arm with 
tumor samples at baseline, 4 had EGFR mutations, 
and 2 of these 4 went on to have PRs. In the erlotinib 
arm, of the 17 available samples, 2 were positive 
for EGFR mutations, and only 1 of these had a PR. 
Salient grade 3 or 4 adverse events (AEs) reported 
in the PF-3512676 plus erlotinib/erlotinib alone 
arms were: diarrhea (5/0), dyspnea (5/6), fatigue 
(4/1), other Áu-like symptoms (2/0), anemia (2/1), 
and lymphocytopenia (1/4). Injection-site reactions, 
decreased appetite, and Áu-like illness were common 
AEs considered related to PF-3512676, but these 
were mostly grade 1 or 2. There were no study-
related deaths. 
Conclusion: Addition of PF-3512676 to erlotinib did 
not show any potential for increase in PFS compared 
with erlotinib alone in patients with advanced 
recurrent EGFR-positive NSCLC. The combination 
of PF-3512676 plus erlotinib was tolerable and did 
not have a signiÀcant effect on immune activation 
biomarkers.
Keywords: PF-3512676, erlotinib, Non-small cell 
lung cancer, immunotherapy
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P3.086 ELDERLY PATIENTS WITH 
ADVANCED NSCLC IN PHASE III 
CLINICAL TRIALS: ARE THE ELDERLY 
EXCLUDED FROM PRACTICE-
CHANGING TRIALS IN ADVANCED 
NSCLC?
Adrian Sacher, Natasha Leighl, Linda Coate 
Medical Oncology, Princess Margaret Hospital/
Canada
Background: Elderly patients constitute a large 
proportion of patients with advanced non-small cell 
lung cancer (NSCLC). The median age of newly 
diagnosed patients with lung cancer in the United 
States is approximately 70 years of age. Despite 
this, the elderly are signiÀcantly underrepresented 
in clinical trials in the treatment of advanced 
NSCLC. This has led to uncertainty as to the 
optimal treatment of older patients. Here we seek to 
determine the proportion of elderly patients in key 
phase III clinical trials in advanced NSCLC. 
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P3.088 PRELIMINARY REPORT OF A 
RANDOMIZED TRIAL OF COMPUTER-
ASSISTED QUALITY OF LIFE 
ASSESSMENT IN ADVANCED NSCLC 
PATIENTS
Natasha B. Leighl1, Alexandra Salvarrey1, Farrah 
Kassam1, Lisa Le2, Frances A. Shepherd1, Ronald 
Feld1, Fion Tang2, Patricia Hollen3, Richard J. Gralla4 
1Medical Oncology, Princess Margaret Hospital/
Canada, 2Biostatistics, Princess Margaret Hospital/
Canada, 3Oncology Nursing, University Of Virginia 
School Of Medicine/United States Of America, 
4Medical Oncology, Hofstra North Shore - Lij School 
Of Medicine/United States Of America
Background: Maximizing health-related quality 
of life (QoL) is a fundamental goal in the systemic 
treatment of advanced non-small cell lung cancer 
(NSCLC). However, the routine assessment of QoL 
in clinical practice has been complicated by lengthy 
questionnaires, and the inability to access results in 
a timely manner. The 9-item Lung Cancer Symptom 
Scale (LCSS) has been developed in electronic 
form using a hand-held pocket personal computer 
(eLCSS-QL). With equivalent feasibility, reliability, 
and validity to the LCSS paper version, the 
electronic version permits instant data transfer in an 
easy-to-use graphic format with trends for clinician 
use. Using a randomized trial design, we explored 
the impact of using the eLCSS-QL on treatment 
patterns in patients with advanced NSCLC receiving 
Àrst-line chemotherapy. Primary endpoints include 
palliative care referral rates and duration of systemic 
therapy; secondary endpoints include the use of 
supportive interventions and QoL during treatment.
Methods: Eligible patients are required to: have 
a diagnosis of incurable (M1a or b) NSCLC; be 
scheduled for Àrst-line chemotherapy outside of a 
clinical trial; performance status (PS) 0-3; be literate 
in one of English, French, Portuguese, Spanish, 
Italian, or Chinese; and be able to provide informed 
consent. Patients are excluded if unable to complete 
the eLCSS-QL independently, or if they do not start 
chemotherapy. Patients, stratiÀed by oncologist 
and planned treatment (platinum doublet vs. single 
agent), are randomized either to have the oncologist 
receive their eLCSS-QL data in real time (Arm A), 
or not (Arm B, usual care). All patients complete 
the eLCSS-QL at baseline, at the beginning of 
of Pemetrexed platinum based combination 
chemotherapy in the 1st line treatment of advanced 
Non squamous NSCLC 2) To compare the efÀcacy 
of Pemetrexed based chemo in EGFR wild type vs 
EGFR mutant population 
Methods: Chemotherapy naïve patients with 
histologically/ cytology proven Non squamous 
NSCLC with at least 1 measurable disease site, 
ECOG performance status <2, were included. 
Patients with brain metastases, Inadequate bone 
marrow reserve or deranged renal function tests were 
excluded. EGFR mutation test were performed in all 
the patients where Biopsy specimen were available 
Patients were treated with Inj Pemetrexed 500 mg/
m2 & Cisplatin 75 mg/m2 or Carboplatin AUC 5 q 
3weekly after Folic acid, Vit B12 & Dexamethasone 
premedication. Patients were evaluated every 3 
cycles with CT scans. A maximum of 6 cycles of 
combination chemotherapy were given.
Results: 50 patients were analyzed. The 
Demographic details and efÀcacy analysis are 
mentioned as below: 
Median Age 62 years 
Male : female 65:35 
Smoking status 35 smokers, 15 never smokers 
ECOG PS 0,1 40 
ECOG PS 2 10 
EGFR mutation present 11/50 
Complete Response 2/50 
Partial response 20/50 
Stable disease 13/50 
Progression Free survival 5.2 months 
Median no of cycles 5 
Safety analysis: The combination chemotherapy was 
well tolerated with only 4% of patients developing 
Grade III/ IV hematological toxicity. Dose delays & 
modiÀcations were also infrequent <5%. EfÀcacy in 
EGFR mutation positive patients: In 11 patients who 
were mutation positive, 2 patients had CR while 4 
patients had partial response.
Conclusion: Pemetrexed Platinum combination is 
highly active in Non squamous NSCLC with good 
efÀcacy & safety proÀle. In patients who are EGFR 
mutant, Pemetrexed based combination chemotherapy 
was highly active which raises the question whether 
this subtype of patients have inherent good prognosis. 
However the number of patients in this study are too 
low to reach any deÀnite conclusions. 
Keywords: Pemetrexed, NSCLC, First line 
treatment
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is leading to increased numbers of elderly patients 
referred to medical oncologists for the management 
of lung cancer. Studies have demonstrated that 
geriatric assessment and intervention may improve 
outcomes of the elderly with cancer and guide 
treatment decisions for older patients with lung 
cancer. Therefore, understanding the proÀle and 
outcomes of elderly patients with lung cancer 
are important for creating personalised treatment 
plans. We set out to describe the characteristics 
and outcomes of elderly patients with lung cancer 
referred to the geriatric oncology program at the 
Royal Adelaide Hospital Cancer Centre (RAHCC).
Methods: Patients aged 70 years and older with 
lung cancer treated at the RAHCC during the 
period between Jun 2008 and Jun 2010, were asked 
to complete a self administered questionnaire 
covering co-morbidities, medications, physical 
function, social supports, exhaustion, nutrition, 
cognition and psychological wellbeing. Based on 
their questionnaire, patients were classiÀed as Àt, 
vulnerable or frail. The patients continued to receive 
standard care as deemed appropriate by their treating 
physicians. A retrospective chart review identiÀed 
demographics, diagnosis, treatment regimes and 
mortality.
Results: One hundred and twenty patients were 
seen in this period (mean age 75.6 years, male 
65%). One hundred and three patients (86%) were 
diagnosed with NSCLC (13 (12.6%) early stage, 34 
(33%) locally advanced and 56 (54%) metastatic), 
and 17 (14%) with SCLC (4 (24%) limited stage 
and 13 (76%) extensive stage). The Charlson co-
morbidity score was 2 in 80%, with 37% having >3 
co-morbidities. SigniÀcant weight loss (>10%) was 
seen in 33% of patients. Sixty percent of patients 
lived with partners, 26% lived alone, 11% lived with 
children and 2% lived in other accommodation (no 
data on 4 patients). Patients were categorised into 
three groups: Àt 29 (24%), vulnerable 74 (62%) and 
frail 17 (14%). As a result of the assessment, 91 
(75%) patients had referrals made, most commonly 
24 to dietetics, 18 to social work, 17 to palliative 
care team, 13 to geriatrics, and 10 to occupational 
therapy. Seventy-seven patients (47% of frail, 66% 
of Àt and 68% of vulnerable patients) were treated 
with chemotherapy. The majority of the Àt (74%), 
vulnerable (70%) and frail (62%) patients completed 
the planned cycles of chemotherapy. Seventeen 
percent of the frail group proceeded onto second 
line chemotherapy. After a median follow-up of 19 
months, the frail patient group had a signiÀcantly 
each cycle of chemotherapy, and at follow up visits 
until disease progression (initiation of subsequent 
therapy).
Results: To date, 101 potentially eligible patients 
have been enrolled; 1 was not randomized (clinical 
deterioration). Six did not begin chemotherapy as 
planned (5 Arm A, 1 Arm B), and are not included 
in outcome analyses. Of the 94 remaining eligible 
patients, 43 were randomized to Arm A, 51 to Arm 
B; 13 remain on chemotherapy. Characteristics 
are similar between the groups. Median age of the 
sample is 65 years (range 39 to 80), 56% are male, 
7%/55%/32%/5% are PS 0/1/2/3. 44% are stage 
M1a. Of those enrolled, 85% received single agent 
therapy, and 15% a platinum doublet. Baseline 
LCSS scores are similar between the groups, 
although numerically higher in Arm B (control). 
Referral rates to palliative care during Àrst-line 
therapy trended higher in Arm A, 44% versus 
35% in Arm B, although not signiÀcantly different 
in this number of patients (p=0.38). The median 
duration of chemotherapy was 4 cycles in both 
groups. Additional data on secondary endpoints of 
supportive interventions used and QoL over time in 
both arms will be presented.
Conclusion: Computer-assisted QoL assessment is 
feasible in clinical practice, and has the potential to 
demonstrate the impact of supportive and palliative 
care interventions in advanced NSCLC. Larger 
trials may be required to demonstrate statistically 
signiÀcant differences in outcomes with the routine 
use of QoL assessment.
Keywords: Lung Cancer Symptom Scale, Advanced 
NSCLC, Quality of Life, randomized trial
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P3.089 OUTCOMES OF GERIATRIC 
ASSESSMENT FOR OLDER LUNG 
CANCER PATIENTS FROM A 
DEDICATED GERIATRIC ONCOLOGY 
PROGRAM
Hong bing Cheng1, Timothy To2, Rohit Joshi3, Nimit 
Singhal1 
1Medical Oncology, Royal Adelaide Hospital/
Australia, 2Rehabiliation And Aged Care, 
Repatriation General Hospital/Australia, 3Medical 
Oncology, Lyell Mcewin Hospital/Australia
Background: The ageing population in Australia 
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status (PS) 1 and three with PS 2. One patient had the 
sensitive mutation of epidermal growth factor receptor 
(EGFR), one had negative mutation and other eight 
had unknown status. Ninety percent had received 
more than one prior chemotherapy regimen, 80 
percent had received platinum-based chemotherapy, 
and 30 percent had received prior geÀtinib treatment. 
Erlotinib was given as a Àrst-line therapy in one 
patient, second-line in three patients, third-line in three 
patients, fourth-line in one patient, and Àfth-line in 
two patients. The response rate was 30 percent (three 
PR and two SD); the median duration of the exposure 
and the median overall survival were 5 months and 
8.5 months, respectively. At the time of data cut-off, 
one patient continued erlotinib treatment; four patients 
received chemotherapy and Àve patients received best 
supportive care after termination of erlotinib. Eight 
deaths had occurred but two patients were alive at the 
time of analysis. The patient who continued erlotinib 
had the 24-months-survival and had the sensitive 
mutation of EGFR. Most frequent toxic effect was 
rash (70 percent); liver dysfunction was shown in one 
patient and stomatitis was shown in one patient. 
Conclusion: Erlotinib treatment was selected as a 
second-line therapy or later and its side effects were 
acceptable. As compared with BR.21 trial, response 
rate was 30 percent (8.9 percent in BR.21); median 
progression free survival was 5 months (2.2 months 
in BR.21); median overall survival was 8.5 months 
(6.7 months in BR.21). In conclusion, erlotinib was 
the safe and effective option for the patients who were 
diagnosed with postoperative recurrence of NSCLC. 
Keywords: erlotinib, postoperative recurrence, non–
small-cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.091 PLASMA HOMOCYSTEINE 
LEVELS ARE ASSOCIATED WITH THE 
HEMATOLOGICAL TOXICITY OF 
PEMETREXED EVEN WITH FOLATE 
SUPPLEMENTATION
Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, 
Ryota Saito, Kyohei Kaburaki, Noriko Yanagitani, 
Keita Kudo, Fumiyoshi Ohyanagi, Sachiko 
Hagiwara, Takeshi Horai, Makoto Nishio 
higher mortality (94%) as compared to the other two 
groups (Àt 55%, vulnerable 67%).
Conclusion: The preliminary analysis demonstrates 
that this elderly group of patients have a wide 
variation in functional status and social situations. 
A similar proportion of Àt, vulnerable and frail 
patients received treatment, but there was no survival 
beneÀt for frail patients. Proper geriatric oncology 
assessments may help deliver appropriate treatment 
to the right person and avoid potentially toxic 
treatments.
Keywords: older lung cancer patients, geriatric 
oncology
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P3.090 THE EFFICACY AND THE 
SAFETY OF ERLOTINIB FOR THE 
PATIENTS WHO WERE DIAGNOSED 
WITH POSTOPERATIVE RECURRENCE 
OF NON–SMALL-CELL LUNG CANCER 
(NSCLC)
Arifumi Iwamaru 
Surgery, Tachikawa Hospital/Japan
Background: Although BR.21 trials revealed that 
erlotinib can prolong survival in patients with stage 
IIIB or IV non–small-cell lung cancer (NSCLC) after 
Àrst-line or second-line chemotherapy, little is known 
about the efÀcacy and the safety of erlotinib for the 
patients who were diagnosed with postoperative 
recurrence of NSCLC.
Methods: Twenty seven patients received erlotinib 
treatment at a dose of 150 mg daily between June 1, 
2008 and December 31, 2010 and ten patients (37%) 
had been diagnosed with postoperative recurrence. 
The patients’ characteristics, response rate, toxic 
effect and survival were investigated retrospectively. 
The response rate was evaluated on the basis of 
Response Evaluation Criteria in Solid Tumors 
(RECIST) by means of computed tomography and 
tumor markers (if available). The toxic effects were 
assessed according to National Cancer Institute 
Common Toxic Criteria (NCI-CTC).
Results: The median age of the ten patients was 
73 years (range 44-80); seven males and three 
female; seven adenocarcinomas, two squamous 
cell carcinomas and one large cell neuroendocrine 
carcinoma; seven patients with an Eastern 
Cooperative Oncology Group (ECOG) performance 
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P3.092 ADVANCED NON-SMALL CELL 
LUNG (NSCLC) IN YOUNG PATIENTS 
( 40 YEARS) : TREATMENT AND 
CLINICAL OUTCOMES.
Orazio Caffo1, Anna Ceribelli2, Filippo Demarinis3, 
Vanesa Gregorc4, Silvia Novello5, Alessandra 
Bearz6, Andrea Bonetti7, Francesco Grossi8, Viviana 
Murgia1, Serena Ricciardi3, Francesco Rosetti9, 
Marcello Tiseo10, Tiziana Vavalà5, Enzo Galligioni1 
1Medical Oncology Department, Santa Chiara 
Hospital/Italy, 2Division Of Medical Oncology 
A, Regina Elena National Cancer Institute/Italy, 
3Thoracic Oncology Unit I, Carlo Forlanini 
Hospital/Italy, 4Department Of Oncology, Istituto 
ScientiÀco San Raffaele/Italy, 5Thoracic Oncology 
Unit, University Of Turin/Italy, 6Cro Di Aviano/Italy, 
7Medical Oncology, Ospedale Mater Salutis/Italy, 
8Lung Cancer Unit, National Institute For Cancer 
Research/Italy, 9Civil Hospital/Italy, 10Medical 
Oncology Unit, University Hospital Of Parma/Italy
Background: NSCLC is rarely diagnosed in patients 
(pts)  40 years, however in this case it is usually 
considered as a distinct disease, with younger pts 
having a better prognosis compared to older pts. In 
the last decade, the introduction of third generation 
drugs and targeted therapies enhanced survival in 
pts with IIIB/IV stage, with a median survival (MS) 
of 12-14 months. Some studies have reported small 
series of young pts with NSCLC but the age cut-
offs varied among studies and most of them did not 
speciÀcally address the clinical outcomes of the 
IIIB/IV stage pts. The present report speciÀcally 
addresses the treatment and the clinical outcomes 
of pts  40 years with IIIB/IV stage NSCLC treated 
after 2000 in our institutions. 
Methods: We reviewed all pts referred for NSCLC 
from 2000 to 2010 to our Institutions and selected a 
consecutive series of 97 pts  40 years older. Eleven 
pts with early stages were excluded and 86 with 
IIIB/IV NSCLC were assessed. Pts characteristics: 
male/female 58%/42%; median age 36 years (range 
21-40); stage IIIB/ IV 8%/92%; histological type: 
adenocarcinoma 71 %, squamous 9 %, other 20 %. 
Metastatic sites of these pts were lung in 50%, liver 
in 15%, lymph nodes in 43%, brain in 24%, bone in 
28%, pleural in 20%, and adrenal in 8%.
Results: All but 4 pts received systemic treatment 
for their IIIB/IV disease: 41% received only one line, 
Thoracic Oncology Center, Cancer Institute 
Hospital, Japanese Foundation For Cancer 
Research/Japan
Background: Systemic folic acid and vitamin 
B
12
 supplementation is necessary for pemetrexed 
treatment, because severe toxicities of pemetrexed 
treatment without folate supplementation were 
observed in patients who had high levels of plasma 
homocysteine (Hcy) in early clinical trials. However, 
it was not examined whether the plasma Hcy levels 
would still associated with the hematological 
toxicity of pemetrexed in patients receiving folate 
supplementation. The purpose of this study was to 
examine the relationship between the pretreatment 
plasma Hcy levels after folate supplementation 
and the hematological toxicity of pemetrexed 
monotherapy in advanced non-small cell lung cancer 
(NSCLC).
Methods: From June 2009 to November 2010, 58 
NSCLC patients received pemetrexed monotherapy 
(500mg/m2, every 3 weeks) and also received oral 
folic acid (0.5mg) daily and a vitamin B
12
 injection 
(1mg) every 9 weeks, beginning 1 to 2 weeks before 
the Àrst dose and continuing until 3 weeks after 
the last dose of the study treatment. The plasma 
Hcy levels before the Àrst dose of pemetrexed 
were measured. Complete blood cell counts were 
measured at least once a week during Àrst cycle of 
pemetrexed monotherapy. The relationship between 
the plasma Hcy levels and hematological toxicities 
during the Àrst cycle of pemetrexed monotherapy 
were evaluated.
Results: The patient characteristics were as follows: 
male/female: 26/32; median age: 65 years(34-79); 
histology, adeno/large: 56/2; PS, 0/1/2/3: 30/25/2/1. 
The mean pretreatment plasma Hcy was 8.73ƫmol/
ml (3.5-34.6ƫmol/ml). The pretreatment plasma Hcy 
signiÀcantly correlated with the nadir of the absolute 
leukocyte counts (r=-0.374 p=0.004), the nadir of 
the absolute neutrophil counts (r=-0.286 p=0.028), 
and the nadir of the absolute thrombocyte counts (r=-
0.324 p=0.012). In addition, the pretreatment plasma 
Hcy signiÀcantly correlated with the decline rates of 
leukocytes (r=+0.378 p=0.003), neutrophil (r=+0.335 
p=0.009) and thrombocytes (r=+0.363 p=0.005).
Conclusion: Plasma Hcy levels are associated with 
hematological toxicity of pemetrexed monotherapy 
with folate supplementation.
Keywords: Pemetrexed, Homocysteine, folate 
supplementation, Hematological toxicity
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brain metastases, and this subset of patients was 
excluded from initial trials of bevacizumab due to 
the theoretical risk of CNS hemorrhage. 
Methods: Two open-label phase II studies 
investigated the safety and efÀcacy of bevacizumab 
and pemetrexed as second-line therapy after 
a platinum doublet in advanced nonsquamous 
NSCLC with brain metastases. In one study, this 
combination was used exclusively. (Stanford study). 
The other trial included both Àrst and second-line 
combinations; bevacizumab and pemetrexed in 
combination was one of several options for second-
line use at the investigator’s discretion (PASSPORT 
study). In the Stanford study, patients were eligible 
if their CNS disease was radiographically stable at 
least one month after radiation or surgery and they 
no longer required steroids. In PASSPORT, patients 
were eligible 3 months after CNS surgery or 1 week 
after completion of radiation alone provided imaging 
within 1 week of treatment initiation showed no 
CNS progression or hemorrhage. Though cytotoxic 
treatment could start 1 week after radiation, 
bevacizumab was withheld until at least 4 weeks 
after radiation was completed. Patients on both 
studies were treated with pemetrexed 500mg/m2 and 
bevacizumab 15mg/kg on day 1 of each 3 week cycle 
until progression or discontinuation for symptoms 
or adverse events. The primary endpoint was safety, 
speciÀcally CNS hemorrhagic events. Secondary 
endpoints included progression-free survival (PFS) 
and overall survival (OS).
Results: 16 patients were accrued on the Stanford 
study (2 centers), and 22 on the second-line 
pemetrexed arm of PASSPORT (13 centers) for a 
total of 38. The median age for all patients was 60 
(range 33-74). 66% had adenocarcinoma, 13% had 
large cell carcinoma, and 21% had other pathology. 
Patients received a median of 6 cycles of therapy 
(range 1-42). There were no CNS bleeding events 
in either study. Two grade 5 (acute renal failure and 
respiratory distress) and three grade 4 adverse events 
(neutropenia, severe fatigue and pneumonia) were 
observed. There were 2 thromboembolic events 
requiring anticoagulation. Median PFS was 7.2 
months (95% CI 5.5-9.0, mean 10.2), and median OS 
was 14.8 months (95% CI 9.4-20.1, mean 16.6). On 
the Stanford study, a partial response was observed 
in 4 patients (25%), and 14 (88%) demonstrated at 
least stable disease; these data were not collected in 
PASSPORT. 
Conclusion: The combination of pemetrexed and 
bevacizumab is a relatively safe and well-tolerated 
26% two lines, 19% three lines, and 14% four lines. 
Seventy pts received as Àrst-line a platinum-based 
doublet (among them 46 were treated with cisplatin 
+ gemcitabine and 5 received bevacizumab too), 4 a 
platinum-based triplet, 8 a single-agent therapy. The 
response rate was 28% (3 CR + 21 PR). Forty seven 
pts received a second-line treatment (consisting 
of non cross resistant chemotherapy in 30 pts and 
of TKIs in 17), 26 a third-line (15 chemotherapy, 
11 TKi) and 11 a fourth-line treatment (2 received 
chemotherapy, 9 TKi) . The MS is 19 mos with a 
62.8% 1-y OS.
Conclusion: Our experience conÀrmed that  
40 years IIIB/IV NSCLC pts presented survival 
outcomes better than expected in the overall 
population. An ancillary study is ongoing to evaluate 
possible biomarkers as prognostic factors on 
available tumor samples.
Keywords: NSCLC, young patients
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P3.093 A POOLED ANALYSIS OF 
ADVANCED NONSQUAMOUS NSCLC 
PATIENTS WITH STABLE TREATED 
BRAIN METASTASES IN TWO PHASE 
II TRIALS RECEIVING BEVACIZUMAB 
AND PEMETREXED AS SECOND-LINE 
THERAPY
Matthew Gubens1, Wallace Akerley2, Thomas 
Lynch3, Corey J. Langer4, Mark A. Socinski5, A. 
Dimitrios Colevas1, Christelle Clement-Duchene6, 
Heather Wakelee1 
1Stanford Cancer Center, Stanford University School 
Of Medicine/United States Of America, 2Huntsman 
Cancer Institute, University Of Utah/United States 
Of America, 3Department Of Oncology, Yale Cancer 
Center And Smilow Cancer Hospital/United States 
Of America, 4Hematology/oncology, Abramson 
Cancer Center, University Of Pennsylvania/
United States Of America, 5Hematology/oncology, 
University Of North Carolina/United States Of 
America, 6Chu Nancy Service De Pneumologie/
France
Background: The efÀcacy of angiogenesis 
inhibition has been established in the treatment of 
several tumor types, including advanced non-small 
cell lung cancer (NSCLC). However, approximately 
30% of patients with advanced NSCLC will develop 
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outcomes of Àrst line chemotherapy, and second split 
on age of the patients. Three terminal subgroups 
were formed, and the median survival time of the 
three subsets ranged from 1.0 month (95%CI, 0.8-
1.2 m) for those with progression disease outcome 
after Àrst line chemotherapy subgroup, 10 months 
(95%CI, 7.0-13.0 m) in patients with partial response 
or stable disease in Àrst line chemotherapy, and 
younger than 70 years old, to 22.0 months (95%CI, 
3.8-40.2 m) for the patients obtaining partial 
response or stable disease in Àrst line chemotherapy 
at age of 70~81. 
Conclusion: Partial response, Stable disease in Àrst 
line chemotherapy and age ³ 70 is correlated closely 
with long term survival treated by geÀtinib as second 
or third line setting in Chinese advanced NSCLC 
patients. CART can be used to identify previously 
unappreciated patient subsets and is a useful method 
for dissecting complex clinical situations and 
identifying homogeneous patient populations in 
clinical practice. 
Keyword: ClassiÀcation and Regression tree，Non - 
Small Cell Lung Cancer，GeÀtinib
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.095 COST-EFFECTIVENESS OF 
TREATMENT WITH NEW AGENTS IN 
ADVANCED NON-SMALL-CELL LUNG 
CANCER: A SYSTEMATIC REVIEW
Mathilda L. Bongers1, Veerle M.H. Coupé1, E P. 
Jansma2, Egbert F. Smit3, Carin A. Uyl-de Groot1 
1Epidemiology & Biostatistics, VU University 
treatment for second-line use in advanced NSCLC 
patients with stable treated brain metastases. No CNS 
hemorrhage events were noted in either study. PFS 
and OS compare favorably to those of other second-
line treatments in this setting, exceeding those 
observed in the registration trial for pemetrexed 
alone. Larger multiple-arm studies will be required 
to assess the comparative effectiveness of such 
regimens, but these data suggest bevacizumab need 
not be withheld from appropriately selected patients 
with brain metastases. 
Keywords: cns, Metastatic, Pemetrexed, 
bevacizumab
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P3.094 CLASSIFICATION AND 
REGRESSION TREE ANALYSIS OF 
CLINICAL PATTERNS THAT PREDICT 
SURVIVAL IN 127 CHINESE PATIENTS 
WITH ADVANCED NON - SMALL 
CELL LUNG CANCER TREATED BY 
GEFITINIB
Wang Ziping1, Guo Ji-Hong1, Wang Yan1, Yang Juan2 
1Clinical Medical Oncology, Cancer Hospital & 
Institute, Chinese Academy Of Medical Sciences/
China, 2Department Of Epidemiology, West China 
School Of Public Health, Sichuan University/China
Background: GeÀtinib produce tumor regression 
only 10–20% in heavily pretreated unselected 
NSCLC as second and third line setting, and 
responses are more common in female, never 
smokers, adenocarcinoma, and Asian population. 
Nevertheless, it’s hard to Ànd such a patient with all 
about clinical characteristics, and need to identify 
subgroups of patients who will be likely to obtain 
differant survival time before using geÀtinib in our 
clinical practice. 
Methods: The clinical and follow up data of 127 
Chinese NSCLC patients referred to the Cancer 
Hospital & Institute, Chinese Academy of Medical 
Sciences from March 1, 2005 through March 
30, 2010 were analyzed. Multivariate analysis of 
progression free survival (PFS) was performed using 
recursive partitioning referred to as classiÀcation and 
regression tree (CART) analysis
Results: The median PFS of 127 eligible Chinese 
NSCLC patients was 8.0 months(95%CI, 5.8-10.2 
m). CART was performed with an initial split on 
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P3.096 ESTIMATION OF QUALITY-
ADJUSTED PROGRESSION FREE 
SURVIVAL (QA-PFS) OF FIRST LINE 
TREATMENTS IN EGFR MUTATION-
POSITIVE ADVANCED NON SMALL 
CELL LUNG CANCER (NSCLC) 
PATIENTS IN THE NETHERLANDS
S. Cora Verduyn1, Bonne Biesma2, Franz M.N.H. 
Schramel3, Feike W. Van Der Scheer4, Merel K. 
Langenfeld4, Maria A. De Peuter1, Anne-Marie C. 
Dingemans5 
1Clinical And Economic Evidence Team, Mapi 
Values/Netherlands, 2Jeroen Bosch Hospital/
Netherlands, 3Department Of Pulmonology, Sint 
Antonius Hospital/Netherlands, 4Astrazeneca/
Netherlands, 5Academic Hospital Maastricht/
Netherlands
Background: GeÀtinib, a tyrosine kinase inhibitor, 
is an effective treatment for patients with advanced 
NSCLC with an activating mutation in the epidermal 
growth factor receptor (EGFR M+). Randomised 
clinical trials showed a beneÀt in progression 
free survival (PFS) for geÀtinib versus doublet 
chemotherapy in EGFR M+ patients (Mok,2009, 
Mitsudomi,2010, Maemondo,2010). From a patient 
perspective, not only PFS itself is important but also 
their health-related quality of life (QoL). Therefore 
Quality Adjusted Progression Free Survival (QA-
PFS) of geÀtinib versus relevant chemotherapy 
(paclitaxel/carboplatin (Pac/Carb); gemcitabine/
cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); 
was evaluated from a Dutch health care perspective 
in patients with EGFR M+ stage IIIB/IV NSCLC. 
PFS rather than overall survival (OS) was evaluated 
since OS may be largely inÁuenced by subsequent 
treatment lines. 
Methods: Mean PFS for Pac/Carb was obtained by 
extrapolating median PFS as reported in the Iressa-
Pan-Asia Study (IPASS; Mok, 2009). Network meta-
analysis was used to estimate the mean PFS for the 
therapies of interest relative to Pac/Carb. Adjustment 
for QoL was done by incorporating utilities for the 
Dutch population, obtained by converting FACT-L 
data using the Lamers algorithm (2007). FACT-L 
data collected during progression-free state from 
EGFR M+ patients in IPASS treated with either 
geÀtinib or Pac/Carb were used. The utility of the 
other doublet chemotherapy regimens was assumed 
Medical Centre/Netherlands, 2University Library, 
Medical Library, VU University/Netherlands, 
3Department Of Pulmonary Diseases, VU University 
Medical Center/Netherlands
Background: Over the past decades, research 
focusing on new chemotherapeutic agents for 
patients with inoperable NSCLC have reported 
only modest gains in survival. These health gains 
are achieved at considerable costs, but economic 
evidence on superiority of one of the agents in terms 
of cost-effectiveness is lacking. The objective of 
this systematic review is to assess fully published 
cost-effectiveness studies comparing the new agents 
docetaxel, paclitaxel, vinorelbine, gemcitabine and 
pemetrexed, and the targeted therapies erlotinib and 
geÀtinib among each other. 
Methods: PubMed, EMBASE.com and Economic 
Evaluations (via the Cochrane Library, Wiley) were 
systematically searched for fully published studies 
from the past ten years. Studies were screened by 
two independent reviewers according to a priori 
inclusion criteria. The methodological quality of the 
included studies was evaluated by two independent 
reviewers using standardized assessment tools. 
Results: 222 potential studies were identiÀed. 11 
cost-effectiveness and cost-utility studies were 
included. The methodological quality of the full 
economic evaluations was fairly good. Transparency 
in costs and resource use, details on statistical tests 
and sensitivity analysis were points for improvement. 
In Àrst-line treatment, there were indications that 
gemcitabine-cisplatin is cost-effective compared to 
platinum-based regimens containing either paclitaxel 
, docetaxel or vinorelbine (range of incremental life 
years: 0.04-0.13; range of incremental costs: US$ 
-926-US$ -5 686). In one study pemetrexed-cisplatin 
was cost-effective compared to gemcitabine-cisplatin 
in patients with nonsquamous cell carcinoma (ICER 
per life year gained: US$ 83 537). In second-line 
treatment, docetaxel was cost-effective compared 
to BSC (range of ICERs per life year gained: US$ 
22 190-US $32 133). Erlotinib was cost-effective 
compared to placebo (ICER per life year gained: 
US$ 33 728). Docetaxel and pemetrexed were 
dominated by erlotinib. 
Conclusion: We found indications for superiority in 
terms of cost-effectiveness of gemcitabine-cisplatin 
in a Àrst-line setting and for erlotinib in second-line 
setting. 
Keyword: Cost-effectiveness
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Recherche 2, Université Pierre Et Marie Curie, Paris 
Vi/France
Background: Non small cell lung cancer (NSCLC) 
incidence is higher in HIV-infected people, 
even adjusted to the smoking history. Patient’s 
characteristics differ from the general population by 
a younger age and a worse prognosis. Chemotherapy 
is particularly toxic because of drug interactions 
with the antiretroviral therapy. Mutations of the 
epidermal growth factor receptor (EGFR) are a 
favorable prognostic factor in NSCLC and predict 
responsiveness to EGFR tyrosine kinase inhibitors. 
KRAS mutations are mutually exclusive with EGFR 
mutations and might be a negative prognostic factor. 
No data are available on the prevalence of EGFR and 
KRAS mutations in NSCLC of HIV positive patients. 
Methods: Tissue of 41 consecutive HIV infected 
patients with NSCLC were assessed for EGFR and 
KRAS mutations by direct sequencing. 
Results: Thirty Àve patients were male (85%), 
median age was 49 years (range 37-70) and most were 
Caucasians (n=39, 95%). All patients had a smoking 
history, current (n=32, 78%) or former (n=9, 22%). 
Eighteen patients (44%) had stage I-IIIA disease 
and 23 patients (56%) had stage IIIB-IV disease. 
The major histological subtype was adenocarcinoma 
(58.5%). The median CD4 lymphocyte count was 420/
l (range, 3-1070). KRAS mutations were detected 
in the tissue of 4 patients (11%). Tumor EGFR 
mutations were identiÀed in 2 patients (5.5%) with 
two exon 19 deletions. These two patients were male, 
Caucasian, smoker or previous smoker, with stage 
IV adenocarcinoma. EGFR inhibitor (erlotinib) was 
administrated as second line therapy in both patients 
with an excellent tumor response and a time to 
progression of 15 months and 14 months, respectively. 
They are still alive at 33 and 23 months of the 
diagnosis, whereas the median overall survival of 
EGFR wild type patients with stage IIIB-IV NSCLC 
(n=20) was only 4.7 months (CI 2.2-8.1; p=0.011). 
Conclusion: Prevalence of EGFR and KRAS mutations 
are similar in NSCLC among HIV-positive patients 
than in the general population. EGFR mutations are a 
strong prognostic factor of survival and are predictive for 
response to EGFR inhibitors in HIV patients. 
Keywords: mutation Kras, HIV, non small cell 
cancer, mutation EGFR
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
similar to the utility of Pac/Carb. Finally the speciÀc 
utilities were multiplied by the mean PFS for each 
treatment arm to determine the QA-PFS. 
Results: The estimated mean PFS with getitinib 
(10.52 months; 95% conÀdence interval [CI]: 
8.87-12.53 was signiÀcantly higher than that for 
the doublet chemotherapies (Table). In IPASS, the 
FACT-L derived utility at start of study treatment 
was 0.736±0.1059 for all EGFR M+ patients in 
both arms. In the geÀtinib arm, the utility in the PFS 
period increased by 0.0528±0.0095, whilst no change 
in utility was observed for the Pac/Carb treatment 
arm. Combining the utilities with the mean PFS 
resulted in a QA-PFS for geÀtinib of 8.32 months 
(95%CI: 7.01-9.91). In comparison with Pac/Carb, 
Gem/Cis and Pem/Cis, geÀtinib increased the QA-
PFS by more than 3 months (Table). Progression free 
survival (PFS) and Quality Adjusted PFS (QA-PFS) 
in months (mean and 95% conÀdence intervals) 
Pac/Carb Gem/Cis Pem/Cis Ge¿tinib 
PFS 6.65 (5.90; 7.40) 6.98 (6.11; 7.89) 7.15 (6.17; 8.21) 10.52 (8.87; 12.53) 
QA-PFS 4.91 (4.36; 5.51) 5.14 (4.52; 5.83) 5.27 (4.56; 6.07) 8.32 (7.01; 9.91) 
ǻ QA-PFS 3.41 (2.35; 4.79) 3.17 (2.01; 4.58) 3.04 (1.91; 4.41) 
Conclusion: In the Dutch health care setting, the 
PFS beneÀt of Àrst line geÀtinib in advanced NSCLC 
EGFR M+ patients in comparison to standard 
doublet chemotherapy is further supported by the 
QA-PFS, which takes account of the additional QoL 
beneÀts for geÀtinib over doublet chemotherapy.
Keywords: EGFR tyrosin kinase inhibitor, 
Progression free survival (PFS), EGFR mutation, 
Quality of life (QoL)
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P3.097 IMPORTANCE OF EGFR STATUS 
IN HIV INFECTED PATIENTS WITH NON 
SMALL CELL LUNG CANCER
Armelle Lavolé1, Baya Adjeriou2, Virginie Poulot2, 
Nadia Hoyeau3, Christos Chouaïd4, Anne Marie 
Ruppert1, Roger Lacave2, Marie Wislez5, Jacques 
Cadranel5 
1Pneumologie, Hôpital Tenon/France, 2Plateforme 
De Génomique Des Tumeurs Solides Service 
D’histologie – Biologie Tumorale, Hôpital Tenon/
France, 3Service D’anatomopathologie, Hôpital 
Saint Antoine/France, 4Service De Pneumologie, 
Hôpital Saint Antoine, Paris/France, 5Equipe De 
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with EGFR-TKIs as second-line was 11 months 
(p=0.54). In group A, 44% of the patients were 
treated with second-line chemotherapies after Àrst-
line EGFR-TKIs. The other patients did not undergo 
any chemotherapy after treatment of EGFR-TKIs 
due to worsing their performans status. In group B, 
94% of the patients were treated with second-line 
EGFR-TKIs after Àrst-line chemotherapies. mOSs in 
group A and B were 21 and 43 months, respectively 
(p=0.07).
Conclusion: Although there was no difference 
in response of EGFR-TKIs between Àrst- and 
second-line therapy in EGFR-mutated NSCLCs, 
overall survival for patients treated with second-
line EGFR-TKIs tended to be longer than that for 
patients treated with Àrst-line EGFR-TKIs. Since 
a considerable fraction of patients treated with 
Àrst-line EGFR-TKIs could not be treated with 
second-line chemotherapies, the preferable timing 
of treatment of EGFR-TKIs might be second-line 
therapy.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.099 STABLE DISEASE IN ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC) - LACK OF RESPONSE TO 
CHEMOTHERAPY OR RELEVANT 
CATEGORY OF RESPONSE?
Davorin Radosavljevic1, Dusica Gavrilovic2, 
Golubicic Ivana3, Jelic Svetislav1 
1Medical Oncology, Institute For Oncology And 
Radiology Of Serbia/Serbia, 2Data Center, Institute 
For Oncology And Radiology Of Serbia/Serbia, 
3Radiation Oncology, Institute For Oncology And 
Radiology Of Serbia/Serbia
Background: Stable disease is probably the most 
frequent category of response to chemotherapy in 
advanced NSCLC. It reÁects, at some extent, the 
natural course of disease. Therefore, is it the failure of 
treatment or, it should be seen as a relevant response 
category as a part of disease control rate? This 
question is closely related to the relationship between 
response categories and survival in advanced NSCLC 
and prognostic aspects of particular categories.
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P3.098 THE PREFERABLE TIMING OF 
TREATMENT WITH EGFR-TKIS FOR 
NSCLCS WITH EGFR MUTATIONS.
Hirokazu Touge1, Shingo Matsumoto1, Tomohiro 
Sakamoto1, Naoki Kinoshita1, Keiji Matsunami1, 
Masahiro Kodani1, Masaki Nakamoto1, Akira 
Yamasaki1, Hiroki Chikumi1, Yuji Kawasaki2, 
Tadashi Igishi1, Eiji Shimizu1 
1Medical Oncology And Molecular Respirology, 
Faculty Of Medicine, Tottori University/Japan, 
2Regional Medicine, Faculty Of Medicine, Tottori 
University/Japan
Background: Non-small cell lung cancers 
(NSCLCs) with sensitive mutations of the 
pidermal growth factor receptor (EGFR) gene 
are highly responsive to EGFR tyrosine kinase 
inhibitors (TKIs). Recent clinical studies revealed 
that Àrst-line geÀtinib, a EGFR-TKI, improved 
progression-free survival (PFS) for patients with 
EGFR-mutated NSCLCs, as compared with standard 
chemotherapies, but did not improve overall survival 
because of possible efÀcacy of geÀtinib as second-
line or later therapy for patients treated with Àrst-line 
chemotherapy. Thus, the best timing of treatment 
with EGFR-TKIs for cases with EGFR mutations is 
still undetermined. To explore the preferable timing, 
we compared between efÀcacy of EGFR-TKIs as 
Àrst-line and that as second-line in EGFR-mutated 
NSCLCs.
Methods: Thirty seven advanced NSCLC patients 
with sensitive mutations of the EGFR gene, who 
were treated at the Tottori University Hospital, Japan, 
from May 2007 to March 2010, were retrospectively 
evaluated response of therapy according to RECIST 
and progression free survival (PFS). The differences 
in response rate (RR) and median PFS (mPFS) 
between Àrst- and second-line EGFR-TKIs were 
statistically analyzed. Median overall survival (mOS) 
for patients treated with Àrst- and second-line EGFR-
TKIs was also compared.
Results: The 37 patients with median age of 68 years 
included 14 men and 23 women. Among the patients, 
15 patients were treated with EGFR-TKIs as Àrst-
line (group A), and 22 were treated with those as 
second-line (group B). RRs of EGFR-TKIs in group 
A and B were 44% and 57% respectively (p=0.86). 
mPFSs for group A treated with EGFR-TKIs as 
Àrst-line was 8 months, and that for group B treated 
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Christian Manegold1, Lothar R. Pilz9 
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Of Oncology, Vilnius University, Faculty Of 
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Background: This randomized phase II/III trial is 
meant to assess the efÀcacy and safety of cetuximab 
in combination with two different chemotherapy 
regimens. Primary study endpoints: Clinical relevant 
toxicities (phase II) and overall survival (phase III). 
Methods: Chemonaïve patients with histologically 
conÀrmed stage IIIB or IV NSCLC and performance 
status (WHO) 0–2 received cetuximab 400 mg/m² 
as loading dose and then 250 mg/m² weekly either 
combined with gemcitabine 1000 mg/m² days 1 + 
8 for 2 cycles (3qw) followed by docetaxel 75 mg/
m² day 1 for 2 cycles (q3w) (arm A) or carboplatin 
AUC5 day 1 and gemcitabine 1200 mg/m² days 1 
+ 8 for 4 cycles (q3w) (arm B). If patients did not 
progress single agent cetuximab was continued until 
tumor progression or unacceptable toxicity. 
Results: TABLE 1: Toxicities per patient requiring 
clinical intervention. 
Clinical relevant toxicities Arm A Arm B “Maintenance” 
Cetuximab / 
gemcitabine 
n=173 (pts) 
Cetuximab 
/ docetaxel 
n=112 (pts) 
Cetuximab / 
carboplatin/ 
gemcitabine 
n=172 (pts) 
Single-agent 
cetuximab 
n=162 (pts) 
Total number of cycles 
(3qw) 312 203 547 962 
Median number of cycles 
per patient 2 2 4 4 
Anemia +  1 blood 
transfusion 1% 4% 10% - 
Thrombopenia +  1 
platelet transfusion <1% - 11% - 
Febrile neutropenia + IV 
antibiotics <1% 6% 3% - 
Skin reaction (any/grade 3) 80%/6% 25%/6% 79%/9% 34%/6% 
352 patients were enrolled equally in each treatment 
arm in the Phase II part. 345 patients received study 
medication (173/172 arm A/B). 2914 infusions 
of cetuximab combined with chemotherapy and 
2666 infusions without chemotherapy were given. 
Toxicities per patient requiring clinical intervention 
Methods: 362 patients (318 males and 44 
females), median age 57 years, were treated in four 
prospectively conducted clinical trials at one site, with 
platinum-based chemotherapy, with 120mg/m2 of 
cisplatin every 4 weeks or 500mg/m2 of carboplatin 
(later AUC 5). PS 0/1 had 60% patients (pts) and 
stage IIB/IV was recorded in 45%/55% of pts. Median 
number of received cycles was 4, median overall 
survival for the group as a whole was 7 months.
Results: Stable disease (SD) was recorded in 48% 
of patients, response rate (RR = complete + partial 
response) in 32% of pts and progressive disease 
(PD) in 20% of pts. Median number of cycles was 5 
in RR pts, 4 in SD pts and 1 in PD ones and median 
survival times were 11 months, 7 months and 3 
months, respectively. In Cox regression model for 
overall survival, SD category had 39% greater risk 
of death compared with RR patient [HR (95%CI): 
1.39 (1.09-1.78); p<0.001], while PD patient had 4.1 
times greater risk, compared with RR [HR (95%CI): 
4.10 (3.03-5.55); p<0.001]. With landmark method 
on three months, this risk was even smaller for SD/
RR pts [HR (95%CI): 1.32 (1.01-1.72); p=0.044], 
while for PD/RR pts hazard ratio was 2.12 [95%CI: 
(1.49-3.00), p=0.003].
Conclusion: Response category of stable disease seems 
to be closer to response rate than to disease progression 
in front-line chemotherapy in treatment of advanced 
NSCLC. This does not deny that response rate should 
be the most desirable short-term outcome, but conÀrms 
that platinum-based chemotherapy inÁuences patients’ 
outcome even in lack of response, and supports 
administering of chemotherapy in advanced NSCLC.
Keywords: stable disease, response to 
chemotherapy, advance non-small cell lung cancer
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P3.100 ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC) PHASE II/III 
STUDY IN CHEMONAïVE PATIENTS: 
EGFR-TARGETING CHIMERIC 
MONOCLONAL IGG-1 ANTIBODY 
CETUXIMAB ADDED EITHER TO 
GEMCITABINE FOLLOWED BY 
DOCETAXEL OR CARBOPLATIN PLUS 
GEMCITABINE. RESULTS OF THE 
PHASE II STUDY PART.
Gerald Schmid-Bindert1, Saulius Cicenas2, Corinna 
Eschbach3, J. Kollmeier4, Cornelius Kortsik5, 
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Background: Although non-small cell lung cancers 
(NSCLCs) with mutations of the epidermal growth 
factor receptor (EGFR) gene are more sensitive to 
EGFR tyrosine kinase inhibitors than those without 
the mutations, it is still unknown whether there is a 
difference in efÀcacy of systemic chemotherapies 
between the two subtypes of NSCLCs.
Methods: One hundred nineteen advanced NSCLC 
patients, who underwent systemic chemotherapies as 
a Àrst-line therapy at the Tottori University Hospital, 
Japan, from April 2007 to August 2010, were 
retrospectively evaluated chemotherapeutic response 
according to RECIST and progression free survival 
(PFS). The differences in response rate (RR) and 
median PFS (mPFS) between NSCLC cases with and 
without sensitive EGFR mutations were statistically 
analyzed. The difference in efÀcacy between 
plutinum doublet chemotherapies (P) and non-
plutinum chemotherapies (non-P) in EGFR-mutated 
cases or in non-mutated cases was also analyzed.
Results: Among the 119 cases, consisting of 90 
adenocarcinomas, 27 squamous cell carcinomas 
and 2 large cell carcinomas, 26 cases (22%) 
had EGFR mutations. P were performed in 66 
cases, including 13 with EGFR mutations and 53 
without, and non-P were performed in 53 cases, 
including 13 with the mutations and 40 without. 
The P included 21 cisplatin-based regimens and 45 
carboplatin-based ones. The majority (73%) of non-P 
regimens was combination of vinorelbine (VNR) 
and dihydropyrimidine dehydrogenase inhibitory 
Áuoropyrimidines (DIFs, i.e., UFT or S-1). RR in 
NSCLCs with EGFR mutations was signiÀcantly 
higher than that without the mutations (50% vs. 23%, 
p<0.05). There is no difference in mPFS between 
NSCLC patients with and without EGFR mutations 
(6.9 months and 4.3 months, respectively, p=0.31). In 
EGFR-mutated cases, RRs in NSCLCs treated with 
P and with non-P were 48% and 54%, respectively 
(p=0.89), and mPFS for patients treated with non-P 
was signiÀcantly longer than that for patients treated 
with P (10.0 months vs. 3.4 months, p<0.01). Such 
a difference was not found in NSCLC cases without 
EGFR mutations.
Conclusion: Systemic chemotherapies might be 
more effective in NSCLCs with EGFR mutations 
than in those without the mutations. In particular, 
non-plutinum chemotherapies, e.g., combination 
of VNR and DIF, might have long-term effects in 
EGFR-mutated NSCLCs.
Keywords: NSCLC, EGFR, DIF, Vinorelbine
are shown below. 162 patients on single agent 
cetuximab received up to 39 cycles without 
signiÀcant toxicity (arm A: 75 patients, range 
1-35 cycles, median 4, mean 5.9, and 13 patients 
10 cycles; arm B: 87 patients, range 1-39 cycles, 
median 4, mean 6.0 and 12 patients 10 cycles). 
Under treatment with cetuximab in combination 
with chemotherapy, grade 3 or 4 hematological 
toxicity was more common in patients receiving 
carboplatin/gemcitabine (anemia 3%, leukopenia 
17%, neutropenia 25%, and thrombopenia 2%, arm 
A versus anemia 10%, leukopenia 29%, neutropenia 
38%, and thrombopenia 40%, arm B, respectively, 
all p<0.01, Ƶ²-test). Skin reactions were common and 
occurred in 79% of patients in both treatment arms. 
32% of patients (arm A) and 42% (arm B) completed 
the protocol, and overall response rates were 
19%/31% in arm A/B, respectively. Overall survival 
as a secondary aim of the Phase II part showed no 
statistically signiÀcant differences (hazard ratio 
1.102, p=0.4288, Ƶ²-test).
Conclusion: Cetuximab in combination with single 
agent gemcitabine-docetaxel and with carboplatin/
gemcitabine is well tolerated. Patients on weekly 
single agent cetuximab received up to 39 cycles. 
Toxicity signals were as expected with slightly 
higher toxicity in carboplatin/gemcitabine treatment 
as well as higher rates of completion of protocol 
and response. In overall survival no statistically 
signiÀcant difference is seen so far. The study 
continues as a Phase III trial with a total of 608 
patients. 
Keywords: safety, Overall survival, Non-small cell 
lung cancer, cetuximab
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P3.101 THE DIFFERENCE IN 
CHEMOTHERAPEUTIC EFFICACY 
BETWEEN ADVANCED NON-SMALL 
CELL LUNG CANCERS WITH AND 
WITHOUT EGFR MUTATIONS
Shingo Matsumoto1, Hirokazu Touge1, Masahiro 
Kodani1, Hirofumi Nakazaki1, Keiji Matsunami1, 
Haruhiko Makino1, Jun Kurai1, Masaki Nakamoto1, 
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in China, out of a total of 1242 patients in the Asian 
subpopulation and 6665 patients in the overall study 
population. The 6-month PFS rate for all Chinese 
patients was 50.5%; however, this rate rose to 59.9% 
in female never-smokers with adenocarcinoma 
histology (n=177). Median PFS and OS by clinical 
characteristics are reported in the table for the 
Chinese subpopulation. As shown, the PFS results 
are consistent with those of the wider Asian 
subpopulation in TRUST. Full multivariate subgroup 
analyses will also be presented. Reported adverse 
events in the Chinese subpopulation were consistent 
with those in the overall Asian subpopulation.
Conclusion: Clinical characteristics such as 
adenocarcinoma/bronchoalveolar carcinoma 
histology, female gender and never-smoker status 
were associated with longer PFS and OS in the 
Chinese and Asian subpopulations of this open-label 
study of erlotinib. It is likely that these results can be 
attributed to the higher incidence of activating EGFR 
mutations in these clinical subgroups. 
Keywords: Non-Small-Cell Lung Cancer, erlotinib, 
Asian patients, TRUST
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P3.103 EFFICACY OF CRIZOTINIB IN 
RETROSPECTIVE COMPARISONS WITH 
STANDARD-OF-CARE (SOC) REGIMENS 
FROM THREE PFIZER-SPONSORED 
CLINICAL TRIALS IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Yiyun Tang1, Bo Huang2, Keith Wilner1, Paulina 
Selaru1 
1Oncology, PÀzer Oncology,/United States Of 
America, 2Clinicial Leads - Oncology, PÀzer 
Oncology,/United States Of America
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.102 EFFICACY OF ERLOTINIB 
ACROSS CLINICAL SUBGROUPS IN 
CHINESE PATIENTS AND A BROADER 
ASIAN SUBPOPULATION WITH 
ADVANCED NON-SMALL-CELL LUNG 
CANCER (NSCLC): SUB-ANALYSIS OF 
THE TRUST STUDY
Yi-Long Wu1, Caicun Zhou2, Li Zhang3, Reury-Perng 
Perng4, Tony Mok5 
1Academy Of Medical Sciences, Guangdong Lung 
Cancer Institute/China, 2Medical Dept, Shanghai 
Pulmonary Hospital/China, 3Medical Oncology, Sun 
Yat-sen University Cancer Center/China, 4Taipei 
Veterans General Hospital/Taiwan, 5Department Of 
Clinical Oncology, The Chinese University Of Hong 
Kong/China
Background: The epidermal growth factor receptor 
(EGFR) tyrosine-kinase inhibitor erlotinib has 
proven efÀcacy in multiple treatment settings for 
advanced NSCLC (Shepherd et al, 2005; Cappuzzo 
et al, 2010; Zhou et al, 2010). The global, phase IV 
TRUST study provided the opportunity to gather 
clinical data on the efÀcacy and tolerability of 
erlotinib in patients who had progressed following 
Àrst-line chemotherapy (or were unsuitable to receive 
such therapy). The results for the overall population 
and the Asian subpopulation of this study have been 
published (Reck et al, 2010; Mok et al, 2010). We 
carried out an additional sub-analysis to examine 
the efÀcacy of erlotinib across clinical subgroups in 
the Chinese and Asian subpopulations of TRUST, to 
determine whether clinical characteristics inÁuenced 
outcomes with erlotinib in these patients. 
Methods: TRUST was an open-label, non-
randomised study. Eligible patients had stage IIIB/IV 
NSCLC and had either failed on or were unsuitable 
to receive chemo-/radiotherapy. Oral erlotinib 
150mg/day was given until disease progression 
or unacceptable toxicity. This analysis reports 
progression-free survival (PFS) and overall survival 
(OS) outcomes in the Chinese subpopulation of 
TRUST by gender, histology and smoking status. 
Results: The study included 519 patients enrolled 
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regimens ranged from 0.28 to 0.38. The median 
OS of crizotinib in the clinical trial has not yet 
been reached. However, the hazard ratios for OS of 
crizotinib versus the three control regimens ranged 
between 0.25 and 0.47. 
Conclusion: There is supporting evidence that 
crizotinib treatment may provide clinical beneÀt 
for the treatment of patients with ALK+ advanced 
NSCLC in the context of SOC therapies in Àrst- or 
later-line treatment settings. 
Keywords: PF-02341066, Non-small cell lung 
cancer, Crizotinib
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P3.104 INDIRECT COMPARISON OF 
EFFICACY, SAFETY, AND COST: 
PEMETREXED/CISPLATIN VERSUS 
BEVACIZUMAB/GEMCITABINE/
CISPLATIN IN PATIENTS WITH 
ADVANCED NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER
Mauro Orlando1, Helen Barraclough2, Sergey Orlov3, 
Narayan Rajan2, Peter Davey4, Yana Kanivets5, 
Baoguang Han6, Alan Brnabic2 
1Regional Medical Oncology, Eli Lilly Interamerica 
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Federation, 4Illuminate Health Consulting/Australia, 
5Eli Lilly And Company/Russian Federation, 6Eli 
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Background: Two regimens have recently been 
approved in several countries for the treatment of 
non-squamous advanced non-small cell lung cancer 
(NSCLC): (i) the doublet pemetrexed/cisplatin 
(PemC), and (ii) the triplet of bevacizumab (Bev) 
with gemcitabine/cisplatin (GC). In the absence 
of head-to-head evidence between the 2 regimens, 
they have been compared indirectly via a common 
comparator arm, GC, using data from the AVAiL 
and JMDB phase 3 studies. The AVAiL study had 
3 arms comparing 7.5 mg/kg BevGC (7.5BevGC), 
15 mg/kg BevGC (15BevGC), and GC.1 The JMDB 
study compared PemC to GC.2 Indirect comparison 
between BevGC and PemC is possible given similar 
characteristics of the trial design and patients. The 
results, only in terms of the progression free survival 
(PFS) hazard ratio (HR), have been previously 
reported (HR [7.5BevGC vs. PemC]=0.83, with no 
Background: Crizotinib is a potent, selective, ATP-
competitive, small-molecule anaplastic lymphoma 
kinase (ALK) inhibitor. In an expanded cohort of an 
early clinical study in patients with advanced ALK+ 
NSCLC, crizotinib demonstrated clinical activity 
with a high response rate. Results of retrospective 
analyses comparing the efÀcacy of crizotinib in 
patients with advanced NSCLC with that of SOC 
regimens (paclitaxel/carboplatin or gemcitabine/
cisplatin as Àrst-line treatment and erlotinib as 
second-/third-line treatment) in three PÀzer-
sponsored clinical trials are reported. 
Methods: We conducted two types of analysis: 
(1) covariate-matched simulations of randomized 
controlled trials of crizotinib versus SOC for 
advanced NSCLC from control arms of the 
three PÀzer-sponsored trials to compare efÀcacy 
outcomes in patients with comparable baseline 
characteristics (adenocarcinoma histology, smoking 
classiÀcation, age, and race [Asian/non-Asian]), 
and (2) a covariate-adjusted modeling analysis to 
retrospectively predict the response rates of patients 
treated with crizotinib who had the same baseline 
characteristics (adenocarcinoma histology, smoking 
classiÀcation, age, race [Asian/non-Asian], gender, 
disease stage, ECOG performance status, and 
weight) as those treated with a SOC regimen from 
a control arm in the three PÀzer-sponsored trials. 
Information about ALK status was not available 
from the three control trials. 
Results: Crizotinib therapy was associated with a 
higher objective response rate (ORR; 61%; 95% 
conÀdence interval [CI]: 52, 70%) than ORRs of 
the covariate-matched unselected historical controls 
from the three PÀzer-sponsored trials, ranging from 
10% to 24%. Similar results were observed using 
the covariate-adjusted modeling approach with 
estimated ORRs for the standard regimens ranging 
from 15% to 21% after simultaneous adjustment for 
eight baseline characteristics. Overall, the estimated 
magnitudes of the ORRs generated for unselected 
controls using both approaches were at least 
50% lower relative to the ORR of 61% observed 
with crizotinib. An assessment of the secondary 
endpoints, progression-free and overall survival 
(PFS; OS), produced similar results. The preliminary 
median PFS of crizotinib therapy was 10 months 
(95% CI: 8.2, 14.7 months) in heavily pretreated 
patients, which was longer than PFS reported in the 
covariate-matched unselected historical controls, 
ranging from 1.9 to 5.9 months. The hazard ratios 
for PFS of crizotinib versus each of the three control 
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P3.105 POOR SLEEP QUALITY AND 
FATIGUE AMONG PATIENTS WITH 
LUNG CANCER
Paul Zarogoulidis1, Paschalis Steiropoulos2, 
Evangelia Nena2, Kostas Archontogeorgis2, 
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Angelopoulou3, Georgia Trakada1, Kostas 
Zarogoulidis1 
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Background: Poor sleep quality in patients with 
cancer may be the cause of the commonly described 
fatigue and sleepiness in these patients. Aim of this 
study was to assess the sleep quality of patients with 
lung cancer and to explore possible correlations with 
daytime fatigue and sleepiness. 
Methods: Forty-eight recently diagnosed with 
lung cancer patients were initially enrolled. 
Eighteen of them were re-evaluated after 3 cycles 
of chemotherapy. Sleep quality was subjectively 
assessed by Pittsburgh Sleep Quality Index (PSQI), 
daytime sleepiness was assessed by Epworth 
Sleepiness Scale (ESS) and daytime fatigue by 
Fatigue Severity Scale (FSS). 
Results: In all patients poor sleep quality (PSQI>5), 
as well as daily fatigue (FSS>4) was revealed. PSQI 
and FSS scores correlated in a statistically signiÀcant 
way (p=0.002), while ESS scores showed no 
correlation. Further analysis of the PSQI components 
revealed a signiÀcant correlation between FSS and 
Subjective Sleep Quality (p<0.001), Sleep Duration 
(p=0.011) and Daytime Dysfunction (p=0.016). 
Among the 18 patients who were reevaluated 
after chemotherapy, a signiÀcant correlation was 
found between FSS and Habitual Sleep EfÀciency 
(p<0.001), Subjective Sleep Quality (p=0.027) and 
Sleep Disturbances (p=0.024). 
Conclusion: Poor sleep quality is associated with 
daytime fatigue among patients with lung cancer, 
both at the diagnosis and during treatment. 
Keywords: NSCLC, SLEEP DISTURBANCES, 
fatigue, SLEEP QUALITY
conÀdence interval [CI] or P value cited).3 The aims 
of this study were to indirectly compare the regimens 
in terms of overall survival (OS), safety, and cost, 
plus to provide complete results for PFS. This may 
have important implications in decision making for 
clinical as well as economic reasons.
Methods: An indirect comparison of both regimens 
in the non-squamous NSCLC population was 
performed using the Bucher method. Analyses 
included OS as the primary endpoint, PFS, safety, 
and cost.
Results: The indirect comparison of the doublet 
PemC with the triplet BevGC for OS numerically 
favored PemC (HR [PemC vs. 7.5BevGC]=0.87, 
95% CI: 0.69 - 1.10, p=0.242 and was statistically 
signiÀcant for HR [PemC vs. 15BevGC]=0.79, 95% 
CI: 0.62 - 0.99, p=0.042). In contrast, the indirect 
comparison for PFS numerically favored BevGC 
(HR [7.5BevGC vs. PemC]=0.83, 95% CI: 0.69 - 
1.01, p=0.066 and HR [15BevGC vs. PemC]=0.94, 
95% CI: 0.77 - 1.16, p=0.585). The percentage of 
patients suffering at least 1 severe adverse event (ie, 
Grade 3) was signiÀcantly lower with PemC (odds 
ratio: OR [PemC vs. 7.5BevGC]=0.59, 95% CI: 0.39 
- 0.89, p=0.013 and OR [PemC vs. 15BevGC]=0.46, 
95% CI: 0.30 - 0.71, p<0.001). For PemC, rates 
of neutropenia (p<0.001), thrombocytopenia 
(p<0.001), and hypertension (p=0.009 and p=0.001 
for 7.5BevGC and 15BevGC, respectively) were 
statistically signiÀcantly lower for PemC when 
compared to both doses of BevGC. A costing model 
developed for Russia, considering mean treatment 
cycles calculated from the trials and pharmacy drug 
costs, showed a savings of $11,100 USD with the 
PemC doublet, driven mostly by drug costs ($10,900 
USD).
Conclusion: PemC produced at least comparable 
OS outcomes with signiÀcantly fewer toxicities 
and was cost-saving in non-squamous NSCLC 
patients. Based on this indirect comparison PemC 
should be considered the preferred regimen in this 
setting. References 1. Reck et al. J Clin Oncol. 
2009;27(8):1227-34. 2. Scagliotti et al. J Clin Oncol. 
2008;26(21):3543-51. 3. Nuijten et al. Lung Cancer. 
2010;69 Suppl 1:S4-10.
Keywords: NSCLC, Pemetrexed, bevacizumab, cost 
analysis
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P3.107 A PHASE II TRIAL OF 
PEMETREXED (P), GEMCITABINE 
(G), AND BEVACIZUMAB (BV) IN 
UNTREATED PATIENTS (PTS) WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Antoinette Wozniak1, Gregory Kalemkerian2, Shirish 
M. Gadgeel1, Nithya Ramnath2, Bryan Schneider3, 
Manuel Valdivieso1, Daryn Smith1, Deborah 
Hackstock1, Wei Chen1, John Ruckdeschel4 
1Oncology, Karmanos Cancer Institute/wayne State 
University/United States Of America, 2Medicine, 
University Of Michigan Medical Center/United 
States Of America, 3Weill Cornell Medical College/
United States Of America, 4Nevada Cancer Institute/
United States Of America
Background: P and G are active agents with 
acceptable toxicity proÀles in the treatment of 
NSCLC. The addition of BV to chemotherapy has 
resulted in a signiÀcant improvement in survival 
for pts with non-squamous NSCLC. We conducted 
a phase II trial of P, G and BV on a novel every 
two week schedule in untreated pts with advanced 
NSCLC.
Methods: Advanced, non-squamous NSCLC 
pts with measurable/evaluable disease, no prior 
treatment for advanced disease, PS 0-1, adequate 
hepatic, renal and bone marrow function, treated 
brain metastases were eligible. No unstable 
hypertension, cardiac/vascular disease, hemoptysis, 
anti-coagulation, recent major surgery, no cavitation 
or close proximity of primary cancer to a major 
vessel were allowed. Pts received P 500 mg/m2, G 
1500 mg/m2, and BV 10 mg/kg every 2 weeks for 
12 cycles. Doses were reduced to P 400 mg/m2 and 
G 1200 mg/m2 when grade 4 neutropenia occurred 
in the Àrst 2 patients. BV was continued until 
disease progression or toxicity. Primary endpoint 
was progression-free survival (PFS). Secondary 
endpoints were response rate (RR), toxicity, time to 
progression (TTP) and overall survival (OS).
Results: 39 pts were accrued. Median age 62 yrs, 
males 56%, stage IV 87%, adenocarcinoma 82%. 
38 pts are response evaluable. 16 pts (42% ) had a 
response (1 CR, 15 PR) (90% CI for RR is 0.30 - 
0.55), and 12 had SD (32%) for a disease control 
rate of 74%. Currently the median treatment cycles 
for all pts are 7 (range 1-23, for P,G and 1-57, for 
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P3.106 IMPACT AND SAFETY PROFILE 
OF ERLOTINIB TREATMENT IN 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER – A SMALL 
PROSPECTIVE STUDY
Laura Mazilu1, Polixenia Iorga2, Andra-Iulia 
Suceveanu3, Irinel Parepa3, Adrian Suceveanu3, 
Doina Tofolean3, Tatiana Adam3, Dan Jinga2 
1Oncology Department, Clinical Emergency Hospital 
Of Constanta/Romania, 2Oncology Department, 
University Hospital Of Bucharest/Romania, 
3Internal Medicine, Clinical Emergency Hospital Of 
Constanta/Romania
Background: Erlotinib is a small molecule inhibitor 
of epidermal growth factor receptor tyrosine-
kinase activity that has been shown to signiÀcantly 
increase survival for patients with previously treated 
advanced non-small cell lung cancer (NSCLC). 
We aimed to investigate the impact of erlotinib as 
a second or third line treatment in patients with 
advanced NSCLC and associated adverse events. 
Methods: Seventeen patients with stage IIIB and IV 
NSCLC, previously treated with at least one regimen 
of platinum-based chemotherapy received 150 mg of 
erlotinib orally, once a day, till disease progression.
Results: Mean age of studied patients was 65.29 
± 10.90 (range 41-83, 95% CI 59.69-70.90). The 
disease control rate was 47.05%. Among studied 
patients, there was partial remission (PR) in 4 cases 
(23.52%), stable disease (SD) in 4 cases (23.52%), 
and progressive disease (PD) in 9 cases (52.94%). 
Median progression-free survival and overall 
survival times were 8.29 ± 5.10 months (range 2-19, 
95% CI 5.66-10.92) and 21.63 ± 7.782 months 
(range 11-36, 95% CI 16.12-29.13), respectively. 
The 1-year survival rate was 52.94%. Among studied 
patients, 11 (64.70%) experienced erlotinib-related 
adverse events. Most of the patients experienced 
erlotinib-related rash (n=10, 58.82%); grade 1/2 in 6 
cases (54.54%) and grade 3 in 4 cases. One patient 
developed grade 1 trombocytopenia. Dose reduction 
was registered in only 1 case of grade 3 rash. 
Conclusion: Our study conÀrm the favorable 
efÀcacy and safety proÀle of erlotinib in patients 
with advanced NSCLC. 
Keywords: erlotinib, advanced non-small lung 
cancer, disease control, safety proÀle
S1234 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
preclinically, most likely through decreasing the 
interstitial Áuid pressure by inhibiting PDGF-R, 
providing rationale for a phase II single arm trial in 
platinum-refractory NSCLC in combination with 
docetaxel. 
Methods: Patients with metastatic NSCLC (any 
histologic subtype); platinum-refractory with < 1 
prior treatment, ECOG PS 0-2 were treated with 
intravenous docetaxel (60 mg/m2 every 3 weeks), 
and oral imatinib mesylate (400 mg daily) initiated 
on day 1 until disease progression. Consenting 
patients received perfusion CT scans for analysis 
of tumor perfusion at baseline and week 3 and 
had serum specimens analyzed for PDGF levels 
at baseline, week 3, week 6 and at the off-study 
time. Baseline tumor specimens were collected for 
immunohistochemical (IHC) analysis of CD117 
(c-kit), PDGFR-a, PDGFR-b and PDGFRB gene 
copy number by Áuorescence in situ hybridization. 
Results: Twenty-two patients were enrolled onto 
the study, response was seen in one (4.5%) and was 
long –lasting (158 weeks), while disease control 
was achieved in 9 patients (40.9%). With a median 
follow up of 36 weeks, the median progression-free 
survival was 7.9 weeks, and overall survival was 
35.6 weeks. The main adverse events were grades 
1-2 diarrhea, neuropathy, and nausea/vomiting 
and grade 3 dyspnea, fatigue, and edema. Seven 
patients experienced at least one grade 3 adverse 
event and 10 patients experienced at least one grade 
2 adverse event. Of 5 consenting patients with 
baseline serum PDGF levels, 3 had progression and 
2 had stable disease, and no association of PDGF 
serum level with response, survival, or development 
of adverse events was seen. Of 14 patients with 
tumor specimens, all had CD117 analysis, 13 had 
analyses of the remaining markers. There was no 
association of any of the biomarkers with either 
patient demographics or clinical response, however 
any expression of PDGFR-a in stroma (p=0.04) and 
PDGFR-b (p=0.03) in tumor cytoplasm were both 
associated with a worse PFS, and PDGFR-a in the 
stroma, showed a trend towards a worse overall 
survival. 
Conclusion: The clinical activity of decetaxel-
imatinib in refractory NSCLC is modest. Expression 
of PDGFR-a in stroma, and PDGFR-b in tumor 
cytoplasm are potential negative predictiveand/
or prognostic biomarkers. Further analyses of 
PDGFRB copy number in correlation with survival 
is underway. 
Keywords: NSCLC, PDGFR, Imatinib, Docetaxel
BV). All pts are evaluable for toxicity. Grade 3-4 
toxicities: neutropenia 11, fatigue 7, elevated ALT/
AST 4, dyspnea 4, leukopenia 3, pain 3, anorexia 2, 
hypertension 2, thrombocytopenia 1, lymphopenia 1, 
febrile neutropenia 1, nausea/vomiting 1, perforation 
1, neuropathy 1, otitis media 1, PE 1, and DVT 
1. One grade 5 hemoptysis occurred in a pt off 
treatment for progressive disease. All pts had a 
median PFS of 6.1 months (90% CI 3.6 months, 7.7 
months) with a 1 year PFS rate of 18%. The median 
OS is 19.6 months (90% CI 12.5 months, 29.9 
months) with a 1 year OS rate of 64%. The median 
TTP is 6.1 months (90% CI 4.2 months, 7.8 months).
Conclusion: The combination of P, G, and BV is 
a very active and tolerable treatment for NSCLC. 
Updated results will be presented at the meeting. 
This research is supported by Lilly Oncology and 
Genentech.
Keywords: NSCLC, Pemetrexed, gemcitabine, 
bevacizumab
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P3.108 PHASE II TRIAL OF IMATINIB 
MESYLATE AND DOCETAXEL IN 
PATIENTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER.
Vassiliki Papadimitrakopoulou1, Suyu Liu2, Junya 
Fujimoto1, Ignacio Wistuba3, J. J. Lee4, Edith M. 
Marom5, Chusilp Charnsangavej5, Frank V. Fossella1, 
Hai T. Tran1, George Blumenschein1, Merrill Kies1, 
Waun K. Hong1, David J. Stewart1, Anne Tsao1 
1Thoracic/head And Neck Medical Oncology, UT/
MD Anderson Cancer Center/United States Of 
America, 2Biostatistics, UT/MD Anderson Cancer 
Center/United States Of America, 3Pathology And 
Thoracic/Head & Neck Medical Oncology, UT MD 
Anderson Cancer Center/United States Of America, 
4Biostatistics, UT M.D. Anderson Cancer Center/
United States Of America, 5Diagnostic Radiology, 
UT/MD Anderson Cancer Center/United States Of 
America
Background: Platelet-derived growth factor 
(PDGF) and receptor (PDGF-R) are co-expressed 
in many human cancers and are suspected to have 
a role in regulation of tumor vascular uptake of 
chemotherapy. Imatinib mesylate, inhibits both 
PDGF-R a and b; when it was combined with 
paclitaxel, an additive antitumor effect resulted 
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FISH results were observed in specimens collected at 
the time of original diagnosis compared to specimens 
collected immediately before geÀtinib therapy. In 
14 cases primary tumor biopsy was repeated during 
geÀtinib therapy.
Conclusion: These preliminary data indicate that 
geÀtinib is highly effective in patients with trial 
characteristics. 
Keywords: Non small cell lung cancer, EGFR, 
geÀtinib
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P3.110 ERLOTINIB VS BEST 
SUPPORTIVE CARE AS THIRD-LINE 
TREATMENT OF ADVANCED NSCLC: A 
REAL-WORLD COST-EFFECTIVENESS 
STUDY
Ian Cromwell1, Kimberly Van Der Hoek1, Suzanne 
Taylor2, Barbara Melosky3, Stuart Peacock1 
1Canadian Centre For Applied Research In Cancer 
Control (ARCC), British Columbia Cancer Agency/
Canada, 2Provincial Pharmacy Program, British 
Columbia Cancer Agency/Canada, 3Medical 
Oncology, British Columbia Cancer Agency/Canada
Background: The British Columbia Cancer Agency 
(BCCA) began funding erlotinib as third-line 
treatment for advanced NSCLC in 2004. This study 
investigated the real-world cost-effectiveness of 
third-line erlotinib in patients treated across British 
Columbia, Canada.
Methods: This was a retrospective study of all 
BCCA patients who received 3rd line erlotinib 
compared to a historical group treated with 2nd-line 
docetaxel then no further active treatment (best 
supportive care – BSC). The primary endpoint was 
cost-effectiveness, measured as cost per years of 
life gained. The calculation of life years gained was 
based on the area under the Kaplan-Meier curve 
of overall survival, deÀned as days between end of 
second line chemotherapy and death or censoring. 
Analysis was performed from the perspective of 
the British Columbia Ministry of Health Services, 
and was included the costs of drugs, radiation, 
hospitalization, appointments, tests, and home/
community care. 
Results: A total of 78 erlotinib patients and 69 BSC 
patients were identiÀed in our study. There was 
no signiÀcant difference in either survival or cost 
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P3.109 GEFITINIB IN EGFR FISH 
POSITIVE/PHOSPHO-AKT POSITIVE 
AND/OR NEVER SMOKER NON-
SMALL CELL LUNG CANCER (NSCLC), 
CLINICAL AND BIOLOGICAL EFFECTS.
José M. García-Bueno1, Hernán GiosefÀ2, Agustín 
Valls2, Sara Saglieti2, José M. Mas2, Roberto Vera3, J. 
L. Sánchez-Sánchez1 
1Medical Oncology, Hospital General Albacete/
Spain, 2Policlínica Miramar/Spain, 3Pathology, 
Hospital General Albacete/Spain
Background: Effectiveness of geÀtinib, a tyrosine 
kinase inhibitor of the epidermal growth factor 
receptor (EGFR), in never smokers and/or EGFR 
FISH positive NSCLC patients has been evaluated 
only in retrospective studies and few data exist on 
the biological effects of geÀtinib therapy in tumor 
samples. 
Methods: This study has been designed to include 
39 patients EGFR FISH positive/phospho-Akt 
(p-AKT) positive and/or never smokers with 
advanced or metastatic NSCLC. GeÀtinib is 
given at the daily dose of 250 mg. When feasible, 
primary tumor biopsy was repeated immediately 
before therapy, during therapy and at progression. 
Specimens were evaluated for EGFR and HER2 
gene copy number by FISH, EGFR gene mutation 
by DNA sequencing, and EGFR and p-AKT protein 
expression by immunohistochemistry.
Results: Data from the Àrst 28 enrolled patients 
are available: median age was 60 years (range, 
43–80); male/female: 7/21; stage IIIB/IV: 2/26; 
ECOG PS 0/1/2: 18/6/4; 25 patients had a diagnosis 
of adenocarcinoma and/or bronchioloalveolar 
carcinoma; 13 patients had brain metastases, and in 
10 cases geÀtinib was offered as Àrst-line therapy. 
Twenty-four patients were never smokers and 19 
were EGFR FISH positive. Overall response rate was 
54%, including 1 complete and 14 partial responses. 
Median time to progression was 6.45 months, and 
median survival was not reached. Response to 
therapy was not inÁuenced by previous therapies or 
presence of brain metastases. Toxicity was mild, and 
consisted in grade 1–2 skin rash (68%) and diarrhea 
(57%). One patient developed grade 3 diarrhea and 
another patient was hospitalized for acute interstitial 
lung disease. In patients exposed to previous 
chemotherapy, no difference in EGFR or HER2 
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Background: Bevacizumab, is a humanized 
monoclonal antibody to vasculo-endothelial-
growth-factor, with anti-cancer activity in non-
small-cell-lung cancer (NSCLC) patients. Results 
from a previous dose/Ànding phase I study in 
advanced NSCLC patients, described the anti-
angiogenic and toxicological effects of a newest 
bevacizumab combination with metronomic 
chemotherapy with cisplatin and oral etoposide 
(mPEBev regimen) and identiÀed the bevacizumab 
dosage to use in future trials. We therefore, 
designed a phase II trial to evaluate in advanced 
NSCLC patients the antitumor activity of this 
metronomic dose/dense regimen.
Methods: 45 patients (36 males and 9 females), 
with a mean age of 54 years, an ECOG 2, stage 
IIIB/IV and NSCLC (34 adenocarcinoma, 10 
squamous cell carcinoma, 1 undifferentiated 
carcinoma) were enrolled. They received every 
three weeks, cisplatin (30 mg/sqm, days 1-3), oral 
etoposide (50 mg, days 1-15) and bevacizumab 
(5 mg/kg, day 3). Responsive patients received 
maintenance therapy after 4 chemotherapy cycles 
with bevacizumab 5mg/kg every 3 weeks and daily 
erlotinib (150 mg). Kaplan Meier curves were used 
to estimate survival (OS) and progression free 
survival (PFS).
Results: Grade I-II hematological, mucosal toxicity 
and alopecia were the most common adverse 
events. The occurrence of severe infections (17%), 
thromboembolic episodes (4.4%) and severe mood 
disturbances (6.7%) were also recorded. There 
was a partial response in 31 (68.8%) patients, 
a stabilization in 8 (17.8%), and a progressive 
disease in 6 (13.3%) with a median PFS of 8.00 
(95%CI;6.192-9.808) months and median OS of 15 
months (95% 10.660-19.340).
Conclusion: Our bio-chemotherapy regimen 
resulted very active in advanced NSCLC however, 
the toxicity associated with the treatment will 
require strict selection of the patients to enroll in 
future studies.
Keywords: NSCLC, bevacizumab, metronomic-
chemotherapy
between the two groups in the real-world setting. 
Results are presented in the table. 
Parameter Erlotinib N = 78 Best Supportive Care 
N = 69
Median OS – days (95% CI) 231 (26, 831) 138 (27, 428) 
Mean OS – days (95% CI) 291 (233, 349) 181 (141, 222) 
Difference 110 days 
Median PTD – days (95% CI) 114 (6, 807) 68 (7, 309) 
Mean PTD – days (95% CI) 195 (148, 242) 105 (82, 129) 
Difference 90 days 
1-year OS - % 33.3 10.1 
Mean drug cost/patient 
(range); $ 
$7,823 ($1,166, $36,550) $171 ($0, $6,959) 
Mean radiotherapy cost/patient 
(range); $ 
$2,629 ($0, $16,273) $1,901 ($0, $11,391) 
Mean MSP-billable services; $ $2,363 ($74, $9,052) $2,003 ($32, $8,921) 
Mean PharmaCare cost/
patient; $ 
$4,276 ($0, $25,534) $4,271 ($0, $46,273) 
Mean HCC cost/patient; $ $107 ($0, $6,815) $384 ($0, $11,223) 
Mean hospital cost/patient; $ $17,127 ($547, $81,653) $14,494 ($0, $60,821) 
Mean overall cost/patient 
(range); $ 
$34,326 ($6,569, $99,370) $23,224 ($1,095, $78,775) 
Difference $11,102
An ICER of $36,838 was calculated based on the 
above results. More than 30% of a Monte Carlo 
sampling of 1000 probable ICERs dominated (cost 
less, were more effective than) BSC. No sampled 
ICERs were dominated by BSC. 
Conclusion: Third-line erlotinib is cost-effective 
compared to best supportive care. Patients in the 
BCCA can expect an average of 110 days additional 
survival with erlotinib. 
Keywords: health economics, erlotinib, 
retrospective trial, cost effectiveness
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P3.111 ANTITUMOR ACTIVITY OF 
BEVACIZUMAB IN COMBINATION 
WITH METRONOMIC CHEMOTHERAPY 
(MPEBEV REGIMEN) IN METASTATIC 
NON-SMALL CELL LUNG CANCER
Pierpaolo Correale1, Cirino Botta1, Ignazio 
Martellucci1, Antonella Licchetta1, Cristina Migali1, 
Elena Bestoso1, Serena Apollinari1, Annamaria 
Guglielmo1, Marcello Rossi2, Raffaele Addeo3, Luca 
Luzzi4, Giuseppe Gotti5, Pierosandro Tagliaferri6 
1Oncology, “S.Maria Alle Scotte” Hospital/
Italy, 2Respiratory Disease, “s.maria Alle Scotte” 
Hospital/Italy, 3”S.Giovanni Di Dio” Hospital/
Italy, 4Thoracic Surgery Unit, “S.Maria Alle Scotte” 
Hospital/Italy, 5”S.Maria Alle Scotte” Hospital/Italy, 
6”Magna Graecia” University/Italy
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existed between G2677T/A and leucopenia 
(P=0.041) and between SLCO1B3 and neutropenia 
(P=0.038). Both G2677T(A) and C3435T 
genotype were correlated with leucocytes(P=0.011 
and P=0.06), neutrophils(P=0.019 and 
p=0.059), hemoglobin(p=0.037 and p=0.01), 
hematocrit(P=0.04 and P=0.004) with statistical 
signiÀcance. 
Conclusion: Taken together, our data suggest that 
G2677T/A (MDR1) and SLCO1B3 might be major 
pharmacogenomic predictors for severe leucopenia 
and neutropenia in the cancer patients who docetaxel 
containing chemotherapy is given. 
Keywords: Docetaxel, SLCO1B3, toxicity, 
G2677T/A
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.113 EFFICACY OF ERLOTINIB 
AFTER THE FAILURE OF GEFITINIB 
IN PATIENTS WITH ADVANCED OR 
METASTASIS NON-SMALL CELL LUNG 
CANCER
Wang Yan, Li Junling, Wang Ziping, Guo Jihong, 
Yu Shufei, Hao Xuezhi, Hu Xingsheng, Wang Bin, 
Zhang Xiangru, Shi Yuankai 
Clinical Medical Oncology, Cancer Hospital & 
Institute, Chinese Academy Of Medical Sciences/
China
Background: Tyrosine kinase inhibitors (TKIs) is 
an active agent for advanced or metastasis non-small 
cell lung cancer. Unfortunately, resistant will appears 
unavoidably. The optimal treatment for patients with 
progressive non-small cell lung cancer who initially 
show a good response to TKI is not well known. 
This study is to evaluate the activity of erlotinib in 
patients who failure to geÀtinib.
Methods: 40 Chinese patients who experienced 
treatment failure after achieving disease control 
with geÀtinib (250mg daily) were analyzed 
retrospectively. 16 patients shifted to erlotinib 
(150mg daily) immediately, the other 24 patients 
received chemotherapy Àrst and thereafter erlotinib 
(150mg daily).
Results: In all population, the disease control rate 
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P3.112 GENETIC POLYMORPHISMS 
OF DRUG TRANSPORTER ARE 
ASSOCIATED WITH HEMATOLOGIC 
TOXICITIES IN KOREAN CANCER 
PATIENTS RECEIVING DOCETAXEL 
CONTAINING CHEMOTHERAPY.
J. O. Kim1, E. K. Jeon2, J. Y. Shin1, X. H. Zhang1, J. 
Y. Oh1, J. Y. Park3, K. A. Kim3, J. H. Kang2 
1Laboratory Of Medical Oncology,reserch Institutes 
Of Medical Science, The Catholic University Of 
Korea/Korea, 2Division Of Medical Oncology, 
Department Of Internal Medicine, College Of 
Medicine,catholic University, The Catholic 
University Of Korea/Korea, 3Department Of Clinical 
Pharmacology And Toxicology, Anam Hospital, 
Korea University College Of Medicine, Seoul, 
Korea/Korea
Background: Docetaxel (Taxotere) has been 
known as one of the most active anti-cancer drugs 
for breast, ovary, head and neck, prostate, and non-
small cell carcinoma. Neutropenia is a frequent toxic 
reaction observed during its treatment. We carried 
out association study between docetaxel-related 
hematologic toxicities and genetic polymorphisms of 
CYP3A4, CYP3A5, ABCC2, and SLCO1B3. .
Methods: Clinical information was collected 
from 79 cancer patients who received docetaxel 
containing chemotherapy. We extracted genomic 
DNA from periphreal blood and genotyped 
CYP3A4 (CYP3A4*1B, CYP3A4*18, CYP3A4*3), 
CYP3A5(CYP3A5*2, CYP3A5*3), ABCB1 
(C1236T, G2677T/A, C3435T), SLCO1B3 
(rs11045585), ABCC2 (rs12762549) using direct 
sequencing and pyrosequencing. 
Results: Mean age was 58.1 and sex ratio 59:20. 
Most of all pts was advanced non-small cell lung 
cancer (77%). Pts receiving over 60mg/m2 of 
docetaxel were 84.8%. Severe neutropenia(G3-4) 
occurred in 56pts (70.9%). And, mild-to moderate 
leucopenia, anemia and thrombocytopenia(G1-2) 
were observed in 48(60.8%), 75(94.9%) and 
78(98.7%), respectively. Genetic variants of 
CYP3A4 (CYP3A4*1B, CYP3A4*18, CYP3A4*3) 
and CYP3A5*2 were not found. Allele frequency of 
CYP3A5*3, ABCB1(C1236T, G2677T/A, C3435T), 
SLCO1B3 (rs11045585), and ABCC2 (rs12762549) 
were 0.73, 0.36, 0.39, 0.62, 0.7, and 0.86, 
respectively. Statistically signiÀcant associations 
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months. Single case reports indicate that geÀtinib 
may lead to sustained disease control in pts lacking 
the classical molecular and clinical predictive factors 
(EGFR mutation, asian background, female gender, 
never-smoking and adenocarcinoma). The aim of our 
study was to characterize long-term survivors in an 
unselected Caucasian population of pts with NSCLC 
treated with geÀtinib.
Methods: The Swiss Expanded Access Program 
(EAP) was open between Nov 2000 and Apr 
2004 to provide pts with locally advanced and/or 
metastatic inoperable NSCLC access to geÀtinib 
on a compassionate use basis before marketing 
authorization. Eligible pts received 250mg 
of geÀtinib daily until disease progression or 
unacceptable toxicity. Patients were registered in an 
anonymized way, including the date of the Àrst and 
the last drug order by the treating physician. The 
reporting of SAEs was requested. For the current 
study, we selected pts with a minimum of 2 years 
therapy with geÀtinib, and retrospectively collected 
age, gender, smoking status, tumor histology, tumor 
stage, sites of metastases, and EGFR mutation status 
if available.
Results: 464 pts were registered to the Swiss EAP, 
and 430 received at least one order of geÀtinib, 
corresponding to 3 months of therapy. The median 
and mean duration of treatment was 3 months and 
6 months, respectively (range 0.1 to 84+ months). 
Treatment was well tolerated in the overall 
population; drug-related SAEs were reported in 21 
(4.9%) of the 430 pts. In this genetically unselected 
population, 36 (8.4%) pts received geÀtinib for 
longer than 1 year and 18 (4.2%) pts for 2 years or 
more (up to 7 years and therapy ongoing). Clinical 
characteristics were available for 10 of the 18 long-
term survivors. Three pts were male and 7 were 
female, age at diagnosis was 35 to 76 years. Seven 
pts were active smokers (up to 40 pack years). 
Performance status (PS) was PS0/1 in 8 pts and PS2 
in 2 pts. Six pts had received prior chemotherapy 
and 3 pts prior radiotherapy. Tumor EGFR mutation 
status was available for 4 pts, 3 pts had activating 
EGFR mutations and one pt had wild type EGFR. 
In the 18 long-term survivors, treatment was well 
tolerated. One cardial SAE was reported, which was 
unrelated to geÀtinib. Two pts had diarrhea, and 
three pts had skin rash.
Conclusion: GeÀtinib can lead to long-lasting 
disease stabilization in individual pts, and long-
lasting geÀtinib therapy appears to be well tolerated. 
Unexpectedly, the group of long-term survivors 
for erlotinib was 52.5% (21/40) while the objective 
response rate was only 10.0% (4/40). The median 
progression free survival (PFS) and the overall 
survival (OS) were 3.0 months and 12 months, 
respectively. However, no statistically difference 
was observed in disease control rate between 
two treatment groups (56.3% for erlotinib group 
and 50.0% for erlotinib following chemotherapy, 
respectively, p=0.755). The median PFS and the 
OS were similar (4 months vs. 2months for PFS, 
p=0.768; 12months for OS in both groups, p=0.51).
Conclusion: Erlotinib could be considered either 
immediately after geÀtinib failure or following 
chemotherapy after geÀtinib failure in progressive 
non-small cell lung cancer patients who initially got 
beneÀt from geÀtinib.
Keyword: Erlotinib, GeÀtinib, non-small cell lung 
cancer
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P3.114 LONG-LASTING DISEASE 
CONTROL WITH GEFITINIB IN 
PATIENTS (PTS) WITH ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC) LACKING THE CLASSICAL 
PREDICTIVE FACTORS: REPORT FROM 
AN EXPANDED ACCESS PROGRAM 
(EAP)
Oliver Gautschi1, Claudius Irlé2, Antonello 
Calderoni3, Adrian Casty4, Rudolf Morant5, Christa 
Baumann4, Erica Pellicioli6, Daniel Betticher7 
1Medical Oncology, Luzerner Kantonsspital/
Switzerland, 2Department Of Medical Oncology, 
Hôpital De La Tour/Switzerland, 3Department Of 
Medical Oncology, Clinica Sant’anna Di Sorengo/
Switzerland, 4Department Of Medical Oncology, 
Lindenhofspital/Switzerland, 5Onkologisches 
Tumorzentrum Zetup/Switzerland, 6Medical 
Department, Astrazeneca Ag/Switzerland, 
7Department Of Medical Oncology, Hôpital 
Cantonal/Switzerland
Background: According to literature for pretreated, 
unselected pts with advanced NSCLC the median 
duration of treatment with geÀtinib was 2 to 3 
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decline in physical function, self-reported global 
HRQoL had a non signiÀcant improvement from 
baseline to 2 months, followed by a decline in global 
HRQoL from 2 to 4 months that was not statistically 
signiÀcant. 
Conclusion: Patients with advanced NSCLC 
have clinically signiÀcant lowered physical 
function at commencement of treatment. Function 
continues to decline signiÀcantly over time, despite 
improvements in self-reported HRQoL from baseline 
to 2 months. Future interventional studies are needed 
to address this issue. Funding for this study was 
provided by a NHMRC Palliative Care Grant 
Keywords: Physical function, Health-related quality 
of life, Advanced NSCLC
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P3.116 LUNG CANCER PATIENTS 
ACCEPT POTENTIALLY RISKY 
PROCEDURES PERFORMED SOLELY TO 
DETERMINE OPTIMAL TREATMENT
Matthew Peters1, Erica Meggitt1, Lucy Morgan2 
1Thoracic Medicine, Concord Hospital/Australia, 
2Respiratory Medicine, Australian School Of 
Advanced Medicine/Australia
Background: Some novel treatments for lung 
cancer require analysis of biopsy material that is 
in excess of that needed just to deÀne the tumour 
histologically. Obtaining this added material may 
create risks, discomfort or inconvenience for 
patients and the attitudes of actual patients to this are 
unknown. There is added the risk that the test will 
be considered futile if the result most desired is not 
generated.
Methods: Patients living with lung cancer were 
presented with a construct not relating directly to 
their own care. It stated that, in order to determine 
whether a novel but potentially highly effective 
treatment might be suitable for them, additional 
testing would be needed. The procedures were 
a blood test (no risk), core needle node biopsy. 
excision of a cervical node and mediastinoscopy. 
Test yield was stated as 25% and treatment response 
rate 95%. Procedural discomforts were described 
as was mortality for each procedure. Patients 
were asked to mark on a 100mm VAS score line, 
how likely it is that they would agree to have the 
procedure. 0mm was ‘I would deÀnitely have the 
included patients lacking the classical predictive 
factors, including several active smokers, and at least 
one pt with wild type EGFR.
Keywords: geÀtinib, caucasions, EGFR-mutation, 
long-term tolerability
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P3.115 FUNCTIONAL DECLINE IN 
PATIENTS WITH ADVANCED STAGE 
NON-SMALL CELL LUNG CANCER
Andrew Murnane1, Meinir Krishnasamy2, Linda 
Denehy3, Catherine Granger3, Linda Mileshkin4 
1Supportive Care Research & Physiotherapy Dept, 
Peter MacCallum Cancer Center/Australia, 2Peter 
MacCallum Cancer Center/Australia, 3Dept Of 
Physiotherapy, The University Of Melbourne/
Australia, 4Medical Oncology, Peter MacCallum 
Cancer Center/Australia
Background: The functional decline that is seen in 
patients with lung cancer is a complex issue. It is 
well recognised by treating clinicians that patients 
with advanced NSCLC decline physically over time; 
however this has been poorly studied to date. This 
study aimed to quantify the physical function and 
health-related quality of life (HRQoL) of patients 
with advanced non-small cell lung cancer (NSCLC). 
Methods: A descriptive cohort study was performed. 
Patients with stage III and IV NSCLC were 
recruited within one month of starting treatment and 
completed assessments bi-monthly to six months 
or until they became too unwell to participate. 
HRQoL and functional status data were collected 
using the EORTC QLQ-C30, the 6-minute walk 
distance (6MWD) and timed up and go test (TUG). 
Preliminary results from the study are presented.
Results: 36 patients with a mean age of 62 years (18 
males) had a mean 6MWD at baseline of 416.7m, 
signiÀcantly lower than predicted for age, sex and 
height (562.6m). This signiÀcantly declined from 
baseline to 2 months (n=22) by a mean of 35.8m 
(95%CI:14.7 to 56.9; p=0.02), with a signiÀcant 
decline from baseline to 4 months (n=16) of 53.8m 
(95%CI:17.3 to 90.4; p=0.007). Time taken to 
complete the TUG increased (worsened) signiÀcantly 
from baseline (mean 7.7 seconds) by a mean 0.83 
seconds (95%CI: 0.56 to 1.11; p<0.05) at 2 months 
(n=22) and a mean of 1.04 seconds (95%CI: 0.7 
to 1.39; p<0.05) at 4 months (n=16). Despite the 
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Methods: Pts with metastatic or advanced NSCLC 
who had built up a resistance to prior G were 
eligible. Other prior chemotherapeutic regimens 
and the lines of treatment were not included in the 
criteria. Pts received 150 mg of E orally every day. 
Results: From February to November 2007, 10 pts 
who had experienced PD or relapse in the treatment 
with G received E. All 10 pts had adenocarcinoma, 
median age was 60.5 (range 41-74), 9 were women 
and 5 were smokers. Five of the 10 pts were 
examined for EGFR mutation status and all 5 pts had 
EGFR mutation. The response rate and the disease 
control rate were 20 % and 80 %, respectively. 
Five pts were given E in the third or fourth line 
treatment. The other 5 pts were given E in the Àfth 
or later line treatment. The effects of E were similar 
in both groups of pts. Two pts had received G for 
more than one year and were expected to respond 
well to E judging from prior reports. Contrary to our 
expectations, the therapeutic results of E were PD in 
both pts.
Conclusion: E is a possible option for pts who 
show resistance to G, and could be given as the 
third, fourth or later line treatment. However, a 
long duration of response to G is not necessarily a 
predictive factor of the responder to E.
Keywords: erlotinib, geÀtinib, NSCLC
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P3.118 PROGRESSION FREE SURVIVAL 
MORE THAN 12 MONTHS UNDER 
THE TREATMENT OF ERLOTINIB 
IN PATIENTS WITH NSCLC ST III/
IV: A RETROSPECTIVE STUDY OF 
PATIENT HEALTHCARE UTILIZATION, 
TOXICITIES AND OUTCOME
Natalie Maimon-Rabinovich1, Maya Gottfried2 
1Lung Unit Cancer. Oncology Departement, Meir 
Medical Center/Israel, 2Lung Unit Cancer. Oncology 
Departement, Meir Medical Centre/Israel
Background: Erlotinib was approved by the US 
FDA on November 2004 for Patient with advanced 
or metastatic NSCLC. Clinical trial have shown 
response rate of less than 10% to Erlotinib and 
procedure’ and 100mm was ‘ I would deÀnitely not 
have the procedure’.
Results: 24 patients were enrolled; 20 male with 
median age 73. All stages were represented and 
experience of treatment included all modalities. 
Results are summarised in the table
Stated mortality VAS - mean (SEM) 
Subjects with VAS 
>50mm 
Blood test 0 5(1.0) 0 
Core needle biopsy 0.1% 4(0.9) 0 
Surgical node excision 0.4% 8(1.6) 0 
Mediastinoscopy 1.0% 14(3.0) 2 
Conclusion: There is a high level of acceptance of 
supplementary procedure that could generate access 
to an effective treatment. This is seen even when 
risks are somewhat overstated and the likelihood 
is that the procedure will be a negative result. In 
determining appropriate investigative pathways 
for lung cancer, the high level of willingness of 
patients to have such procedures with inconvenience, 
discomfort and potentially grave risk should be 
considered. 
Keywords: gene testing, personalised medicine, 
patients beliefs
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P3.117 THE THERAPEUTIC OUTCOMES 
OF ERLOTINIB AFTER FAILURE OF 
GEFITINIB FOR PATIENTS WITH NON-
SMALL CELL LUNG CANCER
Keiji Matsunami1, Shingo Matsumoto1, Hisashi 
Suyama1, Masahiro Kodani1, Hirokazu Toge1, Yuji 
Kawasaki1, Tadashi Igishi1, Hiroshige Nakamura2, 
Eiji Shimizu1 
1Division Of Medical Oncology And Molecular 
Respirology, Tottori University Faculty Of Medicine/
Japan, 2General Thoracic Surgery, Tottori University 
Hospital/Japan
Background: Erlotinib (E) has been approved for 
use on patients (pts) with metastatic/advanced non-
small cell lung cancer (NSCLC) who had received 
chemotherapy since December 2007 in Japan. 
There has been some controversy about whether E 
is effective even for the pts who had already been 
treated with geÀtinib (G). The aim of this study is 
to investigate the therapeutic outcomes of E after 
failure of G at our hospital, retrospectively. 
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P3.119 PARTIAL RESPONSE TO FIRST-
LINE GEFITINIB FOR ADVANCED 
PULMONARY ADENOCARCINOMA 
HARBORING BOTH SYNCHRONOUS 
EGFR MUTATION AND EML4-ALK 
FUSION: REPORT OF TWO CASES
Jinji Yang1, Xu-Chao Zhang2, Jian Su2, Chong-Rui 
Xu2, Yi-Sheng Huang2, Yi-Long Wu2 
1Division Of Pulmonary Oncology, Guangdong 
General Hospital, Guangdong Academy Of Medical 
Sciences/China, 2Guangdong Lung Cancer Institute, 
Guangdong Academy Of Medical Sciences & 
Guangdong General Hospital/China
Background: The fusion of the anaplastic 
lymphoma kinase (ALK) with the echinoderm 
microtubule-associated protein-like 4 (EML4) and 
epidermal growth factor receptor (EGFR) mutations 
are reported mutually exclusive. Advanced non-small 
cell lung cancer (NSCLC) patients with EML4-ALK 
did not beneÀt from EGFR tyrosine kinase inhibitors 
(TKIs).
Methods: Multiplex reverse transcriptase-
polymerase chain reaction (RT-PCR) followed by 
sequencing was performed for EML4-ALK fusion 
status detection. EGFR and KRAS mutations were 
determined by direct DNA sequencing. Positive 
results of EML4-ALK fusion were also conÀrmed by 
RACE-coupled PCR sequencing. 
Results: From March 2010 to August 2010, 
two female patients with advanced pulmonary 
adenocarcinoma were found to harbor both 
synchronous EGFR mutation (exon19 deletion 
and exon21 L858R respectively) and EML4-ALK 
fusion (Variant 6 and Variant 1 respectively). Being 
relatively young (aged 44 and 56 respectively), 
both patients were never smokers. They were also 
found to have wild type KRAS. 122 and 36 days 
respectively after receiving Àrst-line EGFR TKI 
geÀtinib, they achieved partial reponse. 
Conclusion: Advanced NSCLC patients harboring 
synchronous EGFR mutation and EML4-ALK fusion 
are sensitive to geÀtinib. Whether they could also 
beneÀt from ALK inhibition after failure to geÀtinib 
warranted further investigation.
progression free survival of 2 months in second line 
treatment with Erlotinib. We present a review of 41 
patient with prolong survival, more than 12 months, 
under the treatment of Erlotinib. The goal of this 
study was to analyze epidemiological factors, tissue 
histology and side effect in this group of patient with 
prolong progression free survival.
Methods: Patients with stage IIIB or IV NSCLC 
cancer were treated in Meir medical centre and 
received treatment with Erlotinib more than 12 
months. Data were collected on age, gender, 
performance status, smoking status, length of 
treatment, toxicities proÀles, Progression Free 
Survival (PFS), overall survival (OS) and analyses 
were carried out.
Results: A number of 41 patients with stage IIIB/
IV disease were analyzed. Of them, 73% (30) were 
female with mean age of 65 and 27% were male with 
mean age of 68. Performance status (PS) average 
was 1 and improved during the Àrst half of the year 
of treatment. Over 91% (37) of the patients had 
previous chemotherapy. About 10% (4) had stage III 
disease with malignant pleural effusion. About 90% ( 
37) had stage IV disease and of them, 68% (28) of all 
the patients had only lung metastasis. Patients treated 
with Erlotinib had an average PFS of 128 weeks, and 
OS of 178 weeks. Over 75% (31) of the patients did 
not smoke. The PFS among smoker was 121 weeks 
and PFS among non-smokers was 130 weeks. The 
patients who had skin toxicities had an average PFS 
of 121 weeks, in contrast to patients without skin 
toxicities that had an average PFS of 81 weeks. The 
most common reasons for dose reduction were skin 
toxicities 52% (21). 
Conclusion: The data above represent our site 
experience with Erlotinib. The results represent an 
extraordinary PFS and OS among those patients. 
The correlation between response rate, toxicities 
proÀles, and other contributing factors (non smoking, 
female) support the major data from clinical study 
in this Àeld. In contrast, the actual response rate is 
signiÀcantly higher than reported in those clinical 
trials. In the future, a Molecular factor should be 
further investigated in this group of patients.
Keyword: NSCLC, OS, PFS, US FDA
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TTP (>9 mo) it might be a reasonable option. 
Keyword: Lung cancer, Chemotherapy, Re-
challenge
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P3.121 SEVERITY OF ANXIETY AND 
DEPRESSION AMONG LUNG CANCER 
PATIENTS USING THE HAMILTON 
RATING SCALE
Elisna Syahruddin, Alia Haris, Mardi Susanto, Aria 
Kekalih 
Pulmonary And Respiratory Medicine, Faculty Of 
Medicine, Universitas Indonesia/Indonesia
Background: Trend for lung cancer cases is rising 
in both male and female Indonesian. Previous 
study shown that around 51% of lung cancer 
patients had psychiatric disorder ranging from 
adjustment disorders to severe depression. We did a 
collaborative study to detect any psychiatric disorder 
in lung cancer patients.
Methods: Subject of the research were recruited 
consecutively after informed consent given. All 
subjects were interviewed by using Hamilton Anxiety 
and Depression Scale Questionnaire. We analyzed 
the data to Ànd the incidence, severity of psychiatric 
disorder and its correlation with other factors (gender, 
age, level of education and socio-economic). 
Results: We recruited 64 lung cancer patients which 
comprise of 77% male and 23% female. The mean 
age was 56 years old. Most of the patients were 
in advanced stage of adenocarcinoma. In regards 
of anxiety, we found that in 31 out of 64 patients 
(48.4%) suffers anxiety, of which 20 out of 31 (64.5 
%) were categorized as mild anxiety. In terms of 
depression, we found that 29 out of 64 patients 
(45.3%) suffers depression with 25 out of 29 (86.2%) 
were categorized as mild depression. All of those 
patients with depression were also diagnosed to 
have anxiety as well. The incidence of anxiety had 
a signiÀcant correlation with gender (OR, 3; 95% 
CI, 1.62 to 11.06) and education (OR, 2.98; 95% 
CI, 1.89 to 10.18). However, only level of education 
had signiÀcant correlation with depression (OR, 
3.43; 95% CI, 1.02 to 11.96) which was analyzed by 
multivariate analysis.
Conclusion: Anxiety and depression are common 
among lung cancer patients, and physician should be 
aware of these conditions for the better management 
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P3.120 IS THERE A ROLE FOR 
CHEMOTHERAPY RE-CHALLENGE IN 
NON SMALL CELL LUNG CANCER?
Alexios S. Strimpakos, Effrossini Patsourou, Dimitra 
Pouli, Christina Fevranoglou, Ioannis Gkiozos, 
Nikolaos Katirtzoglou, Kostas N. Syrigos 
Oncology Unit, 3rd Dept Of Medicine, Sotiria 
General Hospital/Greece
Background: Chemotherapy re-challenge (CTR) is 
an established and recommended clinical practise in 
some solid tumours in particular ovarian and small 
cell lung cancers, based on a presumed sensitivity 
of cancer cells to speciÀc cytotoxics. Considering 
the limited treatment options in non small cell lung 
cancer (NSCLC), it would be worth exploring the 
incidence and impact of CTR.
Methods: Medical records of 2150 patients 
(pts) diagnosed with NSCLC and treated with 
chemotherapy (CT) at our institution, between 2003-
2011, were screened. We identiÀed pts treated with 
CTR during the course of their disease. We examined 
patients’ clinical and treatment data.
Results: 9/2150 pts (0.4%) were offered a CTR 
regimen. Male:female ratio was 6:3 and median age 
56 years (range 51-76). The histological subtypes 
were adenocarcinoma (A) (4 pts), squamous cell 
carcinoma (3 pts) and not speciÀed (NS) (2 pts). 
All patients were of good Performance Status (0-
1), and the majority without any comorbidities 
(6/9). All pts were treated with a platinum agent 
combined with either pemetrexed (5pts), taxane 
(3 pts) or gemcitabine (1 pt). 3/9 pts had initially 
received CT in the adjuvant setting and rechallenge 
on relapse, whereas 6 pts were treated for advanced/
metastatic disease. In the later 6 pts, partial response 
(PR) as best response was observed in 5 (83.3%).
The median time to progression (TTP) after the Àrst 
chemotherapy course was 10 months (range 3.6-
37.5). Best responses following CTR were PR in 2 
(22%), stable disease (SD) in 3 (33%) and disease 
progression (PD) in 4 (44%), whereas median TTP 
after CRT was 3 months (2.5-12). The 2 pts with PR 
after CTR (1 A, 1 NS) had both demonstrated PR 
after the initial CT with platinum-pemetrexed and 
TTP of 9 and 17 mo respectively.
Conclusion: CTR is rarely observed in NSCLC, and 
has a limited role and unlike success. In selected though 
patients with a very good initial response and satisfactory 
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and for whom EGFR mutation testing is planned, 
at approx. 130 sites (100 hospital-based, 30 ofÀce-
based) throughout Germany. The primary aim is to 
collect epidemiological data on the EGFR mutation 
status in the German patient population and to 
correlate the EGFR mutation status with clinico-
pathological characteristics (e.g. smoking status, 
gender, histology, etc.). As secondary objectives, 
real-life clinical outcome data of all EGFR mutation 
positive patients (i.e. PFS, OS, DCR), clinical 
management and pharmaco-economic data (such 
as resource use) associated with the diagnosis and 
treatment of EGFR mutation pos. patients with 
advanced NSCLC will be collected. 
Results: Between Nov 2009 and Jan 2011, 3504 
patients have been registered into REASON with 
enrolment ending March 2011. Methods and Àrst 
data on the frequency of EGFR mutations in German 
patients with stage IIIB/IV NSCLC will be presented. 
Conclusion: REASON is a German registry aiming 
to provide the largest data base yet on baseline epide-
mio logical and clinico-pathological characteristics 
of patients with newly diagnosed stage IIIB/IV 
NSCLC in a predominantly Caucasian population. 
In addition, real-life information will be collected 
on treatment patterns of patients with stage IIIB/
IV EGFR mutation positive NSCLC, pharmaco-
economic para meters (resource use, hospitalisations, 
etc.), and clinical outcomes. 
Keywords: locally advanced or metastatic NSCLC, 
EGFR mutation, newly diagnosed NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.123 A PHASE II TRIAL OF LOW-DOSE 
METRONOMIC ORAL VINORELBINE 
COMBINED WITH BEVACIZUMAB 
IN PATIENTS WITH PRETREATED, 
ADVANCED NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER (NSCLC). 
PRELIMINARY RESULTS
E Kontopodis, Z Saridaki, N Kentepozidis, S 
Giassas, A Polyzos, I Bobolaki, Ch Christophyllakis, 
S Patramani, M Rovithi, V Georgoulias, S Agelaki 
(HORG) Hellenic Oncology Resarch Group/Greece
of lung cancer. 
Keyword: lung cancer, anxiety, depression, the 
Hamilton Rating Scale.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.122 REASON: A REGISTRY FOR THE 
EPIDEMIOLOGIC AND SCIENTIFIC 
EVALUATION OF EGFR MUTATION 
STATUS IN NEWLY DIAGNOSED NSCLC 
PATIENTS STAGE IIIB/IV IN GERMANY
Wolfgang Schuette1, Wilfried Eberhardt2, J. Mathias 
Graf Von Der Schulenburg3, Manfred Dietel4, Peter 
Schirmacher5, Brigitte Gutendorf6, Michael Thomas7 
1Clinic Of Internal Medicine Ii, Hospital Martha-
maria Halle-doelau/Germany, 2West German 
Tumor Center, University Hospital Essen/
Germany, 3Leibnitz University Hannover/Germany, 
4Pathological Institution Of Humboldt University 
Berlin/Germany, 5Pathological Institution Of 
University Heidelberg/Germany, 6Astrazeneca/
Germany, 7Thoracic Oncology, University Of 
Heidelberg/Germany
Background: Lung cancer is the leading cause of 
cancer deaths worldwide. In Germany alone, each 
year approx. 33,000 men and 13,200 women are 
newly diagnosed with lung cancer and approx. 41000 
die of the disease. 70-80% of patients present with 
non-small-cell lung cancer (NSCLC). Studies have 
shown in recent years that somatic mutations in the 
EGFR gene predict for sensitivity to EGFR tyrosine 
kinase inhibitors (TKI) in patients with advanced 
NSCLC. Certain clinico-pathological characteristics 
are associated with a positive EGFR mutation 
status (i.e. adenocarcinoma histology, Asian origin, 
non-smoking history, female gender), however, 
most of this information arises from Asian studies. 
The REASON study was set up to investigate the 
prevalence of EGFR mutations in German patients 
with advanced NSCLC and the association with 
clinico-pathological parameters, thus generating data 
from a predominantly Caucasian population. 
Methods: REASON is an AstraZeneca sponsored 
registry (ClinTrials ID: NCT00997230). It is planned 
to include 4000 subjects with stage IIIB/IV NSCLC 
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P3.124 COST-EFFECTIVENESS 
ANALYSIS (CEA) BETWEEN ERLOTINIB 
AND GEFITINIB FOR PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC) IN THAILAND
Naiyarat Prasongsook1, Sureerat Jaruhathai2, Savitree 
Maoleekulpairoj3, Chaoncin Sooksriwong4 
1Medicine, Phramongkutklao Hospital/Thailand, 
2Internal Medicine, Police Hospital/Thailand, 
3Medical Audit, Health Systems Research Institute/
Thailand, 4Faculty Of Pharmacy, Mahidol 
University/Thailand
Background: Both Erlotinib and GeÀtinib are 
registered in Thailand for treating advanced NSCLC. 
All advanced NSCLC patients who were treated with 
TKIs are required to register with the Central Health 
Informatics (CHI) for reimbursement. There is no 
data on the economic analysis of these two drugs. 
This study compared the cost-effectiveness between 
Erlotinib and GeÀtinib which will be translated to 
other healthcare systems.
Methods: This is a retrospective cohort study of 
Thai patients who were diagnosed with advanced 
NSCLC and treated with EGFR TKIs during January 
2006 to December 2010. The clinical beneÀts of 
TKIs were evaluated over the duration of the TKIs’ 
treatment. The cost-effectiveness analysis adopted 
the healthcare system perspective which was 
measured in terms of cost per-life-day-gained and 
costs included all direct drugs costs for treatment.
Results: Seven hundred and seventy-eight 
consecutive cases were available for analysis. 
According to the comparative results shown in 
the Table, the incremental survival and duration 
of clinical beneÀts were 74 days and 59 days 
respectively in favor of GeÀtinib which result in 
cost-saving of 1,078.5 baht and 1,352.7 baht per-life-
day gained. 
Ge¿tinib Erlotinib 
No. of patients 301 477 
Duration of clinical bene¿ts (days) 281.8 222.7 
Direct medical costs during TKIs (baht) 595,424.1 674,923.5 
Overall survival (days) 455 381 
Mean total direct medical costs (baht) 717,819 797,639 
(Exchange rates in February 2011: US dollar 
$1=30.77 Thai baht)Price /package (30 tablets): 
Background: Frequent administration of low doses 
of cytotoxic drugs (metronomic chemotherapy) has 
been suggested to suppress tumor growth possibly by 
inhibiting tumor angiogenesis. In a previous phase 
II trial from our group, metronomic oral vinorelbine 
showed promising activity as salvage treatment of 
NSCLC. We conducted a phase II trial to evaluate 
the antitumor activity and toxicity of metronomic 
oral vinorelbine combined with bevacizumb, a 
monoclonal antibody against vascular endothelial 
growth factor (VEGF), in pretreated patients with 
advanced or metastatic non-squamous NSCLC.
Methods: Patients (pts) with conÀrmed non-
squamous NSCLC and measurable disease, 
pretreated with at least one chemotherapy regimen, 
were eligible. Oral vinorelbine was administered 
at a Àxed dose of 50 mg three times a week, and 
bevacizumab was administered intravenously 
at a dose of 10 mgr/Kg every two weeks. Each 
treatment cycle consisted of 28 days. Treatment 
was administered until disease progression or 
unacceptable toxicity.
Results: Twenty eight patients, of the forty 
eight projected, have been enrolled. Median age 
was 57.5 years (range, 42-73), 75% were male, 
96.4% had disease stage IV, and 89% had an 
ECOG performance status of 0-1. Treatment was 
administered as second-line in 6 (21%) pts and as 
 third line in 22 (79%). All pts were evaluable 
for toxicity and response assessment. Grade 
3/4 neutropenia was observed in 2 pts (7.1%), 
and grade 3 thrombocytopenia in 1 (3.6%). One 
patient (3.6%) died due to treatment-related febrile 
neutropenia. Non-hematologic toxicity included 
grade 2 neurotoxicity in 1 pt (3.6%), grade 2/3 
fatigue in 5 pts (17.8%), grade 2 diarrhea in 1 pt 
(3.6%) and grade 2 constipation in 1 pt (3.6%). In 
an ITT analysis, 2 (7.1%) partial responses (PR) 
were recorded, 3 (10.7%) pts had stable disease (SD) 
and 23 (82.1%) progressed. Tumor growth control 
rate (PR + SD) was 17.8%. Median time to tumor 
progression (TTP) was 1.3 months (range, 0.8 - 
10.1) and median overall survival (OS) 9.6 months 
(range, 1.0 - 23.4). The 1-year survival Kaplan-Meier 
estimate was 37.6%.
Conclusion: These preliminary results suggest that 
the combination of metronomic oral vinorelbine and 
bevacizumab is safe and demonstrates antitumor 
activity in a population consisting mostly of heavily 
pretreated pts with advanced NSCLC.
Keywords: metronomic vinorelbine, bevacizumab, 
NSCLC, phase II trial
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which EGFR mutation was positive (5 cases with 
erlotinib, 31 cases with geÀtinib), and 33 cases were 
treated with EGFR-TKI of which EGFR mutation 
was negative (17 cases with erlotinib, 16 cases with 
geÀtinib). Out of 69 cases, 15 cases (22%) were 
eligible for this analysis. Categories were 8 cases in 
A and 7 cases in B, respectively. Overall accordance 
rate was 87% (13/15) among three methods. We 
found one case which was EGFR mutation positive 
by both PNA-LNA PCR clamp and Cycleave 
methods in spite of being negative by PCR invader 
method, and found one case which was EGFR 
mutation negative by Cycleave method in spite of 
being positive by PCR invader method (being not 
evaluated by PNA-LNA PCR clamp method due to 
small specimen). The former had partial response 
(PR) for erlotinib, and the latter had progressive 
disease (PD) for erlotinib. There were 4 cases which 
had PR for erlotinib although EGFR mutation was 
negative by above three methods. In contrast, no 
responder for geÀtinib was observed in 16 cases 
without EGFR mutation.
Conclusion: Although our study restricted to the 
patients showing unexpected clinical behavior 
after administration of EGFR-TKI, the accordance 
rate among high sensitive methods was still high. 
However, because EGFR mutation testings do not 
always show the same results among three high 
sensitive methods, if the treatment result of EGFR-
TKI is not consistent with EGFR mutation status, 
the re-examination of EGFR mutation in a different 
method using the same samples may be useful. And 
even if EGFR mutation is negative, erlotinib may be 
effective.
Keywords: Epidermal growth factor receptor, Non 
small cell lung cancer, EGFR mutation, EGFR-TKI
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P3.126 PHASE 1 STUDY OF ORAL 
VINORELBINE IN COMBINATION WITH 
ERLOTINIB IN ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) USING A 
METRONOMIC SCHEDULE
Clarinda Chua1, Balram Chowbay2, Eng-Huat Tan1, 
Kam-Man Hui3, Chee-Keong Toh1, Swan-Swan 
Leong1, Mei-Kim Ang1, Raymond Ng1, Xuan Hou4, 
Wan-Teck Lim1 
1Medical Oncology, National Cancer Centre 
Singapore/Singapore, 2Clinical Pharmacology, 
GeÀtinib = 73,890 baht, Erlotinib = 90,808 baht. 
Conclusion: In clinical beneÀts of GeÀtinib were 
not inferior to Erlotinib in realized practice and 
more cost-effective than Erlotinib in the treatment 
of Thai patients with advanced NSCLC on payer’s 
perspective.
Keywords: TKI, Cost-effectiveness, geÀtinib, 
erlotinib
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.125 ROLE OF RE-EXAMINATION FOR 
EGFR MUTATION USING THE SAME 
SAMPLES IN PATIENTS SHOWING 
UNEXPECTED CLINICAL BEHAVIOR 
AFTER ADMINISTRATION OF EGFR-TKI
Tsuneo Shimokawa, Yuki Misumi, Akira Sato, 
Fumihiro Kashizaki, Mari Ishii, Naoya Hida, Hiroaki 
Okamoto 
Department Of Respiratory Medicine, Yokohama 
Municipal Citizen’s Hospital/Japan
Background: Epidermal growth factor receptor 
(EGFR) mutation has great inÁuence on effect of 
EGFR tyrosine kinase inhibitor (EGFR-TKI) (ex. 
geÀtinib and erlotinib) in lung cancer treatment. 
However, no best assay for EGFR mutation has 
been established at this time. We investigated the 
accordance rate of PNA-LNA PCR clamp method, 
PCR invader method, and Cycleave method, which 
are all high sensitive and approved methods of 
EGFR mutation examination in Japan.
Methods: PCR invader method was routinely 
used for clinical practice in our hospital. If there 
was discrepancy between clinical behavior after 
administration of EGFR-TKI and EGFR mutation 
status, other analyses were additionally performed 
using the same samples. Either cases which were not 
effective for EGFR-TKI although EGFR mutation 
was positive (A), or cases which were effective for 
EGFR-TKI although EGFR mutation was negative 
(B) was eligible for this analysis.
Results: Between May 2007 and December 2010, 
a total 69 cases were treated with EGFR-TKI after 
Ànishing initial EGFR mutation examinations. 
Thirty-six cases were treated with EGFR-TKI of 
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P3.127 CLINICAL SIGNIFICANCE 
OF CASPASE-3 EXPRESSION IN 
PATHOLOGIC-STAGE I, NONSMALL- 
CELL LUNG CANCER
Dong Jiang1, Shiying Zheng1, Hong Li2 
1Department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China, 
2Department Of Geriatrics, The First AfÀliated 
Hospital Of Soochow University/China
Background: Caspase-3 is a cysteine protease that 
plays an important role in the process of apoptotic 
cell death. Whereas many studies on the clinical 
signiÀcance of apoptosis in the therapy of malignant 
tumors have been reported, little has been studied 
clinically on caspase-3. In the present study, the 
clinical signiÀcance of caspase-3 expression in 
resected nonsmall-cell lung cancer (NSCLC) and 
its correlation with incidence of apoptosis were 
examined.
Methods: A total of 118 consecutive patients who 
had undergone complete resection for pathologic 
Stage I NSCLC were retrospectively reviewed. 
Caspase-3 expression was examined immuno- 
histochemically using a polyclonal antibody that 
recognized uncleaved caspase-3.
Results: 1)Caspase-3 was expressed in both the 
nucleus and the cytoplasm of cancer cells. All the 
tumors with caspase-3 staining had a diffuse pattern. 
The distribution of staining was homogenous in 
both the nucleus and the cytoplasm. There was 
no signiÀcant correlation between the degree of 
caspase-3 expression and age, sex, performance 
status (PS), pathologic (p-) T-factor, histologic type, 
or degree of cancer cell differentiation. In addition, 
we could not demonstrate a direct or an inverse 
proportion between caspase-3 expression and AI, PI, 
and p53 status; 2) Postoperative survival according 
to the degree of caspase-3 expression is shown in. 
Five-yearsurvival rates for caspase-3 (+++) patients 
and caspase-3 (++) patients were 60.0% and 68.4%, 
respectively; those for caspase-3 (+) patients and 
caspase-3 (- to ±) patients were 82.6% and 80.8%, 
respectively. Because a deÀnite difference in 
postoperative survival between caspase-3 (++) and 
(+++) patients and caspase-3 (- to ± ) and (+) patients 
was suggested, postoperative survival of these two 
patient groups was compared. Five-year survival 
rates for “strong” (++ or+++) caspase-3 expression 
National Cancer Centre Singapore/Singapore, 
3Division Of Cellular And Molecular Research, 
National Cancer Centre Singapore/Singapore, 
4Division Of Clinical Trials And Epidemiological 
Sciences, National Cancer Centre Singapore/
Singapore
Background: In the salvage setting for NSCLC, 
response rates of around 10% are achieved with 
monotherapy erlotinib in unselected patients. 
Combining oral vinorelbine with erlotinib offers 
potential synergism and convenience of oral 
therapy with potential of increasing response rate. 
Metronomic vinorelbine thrice a week (TIW) 
provides additional potential for anti-angiogenic 
effects. 
Methods: A phase I study utilizing a 3+3 design was 
conducted. Erlotinib was dosed 100 mg OD with 
escalating doses of vinorelbine starting at 30 mg 
TIW. Advanced (stage IIIB/IV) NSCLC who had at 
least 1 prior line of chemotherapy (> 1 line 61.5%) 
were included. Patients with BSA < 1.4 kg/m2 were 
excluded. Correlative studies of pharmacokinetics of 
both drugs and levels of circulating endothelial cells 
(CEC) and circulating endothelial progenitors (CEP) 
were examined. 
Results: Thirteen patients were accrued. 
Patient tumour types included adenocarcinoma 
(54%). squamous cell carcinoma (23%), 
lymphoepithelioma-like carcinoma (8%) and NOS 
(15%). All patients had ECOG status 0-1 and 70% 
(n=9) were non-smokers while the remaining 
30% were ex- or current smokers. Dose limiting 
toxicity of grade 4 neutropenia was reached with 
the combination of vinorelbine 140 mg (50, 50, 40) 
a week and erlotinib 100 mg daily. Other Grade 3/4 
toxicities included diarrhea (7.7%), fatigue (7.7%), 
infection (7.7%) and neutropenia (15.4%). Among 
the 13 patients accrued, 40% (4 of 10) achieved 
SD and 60% had PD. Three patients remained on 
treatment. 
Conclusion: The recommended phase II dose for 
metronomic schedule vinorelbine is 40 mg thrice 
a week with erlotinib 100 mg OM. Additional 
pharmacokinetic data and CEC/CEP correlations will 
be updated at the meeting. 
Keyword: metronomic
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on an automatic analyzer (Elecsys 2000; Roche 
Diagnostics). CEA Assays were performed using 
commercial kits (CEA test; CIS BioInternational, 
France). Normal reference values for CEA were upto 
5 ng/mL. Response was evaluated using RECIST 
criteria. 
Results: 10 patients had partial response, 9 patients 
had stable disease and 9 had progressive disease. 
None of the patients had complete response. 21/29 
(72 %) patients had an elevated baseline value of 
CYFRA 21-1. 62 % patients (18/29) had a decrease 
in CYFRA 21-1 after 1 cycle of chemotherapy. The 
average reduction in the 2nd reading was irrespective 
of whether baseline value was normal or not. The 
average reduction was statistically signiÀcant (P 
= 0.002; 95% CI, from 0.8369 to 3.49464; paired 
sample t test). 8/ 10 (80%) patients with partial 
response had a reduction in their 2nd reading of. 
CYFRA 21-1 () which was signiÀcant. We observed 
that 6/9 (66%) patients whose disease remained 
stable also had a decrease in their subsequent reading 
(P=0.0106), though it was not signiÀcant statistically. 
Although 5/ 9 (55%) patients, who had an increase in 
their 2nd reading had progressive disease, but it was 
not statistically signiÀcant (P= 0.537). 14/ 19 (73%) 
who either had partial response or stable disease, 
had a reduction in their 2nd value of CYFRA 21-1 
and was signiÀcant statistically (P 0.004). We also 
observed that except for 1 patient, all patients who 
had a decrease of 42% or more, were those who 
had either responded to chemotherapy or had stable 
disease (P 0.001), which was statistically signiÀcant. 
While correlating the values of CEA we found that 
15 / 29 (51%) patients had an elevated baseline 
CEA. The increase was however not signiÀcant 
statistically (P = 0.261). 7/15 had a decrease from 
their baseline value which was irrespective of 
whether baseline value was normal or not. 2/10 
(20%) patients with partial response had a reduction 
in their 2nd reading of CEA (P= 0.719) which was 
not signiÀcant statistically. 3/9 (33%) patients whose 
disease remains stable also had a decrease in their 
subsequent reading, though it was not signiÀcant 
statistically (P=0.5106). 4 / 9 (44%) patients, who 
had an increase in their 2nd reading had progressive 
disease, but it was not statistically signiÀcant (P= 
0.427). 
Conclusion: Monitoring of serum marker CYFRA 
21-1, early during Àrst-line chemotherapy may be a 
useful prognostic tool for evaluation of early tumor 
response in patients with advanced NSCLC. We 
failed to demonstrate any predictive value of CEA 
pa-tients and “weak” (- to ± or +) caspase-3 
expression patients were 66.6% and 82.1%, showing 
a signiÀcant poor prognosis for “strong” caspase-3 
expression patients. 3) Multivariate analysis 
conÀrmed that enhanced caspase-3 expression was 
an independent and signiÀcant factor for predicting a 
poor prognosis. Sex and aberrant expression of p53 
were also signiÀcant prognostic factors.
Conclusion: Our study demonstrates that the 
postoperative prognosis of patients with tumors 
showing enhanced expression of “uncleaved” 
caspase-3 was poor even when complete resection 
could be performed. These results suggest that 
enhanced expression of “uncleaved” caspase-3, 
inactivated caspase-3, is correlated with poor 
prognosis in resected NSCLC.
Keywords: caspase-3, Prognosis, Lung cancer, 
apoptosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.128 CEA AND CYFRA 21-1 AS AN 
EARLY PREDICTOR TO RESPONSE 
TO FIRST LINE CHEMOTHERAPY IN 
ADVANCED NON SMALL CELL LUNG 
CANCER
Kashif Iqbal 
Department Of Oncology, Nuclear Medicine, 
Oncology And Radiotherapy Institute/Pakistan
Background: In an era of ever evolving, promising 
new therapies for advanced NSCLC, early predictors 
of response to therapy, are needed. We evaluated 
early variations in CYFRA 21-1 and CEA serum 
levels of patients with advanced NSCLC receiving 
Àrst line chemotherapy and correlated the results 
with objective tumor response
Methods: 29 consecutive, previously untreated, 
patients of advanced NSCLC, with measurable 
disease on CT scan were evaluated. All patients were 
treated with conventional systemic chemotherapy, 
although the choice of chemotherapy was left to 
the discretion of the treating physicians. Serum 
samples were obtained before start of 1st and 2nd 
cycles of chemotherapy. CYFRA 21-1 was measured 
with an electrochemiluminescense immunoassay 
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plus N1 (P=0.12), and ADC plus N2/3 (P=0.01) 
were associated with the brain metastasis as Àrst 
relapse site at 24-month. The nomogram showed a 
moderate accuracy for prediction of 24-month brain 
metastasis, with an area under the curve (AUC) of 
0.768 (bootstrap corrected, 0.730).
Conclusion: The nomogram integrates 3 
clinicopathologic variables to provide an individual 
risk estimate of brain metastasis as Àrst relapse 
site in a patient with NSCLC receiving curative 
resection. This nomogram could be used to develop 
radiologic screening or preventive treatment 
strategies for brain metastasis. 
Keywords: nomogram, Brain Metastasis, Non-small 
cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P3.130 THE SIMILAR SURVIVAL 
BENEFITS OF STABLE DISEASE AND 
PARTIAL RESPONSE TO FIRST-LINE 
GEMCITABINE/CARBOPLATIN IN 
ADVANCED NON-SMALL CELL LUNG 
CANCER PATIENTS
Jinji Yang1, Ri-Qiang Liao1, Yi-Sheng Huang2, Qing 
Zhou2, Chong-Rui Xu2, Zhen Wang2, Hong-Hong 
Yan2, Yi-Long Wu2 
1Division Of Pulmonary Oncology, Guangdong 
General Hospital, Guangdong Academy Of Medical 
Sciences/China, 2Guangdong Lung Cancer Institute, 
Guangdong Academy Of Medical Sciences & 
Guangdong General Hospital/China
Background: The role of stable disease (SD) in 
survival beneÀts has not been clearly demonstrated 
in advanced non-small cell lung cancer (NSCLC) 
treated with Àrst-line platinum-based chemotherapy. 
The aim of this study is to evaluate survival beneÀts 
of Àrst-line gemcitabine /carboplatin (GC) in 
Chinese patients with advanced NSCLC achieving 
SD in routine clinical practice.
Methods: We retrospectively investigated 146 
advanced NSCLC patients receiving Àrst-line GC 
chemotherapy in the electronic medical records from 
January 2003 to July 2006. Survival was estimated 
according to the Kaplan-Meier method. Multivariate 
for response to chemotherapy. It may be concluded 
that monitoring of CYFRA 21-1 and not of CEA 
may be used as a putative marker of response to 
chemotherapy in advanced NSCLC 
Keywords: Non small cell lung cancer, 
Chemotherapy, Cyfra 21-1, CEA
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P3.129 A NOMOGRAM TO PREDICT 
BRAIN METASTASIS AS FIRST RELAPSE 
SITE IN CURATIVELY RESECTED NON-
SMALL CELL LUNG CANCER PATIENTS
Young-Woong Won1, Jungnam Ju2, So Hee Kim2, 
Geon Kook Lee1, Ji-Youn Han1, Heung Tae Kim1, Jin 
Soo Lee1, Hyun-Sung Lee1, Moon Soo Kim1, Jong 
Mog Lee1, Jae Ill Zo1, Tak Yun1 
1Center For Lung Cancer, National Cancer Center/
Korea, 2Center Biostatistics Branch, National 
Cancer Center/Korea
Background: Metastasis to the brain is diagnosed 
in 40 to 50% of patients with locally advanced 
non-small cell lung cancer (NSCLC). However, 
the occurrence of brain metastasis from completely 
resected NSCLC cannot be accurately predicted 
in patients receiving curative resection. We 
hypothesized that a nomogram could be constructed 
by combining selected clinical and pathological 
variables to predict the likelihood of occurrence of 
brain metastasis as Àrst relapse site in patients with 
NSCLC receiving curative resection.
Methods: From 2001 to 2008, 1677 consecutive 
patients treated with curative surgery for NSCLC 
were identiÀed. The logistic regression analysis 
to predict the brain metastasis at 24-month was 
performed. The clinical and pathologic variables 
with P-value <0.15 were built into a nomogram 
estimating probability of brain metastasis as Àrst 
relapse site at 24-month after curative resection. 
The model was validated for discrimination and 
calibration using bootstrap resampling. 
Results: Two hundred six patients with follow-
up duration of less than 12 months were excluded 
from analysis. Finally, a total of 1471 patients 
were analyzed. Median follow-up duration was 
42.3 months (range, 12.0-114.9). Brain metastasis 
as Àrst relapse site occurred in 76 patients (5.2%). 
The logistic regression analysis exhibited that 
smoking (P=0.11), adenocarcinoma (ADC) histology 
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immunohistochemistry (Dako EGFR staining kit). 
EGFR over-expression was present if more than 
10 percent of tumour cells demonstrated weak to 
moderate membrane staining (score 2+) or, strong, 
complete membrane staining (score 3+). Patients 
were of WHO performance status (PS) 0-2. Erlotinib 
was administered at 150mg daily until disease 
progression, unacceptable toxicity or at patient 
request. The primary end point was objective tumour 
response rate. 
Results: Between June 2008 and October 2010, 
twenty-six patients were accrued. Most patients 
were PS 1 (PS 0, 31%; PS 1, 69%; PS 2, 0). Partial 
response occurred in three patients (11.5%), stable 
disease in eight patients (30.8%), and progressive 
disease in thirteen patients (50%); two patients were 
not evaluable. The most common adverse events 
were rash (any grade, 92%; grade 3, 11.5%) and 
diarrhoea (any grade, 65.4%; grade 3, 11.5%). @
font-face { font-family: “Arial”; }@font-face { font-
family: “Cambria”; }p.MsoNormal, li.MsoNormal, 
div.MsoNormal { margin: 0cm 0cm 0.0001pt; font-
size: 12pt; font-family: “Times New Roman”; }
div.Section1 { page: Section1; } The median time 
to progression was 2.5 months. Median overall 
survival was 6.7 months. Mutational analysis was 
performed in twenty patients (77%): two patients had 
EGFR mutations (one sensitising mutation and one 
resistance mutation), and six patients were positive 
for KRAS mutation.
Fifteen patients (57.8%) proceeded to second-line 
platinum-based chemotherapy (partial response n=3, 
stable disease n=5, progressive disease n=5 and NA 
n=2). Three patients (11.5%) underwent third line 
chemotherapy (partial response n=2, progressive 
disease n=1). 
Conclusion: In patients selected on the basis 
of EGFR protein over-expression, erlotinib 
demonstrates modest activity in the Àrst-line setting. 
Keywords: Àrst-line, EGFR, NSCLC, erlotinib
Cox regression analysis was performed to identify 
prognostic factors.
Results: No patients acheived complete response 
(CR). 27 attained partial response (PR) and the 
objective response rate (ORR) was 18.5% (27/146). 
61 had SD. Disease control rate (DCR), consisting 
of CR, PR and SD, was 60.3% (88/146). Median 
progression-free survival (mPFS) was 6.6 months 
(95%CI, 5.2-8.1) for patients with PR and 6.7 
months (95%CI, 6.3-7.2) for patients with SD, P 
= 0.341. Wet stage B and PR or SD to GC were 
signiÀcantly associated with better PFS (P = 0.024, 
0.000 and 0.000 respectively). Median overall 
survival (mOS) was 17.5 months (95% CI, 10.6-
24.4) for patients with PR and 15.1 months (95% CI, 
11.4-18.8) for patients with SD, P = 0.552. Wet stage 
B, PR or SD to GC, and subsequent treatment with 
epidermal growth factor receptor tyrosine kinase 
inhibitors were signiÀcantly associated with better 
OS (P = 0.002, 0.000, 0.000 and 0.004 respectively).
Conclusion: First-line GC chemotherapy has 
comparable PFS and OS beneÀts in Chinese patients 
with advanced NSCLC achieving PR or SD. PR or 
SD is a strong predictor of PFS and OS.
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P3.131 PHASE II TRIAL OF ERLOTINIB 
AS FIRST-LINE THERAPY IN NON-
SMALL CELL LUNG CANCER OVER-
EXPRESSING EGFR
Felicity Murphy1, David N. Church1, Louise 
Medley1, J. M. Davies1, David Breen2, Colin 
Clelland3, David Mackintosh1, Hood Mugalaasi4, 
Rachel Butler4, Denis C. Talbot1 
1Medical Oncology, Oxford Radcliffe Hospital/
United Kingdom, 2Chest Unit, Oxford Radcliffe 
Hospital/United Kingdom, 3Department Of Cellular 
Pathology, Oxford Radcliffe Hospital/United 
Kingdom, 4All Wales Regional Genetics Laboratory/
United Kingdom
Background: Erlotinib has demonstrated efÀcacy in 
the second-line management of non-small cell lung 
cancer. This study was undertaken to investigate its 
use in chemotherapy-naïve patients with tumours 
that over-express EGFR. 
Methods: Eligible patients had cytologically 
or histologically conÀrmed stage IIIb/IV non-
small cell lung cancer over-expressing EGFR on 
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Ànal analysis evaluated PFS, overall survival (OS), 
objective response rate (ORR), disease control rate 
(DCR) and duration of response (DOR), as well as 
the safety proÀle and tolerability of VAN. 
Results: The intention-to-treat (ITT) analysis 
comprised 117 pts (75, VAN; 42, P), excluding 1 
pt randomized to VAN but not treated. The median 
duration of follow-up was 12.1 mo with VAN 
and 17.0 mo with P. Baseline characteristics were 
balanced in both arms (overall: 64% male, 74% 
WHO PS 1, 64% smokers, 74% adenocarcinoma 
histology and 63% partial responders to 
chemotherapy). The Ànal analysis showed that 
median PFS was 2.7 mo (95% CI: 1.9, 4.4) with 
VAN and 1.7 mo (95% CI: 0.9, 2.6) with P; median 
OS was 15.6 mo with VAN and 20.9 mo with P; 
ORR was 18.7% (95% CI: 9.9, 27.5) with VAN and 
2.4% (95% CI: 0.0, 7.0) with P; DCR with VAN was 
44.0% (95% CI: 32.8, 55.2) and 40.5% (95% CI: 
25.6, 55.3) with P, and median DOR with VAN was 
9.2 mo (95% CI: 5.0, -). For pts receiving VAN, the 
most common adverse events were rash, diarrhoea, 
pruritus and anorexia; there were no deaths due to 
treatment-related serious adverse events. 
Conclusion: These results show that single-agent 
vandetanib maintenance treatment, after 4 cycles 
of platinum-based chemotherapy, was tolerable 
and prolonged PFS in pts with NSCLC compared 
with placebo. Based on these results, vandetanib 
maintenance therapy should be considered for 
further study. Correlative biomarker analysis will be 
presented. 
Keywords: Phase II, maintenance, Non-Small-Cell 
Lung Cancer, vandetanib
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P3.133 CHEMOTHERAPY-INDUCED 
NEUTROPENIA AS A PROGNOSTIC 
FACTOR IN PATIENTS WITH ADVANCED 
NON-SMALL CELL LUNG CANCER 
TREATED WITH MORE THAN 4 CYCLES 
OF FRONT-LINE PLATINIUM-BASED 
CHEMOTHERAPY.
Jeong Eun Lee1, Su Jin Yoo1, Ju Ock Kim2, Hee Sun 
Park2, Sun Young Kim2 
1Internal Medicine, Chungnam National University 
Hospital/Korea, 2Internal Medicine, Chungnam 
National University/Korea
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.132 RANDOMIZED, DOUBLE-
BLIND, PLACEBO-CONTROLLED 
PHASE II STUDY OF VANDETANIB 
MAINTENANCE THERAPY FOR 
ADVANCED OR METASTATIC NON-
SMALL-CELL LUNG CANCER (NSCLC) 
FOLLOWING 1ST-LINE PLATINUM-
DOUBLET CHEMOTHERAPY
Myung-Ju Ahn1, Keunchil Park1, Jin Seok Ahn1, Eun 
Kyung Cho2, Dae Ho Lee3, Gyeong Won Lee4, Jin-
Hyoung Kang5, Sang-We Kim3, Jong-Seok Lee6, Ki 
Hyeong Lee7 
1Department Of Medicine, Sungkyunkwan University 
School Of Medicine, Samsung Medical Center/
Korea, 2Department Of Hematology And Oncology, 
Gachon University Gil Hospital/Korea, 3Department 
Of Oncology, University Of Ulsan College Of 
Medicine, Asan Medical Center/Korea, 4Division Of 
Hematology And Oncology, Gyeongsang National 
University Hospital/Korea, 5Department Of Medical 
Oncology, The Catholic University Of Korea, Seoul 
St. Mary’s Hospital/Korea, 6Division Of Hematology 
And Oncology, Seoul National University Bundang 
Hospital/Korea, 7Department Of Hematology And 
Oncology, Chungbuk National University Hospital/
Korea
Background: Vandetanib (VAN) is a once-
daily oral inhibitor of VEGFR, EGFR and RET 
signalling. Several studies have shown the efÀcacy 
and tolerability of vandetanib in patients (pts) 
with advanced NSCLC. This study assessed VAN 
maintenance therapy in NSCLC. 
Methods: Pts who had not progressed after 4 cycles 
of platinum-based chemotherapy were randomized 
1:1 to VAN 300 mg/day or placebo (P). The primary 
objective was to compare indirectly the progression-
free survival (PFS) rate at 3 months (mo) at the 
interim analysis, which was conducted once 24 
PFS-evaluable pts had been accrued to each arm and 
followed for 3 mo. According to the optimal two-
stage design by Simon (1989), it was planned that 
additional enrolment would proceed only if there 
were at least 9 pts who remained progression-free 
at 3 mo. At the interim analysis, the numbers of 
progression-free pts at 3 mo were 9/24 in the VAN 
arm, with acceptable toxicities, and 7/24 in the P 
arm. Additional pts were therefore enrolled to the 
VAN arm and accrual to the P arm was stopped. The 
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Background: Relationship of estrogen use, smoking, 
and NSCLC has been reported in several studies. 
Capthesin B is expressed on most NSCLC and is the 
major metabolizing enzyme for CT-2103. It is under 
control of estrogen and in phase III front line studies, 
women with estradiol levels >30 had the largest 
survival beneÀt. The objective of this study was to 
evaluate CT-2103 as single agent therapy for women 
with baseline estradiol levels >30 or in combination 
with EstroGel in post-menopausal women with 
heavily pretreated advanced NSCLC. The primary 
endpoint was progression free survival with 
safety, response, and overall survival as secondary 
endpoints. 
Methods: 29 stage IV NSCLC patients with PS 0, 
1 or 2 who had previous treatment with at least one 
cytotoxic chemotherapy and an EGFR inhibitor, 
participated. CT-2103 was given as IV infusion once 
every 21 days (1 cycle). Tumor response (using 
RECIST criteria) was assessed after even numbered 
cycle. Toxicities assessed at each patient visits. 
Study discontinued at the time of progression or 
unacceptable toxicity. 
Results: 29 patients with 3.4 average lines (ranging 
2-7) of previous treatment (8 patients received 4 or 
more lines of therapy), received CT-2103 treatment. 
Plus estradiol patches for serum levels <30. Average 
number of CT-2103 cycles was 2.8 (1-6 cycles). 
Median time to progression was 44 days (36.5-51.5) 
with median overall survival 223 days (153-282). 
11 (37.9%) of 29 patients had stable disease and 1 
(3.4%) partial response. No major toxicity reported 
except grade I and II peripheral neuropathy in 6 
(20.6%), no hair loss or allergic reaction reported. 
Conclusion: Paclitaxel poliglumex was relatively 
well tolerated. Despite encouraging preliminary 
clinical results in women with high estradiol levels 
and intriguing preclinical observations, the PFS and 
overall survival results suggest that further testing of 
this treatment strategy is not warranted. 
Keywords: Non-small cell lung cancer, new 
treatment, paclitaxel poliglumex
Background: Neutropenia is a common side effect 
of platinium-based chemotherapy. We analyzed the 
association between the grade of chemotherapy-
induced neutropenia and the clinical outcome 
for patients with advanced non-small-cell lung 
cancer (NSCLC). A possible explanation for 
the association between chemotherapy-induced 
neutropenia and clinical outcome is that the absence 
of neutropenia may suggest a lack of efÀcacy of the 
administered chemotherapy regimen possibly due to 
pharmacogenetic reasons and varied metabolism of 
anticancer drugs. 
Methods: Thirty nine patients with locally 
advanced/metastatic NSCLC, treated with front-line 
more than 4 cycles of platinium based chemotherapy 
were retrospectively analyzed. The mean number of 
cylces of front-line chemotherapy they were treated 
was 5.8. Patients were categorized into two groups 
according to the presented worst neutropenia grade: 
mild (grades I/II) and severe (grades III/IV). 
Results: One year survival was signiÀcantly better 
in patients developing severe grade of neutropenia 
compared with those with mild neutropenia; the 1 
year survival rate were 18.2%(2/11), 60.7%(17/28) 
for the groups with mild and severe neutropenia, 
respectively(p value=0.017). The median overall 
survival were 8.4, 20.4 months for the same groups, 
respectively. The disease controlled rate (including 
complete remission, partial response and stable 
disease) was better in patients with severe grade of 
neutropnenia; 45.5%(5/11) and 60.7%(17/28) for the 
groups with mild and severe neutropenia, but there 
was no statistical signiÀcance(p value=0.387). 
Conclusion: Chemotherapy-induced neutropenia can 
be a predictor of better clinical outcome for patients 
with advanced NSCLC. 
Keywords: neutropenia, NSCLC
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P3.134 PHASE II TRIAL OF PACLITAXEL 
POLIGLUMEX(CT-2103) IN PRE- AND 
POST-MENOPAUSAL WOMEN ON 
HORMONAL REPLACEMENT THERAPY 
(HRT) WITH NON SMALL CELL LUNG 
CANCER (NSCLC)
Roozbeh Mohajer1, Marta Batus2, Debra Pach2, 
Sanjib Basu2, Mary J. Fidler2, Philip Bonomi2 
1Oncology, Rush Univesity Medical Center/United 
States Of America, 2Hematolog/Oncology/bmt, Rush 
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29.2 versus 0% OR, respectively (p=0.15), and 
3.0 versus 1.9 months of median PFS (p=0.056). 
The two patients treated with pemetrexed 
monotherapy have experimented prolonged 
response over 10 and 20 months, respectively. 
In univariate Cox model analysis, a signiÀcantly 
probability of improved PFS was associated with 
use of taxan-based chemotherapy and pemetrexed 
monotherapy (HR=0.44, 95% CI, 0.21-0.90, 
p=0.026)(see Àgure below). Difference in PFS, OR 
and DCR between taxan-based chemotherapy and 
pemetrexed monotherapy versus gemcitabine-based 
chemotherapy was preserved in third-line treatment.
Conclusion: Our results showed that: 1) only 50% 
of advanced BAC treated in Àrst-line with G had 
received a second-line chemotherapy regimen; 2) 
a platin-doublet could be administered with some 
evidence of effectiveness to these patients with PS 
0 or 1; 3) taxan-based and pemetrexed monotherapy 
seemed to be good candidates for future clinical 
trials and led us to choose this drugs to be tested in 
IFCT-0504 trial. 
Keywords: bronchioloalveolar carcinoma, 
Chemotherapy
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P3.135 CHEMOTHERAPY 
EFFECTIVENESS AFTER FIRST-
LINE GEFITINIB (G) TREATMENT OF 
ADVANCED BRONCHIOLOALVEOLAR 
CARCINOMA (BAC): EXPLORATORY 
ANALYSIS OF THE IFCT-0401 TRIAL
Michael Duruisseaux1, Franck Morin1, Laurence 
Baudrin1, Elisabeth Quoix1, Denis Moro-Sibilot1, 
Daniel Coetmeur1, Isabelle Monnet1, Jean-Fraonçois 
Morère1, Pierre Mourlanette1, Jean-Charles Soria1, 
Virginie Westeel1, Jacques Cadranel2 
1IFCT/France, 2IFCT/France
Background: At the present time, there is no 
treatment standard for the patients with advanced 
BAC. Chemotherapy is widely perceived to be 
ineffective in advanced BAC. No information was 
available concerning platin doublets. Two phase II 
prospective trials have tested two different schedules 
of paclitaxel monotherapy as front-line therapy with 
low OR of 11-14% and a relatively high toxicity. 
Interestingly, only mucinous cytological subtype (M) 
might be more responsive to paclitaxel. EGFR-TKI 
have demonstrated interesting activity in three phase 
II trials, particularly in non-mucinous cytological 
subtype (NM) as shown in the IFCT-0401 trial 
using G as Àrst-line therapy. We aimed to study 
chemotherapy efÀcacy after geÀtinib failure among 
patients enrolled in the IFCT-0401 trial. 
Methods: 88 patients with advanced BAC were 
enrolled in the IFCT-0401 trial and received G 250 
mg/d as front-line therapy. For patients still eligible 
for chemotherapy after G-failure, carboplatin plus 
paclitaxel regimen was recommended for PS 0-1 
patients and gemcitabine monotherapy for PS 2 
patients. 
Results: 44 patients received a second-line 
treatment after G failure and 41 were treated with 
chemotherapy. 40 patients had a PS 0 or 1. 27 
patients received a taxan-based chemotherapy (22, 
paclitaxel+carboplatin and 5, docetaxel+cisplatin), 
12, a gemcitabine-based chemotherapy (9, with 
cisplatin and 3, monotherapy), 2, a pemetrexed 
monotherapy and 3, other regimens (2, bortezomib 
and 1, erlotinib). PFS in second-line setting was 
2.8 months (95% CI, 2.3-4.2). OR was 23% (8 
PR, 15 SD, 15 PD, 6 NE) and DCR at time of the 
best response was 65.7%. Taxan-based (n=27) and 
gemcitabine-based (n=12) chemotherapies achieved 
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pts (66%), lung 1, bone 2 and adrenal gland 1. Local 
control of SSP was obtained by radiotherapy in 88% 
of pts (CR 2 pts, PR 6, stable disease 2, progression 
2). After SSP, all patients continued EGFR-TKIs 
for a median time of 7 mos (range 1.6-48.8). Up 
to now 8 pts had further progressive disease and 
stopped EGFR-TKIs while 4 are still on treatment 
experiencing disease control. Actuarial median 
freedom from progression (FFP) evaluated from 
EGFR-TKI starting until SSP was 8.9 mos; FFP from 
SSP to SPD was 8.2 mos. Overall median FFP was 
24.6 mos (from EGFR-TKI starting until SPD) and 
median overall survival was 39.7 mos. The toxicities 
associated with the protracted EGFR-TKI treatment 
were generally acceptable and comparable to those 
observed for the initial EGFR-TKI therapy. 
Conclusion: Our data suggest that the protracted 
use of an EGFR-TKI after SPD and local treatment, 
particularly beyond brain progression, can be 
an effective treatment option for EGFR-TKI 
responders since this seems to be associated with 
further systemic disease control and possibly longer 
survival. We believe that these results deserve further 
study since they could have important clinical 
implications. 
Keywords: geÀtinib, erlotinib, EGFR, NSCLC
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P3.137 EFFICACY AND SAFETY IN THE 
CROSS-OVER ARM OF OAM4558G; 
A PHASE II STUDY EVALUATING 
METMAB IN COMBINATION WITH 
ERLOTINIB IN ADVANCED NSCLC.
Rodryg Ramlau1, David Spigel2, Thomas Ervin3, 
Davey B. Daniel4, Jerome Goldschmidt5, George 
Blumenschein6, Ramaswamy Govindan7, Anshu 
Vashishtha8, Wei Yu8, Premal Patel8, Amy Peterson8 
1Oncology, Wielkopolskie Centrum Pulmonologii 
I Torakochirurgii, Poznan University Of Medical 
Sciences/Poland, 2Sarah Cannon Research Institute 
And Tennessee Oncology, Pllc/United States Of 
America, 3Florida Cancer Specialists/United States 
Of America, 4Chattanooga Oncology Hematology 
Associates/United States Of America, 5Blue Ridge 
Cancer Centre/United States Of America, 6University 
Of Texas M.D. Anderson Cancer Center/United 
States Of America, 7Washington University School 
Of Medicine/United States Of America, 8Genentech/
United States Of America
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P3.136 A RETROSPECTIVE ANALYSIS 
OF THE CLINICAL RESPONSES TO 
EGFR-TYROSINE KINASE INHIBITOR 
(EGFR-TKI) CONTINUOUS TREATMENT 
BEYOND SINGLE SITE DISEASE 
PROGRESSION IN METASTATIC NON-
SMALL CELL LUNG CANCER PATIENTS 
WHO BENEFITED FROM PRIOR EGFR-
TKI THERAPY
Hector J. Soto Parra1, Rita Chiari2, Alessandra 
Bearz3, Raffaele Cavina4, Pietro Spadaro5, Fiorenza 
Latteri1, Roberto Bordonaro1 
1Medical Oncology, Ospedale Garibaldi/Italy, 
2Medical Oncology, Ospedale Di Perugia/Italy, 3Cro 
Di Aviano/Italy, 4Medical Oncology, Irccs Humanitas 
Rozzano-milano/Italy, 5Medical Oncology, Clinica 
Villa Salus/Italy
Background: Few treatment options are available 
for metastatic non-small cell lung cancer (NSCLC) 
patients who have responded to an EGFR-TKI 
treatment showing tumor progression. Whether to 
continue the same or another EGFR-TKI (erlotinib 
or geÀnitib) after single site disease progression 
(SSP) is an important unanswered clinical 
question. Unfortunately, there is little evidence 
to guide decision-making. The modest toxicity 
and the possible, but unproven, beneÀt from the 
continued use of an EGFR-TKI suggest to continue 
administration of this drugs after local treatment of 
SSP until subsequent systemic progressive disease 
(SPD). The present study was conducted to evaluate 
the efÀcacy and toxicity of this therapeutic strategy.
Methods: We retrospectively analyzed 12 patients 
who had obtained a partial response (PR) or stable 
disease (SD) by treatment with an EGFR-TKI to 
describe their clinical outcome once receiving local 
treatment for SSP and continuing an EGFR-TKI until 
further SPD 
Results: Between December 2001 and November 
2010 we identiÀed 12 pts at 4 Italian Institutions 
(Aviano, Catania, Milano and Perugia): median 
age: 62 yrs (range 44-78), male: 7 pts, PS0: 6 pts, 
smokers: 7pts. EGFR mutated:4, wild-type:2, 
unknown 6. Eight pts were treated with erlotinib and 
4 with geÀnitib (Àrst-line 1 pt, second 7 pts and third 
4 pts). One pt achieved CR (8%), 6 pts PR (50%) 
and 5 stable disease (42%). SSP occurred after a 
median time of 9.8 mos (range 1.2-28.6 ) in brain 8 
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Conclusion: Met ampliÀcation/activation has been 
described as a mechanism of resistance to EGFR 
inhibition, providing a rationale to add M to E 
following progression on E alone. While this data 
set is limited, it is intriguing that of the patients that 
crossed over to M+E, a small fraction (regardless of 
Met status at time of randomization) had a longer 
PFS on M+E than on P+E. Tissue was not available 
in this study to assess Met status at time of crossover, 
but would be a consideration for future studies. 
Keywords: cMet, MetMAb, erlotinib, NSCLC
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P3.138 BEVACIZUMAB BEYOND 
PROGRESSION IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): PRELIMINARY 
RESULTS OF A PHASE II STUDY
Johanna N.H. Timmer-Bonte1, Desiree G.M. Van 
Den Hurk2, Miriam A. Dohmen3, Chantal A. Smits-
Vandergraaf2, Miep Van Der Drift2 
1Medical Oncology, Radboud University Nijmegen 
Medical Centre/Netherlands, 2Pulmonary Diseases, 
Radboud University Nijmegen Medical Centre/
Netherlands, 3Iko Trial And Datamanagment, 
Radboud University Nijmegen Medical Centre/
Netherlands
Background: The VEGF and epidermal growth 
factor receptor (EGFR) pathways represent 2 
clinically validated and interrelated targets for 
NSCLC. Adding the anti-vascular endothelial 
growth factor (VEGF) monoclonal antibody 
bevacizumab (B) to Àrst line platinum-based 
chemotherapy improves outcome in NSCLC. 
However, the optimal duration of treatment with 
B is unknown. Preclinical data suggest rapid 
vascular re-growth in tumours after reversal of 
VEGF inhibition supporting studying the concept 
of continued use of VEGF inhibition in progressive 
patients. Preclinical studies have shown that 
VEGF and EGFR inhibitors (e.g. erlotinib) can 
have additive effects and clinical trials have also 
produced promising data. In second line therapy 
combining bevacizumab with anti-EGFR directed 
therapy increases beneÀt compared with anti-
EGFR agents alone. This open label single centre 
phase II study investigates the efÀcacy of 2nd line 
erlotinib plus bevacizumab (BE) subsequent to a 
Background: A global Phase II double-blinded, 
randomized trial comparing MetMAb+erlotinib 
(M+E) versus placebo+erlotinib (P+E) in 2nd/3rd line 
NSCLC was recently completed. M+E demonstrated 
both PFS and OS advantages in Met Dx+ NSCLC. 
Following disease progression, eligible patients on 
the P+E arm were allowed to crossover to receive 
open-label M+E
Methods: EfÀcacy (PFS and OS) and Safety were 
assessed in the crossover patients. Eligibility criteria 
for crossover included: ECOG PS 0-2, absence of 
untreated and/or active CNS metastasis, initiate M+E 
within 28 days from documented PD.
Results: Of the 128 randomized patients, 26 
participated in the crossover, of which 12 were Met 
Dx+,12 were Met Dx-, and 2 were undetermined. 
Among the 12 Met Dx+ patients, 11 (92%) patients 
had ECOG 0/1 at baseline, 2 (17%) patients had 
squamous tumor, 2 (17%) patients never smoked, 
4 had KRAS mutant tumors and none had EGFR 
mutant tumor. Among the 12 Met Dx- patients, all 
patients had ECOG 0/1 at baseline, 4 (33%) had 
squamous tumors, 1 (8%) never smoked, 3 (25%) 
had KRAS mutant tumors and 2 (17%) had EGFR 
mutant tumors. Most patients progressed at the Àrst 
tumor assessment following cross-over to M+E. 
Among 12 Met Dx+ patients, 5 patients died and 3 
progressed at or prior to the Àrst tumor assessment; 
of the 4 patients who did not progress at the Àrst 
tumor assessment, the median PFS was 5.2 months 
(95%CI: 2.7-NA months) after crossover. Among 
12 Met Dx- patients, 4 patients died prior to and 5 
progressed at the Àrst tumor assessment; of the 3 
who did not progress at Àrst tumor assessment, 2 
discontinued treatment (MD decision) and the 3rd 
continues on M+E (>7 months). After crossover to 
M+E, the Met Dx+ patients had median OS (mOS) 
post PD (deÀned as time from 1st PD to death from 
any cause) of 2.2 months (95%CI: 1.1-6.4 months); 
and the Met Dx- patients had an unreached mOS post 
PD. For patients in P+E arm who had progressive 
disease but did not crossover to M+E (n=19), the 
Met Dx+ patients (n=10) had mOS post PD of 3.5 
months (95%CI: 0.6-5.7 months); and the Met 
Dx- patients (n=8) had mOS post PD of 6.7 months 
(95%CI: 1.1-NA months). The most frequent adverse 
events regardless of attribution include: nausea (n=7; 
27%), dyspnoea (n=6; 23%), vomiting (n=6; 23%), 
diarrhoea (n=5; 19%), and rash (n=4; 15%). Overall 
incidence and spectrum of adverse events following 
crossover is comparable to the known safety proÀle 
of the combination. 
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P3.139 THE ROLE OF NANOPARTICLE 
ALBUMIN-BOUND PACLITAXEL (NAB-P) 
IN THE NON-SMALL-CELL LUNG 
CANCER (NSCLC) PATIENTS.
Alexandros Kavvadias1, Andriani G. Charpidou2, 
Ioannis Gkiozos2, Kostas N. Syrigos2 
14th Respiratory Department, 4th Respiratory 
Department, General & Chest Diseases Hospital 
“Sotiria”/Greece, 2Oncology Unit Gpp, University 
Of Athens, Medical School General & Chest 
Diseases Hospital “Sotiria”/Greece
Background: The well known P and docetaxel are 
hydrophobic substances, they need premedication 
with steroids and antihistamine, long infusion 
time and they present serious adverse events, 
sometimes caused by the solvent in use. Nab-P is a 
novel water-soluble formulation of P prepared by 
high-pressure homogenization of P in the presence 
of serum albumin into a nanoparticle colloidal 
suspension. Nab-P utilizes the albumin receptor 
(gp60)/caveolin-1 (CAV1) pathway achieving high 
intratumoral paclitaxel accumulation. Aim of this 
article is to present the latest data on the use of nab-P 
in the treatment of NSCLC.
Methods: Our source was MEDLINE till the end of 
2010 with key words nab-P and NSCLC.
Results: We found three phase I trials, three phase 
II trials and one dose-Ànding non-randomized 
trial for a phase III trial. We have also found the 
abstract of the last nominated phase III randomized 
trial presented in the American society of clinical 
oncologists (ASCO) annual meeting of 2010. Nab-P 
presents some technical advantages over P including 
shorter infusion time of 30 minutes and no need for 
steroid and antihistamine premedication. Nab-P has 
signiÀcant single agent activity. When combined 
with carboplatin (C) or C and bevacizumab, nab-P 
has promising activity in the Àrst line treatment of 
NSCLC. A recent phase III trial with 1038 patients 
has shown that nab-P in combination with C 
signiÀcantly improves overall response rate (ORR) 
versus P-C. Histologic subset analysis has shown 
signiÀcantly improved ORR for nab-PC versus PC 
in squamous cell carcinoma patients. Regarding 
the toxicity proÀle of nab-P presented signiÀcantly 
less high-grade adverse events and reduced risk of 
hypersensitivity reactions compared with P.
Conclusion: Nab-P has a safe and efÀcient proÀle. 
1st line combination of carboplatin, paclitaxel and 
bevacizumab (CPB).
Methods: Previously untreated patients with 
advanced non-squamous NSCLC receive 1st line 
treatment with 3-weekly C (AUC 6 day 1 i.v.) P 
(200 mg/m2 i.v. day 1) B (15 mg/kg i.v. day 1) 
for a maximum of 4 cycles or less in case of early 
progression, 3-weekly bevacizumab continues until 
progression. At (early) progression B continues 
and E (150 mg/day orally) is added. The primary 
objective of the study is to assess the efÀcacy, 
deÀned as disease control rate (CR+PR+SD 
according to RECIST) at 12 weeks treatment BE. 
Results: Informed consent was obtained from 
25 patients (pts), 23 started therapy; at Àrst data-
analysis 12 pts progressed of whom 8 pts started 
2nd line BE. Reasons for not entering 2nd line were 
rapidly declining PS in 2 pts and pt’s wish in the 
other 2. Of the 8 pts with BE, 1 received 9 cycles 
of BE (27 weeks, best respons SD) and 1 received 
4 cycles (12 weeks, SD). Of the remaining 6 
pts, 2 progressed within the Àrst 6 weeks, 3 pts 
discontinued treatment before Àrst radiological 
evaluation (pt wish in all 3 due to declining 
performance status, most likely disease-related), 
and 1 pt died of pulmonary hemorrhage (PH) after 
5 weeks BE. No unexpected (serious) adverse 
events were observed. Besides the one treatment 
related death (PH), 2 other SAE were reported: 
one treatment related (dehydration caused by 
diarrhea) and one disease related (pain syndrome 
necessitating hospital admission). 
Conclusion: The study is ongoing. The minimum 
DCR below which 2nd line BE treatment after Àrst 
line CPB is of no interest is set at 35%, hence 
if at most 8 of Àrst 21 patients show controlled 
disease, the trial will be stopped concluding BE is 
not effective enough (2-phase Simon ‘minimax’ 
design; power 80%; type I error 5%;). Otherwise, 
a total of 39 pts will be entered in the BE; if 19 
pts or more show DCR, the conclusion will be that 
the effectiveness of the treatment is larger than 
35%. Currently DCR at 12 weeks is 2 out of 8 and 
treatment with 2nd line BE seems feasible. 
Keywords: Advanced NSCLC, targeted therapies, 
bevacizumab beyond progression, erlotinib
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of supportive medications, including antiemetics 
(44% vs. 13%; p = .023) and growth factors (36% 
vs. 9%; p = .03). Overall, the most common AEs 
were rash (29%), fatigue (26%), decreased appetite 
(23%), diarrhea (21%), anemia (19%), and nausea 
(18%). PEM patients had more Hematologic related 
nonserious AEs (41% vs. 9%; p = .009), and were 
signiÀcantly more likely to have serious AEs (33% 
vs. 9%; p = .03; see Table). ERL patients had 
signiÀcantly more Skin related nonserious AEs (65% 
vs. 18%; p = .0003). The most common self-reported 
symptoms rated as severe were fatigue (41%), pain 
(33%), sexual problems (27%) and shortness of 
breath (25%). Diarrhea was more likely to be self 
rated as severe by ERL patients (23% vs. 3%; p = 
.03). Self rated severe rash was nominally higher 
among the ERL group (9% vs. 0%; p = .15). 
Serious Adverse Events Erlotinib (N=23) 
Pemetrexed 
(N=39) 
Patients with  1 SAE 2 13 
Neutropenia 0 1 
Pancytopenia 0 1 
Thrombocytopenia 0 1 
Gastrointestinal Disorders* 1 2 
Infections And Infestations* 0 3 
Blood Creatinine Abnormal 1 0 
Dehydration 1 0 
Hyperkalaemia 1 0 
Muscular Weakness 0 1 
Renal Failure Acute 0 1 
Respiratory, Thoracic And 
Mediastinal Disorders* 0 7 
Oesophageal Stent Removal 0 1 
Arterial Thrombosis 0 1 
* System organ class of SAEs 
Conclusion: These data from the US community 
setting conÀrm previous clinical trial data that 
patients treated with second or third line ERL have 
fewer side effects when compared to cytotoxic 
chemotherapy. 
Keywords: NSCLC, safety, erlotinib, Pemetrexed
In patients with hypersensitivity reactions after 
receiving the older taxanes can be an alternative 
solution. Squamous cell carcinoma histotype may 
have an advantage if treated with nab-P which 
may in part be attributed to the aberrant CAV1 
overexpression in these patients and the high 
intratumoral accumulation of nab-P via the gp60-
CAV1 pathway.
Keywords: nab-p, treatment, NSCLC, squamous cell 
carcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.140 PROSPECTIVE OBSERVATIONAL 
COMPARISON OF SAFETY IN PATIENTS 
RECEIVING SECOND OR THIRD 
LINE TREATMENT FOR NON-SMALL 
CELL LUNG CANCER (NSCLC) IN US 
COMMUNITY PRACTICES
L. Johnetta Blakely1, Mark S. Walker1, Carolina 
Reyes2, Edward J. Stepanski1 
1Acorn Research, Llc/United States Of America, 
2Health Outcomes And Payer Support, Genentech, 
Inc/United States Of America
Background: This prospective observational study 
was designed to evaluate health-related quality 
of life, adverse events, and healthcare utilization 
among patients receiving either pemetrexed (PEM) 
or erlotinib (ERL) as a single agent for second line 
treatment of NSCLC in community clinics in the 
United States.
Methods: Patients with ECOG=0-2 and a conÀrmed 
diagnosis of advanced or metastatic NSCLC 
beginning single agent second or third line ERL 
therapy, or second line PEM therapy were enrolled 
at 15 community sites. Patients were observed for 12 
weeks or until discontinuing treatment. In addition 
to provider ratings of adverse events (AEs), patient 
reported outcomes were also collected. 
Results: 62 patients (ERL=23; PEM=39) were 
enrolled. ERL patients were older than PEM patients 
(70.6 vs. 65.9; p = .04), and more likely to be White 
(91% vs. 67%; p = .03). There were no group 
differences in disease characteristics or treatment 
history. PEM patients had signiÀcantly greater use 
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A median of 4 cycles (1 - 25) of treatment was 
delivered to patients randomized to vandetanib 
maintenance, while a median of 3 cycles (1 - 19) 
was delivered to patients randomized to placebo 
maintenance. Toxicity was assessed on day 1 of 
each cycle, at least once for 157 treated patients, of 
whom 19 (9 vandetanib maintenance and 10 placebo 
maintenance) experienced no grade  3 toxicity. 
There was no difference between arms in the number 
of cycles administered (exact p=0.62) or the worst 
degree toxicities (exact p=0.92). Toxicities ( grade 
3) occurring at a rate of 5% included neutropenia 
(48%), leukopenia (18%), diarrhea (12%), fatigue 
(11%), febrile neutropenia (11%), dyspnea 
(11%), thrombosis / thrombus /embolism (10%), 
dehydration (9%), rash/desquamation (8%), back 
pain (8%), hyponatremia (7%), hypokalemia (6%), 
anemia (6%), and lung infection with unknown 
absolute neutrophil count (5%). Diverticulitis was 
noted on several serious adverse event reports, so 
we explored potentially related symptoms, including 
diarrhea, mucositis, enteritis, GI hemorrhage, 
abdominal pain, colitis, Àstula, and GI perforation. 
98 patients had  one of these symptoms, 31 grade 3 
and 1 grade 4 (20% gr 3-4). One grade 3 perforation 
of diverticulitis was reported. Three events (2%) 
included the word “diverticulitis” in the narrative of 
a serious adverse event (SAE). The lack of a speciÀc 
NCI CTCAE term for diverticulitis may lead to 
inconsistencies in reporting and is representative of 
difÀculties that may exist in assessing this and other 
targeted therapy toxicities.
Conclusion: s: In this study, maintenance oral 
antiangiogenic therapy with vandetanib improved 
PFS and showed toxicities similar to other 
angiogenesis inhibitors.
Keywords: Tyrosine kinase inhibitor toxicities, 
Advanced Non-Small Cell Lung Cancer, 
maintenance therapy
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P3.142 RAPID DISEASE PROGRESSION 
IN NON-SMALL CELL LUNG CANCER 
PATIENTS PREVIOUSLY STAGED BY 
PET/CT
Miranda B. Kim, Geoffrey A. Geiger, John P. 
Plastaras, Ramesh Rengan 
Radiation Oncology, Hospital Of The University Of 
Pennsylvania/United States Of America
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P3.141 VANDETANIB PLUS 
CHEMOTHERAPY FOR INDUCTION 
THERAPY FOLLOWED BY VANDETANIB 
OR PLACEBO AS MAINTENANCE 
FOR ADVANCED NON-SMALL-CELL 
LUNG CANCER (NSCLC): EFFICACY 
AND TOXICITIES UPDATE. A PHASE II 
PRECOG, LLC STUDY (PRE0501)
Joseph Aisner1, Judith Manola2, Shaker Dakhil3, 
Phillip J. Stella4, Joan Schiller5 
1Medicine, The Cancer Institute Of New Jersey/
United States Of America, 2Biostatistics, Dana-
farber Cancer Institute/United States Of America, 
3Cancer Center Of Kansas P.a./United States Of 
America, 4Medical Oncology, St. Joseph Mercy 
Health System & Ncctg/United States Of America, 
5University Of Texas Southwestern Medical Center/
United States Of America
Background: We conducted a randomized phase 
2 study to test if vandetanib, a VEGFR and EGFR 
tyrosine kinase inhibitor, could improve PFS, 
compared to historical controls, in patients with 
NSCLC when given as induction therapy with 
docetaxel and carboplatin, followed by maintenance 
vandetanib or placebo. We examined safety and side 
effects, and in particular, those related to actual and 
presumed vascular events and diverticulitis.
Methods: Patients with stage 3B or 4 NSCLC 
were randomized to induction docetaxel (75 mg/
m2) and carboplatin (AUC 6) on day 1 of a 21-day 
cycle, with daily vandetanib (100 mg/day po) for 4 
cycles, followed by daily vandetanib (300 mg/day) 
or placebo until progression. Eligibility required 
good performance status (ECOG 0-1), measurable 
disease, and no prior cytotoxic or targeted agents 
for advanced disease. Ineligibility included 
uncontrolled hypertension, arrhythmia, or history 
of QT prolongation. Patients were assessed for 
adverse events (AEs) during every cycle and for 30 
days post-treatment. AEs were also reported during 
follow-up.
Results: 162 patients were randomized between 
May 2008 and November 2009, and 158 began 
treatment. Median age was 63 (36-82). 91% had 
stage IV or recurrent disease and 52% were male. 
EfÀcacy results previously reported; showed 
prolonged PFS for vandetanib maintenance in a 
multivariate model adjusting for stage (p=0.02). 
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initial staging PET/CT resulted in the identiÀcation 
of critical new Àndings. For a subset of patients who 
underwent both scans under identical conditions, 
upstaged patients had a signiÀcantly higher SUV 
velocity than patients who were not upstaged, 
which was statistically signiÀcant. Overall, 24% 
of patients had interval progression changing 
treatment intent from curative to palliative. Nearly 
one half progressed in N or M stage. Without the 
repeat PET/CT, a substantial proportion of patients 
may have received inappropriate treatment for 
metastatic disease. This study supports the notion 
that progression of disease may occur between 
the staging PET/CT and initiation of therapy 
with increasing interval from the scan. Therefore, 
clinicians should exercise caution when time to 
initiation of therapy is greater than 30 days from the 
staging PET/CT. 
Keywords: PET/CT, treatment planning, Lung 
cancer, RADIATION
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P3.143 CHEMOTHERAPY VERSUS 
ERLOTINIB IN THE SECOND LINE 
TREATMENT OF ADVANCED NON-
SMALL CELL LUNG CANCER
Ondrej Fiala1, Milos Pesek2, Jana Krejci3, Michal 
Sticha4, Marek Minarik5 
1Department Of Tuberculosis And Respiratory 
Diseases, Teaching Hospital In Pilsen/Czech 
Republic, 2Department Of Respiratory Diseases 
And Tb, University Hospital Plzen/Czech Republic, 
3Department Of Pneumology And Thoracic Surgery, 
Teaching Hospital In Prague-bulovka/Czech 
Republic, 4Institut Of Biostatistics And Analyses, 
Masaryk University, Brno/Czech Republic, 5Center 
For Applied Genomics Of Solid Tumors, Genomac 
International/Czech Republic
Background: Modern treatment modalities in 
pneumooncology include „targeted therapy“of 
tyrosine kinase inhibitors, designed to block 
epidermal growth receptor (EGFR) initiation 
cascade. Erlotinib (Tarceva®) is EGFR tyrosine 
kinase inhibitor commonly used in clinical setting 
for the treatment of advanced non-small cell lung 
cancer (NSCLC). Presented study is directed on 
erlotinib and chemotherapy efÀcacy comparison in 
the second line treatment of advanced NSCLC. 
Background: PET/CT scanning is becoming 
increasingly prevalent for treatment planning in 
patients with non-small cell lung cancer (NSCLC). 
However, the majority of PET/CT treatment 
planning is performed with fusion of previously 
obtained PET/CT scans and the interval between 
the acquisition of these scans and simulation can 
vary from weeks to months. This investigation was 
performed to determine whether appropriately staged 
patients undergoing PET/CT simulations on a hybrid 
unit had either staging or treatment intent changes 
despite having PET/CT scans performed within the 
prior four months. 
Methods: 115 consecutive patients were simulated 
on a dedicated PET/CT scanner between 4/29/09–
2/15/11 with the intent of deÀnitive treatment for 
non-metastatic, non-recurrent stage II-III NSCLC. 
All patients had accompanying diagnostic nuclear 
medicine interpretations. Of these, 42 patients had 
previous PET/CTs in the four months preceding 
simulation and all were appropriately staged without 
evidence of distant metastases. Patients were 
analyzed for change in stage and/or treatment intent 
and disease progression was deÀned as a change in 
TNM stage grouping. SUV velocity was deÀned 
as [(SUVscan2-SUVscan1)/ interscan interval]. 
Probability of upstaging as a function of interscan 
interval was performed using a non-parametric, 
right-censored distribution analysis plotted in the 
reverse Kaplan-Meier fashion. AJCC 2002 staging 
was used for all patients. 
Results: A total of 42 patients were eligible for 
inclusion, of which 20 were males and 22 were 
females. The median age was 69. Overall, 20 of 42 
patients (48%) were upstaged following treatment 
planning PET/CT. Twelve (29%) had evidence of 
new metastatic disease with the remaining 8 (19%) 
diagnosed with a change in T or N staging requiring 
alteration of treatment Àelds (i.e., new N2 or N3 
disease). Ten patients (24%) were not treated with 
radiation and received systemic therapy alone. The 
median interval between scans for all patients was 
45 days. At a scan interval of 30 days, the rate of 
upstaging was 10%. Further numerical analysis was 
performed with the Penn-only cohort of patients 
(n=11) scanned under identical conditions. Non-
upstaged patients had a mean SUV velocity of 0.071 
units/day compared to a SUV velocity of 0.14 in 
patients upstaged by their second PET/CT scan 
(p=0.011). 
Conclusion: Radiation treatment planning with 
hybrid PET/CT scans repeated within 120 days of an 
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P3.144 ERLOTINIB POST-MARKET 
SURVEILLANCE STUDY IN A FRENCH 
ACADEMIC HOSPITAL
Jose Hureaux1, Thierry Urban2 
1Pyver Team, Lunam Université/France, 
2Pulmonology, Academic Hospital/France
Background: Lung cancer is the leading cause of death 
related to cancer in developed countries. Erlotinib, an 
epidermal growth factor receptor (EGFR) inhibitor, has 
been authorized in treatment for non-small cell lung 
cancer (NSCLC) patients who have already had another 
chemotherapy. In France, 35% and 50% of NSCLC 
patients receive erlotinib in second or third line of 
treatment, respectively. In total, more than 10 000 new 
treatments with erlotinib are started each year in France.
Methods: We analysed retrospectively the Àrst consecutive 
one hundred NSCLC patients treated with erlotinib in your 
academic hospital, located in the west of France.
Results: Between May 2005 and October 2007, 
erlotinib was prescribed to 80 men and 20 women 
with a NSCLC median diagnosis age of 61.1 and 
60.3 years, respectively. During this period, none 
genetic analysis was available. Histology was 
adenocarcinoma/squamous carcinoma/large cell 
carcinoma in 52/33/15 cases. Erlotinib was started in 
1st/2nd/3rd/4th/5th/6th line in 1/20/59/4/0/6 cases, 
respectively. Twenty patients received erlotinib 
with French ‘Temporary Use Authorization’. Only 
6 patients had no metastatic NSCLC at the erlotinib 
start. Median erlotinib therapy duration was 52 days. 
Six patients received erlotinib therapy longer than 
one year. The best therapeutic response according 
to RECIST 1.0 criteria was: partial response: 6%; 
stable disease: 12%; progressive disease: 53% and not 
evaluable: 29%. No complete response was observed. 
The most frequent side effects were: rash skin (40%), 
diarrhoea (23%), dry skin (11%) and nausea (7%).
Conclusion: This mono-centric post-market 
surveillance study reveals that erlotinib is usually 
used in 2nd and 3rd line in NSCLC patients in your 
hospital. Our results are compatible with other 
French post-market surveillance studies.
Keywords: Non-small cell lung cancer, post-market 
surveillance study, erlotinib
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Methods: We have analysed data from Tarceva 
register of advanced NSCLC patients, treated at 
the Department of Tuberculosis and Respiratory 
Diseases, Teaching Hospital in Pilsen. 290 patients 
were analysed. Population treated by chemotherapy 
in the second line and by erlotinib in the third 
line concerns 150 patients, 40 females and 110 
males, 79 squamous cell carcinoma patients, 59 
adenocarcinoma patients, 10 undifferentiated 
NSCLC patients, and 2 patients with nonspeciÀed 
type of NSCLC, 138 patients with positive smoking 
history and 12 non-smokers. Population treated by 
erlotinib included 140 patients, 43 females and 97 
males, 67 squamous cell carcinoma patients , 61 
adenocarcinoma patients, 8 undifferentiated NSCLC 
patients and 4 nonspeciÀed type of NSCLC patients, 
107 patients with positive smoking history and 33 
non-smokers. 
Results: 2 patients treated by chemotherapy reached 
CR, 23 PR, 51 SD, 63 PD and response was not 
assessed for 11 patients, while from erlotinib treated 
patients, 5 reached CR, 10 PR, 55 SD, 58 PD and 
12 patients were not asessed for treatment response. 
There was no statistically signiÀcant difference 
between the compared groups (p = 0.300). From 
9 patients wih positive EGFR mutation treated by 
erlotinib, 4 patients had CR, 2 PR and 3 had SD. 
Chemotherapy treated patients reached median 
TTP of 2.1 months, median TTP for patients treated 
by erlotinib, without documented EGFR mutation 
(including patients not assessed for EGFR), was 1.9 
months. The difference between compared arms was 
not statistically signiÀcant (p = 0.879). Patients with 
activating EGFR mutation treated by erlotinib had 
median TTP 8.4 months and the difference between 
the 2 previous groups was statistically signiÀcant (p 
= 0.027). Results of OS are currently under analysis 
and are not at disposal yet. 
Conclusion: The results of our analysis 
demonstrate beneÀt of erlotinib treatment in the 
second line NSCLC treatment also for patients 
without documented activating EGFR mutation 
and the beneÀt is comparable with conventional 
chemotherapy treatment, which is associated with 
signiÀcantly higher risk of serious adverse reactions. 
The TTP comparison, as well as the analysis of best 
achieved response rate demonstrated signiÀcant 
beneÀt of erlotinib treatment for patients with 
positive EGFR mutation.
Keywords: EGFR-TKI, targeted therapy of NSCLC
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NSCLC. 
Keywords: Non small cell lung cancer, Carboplatin, 
Docetaxel, bevacizumab
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P3.146 A PHASE II STUDY OF 
ERLOTINIB IN JAPANESE EGFR 
MUTATION POSITIVE PATIENTS WITH 
PRETREATED NON-SMALL CELL LUNG 
CANCER (NSCLC):LUNG ONCOLOGY 
GROUP IN KYUSHU, JAPAN (LOGIK0803)
Kazuhiko Yamada1, Satoru Kawakami2, Kouichi 
Saruwatari3, Ryotaro Morinaga4, Miiru Izumi5, 
Naoko Aragane6, Shuya Nagata7, Junji Kishimoto8, 
Koichi Takayama5, Yukito Ichinose9 
1Division Of Respirology, Neurology And 
Rheumatology, Department Of Internal Medicine, 
Kurume University School Of Medicine/Japan, 
2Kyushu Kosei-nenkin Hospital/Japan, 3Japanese 
Red Cross Kumamoto Hospital/Japan, 4Oita 
University/Japan, 5Research Institute For Diseases 
Of The Chest, Graduate School Of Medical Sciences, 
Kyushu University/Japan, 6Saga University/Japan, 
7University Of Occupational And Environmental 
Health/Japan, 8Kyushu University Hospital Center 
For Clinical And Translational Research/Japan, 
9Department Of Thoracic Oncology, National 
Kyushu Cancer Center/Japan
Background: It has been reported that erlotinib is 
useful for treatment of non-small cell lung cancer 
(NSCLC) in EGFR mutation positive (EGFR-mt) 
patients (SLCG NEJM 2009 OPTIMAL ESMO 
2010). However, there is no study in the Japanese 
population. We conducted a multicenter Phase II 
study to evaluate the efÀcacy and safety of erlotinib 
in EGFR-mt Japanese patients with NSCLC.
Methods: For EGFR-TKI-naive EGFR-mt patients, 
erlotinib was administered at a daily dose of 150 
mg. The primary endpoint was the overall response 
rate (ORR). The secondary endpoints included the 
disease control rate (DCR), progression-free survival 
(PFS) and safety.
Results: At 15 participating institutions, 26 patients 
were enrolled between April 2009 and January 
2011. Demographic and baseline characteristics of 
patients were: median age 67 years (51 to 79 years); 
males/females 11/15; adenocarcinoma/others 24/2; 
smoking/nonsmoking 20/6; ECOG PS 0/1/2 15/9/2; 
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P3.145 CARBOPLATIN-DOCETAXEL- 
BEVACIZUMAB (BVZ) AS FRONT-LINE 
TREATMENT IN PATIENTS (PTS) WITH 
STAGE IV NOSQUAMOUS NON SMALL 
CELL LUNG CANCER (NSCLC). A PHASE 
II STUDY.
Manuel Domine, Jose Antonio Lopez-VilariÑo, 
Raquel Fuentes, Gloria Serrano, Cristina Carames, 
Gustavo Rubio, Jose Ignacio Martin-Valades, Yann 
Izarzugaza, Juan Luis Arranz, Victoria Casado, Ana 
Leon, Francisco Lobo 
Oncologia, Fundacion Jimenez Diaz. Universidad 
Autonoma De Madrid/Spain
Background: BVZ added to carboplatin-paclitaxel 
has demonstrated to prolong overall survival in 
nonsquamous NSCLC. However, the combination of 
BVZ with carboplatin-docetaxel has not been widely 
explored. We have designed a phase II trial to study 
the efÀcacy and tolerability of this combination in 
this setting. 
Methods: Pts were treated with up to 6 cycles of 
carboplatin (AUC 5), docetaxel (75 mg/m2), and 
BVZ (7.5 mg/kg) on day 1 every 21 days. Pts with 
an objective response or stable disease continued 
maintenance BVZ (7.5 mg/kg) every 21 days 
until disease progression. The primary endpoint 
was median progression-free survival. Secondary 
endpoints were safety, response rates, and overall 
survival. 
Results: 26 pts were enrolled, 16 male and 10 
female. Median age was 61 years (range 39- 
70); ECOG 0/1/2: 4%/77%/19%; 23 pts had 
adenocarcinoma and 3 pts undifferentiated large cell 
carcinoma. The median number of chemotherapy 
and maintenance BVZ cycles/patient was 6 (3-6) and 
9 (3-19), respectively. All the pts were evaluable for 
efÀcacy and toxicity. In an intent to treat analysis the 
response rate was 57.7%, 30.8% of pts showed stable 
disease and 11.5% progression. Median progression 
free survival was 10 months (95% CI: 8 – 12 m) 
and median survival 19 months (95% C.I: 10 – 28 
m). Grades 3-4 adverse events included neutropenia 
(15.3%), febrile neutropenia (7.69%), anemia 
(3.8%), mucositis (3.8%), diarrhea (3.8%), nausea/
vomiting (3.8%). 
Conclusion: Carboplatin, docetaxel, and BVZ 
demosntrated to be feasible and very effective 
as front-line treatment of stage IV nonsquamous 
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than objective tumour response. 
Methods: Eligibility: advanced recurrent NSCLC 
with at least stable disease after only one prior 
platinum-based regimen for advanced disease 
(adjuvant chemotherapy also permitted); age > 18; 
ECOG PS 0-2; no prior EGFR inhibitors; adequate 
organ function and no signiÀcant proteinuria; written 
informed consent. AZD0530 is administered at 175 
mg po daily in 28-day cycles; response assessed 
by RECIST q2 cycles, toxicity by CTCAE v 3.0. 
Primary end point is the proportion of patients (pts) 
progression-free (PF) at the end of cycle 4. Two-
stage design with H0 < 15 % and H1 > 35 %: if > 
3 of 17 PF at cycle 4, then go to stage II; accept 
as active if > 8 of 32 PF. Levels of c-Src protein 
expression and activity on archival tissue will be 
correlated to outcomes. 
Results: As of 01/11, 32 pts accrued: median age 65 
(range 33-77), female = 24, PS 0/1 = 31. All 32 pts 
are evaluable for toxicity. The most common adverse 
events considered at least possibly related to study 
therapy were: fatigue (n=10; 2 gr3); nausea (n=11, 
0 gr3); anorexia (n = 11, 0 gr3); diarrhea (n=9, 2 
gr3); proteinuria (n=7, 1 gr3); anemia (n=9, 1 gr4); 
AST / ALT increase (n=7 each; 1 gr3 ALT). Three 
patients came off study prior to response assessment 
due to potentially-related toxicity: one each with gr4 
gastrointestinal hemorrhage, gr3 pneumonitis and 
gr3 diarrhea; there were no gr5 toxicities. To date, 23 
pts are evaluable for efÀcacy (2 too early, 3 off prior 
to cycle 4 due to pt request without progression, 
3 off for toxicity, 1 pt ineligible as determined on 
pathology review to not have NSCLC). 5 / 23 pts 
were PF after 4 cycles; in two of these pts, conÀrmed 
partial responses were observed. 
Conclusion: Stage II will continue until 32 
response-evaluable pts accrued. Treatment with 
AZD0530 is generally well-tolerated. AZD0530 
has shown preliminary interesting activity in pts 
with recurrent platinum-pretreated NSCLC, with 2 
PR and several pts with prolonged stabilization of 
disease. Correlative studies on archival tissue will be 
available for presentation. 
Keywords: src kinase inhibitor, non-small cell, 
Phase II
exon 19/21 19/7; and second/third treatment line 
25/1. Thirteen patients were evaluable as of January 
2011. The median duration of treatment was 301 
days (range: 50 to 446). PR and SD were observed 
in 9 (70%) and 2 patients (15%), respectively. Of 
11 patients with EGFR mutation in exon 19, PR, 
SD and PD were observed in 7, 2 and 2 patients, 
respectively. PR was observed in 2 patients with 
EGFR mutation in exon 21. Common adverse 
reactions included rash (92.3%), pruritus (76.9%) 
and hepatic function disorder (46.2%). Most of 
adverse reactions were grade 2, and tolerable in 
all patients. Neither interstitial lung disease nor 
treatment related death was observed.
Conclusion: This is the Àrst prospective study of 
erlotinib performed in EGFR-mt Japanese NSCLC 
patients. The results were comparable to those 
obtained from studies of geÀtinib (NEJ002 NEJM 
2009 and WJTOG3405 2010). Currently, patients 
are under follow-up. Analysis of Ànal results will 
be completed in June 2011. The presentation at this 
meeting will be done for results including PFS data.
Keywords: erlotinib, EGFR mutation, Non-small 
cell lung cancer
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P3.147 AZD0530, AN INHIBITOR OF SRC 
KINASES, IN PLATINUM-PRETREATED 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): A TRIAL OF THE 
PMH PHASE II CONSORTIUM.
Scott A. Laurie1, Glenwood D. Goss1, Frances A. 
Shepherd2, Neil Reaume1, Garth Nicholas1, Lindsay 
Philip2, Lisa Wang2, Amit Oza2, Vera Hirsh3, James 
Wright4, Natasha Leighl2 
1Medical Oncology, Ottawa Hospital Cancer Centre/
Canada, 2Medical Oncology, Princess Margaret 
Hospital/Canada, 3Department Of Oncology, Mcgill 
University Health Centre/Canada, 4Cancer Therapy 
Evaluation Program/United States Of America
Background: Src kinases, overexpressed in many 
malignancies including NSCLC, may play an 
important role in tumour cell migration, invasion 
and metastases, and thus are potential therapeutic 
targets. AZD0530 (saracatanib) is an orally available 
small molecule inhibitor of Src kinases. Given the 
purported role of Src in the malignant phenotype, 
disease stabilization may more likely be observed 
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progression. All pts received vitamin B
12
, folic acid, 
and dexamethasone when receiving Pem. Primary 
endpoint was PFS from time of randomization 
and was analyzed using a Cox model stratiÀed for 
response to induction at a one-sided alpha of 0.2.
Results: Between 1/2008 and 8/2009, 108 pts with 
Non-sq NSCLC were entered; 55 were randomized 
to maintenance treatment. The primary endpoint, 
PFS in the maintenance phase, was signiÀcant at the 
one-sided 0.2 alpha level (HR= 0.76; 95% CI: 0.42 - 
1.37; p<0.2). 
Conclusion: This phase II study met its primary 
endpoint of improved PFS. Induction Pem-Cis and 
maintenance Pem were well tolerated.
Keywords: NSCLC, Pemetrexed
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P3.149 PHASE II STUDY OF 
BEVACIZUMAB AND ERLOTINIB 
IN TREATMENT-NAïVE ELDERLY 
PATIENTS (> 65 YEARS OF AGE) WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Hossein Borghaei1, Ranee Mehra1, Michael 
Millenson1, Holly Tuttle2, Karen Ruth3, Anthony 
Magdalinski4, David Mintzer5, James Lee6, James 
Stevenson7, Corey J. Langer8 
1Medical Oncology, Fox Chase Cancer Center/
United States Of America, 2Extramural Research, 
Fox Chase Cancer Cenetr/United States Of America, 
3Biostatisitics, Fox Chase Cancer Cenetr/United 
States Of America, 4Grandview Hospital/United 
States Of America, 5Pennsylvania Hematology And 
Oncology Associates/United States Of America, 
6Virtua Hospital/United States Of America, 
7Hematology/oncology, Abramson Cancer Center, 
University Of Pennsylvania/United States Of 
America, 8Abramson Cancer Center, University Of 
Pennsylvania/United States Of America
Background: The median age of newly diagnosed 
NSCLC patients (pts) in the US is 71 and more than 
60% of newly diagnosed pts are 65 years of age or 
older. The ‘Àt elderly’ (PS 0-1) derive the same level 
of beneÀt from systemic therapy as others, but with 
a lower tolerance for toxicities. Innovative treatment 
strategies with less toxicity are, therefore, needed. 
Our study explored the efÀcacy and tolerability of an 
‘all-biologic’ therapy in treatment-naïve elderly pts 
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P3.148 A RANDOMIZED PHASE 2 
STUDY COMPARING MAINTENANCE 
PEMETREXED (PEM) PLUS BEST 
SUPPORTIVE CARE (BSC) VERSUS 
BSC ALONE FOLLOWING INDUCTION 
TREATMENT WITH PEM-CISPLATIN 
(CIS) IN ADVANCED NONSQUAMOUS 
(NONSQ) NON-SMALL CELL LUNG 
CANCER (NSCLC)
Mohamed Meshref1, Rabab M. Gaafar2, Samir 
Shehata3, Tarek Hashem4, Dani Abi Gerges5, Hamdy 
Abdel Azim6, Gamal El-Husseiny7, Hamed Al-
Husseini8, Zhixin Liu9 
1Medical & Regulatory, Eli Lilly & Company 
Middle East And North Africa/Egypt, 2Medical 
Oncology, National Cancer Institute/Egypt, 3Faculty 
Of Medicine, Assiut University Cancer Centre/
Egypt, 4MenouÀa University Cancer Centre/Egypt, 
5 Middle East Institute Of Health/Lebanon, 6Kasr 
El-Einy Cancer Institute, Cairo University/Egypt, 7 
Alexandria University Cancer Centre/Egypt, 8King 
Faisal Specialist Centre And Research Centre/Saudi 
Arabia, 9Eli Lilly Australia/Australia
Background: In a previous phase III study among 
patients (pts) who had received 4 cycles of platinum-
based chemotherapy, maintenance therapy with 
Pem resulted in improved progression-free survival 
(PFS) and overall survival (OS) when compared 
with placebo (Ciuleanu, Lancet, 2009). PrespeciÀed 
histology subgroup analyses of the trial demonstrated 
that the beneÀt of Pem was limited to pts with 
Nonsq NSCLC (OS=15.5 m for Pem and 10.3 m for 
placebo in Nonsq group, P<0.001). We report the 
Ànal results of a randomized phase II trial comparing 
maintenance Pem plus BSC versus BSC alone 
following 4 cycles of Pem-Cis induction therapy in 
advanced Nonsq NSCLC.
Methods: Pts with Stage IIIB/IV NSCLC and 
good performance status (ECOG PS 0 or 1) were 
included. In response to phase III trial data, in July 
2008, a protocol amendment restricted enrollment 
and the primary analysis population to pts with 
predominantly Non-sq histology only. Induction 
treatment consisted of 4 cycles of Pem (500 mg/m2) 
and Cis (75 mg/m2) repeated once every 3 weeks. 
Pts without disease progression were randomized to 
receive maintenance Pem (500 mg/m2, repeated once 
every 3 weeks) plus BSC or BSC alone until disease 
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Background: Preclinical data suggests rapid 
regrowth of tumor vasculature following cessation 
of bevacizumab (bev) therapy which may lead to 
accelerated tumor growth. This may result in a 
shorter overall survival following discontinuation of 
1st line bev containing regimen. 
Methods: We investigated the effect of bev therapy 
in the Àrst line setting on post bev survival (PBS) 
in patients (pts) treated for metastatic NSCLC at 
our institution, we calculated PBS of all pts who 
received bev in the Àrst line setting for the diagnosis 
of NSCLC from January 2006 until February of 2011 
and compared it to the published OS of the two arms 
of the TAX-317 study. TAX-317 was chosen because 
it predated the Bev era and gave us a good estimate 
of OS following failure of 1st line therapy with and 
without second line therapy. OS as calculated in 
TAX-317 is comparable to the PBS endpoint of our 
study. PBS was calculated from the time bev was 
discontinued until death. 
Results: Bev was prescribed for 106 pts. 50 pts met 
our inclusion criteria of receiving more than one 
dose of bev in the Àrst line setting only. The median 
PBS for pts receiving 2nd line therapy beyond Àrst 
line bev containing therapy (36 pts, group 1) was 
12.9 months (CI 7.4-18.8). The lowest conÀdence 
interval (CI) limit of 7.4 is within the CI limits of 
the median OS for pts treated with 2nd line Docetaxel 
in TAX-317. The median PBS for pts not receiving 
therapy beyond 1st line bev therapy (14 pts, group 2) 
was 4.9 months (CI 1.1-13.4). 
Median 95% CI 
Group 1 12.9 7.4-18.9 
Tax-317 Docetaxel arm 7 5.5-9.0 
Group 2 4.9 1.1-13.4 
Tax-317 BSC arm 4.6 3.7-6.0 
Conclusion: The results of our retrospective 
analysis show no apparent detriment to survival post 
cessation of bevacizumab. 
Keywords: NSCLC, bevacizumab
with advanced NSCLC.
Methods: Fit elderly pts (>65 years) with treatment-
naïve stage IV or IIIB (malignant pleural effusion 
(MPE)) were treated with full dose erlotinib (150 
mg/d) and bevacizumab (15 mg/kg Q 3 wks) in 21 
day cycles. Progression Free Survival (PFS) was the 
primary endpoint. EGFR status was not required for 
enrollment. Imaging was performed every 2 cycles. 
Attributable grade 3 and 4 adverse events (AEs) 
were documented.
Results: Enrollment was completed between Aug. 
2007 and Jan. 2011. Mature data are available for 26 
of 33 patients accrued. Median age is 74 (range: 70-
84). Sixteen pts (62%) have ECOG PS of 1. Seven 
pts have stage IIIB disease by the AJCC v. 6 criteria. 
Kaplan-Meier estimate of median time from starting 
therapy to going off protocol is 4.8 months (95% 
conÀdence interval = 1.7-14.9). Of the 20 pts now off 
protocol, the median number of cycles is 4 (range: 
1-40). Six pts are currently on protocol, (range 4 
to 33 cycles). Drug-related grade 3(G3) and 4(G4) 
AEs include hypertension (G3: 5 pts), fatigue (G3: 
1 pt), rash (G3: 3 pts), diarrhea (2 G3 and 1 G4), 
anorexia (G3: 1 pt), infection with neutropenia (G3: 
1 pt), bowel perforation (G3: 1 pt), abnormal protein/
creatinine ratio (G3: 1 pt). Eight patients have had 
partial responses, thirteen stable and Àve progressive 
diseases. The estimated median PFS for all patients 
is 6.6 months (95% CI =3.6-14.9 months). Fourteen 
of 26 patients have died; estimated one year OS is 
56.6% (95%CI=24.7-65.4%), and estimated median 
OS is 14.1mo (95%CI 6.2mo-undeÀned). Smoking 
and EGFR status data have been collected.
Conclusion: Our data suggest that a non-cytotoxic 
combination of erlotinib and bevacizumab is 
effective and well tolerated for the Àrst-line 
management of elderly patients with advanced 
NSCLC. Correlation of outcome with EGFR and 
smoking status is pending.
Keywords: Lung cancer, erlotinib, bevacizumab, 
Elederly
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.150 SURVIVAL AFTER FAILURE 
OF FIRST LINE BEVACIZUMAB 
COMBINATION THERAPY IN NON 
SMALL CELL LUNG CANCER PATIENTS.
Haythem Ali1, Javier Munoz1, Bertha E. Sanchez2, 
Diana Kostoff1, Vishnuprabha Dhanapal1, Michelle 
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head/neck) attained partial response while on study 
with mean tumor shrinkage 44% (31-71%), and 
median duration 12 weeks (8+ to 56). Details on 
efÀcacy and scheduling will be presented.
Conclusion: Orally administered tivantinib at the 
MTD of 360 mg bid in combination with Gem is 
generally well tolerated and shows encouraging signs 
of antitumor activity in lung and head/neck cancer.
Keywords: c-Met, targeted therapy, phase 1
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P3.152 IMPACT OF PROLONGED 
CHEMOTHERAPY EXPOSURE ON 
METASTATIC NON-SMALL CELL LUNG 
CANCER SURVIVAL: BENEFITS OF 
SECOND-LINE AND EXTENDED FIRST-
LINE.
Luiz henrique De Lima Araújo, Clarissa seródio 
Baldotto, Mauro Zukin, Fernando meton Vieira, 
Rafaela c Helal, Jonas hauben Salem, Tatiane silva 
Gomes, Aline negrão Almeida, Nelson Teich, Carlos 
g Ferreira 
Núcleo De Oncologia Torácica (NOT), Clínicas 
Oncológicas Integradas (COI) And Instituto Coi 
(ICOI)/Brazil
Background: The optimal duration of chemotherapy 
(CT) remains an open question in metastatic non-
small cell lung cancer (NSCLC), and a metanalysis 
suggested a minor survival beneÀt from extended 
CT. Moreover, maintenance and early second-line 
CT are now acceptable options in this setting, while 
second-line treatment demonstrated proven impact 
in phase III trials. Our group therefore evaluated the 
concept of prolonged CT exposure in a real-world 
scenario.
Methods: Medical charts from patients with 
metastatic NSCLC treated in a private oncologic 
center in Brazil between 1999 to 2010 were 
retrospectively reviewed. The aim was to assess the 
impact of extended chemotherapy - deÀned as more 
than 4 cycles in the Àrst-line - and of multiple lines 
of treatment. Altogether, the prolonged CT exposure 
was evaluated as a prognostic factor, comprising 
extended Àrst-line and subsequent lines of therapy. 
Statistical analyses were performed using the SPSS 
17.0 software.
Results: Two-hundred thirty-nine patients were 
included. Median age was 63.1 years (range 27.7-
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P3.151 PHASE 1B RESULTS OF C-MET 
INHIBITOR TIVANTINIB (ARQ 197) IN 
COMBINATION WITH GEMCITABINE 
(GEM) IN A COHORT OF PATIENTS (PTS) 
WITH ADVANCED THORACIC TUMORS.
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M. Saleh5 
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Background: ARQ 197 is an oral, selective, non-
ATP competitive inhibitor of c-MET. In vitro data 
suggest its synergy with Gem in several tumor 
cell lines. This Phase 1b study evaluates safety, 
pharmacokinetics (PK), biomarkers, and preliminary 
efÀcacy of the combination of tivantinib with Gem 
in pts with advanced solid tumors. Here we present 
results in the cohort of pts with thoracic tumors.
Methods: Multi-center, Phase 1b 3+3 dose 
escalation trial. Oral tivantinib was administered at 
doses of 120-360 mg bid across different schedules 
(continuous vs. continuous with 1 week (wk) break 
every 2 or 3 wks) in combination with Àxed Gem 
dosing and frequency (1000 mg/m2/weekly 3 out of 
4 wks). Tumor assessments occurred every 8 weeks.
Results: As of January 28, 2011, a total of 7 pts 
with thoracic tumors were enrolled, including 6 with 
Non Small Cell Lung Cancer (4 adenocarcinoma, 
2 squamous) and 1 with squamous head/neck 
carcinoma (ECOG 1; mean age 61 yrs, range 40-
77 yrs; with median number of prior systemic 
therapies 3 [1-4]). All pts were Gem-naÃ¯ve. 
Adverse events (AEs) considered at least possibly 
treatment-related were reported in 6 pts. The most 
commonly observed (>30%) AEs in this patient 
population include neutropenia (6pts; 4 were G3-
4), nausea (5 pts, no G3-4), fatigue (4 pts; 2 were 
G3-4), thrombocytopenia (3 pts; 1 was G3). Two 
pts experienced treatment-related serious AEs 
(pneumonitis, stomach angiodysplasia). Five pts 
remained on study for >12 wks (median 13; range 
6-64), 4 are ongoing. Six pts are evaluable for post-
baseline tumor assessment (assessments occur every 
8 weeks). Four pts (3/3 lung adenocarcinoma, 1 
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Background: As the patients with metastatic 
NSCLC survived longer, the incidence of 
leptomeningeal carcinomatosis(LC) has increased. 
However, the clinical features and prognostic 
factors of LC in NSCLC patients have not been well 
identiÀed. The aim of this study was to identify the 
clinical features and prognostic factors of NSCLC 
patients with LC. 
Methods: 149 NSCLC patients who had a diagnosis 
of cytologically proven LC between 2000 and 2008 at 
Samsung Medical center were retrospectively reviewed.
Results: The median age was 58 years (range, 
34-80). Most of the patients (135, 95%) had 
adenocarcinoma histology. During median follow-up 
duration of 34 months, median overall survival from 
diagnosis of LC was 14 weeks (95% C.I ; 12-16). 
Univariate analysis revealed that good performance 
status (ECOG PS <2), high glucose, low protein 
and low WBC of initial spinal Áuid, intrathecal 
(IT) chemotherapy and systemic chemotherapy 
were positive predictor for overall survival. 
At multivariate analysis, good PS (p=0.007), 
low protein (p=0.002), low WBC (p=0.014), IT 
chemotherapy (p<0.001) and systemic chemotherapy 
(p<0.001) remained as signiÀcant good prognostic 
factors for survival. 
Conclusion: Even though the prognosis of LC from 
NSCLC is poor, small subsets of these patients 
survive longer. So, patients with good PS, low 
protein and WBC of initial spinal Áuid need to be 
treated actively with IT and systemic chemotherapy.
Keywords: prognostic factors, Non-small cell lung 
cancer, leptomeningeal carcinomatosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.154 WT1 AND MUC1-PULSED 
DENDRITIC CELL VACCINATION 
THERAPY FOR NON-SMALL-CELL 
LUNG CANCER
Takashi Kobayashi1, Tomonobu Koizumi2, Kazunari 
Tateishi1, Kazuhisa Urushihata1, Hiroshi Yamamoto1, 
Masayuki Hanaoka1, Keishi Kubo1, Shigetaka 
Shimodaira3, Ryu Yanagisawa4, Saori Muramatsu5, 
Yumiko Higuchi3, Takahumi Goto3, Shinsuke 
Ishikawa6 
85.9). Most patients presented with advanced disease 
(80% frequency for stage IV / wet IIIB), 18% were 
never-smokers, and adenocarcinoma was the most 
frequent histology (50%). Twenty-nine percent of 
patients received more than 4 cycles of Àrst-line CT, 
and 7% received more than 6 cycles. Second-line 
CT was used in 46%, while third-line was in 15%. 
After 11 months median follow-up, the median 
overall survival was 11.6 months (95% CI, 9.1-14.2). 
Patients treated with more than 4 cycles in the Àrst-
line presented longer overall survival (median 21.4 
[95% CI, 17.1-25.8] vs 7.7 months [95% CI, 5.8-
9.6]; P=.0001), which was corroborated in patients 
receiving more than 6 cycles (median 26.7 [95% CI, 
5.8-9.6] vs 9.7 months; P=.003). Second-line CT was 
strongly correlated with higher survival (median 16.4 
[95% CI, 13.7-19.2] vs 6.3 months [95% CI, 4.7-8.0]; 
P=.0001), as well as third-line (median 22.7 [95% CI, 
15.8-29.6] vs 9.0 months [95% CI, 7.6-10.5]; P=.002). 
Notably, patients receiving both extended Àrst-line 
and subsequent second-line CT achieved the greatest 
beneÀt from these strategies (median survival 21.5 
[95% CI, 17.2-25.7] vs 8.4 months [95% CI, 7.2-
9.5]; P=.0001). In the multivariate analysis, receiving 
more than 4 cycles in the Àrst-line (HR 0.52; 95% CI, 
0.29-0.94; P=.02) and the use of second-line CT (HR 
0.37; 95% CI, 0.22-0.63; P=.0001) were considered 
independent prognostic factors. Current or former 
smoking status (HR 2.6; 95% CI, 1.10-6.00; P=.01) 
and weight loss (HR 2.2; 95% CI, 1.30-3.72; P=.003) 
were other independent factors.
Conclusion: Patients submitted to prolonged CT 
exposure demonstrated a signiÀcant and independent 
survival beneÀt in comparison to patients with lower 
CT exposure length. These data support the concept 
of prolonged treatment in metastatic NSCLC, both in 
the Àrst- and second-line.
Keywords: Lung neoplasms, Chemotherapy, 
maintenance, Second-line
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P3.153 PROGNOSTIC FACTORS OF 
LEPTOMENINGEAL CARCINOMATOSIS 
IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
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in 17 % of response rate and 33% of disease control 
rate, respectively. Median survival time from start 
of DC vaccination therapy was 174 days. 43% of 
the patients showed temporal fever due to DC and/
or OK-432 at grade 1 to 2 toxicity. All of the patients 
revealed erythema with or without induration at the 
sites of i.d. DC.
Conclusion: Case series of WT1 and MUC1-pulsed 
DC vaccination therapy suggested a feasible, well-
tolerable, and might provide an alternative treatment 
option for advanced NSCLC patients.
Keywords: NSCLC, DC, WT1
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P3.155 THE OUTCOME OF THE 
ADVANCED NON-SMALL CELL 
LUNG CANCER TREATMENT USING 
STANDARD DOUBLETS OUTSIDE OF 
CLINICAL TRIALS.
Ewa Chmielowska1, Mariusz Kwiatkowski1, Maciej 
Studziĸski1, Ryszard Chabowski1, Katarzyna 
Kalinowska2, Jan Kopeþ1, Anna Krauze1, Kinga 
Lewandowska1, Moinka Olejniczak1, Marcin 
Ŋwieŧyĸski1 
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Background: Among patients with locally advanced 
or disseminated non-small lung cancer not eligible 
for radical radiochemotherapy, chemotherapy is 
a standard treatment modality. Only patients with 
good performance status without additional severe 
comorbidities can be treated within clinical trials. 
Patients not eligible for clinical trials are treated 
accordingly to standards and Ànancial means of 
particular country. Palliative chemiotherapeutic 
regimens can be divided into Àrst-line, second-line 
and third-line settings. Palliative chemotherapy has 
been used long enough that its effectiveness can be 
a valuable database for comparison with nowadays 
more widely used targeted chemotherapies. 
Methods: It is a retrospective analysis of group 
of patients treated outside clinical trials between 
September 2006 and September 2010 in Clinical 
Oncology Unit in Oncology Centre, accordingly to 
contemporary chemotherapy standards. Criteria by 
which data were evaluated were: sex, histological 
type of tumor, chemotherapy regimen, number of 
chemotherapy lines and overall survival time.
1First Department Of Internal Medicine, 
Shinshu University School Of Medicine/Japan, 
2Comprehensive Cancer Center, Shinshu University 
Hospital/Japan, 3Center For Advanced Therapy, 
Shinshu University Hospital/Japan, 4Department 
Of Pediatrics, Shinshu University Hospital/Japan, 
5Department Of Breast And Endcrine Surgery, 
Shinshu University Hospital/Japan, 6Division Of 
Blood Transfusion, Shinshu University Hospital/
Japan
Background: Dendritic cell (DC)-based 
immunotherapy has been recognized as limited 
clinical success of cancer vaccination with few 
adverse reactions. To overcome the problem of 
cancer vaccination treatment, both WT1 and MUC1 
peptides, the most potent cancer associated antigens, 
applied on DC-based immunotherapy could be 
potentially strong therapeutic strategy against 
cancers.
Methods: Clinical investigation of WT1 and MUC1-
pulsed DC vaccination therapy was conducted for 
primary endpoint as safety with the efÀcacy being 
a secondary endpoint in cancer patients approved. 
Patients who underwent intractable for a standard 
operation, radiotherapy, chemotherapy against 
non-small cell cancer (NSCLC) met the inclusion 
criteria: advanced cancer with clinical stage III or IV 
disease at the diagnosis; recurrence of cancer after 
standard treatment; progressive disease resistant 
to chemotherapy. Both WT1 for HLA-A*2402 or 
A*0201 typing and MUC1 peptides-pulsed DC 
vaccinations were manufactured from autologous 
aphaeresis monocytes ex vivo at Shinshu University 
Hospital following the SOP established by tella, 
Inc. (Tokyo, Japan). 1-2x107 of mature DC 
harboring WT1 and MUC1 peptides were performed 
intradermal (i.d.) injection at axillar and inguinal 
areas together with tolerable 1 to 5KE/dose of OK-
432 every 2 weeks for at least 5 to 7 times (one 
course) during individual chemotherapy regimen.
Results: 9 patients, median age of 60 years 
old (range 34 to 67), 6 male and 3 female were 
enrolled. 7 patients had adenocarcinoma, 1 had 
squamous cell carcinoma, and 1 had non-classiÀed 
NSCLC. Stage IIIA/IIIB/IV was 1/1/7, respectively. 
Performance status 0/1/2/3 was 1/5/2/1, respectively. 
DC vaccinations were administered 1 to 31 times 
(average was 9 times). 6 patients were evaluated 
according to the RECIST after completing at least 
one course of DC vaccination. 1 patient achieved 
partial response and 1 was stable disease, resulted 
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P3.156 PRELIMINARY RESULTS OF 
INDUCTION CISPLATIN/DOCETAXEL 
FOLLOWED BY SHORT COURSE 
THORACIC RADIOTHERAPY 
AND CISPLATIN/DOCETAXEL OF 
CONSOLIDATION IN LOCALLY 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): A PROSPECTIVE 
PHASE II TRIAL.
Giovenzio Genestreti1, Sara Piciucchi2, Antonino 
Romeo3, Elisabetta Parisi3, Manuela Monti4, Noemi 
Giovannini1, Venerino Poletti5, Federica Matteucci6, 
Rolando Polico3 
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6Nuclear Medicine, Irst/Italy
Background: Standard fractionated radiotherapy 
combined with concomitant radiosensitive 
chemotherapy represents standard treatment for 
locally advanced (LA) Non-Small Cell Lung 
Cancer (NSCLC). 3-Dimensional-Hypofractionated 
Accelerated Radiotherapy (3D-HAR) delivered 
by helical tomotherapy may improve local control 
disease and reduce the duration and incidence of side 
effects due to radiotherapic treatment. In our ongoing 
phase II prospective trial full dose chemotherapy 
is combined with 3D-HAR for treatment of LA-
NSCLC to verify their activity and tolerance. 
Methods: Patients with biopsy proven involvement 
of 3 or more ipsi- or controlateral mediastinal 
lymph nodes (N) or with radiological evidence of 
mediastinal inÀltration were treated with induction 
chemotherapy with Cisplatin (75 mg/m2; day 1 every 
21 days) combined to Docetaxel (75 mg/m2; day 1 
every 21 days) for 2 courses followed by 3D-HAR 
(30 Gy in 5 fractions at the reference isodose) and 
afterword 2 courses of consolidation chemotherapy 
with Cisplatin (75 mg/m2; day 1 every 21 days) 
combined to Docetaxel (60 mg/m2; day 1 every 21 
days). All patients performed a total-body CT scan 
and a PET/CT-scan of staging and restaging. Hence 
a bronchoscopy was performed at staging, at the end 
of radiotherapy and at treatment completion. 
Results: From December 2008 to December 2010, 
16 patients were analyzed of whom 3 (19%) females 
and 13 (81%) males with a median age of 60 years 
(range: 44 – 70) and with adenocarcinoma in 10 
Results: A total of 390 patients were treated with 
palliative chemotherapy - among them were 103 
women and 287 men. Of those 109 (27,9%) had been 
evaluated as a locally advanced disease and were 
not candidates for radical R-CHTH treatment. 281 
patients (72%) had disseminated disease at a time 
of diagnosis. Histological subtypes of NSLC were: 
squamous cell lung carcinoma and adenocarcinoma 
in 118 (30,2%) and 98 patients (25,1%) respectively. 
The rest of 174 patients had been diagnosed by usage 
of Àne-needle biopsy as a non-small lung cancer 
without additional pathological subtype speciÀcation.
All patients had good performance status (PS 0 - 2), 
all of them had some cardiovascular issues, only 
few were not tobacco users. All patients received at 
least one line of chemotherapy, mainly platinum-
based regimens. Used chemotherapy schedules 
were: cisplatin/vinorelbine (129 patients - 33,1%), 
carboplatin/vinorelbine (126 - 32,3%), carboplatin/
gemcytabine (48 - 12,3%), cisplatin/gemcytabine (44 
- 11,2%), paclitaxel/cisplatin (30 - 7,7%), docetaxel/
cisplatin (9 - 2,3%), pemetrexed (4 - 1%). 57 patients 
(15%) received only 1 or 2 courses of chemotherapy 
because of disease progression or rapid deterioration 
in general condition. 105 patients (27,9%) received 
second-line therapy - among used schedules were 
docetaxel in monotherapy (46 patients - 11,8%), 
pemetrexed (7 - 1,8%), erlotinib (6 - 1,5%) and 46 
patients (11,8%) again received platinum-based 
agent. In third-line chemotherapy, administered to 23 
patients (5,9%), pemetrexed or erlotinib were used. 
Median survival time was 11,98 months. One third 
(34,27%) of patients did not survive more than 5 
months from the beginning of treatment. It is a group 
of patients who did not receive more than 2 courses 
of chemotherapy because of disease progression. 
Long-time survival rate (more than 24 months) was 
noted in 47 patients (12%). 
Conclusion: Demonstrated results seem to support 
usefulness of usage of palliative chemotherapy 
among patients with advanced non-small lung 
cancer. Our results are consistent with the 
observations reported in other publications. 
Keywords: non-small lung cancer, advenced non-
small lung cancer, Chemotherapy, Overall survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.157 COST-EFFECTIVENESS OF FIRST 
LINE TYROSINE KINASE INHIBITOR 
TREATMENT IN EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATED 
ADVANCED NON SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS : A 
MARKOV MODEL
Isabelle Borget1, Alain Vergnenegre2, Christos 
Chouaid3 
1Health Economy Service, Biostatistic And 
Epidemiology Departement, Institut Gustave 
Roussy/France, 2Pathologie Respiratoire, Hôpital 
Du Cluzeau/France, 3Service De Pathologie 
Respiratoire, Chu Saint Antoine/France
Background: EGFR testing and Àrst line tyrosine 
kinase inhibitor (TKI) for patients with activating 
mutations is an option for the treatment of advanced 
non-small cell lung cancer. There is few data’s on 
the cost-effectiveness of this strategy. The objective 
of this study was to determine the incremental cost-
effectiveness ratio of Àrst-line treatment with TKI 
compared to recommended chemotherapy (cisplatin 
pemetrexed doublet) in patients with EGFR 
mutation. 
Methods: A Markov model was developed. The 
model used clinical outcome and cost data from 
randomized clinical trials or prospective French 
cohort and utility scores derived from published 
data’s. Costs were limited to direct costs for 
medications, physician visits, hospitalizations and 
treatment of adverse events. Analysis was limited to 
the period between initiation of treatment until Àrst 
progression. All costs and cost-effectiveness ratios 
were expressed in 2010 Euro. Sensitivity analyses 
were performed.
Results: First line treatment with TKI was more 
effective than recommended chemotherapy 
(respectively 0.716 and 0.422 QALY), but also 
more expensive (respectively 29 702 and 18 796 per 
patient). The incremental cost-effectiveness ratio 
was then estimated at 37 095 €/QALY. Sensitivity 
analyses showed the robustness of the results.
Conclusion: Based on these data, Àrst line treatment 
based on TKI appeared as cost effective in EFGR 
mutated advanced NSCLC patients.
Keywords: EGFR mutation, Cost-effectiveness, 
TKI, FIRST LINE
(63%) patients and squamous cell carcinoma in 6 
(37%) patients. Pathological mediastinal lymph 
nodes involvement (pN) were documented in 10 
(63%) patients, whereas radiological mediastinal 
inÀltration of disease was detected in 10 (63%) 
patients. Overall there were 3 (19%) stage IIIA 
disease and 13 (81%) stage IIIB disease; side disease 
was left in 6 (37%) patients and right in 10 (63%) 
patients. Overall 57 courses of chemotherapy were 
infused (range: 1 – 4). One patient stopped treatment 
after Àrst course of induction chemotherapy for 
the onset of grade 4 apiretic neutropenia and 
hypovolemic shock due to grade 3 vomiting; one 
patient interrupted treatment after Àrst course of 
consolidation chemotherapy for the onset deep 
venous thrombosis with worsening of clinical 
performance status. Overall only one patient did not 
performed 3D-HAR for treatment interruption after 
Àrst course of induction chemotherapy. Hematologic 
grade 3/4 toxicity was mainly neutropenia occurred 
in 13 (81%) patients and corrected with the use 
of granulocyte colony stimulating factors. Non-
hematologic grade 3/4 toxicities were represented 
by: diarrhea in 1 (6%) patient, asthenia in 1 (6%) 
patient and nausea/vomiting in 3 (19%) patients of 
whom one with hypovolemic shock successfully 
corrected with intravenous hydration. No grade 3/4 
toxicities related to radiotherapy was recorded. 
Conclusion: Our preliminary results of prospective 
phase II trial using 3D-HAR combined with 
induction and consolidation full dose chemotherapy 
with Cisplatin and Docetaxel seems to be well 
tolerated without severe side effects in thorax; 
the grade 3/4 side effects recorded were related to 
systemic toxicity and they have been successfully 
treated. We are waiting adequate follow-up for the 
efÀcacy analysis. Supported by GIPO. 
Keywords: short course thoracic radiotherapy, 
induction Cisplatin/Docetaxel
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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the study because of deterioration, withholding of 
consent after mutation analysis, or failing other 
clinical selection criteria. Forty six pts (8 male, 38 
female) with median age of 72 years (35-83), median 
performance status of 1 (1-3) stage distribution Ib 
(1), IIIb (4) and IV (41) patients were included. 
EGFR mutations found: exon 18 (1), exon 19 (27), 
exon 20 (3) and exon 21 (15). Smoking history: 38 
never smokers, 7 past smokers, 1 smoker. Median 
follow-up is 83 weeks. PFS was 83 % at 3 months 
and 74% at 6 months. Best response was: PR 26; 
SD 10, PD 10. The median time to progression 
and overall survival are not reached: 44+ and 56+ 
weeks respectively. One patient ended treatment 
prematurely because of skin toxicity while in PR for 
83+ wks. 
Conclusion: In this Àrst formal prospective phase 
II genotype based study with erlotinib in Àrst-line 
treatment of Caucasian pts with EGFR mutant 
advanced NSCLC, efÀcacy appears similar to 
the results obtained with geÀtinib and erlotinib 
in randomized studies involving Asian patients 
and other Àrst-line data with erlotinib. The study 
achieved its primary end point (PFS  70% at 3 
months). The wider genotyping of the screened 
population and genotypic-clinical correlations will 
be presented. 
Keywords: erlotinib, non-small lung cancer, EGFR 
mutation, Phase II
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P3.159 LONG-TERM SURVIVAL IN 
PATIENTS WITH NON-SMALL CELL 
LUNG CANCER AND SYNCHRONOUS 
BRAIN METASTASIS TREATED WITH 
WHOLE-BRAIN RADIOTHERAPY AND 
THORACIC CHEMORADIATION
M. Dolores De La Mata1, Cynthia Villarreal-Garza2, 
Mónika Blake-Cerda1, Luis Martínez-Barrera3, 
Dolores Gallardo2, Jesús Herrera-Zamora1, Oscar 
Arrieta2 
1Radiation Oncology, Instituto De Cancerologia 
De Mexico/Mexico, 2Medical Oncology, Instituto 
De Cancerologia De Mexico/Mexico, 3Department 
Oncology, Instituto De Cancerologia De Mexico/
Mexico
Background: Brain metastases occur in 30% to 50% 
of patients with non-small cell lung cancer (NSCLC) 
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P3.158 FIRST-LINE ERLOTINIB IN 
PATIENTS (PTS) WITH ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC) CARRYING AN ACTIVATING 
EGFR MUTATION: A MULTICENTRE 
ACADEMIC PHASE II STUDY IN 
BELGIUM
Jacques De Greve1, Jan P. Van Meerbeeck2, Johan 
Vansteenkiste3, Erik Teugels4, Caroline Geers4, Anne-
Pascale Meert5, Peter Vuylsteke6, Christian Focan7, 
Jean-Luc Canon8, Yves Humblet9, Guy J. Berchem10, 
Benoit Colinet11, Daniella Galdermans12, Lionel 
Bosquée13, Christophe Dooms14, Lore Decoster4, 
Joanna Vermeij15, Alex Dewaele4, Denis Schallier1 
1Medical Oncology, Oncologisch Centrum Uz 
Brussel/Belgium, 2Respiratory Medicine, Ghent 
University Hospital/Belgium, 3Univ. Hospital 
Leuven/Belgium, 4Oncology, Uz Brussel/Belgium, 
5Intensive Care And Thoracic Oncology, Institut 
Jules Bordet/Belgium, 6Sainte Elisabeth/Belgium, 
7Chc Clinique Saint-joseph/Belgium, 8Oncologie 
Médicale, Grand Hôpital De Charleroi/Belgium, 
9Centre Du Cancer, Université Catholique De 
Louvain/Belgium, 10Hémato-cancérologie, Centre 
Hospitalier De Luxembourg/Luxembourg, 11Grand 
Hôpital De Charleroi/Belgium, 12Department Of 
Pulmonary Medicine, Zna Middelheim Hospital/
Belgium, 13Chu Sart Tilman/Belgium, 14Respiratory 
Oncology Unit, University Hospitals Leuven/
Belgium, 15Zna Campus Jan PalÀjn Middelheim/
Belgium
Background: Compared to chemotherapy, 1st 
line treatment with EGFR-TK inhibitors results in 
superior progression-free survival (PFS) in patients 
with advanced NSCLC with activating EGFR TK 
domain mutations. We conducted a prospective study 
with 1st line erlotinib in Belgian pts with EGFR TK 
domain mutations.
Methods: Multicentre phase II study. EGFR 
mutation status was determined in a central lab on 
macro-dissected biopsies obtained from pts with 
advanced adenocarcinoma with a non- or past 
smoking history. Pts were given erlotinib, 150 mg 
daily till disease progression or prohibitive toxicity. 
The primary end point of the study was a 70% PFS 
at 3 months. 
Results: An EGFR mutation was found in 64 (28%) 
of 247 pts screened. Eighteen pts did not enter 
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Background: The anticancer immunresponse may 
determine the outcome of lung caner. Few data are 
available on how effector T, NK cells and various 
regulatory subsets like Treg-s (foxp3+), or NK T-s 
respond to lung cancer (LC) or cancer treatment. 
Methods: Blood was drawn from 28 pts (age 44 
to 82, males12, females 16) suffering from non-
small cell lung cancer (NSCLC, n=22) or small 
cell lung cancer (SCLC, n=6). Since 60% of 
LC pts also suffered from chronic obstructive 
pulmonary disease (COPD), one control group was 
formed from COPD pts (n=28) and another one 
from healthy individuals (n=28). Peripheral blood 
mononuclear cells were separated and analyzed by 
FACS using labeled monoclonal antibodies
Results: Activated effector T cells were determined 
by CD4CD45RO and CD8CD45RO positivity, 
the naive T cells were speciÀed by CD4CD45RA 
and CD8CD45RA positivity, and the regulatory T 
lymphocytes by CD8FoxP3 positivity. The NKT 
cells were deÀned by Va24Vb11 (iNKT) and 
CD161CD3 (NKT) markers. In lung cancer pts, 
the ratio of activated CD4+ effector T cells was 
increased and the ratio of naiv CD4+ lymphocytes 
was decreased, as compared to COPD or healthy 
groups (p<0,05). In the CD8+ subgroup, the 
decrease of the number of naiv T cells was 
observed. The ratio of regulatory T lymphocytes 
(CD8+FoxP3+) was signiÀcantly elevated in lung 
cancer pts when compared with COPD and healthy 
groups (p<0,001). The numbers of iNKT and NKT 
cells decreased in COPD and this reached the level 
of lung cancer pts, and healthy control. The level of 
lymphocytes subpopulations did not changed after 
chemotheraphy
Conclusion: There was an important change of T 
lymphocytes subsets in lung cancer, as effectors, 
CD4 cells activated, naiv, CD8 cells diminished and 
regulatory, suppressive T cells increased. The NKT 
cells also activated in COPD, but their effectivity 
changed in lung cancer. 
Keyword: lung cancer, regulatory T cells, naive T 
cells
and confer a worse prognosis and quality of life. These 
patients are usually treated with whole brain radiotherapy 
(WBRT) followed by systemic therapy. Few studies 
have evaluated the role of chemoradiotherapy to the 
primary tumor after WBRT as deÀnitive treatment in 
the management of patients with NCSLC with isolated 
synchronous brain metastasis.
Methods: We reviewed the outcome of 30 patients 
with primary NSCLC and synchronous brain 
metastasis at diagnosis without evidence of other 
sites of metastatic disease. Patients were treated 
with WBRT and induction chemotherapy with 
paclitaxel and cisplatin for two cycles. In the absence 
of progression, concurrent chemoradiotherapy 
for the primary tumor with weekly paclitaxel and 
carboplatin was indicated, with a total effective dose 
(BED) of 60 Gy. If disease progression was ruled 
out, four chemotherapy cycles followed
Results: Median progression-free survival (PFS) and 
overall survival (OS) were 8.43 ±1.5 and 31.8 ±15.8 
months, respectively. PFS was 39.5% at 1 year and 
24.7% at 2 years. The 1- and 2-year OS rates were 
71.1% and 60.2%, respectively. Three-year OS was 
signiÀcantly superior for patients with N0-N1 stage 
disease vs. N2-N3 (60% vs. 24%, respectively, RR 
0.03, p=0.038).
Conclusion: Patients with NSCLC and synchronous 
brain metastasis might beneÀt from treatment with 
WBRT and concurrent chemoradiotherapy to the 
primary lesion. The subgroup of patients with N0-N1 
stage seems to achieve the greatest beneÀt. The result 
of this study warrants a prospective trial in stage IV 
disease with only brain metastasis to conÀrm the 
beneÀt of this treatment.
Keywords: NSCLC, Non-small cell lung 
cancer, synchronous brain metastases, deÀnitive 
chemoradiotherapy
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P3.160 THE ROLE OF REGULATOR 
AND EFFECTOR T LYMPHOCYTES IN 
CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE AND LUNG CANCER
Gabriella Galffy1, Aron Cseh2, Dora Bartusek2, 
Andrea Nagy2, Zsuzsanna Szarvas2, Rita Horvath2, 
Zsolt Komlósi2, Barna Vasarhelyi2, Gyorgy 
Losonczy2 
1Pulmonology, Semmelweis University/Hungary, 
2Semmelweis University/Hungary
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main side-effect during PV was myelotoxicity, GIII-
IV neutropenia occurring in 11%. Median TTP was 
21 weeks (range: 1-91 weeks). 
Conclusion: Sequential administration of cisplatin 
plus vinorelbine followed by weekly docetaxel in 
Àrst-line treatment of advanced NSCLC was feasible, 
with high antitumor response and favorable toxicity 
proÀle. The study is ongoing. 
Keywords: Advanced NSCLC, sequential 
chemotherapy
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P3.162 CLINICAL OUTCOMES FOR 
SPECIAL POPULATIONS OF PATIENTS 
WITH NON-SQUAMOUS NON-SMALL 
CELL LUNG CACER TREATED WITH 
FIRST LINE BEVACIZUMAB-BASED 
THERAPY IN AN OBSERVATIONAL 
STUDY (AVVA)
Javier De Castro1, Manuel Domine2, José M. García-
Bueno3, Salvador Saura4, Ramon Garcia-Gomez5, 
María Sereno6, Oscar Juan Vidal7, Eduardo Pujol8, 
Belén Rubio9, Jose V. Cardona10, Manuel Cobo11 
1Medical Oncology, Hospital Universitario La Paz/
Spain, 2Fundación Jiménez-díaz/Spain, 3Medical 
Oncology, Hospital General Albacete/Spain, 
4Medical Oncology, Hospital Universitario De 
Gran Canaria Dr. Negrín/Spain, 5Hospital Gregorio 
Maranon/Spain, 6Hospital Infanta Sofía/Spain, 
7Hospital Arnau De Vilanova De Valencia/Spain, 
8Hospital Santa Bárbara/Spain, 9Centro Integral 
Oncológico Clara Campal/Spain, 10Medical Affairs, 
Roche Farma, S.a./Spain, 11Hospital Regional 
Universitario Carlos Haya/Spain
Background: More than 50% of cases of advanced 
NSCLC are diagnosed in patients (p) older than 65 
years. Furthermore, the majority of p with NSCLC 
present at the time of the diagnosis one or more 
comorbidities. Both subgroups are often under-
represented in clinical trials based on perceptions 
that they do not wish for and/or cannot tolerate 
active systemic therapy.
Methods: AVVA is a multicenter, observational 
study in p with advanced non-squamous NSCLC 
(stage IIIB non candidates for radiotherapy or IV) 
treated with Àrst-line bevacizumab-based regimen. 
A sub-analysis according to age 65 years or older 
and at least 1 comorbid condition was performed. 
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P3.161 SEQUENTIAL CHEMOTHERAPY 
WITH CISPLATIN PLUS VINORELBINE 
FOLLOWED BY WEEKLY DOCETAXEL 
IN LOCALLY ADVANCED OR 
METASTATIC NON SMALL-CELL LUNG 
CANCER: PRELIMINARY RESULTS
Francesca Sperandi, Claudia Degli Esposti, Annalisa 
Berselli, Barbara Melotti, Andrea A. Martoni 
Medical Oncology Unit, S.orsola-malpighi Hospital/
Italy
Background: The use of platinum-based therapy 
prolonged survival in patients with NSCLC. A 
platinum-based doublet with a third-generation agent 
(vinorelbine, gemcitabine, paclitaxel, docetaxel) 
represents the standard Àrst-line treatment for 
advanced NSCLC with good performance status. 
Traditional chemotherapy provides response rates of 
20-40% and a median survival of 8-10 months. In an 
attempt to improve outcome, alternative schedules 
have been proposed, namely sequential, alternating, 
and maintenance/consolidation therapy. Sequential 
chemotherapy with a platinum-based doublet 
followed by a single agent is feasible in patients 
with a good PS. In our previous study, the planned 
sequential administration of GEM and VNR in 
elderly patients with locally advanced or metastatic 
NSCLC, suggests that the TTP may be increased 
with the use of the 2 single agents.
Methods: On the grounds of these data we designed 
a phase II study on sequential strategy using weekly 
docetaxel (D) (35 mg/sm day 1 and 8 every 3 weeks) 
given after 3 courses of cisplatin (75 mg/sm/iv day 1) 
and vinorelbine (25 mg/sm/iv day 1 and 60 mg/sm/
os day 8) (PV) every 3 weeks as Àrst-line treatment 
in patients with locally advanced, unresectable, or 
metastatic NSCLC. The treatment was continued 
until disease progression. All patients were restaged 
after every three courses by CT-scan.
Results: Thirty-six patients were enrolled from 
November 2008 to December 2010: 24 males and 12 
females, median age 62 years (range: 37-69), median 
PS 90% (range: 60-100), 7 stage IIIB and 29 stage 
IV (11 pts with brain mets.), histology: 12 squamous 
and 24 non-squamous. At the moment all the patients 
are evaluable for toxicity and 33 for response. The 
overall best objective response was 17 (51.5%) 
partial response, 11 (33.3%) stable disease and 5 
(15.15%) progressive disease. Toxicity was mild, the 
S1272 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: The BTOG2 trial is a large phase 
III randomised clinical trial which investigated 
the optimal dose of cisplatin (50 versus 80 mg/
m2 3-weekly), in combination with gemcitabine, 
and whether carboplatin (AUC6-Wright) could 
safely and effectively be substituted for the optimal 
cisplatin dose in the treatment of advanced NSCLC. 
The protocol recommended that cisplatin would be 
given as an out-patient regimen, designed to ensure 
diuresis whilst maintaining electrolytic balance. A 
previously reported audit by these authors found 
that almost half (48%) of hospitals surveyed were 
admitting NSCLC patients, often overnight for 
cisplatin /gemcitabine chemotherapy delivery. 
Methods: Between April 2005 and November 2009, 
909 patients were randomised to receive cisplatin, 
in the UK and Eire, from 78 centres. Adverse 
event (AE) data was also collated as a secondary 
endpoint. The trial mandated submission of proposed 
chemotherapy delivery schedules and changes 
were required if necessary to reduce total duration 
of delivery, mandatory use of mannitol, short 1 hr 
delivery of cisplatin and decreasing of total Áiud 
volume delivered to < 4 L. Data mining was used to 
investigate those AEs relating to renal function. In 
addition, data was examined for the worst reported 
serum creatinine values for each cycle. 
Results: 2853 treatment cycles were available 
for analysis. The average duration of treatment 
duration decreased from nearly 9 to 6 hours and 
total volume of Áuid delivered decreased from as 
much as 7 to less than 4 litres. These changes meant 
the rate of outpatient delivery of cisplatin increased 
from 48 to 97%. Toxicities feasibly related to the 
manner in which cisplatin was administered were 
comparable to the current available literature with 
< <1% experiencing grade >2. This concurred with 
the variation in serum creatinine throughout the 
treatment phase which showed <2% of patients with 
levels >160umol/L. When monitored as a time series 
on a patient by patient basis a slightly greater number 
(~4%) showed a increases from their own baseline 
serum creatinine levels of above 1.5 times, at some 
point throughout their treatment. Dehydration and 
electrolyte disturbances such as hypomagnesaemia, 
hypokalaemia and hypophosphataemia were each 
experienced by <2% of patients. 
Conclusion: As a result of participating in BTOG2 
97% of surveyed hospitals were able to deliver 
cisplatin in a day case setting. The perverse 
incentives of the current NHS Tariffs in the UK 
quote a higher price of almost 60% for patients 
Preliminary results are presented.
Results: A total of 148 p were evaluated. Median 
age 57.5 (50-64) years; male 64%; tumor histology: 
77% adenocarcinoma, 14% large-cell carcinoma; 
disease stage IV/IIIB 93%/7%; ECOG 0/1/2 
37%/56%/7%. 24% of patients were 65 years or 
older and 64% of p presented at least 1 comorbid 
condition at baseline, being the most frequent HTN 
(19%), Dyslipidemia (16%), DM (12%), CVD 
(7%) and COPD (6%). Commonly used Àrst-line 
chemotherapy (CT) regimens in combination with 
bevacizumab were carboplatin doublets in 71% 
of p and cisplatin doublets in 26%. In the whole 
population (n=148) median number cycles received 
was 6 and 8 for CT and bevacizumab respectively. 
Median PFS was 7.6 months (95%CI: 7.2-8.0) and 
DCR 85%. In patients 65 years or older (n=35) 
median no. of cycles was 6 for both CT and 
bevacizumab, PFS 6.6 months (95%CI:5.0-8.2) and 
DCR 85.6%. In patients with at least one morbid 
condition (n=95), median number of cycles received 
was 6 and 8 for CT and bevacizumab respectively, 
median PFS was 7.4 (6.3-8.2) and DCR 84.1%. 
The main grade (g) 3 or greater toxicity was DVT 
in 2.7% of p. The incidence of g3 or greater AEs of 
special interest were: hemoptysis 1%, proteinuria 
1%, HTN 0%, thromboembolism 1%. DVT (2%) 
was the only g3 or greater AE reported in elderly 
p. In p with at least one comorbidity, DVT (3%), 
neutropenia (1%) and infection (1%) were the only 
g3 or greater AEs reported.
Conclusion: First-line bevacizumab-based therapy 
was effective and safe in older p and p with at least 
one comorbid condition. No new safety signals have 
been indentiÀed and efÀcacy results match with 
previously reported data.
Keywords: NSCLC, Àrst-line, bevacizumab, special 
populations
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P3.163 DAY CASE CISPLATIN DELIVERY 
FOR ADVANCED NSCLC PATIENTS: 
FASTER, CHEAPER, MORE DESIRABLE
Hugh Jarrett1, Michelle Hill1, Lucinda Billingham1, 
Kenneth J. O’Byrne2, David Ferry3 
1Crctu, University Of Birmingham/United Kingdom, 
2Oncology, St James’s Hospital/Ireland, 3New Cross 
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efÀcacy of new estimating method of renal function 
for Japanese patients with lung cancer. Consecutive 
patients treated with carboplatin containing 
chemotherapy were examined. Dose of carboplatin 
were determined by the Calvert formula with target 
AUC of 5 and GFR calculated by the equation 
described above. Relationship between adverse 
effects and clinical features were analyzed. 
Results: A total of 34 patients (male 22/female 12) 
were included. The number of patients received each 
chemotherapy were 15 for carboplatin/gemcitabine 6 
for carboplatin/paclitaxel, 1 for carboplatin/docetaxel 
and 7 for carboplatin/pemetrexed. The mean count of 
neutrophil cyte and platelet at nadir was 1377±1160/
ƫl and 12.3±6.8×104/ƫl respectively. One patient 
experienced severe thrombocytopenia requiring 
a blood transfusion, however the hematological 
toxicity of the others were mild. There were no 
correlation between hematological toxicity and 
clinical values including renal function, age, sex and 
body surface area.
Conclusion: The newly developed formula is 
effective to compensate inter-patient variability 
including age, sex and renal function in Japanese 
patients treated by carboplatin. Ethnic difference 
including renal function should be taken into 
consideration for personalized dosing. 
Keywords: renal function, Carboplatin, personalize 
dosing, Calvert formula
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P3.165 DELIVERED DOSE INTENSITY 
OF GEMCITABINE 1250MG/M2 WITH 
CISPLATIN AT 80MG/M2 (GC80) AND 
50MG/M2 (GC50) AND CARBOPLATIN 
AUC 6 (GCB6) IN A PHASE III TRIAL OF 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): CORRELATIONS 
WITH CLINICAL OUTCOMES
David Dunlop1, David Ferry2, Hugh Jarrett3, Lucinda 
Billingham3, Joyce Thompson4, Muthu Kumar5, 
Geraldine Skailes6, Marianne Nicolson7, Riyaz 
Shah8, Pauline Leonard9, A Chetiyawardana10, Paula 
Wells11, Conrad Lewanski12, Penella Woll13, Barbara 
Crosse14, Kenneth J. O’Byrne15 
1Oncology, The Beatson West Of Scotland Cancer 
Centre/United Kingdom, 2New Cross Hospital/United 
Kingdom, 3Crctu, University Of Birmingham/United 
Kingdom, 4Birmingham Heartlands Hospital/United 
being admitted for cisplatin treatment as opposed 
to receiving it as an outpatient. With the prima 
facie case that patients prefer outpatient treatment 
over being admitted, it is important to achieve 
the maximum beneÀt from the existing drugs in a 
clinically deliverable way. The results indicate that 
administering cisplatin via a short hydration schedule 
of < 6 hours, even at 80 mg/m2, is safe. If all 
currently delivered in-patient cisplatin is switched to 
outpatient treatment not only will patients beneÀt but 
costs will fall. It is unlikely that the many hospitals 
who changed their practice would have done so 
without the support of a running RCT. This is yet 
another unrecognised beneÀt of RCTs. 
Keywords: BTOG2, Cisplatin, Hydration
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P3.164 EVALUATION OF THE FORMULA 
DEVELOPED BY THE JAPAN SOCIETY 
OF NEPHROLOGY FOR ESTIMATING 
RENAL FUNCTION OF PATIENTS 
WITH LUNG CANCER TREATED 
WITH CARBOPLATIN CONTAINING 
CHEMOTHERAPY.
Toshimichi Miya1, Kosuke Sakai1, Minoru Inomata1, 
Yutaka Kokubo1, Yuji Kusunoki1, Akihiko Gemma2 
1Pulmonary Medicine/medical Oncology, Nippon 
Medical School Tamanagayama Hospital/Japan, 
2Department Of Internal Medicine, Division Of 
Pulmonary Medicine, Infectious Diseases And 
Oncology , Nippon Medical School, Tokyo, Japan, 
Nippon Medical School Hospital/Japan
Background: The Calvert formula is routinely 
applied for the dosing of carboplatin based on 
glomerular Àltration rate (GFR) as accurately 
measured using the 51-Cr-EDTA clearance. In 
general practice, an estimated value of creatinine 
clearance calculated by the Cockcroft-Gault formula 
is widely used as a substitution of the GFR. It is 
reported that there is ethnic difference in renal 
function and that decrease of GFR by aging is less 
in Japanese than Caucasian. In 2008, the project 
of Japan Society of Nephrology developed the 
following formula for calculation of GFR Àtting 
to Japanese patients: GFR (ml/min/1.73m2)= 
194×Serum creatinine -1.094×Age-0.287 (×0.739, if 
female)
Methods: The aim of this study is to evaluate the 
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Dose reductions on cycles 2-4 were more apparent 
for GC80 compared to GC50 (56% vs 42% of 
patients experienced at least one dose reduction). 
The dose delivered still remained high with 
reductions to median dose of 77mg/m2 by cycle 4. 
Dose reduction rate was highest on GCb6 with 71% 
of patients experiencing at least one reduction, with 
median dose of AUC 4.5 at cycle 4. Gemcitabine 
dose reductions paralleled those seen with platins, 
occurring more frequently with GCb6. Overall DDI 
for platinum was high for all treatments but lowest 
for GCb6 (96% vs 99% vs 87%) and reduced across 
all cycles for GC80 and GCb6. Response rates were 
GC50 23%, GC80 33% and GCb6 28%. There was 
no evidence that dose reductions, treatment delays or 
DDI was associated with response thus the delivered 
dose of GC80 was sufÀcient to generate this 10% 
difference.
Conclusion: Doses of cisplatin at 80mg/m2 and 
carboplatin at AUC6 based on the Wright formula 
in combination with gemcitabine are deliverable but 
individuals have higher chance of treatment delays 
and dose reductions. However the reduced DDI does 
not appear to have an effect on clinical outcomes. 
Keywords: BTOG2, Dose Intensity, NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 3 – NSCLC – Advanced Stage Wednesday, 6 July 2011 
12:15-14:15
P3.166 LONG TERM ERLOTINIB 
RESPONDERS –CHARACTERISTICS 
OF NSCLC PATIENTS WITH A 
PROGRESSION FREE SURVIVAL OF 
MORE THAN 1 YEAR.
Jens B. Sorensen1, Anders Mellemgaard2, Henrik A. 
Nielsen3, Nina Jeppesen4, Cecile Holländer1, Ida R. 
Madsen5, Karin H. Hansen5 
1Oncology, Finsen Centre/national University 
Hospital/Denmark, 2Herlev University Hospital/
Denmark, 3Hillerød Hospital/Denmark, 4Roskilde 
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Background: Erlotinib used in second or following 
lines for advanced NSCLC yields modest increase in 
progression free survival (PFS) compared to placebo 
(Schiller 2005).However, some patients experience 
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Background: All drugs, including chemotherapy 
agents have dose-related effectiveness. For 
chemotherapy this is referred to as dose-intensity and 
is usually expressed as dose per unit of time. Drugs 
such as platins adduct DNA by zero order kinetics, 
thus the amount of DNA adduction is proportionate 
to dose. The key clinical question is whether this 
translates into superior meaningful clinical outcomes 
such as response rate and survival. Answering these 
key questions was the rationale behind choosing to 
compare two dose of cisplatin and a highest dose 
possible of carboplatin in the BTOG2 trial. In this 
large phase III trial supported by the British Thoracic 
Oncology Group patients with advanced non-
small cell lung cancer were randomised to receive 
gemcitabine (1250 mg/m2 on day 1 and 8) with 
either cisplatin at 80mg/2 or cisplatin at 50mg/m2 or 
carboplatin AUC6. The protocol speciÀed planned 
doses and durations of chemotherapy but in reality 
treatment delays and dose reductions due to toxicity 
mean that patients do not actually receive planned 
treatments. The BTOG2 trial provides an opportunity 
to investigate the delivered dose intensity (DDI) of 
these treatments in a large group of patients.
Methods: Carboplatin dose was calculated using the 
Calvert equation, incorporating estimated GFR based 
on the Wright equation including creatinine kinase. 
Dose intensity, response and toxicity were important 
secondary outcome measures in the trial contributing 
to the interpretation of the results of the primary 
outcome measure, overall survival time. Delivered 
dose intensity (DDI) for each patient was calculated 
as the mean of the per-cycle DDI which is the 
ratio of the delivered versus planned dose per day, 
calculated for platinum and gemcitabine separately. 
Results: Starting doses for cycle 1 were generally 
as per protocol with 95% of GC80 starting on doses 
>75mg/m2, 97% on GC50 >45mg/m2 and 93% of 
GCb6 >AUC5. Doses of carboplatin are higher 
using estimated GFR from the novel Wright formula 
compared to standard Cockcroft-Gault approach. 
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Background: MetMAb (M) is a monovalent 
monoclonal antibody that blocks HGF-induced 
Met signalling. A Phase II double-blinded, 
randomized trial of MetMAb+erlotinib (M+E) 
or placebo+erlotinib (P+E) in 2nd- and /3rd- line 
NSCLC has been recently completed. The M+E arm 
demonstrated both PFS and OS advantages in the 
c-Met IHC expression-positive 2+ /3+ (Met Dx+) 
patients only. 
Methods: Adverse events (AEs) were assessed for 
relationship to MetMAb in the patients in different 
diagnostic groups. Tumor growth rate and onset 
of new lesions were also examined in order to 
understand their potential contribution to the clinical 
outcomes. 
Results: In the M+E arm, median cycles of M were 
higher in Met Dx+ vs. Met Dx- pts (4 vs. 2) as were 
median E doses (61 vs. 42 respectively). The overall 
pattern of AEs was similar in the two treatment arms, 
with the exception of peripheral edema, which was 
higher in M+E treated patients regardless of c-Met 
long PFS, some of these due to presence of EGFR 
mutations. We studied clinical parameters in a cohort 
of NSCLC patients with a PFS 1 year who were not 
examined for EGR expression or EGFR mutations. 
Methods: Advanced disease NSCLC patients who 
received erlotinib treatment were identiÀed and 
those with a PFS 1 year were included. Testing for 
EGFR mutations or EGF expression were not part 
of clinical practice during study period. Patients 
characteristics and treatment outcome was registered 
from patients records. 
Results: A total of 46 patients from 5 hospitals 
fulÀlled the inclusion criteria. None had known 
activating mutations in the EGF receptor. The 
majority of patients (70%) had received prior 
platinum based doublet chemotherapy. All were 
caucasians, with the following characteristics: 
Males (37%), age>75 years (46%), Squamous 
cell carcinoma (7% of patients), active smoker 
(11%), ECOG Performance Status 3 (9%), previous 
radiotherapy (28%), erlotinib as 2nd-4th line (70%). 
Rash appeared in 89% (grade 1, 2, and 3 in 30%, 
48%, and 11%, respectively) and diarrhea in 
59% (grades 1, 2, and 3 in 33%, 20%, and 4%, 
respectively). There were no difference in occurrence 
of rash between patients 75 years and >75years 
being 88% and 90 %, respectively, while frequencies 
of diarrhea were 72% and 43%, respectively (not 
signiÀcant (ns)). There were 13% partial and 2% 
complete responses overall, while response rates 
among patients 75 years and >75years were 12% 
and 19%, respectively (ns). Mean response duration 
was 85+ weeks. 22% are still on erlotinib treatment 
while 61% had progressed after mean of 91 weeks. 
Other reasons for discontinuation were side effects 
(7% overall, 4% in age 75 years, and 10% in age 
>75 years (ns)) and various other reasons (9%). 
Conclusion: Long term PFS in excess of 1 year 
is possible with erlotinib both for patients having 
squamous cell carcinoma, performance status 3, 
advanced age >75 years, and for active smokers. 
Also heavily pretreated patients receiving erlotinib as 
3rd or 4th line treatment are observed to achieve PFS 
1 year. In this long-treated patient population age 
had no major impact on toxicity though with a non-
signiÀcant trend towards less diarrheafewer diarrheas 
in elderly patients. Erlotinib may be a valid treatment 
choice for a wide range of clinical scenarios offering 
a possibility for long-term PFS in some patients. 
Keywords: Targeted treatment, erlotinib, long-time 
responders, Advanced NSCLC
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Background: Advanced stage non-small cell lung 
cancer (NSCLC) represents a 80% all lung cancer. 
Recently a noninferiority phase III study was proved 
that in adenocarcinoma and large-cell carcinoma 
histology advanced NSCLC, cisplatin/pemetrexed 
provides better efÀcacy than cisplatin/gemcitabine. 
This was the Àrst prospective phase III study in 
NSCLC to show survival differences based on 
histologic type. We conducted a multicenter study 
in advanced NSCLC to evaluate the tolerance and 
efÀcacy of Àrst-line pemetrexed-cisplatin in non-
epidermoid carcinoma.
Methods: Patients with advanced NSCLC and non-
epidermoid carcinoma received pemetrexed (500 mg/
m2 day 1) and cisplatin (75 mg/m2 day 1) every 21 days 
(PC) with restaging after 3 and 6 cycles. The primary end 
point was to evaluate the overall response rate.
Results: Ninety-four patients with non-squamous 
carcinoma were accrued from seven centers across 
Galicia. Overall response rate was 42.9% (1.4% of 
complete response and 41.4% of partial response). 
Median overall survival was 12.6 months (95% 
conÀdence interval, 6.76 to 18.43); progression-free 
survival was 4.17 months (95% conÀcence interval, 
3.3 to 5). The treatment was well tolerated, with the 
most common treatment-related side effects being 
grade 1 and 2 asthenia (58.55%), anemia (44.94%) 
and nausea (30.34%). Grade 3 and/or 4 toxic reactions 
were neutropenia (7.86%, 4.49% with fever), vomiting 
(5.62%), anemia, nausea and asthenia (2.25%).
Conclusion: Combination with pemetrexed-cisplatin 
is well tolerated and has activity in advanced 
adenocarcinoma and large-cell carcinoma lung 
cancer, as previous publications have demostrated.
Keyword: pemetrexed, cisplatin, non-squamous
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CHEWING IMPACT THE RESPONSE TO 
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expression levels. Time to onset of any Grade ³3 AE in 
M+E treated patients was also similar across groups. 
In the Met Dx- group, Grade 3 AEs on M+E were 
higher than on P+E (56% vs. 35%), but the rate was 
similar to that observed for Met Dx+ pts on M+E 
(57%) or P+E (53%). The number of AEs leading 
to death was highest in Met Dx- pts on M+E (n=5), 
whereas the number of AEs leading to treatment 
discontinuation was highest in Met Dx+ pts on M+E 
(n=6); no consistent patterns were observed for 
either. The rate of tumor growth was not signiÀcantly 
different between treatment arms or Met sub groups. 
55% of Met Dx+ pts progressed with new lesions vs 
43% of Met Dx- (P+E), but the addition of M had no 
effect on this rate. The power to detect a difference is 
limited by the number of subjects in the study, i.e., 65 
with Met Dx+ (35 on M+E and 30 on P+E) and 56 
with Met Dx- (27 on M+E and 29 on P+E ).
Conclusion: Combination with MetMAb did not 
appear to substantially alter the safety proÀle of 
erlotinib and differences in AEs do not clearly 
explain the PFS and OS outcomes observed in Met 
Dx subgroups on M+E. Furthermore, the addition 
of M to E in Met Dx- patients did not appear to alter 
tumor growth rates or patterns of disease progression
Keywords: NSCLC, cMet, MetMAb, erlotinib
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was 62.5% (5/12). The median followup is 2 months. 
Followup is too short to assess survival results at 
present
Conclusion: A history of tobacco chewing does 
not appear to adversely impact the response rate 
to EGFR TKI compounds. The number of patients 
who are non-smokers, but are tobacco-chewers is 
small. Data regarding the EGFR mutation analysis in 
tobacco chewers will be presented at the meeting. 
Keywords: geÀtinib, NSCLC, tobacco chewing
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Background: Advanced stage non-small cell lung 
cancer (NSCLC) represents a 80% all lung cancer. 
Schemes of polychemotherapy have meant a small 
improvement in overall survival and quality of life. 
We conducted a multicenter study in advanced stage 
squamous NSCLC to evaluate the efÀcacy of Àrst-
line biweekly docetaxel-cisplatin.
Methods: Patients with advanced NSCLC and 
epidermoid histology received biweekly docetaxel 
(50 mg/m2 days 1, 14) and cisplatin (50 mg/m2 days 
1,14) every 28 days (DC) with restaging after 3 and 
4 cycles. The primary end point was to evaluate the 
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2Pathology, Tata Memorial Hospital/India, 3Thoracic 
Surgery, Surgical Oncology, Tata Memorial 
Hospital/India, 4Radiation Oncology, Tata Memorial 
Hospital/India
Background: Response and clinical outcome 
following therapy with an EGFR tyrosine kinase 
inhibitor is markedly different in smokers as 
compared to never-smokers. There is some evidence 
that tobacco chewing increases the risk for lung 
cancer, although the degree of risk as compared to 
cigarette smoking is unknown. There is no data as 
to the incidence of EGFR-activating mutations in 
patients with a history of tobacco chewing and the 
activity of EGFR-TKIs in this patient population. 
We evaluated the efÀcacy of GeÀtinib in patients 
with adenocarcinoma of the lung, who were non-
smokers, but had a history of tobacco-chewing and 
the incidence of EGFR-mutations in this population 
of patients. 
Methods: An audit of all patients in the thoracic 
medical oncology OPD at Tata Memorial Hospital, 
with adenocarcinoma lung, who were started on 
GeÀtinib over the preceeding 6 months, was done. 
All patients who were never-smokers were included 
in the analysis and a history of tobacco chewing 
was elicited. Baseline imaging (CT scan or PET/
CT scan) was performed and GeÀtinib 250mg orally 
once daily was prescribed. Clinical evaluation was 
done monthly and repeat imaging was done every 2 
months. QOL questionnaire was collected every two 
months. Analysis was done with simple percentages. 
EGFR mutation analysis is being done on the 
parafÀn blocks with direct sequencing. 
Results: Of a total of 74 patients started on GeÀtinib, 
59 were never-smokers (25 males and 34 females). 
Of the 25 males who were never-smokers, 8 were 
tobacco-chewers and 17 were non-smokers and 
non-tobacco-chewers. Of the 34 females who were 
never-smokers, 4 were tobacco-chewers and 30 were 
non-smokers and non-tobacco-chewers. Thus, there 
were a total of 12 patients who were never-smokers, 
but were tobacco-chewers, and a total of 47 patients 
who were never-smokers and non-tobacco-chewers. 
The response rate to GeÀtinib assessed at 2 months 
follow-up, in patients who were never-smokers and 
non-tobacco users was 28% (13/47), with a disease 
stabilization rate of 28% (13/47). In patients who 
were never-smokers, but had a history of tobacco-
chewing, the response rate to GeÀtinib assessed at 2 
months, was 33% (4/12) and the stable disease rate 
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analysed. The most common mandatory exclusion 
criteria in Àrst-line chemotherapy trials were used to 
elaborate the results.
Results: A total of 182 patients with stage IV 
disease susceptible of analysis were examined: 155 
males and 27 females, with a median age of 65 
years (range: 36-84). The following table displays 
the breakdown of exclusion criteria, indicating 
the number and percentage of patients potentially 
eligible for accrual after applying them successively: 
EXCLUSION CRITERIA Nº (%) Nº REMAINING (%) 
Other malignancies within 5 years 20 (11%) 162 (89%) 
ECOG 2-4 78 (43%) 84 (46%) 
Intracranial metastases at diagnosis 17 (9%) 67 (37%) 
*Tumour tissue sample not available 16 (9%) 51 (28%) 
*Diagnosis was cytology-based or formalin-Àxed, 
parafÀn-embedded tumour tissue sample was not 
available
Conclusion: In our community-based hospital, a 
signiÀcant percentage of stage IV NSCLC patients 
have clinical characteristics that preclude them from 
participating in clinical trials, mainly due to poor 
performance status. Patient accrued in most clinical 
trials may not reÁect the patient distribution in the 
community. More trials are needed in the group 
of patients with poor PS and unfavorable clinical 
characteristics.
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Background: At present there are two main 
objectives in treating patients with advanced 
NSCLC: life prolongation and control of symptoms. 
Erlotinib has an established role in both of them. 
Here we focus on the Àrst one; we present the 
characteristics of long term survivors treated with 
erlotinib. 
Methods: Between 2007 and 2009, 189 patients with 
progression-free survival.
Results: Forty-Àve patients with epidermoid 
carcinoma were accrued from six centers across 
Galicia. Overall response rates were 45.9%, all them 
had a partial response. Median overall survival was 
12.6 months (95% conÀdence interval, 10 to 15.2); 
progression-free survival was 4.7 months (95% 
conÀdence interval, 3.9 to 5.5). The treatment was 
well tolerated, with the most common treatment-
related side effects being grade 1 anemia (48.8%), 
asthenia (32.5%), nausea (30.2%) and anorexia 
(27.91%). Grade 3 and/or 4 toxic reactions were 
neutropenia (20.9%, 11.6% with fever), diarrhea 
(4.6%), mucositis and neuropathy (2.3% both).
Conclusion: Biweekly docetaxel-cisplatin is active 
and well tolerated in patients with advanced stage 
squamous NSCLC.
Keyword: non-squamous, cisplatin, docetaxel
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Background: Clinical trials are one of the 
cornerstones of clinical research and have been 
increasingly incorporated into our daily clinical 
practice. Nevertheless, we noticed poor accrual 
into some of these trials. To identify which factors 
excluded patients from participating in clinical trials, 
we retrospectively studied all stage IV NSCLC 
patients submitted in the past four years to one of our 
lung cancer units.
Methods: NSCLC patients submitted from January 
2007 to December 2010 were identiÀed from the 
lung cancer registry and the basic clinical data were 
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Background: A possible way to improve the 
treatment efÀcacy of advanced NSCLC lies in 
preliminary selection of patients for individualized 
CT using objective prognostic criteria for tumor 
susceptibility to current antineoplastic chemicals. 
This study was aimed at comparative assessment of 
CT efÀcacy between the standard regimen and an 
individual choice of effective cytostatics in patients 
with NSCLC.
Methods: From December 2005 till November 
2010, 46 patients with NSCLC were examined 
(mean age 58): squamous cell -  24 pts (IIIA- 3 
pts, IIIB - 18 pts, IV - 3 pts), adenocarcinoma 
-  22 pts (IIIA -  1 pt, IIIB -  17 pts, IV -  4 pts). 
Prior to the CT course, patient’s blood was tested 
in vitro response for cytostatics in different doses 
(Etoposide 80-100-120 mg/m², Cisplatinum 50-
75-100 mg/m², Carboplatinum 250-350-450 mg/
m², Doxorubicin 30-50-70 mg/m², Mitomycin C 
3-6-9 mg/m², Gemcitabine 800-1000-1200 mg/m², 
Vinorelbine 20-30 mg/m², etc.). The response was 
evaluated based on the dynamics of thiol-disulÀde 
ratios (TDR) in blood in vitro. This method included 
whole blood incubation with various cytostatics in 
aliquots corresponding to different therapeutic doses, 
Àve determinations of TDR in blood (before and 
in the process of 24-hour incubation), and then a 
selection of one or several optimal agents from those 
tested. The CT regimen in the study group (n = 23) 
was based on a combination of 2-3 cytostatics, with 
susceptibility to them being tested preliminary using 
TDR. In the control group (n = 23), the empirical 
standard regimen CT (EP, EPD, GP, VP, EMP, etc.) 
was used.
Results: Objective responses following 2 CT courses 
were obtained in 7 (30%) pts in the study group 
stage IIIB/IV NSCLC were treated at our Institute, 
of whom 57 (30.1%) survived more than a year after 
starting treatment with erlotinib. Patents received 
erlotinib until disease progression or unacceptable 
toxicity. We collected data on their characteristics, 
response to therapy, toxicity proÀle and outcome.
Results: The average age of long term survivors was 
62.7 years (range 36-81), 34 (59.6%) were females 
and 37 (65%) patients were in good condition 
(ECOG performance status 0 or 1); the remaining 
had PS 2 or 3. 28 (49.1%) were former or current 
smokers, other 29 (50.9%) were non smokers. 
With 51 cases (89.5%), adenocarcinoma was the 
prevailing histologic type; squamous, large cell and 
NSCLC unspeciÀed accounted for 2 (3.5%) each. 
EGFR mutational analysis was not performed before 
the beginning of therapy, because the testing was not 
available. All patients received a standard dose of 
erlotinib (150 mg/day); half of them received it in the 
Àrst, 30% in the second, 2% in third line and 7% as 
mainteinance therapy. Six patients (10.5%) received 
erlotinib intermittently with gemcitabine/cisplatin 
chemotherapy as part of an ongoing clinical trial. All 
patients developed rash (24.6% CTC grade I, 43.9% 
grade II, 29.8% grade III, and one patient grade IV). 
Diarrhoea was present in 33% of patients, 5 patients 
had paronichia and 2 had conjunctivitis (all grade 
I or II). Because of intolerable side effects dose 
lowering was necessary in 12 (21%) and treatment 
was discontinued in 5 (8.7%) patients. Response 
to erlotinib therapy was complete remission in 5 
(8.8%), partial remission in 31 (54.4%) and stable 
disease in 21 (36.8%) of patients. Median PFS 
and OS from the start of erlotinib therapy were 17 
months (C.I.10.5-23.4) and 26 months (C.I. 22-29.9) 
respectively.
Conclusion: Long term survivors do not differ much 
in their clinical characteristics from other patients 
with advanced NSCLC treated with erlotinib, except 
for the frequency of rash. In the analysis that we 
performed on all 189 patients that received erlotinib, 
only half of them developed rash and a third 
developed rash grade II or III, while in the group of 
long term survivors all developed rash and in two 
thirds of them rash was grade II or III. Development 
of rash may possibly predict long-term survival in 
advanced NSCLC treated with erlotinib. 
Keywords: rash, NSCLC, long term survivors, 
erlotinib
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Background: GeÀtinib is an important drug in the 
management of NSCLC. It has been found to be 
effective in patients who are clinically selected. It 
has better activity in patients with EGFR mutations. 
It is commonly used in patients in Àrst and second 
line setting. We retrospectively analyzed our 
prospectively collected data to assess the efÀcacy 
and safety of geÀtinib in these patients. Mutation 
analysis was done on the parafÀn blocks available by 
direct sequencing. 
Methods: The record of patients receiving GeÀtinib 
was retrieved from the data entry done prospectively. 
Source document of these patients were the hospital 
Àle. These patients received GeÀtinib treatment 
for the NSCLC. Patients were followed up every 2 
months with scan, clinically and QOL to assess the 
efÀcacy. Patients were also evaluated for side effects. 
Skin side effects and loose motions were specially 
documented. Scan was evaluated by radiologist who 
was designated for the same. 
Results: There were 54 patients who received 
GeÀtinib. There were 31 females and 23 males. 
Median age was 54 ( range 30-80 years). Response 
rate was evaluated in all 54 patients. 17/54 patients 
had PR, 18/54 had stable disease and rest of them 
had progressive disease at 2 months. 12/31 females 
had partial response, 10/31 females had stable 
disease. 5/23 male patients had PR, 8/23 had stable 
disease and rest had progressive disease. 25/54 
patients had skin side effects. Rash: 9/25, Itching: 
1/25, Abscess: 2/25, Boils on Face or Skin : 2/25, 
Blackish Discoloration of skin : 3/25, Rash + 
Itching : 6/25, Pustules + Boils on legs : 1/25, Skin 
Ulcers : 1 /25. Diarrhea occurred in 2/54 patients.6 
patients had interruption in taking GeÀtinib because 
of skin toxicity. 1 patient had to permanently stop 
due to skin toxicity. In patients with skin toxicity 
10/25 patients had PR. We will be presenting EGFR 
mutation data at the time of presentation. 
Conclusion: GeÀtinib is an effective drug in the 
management of NSCLC. Clinically selected patients 
beneÀt more with this drug. Skin toxicity correlates 
with the response rate. 
Keywords: NSCLC, non-smoker, geÀtinib
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[(PR -  7 (30%) pts, SD -  14 (61%) pts, PD -  2 (9% 
pts] versus 4 (17%) pts in the control group [(PR 
-  4 (17%) pts, SD -  9 (40%) pts, PD -  10 (43%) 
pts]. Subsequently, the patients continued to receive 
the repeated courses of CT with 4-8 week intervals 
depending upon clinical necessity and tolerance. An 
average number of courses administered made up 
to 8 (in a range of 4 to 10) in the study group and 5 
courses (in a range of 3 to 8) in the control group. In 
the study group, median survival was 2, 1 times as 
long (20, 6 months versus 9, 8 months in the control 
group).
Conclusion - Results: Objective responses following 
2 CT courses were obtained in 7 (30%) pts in the study 
group [(PR -  7 (30%) pts, SD -  14 (61%) pts, PD 
-  2 (9% pts] versus 4 (17%) pts in the control group 
[(PR -  4 (17%) pts, SD -  9 (40%) pts, PD -  10 (43%) 
pts]. Subsequently, the patients continued to receive 
the repeated courses of CT with 4-8 week intervals 
depending upon clinical necessity and tolerance. An 
average number of courses administered made up to 8 (in 
a range of 4 to 10) in the study group and 5 courses (in a 
range of 3 to 8) in the control group. In the study group, 
median survival was 2, 1 times as long (20, 6 months 
versus 9, 8 months in the control group).
Keyword: Individualized, Chemotherapy, NSCLC,
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P3.174 EFFECT OF GEFITINIB ON 
CLINICALLY SELECTED NON-SMALL 
CELL LUNG CANCER AND EGFR 
MUTATION RATE – EXPERIENCE FROM 
A SINGLE CENTER FROM INDIA
Kumar Prabhash1, Vanita Noronha1, Nilendu 
Purandare2, Rita Mulerkar3, T Abhishek1, Saral 
Desai4, Nirmala Jambekar4, C. S. Pramesh5, G. 
Karimundackal6, Jai prakash Agarwal7, Anusheel 
Munshi7 
1Medical Oncology, Tata Memorial Hospital/India, 
2Bioimaging, Tata Memorial Hospital/India, 3Basic 
Science, Actrec/India, 4Pathology, Tata Memorial 
Hospital/India, 5Thoracic Surgery, Tata Memorial 
Hospital/India, 6Thoracic Surgery, Surgical 
Oncology, Tata Memorial Hospital/India, 7Radiation 
Oncology, Tata Memorial Hospital/India
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months (mutant vs. wild type EGFR, p=0.020). 
There was no signiÀcant difference in response rate 
between geÀtinib and erlotinib treatment groups 
(33.3% vs. 25.0%, p=0.609). 45.5% of the EGFR-
TKIs responders had been reported to have wild type 
EGFR by the direct sequencing method.
Conclusion: EGFR mutations guaranteed the good 
clinical outcomes during the treatment of EGFR-
TKIs. However, 20% of non-squamous non-small 
cell lung cancer patients with wild type EGFR 
decided by direct sequencing method responded to 
EGFR-TKIs. Therefore, clinical decision making 
whether to administer the drugs based on the 
mutation test result should be very cautious if the 
test, such as direct DNA sequencing, has limited 
sensitivity.
Keywords: Non-small cell lung cancer, EGFR, 
Sequencing
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P3.176 THE INFLUENCE OF GASTRIC 
SECRETION INHIBITORS ON GEFITINIB 
THERAPY IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER
Sho Saeki, Jiichiro Sasaki, Shinya Sakata, Ryo Sato, 
Hidenori Ichiyasu, Kazuhiko Fujii, Naoki Saita, 
Hirotsugu Kohrogi 
Respiratory Medicine, Kumamoto University/Japan
Background: GeÀtinib is orally available, 
selective EGFR tyrosine kinase inhibitor used in 
patients with non-small cell lung cancer (NSCLC), 
especially harboring EGFR activating mutations. 
Pharmacokinetic study revealed absorption of 
geÀtinib was affected by the pH in stomach. 
However, cancer patients in advanced stage are 
frequently administered gastric secretion inhibitors, 
such as proton pump inhibitors (PPIs) and H2 
blockers (H2Bs). We hypothesized that gastric 
secretion inhibitors might suppress the efÀcacy of 
geÀtinib therapy. We studied the inÁuence of PPIs/
H2Bs on the efÀcacy of geÀtinib therapy in patients 
with NSCLC.
Methods: From Apr 2004 to Aug 2009, 100 patients 
with NSCLC received geÀtinib in our hospital. We 
retrospectively analyzed the correlation between use 
of PPIs/H2Bs and efÀcacy or toxicity of geÀtinib 
therapy.
Results: 65%(65/100) patients who received 
P3.175 PREDICTION OF TREATMENT 
RESPONSE TO EGFR TYROSINE 
KINASE INHIBITORS BY DIRECT 
SEQUENCING METHOD FOR EGFR 
MUTATION IN NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER
Seung Hun Jang1, Gee Young Park1, Sunghoon Park1, 
Yong Il Hwang1, Dong Gyu Kim1, Ki Suck Jung1, 
Kyung Wha Lee2, Hee Soon Chung3 
1Pulmonary, Allergy And Critical Care Medicine, 
Hallym University Sacred Heart Hospital/Korea, 
2Genome Application, Hallym Institute For Genome 
Application/Korea, 3Internal Medicine, Boramae 
Hospital/Korea
Background: It has been proven that non-small cell 
lung cancers with epidermal growth factor receptor 
(EGFR) mutation are highly sensitive to EGFR-
tyrosine kinase inhibitors (TKIs). Direct sequencing 
is known to be the standard for detecting EGFR 
mutations, however it has limited sensitivity. This 
retrospective study was aimed to evaluate predictive 
value of direct EGFR sequencing for the treatment 
response to EGFR-TKIs in a university afÀliated 
hospital.
Methods: Direct EGFR sequencing from exon 18 
to 21 of EGFR was done in 89 parafÀn-embedded 
nonsquamous non-small cell lung cancer biopsy 
specimens without a tumor cell-enrichment 
procedure. The associations of the clinicopathologic 
features and EGFR genotypes were analyzed. If the 
patients were treated by EGFR-TKIs during their 
clinical courses, the clinical outcomes were assessed 
according to the EGFR genotypes.
Results: The analyzed cases were composed of 
81 (91.0%) adenocarcinomas, 2 (2.2%) large cell 
carcinomas, and 6 (6.7%) unspeciÀed non-small cell 
carcinomas. The EGFR mutation rate was 29.2%. 
The mutation rates were signiÀcantly different 
according to sex (40.0% in female vs. 18.2% in 
male, p=0.024) and smoking status (42.3% in non- or 
light smoker vs. 10.8% of heavy smoker, p=0.001). 
EGFR-TKIs were administered to 42 patients, and 
the response could be evaluated in 36 patients (24 
patients treated with geÀtinib 250mg/day and 12 
patients with erlotinib 150mg/day). The response 
rates were signiÀcantly different depending on 
the EGFR genotypes (54.5% in mutant EGFR vs. 
20.0% in wild type EGFR, p=0.038). The disease 
control rate was 72.7% vs. 28.0% (mutant vs. wild 
type EGFR, p=0.012). The progression free survival 
of EGFR-TKIs treatment was 8.3 months vs. 1.4 
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line therapy in routine clinical practice. Sites were 
selected to ensure high minority representation. Due to 
persistent challenges in achieving desired enrollment 
of Hispanic and Asian pts, the focus of the study was 
narrowed to a comparison of pts self-reporting as 
Caucasian (C) and African American (AA). This report 
describes Àndings regarding the primary endpoint of the 
study, DCR. Some pts remain under observation—full 
characterization of survival will be available in early 
2011. Non-inferiority was evaluated using logistic 
regression analysis for DCR controlling for predeÀned 
covariates: age, gender, income, marital status, 
insurance type, smoking status, ECOG performance 
score, disease stage, histology, comorbidities, time from 
end of Àrst-line until initiation with P, prior exposure 
to Àrst-line platinum, Àrst-line paclitaxel, and number 
of Àrst-line cycles. The DCR of AAs was considered 
non-inferior to Cs if the upper 95% conÀdence bound 
on the adjusted odds ratio (OR) for Cs vs AAs was less 
than 1.78, corresponding to a difference in proportion 
of 14% assuming Cs to have a DCR of approximately 
50%. The bound was chosen to be one-half of the 
anticipated difference between treatment and no 
second-line treatment.
Results: The unadjusted DCR was 43.4% (116/267) 
for C and 45.8% (27/59) for AA (unadjusted OR=0.91). 
The adjusted OR for the comparison of C to AA in the 
Ànal logistic regression model was 0.79 (95% CI, 0.41, 
1.51). This upper 95% conÀdence bound was within the 
pre-speciÀed acceptable bound of 1.78.
Conclusion: Based on pre-speciÀed analyses, DCR 
of AAs was non-inferior to Cs. Hence, ethnicity 
is not considered a signiÀcant predictor of disease 
control following second-line treatment with P.
Keywords: Pemetrexed, NSCLC
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P3.178 COMPARISON OF 2ND LINE 
TREATMENTS FOR NON SMALL CELL 
LUNG CANCER AT THE EXETER 
ONCOLOGY CENTRE
Amy Ward, Anne Mccormack, Fiona Minear, 
Elizabeth Toy, Nicole Dorey 
Oncology, Royal Devon And Exeter Hospital/United 
Kingdom
Background: In the UK last year there were 
40860 new cases of Non Small Cell Lung Cancer 
representing a signiÀcant proportion of the cancers 
geÀtinib administered PPIs/H2Bs simultaneously. 
Patients with PPIs/H2Bs(PPIs/H2Bs group) had 
similar response rate compared with patients without 
PPIs/H2Bs(non PPIs/H2Bs group) (55.4% vs 40.0%, 
p=0.09). We observed similar disease control rate in 
each group(66.2% vs 60.0%, p=0.47). Progression 
free survival (144days vs 101days, Log-rank test 
p=0.687) and overall survival (555days vs 857, 
Log-rank test p=0.435) were similar between two 
groups. Interstitial lung disease(ILD) occurred more 
frequently in non PPIs/H2Bs group (4.6 vs 20%, 
p=0.03).
Conclusion: Gastric secretion inhibitors didn’t affect 
the efÀcacy of geÀtinib treatment. ILD occurred 
more frequently in non PPIs/H2Bs group. We 
speculate the correlation between development of 
ILD and blood concentration of geÀtinib.
Keywords: geÀtinib, gastric secretion inhibitors
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P3.177 PROSPECTIVE OBSERVATIONAL 
COMPARISON OF OUTCOMES IN 
AFRICAN AMERICAN AND CAUCASIAN 
PATIENTS RECEIVING SECOND-LINE 
TREATMENT WITH PEMETREXED FOR 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Eduardo Pennella1, Gerhardt Pohl2, Gerson Peltz2, 
Allicia Girvan2, Katherine Winfree2, Betzaida 
Martinez2, Coleman Obasaju1, Mark S. Walker3, 
Edward J. Stepanski4, Lee Schwartzberg5, Alex A. 
Adjei6 
1Medical, Eli Lilly & Company/United States Of 
America, 2-, Eli Lilly & Company/United States Of 
America, 3ScientiÀc Management, Acorn Research, 
Llc/United States Of America, 4Acorn Research, Llc/
United States Of America, 5The West Clinic/United 
States Of America, 6Medical Oncology, Roswell Park 
Cancer Institute/United States Of America
Background: Few prospective studies have 
evaluated the impact of race and ethnicity on 
clinical outcomes, during lung cancer treatment. 
This prospective observational study evaluated the 
impact of ethnicity on disease control rate (DCR) in 
patients (pts) with NSCLC treated with second-line 
pemetrexed (P).
Methods: Eligibility criteria included stage IIIB or 
IV NSCLC pts receiving single-agent P for second-
Copyright © 2011 by the International Association for the Study of Lung Cancer S1283
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agent has enabled a larger number of patients to 
receive 2nd line therapy for NSCLC. Erlotinib is 
now increasingly prescribed due to its ease of 
administration, efÀcacy and good toxicity proÀle. 
However Docetaxol continues to be used with a 
positive effect on survival, particularly for patients 
with squamous cell carcinoma. 
Keywords: Non small cell lung cancer, erlotinib, 
Docetaxol
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P3.179 REAL LIFE OUTCOMES AND 
HEALTH-RELATED QUALITY OF LIFE 
(HRQOL) IN 1ST LINE NON-SQUAMOUS 
NON-SMALL CELL LUNG CANCER 
(NSCLC): A EUROPEAN PILOT STUDY 
ANALYSING BEVACIZUMAB-BASED 
VERSUS NON-BEVACIZUMAB-BASED 
TREATMENTS
Christos Chouaid1, Helge Bischoff2, Alain 
Vergnenegre3, David Heigener4, Gavin Taylor-
Stokes5, Adam Roughley5, Stefan Walzer6 
1Department, Hôpital Saint Antoine/France, 
2Thoracic Oncology, Thoraxklinik / University Of 
Heidelberg/Germany, 3Pathologie Respiratoire, 
Hôpital Du Cluzeau/France, 4Thoracic Oncology, 
Hospital Grosshansdorf/Germany, 5Adelphi Real 
World/United Kingdom, 6Global Health Economics 
And Strategic Pricing, F. Hoffmann-La Roche 
Pharmaceuticals Ag/Switzerland
Background: Bevacizumab has been used in 
Àrst line NSCLC in Europe since its regulatory 
approval in 2007 and has demonstrated signiÀcantly 
improved overall survival and/or progression 
free survival in two randomized phase III trials. 
However, HRQoL outcomes have not been reported 
and real life outcomes have been assessed only 
in the US. Objectives: To investigate, in two 
European countries, the Time to Progression 
(TTP) and the comparative HRQoL of patients 
receiving bevacizumab-based therapy versus non-
bevacizumab-based therapy in 1st line non-squamous 
NSCLC. 
Methods: Data were drawn from the Adelphi 
NSCLC Disease SpeciÀc Programme, a large cross-
sectional study of patients in France and Germany in 
2010. Physicians provided retrospective information 
regarding disease status and treatment patterns. TTP 
treated at the Exeter Oncology Centre. In 2008 the 
National Institute for Clinical Excellence (NICE) in 
the UK recommended Erlotinib as an alternative to 
Docetaxel chemotherapy as second line treatment 
for patients with NSCLC. We present a review of 
105 patients initiated on Docetaxol and Erlotinib 
over a three year period (2007- 2010) at the Exeter 
Oncology Centre. 
Methods: Patients receiving Docetaxol or Erlotinib 
outside a clinical trial were identiÀed through 
chemotherapy records. Notes were reviewed 
retrospectively. Data were collected on age, gender, 
histology, smoking status, duration of treatment, 
reasons for stopping treatment, toxicities and 
survival from time of diagnosis. 
Results: 105 patients receiving either Docetaxol 
or Erlotinib were identiÀed. 35 patients received 
Docetaxol and 70 patients received Erlotinib. In the 
Docetaxol group 13 patients (37%) were female 
and 22 patients (62%) were male. Of the 70 patients 
in the Erlotinib group 37 (52.9%) were female 
and 33 (47.1%) male. Median age was similar in 
both groups. Following NICE recommendations in 
2008 the total number of patients receiving 2nd line 
treatment for NSCLC increased by 70% due to a 
large rise in patients commenced on Erlotinib. Pre 
2008 23 patients received Docetaxol and 16 patients 
received Erlotinib. Post 2008 12 patients received 
Docetaxol and 54 received Erlotinib. Mean duration 
of Docetaxol treatment was 54 days (3 weekly 
cycles). Mean duration of Erlotinib treatment was 72 
days. Median survival from diagnosis was 20 months 
in patients receiving Docetaxol and 13 months for 
patients receiving Erlotinib. However in this sample 
size the survival difference was not statistically 
different. The above Àgures and data on histology are 
summarised in the table below and will be updated 
prior to presentation. 
Docetaxol Erlotinib Total 
Population 35 70 105 
Pre NICE recommendation 23 16 39 
Post NICE recommendation 12 54 66 
Adenocarcinoma 13 45 58 
Squamous Cell 13 11 24 
NSCLC NOS 9 14 23 
Median Duration of treatment (Days) 54 72 
Median Survival from initial diagnosis 
(months) 
20 13 
Conclusion: We found that in our series overall 
survival was good in both groups. The 2008 NICE 
recommendation of Erlotinib as an alternative 
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P3.180 TOLERANCE AND EFFICACY OF 
CHEMOTHERAPY WITH PLATINUM 
AND PEMETREXED IN ELDERLY 
PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG 
CANCER (NSCLC)
Etienne Giroux Leprieur, Sylvie Labrune, Violaine 
Giraud, Thierry Gendry, Daniel Cobarzan, Thierry 
Chinet 
Department Of Pulmonary Diseases, Hopital 
Ambroise Pare, Ap-hp, University Of Versailles Sqy/
France
Background: An increasing number of elderly 
patients are diagnosed with lung cancer. A recent 
study has demonstrated a beneÀt of a platinum-
based doublet (carboplatin and paclitaxel) in elderly 
patients with non-small cell lung cancer. 
Methods: Our objective was to determine the 
tolerance and efÀcacy of the platinum-pemetrexed 
doublet in elderly patients with advanced non-
squamous NSCLC, compared with younger patients. 
We retrospectively reviewed the Àles of all patients 
treated by chemotherapy for an advanced non-
squamous cell NSCLC in our department between 
January 2008 and August 2010. 
Results: Forty-Àve patients with a stage IIIb-IV 
non-squamous NSCLC were treated with platinum-
pemetrexed as a Àrst line chemotherapy. Thirteen 
were 75 years old or older. Drugs were administered 
according to standard doses and protocols. The initial 
Performance Status in elderly patients was: 0-1 in 
77% and 2 in 23%, and was similar in the younger 
patients’ group. In the elderly patients’ group, the 
response rate was 33%, and the stabilization rate 
was 33% (versus 44% and 28% in the younger 
patients’ group, p=0.85). The progression-free 
survival (PFS) was not statistically different between 
the 2 groups, with a median at 3 months (IQR 18 
days – 4.3 months) in the elderly patients’ group 
(versus 1 month in the younger patients’ group (IQR 
20 days – 3.6 months), p=0.49). The hematological 
toxicities (all grades) in elderly patients were: 
anemia (incidence: 31%), thrombocytopenia (15%), 
neutropenia (38%); the grade 3-4 hematological 
toxicities in this group were: thrombocytopenia 
(8%) and neutropenia (15%). One patient suffered 
from febrile neutropenia. The most frequent non-
hematological toxicities (all grades) in the elderly 
was deÀned as time from start of treatment to physician-
reported disease progression or two weeks before the 
start of second-line therapy. A log rank test was applied 
to test for differences between the two comparison 
groups. Cox Proportional Hazard Models were Àtted to 
the data. Sensitivity analyses were run to analyse if age 
was a prognostic factor for treatment beneÀt between the 
two groups. For the HRQoL assessment, patients were 
invited to complete a questionnaire including the EQ-5D 
and FACT-L instruments. Propensity scoring methods 
were used to match the two comparison groups on 
confounding variables including age, performance status 
and time since diagnosis. A t-test was used to assess the 
relationship between current treatment and quality of life.
Results: 895 non-squamous patients were included 
in the TTP analyses, of whom 421 had experienced 
disease progression. 301 patients received 
bevacizumab-based treatment and 594 patients 
received a non-bevacizumab treatment Àrst line. 
Bevacizumab-treated patients were younger (mean 
age 58.6 years versus 63.3 years). The median time 
to progression for bevacizumab-treated patients was 
8.5 months compared with 6 months in the non-
bevacizumab treated group (p<0.001). The Hazard 
ratio relating to the treatment effect (bevacizumab-
based versus non-bevacizumab based) was 0.65 
(95% CI 0.52 to 0.81). The differences in TTP 
remain signiÀcant between the two Àrst-line therapy 
groups even after controlling for age. HRQoL was 
assessed for 363 non-squamous patients receiving 
Àrst line treatment of whom 132 were currently 
receiving bevacizumab-based therapy and 231 were 
currently receiving non-bevacizumab-based therapy. 
The HRQOL scores using the FACT-L instrument 
(total scores) were 77.3 for bevacizumab patients 
(95% CI 73.7 to 81.0) compared with 74.1 for 
non-bevacizumab patients (95% CI 70.9 to 77.33), 
p=0.19. The EQ-5D scores for Progression-Free 
Survival were 0.68 for the bevacizumab group 
(95% CI 0.63 to 0.74) and 0.66 for the comparative 
patients (95% CI 0.62 to 0.71), p=0.57.
Conclusion: This real life pilot study demonstrated 
extended TTP for bevacizumab-based versus non-
bevacizumab therapy and showed that bevacizumab-
based therapy does not have any detrimental effect 
on HRQoL as measured by the EQ-5D and the 
FACT-L. The TTP results were consistent with 
Àndings of two phase III trials and real life outcomes 
from a US study.
Keywords: Non-small cell lung cancer, Time 
To Progression, Health Related Quality of Life, 
bevacizumab
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spectacular role for the regulation of cell gene 
expression. Evidence supports the use of miRNAs as 
disease-speciÀc biomarkers. Several recent reports 
show circulating miRNAs in biological Áuids such 
as sputum, serum and plasma, among others, can 
be protected from endogenous RNase activity in 
exosomes, helping to transfer genetic material in 
the human body. The identiÀcation of miRNAs is 
necessary to validate new less invasive biomarkers 
for improving the detection and prognostic of 
patients with lung cancer. The present study aimed 
to obtain miRNA representative signatures in 
patients with lung adenocarcinoma from plasma and 
bronchoalveolar cell fraction.
Methods: Plasma and bronchoalveolar cell fraction 
were collected in six patients who had required 
Áexible bronchoscopy. Taqman Low Density Arrays 
(TLDAs) were used to assess the expression level 
of 381 miRNAs. MicroRNA hyper-expression was 
deÀned as a 5-fold or greater increase in plasma in 
contrast with the bronchoalveolar cell fraction and 
vice versa.
Results: Our goal was to compare patterns from 
circulating plasma miRNAs with the bronchoalveolar 
cell fraction derived miRNA. Patients (4 men and 2 
women) had a median age of 59.5 [range, 54.7-68.0] 
years. All had lung adenocarcinoma stage III or IV. 
To determine the degree of correlation between the 
expression levels of 381 miRNAs of plasma samples 
and bronchoalveolar cell fraction, the miRNA Ct 
values of plasma were compared with respect to the 
Ct values of bronchoalveolar cytology in patients. 
Pearson´s correlation factors were in a range between 
0.636 and 0.794, with p-values lower than 0.001 for 
all patients. In addition, we found that only around 
50% miRNAs were comparable between plasma and 
bronchoalveolar cell fraction and 20 % of miRNAs 
showed similar expression in both samples (Àgure 
1). The proÀles are not comparable; however, there 
is a similarity in the relative expression in a subset 
of miRNAs (miR-17, miR-19b, miR-195 and miR-
20b) between both biological samples in all patients. 
These results show a lack of association of miRNA 
signatures between plasma and bronchoalveolar.
patients’ group were: fatigue (54%), mucositis 
(15%), loss of weight (15%), nausea-vomiting (8%); 
the grade 3-4 non-hematological toxicities were: 
fatigue (31%), mucositis (8%), dysphagia (8%). 
No toxic death occurred. There was no statistical 
difference in the side-effects between the 2 groups, 
except less frequent weight loss (p=0.048) and 
nausea-vomiting (p=0.02) in the elderly patients’ 
group compared with the younger patients’ group. 
No elderly patient received erythropoietin (EPO), 
compared with 34% of younger patients (p=0.02). 
Use of G-CSF in elderly patients was more frequent 
than in younger patients (62% vs 19%, p=0.005). 
The treatment was stopped because of toxicity at a 
similar rate in the 2 groups (15%). Co-morbidities 
and weight loss (of more than 10%) were not 
associated with grade 3-4 toxicities. 
Conclusion: In patients with non squamous NSCLC 
treated with the platinum-pemetrexed doublet as a 
Àrst line chemotherapy, the response rate and PFS 
are similar in elderly and younger patients. The 
tolerance of this doublet appears to be acceptable in 
elderly patients with less frequent weight loss and 
digestive side-effects than in younger patients. 
Keywords: elderly patients, Advanced Non-Small 
Cell Lung Cancer, non-squamous carcinoma, 
Pemetrexed
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P3.181 COMPARISON OF MICRORNA 
PROFILE IN PLASMA VERSUS 
BRONCHOALVEOLAR FLUID 
CITOLOGY IN PATIENTS WITH LUNG 
ADENOCARCINOMA
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Nogal1, J. Martin-Juan2, Miriam González De La 
Peña1, Rocío Suárez1, Ricardo Melendez1, Amancio 
Carnero3, Luis Paz Ares1 
1Molecular Oncology And New Therapies Group, 
Service Of Medical Oncology, University Hospital 
Virgen Del Rocío, Instituto De Biomedicina De 
Sevilla (ibis)/Spain, 2Respiratory Disease Medical 
And Chirurgical Unit, University Hospital Virgen 
Del Rocío, Seville, Spain, Hhuu Virgen Del Rocío/
Spain, 3Molecular Biology Of Cancer Group, Ibis/
Spain
Background: The discovery of microRNAs 
(miRNAs) has revealed an unexpected and 
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mortality. Pemetrexed became one of the standard 
chemotherapeutic options in advanced NSCLC. It is 
recommended both in the 1st line and in the 2nd line. 
Methods: Results of the second line therapy in 
NSCLC with pemetrexed monotherapy were 
evaluated in 10 centres. The Àrst line chemotherapy 
was platinum based regimen. Data of consecutive 
out-patients were prospectively collected from 
January 2008 to december 2010. Demographics, 
tolerance of treatment and prognostic factors were 
discussed. 
Results: The series consisted of 389 patients (pts), 
247 men and 142 women, mean age was 61 years (28 
-80), 77 were non-smokers, 134 ex-smokers and 175 
smokers. PS was 0 in 71 pts, 1 in 278 pts, 2 in 40 pts. 
Adenocarcinoma was present in 236 pts, squamous 
cell carcinoma in 83 pts, non speciÀed NSCLC in 
51 pts, large cell carcinoma in 19 pts. According to 
TNM classiÀcation 17 pts were in stage I, 14 pts in 
stage II, 140 pts in stage III, 214 pts in stage IV, 4 
pts were not classiÀed. Side effects of treatment (Gr 
3, 4) appeared in 113 (29.0%) pts, leucocytopenia 
in 49 pts, neutropenia in 43 pts, anaemia in 33 
pts, trombocytopenia in 13 pts, fatigue in 22 pts, 
nausea/vomiting in 9 pts, infection in 8 pts, rash in 
5 pts. Therapeutic response: CR in 5 pts, PR in 43 
pts, SD 136 pts and PD in 144 pts. Overall disease 
control was achived in 47.4%. The median of overall 
survival (MOS) from the pemetrexed application was 
9.8 months (8.0 m -11.6 m). It was 9.7 m in men, 9.9 
m in women (p 0,081), 7.9 m in smokers and 11.8 m 
in non-smokers (p 0.048), 11.4 m in adenocarcinoma 
and 9.4 m in squamous cell carcinoma (p 0.048). 
MOS according to PS: NA in PS 0, 9.6 m in PS 1, 
4.1 m in PS 2 (p 0.001). MOC according to stages: 
10.6 m in stage I+II, 12.0 m in stage III and 9.2 m 
in stage IV (p 0.163). Median of progression free 
survival (PFS) was 2.7 m (2.4 m – 3.0 m), it was 
2.6 m in men and 2.8 m in women (p 0.729), 2.5 m 
in smokers and 3.3 m in non-smokers (p 0.246), 2.6 
m in adenocarcinoma and 3.1 m in squamous cell 
carcinoma (p 0.996). PFS according to PS: 3.6 m in 
PS 0, 2.6 m in PS 1, 1.4 m in PS 2 (p 0.001). PFS 
according to stages: 5.1 m in stage I+II, 2.8 in stage 
III and 2.4 in stage IV (p 0.157). 
Conclusion: In present study pemetrexed was 
effective and well tolerable drug used in the second 
line chemotherapy of NSCLC treatment. MOS 
was signiÀcantly longer in PS 0 and 1 than in PS 
2, in adenocarcinoma than in squamous carcinoma 
and in non-smokers than in smokers. PFS was not 
inÁuenced by any evaluated parameter except of PS. 
Conclusion: Our data reÁects that there is an 
absence of association between expression 
pattern in the circulating plasma miRNAs and the 
bronchoalveolar cell fraction-derived miRNAs from 
the same patient. Only a small subset of miRNAs 
(from 18% to 27%) is commonly represented in both 
samples, and this considering 5 fold differences as 
equal in the expression levels.
Keywords: plasma, microRNA proÀle, 
bronchoalveolar Áuid cytology, Adenocarcinoma
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P3.182 PEMETREXED IN THE SECOND 
LINE CHEMOTHERAPY OF NON SMALL 
CELL LUNG CANCER. A MULTICENTRE 
PROSPECTIVE ANALYSIS OF DATA 
FROM CLINICAL PRACTICE.
Vitezslav Kolek1, Miloš Pešek1, Ivona Grygárková1, 
Petr Zatloukal2, Jana SkŉiĀková3, Rostislav Vyzula4, 
Leona Koubková5, Jaromír Roubec5, František 
Salajka5, Dimka Sixtova6, Luboš Petruželka7, Michal 
Štícha8 
1Respiratory Medicine, University Hospital/Czech 
Republic, 2Respiratory Diseases, University Hospital 
Bulovka/Czech Republic, 3Respirtatory Diseases, 
University Hospital/Czech Republic, 4Oncological 
Department, Masaryk Memorial Hospital/Czech 
Republic, 5Respiratory Diseases, University 
Hospital/Czech Republic, 6Department Od 
Respiratory Diseases And TB, Thomayer University 
Hospital/Czech Republic, 7Oncological Department, 
University Hospital/Czech Republic, 8Iba, Masaryk 
University/Czech Republic
Background: Non small cell lung cancer 
(NSCLC) is one of the most aggressive tumours 
with unsatisfactory prognosis and extremely high 
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response.
Results: 52 (of 63 planned) pts have been enrolled 
in this ongoing trial. After the Àrst 27 pts were 
enrolled, there were 8 conÀrmed PRs (30%) and 9 
SD (33%), thus, second stage was initiated. 81% of 
pts are Caucasian, with a median age of 64 years. All 
pts have been smokers (mean 49 pk-yrs). Histology 
includes 37 squamous cell, 8 adenocarcinoma, 2 
adenosquamous, and 5 NSCLC (NOS). Grade 3/4 
toxicity experienced by more than 2 patients is listed 
in table 1. Grade 3 neuropathy is signiÀcantly higher 
than seen in prior studies despite being dosed at the 
MTD in combination with carbo. After the Àrst 40 
pts, in consultation with the sponsor, we decreased 
the dose of nab-paclitaxel to 260 mg/m2 because of 
neurotoxicity and have seen no Gr3/4 neuropathy 
in the subsequent 12 pts. Four patients died during 
the Àrst or second cycle of therapy related to sepsis, 
febrile neutropenia and dehydration. 
Table 1: Toxicity Gr3 n (%) Gr4 n (%) 
Hematologic 
· Neutropenia 4 (8%) 8 (15%) 
· Thrombocytopenia 5 (10%) 1 (2%) 
· Anemia 2 (4%) 1 (2%) 
Non-Hematologic 
· Sensory Neuropathy 13 (25%) 0 
· Neutropenic Fever 7 (13%) 2 (4%) 
· Infection without Neutropenia 5 (10%) 5 (10%) 
· Hyponatremia 7 (13%) 0 
· Hypoxia 1 (2%) 2 (4%) 
· Dyspnea 7 (13%) 2 (4%) 
· Dehydration 6 (12%) 3 (6%) 
· Fatigue 10 (20%) 0 
Conclusion: nab-Paclitaxel and carbo on a 3 week 
schedule offers a reasonable treatment option for 
pts with advanced NSCLC with squamous histology 
who are ineligible for Bev. This study was approved 
and funded by the National Comprehensive Cancer 
Network (NCCN) from general research support 
from Celgene.
Keywords: bevacizumab ineligible, nab-paclitaxel, 
squamous carcinoma, neuropathy
Keywords: Pemetrexed, Advanced NSCLC, second 
line chemotherapy
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P3.183 PHASE II TRIAL OF NAB-
PACLITAXEL PLUS CARBOPLATIN IN 
PATIENTS WITH ADVANCED NSCLC 
AT RISK OF BLEEDING FROM VEGF 
DIRECTED THERAPIES
Gregory A. Otterson1, Erin M. Bertino1, Nagla A. 
Karim1, Kavitha Donthireddy1, Ahmed Ghany1, 
Robert Rupert1, Sarah Cantrell2, Meliha Rahmani2, 
Melinda Lynn2, S. P. Nana-Sinkam3, Gary S. 
Phillips4, Miguel A. Villalona-Calero1 
1Medical Oncology/internal Medicine, Ohio State 
University/United States Of America, 2Clinical 
Trials OfÀce, Ohio State University/United States Of 
America, 3Pulmonary Medicine/internal Medicine, 
Ohio State University/United States Of America, 
4Center For Biostatistics, Ohio State University/
United States Of America
Background: Platinum-based chemotherapy is 
standard for patients (pts) with advanced NSCLC. 
When added to chemotherapy, bevacizumab (Bev) 
improves response rate, progression free survival 
and overall survival (RR, PFS and OS), but pts with 
squamous histology or hemoptysis are excluded. 
nab-Paclitaxel (nanoparticle albumin bound 
paclitaxel) has been safe in phase I/II studies. A 
phase III study comparing paclitaxel/carboplatin 
(carbo) to nab-paclitaxel/carbo was reported to 
have met its primary endpoint of response rate. 
The objective of this trial is to determine the 
efÀcacy of nab-paclitaxel/carbo in pts ineligible for 
bevacizumab (Bev). 
Methods: Chemo-naïve pts with advanced NSCLC 
ineligible for Bev therapy (squamous histology, 
thrombotic or embolic events within 6 months, 
hemoptysis, cavitary lung lesions) were included. 
Controlled brain metastases were allowed. Treatment 
with nab-paclitaxel 300 mg/m2 (decreased to 260 
mg/m2 after the Àrst 40 pts) and carbo AUC 6 was 
given every 21 days (up to 6 cycles). We used a 
2-stage design; the 1st stage enrolled 27 pts and the 
2nd stage will enroll 36 pts. The primary endpoint is 
RR by RECIST. Secondary objectives include PFS 
and OS. Correlative studies include blood miRNA 
analysis to evaluate for predictive biomarkers of 
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subjects (n=61) placebo subjects with >8% weight 
loss demonstrated a similar survival disadvantage 
(P=0.04); 4 month Kaplan-Meier estimates 100% vs 
49% ±14.8%. In GTx-024 treated subjects in both 
the ITT and NSCLC groups, increased weight loss 
did not negatively affect survival.
Conclusion: Preceding weight loss among NSCLC 
patients not treated with GTx-024 is predictive of 
decreased overall survival. In this 16 week Phase 
IIb trial, NSCLC subjects randomized to placebo 
with >8% weight loss at baseline were 2 times more 
likely to die than subjects with 8% weight loss. In 
the GTx-024 group weight loss was not predictive 
of overall survival. These data suggest that GTx-024 
treatment may overcome the negative prognostic 
effect of >8% weight loss. Further research is needed 
to assess the effect of GTx-024 on overall survival. 
Keywords: GTx-024, muscle wasting, Cachexia, 
survival
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P3.185 PHASE I CLINICAL TRIAL 
OF ADENOCARCINOMA CELLS 
TRANSFECTED WITH HLA A1 AND 
GP96-IG HEAT SHOCK PROTEIN IN 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS
Luis E. Raez1, Eva Fisher2, Gail Walker3, Jorge 
Gomez1, Paulette Baldie1, Maria C. Mendoza-
Puccini1, Edgardo S. Santos1, Eckard Podack2 
1Hematology/oncology, University Of Miami/United 
States Of America, 2Immunology, Univeristy Of 
Miami/United States Of America, 3Department Of 
Biostatistics, University Of Miami/United States Of 
America
Background: This is a phase I clinical trial to 
determine the safety, immunogenicity, and clinical 
response to our allogeneic gp96-Ig heat shock tumor 
vaccine for NSCLC patients (pts) with advanced 
disease who have failed at least one line of standard 
chemotherapy and erlotinib. 
Methods: Allogeneic, cultured lung adenocarcinoma 
cells transfected with HLA A1 and gp96-Ig were 
irradiated and injected intradermall. Three dose-
schedule 107 cells administered by 9´combinations 
were considered (total of 4.5 biweekly (DS1), 18 
weekly (DS2), or 36 twice weekly (DS3) injections). 
Immune response to vaccination was measured by 
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P3.184 IN A PHASE IIB TRIAL GTX-024 
OVERCOMES THE NEGATIVE IMPACT 
OF >8% WEIGHT LOSS ON OVERALL 
SURVIVAL IN NON-SMALL CELL LUNG 
CANCER (NSCLC) SUBJECTS
Shontelle T. Dodson1, Adrian Dobs2, Mary A. 
Johnston1, Michael L. Hancock1, Mitchell S. Steiner3 
1Medical Affairs, Gtx, Inc./United States Of America, 
2The John Hopkins University/United States Of 
America, 3Gtx, Inc./United States Of America
Background: NSCLC represents greater than 80% 
of newly diagnosed lung cancer with over three 
quarters of patients being diagnosed with Stage III 
or IV disease. Due to the advanced stage of cancer 
at the time of diagnosis, 5 and 10 year survival 
rates are poor. At diagnosis, 60% of lung cancer 
patients have substantial weight loss, increasing 
to >80% prior to death from malignancy. Much 
of this weight loss is attributed to muscle wasting 
leading to a decline in physical function and other 
detrimental consequences early in the course of a 
patient’s malignancy. Studies have demonstrated 
that NSCLC patients with weight loss at diagnosis 
are less likely to tolerate chemotherapy, have worse 
treatment outcomes and shorter overall survival. The 
negative impact of muscle wasting on the patient and 
caregiver underscore the importance of preventing 
and treating this condition early in the course of 
therapy. We conducted a Phase IIb, randomized, 
double blind, placebo controlled, multi-center study 
to evaluate the effect of GTx-024 on muscle wasting 
and physical function in patients with cancer. 
Methods: Subjects (n=159) were randomized to oral 
GTx-024 (1 or 3 mg) or placebo daily for 16 weeks. 
Subjects were males >45 y and postmenopausal 
females, had experienced 2% weight loss in the 6 
months prior to randomization, had a BMI <35 and 
either NSCLC, colorectal cancer, non-Hodgkin’s 
lymphoma, chronic lymphocytic leukemia or breast 
cancer. The primary endpoint was change in total 
lean body mass (muscle). We report on overall 
survival in the entire study population and NSCLC 
cohort based on weight loss of > or 8% in the 6 
months prior to randomization.
Results: In placebo subjects in the ITT population, 
overall survival was signiÀcantly (P=0.003, log rank) 
reduced in subjects with >8% weight loss compared 
to subjects with 8% weight loss. Among NSCLC 
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glucan in MM-10-001 binds to a lectin site within 
the complement receptor 3 on leukocytes, priming 
the receptor to trigger cytotoxic degranulation of 
leukocytes when leukocyte CR3 binds to iC3b-
opsonized tumor cells. This phase I study was 
designed to assess the feasibility and toxicity of 
therapy with beta-glucan MM-10-001. Secondary 
endpoints included exploratory analysis of the effect 
of MM-10-001 on the innate immune compartment 
(in particular NK cell activation and effector status) 
and the cytokine proÀle of the patients as well as 
antitumor efÀcacy and patient reported functional 
status. 
Methods: Patients with advanced NSCLC for which 
standard curative or palliative measures do not exist 
or are no longer effective received orally escalating 
doses of MM-10-001 (5mg, 10 mg and 20 mg); 
a cycle consisted of 28 days. The blood samples 
for correlative studies were collected pre-study 
and weeks 1, 5, 9, 13. Serum cytokine levels were 
measured with 30-plex cytokine/ chemokine/growth 
factor multiplex panels (Invitrogen), and analyzed 
using a FLEXMAP-3D instrument (Luminex). 
Results: To date, 20 patients (7M/13F) have been 
treated (MM-10-001 5 – 20 mg). The median age 
was 72 (range 43-88), with 9 ECOG 0, and 11 ECOG 
1. All patients were evaluable for toxicity. No grade 
3+ treatment related adverse events were noted. 
Grade 2 adverse events reported are fatigue (3 pts), 
anorexia (1 pt), Alk Phos (1 pt), and joint pain (1 
pt), each with an attribution of “possible”. Median 
time to treatment failure was 3.5 months (range 
1-13+ months). Correlative studies on 19 cytokines 
in addition to immunoglobulins (A, M, G), WBC, 
hemoglobin, PLT, ANC, C-reactive protein, and serum 
complements C3 and C4 were conducted on 18/20 
subjects. SigniÀcant cytokine increases were noted in 
three patients concurrent with progression, resulting 
in a positive trend in several cytokines over time. 
Subset analysis, excluding those patients, suggested 
a possible decrease in IL-12 as a function of both 
time and dose (p=0.01, 0.02 respectively), along with 
a decrease in MIP1b as a function of dose (p=0.03). 
These results were not signiÀcant when adjusting for 
multiple comparisons. However, after accounting for 
multiple comparisons, low IL-2R was associated with 
improved survival (p<0.05, log-rank). 
Conclusion: At the time of interim analysis, 
the MTD has not been reached and study will 
continue with escalating doses of MM-10-
001. The preliminary data indicates potential 
immunostimulating activity of MM-10-001. 
determining adenocarcinoma-speciÀc CD8 CTL 
frequencies in ELI-spot assays for interferon-Ƣ 
(IFN-Ƣ) and by measuring the frequency of FoxP3+ 
CD4+ Tregs. If pts had a clinical beneÀt: (CR, PR 
or SD), they continued with the next course of 
vaccinations for up to 3 courses.
Results: 19 pts have been enrolled. Median age was 
65 years; most of the pts were Hispanic females. 
Data is available from 18 pts: 12 pts were treated in 
DS1 cohort, four in DS2 and three in DS3. None of 
the pts experienced serious adverse events (SAE) 
related to vaccine. Grade I: rash, skin induration and 
skin erythema were the most common AEs in the 
3 cohorts. There was not an increment of AEs with 
the increase in the frequency of vaccinations. Six pts 
have achieved transitory disease stabilization (SD). 
Most of the pts had an immunological response 
(CD8 CTL) determined by ELI-spot, and the 
frequency of FoxP3+ CD4+ Treg decreased. 
Conclusion: Minimal toxicity and immunologic 
response have been seen so far in this very advanced 
population of NSCLC pts 
Keywords: NSCLC, immunotherapy, heat shock 
protein gp96
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P3.186 A PHASE I STUDY OF MM-10-001 
IN ADVANCED NSCLC
Marianna Koczywas1, Mihaela Cristea2, Karen L. 
Reckamp1, Arnold Rotter3, Paul Frankel4, Xueli Liu4, 
Vivi Tran5, Emilia Reorizo1, Michael Kalos6, Simon 
F. Lacey5 
1Medical Oncology And Therapeutic Research, 
City Of Hope/United States Of America, 2Medical 
Oncology And Therapeutic Reserach, City Of 
Hope/United States Of America, 3Radiology, City 
Of Hope/United States Of America, 4Biostatistics, 
City Of Hope/United States Of America, 5Clinical 
Immunology, City Of Hope/United States Of 
America, 6Translational And Correlative Studies 
Lab, University Of Pennsylvania/United States Of 
America
Background: MM-10-001 is a bioactive agent 
exported from Shiitake Mycelium in aqueous 
medium. The MM-10-001 contains a triple helix 
beta-glucan, isolated from the cell walls of the 
shiitake mushroom (Lentinula edodes), with 
potential immunostimulating activity. The beta-
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EGFR mutated (EGFR mut ) versus wild-type pts 
(EGFR wt). 
Results: ORR to Àrst line chemotherapy was 43,8% 
(EGFR wt: 52,3% vs EGFR mut: 48,5%) 90 out of 
the 94 treatments with an EGFR-TKI (in 82 patients) 
were evaluable for response. 69/82 pts had a known 
EGFR mutational status (24 pts EGFR wt, 45 pts 
EGFR mut). ORR to EGFR-TKIs was 46,3% (EGFR 
wt: 29,1 % vs EGFR mut: 55.5%). PFS and OS in 
the overall population (123 pts) were respectively 
6,1 and 31,6 months (mo). Median OS for TKI 
treatment (ever/never) was 35 vs 14.4 mo (p=0,002 
Log rank test) PFS/OS in the 87 pts with a known 
EGFR mutational status were respectively: all (6,7 
mo/40 mo) ; EGFR wt (6,5 mo/36 mo); EGFR mut 
(7 mo/43,6 mo). The difference in OS between 
EGFR mutated and wild-type pts was statistically 
signiÀcant (p< 0,09). 
Conclusion: This analysis conÀrmed that 
adenocarcinoma is the most common histology 
subtype in lung cancer of never smokers, with female 
preponderance. In line with literature data, 47,1% 
of the population tested EGFR mutation positive. 
In our experience, EGFR mutation positive status 
do confers a survival advantage even if it does not 
predict for better response rate to chemotherapy. 
Keywords: Lung cancer, never smoker
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P3.188 CLINICAL RESPONSES TO 
GEFITINIB RETREATMENT IN 
NON-SMALL-CELL-LUNG-CANCER 
ADENOCARCINOMA PATIENTS 
WHO BENEFITED FROM PRIOR 
EFFECTIVE GEFITINIB THERAPY: A 
RETROSPECTIVE ANALYSIS
Junling Li1, Wang Yan2, Shi Yuankai2 
1Clinical Oncology, Clinical Medical Oncology, 
Cancer Hospital & Institute, Chinese Academy Of 
Medical Sciences, Beijing, China/China, 2Clinical 
Medical Oncology, Cancer Hospital & Institute, 
Chinese Academy Of Medical Sciences, Beijing, 
China/China
Background: GeÀtinib, an EGFR tyrosine kinase 
inhibitors have been widely used in non-small-cell-
lung-cancer (NSCLC).GeÀtinib is most effective 
in patients with women, never smoked, pulmonary 
adenocarcinomas, and patients of Asian origin. 
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P3.187 LUNG CANCER IN NEVER 
SMOKERS: A MONO-ISTITUTIONAL 
EXPERIENCE
Rita Chiari1, Chiara Bennati2, Carmen Molica1, 
Verena De Angelis2, Vincenzo Minotti3, Giulio 
Metro4, Vienna Ludovini3, Simona Duranti3, Maria 
Francesca Currà4, Chiara Scafati4, Antonella Flacco3, 
Elisa Baldelli4, Lucio Crinò3 
1Medical Oncology Department, Medical Oncology 
Department, S. Maria Della Misericordia Hospital/
Italy, 2Medical Oncology Department, Medical 
Oncology Department, Medical Oncology 
Department, S. Maria Della Misericordia Hospital, 
Perugia, Italy/Italy, 3Medical Oncology Department, 
Medical Oncology , S. Maria Della Misericordia 
Hospital, Perugia, Italy/Italy, 4Medical Oncology 
Department, S. Maria Della Misericordia Hospital;, 
Medical Oncology S. Maria Della Misericordia 
Hospital/Italy
Background: Lung cancer in never smokers seems 
to represent a distinct disease entity with its own 
distinct tumorigenesis, clinical characteristics, and 
response to therapy. From May 2003 to January 
2011, 123 never smoker lung cancer stage IV 
patients (pts) were followed at our Istitution
Methods: Patients’ Characheristics: F/M 73/50 
(59,3/40,7%). Median age was 61yrs (range 29-
78). All of them had a good PS (ECOG 0-1). 
Histology: squamous/adenocarcinoma/NoS 9/95/19 
(7,3/77,2/15,4%). Number of metastatic sites: single/
multiple 57/56 (54,5/45,5%). EGFR mutation 
(sequencing of exons 18-21) was performed in 87 
pts (70,7%) with 47,1% mutated and 52,9% wild 
type. K-RAS mutation (sequencing of exon 2) 
was performed in 85 patients (69,1%) with 8,2% 
mutated and 91,8% wild type. 4/20 (20%) EGFRwt 
and K-RASwt pts scored positive at the EML-ALK 
traslocation analysis by FISH and 3 more pts known 
to be EML4/ALK positive were referred to our 
Institution . Treatment: 111 pts received Àrst line 
chemotherapy: 102 (91,8%) with a platinum doublet 
and 9 (8,2%) mono-chemotherapy with gemcitabine. 
94 pts (76,4%) received an EGFR TKI in either line 
of treatment. 86 pts (77,4%) were treated with both 
chemotherapy and an EGFR-TKI. 64 pts (52%) 
received at least one further line of chemotherapy 
(median 2-4). Response rate, PFS and OS were 
evaluated for the overall population as well as for 
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Background: Cet, a monoclonal antibody (mAb) 
that blocks binding of epidermal growth factor 
(EGF) to EGF receptor (EGFR) or Bev (anti-VEGF 
mAb) has been combined with chemotherapy in 
advanced NSCLC cancer trials with acceptable 
toxicity proÀles and improved survival compared 
to chemotherapy alone. In previous trials, Cet and 
Bev were combined separately with chemotherapy 
and were generally well tolerated. This study aims 
to evaluate the efÀcacy of Cet plus Bev combination 
with chemotherapy in the survival of stage IIIB or IV 
NSCLC patients. 
Methods: Patients with stage IIIB or IV NSCLC 
(n=120) were randomized to receive Cet (400 mg/
m2 on day 1 as initial dose and weekly thereafter at 
250 mg/m2) plus Bev (15 mg/kg on day 8 of each 
3-week cycle) for 6 cycles in combination with either 
6 cycles (arm A) or 3 cycles (arm B) of P (200 mg/
m2) and C (AUC=6 ) on day 1 of each 3-week cycle. 
Patients who demonstrate complete response (CR), 
partial response (PR), progressive disease (PD), 
or stable disease (SD) after six cycles of therapy 
on either arms A or B may continue on weekly 
Cet monotherapy until PD or other withdrawal 
criteria are met. The primary objective is to estimate 
progression free survival (PFS) separately for arm 
A and B. Secondary objectives include estimation 
of overall survival, tumor response rate, duration 
of response, safety and tolerability, and quality of 
life assessment, for each treatment arm. Based on 
available tumor tissue, EGFR expression will be 
analyzed and relationships between PFS, and overall 
survival will be explored. 
Results: Planned enrollment was 120 patients. 
Results for PFS, overall survival, response, toxicity, 
and quality of life will be reported.
Conclusion: Conclusions will be reported later. 
Keywords: Non-small cell lung cancer (NSCLC), 
cetuximab (Cet), bevacizumab (Bev), stage IIIB/IV
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
There are some treatment options for NSCLC 
adenocarcinoma patients who responded to geÀtinib 
initial administration and demonstrated tumor 
progression. Re-administration of geÀtinib in a 
suitable is one choice. The study is to evaluate the 
efÀcacy and toxicity of the re-challenge geÀtinib.
Methods: We retrospectively evaluated the clinical 
charts of 17 NSCLC adenocarcinoma patients who 
had obtained a partial response (PR) or stable disease 
(SD) with geÀtinib treatment and were re-treated 
with geÀtinib after failure of the initial geÀtinib 
treatment.
Results: All of the 17 patients were adenocarcimoma 
of the lung and treated with geÀtinib as the 2nd 
EGFR-TKI. One patient (5.8%) showed CR, 8 (47%) 
achieved SD, and 8 (47%) had progressive disease. 
The disease control rate was 53% and the median 
progression-free survival was 3months (range from 
1month to 29months). The median overall survival 
from the beginning of the Àrst geÀtinib were 
32months (range from 11months to 51months). The 
median overall survival from the beginning of the 
2nd geÀtinib were 11months(range from 5months 
to 40months). The toxicities associated with the 2nd 
geÀtinib were mild. 
Conclusion: Our results indicate that patients with 
NSCLC adenocarcimona may still be expected to 
have prolonged survival if they once responded 
to geÀtinib and then received different treatments 
followed by readministration of geÀtinib.
Keyword: geÀtinb; NSCLC; adenocarcinoma; 
readministration
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P3.189 PHASE II RANDOMIZED, 
OPEN-LABEL STUDY OF CETUXIMAB 
(CET) AND BEVACIZUMAB (BEV) IN 
COMBINATION WITH PACLITAXEL (P) 
AND CARBOPLATIN (C) IN PATIENTS 
WITH STAGE IIIB/IV NON-SMALL CELL 
LUNG CANCER (NSCLC)
Philip Bonomi1, Joseph Mace2, Romeo Mandana3, 
Myo Min4, Olsen Mark5, Hagop YoussouÀan6, Terry 
Katz6, Lorinda Simms7, Hyun Jung Lee8 
1Oncology, Rush University Medical Center/United 
States Of America, 2Gulfcoast Oncology Associates/
United States Of America, 3Integris Cancer Institute 
Of Oklahoma/United States Of America, 4Maryland 
Hematology Oncology Associates/United States Of 
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loss (p<0.0001) were signiÀcantly associated with 
survival, but symptomatic comorbidity score, age  
70, gender, pathological subtype and year of cohort 
were not. For PS2 patients the median survival was 
7.2m and 1 year overall survival 31%. These results 
are comparable to published prospective clinical 
trials. 
Conclusion: There has been a clear increase in 
the use of systemic palliative chemotherapy for 
NSCLC in Northern Ireland. The biggest increase 
has been in patients with poorer performance status 
(PS2), followed by elderly patients and patients 
with signiÀcant comorbidities. Such patients may 
previously have been excluded from chemotherapy 
but recent evidence has given increasing conÀdence 
that they can be treated effectively and safely. The 
outcomes of patients treated in Northern Ireland 
compare favourably to published literature standards. 
Keywords: NSCLC, Chemotherapy
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Background: Erlotinib is a tyrosine-kinase inhibitor 
(TKI) used for the treatment of patients with non 
small cell lung cancer (NSCLC) in Czech Republic 
since 2005. Wide use of erlotinib in patients with 
NSCLC enables to collect a robust data in Czech 
Tarceva patients registry, where are recorded all 
the patients treated with erlotinib in 10 centers 
of excellence in Czech Rep. Objective of this 
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IN NSCLC PATIENTS IN NORTHERN 
IRELAND BETWEEN 2004 AND 2007
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Background: Systemic anti-cancer chemotherapy 
(SACT) is recommended for patients of good 
performance status (PS) with advanced or metastatic 
non-small-cell lung cancer (NSCLC). The literature 
supports the use of SACT for selected PS2 patients 
to improve quality of life. We reviewed all patients 
with NSCLC treated with Àrst-line SACT in 
Northern Ireland from 2004-2007 demonstrating 
a year on year increase in the number of patients 
treated mainly due to increasing treatment of patients 
with PS=2. 
Methods: The patient records of all patients with 
NSCLC referred to oncology services in Northern 
Ireland from 2004 to 2007 were retrospectively 
reviewed; patients treated with Àrst-line SACT 
were selected for analysis. Clinical characteristics 
including patient age, sex, tumour type, PS, smoking 
history, weight loss and comorbities were reviewed. 
Kaplan Meier survival curves with 95% conÀdence 
intervals were generated for the whole study 
population and patients with PS=2. Median survival 
from the time of Àrst chemotherapy and 1 year 
overall survival times were calculated and compared 
to literature standards. 
Results: 434 patients with NSCLC were treated 
with Àrst-line SACT in Northern Ireland from 2004 
to 2007. The numbers of patients treated were 78 
in 2004, 100 in 2005, 108 in 2006 and 148 in 2007. 
This corresponded to an increase in the percentage 
of all NSCLC patients from 15% in 2004 to 27% in 
2007. A rise in the number of patients treated with 
poorer PS was the greatest factor driving the increase 
in SACT use, with PS 2 patients numbers increasing 
from 18 in 2004 (23.1% of treated patients) to 51 
in 2007 (34.4% of treated patients). The median 
survival time of the study population was 8.3 months 
with 1 year overall survival of 35%. On univariate 
analysis PS (p<0.0001), stage (p=0.004) and weight 
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chemotherapy improves outcomes in pts with 
advanced or recurrent NSCLC, as proven in two 
pivotal phase III trials (E4599 and AVAiL).This 
multicentric, single-arm study aimed to further 
assess the efÀcacy and safety proÀle of Àrst-line 
bevaizumab -based therapy in unresectable NSCLC
Methods: Between 2008 to 2010 Inoperable 
non-squamous NSCLC with ECOG PS 0;2, life 
expectancy 40 years;3 months and adequate 
bone marrow, hepatic and renal function were 
enrolled in the study with informed consent. The 
dosing regime was bevaizumab 7.5 mg/kg plus 
chemotherapy for up to 6 cycles,followed by 
sequential local radiotherapy with 60 Gy in 30 
fractions with 3DCRT followed by single-agent 
bevaizumab until progression. Exclusion criteria 
included evidence of CNS metastases, even if 
previously treated, major blood vessel invasion, 
haemoptysis (MORE than;2.5mL red blood), history 
of coagulation disorders, uncontrolled hypertension, 
clinically signiÀcant cardiovascular disease and 
gastrointestinal perforation within 6 months of 
enrolment. Primary endpoint was safety; secondary 
endpoints included TTP and OS
Results: The intent-to-treat population (n=14) was: 
male 8, female 6; mean age 56 years; past or active 
smokers 6; stage IV disease 9/14. Median number of 
bevaizumab cycles was 9, with 12/14 of pts receiving 
;7 Bv cycles. Incidence of clinically signiÀcant 
adverse events (AEs) was low. 11/14 pts had an 
AE of special interest of any grade (G), the most 
common being G ;2 proteinuria (4/14) and epistaxis 
(3/14). AEs of special interest were reported in only 
1/14 of pts and included proteinuria, hypertension 
, epistaxis . Only one G 1 CNS bleeding events 
were reported, among the 2 pts who developed CNS 
metastases during therapy. No G ;3 wound-healing 
complications or congestive heart failure events were 
reported. Bevaizumab was infrequently interrupted 
due to AEs in 4/14 patients. EfÀcacy outcomes were 
remarkable: overall response in 12/14; median TTP 
8.3 months; median OS 18.9 months
Conclusion: The safety and remarkable efÀcacy of 
Àrst-line bevaizumab plus chemotherapy followed 
with local RT was conÀrmed in this small pilot 
trial with advanced non-squamous NSCLC. These 
Àndings are consistent with those of the overall 
population in the pivotal phase III trials, E4599 and 
AVAiL. No new safety signals were reported in this 
analysis.
Keywords: NSCLC, Advanced, bevacizumab, Non-
squamous
retrospective analysis is to compare treatment 
efÀcacy in the subgroup of patients outside the 
clinical studies and try to Ànd factors inÁuencing the 
treatment effect.
Methods: Retrospective analysis of all data 
from the Tarceva registry was performed. In this 
analysis, the inÁuence of particular clinical factors 
on the treatment results and the survival data were 
evaluated.
Results: : In total, the complete data of 1735 patients 
(median age 65 years; 64,4% women and 35,6% 
men; 21,6% nonsmokers, 39,5% stop-smokers and 
38,9% current smokers; 63,9% PS 0/1, 36,1% PS 
2/3) were available at the date of evaluation (19 
January, 2011). The most frequent histological types 
were adenocarcinoma (42,3%) and squamous cell 
carcinoma (39,2%). Highly signiÀcant (p < 0,001) 
correlations in treatment outcomes determined 
using Pearson Chi-square test were found in all the 
evaluated clinical factors, such as gender, occurrence 
of treatment adverse effect generally and rush in 
particular, smoking status and performance status. 
Surprisingly, the histological type was found as 
the weakest, however still signiÀcant predictor of 
treatment response (p = 0,046) with mOS – p = 0,016 
and mPFS – p = 0,082).
Conclusion: The analysis of a non-selected group 
of NSCLC patients treated with erlotinib in real 
life practice showed the most powerful factors 
inÁuencing the treatment results and survival. In 
our group, the general clinical factors were more 
powerful predictors of the result of treatment as the 
histological type of tumor. In global picture of these 
results we have to bare in mind, that all the clinical 
factors that we have evaluated are considered much 
more prognostic than predictive factors.
Keywords: NSCLC, erlotinib, clinical predictors
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Background: First line bevaizumab plus 
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the carboplatin-paclitaxel combination (11.4%), 
vinorelbine (8.6%), and gemcitabine (5.7%). The 
performance status (PS) was 0-1 in 91.7%, and there 
was a predominance of adenocarcinoma hystologic 
subtype (65.7%). Only 12.5% were never-smokers 
and 57.1% had a history of weight lost. The disease 
stage at presentation, according to AJCC 6th edition 
was: I-IIIB 11.4% and wet IIIB-IV 88.6%. Of 
note, none of these characteristics was statistically 
different from the subgroup that was not treated 
beyond second-line treatment in comparison to the 
best supportive care (BSC) group. Patients receiving 
third-line or greater were signiÀcantly younger, 
with median age 58 years vs. 64 years, respectively 
(p=0.016). Notably, median overall survival for 
patients receiving third-line cytotoxic treatment 
and greater compared to BSC was 22.7 (95% CI, 
15.8-29.5) months vs. 9 (95% CI, 7.6-10.5) months, 
respectively (p=0.002).
Conclusion: This retrospective study identiÀed 
a subgroup of patients that was treated outside of 
predeÀned guidelines. The wide array of cytotoxic 
treatment utilized in third-line and beyond betrays 
a lack of pattern in the therapy selection. There was 
a small group of remarkably long-lived survivors, 
despite no major clinical differences from patients 
receiving BSC. The association of this survival with 
chemotherapy requires further evaluation.
Keywords: Advanced Non-Small Cell Lung Cancer, 
third-line treatment, Chemotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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TKI VERSES CHEMOTHERAPY FOR 
NSCLC PATIENTS BY DIFFERENT 
SELECTIONS.
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Background: EGFR TKI has been the most 
perspective treatment in advanced non-small cell 
lung cancer in the past ten years. Several clinical 
trials have shown geÀtinib and erlotinib is not as 
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Background: Despite recent advances in non-small 
cell lung cancer (NSCLC) treatment, so far there 
are only three approved lines for clinical use and 
no third-line cytotoxic drug considered standard of 
care. To date, there is limited clinical data suggesting 
survival beneÀt for third-line cytotoxic treatment 
and beyond. Therefore, the treatment choice in this 
setting has been a matter of individual decision. This 
retrospective study reports the clinical characteristics 
and outcome for cytotoxic treatment administered in 
third-line and beyond in a real-world scenario of a 
developing country.
Methods: Medical charts from patients with 
metastatic NSCLC treated between 1999 to 
2010 in a private oncology center in Brazil, were 
retrospectively reviewed. Patients with documented 
exposure to third-line and beyond cytotoxic 
treatment were identiÀed and followed. The aim was 
to assess the clinical features and survival of this 
subgroup and compare them to the subgroup that did 
not receive cytotoxic therapy beyond second-line. 
Patients were excluded if there was insufÀcient data. 
Statistical analyses were performed using the SPSS 
17.0 software.
Results: Two hundred thirty-nine patients presenting 
with advanced disease were included. Thirty-Àve 
patients (14.6%) received third-line, 14 patients 
(5.8%) received fourth-line and 5 patients (2.1%) 
received Àfth-line treatment. Most common 
cytotoxic treatments administered in third to Àfth 
line were: pemetrexed (31.4%), docetaxel (25.7%), 
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the TKI is not superior to the chemotherapy. When 
choose the patients with clinical characters the ORR 
of TKI is better than the chemotherapy, thouth the 1 
year survival is similar. For EGFR mutation patients 
the ORR, DCR and 1 year survival is better than 
chemotherapy signiÀcantly.
Keywords: Chemorherapy, target therapy, EGFR 
mutation
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Background: GeÀtinib and Erlotinib, epidermal 
growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKI) are increasingly used for the treatment 
of metastatic non-small cell lung cancer. Diarrhoea 
is the second most common side effect of EGFR-
TKI. In the ISEL and BR-21 studies, GeÀtinib and 
Erlotinib were respectively responsible for 27 and 
55% of diarrhoea, all National Cancer Institute 
Common Toxicity Criteria grades combined (1,2). 
Reduction in EGFR-TKI dosage is an option when 
diarrhoea does not improve with symptomatic 
treatment, yet carries the risk of decreased efÀcacy 
of anti-cancer therapy. In the BR-21 study, which 
led to Erlotinib approval, diarrhoea was the second 
most frequent cause of dose reduction (5%) and 
treatment interruption (6%). Certain patients can 
be prescribed with EGFR-TKI for a year or even 
longer. For patients facing the prospect of long-term 
EGFR-TKI therapy, poor tolerance can signiÀcantly 
alter quality of life. Yamaguchi et al. demonstrated 
that certain platelet-related factors were elevated 
in Japanese patients receiving geÀtinib, postulating 
that certain geÀtinib toxicities could be related to 
platelet activation (3). In 2006, Kanazawa et al. 
hypothesized that aspirin could decrease toxicity 
induced by EGFR-TKI (4). In a prospective non-
controlled study, they report a decrease in global 
(skin and digestive) geÀtinib-induced toxicity when 
adding low-dose aspirin to geÀtinib treatment. To our 
knowledge, no other experimental study has been 
good as the chemotherapy in all the NSCLC patients. 
Some trials treated the patients with TKI according 
to the clinical characters such as pathological type, 
gender, smoking history or ethnicity. A few studies 
chose only EGFR mutation patients for TKI therapy. 
We want to Ànd out how to select the proper patients 
for TKI or chemotherapy.
Methods: We did a meta-analysis of all randomized 
controlled trials involving patients with advanced 
NSCLC treated with chemotherapy or TKI by 
different selections. EfÀcacy outcomes of interest 
were objective response rate (ORR), disease control 
rate (DCR) based on the Response Evaluation 
Criteria in Solid Tumors (RECIST) and 1 year 
survival of each treatment arm.
Results: 
12 randomized studies comparing chemotherapy 
versus TKI in advanced non-small cell lung cancer 
were selected. 8 trials enrolled NSCLC patients 
without selection and randomized to receive TKI or 
chemotherapy. Two trials selected patients by clinical 
selection of gender and smoking history in Eastern 
Asia. Three trials chose EGFR mutation patients 
for TKI or chemotherapy randomizely. By different 
selections the RR of ORR was .8(9%CI .66-.) of 
without selection, .76(9%CI .67-.86) of clinical 
selection favor TKI and .(9%CI .6-.6) of mutation 
selection favor TKI, respectively.The RR of DCR 
was .(9%CI .9-.8) of without selection, not available 
of clinical selection and .9(9%CI .8-.97) of mutation 
selection favor TKI, respectively. The RR of year 
survival was .8(9%CI .97-.) of without selection, 
.96(9%CI .9-.) of clinical selection and .76(9%CI 
.9-.97) of mutation selection favor TKI, respectively. 
Table 1 Characters of the eligible trials 
Author Year Pts Treatment Arm Control Arm 
Without Selection 
Cufer, T. (SIGN) 2006 141 Ge¿tinib Docetaxel 
Maruyama, R. (V-15-32) 2008 490 Ge¿tinib Docetaxel 
Lilenbaum, R. 2008 103 Erlotinib Paclitaxel+ Carboplatin 
Crino, L. (INVITE) 2008 196 Ge¿tinib Vinorelbine 
Kim, E. S. (INTEREST) 2008 1466 Ge¿tinib Docetaxel 
Lee, D. H. (ISTANA) 2010 161 Ge¿tinib Docetaxel 
Vamvakas, L. 2010 327 Erlotinib Pemetrexed 
Agarwal, S. 2010 35 Ge¿tinib Gemcitabine+Carboplatin 
Clinical Selection 
Lee, J.S. (First-SIGNAL) 2009 309 Ge¿tinib Gemcitabine+Cisplatin 
Mok, T.S. (IPASS) 2009 1217 Ge¿tinib Paclitaxel+ Carboplatin 
Molecular Selection 
Mitsudomi, T. (WJTOG3405) 2010 177 Ge¿tinib Docetaxel+Cisplatin 
Maemondo, M. (NEJSG) 2010 230 Ge¿tinib Paclitaxel+ Carboplatin 
Conclusion: For NSCLC patient without selection 
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Background: Erlotinib is an orally available, 
potent, selective and reversible inhibitor of EGFR 
TK activity, providing signiÀcant survival beneÀts 
as monotherapy for the treatment of patients 
with locally advanced or metastatic non-small-
cell carcinoma (NSCLC), after failure of at least 
one previous chemotherapy regimen. The results 
reporting the general practice use of erlotinib 
(TRUST study), superimposed to those obtained 
in the pivotal BR.21 study; in this trial, clinical 
predictors of response included adenocarcinoma 
histology, even though erlotinib had a signiÀcant 
effect on overall survival (OS) in all subgroups of 
patients. Here it is reported the efÀcacy of erlotinib 
in the 2nd line of patients with non-squamous cell 
carcinoma in a clinical practice setting. 
Methods: Unselected patients with advanced 
NSCLC and non-squamous histology were treated 
with 150 mg/day of erlotinib as 2nd line therapy 
until unacceptable toxicity or progressive disease 
in 4 Galician institutions. Primary endpoint is 
progression-free survival (PFS), and the sample size 
of the study is 70 patients. 
Results: At the time of the analysis, 31 patients were 
included in the dataset. Baseline characteristics: 
median age: 61.9 yrs. (range: 38-81); 75% male; 
68% adenocarcinoma; 78.4% stage IV; 71.4% 
performance status ECOG 0-1. Amongst evaluable 
patients, ORR was 19.2% (95% CI: 5.5-33.7), and 
the disease-control rate 46.1% (95% CI: 21.9-57.8). 
With a median follow-up of 5.9 months, median PFS 
was 5.3 months (95% CI: 2.6-8.0), for a remarkable 
median OS of 10.3 months (95% CI: 7.7-13.0) 
Toxicity was mild and manageable: 39.3% patients 
experienced grade 1/2 cutaneous toxicity; 14.3% 
asthenia and anaemia. 4 patients developed grade 
3/4 adverse events (rash, diarrhoea and asthenia). 
3 patients transiently interrupted the therapy, while 
5 patients underwent dose reduction. No patient 
needed drug discontinuation. 
Conclusion: Data reported from this study on 
unselected patients with advanced NSCLC and non-
squamous cell carcinoma conÀrm the efÀcacy and 
safety of 2nd line erlotinib in routine practice, with 
a remarkable OS above 10 months. The study is 
ongoing and the analysis will be updated, including 
a higher number of patients. EGFR mutations are 
currently well established positive predictive factor 
for EGFR efÀcacy. Data from the mutational status 
of the patients will be also presented. 
Keywords: Non-Small-Cell Lung Cancer, EGFR-
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published in the English literature on the possible 
decrease in EGFR-TKI-induced diarrhoea with 
aspirin. 
Methods: This is a non controlled prospective study.
Results: 
Age/Sex 
(year-old) 
EGFR 
status of 
the tumour 
TKI/dosage
(mg/day) 
Length of 
treatment with 
EGFR-TKI 
(months) 
Diarrhoea 
grade before 
aspirin 
Diarrhoea 
grade with 
aspirin 
77/Female Mutated Erlotinib / 100 9 Grade 2 to 3 Grade 0 to 1 
91/Female Mutated Ge¿tinib / 250 0.5 Grade 1 Grade 0 
54/Female Mutated Erlotinib / 50 10 Grade 2 to 3 Grade 0 
71/Female Mutated Erlotinib / 125 6 Grade 1 to 2 Grade 0 
74/Female Mutated Erlotinib / 100 18 Grade 2 to 3 Grade 0 
71/Female Non 
mutated 
Erlotinib / 150 1 Grade 1 Grade 0 
78/Female Mutated Erlotinib / 100 23 Grade 1 to 2 Grade 0 
Conclusion: According to our experience, although 
limited to seven consecutive Caucasian patients 
who experienced grade 1 to 3 EGFR-TKI-induced 
diarrhoea, despite adequate use of anti-diarrhoeal 
drugs, introduction of aspirin (75 mg/d) induced 
a dramatic, rapid and sustained improvement. A 
randomised controlled study is required in order 
to conÀrm that low dose aspirin improves TKI-
EGFR-induced diarrhoea without decreasing its anti-
cancer efÀcacy. References Thatcher et al. Lancet 
2005;366:1527-37. Shepherd F et al. New Engl J 
Med 2005;353:123-32. Yamaguchi K et al. J Clin 
Oncol 2005 ;23 (Suppl) :244s. Kanazawa S et al. 
Anti-Cancer Drugs 2006;17:423-7. 
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to erlotinib: 12.1% had a partial remission (PR), 
40.7% showed stable disease – SD (disease control 
rate of 51.8%) and 47.2% experienced progressive 
disease.Response rate among EGFR-positive 
patients: 15.0% had PR, 50.0% showed SD (disease 
control rate of 65.0%) and 35.0% experienced PD. 
The response to erlotinib among EGFR-positive 
patients was associated with better control of the 
disease (OR 1.651, 95% CI 0.566 to 4.817) versus 
EGFR-negative patients. The estimated survival after 
erlotinib in EGFR-positive versus EGFR-negative 
patients was 14 and 6 months respectively (p = 
0.003). 
Conclusion: Our study demonstrates that the 
presence of EGFR mutation is associated with better 
overall survival (prognostic factor independent of 
therapy) and better response to erlotinib (predictive 
factor of response)
Thus, since January 2010, determining the EGFR 
mutation status has become a routine test in all 
patients with NSCLC in our unit. 
Keywords: erlotinib, Non-small cell lung cancer, 
EGFR, mutational status
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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DAILY LIVING AND HEALTH RELATED 
QUALITY OF LIFE.
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Background: Health Related Quality of Life 
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Background: Erlotinib is a tyrosine kinase inhibitor 
approved as second and third-line therapy in 
advanced NSCLC. This target molecule has shown 
an impact on median survival and quality of life. 
There are factors that predict a better response to 
erlotinib and include: female gender, Asian ethnicity, 
adenocarcinoma histology, non-smoking status and 
mutational status (MS) of epidermal growth factor 
receptor (EGFR).
Methods: Analysis of an observational study 
was performed in patients that received erlotinib 
as second and third-line therapy between 2006 
and 2010. Parameters: age, sex, smoking habits, 
histologic type, TNM stage at presentation, prior 
chemotherapy regimens, mutational status and 
overall survival according to MS. Assessment of 
response to erlotinib and survival according to MS.
Results: A total of 104 patients were enrolled, 57 
(54.8%) males and 47 (45.2%) females. Forty-
eight (46.2%) were non-smokers, 31 (29.8%) ex-
smokers and 25 (24.0%) smokers. Mean age of 
67.2 ± 12.8 yrs. Histologic types: adenocarcinoma 
in 66 (63.5%) patients, squamous in 18 (17.3%) 
and undifferentiated carcinoma in 20 (19.2%). We 
found 43 (41.3%) patients in stage III, 52 (50.0%) in 
stage IV and the remaining 9 (8.6%) in early stages 
at diagnosis. Àrst-line chemotherapy regimens used 
were platinum + gemcitabine (51.0%), platinum + 
vinorelbine (11.5%), platinum + paclitaxel (11.5%) 
and platinum + pemetrexed (8.6 %). In patients in 
whom erlotinib was third-line therapy, second line 
regimens most commonly used were: pemetrexed 
(61.1%) and taxotere (30.6%). EGFR mutation was 
performed in 82 patients and was positive in 22 cases 
(26.8%). In assessing the overall survival (excluding 
patients in early stage and IIIA), the EGFR-positive 
vs negative patients had an overall survival of 47 vs 
22 months respectively (p = 0.038). Response rate 
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Vesela3 
1Oncology, Specialized Hospital Of St.zoerardus 
Zobor, Nitra/Slovak Republic, 2Slovak Medical 
University, University Hospital, Bratislava/Slovak 
Republic, 3University Hospital, Bratislava/Slovak 
Republic, 4Hospital, Bojnice/Slovak Republic, 
5University Hospital/Slovak Republic, 6Faculty 
Hospital, Banska Bystrica/Slovak Republic, 7Faculty 
Hospital, Trnava/Slovak Republic
Background: There are only limited data about 
the effectiveness of the second and further lines of 
therapy in patients with advanced non-squamous 
NSCLC (NSQ NSCLC) after failure of Àrst line 
chemotherapy with bevacizumab. Chemotherapy 
and EGFR TK inhibitors have been used commonly 
in practice, however, without any phase III trial 
aimed speciÀcally on advanced metastatic NSCLC 
pretreated with bevacizumab. Purpose of this study 
was to evaluate the second and further lines of 
therapy in this group of patients.
Methods: Patients with advanced metastatic NSQ 
NSCLC treated with the Àrst line chemotherapy and 
bevacizumab between July 2007 and March 2010, 
and with further systemic therapy due to disease 
progression were eligible for this retrospective study.
Results: Altogether 39 patients were included (male/
female: 19/20, median age: 56 yrs, range: 33–76). 
EGFR TK inhibitor was used in the second line 
treatment in 22 patients (erlotinib: 21, geÀtinib: 1), 
chemotherapy was used in 17 patients (pemetrexed: 
13, docetaxel: 2, gemcitabine and carboplatin: 
2). Response rate: PR: 5% (95%CI: 1–17), SD: 
51% (95%CI: 36–66), PD: 44% (95%CI: 29–59). 
Progression free survival (PFS) in 39 patients – 
median: 3 months (95%CI: 1.5–4). Estimated overall 
survival (OS) – median: 5 months. There was no 
difference in the PFS or OS between the patients 
treated with EGFR TK inhibitor or chemotherapy in 
the second line. EGFR mutation status was unknown 
in 20 patients and known (positive for sensitizing 
mutations) in 2 patients. These 2 patients achieved 
PFS 16 and 10+ months. Third line chemotherapy 
was administered in 17/32 patients with PD after 
the second line treatment. Erlotinib was used after 
the previous chemotherapy most often – in 9/11 
patients. Docetaxel or pemetrexed were used after 
the 2nd line EGFR TK inhibitor in 4/6 patients, 
other chemotherapeutics in 2 patients. There was 
an impressive difference in OS (from the start of 
the 2nd line therapy) between the patients in which 
(HRQoL) in oncology patients is directly related to 
symptoms. The aim of the study was to assess the 
impact on daily living and HRQoL of the symptoms 
of advanced non-small cell lung cancer (NSCLC). 
Methods: An observational prospective study was 
carried out in 32 Spanish institutions, and included 
257 patients. Patients had stage IIIB NSCLC with 
pleural or pericardial effusion or stage IV NSCLC 
and were about to initiate second-line treatment 
at the time for enrolment. HRQoL and disease-
related symptoms were assessed with the lung-
speciÀc Functional Assessment of Cancer Therapy 
questionnaire (FACT-L) and the Lung Cancer 
Symptom Scale (LCSS), respectively. An ad hoc 
speciÀc questionnaire correlating the impact of 
NSCLC symptoms on daily life was also evaluated.
Results: Preliminary baseline data for 257 patients 
are presented; 56,4% had adenocarcinoma and 
23.7% squamous cell carcinoma; the median 
(SD) age was 65.0 (10.0) years; 79.4% were 
males, 96.5% Caucasian, and 83.5% current/ever 
smokers. ECOG performance status was 0/1/2/3: 
15.2%/56.4%/21.8%/5.4%. At the basal visit the 
mean (SD) LCSS score was 34.2 (19.0) points and 
the mean (SD) FACT-L score (SD) was 80.9 (23.2) 
points. Patients who discontinued the therapy or 
experienced progressive disease showed a signiÀcant 
worsening of symptoms. Impact of LC symptoms 
on daily life shows a high correlation with HRQoL 
assessed according to FACT-L questionnaire 
(r=0.82). 
Conclusion: The presence of symptoms and their 
impact on the daily life was related with a major 
impact on HRQoL. Final analysis showing the QoL 
and symptoms of patients and the correlation with 
second line therapy will be presented. 
Keywords: NSCLC-related symptoms, Health 
Related Quality of Life, Non-Small-Cell Lung 
Cancer, Second line treatment
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P3.199 SECOND AND FURTHER LINES 
OF THERAPY IN ADVANCED NSCLC 
AFTER FAILURE OF CHEMOTHERAPY 
WITH BEVACIZUMAB – A 
RETROSPECTIVE STUDY.
Peter Berzinec1, Maria Cerna2, Peter Kasan3, 
Gabriela Chowaniecova1, Iveta Jancokova4, Elena 
Kavcova5, Iveta Kuliskova5, Marian Martak3, Juraj 
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presentation approaching 70, many patients are well 
into their 8th decade and are less tolerant of the many 
side effects of cytotoxic drugs. Furthermore, given 
the prevalence of signiÀcant, often smoking related 
co-morbidities many patients are not candidates 
for such treatment. We set out to ascertain what 
proportion of stage IV NSCLC patients received 
palliative systemic chemotherapy at our institution. 
For the remaining patients, we determined which 
of the above mentioned factors contributed to the 
decision not to treat systemically. 
Methods: After ethical approval was obtained, 
demographic details, clinical variables and outcome 
data were gathered on patients diagnosed at the 
Tom Baker Cancer Centre (TBCC) from 2003 to 
2006 using the Glans-Look Lung Cancer Database. 
Treatment modalities delivered (cytotoxic treatment, 
anti-epidermal growth factor receptor (EGFR) 
treatment, palliative radiation, etc) were documented. 
Charts were reviewed to ascertain reasons for choice 
of treatment. Statistical analysis was performed using 
the Kaplan-Meier method, multivariate analysis and 
Spearman’s rank correlation. 
Results: 832 patients were diagnosed with stage 
IV NSCLC at the TBCC in 2003-2006. While the 
majority (72.1%) received palliative radiation, only 
23.3% received systemic treatment while 18% 
received no palliative treatment at all. The proportion 
who received systemic treatment was related to age 
with 46% of the under 50yr old group receiving 
systemic treatment vs 17% for the 70-80yr and 3% 
for the over 80 age group. Palliative radiation was 
not associated with a survival beneÀt. However, 
MOS of those who received systemic treatment was 
11.2 vs 2.9 months for those who received none. 
MOS improved with additional lines of treatment: 
8.6 vs. 14.4 vs. 27.7 months for 1st line, 2nd line and 
3rd line of systemic treatment respectively. 
Conclusion: The proportion of patients who receive 
systemic treatment for metastatic NSCLC is low, 
and likely a result of poor performance status, 
advanced age and multiple co-morbidities. However, 
for patients at our institution who were well enough 
to receive systemic therapy, MOS approached 12 
months, comparable to Phase III trials. Clearly, 
new strategies are needed to increase the uptake of 
systemic treatment in metastatic NSCLC. Detailed 
analysis of reasons for not receiving systemic 
chemotherapy will be presented. 
Keywords: Metastatic Disease, Non small cell lung 
cancer, Chemotherapy
it was possible to administer the third line therapy 
comparing with those without further therapy – 
MST (median survival time): not reached yet, but 
will be over 9 months vs 1.5 months. Fourth line 
treatment was administered in 6/12 patients with 
the PD after the 3rd line therapy. MST in the group 
with vs without the 4th line therapy was 13 vs 6.5 
months. Two patients received 5th line chemotherapy 
(oral vinorelbine or etoposide), OS is 30+ and 18+ 
months in these patients. There were no unexpected 
toxicities or serious adverse events (excluding those 
connected with the NSCLC PD) in the whole group 
of 39 patients.
Conclusion: Second and further lines of systemic 
therapies may improve survival of patients with 
NSCLC PD after the Àrst line chemotherapy and 
bevacizumab. Choosing the right time for these 
therapies, i.e. starting treatment in time without any 
unneeded delays seems to be one of the key issues. 
Keywords: Chemotherapy, NSCLC, bevacizumab, 
second line
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P3.200 DELIVERY OF SYSTEMIC 
TREATMENT IN CASES OF 
METASTATIC NON SMALL CELL LUNG 
CANCER AT A SINGLE CANADIAN 
INSTITUTION
Kate Skolnik, Shannon Otsuka, Don Morris, Desiree 
Hao, Dafydd G. Bebb 
Medicine, University Of Calgary/tom Baker Cancer 
Centre/Canada
Background: Despite many innovations in treatment 
and increased emphasis on prevention with smoking 
cessation programs, lung cancer continues to cause 
extensive morbidity and mortality worldwide. Most 
patients present with advanced unresectable disease 
and are candidates only for palliative treatment. 
Since the late 1990s, platin based doublets have been 
the mainstay of palliative chemotherapy regimens for 
metastatic disease and are associated with a 10-12 
month median overall survival (MOS) in phase III 
clinical trials. However, the toxicity associated with 
cytotoxic chemotherapy can adversely affect quality 
of life limiting the applicability of such treatments 
to the general NSCLC population. In addition, 
poor performance status patients do not necessarily 
beneÀt from such treatment. With a median age at 
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m2 is well-tolerated in heavily pretreated NSCLC 
patients and demonstrates encouraging preliminary 
clinical activity. References Chang A, Boros L, 
Asburg R et al. Weekly moderate-dose paclitaxel (P) 
in stage IV non-small cell lung cancer (NSCLC). 
Proc Am Soc Clin Oncol 1998;17:420a. 
Keywords: NSCLC, 3rd and 4th line therapy, 
Weekly paclitaxel
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.202 NUTRITIONAL PARAMETERS 
IMPROVE SURVIVAL OF PATIENTS 
WITH ADVANCED NON-SMALL 
CELL LUNG CANCER DURING 
CHEMOTHERAPY TREATMENT.
Karla Sanchez, Jenny Turcott, Eva Juarez, Geraldine 
Villanueva, Yuzmiren Dorantes, Montserrat 
Garralda, Oscar Arrieta 
Oncologia Medica, Instituto Nacional De 
Cancerologia/Mexico
Background: Lung cancer is one of the most 
common type of cancer worldwide and is the leading 
cause of cancer death. Malnutrition is frequent in 
patients with non small cell lung cancer (NSCLC). 
Early identiÀcation and treatment of nutritional 
deÀciencies can lead to improved outcomes 
including survival. Non invasive techniques are 
needed to evaluate changes in body composition, 
nutritional status and prognosis in these patients. The 
aim of the study was to investigate the prognostic 
role of nutritional parameters in advanced non 
small lung cancer (NSCLC) patients under Àrst line 
chemotherapy
Methods: 119 advanced NSCLC patients naive to 
treatment were included prospectively, anthropometric 
and biochemical like serum albumin level, platelets/
lymphocytes index (P/L), body mass index (BMI) 
and bioelectrical impedance analysis (BIA) including 
phase angle was obtained; Overall Survival was 
calculated with Kaplan Meier method and Cox 
proportional hazard models were constructed to 
evaluate multivariate prognostic effect.
Results: 55 females and 64 males were included, 
mean age was 60.5±12.5 years, IMC =24.8±4.5mg/
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P3.201 WEEKLY PACLITAXEL APPEARS 
ACTIVE AND WELL-TOLERATED IN 
THIRD AND FOURTH-LINE ADVANCED 
NSCLC PATIENTS
Alison Reid, Tom S. Waddell, KoÀ Nimako, David 
Tan, Iannis Xynos, Sanjay Popat, Mary E.R. O’Brien 
Lung Unit, Royal Marsden NHS Foundation Trust/
United Kingdom
Background: Weekly paclitaxel has been evaluated 
in Phase II studies in second-line metastatic NSCLC 
(Chang, 1998) but not widely in the third and fourth-
line setting. The aim of this study was to evaluate 
the activity and toxicity of single-agent paclitaxel 
administered weekly to heavily pretreated patients 
with non-small cell lung cancer (NSCLC). 
Methods: Patients with Stage IV NSCLC who 
have received  2 prior lines of therapy are eligible. 
Patients receive paclitaxel (60-80mg/m2) delivered 
for 3 consecutive weeks on a 4-week cycle. CT scans 
are performed every 2 cycles. Patient data is collated 
from the Royal Marsden NHS Foundation Trust 
electronic patient record. The null hypothesis will be 
rejected if  3/20 (15%) RECIST responses are seen. 
Results: To date, 12 patients (median age 65 years; 
range, 47-73) have commenced treatment. Patient 
demographics including gender, NSCLC histological 
subtype, ECOG performance status and lines of prior 
treatment are detailed in Table 1. No patient to date 
has had an EGFR mutation although all patients have 
received prior erlotinib. Five patients have had a CT 
scan after 2 cycles (8 weeks of treatment) with 2/ 5 
achieving a PR (in both these patients the response 
has been conÀrmed with a second CT scan after a 
further 2 cycles). No Grade 3/4 toxicities have been 
reported to date. 10 patients continue on treatment at 
present. 
Conclusion: Single agent paclitaxel administered on 
3 consecutive weeks out of 4 at a dose of 60-80mg/ 
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Background: Recent technological advances in 
the form of Whole Genome Sequencing (WGS) 
technologies now provide us with platforms to 
interrogate entire human genomes at a fraction of 
the time and cost compared to more traditional 
sequencing technologies. For the Àrst time, next-
generation sequencing (NGS) offer us the ability 
to survey the global somatic landscape of cancer. It 
is now possible with NGS to re-sequence, analyze, 
and compare the matched normal and tumor genes 
of an individual patient’s entire genome. As part of 
a prospective pilot study at our institution, we report 
the results of WGS of paired normal and tumor 
specimens collected from a female never smoker 
with advanced adenocarinoma of the lung.
Methods: After informed signed consent and 
conÀrmation of study eligibility (KPS  80, adequate 
renal, hepatic, and hematologic labs, advanced 
incurable cancer progressed on  1 prior systemic 
therapy), a CT guided biopsy of a lung metastasis 
and whole blood was collected for WGS analysis 
on the Illumina HiSeq2000 system. Data compiled 
will include somatic coding point mutations 
and frameshift mutations including mutations 
in important domains or motifs (kinase, ligand 
binding, etc), genes mapping within focal high level 
amplicons or homozygous deletions, genes involved 
in translocations/fusions, rank order of expressed 
genes, and/or germline mutations or SNPs involved 
in drug metabolism. RNA sequencing of these 
specimens is also ongoing.
Results: A 61 year old woman initially presenting 
with stage 4 adenocarinoma of the lung, was 
previously treated with the following regimens: 
carboplatin and paclitaxel, pemetrexed, and erlotinib. 
After progressing on erlotinib, she underwent a 
lung tumor biopsy and whole blood collection. 
NGS began the Àrst week of January 2011 and as 
of January 31, 2011, a minimum of 23X genome 
coverage on both normal and tumor samples was 
completed. Preliminary results show a TP53 somatic 
mutation, and the absence of EGFR and KRAS 
mutations and EML4/ALK translocation. RNA 
sequencing is in process. Analysis is ongoing and 
Ànal results will be presented at the meeting.
Conclusion: In the Àrst prospective NGS pilot 
study for advanced cancer patients, we successfully 
completed WGS of a paired normal and tumor 
sample in non-small cell lung cancer. With improved 
infrastructure and decreased costs, we anticipate 
that WGS using NGS techniques will become more 
commonplace and has the potential to identify 
m2, patients weight loss average was 8.4% and phase 
angle media was 5.8. Patients with malnutrition 
parameters showed signiÀcantly lower overall 
survival: BMI<20 mg/m2 (p>0.001); Subjective 
Global Assessment (SGA) results as well nutrition 
vs moderate or severe malnutrition(p=0.002); phase 
angle <5.8 (0.014); and platelet/lymphocytes index 
<150 (p=0.032). After multivariate analysis phase 
angle remain signiÀcative (table 1). 
Table 1. Overall Survival Multivariate analysis 
Nutritional parameter RR IC 95% p 
BMI<20 1.48 (0.287-1.377) 0.246 
Albumin<3.5 mg/dl 2.55 (0.955-6.811) 0.062 
Phase angle 1.99 (0.999-3.985) 0.050 
P/L 1.47 (0.698-3.123) 0.308 
SGA 0.17 (0.763-4.328) 0.177 
Conclusion: Malnutrition parameters are 
independent prognostic indicators of poor survival in 
advanced NSCLC. Phase angle value was the most 
signiÀcant parameter as reported in similar recent 
studies. Nutritional interventions could improved 
body weight, BMI, albumin and phase angle and 
potentially lead to an improved survival in patients 
with advanced NSCLC. 
Keywords: survival, Body Mass Index, Malnutrition
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P3.203 ADVANCED NEVER SMOKER 
ADENOCARCINOMA OF THE LUNG: 
REPORT OF PAIRED NORMAL 
AND TUMOR WHOLE GENOME 
SEQUENCING
Glen J. Weiss1, Tyler Izatt2, Winnie S. Liang3, Daniel 
D. Von Hoff1, Michael J. Demeure4, Angela S. 
Baker5, David W. Craig2, John D. Carpten5 
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Center At Scottsdale Healthcare/tgen/United 
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renal failure and the others returned to normal 
creatinine within 2 months. All patients received 
adjuvant intravenous chemotherapy. Median 
hospital stay after IPHC was 7 days (R: 5-27 days). 
During the follow-up period, pleural metastasis was 
controlled in 21 (72.4%) patients and was aggravated 
in 8 (27.6%) patients. Distant metastasis occurred 
in 19 (65.5%) patients. The median time to pleural 
disease progression and distant metastasis were 12.0 
and 12.8 months, respectively. Median survival was 
24.6 months and 3 year survival was 52.5%. 
Conclusion: IPHC is the safe and simple procedure. 
Our results suggest that IPHC is the highly effective 
local control modality in patients with malignant 
pleural seeding or occult effusion resulting from lung 
cancer who also undergo pulmonary resection of 
their primary lesions. These Àndings may affect the 
prolongation of survival. 
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P3.205 SINGLE NUCLEOTIDE 
POLYMORPHISMS IN DNA REPAIR 
GENE ERCC1 PREDICT CLINICAL 
RESPONSE TO PLATINUM-BASED 
CHEMOTHERAPY IN NON-SMALL CELL 
LUNG CANCER
Lin Xu, Binhui Ren, Ming Li, Xin Yang, Feng Jiang, 
Rong Yin 
Thoracic Surgery, Jiangsu Cancer Institute/China
Background: to assessed whether single nucleotide 
polymorphisms (SNP) of DNA-repair genes ERCC1 
predict efÀcacy and prognosis of non-small-cell lung 
cancer (NSCLC) patients treated with platinum-
based chemotherapy 
Methods: A retrospective dataset of 117 patients 
with NSCLC were routinely treated with cisplatin or 
carboplatin based regimens as Àrst- or second-line 
chemotherapy. The allelotyping of DNA-repair genes 
polymorphisms were determined via PCR-RFLP 
using genomic DNA obtained from peripheral WBC.
Results: ERCC1 (Asn118Asn) genotype was 
signiÀcantly associated with response to treatment. 
Patients with either one or two C alleles (C/C, 
C/T) at Asn118Asn were more likely to respond to 
platinum-based chemotherapy compared with those 
without the C allele (Odds ratio=0.19 95% CI 0.041-
0.872 P = 0.033, by binary logistic regression). There 
was a signiÀcant association between the ERCC1 
unique tumor aberrations at an unprecedented depth.
Keywords: Whole genome sequencing, next 
generation sequencing, never smoker, advanced 
adenocarcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.204 MID-TERM RESULTS OF 
INTRAPLEURAL PERFUSION 
HYPERTHERMIC CHEMOTHERAPY 
FOR THE PATIENTS WITH MALIGNANT 
PLEURAL SEEDING AND EFFUSION IN 
NON-SMALL CELL LUNG CANCER
Hee Chul Yang1, Eoksung Park1, Eunee Sim1, Jung-
Moon Lee1, S.-W. Sung2, Sanghoon Jheon1 
1Thoracic And Cardiovascular Surgery, Seoul 
National University Bundang Hospital/Korea, 
2Thoracic Surgery, The Catholic University Of 
Korea/Korea
Background: Chemotherapy is considered as 
the mainstay treatment for non-small cell lung 
cancer (NSCLC) diagnosed with pleural seeding or 
malignant pleural effusion. However, the reported 
median survival of this subgroup entity is only 
6-9 months. Intrapleural perfusion hyperthermic 
chemotherapy (IPHC) may be used for local control 
of pleural disease but the clinical effect has to be 
established. The aim of this study is to evaluate the 
safety and feasibility of IPHC in the treatment of 
lung cancer with pleural metastases.
Methods: From June 2003 to August 2010, 29 
patients who were diagnosed with pleural seeding or 
occult malignant effusion underwent IPHC. Twenty 
one patients underwent IPHC after pulmonary 
resection and 8 patients for recurred lung cancer 
without distant metastasis were also applied. We 
examined perioperative complications, pleural 
disease progression free survival, distant metastasis 
free survival, and overall survival. 
Results: The mean age was 61.3 years (15 male 
and 14 female). Twenty eight patients were 
adenocarcinoma and 1 squamous cell carcinoma. All 
the patients had no intraoperative adverse events. 
Postoperative acute renal insufÀciency occurred in 3 
patients (10.3%). One patient progressed to chronic 
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4.5 /mean 8.7 cycles of chemotherapy (range 2-34). 
Only 2 patients had grade 2 malaise, the rest was 
grade 1 or no toxicity. 7 patients had symptomatic 
improvement. 2 patients had a partial response, 3 
patients minor response, 2 patients stable disease and 
3 patients progressive disease. Median progression-
free survival from the date of starting P was 196 days 
(95% CI 117 - 462 days). Median overall survival 
from starting P was 556 days (95% CI 34 - 1078 
days). Median overall survival from initial treatment 
was 1175 days (95% CI 846 to 1504 days).
Conclusion: In well selected patients with preserved 
performance status and non squamous NSCLC, 
P after 2nd line chemotherapy can result in very 
meaningful palliation of symptoms and prolongation 
in survival.
Keywords: Pemetrexed chemotherapy, metastatic 
NSCLC
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P3.207 CORRELATION OF TIMING AND 
CLINICAL BENEFIT FROM TREATMENT 
WITH PEMETREXED IN METASTATIC 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
Nooshin Hashemi Sadraei1, Cortney Jones1, Ann 
Tan1, Paul Elson2, Tarek Mekhail3, Nathan Pennell1 
1Solid Tumor Oncology, Cleveland Clinic Taussig 
Cancer Center/United States Of America, 
2Quantitative Health Science, Cleveland Clinic/
United States Of America, 3Florida Hospital Cancer 
Institute, University Of Central Florida/United 
States Of America
Background: Pemetrexed is increasingly being used 
in the treatment of advanced stage, non-squamous 
NSCLC. Pemetrexed is introduced mainly as a 
combination therapy for Àrst line treatment or a 
single agent in second line. However, there is little 
data on the efÀcacy of pemetrexed in later lines of 
treatment.
Methods: In a retrospective single institution 
study, we reviewed the outcome of treatment 
with pemetrexed in patients with advanced stage, 
metastatic NSCLC. We evaluated clinical beneÀt 
and toxicities among patients who received the 
treatment at 1st through 5th line of chemotherapy. 
Patient and disease characteristics included age 
and ECOG performance status ( PS) at the time of 
C8092A polymorphism and OS (P =0.001, by log-
rank test), with median survival times of 9 (C/C) and 
16 (C/A or A/A) months, respectively, suggesting 
that any copies of the A allele were associated 
with an improved outcome. Cox’s multivariate 
analysis suggested that the joint effect of ERCC1 
polymorphic variants (C8092A and N118N) (Odds 
ratio, 4.37; 95% CI, 1.26-15.23 P =0.021) was 
independent prognostic factors for OS in advanced 
NSCLC patients treated with platinum-based 
chemotherapy.
Conclusion: Assessment of genetic variations of 
ERCC1 could predict platinum-based chemotherapy 
outcome in advanced NSCLC.
Keyword: Single nucleotide polymorphisms ; 
DNA repair gene ; Non-small cell lung caner ; 
Chemotherapy
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P3.206 PEMETREXED CHEMOTHERAPY 
AFTER SECOND LINE PALLIATIVE 
CHEMOTHERAPY IN METASTATIC NON 
SMALL CELL LUNG CANCER (NSCLC)
Haris Charalambous, Marios P. Decatris 
Oncology, BOC Oncology Centre/Cyprus
Background: Pemetrexed (P) is currently indicated 
only for Àrst, maintenance and second line treatment 
of non squamous NSCLC. There are currently no 
data for its use after second line treatment. Due to 
funding restrictions in Cyprus (P is not reimbursed 
for any indication in patients with NSCLC), P was 
used in selected patients when most other therapeutic 
options had been used (ie post Àrst line gemcitabine 
platinum doublet, second line docetaxel and third 
line erlotinib).
Methods: Ten patients are included in this 
retrospective study. Four patients received this as 
3rd line, Àve as 4th line and one as 5th line (previous 
treatments as above and also Vinorelbine). Patients 
had regular Chest x-rays (every 2 cycles) and CT 
scans (every 3-4 cycles) and assessment of their 
toxicity with CTC criteria every 3 weeks.
Results: 6 males / 4 females, with 3 patients still 
alive and on treatment. Mean age 56 years (range 
49-77), 5 never smokers, performance status 
WHO1 for 7 patients and WHO2 for 3 patients, 
histology adenocarcinoma in 7 patients, mixed 
adenocarcinoma/BAC in 3. They received a median 
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P3.208 THE CHANGES IN PATTERNS 
AND OUTCOMES OF PALLIATIVE 
CHEMOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER (NSCLC) 
PATIENTS DURING THE 2000S : A 
SINGLE CENTER EXPERIENCE FOR 7 
YEARS.
Hee Kyung Ahn, Myeong Ja Kim, Mijoung Han, 
Jin Hyun Cho, Hyun Ae Jung, So Young Cheon, Se 
Young Lee, Jong-Mu Sun, Jin Seok Ahn, Keunchil 
Park, Myung-Ju Ahn 
Division Of Hematology-Oncology, Department Of 
Medicine, Samsung Medical Center/Korea
Background: Platinum-based doublets have been 
the standard care in advanced non-small cell lung 
cancer (NSCLC) patients since the 1990s. During 
the 2000s, epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors(TKIs) and an antifolic 
agent pemetrexed were introduced and showed 
efÀcacy in NSCLC patients, expanding options for 
palliative chemotherapy beyond second line. The 
purpose of this study is to describe the changes in 
patterns and outcomes of palliative chemotherapy for 
NSCLC patients after the advent of the new agents in 
nonselected NSCLC patients in clinical practice. 
Methods: 1,569 patients were diagnosed with 
metastatic NSCLC and received palliative 
chemotherapy at Samsung Medical Center, Seoul, 
Korea between Jan 2002 and Dec 2008. 1,540 
patients with available data were included in 
retrospective analysis, with a follow-up until Dec 
2010. 
Results: 65.6% (n=1,011) had adenocarcinoma, 
and 19.4% (n=299) had squamous cell carcinoma. 
Since 2006, adenocarcinoma started to increase 
in incidence and during 2006-2008 incidence of 
adenocarcinoma was higher (70.1%) than during 
2002-2005 (59.9%) (p=0.001). 79.4% received 
platinum based chemotherapy as the Àrst line. Of 
the 1,540 patients, 61%, 55%, and 25% received 
a second-, third-, and fourth-line chemotherapy. 
Recently diagnosed NSCLC patients (during 2005-
2007) proceeded to more lines of chemotherapy 
with 36.1% (n=234) of more than the fourth 
line, compared with only 24.1% of the patients 
diagnosed during 2002-2005 (p<0.001). The main 
change in patterns of palliative chemotherapy was 
the introduction of pemetrexed and TKIs. Until 
initiating pemetrexed, gender, ethnicity, smoking 
history, stage at the time of diagnosis of lung cancer, 
tumor histology, number and location of metastatic 
involvement at the time of initiating pemetrexed, 
and toxicities. Details of chemotherapies prior to and 
after pemetrexed were also collected.
Results: 135 patients received pemetrexed between 
2004 and 2008. Pemetrexed was given as a single 
agent ( 85%) or in combination with other anti-tumor 
agents ( 15%) and in 1st ( 7%), 2nd ( 59%), 3rd ( 20%), 
and 4-5th ( 13%) line of therapy. Except for age( 
median age 74 years for 1st line vs 60-65 years in 2nd-
5th line, p=0.04) , there was no statistically signiÀcant 
difference in demographic or disease-related 
characteristics between lines of therapy. The median 
number of delivered cycles of pemetrexed, grade 
III/IV toxicities, overall response rate ( ORR) and 
rate of stable disease > 6 months ( SD), progression 
free survival ( PFS), and overall survival ( OS) were 
not signiÀcantly different between groups. Across 
all lines of treatment, single vs combination use 
of pemetrexed or choice of prior treatment did not 
signiÀcantly differ regarding ORR, SD, PFS or OS. 
Across all lines, metastasis to bone ( p=0.008) and 
liver ( p=0.03) were associated with signiÀcantly 
worse ORR and SD, and also worse PFS and OS 
in bone (p= 0.03, p= 0.04 respectively) and liver 
( p<0.001, p=0.02 respectively). In multivariate 
analysis among all lines of treatment, age 65 
years (p=0.02) and  2 sites of extra-pulmonary 
metastasis (p=0.002) were associated with better 
ORR and SD. Longer survival was associated with 
PS1 ( p<0.001), never smoking history ( p=0.01) 
and longer (  18 months) interval from diagnosis to 
initiation of pemetrexed treatment ( p=0.02).
Conclusion: In this cohort of patients, pemetrexed 
appeared to be equally safe and effective earlier 
or later in the course of management of metastatic 
NSCLC. Clinical predictors of beneÀt from 
pemetrexed therapy are not inÁuenced by the timing 
of this treatment or by choice of prior therapies. 
These Àndings however will need to be validated in 
an independent cohort of patients. 
Keyword: non-small cell lung cancer, advanced 
stage, pemetrexed
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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survival while geÀtinib does not. 
Methods: A decision-analytic model was developed 
to determine the comparative clinical efÀcacy 
and cost-effectiveness (CE) of geÀtinib versus 
erlotinib. After testing, patients with activating 
EGFR mutations receive erlotinib vs. geÀtinib in 
the 1st-line setting followed by chemotherapy. 
Patients without activating mutations receive 1st-line 
chemotherapy and 2nd-line erlotinib; while those in 
the geÀtinib arm go on to best supportive care (The 
model assumes that while further chemotherapy 
may be used, beneÀts and costs would be similar in 
both arms). Clinical data are derived from available 
literature and assume that geÀtinib does not improve 
survival in patients without activating EGFR 
mutations while erlotinib does, as extrapolated 
from ISEL and BR21. Societal costs were obtained 
from cancer centers in Singapore. Health effects 
were expressed as life-years (LY) and quality-
adjusted life years (QALY) gained. All costs and 
incremental cost-effectiveness ratios (ICER) are in 
2010 Singapore Dollars (SGD) [1.3SGD=1USD]. 
Sensitivity analyses were conducted to test for 
different clinical and cost scenarios (The base case 
assumes a mutation prevalence of 40%).
Results: In the base case, treatment with erlotinib 
generated an incremental 0.066 LY and 0.037 QALY. 
At listed prices, in which erlotinib is approximately 
50% more expensive than geÀtinib per daily dose, 
incremental cost was SGD 17,460; generating 
an ICER of SGD 265,000/LY and SGD 468,000/
QALY. Sensitivity analyses showed that when 10% 
of patients have activating mutations, erlotinib 
generates an increment of 0.099 LY and 0.056 
QALY, an added cost of SGD 17,860 and ICERs of 
SGD 180,000/LY and SGD 319,000/QALY. After 
discussions with the authors, and realizing its market 
share in Singapore was 30% or less, Roche decided 
to provide erlotinib at a discount that brings it to the 
same cost per dose as geÀtinib. With this changed 
assumption, this model calculates that the ICERs 
for erlotinib when compared to geÀtinib would be 
SGD 164,000/LY and SGD 289,000/QALY, bringing 
it closer to (but still beyond) generally accepted 
thresholds for oncology medications. Of note, when 
both drugs have the same price, the ICERs represent 
an assessment of the CE of erlotinib in the treatment 
of EGFR negative patients. 
Conclusion: Erlotinib improves clinical efÀcacy 
when compared to geÀtinib but it is not cost-effective 
at full listed price in Singapore. At discounted 
price, it is not cost-effective in the treatment of 
2005, these agents consisted 25.7% of second line 
chemotherapy, in contrast to 64.4% since 2006. The 
median overall survival(OS) was 12.9 months (95% 
C.I. 12.1-13.7 months), with 2.0 months increase 
during 2005-2008 (n=1066,median OS 13.6 months, 
95% C.I. 12.7-14.5 months) compared with during 
2002-2004 (n=474,median OS 11.6 months, 95% C.I. 
10.4-12.8 months)(p<0.001). In subgroup analysis 
according to histology, the increased survival was 
signiÀcant only in patients with adenocarcinoma 
(median OS 16.3 months during 2005-2008 vs. 13.0 
months during 2002-2004, p=0.006)
Conclusion: TKIs and pemetrexed has been 
increasingly administered as second- or third- line 
chemotherapy for metastatic NSCLC patients, and 
more patients are being treated with more lines of 
chemotherapy. Overall survival was signiÀcantly 
increased especially in adenocarcinoma patients. 
With the recent approval of these agents as the Àrst-
line chemotherapy, further changes are expected. 
Keywords: Chemotherapy, Non-small cell lung 
cancer, Third-line therapy, second-line therapy
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P3.209 A COMPARATIVE CLINICAL AND 
COST-EFFECTIVENESS EVALUATION 
OF GEFITINIB AND ERLOTINIB IN THE 
TREATMENT OF ADVANCED NON-
SMALL CELL LUNG CANCER
Gilberto D.L. Lopes, Jr.1, Joel Segel2, Daniel Tan3, 
Young Do2, Tony Mok4, Eric Finkelstein2 
1Johns Hopkins Singapore International Medical 
Centre, Johns Hopkins University School Of 
Medicine/Singapore, 2Health Services And Outcomes 
Research, Duke-nus/Singapore, 3National Cancer 
Centre Singapore/Singapore, 4Department Of 
Clinical Oncology, The Chinese University Of Hong 
Kong/China
Background: GeÀtinib and erlotinib improve 
response rates, progression-free survival and quality 
of life (QOL), when compared to chemotherapy, 
in the Àrst line treatment of patients with advanced 
NSCLC who have activating EGFR mutations. 
Pooled data from retrospective series and a small 
prospective study (total=2400 patients), suggest 
that geÀtinib and erlotinib are equivalent in 
Asian populations. After chemotherapy failure 
in unselected patients, erlotinib improves overall 
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tyrosine kinase inhibitor. 9 patients received Àrst line 
treatment and 8 second line treatment. The median 
survival was 42 days (range 11-251 days). There was 
no clinically signiÀcant difference between patients 
treated Àrst line v second line (31days v 47 days). 
6 patients never started treatment. 5 patients died 
within 30 days of treatment. 2 patients lived longer 
than 16 weeks. The median survival of the patients 
with SCLC was 506 days. The median survival of 
the patients with mesothelioma was 591 days.
Conclusion: Our data suggest that poor PS 
patients with NSCLC do not beneÀt from treatment 
with systemic chemotherapy and early referral 
to palliative care specialists would seem more 
appropriate. Treatment with targeted biological 
therapy needs further evaluation in this group of 
patients. The outcomes for poor PS patients with 
SCLC and mesothelioma treated with chemotherapy 
are signiÀcantly better.
Keywords: Chemotherapy, performance status, 
NSCLC
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P3.211 CA(N) AND R497K ARE 
ASSOCIATED WITH PFS TO EGFR TKIS 
IN THE ADVANCED NSCLC PATIENTS 
HARBORING ACTIVATING MUTATION 
OF EGFR.
Jung Young Shin1, E. K. Jeon2, J. O. Kim3, X. H. 
Zhang1, J. Y. Oh1, Eun Kyung Cho4, J. H. Kang5 
1Biomedical Sciences, The Catholic University 
Of Korea/Korea, 2Division Of Medical Oncology, 
Department Of Internal Medicine, College Of 
Medicine,catholic University, The Catholic 
University Of Korea/Korea, 3Research Institutes Of 
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Korea, 4Department Of Hematology And Oncology, 
Gachon University Gil Hospital/Korea, 5The 
Catholic University Of Korea, Division Of Medical 
Oncology, Department Of Internal Medicine, College 
Of Medicine,catholic University/Korea
Background: In non-small cell lung cancer 
(NSCLC) pts harboring activating mutations of 
EGFR (mutEGFR) treated with EGFR tyrosine 
kinase inhibitors (EGFR TKIs), 70~80% of objective 
tumor response are reported, however, the rest 
(20~30%) of the pts barely responds to EGFR TKIs. 
Meanwhile, even in the NSCLC pts having wild type 
mutation negative patients but it is equivalent to 
geÀtinib in the treatment of patients with mutations. 
Comparative efÀcacy and cost effectiveness models 
may help assess the relative clinical and economic 
value of therapeutic interventions and may be used 
as a tool in determining drug prices and in increasing 
access to new innovative cancer drugs and their 
economic value to society. 
Keywords: Lung cancer, geÀtinib, erlotinib, Cost-
effectiveness
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P3.210 AUDIT OF LUNG CANCER 
CHEMOTHERAPY FOR PATIENTS OF 
POOR PERFORMANCE STATUS.
Henry Taylor, Riyaz Shah, Tim Sevitt, Matilda 
Cominos, Russell Burcombe, Sharon Beesley, 
Andrew Visioli 
Lung Cancer Unit, Kent Oncology Centre/United 
Kingdom
Background: Systemic chemotherapy is a 
recommended treatment for patients with advanced 
NSCLC of good performance status (WHO 0-1) 
with trials demonstrating both a survival advantage 
and improvement in quality of life. The treatment of 
patients of performance status (PS) 2 is contentious. 
The aim of this study is to review the outcomes of 
patients of poor PS treated with chemotherapy in our 
unit.
Methods: This is a retrospective review of all 
lung cancer patients treated at the Kent Oncology 
Centre between 1.7.09 and 30.6.10. All patients 
planned for chemotherapy were identiÀed from an 
electronic action sheet database. Patients of poor 
PS (WHO 2-3) were identiÀed and individual case 
notes analysed recording diagnosis, PS, age, line of 
treatment, planned chemotherapy and survival from 
decision to treat.
Results: 199 patients with lung cancer were planned 
for chemotherapy. 23 patients were of poor PS 
(PS2=21, PS3=2). 17 patients were diagnosed with 
non-small cell lung cancer (NSCLC), 4 small cell 
lung cancer and 2 mesothelioma. Of the 17 patients 
with NSCLC 12 were adenocarcinoma cell type, 
4 squamous cell and 1 unspeciÀed NSCLC. The 
median age was 66 years (range 41-79 years). 6 
patients were planned for doublet chemotherapy, 8 
single agent chemotherapy and 3 treatment with a 
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3First Department Of Surgery, University Of Toyama/
Japan, 4Department Of Surgical Pathology, Toyama 
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Background: The epidermal growth factor receptor 
(EGFR) gene mutation has been reported as an 
important predictive factor for EGFR-tyrosine kinase 
inhibitor (TKI) efÀcacy in NSCLC. In “The Lung 
Cancer Diagnosis and Treatment Guideline published 
by The Japan Lung Cancer Society 2010 edition”, 
the EGFR gene mutation is strongly recommended 
to be analyzed in deciding the treatment policy of 
advanced NSCLC. In addition, it is known that 
the EGFR gene mutation is frequently observed in 
adenocarcinoma (Ad), but very rare in squamous cell 
carcinoma (Sq). EfÀcacy of EGFR-TKI in EGFR 
gene mutation positive Sq has not examined enough.
Methods: We obtained tumor samples from 27 
patients diagnosed as Sq (excluded Ad-Sq carcinoma) 
by two or more pathologists between January 2008 
to December 2010. The EGFR mutation status 
was determined by PCR-Invader assay (BML 
Incorporation) and direct sequencing method.
Results: EGFR mutations were detected in 2 of 
27(7.4%) samples. Common characteristics of two 
patients were male, elderly, high level of CEA, and 
good PS. One patient was a non-smoker, and the 
other was a heavy smoker. Exon 21 point mutations 
(L858R) were observed in both patients. GeÀtinib 
was administered to one patient (non-smoker), and 
the partial response was observed.
Conclusion: The frequency of the EGFR gene 
mutation in Sq was low. However, it was suggested 
that gene mutation positive Sq is responded to 
EGFR-TKI. It is necessary to analyze the EGFR 
gene mutation in Sq.
Keywords: EGFR, NSCLC, squamous cell 
carcinoma, geÀtinib
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P3.213 CHEMOTHERAPY IN NON SMALL 
CELL LUNG CANCER PATIENTS WITH 
BRAIN METASTASES
Gokul Sathyarathnam1, Clive Peedell2 
1Department Of Oncology, Sheikh Khalifa Medical 
City/United Arab Emirates, 2Department Of 
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EGFR. favorable tumor response to EGFR TKIs is 
sometimes observed. We investigated the mutation 
status and genotype of genetic polymorphisms of 
EGFR gene in NSCLC pts receiving EGFR TKIs and 
analyzed an association between them and clinical 
outcomes and toxicities.
Methods: In 165 advanced or metastatic NSCLC pts 
receiving geÀtinib or erlotinib, we assayed EGFR 
mutation in parafÀn embedded tumor tissue using 
direct sequencing and genotyped six different SNPs 
in genomic DNA extracted from peripheral blood; 
promotor 191C>A, 216 G>T, intron 1, CA repeat 
number (CA)n, exon 13, R497K, exon 20, 2607G>A, 
and exon 25, D994D.
Results: Sex ratio (M: F) was 80:85 and mean 
age was 63.1. All pts were stage III or IV and 
histological subtype was as follows: adenocarcinoma 
136, squamous cell carcinoma 22, miscellaneous 7. 
The objective response rate (CR+PR) was 38.2% 
(65 pts) and SD was 31.5% (52 pts). mutEGFR was 
associated with (CA)n (36 vs.>36) with statistical 
signiÀcance (p=0.018). Statistical correlation 
existed between objective tumor response and (CA)
n (p=0.05). In both all pts and mutEGFR group, 
mutant type (RK/KK) of R497K showed much more 
prolonged PFS (4.2 vs.15.9 mo, p=0.002) and OS 
(10 vs. 32 mo, p=0.007) when compared with wild 
type (RR). Of 143 pts assessed for skin toxicities, 
G2607A was statistically correlated with skin rash 
(p=0.04).
Conclusion: Taken together, shorter (CA)n (36) 
is associated with favorable tumor response to 
EGFR TKIs as well as mutEGFR. RK/KK mutants 
of R497K located on EGFR exon13 might be a 
pharmacogenetic biomarker to predict prolonged 
PFS and OS in the NSCLC pts harboring mutEGFR 
who are treated with EGFR TKIs.
Keywords: NSCLC, EGFR TKI, CA repeat, R497K
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P3.212 MUTATION OF EPIDERMAL 
GROWTH FACTOR RECEPTOR GENE 
IN SQUAMOUS CELL CARCINOMA OF 
LUNG
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P3.214 A PRONOSTIC SCORE BASED ON 
CLINICAL FACTORS AND BIOMARKERS 
FOR ADVANCED NON-SMALL CELL 
LUNG CANCER
Jaume Trapé1, Jesus Montesinos2, Silvia Catot2, 
Josep Buxó2, Fina Franquesa1, Sala Sala1, Montserrat 
Domenech2, Francesc Sant1, Josep Badal1 
1Biological Diagnosis,, Hospital Sant Joan De 
Déu, Althaia Xarxa Asiistencial De Manresa/Spain, 
2Oncology, Hospital Sant Joan De Déu, Althaia/
Spain
Background: Survival of patients diagnosed of 
advanced stage non-small cell lung cancer (NSCLC) 
is poor. Several studies have demonstrated that the 
performance status (PS), tumour stage and treatment 
are independent prognostic factors for survival. 
Other studied variables include age, histology, CNS 
metastases, serum tumour markers, LDH, albumin 
Il-6 and PCR. The objective of the present study is 
to determine the prognostic impact of clinical factors 
and biomarkers in patients with advanced stages of 
NSCLC and establish a prognostic classiÀcation of 
these patients. 
Methods: A prospective study of 130 patients with 
non-operable NSCLC stages IIIA-IV with follow-up 
until death of all patients. CEA, CA125, CYFRA 21-
1, albumin, LDH, VSG and leucocytes levels were 
determined. 
Results: Multivariate analysis showed PS (ECOG) 
>1 HR=2.4 (95% CI, 1.5-3.9), stage IV HR=2.23 
(95% CI, 1.4-3.4), no treatment HR=2.5 (95% CI, 
1.5-4.1), CA125>35U/mL HR=2.4 (95% CI, 1.5-
3.7), CYFRA 21-1>3.6ng/mL HR=1.9 (95% CI, 
1.2-2.9) and leucocytes >10000/L HR= 1.77 (95% 
IC, 1.1-2.7) as independent prognostic factors for 
survival. One point was assigned for each adverse 
prognostic factor (APF) except for treatment. 
Patients were classiÀed into three groups according 
to the number of APF: “low risk” 0-1 APF; medium 
risk 2-3 APF (HR= 2.8; 95% CI, 1.6-4.9) and high 
risk 4-5 APF (HR=9.2; 95% CI, 4.8-17.9). Mean 
survival of patients was 15 months (95% CI, 6.2-
23.8) in group 0-1, 6 months (95% CI, 5.5- 6.5) in 
group 2-3 and 2 months in group 4-5 (95% CI, 1.1-
2.9). When classifying patients according to whether 
or not they had received chemotherapy, both groups 
presented similar results to the total group as higher 
numbers of APF correlated with shorter survival. 
Background: The prognosis of non small cell lung 
cancer which has metastasised to the brain is very 
poor and the expected survival without treatment is 
about one month. Steroids and radiotherapy are used 
for symptom control, but the role of chemotherapy 
in these patients is not well established. There are 
some small single institution non randomised studies 
which suggest that Àt patients with brain metastases 
due to non small cell lung cancer that have 
chemotherapy, do as well as other stage IV non small 
cell lung cancers without brain metastases getting 
chemotherapy. 
Methods: From March 2005 to May 2007, at James 
Cook university hospital, Middlesbrough, UK, 
we treated 9 patients with brain metastases from 
non small cell lung cancer with carboplatin and 
gemcitabine chemotherapy. Seven of these patients 
had WHO PS of 1, while 2 patients were WHO PS 2. 
Four of the nine patients had extracranial metastases 
while 5 patients had just brain metastases and no 
other extrathoracic metastases. The median age of 
the patients was 66 years (range 49 - 74 years). 
Results: Four patients had a partial response to 
chemotherapy (44%), 4 had stable disease (44%) and 
one had progressive disease on chemotherapy. The 
median survival was 8 months (range 2 - 13 months). 
There were 2 patients (22%) who survived over a 
year. Chemotherapy was generally well tolerated 
in these patients. There were only three episodes 
of hospital admissions with grade III or worse 
haematological toxicity and neutropaenic fever (of a 
total of 24 cycles of chemotherapy). There were no 
chemotherapy related deaths. Four of nine patients 
had radiotherapy after chemotherapy, three patients 
had radiotherapy prior to chemotherapy and two had 
no radiotherapy. Of the 2 patients with WHO PS 
2, one progressed on chemotherapy and the other 
survived for 6 months. 
Conclusion: Though this is a small study, we think 
this is signiÀcant because the median survival of 
patients in this small study is comparable to stage IV 
non small cell lung cancer without brain metastases. 
Chemotherapy in non small cell lung cancer patients 
with brain metastases is not standard practice, but we 
think in a selected group of patients with WHO PS 1 
or better, combination chemotherapy may improve 
survival without causing much toxicity. 
Keywords: Non small cell lung cancer, brain
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and disease control rate (DCR = CR + PR) was 
74.3%. Overall survival (OS) was 27.2 months and 
progression free survival (PFS) was 5.5 months 
in all patients. In sub analysis, the progression 
free survival (PFS) in population with positive 
EGFR mutation was signiÀcantly longer than that 
of negative EGFR mutation. PFS of patients with 
adenocarcinoma was longer than that of other tissue 
types, but there was no difference in PFS between 
male and female. Pts with skin rash had signiÀcantly 
longer PFS than those without it. The past history of 
geÀtinib intake did not affect PFS. The each number 
of adverse events over grade 3 was three pts of skin 
rash, two of diarrhea, two of liver injury respectively. 
There was no patient of drug-induced interstitial 
pneumonitis.
Conclusion: The effectiveness of erlotinib in our 
hospital was as alike as that reported previously. 
Erlotinib was effective in some pts of negative 
EGFR mutation.
Keywords: erlotinib, Advanced Non-Small Cell 
Lung Cancer, geÀtinib, retrospective study
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P3.216 CLINICAL PATTERNS AND 
OUTCOMES FOR THE BEVACIZUMAB 
MAINTENANCE POPULATION IN THE 
ECOG E4599 STUDY OF PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): RESULTS OF AN 
EXPLORATORY ANALYSIS
Alan B. Sandler1, Michelle Byrtek2, Sophie Fages2, 
Joan Schiller3, Afshin Dowlati4, Julie Brahmer5, 
David H. Johnson3 
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Background: Bevacizumab’s mode of action 
supports continued use until progressive disease 
Conclusion: The application of a SCORE which 
includes clinical data and biomarkers may improve 
the prognostic classiÀcation of these patients. Further 
prospective validation studies are needed to conÀrm 
these results. 
Keywords: prognostic factors, tumor markers, score, 
multivariate analysis
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ERLOTINIB FOR TREATMENT OF 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
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Background: Selection of lung cancer patients with 
mutation of EGFR tyrosine kinase in their cancer 
cells is critical for management of their treatment 
strategy. The clinical dose setting of erlotinib was 
determined as its maximum tolerated dose (MTD). 
Erlotinib is expected of its effectiveness whether or 
not lung cancer cells have EGFR mutations. We don 
not have enough data of effectiveness of erlotinib in 
Japanese lung cancer patients.
Methods: To analyze the treatment outcome 
of erlotinib, we retrospectively investigated the 
background, effectiveness, adverse events of 39 
patients (pts) of advanced NSCLC treated with 
erlotinib from January 2008 to May 2010 in our 
hospital.
Results: Patients background was follows; median 
age 66 (range 31 - 85 years old), ratio of male/ 
female = 15/ 24, smoking history +/ - = 24/ 15, 
PS 0/ 1/ 2 = 2/ 24/ 9, tissue type adenocarcinoma/ 
squamous cell carcinoma/ others = 27/ 6/ 2, number 
of previous regimen 0/ 1/ 2/ over 3 = 2/ 25/ 11/ 1, 
previous usage of geÀtinib +/ - = 7/ 32, mutation 
of EGFR gene +/ -/ unknown = 18/ 16/ 5. The best 
response rate; CR/ PR/ SD/ PD/ NE = 0/ 11/ 18/ 
9/ 1. In seven patients who had previously treated 
with geÀtinib, the best response rate SD/ PD = 5/ 
2. Response rate (RR) in all patients was 28.2%, 
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therapy. Best responses for CP non-progressors at 
6 cycles of chemotherapy + 21 days (n=134) were 
complete response (2.3%), partial response (31.3%), 
SD (42.0%), and unknown (24.4%). For CP non-
progressors, the median PFS and OS were 2.8 
months (95% CI: 2.10–3.12) and 11.2 months (95% 
CI: 9.17–13.57), respectively. The median OS from 
start of CP treatment was 16.1 months, with a 1-year 
survival rate of 67.9% (91/134). 
Conclusion: Although retrospective and non-
comparative, these analyses from E4599 show that 
patients in the bevacizumab maintenance population 
had a long median OS of 17.3 months, including a 
median PFS and OS of 4.4 and 12.4 months beyond 
induction, respectively.
Keywords: Non-small cell lung cancer, 
bevacizumab, maintenance, survival
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P3.217 CLINICAL CHARACTERISTICS, 
TREATMENT OUTCOMES, AND 
SAFETY OF EGFR TYROSINE KINASE 
INHIBITON IN ADVANCED NSCLC 
PATIENTS POSSESSING AN EGFR 
MUTATION: THE ALBERTA, CANADA 
EXPERIENCE
Michael R. Humphreys1, Randeep S. Sangha1, 
Anthony M. Magliocco2, Sunita Ghosh1, Charles 
Butts1 
1Department Of Oncology, Cross Cancer Institute/
Canada, 2Department Of Pathology And Laboratory 
Medicine, Tom Baker Cancer Centre/Canada
Background: In three large phase III trials, 
conducted primarily in selected Asian populations, 
Àrst-line geÀtinib monotherapy is associated with 
signiÀcant progression-free survival (PFS) in 
advanced non-small cell lung cancer (NSCLC) 
patients who possess epidermal growth factor 
receptor (EGFR) activating mutations. We 
hypothesized that clinical characteristics portending 
EGFR mutation status, treatment outcomes, and 
toxicity with Àrst-line EGFR tyrosine kinase 
inhibition (TKI) would compare favorably in a North 
American population. 
Methods: A population-based, retrospective, chart 
review was conducted on treatment-naïve, advanced, 
non-squamous, NSCLC patients referred for EGFR 
mutation analysis between March 1, 2010 and 
(PD). In clinical settings, such as colorectal and 
ovarian cancer (eg, BRiTE, ARIES, GOG-218), and 
in preclinical lung cancer models, continuous VEGF 
suppression with bevacizumab has been shown to be 
key to tumor control. The E4599 study that speciÀed 
bevacizumab treatment to progression demonstrated 
signiÀcant survival beneÀts in NSCLC patients. 
Because current data on single-agent bevacizumab 
maintenance in NSCLC are limited, we conducted a 
retrospective analysis of clinical characteristics and 
outcomes for the maintenance population in E4599.
Methods: E4599 included patients with advanced, 
metastatic, or recurrent non-squamous NSCLC 
treated with 6 cycles of induction carboplatin-
paclitaxel (CP) ± bevacizumab (15 mg/kg q3w). 
Patients with an objective response or stable disease 
(SD) after 6 cycles of CP + bevacizumab (CP+B) 
then continued on single-agent bevacizumab 
maintenance until PD or unacceptable toxicity. 
Response rates, progression-free survival (PFS), 
overall survival (OS), and 1-year survival rates were 
assessed using Kaplan-Meier methods for patients in 
the CP+B arm receiving >1 infusion of bevacizumab 
maintenance without PD before start of maintenance 
(maintenance non-progressor population) and 
patients in the CP alone arm without PD after 6 
cycles of CP + 21 days (CP non-progressors).
Results: In the CP+B arm, 258 of 429 patients 
(60.1%) completed 6 cycles of CP+B, and 207 
(48%) patients received bevacizumab maintenance 
without prior PD. Baseline characteristics for the 
maintenance population were similar to the overall 
CP+B population, except for a higher percentage 
of patients with weight loss 5% in the CP+B arm. 
Best responses in the bevacizumab maintenance 
population for the entire treatment period (induction 
+ maintenance) were complete response (1.9%), 
partial response (55.6%), SD (30.4%), and unknown 
(12.1%); median exposure to bevacizumab 
(induction + maintenance) was 12 cycles. The main 
reasons for bevacizumab discontinuation were 
PD (72.5%) and toxicity (9.7%). No signiÀcant 
differences in the safety proÀle were observed 
between the maintenance population and the overall 
CP+B population. In the maintenance population, 
the median PFS and OS from day 1 of cycle 7 
were 4.4 months (95% conÀdence interval [CI]: 
3.88–5.42) and 12.4 months (95% CI: 11.30–15.57), 
respectively. The median OS from start of treatment 
was 17.3 months, with a 1-year survival rate of 
74.9% (155/207). In the CP alone arm, 194 of 440 
patients (44.1%) completed 6 cycles of induction 
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Background: With concurrent chemoradiation, 
RTOG0117 concluded 74 Gy in 7-8 weeks as 
the maximum tolerated radiation (RT) dose for 
stage III Non-Small Cell Lung Cancer (NSCLC). 
We hypothesized that RT dose can be further 
escalated with a shortened treatment duration by 
individualized adaptive RT.
Methods: Two consecutive prospective dose 
escalation trials have been conducted to test the 
hypothesis. The prescription dose of the Àrst trial 
was set individually to correspond to a 15% risk 
of RT-induced lung toxicity (RILT) according to 
a normal tissue complication model. RT dose was 
further escalated in the second trial by adapting 
dose individually to the residual metabolic volume 
on PET obtained during-RT so that the residual 
metabolic volume would receive the maximal dose 
while keeping a tolerable risk of normal tissue 
toxicities. The treatment was to be completed in 
30 daily fractions, with 5 fractions a week for both 
trials. Fraction size, total equivalent dose at 2 Gy 
fraction size (ED
2
), and biologic equivalent dose 
(BED) ranged from 2 to 3.8 Gy, 66 to 100 Gy, 
and 79.2 to 120 Gy, respectively. Carboplatin and 
paclitaxel were given concurrently and adjuvantly. 
Mature data from the Àrst and the interim results 
from the second trial are reported.
Results: The median ED
2
 were 66 Gy (range 66-
100) and 100 Gy (range 80-100) (P<0.01) for trial #1 
and #2, respectively. Of 18 patients treated on trial 
#1, with a minimum follow-up of 50 months, the 
median and 5-year overall survivals were 30 months 
and 33%, respectively. 12 patients died: 5 from local 
failure, 3 distant metastasis, 3 heart diseases, and 1 
radiation pneumonitis. 6 patients were alive: 1 with 
local progression and 5 with no evidence of disease 
at the last follow-up. Patients treated to higher 
dose had signiÀcantly better survival (P=0.02). For 
toxicity, 5 (22%) patients had grade  2 RILT and 
10 (55%) grade  2 radiation esophagitis. A total of 
33 patients enrolled on trial #2, 18 of them with a 
minimum followed up of 6 months were included 
in this analysis. All 18 patients had tumor reduction 
during-RT and received at least 74 Gy ED
2
 within 
6 weeks; 10 received the maximum trial dose of 
100 Gy ED
2
. Overall, 1 had grade 3 RILT and 7 had 
grade 2 esophagitis. With a median follow-up of 
10 (range 6-26) months, there were 2 deaths, one 
from GI bleeding at 6 months, the other at 20 months 
with unknown etiology without evidence of disease 
progression. None of the patients had local regional 
failures at this time.
March 1, 2011 in Alberta, Canada. Baseline clinical 
characteristics, mutation status, treatment, response 
rate (RR), and toxicity data were collected. 
Results: To date, 120 patients have been analyzed 
for EGFR mutational status analysis. 31 (25.8%) 
harboured EGFR activating mutations: 21 (68%) with 
exon 19 in-frame nucleotide deletion, 7 (23%) with 
exon 21 L858R point mutation, and 3 (10%) with both 
exon 19 and 21 mutations. Clinical characteristics 
associated wtih EGFR mutations were never-smokers 
or former light-smokers (OR: 9.8; 95% CI, 3.2 - 30.3), 
and Asian ethnicity (OR: 3.0; 95% CI, 1.0 - 9.2). 
Gender and age were not associated with the EGFR 
mutation. Of the EGFR mutation positive patients, 24 
(77%) received Àrst-line geÀtinib, 3 (10%) received 
systemic chemotherapy, and 4 (13%) received best 
supportive care only. One of the 20 evaluable patients 
receiving geÀtinib had a CR (5%), 12 patients had 
a PR (60%), and 7 patients displayed stable disease 
(35%). Treatment was well tolerated with only one 
patient having to discontinue geÀtinib due to grade 3 
liver transaminitis. 
Conclusion: This study demonstrates that in an 
Albertan population of non-squamous advanced 
NSCLC patients, EGFR mutations occur at an 
incidence of 25.8%. Smoking status and ethnicity 
were strongly associated with the presence of EGFR 
mutations within this population. Response rates 
compare similarly to Asian populations treated with 
Àrst-line EGFR tyrosine kinase inhibition. Further 
analysis of survival data are ongoing. 
Keywords: Non-small cell lung cancer, Non-
squamous, Epidermal growth factor receptor, 
geÀtinib
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P3.218 USING DURING-RT PET TO 
INDIVIDUALIZE ADAPTIVE RT FOR 
PATIENTS WITH STAGE III NSCLC: A 
MULTICENTER PLANNING STUDY
Feng-Ming (Spring) Kong1, Randall K. Ten 
Haken1, James A. Hayman1, Kemp Cease2, Nithya 
Ramnath2, Douglas Arenberg2, Jeffrey L. Curtis2, 
Mark Orringer3, Gregory Kalemkerian2, Theodore 
Lawrence1 
1Radiation Oncology, University Of Michigan/United 
States Of America, 2Internal Medicine, University 
Of Michigan/United States Of America, 3Surgery, 
University Of Michigan/United States Of America
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Patients receiving ophthalmic therapy or with 
incomplete data were excluded. Toxicities listed 
above were deÀned and graded according to the 
Common Toxicity Criteria v4.0. 
Results: 149 patients were included in analysis. 
Baseline characteristics are shown (table 1). 
Hypertension and proteinuria occurred in 62% and 
18% of patients respectively (table 2). There were 
3 reports of DVT within 3 weeks of bevacizumab 
administration; 2 occurring in colon cancer patients 
and 1 occurring in an ovarian cancer patient . One 
peritoneal hemorrhage occurred in a colon cancer 
patient. 
Table 1: Demographics 
Baseline characteristics (n = 149) 
Gender Female 57% 
Ethnicity African American Caucasian Other 72% 24% 4% 
Median age 60 (range 27-85) 
Disease state Non-small cell lung cancer Breast 
cancer Colon cancer Glioblastoma Renal Other 
28% 13% 47% 2% < 1% 10% 
Past medical history HTN Renal failure 49% 1% 
Current medications Antihypertensives Antiplatelet 
agents Anticoagulants 
47% 2% 11% 
Bevacizumab dose range Median dose Median 
number of doses 
600 mg (range 190-3050 mg) 2 
(range 1 – 22) 
Table 2. Incidence of HTN, proteinuria, and no dose adjustment/discontinuation for 
toxicity 
HTN 
Disease state(n) N (%) Grade 3/4, n (%) No dose delay, adjustment or discontinuation, n (%) 
NSCLC (41) 22 (54) 6 (15) 4 (67) 
Colon (70) 47 (67) 19 (27) 10 (53) 
Breast (19) 11 (58) 5 (26) 3 (60) 
Glioblastoma (3) 1 (33) 1 (33) 1 (100) 
Renal (1) 1 (100) 1 (100) - 
Other (15) 11 (73) 3 (20) 2 (67) 
Total (149) 93 (62) 35 (23) 20 (57) 
Proteinuria 
Disease state (n) N (%) Grade 2 – 4, n (%) No Dose delay, adjustment or discontinuation, n (%) 
NSCLC (41) 5 (12) 2 (5) - 
Colon (70) 16 (23) 11 (16) 2 (18) 
Breast (19) 3 (16) 1 (5) 1 (100) 
Glioblastoma (3) 1 (33) 1 (33) - 
Renal (1) - - - 
Other (15) 2 (13) 1 (7) - 
Total (149) 27 (18) 15 (10) 3 (20) 
Conclusion: The incidence of grade 3/4 HTN and 
grade 2 – 4 proteinuria was higher than reported in 
the literature. This may be a refection of the large 
number of African-American patients in our cohort. 
Blood pressure monitoring was routine, however, 
grade 3/4 hypertension had little documentation 
of dose adjustment, delay, or discontinuation. 
Monitoring of proteinuria was variable. Standard 
Conclusion: Local failure was the major cause of 
death in trial #1 with most patients not receiving 
high dose RT due to estimated RILT limitations 
in patients with stage III NSCLC. An adaptive RT 
treatment, using during-RT PET, allowed higher 
RT dose delivered with concurrent chemotherapy, 
achieved promising local regional control in 
this limited series. RTOG 1106 will validate this 
promising results and compare it with conventionally 
fractionated 74 Gy RT. 
Keywords: Non-small cell lung cancer, Adaptive 
dose escalation, conurrent chemoradiation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.219 DOSE ADJUSTMENTS ARE 
PROBLEMATIC IN COMMON 
TOXICITIES OF BEVACIZUMAB
Sundae D. Stelts1, Laleh Azari1, Robert A. Ramirez2 
1Pharmacy, Methodist University Hospital/United 
States Of America, 2Department Of Hematology/
oncology, University Of Tennessee Cancer Institute/
United States Of America
Background: Bevacizumab is used in non-
small cell lung cancer (NSCLC), colon cancer, 
glioblastoma, renal cell carcinoma, and breast 
cancer. Whether there are differences in incidence 
or severity of toxicity across these diseases is 
unknown. Bevacizumab has been associated with 
life threatening toxicities including hemorrhage 
and thrombosis along with common toxicities of 
hypertension (HTN) and proteinuria occurring in 
more than 20% of patients. While close monitoring 
for these toxicities can prevent excess morbidity and 
mortality, recommendations for monitoring and dose 
reduction are vague. In landmark studies, the dose 
was held for hemorrhage, proteinuria greater than 
2 g/L, and grade 4 hypertension. We examined the 
incidence of bevacizumab common toxicities and 
determined if dose adjustments or discontinuation 
occurred across diseases. 
Methods: A retrospective chart review was 
conducted of patients receiving at least one dose 
of bevacizumab at Methodist University Hospital 
between January 1, 2008 and December 31, 2010. 
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and tissue available for biomarker assessment, were 
randomized (1:1) to erlotinib 150 mg PO QD days 
1-28 plus entinostat 10mg PO or placebo days 1 and 
15 Q 28 days [ = 1 cycle] for a maximum of 6 cycles. 
Treatment was unblinded upon documentation of 
both disease progression and the patient’s desire to 
continue on study in the open label crossover study 
phase should they have been on placebo.
Results: 132 patients were enrolled to achieve 110 
evaluable. All patients have completed the double-
blind study phase as well as exploratory cross-over 
option. 16 patients elected to participate in the 
cross-over option and entinostat was added upon 
erlotinib progression. 5 of 16 (31%) patients had 
disease stabilization >60 days (range 61-139); 2 of 
16 (13%) had disease stabilization < 60 days; 4 of 
16 (25%) had progressive disease and 5 of 16 (31%) 
could not be evaluated. The median PFS for the 16 
patients on erlotinib alone was 1.97 months and an 
additional 1.78 months in the cross-over portion with 
entinostat. Summary of EGFR sequence, EGFR copy 
number, KRAS status, Veristrat classiÀcation and 
E-cadherin IHC protein expression for the cross-over 
patients will be presented. 
Conclusion: A randomized, placebo controlled 
phase II trial of erlotinib+ entinostat or erlotinib 
+ placebo has been completed with exploratory 
analysis of biomarkers selected for analyzing the 
potential for epigenetic therapy to overcome EGFRi 
drug resistance identifying a subset of patients that 
have high e-cadherin expression levels at time of 
diagnosis deriving the greatest clinical beneÀt from 
the combination of entinostat and erlotinib. Results 
from the cross-over portion further demonstrate that 
select patients with resistance to erlotinib therapy 
may derive clinical beneÀt with the addition of 
entinostat. Future studies are planned to conÀrm the 
role of tumor phenotype in determining sensitivity to 
erlotinib – entinostat combination therapy. 
Keywords: EGFR-TKI resistance, histone 
deacetylase, erlotinib, Phase 2
algorithms need to be implemented for dosing 
adjustments in these common toxicities
Keywords: bevacizumab, hypertension, proteinuria
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P3.220 ANALYSIS OF CROSS-
OVER PORTION OF ENCORE-401, 
A RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED PHASE 2 
STUDY OF ERLOTINIB WITH AND 
WITHOUT ENTINOSTAT, A CLASS 
1 ISOFORM SELECTIVE HISTONE 
DEACETYLASE INHIBITOR (HDAC) 
IN PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER
Samir Witta1, Robert Jotte2, Marcus Neubauer3, 
Alexander Spira4, Robert Ruxer5, Kartik Konduri6, 
Fred R. Hirsch7 
1Oncology And Internal Medicine, Mountain Blue 
Cancer Center/United States Of America, 2Lung 
Cancer, Lung Cancer Clinic Of The Rockies/United 
States Of America, 3Kansas City Cancer Center/
United States Of America, 4Fairfax Northern Va/
United States Of America, 5Texas Oncology/United 
States Of America, 6Texas Oncology Pa/United 
States Of America, 7Cancer Center, University Of 
Colorado/United States Of America
Background: Drug resistance in cancer therapy 
represents a signiÀcant hurdle for improving 
clinical outcome with both targeted agents as well 
as cytotoxic chemotherapy .ENCORE-401 was 
conducted based on preclinical data demonstrating 
that epigenetic modiÀers can delay and/or reverse 
tolerance to epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI) treatment. 
The primary efÀcacy data and preliminary subset 
analysis for ENCORE-401 demonstrated that in 
the unselected patient population no added clinical 
beneÀt was observed with the addition of entinostat 
while in a group of patients with high e-cadherin 
(3+, IHC) levels at time of diagnosis, improvement 
was observed in both PFS (3.7 mos vs 1.9 mos; HR 
0.55 (95% CI 0.22-1.37 p=0.19))and OS (9.4 mos 
vs 5.4 mos; HR 0.36 (95% CI 0.14-0.94 p=0.03))1. 
The results of the cross-over portion of the study are 
presented here.
Methods: 132 patients with previously treated 
stage IIIB/IV NSCLC, no-prior erlotinib, PS < 2, 
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pemetrexed/platinum and 13 patients received 
taxane/platinum. Responses in each group were: non-
squamous (pemetrexed/platinum): 2 (13.3%) PR and 
13 (86.7%) SD; non-squamous (taxane/platinum): 1 
(8.3%) PR and 11 (91.7%) SD; squamous (taxane/
platinum): 1 (25%) PR and 3 (75%) SD. Median 
progression-free survival time were 191 days in the 
non-squamous group and 188 days in the squamous 
group. Median overall survival has not been reached 
in both groups. 
Conclusion: Pemetrexed/platinum given to the 
non-squamous NSCLC patients provides better 
response than taxane/platinum regimen in Thai 
patients. Taxane/platinum regimen remains standard 
in squamous NSCLC with comparable progression 
–free survival beneÀt to the non-squamous group. 
Keywords: histology, Pemetrexed, taxane, platinum
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P3.222 NOVEL EGFR ANTIBODIES WITH 
INCREASED ACTIVITY TOWARDS 
MUTANT EGFRS AND POTENTIALLY 
REDUCED TOXICITY
Vincent Sylvie1, Fang Wang2, Donna Mcintosh3, 
Steve Bottega3, Yinghui Zhou3, Christina Fleet3, 
Steven Tyler3, Kristan Meetze3, Jinwei Jiang3, Ting 
Chen3, Solly Weiler3, William Winston3, Joerg 
Heyer3, Steve Clark3, Jeno Gyuris3 
1Department, Aveo Pharmaceuticals/United States 
Of America, 2Agios/United States Of America, 3Aveo 
Pharmaceuticals/United States Of America
Background: Non-small cell lung cancers (NSCLC) 
driven by ligand-independent activating mutations 
in epidermal growth factor receptor (EGFR) often 
respond to treatment with EGFR tyrosine kinase 
inhibitors (TKIs). About half of acquired resistance 
to EGFR-TKI therapy results from a secondary point 
mutation in the EGFR tyrosine kinase domain at 
amino acid position 790 (T790M). T790M mutants 
also display reduced sensitivity to Cetuximab 
treatment in preclinical models.
Methods: We have investigated the molecular 
mechanism responsible for the reduced Cetuximab 
sensitivity and found that T790M mutant receptors 
primarily exist and signal as monomers. We have 
exploited this characteristic of the T790M mutant 
to isolate novel EGFR inhibitory antibodies with 
activities against all EGFR variants.
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P3.221 EFFICACY AND SURVIVAL 
DATA FROM A PHASE II STUDY OF 
HISTOLOGY-GUIDED CHEMOTHERAPY 
IN STAGE IIIB/IV NON-SMALL CELL 
LUNG CANCER WITH PEMETREXED 
PLUS PLATINUM FOR NON-SQUAMOUS 
AND TAXANE PLUS PLATINUM FOR 
SQUAMOUS AND NON-SQUAMOUS 
CARCINOMAS
Patrapim Sunpaweravong1, Arunee Dechaphunkul2, 
Sitang Nirattisaikul3, Kanita Kayasut3, Vilaiwan 
Viriyachaiyo3, Siwasak Juthong3, Warangkana 
Keeratichananont3, Asma Navasakulpong3, 
Katekanok Kamonmarttayakul3 
1Holistic Center For Cancer Study And Care, 
Division Of Medical Oncology, Department Of 
Medicine, Prince Of Songkla University Hospital/
Thailand, 2Division Of Medical Oncology, 
Department Of Medicine, Prince Of Songkla 
University Hospital/Thailand, 3Prince Of Songkla 
University Hospital/Thailand
Background: Pemetrexed/platinum has become 
one of the standard regimens in treatment of non-
squamous non-small cell lung cancer (NSCLC). 
This study aimed to examine efÀcacy of pemetrexed/
platinum in treating Thai NSCLC patients comparing 
to the taxane/platinum regimen.
Methods: Two platinum-doublet regimens were 
assigned for newly-diagnosed stage IIIB (malignant 
pleural effusion)/IV NSCLC patients. For non-
squamous carcinomas, 16 patients were categorized 
to receive 500 mg/m2 of pemetrexed in combination 
with platinum (cisplatin 80 mg/m2 or carboplatin 
AUC = 5) and 16 patients with 175 mg/m2 of 
paclitaxel or 75 mg/m2 of docetaxel in combination 
with platinum. Eight patients with squamous cell 
carcinoma were allocated to taxane and platinum. 
Cycles were repeated every 3 weeks until disease 
progression with 6 cycles maximum. Response 
evaluation was performed every 2 cycles. 
Results: From December 2009 to February 2011, 
37 NSCLC patients gave consent. Five patients 
were excluded from the analysis (early death 
before treatment, co-primary cancers, unmet liver 
function, each, and consent withdrawal (2)). Among 
32 eligible patients, 28 patients had non-squamous 
whereas 4 patients were squamous histology. 
Fifteen patients in the non-squamous group received 
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economics, assists in making this trade-off.
Methods: We examined whether to adopt 
proton therapy, as compared to stereotactic body 
radiotherapy, in the treatment of inoperable stage 
I non-small cell lung cancer. Three options are 
available: adopt without further research; adopt and 
undertake a trial; or delay adoption and undertake a 
trial. The decision depends on the expected net gain 
of each option, calculated by subtracting its total 
costs from its expected beneÀts.
Results: Adopt and trial was the preferred option, 
with the highest expected net gain for a sample size 
of 200 patients. Increase of treatment costs abroad 
and costs of reversal altered the preferred option.
Conclusion: We have shown that ROA provides 
a transparent method of weighing the costs and 
beneÀts of adopting and/or further researching new 
and expensive technologies.
Keywords: proton therapy, cancer care, innovation, 
decision-making
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P3.224 SERUM SIALYL LEWISX 
PREDICT BRAIN METASTASIS IN 
PATIENTS WITH STAGE I NON-SMALL 
CELL LUNG CANCER
Shinjiro Mizuguchi 
Thoracic Surgery, Yodogawa Christian Hospital/
Japan
Background: Surgical treatment is the most efÀcient 
therapy for early non-small lung cancer (NSCLC). 
However, even after radical surgery (R0) many 
patients relapse or progress to systemic disease. 
Recurrence has been detected in approximately 30-
40% of patients with NSCLC, even in stage I. Brain 
metastasis is critical metastasis site. Developments of 
whole brain radiotherapy and/or molecular-targeting 
therapies (mainly EGFR inhibitor) progress the 
survivals of these patients, therefore it is important 
to detect the early brain metastasis to improve their 
survivals. The aim of this study is to determine the 
predictors of brain recurrence preoperatively; we 
compared SLX with two widely used tumor markers, 
CEA and CYFRA 21-1 in patients with stage I 
NSCLC. 
Methods: The study involved 213 patients (132 
male, 81 female; median age 69 years; range 44-93 
years) with completely resected stage I NSCLC. 
Results: 12D03 monoclonal antibody presents high 
binding toward EGFRL858R/T790M and potently 
down-regulates this receptor. In vivo tumor growth 
inhibition was demonstrated in various tumor 
models, driven by either EGFRL858R/T790M, 
EGFRvIII or overexpressed wtEGFR. As opposed 
to other EGFR inhibitory antibodies, these novel 
antibodies have reduced ligand binding inhibitory 
activity and minimal inhibitory effect on EGF 
induced human primary keratinocyte proliferation, 
suggesting a potentially reduced skin toxicity proÀle.
Conclusion: The broad activity proÀle, combined 
with potentially reduced skin toxicity, suggests 
that these antibodies will have great potential for 
combinability with other therapeutic agents. 
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P3.223 WHEN WAIT FOR MORE 
EVIDENCE? REAL OPTIONS ANALYSIS 
IN PROTON THERAPY
Janneke Grutters1, Keith Abrams2, Dirk De 
Ruysscher3, Madelon Pijls-Johannesma3, Hans 
Peters4, Eric Beutner4, Manuela Joore5 
1Health Organization, Policy And Economics, 
Maastricht University/Netherlands, 2Department 
Of Health Sciences, University Of Leicester/United 
Kingdom, 3Department Of Radiation Oncology 
(MAASTRO Clinic), Maastricht University Medical 
Centre/Netherlands, 4Department Of Quantitative 
Economics, Maastricht University/Netherlands, 
5Clinical Epidemiology And Medical Technology 
Assessment, Maastricht University Medical Centre/
Netherlands
Background: Trends suggest that cancer spending 
growth will accelerate. One method for controlling 
costs is to examine whether the beneÀts of new 
technologies are worth the extra costs. However, 
especially new and emerging technologies are often 
more costly, while limited clinical evidence of 
superiority is available. In that situation it is often 
unclear whether to adopt the new technology now, 
with the risk of investing in a suboptimal therapy, 
or to wait for more evidence, with the risk of 
withholding patients their optimal treatment. This 
trade-off is especially difÀcult when it is costly to 
reverse the decision to adopt a technology, as is 
the case for proton therapy. Real options analysis 
(ROA), a technique originating from Ànancial 
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P3.225 CISPLATIN-ETOPOSIDE 
COMBINATION IN THE ADJUVANT 
THERAPY FOR NON-SMALL CELL 
LUNG CANCER – A BRAZILIAN 
EXPERIENCE
Leticia B. França1, Marcia A. Oliveira1, Isabele 
A. Small2, Mauro Zukin1, Luiz Henrique De Lima 
Araújo2 
1Medical Oncology Department, Brazilian National 
Cancer Institute (inca)/Brazil, 2Clinical Research 
Coordination, Brazilian National Cancer Institute 
(inca)/Brazil
Background: Adjuvant chemotherapy is generally 
recommended in most patients with resected 
non-small cell lung cancer (NSCLC), with some 
restrictions according to tumor stage and size. 
However, different cisplatin-doublets were used in 
phase III trials, and the best choice remains unclear. 
The purpose of this study is to describe the Brazilian 
National Cancer Institute (INCA) experience with 
the cisplatin-etoposide (Cis-Vp) combination in this 
situation, with special interest to survival data.
Methods: We retrospectively evaluated the medical 
charts of patients receiving adjuvant treatment for 
NSCLC at INCA between 2004 and 2008. The 
primary outcome was overall survival (OS) and 
prognostic factors were analyzed using log-rank.
Results: Fifty-one patients were included, all treated 
with Cis-Vp. Median age was 61 years (40-76), and 
53% were female. Adenocarcinoma was the most 
frequently reported histological subtype (57%), 
while squamous cell carcinoma was detected in 
33%. Forty percent of patients were diagnosed with 
pathologic stage I, 33% with stage II, and 27% 
with stage III. Lobectomy was the predominant 
surgical procedure (80%), whereas pneumectomy 
was performed in 14%, and bilobectomy in 6%. The 
median number of cycles was 4 (1-4). Fifty-nine 
percent of patients received 80 mg/m2 of cisplatin 
and 76% received 300 mg/m2 of etoposide at the Àrst 
cycle. Eleven patients (22%) were also treated with 
adjuvant radiation therapy. After 31 months median 
follow-up, the median OS was 57 months. In the 
univariate analysis, survival was inferior in advanced 
stage (III vs. I-II; median 34 vs. 57 months, 
respectively; p=0.22) and after RT (median 19 vs. 57 
months; p=0.001). No difference was detected for 
OS according to gender (p = 0.70), histology (p = 
Our study excluded patients with any other cancers 
and those who underwent neoadjuvant therapy. 
Among the 213 patients, we identiÀed 48 with 
recurrence within 3 years. The patients were divided 
into three groups with regard to the recurrence site: 
no recurrence within 3 years (n=165); recurrence 
without brain metastasis (n=34); and recurrence with 
brain metastasis (n=14). The duration of the free-
from-recurrence period was measured from the date 
of operation until the Àrst evidence of recurrence on 
an imaging study, or the last date of follow-up for 
patients who remained alive and without recurrence. 
Results: The mean follow-up period for the entire 
study population was 54 months. On pathologic 
examination, 146 patients had adenocarcinoma 
(included 8 BAC), 47 had squamous cell 
carcinoma, 4 had large cell carcinoma, and 5 had 
adenosquamous carcinoma. 113 patients were 
in stage IA, 100 in stage IB. The 3-and 5-year 
survival rates in total patients were 89%, and 
79%respectively. The 3-year survival rates in 
patients with three groups (no recurrence, recurrence 
without brain metastasis, and recurrence with brain 
metastasis) were 96%, 65%, and 61%, respectively. 
The medians and ranges of serum concentration of 
SLX in patients with no recurrence were 23.6 ng/
mL (10.6–51.7 ng/mL); for those with recurrence 
without brain metastasis was24.5 ng/mL (10.0–
85.4 ng/mL), and for those with recurrence with 
brain metastasis 36.2 ng/mL (15.9-57.6 ng/mL), 
respectively (Kruskal-Wallis test; P < .001). The 
concentrations of SLX were signiÀcantly higher 
in patients with brain metastasis than in those with 
recurrence without brain metastasis (Mann-Whitney 
U-test; P =.0047). No signiÀcant difference for 
serum CEA and CYFRA concentration was evident 
among the three groups. 
Conclusion: The concentration of SLX in serum 
can predict the risk of brain recurrence in stage 
1 NSCLC. Follow-up evaluation included brain 
MRI and adjuvant therapies should be considered 
to improve prognosis in patients with high 
concentration of SLX. 
Keywords: SLX, Lung cancer, stage 1, Brain 
Metastasis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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adenocarcinoma in 27 patients (37%), squamous 
cell carcinoma in 35 patients (47.9%) and others 
11 patients (15%), and higher proportion of 
squamous cell carcinoma patients were observed. 
It was disposed that the patients with squamous 
cell carcinoma had better prognosis than that of 
the patients with other histological types, and also 
that the patients with right upper lobe location of 
primary tumor had better prognosis than Those with 
other locations. In the multivariate analysis by the 
proportional hazard model the number of station of 
lymphadenopathy on CT (single or multi) was the 
only prognostic factor (relative risk 2.54, p=0.05). 
When the CYFRA value exceeded the standard 
value, the possibility that was pN1 or more was high.
( Ƶ square test, p=0.048). 
Conclusion: Patients with cN1 disease were proved 
to have unexpected pN2 involvement in high 
incidence. CYFRA value can be a possible predictor 
of pN2 involvement.
Keywords: Non small cell lung cancer, Clinical N1, 
Pathological N2
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P3.227 AN UPDATE OF THE PHASE III 
STUDY OF ADJUVANT VINORELBINE 
PLUS CISPLATIN (NP) VERSUS NP PLUS 
ENDOSTAR (NPE) IN PATIENTS WITH 
COMPLETELY RESECTED STAGE IB-
IIIA NON-SMALL CELL LUNG CANCER 
(NSCLC)
Jie He1, Xiangru Zhang2, Junling Li2, Baohui Han3, 
Yongyu Liu4, Shixiu Wu5, Y. Kuang6, Yi Shen7, Chun 
Chen8, Qun Wang9, Qiang Li10, Haitao Ma11, Shidong 
Xu12, Shaofa Xu13, P. Wang14, Weimin Mao15, Z. 
Pang6, S Hou16, Y. Yang17 
1Department Of Thoracic Surgery, Cancer Institute 
And Hospital, Chinese Academy Of Medical 
Sciences/China, 2Cancer Institute And Hospital, 
Chinese Academy Of Medical Sciences/China, 
3Shanghai Jiaotong University AfÀliated Shanghai 
Chest Hospital/China, 4Liaoning Cancer Hospital 
& Institute/China, 5The First AfÀliated Hospital 
Of Wenzhou Medical College/China, 6Jiangxi 
Cancer Hospital/China, 7The AfÀliated Hospital 
Of Qingdao University Medical College/China, 
8Fujian Medical University Union Hospital/China, 
9Zhongshan Hospital AfÀliated To Fudan University/
China, 10Sichuan Cancer Hospital/China, 11The First 
0.33), or platinum dose (p = 0.13).
Conclusion: The outcomes described in our 
institution are in line with those reported in the early 
IALT study publication, in which 57% of patients 
received Cis-Vp. Nevertheless, recent data suggest 
more consistent results with cisplatin in combination 
with novel-generation agent vinorelbine, especially 
after long-term follow-up. These data support the 
need for long follow-up in the adjuvancy.
Keywords: Survival analysis, Lung neoplasms, 
Adjuvant chemotherapy
Poster Session 3 – NSCLC - Early Stage Wednesday, 6 July 2011 12:15-
14:15
P3.226 EVALUATION OF CLINICAL 
N1 NON SMALL CELL LUNG 
CANCER PATIENS TO ELUCIDATE 
PATHOLOGICAL N2 SUBGROUP.
Ryo Miyahara1, Makoto Sonobe2, Fengshi Chen1, 
Toshihiko Sato1, Tsuyoshi Shoji1, Takuji Fujinaga1, 
Hiroaki Sakai1, Toru Bando1, Cheng-Long Huang1, 
Hiroshi Date1 
1Thoracic Surgery, Kyoto University/Japan, 
2Thoracic Surgery, Kyoto University Hospital/Japan
Background: Introduction: For a clinically 
diagnosed as N1 disease (cN1), there exist the 
different cases of the pathologic stage of a disease. 
The mixture of the patients of pathologically proven 
ipsilateral N2 involvement (pN2) in particular may 
diminish the prognosis of this group. This study was 
conducted to evaluate the clinical N1 disease and to 
elucidate predictors for pN2 disease. 
Methods: We reviewed 1,080 the clinicopathological 
records and CT Àlms and/or PET Àlms of 
consecutive patients who underwent complete 
resection for non–small cell lung carcinoma in Kyoto 
University Hospital for ten years from January, 2000 
to December, 2009. We examined the histological 
typing, T factor, location of the main tumor (hilum 
or peripheral), CYFRA value, CEA value, and status 
of lymph nodes involvement (single station or multi 
station) as prognostic factor and /or predictive factor 
of pN2 involvement. 
Results: Among 1,080 patients 73 patients (6.8%) 
were diagnosed as cN1 with 55.9% Àve year over 
all survival. Five year survival rate of pN0 (n=24, 
33%), pN1 (n=31, 42%) and pN2 (n=18 25%) 
were 73.5%, 53.8% and 19.0% respectively. The 
tumor histological typing of these 73 patients were 
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months vs. 24.6 months), although the difference 
was not statistically signiÀcant until now. The 
toxicity proÀles for both arms were tolerable in this 
study. The patient follow-up is ongoing. 
Keywords: Endostar, Vinorelbine, Cisplatin, Non-
small cell lung cancer (NSCLC)
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P3.228 EVALUATION OF CLINICAL 
CHARACTERS COMBINED WITH 
COMPUTED TOMOGRAPHY SIGNS IN 
DIAGNOSING SOLITARY PULMONARY 
NODULE
Jun Wang1, Xiaolin Pu1, Dongsheng Jing1, Lin Xu2 
1Department Of Oncology, Jiangsu Province 
Geriatric Hospital/China, 2Thoracic Surgery, Cancer 
Hospital Of Jiangsu Province/China
Background: To evaluate the feasbility of 
clinical characters combined with computed 
tomography(CT) signs in diagnosing solitary 
pulmonary nodule(SPN) in the civil servants of 
Nanjing in P.R. China.
Methods: All the cases received chest X-rays when 
they took their routing health examinations. If SPN 
was detected, then the patient was conÀrmed by 
spiral CT scan and all the clinical characters and 
CT signs were recorded .The patients could receive 
Àberbronchoscopy, percutaneous aspiration lung 
biopsy, video assisted thoracoscopic sugery(VATS) 
, thoracotomy or just follow- up-visited according 
to the advises of clinical Doctors. Totally 431 cases 
of SPN were found in civil servants of Nanjing in 
the routing health examinations from January 2004 
to April 2010 in the medical examination center 
of our hospital. Excepting 21 cases of lost-follow 
up, 410 patients were enrolled in the test, of which 
189 malignant cases and 207 benign cases were 
diagnosed by pathology and 14 cases were clinically 
diagnosed of benignity because the nodules had no 
changes in the at least two-year follow-up visiting. 
60 cases of malignancy and benignity were randomly 
taken from pathologic detected patients respectively. 
Comparing the clinical characters and CT signs of 
the two groups, four clinical characters and nine 
CT signs were found to have signiÀcant different 
display between the two group P<0.2), which 
included the patients’ age(<40 year, 40-60 year, or 
>60year), quantity of smoking(<400/year, 400-800/
AfÀliated Hospital Of Soochow University/China, 
12Harbin Medical University Cancer Hospital/China, 
13Beijing Chest Hospital/China, 14The First People’s 
Hospital Of Yunnan Province/China, 15Zhejiang 
Cancer Hospital/China, 16Beijing Chaoyang 
Hospital/China, 17Beijing Cancer Hospital/China
Background: Adjuvant chemotherapy demonstrated 
a 5-15% beneÀt in 5-year survival in early-stage 
NSCLC. However, it is clear that current therapies 
are far from satisfying. Endostar, a recombinant 
human Endostatin, could inhibit tumor angiogenesis. 
In a phase III trial, the addition of Endostar to NP 
regimen resulted in higher response rate, clinical 
beneÀt rate and longer median time to progression 
compared with NP alone in advanced NSCLC 
patients. In this study, we tried to investigate 
adjuvant NP regimen with or without Endostar in 
early-stage NSCLC patients.
Methods: Completely resected patients (stage IB-
IIIA) were randomized to receive adjuvant NP plus 
Endostar (arm A, Vinorelbine 25mg/m2 on d1 and d8 
plus Cisplatin 80 mg/m2 intravenously, plus Endostar 
7.5mg/m2 per day, iv, for 14 consecutive days. Every 
21 days as one cycle, for 4 cycles) or NP regimen 
alone (arm B). The randomization was stratiÀed by 
gender, stage and histology. The primary endpoint 
was overall survival (OS) and the secondary 
endpoints were relapse-free survival (RFS) and 
safety. 
Results: 905 patients (arm A: 449; arm B: 456) 
from 43 centers in China were enrolled between 
9/2007 and 12/2010. Two arms were well-balanced 
with regard to age, gender, histology, stage, and 
resection type. 80 patients in arm A and 91 patients 
in arm B had relapsed disease. The median RFS 
was 27.7 months in arm A and 24.6 months in arm 
B (p=0.6009). 80.3% of patients in arm A Ànished 4 
cycles of treatment and 77.8% of patients in arm B 
received 4 cycles of chemotherapy. Median survival 
time was not available at this moment because only 
very few patients had died. Grade 3/4 toxicities in 
arm A included leukopenia (58.4%), neutropenia 
(77.4%), anemia (13.1%), nausea (12.4%). Grade 
3/4 toxicities in arm B included leukopenia (35.5%) 
neutropenia (61.6%), anemia (8.5%) and nausea 
(8.5%). It is worth noting that the incidence of 
cardiac toxicities in arm A (28.0%) was higher than 
that in arm B (21.1%). 
Conclusion: The preliminary result showed that 
patients in arm A experienced a longer median 
relapse-free survival time than in arm B (27.7 
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University/Japan, 3Tottori University/Japan, 
4Kawasaki Medical School/Japan, 5Shikoku Cancer 
Center/Japan, 6Osaka City General Hospital/Japan, 
7Uwajima Municipal Hospital/Japan, 8Chugoku 
Central Hospital/Japan, 9Hiroshima University/
Japan, 10Nagoya University/Japan, 11Kagawa 
Prefectural Central Hospital/Japan, 12Okayama 
University/Japan, 13Thoracic Surgery, Kyoto 
University Hospital/Japan
Background: Recent studies have demonstrated that 
adjuvant chemotherapy provides a survival beneÀt 
in patients with resected NSCLC. We conducted 
a phase III study of carboplatin/paclitaxel versus 
oral uracil-tegafur as the adjuvant chemotherapy in 
resected NSCLC. On November 2010, planned 402 
cases were enrolled and registration was completed. 
Here, we show the characteristics of enrolled patients 
with survival data of analyzed patients. 
Methods: The patients with pathological stage IB-
IIIA NSCLC who underwent complete resection 
were randomized 1:1 to carboplatin (AUC 5) /
paclitaxel (175 mg/m2) every 3 week for 4 cycles (A 
arm) or uracil-tegafur (250 mg/m2) daily for 2 years 
(B arm). The primary endpoint was overall survival 
(OS) and secondary endpoints were disease-free 
survival and toxicity. The accrual of 200 patients per 
arm is required to demonstrate an improvement of 
OS (15% increase) in the arm A arm compared to B 
arm.
Results: Between November 2004 and November 
2010, 402 patients from 31 Japanese centers were 
randomized. Median age was 67 (range; 44-82) 
years. A total of 402 patients consisted of 262 male 
and 140 female. Two-hundred ninety nine patients 
had PS of 0, 98 had PS of 1, and 5 had PS of 2. 
Two-hundred sixty six patients had adenocarcinoma, 
100 had squamous cell carcinoma, and 36 had other 
histologies. Disease stage was IB in 229, IIA in 40, 
IIB in 81, and IIIA in 52 patients. Toxicities observed 
during adjuvant chemotherapy were well tolerable. 
There was no toxic death. The 3-year and 5-year 
overall survival rates of A and B arms combined was 
75.9 % and 62.9%, respectively.
Conclusion: The present phase III trial with 
carboplatin/paclitaxel or uracil-tegafur is feasible 
with manageable toxicity.The Ànal result of study is 
planned to be opened in 2016.
Keywords: Adjuvant chemotherapy, uracil-tegafur, 
Carboplatin, NSCLC
year, or >800/year), tumor marks of blood serum(0-2 
items higher than normal, 3-4 items higher, or 5 
items higher), family history of malignant diseases, 
the size(0.5-1 centimeter, 1-2 centimeter, or 2-3 
centimeter ), contour(smooth, shallow or deep 
lobulation) and pattern of calciÀcation of the nodule, 
spicula sign, vascular convergence sign, bronchi 
sign, cavity, vacuole sign, and enhancement(<20 
hounsÀeld unit(HU), 20-60HU or >60HU). 2/3 of 
the 410 patients (malignancy, n=122; benignity, 
n=151)formed the training set, and the other 137 
patients formed the test set(malignancy, n=67; 
benignity, n=70) Utilizing Bayes analysis Œthe prior 
odds of malignant SPNs and the likelihood ratios 
of the 4 clinical characters and the 9 CT signs were 
taken from the training set which were then used 
to calculate the probability of malignancy of each 
patient of the training set and the test set. Patients 
whose calculated probabilities were50% were 
then judged as malignancy and those with<50% 
calculated probabilities were judged as benignity.
Results: In the training set, the sensitivity(SEN), 
speciÀcity(SPE), diagnostic odd ratio(DOR) and 
positive likelihood ratio(+LR) were 0.85, 0.83, 
27.8 and 4.95 respectively; at the same time ,these 
datum of the test set were 0.85, 0.80, 22.8 and 4.26 
respectively.
Conclusion: With the application of Bayes analysis, 
clinical characters combined with CT signs may be a 
feasible method in distinguishing between malignant 
and benign SPNs of civil servants of Nanjing.
Keywords: Solitary pulmonary nodule, diagnosis
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P3.229 A PHASE III STUDY OF 
CARBOPLATIN/PACLITAXEL VERSUS 
ORAL URACIL-TEGAFUR AS THE 
ADJUVANT CHEMOTHERAPY IN 
RESECTED NON-SMALL CELL LUNG 
CANCER (NSCLC) – CONDUCTED BY 
SETOUCHI LUNG CANCER GROUP 
(SLCG) –
Norihito Okumura1, Shinichi Toyooka2, Hiroshige 
Nakamura3, Masao Nakata4, Motohiro Yamashita5, 
Tada Hirohito6, Shinsuke Kajiwara7, Naoki 
Watanabe8, Morihito Okada9, Junichi Sakamoto10, 
Motoi Aoe11, Shinichiro Miyoshi12, Hiroshi Date13 
1Thoracic Surgery, Kurashiki Central Hospital/
Japan, 2General Thoracic Surgery, Okayama 
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P3.231 A STUDY OF THE SUCCESSFUL 
EXECUTION RATE BY THE CDDP+VNB 
BI-WEEKLY TREATMENT OF THE LUNG 
CANCER POSTOPERATIVE PATIENT
Yasushi Ohno1, Junki Endo1, Norihiko Funaguchi2, 
Fumihiko Ito2, Fumihiko Kamiya1, Koumei Yanase1, 
Hidenori Mori1, Masahiro Asano1, Hirotoshi Iihara3, 
Shinya Minatoguchi1 
1Second Department Of Internal Medicine, Gifu 
Univarsity School Of Medicine/Japan, 2Second 
Department Of Internal Medicine, Gifu University 
School Of Medicine/Japan, 3Department Of 
Phamacy, Gifu University Hospital/Japan
Background and Objectives: Poor successful 
execution rate has been a common feature in 
clinical trials of cisplatin (CDDP) based adjuvant 
chemotherapy for NSCLC with only 48% to 69% 
of patients completing all planned cycles. We 
evaluated compliance and toxicity of postoperative 
cisplatin(CDDP) and vinorelbine(VNB) bi-weekly 
chemotherapy. 
Patients and Methods: Patients who received 
adjuvant chemotherapy after complete resection of 
NSCLC between January 2008 and December 2010 
were analyzed prospectively. Patient demographics, 
ECOG status, stage, pathologic subtype and type of 
surgery were recorded. The number of chemotherapy 
cycles, delays, dose reductions and change of 
chemotherapy were reported. 
Results: Eleven patients were identiÀed. The median 
age was 66 years (range of 54-75). Eight patients 
completed all 4cycle treatment under CDDP 40mg/
m2 and VNB 25mg/m2 bi-weekly. Three patients 
were reported event of grade four neutropenia 
and four patients required delays in treatment. 
There were no toxic deaths. Multivariate analysis 
showed no effect of age, gender, extent of surgery 
or ECOG status on compliance, need for treatment 
modiÀcation or toxicity. 
Conclusion: Compared to historical trials, adjuvant 
cisplatin and vinorelbine bi-weekly chemotherapy 
for resected NSCLC is now accepted by patients 
and physicians with a high degree of successful 
execution rate. 
Keyword: CDDP VNB chemotherapr postoperation
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P3.230 IS THERE A SURVIVAL 
DIFFERENCE BETWEEN THE 
PREVIOUS AND NEW T STAGES OF THE 
OPERATED N0 NON-SMALL CELL LUNG 
CANCER PATIENTS ?
Ozan Usluer, Seyda O. Kaya, Ozgur Samancilar, 
Kenan C. Ceylan, Serpil Sevinc 
Thoracic Surgery, Dr. Suat Seren Chest Diseases And 
Thoracic Surgery Training And Research Hospital/
Turkey
Background: In this study, the survival rates of 
the operated non-small cell lung cancer patients 
classiÀed according T factor of the previous and the 
new TNM staging are compared.
Methods: The medical records and the follow-up 
data of the patients operated for non-small cell lung 
cancer between January 2005 and December 2009 
is analyzed retrospectively. The pateints are staged 
according to the previous and the new TNM staging. 
The survival data of pateints with stages T1N0M0 
(n=68), T2N0M0 (n=121) (classiÀed as T2 because 
of the diameter of the tumor) according to previous 
TNM staging and the patients with stages T1aN0M0 
(n=35), T1bN0M0 (n=33), T2aN0M0 (n=73), 
T2bN0M0 (n=48), T3N0M0 (n=30) (classiÀed as T3 
because of the diameter of the tumor) according to 
new TNM staging are compared.
Results: There is no survival difference between 
T1aN0M0, and T1bN0M0, versus T1N0M0 
(previous staging) and T2aN0M0, T2bN0M0, and 
T3N0M0 versus T2N0M0 (previous staging) (p
Conclusion: Subgrouping the operated non-small 
cell lung cancer patients according to new T factor 
by the tumor diameter does not result with a 
signiÀcant survival difference when compared to 
previous TNM staging.
Keyword: lung cancer, staging
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.233 ‘REAL WORLD’ 
DELIVERABILITY OF ADJUVANT 
CHEMOTHERAPY IN NON SMALL CELL 
LUNG CANCER (NSCLC)
Gordon N. Urquhart1, Marianne C. Nicolson2, Keith 
M. Kerr3, H. Remmen2 
1Cancer Medicine Write Up Room, Polwarth 
Building, Foresterhill, University Of Aberdeen, 
Room 1:129/United Kingdom, 2Anchor Unit, 
NHS Grampian/United Kingdom, 3Department 
Of Pathology, Aberdeen Royal InÀrmary/United 
Kingdom
Background: Following a number of large 
randomized controlled trials describing survival 
beneÀt, adjuvant chemotherapy has been adopted 
into the management of early stage Non Small Cell 
Lung Cancer (NSCLC).The LACE meta-analysis 
demonstrated vinorelbine plus cisplatin (VC) to 
be marginally more effective than other platinum 
doublets (ref 1). Since 2005, our standard practice 
has been to treat with VC patients with resected 
pathological stage II-IIIa . We have audited the 
deliverability and toxicity of adjuvant VC and 
measured the impact of adjuvant chemotherapy 
on survival when compared with patients whose 
resections predated its introduction.
Methods: All patients (Aberdeen, Scotland) who 
between 1999-2003 and 2005-2009 underwent a 
pneumonectomy, lobectomy or wedge resection 
for non-small cell lung cancer were identiÀed from 
pathology records. Patient characteristics, surgical 
procedure and survival analysis were tabulated and 
compared. All patients were diagnosed received all 
treatment in one hospital; Aberdeen Royal InÀrmary. 
Case records and clinical databases were interrogated 
to record demographics (age, gender, performance 
status, co-morbidity) and clinical characteristics 
(histology, pathological stage, surgical procedure, 
length of surgical admission, 30 day surgical 
mortality rate, 30 day readmission rate, overall 
survival). Uptake of adjuvant chemotherapy was 
determined in the 2005 to 2009 cohort. The reasons 
for non-delivery of chemotherapy were recorded. 
We reviewed patient outcomes for those patients 
who underwent adjuvant chemotherapy recording 
the dosing of chemotherapy delivered (individual 
drug dosing, number of cycles completed) along 
with individual toxicity proÀles ( type, severity, 
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P3.232 DIAGNOSIS AND TREATMENT 
OF ATYPICAL ADENOMATOUS 
HYPERPLASIA IN LUNG
Yi Zhang, Xiuyi Zhi 
Thoracic Surgery, Xuanwu Hospital/China
Background: The purpose of our study was to 
analyze the characteristic of atypical adenomatous 
hyperplasia(AAH) on CT scan, pathology and 
surgical mode. 
Methods: We retrospectively evaluated 10 atypical 
adenomatous hyperplasias(AAH) that were 
histologically conÀrmed and that manifested Male 
2 and female 8, median age 54.4. All of the patients 
had the surgery. We compared the characteristic of 
CT scan and pathology. 10 patients were following 
up. 
Results: All cases were peripheral nodule which 
located at left upper lobe 4, left lower lobe 2 
and right lower lobe 4. GGO was manifested 
on thin-section helical CT scans. Diameter 
from 0.5~1.2 cm. The borderline of GGO was 
clear and the density was equality. Two of 10 
cases had undergone wedge resection and 8 for 
lobectomy. Postoperative patients recovered 
quickly without severely complication. Under 
microscope it manifests local lung alveolus 
epithelium hyperplasia apparently. The interval 
slightly incrassation and local Àbre cell hyperplasia 
with slightly nucleus heteromorphism. The follow 
time was from two months to Àve years. Now, 10 
patients with good life quality are still alive without 
recurrence and metastasis. 
Conclusion: The preoperative diagnosis rate of 
AAH is improved by high-differentiate enhance CT 
scan and the CT number histograms, but the Ànally 
diagnosis still need the histological evidence. 
Surgery is one of the most reliable means to treat 
AAH. 
Keywords: high-differentiate CT scan, Surgery, 
lung atypical adenomatous hyperplasia, pathology
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P3.234 FACTORS ASSOCIATED 
WITH RECURRENCE AND 
SURVIVAL IN PATIENTS WITH 
CURATIVELY RESECTED STAGE IA 
ADENOCARCINOMA OF THE LUNG: 
LYMPHOVASCULAR INVASION CAN 
PREDICT RECURRENCE
Masahiko Harada, Tai Hato, Hirotoshi Horio 
Division Of Thoracic Surgery, Tokyo Metropolitan 
Cancer And Infectious Diseases Center Komagome 
Hospital/Japan
Background: Even when meticulously clinically 
and pathologically studied, completely resected 
stage IA adenocarcinoma of the lung does recur. 
However, there are few data regarding the patterns of 
recurrences and their risk factors in this population. 
Therefore, this study characterizes cancer recurrence 
and its risks and assesses recurrence-free survival 
in patients with curatively resected stage IA 
adenocarcinoma.
Methods: Between January 1990 and December 
2005, a total of 214 patients were given a Ànal 
diagnosis of pathologic stage IA (UICC-6) 
adenocarcinoma of the lung. The medical records 
of these patients were retrospectively reviewed with 
regard to patient characteristics, tumor pathologic 
Àndings and follow up status. Survival was analyzed 
by the Kaplan-Meier method, log-rank test, and Cox 
proportional hazards analysis.
Results: The median follow up after curative 
resection was 66 months. Cancer recurred in 28 
patients (13%). Among them, local recurrence 
occurred in 10 patients (5%), whereas distant 
recurrence occurred in18 patients (8%). Recurrence 
earlier and later than 5 years after surgery was in 15 
patients (7%) and in 13 patients (6%), respectively, 
with nearly constant risk. At 5years after index 
resection, 169 patients (79%) were alive without 
evidence of cancer recurrence, 27 patients (13%) 
had experienced recurrence of cancer but still alive 
and 1 patient had died with non-cancer causes. 
Recurrence-free 5- and 10-year survival rates were 
92.5 and 70.0%, respectively. Univariate analysis 
revealed Àve signiÀcant prognostic factors: gender 
(p=0.0177); BAC component (p =0.0007); tumor 
location (p=0.0099); pleural invasion (p=0.0274) 
and lymphatic or vascular vessel invasion (LVI) 
(p< 0.0001). Multivariate analysis revealed BAC 
frequency, number of hospital admissions). Overall 
survival (date of surgery till date of death/censoring 
date) was used in the survival analysis. Survival 
comparisons, using Kaplan-Meier, between the two 
cohorts (1999-2003 and 2005-2009) were made.
Results: There were 144 patients with resected 
NSCLC between 2005 and 2009, and 183 
between 1999 and 2003. There were no signiÀcant 
differences in terms of patient characteristics, stage 
or histology between these year groups. Within 
the 2005-2009 cohort, there were signiÀcantly 
fewer pneumonectomies (Table 1) (X2 13.9, 1df, 
p<0.005) but duration of surgical admission, 30day 
readmission rate, and 30 day surgical mortality rate 
were very similar. Within the 2005-2009 cohort 52 
stage II-IIIa cases were identiÀed. Of these, three 
died within 30 days of surgery. Forty one (84%) 
patients were referred to Oncology for discussion of 
adjuvant chemotherapy with an uptake rate of 76% 
(n=31). Those not treated with chemotherapy were 
more likely to be older, have signiÀcant co-morbidity 
or to have sustained post-operative complications 
resulting in a longer surgical admission and a higher 
30 day re-admission rate (Table2). The delivery of 
adjuvant vinorelbine chemotherapy was signiÀcantly 
limited by haematological toxicities. There was one 
early chemotherapy related death due to neutroenic 
sepsis. The mean number of cisplatin cycles 
delivered was 2.7. Haematological toxicity resulted 
in 40% (n=11) of patients being withdrawn from 
treatment early. Individual drug dosing and toxicity 
proÀles will be presented. Survival analysis will be 
formally performed in June 2011 however initial 
analysis suggests a signiÀcantly longer survival in 
the 2005-2009 cohort (p=0.041) (Figure1). 
Conclusion: 1. Favourable uptake of adjuvant 
chemotherapy 2. Delivery limited by haematological 
toxicity 3. SigniÀcant survival improvement, 2005-
2009 cohort
Keywords: Adjuvant chemotherapy, Early Stage 
NSCLC, Survival analysis, toxicity
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AJCC staging, 92 patients were stage IA and 63 
were stage IB via PET-CT. Of the 155 patients in 
this series, 113 (73%) were correctly staged for both 
T and N stage via PET-CT based on the 6th edition 
of AJCC staging: 75% correct for clinical stage IA 
(McNemar’s Ƶ2= 11.6, p < 0.001), 70% correct for 
clinical stage IB (McNemar’s Ƶ2 = 2.13, p = 0.2). 
Using the 7th edition of AJCC staging, 97 of the 155 
patients (63%) were staged correctly with PET-CT: 
71% correct for clinical stage IA (McNemar’s Ƶ2 = 
16.0, p < 0.000), 47% correct for clinical stage IB 
(McNemar’s Ƶ2 = 1.6, p = 0.3). Of the 155 patients 
in this series clinically staged as IA or IB by PET-
CT, 12 patients (8%) were upstaged at pathological 
dissection due to the presence of N2 disease, 7 
of whom also had occult N1 nodal disease. Eight 
patients had N1 positive nodes in the absence of 
N2 positive nodes. Thus, 13% of clinically stage I 
patients in this series harbored occult lymph node 
metastases. Regarding 6th edition T stage, 22 
patients were upstaged, 12 due to visceral pleural 
invasion, and six patients were downstaged. In the 
7th edition, 46 patients were upstaged and 11 were 
downstaged.
Conclusion: PET-CT has an excellent negative 
predictive value for predicting the absence of 
nodal disease in patients with clinical T1-2N0 
lung cancer in the AJCC 6th edition. The NPV of 
PET-CT in nodal staging has implications for non-
surgical treatment of lung cancer with stereotactic 
body radiotherapy where routine pathologic nodal 
staging is not performed. Identifying radiographic 
characteristics that correlate with the absence of 
nodal disease would be helpful in patient selection. 
For both the 6th and 7th editions, clinical stage IA 
was more likely to match the pathological stage than 
was clinical stage IB. In our series, the accuracy 
of PET-CT in predicting AJCC 7th edition stage is 
lower than that for the 6th edition.
Keywords: early-stage, pathologic stage, PET-CT
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P3.236 SERUM SIALYL LEWISX LEVEL 
INDICATES NODAL EXTENSION IN 
PATIENTS WITH CLINICAL STAGE 1A 
NON-SMALL CELL LUNG CANCER
Takuma Tsukioka, Noritoshi Nishiyama, Takashi 
Iwata, Koshi Nagano, Nobuhiro Izumi, Shinjiro 
Mizuguchi, Keiko Tei, Shigefumi Suehiro 
component, tumor location, and LVI as signiÀcant 
factors. Hazard ratios for recurrence were 0.381 for 
having BAC component (95% CI, 0.147-0.979; p= 
0.0451), 0.361 for right sided tumor (95% CI, 0.188-
0.692; p= 0.0022), and 2.785 for having LVI (95% 
CI, 1.392-5.555; p= 0.0038).
Conclusion: Surgically “cured” stage IA 
adenocarcinoma of the lung recurs. Our analyses 
indicate BAC component, tumor location, LVI as 
an independent indicator for cancer recurrence. 
Identifying high-risk patients for recurrence will 
simplify decision making for postoperative treatment 
strategies.
Keywords: adenocarcinoma of the lung, p-stage IA, 
recurrence, lympphovascular invasion
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P3.235 NEGATIVE PREDICTIVE VALUE 
(NPV) OF PET-CT IN NODE-NEGATIVE 
EARLY STAGE LUNG CANCER: 
IMPLICATIONS FOR NON-SURGICAL 
MANAGEMENT
Anthony Paravati1, David Johnstone2, Candice 
Johnstone3 
1Dartmouth Medical School/United States Of 
America, 2Cardiothoracic Surgery, Dartmouth 
Medical School/United States Of America, 
3Radiation Oncology, Medical College Of Wisconsin/
United States Of America
Background: Increasingly, non-surgical methods 
are utilized for the management of early stage lung 
cancer. We sought to investigate the accuracy and 
negative predictive value (NPV) of PET-CT at 
our center in the nodal staging of clinically node-
negative lung cancer.
Methods: All patients treated surgically from 
January 2005 to December 2008 at Dartmouth-
Hitchcock Medical Center who were AJCC 6th 
edition clinical stage I lung cancer by pre-operative 
PET-CT staging were included in this analysis. 
The relationship between both the 6th edition 
and 7th edition AJCC clinical stage based on pre-
treatment PET-CT and true stage based on pathologic 
dissection was assessed with McNemar’s Test.
Results: Of 155 clinically node-negative patients, 
135 were pathologically node-negative. The negative 
predictive value of PET-CT for predicting lymph 
node involvement was 87%. Based on 6th edition 
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Conclusion: Patients with a serum SLX level of >26 
U/mL were likely to have nodal extension. To decide 
on appropriate postoperative treatment, patients 
with a positive level of SLX should be treated with 
conventional pulmonary resection plus mediastinal 
lymph node dissection to evaluate the disease extent.
Keywords: Non small cell lung cancer, SLX, nodal 
extension
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P3.237 THE PROGNOSIS OF 
SURGICALLY RESECTED 
SPUTUM CYTOLOGY-POSITIVE 
ADENOCARCINOMA OF THE LUNG
Yukio Tsushima, Kazuya Takamochi, Shiaki Oh, 
Kenji Suzuki 
Division Of Thoracic Surgery, Juntendo University 
School Of Medicine/Japan
Background: Unlike the representative of central-
type primary lung cancer such as squamous 
cell carcinoma and small cell carcinoma, 
adenocarcinoma is less often diagnosed by sputum 
cytology. Recently with the spread of high-resolution 
computed tomography, cases of screening detected 
early stage peripheral-type adenocarcinoma of the 
lung have been increasing, while a few are diagnosed 
by sputum cytology before surgery. Purpose: We 
evaluated the prognosis of the patients who had 
surgical resection of the lung with diagnosis of 
adenocarcinoma by the pre-operative sputum 
cytology. 
Methods: We retrospectively reviewed 1006 
consecutive patients who underwent surgical 
resection for primary lung cancer at our institution 
between 1996 and 2010. Preoperative factors and 
overall survival from surgery to death was assessed. 
Overall survival was analyzed by the Kaplan-Meier 
method, and differences in variables were calculated 
by the log-rank test.
Results: There were 20 patients who were diagnosed 
with adenocarcinoma by the pre-operative sputum 
cytology (Group-S). The remaining 986 patients 
were diagnosed with adenocarcinoma by other 
diagnostic methods, such as trans-bronchial lung 
biopsy, trans-bronchial needle aspiration cytology, 
bronchial washing cytology, CT guided biopsy, 
VATS biopsy, intra-operative fresh frozen section, 
and so on (Group-O). Group-S had signiÀcantly 
Thoracic Surgery, Osaka City University Hospital/
Japan
Background: It is well known that nodal extension 
is diagnosed postoperatively in patients with small-
sized non-small cell lung cancer (NSCLC) who 
exhibit no evidence of nodal extension on chest CT. 
Nodal extension is a signiÀcantly poor prognostic 
factor. Patients with operable advanced NSCLC are 
commonly treated with pulmonary resection plus 
lymph node dissection with pre- or postoperative 
chemotherapy. Treatments for patients with early-
stage NSCLC contain several therapeutic procedures, 
including lobectomy, segmentectomy, and partial 
resection, with or without lymph node dissection. 
The imprecise diagnosis of node-positive NSCLC 
leads to insufÀcient treatment, as well as incomplete 
removal of the lesion. The prediction of nodal 
extension is therefore particularly important for 
patients with clinically early stage (but in fact more 
advanced) NSCLC to receive appropriate treatment.
Methods: We retrospectively analyzed the 
relationship between pathologically proven nodal 
extension and the clinicopathologic features in 
patients with clinical stage 1A NSCLC. From 
January 2004 to December 2008, 299 patients 
with NSCLC underwent pulmonary resection 
with mediastinal lymph node dissection at Osaka 
City University Hospital (Osaka, Japan). Of these, 
131 patients with clinical stage 1A NSCLC were 
investigated in this study.
Results: The mean age of patients was 67 years 
(range, 20 to 93 years). There were 72 males and 
59 females. There were 113 patients without nodal 
extension (107 patients with p-stage 1A disease and 6 
patients with stage 1B), 6 patients with pathological 
N1 nodal extension (3 patients with stage 2A disease 
and 3 patients with stage 2B disease), and 12 patients 
with pathological N2 nodal extension (all patients 
with stage 3A disease). The preoperative serum sialyl 
Lewisx level (SLX, p = 0.001) was signiÀcantly 
elevated in patients with compared to those without 
nodal extension. A ROC curve was constructed 
to determine if serum SLX levels could be used 
to differentiate between patients with and without 
nodal extension. The predictive cut-off value for 
SLX according to the ROC curve was 26 U/mL. On 
univariate analysis, being SLX-positive (risk ratio = 
3.361, p = 0.021) was a signiÀcant predictive factor 
for nodal extension. On multivariate analysis, being 
SLX-positive was an independent predictive factor 
for nodal extension (risk ratio = 3.527, p = 0.021).
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P3.238 BETTER ESTIMATES 
OF SURVIVAL FOR PATIENTS 
CONSIDERING ADJUVANT 
CHEMOTHERAPY AFTER SURGERY 
FOR EARLY NON-SMALL-CELL LUNG 
CANCER (NSCLC)
Georgia J. Mccaughan1, Michael Boyer2, Martin 
Stockler3, Prunella L. Blinman3 
1Sydney Cancer Centre, Royal Prince Alfred 
Hospital/Australia, 2Medical Oncology, Sydney 
Cancer Centre/Australia, 3Nhmrc Clinical Trials 
Centre/Australia
Background: Discussions about prognosis are 
an important part of a patient’s consultation with 
their lung cancer clinician and many patients have 
a poor understanding of their prognosis. Good 
communication by cancer clinicians has been 
shown to have a measurable effect on patient 
outcomes. Currently there are only limited resources 
to assist clinicians in discussing prognosis in an 
understandable and comprehensive way in the 
adjuvant lung cancer setting.
Methods: We searched MEDLINE and the 
Cochrane Central Register of Controlled Trials for 
unconfounded randomised trials of cisplatin-based 
adjuvant chemotherapy published in English with 
overall survival (OS) curves. We digitized the OS 
curves with ‘Un-Scan-It ®’ and recorded the OS 
rates at 1, 2, 5, 7 and 10 years and the following 
percentiles (scenario): 90th (worst case), 75th (lower 
typical), median, 25th (upper typical) and 10th (best 
case). 
Results: We analysed 38 OS curves from 19 trials 
(7042 patients). The median patients per arm was 
106 (range 33 -935), median age was 61 and the 
median proportion male was 75%. With adjuvant 
chemotherapy the median OS rate (interquartile 
range, IQR) at 1y was 91% (85-95), 2y was 73% 
(69-88), 5y was 61% (45-65) and 7y was 49% (38-
65). With observation only, the median OS rate 
(IQR) at 1y was 88% (83-92), 2y was 74% (65-82), 
5y was 55% (42-58) and 7y was 40% (34-45). In 
both arms, survival rates at 1, 2, 5 and 7 years were 
well estimated by raising the 1 year survival rate 
to the power of 2, 5 and 7 respectively (83%, 62%, 
49% in the adjuvant arm and 77%, 53%, 41% in the 
observation arm). Few trials reported survival rates 
at 10 years. The median OS time (IQR) for the worst 
larger tumor in size and higher incidence of lymph 
node metastasis than Group-O. Median follow-up 
was 22 months (range 1-166). Overall 5-yr survival 
for the cohort was 75% (Figure 1) . Group-S had 
signiÀcantly worse 5-yr survival of 42% compared 
with 77% for Group-O (p=0.002) (Figure 2) .
Conclusion: The stage of Group-S was more 
advanced stage of Group-O. Group-S had a 
siginiÀcant worse prognosis than Group-O. 
It is supposed that patients diagnosed with 
adenocarcinoma by the pre-operative sputum 
cytology have biologically higher malignancy in 
lung adenocarcinoma patients with surgical resection 
of the lung. 
Keywords: surgical resection, sputum cytology, 
Adenocarcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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19%, MST were 37.4 months and 56.47 months, 
respectively. Results showed no beneÀcial effect 
of neoadjuvant chemotherapy on overall survival 
(HR, 1.245; 95% CI, 0.954 to 1.626; P =0.107) and 
on disease-free survival (HR, 1.281; 95% CI, 0.883 
to 1.857; P =0.193). No difference on OS and DFS 
were seen in stage I to stage IIIA NSCLC
Conclusion: Neoadjuvant chemotherapy with 
second generation regimens can’t improve overall 
survival and disease-free survival of NSCLC. The 
future of peri-operative treatment for NSCLC 
may lie in the outcome of trials investigating third 
generation regimens, molecularly targeted agents, 
anti-angiogenic agents, or multitargeted agents.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.240 FEASIBILITY STUDY OF S-1 
ADJUVANT CHEMOTHERAPY IN 
PATIENTS WITH COMPLETELY 
RESECTED NON-SMALL CELL LUNG 
CANCER
Shunsuke Okumura, Takaaki Sasaki, Yoshinori 
Minami, Masahiro Kitada, Yoshinobu Ohsaki 
Respiratory Center, Asahikawa Medical University 
Hospital/Japan
Background: Adjuvant chemotherapy is important 
for preventing the recurrence in patients with 
completely resected non-small cell lung cancer 
(NSCLC). In stage II and IIIA NSCLC, Cisplatin-
based combination chemotherapy is recommended 
for the adjuvant chemotherapy. In Japan, Tegafur/
Uracil (UFT) is also used in patients given a 
diagnosis of stage IA (Tumor size  2 cm) or IB lung 
adenocarcinoma. However, the absolute beneÀt of 
the adjuvant chemotherapies is about 5% increase of 
survival at 5 years after surgery. Therefore, the novel 
therapeutic strategy is required in the postoperative 
patients. In the present study, we evaluated feasibility 
and efÀcacy of single-agent S-1, an oral Áuorouracil 
agent, in patients with completely resected NSCLC. 
Methods: We conducted the single-arm, multicenter 
phase II study of S-1 feasibility. Primary endpoint 
was the relative dose intensity (RDI), which was 
deÀned as the ratio of the actual dose to the planned 
case scenario was 13 months (9-21), for the lower 
typical was 24 months (19-39) and for the median 
was 54 months (34-70). Median overall survival 
times could be predicted using simple multiples 
of the median: 0.25 x median estimated the 90th 
percentile, 0.5 x median estimated the 75th percentile. 
No trials reached 25th or 10th percentile. 
Conclusion: Simple percentages and their powers 
provide a useful starting point for estimating and 
describing survival to patients considering adjuvant 
chemotherapy after surgery for NSCLC.
Keywords: Non-small cell lung cancer, survival, 
adjuvant, Chemotherapy
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P3.239 LONG-TERM RESULTS OF 
PERI-OPERATIVE CHEMOTHERAPY 
IN PATIENTS WITH COMPLETED 
RESECTED NON–SMALL-CELL LUNG 
CANCER
Zhiwei Chen1, Meilin Liao1, Jiaan Ding2, Shun Lu1, 
Zhen Zhou1, Baijun Cheng1 
1Shanghai Lung Cancer Center, Shanghai Chest 
Hospital AfÀliated To Jiaotong University/China, 
2Thoracic Surgery, Shanghai Pneumology Hospital/
China
Background: To evaluate the effect of cisplatin-
based peri-operation chemotherapy (CT) on survival 
after completed resection of non-small cell lung 
cancer (NSCLC).
Methods: A randomized, multicenter study was 
conducted by Shanghai Lung Cancer Team since 
Feb 1995 to Feb 1996 for stage I-IIIA NSCLC 
with completed resection. Patients were randomly 
assigned to receive neoadjuvant chemotherapy 
(MMC/EPI/DDP, MMC/ADM/DDP) for 2 cycles 
or no  neoadjuvant chemotherapy. Adjuvant 
chemotherapy was given for majority of the patients, 
except for partial stage I patients. Accumulated 
survival, log rank, MST, Cox uni-variance and multi-
variance analyses, HR were used as statistics for 
evaluation.
Results: The trial included 337 patients with 
a follow-up of 15 years, 169 cases received 
neoadjuvant chemotherapy, and 168 cases didn’t 
receive neoadjuvant chemotherapy. The 15 years 
survival rate of the neoadjuvant chemotherapy and 
no neoadjuvant chemotherapy group were 25% and 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1327
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Of Pulmoner Medicine, Dokuz Eylul University, 
School Of Medicine/Turkey, 3Department Of Medical 
Oncology, Dokuz Eylul University, School Of 
Medicine/Turkey, 4Department Of Chest Surgery, 
Dokuz Eylul University, School Of Medicine/Turkey
Background: The exact staging in non-small 
cell lung cancer (NSCLC) is the most important 
parameter in managing of the patients. There is 
still debate the need of the adjuvant chemotherapy 
in early stage NSCLC patients. In this study, we 
aimed to investigate a prediction value of SUVmax 
in primary tumor for the decision of the adjuvant 
chemotherapy and the correlation between SUVmax 
value and the histopathological parameters such 
as arteriovenous invasion, lymphatic invasion, 
perineural invasion, pleural invasion.
Methods: In a retrospective study, 33 NSCLC 
patients (31M, 2W) who were diagnosed as stage I 
and II (IA:8 patients, IB:15 patients, IIB: 10 patients) 
were included in this study . Primary tumors were 
resected by surgery. The marginal regions of all 
tumors were negative for all patients. A total of 20 
patients received adjuvant chemotherapy (CT), 13 
patients did not receive (Non-CT). The average 
follow-up duration was 11 months (± 0,7). All of 
the patients underwent F-18 FDG PET-CT imaging 
before surgery for staging. SUVmax values of the 
primary tumor were obtained. Mann-Whitney U, 
Pearson correlation test and Kaplan Meier analysis 
were performed for the evaluation.
Results: The average of SUVmax values were 
9.44, 10.33 and 8.09 in all patients, CT group 
and Non-CT group respectively. There was no 
statistical difference in SUVmax values between 
CT group and Non-CT group (p=0,397). Disease 
free survival (DFS) was not statistically different 
between CT group and Non-CT group. DFS was 
shorter in patients with SUVmax>11 than in patients 
with SUVmax<11. (p:0.027). Although DFS was 
shorter in both CT and Non-CT group patients with 
SUVmax>11 than in patients with SUVmax<11, 
there was no statistically signiÀcant difference. This 
is probably due to limited number of patients.
There is no statistically difference between SUVmax 
and artery invasion (p=0.557), venous invasion 
(p=0.271), lymphatic invasion (p=0.259), perineural 
invasion (p=0.302), visseral pleural invasion 
(p=0.285), parietal pleural invasion (p=0.826).
dose. Secondary endpoints were safety and 1-year 
disease free survival (1y-DFS). The present study 
had 90% power to demonstrate that the RDI was not 
fewer than 50% with a one-sided alpha 5% when 
the RDI was in fact over 80%. Eligibility criteria 
included; 1) stage IB to IIIA NSCLC, 2) patients 
who received the complete resection, 3) 20 to 75 
years old. S-1 (80mg/m2) was given for 4-week oral 
administration followed by 2-week rest, within 8 
weeks after surgery.
Results: From May 2007 to Oct 2009, total 28 
patients were enrolled from three hospitals in 
Hokkaido, Japan. The RDI was 63.1% (95% 
CI, 48.6% to 77.7%), and an average of courses 
of S-1 was 5.3. There was no grade 3 or worse 
hematological toxicity in the present study. Four 
patients (14.3%) had grade 3 non-hematological 
toxicities, and no one had grade 4 or worse non-
hematological toxicities. Four patients had the 
recurrences and probability of 1-y DFS was 85.7% 
(95% CI, 72.8% to 98.6%). In the present study, 
the median RDI in patients over 65 years was 
less than that in patients 65 years or younger (P = 
0.013, Mann-Whitney U test). In the over 65 years 
group, more patients experienced grade 2 or 3 non-
hematological toxicities. 
Conclusion: S-1 chemotherapy, in which S-1 is 
given for 4-week oral administration followed by 
2-week rest, is not feasible as the standard regimen 
of administration for the adjuvant chemotherapy 
in patients with completely resected NSCLC. 
The modiÀed S-1 regimen that consists of 
2-week administration and 1-week rest would be 
recommended for adjuvant chemotherapy. 
Keywords: Non-small cell lung cancer, Adjuvant 
chemotherapy, S-1
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P3.241 CAN MAXIMUM STANDARDIZED 
UPTAKE (SUVMAX) OF F-18 FDG BE 
AN INDICATOR OF PREDICTING THE 
ADJUVANT CHEMOTHERAPY IN 
EARLY STAGE NON-SMALL CELL LUNG 
CANCER?
Erdem Surucu1, Canan Karaman2, Yusuf Demir1, 
Ilhan Oztop3, Nezih Ozdemir4, Atilla Akkoclu2, 
Berna Degirmenci Polack1 
1Department Of Nuclear Medicine, Dokuz Eylul 
University, School Of Medicine/Turkey, 2Department 
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Background: The combination of docetaxel and 
carboplatin is a well-established regimen in the 
treatment of late-stage non-small cell lung cancer 
(NSCLC). There are little data, however, regarding 
the safety and tolerability of this regimen in the post-
operative setting for early stage patients, criteria 
which are critical to the successful application of 
an adequate course of adjuvant therapy intended to 
bolster the success of curative surgical resection. 
Previous studies of adjuvant chemotherapy for 
NSCLC have reported rates of treatment protocol 
completion as low as 60%.
Methods: A total of 133 patients with stage Ib-
IIIa NSCLC were enrolled in an open-label, single 
arm study to assess the safety and tolerability 
of docetaxel (75 mg/kg) and carboplatin (AUC 
5.5) administered for 3 cycles after attempt at 
curative resection (lobectomy, bilobectomy or 
pneumonectomy). A new cooperative research body, 
the China Clinical Trials Consortium (CCTC), 
comprised of leading centers of lung cancer 
treatment in four cities in China, was enlisted to 
accelerate accrual of the target sample. The primary 
endpoint of the study was safety, as reÁected 
in the rate of febrile neutropenia believed to be 
associated with the treatment regimen, with a febrile 
neutropenia rate of less than 10% considered to be 
safe.
Results: Patient accrual was completed at 1 center 
in the US (2 patients) and 10 centers in China (131 
patients) in less than six months. Surgeon preference 
resulted in 66 procedures (50%) being performed 
using a video-assisted thoracoscopic surgical (VATS) 
approach, including 62 of 118 lobectomies (53%). 
Successful completion of the entire three-course 
adjuvant regimen was achieved in 115 patients 
(86%) according to the study protocol; of those, 
113 patients (98%) received greater than 66% of 
the target dose of carboplatin. VATS resection was 
associated with a higher rate of both delivery of 3 
full cycles of chemotherapy (94% vs. 79%, P=0.01) 
and delivery of at least 90% of the target carboplatin 
dose (99% vs. 70%, P=0.001) compared to the open 
approach. Febrile neutropenia complicated treatment 
in 12 patients (9.0%), below the predetermined 
safety threshold of 14 patients. Serious adverse 
events (SAEs) were observed in 13 (9.8%) patients. 
There were no deaths attributable to the study 
regimen.
Conclusion: In this prospective study, docetaxel 
and carboplatin were well-tolerated in the adjuvant 
treatment of NSCLC. Very rapid patient accrual was 
Table 1 
SUV>11 SUV<11 P 
All patients(months) 9,7 (±0,7) 17,5 (±0,6) 0,027 
CT group(months) 9,8 (±0,7) 16,3 (±2,2) 0,08 
Non-CT group (months) 9,5 (±1) 15,6 (±0,8) 0,26 
Conclusion: This preliminary study indicates 
that SUVmax: 11 might be a threshold value for 
predicting DFS for early stage NSCLC. The fact 
that no correlation was found between SUVmax 
and histopathological parameters, SUVmax may 
be an independent predictor of DFS. Adjuvant 
chemotherapy after surgery in early stage NSCLC 
patients with SUV>11 may be considered as an 
independent parameter. The further studies to 
examine this hypothesis are needed in larger groups 
of patients.
Keywords: SUVmax, early stage non-small cell 
lung cancer, F-18 FDG PET-CT
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P3.242 SAFETY AND TOLERABILITY 
OF DOCETAXEL-CARBOPLATIN IN 
THE ADJUVANT TREATMENT OF NON-
SMALL CELL LUNG CANCER, A CHINA 
CLINICAL TRIALS CONSORTIUM 
STUDY
Xiuyi Zhi1, Jianxing He2, Wen Gao3, Baohui Han4, Yue 
Yang5, Hui Li6, Deruo Liu7, Changli Wang8, Min Gong9, 
Hao Long10, James R. Rigas11, Mark Carey11, Thierry 
Jahan12, David M. Jablons13, Michael J. Mann13 
1Thoracic Surgery Dept., Beijing Lung Cancer 
Center,cmu/China, 2Department Of Cardiothoracic 
Surgery, The First AfÀliated Hospital Of Guangzhou 
Medical College/China, 3Shanghai Pulmonary 
Hospital/China, 4Shanghai Jiaotong University 
AfÀliated Shanghai Chest Hospital/China, 5Beijing 
Cancer Hospital/China, 6Department Of Thoracic 
Surgery, Beijing Chao-yang Hospital, Capital 
Medical University/China, 7Beijing Sino-Japan 
Hospital/China, 8Tianjin Cancer Hospital/China, 
9Beijing Lung Cancer Center, Cmu/China, 10Sun 
Yat-sen University/China, 11Thoracic Oncology, 
Dartmouth Hitchcock Medical Center/United States 
Of America, 12Thoracic Oncology, Univeristy Of 
California, San Francisco/United States Of America, 
13Surgery, University Of California/United States Of 
America
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with vinorelbine 80mg/m2 D1 and D8 given orally (after 
a Àrst cycle at 60 mg m,2 with myelosensitivity control ). 
After radical resection, ACT (4 cycles of 21 day regimen) 
was applied to outpatients with stage IB, II, and IIIA of 
NSCLC in 16 centres. 
Results: ACT was applied to 104 eligible patients (72 
men, 32 women, median of age 64 years). Out of them, 
41 were smokers, 57 ex-smokers and 5 non smokers. 
Surgically determined stages were IB in 32 pts, II 36 
pts and IIIA in 36 pts. Altogether 401 cycles were 
administered, 89.4% of patients Ànished four cycles 
of planned ACT. The reasons for 11 patients ending 
ACT prematurely were hematological toxicity in 8 
pts and non-hematological toxicity in 3 pts. The most 
frequent WHO grade 3/4 of toxicity accounted on the 
cycle were neutropenia in 10.3%, leucopenia in 5.03%, 
thrombocytopenia in 1.01%, anemia in 0.76% , alopecia 
in 3.27%, nausea in 4.02%, neurotoxicity, diarrhoea 
and mucositis in 0.25%. During the follow-up period, 
median 0.98 year (11.7m), 11 (10.6%) pts died, 2 (1.9%) 
pts died because of the different reason than toxicity or 
progression. 91 (87.5%) pts lived, 13 (12.5%) pts of them 
survived with appearance of recurrence and 78 (75%) pts 
lived without progression of the disease. 
Conclusion: ACT with carboplatin and vinorelbine 
given orally on day 1 and 8 appears to be a feasible and 
tolerable regimen in radically resected NSCLC. Present 
study is ongoing and the trends of overall survival, 
disease free interval and other survival parameters will be 
evaluated in the future. 
Keywords: neoadjuvant chemotherapy, Vinorelbine, 
NSCLC, Carboplatin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.244 EVALUATION OF RELATIONSHIP 
BETWEEN SERUM PROTEIN PROFILES 
AND LUNG CANCER BY SELDI-TOF-
MS (SURFACE ENHANCED LASER 
DESABSORBTION IONIZATION TIME 
OF FLIGHT MASS SPECTROMETRY) 
METHOD
Ahmet S. Yurdakul1, Özlem S. Sönmez2, Cebrail 
ûimüek2, Nurullah Zengin3, Atilla Keyf2, Can 
Öztürk1, Berna Öksüzoùlu3, Dilek Kubilay4, Özlem 
Gülbahar5, Senem Karatayl×6, Mithat Bozday×6 
achieved at sites participating in the CCTC with 
protocol compliance that was high compared to that 
observed in similar adjuvant studies. Furthermore, 
this high compliance was achieved despite the pre-
study perception among many Chinese investigators 
that these “Western” doses of the study drugs were 
too high to be tolerated by their Chinese patients. 
This new research body may therefore have the 
capability to substantially impact the clinical 
development of novel therapies for lung cancer, 
which has traditionally been hampered by slow 
patient accrual in deÀnitive, large-scale studies.
Keywords: Adjuvant chemotherapy, Docetaxel, 
Carboplatin, China Clinical Trials Consortium
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P3.243 ORAL VINORELBINE IN 
COMBINATION WITH CARBOPLATIN 
IN ADJUVANT CHEMOTHERAPY OF 
NON-SMALL CELL LUNG CANCER: A 
PROSPECTIVE MULTICENTRE STUDY 
OF FEASIBILITY AND TOLERABILITY.
Vitezslav Kolek1, Jiŉí Chalupa2, Ivona Grygárková1, 
Leona Koubková3, Tereza Janásková4, Dimka 
Sixtova5, Jaromír Roubec6, Eva Pavlíková2, Petr 
Chaloupka4 
1Respiratory Medicine, Palacky University Hospital/
Czech Republic, 2Oncological Department, Hospital/
Czech Republic, 3University Hospital Motol/
Czech Republic, 4Respiratory Diseases, Hospital/
Czech Republic, 5Respiratory Diseases, Thomayer 
University Hospital/Czech Republic, 6Respiratory 
Diseases, University Hostpital/Czech Republic
Background: Adjuvant chemotherapy (ACT) has 
become a new standard in patients with stages IIA, 
IIB, and IIIA of non-small cell lung cancer (NSCLC) 
after radical resection. Results in stage IB are still 
not conclusive. Vinorelbine is a preferable associated 
drug in this indication and in advanced NSCLC , a 
randomized study proved the comparable effectiveness 
and tolerability of vinorelbine given both orally or 
intravenously (i.v.). Meanwhile oral vinorelbine gives 
better comfort to patients. Cisplatin is preferred to 
carboplatin in ACT combination, but compliance seems 
to be a problem in daily practice. 
Methods: This prospective multicentre study evaluates 
the feasibility, toxicity and short time survival of adjuvant 
chemotherapy based on carboplatin- CBDCA (AUC 5) 
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Table 2. Discriminatory peaks between non-
squamous and squamous cancer groups. 
Conclusion: Proteomic patterns could provide some 
valuable clues on the carcinogenetic mechanism of 
different types of lung cancer and may help us to 
discover some potential subtype-speciÀc biomarkers 
of lung cancer by SELDI-TOF-MS method. 
Keywords: proteomics, Lung cancer
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P3.245 HIGH RISK FEATURES 
IMPROVE PROGNOSTICATION IN 
RESECTED STAGE I NSCLC: A SINGLE 
INSTITUTION RETROSPECTIVE 
REVIEW.
Aaron R. Hansen1, Maree Colosimo2, Belinda E. 
Clarke3, Edwina E. Duhig3, Kevin Matar1, Morgan 
Windsor1, Rayleen Bowman1, Ian A. Yang1, Kwun 
M. Fong1 
1Thoracic Medicine Department, The Prince 
Charles Hospital/Australia, 2Cancer Care Services, 
Holy Spirit Northside/Australia, 3Department Of 
Anatomical Pathology, The Prince Charles Hospital/
Australia
Background: In 2010 the seventh edition of 
the TNM staging for non-small cell lung cancer 
(NSCLC) was published. Like previous editions, 
the current system is an anatomical classiÀcation. 
However, the addition of various histological 
features to a tumour’s stage may more accurately 
predict outcomes. In this vane, this study aims 
to evaluate the effect of certain histopathological 
features on the prognosis for resected NSCLC in 
light of the new staging system. 
Methods: This is a retrospective review of 1513 
patients (1005 M, 508 F) who underwent surgical 
resection for NSCLC from 1979 to 2009 at the 
Prince Charles Hospital (TPCH). Data extracted 
from the pathology reports include the presence of 
the following variables: vascular, lymphatic and 
perineural invasion. These variables are compared 
to clinical phenotypes including stage and overall 
survival by the univariate Kaplan-Meier method and 
multivariate Cox regression model.
Results: Of the 1513 patients, 56.5% were stage 
I and 22.4% were stage II. In the entire cohort of 
patients vascular, lymphatic and perineural invasion 
was present in 38.6%, 23.8% and 8.8% respectively. 
1Pulmonology, Gazi Univercity, Faculty Of Medicine/
Turkey, 2Atatürk Chest Disease And Surgery Reseach 
Hospital/Turkey, 3Department Of Oncology, Numune 
Hospital,/Turkey, 4Oncology Hospital/Turkey, 
5Biochemistry, Gazi Univercity, Faculty Of Medicine/
Turkey, 6Institute Of Hepatology, Ankara University, 
Faculty Of Medicine/Turkey
Background: Advances in the proteomics study 
have introduced novel techniques for the diagnosing 
and screening of cancer biomarkers. The goal of this 
study was to establish proteomic patterns of tumor 
subsets in lung cancer patients with surface enhanced 
laser desabsorbtion ionization time of Áight mass 
spectrometry (SELDI-TOF-MS) method. 
Methods: 142 non-small cell lung cancer (NSCLC) 
and 27 small cell lung cancer (SCLC) totally 169 
patients were included in this study. In non-small 
cell lung cancer group, there were 60 squamous cell 
carcinoma, 38 non-squamous cell carcinoma and 
44 unclassiÀed type of non-small cell lung cancer 
patients. Venous samples were taken from all cases. 
All of the serum samples were analyzed by SELDI-
TOF-MS method for proteomics investigation. 
Results: When the Mann–Whitney non-parametric 
test was used between NSCLC and SCLC groups, 
only 3 peaks were found to be discriminatory in 
serum SELDI proÀles (Table 1). All of these 3 peaks 
showed higher intensity in patients with SCLC. 
Proteomic feature (m/z) p value AUROC 
9065 0.003 0.66 
9175 0.017 0.63 
9394 0.026 0.63 
Table 1. Discriminatory peaks between NSCLC 
and SCLC cases. When analysis was performed 
between non-squamous and squamous cancer groups 
of NSCLC, 8 proteomic features were found to be 
discriminatory (Table 2). Among these peaks only 
2 of them (5815 m/z, 5906 m/z) showed higher 
intensity in patients with non-squamous group. 
Proteomic feature (m/z) p value AUROC 
15879 0.0085 0.64 
3145 0.0093 0.65 
16051 0.0098 0.66 
2855 0.0115 0.64 
8683 0.0267 0.63 
15172 0.0321 0.63 
5815 0.0392 0.64 
5906 0.0408 0.63 
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both orally or intravenously (i.v.) in advanced 
NSCLC, meanwhile oral vinorelbine gives better 
comfort to patients. 
Methods: This prospective multicentre study 
evaluates the feasibility, toxicity and 3-year survival 
of adjuvant chemotherapy (ACT) based on cisplatin- 
CDDP (80mg/m2) or carboplatin- CBDCA (AUC 5) 
with vinorelbine (25 mg/m2 D1 i.v. and 60mg/m2 D8 
given orally). After radical resection, ACT (4 cycles 
of 21 day regimen) was applied to patients with stage 
IB, II, and IIIA of NSCLC in 21 Czech and Slovak 
centres. Selection of CDDP or CBDCA was based on 
individual centre preference. Recruitment of patients 
started on the 12th of January 2005 and Ànished on 
the 5th of December 2008. Evaluation was closed on 
the 31st of January 2011. 
Results: ACT was applied to 154 eligible patients 
(110 men, 44 women, median of age 63 years). 
Out of them, 89 were smokers, 49 ex-smokers 
and 16 non smokers. Surgically determined stages 
were IB in 46 pts, IIA in 18 pts, IIB in 38 pts and 
IIIA in 52 pts. CBDCA was given to 77 patients 
and CDDP to 77 patients, 4 of whom switched to 
CBDCA. All of them were treated as out-patients. 
Altogether 586 cycles (mean no 3.81, in CDDP 3.77, 
in CBDCA 3.84) were administered, 84% of patients 
Ànished four cycles of planned ACT. The reasons 
for 25 patients ending ACT prematurely were 
hematological toxicity in 8 pts, non-hematological 
toxicity in 9 pts and other reasons in 8 pts. The 
most frequent WHO grade 3/4 of toxicity were 
neutropenia in 10.3%, leucopenia in 4%, anemia 
in 4.5%, thrombocytopenia in 1.9%, alopecia in 
2.9%, nausea in 5.8%, neurotoxicity, diarrhoea and 
mucositis in 0.7%. There was signiÀcantly higher 
incidence of neutropenia (p 0.034) and slightly 
higher incidence of vomiting (p 0.055) in CDDP 
regimen, and non signiÀcantly higher incidence of 
anemia (p 0.054) in CBDCA regimen. Median of 
follow-up was 31 month, 3-year survival during 
this period was 69,8%. After evaluation closing 
98 pts has lived, 31.2 % (48 pts) died because of 
NSCLC , 5,2 % (8 pts) died because of the different 
reasons than toxicity or progression (7 pts died 
without progression, 1 patient died during the cancer 
recurrence but progression was not the reason of 
the death). Out of all alive patients, 18 survived 
with appearance of the recurrence and 80 pts lived 
without progression of the disease. Disease free 
interval was 43 months. 
Conclusion: ACT with vinorelbine given orally on 
day 8 appears to be a feasible and tolerable regimen 
Subjects with resected stage I NSCLC had a poorer 
prognosis if either vascular (HR 1.389, p = 0.001) 
or lymphatic invasion (HR 1.828, p <0.0001) were 
present, but not if perineural invasion (HR 1.235 p 
= 0.362) was present. In all subjects, preliminary 
multivariate analysis showed that vascular invasion 
remained a statistically signiÀcant prognostic 
variable independent of stage.
Conclusion: This is the largest single institution 
review of its kind and the Ànal analysis is proceeding 
and will soon be ready to publish. However the 
preliminary analysis of our data suggests that in 
patients with resected stage I NSCLC the presence 
of vascular invasion portends a signiÀcantly worse 
prognosis. This study proposes that by considering 
vascular invasion in patients with resected Stage I 
NSCLC, a more precise prognosis can be determined 
so that adjuvant chemotherapy may be offered to 
those at higher risk with a better treatment beneÀt 
ratio. 
Keywords: NSCLC, Lymphatic Invasion, Vascular 
Invasion, Perineural Invasion
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P3.246 ORAL VINORELBINE IN 
COMBINATION WITH CISPLATIN 
OR CARBOPLATIN IN ADJUVANT 
CHEMOTHERAPY OF NON-
SMALL CELL LUNG CANCER: A 
PROSPECTIVE MULTICENTRE STUDY 
OF FEASIBILITY,TOLERABILITY AND 
3-YEAR SURVIVAL.
Vitezslav Kolek1, Ivona Grygárková1, Jiŉí Chalupa2, 
Leona Koubková3, Jiŉina Švecová2, Jana SkŉiĀková3, 
Lenka Ostŉížková2, Dimka Sixtová4 
1Respiratory Medicine, Palacky University Hospital/
Czech Republic, 2Oncological Department, Hospital/
Czech Republic, 3Respiratory Diseases, University 
Hospital/Czech Republic, 4Respiratory Diseases, 
Thomayer University Hospital/Czech Republic
Background: Adjuvant cisplatinum-based 
chemotherapy is recommended for routine use in 
patients with stages IIA, IIB, and IIIA of non small-
cell lung cancer (NSCLC) after radical resection. 
Results in stage IB were not conclusive. Vinorelbine 
is a preferable associated drug in this indication 
and a randomized study proved the comparable 
effectiveness and tolerability of vinorelbine given 
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a history of hemoptysis received preoperative 
bevacizumab (15mg/m2) alone followed by a repeat 
CT scan 2 weeks later. Thereafter, patients received 
4 cycles of docetaxel and cisplatin and 2 additional 
cycles of bevacizumab. Correlation between 
downstaging and response to bevacizumab was 
assessed by Wilcoxon rank test. 
Results: Thirty nine patients evaluable for response 
were- Stage IB: N=6 (15%); Stage II: N=6 (15%); 
Stage IIIA: N=27 (69%). KRAS mutations: 10/34 
(29%); EGFR mutations: 4/34 (12%). Two weeks 
after bevacizumab, 37/39 patients (95%) had a 
reduction in bidimensional measurement (Figure 1). 
Six of 39 (15%) had a >25% response at 2 weeks. 
9/34 patients (26%) developed new tumor cavitation 
at 2 weeks following single agent bevacizumab. 
TTP in patients with and without cavitation was not 
reached versus 17 months. 15/35 evaluable patients 
(43%) were downstaged. 11/23 stage IIIA patients 
(48%) achieved nodal downstaging. There was no 
correlation between response to bevacizumab at 
2 weeks and downstaging (p=0.17). 6/34 (18%) 
patients had >90% tumor necrosis in the resection 
specimen. With a median follow-up of 18 months, 
all patients with >90% tumor necrosis were alive and 
disease-free. Of note, 4/6 patients with >90% tumor 
necrosis were those who developed new cavitation at 
2 weeks following 1 dose of bevacizumab. 
Conclusion: Nearly all patients had a reduction in 
bidimensional measurement at 2 weeks following 
single-agent bevacizumab. The magnitude 
of response did not, however, correlate with 
downstaging. Cavitation following single-agent 
bevacizumab may predict for marked pathologic 
treatment effect and may be associated with 
improved TTP. 
Keywords: bevacizumab, Non small cell lung 
cancer, neoadjuvant
in radically resected NSCLC. Short time survival 
results are optimistic. Present study is ongoing and 
the trends of overall survival, disease free interval 
and other survival parameters will be evaluated in 
longer follow-up period. 
Keywords: oral vinorelbine, Adjuvant 
chemotherapy, short time survival, NSCLC
Poster Session 3 – NSCLC - Early Stage Wednesday, 6 July 2011 12:15-
14:15
P3.247 A WINDOW STUDY EVALUATING 
THE ACTIVITY OF SINGLE AGENT 
BEVACIZUMAB PRIOR TO INDUCTION 
CHEMOTHERAPY FOR OPERABLE 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
Paul K. Paik1, Geoffrey R. Oxnard1, Katharine Price1, 
Camelia S. Sima2, Michelle S. Ginsberg3, William 
D. Travis4, Valerie Rusch5, Mark G. Kris1, Naiyer A. 
Rizvi1 
1Medicine, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 2Epidemiology 
And Biostatistics, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 3Radiology, 
Memorial Sloan-Kettering Cancer Center/United 
States Of America, 4Pathology, Memorial Sloan-
Kettering Cancer Center/United States Of America, 
5Thoracic Surgery, Memorial Sloan-Kettering 
Cancer Center/United States Of America
Background: Neoadjuvant and adjuvant 
chemotherapy are integral components of treatment 
for resectable NSCLC. The 5 year survival for stage 
IB-IIIA NSCLC, however, remains disappointing. 
Incorporating new agents into preoperative treatment 
allows for an in vivo evaluation of treatment effect 
and pathologic correlation at resection. Bevacizumab 
added to chemotherapy beneÀts patients with 
advanced NSCLC. Its single agent activity is not 
well characterized, however. We hypothesized that 
the addition of bevacizumab prior to neoadjuvant 
chemotherapy would be an effective preoperative 
approach. Our speciÀc objectives were to determine: 
1) response to single agent bevacizumab, and 
2) subsequent rate of downstaging compared to 
historical controls treated without bevacizumab. We 
report the results of this correlative radiologic study 
herein. 
Methods: Patients with resectable stage IB-IIIA 
adenocarcinoma and large-cell carcinoma without 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1333
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
considering recommending adjuvant chemotherapy 
with a 5 year survival probability of 40%, 60% and 
80% respectively, clinicians reported an expected 
a mean gain (SE) of 20.8% (2.7), 15.6% (2.4) and 
13.2% (2.1) against an expected of 12%, 8% and 4% 
respectively with a hazard ratio of 0.80. 
Conclusion: Our survey suggest oncologists as 
the clinicians best able to calculate the individual 
beneÀt of adjuvant chemotherapy and the majority 
of specialities polled agreed oncologists as the 
more appropriate initial person to discuss adjuvant 
chemotherapy with patients after radical surgery 
for lung cancer. The perceived value prior to 
recommending adjuvant chemotherapy in clinicians 
greatly exceeds current published results.
Keywords: Non-small cell lung cancer, Surgery, 
Adjuvant chemotherapy
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P3.249 NON-SMALL CELL LUNG 
CANCER PATIENTS WITH VERY GOOD 
PROGNOSIS: INTRODUCTION OF A 
NOVEL ‘TRIPLE-NEGATIVE’ ENTITY.
Akif Turna1, Kamil Kaynak1, Ahmet Demirkaya1, 
Serkan Ozkul1, Mustafa Yaman2, Buge Öz3 
1Department Of Thoracic Surgery, Istanbul 
University Cerrahpasa Medical Faculty/Turkey, 
2Department Of Chest Diseases, Istanbul University 
Cerrahpasa Medical Faculty/Turkey, 3Department Of 
Pathology, Istanbul University Cerrahpasa Medical 
Faculty/Turkey
Background: Staging is of paramount importance 
in treatment planning, recommendation of best 
treatment modality and survival predilection.Despite 
the multinational, multiinstitutional basis of the 
database which has been used for construction of 7th 
staging system, data regarding lymph node staging 
and histopathologic markers remained suboptimal 
and it prones to selection-bias. We aimed to evaluate 
the prognostic importance of lymphatic and 
perineural invasion in patients with N0 disease and 
try to deÀne a new triple-negative group of patients.
Methods: Two hundred sixtyeight patients (221 
men, 47 women)who had undergone complete 
surgical resection for non-small cell lung cancer 
between January 2005 and December 2010 were 
investigated.. Mean age was 59.8 (ranging from 
20 to 82) years. Mean follow-up time was 23 
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P3.248 ONCOLOGISTS, PHYSICIANS 
AND SURGEONS OPINIONS ON 
THE PERCEIVED VALUE AND 
APPROPRIATENESS OF THE 
SPECIALITY TO INFORM PATIENTS ON 
ADJUVANT CHEMOTHERAPY AFTER 
RADICAL SURGERY FOR NON-SMALL 
CELL LUNG CANCER
F. W. D. Tai1, Keng Suan Khor1, Sanjay Popat2, 
Michael Beckles3, Maria Leung1, May Al-Sahaf1, 
Eric Lim1 
1Department Of Thoracic Surgery, Royal Brompton 
Hospital/United Kingdom, 2Department Of 
Oncology, The Royal Marsden Hospital/United 
Kingdom, 3The Royal Free Hospital/United Kingdom
Background: The beneÀt of adjuvant chemotherapy 
after radical surgery for non-small cell lung cancer 
is established, but the roles and responsibilities 
of discussing adjuvant chemotherapy are not well 
established. Whilst the risks are relatively straight 
forward to convey, the difÀculties in conveying 
the beneÀt results from published hazard ratios in 
the literature as the beneÀt varies with stage and 
therefore needs to be calculated individually and 
conveyed in a language that is understood by the 
patient.
Methods: From 2010 to 2011, a survey was 
conducted by email to cancer physicians, oncologists 
and surgeons in the United Kingdom. Clinicians 
were asked to rank who they felt were the most 
appropriate to discuss adjuvant chemotherapy with 
patients, to calculate expected survival with adjuvant 
chemotherapy given baseline survival probability of 
80% and a hazard ratio of beneÀt of 0.80, and then 
surveyed for the additional expected gain in survival 
in cohorts with a 5 year survival probability of 
40%, 60% and 80% respectively before they would 
recommending adjuvant chemotherapy
Results: A total of 202 responses were received 
from 27 surgeons, 77 physicians, 87 oncologists (11 
were others or unstated). The majority of 56% of 
surgeons, 79% of physicians and 61% of oncologists 
felt an oncologist as the most appropriate initial 
clinician to discuss adjuvant chemotherapy with 
patients after surgery. In total 33% of surgeons, 53% 
of physicians and 73% of oncologists were able to 
correctly calculate the expected survival of patients. 
When asked about the perceived value before 
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identify a lymph node which receives Àrst lymphatic 
Áow from the regional segment containing a lung 
tumor (ie, sentinel lymph node; SN). We have 
developed computed tomography lymphography 
(CTLG) by transbronchial injection of a water-
soluble extracellular CT contrast agent of iopamidol 
to identify the SNs in preoperative NSCLC patients. 
This study was conducted to evaluate feasibility of 
safety of this method.
Methods: Eleven patients with clinical stage I 
NSCLC were enrolled in the study. They included 
3 males and 8 females and their mean age was 
65.1 (range; 47 - 76). Mean tumor size was 20.5 
mm (range; 14 - 35). The histologic types were 
adenocarcinoma in 10 patients and squamous cell 
carcinoma in 1 patient. Tumor locations were as 
follow; right upper lobe in 6, right lower lobe in 
2, left upper lobe in 2, and left lower lobe in 1. 
Virtual bronchoscopic navigation images which 
aid bronchoscopists in guiding the bronchoscope 
to a targeted location were reconstructed using 1 
mm thickness CT scan data prior to the CTLG. 
An ultra-thin bronchoscope was inserted to the 
targeted peripheral bronchus under a guidance of the 
navigation images. A sheath was inserted through a 
channel of the bronchoscope and 3ml of iopamidol 
was injected. CT images (1 mm thickness) of the 
chest were obtained at 30 seconds and 5 minutes 
after injection. The respective CTLG and contrast 
enhanced CT images were checked simultaneously 
on a workstation. Max CT number of every 
pulmonary, hilar and mediastinal lymph node was 
measured. SNs were identiÀed when the lymph 
nodes were enhanced clearly in the postcontrast CT 
images, or max CT number of the lymph nodes in the 
postcontrast CT images (30 seconds after injection) 
increased by more than 30 HounsÀeld unit (HU) 
higher compared to the precontrast ones. Patients 
underwent lobectomy with standard lymph node 
dissection. All lymph nodes include the SNs were 
histopathologically examined by hematoxylin and 
eosin staining.
Results: The ultrathin bronchoscope could access 
targeted bronchus and iopamidol was delivered 
into peritumoral area in all patients without any 
complication. CTLG was usually performed after 
transbronchial tumor biopsy (10/11), and it took 
about 10 minutes to complete the CTLG method 
itself. SNs were identiÀed in all patients and the 
average number of SNs was 1.54 (range: 1-2). SNs 
were identiÀed at pulmonary or hilar station in all 
patients and at mediastinal station in 4 patients. CT 
months (ranging from 1 to 111 months). Kaplan 
Meier analysis along with log-rank test and Cox 
multivariate analysis were used.
Results: The 5-year survival of in our series was 
61.5%, median survival time was 59±5 months 
(95% CI:52-70 months). Statistically signiÀcantly 
different stage stratiÀcations according to new T 
staging were observed (p=0.03). Mediastinal nodal 
tumor involvement was found to be a prognostic 
factor (p=0.02).Perineural involvement and Among 
patients without mediastinal lymph node metastasis, 
perin lymphatic invasion independently indicated 
worse survival (p=0.02 and p=0.04 respectively). N0 
patients without lymphatic and perineural invasion 
(triple negative patients) had the best survival 
(mean survival time was 75±7 months (95% CI: 
62 -88 months). The survival rate of triple negative 
patients was statistically better that that of N0 
patients(p=0.0351)
Conclusion: : Perineural invasion and lymphatic 
invasion seemed to be good prognosticators. Patients 
with triple negative tumors (N0, lymphatic invasion- 
perineural invasion-) had the best survival.
Keywords: Perineural Invasion, early stage lung 
cancer, Lymphatic Invasion, triple negative tumor
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P3.250 COMPUTED TOMOGRAPHY 
LYMPHOGRAPHY BY 
TRANSBRONCHIAL INJECTION OF A 
WATER-SOLUBLE EXTRACELLULAR 
CT CONTRAST AGENT TO IDENTIFY 
THE SENTINEL LYMPH NODES IN 
PREOPERATIVE NSCLC PATIENTS
Hiromitsu Takizawa1, Kazuya Kondo2, Hiroaki 
Toba1, Koichiro Kajiura1, Mika Takashima1, Koh 
Uyama1, Yasushi Nakagawa1, Yukikiyo Kawakami1, 
Koichiro Kenzaki1, Shoji Sakiyama1, Akira Tangoku1 
1Department Of Thoracic, Endocrine Surgery And 
Oncology, The University Of Tokushima Graduate 
School/Japan, 2Department Of Oncological Medical 
Services, Institute Of Health Biosciences, The 
University Of Tokushima Graduate School/Japan
Background: Segmentectomy for clinical stage 
IA peripheral non-small lung cancer (NSCLC) 
patients should be converted to lobectomy when 
intraoperative frozen section reveals metastasic 
hilar or mediastinal lymph nodes. It is important to 
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Methods: From our cancer tumor registry, we 
identiÀed retrospectively patients with resected 
NSCLC from 2007 to 2009. Patients from the tumor 
registry were excluded with diagnosis other than 
NSCLC, wedge resection, incomplete nodal staging 
and R1 resection as major ineligibility requirements 
of these adjuvant trials. We then compared the 
results from the cancer registry analysis with the 
number of patients approached in the clinic to 
participate in 1 of 2 adjuvant placebo-controlled 
targeted therapy trials with either EGFR tyrosine 
kinase inhibitor (RADIANT) or the melanoma 
antigen vaccine MAGE-A3 (MAGRIT). Participants 
initially consented to have their resected tumor tissue 
evaluated for targets either EGFR or MAGE. If the 
target was identiÀed, participants would then consent 
to enroll in the treatment portion of these clinical 
trials. In both clinical trials, patients were permitted 
to receive standard adjuvant chemotherapy. 
Results: From our tumor registry, we identiÀed 
135 patients with resected stage I to IIIA NSCLC 
who were potential candidates to participate in 
these adjuvant treatment trials, RADIANT or 
MAGRIT. From these 135 patients, only 43 (32%) 
pre-screened patients consented to have their tumor 
tissue evaluated for either EGFR (16 patients) or 
MAGE (27 patients). Twenty-two (22) participants 
of the 43 consented patients (51%) had a positive 
tissue target identiÀed for participation in the 
treatment portion of either the RADIANT (15 of 
16 patients, 94%) or MAGRIT (7 of 27 patients, 
26%). Of these 22 participants, only 6 patients (27%) 
enrolled in the treatment portion of these clinical 
trials; RADIANT (4 patients, 27%) or MAGRIT 
(2 patients, 28%). Overall, from the 135 patients 
identiÀed retrospectively in our tumor registry 
only 4% enrolled in these 2 trials. The reasons for 
non-participation were 1) ineligibility at initial 
pre-screening, 2) treatment at another institution, 
3) unacceptable frequency of follow-up visits and 
4) declining any further therapy after adjuvant 
chemotherapy. Inability to comply with the protocol 
and the placebo-controlled study design were less 
common reasons for non-participation. 
Conclusion: Accrual to adjuvant targeted cancer 
clinical trials is further impeded by the need 
for molecular selection of participants. Broader 
eligibility requirements not related to molecular 
selection, integrated treatment strategy of 
conventional and investigational therapies, reduction 
in the frequency of follow-up evaluations, and 
improved clinical trials education for investigators 
images at 30 seconds were suitable to identify SNs 
visually. Max CT number of the SNs of precontrast, 
postcontrast at 30 seconds and 5 minutes after 
injection were 107 ± 31 HU, 243 ± 217 HU, and 
179 ± 108 HU, respectively. Pathologic examination 
revealed n2 in one patient. This metastatic lymph 
node was included in the SNs.
Conclusion: CTLG by transbronchial injection of 
iopamidol was safe and useful method to identify the 
SNs in NSCLC patients.
Keywords: lymphography, segmentectomy, Sentinel 
lymph node, computed tomography
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P3.251 ACCRUAL TO ADJUVANT 
TARGETED CLINICAL TRIALS IN 
RESECTED NON-SMALL CELL LUNG 
CANCER: MORE HOLES IN THE 
“LEAKY PIPE.”
James R. Rigas1, Kathryn L. Abraham1, Konstantin 
H. Dragnev2, Peter A. Delong1, David Johnstone3, 
Cherie P. Erkmen4, William Nugent4, Candice C. 
Black5, Sara Simeone1, Paula A. Caron6, Amy J. 
Frandsen1 
1Dartmouth Medical School, Norris Cotton Cancer 
Center/United States Of America, 2Medicine, 
Dartmouth Medical School/United States Of 
America, 3Cardiothoracic Surgery, Dartmouth 
Medical School/United States Of America, 
4Dartmouth-Hitchcock Medical Center/United States 
Of America, 5Pathology, Dartmouth Hitchcock 
Medical Center/United States Of America, 6Thoracic 
Oncology, Dartmouth Hitchcock Medical Center/
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Background: Accrual to clinical trials is the 
primary approach for developing novel and 
improved treatment strategies for patients with 
cancer. A clinical trials design strategy to improve 
the therapeutic index for novel targeted therapies is 
to select individuals with speciÀc tumor molecular 
characteristics. Overall, accrual to therapeutic 
clinical trials has been a concern and reported 
analogous to a “leaky pipe.” Now with the addition 
of molecular patient selection accrual may further be 
impeded. For this report, we evaluated the accrual 
to 2 international adjuvant targeted treatment trials 
for patients with resected non-small cell lung cancer 
(NSCLC) at our institution. 
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of squamous carcinoma, 1 case each of atypical 
carcinoid, large cell neuroendocrine carcinoma, 
and mucoepidermoid carcinoma. Pathological stage 
breakdown: 47 cases of Stage I, 2 of Stage II, and 
1 of Stage III. During a mean observation period of 
514 days (283 - 608), 4 recurrences were conÀrmed 
in the solid group. 
Conclusion: No statistical difference was found 
between the aerated and solid groups (Log-rank test, 
p=0.1089) due to the small sample number of 50. We 
continue our observation for future re-analysis on 
survival and recurrence. 
Keywords: Thin-section CT, recurrence, small-size 
lung cancer, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.253 PROGNOSTIC VALUE OF 
PREOPERATIVE FDG-PET IN STAGE IA 
LUNG ADENOCARCINOMA
Shuji Murakami1, Haruhiro Saito1, Tetsuro Kondo1, 
Funihiro Oshita1, Hiroyuki Ito1, Masahiro Tsuboi1, 
Tomoyuki Yokose2, Yoichi Kameda2, Haruhiko 
Nakayama1, Kouzo Yamada1 
1Department Of Thoracic Oncology, Kanagawa 
Cancer Center Hospital/Japan, 2Department Of 
Pathology, Kanagawa Cancer Center/Japan
Background: Maximum standardized uptake value 
(SUVmax) of 18F-Áuorodeoxyglucose positron 
emission tomography (FDG-PET) has been found 
to have prognostic value. We previously reported 
the correlation between SUVmax and pathological 
invasive area, and determined a SUVmax cut-off 
value of 2.15 for predicting the recurrence potential of 
an invasive area of diameter 5 mm. Here, we evaluate 
the validity of FDG-PET for prediction of recurrence 
in pathological stage IA lung adenocarcinoma.
Methods: From February 2006 to May 2008, 
100 patients with pathological stage IA lung 
adenocarcinoma underwent complete resection at our 
hospital. Tumors were classiÀed as air-type or solid-
type based on thin-section computed tomography 
(TS-CT) Àndings and the inÁuence of TS-CT 
classiÀcation, SUVmax, and clinicopathologic 
features in terms of the incidence of recurrence were 
evaluated.
and participants may lead to enhanced participation 
in adjuvant targeted clinical trials in NSCLC. 
Keywords: clinical trials accrual, Adjuvant targeted 
therapies
Poster Session 3 – NSCLC - Early Stage Wednesday, 6 July 2011 12:15-
14:15
P3.252 PROSPECTIVE STUDY OF 
PROGNOSTIC FACTORS IN SMALL 
PERIPHERAL LUNG CARCINOMAS
Tetsuro Kondo1, Miki Ohe1, Takeshi Honda1, Shuji 
Murakami1, Haruhiro Saito1, Funihiro Oshita1, 
Kimitoshi Nawa2, Hiroyuki Ito2, Masahiro Tsuboi2, 
Haruhiko Nakayama2, Tomoyuki Yokose3, Yoichi 
Kameda3, Kouzo Yamada1 
1Thoracic Oncology, Kanagawa Cancer Center/
Japan, 2Thoracic Surgery, Kanagawa Cancer 
Center/Japan, 3Pathology, Kanagawa Cancer 
Center/Japan
Background: Some cases of peripheral lung 
carcinoma with the largest nodule diameter < 3 
cm have poor outcomes after early post-operative 
recurrence. We prospectively collected data on 
peripheral lung carcinoma cases with the largest 
nodule diameter < 3 cm conÀrmed by thin-section 
computed tomography (TSCT) to Ànd statistical 
differences in prognosis between the cases with air-
containing type lesion and those with solid density 
type lesion. Further, we aimed to clarify other 
prognostic factors that may contribute to early post-
operative recurrence of peripheral lung carcinoma. 
Methods: 50 patients with peripheral lung 
carcinoma conÀrmed at our hospital between 
January and October 2009 were enrolled. In all 
cases, the largest nodule diameter was < 3 cm in 
TSCT images and carcinoma was histopathologically 
conÀrmed. A written agreement [Informed consent] 
for participation in the study was obtained from 
each patient. Investigated prognostic factors are age, 
gender, smoking history, and classiÀcation of the 
tumors (air-containing type lesion or solid density 
type lesion) by TSCT. 
Results: The study enrolled 23 male and 27 female 
patients, median age 69 years (range: 40 - 86). There 
were 23 smokers and 27 non-smokers in the group. 
The number of air-containing type lesion was 19 
and that of solid density type lesion was 31, based 
on the Àndings of the TSCT images. Histological 
breakdown: 40 cases of adenocarcinoma, 7 cases 
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the 119 BACs to improve our understanding of this 
tumor and, especially, to focus on the underlying 
etiology of male patients with BAC. 
Methods: Among 2087 patients who underwent 
surgery for primary lung cancer in our institute 
from 1995 to 2010, 1549 patients had lung 
adenocarcinoma and 119 (7.8%) of them were 
BAC. As comparison groups, we used invasive 
adenocarcinomas (n=1430, Group 1) and NSCLCs 
other than adenocarcinoma (excluding bronchial 
gland carcinoma and carcinoid) (n=438, Group 2). 
We studied the gender distribution and smoking habit 
of BAC patients in comparison with other Groups. 
Pathological Àndings of these BACs such as size, 
presence of mucin, multiplicity and coexistence of 
other tumors were also examined. Thirty of 34 male 
patients and 27 of 85 female patients, whose samples 
were available, were also analyzed for EGFR 
mutations. 
Results: There were 34 males and 85 females. The 
rates of males among the BAC patients, Group 1 and 
Group 2 were 29, 50 and 87 (%). The smoker rates 
were 26, 48 and 92 (%) (68, 79 and 95 (%) for male, 
and 9, 18 and 71 (%) for female, respectively). The 
mean age was 61±10, 64±10, 67±9.0, which showed 
no gender difference. The mean size was 16±10 mm. 
Histologically, 9 of 119 (8%) were mucinous BAC, 
21 (18%) were multiple, 13 (11%) were presented 
with advanced lung cancer (12 with adenocarcinoma 
and 1 with squamous cell carcinoma) and 21 (18%) 
were presented with AAH in the same resected 
specimen. None of these histological characteristics 
showed gender difference. Among male patients with 
BAC, EGFR mutations were identiÀed in 47% (14 
of 30) while there were 67% (18 of 27) in female 
patients. 
Conclusion: There was a gender difference among 
BAC patients, 2.6 times more in female than male, 
and younger patients were affected compared to 
other Groups of lung cancer. All these data were 
comparable with former reports. The rate of smokers 
among BAC was lower (26%) than those of the 
other Groups as was also expected, although this 
was much evident when only female patients are 
considered (9%) and was not so low in male (68%). 
EGFR mutation rate was quite high both in male 
and female (47% and 67%, respectively), while it 
was equal between smoker and non-smoker (56% 
and 57%), suggesting that smoking habit is not a 
causative factor for BAC (the mutation data is not 
yet attained in all the cases, though.) Although it 
seems that BAC has least effects of smoking for its 
Results: Unlike air-type adenocarcinomas, 
recurrent disease was detected in 8 of 62 solid-
type adenocarcinomas. SUVmax and diameter of 
invasive area were signiÀcantly correlated with 
recurrence and a shorter time to recurrence. All 8 
recurrent cases had pathological invasive area > 
5 mm. All except one case of recurrence showed 
solid-type adenocarcinomas with SUVmax >= 2.15. 
Three-year disease-free survival rates were 100% 
in air-type adenocarcinomas, 97.3% in solid-type 
adenocarcinomas with SUVmax < 2.15, and 74.1% 
in solid-type adenocarcinoma with SUVmax >= 
2.15.
Conclusion: Combined evaluation of TS-CT 
classiÀcation and SUVmax had signiÀcant 
value in predicting recurrence in stage IA lung 
adenocarcinoma, reÁecting the aggressiveness of 
primary lung adenocarcinoma. Prediction of tumor 
aggressiveness could contribute to decision-making 
regarding the choice of surgical procedure and 
treatment after surgery.
Keywords: FDG-PET, Thin-section CT, 
Adenocarcinoma
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P3.254 ASSESSMENT FOR 
UNDERLYING ETIOLOGY OF 
BRONCHIOLOALVEOLAR CARCINOMA 
(BAC). IMPACTS OF SMOKING HABIT 
AND EGFR MUTATION.
Miyako Hiramatsu1, Hiroko Nagano1, Seijiro Sato1, 
Hironori Ninomiya1, Kentaro Inamura1, Noriko 
Motoi1, Hirofuimi Uehara2, Mingyon Mun2, Yukinori 
Sakao2, Sakae Okumura2, Yuji Shiraishi3, Ken 
Nakagawa2, Yuichi Ishikawa1 
1Pathology Department, Japanese Foundation 
For Cancer Research/Japan, 2Thoracic Surgical 
Oncology, Cancer Institute Hospital/Japan, 
3Thoracic Suregery, Fukujuji Hospital/Japan
Background: Bronchioloalveolar carcinoma (BAC, 
or adenocarcinoma in situ) is a non-invasive variant 
of lung adenocarcinoma which is expected to 
have 100% cause-speciÀc survival after complete 
removal. This tumor is generally recognized to be 
more frequent in female than in male, more in non-
smokers than in smokers, but the fact is not fully 
examined. In this study, we investigated clinical 
backgrounds and pathological characteristics of 
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important utility for early detection and routine 
diagnosis of NSCLC in combination with imaging 
technologies. 
Keywords: NSCLC, Early Detection, mAB 
proteomics, blood biomarkers
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.256 PROGNOSTIC SIGNIFICANCE OF 
FDG-PET IN SURGICALLY TREATED 
PATHOLOGICAL STAGE I LUNG 
ADENOCARCINOMA
Mitsunori Higuchi, Hiroyuki Suzuki, Yutaka Shio, 
Jun Osugi, Mika Hoshino, Yoko O. Mera, Atsushi 
Yonechi, Takeo Hasegawa, Hiroshi Yaginuma, 
Naoyuki Okabe, Satoshi Mutoh, Takumi Yamaura, 
Yuzuru Watanabe, Mitsukazu Gotoh 
Thoracic Surgery, Fukushima Medical University/
Japan
Background: We often experience recurrent disease 
after surgery in adenocarcinoma even in the early 
staged patients. In general, pathological (p-) stage 
IB to III cases are considered to be good candidates 
for adjuvant chemotherapy, and furthermore p-stage 
IA cases over 2 cm in size are also regarded to 
be candidates of adjuvant uracil-tegafur in Japan. 
We have conducted this retrospective study to 
evaluate whether we could determine the indication 
of adjuvant chemotherapy by using maximum 
standardized uptake value (SUVmax) on FDG-PET 
in p-stage I adenocarcinoma patients.
Methods: We analyzed consecutive 157 patients 
who underwent curative surgical resection for lung 
adenocarcinoma and diagnosed as p-stage IA or IB 
between April 2004 and October 2010 who have 
also examined preoperative FDG-PET imaging. 
We analyzed the association between disease free 
survival (DFS) and clinicopathological factors. DFS 
was calculated by means of Kaplan-Meier analysis 
and statistical signiÀcance between the groups was 
analyzed by using log-rank tests. Cox proportional 
hazard regression was used to ascertain independent 
predictors of recurrence.
Results: The median follow-up time was 30.7 
months. 5-year DFS was 80.8%. There were 14 
carcinogenesis, we will still elucidated whether or 
not BAC of smokers and that of non-smokers are 
really similar from viewpoints of pathology and 
signaling pathway. 
Keywords: EGFR mutation, Smoking, lung 
adenocarcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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OF A PLASMA PROTEIN BIOMARKER 
PANEL FOR EARLY DETECTION OF 
NON SMALL CELL LUNG CANCER
Mariana Mariana Guergova-Kuras1, Istvan Kurucz2, 
William Hempel1, Nadège Tardieu1, János Kádas2, 
Carole Carole Malderez-Bloes1, Yann Kieffer1, Anne 
Jullien1, Eszter Csanky3, Laszlo Takacs1 
1Research, Biosystems International Sas/
France, 2Biosystems International Kft/Hungary, 
3Pulmonology, Semmelweis Hospital, Miskolc/
Hungary
Background: Successful treatment of lung cancer 
suffers from the lack of tools for early diagnosis. 
Here, we describe the discovery and a panel of 
biomarkers to detect stage I non small cell lung 
cancer (NSCLC). 
Methods: We produced complex nascent 
monoclonal antibody libraries (> 1200 mABs) 
directed against the natural protein antigens present 
in the plasma of patients. Unbiased mAB proÀling 
of plasma proteomes of lung cancer patients and 
controls (301 patients and 235 controls) from 
independent clinical cohorts, identiÀed thirteen 
cancer speciÀc (p<0.05) mABs, recognizing Àve 
plasma proteins. Using quantitative sandwich ELISA 
for each protein we have developed a Àve biomarker 
classiÀer for early detection of NSCLC. 
Results: The majority of the mABs detect antigens 
present in the cancer tissue in-situ. The panel had 
a diagnostics performance of 77% sensitivity and 
87% speciÀcity (all stages). Combination of the new 
panel with a well established marker, results in a 
performance of 83 % sensitivity at 95 % speciÀcity 
for stage I NSCLC. 
Conclusion: The new composite panel may have 
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Memorial Cancer Center And Institute Of Oncology, 
Gliwice Branch/Poland
Background: The results of several randomized 
clinical studies and meta-analyses demonstrated that 
the addition of thoracic irradiation to chemotherapy 
signiÀcantly improved overall survival in limited-
disease small-cell lung cancer (LD-SCLC). 
However, the choice of optimal fractionation 
schedule and the timing of thoracic radiation is 
still controversial. The phase III trial (Turrissi et 
al., 1999) reported improved overall survival rates 
with accelerated hyperfractionated (45 Gy radiation 
therapy, 1.5 Gy twice daily) compared to once daily 
conventional radiotherapy. A limitation of the study 
was, however, that total radiation dose in control 
arm was low according to present-day standards. 
Ongoing CONVERT study compares twice daily 
thoracic radiotherapy (45Gy in 30 fractions) to a 
higher dose of conventional radiation (66 Gy w 33 
fractions). 
The aim of the present study is to compare the 
effectiveness of hyperfractionated, conventional 
and split-course hypofractionated radiotherapy in a 
large series of patients with LD-SCLC treated in a 
single institution. The effect of prophylactic cranial 
irradiation is also addressed.
Methods: Between 1994 and 2009 505 patients with 
LD-SCLC were treated in Center of Oncology Maria 
Sklodowska-Curie Memorial Institute, Gliwice, 
Poland. All patients received platinum based 
chemotherapy and thoracic radiotherapy: 77 patients 
received accelerated hyperfractionated radiotherapy 
(45Gy in 30 fractions, 1,5 Gy per fraction given 
twice a day), 364 patients received conventional 
radiotherapy (50,4-60 Gy in 1,8 to 2.0 Gy per 
fraction) and 64 patients received hypofractionated 
split-course radiotherapy (40-51 Gy in 3,0 to 4,0 Gy 
per fraction). The characteristics of the groups was 
comparable with respect to gender, age and use of 
chemotherapy. 170 patients received prophylactic 
cranial irradiation. Kaplan-Meier method was used 
to plot survival curves, the curves were compared 
using Mantel procedure and chi-square statistics. 
Results: The 2-years overall survival rate was 23% 
for accelerated hyperfractionated radiotherapy, 
16% for conventional radiotherapy and 10% for 
hypofractionated radiotherapy, (p=0,007). Use 
of prophylactic cranial irradiation signiÀcantly 
improved overall survival (2-years overall survival 
rate was 22% and 13% respectively, in the group 
with and without cranial irradiation, p<0,001). The 
patients (8.9%) with recurrence after surgery. We 
divided patient population into two groups according 
to SUVmax of 2.5. The 5-year DFS of the group 
with SUVmax of less than 2.5 was signiÀcantly 
better compared with the group with SUVmax more 
than 2.5 (96.4% and 71.0%, respectively, p=0.0119). 
These groups were subdivided by using tumor 
diameter of 2.0cm. The 5-year DFS for patients with 
both SUVmax less than 2.5 and tumor diameter 
less than 2cm was 100%, for those with SUVmax 
less than 2.5 and tumor diameter more than 2cm, it 
was 88.9%, for those with SUVmax more than 2.5 
and tumor diameter less than 2cm, it was 68.1%, 
for those with SUVmax more than 2.5 and tumor 
diameter more than 2cm, it was 73.8%, respectively.
Conclusion: The results of this study suggested 
that we could decide the indication of adjuvant 
chemotherapy by means of SUVmax regardless of 
tumor size in p-stage I adenocarcinoma. 
Keywords: pathological stage I adenocarcinoma, 
recurrent disease, FDG-PET, Adjuvant chemotherapy
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survival (PFS). Data were evaluated using a two-
tailed Student’s t-test and adjusted for age, gender 
and performance. Survival time was estimated by 
the Kaplan-Meier method and the survival difference 
between groups was assessed by the log-rank test.
Results: 75 patients, 29 women and 46 men, with a 
mean age of 66 years (range 49 - 81) were included 
between 2007 and 2009. Follow up was at least 12 
months. Patients diagnosed with limited disease (LD) 
were treated with surgery (n=4) or chemo/radiotherapy 
(n= 26). Patients with extended disease (ED) with 
chemotherapy alone (n=28) or, due to bad performance, 
no treatment (n=10) SigniÀcant lower SUVmax values 
of the primary tumor were observed in patients with 
LD (9.6) compared to ED (11.9) (p-value= 0.02). For 
overall survival, SUVmax was not discriminatory 
comparing the whole group of patients, LD and ED, 
treatment and no treatment. In a subgroup analysis it 
was found that in patients, staged as ED and treated 
with chemotherapy, signiÀcant differences in OS and 
PFS were found between the low and high SUVmax. 
Patients with ED and a high SUVmax value had a 
signiÀcant better OS (8.7 months) compared to the 
patients with ED and a low SUVmax (4.5 months) 
(p-value 0.008). Also longer PFS, 5.9 versus 3.2 
months, between high and low SUVmax in patients 
with ED were observed (p-value 0.002).
Conclusion: In patients with SCLC, SUVmax was 
higher in ED compared to LD. Although data are still 
limited due to low patient numbers, a high SUVmax 
showed to be a factor for prolonged PFS and OS.
Keywords: PET scan, Small cell lung cancer, 
SUVmax
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P3.259 INCIDENCE AND IMPACT 
SYNDROME OF INAPPROPRIATE 
ANTI-DIURETIC HORMONE 
HYPERSECRETION (SIADH) IN SMALL 
CELL LUNG CANCER (SCLC).
Nicholas Choong1, Malika Siker2, Tisha Suboc3, 
Kiran Devisetty2, Patrick Foy1, Elizabeth M. Gore2 
1Hematology And Oncology, Medical College Of 
Wisconsin/United States Of America, 2Radiation 
Oncology, Medical College Of Wisconsin/United 
States Of America, 3Medicine, Medical College Of 
Wisconsin/United States Of America
Background: Small cell lung cancer (SCLC) is a 
common cause of Syndrome of Inappropriate Anti-
best 2-years overall survival (25%) was observed in 
a group of patients with hyperfractionated thoracic 
radiotherapy and prophylactic cranial irradiation. 
Conclusion: This study shows that routine use of 
hyperfractionated thoracic radiotherapy with cranial 
irradiation in LD-SCLC patients allows to achieve 
results that are comparable to those attained in 
published clinical trials. Hypofractionated split-
course thoracic radiotherapy and lack of prophylactic 
cranial irradiation does not allow to achieve similar 
results and has, thus, only historical value. 
Keywords: SCLC, Hyperfractionated radiotherapy, 
prophylactic cranial irradiation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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PET SCANNING IN SMALL CELL LUNG 
CANCER.
Cor Van Der Leest1, Egbert F. Smit2, Jim Baas3, Rob 
Versteijlen3, Nico Van Walree1, Henk Hoogsteden4, 
Joachim Aerts1 
1Pulmonary Diseases, Amphia Hospital/Netherlands, 
2Pulmonology Department, Vrije Universiteit 
Medical Centre/Netherlands, 3Amphia Hospital/
Netherlands, 4Erasmus Medical Center/Netherlands
Background: Small cell lung cancer (SCLC) is 
an aggressive tumor with poor prognosis. Limited 
results of the prognostic and predictive value of the 
maximum standard uptake values (SUVmax) in 
SCLC are available.
Methods: An observational study in 75 chemonaive 
patients diagnosed with SCLC who underwent a 
positron emission tomography (PET) scan was 
performed. SUVmax was deÀned as maximum 
tumor concentration of FDG divided by the injected 
dose, corrected for the body weight of the patients: 
(SUVmax = maximum activity concentration/
[injected dose/body weight]). The SUVmax was the 
peak SUV in one pixel with the highest counts within 
the region of interest. The region of interest was only 
the primary tumor. With use of the CT scan, primary 
tumor was localized by the radiologist. Patients were 
subdivided into high and low SUVmax according 
to median SUVmax level. SUVmax values were 
related to overall survival (OS) and progression free 
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P3.260 PHASE II STUDY OF IRINOTECAN 
AND CISPLATIN WITH CONCURRENT 
SPLIT-COURSE RADIOTHERAPY IN 
LIMITED-DISEASE SMALL-CELL LUNG 
CANCER
Takaya Ikeda1, Hiroyuki Yamaguchi2, Seiji Doi3, 
Katsumi Nakatomi1, Yoichi Nakamura1, Seiji 
Nagashima4, Hiroshi Takatani4, Minoru Fukuda5, 
Hiroshi Soda3, Mikio Oka6, Shigeru Kohno1 
1Second Department Of Internal Medicine, Nagasaki 
University Hospital/Japan, 2Nagasaki Prefectural 
Shimabara Hospital/Japan, 3Sasebo General 
Hospital/Japan, 4Japanese Red Cross Nagasaki 
Atomic Bomb Hospital/Japan, 5Nagasaki Municipal 
Hospital/Japan, 6Kawasaki Medical School/Japan
Background: Irinotecan and cisplatin is a standard 
treatment in patients with extensive-stage small cell 
lung cancer. To determine the efÀcacy and toxicity of 
irinotecan and cisplatin with concurrent split-course 
thoracic radiotherapy in limited-disease small-cell 
lung cancer, we conducted a phase II study.
Methods: Thirty-Àve patients fulÀlling the following 
eligibility criteria were enrolled: chemotherapy-
naïve, good performance status (PS 0-1), age < 75, 
limited-disease, and adequate organ function. Based 
on the phase I study (Eur J Cancer 38:1998, 2002), 
the patients received irinotecan 40 mg/m2 i.v. on 
days 1,8 and 15, and cisplatin 60 mg/m2 i.v. on day 
1. Four cycles of chemotherapy were repeated every 
4 weeks. Split-course thoracic radiotherapy of 2 Gy/
day commenced on day 2 of each chemotherapy 
cycle, with 26 and 24 Gy administered in the Àrst 
and second cycles, respectively.
Results: Thirty-Àve patients were eligible and 
34 patients were assessable for response, toxicity 
and survival. Patients’ characteristics were as 
follows: male/female=29/5; PS 0/1=18/16; 
median age(range)=67(50-73); stage IB/IIA/
IIB/IIIA/IIIB=2/2/3/16/11. The overall response 
was 100% (CR 7, PR 27). Grade 4 leukopenia, 
neutropenia, grade 3-5 pneumonitis, diarrhea and 
esophagitis occurred in 22%, 39%, 6%, 3%, and 0%, 
respectively. There were 2 treatment-related deaths 
from pneumonitis. The median overall survival 
time, and the 2- and 5-year survival rates were 28.9 
months, 58.6% and 34.4%, respectively.
Conclusion: Irinotecan and cisplatin with concurrent 
split-course thoracic radiotherapy was effective in 
untreated limited-disease small cell lung cancer. 
Diuretic Hormone hypersecretion (SIADH). This 
study was performed to investigate the incidence and 
prognostic impact of SIADH in SCLC. 
Methods: A retrospective review was performed 
after IRB approval on data abstracted from 
consecutive SCLC patients at the Medical College of 
Wisconsin (MCW) and its afÀliate Veterans Affairs 
Medical Center (VAMC) from 2003 to 2010. Patients 
with hyponatremia were classiÀed to have SIADH if 
they had normal renal function, were euvolemic and 
had urine osmolality over 100mOsm/kg.
Results: A total of 197 patients with small cell 
lung cancer were included. Patient demographics 
were: median age 65.9 years (41-87 years), male 
153 (78%); race - Caucasian 171 (86%), African 
American 26 (13%); stage – limited stage 67 (34%), 
extensive stage 130 (66%); treating site - VAMC 117 
(59%), MCW 80 (41%). Out of the 197 patients, 23 
patients (12%) had SIADH with a median sodium 
level of 119 mmol/L (112-133mmol/L). Fourteen 
patients (61%) had extensive stage disease and 
9 (39%) had limited stage disease. Symptomatic 
hyponatremia was observed in 15 patients (65%). 
These patients had a median sodium level of 116 
mmol/L (112-132 mmol/L) compared to 121 mmol/L 
(112-133 mmol/L) in the 8 (35%) asymptomatic 
patients (p=0.12). The most common presenting 
symptoms were weakness (47%), confusion 
(33%), refractory nausea (13%) and seizures (7%). 
Out of the 23 patients with SIADH, 2 patients 
did not receive treatment for SCLC. Following 
chemotherapy, 15 out of 21 patients (71%) had 
normalization of sodium levels. Median overall 
survival in limited stage SCLC patients with and 
without SIADH were 12.5 and 15.8 months (log-
rank p=0.425), respectively. Median overall survival 
in extensive stage SCLC patients with and without 
SIADH were 7.2 and 6.8 months (log-rank p=0.808), 
respectively.
Conclusion: SIADH occurs in approximately 12% 
of patients with SCLC but does not appear to impact 
overall survival in SCLC.
Keywords: Small cell lung cancer, Syndrome of 
Inappropriate Anti-Diuretic Hormone hypersecretion, 
Hyponatremia
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survival (FFS) (17% vs. 5%, p=0.0132) and overall 
survival (OS) (33% vs. 21%, p=0.0459) over those 
who did not. Patients with PCI (n=8) or whole brain 
RT for metastases (n=2) had improved 1 yr brain 
metastasis FFS (60% vs. 13%, p=0.0003) and OS 
(60% vs. 18%, p=0.0013) over those with no cranial 
RT.
Conclusion: In our series, 90% of ES-SCLC pts 
present with disease conÀned to 1-3 metastatic sites. 
Even after primary chemotherapy or chemotherapy 
+ consolidative chest RT, the majority of failures 
continued to be limited to 1-3 sites. Local RT to both 
the chest and brain improved site speciÀc FFS and 
OS, thus local treatment to limited metastatic sites 
may similarly improve survival. This is currently 
being tested in RTOG 0937.
Keywords: Oligometastasis, Patterns of failure, 
Radiation Therapy, Small cell lung cancer
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P3.262 PHASE I/IIA STUDY 
OF CHEMOTHERAPY WITH 
BENDAMUSTINE AND IRINOTECAN 
(BI) FOLLOWED BY ETOPOSIDE/
CARBOPLATIN (EC) IN UNTREATED 
PATIENTS (PTS) WITH EXTENSIVE 
SMALL CELL LUNG CANCER (E-SCLC)
Rodolfo Bordoni1, Scott Lindhorst2, Mansoor Saleh1, 
Mary Jerome2, Kelly Baker2, Pam Dixon2, Vishnu 
Reddy2, Alan Cantor2, Ashley Milford2, Francisco 
Robert2 
1University Of Alabama At Birmingham 
Comprehensive Cancer Center, Georgia 
Cancer Specialists/United States Of America, 
2Comprehensive Cancer Center, University Of 
Alabama At Birmingham/United States Of America
Background: The results of Àrst-line therapy (EC) 
for E-SCLC remain poor with progression-free 
survival and overall survival of approximately 4 
months and 9 months, respectively. The goal of this 
study is to evaluate the safety and early efÀcacy 
of a novel combination of BI followed by EC. 
Bendamustine, an alkylating agent with a purine-like 
benzimidazole ring, and irinotecan have single-agent 
Keywords: irinotecan, chemoradiotherapy, Clinical 
trial, Small-cell lung cancer
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P3.261 EXTENSIVE STAGE SMALL 
CELL LUNG CANCER: METASTATIC 
PRESENTATION, PROGRESSION, 
AND IMPLICATIONS FOR 
OLIGOMETASTATIC TREATMENT
Kiran Devisetty1, Malika Siker1, Tisha Suboc2, 
Nicholas Choong3, Elizabeth M. Gore1 
1Radiation Oncology, Medical College Of Wisconsin/
United States Of America, 2Medicine, Medical 
College Of Wisconsin/United States Of America, 
3Hematology And Oncology, Medical College Of 
Wisconsin/United States Of America
Background: Treatment of oligometastatic cancer 
with deÀnitive radiation therapy (RT) is emerging 
as an option for patients once considered incurable. 
Extensive Stage Small Cell Lung Cancer (ES-SCLC) 
is considered a widely metastatic cancer, however 
its sites of metastatic presentation and progression 
are not well characterized. The purpose of this study 
is to explore if ES-SCLC is appropriate for this 
paradigm.
Methods: From 2003-2010, 115 pts with ES-
SCLC were treated at 2 hospitals afÀliated with 
the Medical College of Wisconsin. The median age 
was 68 yrs (range 47-87) and 82% were male. Only 
57 pts received 2 or more cycles of chemotherapy 
and had a median follow-up 8.5 months (range 2.3-
43.8). Of these, 39 pts were treated with primary 
chemotherapy (+/- palliative RT) and 18 pts received 
chemotherapy + consolidative chest RT (median 45 
Gy, range 34-62). In these two cohorts, prophylactic 
cranial irradiation (PCI) was administered in 1 and 7 
pts, respectively.
Results: At initial presentation, the most common 
sites of metastases were to the liver (53%), bone 
(31%), and brain (30%); 90% were limited to 
1-3 sites [Table]. For pts treated with primary 
chemotherapy, metastatic progression was most 
common in the liver (36%), brain (33%), and bone 
(31%); 72% progressed in 1-3 sites. For patients 
treated with chemotherapy + consolidative chest RT, 
metastatic progression was most common in the liver 
(33%), brain (33%), and adrenal glands (28%); 61% 
progressed in 1-3 sites. Patients with consolidative 
chest RT had improved 1 yr chest failure free 
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1Radiation Oncology, Cleveland Clinic/United States 
Of America, 2Medical Oncology, Cleveland Clinic/
United States Of America
Background: Purpose: Stage I Small Cell Lung 
Cancer (SCLC) is a rare disease presentation which 
generally includes resection for primary tumor 
management. We now wish to report on outcomes for 
a series of medically inoperable early stage SCLC 
patients for whom Stereotactic Body Radiotherapy 
(SBRT) was employed to manage the primary. 
Methods: Review of the Cleveland Clinic IRB-
approved SBRT registry revealed 6 cases of stage 
I SCLC out of 430 patients treated over the period 
2004-2010. All patients had biopsy proven disease 
and had been deemed medically inoperable by 
a thoracic surgeon. Staging consisted of PET/
CT and MRI brain scans. The treatment model 
consisted of SBRT to the primary tumor followed by 
platinum/etoposide chemotherapy (CHT) and then 
prophylactic cranial irradiation (PCI). SBRT was 
delivered employing a Novalis/BrainLAB platform 
and Exactrac for image-guidance. 
Results: Patient characteristics revealed: median 
KPS was 80 (range 50-90), median age was 68 
years (range 57-73), 66.7% of patients were female, 
median BMI was 27.55 (range 20.1-31.9), 17% of 
were smoking at treatment, and impaired pulmonary 
function was the reason for inoperability in 50% 
of cases. Tumor characteristics revealed: median 
tumor size was 2.6 cm (range 1.4-3.6), with 4 T1a 
and 2 T1b cases, 1 (17%) tumor was “central” (per 
RTOG 0236 criteria), median PET-SUVmax was 9 
(range 2.8-21.1). One patient had a mediastinoscopy, 
one had CHT before SBRT, one died after SBRT of 
a brain aneurysm and never received CHT or PCI 
and was one of 2 patients who died before receiving 
PCI. SBRT was 60 Gy/3 fractions (50%), 50 Gy/5 
fractions (33%), 30 Gy/1 fraction (17%). Median 
follow up was 11.9 months. There was no grade 3 or 
higher toxicity and only one grade 2 toxicity (chest 
wall). Three patients were alive at analysis and 3 
had died of non-cancer causes, although one did 
have distant disease. At one year, local control was 
100%, there was no regional nodal failure and one 
(17%) distant failure (liver). Overall and disease-free 
survival at 1 year were 63% and 75%, respectively. 
Conclusion:  1. SBRT for stage I medically 
inoperable SCLC is feasible, with excellent local 
control. 2. Disease-speciÀc survival is encouraging. 
3. The absence of regional nodal failure lends 
support to PET for mediastinal staging. 4. Platinum-
activity in SCLC with a tolerable safety proÀle.
Methods: This is an ongoing phase I/IIa study in 
untreated pts with E-SCLC with performance status 
of 0-2 and adequate organ function. Three dose levels 
(DL) of B (80 mg/m2, 100 mg/m2, 120 mg/m2 - days 1, 
2) in combination with I (150 mg/m2 - day 1) every 3 
weeks [Regimen A] for 3 cycles, followed by 3 cycles 
of E (100 mg/m2 - day 1-3), and C (AUC 6, day1) 
[Regimen B] are evaluated in the phase I portion of 
this study. Dose limiting toxicity (DLT) and maximum 
tolerable dose (MTD) of Regimen A are evaluated in 
cycle 1 in 3-6 pts in each dose level. Toxicity (CTCAE) 
is evaluated with CBC (weekly) and chemistry (every 3 
weeks), and response (RECIST) with imaging studies at 
the end of Regimen A and B. Exploratory correlations 
of tumor expression of ERCC1 and topoisomerases 
with efÀcacy parameters are evaluated
Results: Fourteen pts (DL 1-3, DL 2-6, and DL 3-5) 
have been enrolled in the phase I portion of the study. 
Baseline characteristics include: median age, 65 
years; male, 69%; increased LDH, 54%; low albumin, 
31%; and 1 pt with brain metastases. There was 1 
DLT in DL2 ) grade [gr] 3 diarrhea) and 1 DLT in 
DL3 (gr 3 nausea/vomiting/diarrhea). Worst toxicities 
during each regimen included: Regimen A - 3/14 gr 3 
diarrhea; 2/14 gr 3 nausea/vomiting; and 5/14 gr 3-4 
neutropenia. Regimen B - 1/13 gr 3 anemia; 1/13 gr 
3 neutropenia; and 1/13 gr 4 thrombocytopenia. Dose 
reduction was required in 2 and 3 pts in Regimen 
A and B, respectively. The objective response 
after Regimen A was 67% (PR-8) with 2 pts with 
progressive disease and 2 pts too early for evaluation.
Conclusion: Bendamustine/Irinotecan combination 
chemotherapy appears to be a generally well 
tolerated and active regimen in E-SCLC; and 
assessment of DL-3 (B - 120 mg/m2) is ongoing for 
MTD and phase II dose recommendation.
Keywords: Extensive small cell lung cancer, 
Bendamustine-based chemotherapy, Phase I/II 
clinical trial
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P3.263 A STEREOTACTIC BODY 
RADIOTHERAPY-BASED TREATMENT 
MODEL FOR STAGE I MEDICALLY 
INOPERABLE SMALL CELL LUNG 
CANCER.
Gregory M. Videtic1, Kevin Stephans1, Neil Woody1, 
Nathan Pennell2, Marc Shapiro2, TouÀk Djemil1, 
Chandana Reddy1 
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patients as the Àrst-line treatment. Among the several 
agents, AMR were the most used regimens for 
second- and third-line chemotherapy (44% and 51%, 
respectively) and the second most used regimen for 
the fourth-line.
Conclusion: A substantial proportion of relapsed 
SCLC patients received second- to fourth-line 
chemotherapy including AMR in a university-
afÀliated hospital in Japan.
Keywords: Small-cell lung cancer, amrubicin, 
second-line chemotherapy, third-line chemotherapy
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P3.265 A PHASE I STUDY OF 
EVEROLIMUS PLUS PACLITAXEL IN 
PATIENTS WITH SMALL CELL LUNG 
CANCER
Jong-Mu Sun, Jeeyun Lee, Yeon Hee Park, Jin Seok 
Ahn, Myung-Ju Ahn, Keunchil Park 
Internal Medicine, Samsung Medical Center/Korea
Background: Paclitaxel (P) was proved to have 
clinical effects in small cell lung cancer (SCLC). 
Everolimus (E) has previously shown preclinical 
activity in SCLC cell lines but has limited single-
agent antitumor activity in patients with pretreated 
SCLC. The synergism between P and E was suggested 
in a preclinical study. We conducted a phase 1, dose-
escalation study of E in combination with P in patients 
with SCLC who failed standard chemotherapy. 
Methods: Eligibility included SCLC with disease 
progression after at least 2 prior chemotherapy 
regimens, ECOG performance status (PS) 0-2, and 
adequate organ function. We excluded patients with 
poorly controlled diabetes mellitus (fasting blood 
glucose > 165 mg/dl) or hypercholesterolemia 
(grade 3 or 4). In this phase Ib using classic 3+3 
dose escalation study, patients were treated with E 
2.5mg/d (level 1), 5mg/d (level 2), or 10mg/d (level 
3) in combination with P (175mg/m2 every 3 weeks). 
Tumor measurements performed every 2 cycles or at 
the appropriate time. 
Results: Fifteen pts were enrolled: 13 males/2 
females; median age 60 years (44-72); PS 1/2: 
10/5 pts; sensitive/refractory relapse (sensitive 
relapse: > 60 days from completion of second-line 
chemotherapy): 6 pts/9 pts. Four pts experienced 
end-of-cycle 1 dose-limiting toxicities (DLTs). After 
identifying no end-of-cycle 1 DTL in the Àrst 6 pts 
at the levels of 1 and 2, three pts were further treated 
based CHT is feasible in this vulnerable population. 
Keywords: Small cell lung cancer, Stage I, 
stereotactic body radiotherapy, outcomes
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P3.264 RETROSPECITIVE ANALYSIS 
OF THE TREATMENT FOR RELAPSED 
SMALL-CELL LUNG CANCER IN A 
UNIVERSITY-AFFILIATED HOSPITAL IN 
JAPAN.
Hajime Asahina, Satoshi Oizumi, Eiki Kikuchi, 
Jun K. Sakakibara, Naofumi Shinagawa, Masaharu 
Nishimura 
First Department Of Medicine, Hokkaido University 
School Of Medicine/Japan
Background: The limited impact of survival beneÀt 
of topotecan (TPT) monotherapy for patients with 
relapsed small-cell lung cancer (SCLC) warrants 
the need for more effective treatments. Amrubicin 
(AMR) was approved by Japanese Ministry of 
Health, Labor and Welfare for patients with SCLC 
in 2002 and several clinical trials of AMR have 
been conducted, demonstrating promising efÀcacy. 
The objective of this study was to describe the 
clinical outcome of second-, third-, and fourth-line 
chemotherapy for the treatment of relapsed SCLC.
Methods: We retrospectively evaluated consecutive 
patients with relapsed SCLC who received Àrst-line 
chemotherapy between January 2003 and December 
2009 at our institution.
Results: Seventy-nine patients were evaluable. 
Patient characteristics were as follows: median 
age; 66 years (range 45-86), male/female; 60/19 
(cases), ECOG performance status 0/1/2/3; 9/54/12/4 
(cases), limited disease/extensive disease; 27/52 
(cases), sensitive relapse/refractory relapse; 33/46 
(cases). Overall, 61(77%), 43(54%), and 27(34%) 
of the patients with relapsed SCLC received second-
line to fourth-line chemotherapy, respectively. 
The mean number of chemotherapy regimens was 
2.8±1.3. Patients with sensitive relapse received 
more chemotherapy regimens than those with 
refractory relapse (3.5±1.1 vs. 2.3±1.3, p<.0001). 
For all relapsed patients, the median survival times 
(95% conÀdence interval) from the start of Àrst-line, 
second-line, third-line, and fourth-line chemotherapy 
were 18.9 (14.8 – 22.9), 11.3 (8.7 – 15.7), 9.2 (4.8 
– 11.7), and 7.0 (3.1 – 8.7) months, respectively. 
Platinum-based chemotherapy was conducted for all 
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Background: Recently, a randomized clinical trial 
revealed 20 percent fewer lung cancer deaths seen 
among those who were screened with chest CT than 
with chest X-ray. Patients with small-cell lung cancer 
(SCLC) usually presents more rapid progress than 
non-small cell lung cancer (NSCLC) and are found 
from some symptoms, but rarely detected by such 
chest CT and X-ray mass-screenings.
Methods: We retrospectively analyzed the clinical 
courses of SCLC patients found from chest CT and 
X-ray mass-screenings 1998 to 2010, and compared 
them.
Results: We found 8 SCLC patients from CT 
screenings ( clinical stage IA, 3 (37.5%) patients; 
IB, 1 (12.5%) patient; 2 (25.0%) patients; B, 1 
(12.5%) patient; 1 (12.5%) patient) and 14 patients 
from X-ray screenings (clinical stage B, 3 (21.4%) 
patients; A, 6 (42.9%) patients; B, 4 (28.5%) 
patients; 1 (7.1%) patient) during 1998 and 2006. 
Surgical resections were performed 6 (75.0%) 
patients in CT group and 1 (7.1%) patient in X-ray 
group. There were no signiÀcant difference in the 
survival of CT group and that of X-ray group.
Conclusion: Chest CT mass-screenings detected 
earlier stage SCLC and could lead more patients to 
surgical resections than chest X-ray mass-screenings, 
but survival of CT screening group were not different 
from that of X-ray screening group in this study.
Keywords: Small-cell lung cancer, chest CT mass-
screening
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P3.267 PROGNOSTIC FACTORS IN SET 
OF LIMITED DISEASE SMALL-CELL 
LUNG CANCER PATIENTS TREATED 
WITH CHEMORADIOTHERAPY
Milada Zemanova, Lubos Petruzelka, Hana Honova 
Clinic Of Oncology, Charles University In Prague, 
First Faculty Of Medicine/Czech Republic
Background: Combined chemoradiotherapy is the 
standard treatment for patients with limited disease 
small cell lung cancer (LD SCLC). Prophylactic 
cranial irradiation (PCI) is recommended in case 
of complete remission (CR) since late 90´ and for 
partial remissions last few years. Early concurrent 
radiation (RT) has been found as slightly beneÀcial 
at cost of higher toxicity. Use of granulocyte colony-
stimulating factor (G-CSF) for prophylaxis of 
febrile neutropenia is controversial in SCLC. We 
at the level of 3 where two pts experienced end-
of-cycle 1 DLTs (one febrile neutropenia and one 
grade 3 hyperglycemia). Two end-of-cycle 1 DLTs 
were also detected among three additional pts at the 
level of 2 (one grade 4 thrombocytopenia and one 
febrile neutropenia; 2 events among total 6 pts). We 
regarded level 1 (2.5mg/d) as the recommended dose 
after assuring there was no event in additional three 
pts at the level 1; no event among total 6 pts). On the 
basis of observed DLTs, 2.5mg/d was determined as 
the recommended dose for future trials. The common 
treatment-related toxicities (all grades) were anemia 
(n=13), neutropenia (n=12), hyperglycemia (n=12), 
thrombocytopenia (n=9), hypercholesterolemia 
(n=7), peripheral neuropathy (n=7), and stomatitis 
(n=7). The median progression-free survival was 
11.4 weeks (95% CI: 7.1-15.8 weeks). Among 13 pts 
who could be evaluated, objective response rate was 
31% (4/13: one at the each levels of 1 and 2, and two 
at the level of 3). 
Dosage by Grade 
All
(n=15) 
2.5mg
Daily
(n=6) 
5mg
Daily
(n=6) 
10mg
Daily
(n=3) 
Adverse Event 1/2 3/4 1/2 3/4 1/2 3/4 Any Grade 
<Hematologic disorder> 
Anemia 5 0 5 0 3 0 13 
neutropenia 3 1 0 5 1 2 12 
Thrombocytopenia 2 0 3 1 2 
Conclusion: The combination of E with P has shown 
promising antitumor activity in pts with heavily 
pretreated SCLC and warrants further investigation. 
Keywords: everolimus, paclitaxel, phase 1, Small 
cell lung cancer
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P3.266 COMPARATIVE ANALYSIS IN 
PATIENTS WITH SMALL-CELL LUNG 
CANCER (SCLC) DETECTED BY CHEST 
COMPUTED TOMOGRAPHY (CT) AND 
X-RAY MASS-SCREENINGS
Shintaro Kanda1, Toshiro Fukushima1, Kazunari 
Tateishi1, Toshihiko Agatsuma1, Tomonobu 
Koizumi2, Keishi Kubo1, Takayuki Shiina3, Kazuo 
Yoshida3, Shusuke Sone1 
1The First Department Of Internal Medicine, 
Shinshu University, School Of Medicine/Japan, 
2Comprehensive Cancer Center, Shinshu University 
Hospital/Japan, 3Thoracic Surgery, Shinshu 
University Hospital/Japan
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P3.268 WEEKLY SEQUENTIAL 
DOXORUBICIN, CYCLOPHOSPHAMIDE, 
CARBOPLATIN, VINCRISTIN AND 
ETOPOSIDE (ACOCEV) FOR ELDERLY/
POOR PERFORMANCE STATUS (PS) 
SMALL CELL LUNG CANCER (SCLC) 
PATIENTS (PTS): AN OBSERVATIONAL 
STUDY
Antonio Santo, Eleonora Lucchini, Melissa 
Frizziero, Francesca Maines, Sara Cingarlini, Andrea 
Tommasini, Annamaria Molino, Gianluigi Cetto, 
Alberto Terzi, Antonio Iannucci, Marco Chilosi 
Givop (interdisciplinary Group Oncopneumology, 
Verona), Azienda Ospedaliera Universitaria 
Integrata Verona/Italy
Background: SCLC is characterized by rapid 
kinetics, early metastatic involvement and frequent 
development of drug resistance. A dose-intense 
(i.e.weekly) sequential use of active drugs with 
non-overlapping toxicities, may play a role for a 
better disease control owing to a non cross-resistent 
mechanism of action in elderly or poor PS pts. 
Methods: Sequential ACOCEV (Doxorubicin 30 
mg/m2, Cyclophosphamide 400 mg/m2 on day 1 
of every Àrst week, Vincristin 1,4 mg/m2 on day 
1 of every second and fourth week, Carboplatin 
AUC 4 and VP16 60 mg/m2 on day 1 of every 
third week, every 28 days for 3 to 4 cycles) were 
administered to 24 pts enrolled from March 2005 to 
July 2010; median age was 71.5 years (range 54-84). 
To determine the toxicity and the response rate of 
the treatment we evaluated patients who completed 
almost 2 cycles of chemotherapy (18 patients). 11 
patients (61%) had a PS (ECOG) 2 and 4 patients 
had a PS 3; 15 patients (84%) had Extensive Disease 
(ED) at diagnosis and 6 patients (33,3%) were 
previously pretreated. 
Results: We observed a 72% overall response 
rate (only partial response). Stable disease (SD) 
was observed in one patient, progression of 
disease (PD) in 4 patients (22%). Median time to 
progression (TTP) was 5,5 months. Hemathologic 
toxicity includes 22% G3-G4 neutropenia without 
neutropenic febrile episodes and 5% G3-G4 
piastrinopenia. We observed moreover 22% G2 
neurotoxicities (paresthesia); 2 and 3 patients 
presented constipation and alopecia respectively. 
Conclusion: ACOCEV has comparable efÀcacy to 
conventional chemotherapy schedules with a more 
analyzed patients and treatment related variables 
for prognostic signiÀcance in long term follow-up 
of regional treatment protocol since 2000 in VFN, 
University Hospital Prague.
Methods: The planned treatment consisted of 4 to 
6 courses of platinum/etoposide chemotherapy (CT) 
and thoracic irradiation of 45 to 66 grays with one 
daily fraction. Patients with CR or later with PR 
were assigned to PCI (30Gy in 15 fractions) at the 
end of treatment. Sequential strategy was preferred 
due to age over 70 or worse performance status. 
In some patients G-CSF prophylaxis was used. 
InÁuence of factors as sex, age, timing and dose 
of RT, dose and regimen of CT, G-CSF delivery, 
treatment response and PCI yes or not, were tested 
for survival impact.
Results: Eighty consecutive patients were treated 
between Jan-2000 and Sep-2010, 49 men, 31 
women, median age 62 years (range 49 – 80). CT in 
median dose of 5 cycles was predominantly cisplatin 
based, RT in median dose of 57.6 Gy was given 
concurrently in 56% and sequentially in 33% of 
patients. Thoracic RT was omitted in 9 patients, for 
poor performance status or progressive disease in 6 
and due to radical surgery in 3 subjects. Esophagitis 
grade 3-4 occurred in 42%, signiÀcantly more often 
in concurrent RT (60% vs. 19%, p< 0.01). Response 
rate (RR) 90% and CR 62% in concurrent group did 
not differ signiÀcantly from sequential one (RR 88%, 
CR 52%). The median survival was 19.5 months and 
3- and 5-year survival was 27% in all the patients. 
Survival differences in groups according to sex, age, 
stage, carbo or cisplatin and partial versus complete 
treatment response did not differ signiÀcantly. 
SigniÀcantly longer survival was observed in groups 
with PCI, with concurrent radiation or in patients 
treated with G-CSFs. Median time to progression 
was 14 months for the whole group. SigniÀcantly 
longer time to progression was in CR patients, 
concurrent RT, PCI patients and G-CSF delivery.
Conclusion: Concurrent early chemoradiotherapy, 
PCI delivery and G-CSF treatment have shown 
signiÀcant impact on time to progression and overall 
survival in our group of LD SCLC patients.
Keywords: Small cell lung cancer, limited disease, 
chemoradiotherapy, prognostic factors
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of toxicity using Spearman’s rank correlation (rs) and 
logistic regression. 
Results: Of the 93 patients 56 (60%) were male and 
the median age was 67 years (range 45 to 83). The 
median follow-up time was 19 months (range 2 to 
104). Seventy patients (75%) received 40Gy in 15 
fractions and 23 patients (25%) received 45Gy in 30 
fractions BiD. Seventy-six patients (82%) received 
concurrent chemotherapy of which 66 (87%) 
received early (cycle 1-3) concurrent chemotherapy. 
Sixty (65%) patients were former smokers and 33 
(35%) patients were current smokers. The median 
survival was 22 months. Nine patients developed 
RP: 5 G2, 1 G3 and 3 G5 events. The median time 
from radiation to the Àrst incidence of G3+ RP was 
5 months (range 2 to 8 months). The cumulative 
incidence rate of RP was 8% at 1 year for the 
40/15 group and 18% at 1 year for the 45/30 group 
(p=0.15) . Fifty-eight patients developed esophagitis: 
49 G2 and 9 G3 events. The median time from 
radiation to the Àrst incidence of G3 esophagitis 
was 21 days (range 1 day to 1.5 months). The 
cumulative incidence rate of G3 esophagitis was 9% 
at 3 months for the 40/15 group and 13% at 3 months 
for the 45/30 group (p=0.52). G3+ pneumonitis was 
correlated with V20 (rs = 0.19, p = 0.03) and mean 
lung dose (rs = 0.19, p = 0.03). G3+ esophagitis was 
correlated with mean esophagus dose (rs = 0.22, p = 
0.02). 
Conclusion: Toxicity was not signiÀcantly different 
in patients who received 40/15 or 45/30. Mean dose 
and V20 were correlated with radiation pneumonitis 
and mean dose was correlated with esophagitis in our 
population. 
Keywords: small cell, pneumonitis, esophagitis
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P3.270 NGR-HTNF PLUS DOXORUBICIN 
IN RELAPSED SMALL CELL LUNG 
CANCER (SCLC)
Silvia Novello1, Raffaele Cavina2, Maria G. Viganò3, 
Francesco Grossi4, Armando Santoro2, Vanesa 
Gregorc3, Giorgio Scagliotti1, Isabella Garassino2, 
Gilda Rossoni3, Matteo G. Levra1, Carlo Genova4, 
Antonio Lambiase5, Claudio Bordignon5 
1Thoracic Oncology Unit, University Of Turin/Italy, 
2Oncology, Humanitas/Italy, 3Oncology, San Raffaele 
Hospital/Italy, 4Oncology, Istituto Nazionale Per La 
Ricerca Sul Cancro/Italy, 5Clinical Development, 
Molmed/Italy
favourable toxicity proÀle and signiÀcant clinical 
beneÀt; also it is feasible in patients with a poor PS 
or elderly. Further investigations on a larger patient 
population are needed. 
Keywords: SCLC, weekly chemotherapy
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P3.269 CORRELATION OF DOSIMETRIC 
FACTORS IN THE DEVELOPMENT 
OF ESOPHAGITIS AND RADIATION 
PNEUMONITS IN PATIENTS WITH 
LIMITED STAGE SMALL CELL LUNG 
CARCINOMA
Meredith E. Giuliani1, Patricia E. Lindsay1, 
Alexander Sun1, Andrea Bezjak1, Lisa Le2, Anthony 
Brade1, John Cho1, Natasha B. Leighl3, Frances A. 
Shepherd3, Andrew Hope1 
1Department Of Radiation Oncology, Princess 
Margaret Hospital/Canada, 2Biostatistics, Princess 
Margaret Hospital/Canada, 3Medical Oncology, 
Princess Margaret Hospital/Canada
Background: Esophagitis and radiation pneumonitis 
(RP) are signiÀcant sources of morbidity and 
mortality in patients receiving curative intent 
chemo-radiotherapy for limited stage small cell lung 
carcinoma (LS-SCLC). The purpose of this study was 
to correlate dosimetric factors with the development 
of esophagitis and RP in patients with LS-SCLC. 
Methods: Between December 2004 and July 2009 
93 patients were treated with curative intent chemo-
radiotherapy for LS-SCLC and had electronically 
archived radiation treatment plans available for 
analysis. All patients were CT simulated and planned 
in Pinnacle treatment planning system with doses 
corrected for tissue heterogeneity. The medical 
charts were reviewed retrospectively to determine 
demographic information, chemotherapy details, 
toxicity (graded per CTCAE v3.0) and vital status. 
Each patient’s original treatment plan was reviewed, 
dose delivered conÀrmed and critical structure 
delineation reviewed/corrected for lungs, heart and 
esophagus. Treatment planning data were exported 
from the treatment planning system and analyzed using 
CERR (Computational Environment for Radiotherapy 
Research). Overall survival (OS) was determined using 
the Kaplan-Meier Method. Patients lost to follow-up 
were censored. The cumulative incidence of RP and 
esophagitis were calculated and compared using Gray’s 
test. Dosimetric parameters were correlated to the risk 
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and 4.1 months and 44% in patients pretreated with 
2 or more regimens, respectively. By Cox analyses, 
either PFS or OS did not correlate with age, gender, 
PS and platinum sensitivity, while only NLR resulted 
associated with OS (HR=0.30). The 1-year OS rates 
in patients with NLR lower or higher than the median 
value were 48% and 10%, respectively (p=0.01). 
Conclusion: Further development of NGR-hTNF 
plus doxorubicin in platinum resistant or sensitive 
SCLC is of interest. 
Keywords: NGR-hTNF, SCLC, Doxorubicin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.271 THE SEROLOGICAL FEATURES 
OF HIGH-GRADE NON-SMALL CELL 
NEUROENDOCRINE CARCINOMA
Akira Ono1, Ichiro Ito2, Takehito Syukuya1, Asuka 
Tsuya1, Yukiko Nakamura1, Hirotsugu Kenmotsu1, 
Tateaki Naito1, Haruyasu Murakami1, Toshiaki 
Takahashi1, Masahiro Endo3, Toru Kameya2, Takashi 
Nakajima2, Nobuyuki Yamamoto1 
1Thoracic Oncology, Shizuoka Cancer Center/Japan, 
2Diagnostic Pathology, Shizuoka Cancer Center/
Japan, 3Diagnostic Radiology, Shizuoka Cancer 
Center/Japan
Background: Pro-gastrin-releasing peptide 
(ProGRP) and neuron-speciÀc enolase (NSE) are 
speciÀc neuroendocrineserological markers of small 
cell lung cancer (SCLC), the carcinoembryonic 
antigen (CEA) is not as speciÀc marker for SCLC. 
Some of non-small cell lung cancer (NSCLC) raises 
serum neuroendocrine markers
level. The aim of this study is to assess the feature 
of serological markers between with SCLC and 
high-grade non-small cell neuroendocrine carcinoma 
(HNSCNEC) proposed by us, which likely includes 
most pulmonary large cell neuroendocrine carcinoma 
(LCNEC) except for combined types. 
Methods: Newly diagnosed patients with SCLC and 
HNSCNEC at our institution between September 
2002 and June 2010, we retrospectively reviewed 163 
patients with SCLC and 35 patients with unresectable 
HNSCNEC, which was deÀned using biopsy specimens. 
Results: Sixty-three (38.6%) pts had limited stage 
disease (LD) and 100 (61.3%) pts had extensive stage 
Background: NGR-hTNF consists of human tumor 
necrosis factor fused with the peptide NGR, which 
speciÀcally binds to a CD13 overexpressed on 
tumor blood vessels. Preclinically, NGR-hTNF is 
able to improve the intratumoral doxorubicin uptake 
by selectively damaging tumor vasculature and 
decreasing tumor interstitial Áuid pressure. A phase I 
trial previously selected NGR-hTNF 0.8 g/m2 plus 
doxorubicin 75 mg/m2 for further phase II testing. 
Methods: SCLC patients relapsing after a platinum-
based regimen received every 3 weeks NGR-hTNF 
until progression (PD), while the maximum lifetime 
dose of doxorubicin was capped at 550 mg/m2. 
Progression-free survival (PFS) was the primary study 
aim. The trial had two-stage design with 16 and a total 
of 27 patients to be accrued. 
Results: Twenty-eight patients with a median age 
of 63 years (range 41-76) were recruited. Baseline 
characteristics were: men/women 19/9; PS 0/1-2 
13/15; brain metastases (yes/no) 9/21. The baseline 
serum neutrophil-to-lymphocyte ratio (NLR), an index 
of the systemic host immune response to tumor, was 
lower or higher the median value of 4 in 18 and 10 
patients, respectively. Prior treatment lines ranged 
from 1 to 3 (median 1) and eight patients (29%) were 
pretreated with two or more regimens. The median 
treatment-free interval from last chemotherapy line 
was 2.8 months (95% CI, 1.0-3.9). (57%) presented 
with platinum-refractory or resistant disease 
(platinum-R; PD  3 months) and 12 patients (43%) 
with platinum sensitive disease (platinum-S; PD > 3 
months). A total of 114 cycles were delivered (median 
3; range 1-10) and 7 platinum-R patients (44%) and 6 
platinum-S patients (50%) received  4 cycles. NGR-
hTNF did not increase doxorubicin-related toxicity. 
No grade 3 to 4 toxicities related to NGR-hTNF were 
noted, while common grade 1 to 2 related events 
were transient chills (61%). Six patients had partial 
response (PR; 22%) and nine stable diseases (SD; 
33%), yielding an overall disease control rate of 55% 
(95% CI 35-74). The median PFS was 3.2 months 
(95% CI 2.6-3.8). The patients who achieved PR had 
a median PFS of 6.3 months, and those with SD had 
a median PFS of 4.1 months. With median follow-up 
time of 19.3 months, the 6-month and 1-year overall 
survival (OS) rates were 49% and 34%, respectively. 
By subset analyses, response rates were 19% and 
27% (p=0.66), median PFS were 2.7 and 4.1 months 
(p=0.07), and 1-year OS rates were 27% and 42% 
(p=0.81) in platinum-R and platinum-S patients, 
respectively. Median PFS and 1-year OS were 3.3 
months and 27% in patients with brain metastases, 
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formulation of paclitaxel with superior toxicity and 
efÀcacy proÀle compared with standard paclitaxel, 
given weekly or every 3 weeks together with 
carboplatin may provide improved toxicity with 
acceptable efÀcacy. The primary objective was 
overall response rate; secondary objectives included 
progression free survival (PFS), overall survival 
(OS) and assess the toxicity proÀle.
Methods: Patients with ES-SCLC, ECOG PS 0-2, 
and no prior chemotherapy were randomized in a 
1:1 ratio to Arm A (carboplatin AUC=6 IV on day 
1, abraxane 300mg/m2 IV day 1; q21 days) or Arm 
B (carboplatin AUC=6 IV on day 1, abraxane 100 
mg/m2 IV days 1, 8, 15; q21 days) for 4-6 cycles. 
Response was assessed every 2 cycles.
Results: Baseline characteristics were similar 
between arms. Exposure to chemotherapy in each 
arm was similar. Due to excessive toxicities and dose 
delays, an unplanned interim analysis was performed 
after the Àrst 10 patients in each arm; abraxane 
doses were reduced to 240mg/m2 and 80 mg/m2 
respectively for Arms A and B. Median follow-up 
times are 18.6 and 16.1 months, respectively. Results 
are reported in the table by Arm for all evaluable 
patients. Four patients were evaluable for toxicity 
(3 in arm A; 2 in arm B) but died during treatment. 
Response rate is reported by intention to treat. Table: 
Results by arm
Cbp+Abraxane 
(q3wks) Arm A 
(N=14) 
Cbp+Abraxane 
(weekly) Arm B 
(N=13) 
BASELINE 
DEMOGRAPHICS 
Gender (male) 10 8 
Race (Caucasian) 13 11 
ECOG PS 
0 5 2 
1 8 11 
2 1 0 
Age, median (range) 60 (45-80) 67 (52-72) 
EFFICACY 
Partial Response 11 (79%) 11 (85%) 
Median PFS, (mo) 5.8 5.2 
Median Survival (mo) 8.6 11.6
Overall Survival (1 year) 36% 42% 
SAFETY
(All  Grade 3/4) 
Neutrophils 8 (57%) 5 (38%) 
Hemoglobin 4 (29%) 4 (31%) 
Platelets 3 (21%) 3 (23%) 
Neuropathy:sensory 3 (21%) 0 
Pain 4 (29%) 0 
Fatigue 0 1 (8%) 
Nausea 0 3 (23%) 
Vomiting 0 2(15%) 
Diarrhe 1 (7%)  (8%)
disease (ED) in SCLC. The serum ProGRP levels were 
elevated (>46 pg/ml) in 130 SCLC patients(81.2%, 
median levels: 407pg/ml) and in 14 HNSCNEC 
patients (40.0%, median levels: 27.4pg/ml) (p<0.0001), 
NSE levels were elevated(>10ng/ml) in 145 SCLC 
patients (90%, median levels: 32ng/ml) and in 29 
HNSCNEC patients (82.8%, median levels: 25.0ng/
ml) (p=0.09), CEA levels were elevated(>5nf/ml) in 
85 SCLC patients (54%, median levels: 5.7ng/ml) 
and in 24 HNSCNEC patients (68.5%, median levels: 
12.3ng/ml) (p=0.01),respectively. Comparing the area 
under curve (AUC) of receiver operating characteristics 
(ROC) analysis of the ratio of ProGRP to CEA (AUC: 
0.80) with that of NSE to CEA (AUC: 0.66), the ratio 
of ProGRP to CEA wasa favorable ratio to distinguish 
between SCLC and HNSCNEC. 
Conclusion: In this series, signiÀcantly low serum 
ProGRP levels and high serum CEA levels compared 
with SCLC patients
represent clinical features of serological marker in 
HNSCNEC, while NSE is high positive rate in both 
SCLC and HNSCNEC. 
Keywords: Small-cell lung cancer, Neuroendocrine, 
tumor marker, Non small-cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.272 A RANDOMIZED PHASE II STUDY 
OF CARBOPLATIN AND ABRAXANE 
WITH TWO DIFFERENT SCHEDULES, 
IN PATIENTS WITH EXTENSIVE STAGE 
SMALL CELL LUNG CANCER (ES-SCLC)
Juneko Grilley-Olson1, Vicki L. Keedy2, Alan 
Sandler3, Mark A. Socinski4, Dominic T. Moore5, 
Thomas Stinchcombe4 
1Medicine, Division Of Hematology/oncology, 
University Of North Carolina/lineberger 
Comprehensive Cancer Center/United States Of 
America, 2Vanderbilt University/United States Of 
America, 3Oregon Health Sciences University/United 
States Of America, 4Lineberger Comprehensive Cancer 
Center/United States Of America, 5Biostatistics, 
University Of North Carolina/United States Of America
Background: In the United States, standard cisplatin 
and etoposide chemotherapy for SCLC has remained 
unchanged since the 1980s. It is hypothesized 
that abraxane, the nanoparticle albumin-bound 
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45 Gy in 30 fractions of 1.5 Gy BID (mean total 
dose of 44.64 Gy, range 36-45). Prophylactic cranial 
irradiation was performed in 146 patients, at a mean 
total dose of 31.47 Gy (range 4-40) in daily fractions 
of 1.8-2.5 Gy. One patient rejected the treatment 
after the second fraction and was analyzed as 
intention-to-treat.
Results: Overall survival (OS) is 23.4% at 5 years 
and median overall survival is 20.7 months. Three-
year OS for patients receiving hyperfractionated 
radiotherapy and conventional daily radiotherapy 
were 45.6% and 30.1%, with median survival of 
33.4 and 19.7 months, respectively (NS). We have 
found a clear beneÀt (p=0.03) for patients receiving 
prophylactic cranial irradiation, with median OS 
of 24.5 months, while those who were not treated 
obtain a median OS of 18.4 months. Patients 
receiving systemic concurrent chemotherapy achieve 
a median OS of 26.9 months and a 5-year OS of 
28.9% while patients with sequential treatment have 
a median OS of 18.1 months and a 5-year OS of 
16.8% (p=0.007).
Conclusion: Our results conÀrm that survival 
in limited stage small-cell lung cancer is 
signiÀcantly improved by concurrent CTRT and 
prophylactic cranial irradiation. Nowadays, is 
early for us to demonstrate the beneÀt of the use of 
hyperfractionated radiotherapy that still have not 
obtained better results than conventional treatment.
Keywords: prophylactic cranial irradiation, 
concurrent chemoradiotherapy, Limited stage small-
cell lung cancer, Hyperfractionated radiotherapy
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P3.274 SURVIVAL OUTCOMES OF 
SMALL CELL LUNG CANCER PATIENTS 
(SCLC) TREATED WITH CISPLATIN-
ETOPOSIDE (EP) VS. CARBOPLATIN-
ETOPOSIDE (EC) IN BRITISH 
COLUMBIA (BC)
Shi Yuan Jiang1, Devin Schellenberg1, Irene Karam1, 
Christopher W. Lee2 
1Radiation Oncology, British Columbia Cancer 
Agency/Canada, 2Medical Oncology, British 
Columbia Cancer Agency/Canada
Background: Lung cancer is the leading cause of 
cancer deaths with SCLC representing approximately 
13% of all cases. Although a previous randomized 
study did not demonstrate an advantage for EP over 
Conclusion: Carboplatin and abraxane (given 
weekly or every 3 weeks) appear to have activity 
with encouraging RR in both arms; Arm B appears 
somewhat better tolerated. The majority of toxicities 
are hematologic in both arms.
Keywords: Small cell lung cancer, Abraxane, 
Carboplatin, Chemotherapy
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P3.273 HOW DOES INFLUENCE 
CHANGES IN STANDARD TREATMENT 
IN OUTCOME RESULTS FOR LIMITED 
STAGE SMALL-CELL LUNG CANCER 
PATIENTS IN A RADIATION ONCOLOGY 
DEPARTMENT?
Josep Jové, Antonio Arellano, Rosa Ballester, 
Victòria Tuset, Mónica Caro, Cristina Moretones, 
Alejandro Melero, Salvador Villà, Jaume Molero, 
Anabel Mañes, Ernest Luguera, Isabel Planas 
Servei D’oncologia Radioteràpica, Ico Hospital 
Germans Trias I Pujol/Spain
Background: The purpose of this study is to 
evaluate the treatment outcome of standard 
chemoradiotherapy (CTRT) for patients with limited 
stage small cell-lung cancer in the daily clinical 
practice. Secondarily, we analyze the effect in 
survival produced by the evolution of the treatment 
in the last years.
Methods: We review the treatment in our Radiation 
Oncology Department, for patients diagnosed 
of limited stage small-cell lung cancer. At the 
beginning, patients were submitted after induction 
chemotherapy and received sequential radiotherapy. 
Since 2001 concurrent CTRT was administered to 
nearly all patients and radiotherapy volumes were 
signiÀcantly reduced to the visible lesions by CT 
and affected regional lymphatic areas. Finally, 
logistics permitted in 2006 the systematic use of 
hyperfractionated radiotherapy. Two hundred and 
sixty-six patients (236 males and 30 females) were 
treated between May 1994 and December 2010. The 
mean age was 62.97 years (range 36-85). All patients 
except 5 received chemotherapy. At least one cycle 
of previous chemotherapy was administered to 257 
patients but only 141 patients received concomitant 
CTRT. Conventional daily radiotherapy was used in 
211 patients at 1.8-2 Gy per fraction and mean total 
dose of 46.49 Gy (range 16-66). Fifty-Àve patients 
were treated with hyperfractionated radiotherapy, 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1351
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: The aim of our research is to increase 
the efÀciency of the treatment of malignant pleural 
mesothelioma. 
Methods: Materials and Methods: the randomized 
research from 2006 to 2011 includes 22 patients 
with biopsy-proven and immunohistochemical 
conÀrmed malignant pleural mesothelioma. 
The patients were randomized into two groups: 
1) extrapleural pneumonectomy and 4 courses 
adjuvant chemotherapy (cysplatin 90 mg/m2 in 
1st day+vinorelbine 30 mg/m2 in 1st and 8th days) 
– 11 patients: 2 women and 9 men from 38 to 
65 years old (mean 53,5) (combined treatment); 
2) intrapleural perfusion thermochemotherapy 
(ThermoChem HT-1000, regimen 42Ð¾C in an 
hour, cysplatin 120 mg/m2 + vinorelbine 30 mg/
m2), extrapleural pneumonectomy and 4 courses 
adjuvant chemotherapy (cysplatin 90 mg/m2 in 1st 
day+vinorelbine 30 mg/m2 in 1st and 8th days) – 11 
patients: 6 women and 5 men from 30 to 65 years old 
(mean 51,4) (multimodality treatment). 
Results: The III stage of malignant pleural 
mesothelioma was diagnosed at all patients in 
the group of combined treatment. In the group of 
multimodality treatment there was only 1 patient 
with II stage of the disease and 9 with III stage. After 
intrapleural thermochemotherapy 2 patients (18%) 
had complications: 1 patient had pleural empyema 
and 1 patient – renal and hepatic failure, there was 
no cases of lethality. Postoperative complications 
were registered at 5 patients (45,5%) in the group 
of combined therapy: pleural empyema (n=2), heart 
rate failure (n=1), thromboembolism of pulmonary 
artery (n=1), intrapleural bleeding (n=1). Mortality 
was 18,2% in this group (n=2 – thromboembolism, 
bleeding). In the group of multimodality treatment 
complications after extrapleural pneumonectomy 
were observed at 3 patients (27%): intrapleural 
bleeding (n=1), heart failure (n=1), acute respiratory 
distress syndrome (n=1). Mortality was 18% in this 
group (n=2 – heart failure, acute respiratory distress 
syndrome). In the Àrst group local recurrence was 
registered at 1 patient, at 4 patients were observed 
recurrence in peritoneum, 2 patients had distant 
metastasis. In the second group local recurrence 
was not registered, 4 patients had distant metastasis. 
2-years survival is 12,5±11,7% in the group with 
combined treatment and 71,4±17,1% in the group 
with multimodality treatment (p=0,1). 
Conclusion: Multimodality treatment does not 
increase the frequency of complications and the 
rate of mortality in comparison with the combined 
EC, cisplatin-based therapy remains the standard 
in North America. The purpose of this study was to 
compare survival outcomes between EP and EC at a 
population level. 
Methods: A retrospective review was performed 
that included all SCLC patients in the BC Cancer 
Agency database diagnosed from January 2006 to 
December 2008, and treated with EP or EC. All 
patients were categorized as having limited (LD) 
or extensive disease (ED) according to treatment 
intent. Demographic comparisons were made using 
Fisher’s exact test for discrete variables and the 
Mann-Whitney non-parametric test for continuous 
variables. Overall Survival (OS) was determined 
from the date of diagnosis and survival curves were 
calculated using the Kaplan-Meier method. Median 
follow-up time was calculated using the reverse 
Kaplan-Meier estimator. 
Results: 351 patients with SCLC were included 
in the review. Of the 168 with LD disease, 98 
received EP and 70 received EC. For the 183 with 
ED disease, 99 received EP and 84 received EC. In 
both groups, EC patients were signiÀcantly older 
(median age 74 vs. 62 with LD and 71 vs. 61 with 
ED, p<0.0001). Median follow up was at least 21.4 
months in all subgroups. There was no statistically 
signiÀcant difference in the median OS between the 
EP and EC subgroups with LD (21.5 vs. 22.1 months 
respectively, p=0.633) or ED (10.8 vs. 11.1 months 
respectively, p=0.584). The two year survival rates 
were also similar in both LD (EP-41%, EC-47%) and 
ED (EP-11%, EC-12%). 
Conclusion: Despite the preferential use of EC in an 
older population, the median survival time and two-
year survival rates were similar to patients treated 
with EP. We plan on examining local control rates 
of patients receiving EP vs. EC and the effects of 
concurrent thoracic radiation. 
Keywords: survival, Small cell lung cancer, 
Cisplatin Etoposide, Carboplatin Etoposide
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P3.275 MULTIMODALITY TREATMENT 
OF MALIGNANT PLEURAL 
MESOTHELIOMA
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whereas radiological response (RR) from CT-scan 
was determined according to RECIST-modiÀed 
criteria [2]. 
Results: From January 2004 to December 2010, 15 
patients with a median age of 66 years (range: 54 
– 77) and with biopsy proven MPM (14 epithelial, 
1 biphasic) were assessable for metabolic and 
radiologic response with 18F-FDG PET-CT scan. On 
average 3.5 courses (range: 3 – 4) of chemotherapy 
were administrated between the two exams. An 
average of 25 days (range 3 - 42) elapsed between 
18F-FDG PET/CT scan staging and the Àrst course 
of chemotherapy and 26 days (range 6 - 48) elapsed 
from the last cycle of chemotherapy to the re-staging 
18F-FDG PET/CT scan. There were respectively 
one (6.7%) RR, 6 (40%) and 4 (26.7%) MR at 
the SUVmax and SUVmean analyses. As far as 
concordance between metabolic and radiological 
response is concerned, overlapping of the two 
evaluations was more frequent for the SUVmean 
(10/15, 67%) than for the SUVmax analysis (2/15, 
13%). No advantage in survival was seen for patients 
with responsive disease over those with stable or 
progressive disease at SUVmax analysis (75%, 95% 
CI 33 - 100, vs. 37%, 95% CI 4 -71) and SUVmean 
analysis (50%, 95% CI 1 - 99, vs. 48%, 95% CI 11 - 
85) or at the radiological evaluation (100% vs. 47%, 
95% CI 17 - 78 all performed at 24 months). 
Conclusion: In our experience MR expressed 
by SUVmax and SUVmean analysis and RR are 
not predictive for survival in patients with MPM 
treated with platinum and pemetrexed; this may 
be due to the limited number of patients analyzed. 
References: 1. Young H, Baum R, Cremerius U, et 
al. Measurement of clinical and subclinical tumour 
response using [18F]-Áuorodeoxyglucose and 
positron emission tomography: review and 1999 
EORTC recommendations. European Organization 
for Research and Treatment of Cancer (EORTC) 
PET Study Group. Eur J Cancer 1999;35:1773-
1782. 2. Byrne MJ, Nowak AK. ModiÀed RECIST 
criteria for assessment of response in malignant 
pleural mesothelioma. Ann Oncol 2004;15:257-260. 
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therapy. Intrapleural perfusion thermochemotherapy 
increases the efÀciency of the treatment of malignant 
pleural mesothelioma. 
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P3.276 RESPONSE EVALUATION AND 
PROGNOSIS WITH COMBINED 18F-FDG 
PET-CT SCAN IN MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) TREATED 
WITH PLATINUM AND PEMETREXED 
DOUBLET CHEMOTHERAPY.
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Moretti3, Anna Maria Marzullo3, Riccardo Galassi3, 
A. Santo4, Emanuela Scarpi5, Noemi Giovannini1, 
Federica Matteucci3 
1Oncology, Irst Meldola/Italy, 2Radiology, Irst/Italy, 
3Nuclear Medicine, Irst/Italy, 4Ospedale Di Verona/
Italy, 5Unit Of Biostatistics, Irst/Italy
Background: Malignant pleural mesothelioma 
(MPM) represents a very aggressive and rare 
tumor where platinum-based chemotherapy 
may improve survival. Monitoring therapeutic 
evaluation represents a challenge in this setting. 
The aim of this study was to evaluate the impact of 
standard uptake value (SUV) max and SUVmean 
of [18F]Fluorodeoxyglucose (FDG) measured by 
photon emission tomography (PET) integrated 
with Computed Tomography (CT) imaging in the 
assessment of chemotherapic response and the 
relationship with prognosis. 
Methods: Patients with histologically proven MPM 
performed chemotherapy with platinum-based 
(Carboplatin or Cisplatin) regimen combined to 
Pemetrexed were eligible for this study. All patients 
were evaluated by PET/CT-scan at baseline and after 
three-four courses of chemotherapy: they fasted and 
received a 5,18 MBq FDG per kilogram of FDG 
dose. Whole-body emission studies were acquired, 
followed by whole-body transmission scans with 
iterative reconstruction. Metabolic response (MR) 
was evaluated according to EORTC-criteria [1], 
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and RECIST [2] criteria, after a median follow-up of 
30 months (range: 7 – 44) there was a concordance 
between the radiologic and metabolic SUVmean 
and SUVmax responses in 6 (75%) and 3 (37.5%) 
patients, respectively.
Conclusion: In our series, MPM patients treated 
with TP and chemotherapy, metabolic response to 
chemotherapy expressed with SUVmean seems to 
be in better agreement with radiological response 
than the SUVmax, thereby SUVmean index may 
be helpful to distinguish sensitive or resistant 
disease to chemotherapy. References: 1. Young 
H, Baum R, Cremerius U, et al. Measurement 
of clinical and subclinical tumour response 
using [18F]-Áuorodeoxyglucose and positron 
emission tomography: review and 1999 EORTC 
recommendations. European Organization for 
Research and Treatment of Cancer (EORTC) PET 
Study Group. Eur J Cancer 1999;35:1773-1782. 2. 
Byrne MJ, Nowak AK. ModiÀed RECIST criteria 
for assessment of response in malignant pleural 
mesothelioma. Ann Oncol 2004;15:257-260. 
Supported by GIPO and GIVOP. 
Keyword: talc pleurodesis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.278 PHASE II STUDY OF 
CARBOPLATIN AND VINORELBINE 
1ST LINE TREATMENT IN 
ADVANCED MALIGNANT PLEURAL 
MESOTHELIOMA
Jens B. Sorensen1, Cecilia Bech1, Peter Sørensen2, 
Hanna Frank3 
1Oncology, Finsen Centre/national University 
Hospital/Denmark, 2Odense University Hhospital/
Denmark, 3Aalborg University Hospital/Denmark
Background: Platinum-based combination 
chemotherapy improve survival and quality of 
life in Malignant Pleural Mesothelioma (MPM). 
Vinorelbine (VNB) is also among the most active 
drugs. Thus, the combination of Carboplatin with 
VNB was explored.
Methods: Chemotherapy naïve inoperable MPM 
patients (pts) in performance status (PS) 0-2, normal 
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P3.277 FDG PET/CT RESPONSE 
EVALUATION IN MALIGNANT 
PLEURAL MESOTHELIOMA PATIENTS 
TREATED WITH TALC PLEURODESIS 
AND CHEMOTHERAPY
Giovenzio Genestreti1, Andrea Moretti2, Sara 
Piciucchi3, Noemi Giovannini1, Carlo Milandri1, 
Anna Maria Marzullo2, Emanuela Scarpi4, A. Santo5, 
Venerino Poletti6, Federica Matteucci2 
1Oncology, Irst Meldola/Italy, 2Nuclear Medicine, 
Irst/Italy, 3Radiology, Irst/Italy, 4Unit Of 
Biostatistics, Irst/Italy, 5Ospedale Di Verona/Italy, 
6Pneumology, Hospital Morgagni/Italy
Background: Talc pleurodesis (TP) is worldwide 
employed for the management of persistent 
pneumothorax or pleural effusion, particularly if 
malignant origin. In this setting, the concomitant 
presence of a procedure like TP and a disease 
such as malignant pleural mesothelioma (MPM), 
may interfere in metabolic assessment and in 
chemotherapeutic tumor response evaluation. The 
aim of this retrospective MPM case series was to 
report the concordance rate between radiologic and 
metabolic response, expressed by SUVmean and 
SUVmax, after TP and chemotherapy. 
Methods: Patients with histologically proven MPM 
underwent to TP and following to integrated PET/
CT-scan of staging and restaging after three-four 
courses of Pemetrexed-based chemotherapy. All 
patients fasted and received a 5,18 MBq FDG per 
kilogram of FDG dose. Whole-body emission studies 
were acquired, followed by whole-body transmission 
scans with iterative reconstruction. 
Results: From January 2004 to March 2010, 8 
patients with a median age of 65 years (range: 54 
– 77) and with biopsy proven MPM (7 epithelial, 
1 biphasic). Overall 5 (63%) MPM were located 
on the left side and 3 (37%) MPM on the right 
side with 7 (88%) patients at stage I and 1 (12%) 
patient at stage II disease. Three patients received 
Pemetrexed combined with Carboplatin, 4 patients 
Pemetrexed combined with Cisplatin and Ànally 
one patient Pemetrexed alone. The mean number 
of chemotherapic courses received before restaging 
was 3.5 (range: 3 - 4). On average there were 14 
days (range: 9 – 22) and 125 days (range: 76 – 162) 
between TP and respectively staging and restaging 
PET/CT-scan. According to modiÀed EORTC [1] 
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Melissa Bersanelli4, Marcello Tiseo5, Alessandra 
Dubini6, Federica Matteucci2 
1Oncology, Irst Meldola/Italy, 2Nuclear Medicine, 
Irst/Italy, 3Radiology, Irst/Italy, 4Department 
Of Medical Oncology, Azienda Ospedaliera-
universitaria/Italy, 5Medical Oncology Unit, 
University Hospital Of Parma/Italy, 6Pathology, 
Morgagni Hospital/Italy
Background: Malignant pleural mesothelioma 
(MPM) is a rare and aggressive tumour with 
disappointed results in terms of survival. However 
this disease may have a variable clinical course, with 
occasional long-term survivors. Standard uptake 
value (SUV) of 18F-Fluorodeoxyglucose ([18F]FDG) 
evaluated by photon emission tomography (PET) 
is now widely accepted as an important prognostic 
indicator in several malignancies. The aim of this 
study is to verify if SUVmax and SUVmean is 
inversely correlated to prognosis and if there is a 
correlation between grading and stage disease with 
SUV value. 
Methods: Patients with histologically proven 
MPM underwent integrated PET and computed 
tomography (CT) scanning. Patients fasted and 
received a 5,18 MBq [18F]FDG per kilogram of 
weight. Studies were acquired from the upper thighs 
to the head, followed by CT transmission scan 
with iterative reconstruction. Receiver operating 
characteristics (ROC) curve analysis was used 
to calculate SUVmax and SUVmean value. On 
the basis of the maximal Chi-Square method, a 
SUVmax of 4.21 and a SUVmean of 2.78 were 
chosen as threshold to classify patients as good or 
poor prognosis. Survival probabilities for both SUV 
groups were estimated by the Kaplan-Meier method.
Results: From January 2004 to December 2010, 27 
patients with a median age of 65 years (range: 54 – 
77) and with biopsy proven MPM (23 epithelial, 4 
biphasic) were analyzed. Histological exam revealed 
an epitheliod subtype in 23 (85%) patients and a 
biphasic subtype in 4 (15%) patients. Regarding the 
histological grading lesions, we recognized: well 
differentiated disease in Àve patients, moderately 
differentiated disease in thirteen patients, poorly 
differentiated disease in seven patients and Ànally 
very poor differentiated disease in two patients. The 
disease localization was left in 16 (59%) patients and 
right in 11 (41%) patients with: 15 (55%) stage I, 
4 (15%) stage II and 8 (30%) stage III disease. The 
median follow-up was 23 months (range: 1 - 52), 
there is no difference in term of median survival 
renal function, no major comorbidity, and no upper age 
limit received Carboplatin AUC 5 and VNB 25 mg/
m2 i.v. day 1 and VNB 80mg/m2 p.o. day 8 q. 3 weeks 
for 4-6 courses. CT-scans were done initially and for 
every 2 courses. ModiÀed recist criteria were used for 
response assessment. The study was approved by the 
National Health Authorities and the regional ethical 
committees. Pts gave written informed consent.
Results: Median age among 47 pts included was 
66 years (range 42-79), there were 89% males, 59% 
had epithelial subtype while 11% and 30% had 
sarcomateous or biphasic subtypes, respectively. 
55% had IMIG stage stage IV, and PS 1 and 2 
occurred in 66% and 11%, respectively. Median 
no. of courses were 4 (range 1-6) and median time 
on treatment was 15 weeks. Toxicity was modest, 
only grade 4 toxicity encountered was leucopenia 
(8.5 % of pts). There were 3 episodes of febrile 
leucopenia (7%), no bleeding episodes and no toxic 
deaths. Dose reductions were done in 13 pts (39%). 
Partial remission occurred in 13 pts (28%) and 
Complete remission in one patient (2%). Medians 
of Progression Free Survival was 7.2 months (range 
1.4-49.4+ months), Overall Survival was 14.6 
months (range 1.4-57.1+ months), and 1- and 2-years 
survival rates 53% and 19%, respectively. 
Conclusion: Carboplatin with VNB was safe among 
MPM pts including poor prognostic and frail pts in 
PS2, sarcomateous and biphasic subtypes, and age 
>70 years. The overall survival is among the longest 
reported for any chemotherapy regimen in MPM and 
the activity is comparable to that of other regimens 
combining platinum with drugs such as Pemetrexed, 
Raltitrexed, Gemcitabine, or Epirubicin in this 
patient population. 
Keywords: mesothelioma, Chemotherapy, 
Vinorelbine, phase II trial
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P3.279 PROGNOSTIC VALUE OF 
STANDARD UPTAKE VALUE (SUV) 
OF 18F-FDG ASSESSED BY POSITRON 
EMISSION TOMOGRAPHY (PET) 
INTEGRATED WITH COMPUTED 
TOMOGRAPHY (CT) SCAN IN 
STAGING OF MALIGNANT PLEURAL 
MESOTHELIOMA (MPM).
Giovenzio Genestreti1, Andrea Moretti2, Riccardo 
Galassi2, Anna Maria Marzullo2, Sara Piciucchi3, 
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Methods: We evaluated pre-treatment HDAC 
activity in the peripheral blood mononuclear cells 
(1×105) of patients with MPM (n=42) and healthy 
volunteers without asbestos exposure (n=25) using 
HDAC Áuorometric assay. 
Results: The level of HDAC activity in patients with 
MPM was signiÀcantly higher than that in normal 
subjects (p<0.01). The median HDAC activity in 
epithelioid subtype (n=29) was higher than that 
in non-epithelioid subtype (n=13), which was not 
statistically signiÀcant. MPM with early clinical 
stage (IMIG T1 stage, n=4) showed an increase 
in HDAC activity, and there was no signiÀcant 
difference among the IMIG clinical stages. 
Conclusion: MPM patients had a markedly 
increased level of pretreatment HDAC activity in 
peripheral blood mononuclear cells. This Ànding 
suggests that HDAC activity can be surrogate marker 
in the treatment of MPM with HDAC inhibitor. 
Keywords: surrogate marker, malignant pleural 
mesothelioma, histone deacetylase activity
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P3.281 TREATMENT AND PROGNOSIS 
OF RECURRENT THYMOMA
Mi Kyung Bae, Chun Sung Byun, Chang Young Lee, 
Jin Gu Lee, Dae Joon Kim, Kyung Young Chung 
Thoracic And Cardiovascular Surgery, Yonsei 
University College Of Medicine/Korea
Background: The treatment of recurrent thymoma 
and its result are not well known. This study was 
designed to evaluate the results of treatment and to 
analyze the prognosis of recurrent thymoma.
Methods: Between 1987 and 2009, Forty-one 
patients out of 305 patients who underwent resection 
for thymoma had recurrence. We reviewed these 
patients retrospectively. 
Results: Median time to recurrence was 52 months 
(range, 6 to 234 months). Median follow up time 
after recurrence was 25 months (range, 2 to 134 
months). 12 patients had local recurrence, 28 had 
regional recurrence, 10 had distant recurrence, 
and 7 had overlapped recurrence. 15 patients 
underwent re-resection for recurrent tumors. 
The mediastinal mass resections were in 2 cases, 
pleural or pericardial metastasectomes in 10, 
both mediastinal mass resection and pleural 
metastasectomy in 1, pulmonary metastasectomy in 
neither with high or low SUVmax [26 months (95% 
CI: 11 – not reach) versus 19 (95% CI: 12 – not 
reach); p=0.811] nor with high or low SUVmean 
[26 months (95% CI: 8 – not reach) versus 19 
(95% CI: 11 – not reach); p=0.831]. High SUVmax 
(p=0.018) is statistically related to high stage disease 
whereas there is no correlation with high SUVmean 
(p=0.203). Regarding the relationship between 
high histological grade disease and SUVmax 
or SUVmean value, no statistical signiÀcant 
correlations were found (respectively: p=0.268 and 
p=0.083). 
Conclusion: In our series there is correlation 
between high SUVmax value and high stage disease 
and only a trend in the correlation between high 
SUVmean value and high grade histological disease. 
Supported by GIPO. 
Keyword: malignant pleural mesothelioma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 3 – Mesothelioma, Thymoma and other Thoracic 
Malignancies Wednesday, 6 July 2011 12:15-14:15
P3.280 HISTONE DEACETYLASE 
ACTIVITY IN PERIPHERAL BLOOD OF 
PATIENTS WITH MALIGNANT PLEURAL 
MESOTHELIOMA.
Asuka Okada1, Takashi Nakano1, Kuninobu Tamura1, 
Taiichiro Otsuki1, Hisaya Okuwa1, Hitomi Kamiya1, 
Eriko Masachika1, Miki Honda1, Kouji Mikami1, 
Yoshitaka Nogi1, Chiharu Tabata1, Risa Maeda1, 
Kazuya Fukuoka2 
1Division Of Respiratory Medicine, Department Of 
Internal Medicine, Hyogo College Of Medicine/
Japan, 2Cancer Center, Hyogo College Of Medicine/
Japan
Background: Histone deacetylase (HDAC) is 
currently the focus of new target for cancer therapy, 
because of its role in cell cycling, apoptosis and 
differentiation There is an increasing amount of 
preclinical data on the effectiveness of HDAC 
inhibition in mesothelioma cell lines and mouse 
xenograft models. One of issues in the treatment 
of malignant pleural mesothelioma (MPM) with 
HDAC inhibitor is to determine the most appropriate 
surrogate marker for predicting and monitoring the 
molecular effect of this agent. 
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number of patients become potential candidates for 
surgery. Aim of this study was to evaluate the impact 
of surgery alone or as part of multimodal therapy 
approaches on patients’ outcome.
Methods: We performed a retrospective analysis 
of all consecutive MPM patients referred to our 
institution for surgical curative therapy from 01/1994 
to 10/2010. Overall survival was the primary 
endpoint. Patients were also analyzed with regard to 
hospital and ICU stay.
Results: 66 patients were identiÀed in our database 
with mean age 61 ± 9 years. (14 female, 52 male). 
Histopathology was epithelial, nonepithelial, and 
unclassiÀed in 42, 20 and 4 patients, respectively. 
13 patients were in stage I, 16 patients in stage II, 
31 patients in stage III and 6 patients in stage IV. 
All patients underwent surgical treatment, either 
alone (n=28) or in multimodality treatment protocols 
(n=38). Among the multimodality treatment 
group, patients received additionally to surgery: 
neoadjuvant chemotherapy (n=28), adjuvant chemo- 
and radiotherapy (n=5), adjuvant radiotherapy 
(n=12), and adjuvant chemotherapy (n=11). Surgical 
treatment was extrapleural pneumonectomy in 58, 
pleurectomy/decortication in 5 and other surgical 
procedures in 3 cases. Mean overall survival of all 
patients was 447 ± 461 days (range: 8 to 2325 days, 
30 days survival: 90%, 1 year survival 47%, 3 years 
survival 17%). Patients undergoing multimodal 
therapy had a signiÀcant (Log Rank: p= 0.000) 
longer mean overall survival (598 days) than patients 
undergoing surgery alone (318 days). Histological 
and lymph node status had a signiÀcant inÁuence on 
overall survival. Perioperative complications did not 
differentiate signiÀcantly between both treatment 
groups (multimodal treatment: n= 13; surgery alone: 
n= 15). There was no signiÀcant difference between 
both treatment groups with regard to hospital and 
ICU stay.
Conclusion: Surgery as part of multimodal treatment 
protocols had a signiÀcant impact on patients overall 
survival. Perioperative complication rate or length 
of hospital and ICU stay were not enhanced in these 
patients compared to patients treated with surgery alone.
Keywords: pleural mesothelioma, Extrapleural 
pneumonectomy, multimodality treatment
1, and all mediastinal mass, pleural metastasectomy 
and pulmonary metastasectomy in 1. 13 patients 
underwent complete resection of the recurrent 
tumor and 2 incomplete resection. 11 patients 
received chemotherapy for recurrent thymoma and 
5 chemoradiotherpy, 9 patients did not receive any 
treatment and one received other treatment. Overall 
Àve-year and 10-year survival rate after recurrence 
were 59.7% and 33.2%, respectively. Survival rate 
after initial thymoma resection was not different 
between patients without recurrence and patients 
who underwent re-resection for recurrent thymoma 
(Àve year survival, 90.7% vs 91.7%, p=0.618). 
Patients who did not underwent re-resection or 
underwent incomplete re-resection had poor survival 
compared to patients without recurrence (90.7% 
vs 77.7% p<0.0001). Survival after recurrence was 
signiÀcantly different between complete re-resection 
group and others(90.9% vs 44.7%, p=0.014). 
According to the pattern of recurrence, WHO 
histologic classiÀcation, Masaoka stage of initial 
thymoma and time to recurrence, survival difference 
after recurrence was not signiÀcant. 
Conclusion: Patients who underwent complete re-
resection for recurrent thymoma had comparable 
survival to patients without recurrence. In addition, 
patients who did not undergo complete re-resection 
had poor prognosis. Lifetime surveillance is essential 
to increase the chance of the complete re-resection of 
the recurrent thymoma.
Keywords: treatment, Prognosis, recurrent thymoma
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P3.282 THE IMPACT OF SURGERY AS 
PART OF MULTIMODAL TREATMENT 
APPROACHES IN MALIGNANT 
PLEURAL MESOTHELIOMA PATIENTS - 
A SINGLE CENTER EXPERIENCE
Mir Alireza Hoda1, Bahil Ghanim1, Thomas 
Klikovits1, Clemens Aigner1, Shahrokh Taghavi1, 
Gyoergi Lang1, Madeleine Arns-Dietl2, Walter 
Klepetko1 
1Division Of Thoracic Surgery, Medical University 
Vienna/Austria, 2Department Of Pneumology, Lkh 
Grimmenstein/Austria
Background: Malignant Pleural Mesothelioma 
(MPM) is a rare but aggressive disease. However 
with advances in neoadjuvant therapy, a higher 
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January 08 - an Italian registry of Net of the lung 
(all histologies), with the collaboration of many 
Italian centers. The purpose is to have more data 
about incidence, prognosis and treatment of this rare 
disease. At January 11, 23 centers have given their 
adhesion and 120 cases are reported. We think that 
is useful the effort of all Italian centers to have more 
data and increase the knowledge of the disease. The 
next question: is useful an European registry?
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P3.284 DIFFERENTIATION 
OF MALIGNANT PLEURAL 
MESOTHELIOMA FROM BENIGN 
ASBESTOS-RELATED PLEURAL 
DISEASE WITH MICRORNA AND GENE 
EXPRESSION PROFILING
Güntülü Ak1, Muzaffer Metintas1, Sandra Tomaszek2, 
James R. Jett3, Selma Metintas1, Huseyin Yildirim1, 
Emine Dundar1, Marie Christine Aubry2, Sertac 
Arslan1, Jie Dong2, Dennis A. Wigle2, Charles F. 
Thomas2 
1Division Of Chest Disease, Eskisehir Osmangazi 
University Medical Faculty/Turkey, 2Pulmonary And 
Critical Care Medicine, Mayo Clinic/United States 
Of America, 3Oncology, National Jewish Health/
United States Of America
Background: Malignant pleural mesothelioma 
(MPM) is an aggressive tumor which remains a 
worldwide problem because of its poor prognosis 
and increasing incidence. The major risk factor for 
this cancer is exposure to asbestos. The diagnosis 
of MPM is based on immunohistochemical stain of 
the pleural tissue obtained by biopsy. Differentiating 
between MPM and benign pleural disease (BAP) 
on pleural biopsy may be difÀcult in some cases. 
Although MPM has poor clinical outcomes 
overall and is frequently untreatable, recent series 
show that overall survival of this disease with 
aggressive treatment strategies is much longer than 
previously thought when it is diagnosed at an early 
stage. One of the most recent advances in cancer 
molecular biology is the identiÀcation of a role for 
microRNAs (miR) in regulating gene expression 
at the posttranscriptional level. In this study, we 
investigated the expression of miRs and their target 
mRNAs in both MPM and BAP. 
Methods: All of the patients provided written 
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P3.283 NET OF THE LUNG , FROM 
A SINGLE INSTITUTION TO THE 
CREATION OF AN ITALIAN REGISTRY
Giuseppe Vamadre1, Claudio Della Pona2, Casimiro 
Giorgetta2, Renzo Epis1, Mario Robustellini2 
1Oncology And Hematology, E.morelli Hospital 
Sondalo/Italy, 2Thoracic Surgery, E.morelli Hospital 
Sondalo/Italy
Background: Pulmonary NETS are typical 
carcinoid (TC), atypical carcinoid (AC), large-cell 
neuroendocrine carcinoma (LCNC), and SCLC. 
Purpose: to evalue prognosis of pulmonary well 
differentiated NET and establish an Italian registry.
Methods: From 1996 to 2007 our lung cancer 
working group followed 51 pulmonary NETs. 2/51 
were metastatic at the diagnosis. 44/51 underwent 
radical surgical resection with adenectomy. 2/51 
TC had deÀnitive endobronchial laser, 3/51 had 
disostructive laser (2/3 followed by bilobectomy). 
37/51 (72%) are TC. 11/51 (21%) are AC, 2/51 (4%) 
undetermined.
Results: Follow-up at dec 07: 3/51 were lost. 1 AC 
dead 7 yrs after diagnosis for progressive disease 
(liver metastasis, high CgA, and 3 yrs of octreotide). 
1 undeterminated histology dead 1 yr after diagnosis 
(high CgA, octreotide therapy). 7 had preoperating 
CgA: 2 high (1 developed hepatic metastasis, in 1 
normalized and 48 mths DFS). 3 TC had progressive 
disease. 1 TC (IA,high pre-lobectomy CgA), had 
persistent high CgA and hepatic lesion octreoscan+, 
4 mths later: PR after 18 mths of octreotide. 1 TC 
(IB) with normal pre-lobectomy CgA had carcinoid 
syndrome with high CgA and octreoscan positivity, 4 
mths later: negative restaging at 34 mths with 1 yr of 
octreotide. A sixteen girl -  TC IB -  with high CgA 
(normal after pneumonectomy) developed octreoscan 
+ thoracic lesions, 18 mths later. PR after 56 mths 
with radiometabolic therapy.
Conclusion: NETS are heterogeneous lung cancers. 
AC radically resected had good prognosis (1/11 
metastasis), sometimes TC gave metastasis (2/37). 
Octreotide- and radiometabolic therapy can control 
metastatic disease. CgA is not indicative of relapse 
but correlates with the extension of metastatic 
disease. High CgA values are not predictive of 
carcinoid syndrome. It is important to evalue 
CgA before and 2-3 mths after surgery. From this 
experience, we have created an Italian registry; since 
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P3.285 LOW-DOSE GEMCITABINE 
IN PROLONGED INFUSION AND 
CISPLATIN FOR THE TREATMENT 
OF MALIGNANT PLEURAL 
MESOTHELIOMA
Vilijem Kovac, Matjaz Zwitter, Mirjana Rajer 
Department Of Radiotherapy, Institute Of Oncology 
Ljubljana/Slovenia
Background: After favorable experience with 
gemcitabine in low dose (130-250 mg/m2) in 
6-hours infusion in combination with cisplatin 
for the treatment of advanced non-small cell lung 
cancer, we conducted a phase II trial of the same 
chemotherapy regimen in patients with malignant 
pleural mesothelioma (MPM).
Methods: Eligible patients had biopsy-proven 
medically inoperable MPM, were chemo-naïve, 
were in fair general condition (Eastern Oncology 
Cooperative Oncology Group performance status 
0-2), had normal hematopoietic, liver and renal 
function and gave informed consent. Treatment 
consisted of gemcitabine 250 mg/m2 in 6-hour 
infusion on days 1 and 8 and cisplatin at 75 mg/m2 
on day 2 of a 3-week cycle for 4 cycles, followed by 
2 additional cycles without cisplatin. 
Results: Between December 2002 and May 2008, 
78 patients (58 male, 20 female; age 33 to 82 years, 
median 61.5) were included in the trial. Histologic 
subtype analysis revealed epitheloid in 56 (71.8%); 
sarcomatoid in 4 (5.1%); mixed in 15 (19.2%), and 
“not otherwise speciÀed” mesothelioma in 3 (3.8%) 
of cases. Median number of treatment cycles was 
6 (1-6). Grade III/IV toxicities were anemia in 2 
(2,6%), leucopenia in 4 (5,1%), neutropenia in 18 
(23,1%) patients and nausea/vomiting in 1 (1,2%) 
patient. Alopecia was seen in 60 (76.9%) patients; 53 
patients (67.9%) had thrombocytosis with platelets 
over 500 x 109 /L. Four (5.1%) patients had complete 
response and 35(44.9%) had partial response; 
additional 36(46.2%) patients had minimal response 
with symptomatic improvement or stable disease. 
Four (5.1%) patients had disease progression during 
treatment. Median progression free survival was 8.0 
months (C.I. 7.0-9.0) and median overall survival 
was 16.0 months (C.I. 13.6-18.3). One, two, three 
and Àve year survival were 67.2%, 30.3%, 14.5%, 
and 8.5%, respectively. 
Conclusion: Due to the acceptable toxicity, 
remarkable efÀcacy and reasonable cost, this 
informed consent for genetic analysis on their pleural 
specimens. Biopsy specimens from 18 MPM and 
6 BAP patients who were diagnosed and followed 
up at the Eskisehir Osmangazi University Hospital 
in Turkey were enrolled in this study. Specimens 
were obtained by medical thoracoscopy, CT-guided 
Abrams needle, or thoracotomy. All biopsy samples 
underwent review in Turkey by a single pathologist 
and these were conÀrmed by a lung pathologist at 
Mayo Clinic. None of the patients had received 
chemotherapy or radiotherapy prior to diagnosis. 
Clinical data including age, sex, asbestos exposure 
history, smoking history, Karnofsky performance 
status, histology, stage, treatment history, and 
survival characteristics were collected from all 
mesothelioma patients, while age, sex, asbestos 
exposure history and survival data were collected 
from the BAP patients. Follow-up was for 3 years 
or death. Gene expression proÀling of mRNA 
was performed using the Affymetrix GeneChip® 
Human Genome U133 Plus 2.0 array in the Mayo 
Clinic Advanced Genomic Technology Center 
Microarray Shared Resource. ProÀling of microRNA 
expression was performed using the TaqMan® 
Human MicroRNA Array Card A on the 7900HT 
fast Real-Time PCR System. Expression data were 
normalized in standard fashion and both MPM and 
BAP microRNA data were normalized separately to 
a miR mammalian U6 endogenous control gene. 
Results: We discovered differential expression 
of miR and mRNA between the MPM and BAP 
samples. The most signiÀcant miRs included 
Hsa-let-7c-4373167, Hsa-miR-24-437-3072, 
Hsa-miR-29a-4395223, Hsa-miR-92a-4395169, 
Hsa-miR-191-4395410, Hsa-miR-193b-4395478, 
Hsa-miR-197-4373102, Hsa-miR-320-4395388, 
Hsa-miR-155-4395459, Hsa-let-7b-4395446, Hsa-
miR-484-4381032, Hsa-miR-532-3p-4395466, 
and Hsa-miR-574-3p-4395460. Within the MPM 
samples, unique differences in miR levels were 
found for stage and prognosis, which included 
the following: Hsa-miR-193b-4395478, Hsa-
miR-320-4395388, Hsa-miR-494-4395476 and Hsa-
miR-532-3p-4395466. 
Conclusion: We have identiÀed speciÀc miRs 
as potential diagnostic and prognostic utility for 
patients with MPM or BAP. 
Keywords: malignant pleural mesothelioma, 
microRNA, gene expression, asbestos
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P3.287 PEMETREXED IN THE 
FIRST LINE CHEMOTHERAPY 
OF MALIGNANT PLEURAL 
MESOTELIOMA. A MULTICENTRE 
PROSPECTIVE STUDY.
Vitezslav Kolek1, Petr Zatloukal2, Miloš Pešek1, 
František Salajka1, Miloslav Marel3, Jaromír 
Roubec1, Jana Skrickova1, Dimka Sixtova4, Luboš 
Petruželka5, Ivona Grygárková1, Leona Koubková3, 
Michal Štícha6 
1Respiratory Diseases, University Hospital/
Czech Republic, 2Respiratory Diseases, University 
Hospital, Bulovka/Czech Republic, 3University 
Hospital Motol/Czech Republic, 4Respiratory 
Diseases, Thomayer University Hospital/Czech 
Republic, 5Oncologoical Department, Charles 
University Hospital/Czech Republic, 6Iba, Masaryk 
University/Czech Republic
Background: Malignant pleural mesothelioma 
(MPM) is a tumour with extremely unfavourable 
prognosis. Early diagnostic is rarely possible 
and chemotherapy has only a limited value 
in prolongation of survival. During the last 
years pemetrexed became the standard 1st line 
chemotherapy. 
Methods: Results of MPM treatment with 
pemetrexed and platinum in the 1st line were 
evaluated in 9 centres. Data about consecutive 
patients were prospectively collected from January 
2008 till December 2010. Demographics, tolerance 
of therapy and prognostic factors were discussed. 
Results: The series consisted of 85 patients (pts) 60 
men and 25 women, mean age 61 years (26 -84), 29 
were nonsmokers, 32 exsmokers, 24 smokers. PS 
was 0 in 16 pts, 1 in 58 pts, 2 in 11 pts. TNM was I 
in 6 pts, II in 18 pts, III in 27 and IV in 31 pts. The 
professional exposition was found in 21 pts (median 
of exposition was 15 years), nonprofessional 
exposition was known in 14 pts. Side effects of 
treatment (Gr 3, 4) appeared in 22 pts, leucopenia 
in 11, neutropenia in 10, nausea/vomiting in 9, 
fatigue in 7, trombocytopenia in 7, anaemia in 6 
pts. Therapeutical response: PR in 27, SD 38, PD in 
22 pts, overall therapeutical response was 71.8%. 
Median of progression free survival (PFS) was 8.2 
months, it was 8.1 m in men and 9.9 m in women (p 
0.444). The median of overall survival (MOS) was 
13.4 m, it was 13.4 m in men and 15.2 m in women 
treatment should be further explored.
Keywords: Cisplatin, malignant pleural 
mesothelioma, Chemotherapy, gemcitabine
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P3.286 CLINICAL ANALYSIS AND 
TREATMENT OUTCOME OF PRIMARY 
MALIGNANT GERM CELL TUMOR IN 
MEDIASTINUM - A 30-YEAR SINGLE 
INSTITUTION EXPERIENCE.
Shintaro Kanda1, Tomonobu Koizumi2, Kazunari 
Tateishi1, Toshihiko Agatsuma1, Keishi Kubo1, 
Kazutoshi Hamanaka3, Takayuki Shiina3, Kazuo 
Yoshida3 
1The First Department Of Internal Medicine, 
Shinshu University, School Of Medicine/Japan, 
2Comprehensive Cancer Center, Shinshu University 
Hospital/Japan, 3Thoracic Surgery, Shinshu 
University Hospital/Japan
Background: The treatment of primary mediastinal 
germ cell tumors (GCT) with cisplatin-based 
chemotherapy, followed by surgical resection of 
residual disease, has been established. We reviewed 
our institution’s 30-year experience in the treatment 
outcome in patients with primary mediastinal 
malignant GCTs.
Methods: We identiÀed 16 patients (15 males and 
1 females), with a mean age of 27 years (range, 19 
to 43 year) in our insitutde from 1982-2011. There 
were 11 patients with nonseminomatous GCTs and 5 
seminoma. One patient had a hepatic metastasis, but 
other had located diseases.
Results: Cisplatin-based chemotherapy with VAB-
6, PE and BEP was performed in three, Àve and 
seven cases, respectively. After 2-8 cycles of the 
chemotherapy, 14 cases underwent thoracic salvage 
resection. Two patients died 13 and 19.5 months 
after initiation of therapy, respectively, who was 
treated with VAB-6 and viable malignant cells were 
observed in the resected specimens. Other patients 
are currently disease free with a median survival 
period of 108 months (range 7-324 months).
Conclusion: Our institutional experience indicated 
that an improved survival advantage was ensured 
with preoperative chemotherapy in patients with 
primary mediastinal GCTs.
Keyword: Germ cell tumor
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previously received chemotherapy. Somatostatin 
analogues had been given to 5 patients prior to start 
of Lutetium, and was given to 4 additional patients 
during the Lutetium therapy. Median follow-up was 
22 months from start of Lutetium and 109 months 
from initial diagnosis.
Results: There were no complete responses. A 
partial response was seen in 6 patients (50%), stable 
disease in 5 (42%) and progressive disease in 1 
patient (8%). Three patients with stable disease and 
one with partial response have later progressed. 
Three patients have died and the remaining 9 are 
alive, median 28 months from start of Lutetium and 
median 115 months from initial diagnosis. Bone 
marrow toxicity was mild.
Conclusion: Treatment with 177Lu-DOTA-
Octreotate is active and well tolerated in patients 
with metastatic bronchial carcinoids, and should be 
considered as Àrst-line therapy in this patient group.
Keywords: PRRT, Bronchial carcinoids, 
177Lutetium-octreotate
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.289 ANALYSIS OF SOLUBLE 
MESOTHELIN-RELATED PEPTIDES 
AS DIAGNOSTIC MARKERS 
OF MALIGNANT PLEURAL 
MESOTHELIOMA EFFUSIONS
Antonella Vigani1, Pier Aldo Canessa2, Paola Ferro3, 
Enrico Battolla4, Carmen Manta2, Maria Cristiana 
Franceschini3, Massimiliano Sivori2, Vincenzo 
Fontana5, Franco Fedeli3, Maria P. Pistillo6, Silvio 
Roncella3 
1Division Of Oncology, Asl 5 La Spezia/Italy, 
2Division Of Pneumology Asl5 La Spezia/Italy, 
3Division Of Pathology And Cytopathology Asl5 La 
Spezia/Italy, 4Division Of Clinical Pathology Asl 
5 La Spezia/Italy, 5National Institute For Cancer 
Research, Unit Of Epidemiology And Biostatistics/
Italy, 6National Institute For Cancer Research, Units 
Of Tumor Genetics And Epigenetics, Ist Genova/Italy
Background: It has been reported that the serum 
levels of soluble mesothelin-related peptides 
(SMRP) are higher in patients with malignant 
(p 0.921). PFS according TNM staging: 16.6 m 
in stage I, 13.4 m in stage II, 4.9 m in stage III (p 
0.001). MOS according TNM staging: NA in stage I, 
13.4 m in stage II, 9.7 m in strage III (p 0.063). PFS 
according PS: 16.6 m in PS 0, 9.9 m in PS 1, 2.6 m 
in PS 2 (p 0,008). MOS according PS: NA in PS 0, 
11.9 m in PS 1, 3.3 m in PS 2 (p 0.001). 
Conclusion: Pemetrexed is an effective and well 
tolerable drug in routine MPM treatment. PS and 
TNM staging inÁuenced the prognosis, albeit sex, 
age and type of asbestos exposure had no prognostic 
impact in this study. 
Keywords: malignant pleural mesotelioma, 
Pemetrexed, Àrst line chemotherapy, survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.288 TREATMENT WITH 177LU-DOTA-
OCTREOTATE IN PATIENTS WITH 
BRONCHIAL CARCINOIDS
Ulrike Garske1, Daniel P. Lindholm2, Mattias 
Sandström3, Pantelis Antonodimitrakis4, Silvia 
Johansson1, Anders Sundin5, Barbro Eriksson2, Dan 
Granberg4 
1Department Of Nuclear Medicine, Institution Of 
Radiology, Oncology And Radiation Science/Sweden, 
2Department Of Endoccrine Oncology, Institution Of 
Medical Sciences/Sweden, 3Department Of Medical 
Physics, Instituition Of Radiology, Oncology 
And Radiation Sciences/Sweden, 4Department 
Of Endocrine Oncology, Instituiton Of Medical 
Sciences/Sweden, 5Department Of Radiology, 
Institution Of Radiology/Sweden
Background: Metastatic bronchial carcinoids are 
rare tumors, where efforts of medical treatment thus 
far have been disappointing. A previous study has 
reported favourable results of treatment with 177Lu-
DOTA-Octreotate in these patients.
Methods: Twelve patients with metastatic bronchial 
carcinoid have so far been treated with 177Lu-
DOTA-Octreotate at our center between 2006 and 
2011. Five tumors were classiÀed as atypical and 3 
as typical carcinoids, whereas 4 tumors could not be 
classiÀed. One patient had ectopic ACTH production, 
resulting in Cushing’s syndrome. Seven patients had 
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marker to distinguish MPM PE from benign and PM 
PE.
Keyword: malignant pleural mesothelioma, Soluble 
mesothelin-related peptides, pleural effusion
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P3.290 THE DIAGNOSTIC ROLE OF 
F-18 FDG PET/CT IN PATIENTS WITH 
PLEURAL THICKENING AND PLEURAL 
EFFüSION
Mine ûencan Eren1, Canan Karaman2, Melahat 
Aslan1, Oya It×l2, Atilla Akkoclu2, Ozhan Ozdogan1, 
Berna Degirmenci Polack1 
1Department Of Nuclear Medicine, Dokuz Eylul 
University School Of Medicine/Turkey, 2Department 
Of Chest Diseases, Dokuz Eylul University School Of 
Medicine/Turkey
Background: AIM:To investigate the diagnostic 
role of F-18 FDG PET/CT in patients with pleural 
thickening and pleural effusion.
Methods: The mean age of the patients were 
61.9±12.7 (26 patients; 21 male, 5 female) in this 
retrospective study. Three patients had only pleural 
effusion (PE), 4 patients had both pleural effusion 
and pleural thickening (PT), the rest of the patients 
had pleural nodules (PN) and (PT). All patients were 
fasted for at least 12 h (blood glucose level <200 
mg/dL) before FDG PET/CT examinations. A low-
dose CT was performed prior to the PET images 
(1.5 min/bed position) and obtained 60 min after 
F-18 FDG injection. The Ànal diagnosis was reached 
by histopathological examination or by clinical 
follow-up. The SUVmax values were calculated 
and the highest values for the patients were used 
for statistical analyses. Mann Whitney U test was 
performed for statistical analysis.
Results: All the lesions were benign in PE patients. 
The Ànal diagnosis revealed a malignant lesion in 
2, and a benign lesion in the the other 2 referred 
with both PE and PT. In PN and PT group 12 were 
diagnosed to have malignant lesions and the rest 
were benign. The mean SUVmax value of the 
benign PE was 2.6 ± 0.9. One of the two patients 
with both PE and PT was diagnosed to have 
Àbrous pleuritis (SUVmax: 6.5) and the second 
with tuberculosis (no increased uptake, SUVmax: 
1.0). The rest of two patients were diagnosed as 
metastatic pleural involvement; the one with a 
pleural mesothelioma (MPM) than in other patients. 
Therefore, serum SMRP was proposed as a marker 
for mesothelioma diagnosis. However, few studies 
have shown the potential value of SMRP for the 
differential diagnosis of pleural effusions (PE). In 
the present study we assessed the PE levels of SMPR 
from a large panel of patients and investigated their 
possible utility in routine clinical practice. 
Methods: We evaluated SMRP in a total of 211 
PE (38 from MPM, 71 from non-MPM pleural 
metastasis (PM), 102 from benign PE) by means of 
the MesoMark enzyme-linked immunosorbent assay 
kit (Fujirebio Diagnostic, Malvern, PA). Mesothelin 
dignostic performance parameters were estimated 
through the receiver operating characteristic (ROC) 
analysis. In particular, the area under the ROC 
curves (AUC) was used as an index of pure accuracy, 
namely the overall proportion of correctly classiÀed 
patients. Youden’s index was applied to obtain the 
biomarker’s cut off level of maximum discrimination 
between patient groups. For each cut off, empirical 
accuracy (Ac), positive (PPV) and negative (NPV) 
predictive values, along with sensitivity (Se) and 
speciÀcity (Sp), were calculated. Finally, the degree 
of correlation between SMRP levels and patients’ 
disease stutus was estimated using the Diagnostic 
Odds Ratio (DOR). For each index 95% conÀdence 
limits (95% CLs) were also computed and, wherever 
appropriate, chi-square test was performed to 
assess the statistical signiÀcance (P) of the study 
comparisons.
Results: The Mean PE SMRP level was higher in 
MPM (41.7±49.4 nM/L) than in patients with PM 
(8.8±14.1 nM/L) or benign PE (4.8±8.4 nM/L). We 
found a statistically signiÀcant difference between 
SMR levels in MPM vs benign PE (DOR=30.8, 
P<0.001), vs PM (DOR=11.8, P<0.001) and vs 
all other PE (DOR=15.7, P< 0.001). The AUC for 
SMRP-differentiating MPM PE and benign PE was 
79.8 (cut off=10.8 nM/L, Se=65.8%, SP=94.1%, 
Ac=86.4%, PPV=80.6% and NPV=88.1%), the AUC 
for SMRP-differentiating MPM PE and PM PE was 
75.6 (cut off=11.8 nM/L, Se=63.2%, SP=87.3%, 
Ac=78.9%, PPV=72.7%, NPV=81.6%). Finally, 
the AUC for SMRP-differentiating MPM PE and 
all other disease PE was 78.1 (cut off=10.9 nM/L, 
Se=63.2%, SP=90.2%, Ac=85.3%, PPV=58.5%, 
NPV=91.8%). At the cut off of 10.9 we found higher 
SMPR values in 25/38 (66%) MPM PE, 13/71 (18%) 
of PM PE and 8/102 (8%) of benign diseases PE. 
Conclusion: Our Àndings show that SMPR level in 
PE, as reported in serum, is a promising diagnostic 
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P3.291 PRIMARY SARCOMA OF THE 
LUNG: A SURGICAL SERIES
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Zaimi1, Sonia Ouerghi1, Belhassen Smati1, Taher 
Mestiri1, Tarek Kilani1, Hamouda Boussen1 
1Cardio-thoracic Surgery, Abderrahmen Mami 
Hospital/Tunisia, 2Pulmonary Disease Service “D”, 
Abderrahmen Mami Hospital, Ariana, Tunisia/
Tunisia, 3Pathology And Cytology Department, 
Abderrahmen Mami Hospital, Ariana/Tunisia
Background: Primary pulmonary sarcomas (PPS) 
are rare mesenchymal tumors, accounting for 0.013% 
to 0.4% of all lung malignancies. Their prognosis 
remains poor, despite the entire therapeutic arsenal 
that is available for the treatment of non-small-cell 
lung cancer (NSCLC). The aim of this study is to 
investigate clinical, histological characteristics and 
survival after resection of these tumors.
Methods: On a series of 1582 patients operated on 
for lung cancer, 43 patients were retrospectively 
identiÀed as having been treated surgically for 
primary pulmonary sarcoma. The records of all 
patients were reviewed.
Results: There were 33 males and 10 females with a 
mean age of 55 (range 12-75). Clinical Àndings were 
dominated by thoracic symptoms. Imaging Àndings 
showed a peripheral mass in the majority of cases 
(n=29). The mean tumor’s size was 5.2 cm (range, 
1 - 17.5cm). Careful investigation failed to discover 
a primary lesion elsewhere. The preoperative 
histological diagnosis was a NSCLC in 19 patients. 
Seven patients received induction therapy for wall 
involvement. Lobectomy or bilobectomy was 
performed in 30 patients and pneumonectomy in 
11 patients. One patient underwent exploratory 
thoracotomy and one underwent a resection of a 
nodule. Of the resected patients, 3 had a positive 
resection margin. The histologic diagnoses were: 
pleomorphic carcinoma (n=28), carcinosarcoma 
(n=5), angiosarcoma (n=3), leiomyosarcoma (n=1), 
rhabdomyosarcoma (n=2), blastoma (n=3), and 
primitive neuroectodermal tumor (n=1). Different 
stages were: Ia (n=2), Ib (n=13), IIb (n=14), IIIa 
(n=5), IIIb (n=6) and IV (n=7). There were no 
operative deaths. Two died within 1 month of 
surgical complications and 5 died of disease within 
17 months. Adjuvant therapy was performed in 8 
metastatic lesion due to a prostate cancer was 
F-18 FDG negative (SUVmax: 1.0), the other with 
nonsmall cell lung cancer had a SUVmax of 12.9. 
In 19 patients with PT and PN were diagnosed 
as benign pleural changes (7 patients), malignant 
mesothelioma (6 patients) and metastatic pleural 
involvement (6 patients). The mean SUVmax were 
2.43±2.15, 10.13±3.0, and 9.05±6.0 for benign 
lesions, malignant mesothelioma and metastatic 
involvement, respectively. The SUVmax values 
ranged between 1.0-6.80 and 1.0-21.5 in benign 
and malignant lesions respectively. There was 
signiÀcant difference of SUVmax values between 
benign and all malignant lesions (p<0.0001). There 
was also a signiÀcant difference between benign and 
malignant mesothelioma lesions (p: 0.001). There 
was not a difference of SUVmax values between 
malignant mesothelioma and metastatic lesions (p: 
0.25). In malignant mesothelioma patients, PET/
CT demonstrated two nodular lesions which were 
located in paracaval (SUVmax: 5.0) and paracardiac 
(SUVmax: 10.0) regions that were not reported by 
diagnostic CT study. A high F-18 FDG uptake was 
also demonstrated on femoral diaphysis.
Conclusion: PET/CT may be valuable diagnostic 
tool in evaluating patients with pleural lesions. 
It should be taken into consideration that benign 
lesions could demonstrate reasonably increased FDG 
uptake. The crucial diagnostic role of PET/CT may 
be the demonstration of extrapleural dissemination 
and the determination of small lesions that were not 
reported on CT. 
Keywords: FDG PET/CT, Pleural effusion and 
thickening, mesothelioma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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over 1 week to the entire hemithorax. Acute 
treatment related toxicities are presented (deÀned 
as any toxicity seen within 3 month of treatment 
completion). Toxicities are graded according the 
CTCAE v3.0 criteria. 
Results: Nine patients (6 males) of an intended 12 
have been accrued to this feasibility study. Mean 
age is 63 years (range: 46-72 years). All patients 
were ECOG  1. Median follow-up is 8 months 
from time of EPP. All patients were clinically staged 
cT1-3 N0 M0. After EPP, the pathological stages 
were: ypT3 N0 M0 (1); ypT4 N0 M0 (2); ypT3 N2 
M0 (1); ypT4 N2 M0 (4); and ypT4 N3 M0 (1). 
No fatal or life threatening toxicities (G4+) were 
observed during treatment. Four patients developed 
severe (G3) toxicities, seen during the peri-operative 
period (thromboembolism requiring anticoagulation; 
hemothorax requiring operative correction, atrial 
Àbrillation, infection). Two patients have recurred 
(both distantly). 
Conclusion: These results are preliminary and 
should be interpreted cautiously. Short accelerated 
neoadjuvant hemithoracic RT followed by EPP 
appears feasible. More mature follow-up is needed to 
evaluate outcomes and late toxicities. 
Keywords: mesothelioma, Radiotherapy, 
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P3.293 SECOND-LINE THERAPY 
IN PATIENTS WITH MALIGNANT 
PLEURAL MESOTHELIOMA. FRENCH 
RETROSPECTIVE STUDY 2005-2006
Jacques Margery1, Pierre RufÀe2, Hervé Le Floch1, 
David Planchard2, Frédéric Riviere1, Wanda 
Gaspard1, Patrick Saint Blancard2, Benjamin Besse2, 
Fabien Vaylet1 
1Pneumologie, Hôpital D’instruction Des Armées 
Percy/France, 2Oncologie Médicale, Institut Gustave 
Roussy/France
Background: The role of second-line chemotherapy 
(SLC) is not yet established in malignant pleural 
mesothelioma (MPM) but SLC is being used 
increasingly in our experience because many patients 
are still Àt at the time of disease progression. 
Methods: In this retrospective study, we reviewed 
our experience of SLC in pemetrexed-pretreated 
patients with MPM at two French thoracic oncology 
patients. Recurrence happened in 4 patients within 
12 months after operation. Median survival for all 
patients was 8 months.
Conclusion: Resection of primary pulmonary 
sarcomas is associated with an acceptable survival 
rate if the resection is complete. The particularity of 
our study is that, despite the large size of the tumor, 
an acceptable survival can be obtained. Nevertheless, 
these patients require carefully follow-up to evaluate 
local recurrence, and metastases.
Keywords: Lung cancer, Pulmonary sarcomas, 
Surgery
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P3.292 ACUTE TOXICITIES OBSERVED 
WITH NEOADJUVANT SHORT 
ACCELERATED HEMITHORACIC 
RADIOTHERAPY (RT) FOLLOWED BY 
EXTRA-PLEURAL PNEUMONECTOMY 
(EPP) FOR MALIGNANT PLEURAL 
MESOTHELIOMA (MPM): 
PRELIMINARY RESULTS
John Cho1, Ronald Feld2, Natasha B. Leighl2, Marc 
De Perrot3 
1Radiation Oncology, Princess Margaret Hosptial/
Canada, 2Medical Oncology, Princess Margaret 
Hospital/Canada, 3Division Of Thoracic Surgery, 
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Background: MPM is a rare, aggressive tumour 
with poor outcomes. We have routinely treated 
suitable patients with neoadjuvant chemotherapy 
(currently cisplatin and pemetrexed/raltitrexed), 
followed by EPP, followed by adjuvant high dose 
hemithoracic radiation over the past 10 years. Many 
patients develop distant disease in the peritoneum or 
contralateral lung, suggesting incidentally seeding 
at time of EPP to these areas. We are, therefore, 
conducting a study where MPM patients are treated 
with short accelerated neoadjuvant hemithoracic RT 
followed by EPP and present the acute treatment 
toxicities seen. 
Methods: We are conducting an REB approved 
prospective study evaluating the feasibility of 
neoadjuvant short accelerated hemothoracic RT 
followed by EPP within 1 week for clinically 
resectable early stage MPM followed by adjuvant 
chemotherapy if mediastinal nodes are involved. 
The dose prescribed is 25 Gy/5 daily fractions 
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at Masaoka stage IVa between January 2000 
and December 2010 at a single institution and 
were included in the present study. Preoperative 
imaging studies included computed tomography 
and magnetic resonance imaging of the chest. All 
patients underwent needle biopsy for histological 
classiÀcation. World Health Organization 
classiÀcation were Type AB (n=2), Type B3 (n=3) 
and Type C (n=6), respectively.
Results: After 6 cycles of platinum-based induction 
chemotherapy, 3 patients were inoperable at the time 
of surgery and proceeded to chemoradiation therapy 
due to inÀltration of the arcus aortae (n=2) and conus 
pulmonalis (n=1), respectively. Complete mediastinal 
tumor resection and pleurectomy were performed 
in 8 patients. Complete pleurectomy was performed 
in 2 patients. Two patients underwent 4 cycles of 
platinum-based induction chemotherapy. Six patients 
without induction therapy proceeded to adjuvant 
chemoradiation (n=3) or adjuvant radiation (n=3), 
respectively. Morbidity occured in 2 patients (25%) 
including chylothorax and the necessity of mechanical 
ventilation because of myasthenic crisis. No mortality 
occurred. No patient was lost to follow-up and mean 
follow-up was 40.3 ± 22.4 months. Pleurectomy 
resulted in prolonged survival (66.1 ± 3.6 months) 
compared to unresectable patients who underwent 
chemoradiation (22.4 ± 9.2 months, p=0.017).
Conclusion: Locally advanced Masaoka stage 
IVa thymoma can be treated by pleurectomy 
with low morbidity and mortality. Exploratory 
thoracotomies might occur because of possible gray 
zones in distinguishing between tumor invasion 
and attachments despite imaging studies. Long-
term survival can be achieved in highly selected 
patients. The time of application chemotherapy 
and radiotherapy (neoadjuvant vs. adjuvant setting) 
remains unanswered.
Keywords: pleurectomy, Thymoma, locally 
advanced, Surgery
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P3.295 EXPERIENCE OF THE 
TREATMENT OF MALIGNANT 
MESOTHELIOMA AT A UK CANCER 
CENTRE
Victoria A. Brown1, Liz Darlison2, Erik M. Von 
Meyenfeldt2, Apostolos Nakas2, David Waller2, 
Samreen Ahmed1 
units (Institut Gustave Roussy, Villejuif ; Hôpital 
Percy, Clamart).
Results: Between January 2005 and December 2006, 
84 consecutive patients with MPM who progressed 
after pemetrexed-chemotherapy were enrolled. 
Forty-four patients (52,3%) received a SLC. There 
were 30 men and 14 women. The median age was 
58 years (range, 34-76). Most patients had a PS 
 1 (82%) and an epithelial histologic subtype 
(91%). The median time to progression (TTP) after 
Àrst-line chemotherapy was 6,1 months. The SLC 
was a pemetrexed therapy in 21 patients (with a 
relapse more than 3 months), and a new regime in 
20 patients (gemcitabine alone or with oxaliplatin). 
The other 3 patients were enrolled in a phase I study. 
According to RECIST criteria, a partial response 
was observed in 7 patients and 9 patients had stable 
disease after SLC. The median TTP after SLC was 
3,8 months. The median survival was 12,2 months 
(range: 2 to 72 months). Four of these 44 patients 
then received third-line (4,8%) and two received 
fourth-line therapy (2,4%).
Conclusion: Our experience suggests the feasibility 
of giving SLC to patients with MPM who are 
healthy at the time of disease progression. The 
optimal treatment has not been deÀned to date and 
prospective trials are needed in this setting. 
Keywords: pleural mesothelioma, Chemotherapy, 
second-line therapy
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P3.294 PLEURECTOMY FOR THE 
TREATMENT OF MASAOKA STAGE IVA 
THYMOMA
Servet Bölükbas1, Michael Eberlein2, Natalie 
Kudelin1, Joachim Schirren1 
1Thoracic Surgery, Dr. Horst Schmidt Klinik/
Germany, 2Division Of Pulmonary And Critical 
Care Medicine, Johns Hopkins University School Of 
Medicine/United States Of America
Background: The surgical approach to Masaoka stage 
IVa thymoma is not standardized but challenging. 
Pleuropneumonectomy for Masaoka stage IVa 
thymoma is associated with high morbidity and 
mortality. We investigated the outcome of pleurectomy 
in locally advanced Masaoka stage IVa thymoma.
Methods: Eleven patients (56 women, age 50.3 
± 14.4 years) were diagnosed with thymoma 
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(n=9), progressive disease (n=7) and other (n=3). 
Radiological assessment included stable disease 
(n=15), partial response (n=9), progressive disease 
(n=6). Main reasons for no radiological assessment 
included chemotherapy given in the adjuvant 
setting (n=5) and toxicity/progressive disease 
(n=5). Second line chemotherapy administered 
included gemcitabine (n=2), vinorelbine (n=4) or 
pemetrexed (n=4) as single agents. Doublet regimes 
included gemcitabine/vinorelbine (n=1) or platinum/
pemetrexed (n=2). Mean survival was 266 days (8.9 
months). Survival was longer in those able to receive 
chemotherapy (402 versus 219 days p 0.001).
Conclusion: This is a comprehensive audit of 
mesothelioma patients diagnosed in Leicester. A 
histopathological diagnosis was obtained in the vast 
majority of patients. A third of patients underwent a 
surgical treatment and of those assessed in oncology 
over half received chemotherapy. Very few patients 
were enrolled into a clinical trial.
Keywords: mesothelioma, Audit
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P3.296 HIGH RESPONSE OF SECOND-
LINE CHEMOTHERAPY WITH 
PEMETREXED COMBINED WITH 
CARBOPLATIN IN PATIENTS WITH 
UNRESECTABLE MALIGNANT 
MESOTHELIOMA EXPERIENCING 
PROGRESSION AFTER THREE MONTHS 
OF CONCLUDING PLATINUM-BASED 
CHEMOTHERAPY
Daniela Morales-Espinosa1, Oscar Arrieta2 
1Cancer Center, Medica Sur Foundation And Clinic/
Mexico, 2Medical Oncology, Instituto Nacional De 
Cancerologia/Mexico
Background: Malignant Pleural Mesothelioma 
(MPM) is in most cases a lethal neoplasm; few 
patients are candidates for surgical treatment. 
Chemotherapy remains a challenging issue in this 
entity. Platinum analogues, doxorubicin and some 
antimetabolites such as pemetrexed have a modest 
activity against malignant mesothelioma when used 
in Àrst line as single agents with response rates 
ranging from 10 to 40 percent. The combination 
of antimetabolite with a platin like pemetrexed/
cisplatin has shown an improvement in survival, 
lung function and symptom control when compared 
1Oncology Dept, Leicester Royal InÀrmary, 
University Hospitals Of Leicester/United Kingdom, 
2Thoracic Surgery, GlenÀeld Hospital, University 
Hospitals Of Leicester/United Kingdom
Background: An audit was conducted to describe 
the demographics, treatment modalities utilized and 
survival of patients with malignant mesothelioma in 
Leicester.
Methods: Retrospective audit was undertaken 
including all mesothelioma patients referred to 
Leicester Lung Cancer MDT from 01/01/2006 to 
31/12/2009.
Results: There were 108 patients discussed at the 
MDT, mean age 71yrs (39-89 yrs) (88% male). 
106 cases of pleural and 2 cases of peritoneal 
mesothelioma were diagnosed. Histological 
diagnosis was obtained in the majority (n=99), with 
the remainder cytological (n=7), radiological (n=1) 
and at post mortem (n=1). The epithelioid subtype 
was the most common (n=67). Other subtypes 
included sarcomatoid (n=20), biphasic (n=15) and 
malignant mesothelioma not otherwise speciÀed 
(NOS) (n=5). 66.6% had a deÀnite recall of exposure 
to asbestos. At presentation 65.7% of patients had 
a performance status (PS) 0 or 1. 15.7% had no 
PS recorded. The main presenting symptoms were 
breathlessness (n=87), chest pain (n=45), cough 
(n=38) and weight loss (n=32). A third of patients 
received a surgical treatment (EPP, decortication 
or pleurectomy) and 75.9% were referred for 
oncological assessment. 39.8% of all patients had 
Àrst line chemotherapy and 41.7% had radiotherapy 
to the biopsy/scar site (n= 26) or for symptom 
management (n=26). 4 patients were enrolled into 
a clinical trial. 13% and 2.7% received second 
and third line chemotherapy respectively. Main 
reasons for not receiving Àrst line chemotherapy 
were poor performance status (n=49), patient 
refusal (n=6). 4 patients underwent a watch and 
wait policy but deteriorated before treatment. Of 
43 patients that received Àrst line chemotherapy, 
majority had doublet (n=42) containing either 
cisplatin (n=25) or carboplatin (n=17) alongside 
pemetrexed (n=28) or vinorelbine (n=14). Cisplatin 
switched to carboplatin in 5 patients due to falling 
GFR (n=3) or other toxicities (n=2). Vinorelbine 
doublet switched to gemcitabine doublet in 2 
patients (abnormal LFT’s). Due to deteriorating PS, 
cisplatin/pemetrexed was switched to pemetrexed 
single agent in one patient. Mean number of cycles 
3.4 (range 1-6). 19 discontinued due to toxicity 
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time to progression greater than 3 months. Response 
rates with this second-line treatment correlate with 
progression free survival in previously platinum-
treated patients. Further studies need to be carried 
out.
Keywords: second line chemotherapy, Malignant 
mesothelioma, Pemetrexed-cisplatin
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P3.297 PEMETREXED/
CARBOPLATIN(AC) OR PEMETREXED/
CISPLATIN (AP) AS FIRST LINE 
TREATMENT OF MALIGNANT 
PLEURAL MESOTHELIOMA (MPM): 
TOLERABILITY AND RESPONSE RATE 
IN OPERABLE PATIENTS.
Giulia Pasello1, Giuseppe Marulli2, Samuele 
Nicotra2, Federico Rea2, Lucio Loreggian3, Laura 
Bonanno4, Adolfo Favaretto4 
12nd Medical Oncology, Istituto Oncologico Veneto/
Italy, 2Thoracic Surgery Dept, University Hospital/
Italy, 3Radiotherapy, Istituto Oncologico Veneto/
Italy, 4Second Medical Oncology, Istituto Oncologico 
Veneto/Italy
Background: Trimodality treatment based on 
preoperative chemotherapy, surgery and adjuvant 
radiotherapy can be considered an effective 
therapeutic option for MPM selected patients. 
The objective of this study is to evaluate the 
tolerability and activity of pemetrexed/carboplatin 
(AC) or pemetrexed/cisplatin (AP) as neoadjuvant 
chemotherapy.
Methods: Patients with histologically conÀrmed 
MPM, stage I-III, ECOG PS=0-1, received three 
cycles of pemetrexed 500mg/m2 plus carboplatin 
AUC5 or cisplatin 75mg/m2 on day 1 every 21, 
with standard premedication. From January 2005 
to December 2009 Àrst-line chemotherapy was 
based on pemetrexed plus carboplatin, the standard 
regimen we used in this setting. From June 2005 to 
December 2007 patients were included in a clinical 
trial ongoing at our centre, and they were treated 
with pemetrexed plus cisplatin. Baseline staging and 
preoperative restaging were assessed with CT-scan 
and PET-CT. Patients without disease progression 
underwent surgery followed by radiotherapy.
Results: Since 2005, 54 patients were included 
in the study, 30 treated with AC, 24 with AP. 
to single drug cisplatin. There is no standard second 
line chemotherapy for treatment of malignant 
mesotheliomaMPM. Second-line therapies are 
being increasingly used in the clinical practice 
since patients frequently have a good performance 
status at the time of disease progression. However, 
the role of these treatments in MPM is unproven; 
and the optimal regimens still remain to be deÀned. 
We reporte our experience with the combination of 
carboplatin and pemetrexed as second-line treatment 
for patients with MPM. 
Methods: Patients with histologically proven 
MPM experiencing progression 3 months after 
conclusion of chemotherapy (doxorrubicin-cisplatin 
or gemcitabine-cisplatin) received pemetrexed-
carboplatin as second line treatment. Patients were 
age 18 or older, had a good performance status 
(ECOG 0 to 2), measurable disease and written 
informed consent. Life expectancy of at least 3 
months.Pemetrexed was administered at 500 mg 
per square meter in a 10 minute-infusion and 
Carboplatin at AUC of 5 on day 1 in 21-days cycles. 
Response was evaluated using the RECIST criteria 
after every two treatment cycles. The study protocol 
was approved by both the Institutional Boards. 
Results: A total of 30 patients with unresectable 
MPM were included. Previous chemotherapy 
regimens included: gemcitabine-cisplatin (6 patients) 
or doxorrubicine-cisplatin (24 patients). Twenty-
three patients were males and 7 were females. 25 
patients had stage III disease, the remaining 5 had 
stage IV disease. The mean age was of 60 ± 13 years. 
Five patients had a good EORTC while 25 had a bad 
prognosis. Histological subtypes were: 21 epithelioid 
mesotheliomas, 2 sarcomatoid mesotheliomas and 
7 mixed mesotheliomas. Partial response was seen 
in 9 patients, 11 patients had stable disease and 7 
progressive disease. Response was not evaluable in 
3 patients. Progression free survival was of 7 ± 3 
months. Overall Survival was of 21.9 ± 8.7 months. 
Nine patients had a three month interval between 
end of chemotherapy and progression. 6 out of 
nine (66%) patients had over 6 months with partial 
response. 3 out of 21 patients had a partial response 
duration of less than three months. Pemetrexed-
carboplatin has a high response rate in patientes with 
a period of more than three months between the end 
of chemotherapy and progression. 
Conclusion: The use of the pemetrexed-carboplatin 
combination as second-line chemotherapy seems 
to have a place in the management of patients with 
unresectable MPM, especially those with an interval 
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Background: The MM is a tumor originating 
from the mesothelial surface surface of the pleural 
cavity. It has an insidious onset and generally affects 
individuals between 50-70 years. MM is a highly 
malignant tumor and has a poor prognosis with 
median survival between 6 and 18 months. Portugal 
is a country of low incidence of MM in which the 
peak has not yet been reached. 
Methods: Retrospective analysis of patients with 
MM diagnosed between April 1998 and April 2009. 
The parameters evaluated included age, gender, job, 
occupational history, smoking habits, assessment of 
performance status (Zubrod score) and symptoms 
at presentation, TNM staging, diagnostic methods, 
histology, therapy and median survival. 
Results: A total of 27 patients were studied, 19 
(70.4%) males and eight (29.6%) females. Mean 
age at diagnosis was 62.8 ± 10.33 yrs. Four (14.8%) 
patients had a history of direct asbestos exposure 
and 10 (37.0%) of them had a high-risk occupation. 
Most (55.6%) were non-smokers, 5 (18.5%) were 
ex-smokers and 4 (14.8%) current smokers. Twenty-
two patients (81.5%) were Zubrod 1 and 3 (11.1%) 
Zubrod 2. Most common symptoms at presentation 
were dyspnea (48.1%), chest pain (37.0%), asthenia 
(33.3%) and weight loss (29.6%). TNM staging: 19 
(70.4%) were in stage III, 7 (25.9%) in stage IV and 
1 (3.7%) in stage I. The most common methods used 
for deÀnitive diagnosis were thoracoscopy (52.2%) 
and transthoracic biopsy (21.7%). The most common 
histological type was epithelial mesothelioma. First-
line chemotherapy regimens used were cisplatin/
pemetrexed (45.0%) and cisplatin/ gemcitabine 
(45.0%). As second-line therapy, 11 (40.7%) 
received pemetrexed or gemcitabine. Three 
(11.1%) were enrolled in a clinical trial. All patients 
performed prophylatic radiotherapy directed to the 
site of puncture or diagnostic thoracoscopy. One 
patient underwent surgery.
Fourteen (51.9%) died, 8 (29.6%) were lost to 
follow-up and 5 (18.5%) are still alive. 
Conclusion: Similarly to international data, MM 
was diagnosed in advanced stages in most patients. 
Moreover, median overall survival (18 months) is 
consistent with results from the best international 
series. Our study showed that in most cases, it 
was possible to identify an occupational source, 
which conÀrms the importance of exposure in the 
development of MM. In our country, given the 
paucity of references in relation to survival of MM, 
this might be a modest contribution in understanding 
the behavior of the disease in Portugal. 
Haematological toxicity by patient in the intent to 
treat (ITT) population showed grade-3 leucopenia 
(7%), neutropenia (13%), thrombocytopenia (7%) 
and anaemia (3%) in AC-treated patients and 
leucopenia (8%), neutropenia (17%), anaemia 
(8%) in the AP group. No grade 4 haematological 
toxicities were shown in the two groups. Grade-3 
non-haematological toxicities were diarrhoea 
(3%) and asthenia (4%) in AC and AP cohorts 
respectively. Cumulative grade 2-3 asthenia at the 
last cycle of chemotherapy was commoner with 
AP (21%) than with AC (7%); worsening of PS 
was shown in 29% and 17% of patients in the two 
groups respectively. 2(8%) AP-treated patients 
had dose reduction because of hypercreatininemia 
and infection, and 1(4%) died within 30 days from 
surgery for endocarditis. Response to AC and AP 
were: complete 3% vs 0%, partial 30% vs 17%, 
stable disease 64% vs 79%, progressive disease 
3% vs 4% (DCR 97% vs 96%; RR 33% vs 17%). 
Patients in AC and AP groups showed: resection 
rate 87% vs 79%; median overall survival (OS) in 
patients treated with carboplatin and cisplatin was 
118 vs 66 weeks respectively (p=0.03); progression 
free survival was 76 and 57 weeks (p= 0.07) in 
the two groups. Multivariate analysis showed the 
histologic subtype (p
Conclusion: AC and AP are active and feasible 
neoadjuvant regimens without major toxicities. AC 
apparently gave higher response rate and OS, but 
resection rate and progression free survival were 
similar. Cumulative non-haematological toxicities 
and PS worsening were commoner in AP-treated 
patients, and this could impair the clinical conditions 
of patients undergoing surgery.
Keywords: Malignant mesothelioma, 
Chemotherapy, Carboplatin, Cisplatin
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P3.298 MALIGNANT MESOTHELIOMA 
(MM) – 11 YEARS IN REVIEW
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was deÀned as grade 3 non-hematologic or grade 4 
hematologic toxicity that was possibly, probably or 
deÀnitely related to PDT. We have also evaluated 
the efÀcacy of HPPH-mediated PDT with a 24h vs 
48h drug light interval in an ectopic murine model of 
MPM.
Results: To date 12 patients with pleural 
dissemination of malignancy limited to one 
hemithorax (9 MPM, 3 carcinoma metastatic to 
pleura) have been treated at 5 dose levels. In all 
patients, a lung sparing, macroscopically complete 
tumor resection was achieved. In 11 patients treated 
with a 48h drug light interval, there were no DLT 
with 3 patients treated at 15, 22.5 or 30 J/cm2 and 2 
patients treated at 45J/cm2 light dose. One patient 
treated at a 24h drug light interval and 15 J/cm2 
light dose experienced edema-related complications 
including abdominal compartment syndrome and 
ARDS that were deÀnitely related to PDT. In 
preliminary studies of PDT efÀcacy using ectopic 
murine AB12 mesothelioma tumors, a similar level 
of cure rate could be achieved in mice by a 2.5 fold 
increase in light dose with 48h as compared to 24h 
drug light interval. Interestingly, at these light doses, 
the animals treated with 48h drug light interval 
experienced decreased edema at the treatment site.
Conclusion: In humans, HPPH-mediated PDT can 
be safely combined with surgical resection with a 
48h drug light interval. However, while increased 
light dose can compensate for increased drug light 
interval in animal studies, both humans and animals 
experienced markedly more severe edema-related 
toxicities at 24h versus 48h drug light interval.
Keywords: malignant pleural mesothelioma, radical 
pleurectomy, Thymoma, intraoperative therapy
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IN DISTINGUISHING THYMIC 
CARCINOMAS FROM THYMOMAS AND/
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.299 THE EFFECT OF 24 VERSUS 48 
HOUR DRUG LIGHT INTERVAL ON THE 
TOXICITY OF HPPH-MEDIATED PDT IN 
PATIENTS WITH MALIGNANT PLEURAL 
MESOTHELIOMA UNDERGOING 
RADICAL PLEURECTOMY
Keith Cengel1, Sai Yendamuri2, Todd L. Demmy2, 
Melissa Culligan3, Katelyn Maccready1, Daniel H. 
Sterman4, James Stevenson5, Theresa Busch1, Eli 
Glatstein1, Stephen Hahn1, Joseph Friedberg3 
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Background: For patients with pleural 
dissemination of malignancy, the current standard 
of care is palliative chemotherapy. We have 
previously demonstrated that multi-modality therapy 
including surgical resection with intraoperative 
porÀmer sodium-mediated photodynamic therapy 
(PDT) can be effective in the treatment of patients 
with malignant pleural mesothelioma (MPM) or 
pleural dissemination of non-small cell lung cancer 
(NSCLC) or recurrent thymoma. HPPH is a novel 
second-generation photosensitizer with superior 
photophysical properties and signiÀcantly decreased 
duration of skin photosensitivity as compared to 
porÀmer sodium.
Methods: In this study, we have evaluated the 
toxicity of HPPH-mediated PDT delivered to the 
entire pleural surface when combined with lung 
sparing surgical resection in patients with pleural 
dissemination of malignancy. The PDT dose 
was increased by either shortening the drug light 
interval or increasing the light dose from 15-45 J/
cm2 of 661nm light. Dose limiting toxicity (DLT) 
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type B3 thymomas in varied numbers.
Conclusion: Both c-kit and CLDN-1 are useful 
markers for distinguish thymic carcinoma from 
SCC and type B3 thymoma, although they are 
not speciÀc for thymic carcinomas. Especially, 
membrane-immunostaining, but not cytoplasmic 
immunostaining, of c-kit is highly speciÀc for thymic 
carcinoma, and may be one of the most reliable 
markers of thymic carcinoma. The presences of 
TCDM and/or THY are useful functional markers to 
distinguish thymomas including B3-thymomas from 
thymic carcinomas.
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P3.301 THE BURDEN OF 
MESOTHELIOMA MORTALITY: 
ESTIMATION AS THE FIRST STEP TO 
PREVENTION.
Aiza Jamil, B. Prathibha 
Medicne, East Kent Hospitals NHS Trust/United 
Kingdom
Background: Mesothelioma is a rare cancer that 
principally affects the pleura and is almost always 
caused by asbestos exposure. The disease is rapidly 
fatal; most of those affected dying within a year of 
diagnosis. There is a long latent period between Àrst 
exposure to asbestos and diagnosis of mesothelioma 
that is seldom less than 15 years and often exceeds 
60 years. Mesothelioma incidence has increased 
in South East England of which East Kent is a 
major part, particularly for men aged over 70 years, 
reÁecting areas of asbestos use in shipbuilding and 
industry in the past. 
Methods: Work-related cancers are largely 
preventable. The aim of the study is to estimate 
the current burden of cancer in the area of East 
Kent in the UK attributable to occupational factors, 
and identify carcinogenic agents, industries and 
occupations for targeting risk prevention. Data of all 
cases diagnosed at East Kent Hospitals NHS Trust 
were collected retrospectively from April 2009 to 
March 2010. 
Results: There were a total of 15 cases in East Kent 
Hospital NHS trust, UK over the period of one year 
which is a signiÀcantly high number as compared 
to previous years,the current population being 
614,576. All of them were male. Median age was 74 
years and median survival from diagnosis was 8.9 
Background: Thymic carcinomas are rare 
epithelial neoplasms of anterior mediastinum with 
higly malignant nature and thought to be derived 
from epithelial cells of thymic origin. Although 
some thymic carcinomas are morphologically 
indistinguishable from typical forms of tissue-
common carcinomas, such as squamous cell 
carcinoma (SCC), adenoid cystic carcinoma, 
mucoepidermoid carcinoma, and adenocarcinoma, 
in the vast majority of thymic carcinomas tumor 
cells exhibit uniformly solid microscopic appearance 
without forming any particular architecture. It is, 
however, not infrequently difÀcult to distinguish 
thymic carcinomas from type B3 thymoma and 
SCC. In this study, we attempted to Ànd reliable 
immunohistochemical markers to distinguish thymic 
carcinomas from type B3 thymomas and/or SCC.
Methods: Formalin-Àxed, parafÀn-embedded tissue-
sections of thymic carcinomas (17 cases), type B3 
thymomas (11 cases), and SCC (lung cancers; 13 
cases) were examined immunohistochemically. 
Monoclonal antibodies against cytokeratin AE1/
AE3 (CK), c-kit, MIB-1, synaptophisin, claudin-1 
(CLDN-1), fascin, HLA-DR, CD68, CD99, and 
CD205 were used. Single immunoperoxidase method 
was performed.
Results: In all cases of thymic carcinomas examined, 
tumors were composed of solid sheets of polygonal 
CK+ tumor cells without squamous or glandular 
differentiation and abundant hyalinized Àbrous 
stroma. In these cases, cellular atypia of tumor cells 
were manifest and mitosis and tumor necrotis were 
frequently observed. In 15 out of 17 cases of thymic 
carcinoma, tumor cells were positive for c-kit. The 
immunoreactions for c-kit were detected intensely at 
cell-membrane and in cytoplasm of tumor cells. In 3 
out of 13 cases of SCC, tumor cells were positive for 
c-kit. However, the immunoreactions for c-kit were 
detected in cytoplasm but scarcely at cell-membrane. 
Although c-kit was detected in 3 out of 11 cases of 
B3 thymoma, membrane immunoreactions to c-kit 
was detected in only one case. CLDN-1 was detected 
at cell-membrane in all cases of thymic carcinomas 
and SCC, while this antigen was detected in only 2 
cases of type B3 thymoma. Average of MIB-1 index 
of thymic carcinomas were not signiÀcantly different 
from that of SCC, but it was signiÀcantly higher 
than that of B3 thymoma (p<0.05). None of thymus-
speciÀc cells, such as thymic cortical dendritic 
macrophages (TCDM), and CD99+ thymocytes 
(THY) were detected in any cases of thymic 
carcinoma or SCC, while these cells were detected in 
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this study we assess our treatment results with 
pemetrexed+cisplatin or pemetrexed+carboplatin 
combinations in patients with MPM. 
Methods: Fifty-four chemo naïve patients who were 
treated between 1999 and 2010 were retrospectively 
evaluated. Chemotherapy consisted of pemetrexed 
500 mg/m2 in combination with either cisplatin 75 
mg/m2 or carboplatin AUC= 5 mg/mL/min , once 
every 21 days. All patients received folic acid and 
vitamin B12 supplementation. 
Results: Patients were 34 males and 20 females with 
a median age of 33 years old (range, 53-80). The 
most commonly seen histopathology was epitheliod 
type (83%) and 80% of the patients had prior 
environmental mineral Àbre exposure (tremolite 
asbestos or Àbrous zeolite). Twenty patients received 
pemetrexed+cisplatin and 34 patients received 
pemetrexed+carboplatin doublets of median 6 cycles 
(range, 1-8). Twenty-nine patients (54%) received 
radiotherapy (6 preventive, 11 palliative, and 12 
curative intent). Twenty-two patients had debulking 
surgery (9 pleurectomy+decortication-P/D- and 
13 extrapleural pneumonectomy-EPP-). Median 
overall survival for the whole group was 16 months 
(range, 1-69). Patients with epithelioid type of 
histopathology have better prognosis. The median 
overall survival and time to relapse values for 
pemetrexed+cisplatin and pemetrexed+carboplatin 
groups were 15 months vs. 20 months (p=0.0097) 
and 9 months vs. 10 months (p=0.95) respectively. 
Overall objective response rate (complete and partial 
response) to chemotherapy was 59%. There was 
no difference in response to the two chemotherapy 
regimens (p=0.087). The type of surgery effects the 
time to relapse. Patients who had EPP and P/D have 
longer time to relapse (12 months vs. 9 months, 
p=0.047). Fifteen patients who received median 4 
cycles of (range,2-13) maintenance single agent 
pemetrexed showed increase in median survival (30 
months vs. 16 months, p=0.03). Both doublets were 
well tolerated. There was no difference in terms of 
adverse haematological toxicity between the two 
chemotherapy groups. Non haematological toxicities 
were negligible. 
Conclusion: Our results showed highly encouraging 
long term median survival outcome in patients 
treated with pemetrexed+carboplatin. This 
combination seems to be a well tolerated and a valid 
option as a Àrst line treatment in MPM. 
Keywords: malignant pleural mesothelioma, 
pemetrexed-platinum doublets
months. All of them had histological or cytological 
conÀrmation and 85% had documented evidence of 
deÀnite or probable exposure to asbestos. There were 
seven cases that were treated with chemotherapy 
and 6 patients had advanced malignancy and 
received radiotherapy and 2 patients with advanced 
malignancy had palliative treatment only. No patient 
had radical surgery and there was minimal difference 
in relative survival between men with localised and 
non-localised disease stage. 
Conclusion: In Great Britain, where asbestos use 
continued later than many other countries, the peak 
is anticipated to occur later between 2011 and 2115. 
Between 1981 and 2000, North East England and 
South East England were the areas with the highest 
standardised mortality ratios. Cancer networks, 
especially those with primary care trusts with high 
incidence, need to be aware of this disease and 
ensure that risk reduction strategies and services 
are in place to assist these patients. More research 
is needed to understand the interrelationships of 
prognostic factors, treatment choices and survival, 
and to determine the best care and support for these 
patients and their families. 
Keyword: mesothelioma
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P3.302 PEMETREXED-CARBOPLATIN 
DOUBLETS SHOWED BETTER MEDIAN 
SURVIVAL THAN PEMETREXED-
CISPLATIN IN THE TREATMENT OF 
TURKISH MALIGNANT PLEURAL 
MESOTHELIOMA PATIENTS
Salih Emri1, Pervin Hürmüz2, Cem Kadilar3, Ayten 
K. Cangir4, Faruk Zorlu2, R×za Dogan5, Fadil Akyol2 
1Department Of Chest Diseases, Hacettepe 
University Faculty Of Medicine/Turkey, 2Department 
Of Radiation Oncology, Hacettepe University 
Faculty Of Medicine/Turkey, 3Deparment Of 
Statistics, Hacettepe University/Turkey, 4Department 
Of Thoracic Surgery, Ankara University Faculty Of 
Medicine/Turkey, 5Department Of Thoracic Surgery, 
Hacettepe University Faculty Of Medicine/Turkey
Background: Malignant pleural mesothelioma 
(MPM) is a highly aggressive tumour and commonly 
presents at an advanced stage. Antifolate-platinum 
doublets are commonly used chemotherapy 
regimens with a shown survival advantage. In 
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in PFS (P=.394) between invasive and non invasive 
groups. 
Conclusion: We speculate that the most Iranian 
patients referred to our institute were diagnosed 
in advanced stages and it could probably translate 
higher recurrence rate and poorer 5-year survival 
compare to other reports.
Keyword: Thymoma
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P3.304 EXTRAPLEURAL 
PNEUMONECTOMY (EPP) 
FOR MALIGNANT PLEURAL 
MESOTHELIOMA: WHAT IS THE 
QUALITY OF LIFE OF SURVIVORS?
Jocelyn M. Mclean, Brian Mccaughan 
Cardiothoracic Surgery, Royal Prince Alfred 
Hospital/Australia
Background: The outcomes of treatment and 
prognostic factors of our Àrst 70 extrapleural 
pneumonectomy patients have been reported by Yan 
et.al 2009. We are now reporting the quality of life of 
survivors of this group of patients as well those who 
have since had EPP and are living with or without 
disease. The study was approved by our local Ethics 
Review Committee and comprises of a quantitative 
component followed by a qualitative component. 
Methods: The quantitative component consisted of 
inviting patients to complete quality of life (QOL) 
questionnaires. The two questionnaires have been 
proven to be reliable and valid in assessing cancer 
related QOL. They were The European Organization 
of Research and Treatment of Cancer (EORTC) 
QLQ-C30 and LC13and the McGill Quality of 
Life Questionnaire. The qualitative component 
consisted of in-depth interviews of patients and 
carers. A phenomenological methodology was used 
to transcribe the interviews into text. The text is then 
interpreted in order to explore the lived experience 
of recovery following surgery. 21 patients who had 
surgery between 2003 and December 2009 were 
invited to participate, however only 14 completed 
the questionnaires. This data was analyzed in July 
2010. Another round of questionnaires was mailed to 
the same patients in February of 2011 and to a new 
group of 8 patients who had surgery during 2010 
and 2011. The complete data will be analyzed using 
SPSS Graduate Pack 13.0 in accordance with the 
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P3.303 CLINICO-PATHOLOGICAL 
CHARACTERISTICS OF IRANIAN 
PATIENTS WITH THYMOMA REFERRED 
TO NATIONAL RESEARCH INSTITUTE 
OF TUBERCULOSIS AND LUNG 
DISEASE: A SINGLE INSTITUTE STUDY 
FROM IRAN
Kian Khodadad1, Golnar Abbasi-Dezfooli1, Shirin 
Karimi2, Zahra Esfahani-Monfared1, Adnan 
Khosravi1 
1Thoracic Oncology Department, National Research 
Institute Of Tuberculosis And Lung Disease/Iran, 
2Pathology Department, National Research Institute 
Of Tuberculosis And Lung Disease, Tehran, Itan/Iran
Background: Thymoma is a neoplasm originating 
from the Thymus. This tumor is usually benign, and 
frequently encapsulated; but it could be invasive or 
rarely metastatic in malignant forms. Thymoma is 
an uncommon tumor, best known for its association 
with some paraneoplastic syndromes including 
myasthenia gravis. In this study we retrospectively 
reviewed Iranian patients, referred to our thoracic 
surgery and/or oncology departments. 
Methods: Retrospectively, the demographic and 
clinico-pathological data of 55 patients with deÀnite 
diagnosis of Thymoma were retrieved from their 
Àles and subsequently their pathology were reviewed 
again. All these patients were referred to our institute 
from different parts of Iran.
Results: In 55 patients, male to female ratio was 
1.25(32/21) with mean age 43.13±13.9 years (range 
17-75). Most Common presenting symptoms 
included cough (43.4%), dyspnea (39.6%), 
myasthenia gravis (20.8%). The other symptoms 
were weight loss, fever, diaphoresis, chest pain and 
aplastic anemia. Eighty three percent of tumors were 
in anterior mediastinum. The majority of patients 
were regionally invasion or metastasis at the time of 
diagnosis (stage I: 27.1%, stage IIa: 6.2%, stage IIb: 
14.6%, stage III: 29.2%, stage IVa: 20.8, stage IVb: 
2.1%). The most common pathologic subtypes were: 
type A: 11.3%, type B1: 26.9%, type B2: 11.3%, 
type AB: 17%, type C: 20.8%, type B3: 26.9%, 
missing data:11.3%. Surgery, radiotherapy and 
chemotherapy were performed in 55.1%, 39.5% and 
30.1% of patients, respectively. Median follow up 
was 2.86 years. Progression Free Survival (PFS) was 
5.75±2.45 years. Log-rank test showed no difference 
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not be classiÀed. Seventeen patients had previously 
received other chemotherapy combinations. 
Temozolomide was given on Àve consecutive days 
every four weeks. The daily dose for the Àrst cycle 
was 150 mg/sqm which was increased to 200 mg/
sqm during subsequent cyles if well tolerated. 
Toxicity was evaluable in 29 of 34 patients, and 23 
patients had CT scans evaluable by RECIST.
Results: There were no complete responses. A 
partial response was seen in 4 patients (17%), stable 
disease in 11 (48%) and progressive disease in 8 
patients (35%). Median progression-free survival 
was 5.5 months and median overall survival was 
34.2 months from start of temozolomide and 80.1 
months from diagnosis. Bone marrow toxicity was 
moderate.
Conclusion: Temozolomide as monotherapy 
shows activity in patients with metastatic bronchial 
carcinoids. Bone marrow toxicity was moderate. 
Combinations of temozolomide with other agents 
(e.g. capecitabine and/or bevacizumab, everolimus) 
should be further studied in these patients.
Keywords: Temozolomide, Bronchial carcinoid, 
Chemotherapy
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P3.306 TYPE AB THYMOMA IS NOT A 
MIXED TUMOR OF TYPE A AND TYPE B 
THYMOMAS BUT A DISTINCTIVE TYPE 
OF TYMOMA
Yukari Miki, Takumi Fumon, Atsushi Hayashi, 
Kiyoshi Takahashi 
Graduate School Of Health Science, Okayama 
University/Japan
Background: Type AB thymoma is generally 
regarded as a mixed tumor of type A and type B 
thymomas in WHO classiÀcation. However, the 
nature of type AB thymoma remains obscure. On 
the other hand, we previously reported the presence 
of thymic cortex-speciÀc macrophages named 
“thymic cortical dendritic macrophages” (TCDM) 
as scavengers for apoptotic thymocytes in the 
human thymus. (Immunobiology 213:837, 2008) We 
recently found that TCDM, as well as thymocytes, 
are useful micro environmental markers for thymic 
cortex in studying thymomas. We also found that 
mature dendritic cells (mDC) are also useful micro 
environmental markers for thymic medulla. Using 
scoring manuals from EORTC and McGill Quality 
of Life Questionnaire. Taped interviews are taking 
place. Each interview will be transcribed into text 
and scrutinized for key concepts from which a 
number of thematic statements will be derived. 
Results: The results of the initial 14 quantitative 
QOL questionnaires showed that the quality of life 
of those survivors was comparable to or in some 
categories better than three other patient groups. 
One group was living with Mesothelioma without 
treatment, one group were receiving chemotherapy 
for Mesothelioma, and the third group were pre-
operative patients who were having potentially 
curative surgery for primary non small cell lung 
cancer. 
Conclusion: This study will enable the voices of 
patients and carers who are survivors after EPP to 
be heard. It will provide real patient experiential 
information, and it is our intention to make this 
available to new patients who are considering the 
option of radical surgery to prolong their life. 
Keywords: Quality of Life, survivors, Extrapleural 
pneumonectomy, mesothelioma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.305 TEMOZOLOMIDE IN PATIENTS 
WITH METASTATIC BRONCHIAL 
CARCINOIDS
Daniel P. Lindholm1, Irina Fanola2, Pantelis 
Antonodimitrakis1, Kjell Öberg1, Barbro Eriksson1, 
Dan Granberg1 
1Department Of Endoccrine Oncology, Institution 
Of Medical Sciences/Sweden, 2Department Of 
Radiology, Instituition Of Radiology/Sweden
Background: Malignant bronchial carcinoids are 
rare neoplasms. Treatment of patients with metastatic 
disease have thus far been disappointing. A previous 
study from our center has however indicated that 
temozolomide as monotherapy might be of value.
Methods: All patients with metastatic bronchial 
carcinoid treated with temozolomide as monotherapy 
at our center between 2004 and 2010 (n=34) were 
included. Ten tumors were typical carcinoids and 14 
were atypical carcinoids, whereas 10 tumors could 
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cells with insufÀcient function of cTEC. In contrast, 
tumor cells in type B1 and B2 thymoma have 
sufÀcient function to induce mature thymic organoid. 
Thus, type AB thymoma is not a mere mixed tumor 
of type A and type B thymoma but a distinct type of 
thymoma.
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P3.307 PROTEIN EXPRESSION 
OF EXCISION REPAIR CROSS 
COMPLEMENTATION GROUP 1 (ERCC1) 
AND THYMIDYLATE SYNTHASE 
(TS) IN MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) PATIENTS 
UNDERGOING EXTRAPLEURAL 
PNEUMONECTOMY (EPP)
Steven C. Kao1, Kenneth Lee2, Sonja Klebe3, 
Douglas W. Henderson3, Brian Mccaughan4, Janette 
Vardy5, Stephen Clarke6, Nico Van Zandwijk7 
1Medical Oncology, Asbestos Diseases Research 
Institute/Australia, 2Anatomical Pathology, 
Concord Repatriation General Hospital/Australia, 
3Anatomical Pathology, Flinders Medical Centre/
Australia, 4Cardiothoracic Surgery, Royal Prince 
Alfred Hospital/Australia, 5Medical Oncology, 
Sydney Cancer Centre/Australia, 6Royal North Shore 
Hospital/Australia, 7Asbestos Diseases Research 
Institute/Australia
Background: Many studies have demonstrated that 
high TS expression is signiÀcantly correlated with 
higher proliferative activity of tumour cells, while 
untreated patients with non-small-cell lung cancer 
tended to have longer survival if the tumour ERCC1 
expression is high. We hypothesised that in patients 
with MPM undergoing EPP, high ERCC1 and low 
TS are associated with prolonged survival. 
Methods: Consecutive MPM patients, who 
underwent EPP at Royal Prince Alfred and 
StrathÀeld Private Hospitals, Sydney, Australia 
from 1994 to November 2009 were reviewed in the 
study. Tissue microarrays were constructed from 
eligible patients and Àve 1mm cores per patient were 
taken. TS and ERCC1 protein expression levels 
were evaluated by immunohistochemistry using the 
score derived from the percentage of cells labelled 
positive. The average scores from evaluable cores 
were assessed and the median score was used to 
divide the group. Overall survival (OS) from the 
these cells as thymic micro environmantal markers, 
we investigated the nature of type AB thymoma. 
Methods: Formalin-Àxed, parafÀn-embedded 
tissues of type A (4 cases), AB (12 cases)¸ and B1 (6 
cases), and B2 (5 cases) thymomas were examined 
by immunohistochemical methods. Monoclonal 
antibodies against pancytokeratin (CK:AE1/
AE3), claudin-1 (CLDN-1), vimentin, epithelial 
membrane antigen (EMA), CD99, fascin, and 
HLA-DR were used. TCDM were deÀned as fascin+ 
HLA-DR- dendriform cells, mDC as fascinhi HLA-
DRhi dendriform cells, and thymocytes as CD99+ 
lymphocytes. 
Results: In all cases of type A thymoma examined, 
tumor cells were composed solely of CK+ vimentin- 
EMA- CLDN-1+ short spindle cells. TCDM, 
thymocytes, and mDC were almost completely 
absent. Type AB thymoma was mixture of type 
A-like areas, where long spindle cells formed 
bundles, and type B-like areas, where numerous 
lymphocytes were densely distributed. In all cases 
examined, long spindle cells in type A-like areas 
were CK- vimentin+ EMA+ CLDN-1- Àbroblast-like 
cells. Type B-like areas were composed of wide 
cortical areas, where small nondendriform fascindim 
TCDM were scattered among numerous thymocytes, 
and narrow indistinct medullary areas, where several 
mDC and mature T-cells were compactly distributed. 
CK+ epithelial cells were detected exclusively 
in type B-like areas, where they were identiÀed 
as irregularly shaped epithelial cells randomly 
extending numerous long cytoplasmic projections, 
and were morphologically different from normal 
thymic cortial epithel cells (cTEC), which were 
characterized by narrow cytoplasm and a few slender 
cytoplasmic projections. All cases of type B1 and B2 
thymoma examined were composed of wide cortical 
areas and conspicuous medullary areas. In cortical 
areas, fascin+ large dendriform TCDM, as seen in 
normal thymic cortex, were regularly distributed 
among numerous thymocytes. Immunostaining 
for CK indicated that tumor cells in type B1, B2 
thymoma were closely similar to normal cTEC, but 
largely different from those in type AB thymoma in 
morphology. 
Conclusion: Type A-like areas of type AB 
thymoma are composed of certain particular type 
of epithelial cells with Àbroblast-like appearace, 
whose signiÀcance should be discussed. Although 
type B-like areas of type AB thymoma are not mere 
lymphocyte-inÀltration but thymic organoid, they 
seem to be immature organoid induced by tumor 
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macrophages (TCDMs) in the human thymus as 
scavengers of apoptotic thymocytes (Immunobiology 
213:837 2008). We recently found that TCDMs, as 
well as thymocytes (THYs) are frequently present in 
B3-thymoma in varied numbers. Because thymomas 
are known to be functional tumors, we consider that 
distributional patterns of these cells in thymomas 
reÁect some functions of TEC. Therefore, using 
these cells as functional markers, we attempted to 
classify B3-thymomas.
Methods: We examined 11 cases of B3-
thymomas and 11 cases of thymic carcinomas 
immunohistochemically. We used monoclonal 
antibodies against cytokeratin AE1/AE3 (CK AE1/
AE3), fascin, CD99, HLA-DR, claudin-1 (CLDN-
1), and MIB-1(Ki-67). TCDM is deÀned as fascin+ 
HLA- DR- dendriticform cell and THY as CD99+ 
lymphocyte. CLDN-1 is a member of tight-junction 
protein family, and is used as a marker for medullary 
(m) TEC.
Results: B3-thymomas are subclassiÀed into three 
groups. The Àrst group (4 cases) were characterized 
by the presence of relatively large numbers of 
TCDMs and THYs. Tumor cells were CK+ CLDN-
1- polygonal cells, and relatively large numbers of 
TCDMs and THYs were scattered among tumor 
cells. MIB-1 index of tumor cells was around 
5% in average. These Àndings suggest that tumor 
cells of the Àrst group retain functions of TEC in 
considerable extent, and we regard this group as 
differentiated subtype. The second group (2 cases) 
were characterized by the absence of TCDM and 
THY. Tumors were composed of CK+ CLDN-1+ 
small polygonal cells distributed densely, and their 
MIB-1 index was around 20 % in average. These 
Àndings suggest that tumor cells of this group 
almost lack the functions of TEC, and we regard 
the second group as anaplastic subtype. The third 
group (5 cases) were characterized by the presence 
of a considerable number of TCDMs and a paucity 
of THYs. Tumor cells were CK+ CLDN-1- large 
polygonal cells arranged in epithelioid pattern, and 
their MIB-1 index was around 5% in average. These 
Àndings suggest that tumor cells retain minimal 
functions of TEC, and we regard the third group 
as intermediate subtype. In all cases of thymic 
carcinomas examined, neither TCDM nor THY were 
detected, and tumor cells were positive for CK and 
CLDN-1 strongly, and their MIB-1 index was around 
32.1% in average.
Conclusion: Because tumor cells of differentiated 
and intermediate subtypes of B3-thymoma are 
time of surgery was determined by Kaplan-Meier 
method and results compared by log-rank test. 
Results: There were 80 patients in the EPP cohort 
that had undergone radical surgery: median age 58 
years (range 22-74); 79% male; 76% epithelial and 
24% biphasic subtype; 25% AJCC stage I-II and 
73% stage III-IV. The median OS was 18.2 months 
(95% CI: 11.8-24.5 months) with 80% of patients 
deceased at the time of analysis. Nineteen patients 
received neo-adjuvant chemotherapy, 1 patient 
received adjuvant chemotherapy and an additional 
20 patients received palliative chemotherapy in this 
series. The median TS score was 10.2 (range 0-91.3) 
while the median ERCC1 score was 35 (range 0-90). 
There was no correlation between the TS protein 
expression and OS (13.7 vs. 21.6 months for low and 
high TS levels respectively; p=0.32). There was a 
trend between high ERCC1 protein expression and 
longer OS (27.6 vs. 10.3 months; hazard ratio [HR], 
1.63; 95% conÀdence interval [CI], 0.98 to 2.70; 
p=0.06). 
Conclusion: In this series of MPM patients who 
underwent EPP, TS protein expression was not 
associated with survival, but there was a trend for 
a longer survival in patients with high ERCC1 
expression. 
Keywords: malignant pleural mesothelioma, 
excision repair cross complementation group 1, 
Thymidylate synthase
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P3.308 TYPE B3 THYMOMA 
CAN BE SUBCLASSIFIED INTO 
DIFFERENTIATED, INTERMEDIATE, 
AND ANAPLASTIC SUBTYPES.
Takumi Fumon, Yukari Miki, Atsushi Hayashi, 
Kiyoshi Takahashi 
Graduate School Of Health Science, Okayama 
University/Japan
Background: Thymomas are known to be tumors 
of thymic epithelial cells (TEC) with variety 
of histological appearances and difÀcult to be 
classiÀed. Type B3 thymoma is morphologically 
and phenotypically heterogenous, and some of 
B3-thymomas are difÀculte to be distinguished 
from thymic carcinomas. On the other hand, we 
previously reported the presence of thymic cortex-
speciÀc macrophage named thymic cortical dendritic 
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Results: DDB reviewed 270 applications in this time 
period, of whom 159 consented: median age 71 years 
(range 45-91); 93% male; 60% epithelial subtype; 
median NLR 3.5 (87 results available). Median OS 
was 11.7 months (95% CI: 9.3-14.1 months). The 
following variables were predictive of longer OS: 
younger age (p<0.001); epithelial subtype (p<0.001); 
lower AJCC stage (p<0.01); deÀnite pathological 
diagnosis (p<0.01); typical diagnostic IHC stains 
(p<0.01); and low NLR (p<0.01). A multivariate 
analysis (117 deaths) showed the following variables 
to be independently associated with prognosis: 
age 65 vs. <65 years (HR 1.8; 95% CI, 1.1-3.0; 
p=0.03); epihelial vs. non-epithelial subtype (HR 
0.3; 95% CI, 0.2-0.5; p<0.001); an increase in one 
AJCC stage (HR 1.4; 95% CI, 1.1-1.8; p<0.01); and 
NLR 3 vs. <3 (HR 2.0; 95% CI, 1.2 - 3.4; p=0.01).
Conclusion: The prognostic signiÀcance of 
recognised factors such as age, histological subtype 
and AJCC stage was conÀrmed in this study. These 
factors should be routinely used for stratiÀcation 
in clinical trials. In addition, NLR, an index of 
systemic inÁammation was independently associated 
with survival, conÀrming our previous Àndings 
and highlighting the importance of inÁammation in 
relation to prognosis in MPM patients.
Keywords: Malignant mesothelioma, prognostic 
factor, neutrophil-to-lymphocyte ratio
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P3.310 SURGICAL MANAGEMENT OF 
LOCO-REGIONALLY RECURRENT 
THYMOMA
Joon Suk Park1, Byungjoon Park1, Hong Kwan Kim1, 
Yong Soo Choi1, Kwhanmien Kim1, Young Mog 
Shim1, Jhingook Kim1, Sumin Shin2 
1Department Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea, 2Thoracic 
Surgery, Samsung Medical Center/Korea
Background: There is no standard treatment for 
recurrent thymoma, and it has been mostly palliative 
therapy. In this article, we retrospectively reviewed 
our experiences, to discuss efÀcacy of surgical 
treatment and adequate extent of resection.
Methods: From January 1997 to December 2007, 
15 patients underwent surgical resection for 
locoregional recurrence of thymoma in Samsung 
Medical Center. There were 7 male and 8 female 
thought to retain some TEC-functions, we consider 
that these tumors should be called “thymoma”. 
Because tumor cells of anaplastic subtype of B3-
thymoma thought to lack TEC-functions, it is 
reasonable to consider that tumors of this type are 
carcinomas rather than thymoma. The present study 
also suggested that CLDN-1 is closely associated 
with malignancy rather than medullary origin in B3-
thymomas. 
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P3.309 PROGNOSTIC FACTORS 
IN MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) IN A COHORT 
OF PATIENTS COMPENSATED BY THE 
DUST DISEASES BOARD
Steven C. Kao1, Stephen Clarke2, Mark ChatÀeld3, 
Peter Corte4, Christopher Clarke5, Janette Vardy6, 
Nico Van Zandwijk5 
1Medical Oncology, Asbestos Diseases Research 
Institute/Australia, 2Royal North Shore Hospital/
Australia, 3Nhmrc Clinical Trial Centre/Australia, 
4Royal Prince Alfred Hospital/Australia, 5Asbestos 
Diseases Research Institute/Australia, 6Medical 
Oncology, Sydney Cancer Centre/Australia
Background: Survival in MPM patients is variable. 
There are few validated factors that can be used to 
stratify patients. We aimed to investigate potential 
prognostic factors in a cohort of MPM patients 
who received Ànancial compensation from the Dust 
Diseases Board (DDB), New South Wales, Australia. 
Methods: MPM patients applying for compensation 
at the DDB from March 07 to March 09 were 
included. After obtaining informed consent, DDB 
Àles were reviewed and where necessary, treating 
physicians and hospitals were contacted for 
additional information. Overall survival (OS) from 
diagnosis was determined by the Kaplan Meier 
method. Prognostic factors under investigation 
included: age, gender, histological subtype, 
AJCC stage, duration of symptoms, certainty of 
pathological diagnosis, the immunohistochemical 
(IHC) proÀle, and the neutrophil-to-lymphocyte ratio 
(NLR) at the time of the diagnosis. The prognostic 
value of these variables was examined using Cox 
regression analysis and all factors were entered into 
a multivariate model to determine their independent 
effect.
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patients treated with CHOP alone: CR: 88%, PFS:64 
% and OS: 55 % in 67 patients. Acute and late 
toxicities were minimal .
Conclusion: The addition of rituximab to 
conventional chemotherapy in limited DLBCL-PL 
appear to improve PFS and OS, limited number of 
patients did limited the performed controlled clinical 
trials.
Keywords: primary lung lymphoma, rituximab
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.312 PLATINUM AND THIRD-
GENERATION ANTICANCER AGENT 
DOUBLET CHEMOTHERAPY IN 
FRONT-LINE CHEMOTHERAPY FOR 
ADVANCED THYMIC CARCINOMA
Yusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, 
Yusuke Takagi, Mari Iguchi, Tatsuru Okamura, 
Masahiko Shibuya 
Department Of Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center 
Komagome Hospital/Japan
Background: Thymic carcinoma is rare malignant 
mediastinal tumor and deÀnitively distinguished 
from thymoma because of wide extensiveness and 
poor prognosis. At present, cisplatin based triplet or 
quartet with the second-generation antitumor drugs 
referred to Einhorn’s protocol of germ cell tumor 
are availed in the front-line setting for advanced 
thymic carcinoma since 1990’s. However, no optimal 
chemotherapeutic regimen is realistically determined 
and recent small case studies with carboplatin 
and paclitaxel doublet demonstrate the similar 
efÀcacy with less toxicity than those of previous 
regimens. Also, platinum-doublets chemotherapy is 
the recommended standard treatment in front-line 
setting for advanced non-small-cell lung cancer. And 
efÀcacy outcomes associated with cisplatin-based 
and carboplatin-based doublets are almost similar, 
the decision about which platinum-based doublet 
to use is based on tolerance. We retrospectively 
evaluated effectiveness and toxicity of platinum and 
the third-generation anticancer drugs combination 
(platinum doublet) for patients with advanced thymic 
patients. age of patients at recurrence ranged from 23 
to 63 years. World Health Organization histological 
classiÀcation of tumor at the initial resection was B1 
in 2 patients, B2 in 6, B3 in 3 and C in 4. Complete 
resection was achieved in 12 patients by pleurectomy 
(n=11) or extrapleural pneumonectomy (n=1).
Results: There was neither perioperative mortality 
nor signiÀcant immediate postoperative morbidity. 
As follow-up, physical exam and Chest CT scan 
was evaluated by 3 to 6 months interval and median 
follow up duration was 45 month. At now, 10 
patients survived with (n=5) or without (n=5) re-
recurrence (3-year survival = 84.0%) Survival was 
signiÀcantly superior in patients with complete 
resection compared with those with incomplete 
resection. (p=0.008) 
Conclusion: Surgical resection must be considered 
in patients with loco-regionally recurrent thymic 
epithelial tumor because it can be performed safely, 
and offer a chance of long-term survival in selected 
patients. To achieve complete resection, more 
extended surgery must be considered in multiple 
pleural metastases.
Keywords: recurrent thymoma, Surgery, Thymic 
Carcinoma
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P3.311 RITUXIMAB IN PRIMARY LUNG 
LYMPHOMA
Agustin Aviles 
Oncology Research Unit, Instituto Mexicano Del 
Seguro Social/Mexico
Background: RITUXIMAB IN PRIMARY LUNG 
LYMPHOMA Diffuse large B-cell lymphoma 
primary of the lung (DLBCL-PL) is rare presentation 
of malignant lymphoma an standard treatment if not 
available,thus we assess if the additionn of rituximab 
to conventional chemotherapy can improve the 
outcome.
Methods: Twenty-eigh patients with DLBLC-PL, 
previously untreated, age 34 to 63 years, stage IE 
(20) or IIE(8), low or low-intermediate clinical risk 
and Germinal center B-cell origen, were treated with 
R-CHOP( rituximab,cyclophosphamide,doxorubicin,
vincristine and prednisone) by 6 cycles
Results: Complete response (CR) was achieved in 
26 patients (92%), with a median follow-up of 42.6 
months ( range:21 to 67 months), actuarial curves at 
5-years showed that progression free-survival (PFS) 
was 84 % and overall survival (OS) was 82 %, these 
results were better when compared to historical 
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2Department Of Respiratory Medicine, Newham 
University Hospital Nhs Trust/United Kingdom, 
3Department Of Respiratory Medicine, Homerton 
University Hospital NHS Foundation Trust/United 
Kingdom
Background: The North East London Cancer 
Network (NELCN) has the second highest incidence 
of mesothelioma in the UK. The NELCN has a 
population of 1.6 million, who are young and 
ethnically diverse with high levels of deprivation. 
The now defunct local asbestos processing factories, 
large motor manufacturing plants and commercial 
dockyards have lead to a high incidence of asbestos 
related lung disease in the region. The 2010 ERS/
ESTS guidelines for the management of malignant 
pleural mesothelioma have subjected the evidence to 
systematic review. With such a signiÀcant change in 
the evidence based management of this condition it 
was felt that the network should audit its own service 
provision and processes. 
Methods: Each hospital in the network provided 
data for mesothelioma diagnosed between 1st April 
2009 and 31st March 2010. 
Results: There were 52 new cases of mesothelioma 
in the NELCN over the audit period. Full data was 
received on 34 patients. Of these patients 91% 
were pleural and 9% peritoneal. Over 90% was 
conÀrmed histologically, 59% via video assisted 
thoracoscopic (VATS) biopsy; 70% was epitheliod, 
9% sarcomatoid. All patients were discussed in a 
multidiciplinary team meeting (MDT). Just over 
50% received chemotherapy, although it was planned 
in 74%. All patients who had a VATS biopsy had a 
surgical pleurodesis. At the end of the audit deadline 
11/34 patients had died including all patients with 
sarcomatoid histology. This is in line with NCIM 
data 2002-2006, with 33-37% dead at 1 year. 
Conclusion: NCIN data suggests that despite good 
compliance with cancer targets, lung cancer patients 
in North East London have poor survival Àgures. 
It is thought that this may be partly due to late 
presentation with advanced disease. In this audit, 
only 41% of patients came through a respiratory 
specialist as a Àrst port of call, and only 35% as 
urgent cancer referrals. Histology was obtained for 
94% of patients via a high number of thoracoscopic 
biopsies were performed in line with the recent 
ERS/ESTS guidance. Staging and performance 
status were well documented. Chemotherapy was 
offered to three quarters of patients, half went on 
to have it. In the majority of cases of those who 
carcinoma in clinical practice for over nine years in 
our institution.
Methods: Between January 1, 2002 and January 31, 
2011, we identiÀed patients with advanced thymic 
carcinoma, who treated with platinum and the third-
generation anticancer drugs doublet chemotherapy 
from our database and medical records 
retrospectively. The objects of this study were set in 
response rate, disease control rate, progression free 
survival, and overall survival. We also assessed any 
signiÀcant hematological and non-hematological 
toxicity. 
Results: A total of 13 patients who treated with 
platinum doublets chemotherapy (cisplatin/
irinotecan;10 cisplatin/gemcitabine;1 carboplatin/
gemcitabine;1 carboplatin/paclitaxel;1) were 
identiÀed in the front-line chemotherapy. The 
clinical response rate was achieved in 61.5 %. The 
disease control rate was achieved in 92.3 %. The 
median progression-free survival was 7.9 months 
(95% CI 1.3–10.0) and median overall survival 
was 33.8 months (95% CI 8.3–45.9). The toxicity 
proÀles of platinum doublets demonstrated Grade 3/4 
hematological toxicities were observed in 2 patients 
(18%). Grade 3/4 non-hematological toxicities were 
seen in 2 patients (18%). No febrile neutropenia and 
toxic death was recorded. The data will be updated in 
the presentation.
Conclusion: We concluded that platinum doublet 
chemotherapy is active and tolerable for advanced 
thymic carcinoma in the front-line setting with 
regard to efÀcacy, toxicity, and usage in clinical 
setting. 
Keywords: Thymic Carcinoma, Chemotherapy, 
Cisplatin, the third anticancer agent
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P3.313 MESOTHLIOMA IN NORTH EAST 
LONDON: A REVIEW OF SERVICE 
PROVISION, MANAGEMENT AND 
OUTCOME
Elizabeth M. Hadley1, Terence O’Shaughnessy2, 
Fiona Breen3, Michael Apps1 
1Chest Clinic, Barking, Havering & Redbridge 
Hospitals University Nhs Trust/United Kingdom, 
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patients treated with EPP+PDT. Here, we review our 
results with an expanded cohort of RP+PDT patients. 
In addition, we have explored whether targeting 
Epidermal Growth Factor Receptor (EGFR) and 
Signal Transducer and Activator of Transcription-3 
(STAT3) (respectively expressed in 75% and 
79% of MPM) signaling enhances the cancer cell 
cytotoxicity of PDT and therefore might be a novel 
strategy to improve locoregional disease control in 
patients treated with RP+PDT.
Methods: In an Institutional Review Board approved 
retrospective study RP followed by intraoperative 
porÀmer sodium-mediated PDT (RP+PDT), 38 
patients (42-81 yr) with a diagnosis of MPM (31/38 
epithelial, 7/38 non-epithelial subtype) were treated 
from 2004-2009. Treatment and outcome data 
was reviewed, with locoregional control deÀned 
as absence of recurrence in the ipsilateral pleura, 
lung parenchyma or mediastinal nodes. Cell culture 
studies were performed using cultured human and 
murine cancer cell lines and in vitro PDT clonogenic 
survival assays. Murine tumor experiments were 
performed with ab12 tumors grown in the Áanks of 
Balb-c mice.
Results: The majority of patients (36/38) had AJCC 
Stage III/IV disease. Nevertheless, a lung-sparing 
macroscopically complete RP was achieved in 37/38 
patients. At a median follow-up of 18.6 months, the 
median overall survival has not yet been reached 
and the 2-year is 72%. In the 21 epithelial patients 
with N2 metastatic cancer, overall survival was not 
adversely affected, with a 2-year overall survival of 
82%. Despite these excellent results, local control 
of MPM remains a problem, with 16/19 patients 
experiencing locoregional failure as a component 
of disease progression (8 locoregional only, 8 
locoregional + systemic progression). In studies 
of lung and MPM cell lines and tumors, we have 
found that PDT activates association and nuclear 
translocation of EGFR and STAT3 and that inhibition 
of EGFR and STAT3 signaling signiÀcantly enhances 
the cancer cell cytotoxicity of PDT.
Conclusion: In this expanded cohort of 38 MPM 
patients, we have established that RP+PDT 
demonstrates an overall survival that is longer than 
previously published series of similarly staged MPM 
patients. Nevertheless, local disease progression of 
MPM remains a major source of treatment failure in 
these patients. While these results demonstrate the 
value of PDT for treating patients with this disease 
who otherwise have few good treatment options, 
clearly new strategies are still needed. The high 
did not have chemotherapy, the patient was too ill. 
However in two cases chemotherapy was delayed in 
order to wait for symptoms. The current ERS/ESTS 
evidence suggests that early chemotherapy before 
symptom progression has a better outcome. Port 
site radiotherapy was given to a third of patients, 
only those who did not have chemotherapy. This 
is in line with the BTS 2007 statement, but it is 
likely that the amount of radiotherapy will fall in 
future years. The NELCN has a high case load of 
mesothelioma. Diagnostics are moving uniformly 
across the network towards early CT biopsy or VATs 
biopsy. Palliative surgical pleurodseis is common 
and chemotherapy is being offered to three quarters 
of patients. Mesothelioma MDTs are operational and 
assist in optimizing patient pathways. 
Keywords: London, outcomes, mesothelioma, 
service
Poster Session 3 – Mesothelioma, Thymoma and other Thoracic 
Malignancies Wednesday, 6 July 2011 12:15-14:15
P3.314 RADICAL PLEURECTOMY WITH 
INTRAOPERATIVE PHOTODYNAMIC 
THERAPY IN THE TREATMENT OF 
PATIENTS WITH MALIGNANT PLEURAL 
MESOTHELIOMA: TARGETING 
EGFR AND STAT3 TO ENHANCE 
LOCOREGIONAL CONTROL
Keith Cengel1, Melissa Culligan2, Rosemary Mick3, 
Sarah Hagan1, Molly Peterlin1, Daniel H. Sterman3, 
James Stevenson4, Eli Glatstein1, Stephen Hahn1, 
Joseph Friedberg2 
1Radiation Oncology, University Of Pennsylvania/
United States Of America, 2Surgery, University Of 
Pennsylvania/United States Of America, 3University 
Of Pennsylvania/United States Of America, 
4Hematology/oncology, Abramson Cancer Center, 
University Of Pennsylvania/United States Of 
America
Background: We have previously shown that with 
photodynamic therapy (PDT) as an intraoperative 
adjuvant, the survival of malignant pleural 
mesothelioma (MPM) patients treated with a lung 
sparing, macroscopically complete surgical resection 
(radical pleurectomy, RP) is superior to the survival 
of similar patients treated with PDT and extrapleural 
pneumonectomy. However, in this series, the 
locoregional control of patients treated with 
RP+PDT was inferior to the locoregional control of 
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individuals the diagnostic work-up was employed. 
Within the group of 94 surgically treated patients 59 
lung cancers were diagnosed. 63 lobectomies (23 
VATS - %), 1 segmentectomy, 21 wedge resections 
and 6 tumorectomies were performed. Fifty (84,75 
%) operated patients were in stage I, 4 (6,78%) in 
stage II, 5 (8,47%) in stage III. 
Conclusion: Lung cancer screening with LDCT 
allows to detect lung cancer in early, curable stage, 
thus allowing implementation of minimally invasive 
surgical techniques. The incidence of pulmonary 
nodules is relatively high and requires follow up. 
Keyword: Lung cancer, Early diagnosis, Screening, 
Computed tomography
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P4.002 DETECTION OF SINGLE TUMOR 
MAKER FOR EARLY DIAGNOSIS OF 
LUNG TUMORS THROUGH COMMON 
FRAGMENT SEQUENCE IN MULTIPLE 
LUNG TUMOR MARKERS.
Farhan Ul Haq Subhani 
Post Graduation Study/Pakistan
Background: Lung cancer is currently the most 
frequently diagnosed major cancer in the world 
and the most common cause of cancer mortality 
worldwide. An early diagnosis at stage Ia or Ib 
have very good prognosis in the treatment regimes. 
Different tumor markers are in clinical practice or 
clinical trials for the early detection of lung tumors.
Methods: It is a review in which we will discuss 
the structural common fragment of current tumor 
markers of lung carcinoma to attain a common 
amino acid sequence as a single tumor marker for 
lung carcinoma diagnosis at stage Ia and Ib.
Results: Different lung tumor maker are studied for 
their structural fragment which can be concluded 
as single common sequence in multiple tumor 
markers to achieve a single marker which have 
more speciÀcity and sensitivity. The tumor makers 
CYFRA 21-1, PGP9.5, BAX, p16INK4A, HER-2/
neu, Fucosyl-GM
1
, Pro-Gastrin-Releasing Peptide 
(31-98), ADAM8, Angiopoietin-2 are compared for 
their structural sequences. These all tumor markers 
showed some structural common fragments but a 
speciÀc common serological fragment is seems to 
be more realistic in the structural resemblance of 
antibody.
levels of EGFR and STAT3 expression in MPM 
and the preclinical efÀcacy of PDT with EGFR and 
STAT3 inhibition suggest that targeted inhibition 
of EGFR/STAT3 pathways may improve the 
locoregional control in MPM patients treated with 
RP+PDT.
Keywords: photodynamic therapy, malignant pleural 
mesothelioma, Surgery, intraoperative therapy
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P4.001 POLISH LUNG CANCER EARLY 
DETECION TRIAL
Malgorzata M. Jelitto-Gorska, Witold Rzyman, 
Adam Sternau, Janina Ksiazek, Iwona Biadacz, 
Robert Dziedzic 
Department Of Thoracic Surgery, Medical University 
Of Gdansk/Poland
Background: Eight thousands twenty eight 
individuals with a high risk of developing 
lung cancer were enrolled into the PILOT 
POMERANIAN LUNG CANCER SCREENING 
TRIAL between February 2009 and March 2010. 
The purpose of this report is the preliminary analysis 
of the early results. 
Methods: The risk group of developing lung cancer 
was deÀned as : age 50-75 years, smoking history 
of at least 20 pack-years without symptoms of the 
disease. People with family history of lung cancer 
and occupational exposure to carcinogens were 
enrolled with a history of 10 pack years. Low dose 
computed tomography (LDCT) was performed in 
8028 individuals between January 2009 and March 
2010 . Enrollment to the trial was done via hotline, 
website and by the medical staff. I-ELCAP screening 
protocol was applied for the screnning. Patients 
with detected nodules in LDCT were subjected to 
consecutive LDCT examinations based on tumor 
diameter (<5 mm, 5-10 mm and >10 mm). 
Results: A high rate (53% - 4257) of positive CT 
results was observed. Two thousands and nineteen 
(47,4%) nodules less than 5 mm, 1884 (44,3%) 
with diameter of 5-10 mm and 354 (8,3%) with 
diameter of more than 10mm were detected. In 265 
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in salivary DNA adduct(8-OHdG) than in blood. 
Direct interaction of salivary cells to tobacco product 
exposures could be one of the reasons. 
Conclusion: Conclusion: The study suggests that 
salivary DNA adduct is a better indicator of DNA 
damage in HNSCC patients. The result also suggests 
that DNA adduct (8-OHdG) is more predominant in 
oral reason that neck region. 
Keywords: OGG1, 8-OHdG, polymorphism, saliva
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P4.004 MANAGING LUNG CANCER : 
SHIFT IN STRATEGY
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: Elderly patients of Lung cancer 
provide challenging situation for
oncologists. We undertook this two year old project 
targeted at geriatric cancer patients from rural/
tribal India. Since geriatrics specialty is unheard 
of in rural India, we decided to address this 
burning issue of geriatric Lung cancer patients. A 
standardized geriatric evaluation is essential for the 
multidisciplinary approach of cancer Rx in patients 
with Lung cancer. In developed nations geriatric as 
well as an oncological evaluation are mandatory to 
offer to these patients the best therapeutic option and 
improve their prognosis as well as their quality of 
life. But this facility is
a luxury in Asian/African nations. Hence our Cancer 
NGO team evaluated frailty and suggested plan to 
include it in lung-cancer care of rural health set-up.
Methods: 6 tertiary care hospitals and two NGOs 
included in study. 64 healthcare providers given 
questionnaire on needs of geriatric cancer patients, 
their needs. 132 terminally ill geriatric Lung 
cancer patients with a life expectancy of 2 yrs were 
interviewed/evaluated by Geriatric Depression Scale 
used for the geriatric evaluation. A standardized 
geriatric evaluation is essential for multidisciplinary 
discussion of elderly patients with Lung cancer. 
A geriatric as well as an oncological evaluation 
are mandatory to offer to these patients the best 
therapeutic option and improve their prognosis as 
well as their quality of life Patients were asked to 
mark cancer care as satisfactory or non-satisfactory 
and asked to rate incidence/severity of depression 
Conclusion: Although different lung tumor markers 
have some common molecular sequences but these 
sequences need further veriÀcation for the hypothesis 
of common fragment detection on serological 
test. But an antibody titer can be more appropriate 
as common tumor marker through the common 
fragments of above mentioned lung tumor markers.
Keyword: Tumor marker, CYFRA 21-1, PGP9.5, 
BAX, p16INK4A, HER-2/neu
Poster Session 4 – Early Detection and Screening Thursday, 7 July 
2011 10:00-12:30
P4.003 ASSESSMENT OF HOGG1 
SER326CYS POLYMORPHISM AND 
DNA DAMAGE IN HEAD AND NECK 
SQUAMOUS CELL CARCINOMA IN 
NORTH INDIA
Anil Kumar, Shashi Khandelwal 
Immunotoxicology, Indian Institute Of Toxicology 
Research/India
Background: Head and neck squamous cell 
carcinoma(HNSCC) is the sixth most common 
cancer world wide. In India, it accounts for 21 % 
of total cancer burden and here we tested the role 
of hOGG1 ser326cys polymorphism and oxidative 
DNA damage in HNSCC patients in North India. 
hOGG1 8-oxoguanine DNA glycosylase , one of 
the key members of Base Excision DNA repair 
pathway , eliminates the mutagenic base oxidation 
product 8-oxoguanine, which is produced as a result 
of exposure to reactive oxygen species. Pan masala, 
gutka , khaini , bhidi and cigarette are commonly 
used in North India which could account for a 
higher incidence of HNSCC cases. These tobacco 
products have clastogenic and carcinogenic effects 
and are capable of generating free radicals during 
auto oxidation of polyphenols in saliva of tobacco 
users. Salivary cells are the Àrst to encounter various 
environmental products that soon reach the various 
body organs via blood. 
Methods: Genomic DNA from human salivary cells 
and whole blood of 40 controls and equal number of 
HNSCC cases was isolated and the polymorphism of 
hOGG1 was studied by PCR-RFLP method . Blood 
and salivary DNA adduct (8-OHdG) was measured 
by ELISA base colorimetric assay. 
Results: The results indicated no difference in 
hOGG1 polymorphism in both blood and saliva 
samples. However, more apurinic sites was evident 
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regulate cytoskeletal remodeling and endocytic 
pathways that promote normal epithelial functions. 
Silencing of RIN1 leads to increased motility of 
epithelial cells. Onco-protein Snai1 inhibits the 
expression of RIN1 in transcriptional level. In breast 
cancer, RIN1 inhibits the initiation and progression 
of tumorigenesis, but in lung cancer cells, high-
expressed RIN1 stimulates the cell proliferation.
Methods: Real-time PCR and Western blot assays 
were performed to detect the expression of RIN1 
mRNA and protein in Non-small cell lung cancer 
tumor tissues (TT) and matched tumor-free tissues 
(TF) and the association with clinical pathological 
characteristics including survival data was analyzsed. 
The expression of Snail protein was also explored.
Results: In total 140 patients, the levels of RIN1 
mRNA was down-regulated (less than 50%) in 
81 patiens (58%), and up-regulated (more than 
2-fold) in 29 patients (21%). The levels of RIN1 
protein were down-regulated in 74% patients and 
up-regulated in 26% patients. Correspondently 
well, Snail protein levels were up-regulated in 
81% patients and down-regulated in 19% patients. 
Moreover, the poor RIN1 mRNA expression was 
closely correlated with higher pathological N-stage 
(P = 0.004), poorer pathological TNM stage (P = 
0.008) and signiÀcantly shorter progression free 
survival.
Conclusion: The expressions of RIN1 mRNA were 
down-regulated in the majority of NSCLC, and low-
expressed RIN1 indicated advanced stage and poorer 
prognosis. The expression of RIN1 protein was also 
down-regulated in the majority of NSCLC, and 
negatively correlated to Snai1 protein well. RIN1 
may act as tumor suppressor in NSCLC.
Keywords: RIN1, SNAI1, Prognosis, Non small cell 
lung cancer
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P4.006 UNITED KINGDOM LUNG 
CANCER SCREENING (UKLS) TRIAL
John K. Field1, Stephen Duffy2, D. Baldwin3, K. 
Brain4, T. Eisen5, Christopher J.D. Hands6, K. M. 
Kerr7, R. Page8, Mahesh Parmar9, N. Wald10, D. 
Weller11, D. Whynes12, P. Williamson6, D. Hansell13 
1Cancer Research Centre, University Of Liverpool/
United Kingdom, 2Barts And The London School Of 
Medicine/United Kingdom, 3Nottingham University 
Hospitals Nhs Trust/United Kingdom, 4School Of 
on diagnosis of Lung-Ca. Due to enormity of project 
we had initially taken frailty/depression as primary 
parameter for evaluation. Then responses of cancer 
service providers were rated against suggestions 
given by patients. 
Results: 132 patients over 2-year period. mean 
age 58.2 ± 3,6 years old), 82% male, 18% females. 
72% subjects had symptoms of cognitive disorder 
[Folstein MMSE]. The mini-GDS used to detect 
depression, was positive in 72% of the evaluations. 
We can clearly identify frailed patients (72%) who 
did not received any counseling/psychotherapy. 
86% patients pointed to lack of psycho-social care. 
counseling as major lacunas in current set-up. 
Inadequate patient education on nutrition, social 
support and absence of trained psychologist were 
mentioned as dominant factor in responses by 64 
healthcare providers who participated in our project. 
We present our NGO project Ànding in printed chart-
form at 14th WCLC-2011 conference, Amsterdam. 
Conclusion: Our two year on-hand experiences 
clearly show need and beneÀt of close collaboration 
between geriatricians and oncologist. Sadly 
counseling/geriatric care is virtually non-existent 
in India. In daily management of elderly patients, 
alteration are needed in 72% of patients by 
geriatric assessment. We need strong platform like 
IASLC-2011-conference to show our Àndings to 
researchers/activists from developed world and get 
their guidance on this difÀcult issue. Government 
must carry out supportive-care-programmes with 
NGO-counselors to bring down incidence of frailty/
depression in thoracic cancer patients. 
Keywords: counseling, psychotherapy, Lung cancer
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P4.005 LOW-EXPRESSED RIN1 
INDICATED POOR PROGNOSIS AND 
NEGATIVELY-CORRELATED WITH 
SNAI1 IN NSCLC
Xiaokun Shen1, Ping Zhan2, Mingke Shi3, Tangfeng 
Lv4, Like Yu2, Yong Song4 
1Department Of Respiratory Medicine, Nanjing 
University, Jinling Hospital/China, 2Nanjing Chest 
Hospital/China, 3AfÀliated Drum Tower Hospital/
China, 4Nanjing University, Jinling Hospital/China
Background: The RAS effector RIN1 activates 
ABL tyrosine kinases and RAB5 GTPases to 
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and health economic implications. Individuals with 
a smoking history will receive smoking cessation 
advice. 
Results: Establishing and maintaining accurate 
CT interpretation is crucial for the trial’s success. 
CT scans will be read locally and centrally (double 
reading) optimising the sensitivity and speciÀcity of 
CT screening. UKLS employs volumetric analysis, 
where possible, with a single initial screen design. 
Follow-up includes repeat CT for indeterminate 
nodules and calculation of volume doubling time. 
Mortality will be measured after 10 years of follow-
up. This modelling has resulted in the development 
of the UKLS care pathway to manage identiÀed 
abnormalities (Baldwin et al 2011). The pilot study 
aims to optimise reporting methods including 
investigating efÀcacy of different methods of training 
observers and appropriateness of radiologists versus 
non-radiologists as local readers.
Conclusion: The aim of the main UKLS trial is to 
demonstrate a mortality advantage of 30 percent 
and cost effectiveness in the UK. This project 
was funded by the NIHR Health Technology 
Assessment programme and will be published in 
full in the Health Technology Assessment journal 
series. Visit the HTA programme website for more 
details to project page. The views and opinions 
expressed therein are those of the authors and do not 
necessarily reÁect those of the Department of Health. 
Keywords: lung cancer screening, Wald Single 
Screen Design, CT screening
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P4.007 THE LUCED TEST FOR 
DETECTION OF EARLY LUNG CANCER: 
A CRITERION TO COMPLETE THE TEST 
WITH HIGH SENSITIVITY
Michael Meyer1, Thomas Neumann2, Florence 
Patten2, David Steinhauer2, Jon Hayenga2, Scarlett 
Spring2, Alan Nelson2 
1Image Engineering, Visiongate/United States Of 
America, 2Visiongate/United States Of America
Background: The Cell-CT imaging platform 
produces 3D volumetric cell images based upon 
computed tomography as shown in the Àgure. 
The Cell-CT’s cell-by-cell morphological analysis 
in 3D overcomes obscuration issues and biases 
associated with perspective and focal plane selection 
Medicine, Cardiff University/United Kingdom, 
5University Of Cambridge/United Kingdom, 
6University Of Liverpool/United Kingdom, 7Aberdeen 
Royal InÀrmary/United Kingdom, 8Liverpool Heart 
And Chest Hospital/United Kingdom, 9Clinical 
Trial Unit London, Medical Research Council/
United Kingdom, 10Wolfson Institute, London/
United Kingdom, 11University Of Edinburgh/
United Kingdom, 12University Of Nottingham/
United Kingdom, 13Royal Brompton Hospital/United 
Kingdom
Background: Lung cancer kills more people 
worldwide than any other malignancy. Currently 
33,500 individuals die each year in the UK from 
lung cancer. Screening patients before they develop 
symptoms is a control measure urgently requiring 
evaluation as early surgical resection offers the 
best chance of cure. The overall aim of UKLS is 
to provide data required for an informed decision 
about the desirability of introducing population 
screening for lung cancer in the UK. This involves 
establishing the impact of screening on lung cancer 
mortality, determining the best screening strategy, 
assessing physical and psychological consequences 
and determining health economic implications of 
screening. The UKLS pilot trial starts in 2011. It 
will randomise 4,000 high risk patients identiÀed by 
the Liverpool Lung Project (LLP) Risk Prediction 
Model. If progression criteria are met, and funding 
available, we plan randomising a further 28,000 
subjects from seven centres in the UK. Subjects are 
selected if they have a 5% risk of developing lung 
cancer over 5 years as predicted by the LLP risk 
model. 
Methods: The “Wald Single Screen” Design 
(Baldwin et al 2011) has been chosen for the UKLS 
trial. Individuals meeting the inclusion/exclusion 
criteria will be sent invitations to participate and 
selected on the basis of the LLP risk questionnaire 
(Cassidy et al 2008). Before consenting, participants 
are shown a DVD and offered the opportunity to 
ask questions. After consenting, the research nurse 
will undertake spirometry and the participant asked 
to provide blood, buccal swab, nasal brushings and 
sputum samples and to complete baseline lifestyle, 
psychosocial, and health economic questionnaires.
Consenting participants are randomised to receive 
a single low dose Computed Tomography (CT) 
scan on the study arm or usual care on the control 
arm. Both arms will be followed-up for lung cancer 
incidence and mortality, psychosocial consequences, 
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P4.008 EFFECTIVENESS OF CHEST 
X-RAY SCREENING FOR LUNG CANCER 
IN SMOKERS. A POPULATION-BASED 
COHORT STUDY IN VARESE, ITALY
Andrea Imperatori1, Nicola Rotolo1, Albino Poli2, 
William Mantovani2, Antonio Paddeu3, Marco 
Spagnoletti1, Francesca Franzi4, Fausto Sessa5, 
Lorenzo Dominioni1 
1Center For Thoracic Surgery, University Of 
Insubria/Italy, 2Department Of Medicine And Public 
Health, University Of Verona/Italy, 3Respiratory 
Care Unit, Department Of Medicine, Ospedale S. 
Anna/Italy, 4Department Of Pathology, University Of 
Insubria/Italy, 5Department Of Pathology, University 
Of Insubria And Multimedica Irccs/Italy
Background: The effectiveness of screening for 
lung cancer (LC) on a population level is unknown. 
In this study the effectiveness of chest x-ray (CXR) 
screening offered to a population-based cohort of 
smokers was estimated by the LC standardized 
mortality ratio (SMR). 
Methods: In July 1997 all the asymptomatic 
cigarette ever smokers of more than 10 pack-years, 
aged 45-75 years, of both genders, registered in 
the medical records of 50 National Health Service 
(NHS) general practitioners of the Varese Province 
(Italy), were invited to annual CXR screening for 
four years, free of charge. The further eligibility 
criteria were: subjects without diagnosed or 
suspected LC and Àt for thoracic surgery. Overall 
5,815 smokers were invited to the screening (median 
32.8 pack-years) and formed the population-based 
cohort of this study. 21% of the cohort (1,244 
subjects) self-selected to participate in screening, 
undertaking the baseline CXR exam in the years 
1997-2001 median 3 screening rounds instead of 
the Àve expected); 79% (4,571 subjects) did not 
participate. The cohort received NHS usual care, 
with addition of screening CXR to participants. The 
cohort was followed-up until December 2006, all LC 
deaths being recorded. We estimated the LC SMR 
of the cohort in the eight-year period 1999-2006, 
based on the LC mortality recorded in smokers in 
the Varese Province (reference population) receiving 
NHS usual care, matched by location, age, gender, 
smoking history and calendar period.
Results: In the period 1999-2006 the annual LC 
mortality progressively decreased in the cohort 
inherent to slide imaging and 2D analysis. Thus, 
regression of 3D cell features to expertly identiÀed 
cell type produces a classiÀer that almost perfectly 
distinguishes cancer from normal cells. This Cell-CT 
classiÀer forms the basis of VisionGate’s LuCED test 
to triage the population at high risk for lung cancer 
to X-Ray CT for tumor localization and treatment. 
Since LuCED evaluates mostly normal cases, a 
criterion is needed to determine when to discontinue 
analysis of additional cells while preserving high 
sensitivity for cases with diagnostic (dysplasia 
and cancer) cells. This criterion can be found by 
assessing the prevalence of diagnostic cells and other 
normal epithelial cells in sputum. These results are 
presented here. 
Methods: Specimens were obtained from an FDA 
phase III trial to assess a sputum expectorant. 
Patients were enrolled based on high likelihood 
of lung cancer and contributed spontaneous and/
or induced sputum. Cancer presence and type was 
established through biopsy 120 days after the trial 
completion. A portion of each sputum was stained 
and deposited on a slide. These slides were scanned 
by a cytotechnologist to produce counts of various 
cell types. Results were analyzed to determine the 
proportion of diagnostic cells to normal epithelial 
cells. 147 patients comprised our study group that 
produced 180 specimens with diagnostic cells. 
Sputum from 44 patients with adenocarcinoma, 68 
with squamous cancer, and 68 with other types of 
lung cancer were analyzed. 
Results: Statistical characteristics of diagnostic cells 
and normal epithelial cells were assessed across 
many sputa to determine a criterion to terminate the 
LuCED test. Results show that 90% of the sputum 
specimens have at least one diagnostic cell per 100 
epithelial cells irrespective of tumor type. 
Conclusion: Our results show that analysis of 
sputum by the LuCED test should proceed until 
100 epithelial cells have been examined. Doing so 
establishes an efÀcient way to discontinue LuCED 
sputum processing for normal cases, and ensures that 
the patient is forwarded for additional testing if the 
sputum contains diagnostic cells. 
Keywords: Lung cancer, Early Detection, 3D, 
Optical Projection Tomography
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a Áuctuating type, in which the size of the GGN 
increased, but later decreased, and then increased 
again; and a stable type, in which the size and 
attenuation of the GGN were stable.
Results: CT screening detected 258 GGNs equal 
to or larger than 5 mm in diameter (mean size, 6.9 
mm; range, 5-20 mm) in 95 females and 71 males 
(mean age, 59.8 years; range, 41-78 years). The 
median follow-up period was 69 months (range, 16-
80 months). During follow-up, 29 GGNs (11.6%) in 
27 patients (16.8%) increased in size (growing type), 
eight GGNs (4.8%) in eight patients (4.8%) decreased 
in size (shrinking type), one GGN (0.4%) had 
decreased in size at six months after having increased 
in size and in attenuation (Áuctuating type), and 220 
GGNs (85%) in 130 patients (78%) remained stable 
(stable type). Five of the 29 growing-type GGNs had 
been resected by October 2010. The histopathological 
diagnosis was invasive adenocarcinoma in four of 
them and adenocarcinoma in situ in one.
Conclusion: The natural history of some of the 
GGNs detected by CT screening was revealed during 
a 5-year follow-up period, and the results showed 
that 85% of the GGNs equal to or larger than 5 mm 
in diameter had remained stable. A limitation of this 
study is that the diagnosis of only 2% of the GGNs 
has been determined pathologically.
Keyword: lung, ground-glass nodule (GGN), CT, 
screening
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P4.010 THE ROLE OF A CONVENTIONAL 
BRONCHOSCOPY IN THE WORK-UP OF 
SUSPICIOUS CT SCREEN DETECTED 
PULMONARY NODULES
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Vernhout1, Harry J.M. Groen2, Jan-Willem J. Lammers3, 
Carla Weenink4, Kristiaan Nackaerts5, Matthijs 
Oudkerk6, Willem Mali7, Frederik B. Thunnissen8, 
Harry J. De Koning9, Rob J. Van Klaveren1 
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Gasthuisberg/Belgium, 6Radiology, Umc Groningen/
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compared to the mortality observed in the reference 
population; cumulatively the LC deaths observed 
in the cohort were 172 in comparison to 210 
expected on the basis of the reference population. 
The LC SMR was 172/210=0.82 (95%CI 0.67-0.99; 
p=0.048), showing 18% reduction of LC mortality in 
the study cohort.
Conclusion: In a population-based cohort of 
ever smokers the speciÀc LC mortality decreased 
signiÀcantly after implementation of CXR screening. 
Keywords: chest x-ray (CXR) screening, smokers, 
population-based study, standardized mortality ratio
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P4.009 GROUND-GLASS NODULES 
DETECTED BY CT LUNG CANCER 
SCREENING: RESULTS OF AN 
EVALUATION OF PROGRESSION 
DURING A 5-YEAR FOLLOW-UP PERIOD
Ryutaro Kakinuma1, Masahiro Kaneko2, Takaaki 
Tsuchida2, Masahiko Kusumoto2, Hisao Asamura2, 
Noriyuki Moriyama1 
1Screening Technology And Development Division, 
National Cancer Center, Research Center For 
Cancer Prevention And Screening/Japan, 2National 
Cancer Center Hospital/Japan
Background: To evaluate the progression of ground-
glass nodules (GGNs) during a 5-year follow-up 
period after detection by computed tomography (CT) 
lung cancer screening.
Methods: During 2004, 3606 individuals underwent 
a low-dose CT lung cancer screening examination 
at the Research Center for Cancer Prevention and 
Screening. A total of 166 screenees in whom at least 
one GGN equal to or larger than 5 mm in diameter 
had been detected were followed-up in our clinic. 
Follow-up CT scans were generally performed at 
three months and nine months after the baseline 
CT scan, and then every year thereafter except in 
the event of GGN progression. The GGNs were 
classiÀed into four types according to changes in size 
and attenuation: a growing type, in which the size of 
the GGN increased regardless of whether there was 
an increase in GGN attenuation, or, in which a solid 
component(s) developed regardless of whether there 
was an increase in GGN size; a shrinking type, in 
which the size of the GGN decreased regardless of 
whether there was an increase in GGN attenuation; 
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Low-dose spiral CT is capable of detecting lung 
neoplasms in asymptomatic individuals however, 
it suffers from low speciÀcity which forces 
unnecessary biopsies or surgery for diagnosis.
Some of the genetic changes associated with lung 
cancer development were shown to be expressed 
in exfoliated cells in sputum. In pervious studies 
combination of cytology and genetic analysis of two 
FISH biomarkers located at 3p22.1 and 10q22.3, 
proved to be sensitive and speciÀc even in early-
stage lung cancer.
Our hypothesis is that combination of cytology and 
FISH in induced sputum samples, will lead to the 
development of an effective aiding tool for early 
detection of lung cancer in patients with suspicious 
radiological Àndings.
Methods: Induced sputum was collected from lung 
cancer and high-risk (i.e. heavy smoker, COPD) 
patients and healthy non-smoking controls (3, 19 and 
5 respectively).
All high risk patients were screened by low-dose 
CT and followed-up 12 month later. If suspicious 
nodules were found at baseline CT, an additional CT 
scan was performed 3 months later. Biopsies were 
performed if indicated.
Cells were isolated from sputum, stained in 
Papanicolaou, scanned and analyzed using automated 
scanning station (DuetTM BioView Ltd, Rehovot, 
Israel), allowing the analysis of the same cell under 
two different staining Methods: morphology and 
FISH. During the morphology scan, “Target cells”, 
cells derived from the lower airways and the lungs, 
were selected. Subsequently, cells were hybridized 
to a 3-color probe mixture containing two locus-
speciÀc probes (located at 3p22.1 & 10q22.3) and a 
centromeric 10 probe. Then, the slides were scanned 
again and target cells were relocated and analyzed by 
their FISH pattern.
Results: The FISH results were compared to the 
clinical diagnosis based on the CT Àndings. Genetic 
abnormalities detected from lung cancer patients 
were signiÀcantly higher than in healthy controls 
(15.04 and 4.62 respectively, P=0.0001).
Four lung cancer patients were tested – 3/4 were 
diagnosed prior to the CT and 1/4 was diagnosed 
by the CT. All patients were identiÀed correctly by 
FISH (100% sensitivity).
1/23 non-cancer patients had false-positive FISH 
result (95% speciÀcity). This patient was also highly 
suspected for cancer by CT but the presence of 
cancer was ruled out in biopsy.
In 7/19 high-risk patients, suspicious nodules were 
Background: The objective was to investigate 
prospectively the diagnostic value of a conventional 
white-light bronchoscopy in the Dutch-Belgian lung 
cancer screening trial; and to determine whether a 
bronchoscopic evaluation could be eliminated form 
the standard work-up of a suspicious pulmonary 
nodule. The cost-effectiveness of a screening 
program could be enhanced and the potential harms 
of a bronchoscopy avoided. 
Methods: All consecutive participants with 
a positive test result between April 2004 and 
December 2008 were enrolled. The diagnostic 
sensitivity and negative predictive value (NPV) were 
calculated at the level of the suspicious nodules. 
Gold standard for the outcome of the bronchoscopy 
was in 95% of the nodules based on the surgical 
resection specimens. 
Results: A total of 318 suspicious lesions have 
been evaluated by bronchoscopy in 308 subjects. 
The average diameter was 14.6 mm (SD: 8.7) and 
only 2.8% of nodules were > 30 mm in diameter. 
The sensitivity of bronchoscopy was 13.5% 
(95% conÀdence interval (CI): 9.0%-19.6%), the 
speciÀcity was 100%, the PPV was 100% and the 
NPV was 47.6% (95% CI: 41.8%-53.5%) Of all 
cancers detected, 1% was detected by bronchoscopy 
only and retrospectively invisible on both low-dose 
CT and CT with intravenous contrast. 
Conclusion: Conventional white-light bronchoscopy 
should not be routinely recommended for test 
positive participants of a lung cancer screening 
program. 
Keywords: bronchoscopy, lung cancer screening, 
Pulmonary nodule, Tomography, Spiral Computed
Poster Session 4 – Early Detection and Screening Thursday, 7 July 
2011 10:00-12:30
P4.011 COMBINE CYTOLOGY 
AND FLUORESCENT IN SITU 
HYBRIDIZATION (FISH) OF SPUTUM 
CELLS FOR EARLY DETECTION OF 
LUNG CANCER
Avi Gilad1, Tal Kaplan2, Michal Daniely2, Tali Levi1, 
Gershon Fink1 
1Pulmonary, Kaplan Medical Center/Israel, 2R & D, 
Bioview Ltd/Israel
Background: Lung cancer is difÀcult to detect in its 
early stages and therefore has a poor prognosis. The 
treatment of early-stage tumors is more effective.
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variables. Level of statistical signiÀcance was set at 
p < 0.05. 
Results: Majority of the respondents were males 
(65.9%) and the mean age was 22.45± 1.91 years. 
Two hundred and Àve (67.9%) had adequate 
knowledge of the deÀnition, causes and symptoms 
of lung cancer. Over half (77.2%) knew lung cancer 
was preventable however, only 31% were aware of 
lung cancer screening tests. X-ray was recognised 
by 55.6%, CT scan by 69.2%, and MRI by 57.6% as 
lung cancer screening tests. The recognised treatment 
modalities were palliative care (83.1%), surgery 
(71.9%), and chemotherapy (78.8%). Those in Ànal 
year had better knowledge of lung cancer (p<0.005). 
Respondents that knew of lung cancer screening 
tests were aged 25 years and above (p<0.05). Age, 
sex, religion and level of study had no signiÀcant 
association with knowledge of lung cancer screening 
test (p>0.005). 
Conclusion: Majority of medical student were 
knowledgeable about lung cancer however a few 
could identify the screening tests for lung cancer. 
Further educational efforts should be targeted 
towards the training of this group to be able to give 
adequate care to their patients. 
Keywords: Lung cancer, Screening, University 
College Hospital
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P4.013 EARLYCDT(TM)-LUNG TEST: 
AUDIT OF THE FIRST 1000 PATIENTS IN 
CLINICAL PRACTICE
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Background: EarlyCDT-Lung measured 
autoantibodies (AABs) to a panel of six tumor 
associated antigens (TAAs) (p53, NY-ESO1, CAGE, 
GBU4-5, Annexin1 and SOX2) with a speciÀcity 
of 90% and a sensitivity of 40% for lung cancer in 
clinical validation studies. We report on the Àrst 
1010 patients in clinical practice who have taken the 
EarlyCDT-Lung test.
Methods: One thousand and ten (1010) patients in 
North America at high risk of lung cancer, on the 
basis of age and smoking history, had EarlyCDT-
found at baseline CT. Final diagnosis conÀrmed 
cancer in one patient and ruled out the presence of 
cancer in the other six. The FISH identiÀed correctly 
the cancer patient and ruled out 5/6 negative patients.
Conclusion: The combined analysis using 
morphology and biomarkers for chromosomes 
3p22.1 and 10q22-23 was found to be a highly 
sensitive and speciÀc. The test was able to diagnose 
or rule-out the presence of cancer in patients with 
suspicious radiological Àndings. These preliminary 
results imply on the potential of using this assay as 
a non-invasive test for early detection of lung cancer 
as an adjunct method to the currently accepted CT 
scan and need to be further validated.
Keywords: Biomarkers, Induced Sputum, Non-
invasive testing, Áuorescence in situ hybridization
Poster Session 4 – Early Detection and Screening Thursday, 7 July 
2011 10:00-12:30
P4.012 AWARENESS OF LUNG CANCER 
SCREENING AMONG MEDICAL 
STUDENTS AT THE UNIVERSITY 
COLLEGE HOSPITAL, IBADAN
Olusegun A. Ayeni1, Mobolaji M. Salawu2, 
Oluwatosin Ayeni3 
1Nuclear Medicine, University College Hospital/
Nigeria, 2Community Medicine, University College 
Hospital/Nigeria, 3University College Hospital/
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Background: Worldwide, lung cancer is the most 
common cancer and the leading cause of cancer 
related mortality. In Nigeria, lung cancer is rising 
and patients are relatively younger and often with 
more advanced disease at presentation compared to 
developed countries. These poorer prognostic factors 
make cancer prevention and treatment a priority. 
This study therefore assessed the knowledge of lung 
cancer screening and treatment modalities among 
medical students. 
Methods: A cross sectional study was carried out 
among 302 clinical students of the University of 
Ibadan. Respondents were chosen using a stratiÀed 
sampling method. Information was obtained from 
participants using semi structured, pre-tested self 
administered questionnaires. Data on respondents’ 
knowledge of lung cancer, screening measures for 
lung cancer and treatment modalities were collected. 
Data were summarized using proportions, and Ƶ2 test 
was used to explore associations between categorical 
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P4.014 EARLY INDICATORS OF 
MORTALITY IN ASBESTOS WORKERS
Jerry Mclarty1, Sara Shepherd2, George Hurst2, 
Jeffrey Levin2 
1Medicine - Hematology/oncology, Lsu Health 
Sciences Center/United States Of America, 
2Occupational Health Sciences, UT Health Science 
Center At Tyler/United States Of America
Background: From 1954 to 1972 an asbestos pipe 
insulation manufacturing plant was operated in Tyler 
Texas, USA. A cohort of approximately 1100 men 
were exposed to intense levels of amosite asbestos 
dust. Exposure duration ranged from one day to 
20 years, with most of the men exposed only a few 
months. This cohort has been followed intensively 
since 1976 as part of the Tyler Asbestos Worker 
Program. This presentation looks at the relationship 
of early clinical Àndings in this heavily exposed 
group and their subsequent mortality experience 
during the 50 years since opening of the plant.
Methods: In 1976 the Tyler Asbestos Workers 
Program was charged with identiÀcation of all 
individuals exposed at the manufacturing plant and 
offering them screening with fulmonary function 
testing, sputum cytology and chest radiographs. 
In 2003 we attempted to establish the current 
vital status of all the workers examined by the 
surveillance program. Death records were obtained 
from the National Death Index and various 
state Bureaus of Vital Statistics. Cause of death 
was reviewed independently and coded by the 
International ClassiÀcation of Disease Code, version 
9 (ICD-9) by two occupational epidemiologists. 
ConÁicting results were resolved by concensus. 
Data analysis was performed by Kaplan-Meier 
survival curves and Proportional Hazards regression, 
for three speciÀc outcomes: lung cancer mortality, 
non-lung cancer mortality and all cause mortality. 
The regression tested the relationship between 
mortality and the early clinical Àndings while 
adjusting for confounding variables such as age, 
race, smoking and exposure history. The men were 
examined multiple times during the program, but 
this analysis uses the clinical results from the Àrst 
four examinations conducted in the 1970s. Sputum 
results were dichotomized into moderate atypia or 
worse versus normal, squamous metaplasian or mild 
atypia. Radiographic Àndings were collapsed into 
Lung measured (start date May 2009) from 293 
centers across 40 states and signed a HIPAA release 
agreeing to their clinical information being accessed 
as part of this prospective audit. For patients with 
a positive test their physician was contacted to 
establish what course of action had followed the 
test and regular contact maintained until a deÀnitive 
decision had been made. For patients with a negative 
test the physician was contacted after 6 months and 
18 months to ascertain if the patient had developed 
a cancer; in the interim if a patient’s physician 
pro-actively provided such information this was 
recorded. For patients submitting samples in the Àrst 
12 months the 6 month follow up is 98%.
Results: Of the 1010 patients, 26 (2.6%) have been 
diagnosed with lung cancer of whom 10/26 were 
positive for EarlyCDT-Lung giving a sensitivity 
of 38.5%. Of the 10 lung cancers positive for 
EarlyCDT-lung two were stage 1A non-small cell 
lung cancer (NSCLC) both of which were resected. 
A total of 173/1010 patients were positive for 
EarlyCDT-Lung giving a speciÀcity of 82.9%; for 
the Àrst and second 500 samples the Àgures were 
81.7% and 84% respectively.
In this prevalence round 10/173 positive EarlyCDT-
Lung tests have a lung cancer giving a PPV of 5.8% 
(1 in 17.3). In patients with EarlyCDT-Lung negative 
tests 16/837 (1.9%) were found to have a cancer (i.e., 
1 in 52.3). This represents a threefold difference in 
the risk of lung cancer. Of the 837 EarlyCDT-Lung 
negative samples 821 did not have a lung cancer 
diagnosed (98.1%).
Conclusion: This is the Àrst reported data of 
EarlyCDT-Lung being used in clinical practice. 
The results are consistent with the extensive 
validation datasets previously published on this 
test with sensitivity for NSCLC at least as high 
as in the validation studies, including early stage 
disease. A positive test for EarlyCDT-Lung carried 
a threefold difference in risk of lung cancer in this 
population. These Àgures take no account of occult 
lung cancers which may present over the next few 
years as cancers have been shown to stimulate a 
cancer antigen speciÀc autoimmune response up to 5 
years before detection by current imaging methods. 
Any “yet to present” cancers will likely increase 
sensitivity and speciÀcity for this cohort. This 
information can/could be used to help stratify high 
risk patients in diagnostic algorithms.
Keywords: antigen, Lung cancer, biomarker, 
autoantibodies
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Background: Cigarette smoking is well known to 
be the cause of lung cancer especially squamous cell 
and small cell type. The abnormal epitheliums that 
show to be the precursor of squamous cell carcinoma 
are demonstrated in central bronchus and correlated 
with history of smoking. Reported adenocarcinoma 
cell type of lung cancer is growing in its prevalence 
and overcome the prevalence of squamous cell type 
in some area. This study aims to Ànd the prevalence 
of early lung cancer and cell type in heavy smoker 
risk population. 
Methods: Population were anyone who smoked 
cigarette more than 20 pack-year, aged more than 
40 -year-old and did not have active pulmonary 
infection or previous diagnosed of lung cancer. 
The initial screening for lung cancer were chest 
X-ray and sputum cytology. If abnormal cell was 
found by sputum cytological examination, high 
resolution computerized tomography of the chest 
and autoÁuorescence bronchoscopy were performed. 
The Ànal diagnosis was made from any signiÀcant 
abnormality found. 
Results: There were 171 participants. All except 
one were male. Their mean age and amount of 
pack-year were 56.6(SD 9.9) and 51.1(SD25) 
respectively. Sixty had positive sputum cytology. The 
autoÁuorescence bronchoscopy could Ànd abnormal 
lesions in average 3.1lesions per person. Most of 
the pathology result of these lesions was squamous 
metaplasia. Stage 4 peripheral type adenocarcinoma 
lung cancer was found in one participant. No 
squamous cell carcinoma in situ and squamous cell 
carcinoma were found. 
Conclusion: The prevalence of lung cancer was 
0.6%. There were no carcinoma in situ or squamous 
cell carcinoma found in this study. The prevalence 
of central type lung cancer was decreased in smoker. 
The suspected reasons included the different 
compositions and manufactured of cigarette. This 
Ànding needs conÀrmation in larger population. 
Keyword: central type squamous cell carcinoma of 
the lung
any asbestos related abnormalities and any pleural 
abnormalities.
Results: Of the 1130 men identiÀed and examined 
in the program 513 deaths were documented up to 
2004; 76 of the deaths were due to lung cancer, 437 
were due to other causes. The analysis found that all 
three of the clinical modalities, cytology, radiology 
and spirometry, were signiÀcantly associated with the 
long-term mortality outcomes. Pulmonary function 
testing and sputum cytology were signiÀcantly 
associated with lung cancer and all cancer mortality, 
p < 0.002. Radiographic Àndings were also associated 
with lung cancer and all-cause mortality, but less 
signiÀcantly so than cytology and pulmonary function, 
p < 0.05. Only pulmonary function was signiÀcantly 
associated with non-lung cancer mortality, p < 0.001. 
FEV1% was the most consistent early clinical Ànding 
related to mortality. This is illustrated in the Àgure 
which shows the relationship of FEV1% quartiles to 
all-cause mortality. Quartile #1 is the highest quartile, 
#4 is the lowest.
Conclusion: Pleural changes in chest radiographs, 
moderate sputum atypia or worse, presence of 
ferruginous bodies in sputum, and decreased 
pulmonary function (especially FEV1) are each 
signiÀcantly related to subsequent mortality. Early 
screening with these clinical measures may help 
identify those workers at highest risk of dying from 
lung cancer and other diseases.
Keywords: asbestos, sputum cytology, Pulmonary 
function, mortality analysis
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P4.015 PREVALENCE OF CENTRAL TYPE 
SQUAMOUS CELL CARCINOMA OF 
THE LUNG IS DECREASING IN HEAVY 
SMOKER
Jamsak Tscheikuna1, Panthep Suttinont2, Trongtum 
Tongdee3 
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dramatic with regard to respiratory tract cancer 
than with breast cancer and colorectal cancer. For 
instance, if in 1990 proportion of advanced cases of 
respiratory tract cancer in men was 43.4%, in 2009 
– it reached 67.1%, as for breast cancer in women 
- proportion of the advanced cases increased from 
6.5% to 23.3%. IV stage of colorectal cancer in both 
sexes increased – from 25.4 % to 45.0% accordingly. 
The most vulnerable ages were from 45 to 70. Over 
two fold increase in lung cancer cases in men have 
been observed in the age group 45-49 for the last 
three year. 
Conclusion: 1. An upward trend of malignant 
diseases has been observed. 2. Respiratory tract 
(brunches, trachea and lung) cancer in man and 
colorectal cancer are mainly spread malignant 
diseases. 3. SigniÀcant proportion of the primarily 
detected cases was detected in advanced stage (IV 
-incurable). Recommendation: Public heath strategy 
should be focused on the expansion of screening 
programs throughout the country for early detection 
of malignant diseases cases. 
Keywords: Malignant diseases, Trend, Lung cancer, 
advanced stage
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.017 IMPROVING LUNG CANCER 
SPECIFIC OUTCOME WHEN ACCESS IS 
THE KEY–ARE WE THERE YET ?
Zarnie Lwin1, Heather Day2, Peter D. Baade2, Joanne 
F. Aitken2, Ian A. Yang3, Rayleen Bowman3, Kwun 
M. Fong3 
1Medical Oncology, Mater Adult Hospital/Australia, 
2Viertel Centre For Research In Cancer Control, 
Cancer Council Queensland/Australia, 3Department 
Of Thoracic Medicine, The Prince Charles Hospital/
Australia
Background: Access to specialist cancer care 
services is pivotal to improve lung cancer speciÀc 
outcome. Barriers include travel times and 
disadvantaged socioeconomic status. We analysed 
the 5 year lung cancer speciÀc survival in a 
population based study from the second largest state 
of Australia. 
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P4.016 PATTERNS OF MALIGNANT 
DISEASES’S TREND IN GEORGIA
Nanuli Z. Ninashvili1, Mikheil Shavdia2, Nia 
Shavdia3 
1Epidemiology, Tbilisi State Medical University/
Georgia, 2National Cancer Center, Palliative Care 
Clinic/Georgia, 3Aiety, Highest Medical School/
Georgia
Background: 7 000 new cases of cancer are reported 
annually in the country. A vast majority of the cases 
are primarily detected and diagnosed in the advanced 
stage (IV - incurable). Taking into account the severe 
economic conditions in the country for over the past 
two decades it presented an interest to determine 
structure, trend and stages of malignant diseases in 
order to make appropriate changes in the strategy 
and tactics of the malignant diseases’ control and 
prevention program.
Methods: Descriptive epidemiological study 
was conducted. Trend of malignant diseases was 
analyzed for the past two decades from 1988 to 2009. 
Surveillance data and medical records of primarily 
diagnosed cases were reviewed. Structure of malignant 
diseases was determined by site and sex. Incidence 
rates were calculated by age and sex for all and leading 
malignant diseases. M/F ration was calculated for all 
malignant diseases. Statistical tests were employed for 
statistical signiÀcance of the results. 
Results: During the Àrst Àve years of the analyzed 
period incidence rates of all malignant diseases were 
high ranging between 119.5 and 143.0 per 100 000 
population. Beginning from 1984 morbidity with all 
the malignant diseases declined signiÀcantly, mean 
incidence rate composed 93.5 (range 60.1 – 101.8). 
An upward trend was observed since 2001. Incidence 
rate began to increase gradually and in 2005 it 
exceeded the highest level, observed in 1988 (136.8 
per 100 000). The same patterns of the trend were 
characteristic for the diseases in men and women. 
No statistically signiÀcant changes were determined 
in incidence rates by sex, although more cases were 
observed in male than in female subjects. According 
to the structure by sex and tumor site, breast cancer 
in women and respiratory tract (brunches, trachea 
and lung) cancer in man and colorectal cancer – in 
both were found to be mainly spread malignant 
diseases. An upward trend of the advanced cases was 
observed in all three leading diseases. It was rather 
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statistically signiÀcant impacts on outcome in either 
univariate or multivariate analyses. 
Conclusion: Despite a trend towards inferior 
outcome for patients residing in disadvantaged 
socioeconomic areas or less access to specialists, 
our results were not statistically signiÀcant when 
adjusting for demographics and other prognostic 
factors. Prospective studies are warranted to 
determine impact of access to specialist care on lung 
cancer outcomes. 
Keywords: improving lung cancer speciÀc 
outcome, access to specialist services, area level 
socioeconomics
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P4.018 EXTRAPULMONARY 
MALIGNANCIES DIAGNOSED AT LOW-
DOSE CT SCREENING FOR LUNG 
CANCER
Cristiano Rampinelli1, Lorenzo Preda1, Marina 
Maniglio1, Giulia Veronesi2, Massimo Bellomi1 
1Radiology, European Institute Of Oncology/Italy, 
2Thoracic Surgery, European Institute Of Oncology/
Italy
Background: Incidental Àndings are a challenge 
for physicians as these could lead to potential 
beneÀts for patients as well as pose additional costs, 
patient anxiety and iatrogenic injury for clinically 
negligible conditions. The aim of this study was 
to retrospectively assess the detection rate, the 
histology and the clinical stage of the CT screening-
detected extrapulmonary malignancies in high risk 
population for lung cancer.
Methods: 5,203 asymptomatic current or former 
heavy smokers, aged 50 years or above, underwent 
an annual low-dose chest CT for 5 consecutive 
years. The study was approved by our institutional 
Ethics Committee and all participants signed a 
written informed consent form. All the patients with 
at least one “potentially signiÀcant extrapulmonary 
incidental Ànding (PS-IF)” screening detected 
were extracted from the study database. An 
extrapulmonary Ànding were deÀned “potentially 
signiÀcant” if it required a further diagnostic and/
or clinical evaluation. As our screening protocol 
included a PET-CT scan to characterize pulmonary 
nodules larger than 8mm, in the present study 
we also included all incidental malignancies 
Methods: We identiÀed all patients with newly 
diagnosed primary lung cancer and their respective 
treating physicians, registered in the Queensland 
Cancer Registry (QCR) Australia, from 1 July 
2004 to 31 December 2004. Results were linked 
with the Queensland Integrated Lung Cancer 
Outcomes Project (QILCOP) to extract data on 
stage, treatment modalities and outcome. QILCOP 
captures prospective data on approximately 40% 
of all new lung cancer patients notiÀed annually 
through multidisciplinary teams from major public 
and private institutions in Queensland state. To 
collect outcome data on those who were not captured 
through QILCOP we developed survey forms which 
were posted out to the treating physicians. Data 
on initial diagnosis and specialist consultation, 
treatment intent, treatment modalities planned, 
delivered and toxicity were documented. Travel 
time to the closest radiation facility was calculated 
based on usual residence of patients. Incident cases 
were matched with the National Death Index and 
the Registrar of Births, Deaths and Marriages. For 
analyses patients were categorized into quintiles 
of area-level disadvantage based on the Index of 
Relative Advantage and Disadvantage (IRSAD) 
generated by the Australian Bureau of Statistics. Cox 
regression was used to analyse differences in cause- 
speciÀc survival with follow up date censored at 31 
December 2009. 
Results: 856 cases were identiÀed and 829 were 
eligible for our study. After linking with QILCOP 
database, survey forms were posted to 407 
physicians with a 60% response rate. Final data for 
analysis was available for 773 patients. Median age 
at diagnosis was 70 years, 63% were male, 46% had 
ECOG 1 with ECOG unknown in 34%. 73% were 
non small cell lung cancer, 11% were small cell 
lung cancer and 16% unknown. In the entire cohort, 
only 63% had staging data and TNM stage was 
documented in 74% for non small cell lung cancer. 
65% were reviewed by a Respiratory physician 
or Cardiothoracic surgeon, 33% by a Medical 
Oncologist and only 10% by a Radiation Oncologist. 
Those who had access to a radiation facility within 
2 hours travelling time were more likely to consult a 
lung cancer specialist. 5 year cause-speciÀc survival 
for female vs male was 20% vs. 17% respectively 
(adjusted HR 0.76, p<0.001). In univariate 
analysis older age, poor ECOG and advanced stage 
predicted for inferior outcome (p<0.001). Different 
quintiles of area level disadvantage and increased 
travel distances to radiation facility did not show 
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P4.019 JAPANESE GENERAL 
SCREENING STUDY FOR ASBESTOS-
RELATED DISEASES (JG SARD): 
RESULTS OF BASELINE SCREENING
Nobuhiko Seki1, Takuhiro Yamaguchi2, Kenji 
Eguchi3, Masahiro Kaneko4 
1Division Of Medical Oncology, Department Of 
Internal Medicine, Teikyo University School Of 
Medicine/Japan, 2Tohoku University Hospital/
Japan, 3Teikyo University School Of Medicine/Japan, 
4National Cancer Center Hospital/Japan
Background: The number of patients with pleural 
mesothelioma and lung cancer associated with 
asbestos exposure has recently been increasing in 
Japan. The aim of this study was to evaluate the 
results of baseline screening for asbestos-related 
diseases in a group of Japanese general population. 
Methods: This prospective study was approved by 
the institutional review board; informed consent was 
obtained. Between March in 2006 and December 
in 2008, 9810 people (5283 men and 4527 women; 
mean age, 57 years) underwent chest radiography 
and low-dose CT examinations in 26 institutions 
in Japan. Clinical information such as histories 
of smoking and asbestos exposure was reviewed. 
Chest radiographs and CT scans were interpreted 
independently by 15 experienced pulmonologists or 
chest radiologists.
Results: The history of asbestos exposure was 
deÀnitely present in 1253 (12.8%) individuals, 
possibly present in 2058 (21.0%), and absent in 
6499 (66.2%). On chest radiograph, pleural plaque 
and pleural thickening were seen in 61 (0.6%) and 
65 (0.6%) individuals, respectively. On low-dose 
CT, pleural plaque and pleural thickening were 
identiÀed in 264 (2.7%) and 245 (2.5%) individuals, 
respectively, and non-calciÀed pulmonary nodule/
mass was seen in 1003 (10.2%). Furthermore, lung 
cancer was identiÀed in 29 (0.3%) individuals. The 
history of asbestos exposure was not conÀrmed in 
77 out of 264 individuals (29.2%) having pleural 
plaques on low-dose CT. Based on the logistic 
regression analysis, pleural plaque on low-dose CT 
was signiÀcantly correlated with male, age more 
than 60 years, a history of asbestos exposure and 
smoking. Similarly, lung cancer was signiÀcantly 
correlated with age more than 60 years, a history of 
asbestos exposure, and presence of pleural plaques. 
detected when performing this additional PET-CT. 
In retrospect all clinically relevant information, 
including diagnostic workup and Ànal diagnosis of 
the PS-IF were collected. Based on the information 
collected, only histological proven extrapulmonary 
malignancy screening-detected were eventually 
included in this study.
Results: At the end of the Àfth year of CT 
screening, 27 unsuspected extrapulmonary 
malignancies were diagnosed, which represent 
0.5% (27/5201) of volunteers enrolled and the 6.2 
% (27/436) of PS-IF. This means that unsuspected 
cancers were diagnosed with a frequency of 
one case per 200 individuals screened. Eight 
malignancies were diagnosed at the 1st year of 
screening, nine at the 2nd year, four at the 3rd year, 
two at the 4th year and four at the 5th year. Six 
(22%) malignancies were diagnosed by PET-CT 
scan. When compared to the 5-year cumulative 
detection rate of lung cancer of the screening trial 
(n=186, 3.5% of cohort), on average every 7 lung 
cancers diagnosed 1 extrapulmonary malignancy 
was found. The most common extrapulmonary 
primary tumor was renal carcinoma (n=7), 
followed by lymphoma (n=5), thyroid cancer 
(n=3), thymoma (n=2), pancreatic tumor (n=2), 
Schwannoma (n=1), hepatocellular carcinoma 
(n=1), gastrointestinal stromal tumor (n=1), prostate 
cancer (n=1), transitional cell carcinoma (n=1), 
breast cancer (n=1), pheochromocytoma (n=1) 
and ovarian cancer (n=1). The clinical follow-up 
interval was at least 1 year for all patients (range 
12–67 months). Twenty-four of the 27 patients in 
whom a malignancy was diagnosed were alive and 
all of them were disease free at the most recent 
follow-up, except for one patient affected by 
pancreatic tumor.
Conclusion: A considerable number of unsuspected 
extrapulmonary malignancies can be detected at a 
pre-clinical stage in lung cancer screening trials. 
A careful evaluation of extrapulmonary structures, 
with particular attention towards kidneys and lymph 
nodes, is recommended. 
Keywords: incidental Àndings, Lung cancer, 
Screening, CT
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Methods: The study utilises a prospective cohort 
design with annual follow up for incident of lung 
cancer and mortality. In a Àrst step, the LLP risk 
model is used to assess lung cancer risk for patients 
aged 50-80 years attending the General Practitioner. 
Eligibility into the intervention arm is dependent 
on the LLP risk model score (5-year risk 5%) and 
lung function test (FEV
1
/FVC<0.70) results. Also, 
patients in the intervention arm receive sputum 
cytology (suspicious or malignant) and chest X-ray 
(suspicious or malignant) investigations. Based 
on a positive or suspicious result, a broncoschopy 
followed by a CT scan and surgery are recommended 
in succession for deÀnitive diagnosis. Disease free 
participants in the intervention arm are invited 
annually for follow-up clinical investigations. All 
participants are regularly follow-up through the GP 
and/or record linkage with routine data from cancer 
registry and death registration. All participants 
diagnosed with lung cancer are managed by the GP 
following the NHS standard treatment pathway. 
Results: Since study start in January 2009, the 
LLP risk model has been applied to 1192 patients, 
and 271(23%) have been identiÀed as high risk of 
developing lung cancer within 5 years (i.e. 5-year 
risk 5%). Lung function test was performed in 175 
(65%) of high risk patients, of which 142 (81%) 
had FEV
1
/FVC<0.70. To date, no lung cancer 
cases have been identiÀed in the intervention arm, 
but 11 suspicious patients are undergoing clinical 
investigation (bronscoscopy/CT scan). The Àrst 
annual recall for sputum cytology investigation and 
methylation proÀling are now underway. 
Conclusion: The LLP-PCIP investigates the 
effectiveness and clinical feasibility of the combined 
role of the LLP risk model, lung function test, 
sputum cytology and methylation proÀling to 
complement Brochoscopic/CT scan for diagnosis of 
lung cancer, thereby providing a mechanism for early 
detection before onset of symptoms. An evaluation 
of the study progress has provided insight on the 
aspects which need improvement; in particular, how 
to recruit the hard-to-reach and reducing withdrawal. 
The experience gained from this study will be very 
valuable in the planned population-based UK Lung 
Screening trial (UKLS) currently under pilot in 
Liverpool and Cambridge
Keywords: Early Detection, Epidemiology, Lung 
cancer
Conclusion: Our results indicate that the 
detectability of pleural lesions on low-dose CT is 
approximately 4 times higher than that on chest 
radiographs, and that about 30% of individuals with 
pleural plaques on low-dose CT are not aware of the 
asbestos exposure.
Keywords: CT screening, Lung cancer, asbestos-
related diseases, pleural mesothelioma
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P4.020 A PILOT LUNG CANCER EARLY 
DETECTION STUDY IN A PRIMARY 
CARE PRACTICE IN KNOWSLEY, 
MERSEYSIDE: THE LIVERPOOL 
LUNG PROJECT PRIMARY CARE 
IMPLEMENTATION PROGRAMME (LLP-
PCIP)
John K. Field1, Olaide Y. Raji1, Adrian Cassidy1, 
Chris Mimnagh2, John Hughes2, Chris Warburton3, 
Tom Giles4, T. Liloglou1, John Gosney4, Peter 
Calverley3, Stephen W. Duffy5, R. Page6, Matthew 
Ashton7 
1Molecular And Clinical Cancer Medicine, 
University Of Liverpool/United Kingdom, 2Wingate 
Medical Practices, Knowsley/United Kingdom, 
3Aintree University Hospital/United Kingdom, 
4Royal Liverpool Broadgreen University Hospital 
Trust/United Kingdom, 5Queens Mary University 
Of London/United Kingdom, 6Liverpool Heart And 
Chest Hospital/United Kingdom, 7Knowsley Nhs 
Primary Care Trust/United Kingdom
Background: More than 90% of people diagnosed 
with lung cancer in the UK die within a 5-year 
period. The poor survival is partly linked with 
late diagnosis often at an advanced stage when 
various treatment options are less efÀcacious. The 
cornerstone of early diagnosis includes prompt 
identiÀcation of high risk individuals, necessitating 
a need for a validated screening approach that could 
be used in the primary care setting to target people 
before onset of symptoms The LLP-PCIP was set up 
in Knowsley, which has amongst the highest rates of 
lung cancer in the UK, as a pilot study evaluating the 
combined role of the LLP risk model, lung function 
test, sputum cytology and methylation proÀling in 
complementing Bronchospic/CT for early diagnosis 
of lung cancer. We will describe the design, progress, 
limitation and expectation of this pioneer initiative.
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Conclusion: These results enable the CAD system 
to be used as a second reader and might improve the 
accuracy of the diagnosis made by the pulmonologist 
at the diagnostic procedure. Furthermore we see 
that targeting CAD systems not only at lung nodules 
but also inÀltrated areas may be useful in clinical 
practice. 
Keywords: Decision support system, Chest X-Ray 
images, Early Detection, Reader efÀciency
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P4.022 LUNG CANCER SCREENING: 
CLINICAL RISK PROFILING WITH 
LUNG FUNCTION TESTS TO IMPROVE 
EFFICACY
Henry M. Marshall1, Rayleen Bowman1, Jane 
Crossin2, Melanie Fuentes2, Richard Slaughter2, 
Linda Passmore1, Elizabeth Mccaul1, Deborah 
Courtney1, Morgan Windsor3, Ian A. Yang1, Paul 
Zimmerman1, Terry Hayes2, Stanley Redmond2, 
Kwun M. Fong4 
1Thoracic Medicine, The Prince Charles Hospital/
Australia, 2Department Of Medical Imaging, The 
Prince Charles Hospital,/Australia, 3Thoracic 
Surgery, The Prince Charles Hospital/Australia, 
4Department Of Thoracic Medicine, The Prince 
Charles Hospital/Australia
Background: Reports from NLST state that LDCT 
screening can reduce lung cancer (LC) mortality. 
Despite screening ‘very high risk’ participants, most 
studies have baseline cancer prevalence of 1-2% 
and up to 50% ‘false positive’ rates. Obstructive 
spirometry and CT-detected emphysema (CTE) 
indicate lung damage and hence tobacco-smoke 
susceptibility. Both are independently associated 
with LC. Current risk stratiÀcation for screening 
does not account for markers of lung damage. Gas 
transfer (DLCO) has not been studied in LDCT 
screening but may correlate with CTE better than 
spirometry, which may be normal in mild CTE.We 
hypothesized that participants with normal or near-
normal gas transfer have low levels of lung damage 
and could be safely excluded from LDCT screening. 
This will ‘enrich’ cancer prevalence in the screened 
group and increase efÀcacy. 
Methods: We recruited healthy volunteers 
aged 60-74 years with smoking history  30 
pack years (current or quit within 15 years) and 
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P4.021 EARLY LUNG CANCER 
DETECTION USING DECISION SUPPORT 
SYSTEM BASED ON DIFFERENT 
SYMPTOMS ON CHEST RADIOGRAPHS
Dora Bartusek1, Andrea Nagy1, Zoltan Sutto1, Akos 
Horvath2, Janos Nagy2, Gergely Orban3, Aron 
Horvath3, Gabor Horvath3 
1Pulmonology, Semmelweis University/Hungary, 
2X-ray, Innomed Medical Inc/Hungary, 3Budapest 
University Of Technology And Economics/Hungary
Background: Lung cancer is one of the most 
frequent causes of death in the World with especially 
high incidence in Hungary. Lung cancer can appear 
in an early stage not only by nodules, but inÀltrates 
and some other signs on X-Ray images. Therefore 
the main goal is to detect lung nodules and inÀltrated 
areas on chest images by a newly developed CAD 
(computer aided detection) system and this way 
increase the efÀciency of the reader performance.
Methods: Our neural network based algorithms 
Ànd dense, approximately circular shapes and 
blurred inÀltrated areas on chest radiographs. After 
preprocessing suspicious areas are enhanced by 
various image processing algorithms, different Àlter 
methods Ànd small nodules (diameter of 5mm to 
35mm) large nodules (diameter of 30mm – 75mm) 
and inÀltrated objects of arbitrary size. The last 
step involves the fusion of the Àlter outputs and 
false positive reduction. The latter is utilized by an 
adaptive learning classiÀer that is trained on validated 
Àndings of pulmonologists. The Ànal Àndings are 
displayed on the chest radiograph with an approximate 
segmentation to attract attention to suspicious areas 
giving a second opinion for the readers.
Results: We tested our system on healthy 
radiographs and also images containing lung nodules 
and inÀltrated areas validated by a second reader 
using other test methods (CT, US, etc.). Overall 
sensitivity was 70% on approximately 1000 images, 
while producing on average 3 false positives per 
image. We compared our solution to a previous 
version not sensitive to inÀltrates and examined a 
clear improvement. We also compared our system to 
Àrst reader sensitivity where CAD results turned out 
to be slightly more sensitive; however false positive 
rates were much higher as Àrst readers mark only 
one false Ànding only in more than 50 images on 
average.
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P4.023 IDENTIFICATION OF 
EPIGENETICALLY SILENCED 
MICRORNAS IN LUNG 
TUMORIGENESIS.
Hyang Sook Seol, Young-Ah Suh, Se Jin Jang 
Life Science Lab, Asan Medical Center/Korea
Background: Lung cancer is the leading cause of 
cancer mortality worldwide, and non-small cell lung 
cancer (NSCLC) accounts for almost 80% of such 
deaths. Nevertheless, relatively little is known about 
what molecules speciÀcally mediate the initiation and 
progression of NSCLC and therefore a few are used 
for molecular targeted therapies. Recently, aberrant 
expression of microRNA (miRNA) has been reported 
in various cancers. Its role in tumorigenesis would be 
through suppression of translation and/or affaecting 
the stability of target messenger RNAs (mRNAs). 
Methods: To explore the roles of miRNAs in lung 
tumorigenesis, we performed miRNA microarray 
analysis. We treated HDAC inhibitor, SAHA to lung 
cancer cell lines, Calu-6 and H358.
Results: Through this experiment, we found that 
the expressions of 27 miRNAs were signiÀcantly 
changed after SAHA treatment in both lung cancer 
cell lines. In addition, we analyzed the changes 
of miRNA expression between normal and tumor 
lung tissues from patients to conÀrm the role of 
these miRNAs in lung tumors. The expression of 
several miRNAs were also reduced in tumor tissues 
from patients. We also analyzed the changes of 
miRNA expression between untreated and 5-aza-2’-
deoxycytidine (5-aza-CdR) or SAHA-treated lung 
cancer cell by qRT-PCR. Through these experiments, 
we found that the expression of one miRNA was 
reduced in both cell lines and tumor tissues. To study 
the function of this miRNA in lung tumorigenesis, 
we transfected Pre-miRNA to Calu-6. After 
transfection of Pre-miRNA, a signiÀcant reduction 
of cell growth was observed , indicating that this 
miRNA might have lung tumor suppressive effect. 
Further, we analyzed the methylation status of this 
miRNA in lung cancer cell s and tissues by COBRA 
assay to explore the mechanism of silenced miRNA.
Conclusion: These results suggest that the miRNA 
palys a role for the inhibition of lung tumor 
progression. To clarify the function of miRNA 
on cancer cell growth, determination of the target 
mRNAs are under investigation.
FEV1>50%predicted. Volunteers received one 
prevalence scan (Phillips Brilliance 64-slice 
multidetector scanner at 0.9mm slice width). Two 
radiologists independently reported scans. One or 
more nodules 4mm diameter deÀned a positive 
scan. Spirometry and gas transfer were measured 
according to ATS/ERS guidelines. CTE was 
considered present if >1% of the total lung volume 
was below a -950 HU threshold (Phillips Brilliance 
software). 
Results: (Median, range). Between December 2007 
and December 2010, 256 volunteers were screened: 
men 66.8%; age 64 (59-75) years; current smokers 
45.3%; pack-years 54 (22-235); FEV
1
 %predicted 95 
(46.6-155.5); DLCO %predicted (n=128) 75.1 (40.0-
129.9). 53% of baseline scans were positive. Five LC 
were diagnosed (prevalence 1.95%). CTE correlated 
with lung function (FEV1/FVC ratio, FEV
1
, DLCO 
and KCO r=0.57, 0.38, 0.35, and 0.34 respectively). 
Mean KCO was lower in participants with LC; 
Receiver Operating Characteristic area under the 
curve was signiÀcant for KCO.(Table 1). Table 1. 
No cancer 
N=123 
Lung cancer 
N=5 ROC analysis 
mean (SD) p value 2-tailed t-test 
Area under 
the curve P value 
KCO % predicted 82.5 (16.1) 66.0 (16.7) 0.03 0.77 0.04 
DLCO % predicted 76.9 (15.1) 65.0 (13.1) 0.08 0.73 0.08 
FEV1/FVC ratio % 
predicted 92.4 (14.2) 85.3 (16.2) 0.27 0.63 0.31 
FEV1 % predicted 89.8 (18.6) 81.9 (14.4) 0.35 0.65 0.27 
CT emphysema % 
total lung volume 10.4 (5.4) 9.3 (9.4) 0.68 0.61 0.43 
A KCO threshold of >90%predicted would exclude 
30.4% participants from LDCT screening with no 
cancer missed. Extrapolating to the full cohort, 
baseline LDCT cancer prevalence would have 
increased to 5/180 or 2.8%. 
Conclusion: Although based on small numbers this 
study suggests that lung function testing prior to 
LDCT screening is worth exploring in larger studies. 
Even modest reductions in participants requiring 
LDCT could have signiÀcant cost beneÀts at a 
population level. Supported by a Queensland Smart 
State Grant, NCARD and NHMRC. 
Keywords: lung cancer screening, lung function test, 
low dose CT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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mean age 66.8 ± 10.1 years) and 50 controls (74% 
male, mean age 71.2 ± 8.1 years), recruited at 
outpatient clinics in the regions around Amsterdam 
and Nieuwegein, The Netherlands. Cases collected 
sputum before treatment, or at the time progressive 
disease was evident after treatment. Controls were 
patients with COPD without lung cancer in the 
preceding three years. Spontaneous sputum was 
collected at home during nine consecutive days in 
three separate canisters, each representing three 
successive days. DNA was isolated separately from 
all three samples per patient. Each DNA isolate 
was bisulphite treated and subsequently subjected 
to quantitative methylation-speciÀc PCR (qMSP) 
to assess methylation status of the RASSF1A gene 
promoter. As quality control, ampliÀcation of 
housekeeping gene MYOD1 was carried out. All 
samples were tested in duplicate. Statistical analyses 
were conducted using chi-square tests. 
Results: All subjects provided the requested 
sputum samples (n=3x101), and all DNA isolates 
were suitable for qMSP analysis. Analysis of each 
canister separately showed RASSF1A methylation 
in samples of day one to three, four to six, and six to 
nine in 29%, 35%, and 33% of cases, respectively. 
These Àgures were signiÀcantly lower for control 
samples, i.e., 2%, 6%, and 2%, respectively (all 
P-values <0.001). Cumulative analysis of RASSF1A 
methylation, i.e., combining methylation positivity 
outcomes for day to six, and day one to nine, 
revealed RASSF1A methylation in 39% and 47% of 
cases, respectively, versus 8% and 8% of controls, 
respectively. 
Conclusion: Our study suggests that sputum 
collected over multiple successive days results in a 
gain in sensitivity, at the expense of a small loss in 
speciÀcity, for the detection of lung cancer. Given 
these Àndings, it might be considered feasible and 
legitimate to collect sputum during multiple days for 
future screening purposes. 
Keywords: Lung cancer, Screening, Sputum, 
Molecular biomarkers
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P4.025 FREQUENCY OF INTERIM-
DIAGNOSED LUNG CANCER IN THE 
SCREENING TRIALS
Dongming Xu, Claudia I. Henschke, David F. 
Yankelevitz 
Keywords: Lung cancer, HDAC inhibitor, micro 
array, miRNA
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P4.024 EVALUATION OF THE EFFECT OF 
SAMPLING OF SPONTANEOUS SPUTUM 
OVER A PROLONGED PERIOD ON THE 
SENSITIVITY FOR LUNG CANCER.
Anne J. Hubers1, Daniëlle A. Heideman1, Gerarda 
J.M. Herder2, J. A. Burgers3, Peter J. Sterk4, Peter 
Kunst5, Henk J. Smit6, Pieter E. Postmus7, Sylvia 
Duin1, Peter J. Snijders1, Gerrit A. Meijer1, Egbert F. 
Smit7, Erik Thunnissen1 
1Pathology, VU University Medical Center/
Netherlands, 2Pulmonology, St. Antonius Hospital/
Netherlands, 3Thoracic Oncology, The Netherlands 
Cancer Institute/Netherlands, 4Pulmonology, 
Academic Medical Center/Netherlands, 5Pulmonary 
Medicine, Academic Medical Center/Netherlands, 
6Pulmonology, Sint Lucas Andreas Hospital/
Netherlands, 7Pulmonology, VU University Medical 
Center/Netherlands
Background: Lung cancer is the most common fatal 
cancer worldwide with an average 5-year survival 
of 12%. This is mainly due to the advanced stage of 
disease at time of diagnosis. Secondary prevention 
strategies are expected to increase the 5-year survival 
rate by 3-4 folds. Recently, the National Lung 
Screening Trial reported that spiral CT screening 
of lung cancer leads to a reduction of lung cancer 
mortality. CT screening, however, is costly and 
has a high false-positivity rate. Therefore, a clear 
need exists for alternative screening assays. Many 
studies indicate that sputum could be a promising 
remote medium for early detection of lung cancer, 
in particular when combined with DNA-methylation 
based diagnostic assays. Nonetheless, to date all 
evaluated gene promoter methylation marker panels 
for early detection of lung cancer in sputum suffer 
from insufÀcient sensitivity. We hypothesized 
that sensitivity for detection of lung cancer may 
improve when sputum is collected over multiple 
days. Therefore, this study was set out to determine 
whether the detection rate of RASSF1A gene 
promoter methylation is inÁuenced by duration of 
sputum collection. 
Methods: Sputum samples were prospectively 
collected from 51 lung cancer patients (71% male, 
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Lung 
Screening 
Study (LSS) 
7 4 9 9 4 20 20% 
Memorial 
Sloan 
(Randomized) 
¤ 
30* - - - - - - 70 44 144 31% 
23* * - - - - - - 65 56 144 39% 
PLCO # 120 46 53 65 62 68 71 186 179 485 37% 
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P4.026 SELF REPORTING OF 
SYMPTOMS AND DELAYS IN PATIENTS 
PRESENTING TO A RAPID ACCESS 
LUNG CANCER CLINIC (RALCC)
Colm Geraghty, Mateen Uzbeck, Eleanor Dunican 
Respiratory, Beaumont Hospital/Ireland
Background: The rapid access clinic at our hospital 
is aimed at expediting the work up and diagnosis 
of patients with suspected thoracic malignancies. 
The vast majority of patients (98%) are seen within 
2 weeks of referral and the current case Ànd rate 
is 42%. We aimed to explore the pathway prior to 
presentation at our RALCC so as to identify common 
presenting features and potential causes of delays in 
presentation to the clinic 
Methods: We offered a self-reported questionnaire 
to consecutive patients on their Àrst visit to our 
RALCC. The questionnaire contained questions 
about patient’s perception of why they were 
attending the clinic, symptom type and duration of 
symptoms before seeking medical attention, the time 
to referral to the RALCC and risk factors for lung 
cancer 
Results: 154 patients participated, 81 male and 73 
female, mean age 63 years (21-86 years). General 
practitioners made the most referrals 134/154 (87%) 
and 105/159 (68%) perceived abnormal radiology 
to be the main reason for their attendance to the 
RALCC. The majority were symptomatic 132/149 
(88.6%) with 57% reporting 3 symptoms. Cough 
was the most common presenting symptom at 61%. 
Others were fatigue 52%, dyspnoea 45%, chest 
infection 45%, chest pain 40%, weight loss 32%, 
hoarseness 30%, anorexia 31% and haemoptysis 
25%. Patients with haemoptysis had the least delay 
in presenting to a health care provider (mean 30 
days, range 2-120 days) whereas patients with 
cough, dyspnoea and chest pain had a longer delay 
Radiology, Mount Sinai School Of Medicine/United 
States Of America
Background: The aims were to report the frequency 
of interim cancer in the CT screening trials and 
X-ray screening studies, and to present the cell-type 
and stage distribution of interim cancer in both trials. 
Methods: The interim cancers in the low-dose CT 
and X-ray screening were documented through 
New York Early Lung Cancer Action Project (NY-
ELCAP) database review, literature search through a 
computerized database (PubMed) and email contact 
with the research PI.
Results: There were 9 low-dose CT and 3 X-ray 
screening trials included in this study. The proportion 
of interim cancer versus total cancer identiÀed was 
2.4% in the NY-ELCAP, and from 0% to 5.3% in 
the other 8 CT screening studies. The proportion 
was between 20% and 39% in the three X-ray 
studies. In CT screening study, small cell carcinoma 
and adenocarcinoma were the most frequent cell 
types (38% in each); In X-ray screening study, 
adenocarcinoma was the most frequent cell type 
(35%), followed by squamous cell (23%), small cell 
(23%) and other cell type (19%). 78% and 72% of 
interim cancers found in the CT and X-ray screening 
studies were stage III-IV cancer. 
Conclusion: The proportion of interim cancers in 
the CT screening study was signiÀcantly lower than 
in the X-ray study. Interim cancers were mostly 
advanced cancers in both studies. Adenocarcinoma 
and small cell carcinoma were the most frequent 
cell types in the CT screening studies. In the X-ray 
screening studies, there was a wide distribution of 
cell types.
Table 1 Frequency of interim cancer
Study Baseline Interim 1 1st 
repeat 
Interim 
2 
2nd 
repeat 
Interim 
3 
3nd 
repeat 
Interim 
4 
4th 
repeat 
Total 
(Repeat) 
Total 
(interim) 
Total Interim/
Total 
CT screening 
NY-ELCAP 101 3 20 0 20 3 124 2.4% 
Cosmos Italy 55 0 38 1 40 0 36 2 16 130 3 188 1.6% 
NELSON 70 4 54 3 54 7 131 5.3% 
LSS 30 0 8 8 0 38 0% 
Hitachi Japan 37 0 4 4 0 41 0% 
Milan Italy 11 0 11 11 0 22 0% 
Mayo Clinic 31 - - - - - - - - 34 3 68 4.4% 
Toronto * 
Canada 
44 - 10 - 6 - 2 - - 18 3 65 4.6% 
Sone S Japan 23 - 27 - 10 37 0 60 0% 
X-ray 
screening 
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and entered into a patient tracking database. The 
parameters analysed included patient demographics, 
investigations and patient outcomes. All patients had 
a baseline dynamic CT thorax and bronchoscopy. 
Patients where bronchoscopy failed to yield a 
tissue diagnosis had a CT-guided or surgical lung 
biopsy. Staging investigations included PET/CT, 
endobronchial ultrasound and endoscope ultrasound 
guided Àne needle aspirate or mediastinoscopy. 
Patients with a cancer diagnosis were then discussed 
at a weekly multidisciplinary team meeting were a 
management plan was made. 
Results: Median age was 68 years (range 18-89) 
and 301 (60.2%) were male. The median time 
from referral receipt to Àrst rapid access clinic 
assessment was 5.5 days (range 0-26). Patients with 
a malignancy were discussed in a multidisciplinary 
team meeting a median of 5 days from Àrst clinic 
assessment (range 0-31). 206 patients (41.2%) were 
diagnosed with a malignancy. Of the remainder, 79 
patients (26.8%) were identiÀed as having suspicious 
nodules that required further surveillance. 68 patients 
(23.1%) had an alternative respiratory disease and 
29 patients (9.9%) had a non-respiratory condition 
and were referred to the relevant specialists. The 
remaining 118 (40%) were reassured that there 
was no evidence of malignancy and discharged to 
their referring doctor with no pathology found. One 
hundred and seventy nine (35.8%) patients were 
diagnosed with primary lung cancer with a further 
27 (5.4%) patients diagnosed with secondary lung 
cancer and other thoracic tumours.
As part of the diagnostic work up for malignancy, 64 
patients (29%) required a CT guided biopsy and 21 
patients (10.2%) required a surgical biopsy to yield a 
tissue diagnosis in suspected lung cancer.
Histological staging was achieved in 123 patients 
(84%) with NSCLC
For those patients in whom active treatment was 
recommended, 44 (27.9 %) had surgical resection, 
39 (30.2%) chemotherapy and 15 (11.6%) 
radiation monotherapy. Thirty-one patients (24%) 
received chemotherapy, 5 (3.9%) had surgery with 
chemotherapy and 3 (2.3%) had treatment with all 3 
modalities.
Conclusion: Thoracic malignancy is identiÀed 
in over 40% of patients this study shows that 
appropriate patients are being referred to rapid 
access. A higher percent of early stage lung cancers 
are being identiÀed when compared to Àgures from 
averaging 4.5 months. The average delay between 
seeking any medical attention and being seen in the 
RALLC was 14 weeks. The majority of the patients 
referred had at least 1 risk factor for lung cancer. 
72% were current or ex-smokers and 21% reported at 
least one Àrst degree relative with lung cancer. 
Conclusion: There were signiÀcant delays between 
symptom onset and presentation to a health care 
provider. The duration of delay varied depending 
on symptom type. The bulk of the delay was before 
patients sought medical attention but there was still 
a sizeable delay between presentation and referral 
to the RALCC. One in 5 patients had a Àrst degree 
relative with lung cancer and one in ten had two 
or more Àrst degree relatives with lung cancer 
indicating that this may have been a factor in the 
decision to refer. Our study highlights the need for 
increased public awareness regarding the presenting 
symptoms of lung cancer and there exists the 
opportunity to reduce delays in diagnosis resulting in 
better patient outcomes.
Keywords: Lung cancer, presenting features, delays 
in presentation
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P4.027 OUTCOMES OF PATIENTS 
PRESENTING TO A RAPID ACCESS 
LUNG CANCER SERVICE
Eleanor Dunican, Mateen Uzbeck, Colm Geraghty, 
Janet Clince, Siobhan Toner, Seamus Linnane, Ross 
Morgan 
Respiratory Medicine, Beaumont Hospital/Ireland
Background: A new cancer care-pathway was 
developed in Ireland as laid out in the national cancer 
control strategy delineating a clear organisational 
structure and formally linking thoracic surgery 
centers with 8 regional cancer centers. Site-speciÀc 
multidisciplinary teams are at the centre of this 
organisational structure. The aim of Rapid Access 
is to assist in the provision of timely and evidence-
based multidisciplinary lung cancer care, to increase 
the number of patients seen in the early stage of 
their disease when they are candidates for curative 
treatment and to increase the opportunities to offer 
patients clinical trials and studies. 
Methods: The Àrst 500 patients referred to the 
rapid access lung cancer clinic in our institution 
were studied. Data was collected prospectively 
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Methods: In 2006, a prospective longitudinal study 
was initiated on a cohort of 185 asymptomatic 
individuals over 25 years old with conÀrmed HIV 
diagnosis who had a smoking history of greater 
than 20 pack-years. All participants had baseline 
(prevalence) chest CT scanning and 107 patients 
(58.2%) also received at least one subsequent annual 
(incidence) examination of the chest. In the CT 
scans of 136 patients, 3D CT reconstruction and 
software were used to quantify, in a blinded fashion, 
the attenuation values of all the pixels on each scan 
so that pixels with abnormally low attenuation, 
that represented emphysematous lung (attenuation 
volume below ï950 HounsÀeld Units), could 
be discriminated from normal lung by a discrete 
emphysema score.
Results: Of the 185 individuals, 31.4% were 
females, 90.3% African-Americans, 8.7% Caucasian, 
and 1.1% Hispanic. The median age at enrolment 
was 48 years, and the median number of pack-years 
was 34. Non-calciÀed nodules 4mm were detected 
in only 4 participants (2.1%) by prevalent CT and no 
new nodules were observed on incident scans. Only 
one patient with biopsy proven NSCLC was detected 
and this was a large hilar mass seen on incident 
scanning (0.94%). The stage of the NSCLC at the 
time of CT detection was advanced. No biopsies 
were undertaken for benign disease. Additional CT 
Àndings of clinical importance were noted in the 
chest in 132 (71.7%) patients and extrathoracically in 
30 (16.3%) of patients, respectively. On the prevalent 
scans, the median emphysema attenuation score for 
the screened HIV smokers without malignancy was 
1.09% (range, 0.43-22.8%) whereas the single HIV 
patient with NSCLC had an emphysema attenuation 
score of 25.2%. The patient with NSCLC had a 35 
pack year smoking history.
Conclusion: This is the Àrst reported CT lung 
cancer screening trial in HIV smokers. Our results 
show that not only is CT screening feasible in an 
urban population of smokers with HIV, but also 
that the rate of lung cancer detection is in line 
with other single arm CT screening studies in HIV 
indeterminate patients. Our preliminary data of 
quantiÀable CT emphysema attenuation scores 
generate a future exploratory hypothesis that the 
susceptibility of a HIV patient to lung damage by 
cigarette smoking may be a predictor of risk of 
developing subsequent NSCLC.
Keywords: HIV, Non small cell lung cancer, CT 
screening
National Cancer Registry of Ireland. Twenty Àve 
percent of referrals will require ongoing assessment 
for pulmonary nodules. This will pose signiÀcant 
challenges with regards workload for the service in 
the future. 
Keywords: Epidemiology, Patient outcomes, 
Multidiplinary Team, Rapid access lung cancer clinic
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P4.028 PRELIMINARY RESULTS FROM 
A FOUR YEAR LONGITUDINAL CHEST 
CT SCREENING STUDY FOR LUNG 
CANCER IN AN URBAN COHORT OF HIV 
HEAVY SMOKERS
Alicia Hulbert1, Craig Hooker1, Travis Brown1, 
Karen Horton2, John Wrangle1, Elliott Fishman2, 
Kristen Pelosky1, Marian Rutledge1, Beverley Lee1, 
James Shin1, Alli Brocker3, Celis Sam1, Genevieve 
Pridham1, Richard Moore4, Jeanne Kuruly4, James 
Herman1, Gary Taylor5, Robert Brown6, Malcolm V. 
Brock7 
1Oncology, John Hopkins University/United States 
Of America, 2Radiology, John Hopkins University/
United States Of America, 3Physiology, John 
Hopkins Universtiy/United States Of America, 
4Medicine, John Hopkins University/United States 
Of America, 5Infectious Desease, Univerity Of 
Maryland/United States Of America, 6Anestesiology, 
John Hopkins University/United States Of America, 
7Surgery, Johns Hopkins University/United States Of 
America
Background: Within the HIV population, 
the incidence of non small cell lung cancer 
(NSCLC) is estimated to be 2-4 times that of the 
general population. Of the non AIDS associated 
malignancies, lung cancer is the leading cause of 
death among HIV patients who develop malignancy 
because of its advanced stage at presentation. The 
United States National Lung Cancer Screening 
Trial recently reported a 20% reduction in mortality 
for heavy smokers undergoing low dose computed 
tomography (CT) screening, but individuals with 
HIV diagnosis were excluded. We report the results 
of a single arm observational pilot study of lung 
cancer CT screening in a cohort of HIV who are 
heavy smokers that explores the efÀcacy of CT 
screening to detect lung cancer at an earlier stage in 
HIV patients.
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care standards. A T test was used to evaluate the 
differences in T1 and T2 between the two groups.
Results: From an initial population of 151 newly 
diagnosed lung cancer cases, a total of 128 patients 
were eligible after exclusion criteria were applied. 
T1 (suspicion to diagnosis) pre-LNC was 53 days 
and post-LNC was 35 days (P=0.04). T2 (diagnosis 
to treatment) pre-LNC was 32 days and post-LNC 
was 38 days (P=0.39). The available national VA 
quality indicator rates indicate a median time from 
initial suspicion of lung cancer and a pathologic 
diagnosis of 32 days, and from diagnosis to initial 
treatment of 35 days.
Conclusion: The creation of a dedicated lung 
nodule clinic in the SLVHCS improved signiÀcantly 
the timeliness of lung cancer diagnosis making 
our center comparable with the national VA 
standards despite of the disrupted infrastructure as a 
consequence of hurricane Katrina.
Keywords: Lung cancer, diagnosis, TIMELINESS
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 4 – Early Detection and Screening Thursday, 7 July 
2011 10:00-12:30
P4.030 TERT PROMOTER 
METHYLATION IN BLOOD SAMPLES AS 
LUNG CANCER RISK MARKER?
Narek Sarkisyan1, David Scherf1, Woolfgang 
Hagmann1, Thomas Muley2, Michael Meister2, 
Hendrik Dienemann3, Michael Thomas4, Rudolf 
Kaaks5, Christoph Plass1, Angela Risch1 
1Epigenomics And Cancer Risk Factors, German 
Cancer Research Center/Germany, 2Translational 
Research Unit, Thoraxklinik/university Of 
Heidelberg/Germany, 3Dept. Of Surgery, 
Thoraxklinik/university Of Heidelberg/Germany, 
4Thoracic Oncology, Thoraxklinik/university Of 
Heidelberg/Germany, 5Cancer Epidemiology, 
German Cancer Research Center/Germany
Background: The identiÀcation of lung cancer risk 
groups is an important prerequisite for successful 
lung cancer screening programmes. Lung Cancer 
genome-wide association (GWA) studies have 
identiÀed TERT as a candidate lung cancer 
susceptibility gene, but the causal mechanisms have 
not yet been identiÀed. Epigenetic mechanisms 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.029 IMPACT OF LUNG NODULE 
CLINIC IN TIMELINESS OF LUNG 
CANCER, DIAGNOSIS AND TREATMENT
Guillermo J. Arias Howard1, Jaime Palomino2 
1Pulmonary And Critical Care, Tulane University 
Medical Center/United States Of America, 
2Pulmonary, Critical Care And Environmental 
Diseases, Southeast Louisiana Veterans Healthcare 
System. Tulane University/United States Of America
Background: Following hurricane Katrina, the New 
Orleans VA Medical Center outpatient pulmonary 
clinic was not reopened until late 2006. Many 
challenges in the care of patients with suspicious 
Àndings for lung cancer were found in the years 
following this natural disaster. The need to outsource 
diagnostic procedures and some radiographic 
evaluations caused a signiÀcant delay in the 
diagnosis and treatment of this disease. A pulmonary 
lung nodule clinic (LNC) was created in the fall of 
2009 to centralize, expedite and direct the care of 
patients with suspicion of lung cancer. Our study 
is aimed to measure the impact of this clinic in the 
timeliness of diagnosis and treatment of lung cancer 
and to compare these results with the correspondent 
national VA standards in quality of care.
Methods: A retrospective chart review was 
performed for lung cancer cases diagnosed in the 
Southeast Louisiana Veterans Health Care System 
(SLVHCS) from 2007 to 2010. Cases were divided 
in two groups: pre-lung nodule clinic (January 2007 
to September 2009), and post-lung nodule clinic 
(October 2009 to 2010). Primary outcomes consist 
of two quality indicators addressing timeliness of 
care for all incident lung cancer cases: Time from 
suspicion to diagnosis (T1) and time from diagnosis 
to treatment (T2). Inclusion criterion was a new 
lung cancer diagnosis during the above-mentioned 
time in the SLVHCS general pulmonary and Lung 
Nodule clinics. Exclusion criteria were: absence 
of pathologic conÀrmation, and a non-diagnostic 
biopsy result. Data was reviewed for comparison of 
T1 and T2 between pre and post Lung Nodule Clinic 
creation, and with available national VA lung cancer 
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John D. Minna5, Karen Kelly6, Jenny Mao7, Pierre P. 
Massion8, David O. Wilson9, Fred R. Hirsch3, Paul 
Bunn2, Mark W. Geraci2, John K. Kittelson3, Robert 
L. Keith1 
1Division Of Pulmonary Sciences And Critical Care 
Medicine, Veterans Administration Medical Center/
United States Of America, 2University Of Colorado 
Cancer Center/United States Of America, 3University 
Of Colorado Denver/United States Of America, 
4Pathology, Denver Veterans Affairs Medical Ctr/
United States Of America, 5Hamon Center For 
Therapeutic Oncology Research, University Of 
Texas Southwestern Medical Center/United States 
Of America, 6Uc Davis/United States Of America, 
7University Of New Mexico/United States Of 
America, 8Vanderbilt University/United States Of 
America, 9University Of Pittsburgh/United States Of 
America
Background: We conducted a multi-center, double-
blind, placebo controlled Phase II trial of iloprost in 
subjects at risk for lung cancer and found a positive 
result in the primary endpoint, average histologic 
score, in former smokers. Secondary analyses 
revealed results with potentially important design 
implications for future similar Phase II trials.
Methods: Entry criteria included: current or former 
smoker (>20 pack-years); at least mild dysplasia on 
sputum cytology; no previous history of lung cancer. 
AutoÁuorescence and white-light bronchoscopy 
was performed with 6 standard endobronchial sites 
biopsied, along with other abnormal appearing areas. 
Subjects were then randomized to oral iloprost 
(in escalating doses) or placebo for 6 months and 
a second bronchoscopy with repeat biopsy of all 
areas sampled on the Àrst bronchoscopy, as well 
as any new areas suspicious for dysplasia. The 
predetermined primary endpoint for the study was 
average bronchial histologic score (based on WHO 
classiÀcation) in all subjects, as well as in current 
and former smokers separately.
Results: The accrual goal of 152 subjects was 
reached and 125 completed both bronchoscopies 
(60/75 iloprost, 65/77 placebo). Treatment groups 
were well matched for age, tobacco exposure, 
airÁow limitation, and baseline histology. Histology 
was summarized within patients using 3 separate 
measures: average of all biopsy scores (Avg), worst 
biopsy score (Max), and dysplasia index (DI- the 
percentage of biopsies with a score of at least mild 
dysplasia). 74% of subjects had at least one biopsy 
displaying mild dysplasia (WHO score 4.0) or worse 
play an important role in mediating environmental 
inÁuences on gene expression, and promoter 
methylation is involved in lung carcinogenesis. 
TERT promoter methylation was thus investigated as 
a promising lung cancer risk biomarker.
Methods: A discovery (n=34) and a validation 
(n=48) set of non-small cell lung cancer (NSCLC) 
tumors, adjacent normal lung tissue and blood 
samples were assessed for TERT methylation and 
genotype. Additionally, comparative genome-wide 
methylation analysis after MCIp-enrichment was 
performed on blood samples from lung cancer 
cases and controls using whole genome CpG island 
arrays (Agilent). Quantitative high throughput TERT 
promoter methylation analysis using MALDI-TOF 
MS (Sequenom) was performed on DNA isolated 
from blood samples from lung cancer cases (n=866) 
and controls without lung cancer (n=506).
Results: TERT promoter hypermethylation was 
observed in tumors vs. adjacent normal lung tissue 
(p<001). Methylation at one TERT promoter 
CpG unit was signiÀcantly correlated with the 
genotype at rs421629 (p=0.002). In blood samples 
of cases compared to controls, the TERT amplicon 
investigated showed a statistically signiÀcantly 
increased average methylation (p<0.0001). In the 
genome-wide blood-DNA methylation screen, TERT 
was one of the genes identiÀed as differentially 
methylated between cases and controls.
Conclusion: The association of tumor-speciÀc TERT 
methylation with TERT genotype points to a possible 
mechanism of the association with lung cancer risk 
for this GWA-identiÀed susceptibility locus. Our 
Ànding of signiÀcantly increased methylation in 
blood samples from lung cancer cases vs. controls 
makes TERT methylation a potentially interesting 
epigenetic marker for early diagnosis and/or lung 
cancer risk.
Keywords: methylation, epigenetics, NSCLC, lung 
cancer risk
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P4.031 ILOPROST IMPROVES 
ENDOBRONCHIAL DYSPLASIA IN 
FORMER SMOKERS: IMPLICATIONS 
FOR PHASE II CHEMOPREVENTION 
TRIAL DESIGN
York E. Miller1, Patrick J. Blatchford2, Wilbur 
Franklin3, Timothy C. Kennedy3, Daniel Merrick4, 
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evaluate the possible inÁuence of air pollutants on 
the incidence rate of lung adenocarcinoma. 
Methods: The study included 8 counties of 
the Center of Portugal, where information on 
concentrations of air pollutants was available. We 
collected data on air pollutants (NO
2
, NO, NOx, 
SO
2
, O
3
 and CO) from 1999-2008 and correlated 
it with the incidence rates of lung adenocarcinoma 
in the same period. Statistical analysis consisted of 
Spearman correlation between the average levels 
of air pollutants and the incidence rates of lung 
adenocarcinoma. 
Results: There was a positive correlation between 
NO
2
 concentrations and adenocarcinoma incidence 
rates in one county (correlation coefÀcient = 0,900; 
95% CI). On the other hand, we observed a negative 
correlation between O
3
 average levels and the 
incidence of this type of lung cancer (correlation 
coefÀcient = - 0,857; 95% CI). The inÁuences 
of NO, NOx, SO
2
 and CO were not statistically 
signiÀcant. 
Conclusion: Although we observed signiÀcant 
correlations between NO
2
 and O
3
 concentrations and 
the incidence rate of lung adenocarcinoma, the study 
does not allow us to conclude that there is a causal 
relationship. The retrospective nature of the study 
and the size of the sample are important limitations 
and results must be interpreted with caution. 
Keywords: lung adenocarcinoma, air pollutants
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P4.033 CANCER WAITING TIMES: 
ASSESSMENT OF ONE MONTH WAIT 
TARGET FROM DIAGNOSIS TO 
TREATMENT OF ALL CANCERS IN 
ENGLAND
Aiza Jamil, B. Prathibha 
Medicne, East Kent Hospitals NHS Trust/United 
Kingdom
Background: Over the last few years, National 
Health Service (NHS) in UK has focussed its 
attention on reducing waiting times of all the 
cancer patients. The NHS cancer plan 2000 lays out 
the ways of improvement. By 2008, the ultimate 
target was that no patient should wait longer than 
one month from an urgent referral by their GP for 
suspected cancer to the start of treatment. 
Methods: Data regarding all cancer patients 
including breast, lung, upper and lower GI, 
on initial bronchoscopy. A reproducibility study 
with two independent pathologists demonstrated 
that 85% of readings were within one histologic 
grade. Baseline histology was signiÀcantly worse 
for current smokers (Avg 3.0) than former smokers 
(Avg 2.1). Former smokers receiving oral iloprost 
exhibited a signiÀcant improvement in Avg (-.41, p 
= 0.01), Max (-1.10, p = 0.002) adn DI (-12.45%, 
p = 0.006). No histologic improvement occurred 
in former smokers. PrespeciÀed secondary analyis 
restricted to only the 6 standard sites demonstrated 
similar outcomes to all site analysis, demonstrating 
that in this Phase II trial, autoÁuorescence 
bronchoscopy was not necessary for achieving 
a positive outcome. Restricting the analysis 
to sites sampled on both the Àrest and second 
bronchoscopies resulted in a similar treatment effect. 
The largest treatment effects were achieved when 
analysis was restricted to non-normal sites that were 
sampled on both bronchoscopies, but this analysis 
is biased towards a faveorable treatment effect as 
normal biopsies that progress to abnormal were 
excluded.
Conclusion: Oral iloprost signiÀcantly improves 
endobronchial dysplasia in former smokers. 
Secondary analysis demonstrates that in this trial 
autoÁuorescence bronchoscopy was not required 
for achieving a positive outcome, possibly due to 
prespeciÀcation of at least 6 biopsy sites and the high 
incidence of dysplasia in this population. It remains 
to be proven whether histologic summarization 
measures will predict a true chemopreventive effect 
in Phase III trials, but Max exhibited the largest 
treatment effect and therefore might be the preferable 
primary endpoint.
Keywords: prostacyclin, chemoprevention, Lung 
cancer, premalignancy
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P4.032 LUNG ADENOCARCINOMA 
INCIDENCE RATES AND THEIR 
RELATION TO AIR POLLUTION
Cristina P.C. Azevedo, Emanuel Jesus, Maria 
Portela, Helena Gervásio 
Medical Oncology, Portuguese Oncology Institute Of 
Coimbra/Portugal
Background: There may be a relationship 
between air pollution and the incidence of lung 
adenocarcinoma. The objective of this study is to 
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must be met for 95% of all patients covered by the 
target. These new targets have to be achieved from 
October – December 2011.The recommendations 
made to achieve the target are development and 
implementation of effective clinical pathways across 
organisational boundaries and sustainable delivery 
by continuous development of data management 
system so that resources are not diverted and data 
capture is complete and as robust as possible. . 
Keyword: Cancer Waiting Times
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P4.034 FAMILY HISTORY OF LUNG 
CANCER AMONG CHILDREN WITH 
ACUTE LEUKEMIA
Nataliya Kitsera1, Romana Polishchuk2 
1Epidemiology, Institute Of Hereditary Pathology/
Ukraine, 2Regional Specialized Children’s Clinic, 
Lviv, Ukraine/Ukraine
Background: Family history of cancer may 
represent shared genetic and environmental risk 
factors for leukemia.
Methods: We examined associations of family 
history of lung cancer among children acute 
leukemia incidence (main group) by using data 
on 192 patients identiÀed at diagnosis and 192 
population-based controls in the West Ukraine (Lviv 
region) during 1995-2010.
Results: In 192 families with acute leukemia lung 
cancer has been met in 28 (14,6%) families from 
1 to 4 cases. In main group lung cancer families 
has been met often - 28 cases than in the control 
group - 19 cases (P<0.05) regardless of the degree of 
relationship to proband.
Among 35 relatives of probands with acute leukemia 
who have been diagnosed with lung cancer, this 
pathology was found in females in 14(40%) cases 
and in 21 cases (60%) in males. Both groups has 
been met in lung cancer 1.5 times more often in men 
than in women. In both groups, no difference was 
found for the oldest and youngest family members 
with this diagnosis (P> 0,05).
Comparing families of basic and control groups 
there wasn’t revealed signiÀcant difference for other 
families in cancer (P> 0,05).
Conclusion: As in families of maingroup lung 
cancer was detected more frequently than the control 
group, we can assume that carcinogenesis in the 
group with acute leukemia in children a slightly 
skin, gynaecological, urological, head and neck, 
haematological malignancies, children’s cancers, 
sarcomas and others in England were collected 
from the department of health records. All cancer 
patients treated during the period (Oct. 2007 to Oct. 
2008) which fall under the category of one month 
wait target were counted. This also included the 
total number of patients treated during the quarter 
by referral type i.e. urgent GP and other referrals in 
England. The data were analyzed using the excel 
spread sheets. 
Results: Based on all the urgent GP referrals, 80% 
were received with in 24 hours. The highest number 
of referrals were received for breast cancer followed 
by lower GI, skin, lung and head and neck cancers. 
The percentage compliance of 31 day target in 
these cancers was 98-99%. The rest of 19% urgent 
referrals which were received after 24 hours had 
percentage compliance of 90% in 2007 and early 
2008 but was noted to be improved to 94% in the 
last quarter of 2008. The referrals which did not 
meet the target were mainly dermatological followed 
by breast, lower GI, urological, gynaecological and 
head and neck. 
Conclusion: Around 220,000 people are diagnosed 
with cancer each year in England, and the disease 
causes more than 128,000 deaths. The total number 
of new cases of cancer is increasing by 1.4% per 
year, as the UK’s ageing population grows. The NHS 
Cancer Plan (2000) proposed that targeting ‘cancer 
waiting times’ and providing referral guidelines 
would lead to an improvement in the outcome of 
patients with cancer. The 31 day target is indeed a 
challenging target and it has certainly highlighted 
and focused on those patients who have been given 
the diagnosis so that the treatment could be initiated 
as quickly as possible After taking into account of 
the statistics, Better Cancer Care – An Action Plan 
was launched in October 2008. Central to this is 
development of a comprehensive programme of 
work to assure the quality of care delivered. Two 
key and complimentary strands of this work are 
assuring compliance with national clinical standards 
and guidelines through robust clinical governance 
and delivery of two new cancer targets, one of 
which is 31-day target from decision to treat to Àrst 
treatment for all patients diagnosed with cancer 
irrespective of their route of referral and has been 
expanded to cover subsequent treatments for all 
cancer patients including those diagnosed with 
recurrence. The agreed tolerance level is 5% for 
each of these targets, that is the stated waiting time 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1403
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
prevention need to be emphasized locally, nationally 
and internationally to control lung cancer. The 
extensive information, education and behaviour 
change communication campaign should be 
conducted by the district health authority with great 
emphasis laid on young people and school children. 
The local political system should actively participate 
in the implementation of legislative and restrictive 
measures. The de-addiction campaign should be 
conducted every month in the district. The national 
and international coordination and commitment is 
necessary to continue research on different methods 
of smoking cessation. The screening for lung cancer 
is not feasible and lack potential for reducing 
mortality than primary prevention. Therefore, mass 
screening for lung cancer is not recommended as a 
routine public health policy. 
Keywords: Epidemiology, Lung cancer, control
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P4.036 DESCRIBING TREATMENT, 
TREATMENT OUTCOMES, RESOURCE 
USE AND QUALITY OF LIFE OF 
ADVANCED NSCLC PATIENTS - THE 
LUNG CANCER ECONOMICS AND 
OUTCOMES RESEARCH (LUCEOR) 
STUDIES
Gerarda J.M. Herder1, Jason Agulnik2, D. Amadori3, 
Melvin Chin4, Christos Chouaid5, Lars Ek6, Jason 
Lester7, Carsten Ziske8, Jennifer Eriksson9, Henrik 
Finnern10, Johan Vansteenkiste11 
1Antonius Ziekenhuis, Antonius Ziekenhuis/
Netherlands, 2Pulmonary Oncology, Jewish 
General Hospital/Canada, 3Unità Di Biostatistica 
E Sperimentazioni Cliniche, Istituto ScientiÀco 
Romagnolo Per Lo Studio E La Cura Dei Tumori/
Italy, 4Medical Professorial Unit, Prince Of Wales 
Hospital/Australia, 5Chu Saint Antoine/France, 
6Skane University Hospital/Sweden, 7Clinical 
Oncology, Velindre Cancer Centre/United Kingdom, 
8Hämatologisch-onkologische Schwerpunktpraxis, 
St. Joseph-hospital/Germany, 9Innovus, Innovus/
Sweden, 10Boehringer Ingelheim Gmbh/Germany, 
11Respiratory Oncology Unit, University Hospital 
Gasthuisberg/Belgium
Background: Non-small cell lung cancer (NSCLC) 
is the most common type of lung cancer. Published 
international, comparative, real-life data on 1) 
NSCLC treatment patterns, 2) treatment outcomes, 
different way than in population. It is likely that the 
mutation that runs cancer in children, focusing on 
other gene loci than the general population.
Keywords: Lung cancer, acute leukemia, children, 
family
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P4.035 EPIDEMIOLOGY OF LUNG 
CANCER CASES IN A TERTIARY CARE 
CANCER HOSPITAL - SOUTH INDIA
Sanjay M. Pattanshetty 
Public Health, Manipal University/India
Background: Lung cancer is a major Public 
health problem in developed countries. The 
epidemiological cause for the increase in lung cancer 
cases for the past 10 years is mainly due to lifestyle 
factors, tobacco smoking and air pollution due to 
urbanisation and industrialisation. The lung cancer 
cases in developing countries are increasing every 
year. This is due to the tobacco smoking habit, and 
smoking for long duration. Globally, 85% of cases 
in men and 46% in women are due to smoking. In 
developed countries the proportions are 91% for men 
and 62% for women and in developing countries 
76% for men and 24% for women. The objective 
of our study was to see the prevalence lung cancer 
cases in the year 2010.
Methods: The study was conducted in a 300 bed 
cancer hospital attached to tertiary care teaching 
hospital located in the state of Karnataka, South 
India. The data on lung cancer cases reported in 
the year 2010 was collected from medical records 
department and analyzed using SPSS software 
version 17.0. 
Results: In the year 2010, 185 lung cancer 
cases were reported. According to the ICD-10 
classiÀcation, 98% of the lung cancer cases were 
bronchus or Lung unspeciÀed. About 1% had 
overlapping lesions. Majority (75%) of the cases 
were reported between the age group 50-70 years. 
Majority of the cases were reported among males, 
and most of them were above 50 years of age. About 
10% of the lung cancer was reported among females 
and most of the patients were less than 40 years of 
age. There was a history of multiple uses of tobacco 
& its product among 77.1% of the cases. 
Conclusion: In our study, majority of the lung 
cancer cases gave history of smoking. It is a proven 
fact that smoking leads to lung cancer. The primary 
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2Department Of Cardiothoracic And Vascular 
Surgery, University Hospital Tromsø/Norway
Background: Many lives are lost to lung cancer 
because patients are not considered for surgery or 
given appropriate surgical treatment. We explore 
trends in surgical outcomes up to recent time.
Methods: Using data from the Cancer Registry 
of Norway we analyzed outcomes and quality 
indicators of lung cancer surgery in the periods 
1994-95, 2000-01 and 2006-07.
Results: For the three study periods 12 616 cases of 
lung cancer were diagnosed. A total of 2 201 patients 
underwent surgical resection. The age distribution 
of resected patients was stable. The proportion 
of adenocarcinoma was 32% in the Àrst period, 
increasing to 44% and 42% in the following periods 
(p for trend<0.001). Surgery was performed at 24 
hospitals during the Àrst two periods and at 13 in 
the last. Resection rates varied among counties from 
7% to 31%. From the Àrst to the last period national 
resection rates increased from 16% to 19% (p for 
trend =0.001) and one year survival increased from 
73% to 82%. The proportion of resected patients in 
pStage I-II decreased from 87% to 83% (p for trend 
=0.048), the number of pneumonectomies from 
27% to 15% (p for trend<0.001) and the mortality 
rate within 30 days after surgery from 4.8% to 
3.0% (p for trend=0.072). In the Àrst two periods, 
31% of these early deaths were caused by surgical 
complications, whereas in the latter period none 
were related to the surgical procedure itself. The only 
unfavorable trend observed was the waiting time 
from the Ànal diagnostic procedure to surgery, which 
increased from 29 to 40 days throughout the periods 
(p<0.001).
Conclusion: Important aspects of lung cancer 
surgery have improved in recent years except for 
waiting times which increased.
Keyword: lung cancer surgery
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P4.038 PROGNOSTIC INFLUENCE OF 
THE SIMPLIFIED COMORBIDITY 
SCORE (COLINET) IN PATIENTS WITH 
LUNG CANCER: A POPULATION BASED 
STUDY.
David Ball1, Vicky ThursÀeld2, Louis Irving3, Paul 
Mitchell4, Gary Richardson5, Yvonne Torn-broers2, 
Gavin M. Wright6, Graham Giles2 
3) resource utilization and 4) patient reported health-
related quality of life (HRQOL) is limited. The 
LUCEOR studies will provide insight into all four 
areas of research. 
Methods: The LUCEOR-1 study will retrospectively 
collect information on healthcare resource use 
(inpatient/outpatient care, hospice care, emergency 
room visits, laboratory and mutation testing), 
treatment and treatment outcomes (tumor response, 
overall and progression free survival). Information 
will be collected from 2,200 patient charts of 
deceased advanced stage (IIIb/IV) NSCLC patients. 
The LUCEOR-2 study will prospectively collect 
HRQOL data (using the EuroQol questionnaires) 
from 720 advanced stage NSCLC patients. The 
LUCEOR studies will be conducted in 10 countries.
Results: 40 sites were recruited in Australia, Belgium, 
Canada, France, Germany, Italy, Netherlands 
Sweden, Turkey and the UK. 22 (55%) are University 
Hospitals, 12 (30%) General Hospitals, 6 (15%) 
other. On average 173 NSCLC patients (range 25-
483) are treated per site per year. 63% of all treated 
patients are stage IIIb/IV (range 30%-90%). 48% of 
patients have a performance status of 0-1 at initiation 
of Àrst line pharmacotherapy. This rate is lower in 
the UK at 30%. All but one site use CTCAE grading 
for adverse events. 90% of sites use the RECIST 
criteria to evaluate response status and 93% of sites 
assess performance status using the ECOG scale. 
Information on drug utilization, hospitalization, 
outpatient visits and adverse events was found in all 
patient records. 52.5% of sites use a combination 
of electronic and paper records, 15.0% of sites use 
electronic records only and 32.5% paper records only.
Conclusion: Sites have been found to routinely 
collect information on treatment, treatment outcomes 
and resource utilization. Differences exist in site 
designation, percentage of patients diagnosed with 
advanced NSCLC, performance status at initiation 
of pharmacotherapy and means of storing chart 
information. 
Keywords: Advanced Non-Small Cell Lung Cancer, 
chart review, Quality of Life
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P4.037 IMPROVEMENTS IN LUNG 
CANCER SURGERY
Hans Rostad1, Kristian Bartnes2, Trond-Eirik Strand1 
1Department Of Clinical And Registry-based 
Research, Cancer Registry Of Norway/Norway, 
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P=0.047) and NSCLC (HR 1.20, p=0.037). 
Conclusion: In this retrospective analysis of 
population based registry pts, SCS did not provide 
additional information beyond established prognostic 
factors in pts with lung cancer. ECOG performance 
status may be a substitute for the effect of 
comorbidity. 
Keywords: Lung cancer, prognostic factors, 
comorbidity
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P4.039 HISTOLOGICAL SUBTYPES 
OF LUNG CANCER IN OPERATED 
PATIENTS
Ints Silins1, Alvils Krams2, Maris Apsvalks1, Arta 
Sirgeda1, Aigars Petersons3 
1Department Of Thoracic Surgery, Clinic Of Tb 
& Lung Diseases/Latvia, 2Clinic Of Tb & Lung 
Diseases/Latvia, 3Riga Stradins University/Latvia
Background: Lung cancer takes the Àrst place both 
for morbidity and mortality in Latvia and worldwide. 
Adenocarcinoma becomes the most common subtype 
of lung cancer in many countries, however in Latvia 
it is squamous cell lung cancer. 
Methods: We have made a retrospective analysis of 
all lung cancer patients operated at the Department 
of Thoracic Surgery in the Clinic of Tuberculosis 
and Lung Diseases of Latvian Centre of Infectology 
between 2001 and 2010. We have analysed 
demographic data and histological subtypes of 
these operated patients and performed statistical 
analysis using Microsoft OfÀce® Exel and EpiInfo6 
statistical tools.
Results: 1198 lung cancer patients were operated 
during last 10 years: among them 262 (21.9%) 
female and 936 (78.1%) male. Mean age of female 
patients was 60.1(±11.9), but for male patients – 
61.6(±9.2) years. The highest incidence of patients 
was in age group between 61 and 70 – accordingly in 
36.3% of female and in 43.1% of male patients.
Altogether squamous cell lung cancer was diagnosed 
in 551 (46%) cases, adenocarcinoma – 384 (32.1%), 
mixed or other type of non small cell lung cancer 
– 97 (8.1%), small cell lung cancer – 90 (7.5%), 
carcinoid – 51 (4.3%), sarcoma – 14 (1.2%), other – 
11 (0.9%).
For female patients the most common subtype of 
lung cancer was adenocarcinoma (54.6%), second 
– carcinoid (14.1%) and only third – squamous cell 
1Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia, 2Cancer Council Victoria/
Australia, 3Royal Melbourne Hospital/Australia, 
4Austin Health/Australia, 5Cabrini Health/Australia, 
6St Vincent’s Hospital/Australia
Background: Many patients (pts) with lung cancer 
have smoking and lifestyle-related comorbidities 
which may affect survival independently of their 
cancer and treatment. This study was undertaken to 
determine if a SimpliÀed Comorbidity Score (SCS) 
reported by Colinet et al (Br J Cancer 2005; 93: 
1098) provided prognostic information in addition 
to the established prognostic factors (sex, stage, 
performance status, age). 
Methods: Retrospective survey of all pts identiÀed 
by the Victorian Cancer Registry who were 
diagnosed with lung cancer in the 6 month period 
1/2003- 6/2003. Data collection including prognostic 
factors, SCS, treatment given and survival was 
performed retrospectively in 2008. 
Results: There were 921 pts, and 841 (91.3%) for 
whom data were available. 63.1% were male and 
median age was 72 years (range 30-94). 89.9% had a 
tissue diagnosis, of which 86.6% were non-small cell 
(NSCLC), and 13.4% small cell carcinoma (SCLC). 
Stage group: NSCLC – I - 17.7%; II – 5.0%; III – 
25.8%; IV – 51.5%. SCLC stage: limited – 33.3%; 
extensive – 66.7%. Performance status (ECOG): 0 
– 11.5%; 1 – 35.8%; 2 – 13.0%; 3 – 14.4%; 4 5.7%; 
unknown 19.6%. Comorbidities on which the SCS 
is based were distributed: cardiovascular 54.6%; 
respiratory 38.9%; neoplastic 19.9%; renal 4.6%; 
diabetes 11.7%; alcoholism 5.5%; tobacco 83.1%. 
In pts with NSCLC, higher SCS score (>9) was 
associated with increasing stage, ECOG performance 
status, male sex, increasing age, tobacco consumption 
and not receiving treatment. On univariate analysis, 
SCS as a continuous variable had no signiÀcant 
effect on survival (p > 0.05 log rank test for trend 
both all pts and NSCLC). In all pts, an SCS score 
> 9 predicted worse survival (p=0.048), but not in 
pts with NSCLC (p=0.075). Using Cox regression, 
survival was analysed by SCS score after adjusting 
for the effect of age, sex, cell type (NSCLC, SCLC, 
no histology), ECOG performance status and stage 
for all patients and then restricted to NSCLC. As a 
continuous or dichotomous (< or > 9) variable, SCS 
was not a signiÀcant prognostic factor for all pts or 
when restricted to NSCLC. If ECOG performance 
status was removed from the model, SCS > 9 
predicted worse survival both for all cases (HR 1.17, 
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Kaplan-Meier survival analysis to compare the 
survival of patients from urban and rural areas by 
socio-economic deprivation.
Results: A high proportion of urban areas in England 
were classiÀed as deprived, and rural areas were 
mostly afÁuent. The incidence of lung cancer was 
higher in urban areas than in rural areas. However, 
when incidence between urban and rural areas was 
compared by socio-economic deprivation, this 
different disappeared. Survival from lung cancer 
was slightly higher in afÁuent areas than in deprived 
areas. Survival from lung cancer in urban and 
rural areas was similar across all socio-economic 
deprivation quintiles.
Conclusion: The difference in incidence between 
urban and rural areas can be explained by the 
differences in the distribution of socio-economic 
deprivation quintiles in the two urbanisation 
categories. When socio-economic deprivation is 
taken into account little difference is seen between 
both the incidence and survival of lung cancer in 
urban and rural areas.
Keywords: Lung cancer, urbanisation, socio-
economic deprivation, incidence and survival
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P4.041 TRENDS IN INCIDENCE OF 
SMALL CELL LUNG CANCER AND ALL 
LUNG CANCER
Sharma P. Riaz1, Margreet Lüchtenborg2, Victoria 
H. Coupland2, James Spicer2, Michael D. Peake3, 
Henrik Møller2 
1Thames Cancer Registry, King’s College London/
United Kingdom, 2King’s College London/United 
Kingdom, 3GlenÀeld Hospital/United Kingdom
Background: The incidence of small cell lung 
cancer (SCLC) is often quoted as ‘around 20%’ of all 
lung cancers but is reportedly decreasing over time. 
We analysed the trends in incidence of SCLC and 
compared these with the trends in lung cancer overall 
among males and females in South East England. 
Methods: We identiÀed 237,792 patients diagnosed 
with lung cancer (ICD-10 C33-C34) between 1970 
and 2007. We used a Poisson regression age-cohort 
model to estimate the age-speciÀc rates in the 1890 
to 1960 birth cohorts and the 1970 to 2007 calendar 
periods. We computed age-standardised incidence 
rates using the European standard population. In 
addition, we analysed the trends of lung cancer 
lung cancer (13.7%). For male patients squamous 
cell lung cancer was diagnosed most frequently 
(55%), weather adenocarcinoma was second 
(25.7%).
During last 10 years the frequency of 
adenocarcinoma has grown, and the frequency 
of squamous cell carcinoma has decreased: 
comparing the Àrst (between 2001 and 2003) and 
the last (between 2008 and 2010) 3-year periods 
the frequency of adenocarcinoma was accordingly 
22.8% and 37.9% (p<0.001), but the frequency 
of squamous cell lung cancer – 48.3% and 40.6% 
(p<0.05).
Conclusion: In operated patients during last 
10 years, squamous cell lung cancer is mostly 
diagnosed among men and all patients together, but 
adenocarcinoma – among women. We observed the 
statistically signiÀcant growth in the incidence of 
adenocarcinoma and decrease in the incedence of 
squamous cell cancer among operated lung cancer 
patients.
Keywords: Lung cancer, hystological subtypes, 
Adenocarcinoma
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P4.040 LUNG CANCER INCIDENCE AND 
SURVIVAL IN ENGLAND: AN ANALYSIS 
BY SOCIO-ECONOMIC DEPRIVATION 
AND URBANISATION
Sharma P. Riaz1, Marie Horton2, Jagdip Kang2, 
Vivian Mak2, Margreet Lüchtenborg2, Henrik Møller2 
1Thames Cancer Registry, King’s College London/
United Kingdom, 2King’s College London/United 
Kingdom
Background: Most previous studies have 
investigated either socio-economic deprivation or 
urbanisation in relation to lung cancer incidence or 
survival. We investigated the association between 
socio-economic deprivation, urbanisation and lung 
cancer incidence and survival in England.
Methods: We extracted data on patients diagnosed 
with lung cancer (ICD-10 C33-C34) between 
2003 and 2007 who were resident in England. We 
assigned each patient to an urbanisation score and to 
a socio-economic quintile based on their postcode of 
residence. We calculated age-speciÀc incidence rates 
and age-standardised incidence rates (per 100,000 
European standard population) by sex, urbanisation 
and socio-economic deprivation group. We used 
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23/33 (70%) had Stage IV, 6/33 (18%) had IIIA/B, 
and 4/33 (12%) had stage I or II. Adenocarcinoma 
was 29/33 (88%) and NOS was 4/33 (12%). Overall 
survival was 11.6 mo while survival for never-
smokers was only 10.7 months. At presentation, 
16 pts had pleural effusion (48%) and 5 (15%) had 
brain METS . No pt had adrenal METS at time of 
diagnosis. 12/13 (92%) never smokers had stage IV 
disease. 4 never smokers had a distinctive (miliary) 
pattern of innumerable small nodules. 
Smoking 
Status 
Total 
Number 
Bulky 
Pleural 
Disease 
Innumer. 
Small 
Nodules 
Other IV IIIB IIIA I/II Adeno NSC/NOS 
Never 13 7 4 2 12 0 0 1 13 0 
Former 11 6 0 5 3 4 1 3 9 2 
Current 9 6 0 3 8 1 0 0 7 2 
Conclusion: Young women with NSCLC were 
likely to have bulky advanced disease. Unlike other 
settings, non-smokers did not seem to fare better 
than current or former smokers. The miliary pattern 
of innumerable bilateral small pulmonary nodules 
was only seen in never-smokers.
Keywords: Young women with lung cancer, 
metastatic patterns
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P4.043 INITIAL SYMPTOMS AND DELAY 
BETWEEN INITIAL SYMPTOMS, 
DIAGNOSIS AND ONSET OF SPECIFIC 
TREATMENT IN ELDERLY PATIENTS 
WITH LUNG CANCER.
Etienne Giroux Leprieur, Sylvie Labrune, Violaine 
Giraud, Thierry Gendry, Daniel Cobarzan, Thierry 
Chinet 
Department Of Pulmonary Diseases, Hopital 
Ambroise Pare, Ap-hp, University Of Versailles Sqy/
France
Background: Lung cancer is the leading cause of 
death due to cancer. Epidemiological data show that 
more elderly patients are diagnosed with lung cancer. 
Methods: The objectives were to describe 1) the 
initial symptoms of lung cancer in elderly patients 
(> 75 years of age) and 2) the time between the 
initial symptoms and the Àrst visit with a thoracic 
oncologist, the time between the initial symptoms 
and the beginning of the speciÀc treatment of the 
cancer, and the time between the Àrst visit with 
a thoracic oncologist and the beginning of the 
subtypes according to morphology. 
Results: In the most recent time period, SCLC 
accounted for 10% and 11% of cases of all lung 
cancer among males and females, respectively. 
Among the morphologically speciÀed lung cancers, 
SCLC accounted for 15% and 17% among males and 
females, respectively. There was a decrease of SCLC 
incidence over time and by birth cohort in both 
sexes. The decrease in SCLC was more marked than 
that in all lung cancers. 
Conclusion: The decrease in SCLC incidence rates 
may reÁect decreases in the prevalence of cigarette 
smoking, and changes in the type of cigarettes 
smoked. 
Keywords: incidence, Small Cell Lung Carcinoma, 
Lung neoplasms, Smoking
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P4.042 YOUNG WOMEN WITH NON 
SQUAMOUS, NON SMALL CELL LUNG 
CANCER (NSCLC).
Daniel D. Karp1, Jan M. Hanneken1, S. H. Taylor2, 
Taoyan Men1, G Steinhaus1, Katherine Pisters1, 
Vassiliki Papadimitrakopoulou1 
1Thoracic/Head And Neck Medical Oncology, Ut 
M.D. Anderson Cancer Center/United States Of 
America, 2Tumor Registry, Ut M.D. Anderson Cancer 
Center/United States Of America
Background: Women under age 50 with NSCLC 
make up approximately 5% of all lung cancer in 
the U.S. These cases have a disproportionately high 
impact since patients are often raising families and in 
the most productive time of their lives.
Methods: We reviewed a cohort of young women 
with thoracic carcinoma to assess patterns of disease 
at presentation and outcome. 1450 consecutive 
unselected thoracic oncology patients treated by 
a single Oncologist (DDK) at our institution from 
2003 - 2010 were analyzed for smoking status, 
histology, stage and patterns of metastases (METS), 
and survival.
Results: A total of 51 patients seen were women 
under 50. Pts with squamous (5) and small cell (2) 
were virtually all heavy smokers. Other histologies 
(11) consisted of neuroendocrine cancer, carcinoid, 
mesothelioma, and thymoma. The remaining 33 
had ADENO or unspeciÀed non small cell (NOS). 
Smoking status was never = 13, former = 11, and 
current = 9. Age ranged from 22 to 48 (median 42). 
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more frequent in elderly patients. Diagnosis and 
treatment delays were similar in the 2 groups. 
Keywords: elderly patients, Lung cancer, initial 
symptoms
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P4.044 ADHERENCE TO ANTI-CANCER 
TREATMENT : UNIQUE STUDY 
METHOD FOR DEVELOPING NATIONS
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: Adherence to lung cancer treatment 
is complex multi-factorial issue. A clinical audit 
aims to improve patient care and outcomes through 
systematic review of care against explicit criteria. 
Very few studies done to understand this issue.
Methods: A large-scale audit was conducted to 
assess adherence to the lung cancer treatment 
guidelines. Case records of 210 lung cancer 
patients (identiÀed from patient databases and 
pharmacy records) who initiated anti-cancer 
therapy sequentially from early 2007 to late 
2010 were examined retrospectively from 4 sites. 
Information was collected on treating physician, 
patient demographics, ART regimen, and guideline 
recommendations for patient management, 
monitoring and clinical outcomes. Only data 
explicitly stated in the medical records was 
abstracted. Patient de-identiÀed information was 
entered into collective database over 3 months by 
trained data collectors. 
Results: The key changes in lung cancer therapy 
guidelines over time were summarized. This audit 
has demonstrated successful measurement of 
adherence to guidelines for lung cancer therapy 
initiation. Barriers include inadequate infrastrustre 
for such study, resource, time involved and need 
for data collectors with good lung cancer therapy 
experience and knowledge. 
Conclusion: The results of audit will enable 
feedback on clinical practice to improve patient care 
in participating sites and the audit can be repeated 
in future, perhaps in a simpliÀed format, to assess 
changes in adherence to treatment guidelines. There 
is potential to extend the guidelines audit to other 
sites that manage lung cancer in future.
Keywords: Lung cancer, adherence, therapy
treatment. These data were compared with those 
observed in younger patients (<75 years of age). 
Results: One hundred and ninety-three consecutive 
patients with lung cancer, diagnosed between 2006 
and 2008, were included. Fifty-nine (31%) were 
75 years old or older. There were 26 small-cell 
lung cancers and 167 non-small cell lung cancers 
(94 adenocarcinomas, 23 large-cell carcinomas, 
11 undifferentiated carcinomas, 36 squamous cell 
carcinomas, 2 large-cell carcinomas with neuro-
endocrine component, 1 adenosquamous carcinoma). 
We found no statistical difference in sex ratio, 
tobacco status, histological distribution, and TNM 
staging between elderly patients and other patients. 
Elderly patients had more co-morbidities (median 
Charlson score = 2 (IQR 1-3) versus 1 (IQR 0-2) 
in younger patients, p<0.001). The performans 
status (PS) was higher in the elderly group (PS 2: 
31% versus 9% in the younger patients’ group; PS 
3-4: 12% versus 5% in the younger patients’ group, 
p<0.0001). The most frequent initial manifestations 
in elderly patients were general symptoms (37%), 
cough (29%), dyspnea (29%), pain (14%), 
respiratory infection (10%). No statistical difference 
was found between the 2 groups concerning the 
symptoms, except for dyspnea (more frequent in 
elderly patients, p=0.05). Diagnosis was fortuitous 
or obtained by a screening test in 20% elderly 
patients vs 24% in younger patients (p=0.57). The 
delay between the initial symptoms and the Àrst visit 
with a thoracic oncologist was similar between the 
2 groups (median of 1.1 months [IQR 23 days – 3 
months] in elderly patients vs 1.4 months [IQR 19 
days – 3 months], p=0.99). The time between the 
initial symptoms and the beginning of the speciÀc 
treatment of the cancer was similar in the 2 groups 
(median 2.5 months [IQR 1.7 months – 5.8 months] 
in elderly patients versus 2.7 months [IQR 1.6 
months – 4.2 months] in younger patients, p=0.51). 
The time between the Àrst visit and the beginning 
of the treatment was also similar in the 2 groups 
(median 1.2 months [IQR 20 days – 2.1 months] 
versus 1.1 months [IQR 14 days – 1.9 months], 
p=0.35). These three time periods did not differ 
between the 2 groups, irrespective of the histological 
type and the staging. Eighty percent of elderly 
patients were actively treated with chemotherapy, 
surgery and/or radiotherapy, compared with 98% of 
younger patients (p<0.0001). 
Conclusion: We found no difference regarding the 
initial symptoms of lung cancer between elderly and 
younger patients in our population, except dyspnea, 
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patient histotype age atdiagnosis gender 
smoking
habit 
clinical
trials 
biomolecular
features 
1 adenocarcinoma 37 F no yes NA 
2 adenocarcinoma 35 M no yes NA 
3 adenocarcinoma 34 M current yes NA 
4 squamous ca 39 F current no NA 
5 adenocarcinoma 33 M current no EGFR+ 
6 adenocarcinoma 36 M current yes NA 
7 squamous ca 38 M current no NA 
8 adenocarcinoma 39 M no no EML4/ALK+ 
9 MPM 35 M former no NA 
10 adenocarcinoma 36 M no no EGFR- 
11 adenocarcinoma 39 F current yes NA 
12 SCLC 39 F no yes NA 
Conclusion: pts aged 15 to 18 years are unlikely 
to have tumour biology or host physiology that is 
different from those over age 18, yet they usually 
are excluded from Àrst line adult drug development 
studies. Furthermore, while nearly all paediatric 
cancer treatment trials include pts at least to age 
18, a 15 year-old have a disease that is not covered 
by paediatric trials but is ineligible for adults trials 
and the same could happen for young adult pts. A 
dedicated database would be the Àrst step to better 
understand cancer biology and speciÀc features of 
those cancers that occur in this age group, with the 
purpose to develop more speciÀc approaches to these 
pts and personalized clinical trials. 
Keywords: thoracic malignancies, young patients
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P4.046 THE CHANGING LUNG CANCER 
INCIDENCE IN HEALTH AREA NINGBO 
, CHINA
Xi Wei Wang1, Xuan Jun Dong2 
1Nurse Administration, Ningbo No.2 Hospital/China, 
2Disease Prevention Department, Zhenhai Center Of 
Disease Control/China
Background: A previous study demonstrated that 
lung cancer incidence in Ningbo area had increased 
in the past years. We expanded the original data 
set to determine if this increase had continued 
between 2007 and 2010. Objective of this study is to 
identify incidence, mortality rate and characteristic 
of diagnosed lung cancer, and to estimate whether 
it develop work load to health organizations and 
inÁuence health beneÀt. 
Methods: A retrospective observational study 
based on hospital admission/discharge records 
and pathological department data on lung cancer 
was brought to Ningbo No.2 Hospital between 
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P4.045 IMPROVING CLINICAL 
RESEARCH, RESOURCES, SUPPORT 
SERVICES AND HEALTH RELATED 
QUALITY OF LIFE IN AGE-SPECIFIC 
THORACIC CANCER PATIENTS
Tiziana Vavalà1, Antonio M. Alberti2, Valentina 
Monica1, Matteo Giaj Levra1, Enrica Capelletto1, 
Simonetta G. Rapetti1, Maria V. Pacchiana1, Silvia 
Novello1 
1Department Of Clinical And Biologica Sciences, 
University Of Turin, Aou San Luigi/Italy, 2Uoc 
Oncologia Medica, Sandro Pertini Hospital, Rome/
Italy
Background: A retrospective analysis was done 
at M. D. Anderson from 1985 until 1994. The 
comparison between 157 patients (pts) younger 
than 40 years with adenocarcinoma of the lung 
and the counterpart older than 50 years with the 
same diagnosis didn’t show any differences in the 
outcome of the disease in terms of overall survival 
or progression-free survival. As a conclusion authors 
stated that these pts should be treated similarly to 
older pts. However, the common perception is that 
this is a distinct category of pts, who requires a 
different approach during diagnosis and treatment, 
mainly due to a complex psychological environment. 
Unlike paediatric cancer pts, few young adults 
with lung cancer are involved in clinical trials. 
Furthermore, only 20 to 35% of pts between 15 to 
19 years are treated at institutions that are involved 
in NCI-sponsored treatment clinical trials and only 
10% of them are enrolled in trials. By contrast only 
1 to 2% of pts aged between 20 to 39 year-old are 
entered into NCI-registered clinical trials taking into 
consideration that this small percentage could be 
due to the fact that few clinical trials are available 
for this category of pts. To overcome this limit and 
to enhance understanding biological features we 
planned to create a database dedicated to young pts 
with thoracic malignancy. 
Methods: We performed a retrospective analysis at 
the Thoracic Oncology Unit of San Luigi Hospital 
from 2007, January the 1st to 2010, December the 
31st, identifying 12 pts with thoracic carcinoma aged 
between 15-39 year-old. 
Results: In this population, mean age was 36 years 
old. 
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Keywords: Lung cancer Incidence, Work load, 
mortality, health beneÀt
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 4 – Epidemiology Thursday, 7 July 2011 10:00-12:30
P4.047 MODIFICATION OF LUNG 
CANCER IN A FRENCH MONOCENTRIC 
COHORT BETWEEN 1990 AND 2010
Fabien L. Vaylet1, Jacques Margery1, Alexa 
Mairovitz1, Herve Le Floch1, Frederic Riviere1, 
Ignes N’gampolo1, Wanda Gaspard1, Francois Pons2, 
Rene Jancovici2, Jean Philippe Arigon2, Patrick 
Saint Blancard3, Claude Marotel1, Jean-Christophe 
Pouget4, Pierre L’Her1 
1Lung Disease, Hia Percy/France, 2Surgery, Hia 
Percy Clamart/France, 3Pathology, Hia Percy 
Clamart/France, 4Oncologie Post-amm, Pierre 
Fabre Médicament/France
Background: Authors report the analysis of 
monocentric cohort of 1400 patients with lung cancer 
followed between 01.01.1990 and 31.12.2009. 
Methods: 
Cohort 1990-1994 1995-1999 2000-2004 2005-2009 Global 
Sex-ratio M/F 7.3 3.6 2.9 2.7 3.3 
Median age 63 65 65 67 65 
Non smoker 4 % 8 % 8 % 12 % 8 % 
Adenocarcinoma 30 % 39 % 52 % 57 % 47 % 
Epidermoid 41 % 32 % 23 % 19 % 27 % 
Small cell 10 % 10 % 9 % 8 % 9 % 
Stade I 17 % 29 % 22 % 22 % 23 % 
Stade II 9 % 8 % 4 % 4 % 6 % 
Stade III 40 % 35 % 25 % 24 % 28 % 
Stade IV 32 % 29 % 44 % 50 % 40 % 
Diagnosis by endoscopy 73 % 60 % 43 % 44 % 52 % 
Diagnosis by punction 3 % 9 % 21 % 21 % 15 % 
Results: This cohort is the largest single center in 
French literature. The analysis over 20 years shows 
epidemiological and histological changes.
Conclusion: This analysis shows the increase of 
adenocarcinoma with increase of female patients, 
of non smoker-status and increase of diagnosis by 
TDM punction. Non small cell is stable. Median age 
of diagnosis is a little bit increasing. The increase of 
stage IV and the decrease of stage III is due to a best 
staging with the routine use of PET and Brain RMI 
procedures since 2000. 
01/01/2007 and 31/12/2010. 
Results: According to the hospital data the number of 
diagnosed lung cancer carried to Ningbo No.2 Hospital 
was 1605 during study period. Of all malignant tumor 
(10139) collected, 15.8% were lung cancer which 
ranked the highest in every study year. Average age 
of the sample was 62.2 years .The incidence of lung 
cancer was Áuctuated from 367 (2009) to 440 (2008) 
in the hospital records, 371(2007) and 427 (2010) 
respectively. Mortality rate was from 20.8% (2010) to 
35.9% (2008) .General bed occupancy of lung cancer 
were 32597 days which possessed 14.78 % among all 
hospitalized patients during study years. Referring to 
the pathological department data only 822 cases were 
diagnosed as lung cancer which represents just 51.2% 
of the admission/discharge data (1605) at the same 
period. Proportion of diagnosed lung cancer cases 
was unbelievably low .The main reason for the above 
difference between hospital admission/discharge data 
and pathological department is found to be that the 
number of post operated patients from other health 
organizations and chemotherapy cases were not taken 
into account at pathology departments. According to 
pathological records, male to female ratio was 2.2 (567) 
: 1 (255). A signiÀcant rise was observed in women in 
2010( 83) comparing those diagnosed in 2007(38) , 
men patients were increased 1.88 times from the Àrst 
year (109) to fourth year(202).Of all ages the most 
popular group happened to 50-60 years (278/33.8%) 
and 60-70 years (269/32.7%) . There was no signiÀcant 
difference in average age in each study year. According 
to the pathological analysis, the most frequent 
histological characteristics were adenocarcinoma 
(50.3%/413) and squamous cancer ( 28.4%/233).Only 
22 females in squamous within 4 years, however, the 
number of females (168) were close to males(132) in 
adenocarcinoma cases. 
Conclusion: Lung cancer is a health problem of the 
Àrst order in Ningbo area, results reveal that lung 
cancer remains to be the leading cause of cancer 
death in both men and women, female victims 
increased dramatically in malignant tumors. Lung 
cancer has resulted in a big workload of Ningbo 
No.2 hospital. Mean age of the appearance of the 
disease was within the national range, the majority 
of the cases being age over 50 years. The most 
common histology type was adenocarcinoma cell 
carcinoma. With a sustained burden of lung cancer 
pro jected for the coming years, a method of early 
detec tion that could effectively reduce incidence and 
mortality from lung cancer would potentially have an 
enormous public health beneÀt. 
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*InsufÀcient delay. The period analysis shows an 
improvement in relative survival at 5 years by stage. 
Relative Survival at 5 years 1990-1994 1995-1999 2000-2004 
Stage I 57 % 65 % 64 % 
Stage II 37 % 28 % 47 % 
Stage IIIA 8 % 20 % 35 % 
Stage IIIB 7 % 8 % 26 % 
Stage IV 0 % 1 % 5 % 
Conclusion: This analysis shows a very interesting 
increase of the relative survival of lung cancer 
patients since 1990, global and by stage (1997 WHO 
ClassiÀcation). 
Best staging by PET and RMI and best medical 
strategies explain this results, specially for Stage III 
and Stage IV: An Hope for this pathology 
Keywords: Lung cancer, Epidemiology, survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.049 IMPROVEMENT OF THE 
SURVIVAL OF STAGE IV LUNG CANCER 
IN A FRENCH MONOCENTRIC COHORT 
BETWEEN 1990 AND 2010. AN HOPE.
Fabien L. Vaylet1, Jacques Margery1, Alexa 
Mairovitz1, Ignes N’Gampolo1, Herve Le Floch1, 
Frederic Riviere1, Wanda Gaspard1, Jean Philippe 
Arigon2, Francois Pons2, Rene Jancovici2, Patrick 
Saint Blancard3, Nadine Nouken Siewe4, Claude 
Marotel1, Pierre L’Her1 
1Lung Disease, Hia Percy/France, 2Surgery, Hia 
Percy Clamart/France, 3Pathology, Hia Percy 
Clamart/France, 4Institut De Recherche Pierre 
Fabre/France
Background: Authors report the analysis of relative 
survival of stage IV patients from a monocentric 
cohort of 1400 patients with lung cancer followed 
between 01.01.1990 and 31.12.2009. 
Methods: The analysis is done for 367 patients stage 
IV on the 991 lung cancers diagnosed (1997WHO 
ClassiÀcation), over only the period 1990-2004 to 
have a sufÀcient delay. 52 % are adenocarcinomas, 
15 % squamous, 10 % large cell and 16 % small cell. 
Sex ratio Male/Female is 3. Median age is 63 years. 
9 % are non smoker status. Diagnosis is obtained by 
Keywords: Lung cancer, Epidemiology, histology
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.048 SURVIVAL OF LUNG CANCER 
IN A FRENCH MONOCENTRIC 
COHORT BETWEEN 1990 AND 2010: 
IMPROVEMENT AND HOPE.
Fabien L. Vaylet1, Jacques Margery1, Alexa 
Mairovitz1, Frederic Riviere1, Herve Le Floch1, 
Ignes N’Gampolo1, Wanda Gaspard1, Francois Pons2, 
Jean Philippe Arigon2, Rene Jancovici2, Patrick 
Saint Blancard3, Claude Marotel1, Jean-Christophe 
Pouget4, Pierre L’Her1 
1Lung Disease, Hia Percy/France, 2Surgery, Hia 
Percy Clamart/France, 3Pathology, Hia Percy 
Clamart/France, 4Oncologie Post-amm, Pierre 
Fabre Médicament/France
Background: Authors report analysis of 
monocentric cohort of 1400 patients with lung cancer 
followed between 01.01.1990 and 31.12.2009. 
Methods: Kaplan -Meyer and Foucher methods are used.
Results: The survival with Kaplan-Meyer method is 
56 % at 1 year, 23 % at 5 years and 17 % at 10 years. 
Analysis of relative survival, taking into account 
the mortality of the general population without 
lung cancer, is 57% at 1 year, 26% at 5 years and 
22% at 10 years (Method of Foucher, on 1990-2005 
population). 
Relative Survival
at 1 year 
Relative Survival
at 5 years 
Relative Survival
at 10 years 
Stage I 94 % 76 % 64 % 
Stage II 71 % 51 % 38 % 
Stage IIIA 60 % 30 % 21 % 
Stage IIIB 56 % 22 % 16 % 
Stage IV 34 % 6 % 3 % 
The period analysis shows an improvement on 
overall relative survival. 
Relative Survival
at 1 year 
Relative Survival
at 5 years 
Relative Survival
at 10 years 
1990-1994 50 % 16 % 14 % 
1995-1999 59 % 27 % 22 % 
2000-2004 59 % 30 % * 
2005-2009 * * * 
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Background: At present a rise in oncologic diseases 
including lung cancer (LC) is associated with 
increasing environmental pollution with xenobiotics. 
Penetrating into organism xenobiotics are subjected 
to biotransformation processes. Change in the 
activity of xenobiotic biotransformation enzymes 
related to the existence of genetic polymorphism 
results in increased susceptibility of organism to 
deleterious effects and, in consequence, to a rise in 
a risk of developing various oncopathologies. One 
of the causes of tumor development is known to be 
disbalance of activation, inactivation and removal of 
toxic compounds. On this connection it is necessary 
to take into account the total contribution of 
polymorphic variants of genes encoding enzymes of 
I and II xenobiotic biotransformation phases as well 
as P-glycoprotein in detecting predisposition to LC. 
Methods: The study comprised 118 LC patients 
undergoing treatment at Minsk Oncologic Dispensary 
over the period from 2003 to 2009. The control 
group includes 329 persons without oncopathology 
permanently living in the area of Belarus. PCR-
RFLP and multiplex PCR methods were used for 
studying polymorphism of genes: CYP1A2 (C734A) 
– the activation phase; GSTT1 (deletion), GSTM1 
(deletion), NAT2 (C481T, G590A and G857A) – 
the detoxication phase and MDR1 (C3435T) – the 
removal phase. The examined individuals were 
divided into “fast” and “slow” acetylators according to 
the results of genotyping for three NAT2 sites (C481T, 
G590A and G857A). The association of genotypes 
with predisposition to LC was estimated odds ratio 
(OR) and 95%conÀdence interval (CI). 
Results: The combination of genotypes 
«734CACYP1A2/ GSTT1(+)/
GSTM1(+)/3435CTMDR1» was revealed to exert 
a protective effect when the genes CYP1A2 and 
MDR1 are represented with heterozygote and 
the genes GSTT1 and GSTM1 do not contain 
homozygous deletion. The risk of LC development 
is increased in the individuals with the genotype 
combinations «734AACYP1A2/GSTT1(-)» or 
«GSTT1(-)/3435CCMDR1». The combination 
«734AACYP1A2/GSTT1(-)/3435CC MDR1» is 
of the highest risk importance, especially when 
the carrier of such a combination is a “slow” 
acetylator. Table – The most important combination 
of polymorphic gene variants of xenobiotic 
biotransformation enzymes in formation of 
predisposition to lung cancer
endoscopy in 57 %, by pleural (7 %), parenchyma (13 
%) and metastasis (12 %) biopsies. PET-CT and Brain 
RMI are used in routine since 2000.
77 % received Àrst line chemotherapy, 46 % a second 
line chemotherapy, 6% a biotherapy (after 1995). 
Results: The global Kaplan Meyer survival of these 
patients is 31 % at one year, 5.8 % at 3 years and 
3 % at 5 years. The global relative survival, taking 
into account the mortality of the general population 
without lung cancer is 34 % at 1 year , 6 % at 3 years 
and 3 % at 5 years. The period analysis shows an 
improvement in relative survival: 
Relative Survival
at 1 year 
Relative Survival
at 3 years 
Relative Survival
at 5 years 
1990-1994 23.7 % 0 % 0 % 
1995-1999 28.2 % 2.8 % 1.4 % 
2000-2004 38.5 % 10.4 % 5.4 % 
Conclusion: The multivariate analysis made 
by the method of Cox and the Esteve shows an 
improvement of the survival respectively with 
an odds ratio to 0.79 (p = 0.0418) and 0.70 (p = 
0.0012) for the period 2000-2004 compared to 
1990 -1994. It ’s possible to explain this result by 
the best selection of patients after PET and RMI 
and by best therapeutic strategies (more of Àrst line 
chemotherapy, more of second line chemotherapy 
and beginning of biotherapy) available in the recent 
period. An hope for this pathology.
Keywords: Lung cancer, Epidemiology, survival, 
Metastasis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.050 THE INFLUENCE OF GENETIC 
POLYMORPHISM OF CYP1A2, GSTT1, 
GSTM1, NAT2 AND MDR1 ON LUNG 
CANCER PREDISPOSITION
Alena Mikhalenka1, Natalia Chakava2, Evelina 
Krupnova2, Natalia Chebotareva2, Yuri Demidchik3 
1Laboratory Of Modeling Of Genetic Processes, 
Nstitute Of Genetics And Cytology Nasb/Belarus, 
2Laboratory Of Modeling Of Genetic Processes, 
Institute Of Genetics And Cytology Nasb/Belarus, 
3Reception, Belarusian Medical Academy Of Post-
graduate Education/Belarus
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(19.8% vs. 11.1%, p = 0.005) compared to large 
bowel cancer patients. The proportion of patients 
working as industrial workers, construction workers 
or in other polluted working environment was also 
higher among lung cancer patients, as compared to 
large bowel patients (63.4% vs. 48.5%, p = 0.001). 
Especially striking is the difference in metal industry 
workers (35.3% vs. 18.2%, p<0.001). There were 
no statistically signiÀcant differences regarding 
housing conditions, family income, diet and alcohol 
consumption. The importance of smoking and 
polluted working environment was conÀrmed by a 
multivariate analysis. 
Conclusion: When compared to patients with cancer 
of the large bowel, the group of lung cancer patients 
included a higher proportion of immigrants and 
a higher proportion of those working in polluted 
environment. While there is no doubt about the role 
of smoking in lung cancer carcinogenesis, social 
factors such as pollution in the working environment 
also play a role. The inÁuence of polluted working 
environment on lung cancer incidence will be 
evaluated in detail in our future research work. In 
addition, adjusting our programmes to the needs 
of a low social class is essential for effective 
communication and should be considered when 
planning every step, from prevention to palliative 
care. 
Keywords: social status, Epidemiology, Lung 
cancer, colon cancer
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P4.052 FEMALE LUNG CANCER: RE-
ANALYSIS OF NATIONAL SURVEY OF 
LUNG CANCER IN KOREA, 2005
Tae Won Jang1, Young-Chul Kim2, Euntaik Jeong3 
1Internal Medicine, Kosin Medical College/Korea, 
2Lung Cancer Clinic, Chonnam National University 
Hwasun Hospital/Korea, 3Internal Medicine, 
Wonkwang University Hospital/Korea
Background: Female lung cancers have different 
clinical features and therapeutic results. The aim of 
this study was to analyze the differences in between 
women and men in Korean lung cancer.
Methods: We re-analyzed the result of national 
survey of lung cancer conducted by Korean 
Association for the Study of Lung Cancer (KASLC) 
at 2005.
Results: Of the 8,788 patients, 2,124 (24.2%) were 
Genotype OR (95%CI) 
734CACYP1A2/GSTT1(+)/ GSTM1(+)/ 3435CTMDR1 0,37 (0,16-0,91) 
734AA CYP1A2/GSTT1(-) 3,26(1,61-6,60) 
GSTT1(-)/ 3435CC MDR1 3,63 (1,33-9,96) 
734AA CYP1A2/GSTT1(-)/3435CC MDR1 11,37 (2,25-57,39) 
734AA CYP1A2/GSTT1(-)/”slow” acetylator/ 3435CC MDR1 15,49 (1,71-110,56) 
Conclusion: Thus, the study of genetic 
polymorphism of enzymes at all phases of xenobiotic 
biotransformation in an individual increases the 
degree of prognosis accuracy of his predisposition 
to LC. Association of homozygous GSTT1 gene 
deletion with predisposition to LC was detected in 
residents of Belarus. Combinations of polymorphic 
gene loci of biotransformation enzymes exert a 
modifying effect on risk importance of GSTT1 
genotype in lung cancer development. 
Keywords: Lung cancer, genetic polymorphism, 
xenobiotic biotransformation enzymes
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P4.051 LUNG CANCER AS A SOCIAL 
DISEASE
Mirjana Rajer, Matjaz Zwitter 
Department Of Radiotherapy, Institute Of Oncology 
Ljubljana/Slovenia
Background: Apart from a clear association with 
tobacco, other factors of importance for development 
of lung cancer have received little attention. We 
present a case-control study focusing on social 
variables and comparing lung cancer patients to 
those with large bowel cancer. 
Methods: The research project was carried out 
during 2009 and 2010. A written questionnaire 
was completed by 248 consecutive patients with 
lung cancer and 244 patients with large bowel 
cancer treated at our institute. The two groups 
were balanced for gender and age. Data on place 
of birth, smoking history, diet and alcohol intake, 
body weight and height, profession, housing 
conditions and family income were collected and 
analysed. Statistical analysis was performed by using 
descriptive statistics, Mann-Whitney U test, chi-
square test and logistic regression. 
Results: There were signiÀcant differences between 
the groups regarding smoking status: non-smokers 
7% vs. 52.3%, ex-smokers 70% vs. 38.6%, and 
current smokers 20.1% vs. 9.1% for lung and large 
bowel cancer respectively (p<0.001). The share of 
immigrants in patients with lung cancer was higher 
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Methods: In 2009, the Lung Cancer DPM began 
with a draft lung cancer (LC) disease pathway 
by the project’s co-chairs (WKE, YCU) and the 
establishment of Àve multidisciplinary working 
groups that focussed on prevention and screening, 
diagnosis, treatment and palliative care, end-of-life 
and survivorship, as well as a patient and family 
advisory group. Using the draft disease pathway to 
guide discussion, working groups held Àve two-hour 
meetings and developed 17 improvement project ideas 
across the patient journey. Eight of these were selected 
for detailed discussion at a provincial consensus 
conference which voted on priorities for action. 
Results: A Priorities for Action Report has been 
prepared and is being widely circulated. The LC 
disease pathway has been reÀned through substantial 
multidisciplinary discussion, which has helped to 
standardize diagnostic and treatment approaches 
across the province. Regional “roadshows” have 
commenced that share the results of the Action Report 
and present regional LC care providers with region 
speciÀc data on LC incidence, smoking rates, stage 
distribution, wait times for treatment, compliance 
with treatment guidelines, utilization of a standard 
symptom assessment instrument and metrics of the 
quality of end-of-life care. Regional cancer programs 
have been provided with funding to implement LC 
speciÀc quality improvement initiatives. In particular, 
lung cancer diagnostic assessment programs/units 
with nurse navigators and dyspnea management 
standards have been the highest priority initiatives that 
regions have pursued to date. 
Conclusion: A lung cancer DPM initiative in 
Ontario has identiÀed priorities for action to improve 
the quality and processes of diagnosis and care and 
the overall patient experience for those touched 
by lung cancer. Funding is being linked to quality 
improvement initiatives and to the creation of 
diagnostic assessment programs that facilitate timely 
access to diagnosis and treatment. 
Keyword: Pathway Management
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P4.054 NON-SMALL CELL LUNG 
CANCER EPIDEMIOLOGY IN BRAZIL: 
RESULTS FROM 10-YEAR REGISTRY IN 
A PRIVATE ONCOLOGIC CENTER.
Luiz Henrique De Lima Araújo1, Clarissa Seródio 
Baldotto2, Mauro Zukin2, Fernando Meton Vieira2, 
Ana Paula Victorino2, Rafaela C. Helal2, Jonas 
female. The mean age at the diagnosis was 62.5 
years for females and 64.8 years for males, (p
Conclusion: Women with lung cancer were 
relatively overrepresented among younger 
patients and smoked less intensively, raising 
the question of gender-speciÀc differences in 
the lung carcinogenesis. Over-representation of 
adenocarcinoma was observed in the women 
regardless of smoking status. Women with lung 
cancer had a better prognosis than men; however 
smoking female showed the worst prognosis. Gender 
and smoking status are clearly important factors in 
lung cancer approach.
Keywords: Female, Lung neoplasms
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.053 LUNG CANCER DISEASE 
PATHWAY MANAGEMENT IN ONTARIO, 
CANADA
William K. Evans1, Yee C. Ung2, Nathalie Assouad3, 
Brendon Lalonde3, Carol Sawka4 
1Administration, Juravinski Cancer Centre/Canada, 
2Radiation Oncology, Sunnybrook Odette Cancer 
Centre/Canada, 3Clinical Programs, Cancer Care 
Ontario/Canada, 4Clinical Programs & Quality 
Initiatives, Cancer Care Ontario/Canada
Background: Cancer Care Ontario (CCO) is the 
government agency responsible for continuously 
improving cancer services across the province 
of Ontario through 14 regional cancer programs. 
In addition to using funding levers, a deÀned 
performance management cycle and clinical 
engagement, CCO introduced a disease pathway 
management (DPM) approach in 2008 to improve 
cancer care. Its 4 objectives are to integrate all 
provincial quality improvement initiatives on a 
speciÀc tumour type (guideline development, 
clinical quality improvement initiatives, performance 
indicator measurement); to systematically evaluate 
the full continuum of the patient journey and identify 
gaps in evidence, clinical practice and measurement 
that impact the quality of care and the patient 
experience; set and manage regional performance 
indicators across the pathway; and leverage speciÀc 
tools to model the impact of policy decisions.
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Conclusion: The described features are in line with 
the current worldwide literature in NSCLC, and 
outcomes are favorably similar to descriptions from 
developed countries.
Keywords: Lung neoplasms, Epidemiology, 
Registry
Poster Session 4 – Epidemiology Thursday, 7 July 2011 10:00-12:30
P4.055 THE MYTH ABOUT ASBESTOS 
AND PHARAOHS: HOW WE IN THE 
NATURAL SCIENCES DO NOT CHECK 
NON-MEDICAL “FACTS”
Gunnar Hillerdal1, Charlotta Hillerdal2 
1Lung Medicine, Karolinska Hospital And Institute/
Sweden, 2Archeology, University Of Aberdeen/United 
Kingdom
Background: Over the years many times 
presentations on the medical aspects of asbestos have 
started with the sentence: “Asbestos was used in old 
Egypt to protect the mummies of their pharaohs”. 
When challenging this, the answer is: it is on the net. 
We decided to further investigate this. 
Methods: A search of the net and investigating 
whether there is any reality behind this claim.
Results: In Google, a search on “asbestos and 
pharaoh” yields 488 000 hits in 0.44 seconds. A 
random search of some of these show that many 
are from lawyer´s ofÀces offering help to asbestos 
victims who start with an historic review. Many 
others are similar reviews from other sources. If 
there are any references, they are cross-references – i 
e to each other, and none goes back to any reference 
from Egyptology or archeological sources. The 
oldest we have found is from 1947, a medical paper 
giving no reference at all. In the world of egyptology, 
nobody has ever heard of asbestos being used 
anywhere or for anything in the old Egypt. Notably, 
Wikipedia (which is more careful about references) 
does not mention anything about pharaohs in its 
review of asbestos history. 
Conclusion: In the medical sciences, we are very 
careful about medical facts, making sure that we 
have reliable references. However, we are much less 
careful about non-medical “facts”, which we do not 
bother to check very thoroughly. 
Keywords: asbestos, history, old egypt, mummy
Hauben Salem2, Maria Gabriela G. Ayres Lima2, 
Katia Silva Moraes2, Nelson Teich2, Carlos G. 
Ferreira2 
1Núcleo De Oncologia Torácica (NOT), Clínicas 
Oncológicas Integradas (COI) And Instituto Coi 
(ICOI)/Brazil, 2Núcleo De Oncologia Torácica 
(NOT), Clínicas Oncológicas Integradas (COI) And 
Instituto Coi (ICOI)/Brazil
Background: Lung cancer is a major burden around 
the globe and approximately half cases occur in 
developing countries. According to the Brazilian 
National Cancer Institute, 27,660 new cases were 
expected in 2010. However, this Àgure is probably 
underestimated, and speciÀc registries in lung cancer 
are a priority. Capturing these data is crucial to 
better understand local characteristics, the impact of 
incorporating novel treatments/technologies, thereby 
supporting better resources allocation. Access to novel 
treatments/technologies among cancer patients in 
Brazil may differ between public and private sectors 
and features for the latter are not available to date.
Methods: A comprehensive non-small cell lung 
cancer (NSCLC) registry was conducted in a private 
oncologic center in Brazil from 1999 to 2010. 
Pathological diagnosis, disease characteristics, 
treatment modalities, and outcomes were evaluated. 
Staging was classiÀed according to the AJCC 6th 
edition, and survival curves were compared using 
log-rank. Long-term follow-up was enabled through 
active surveillance, using telephone contact.
Results: 449 patients were included, and median age 
was 65 years (range 27-92). Most patients presented 
with advanced disease, with a 54.2% frequency 
for stage IV (includes wet IIIB), 25.2% for stage 
III, 5.6% stage II, and 14.4% stage I. 25% were 
never-smokers, and adenocarcinoma was the most 
frequent histology (49.1%), followed by squamous 
cell carcinoma (20.5%). Surgery was performed in 
26.1% of patients, adjuvant chemotherapy in 11.7%, 
and neoadjuvant chemotherapy in 7.3%. 251 patients 
(56.5%) received palliative chemotherapy, and 127 
(50.6%) were also treated with second-line. 51.8% of 
patients received radiation therapy in some moment 
during disease treatment. After 10.7 months median 
follow-up, the overall survival was 17.6 months 
(95% CI, 15.7-19.6). According to tumor stage, the 
median survival was not reached, 99.7, 20.2, and 
13.8 months for stages I, II, III, and IV, respectively 
(P=.0001). The estimated 3-year overall survival 
according to tumor stage was 83.1%, 69.8%, 32.8%, 
and 19.7%.
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with a hazard ratio range of 0.74 to 1.22.
Conclusion: Treatment rates for lung cancer patients 
seen in 2009 have increased when compared to 
2008, with a reduction in national variation. This is 
associated with a small increase in overall median 
survival. However, national variation persists, even 
after case mix adjustment. Possible explanations 
include differences in co-morbidities that are not 
linked to deprivation, or variations in lung cancer 
pathways. Organisations are encouraged to continue 
to examine their own results and review their local 
guidelines and care pathways in order that regional 
variability is reduced and outcomes are improved.
Keywords: Audit, treatment, survival
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P4.057 IS THERE AN ASSOCIATION OF 
THE SPECIALTY OF THE DIAGNOSING 
PHYSICIAN ON DELIVERY OF 
GUIDELINE-BASED THERAPY FOR 
NON-SMALL CELL LUNG CANCER 
(NSCLC) IN THE US?
Bernardo H.L. Goulart1, Catherine Fedorenko1, Sarah 
Beck1, David Blough2, Lisel Koepl1, Sacha Satram-
Hoang3, Carolina Reyes3, Scott D. Ramsey1 
1Public Health Sciences, Fred Hutchinson Cancer 
Research Center/United States Of America, 
2Pharmacy, University Of Washington/United States 
Of America, 3Genentech Corporation/United States 
Of America
Background: Previous studies have shown that a 
referral to an oncologist is the strongest predictor 
of chemotherapy treatment in patients diagnosed 
with advanced NSCLC. No studies have addressed 
whether the specialty of the physician involved in 
the diagnosis of NSCLC affects the likelihood of 
subsequent delivery of guideline-based therapies. 
Using a nationally representative US sample of 
NSCLC patients, we investigated the association 
between the specialty of the physician involved 
in the initial diagnostic work-up and receipt of 
guideline-based therapy for stages IIIA/B and IV 
NSCLC.
Methods: We performed a retrospective cohort 
study using the SEER-Medicare database. Inclusion 
criteria consisted of patients with newly diagnosed 
stages IIIA/B and IV NSCLC without prior cancer 
history, who were diagnosed between 01/01/2000 
and 12/31/2005. Patients had to be alive at least 2 
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P4.056 ARE LUNG CANCER TREATMENT 
AND SURVIVAL RATES IMPROVING 
IN THE UK? RESULTS FROM THE 
NATIONAL LUNG CANCER AUDIT.
Ian Woolhouse1, Paul Beckett1, Roz Stanley2, 
Michael D. Peake3 
1Royal College Of Physicians/United Kingdom, 
2NHS Information Centre/United Kingdom, 3Clinical 
Standards, Royal College Of Physicians/United 
Kingdom
Background: Lung cancer treatment rates and 
survival previously reported in the UK are low 
by international comparison, with signiÀcant 
geographical variation noted. The national lung 
cancer audit aims to address this via the collection of 
detailed data, case mix adjustment and feedback of 
results to drive local improvement.
Methods: Data are presented at cancer network 
level for patients in England and Wales submitted 
to the audit in 2009, with results for 2008 shown for 
comparison. Casemix adjusted logistic regression 
models were performed for sex, age, stage, 
performance status and deprivation. The models 
compare the odds of an outcome occurring in one 
cancer network compared to the population average.
Results: 32,068 cases were submitted, which 
represents over 97% of expected cases. 76% 
were histologically/cytologically conÀrmed. Cell 
types were non small cell 59%, small cell 11%, 
mesothelioma 5% and carcinoid 1%. The mean, 
range and case-mix adjusted odds ratios for key 
outcomes (excluding mesothelioma) are shown in the 
table. 
Case-mix adjusted odds 
ratios 
mean range minimum maximum 
Histology con¿rmed 2009 76% 64-87% 0.56 2.18 
2008 72% 56-88% 0.47 3.37 
Active treatment 2009 59% 41-69% 0.36 1.71 
2008 54% 39-68% 0.46 2.06 
Surgery in con¿rmed 
NSCLC 
2009 18% 13-24% 0.60 2.13 
2008 14% 5-32% 0.31 3.71 
Chemotherapy SCLC 2009 65% 35-79% 0.28 2.18 
2008 62% 39-84% 0.32 3.45 
Median survival was 189 days (range 150-224 days). 
Following case mix adjustment, the hazard ratio of 
risk of death varied from 0.78 to 1.26. In 2008 the 
median survival was 174 days (range 147-222 days) 
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therapies. These results suggest an opportunity for 
improvement in timely referral of NSCLC patients to 
cancer specialists in order to optimize their access to 
appropriate therapies.
Keywords: diagnosis, SEER-Medicare, Lung 
cancer, physician specialty
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P4.058 INCIDENCE AND 
CHARACTERISTICS OF BRONCHIAL 
COLONIZATION AT THE TIME OF LUNG 
CANCER DIAGNOSIS: A PROSPECTIVE 
STUDY.
Sophie Laroumagne1, Benoit Lepage2, Christophe 
Hermant1, Stephanie Lozano1, Gavin Plat1, Laurence 
Bigay-Game1, Christine Segonds3, Valerie Mallard1, 
Alain Didier1, Julien Mazieres1 
1Thoracic Oncology Disease, Toulouse Universitary 
Hospital/France, 2Epidemiology, Toulouse 
Universitary Hospital/France, 3Bacteriology, 
Toulouse Universitary Hospital/France
Background: Bronchial colonisation is frequently 
reported in patients with lung cancer. These 
colonisations could inÁuence patient therapeutic 
management and prognosis. The aim of our study 
is to reÀne prospectively incidence and nature of 
bronchial colonisations in patients presenting with 
lung cancer. 
Methods: Two hundred and twelve patients with 
lung cancer underwent a Áexible bronchoscopy 
at the time of diagnosis of lung cancer. Bacterial, 
mycobacterial and fungal investigations were 
systematically performed for all patients. Type and 
frequency of these colonisations were analyzed and 
correlated with patients and tumours characteristics 
and outcome. 
Results: Microbiological data were available for all 
patients (n = 212). Potential pathogens were found 
in 48.6% of samples. It is noteworthy that we still 
found 20.3% of infection by using a threshold at 
105 UFC/ml. We identiÀed Gram-negative bacilli 
(Haemophilus inÁuenzae 4.2%, Enterobacter 
sp. 3.8%, Escherichia coli 8.5%, Serratia 3.2%, 
Pseudomonas Aeruginosa 2.4%, Klebsiella 3.3 
%) but also gram positive bacilli (Staphylococcus 
12.3%, Streptococcus pneumonia 3.3%). In addition, 
we found 0.5% of atypical mycobacteria, 42.5% 
of Candida albicans, and 4.7% of Aspergillus 
fumigatus. Our study highlighted that aged patients 
months after diagnosis and have Medicare claims 
data available. We linked the physicians’ unique 
physician identiÀcation numbers (UPINs) available 
in Medicare claims to the American Medical 
Association (AMA) masterÀle database to obtain 
information on physician primary specialty. We 
deÀned the diagnosing physician as the one whose 
UPIN was listed in the closest billing claim for 
NSCLC-related CT scans (93% chest CTs) that 
preceded or were within 45 days of the cytological 
or histological diagnosis of NSCLC. A multi-level 
mixed logistic model was used to measure the 
association of the diagnosing physician specialty 
with receipt of guideline-based therapy within 4 
months of diagnosis, deÀned as chemotherapy with 
surgery, chemoradiation, or chemoradiation and 
surgery for stage IIIA, chemoradiation for stage 
IIIB/NOS, and chemotherapy for stage IV, adjusting 
for patient covariates, including year of diagnosis, 
age, gender, race, co-morbidity, geographic area, 
median household income (census tract level), 
tumor histology, stage, and patient clustering around 
physicians. We estimated odds-ratios (OR) with 
respective 95% conÀdence intervals. 
Results: 30,234 NSCLC patients were included in 
the analysis. Mean age was 75.6 (SD 6.1), 16,005 
(53%) were male, 25,146 (83%) were white, and 
15,505 (51%) had stage IV disease. The number 
(percentage) of patients treated with guideline-based 
therapies within 4 months was as follows: 1,716 
(38%) for stage IIIA (80% chemoradiation, 9% 
chemotherapy and surgery, and 11% chemoradiation 
and surgery); 2,643 (26%) for stage IIIB/NOS 
(chemoradiation); and 7,917 (51%) for stage IV 
(chemotherapy). The six most common diagnosing 
physicians’ specialties were internal medicine 
(10,391, 34% patients), family practice (5028, 17%), 
pulmonology (3,671, 12%), emergency medicine 
(1380, 5%), cardiology (1282, 4%), and hematology-
oncology (1,064, 4%). Relative to internal medicine, 
patients who were diagnosed by hematologists-
oncologists were more likely to receive guideline-
based therapies for any stage (absolute difference 
of 16%; adjusted OR=1.6; 95% CI= 1.4 to 1.8). 
Other specialties were not statistically different than 
internal medicine in regards to the likelihood that 
their patients received guideline-based therapy. The 
associations were similar across all stages.
Conclusion: This observational study showed that 
advanced NSCLC patients managed during the 
peri-diagnostic period by hematologists-oncologists 
were more likely to receive guideline-based 
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Organisation (WHO) to the data of Croatian National 
Cancer Registry (CNCR). 
Results: According to CNCR, approximately 
33% of all deaths in Croatia are caused by cancer. 
Among male population, lung cancer takes 18% and 
among female population 6% of the total number 
of patients diagnosed with cancer. Among males, 
incidence of the lung cancer is in the Àrst place 
and also in the Àrst place by the cause of death. 
Among females, incidence of lung cancer is in the 
third place. The 5-year survival for all stages and 
histological types is approximately 12%. The peak 
incidence is between the ages of 70 and 75, with 
the disturbingly increasing trend above the age of 
60, when 90% of cases are diagnosed. In 2008, 
according to data of CNCR, the overall incidence of 
lung cancer was 57.1/100 000 (94.6/100 000 for men 
and 22.3/100 000 for women). In 1985, according 
to the data of WHO, there were 1919 lung cancer 
deaths (1664 men (76.9/100 000) and 255 women 
(11.05/100 000)). In 2008, number of deaths among 
men was 2139 (100.42/100 000) and among women 
611 (26.65/100 000), which represents the total 
cumulative increase of the mortality rate of 44.5% 
(31% for men and 142% for women) in the 23-year 
period. WHO ranked Croatia as the 12th in the world 
and as 7th in Europe on the list of countries with the 
highest mortality from lung cancer for the year 2008. 
Conclusion: The overall cumulative rate in mortality 
from 44.5% in the period between 1985 and 2008 
is shocking. Despite all efforts in the diagnosis 
and treatment of lung cancer, 80% of patients are 
diagnosed in the advanced stage of the disease. The 
main risk factor is cigarette smoking. In Croatia, 
27.4% of the population are declared smokers, 
which represents a disappointing fact. Although 
contemporary oncology has very effective way of 
treatments, an increased mortality rate is caused by 
late detection of the disease. The Àrst preventive step 
in the Àght against lung cancer in Croatia was made 
in 2009 by the legal prohibition of smoking in all 
public places. The effects of this law will be visible 
in the future. 
Keywords: Epidemiology, mortality, Lung cancer, 
incidence
(p=0.005) with COPD (p=0.02) were signiÀcantly 
more often colonized. At the contrary, tumor stage, 
atelectasis, bronchial stenosis and abnormalities 
of chest X-Ray were not associated with a higher 
rate of colonizstion. Squamous cell carcinoma were 
more frequently colonised than other histological 
subtypes but it was not statistically signiÀcant 
(p = 0.11). Survival data were avalaible for 198 
patients. Bacterial colonisation was associated with 
a worse survival when compared with patients 
without colonisation even if the difference was not 
statistically signiÀcant (p = 0.36). 
Conclusion: Colonisation of airways is reported 
in almost half of the patients presenting with a 
lung cancer. This colonization is more frequently 
observed in fragile patients. Collecting colonisation 
status of patients at the time of diagnosis may help 
clinicians to better predict prognosis and subsequent 
infectious complications of lung cancer. 
Keywords: bronchial colonisation, infection, Lung 
cancer, bronchoscopy
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P4.059 EPIDEMIOLOGY OF LUNG 
CANCER IN CROATIA IN A 23-YEAR 
PERIOD (1985-2008)
Darko Katalinic1, Ivan Aleric2, Stjepko Plestina1, 
Miroslav Samarzija2, Sanja Plestina2 
1Department Of Oncology, University Hospital 
Centre (KBC)/Croatia, 2Department Of Pulmonary 
Medicine, University Hospital Centre (KBC)/Croatia
Background: Worldwide, lung cancer is one of the 
most common cancers in terms of both and mortality 
(around 1.4 million new cases per year and around 1 
million deaths). Rapid increase of lung cancer over 
the last century from a relatively rare disease to an 
epidemic is attributed to the exposure to tobacco 
smoke and other risk factors. Recently published 
epidemiological indicators put Croatia at the top of 
the list of countries with high mortality rates from 
lung cancer.
Methods: The aim was to demonstrate 
epidemiological indicators for lung cancer in Croatia 
(International ClasiÀcation of Diseases, 10th revison, 
codes C33-C34) in the period between 1985 and 
2008 and to compare our results with other European 
countries. We used a wide range of statistical data 
sources (obtained from cancer registry websites or 
annual reports), ranging from those of World Health 
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CI = ConÀdence intervals; NR = Not Reported 
Conclusion: Overall, the incidence of EGFR and 
KRAS mutations were similar for AAs and CAs. 
The observed differences in survival between AAs 
and CAs cannot be explained by differences in the 
molecular entities examined. Detailed demographic 
and survival data will be provided at the meeting.
Keywords: EGFR, Kras, Mutation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.061 DELAY IN DIAGNOSIS OF LUNG 
CANCER IN SOUTHERN INDIA – AN 
ANALYSIS
Kirushna Kumar Kosanam Subramanian1, 
Vijayabhaskar Ramakrishnan2, Krishna Kumar 
Rathnam3 
1Department Of Radiation Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
2Department Of Surgical Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
3Department Of Medical Oncology, Meenakshi 
Mission Hospital And Research Centre/India
Background: Lung cancer is one of the most 
common cancer disease in India. Nevertheless it 
has been diagnosed at a verly late stage, for which 
curative approach is not available. Hence we have 
thought of identifying the reasons for delay in 
diagnosis of Lung cancer. 
Methods: A Prospective study was done on stage 
III and Stage IV patients who had presented to 
our hospital during January 2009 and December 
2010 ,with symptoms of more than one 
month. IdentiÀed patients were asked to Àll a 
Questionnaire,mentioning the details for delay. The 
results were tabulated and analyzed.
Results: During the study period 156 patients were 
evaluated in our outpatient clinic,out of which only 
122 patients were found to be eligible for the study 
and were offered the Questionnaire. Hundred and 
one(82.78%) patients were males and 21(17.22%) 
patients were females.Patients age ranged from 
32 to 78 years(mean – 54.15years). Eight patients 
had taken self medication and had not visited a 
Physician. Fifty one(41.8%) patients were evaluated 
by chest X-ray by the Family physician of which 
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P4.060 EGFR/KRAS MUTATIONS IN 
AFRICAN AMERICANS (AA) VERSUS 
CAUCASIANS (CA) IN PATIENTS (PTS) 
WITH NSCLC: A COMPARATIVE 
ANALYSES OF THE SOUTH CAROLINA 
EXPERIENCE.
Michael M. Goodman1, Keisuke Shirai1, Elizabeth 
Hill2, George Simon1 
1Hematology/Oncology, Medical University Of South 
Carolina/United States Of America, 2Biostatistics 
& Epidemiology, Medical University Of South 
Carolina/United States Of America
Background: AAs with NSCLC has inferior survival 
compared to CAs. We sought to discern whether 
differences in incidence of EGFR or KRAS mutations 
between races could partly explain these differences.
Methods: Pts with NSCLC who were seen at the 
Hollings Cancer Center (HCC) and underwent EGFR 
and KRAS mutation testing in 2010 were included. 
Microdissected formalin-Àxed parafÀn-embedded 
tumors from 89 patients with NSCLC were analyzed 
for EGFR/KRAS mutations by allele-speciÀc PCR. 
Data were compared with previously reported 
experiences from Memorial Sloan Kettering Cancer 
Center (MSKCC), Case Western Reserve (CWR), and 
Louisiana State University Health Sciences Center 
(LSU). We estimated the percentage of EGFR+ and 
KRAS+ AA and CA subjects using exact binomial 
conÀdence intervals, and compared proportions using 
Fisher’s exact test. Aggregate estimates were obtained 
using inverse variance-weighting and random-effects 
modeling to account for study heterogeneity.
Results: Of the 89 pts, 63 were CAs and 26 were 
AAs. In AA population, 24/26 pts had successful 
EGFR and KRAS analysis. In the CA population 
59/63 pts and 61/63 pts had successful EGFR and 
KRAS testing, respectively. Data are in the table 
below. A weighted aggregate are also compiled. 
EGFR Status KRAS Status 
N+/Total N
(%; 95% CI) 
N+/Total N
(%; 95% CI) 
p N+/Total N
(%; 95% CI) 
N+/Total N
(%; 95% CI) 
p 
AA CA AA CA 
HCC 2/24 (8; 1, 27) 10/59
(17; 8, 29) 
0.49 6/24
(25; 10, 47) 
16/61 (26; 
16, 39) 
>0.99 
MSKCC 23/121 (19; 
12, 27) 
61/476 
(13;10, 16) 
0.11 21/121
(17; 11, 25) 
125/476
(26; 22, 30) 
0.04 
CWR 1/53 (2; 0, 10) 15/89
(17; 10, 26) 
0.005 12/53
(23; 12, 36) 
16/76
(21; 13, 32) 
0.83 
LSU NR NR 22/60
(37; 25, 50) 
10/51
(20; 10, 33) 
0.06 
Aggregate 26/198
(10; 0, 21) 
86/624
(14; 11, 16) 
0.51 61/258
(25; 16, 33) 
167/664
(25; 22, 28) 
0.92 
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and males respectively (p<0.001). Only 2% were 
screen-detected. Diagnostic modality was: clinical 
only 10%; cytology alone 20%, histology 70%. 
Considering NSCLC (n=655): adenocarcinoma 
40%, squamous 23%, large cell 13%; stage I/II 
24%, III 26%; PS 0-1 63%; PET scan 43%; invasive 
staging of mediastinum 8%; specialist referral 99%; 
discussed at multi-disciplinary case conference 
(MDM) 33%. Of 206 pts (32%) treated with curative 
intent, 130 (20%) underwent surgery (lobectomy 82, 
pneumonectomy 18, segmental resection 30) with 
86% of patients having a R0 resection and only 7% 
adjuvant chemotherapy. With curative intent, 91 
pts (48%) received radiotherapy. 311 pts (48%) had 
palliative treatment while 138 pts (21%) received 
no therapy. Considering all NSCLC pts, 258 (39%) 
received chemotherapy and 365 (56%) radiotherapy 
at some time during their illness. Considering the 
101 pts with SCLC, 67% had PS 0-1, 33% limited 
disease, 99% saw a specialist and 21% discussed at 
MDM. 9% received no treatment while 27 pts (27%) 
were treated with curative intent, including 16 (20%) 
with chemoradiation. For the 85 pts (10%) who did 
not have a pathological diagnosis, an attempt to 
obtain tissue was made in 62%. As compared with 
patients with a tissue diagnosis, these patients were 
older (79 vs 71 yrs, p<0.001), worse PS (PS 0-1 
13% vs 51%, p<0.001), less frequently presented 
at MDM (11% vs 30%, p=0.001), and more likely 
to have no cancer treatment (84% vs 20%). Median 
survival was 1.1mths (SE0.2). Median and 5-year 
survival were: NSCLC 6.9m (SE 0.42) and 11%; 
SCLC 7.2m (SE 0.96) and 3%, respectively. 
Considering all pts, better survival on multivariate 
analysis was associated with younger age, good PS, 
no weight loss, early stage, never smoking and better 
socio-economic status. Changes from 1993 to 2003 
were: median 3yrs older (69 vs 72yrs respectively, 
p<0.001); fewer males (70% vs 63%, p=0.002); less 
SCLC (14% vs 12%, p=0.10); more adenocarcinoma 
(32% vs 42%) and less squamous (42% vs 23%, 
p<0.001). Patients receiving no treatment were 
similar. Fewer patients went to a deÀnitive surgical 
procedure, possibly due to use of PET scanning. 
When adjusted for age and sex, the overall 5yr 
survival did not change over the decade.
Conclusion: Despite increased use of PET scanning 
and more multi-modality therapy, lung cancer 
survival did not improve over the decade. New 
strategies are required to improve patient outcomes.
Keywords: Lung cancer, population-based, 
Management Survey, Health outcomes
21(17.21%) patients X-ray did not show any Ànding. 
Remaining 30(24.59%) patients were presumed 
to have tuberculosis and was treated empirically 
with antitubercular drugs. Thirty (24.59%) patients 
were advised evaluation by their physician, but 
did not have radiographs done due to Ànancial 
reasons. Twenty eight(22.95%) patients symptoms 
were ignored by the family members. 17(13.93%) 
patients did not proceed for further evaluation as 
their symptoms disappearad after their visit with the 
Physician.10(8.19%) patients were not evaluated 
with chest radiograph as they had symptoms not 
related to chest. Almost one half (48%) of the patient 
had a combination of factors for delay in diagnosis. 
Conclusion: Several reasons for delay in diagnosis 
were found. High prevelance of Pulmonary 
Tuberculosis and the bias of the Family physician 
plays a major part in delayed referral. Low 
socioeconomic status is also a major concern in our 
patient population. 
Keywords: Delay in Diagnosis, Lung cancer,
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P4.062 MANAGEMENT OF LUNG 
CANCER IN AUSTRALIA: HAVE WE 
MADE PROGRESS?
Paul Mitchell1, Vicky ThursÀeld2, Gavin M. Wright3, 
David Ball4, Gary Richardson5, Yvonne Torn-
Broers2, Louis Irving6, Graham Giles2 
1Joint Austin-ludwig Medical Oncology Unit, 
Austin Health/Australia, 2Cancer Council Victoria/
Australia, 3Thoracic Surgery, St Vincent’s Hospital/
Australia, 4Radiation Oncology, Peter MacCallum 
Cancer Centre/Australia, 5Cabrini Health/Australia, 
6Respiratory Medicine, Royal Melbourne Hospital/
Australia
Background: Lung cancer outcomes in Australia 
remain very poor. We aimed to document 
management and compare to a 1993 population-
based survey, which had indicated poor compliance 
with guidelines.
Methods: Patients diagnosed during 6 months of 
2003 were identiÀed from the Cancer Registry and 
data obtained from source documents
Results: Data were available for 841 patients (82% 
of eligible pts): median age 72 yrs and 63% male. 
Most were ex-smokers (57%), with 8% never 
smokers (71% female). For smokers, the median 
exposure was 37 and 52 pack years for females 
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to decrease during the last decade (slope -1,11 with 
SE=0,06). Standardized mortality rates for women 
were at stable level about 3,3-3,9 per 100 000 during 
1999-2009. Mean ratio mortality/incidence was 0,7 
for women and 0,81 for men in the last decade.
Conclusion: Lung cancer mortality trends in men are 
on a downwards path as in most European countries, 
while female rates may continue to rise, points to 
an urgent need for national prevention strategies 
that target tobacco cessation and prevention among 
women.
Keywords: incidence, mortality, Epidemiology
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P4.064 LUNG CANCER IN SOUTHERN 
INDIA – A SINGLE CENTRE 
EXPERIENCE OF PATTERNS OF 
PRESENTATION AND DISEASE 
CHARACTERISTICS
Vijayabhaskar Ramakrishnan1, Kirushna Kumar 
Kosanam Subramanian2, Krishnakumar Rathinam3, 
Anand Selvakumar2 
1Department Of Surgical Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
2Department Of Radiation Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
3Department Of Medical Oncology, Meenakshi 
Mission Hospital And Research Centre/India
Background: Lung cancer is the leading cause of 
cancer death in developed countries and is also rising 
at an alarming rate in developing countries. Very 
little data is available on the pattern of lung cancer 
presentation and treatment results among Indian 
patients. We aim to describe the clinical, histological, 
epidemiological and treatment characteristics of 
patients diagnosed with lung cancer in our hospital. 
Methods: Ours is a retrospective study of patients 
treated in the Department of Oncology between 
January 2008 to December 2010.We did a chart 
review and collected the demographic, clinical and 
treatment details of all the patients diagnosed with 
lung cancer. The data were tabulated and analyzed. 
Results: Two hundred and thirty four patients with 
lung cancer were treated in our department from 
January 2008 to December 2010.Eighty two percent 
were males (n=192) while the rest were females.
{M:F=4.57:1}.The age of presentation ranged from 
31 to 75 years(Mean-57.92 Years).Cough was the 
main presenting symptom in 41% of the patients.
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P4.063 TRENDS IN LUNG CANCER 
INCIDENCE AND MORTALITY IN 
BELARUS, 1970-2009
Natalia Artemova1, Natallia Novikava2, Yuri 
Averkin3, Ilya Veyalkin3 
1Radiation Therapy, Republican ScientiÀc And 
Practical Centre Of Oncology And Medical 
Radiology/Belarus, 2Environmental Medicine, 
International Sakharov Environmental University/
Belarus, 3Republican ScientiÀc And Practical Centre 
Of Oncology And Medical Radiology/Belarus
Background: Lung cancer is the most frequent 
cause of cancer mortality among men and takes sixth 
place in female cancer mortality in Belarus while the 
prevalence of smoking remains unacceptably high. 
The objective was to describe main trends in lung 
cancer incidence and mortality in Belarus population.
Methods: Incidence and mortality trends were 
assessed by means of data derived from National 
Cancer Registry. Age-speciÀc rates were investigated 
and age-standardized rates (ASRs, World) and 
cumulative risk were calculated. Linear regression 
analysis was used to reveal main trends.
Results: Overall, lung cancer incidence rates 
(ASRs) increased more than 100 and 34 % among 
males and females, respectively. ASRs for males 
peaked in 1994 (71,8 per 100 000), for females 
- in 1991 (5,8 per 100 000). ASRs for men were 
increasing up to 1994. SigniÀcant positive slope 
was revealed (1,83 with standard error SE=0,05) 
for this period. Then rates started to decrease and 
showed signiÀcant negative slope (-0,62; SE=0,074). 
In women any clearly deÀned trend has not been 
revealed. The rates were stabilized at around 4,7-
5,6 per 100,000 women. But for urban women a 
slight negative slope was revealed while a positive 
slope was found out for rural women. Crude rates 
showed more pronounced tendency to increase, 
indicating that the major part of the growth was 
due to population ageing. The incidence showed an 
increase with age and reached peak in age group 70-
75 in male and 75-79 in female. Age-speciÀc rates 
showed steady increasing for elder age groups due 
to better diagnostics. But there could be a negative 
upward trend in the middle age groups for rural 
women. Mean cumulative risk was 9,3% (95% 
conÀdence interval 8,5Ã·10,1) for men and 0,99 
(95% conÀdence interval 0,95Ã·1,04) for women. 
Trends in lung cancer mortality in men have tended 
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Background: Tobacco smoking is the major risk 
factor for lung cancer, but approximately 10% of all 
patients are live-time never-smokers. Nevertheless 
lung cancer in never-smokers is an understudied 
entity and data on this issue are limited. We aim 
to assess clinicopatological differences and cancer 
speciÀc survival between smokers, ex-smokers and 
never-smokers with NSCLC. 
Methods: Data was gathered from the Regional 
Lung Cancer Register in the Uppsala/Örebro region 
in Central Sweden, a population-based register 
covering 98% of patients diagnosed with lung cancer 
during the period 1995-2008. 9215 cases of lung 
cancer were analysed with regard to gender, age, 
performance status, histological types, TNM staging 
and survival. 
Results: Of 7177 patients included in the study, 
3321(46,3%) were smokers, 2868 (40,0%) were 
former-smokers and 733 (10,2%) were never-
smokers. During 1995 to 2008 lung cancer in never-
smokers increased from 8% to 11% among all lung 
cancer cases. The number of never-smoking lung 
cancer patients showed an increase with 46%, from 
50 to 73 cases. Among never-smoking patients 70% 
were women. The never-smokers had a higher mean 
age at diagnosis than smokers (70,4 years versus 
65,7 years). Adenocarcinoma was the most common 
histopatological type among all patients, but it was 
proportionally more frequent among never-smokers 
compared to current and former smokers. (69,2% 
versus 40% and 41,9%). Squamous cell carcinoma 
was less common among never-smokers than 
smokers. (11,2% versus 34,7%). There were no 
signiÀcant differences in performace status and TNM 
stage. Survival outcome was signiÀcantly better in 
female never-smokers with stage IA-IIB and stage 
IV as well as in male never-smokers with stage IV 
compared to smokers. 
Conclusion: Lung cancer in never-smokers has 
increased over time, is diagnosed at a higher mean 
age and is more likely to be adenocarcinoma. 
Two thirds of the patients are women and there 
are differences in survival outcome compared to 
smokers. This suggests that lung cancer in never-
smokers and smokers may be considered as two 
separate disease entities and caused by different 
carcinogenesis.
Keywords: survival, Non-small cell lung cancer, 
Never-smoker, tobacco smoking
(n= 96), followed by dyspnea (17.9%),Chest 
Pain(15.4%), Bone pain(10.3%),Headache (7.7%), 
Hemoptysis (4.4%) and Swelling in the neck(3.3%).
More than two thirds of patients had more than one 
presenting complaint. Only 30 patients (12.82%) 
presented to our department within one month of 
onset of symptoms.132 patients (56.41%) presented 
within 1-2 months of onset of symptoms while 72 
patients (30.76%) presented more than 2 months 
after onset of symptoms. CT guided Biopsy/
FNAC was the most common diagnostic modality 
employed(74.4%).Fifty one percent of tumors were 
right sided while 48.2% of patients had left sided 
tumors. In 2 patients, the tumors were bilateral. 
Right upper lobe was the most commonly involved 
lobe in 46.2% of patients(n=102). Adenocarcinoma 
was the most common pathology seen in 43.6%( n= 
102) patients. Squamous cell carcinoma was seen 
in 66 patients. Small cell carcinoma was seen in 42 
patients(17.9%) while 24 patients presented with 
poorly differentiated carcinoma.Only 15.4%(n=36) 
of patients presented with localized/ locally 
advanced disease while the remaining patients had 
metastatic disease at presentation.One hundred and 
twenty six patients(54%) presented with metastasis 
at single site while 72 patients(31.2%) presented 
with metastasis at multiple sites.Bone is the most 
commonly involved metastatic site(36.4%) followed 
by brain (18.2%) and Liver(18.2%) 
Conclusion: More than 80% of lung cancer patients 
were detected in the unresectable advanced stages 
(IIIB and IV).Adenocarcinoma is the most frequent 
histological subtype in our patient population.Bone 
is the most common site of distant metastasis
Keywords: South India, Lung cancer,
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P4.065 NON-SMALL CELL 
LUNG CANCER IN NEVER-
SMOKERS: EPIDEMIOLOGICAL 
CHARACTERISTICS AND SURVIVAL. 
A POPULATION BASED STUDY OF 9215 
CASES.
Annette Karimi1, Fredrik Sandin2, Kristina Lamberg3, 
Mats Lambe2, Gunnar Wagenius4 
1Dept Of Pulmonary Medicine, Dept Of Pulmonary 
Medicine/Sweden, 2Regionalt Onkologiskt Centrum/
Sweden, 3Dept Of Pulmonary Medicine/Sweden, 
4Dept Of Oncology/Sweden
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patients younger than 60 years. After adjustment for 
treatment variables, this improvement remained only 
signiÀcant for patients with stage I and III disease, 
suggesting that changes in survival per stage were 
mainly caused by better staging at diagnosis and only 
partly by improvement in therapy.
Conclusion: Therapy as applied in clinical trials 
with younger patients with good performance status, 
is still at a distance from the application of therapy 
observed in daily practice. Standard of care therapy 
contributed only in a small amount to improvement 
in relative survival for each stage, without an 
improvement for the total group. 
Keywords: Non-small cell lung cancer, survival, 
treatment
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P4.067 COMORBIDITY AND FUTURE 
LUNG CANCER RISK IN A UK HIGH 
RISK PRIMARY CARE PRACTICE
Nicosha B. De Souza1, Olaide Y. Raji2, Chris 
Mimnagh3, John Hughes3, Stephen W. Duffy4, 
Matthew Ashton5, John K. Field2 
1Molecular And Clinical Medicine, University Of 
Liverpool/United Kingdom, 2Molecular And Clinical 
Cancer Medicine, University Of Liverpool/United 
Kingdom, 3Wingate Medical Practices, Knowsley/
United Kingdom, 4Queens Mary University Of 
London/United Kingdom, 5Knowsley Nhs Primary 
Care Trust/United Kingdom
Background: Lung cancer continues to be the 
leading cause of cancer death worldwide. The 
disease is predominantly common among elderly 
patients, thus likely to be preceded or accompanied 
by multiple comorbid conditions. Whilst many 
studies have reported association between pulmonary 
diseases and lung cancer occurrence, the role of 
other chronic conditions that manifest primarily later 
in life are yet to be elucidated. This study describes 
the pattern of comorbidities among individuals in a 
pilot primary care lung cancer early detection study, 
and explores the inÁuence of these chronic diseases 
on future risk of developing lung cancer. 
Methods: Diagnosed medical conditions for 
participants in a pilot lung cancer early detection 
study at a UK primary care practice were obtained. 
Individual’s 5-year absolute risk for future 
development of lung cancer was estimated from 
the LLP risk model, which has been successfully 
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P4.066 STANDARD OF CARE THERAPY 
IMPROVES SURVIVAL TO A SMALL 
EXTENT IN NSCLC PATIENTS IN THE 
LAST 20 YEARS IN THE NETHERLANDS
Miep A. Van Der Drift1, Henrike Karim-Kos2, Esther 
De Vries2, Harry J.M. Groen3, Michel Wouters4, 
Sabine Siesling5, Maryska Janssen-Heijnen6 
1Pulmonology, Radboud University Nijmegen 
Medical Centre/Netherlands, 2Public Health, 
Erasmus MC University Medical Center/
Netherlands, 3Pulmonary Diseases, University 
Medical Center Groningen/Netherlands, 4Thoracic 
Surgery, Netherlands Cancer Institute-antoni Van 
Leeuwenhoek Hospital/Netherlands, 5Registration 
And Research, Netherlands Comprehensive Cancer 
Centre/Netherlands, 6Research, Eindhoven Cancer 
Registry/Netherlands
Background: Treatment of patients with non-small 
cell lung cancer (NSCLC) has changed over time. 
The aim of this study was to describe these changes 
in daily practice in patients with NSCLC in the 
Netherlands during the period of 1989-2008 and 
compare these changes to the guidelines. Potential 
effects on survival were examined. 
Methods: All patients with NSCLC diagnosed 
during the period 1989-2008 were selected from the 
population-based Netherlands Cancer Registry. The 
Cochran-Armitage trend test was used to analyze 
trends in treatment. Relative survival trends were 
estimated by a multivariable linear regression model. 
Follow-up was complete up to February 1st 2010.
Results: NSCLC was diagnosed in 139,309 patients, 
almost 25% being  75 years. Among stage I, 
the proportion of younger patients (< 75 years) 
undergoing surgery increased from 84% in 1989-
1993 to 89% in 2004-08 and among elderly ( 75 
years) from 35% to 49%; for stage II this proportion 
decreased from 80% to 70% in younger patients and 
increased from 21% to 28% in the elderly. Adjuvant 
chemotherapy in stage II increased from 0% to 
24% in younger patients, but remained <5% among 
the elderly. In stage III the proportion of younger 
patients receiving chemoradiation increased from 1% 
to 43% and in elderly from 0% to 13%. In stage IV 
use of chemotherapy in younger patients increased 
signiÀcantly from 10% to 54%, and in elderly from 
2% to 21%. Although Àve-year relative survival 
for the total group has not increased since 1989, 
survival has increased within every stage and for 
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Background: Lung cancer is the leading cause of 
cancer morbidity and mortality worldwide. Over 
the past years, the frequency of adenocarcinoma 
has increased, while, squamous cell carcinoma 
decreased. The aim of the study was to investigate 
histologic types and other clinical characteristics of 
patients with lung cancer during 10-year period.
Methods: A retrospective review of 479 patients with 
lung cancer diagnosed histologically or cytologically in 
Hospital of Lithuanian University of Health Sciences 
Kaunas Clinics. The data was collected from 1998-
1999 years - period 1 and 2008-2009 years - period 2.
Results: In period 1 were 261 cases: 40 female 
(15.3%), 221 male (84.7%) and stage I 22(8.4%), stage 
II 31(11.9%), stage III 125(47.9%), stage IV 83(31.8%) 
and in period 2 were 218 cases: 25 female (11.5%), 193 
male (88.5%) and stage I 21 (9.6%), stage II 24 (11%), 
stage III 99 (45.4%), stage IV 74 (34%); (p>0.05). In 
period 2 patients were older than in period 1 patients at 
the time of diagnosis (68.23±4.98 vs 62.35±5.34 yrs, 
respectively, p<0.05). Histological types were: small 
cell carcinoma 55 (21.1%), NSCLC 206 (78.9 %): 
squamous cell carcinoma 148 (71.8%), adenocarcinoma 
24 (11.7%), large cell carcinoma 1 (0.5%), NOS 33 
(16.0%) in period 1 and small cell carcinoma 43 (19.8 
%), NSCLC 175 (80.2%): squamous cell carcinoma 
6 (38.3%), adenocarcinoma 13 (7.4%), large cell 
carcinoma 6 (3.4%), NOS 89 (50.9%) in period 2; 
(p<0.05). 
Conclusion: During 10-year period NOS and large 
cell carcinoma frequency increased while squamous 
cell carcinoma decreased. Sex and stage distribution 
did not changed during 10-years period. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.069 PROGNOSIS OF LUNG CANCER 
MORBIDITY BASED ON CHANGES OF 
ECOLOGICAL SITUATION. SCIENTIFIC 
SUBSTANTIATION OF METHOD.
Oleksandr V. Voitko1, Serg T. Omelchuk2, Yuriy M. 
Ostapchuk3, Volodymyr O. Voitko4 
1Thoracic Surgery, Kyiv City Clinical Oncology 
Center/Ukraine, 2Food Hygiene, National O.O. 
Bohomolets Medical University/Ukraine, 3State 
Statistics Committee Of Ukraine/Ukraine, 4National 
O.O. Bohomolets Medical University/Ukraine
validated in three independent studies. Patients were 
classiÀed as high or low risk based on a 5-year future 
risk threshold of 5%. Associations of comorbidity 
conditions with the future risk were examined using 
logistic regression analysis. 
Results: The median age of participants was 62yrs 
(range=50-88yrs) and more than half were females 
(53%). Musculoskeletal and connective tissue 
disease (85.5%) and respiratory system diseases 
(82.6%) were the leading comorbid conditions; these 
were mostly dominated by rheumatism (49.8%) and 
acute respiratory infection (76.2%) respectively. 
Prior diagnosis of circulatory disease (OR=1.84, 
95% CI=1.36-2.47) and malignant disease (OR=1.45, 
95% CI=1.05-2.00) were statistically signiÀcantly 
associated with increased risk of lung cancer whilst 
infectious disease (OR=0.47, 95% CI=0.35-0.64) 
and genitourinary system diseases (OR=0.72, 95% 
CI=0.52-0.94) appear statistically signiÀcantly 
protective. SpeciÀcally, COPD (OR=1.85, 95% 
CI=1.33-2.60) and cardiac diseases (OR=2.57, 95% 
CI=1.47-3.05) diagnosed in 22% and 21% of patients 
respectively were signiÀcantly associated with 
increased future risk of lung cancer. 
Conclusion: This study demonstrates strong positive 
relationships between circulatory diseases, cardiac 
diseases in particular, and COPD with future lung 
cancer risk. Evidence from our results supports 
a role for prior diagnosis of circulatory disorders 
such as ischaemic heart diseases in deÀning lung 
cancer high risk individuals. Thus, incorporation 
of objective measures of these diseases and that of 
COPD may improve predictions of existing lung 
cancer risk models. A clearer understanding of the 
inter-relationship between diseases is critical for 
developing future prevention, early detection and 
treatment programmes. 
Keywords: Epidemiology, comorbidity, lung cancer 
risk, primary care
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P4.068 CHANGES IN THE LUNG CANCER 
MORPHOLOGY DURING 10-YEAR 
PERIOD IN LITHUANIA: A SINGLE 
INSTITUTION EXPIERENCE
Marius Zemaitis1, Neringa Vaguliene2, Skaidrius 
Miliauskas1, Raimundas Sakalauskas1 
1Lithuanian University Of Health Sciences/Lithuania, 
2Department Of Pulmonology And Immunology, 
Lithuanian University Of Health Sciences/Lithuania
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is represented by single-type polynomial cubic 
equation for all Ukrainian regions. 2. 2. This formula 
could be used for a medium-term forecast of lung 
cancer morbidity and argumentation of prophylactic 
activities. 
Keywords: morbidity prognosis, Lung cancer, air 
pollution
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.070 FIRST RESULTS OF THE 
PROSPECTIVE SCOT REGISTRY.
Pieter E. Postmus1, Elisabeth Quoix2, Andrea 
Ardizzoni3, Pilar Garrido4, Thierry Le Chevalier5, 
Faisal Mehmud6, Joanne L. Fletcher7 
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Ramon Y Cajal/Spain, 5Insitut Gustave Roussy/
France, 6Oncology Mdc, Glaxosmithkline/United 
Kingdom, 7Oncology Centre Of Excellence, 
Glaxosmithkline/United Kingdom
Background: The SCOT (Small Cell Lung Cancer 
treatment and outcome) registry objective is to 
describe the patterns of care and patient outcomes in 
newly diagnosed patients with SCLC. 
Methods: Currently 526 patients have been recruited 
by 56 centres in 14 countries (Europe 13, Asia 1). 
Patients’ baseline characteristics and initial treatment 
intention are recorded at entry and additional patient 
information is collected every 6 months for 18 
months to track actual treatment, follow-up and 
outcome. In addition healthcare resource utilisation 
is captured. 
Results: Baseline data and 6 months data for 
70% of the patients are available currently. The 
population was mostly represented by male patients 
(73%). Patients median age was 65 years. 5% had 
a previous history of cancer and almost all patients 
had a smoking history (95%) - 50% were current 
smokers. Based on the baseline collected, 42% of the 
patients presented with limited disease (M0) versus 
58% with extensive disease (M1). Metastases were 
most frequently reported in lymph nodes (55%), 
liver (35%), lung (25%) and bones (24%). Initial 
Background: Aim of the project. To check 
possibility of Ukrainian population’s morbidity of 
lung cancer (LC) prognostication based on data due 
to air pollution (AP) in previous years. 
Methods: In our work we have used ofÀcial data 
of the National cancer-register of Ukraine about LC 
morbidity and data of the State Statistics Committee 
of Ukraine about AP in Ukraine and its regions. In 
previous project we have already ascertained, that 
in Ukraine tobacco smoking level have increased 
and LC morbidity decreased during last 20 years. 
Thus, we have started research of major LC risk 
factors. Investigation of correlation between level of 
AP and LC morbidity was one of our research lines. 
Possibility of this dependence based on analysis 
of LC morbidity in 1995-2004 years and AP level 
in 1985-1994 years in the same regions. We have 
used regression analysis method and, as result, 
deduced a formula, which, in our opinion, represents 
this correlation (2008 1st European Lung Cancer 
Conference). For Ukraine in general this formula 
is as follows: y = 0,0018x3 - 0,0967x2 + 2,0553x + 
22,98. The single-type polynomial cubic equation 
represents this correlation for all Ukrainian regions: 
y=ax³-bx²+cx+d · y – the level of LC morbidity, 
· x – air pollution level for 10 years by the time 
of determination of an actual morbidity, · a, b, 
c – factors, which, according to the authors, were 
caused by ecologic-climatic conditions, speciÀcity 
and features of placing manufacture, and others for 
each territory · d – “Background” level of morbidity 
(on conditions that air pollution is absent). Based on 
this formula and data about AP level in 1994-2004, 
we have calculated forecasted level of LC morbidity 
for Ukraine and all Ukrainian regions. We have 
compared the calculated data (155 elements) with 
standardized actual data. 
Results: In 115 pairs of data (74%) calculated rates 
ware in conÀdence interval of analogical actual 
value. In 145 cases (93,54%) Student’s coefÀcient 
was less than 2, which indicates that absence of 
signiÀcant difference between calculated and 
standardized actual value. In 85 pairs (54,84%) the 
difference between calculated and standardized 
actual value was less than 5%, in 43 pairs (27,74%) 
this difference was from 5 to 10% and in 27 cases 
(16,42%) exceeded 10%. In only one case (0,65%) 
Student’s coefÀcient exceeded 3, which indicates that 
presence of signiÀcant difference between calculated 
and standardized actual value.
Conclusion: 1. 1. Revealed correlation between 
lung cancer morbidity and air pollution level, which 
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malignancy with 27,630 new cases estimated for the 
year 2010, divided in 17,800 men and 9,830 women. 
There is an increasing incidence in Brazil, especially 
in females, which is attributed to increased smoking 
habit in this gender. Risk and prognostic factors 
inÁuence treatment results and survival in patients 
with advanced disease. The aim of this study was to 
identify in our population the epidemiological proÀle 
of patients with non-small cell lung cancer (NSCLC) 
in advanced stage and confront the results of treatment 
with the data in the literature.
Methods: This retrospective study included 125 
patients referred to the Clinical Oncology Service 
of our hospital, with NSCLC in stage IIIB with 
pleural effusion and IV and tried to identify the 
epidemiological characteristics, risk and prognostic 
factors and the results obtained with treatment through 
survival analysis using the Kaplan-Meier method.
Results: Of 125 patients enrolled, 52.8% were male, 
median age 58 years, performance status (PS) less 
than 1 in 61.3%, weight loss greater than 10% in 
83.3% and subtype adenocarcinoma in 59.2% of 
cases. Most of the patients (83.2%) were smokers 
or former smokers at the time of diagnosis and 
the most common initial symptoms were chest 
pain (76.5%) and cough (69,9%). Bone and brain 
metastases were detected in 29,6% and 21,4% at 
diagnosis, respectively, similar to that found in the 
literature. Among the 104 patients assessable for 
response, the partial remission rate was 31.7% and 
the stable disease rate was 16.3%. Patients were 
treated with carboplatin-paclitaxel in Àrst line in 
88,6% and docetaxel in second line in 47,1% The 
median survival was 8.3 months (95% CI 6.5 to 
10.1 months) and there was a signiÀcant statistical 
difference in median survival between patients with 
performance status less than 1 versus those equal or 
greater than 2 (p = 0.014).
Conclusion: An equal incidence between sexes 
reÁects the increasing number of cases in females 
following the statistics worldwide. Smoking is still 
the most prevalent risk factor and is more associated 
with the epidermoid histological subtype. In our 
population, the number of cigarretes smoked per day 
was high although the most common subtype was 
adenocarcinoma, in accordance with the statistics of 
growing incidence of this subtype. Overall survival 
was similar to that found in the world literature. This 
study shows the epidemiological proÀle of patients 
with lung cancer in a Southern Brazilian population 
and the impact of prognostic factors in treatment 
outcome. 
treatment intention for the patients presenting with 
M0 disease included chemotherapy alone, for 41% of 
the patients and for 58% the intention was combined 
chemo-radiotherapy. For the majority of patients 
with M1 disease the intention was to treat with 
chemotherapy alone (87%) and 11% with combined 
chemo-radiotherapy. Of the patients with 6 months 
of follow-up completed, 30% of patients with M0 
disease were actually treated with chemotherapy 
alone, 62% with combined chemo-radiotherapy, 
4% surgery and 33% were treated with prophylactic 
cranial irradiation. 60% of patients with M1 disease 
were treated with chemotherapy alone, 28% with 
combined chemo-radiotherapy and 18% were treated 
with prophylactic cranial irradiation. For 67.8% of 
the patients, the initial treatment plan was actually 
delivered. 13.5% of the patient population with 
6 months visit completed (51 patients) had died. 
78.3% of the deceased patients had M1 stage disease. 
27.5% of the deceased patients had not received any 
chemotherapy. 
Conclusion: More than a third of patients presenting 
with M1 stage disease received therapies other 
than chemotherapy alone (chemo-radiotherapy 
or radiotherapy). In patients with M0 stage 
disease, 62% were treated with combined chemo-
radiotherapy and only 33% received prophylactic 
cranial irradiation. This preliminary data suggests 
that treatment based on guidelines is often 
impossible, highlighting a need for more treatment 
options. 
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P4.071 RETROSPECTIVE ANALYSIS OF 
EPIDEMIOLOGICAL AND TREATMENT 
OUTCOME IN PATIENTS WITH 
METASTATIC LUNG CANCER AT 
AN ONCOLOGIC INSTITUTION IN 
SOUTHERN BRAZIL
Thais A. Almeida, Ana Luiza M. Wiermann, Nils 
G. Skare, Johnny Francisco C. Camargo, Rosane R. 
Johnsson, Fabrício Augusto O. Martinelli, Luciano 
S. Biela, Ricardo Y. Nishimoto, Diogo D. Gavarrete, 
Roger A. Shiomi, Marcos Almeida, Thiago Vinícius 
G. Simioni, Camila Zamboni 
Clinical Oncology, Erasto Gaertner Hospital/Brazil
Background: Lung cancer is the most common 
tumor worldwide and a leading cause of preventable 
death. In Brazil it is the third most common 
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had Àrst been seen, which suggests that the resection 
rate could be increased to that observed in thoracic 
surgical centres without a negative effect on survival.
Conclusion: The 27% of patients with NSCLC Àrst 
seen in a thoracic surgical centre are more likely to 
have surgery for their cancer and to beneÀt from 
the survival advantage this confers. There is an 
opportunity to improve the outcome for patients 
with lung cancer in England by improving the care 
pathway for patients Àrst seen at a non-thoracic 
centre. 
Keywords: surgical resection, survival, co-
morbidity, Epidemiology
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P4.073 ASSESSMENT OF THE OFFER 
OF CLINICAL TRIALS IN THORACIC: A 
PILOT STUDY
Andrea T. Shaffer1, Aaron Becker2, Christie Pratt2, 
Gwendolyn Quinn2, Cynthia Shimizu2, E J. Vaughn2 
1Thoracic Oncology, H. Lee MofÀtt Cancer Center/
United States Of America, 2H. Lee MofÀtt Cancer 
Center/United States Of America
Background: Rates of participation in clinical trials 
(CT) among thoracic patients, particularly minority 
and underserved patients remain suboptimal. 
Although patient understanding of CTs and 
identiÀcation of barriers from their perspective is 
a key component of improving access, physician 
offer of CT and barriers from their perspective has 
been understudied. Low accrual rates to trials often 
have the negative impact of prolonging duration of 
study, delaying analysis of study results, and causing 
closure of potentially important studies due to lack 
of timely accrual. The primary objective of this study 
is to retrospectively assess rates of CT offerings to 
thoracic patients and secondarily, assess the reasons 
why a CT was not offered and/or better understand 
the reasons for participation refusal. 
Methods: Conducted a retrospective analysis of 
300 thoracic patient records seen during the period 
of August 2010-October 2010. During the pre-pilot 
phase, the trained abstractors reviewed 5 cases 
to ensure inter-rater reliability. The abstractors 
reviewed records using a data abstraction tool to 
identify if patients were eligible for a treatment CT, 
eligible and offered a CT, eligible but not offered a 
CT and accepted a CT. Abstractors compared each 
record to eligibility criteria from all treatment CTs 
Keywords: Metastatic lung cancer, southern brazil, 
Overall survival, prognostic factors
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P4.072 THE IMPACT OF PATIENT AND 
HOSPITAL FEATURES ON SURGICAL 
RESECTION RATES AND SURVIVAL FOR 
PEOPLE WITH NON-SMALL CELL LUNG 
CANCER IN ENGLAND.
Anna L. Rich1, Laila Tata2, Catherine M. Free3, 
Rosamund Stanley4, Michael D. Peake5, David 
Baldwin1, Richard Hubbard2 
1Respiratory Medicine, Nottingham University 
Hospitals/United Kingdom, 2Epidemiology And 
Public Health, University Of Nottingham/United 
Kingdom, 3GlenÀeld Hospital, University Hospitals 
Of Leicester/United Kingdom, 4The Nhs Information 
Centre For Health And Social Care/United Kingdom, 
5GlenÀeld Hospital/United Kingdom
Background: There is evidence that the surgical 
resection rate and 5-year survival for lung cancer 
varies between and within countries. We used the 
National Lung Cancer Audit linked to Hospital 
Episode Statistics to quantify the extent to which 
these outcomes were modiÀed by patient and/or 
NHS Trust features. 
Methods: We included all English patients with a 
histological diagnosis of non-small cell lung cancer 
(NSCLC). We used logistic regression to quantify 
the independent inÁuence of patient level features, 
including a Charlson Index score of co-morbidity, 
and NHS Trust features on the likelihood of having 
surgery. We used Cox regression to quantify the 
impact of the same variables on survival. 
Results: There were 34,513 patients with non-small 
cell lung cancer in our dataset. Increasing age, 
more advanced disease stage, poor performance 
status and the presence of co-morbid illness were 
all independently associated with a reduced risk 
of having surgery. The 27% of patients Àrst seen 
in thoracic surgical centres were 51% more likely 
to have surgery than those seen in non-surgical 
centres (adjusted Odds Ratio 1.51, 95% conÀdence 
interval 1.16, 1.97). Surgery was the most powerful 
determinant of overall survival, reducing the 
likelihood of death by more than half (adjusted 
Hazard Ratio 0.41, 95% conÀdence interval 0.39, 
0.44). Amongst those patients who received surgery, 
there was no affect on survival based on where they 
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population. We conducted a national cancer database 
(NCDB) to evaluate the stage-speciÀc survival 
according to hospital type.
Methods: NCDB is a database containing 
approximately 70% of all cancer patients diagnosed 
in the United States. All patients with NSCLC and 
deÀned stage, diagnosed between 1998 and 2001, 
were evaluated for survival according to hospital 
type. Hospitals were divided into Community 
Cancer Centers (CCC), Comprehensive Community 
Cancer Centers (CCCC), and Teaching Research 
Centers (TRC), if they had between 100-649 patients 
per year, 650 or more patients per year, or were 
associated with a medical school respectively.
Results: Among the 253,041 patients meeting the 
inclusion criteria, there were 44,981 (18%) CCC, 
127,336 (50%) CCCC, and 80,724 (32%) TRC. 
Community hospitals (CCC and CCCC) were 
associated with a higher percentage of patients older 
than 70 years. In addition, patients with stage I or 
II were less likely to undergo surgery in the CCC 
or CCCC hospitals. TRC was associated with a 
signiÀcant improvement in 5-year survival when 
compared to CCCC and CCC for patients with stage 
I (48% vs 42.2% vs 36%), II (27.6% vs 23.4% vs 
19%), and III (10.6% vs 8.2% vs 7.1%). In patients 
with stage IV, the 6-month and 1-year survival were 
also signiÀcantly better for patients treated in TRCs 
(45.1% and 24%) compared to CCCC (40.8% and 
20.9%) and CCC (38.4% and 19.1%).
Conclusion: In patients with NSCLC, there is a 
signiÀcant difference in outcomes according to 
the hospital type. These differences may be due to 
improved quality of care, patient selection, or both.
Keywords: Non-small cell lung cancer, survival, 
hospital type
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P4.075 LUNG CANCER IN SENEGAL
Jacques Margery1, Abdou Niang2, Khady Fall2, 
Michel Thiakane2, Abdou Ndiaye2, Frédéric Riviere1, 
Hervé Le Floch1, Wanda Gaspard1, Pape Saliou 
Mbaye2, Fabien Vaylet1 
1Pneumologie, Hôpital D’instruction Des Armées 
Percy/France, 2Pneumologie, Hôpital Principal/
Senegal
Background: In Africa the incidence of lung cancer 
is rising rapidly.
Methods: The purpose of this retrospective study 
open during the selected time frame.
Results: The pre-pilot phase demonstrated inter-rater 
reliability (95%) among the abstractors and led to 
the initiation of the Study Implementation Phase. In 
this phase, abstractors are reviewing the 300 patient 
records which were randomly selected from all clinic 
visits during the selected 3 month period. The study 
implementation phase is currently underway and 
results will be available in June 2011.
Conclusion: Previous evidence indicates that 
there may be many reasons for low clinical trial 
participation. While understanding participant 
barriers is clearly important, it is also vital to 
understand physicians’ perceived barriers for 
referral of patients to clinical trials. Increasing 
the offer of CTs to more patients may improve 
participation rates, especially among minority and 
underserved patients who are often least likely to 
be offered a trial. We initiated this study to identify 
our potentially unique reasons or combination of 
reasons. The conclusions obtained from our data will 
drive interventions for increasing accruals that are 
tailored to the address the accrual issues speciÀc in 
our program. The hope is that this concept could be 
replicable for others experiencing decreasing rates of 
CT participation. 
Keywords: accrual, study
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P4.074 NON-SMALL-CELL LUNG 
CANCER SURVIVAL ACCORDING TO 
HOSPITAL TYPE
Daniel Morgensztern1, Saiama N. Waqar2, 
Janakiraman Subramanian3, Frank C. Detterbeck4, 
Ramaswamy Govindan3 
1Internal Medicine, Yale Cancer Center/United 
States Of America, 2Internal Medicine, Hematology/
oncology, Washington University In St. Louis/United 
States Of America, 3Internal Medicine, Medical 
Oncology, Washington University In St. Louis/
United States Of America, 4Department Of Surgery 
(Thoracic), Yale University School Of Medicine/
United States Of America
Background: Several studies have shown improved 
outcomes for non-small-cell lung cancer (NSCLC) 
patients treated at hospitals associated with 
teaching or high-volume surgery. These studies 
however, involved mainly surgical patients, used all 
stages combined, or were restricted to the elderly 
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developed countries and also in developing countries 
as well. Lung cancer become the leading cause of 
mortality in cancer and responsible for about one-
third of all cancer deaths. In Indonesia, lung cancer 
has become in top Àve rank cancers since 2002. 
Until now, data about lung cancer in Indonesia still 
limited. We want to share about epidemiological data 
in lung cancer especially treatment and survival-
related therapy in Indonesian in year 2006-2007.
Methods: We used cross sectional study design 
and we analyzed survival by using Kaplan Meier 
analysis.
Results: In period 2006-2007, we gathered 213 lung 
cancer patients with age varied between 20-83 years, 
mean age was 58.4 years. Male patients (161/76.2%) 
were more frequent than female (52/23.8%). More 
than half NSCLC patients had adenocarcinoma 
histology (59.1%) and more than 75% patients 
had advanced stage. Type of therapies was surgery 
(6.6%), radiotherapy (40.4%), chemotherapy 
(38.5%) and targeted therapy (12.2%). Median 
survival time for patients who had chemotherapy was 
better than not accepted (10.2 month vs 3.2 months). 
The similar result also happened for targeted therapy 
(19.9 months vs 4.4 months). One year survival 
of lung cancer patients in our hospital was 18.3% 
whereas three years survival was 1.9%.
Conclusion: We conclude that chemotherapy and/or 
targeted therapy has shown prolong median survival 
time. 
Keyword: lung cancer, chemotherapy, survival, 
Indonesia
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.077 NON-RESECTABLE MALIGNANT 
PLEURAL MESOTHELIOMA TREATED 
WITH CHEMOTHERAPY AT THE 
UNIVERSITY HOSPITAL OF AARHUS 
2000-2010: A RETROSPECTIVE STUDY
Steffen F. Soerensen, Azza Khalil, Peter Meldgaard 
Department Of Oncology, University Hospital Of 
Aarhus/Denmark
Background: Malignant pleural mesothelioma 
(MPM) is a rare cancer with a poor prognosis. 80% 
of the individuals with MPM have been exposed to 
was to analyze clinical, therapeutic, and prognostic 
features of lung cancer patients treated at the 
Principal Hospital in Dakar between 2003 and 2010.
Results: A total of 89 cases were compiled over 
the 7-year study period. Eighty eight percent 
were male smoker with a mean age of 59.2 years. 
Histological samples were obtained by bronchial 
Àbroscopy (n=62), CT-guided transthoracic needle 
biopsy (n=18), or from a metastatic site (n=9). 
The histological diagnosis was squamous cell 
carcinoma in 44 cases, adenocarcinoma in 21, 
large-cell carcinoma in 17, small-cell lung cancer 
in 5, and bronchiolo-alveolar cancer in 2. Tumor 
staging demonstrated stage I-II in 7 cases, stage 
III in 22, and stage IV in 60. Chemotherapy was 
proposed in 37 cases, radiotherapy for pain relief in 
8, and surgery in 1. Symptomatic management was 
performed in 48 % of patients. Ten patients were lost 
during the follow-up. Median survival was 7 or 3 
months depending on whether or not chemotherapy 
was performed. 
Conclusion: The much higher rate of histological 
diagnosis than in the sub-region is due mainly to 
the availability of trained personnel with access to 
bronchial endoscopy and CT-scan needle biopsy. 
Administration of cytotoxic drugs is feasible but too 
expensive due to the lack of universal health care: 
two-thirds of cases only beneÀt from symptomatic 
management whereas chemotherapy signiÀcantly 
improved median survival by 4 months (p < 0.0001). 
Prognosis of the disease is poor because management 
is undertaken at an advanced stage. Lung cancer 
is a health issue in Dakar, Senegal. It is absolutely 
necessary to quickly propose therapeutic standards 
adapted to the African socio-economic setting as 
well as an anti-tobacco prevention policy. 
Keywords: Lung cancer, africa, Epidemiology
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P4.076 NSCLC IN INDONESIA: 
TREATMENT PRACTICE & 
EFFECTIVITY-SHARING EXPERIENCES 
IN DHARMAIS CANCER HOSPITAL
Noorwati Sutandyo1, Eddy Suratman2, Achmad M. 
Jayusman2, Dewi S. Soeis2, Evlina Suzanna2 
1Internal Medicine, Medical Oncology, “dharmais” 
Cancer Hospital/Indonesia, 2”dharmais” Cancer 
Hospital/Indonesia
Background: Lung cancer is the health problem in 
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P4.078 EPIDEMIOLOGY AND 
SURVIVAL ANALYSIS OF LUNG 
CANCER - 10 YEARS OF EXPERIENCE 
IN A PORTUGUESE RESPIRATORY 
REFERENCE CENTER
Sergio A. Campainha Fernandes1, Ana Antunes1, Ana 
Barroso1, Pedro Brinca2, Sara Conde1, SoÀa Neves1, 
Barbara Parente1 
1Pulmonology, Centro Hospitalar De Vila Nova 
De Gaia/espinho Epe/Portugal, 2Department Of 
Economics, Stockholm University/Sweden
Background: Lung cancer is the third most common 
in Portugal, and the leading cause of death by 
cancer. There are no large scale studies reporting 
its epidemiology and survival analysis in Portugal. 
With this study we aim to make an epidemiological 
analysis by gender, histological type and stage of 
patients diagnosed lung cancer, and determination of 
overall survival in studied population.
Methods: Retrospective analysis of patients who 
attended our Pulmonary Oncology Consultation 
between January 2000 and December 2009.
Results: 1142 patients were followed during that 
period, with a mean age of 64.1±11.9 years; 944 
(82.7%) male. At the time of diagnosis 48.2% were 
smokers and 19.2% non-smokers. Over the years the 
incidence of lung cancer in former smokers increased 
(p=0.001), and decreased in smokers (p=0.001), 
but it did not vary in non-smokers (p=0.42). Most 
patients presented performance status 0 and 1 
(67.6%). The most frequent histological type was 
adenocarcinoma – ADC - (450, 39.4%), followed by 
squamous cell carcinoma – SC - (282, 24.7%), non-
differentiated NSCLC (211, 18.5%), SCLC (139, 
12.2%) bronchiolalveolar carcinoma – BAC - (22, 
1.9%), carcinoid tumor – CT - (22, 1.9%) and large 
cell carcinoma – LCC - (16, 1.4%). In female gender, 
the leading histological type was adenocarcinoma 
(55.6%), followed by NSCLC (37, 18.7%), assuming 
the other types less preponderance. The most usual 
histological type in male was adenocarcinoma (340, 
36.0%), followed by squamous cell carcinoma 
(263, 27.9%), NSCLC (174, 18.4%) and SCLC 
(125, 13.2%). At the time of diagnosis 82.1% of 
patients were on Stage IIIB and IV. Over the years 
the number of diagnoses at stage IA-IIIA did not 
change. Diagnosis at stage IV increased (p<0.001) 
and at stage IIIB decreased (p<0.001) over time. 
Considering patients with lung cancer, increasing age 
asbestos. Other agents are suggested to be DNA-
virus SV40 and other silicates. Late diagnosis, 
staging-difÀculties and underlying illness which 
make the patients unÀt for curatively intended 
trimodal therapy are some of the challenges for this 
cancer. Over the past years it has been discussed 
which platin-based doublet-regime one should use 
as Àrst line palliative treatment. This work aims to 
study the epidemiologic characteristics and overall 
survival of patients with non-resectable MPM treated 
with chemotherapy at the University Hospital of 
Aarhus year 2000 - 2010. 
Methods: Review of journals. Data are structured 
using the Aarhus Lung Cancer Register and statistics 
are analyzed using SPSS.
Results: A total of 80 consecutive patients with 
MPM referred to the oncology department in 
Aarhus. First line chemotherapy includes cisplatin/
vinorelbine (standard Àrst line until summer 
2007), cisplatin/pemetrexed (standard Àrst line 
since summer 2007) as well as monotherapy with 
pemetrexed. The median age of the 80 patients (69 
males and 11 females) at diagnosis was 64 years 
(range 40-80). 46% of the patients had epithelioid 
histologic subtype and 54% had non-epithelioid 
subtype (sarcomatoid, biphasic and NOS). As Àrst 
line treatment 34% received cisplatin/vinorelbine, 
45% received cisplatin/pemetrexed and 21% 
received pemetrexed as monotherapy. Median 
overall survival (mOS) for the whole group was 13,1 
months (95% CI 10,3-16,0). We found no signiÀcant 
difference in mOS between patients treated with 
cisplatin/vinorelbine (mOS 15,2 months, 95% CI 
9,0-21,4) and cisplatin/pemetrexed (mOS 15,1 
months, 95% CI 6,3-24,0). Median OS for patients 
treated with pemetrexed as monotherapy as Àrst line 
was 7,4 months (95% CI 4,2-10,8). Patients with 
epithelioid histologic subtype had a signiÀcantly 
better mOS (15,2 months, 95% CI 11,6-18,8) 
compared to patients with non-epithelioid subtype 
(8,9 months, 95% CI 4,9-12,9). 
Conclusion: We found that subtype of histology is 
signiÀcantly associated with survival. Patients with 
epithelioid histology have a better prognosis than 
patients with non-epitheloid subtype. Our results 
show no signiÀcant difference in overall survival 
in patients who received different platin-based 
doublet-regimes. MPM is still a disease with a poor 
prognosis, and the survival rates in this retrospective 
study are comparable to other published data. 
Keywords: malignant pleural mesothelioma, 
Chemotherapy, survival
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Environmental Tobacco Smoke (ETS) each of them 
were exposed to.
Results: Participants exposed to workplace second-
hand smoke were more likely to have any detectable 
level of NNAL (P=.005) and higher mean levels 
of NNAL (P < .001) compared with non-exposed 
participants. Increased levels of NNAL were also 
associated with hours of a single workplace exposure 
(P=.005). 
Conclusion: Non-smoking employees left 
unprotected from workplace secondhand smoke 
exposure had elevated levels of a tobacco-speciÀc 
carcinogen in their bodies. All workers—including 
bar and restaurant workers—should be protected 
from indoor workplace exposure to cancer-causing 
secondhand smoke.
Keywords: Environmental Tobacco Smoke(ETS), 
Tobacco Control, Cancer, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.080 STUDY OF RELATIONSHIP 
OF AGE AT ONSET OF SMOKING, 
INTENSITY OF SMOKING (MEASURED 
IN PACK YEARS), AND DURATION 
OF SMOKING TO STAGE OF LUNG 
CANCER, PATHOLOGICAL SUBTYPES 
AND OUTCOME: SINGLE CENTER 
EXPERIENCE FROM A COMMUNITY 
CANCER CLINIC SERVING SUBURBAN 
AND RURAL POPULATIONS IN SOUTH 
CAROLINA IN THE US
Kashyap B. Patel1, Akshay Daji2, Asutosh J. Patel2, 
Maharshi Patel2, Asutosh Gor2, Niyati Nathwani2, 
Sashi Naidu2, James Welsh2 
1Medical Oncology, Carolina Blood And Cancer 
Care/United States Of America, 2Carolina Blood And 
Cancer Care/United States Of America
Background: This study was aimed at identifying 
relationship between duration, intensity and quantity 
of smoking (age when started smoking, number of 
pack years, type of cigarettes-with or without Àlters) 
with stage of lung cancer, pathological subtypes and 
response to treatment with different subtypes. We 
intended to carry out multivariate analysis to identify 
if cigarette smoking at a young age with long history 
was associated to decreased risk of ADC, LCC and 
CT (p<0.001), and increased risk of SC (p<0.001). 
Along the years BAC incidence decreased (p=0.01) 
and non-differenciated NSCLC incidence increased 
(p=0.03). Overall median survival was 15.6 months 
and overall survival at 5 years 16.7% We obtained 
the following median survival: NSCLC (including 
non-differentiated NSCLC, ADC, BAC and SC): 
15.8 months; SCLC: 7.4 months; Carcinoid tumors: 
21.0 months. Male gender and smoking history were 
associated to worse prognosis (p<0.01 and p<0.05, 
respectively).
Conclusion: An increase in diagnosis of lung 
cancer in early stages over the years was not seen. 
However, the increasing number of diagnoses in 
stage IV is probably due to the emergence of new 
and more sensitive staging techniques. Surprisingly, 
despite more accurate diagnostic and pathology 
techniques, the number of non-differenciated 
NSCLC has increased over the years. The median 
overall survival, as well as for each histological 
type, falls within the described in literature. Male 
gender and tobacco use history were associated 
to worse prognosis. Further studies are needed to 
enframe these epidemiologic Àndings in national and 
international reality.
Keywords: Epidemiology, Lung cancer
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P4.079 THE RISK OF TOBACCO-
SPECIFIC LUNG CARCINOGEN AMONG 
NON-SMOKING RESTAURANT AND BAR 
WORKERS IN NIGERIA
Emmanuel O. Odiase, 
Tobacco/cancer Control, University Of Ibadan/
smokefree Foundation/Nigeria
Background: To say that tobacco smoking causes 
lung cancer is an understatement. Smoking causes 
numerous cancers but has lung cancer on the highest. 
The alrming issue at the hand is that smoking may 
accrue to lung cancer among non smokers in work 
places or elsewhere. 
Methods: We examined about 200 restuarant and bar 
non-smoking staff in four geo-political locations in 
Nigeria-Lagos, Kano, Port-Harcourt and Abuja from 
2005-2009. Secondhand smoke were compared with 
results from these participants who were exposed to 
it. We took note of how long each staff had worked 
in these bars or restuarents and the amount of 
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Background: Evidences of lung cancer cases from 
scientiÀc researches have being on the rise in the 
last few decades and tobacco which is a major risk 
factor causes about 90% of lung cancer diagnosed 
around the world. The need to reduce this scourge 
has become more important. 
Goal: The goal of this study is to ascertain the 
beliefs, knowledge, understanding, attitudes and 
treatment access to lung cancer among rural dwellers 
in Nigeria. 
Methods: An interview guide was designed 
speciÀcally for these studies in which 700 rural 
dwellers in Nigeria most of which were men, age 45 
and over took part in. It contained questions about 
beliefs, knowledge, understanding and attitudes 
about Lung Cancer Diagnosis and incidences. In 
addition, questions assessing the variables of the 
Health Belief Model and health motivations also 
were included. The data were obtained during face-
to-face interviews in the primary language of the 
participating people. The interviews were translated 
into English. 
Results: Out of the 700 people who participated, 
only 7% of the participants knew about lung 
cancer, 3% had undergone at least one Lung Cancer 
Diagnosis during their lives, and 90% were not 
aware of the disease. There was little or no access to 
treatment even at early detection in these rural areas 
thereby causing vulnerability to loss of life. Majority 
of these rural people (95%) said they knew little or 
nothing about lung cancer. While 15% of the people 
said detecting cancer early was important, only 3% 
reported that cancer could be cured. Age, education, 
or mother tongue showed no statistically signiÀcant 
relationship with the lung health practice scores. 
However, proÀciency with the English language (p 
= 0.009) and number of years exposed to awareness 
and education (p = 0.009) had a signiÀcant 
relationship with the lung health practice scores. The 
signiÀcant explanatory factor for the variable lung 
health practices was a cue to action (p = 0.009). 
Conclusion: The level of awareness and treatment 
access to lung cancer amongst Nigeria’s rural 
dwellers is extremely low thereby making them not 
to engage in screening and/or detection practices. 
This alarming situation calls for urgent intervention 
of medical/health organizations to provide immediate 
lung cancer awareness, diagnosis and care so as to 
reduce incidences or threat at early detection.
Tobacco which is known as a major cause of lung 
cancer (90%) is widely used by these rural dwellers 
was an independent risk factor for development of 
speciÀc type of lung cancer at an advanced stage and 
carried poor prognosis. 
Methods: information regarding smoking history 
(age when started smoking, duration of smoking, 
number of packs smoked per day and number of years 
of smoking) was collected in prospective method for 
patients presenting at a small community based cancer 
clinic in suburban and rural South Carolina in the US. 
Demographic data and other relevant past medical 
history was collated and analyzed from electronic 
health records (Enterprise Healthcare by Agastha 
Healthcare). Statistical methods applied included 
hazard ration and multivariate analysis. 
Results: Data on total of 267 (178 males; 89 
females) patients were reviewed in this study. 168 
patients were diagnosed with advanced (stage III 
and IV AJCC classiÀcation) cancer. Relative risk 
of developing advanced stage cancer with early age 
smoking was 2.82 by hazards ratio. Proportional 
odds ratio revealed a linear relationship between 
intensity of smoking (in terms of number of pack 
years) and advanced stage in lung and head and neck 
cancer. Multivariate analysis conÀrmed that age at 
smoking and intensity of smoking were independent 
risk factors for advanced stage cancer. 
Conclusion: Intensity of smoking (deÀned as 
number of packs of cigarettes smoked per day 
multiplied by number of years smoked = pack years) 
is a very strong and independent risk factor for 
development of advanced lung cancer with hazards 
ratio of 2.82 also conÀrmed by multivariate analysis. 
For every incremental increase in smoking intensity, 
there is an exponential increment in the likelihood 
of early development of cancer and also advanced 
stage at presentation. It is very important to plan and 
carry out aggressive smoking cessation education 
at elementary and middle school level to target 
vulnerable population at a very young age. 
Keyword: smoking, cigarette, lung cancer, stage
Poster Session 4 – Tobacco Control Thursday, 7 July 2011 10:00-12:30
P4.081 THE BELIEFS, KNOWLEDGE, 
UNDERSTANDING, ATTITUDES AND 
TREATMENT ACCESS TO LUNG 
CANCER AMONGST RURAL DWELLERS 
IN NIGERIA
Emmanuel O. Odiase 
Tobacco/cancer Control, University Of Ibadan/
smokefree Foundation/Nigeria
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The greatest percent of the diseased (44.4%), started 
smoking up to the age of 15-years. LC patients, in 
average, smoked almost 29.95±11.03 cigarettes per 
day (c/day), compared to the controls, in whom the 
average was 21.35±9.50 c/day. Most of the members 
in both groups consumed cigarettes with Àlter (LC-
87.1%; CG-97.4%). In the group with LC 33% 
tried to stop smoking, and their stoppage period, in 
average, was 9.48±13.04 months. According to the 
case-control study, CS and FS, together, had 4.40 
(95% CI, 2.44-7.93), times as great risk to become 
ill from LC in relation to the NS. CS who smoked 
>40 c/day had almost four times (OR=3.56; 95% 
CI, 1.23-12.64), signiÀcantly greater risk to get 
LC, compared to those who smoked <40 c/day. CS 
whose length of the smoking period was >40 years, 
had 3.94 (95% CI, 2.11-7.35), times greater risk 
to become ill compared to those who smoked <40 
years. Exposition to passive smoking was registered 
in 82.4% from the members of the IG, i.e. 63.2% 
members of CG. In addition, 42.8% of the diseased 
nonsmokers inspired the cigarettes smoke at the 
working place and at home. Exposition to passive 
smoking lasted longer than 16 years in almost all 
diseased persons (92.9%). The risk of developing 
LC is 2.72 (95% CI, 0.7-10.59), times greater in the 
exposed to passive smoking, compared to the non-
exposed. 
Conclusion: Lung and other cancers caused 
by tobacco are often untreatable at the time of 
diagnosis. The key to reducing these cancers is to 
prevent initiation of smoking in young people, and 
to encourage smokers to quit. Quitting smoking 
substantially reduces cancer risk. 
Keywords: cigarette smoking, passive smoking, 
Lung cancer
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P4.083 TOBACCO CONTROL IN CHINA
Donghong Chen, Xiuyi Zhi 
Thoracic Surgery, Beijing Lung Cancer Center/
China
Background: With 350 million smokersin 2002, 
China accounted for more than one-fourth of the 
world’s annual tobacco consumption and own the 
world’s largest tobacco company.
Methods: The National Prevalence Surveys in 
2002 showed that the smoking rate in adult male 
and female was 66.0% and 3.08% respectively. 
thereby making them so vulnerable. Awareness is 
suggested while providing smoking cessation for 
smokers who intend to quit. 
Keywords: tobacco, Rural Nigeria, Lung cancer, 
diagnosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 4 – Tobacco Control Thursday, 7 July 2011 10:00-12:30
P4.082 TOBACCO USE AND 
SECONDHAND SMOKE AS RISK 
FACTORS FOR LUNG CANCER
Irina Pavlovska, Nikola Orovcanec, Beti ZaÀrova, 
Biljana Tausanova 
Department Of Epidemiology, Institute Of 
Epidemiology And Biostatistics/Macedonia
Background: Cancer represents a particular problem 
in highly developed industrial countries. In these 
countries, a great percent of general population 
belongs to older age categories, in which the risk 
of occurrence of this disorder is higher. Lung 
cancer (LC) is the most frequent malignant disease 
in the world. Worldwide, about 80% of LC cases 
in men and 50% in women are caused by tobacco 
smoking. Other risk factors include secondhand 
smoke and exposure to asbestos, radon, arsenic, and 
air pollution. Tobacco also causes deaths among 
nonsmokers. Exposure to secondhand smoke in the 
home, workplace, and public areas also kills tens of 
thousands of nonsmokers every year. Our speciÀc 
objective was to analyze the role of active and 
passive smoking in lung cancer risk. 
Methods: The investigation was an analytical type 
of case-control study. It elaborated 185 patients 
diseased of lung cancer (investigated group-IG), 
and the same number of persons without malignant 
disease (control group-CG). Both group members 
were interviewed during the initial 18-month 
period of the study. Risk analyses were done using 
unconditional logistic regression, which provides 
results in the form of crude odds ratio. The odds 
ratios and their 95% conÀdence intervals (CI) were 
computed. 
Results: Among patients were 67% of current 
smokers (CS), 23.8% of former smokers (FS) and 
9.2% of never smokers (NS), compared to 40.5% of 
CS, 28.7% of FS and 30.8% of NS among controls. 
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Background: For over twenty years, the tobacco 
industry has made marketing and distribution of 
tobacco products to youths a core of its marketing 
strategy in developing countries.
Methods: This paper will try to educate and expose 
some of the secret parties of British America 
Tobacco and how to prevent students and youths 
from their tricks and secret parties.
Results: Tobacco Control advocates in Nigeria 
lodged in a hotel which the BATN secret party was 
held, this recent event was organized to promote 
the Pall Mall brand of BATN. It was organized 
in all the six geo political zones in the country 
and was heavy on young people. Invitation cards 
were secretly given out in secondary schools and 
colleges and young girls were encouraged to attend. 
A seminar was organized by the tobacco control 
advocates for the same students from different high 
schools in Ogun and Lagos State to sensitize them 
on the harmful effect of tobacco smoking. Attendees 
of the workshop were surprised at the lies of the 
BATN and many of the high school students were 
not aware of the chemicals included in cigarette, 
this facts made students who had intentions to start 
smoking stopped. Most of the teachers and school 
head who attended the workshop also realized the 
damages caused by smoking and immediate actions 
were taking by creating anti-smoking clubs in high 
schools.
Conclusion: Teenagers in the developing countries 
should be encouraged to advocate for tobacco 
control thereby making them role models and not 
smoke models. This effort through a report by the 
print media said to have rescued student for being a 
cancer patient in the future.
Keyword: Role models, Smoke Models
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P4.085 “TOBACCO INDUSTRIES” A 
THREAT TO THE YOUTH
Seye O. Omiyefa 
Programs, Youth Action On Tobacco Control And 
Health (yatch)/Nigeria
Background: The Tobacco multinationals has 
turned to a vampire who kills both day and night, 
the advertisement and secret parties being organized 
by the big tobacco multinationals especially in 
the developing world has recruited hundreds of 
thousands of youths. It was also revealed that the 
From 1984 to 2007, smoking prevalence, especially 
smoking prevalence of males, remained at high levels. 
Subsequently, prevalence of exposure to secondhand 
smoke is also as high as 52.9%. About 540 million 
suffered from Second Hand Smoking exposure in 2005.
Results: China is a FCTC member country. The 10th 
Session of the Standing Committee of the National 
People’s Congress ofÀcially ratiÀed the WHO/FCTC 
on August 28th 2005. FCTC took into effect on Jan 
9th, 2006. Tobacco Control Organizations in China 
include: Ministry of Health, China CDC- National 
Tobacco Control OfÀce, WHO Collaborating 
Center for Tobacco or Health, China Association 
On Tobacco Control, National Health Education 
Institute, China Foundation of Cancer, Think Tank 
Center and so on. In 2004, Premier Wen Jiabao met 
general director of the WHO and promised that the 
2008 Olympic Games would be tobacco free.
Conclusion: Regulations on no-smoking in public 
places in Beijing were enacted from May 1st, 
2008 before the 29th Olympic Games. Smoking is 
forbidden in the following public places: 1. Indoor 
areas of medical organizations; 2. Infant institutions 
and kingdergartens; 3. Middle schools, primary 
schools, mid-level vocational schools; 4. Universities 
and other teaching areas of educational and training 
organizations. 5. Theatres, music halls, exhibition 
halls, museums, art galleries, libraries, science and 
technology museums, archives, children’s palaces, 
memorial halls and other places for science & 
teaching, culture and art. 6. Business center of 
commerce, Ànance, post and tele-communications; 
7. Inside buses, taxis, rail transits and other public 
transportation tools, related ticket ofÀces and indoor 
platforms; 8. Cultural relics protection units open 
to the public; 9. Gymnasiums; 10. Contest area and 
seating area of stadium. 
Keywords: Tobacco Control, China
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.084 TEENAGERS AS A TOOL AGAINST 
TOBACCO SMOKING, NOT MODELS 
FOR TOBACCO INDUSTRIES
Seye O. Omiyefa 
Programs, Youth Action On Tobacco Control And 
Health (Yatch)/Nigeria
Copyright © 2011 by the International Association for the Study of Lung Cancer S1435
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
policies, and secondary prevention scenarios, i.e. 
spiral CT scan. 
Methods: A dynamic model describing the evolution 
of current, former, and never smokers was developed. 
Quit and relapse rates were estimated by Àtting the 
model with smoking prevalence in Italy, 1986-2009. 
The estimated parameters were used to predict 
smoking prevalence and lung cancer smoking 
attributable deaths under different scenarios: 1) 
status quo, i.e. maintaining present smoking habits; 
2) increase in cigarette taxes; 3) implementation of 
cessation treatments (Ànancial coverage of cessation 
treatments, empowering an active quitline, widespread 
use of counselling among general practitioners and 
health professionals); 4) implementation of lung 
cancer screening for heavy smokers and heavy 
former smokers; 5) implementation of lung cancer 
screening for all smokers and former smokers; 6) 
implementation of cessation treatments and screening. 
In the screening scenarios a 20% decrease in lung 
cancer mortality was assumed according to National 
Lung Screening Trial results. 
Results: Quit rates resulted very low: 2000-2009 
weighted means were 2.5% and 1.8% for males and 
females, respectively. Maintaining present smoking 
habits, prevalence will remain higher than 10% in 
the next three decades, however smoking attributable 
deaths for lung cancer will decrease by 30.4%. The 
increase in cigarette taxes showed a 33.2% reduction 
in the number of smoking attributable deaths for 
lung cancer. The lung cancer screening showed a big 
effect in reducing the smoking attributable number of 
deaths for lung cancer in the Àrst decades. It’s effect 
varied largely depending on the population involved: a 
decrease of 39.9% and 33.6% in the number of deaths 
for lung cancer, from 2009 to 2040, was observed 
for screening scenarios for all smokers and heavy 
smokers, respectively. Screening for all smokers was 
the scenario with the major effect until 2020, after 
which the cessation treatments scenario gave higher 
reduction of lung cancer mortality (48.7%). Screening 
for heavy smokers was more effective in reducing 
lung cancer deaths with respect to cessation treatments 
scenario only in the Àrst 2-3 years.
Conclusion: The combination of lung cancer 
screening and cessation treatments could reach the 
best results in terms of lives saved for lung cancer 
mortality. 
Keywords: population model, smoking cessation 
treatments, lung cancer screening, smoking 
attributable death
British American Tobacco (BAT) had conducted 
several surveys to determine the rate of youth 
smoking in Nigeria.
Methods: Research and experience has showed 
various trick and strategies of the tobacco industries. 
It is therefore appropriate to implement laws that will 
curb every secret parties and advert used to promote 
its new product “Pall Mall” in developing countries 
especially Nigeria.
Results: These methods will creatively counter 
and expose the enticing ACTIVITIES of tobacco 
multinationals.
Conclusion: Since the tobacco multinationals are 
recruiting more teenagers and youths everyday, 
thereby killing millions to make billions, efforts 
should be made in monitoring the tobacco industries 
to reduce both direct and indirect advertisement by 
the tobacco companies and engage more teenagers 
and youths in tobacco control activities with 
materials that will reveal the lies of the tobacco 
industry.
Keyword: Youth, Tobacco, Tobacco Industries
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P4.086 PREDICTION OF FUTURE 
SMOKING ATTRIBUTABLE DEATHS 
FOR LUNG CANCER IN ITALY 
UNDER PRIMARY AND SECONDARY 
PREVENTION SCENARIOS
Giulia Carreras, Giuseppe Gorini, Eugenio Paci 
Environmental And Occupational Epidemiology 
Unit, Ispo Cancer Prevention And Research Institute/
Italy
Background: Cigarette tobacco smoking is well 
known to be the major cause for lung cancer and for a 
wide variety of diseases. Smoking prevalence in Italy 
decreased by 21% from 1986 to now for male and 
females, as effect of changes in smoking initiation and 
quit rates, and in part attributable to the development 
of tobacco control policies. As a consequence, 
smoking attributable deaths for lung cancer and for 
other causes decreased in the last years in Italy, mainly 
for men. Policies not yet implemented in Italy and 
lung cancer screening (spiral CT scan) may help in 
further decreasing smoking prevalence, and therefore 
also in reducing smoking attributable deaths. This 
work aims to predict the number of future smoking 
attributable deaths for lung cancer and for all causes 
in Italy, assuming both primary, i.e. tobacco control 
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of special interest to maintain the abstinence from 
smoking to further eliminate tobacco related health 
problems in male smokers participating in a lung 
cancer screening trial. 
Keywords: lung cancer screening, smoking 
cessation, teachable moment, health certiÀcate effect
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P4.088 TOBACCO,WOMEN AND CANCER
Olufunmilayo O. Shaba1
1Administration, Africa Tobacco Control Regional 
Initiative/Nigeria, 2Admin, Africa Tobacco Control 
Regional Initiatiative(atcri)/Nigeria
Background: Tobacco , Women ,and Cancer: 
facts and Àgures of tobacco related diseases that 
is common among women Preamble: As early as 
1939, Franz Hernan Muller, a German researcher 
had observed a relationship between smoking and 
lung cancer. Dr Morton Levin also made a similar 
observation eleven years later and published his 
Àndings in the Journal of the American Medical 
Association (JAMA). Despite these Àndings and that 
of other notable researchers such as Ernst Wynder 
and Evarts Graham, the tobacco industry continued 
to raise doubts about the methodology adopted in 
these works until the landmark work of Doll and 
Hill published in the British Medical Journal in 1954 
which provided the evidence of a dose-response 
relationship between tobacco smoking and lung 
cancer. This prompted the setting up of an Advisory 
Committee and a full-scale investigation by the 
Surgeon General of the United States, Dr Luther 
Terry which culminated in the Surgeon-General‘s 
report on smoking and health published in 1964 
stating that cigarette consumption is a health hazard 
of sufÀcient importance to warrant appropriate 
remedial action.
Methods: Cancer Smokers are at increased risk 
of developing cancer. Common cancers related 
to smoking include cancers of the mouth, throat, 
pharynx, larynx (voice box), oesophagus (food 
pipe), lungs, pancreas, kidney and cervix. Lung 
disease An estimated 85 per cent to 90 per cent of 
lung cancer is attributable to smoking. Smoking 
has also been known to cause chronic obstructive 
pulmonary diseases such as emphysema, bronchitis 
and asthmatic bronchitis. Heart disease Smokers are 
at increased risk for both stroke and cardiovascular 
disease, including high blood pressure and heart 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.087 SMOKING BEHAVIOURAL 
CHANGE IN MALE SMOKERS OF A 
RANDOMIZED CONTROLLED LUNG 
CANCER SCREENING (NELSON) TRIAL: 
4-YEAR FOLLOW-UP.
Carlijn V.D. Aalst1, Rob J. Van Klaveren2, Karien 
V.D. Bergh3, Marc Willemsen4, Harry J. De Koning5 
1Public Health/ Pulmonology, Erasmus MC/
Netherlands, 2Erasmus Medical Center/Netherlands, 
3Pallas/Netherlands, 4Maastricht University/
Netherlands, 5Public Health, Erasmus MC/
Netherlands
Background: Lung cancer screening might be 
a teachable moment for smoking cessation or a 
possible health certiÀcate effect. Previous analysis 
indicates that smokers in the screen arm of the 
Dutch-Belgian lung cancer screening (NELSON) 
trial were less likely to refrain from smoking 
compared with control arm participants after 2-year 
follow-up. Aim of the current study is to investigate 
whether this result persists over time. 
Methods: Two random samples were selected 
of 50-75 years old male smokers randomized to 
the screen (n=641) or control arm (n=643) of the 
NELSON trial. Smoking behavioural change was 
investigated from randomization (T0) to 4 years of 
follow-up (T2). Differences in smoking behaviour 
and predictors of prolonged smoking abstinence 
were investigated. Data was analyzed according to 
the intention-to-treat in addition. 
Results: Responses were 88.2% and 60.2% in 
the screen and control arm. Data was weighted 
for non-response bias in control arm participants. 
At T2, prolonged smoking abstinence rates were 
24.3% (screen arm) and 29.3% (control arm) 
(p=0.09). Multivariate analysis showed that lower 
baseline nicotine dependency and randomization 
to the control arm increased the likelihood of being 
abstinent from smoking at follow-up (p<0.05). 
Conclusion: In conclusion, male smokers who 
received CT screening for lung cancer who were 
more addicted to nicotine were less likely to refrain 
from smoking, although the impact is limited. 
Adequate treatment of nicotine addiction would be 
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continue smoking into pregnancy may smoke more, 
thereby exposing the fetus to the dangerous health 
effects of tobacco more often. Effects on the fetus 
Carbon monoxide, nicotine and other chemicals in 
tobacco smoke enter the mother‘s bloodstream and 
pass into the baby‘s body. This affects the supply of 
food and oxygen a baby needs to grow. Therefore, 
a common effect of smoking during pregnancy 
is low birth weight of the infant. Having a small 
baby does not mean labour and delivery will be 
easier. On the contrary, a smaller baby is not strong 
enough to help in its delivery, making the labour 
more difÀcult. Low-birth-weight infants are also 
more likely to suffer health and developmental 
complications throughout life, including delayed 
speech, cerebral palsy, visual and hearing difÀculties, 
learning disabilities and respiratory problems. 
Other increased risks for babies exposed to tobacco 
before birth include premature labour and delivery 
placenta abnormalities such as low-lying placenta 
or premature separation of the placenta from the 
wall of the uterus; each of these conditions can be 
serious for both mother and baby increased risk of 
spontaneous abortion, miscarriage, stillbirth and 
early infant death increased risk of sudden infant 
death syndrome (SIDS, or crib death) Effects on 
breastfeeding The nicotine in tobacco transfers into 
breast milk. This may affect the way breast milk 
smells and tastes, and may decrease the amount 
of milk produced by a nursing mother. Although 
nursing mothers who use tobacco should not be 
deterred from breastfeeding, quitting tobacco (and 
therefore eliminating nicotine from the mother‘s 
breast milk) is best for both the baby and mother. 
Effects on child development Effects on long-term 
development Children exposed to tobacco before 
birth may experience the negative effects of that 
exposure for years after theyare born. Studies show 
that children are at increased risk for developmental 
and behavioural problems such as immature, 
aggressive, and oppositional or deÀant behaviour  
inattention and impulsivity reduced lung functioning 
poor performance at school disruptive or impulsive 
behaviour depression and anxiety decreased motor, 
memory, language, creativity or reasoning skills 
developing alcohol or other drug problems as they 
get older Evidence suggests that children of mothers 
who smoked during pregnancy are at increased risk 
of developing tobacco dependence later in their 
lives. Also, the transition from initial to daily use 
of cigarettes was more rapid for women who were 
exposed prenatally to tobacco.There is also growing 
attack. Gastrointestinal disease There appears to 
be a link between smoking and the development of 
some stomach and digestive system disorders. Peptic 
ulcers (holes in the stomach or digestive tract) and 
Cohn‘s disease (inÁammation of the digestive tract) 
tend to be more common among smokers than non-
smokers.
Results: Effects on women‘s health Reproduction 
and fertility Smoking may have harmful effects 
on a woman‘s reproductive system and her ability 
to become pregnant. Women who smoke and use 
oral contraceptives (birth control pills) are at risk 
of developing serious cardiovascular side effects 
such as blood clots, heart attack or stroke. Smoking 
can lead to women having problems with becoming 
pregnant, and pregnant women who smoke are more 
likely than non-smokers to havea miscarriage or 
premature birth. Smoking may affect menstruation. 
Monthly periods can stop or be disrupted, and there 
is some evidence that smoking may destroy eggs 
in the ovaries, even in young women. Women who 
smoke are more likely to go through menopause 
early, meaning that their menstrual cycle, and 
therefore their ability to become pregnant, may end 
at an earlier age. Women who smoke are at increased 
risk of developing osteoporosis, a condition in 
which the bones become thin and weak. There is 
some evidence that women are more likely than 
men to develop lung cancer and other respiratory 
diseases after the same levels of exposure to 
cigarettes. Women who smoke are more likely to 
develop cervical cancer than women who do not 
smoke. Women who smoke are at increased risk of 
developing cataracts. Effects during pregnancy There 
is no known safe level of tobacco consumption. 
It is not clear whether a child‘s health problems 
are caused directly by a mother’s use of tobacco 
during pregnancy or in combination with other 
factors including poor nutritional habits alcohol 
consumption using other drugs using more than one 
drug sleep problems a mother‘s general health prior 
to pregnancy genetics how much alcohol, tobacco or 
other drugs are consumed during pregnancy at what 
stage in the pregnancy a substance is consumed  the 
length of time over which a substance is consumed 
The effects of tobacco use have been difÀcult 
to study because these other factors also affect 
pregnancy. However, it is safest to avoid alcohol, 
tobacco and other drugs during pregnancy. Nicotine 
and its metabolite, cotinine, are metabolized much 
more quickly by pregnant women than by non-
pregnant women. This could mean that women who 
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P4.089 NON AIRED MASS MEDIA 
METHODS IN TOBACCO CONTROL
Dilip K. Acharya 
Hon.secretary, Cancer Society Of Madhya Pradesh/
India
Background: World Health Organisation estimates 
that 1.3 million people die of lung cancer worldwide 
every year, 90 percent because of smoking. Tobacco 
is the leading cause of not only Lung Cancer but 
also of Oral Cancers as well as many other cancers.
WHO had proposaed its Àrst health treaty in the 
form of Framework Convention on Tobacco Control 
(FCTC) which has been ratiÀed and implemented 
by many countries, however. tobacco control and its 
different aspects still elude many. In the FCTC & 
MPOWER policy of WHO -W stands to Warn about 
hazards of Tobacco, specially the health hazards. 
Many governments are working on this, however, 
this complex problem requires attention of all parties 
and hence the role of NGO. Cancer Society of M.P. 
has been working in the Àeld of Cancer awareness 
& Tobacco control for many years. We wish to share 
our different methods of tobacco control with all 
the delegates. Although, TV media has the highest 
visibility, non aired mass media methods for creating 
awareness, has its own importance and many a times 
it is much cheaper and gets free coverage also.
Methods: Some of the activities conducted by 
us for Tobacco control and creating awareness 
about its health hazards are:- Posters:We have 
prepared, published and distributed various posters 
for tobacco control and self examination of oral 
cavity. Our posters have won international awards 
and have also been presented in many national & 
international conferences. The release of poster by 
eminent personalities, politicians gives us free media 
coverage on the topic too. One of our posters was 
also tested by Americans for its impact in Egypt. 
Pamphlets:- We have distributed nearly 100 thousand 
pamphlets in the holy Sinhastha Mela (fair) where 
nearly 10 million people participated. Hoardings/
Bill Boards:- Installed at strategic points they are 
a source of constant reminder to th health hazards 
of tobacco. Lectures/symposiums:- Myself & other 
members regularly give lectures on different aspects 
of tobacco control & its health hazards. Exhibitions:- 
Participation & display of banners,posters etc in 
various exhibitions, where many people come & 
see them. Public Rally:- Rally taken out through the 
evidence that children whose fathers smoked before 
conception are at risk of developing childhood 
leukemia as a result of genetic damage caused by 
tobacco exposure.This risk is higher for children 
whose mothers also smoked before conception, and 
children who are also exposed to second-hand smoke 
after birth. Second-hand smoke Second-hand smoke 
contains higher levels of tar, nicotine and carbon 
monoxide than inhaled cigarette smoke. Exposure 
to second-hand smoke, also called passive smoking, 
can cause problems during and after pregnancy 
Effects on women Women exposed to signiÀcant 
amounts of secondhand smoke during pregnancy are 
more likely to give birth to low-birth-weight babies. 
Women, even if they do not smoke, are at risk of 
developing lung cancer and coronary heart disease 
when exposed to second-hand smoke. Smokeless 
tobacco Mothers who use smokeless tobacco during 
pregnancy are at risk of pre-term delivery and 
decreased infant birth weight, even at full gestational 
age. There are indications that using smokeless 
tobacco is just as harmful to fetal health as cigarette 
smoking. Nicotine replacement therapy It is not yet 
known whether nicotine replacement therapy (NRT) 
is safer for a fetus than tobacco exposure. Tobacco 
cessation as early as possible in a pregnancy is 
healthiest for both the mother and her fetus, but more 
research is needed to determine the effects of NRTs 
on an unborn child.
Conclusion: Tobacco cessation Some people think 
that withdrawal from tobacco may be harmful to 
fetal health. However, quitting tobacco is healthiest 
for both the mother and infant, at any stage or 
time during pregnancy. Withdrawal is temporary; 
smoking, on the other hand, even just one cigarette 
a day, constantly exposes the mother and child to 
dangerous health risks. It is never too late to quit 
using tobacco products. Studies show that infants 
of women who quit smoking in the Àrst trimester 
have weight and body measurements similar to 
those among infants of mothers who never smoked 
during pregnancy. The negative health effects that 
may be caused by using smokeless tobacco, smoking 
or being exposed to second-hand smoke eventually 
disappear after quitting tobacco or eliminating 
exposure to second-hand smoke.
Keyword: Communicating effects of tobacco on 
women and the link to cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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ladies receive a gift-Àlled beauty bag containing 
brand-neutral products. The aim is to help women 
regain self-conÀdence and esteem, improve quality 
of life by using beauty techniques to enhance looks 
and improve appearances which may have suffered 
due to the related side effects of the cancer therapy. 
The Look Good ... Feel Better® programme is 
currently active in 22 countries worldwide and 
in 2006 arrived in Italy as “La forza e il sorriso – 
L.G.F.B. Italia”. WALCE Association began its 
collaboration with La forza e il sorriso – L.G.F.B. 
Italia in 2009. 
Methods: From March 2009 to December 2010 
WALCE have organised 34 make-up workshops 
of “La forza e il sorriso – L.G.F.B. Italia” at the 
San Luigi Hospital (Orbassano, Turin-Italy) in 
collaboration with Àve local cancer centres and 
institutes. 248 ladies attended the free make-up 
workshops, guided by 7 voluntary beauticians 
and with support of a psycho-oncologist. 6% had 
a diagnosis of lung cancer and the majority were 
aged between 50-60 yrs old. Everyone Àlled-
in an anonymous beauty-workshop evaluation 
questionnaire. 
Results: 63% were enthusiastic, while 37% were 
greatly satisÀed with the results. 98% declared to 
have learnt useful advice whereas 2% were a little 
doubtful. However, the overall response was most 
positive. Adjectives used to describe patients feelings 
at the end of the work-shop were: beautiful, happy, 
more positive, prettier and attractive. From the 
survey, 86% of the ladies had forgotten about the 
illness during the moment they attended the event. It 
was expressed by an overall 78% as being a positive 
experience meeting other ladies in similar situations. 
Conclusion: Cancer patients tend to cope better 
with the illness and daily-life when self-conÀdence 
and esteem is regained. The sense of well-being 
shared in a relaxed atmosphere and acknowledging 
social, emotional and psychological needs, whilst 
being amongst other ladies who have the same fears 
or anxieties, has proven to be an incentive to Àght-
against cancer. In next workshops a more detailed 
evaluation on patients’ interpersonal relationships, on 
their psychological aspects and the impact on disease 
outcomes will be planned. 
Keywords: Quality of Life, Self-conÀdence, 
advocacy, Lung cancer
city draws attention of public as well as the press. 
Involvement of Priests:-We have taken lectures in 
various temples & holy places and involved priests 
into tobacco control. Car Stickers, pasteing of small 
banners behind autorickshaws, slogan contests & 
involvement of local service clubs in the activities 
helps us reach a larger population.
Results: We have not used any pre and post survey 
to gauze the impact of the activity as its a continuous 
process, which has to have effect on the public.
However, it may be done in future by Govt. or other 
agencies.
Conclusion: The representative photographs of 
all the activities will be displayed and discussed in 
detail, in the presentation.
Keywords: Tobacco Health Hazards & Tobacco 
Control, Mass Media & Tobacco Control
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P4.090 WALCE (WOMEN AGAINST LUNG 
CANCER IN EUROPE) AND MAKE-UP 
PROGRAM FOR WOMEN DIAGNOSED 
WITH CANCER.
Enrica Capelletto1, Maria V. Pacchiana1, Fiorella 
Pacetti1, Sara Demichelis1, Marina Longo1, 
Simonetta G. Rapetti1, Tiziana Vavalà1, Benedetta 
Crida1, Raffaella Ronchetta2, Silvia Novello1 
1Clinical And Biological Sciences, University Of 
Turin, Aou San Luigi/Italy, 2Women Against Lung 
Cancer In Europe, Walce/Italy
Background: The diagnosis of cancer and receiving 
an explanation about its treatment can lead to a 
series of extremely stressful and frightening events 
that cause both patients and their relatives to suffer 
emotionally. Psychological distress in cancer patients 
has been estimated at a range between 20% and 50%, 
but without clear evidence showing of a prevalent 
sex. Depression and anxiety are related to poor 
quality of life in all its shapes and forms, including 
the physical-side. There is also a considerable 
amount of data that shows a correlation between 
the outcome of cancer treatment and suffering from 
diminished self-esteem. The Look Good ... Feel 
Better® is an worldwide free make-up workshop 
programme for women diagnosed with cancer and 
who are undergoing chemotherapy, radiotherapy 
or other cancer treatments. The programme is 
carried out in local hospitals and offers free beauty 
workshops which are strictly non-medical, and the 
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develop this concept. Lung cancer patient advocacy 
program must be tailor-made to suit speciÀc 
communities/countries including socio-economical 
& political considerations. 
Conclusion: What we need is a drug-care supply 
model.Economical factors & access to therapy 
changes out-come of Lung-cancer-Rx. With little 
training our community NGO in rural/tribal India 
formed a well knit volunteers group who is giving 
free part-time dedicated service. This would reduce 
difÀculties faces by resource poor southern countries. 
We urge participants & Pharma Exhibitors at 14th 
WCLC Amsterdam to share views & expertise on 
this burning issue. 
Keywords: socioeconomics, access to drugs, 
Chemotherapy
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P4.092 PATIENT ORIENTED 
EVALUATION IN LUNG CANCER CASES
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: Inspite of media hype & government 
strictures on tobacco use, incidence of lung cancer is 
very high in Asia. No complete cancer care module 
available in India. Some cancer-institutes do provide 
treatment in metro-cities, It is however unclear 
what follow up care patients want or which model 
of follow up is preferred. Hence our Cancer NGO 
team analyzed & suggested plan to include palliative 
care program in cancer care projects of rural health 
set-up. There is no follow-up center for palliative 
care for patients who return to rural/tribal villages 
after treatment in city hospitals. Finally no data is 
available about needs of Lung-cancer patients.
Methods: By deviating from regular methodology, 
qualitative interviews were undertaken on 41 
Lung-cancer patients who had completed palliative 
treatment. Responses analyzed on pre-designed 
patient-response record data [PRRD] charts. But We 
need strong platform like WCLC-2011 conference 
to show our Àndings to researchers/activists from 
developed world & get their guidance on this 
difÀcult issue. 
Results: Our patient-response record data [PRRD] 
charts how [1] Lung cancer patents attitude towards 
their illness and how they cope with feelings. [2] 
Plan to Cope with treatment Ànances, ADR’s [3] 
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P4.091 ACCESS TO CANCER 
CHEMOTHERAPY : ECONOMICAL 
CONSIDERATIONS
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: In resource poor situations, cancer 
NGO’s are main source of cancer care. Cost 
of running Cancer NGO far less than medical 
institution. Cost of anti-cancer drugs is debatable at 
many forums. Govt, Health Depts need to workout 
formula to increase access to chemotherapy. In 
resource poor setting unaffordable cost leads to poor 
therapeutic compliance therefore high mortality. We 
suggest to establish common training program to 
develop of sound & sustainable cancer care programs 
for rural communities. National cancer registry based 
data demonstrated that subsidized chemotherapy 
& treatment-availability are major issues for Lung-
cancer sufferers in resource-poor-nations. Hence 
our Non-Govt-Organisation analyzed & started this 
public health-policy recommendation. 
Methods: cost of chemo-Radio therapy is beyond 
reach of common people in developing nations. 
No national program for Ànancial help to lung 
cancer patients available. In Lung-cancer-sufferers 
Individual’s sexual identity, sexual function and 
sexual relationship is dramatically wounded. Women 
suffer silently physically and emotionally. Hence 
we need Rx-Care programs designed towards 
poor communities from rural/tribal areas. Some 
Cancer NGO’s do offer little psychosocial support 
& subsidized treatment options. But such efforts 
are not cohesive. Our NGO since one year offers 
guidance for Rx-funding, guidance those going to 
city-oncology-centers. This project is unique as we 
are training farmers & village leaders to develop a 
peer-peer model. Depending on support given by 
donors we need to give these poor people Ànancial 
assistance to cover treatment cost. We must help 
these patients in getting access to governmental 
hospitals. 
Results: We all NGO community workers will face 
hiccups in mobilizing volunteers/resources. Initially 
basic cost like food, training materials, posters 
etc is major hurdle. This strategy has minimum 
maintenance cost & high acceptability. Health policy 
planners & forums like IASLC should help like-
minded activists to come together & form a forum to 
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questionnaire speciÀcally designed to assess self-
image of Lung cancer patients and relationship with 
social environment, family support & community 
centers. Cancer educational efforts must be devised 
suitable to local communities. Due to lack of 
resources , this issue of role of education in lung 
cancer care has been neglected for last decade. 
Results: The education signiÀcantly improved 
self-image in lung cancer sufferers group when 
compared to control group (P<0,03). There was no 
signiÀcant difference after education between these 
group with regard to social relationship (P>0,03). 
Due to resource constraints we limited sample size 
& evaluation parameters. But Our cancer NGO is 
seeking multi-institutional-collaborations to conduct 
more-scientiÀc pilot project on this unexplored issue 
in lung-cancer-patients community 
Conclusion: Our cancer NGO has taken initiative on 
this front of cancer patients education as supportive 
care. The education has important contribution in 
establishing self management approach in which 
patients assume responsibility for their behavior, 
for changing their environment, and for planning 
their future. For successful Lung cancer patients’ 
psychosocial adaptation and social participation, it 
is necessary that the whole society provides more 
resources for psychosocial support. This is low cost 
approach to improve care outcomes in resource 
constrained settings. This issue is fertile ground for 
further studies. 
Keywords: education, outcomes, Lung cancer
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P4.094 ASSOCIATION OF INSURANCE 
WITH CANCER CARE UTILIZATION 
AND OUTCOMES IN LUNG CANCER. A 
STUDY FROM INDIA
Anita Chandra 
Medical Oncology Unit , Department Of General 
Medicine, Sri Ramachandra Medical College And 
Research Institution/India
Background: Although there is substantial evidence 
that insurance status is an important factor in access 
to and utilization of cancer care . To address such a 
need in India this study was undertaken to estimate 
the burden of Cancer patient taking treatment each 
year ,to estimate the percentage of patients under 
treatment for Cancer is Insured and Uninsured , to 
estimate the of Insurance Coverage in patients with 
expectations for future [4] difÀculties faced with 
medical team [5] Concerns about addressing issues 
of QOL Majority respondents in our study project 
[>94%] felt that Palliative care needs are neglected 
in developing nations. It is of vital importance and 
should be implemented on priority. 
Conclusion: 23 patients wanted or expected to 
continue in hospital follow up, despite being fully 
aware of and accepting of their diagnosis and 
poor prognosis. Patients were also keen to have 
psychosocial & palliative support. Treatment 
Ànances & family education were given top 
priority by all seven patients from rural/uneducated 
background. Our Indian cancer NGO has taken 
initiative on this front by forming team to get 
training in palliative/psychosocial care. But in such 
initiatives we sincerely need support of IASLC for 
implementation of this policy to serve poor rural/
tribal lung cancer cases. 
Keywords: patient advocacy, Lung cancer, WCLC 
2011
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P4.093 EDUCATION IN LUNG CANCER 
PATIENTS : DOES IT INFLUENCE 
OUTCOMES
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: The essence of Lung cancer patient’s 
education is in providing speciÀc knowledge about 
disease and anticancer treatment, and in educating 
family on home based care. Informed and educated 
patients are able to save self-esteem, to establish 
good relationship with social environment and to 
achieve better social participation. The aim of this 
study was to investigate the impact of the education 
on patient’s self-image and the impact of the 
education on lung cancer patient-social environment 
relationship. Especially lung cancer sufferers who 
return to villages in rural parts of India after taking 
chemotherapy/surgery in city hospitals need this 
assistance. Community NGO’s can play key role in 
providing cancer care including PATIENT & family 
education.
Methods: 42 lung cancer patients (38 men & 4 
women, age 50-60 yrs) included in Our analysis 
and control group ( n=30), all matched regarding 
age and educational level. Both groups answered 
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P4.095 COMPARISON OF JAPANESE 
CURRENT PERCEPTIONS OF LUNG 
CANCER IN THE WORLD- ANALYSIS 
FROM INTERNATIONAL SURVEY BY 
GLOBAL LUNG CANCER COALITION 
(GLCC)
Toshiyuki Sawa1, Matthew Peters2, Jesme Fox2, 
Carolyn Aldige2, Jim Gowing2, Yasuo Iwamoto2, 
Kenji Eguchi2, Hiroshi Semba1, Shinichiro 
Nakamura1, Yoichi Nakanishi1 
1OfÀcial Relations And Public Education, West 
Japan Oncology Group/Japan, 2Global Lung Cancer 
Calition/United Kingdom
Background: West Japan oncology group had 
carried out several activities for patient’s advocacy 
to improve afÀliation rate for lung cancer in this 
decade. To evaluate the outcome of our mission, we 
have analyzed Japanese perceptions of lung cancer 
using an international quantitative survey. 
Methods: This survey was commissioned to 
understand the following among adults, 1) 
perceptions of which cancers kill the greatest number 
of people, 2) attitude towards lung cancer. Nationally 
representative quota sample of 1,272 adults across 
Japan was interviewed. Also, interviews were 
conducted in other 14 countries. 
Results: In Japan, unlike most other countries where 
this survey took place, lung cancer is tied with bowel 
or colon cancer as the cancer that adults perceive to 
kill the most people (65% and 67%). 2) Despite this, 
along with Norway, Japan is the country with the 
greatest proportion of adults who think lung cancer 
is the biggest killer (both 65%). 3) In Japan, unlike 
most other countries, many people are unable to say 
whether they have less sympathy for people with 
lung cancer, given its link to smoking (44%). Of 
those who do give an opinion one way or the other, 
32% say they do not have less sympathy but 20% do, 
which is about average compared to other countries. 
The perception of lung cancer as the biggest killer 
is higher among certain sub-groups, in particular, 
men compared to women (71% compared to 59%) 
, those aged under 65 compared to those aged 65+ 
(68% compared to 55%) and graduate of college 
or university compared to those of high school or 
junior high school (73% compared to 62% and 53% 
respectively) 
Conclusion: It was shown that Japanese has a 
high interest in lung cancer, while there is a little 
Lung Tumours ,to estimate the trends in Insurance 
Coverage and Utilization of Health Care Resources 
for these tumours 
Methods and Materia: Information on insurance 
status was obtained by analysis of data from the 
2008 to 2010.. The. data were gathered through a 
computer-assisted databased of adults aged 18 years 
and older taking treatment in Sri Ramachandra 
Medical College and Research Institute. Data from 
database were used to examine the relationship 
between insurance status at the time of diagnosis 
. Software Oracle was used with Acess, SQL to 
analyse the data. 
Results: Among the patients who met these criteria 
a total of 4453 cases were available for .The total 
number of cases registered for treatment of cancer 
in 2008 was 1250 patients and in 2009 to 1437 and 
further increased to 2166 patients by 2010. Increased 
in number of patients covered by the Insurance 
almost from 35 % at 2008 , to 47 % in 2009 and 
62% by 2010. The State Government of Tamil 
Nadu ,Kalaignar Insurance Scheme for Life Saving 
Treatment in 2010 under Star Health and Allied 
Insurance Company Limited and there were 500 
new cases registered in the same year for treatment 
of cancer( 20 %) of all overall insurance patient 
registered during last 3 years. Trends in Insurance 
Coverage shows an overall increase in In lung 
cancer the number of patients getting treated with 
own payment decreased over the years from 60 % in 
2008 to 20% in 2010. Table . 1 showing increasing 
percentage of patients diagnosed as Lung Cancer 
getting beneÀt from Insurance from 2008 to 2010 
Year Individual Patients/
Paying 
Insurance Patients/
Non paying 
2008 60% 40% 
2009 50% 50% 
2010 20% 80% 
Conclusion: The trends in Insurance Coverage 
shows an overall increase in lung cancer the number 
of patients getting treated with own payment 
decreased with a gradual increase in trend for 
insurance overage the past 3 years were noted. 
Then subsequently health economic assessment 
can be made and proper relocation of resources for 
screening and prevention of cancer done be done 
Keywords: Insurance, lung
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from a low of 10% and 14% in Spain and Argentina 
to a high of 28-29% in Brazil and Argentina. There 
was a trend for stigma to be greater in countries with 
lower smoking rates. 
Conclusion: Throughout the world, there is 
considerable underestimation of the impact of lung 
cancer relative to other cancers. Negative attitudes to 
lung cancer patients are also widespread. Addressing 
ignorance and prejudice may be a necessary 
precondition to achieve appropriate resourcing for 
lung cancer research and improved clinical care. 
Keywords: stigma, Lung cancer, community 
attitudes
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P4.097 UNUSUAL NEUROLOGICAL 
PRESENTATION OF THE NON-SMALL 
CELL LUNG CANCER (NSCLC).
Maria Wilczynska1, Angel Garcia-Alonso2 
1Respiratory Medicine Department, Glan Clwyd 
Hospital/United Kingdom, 2North Wales Cancer 
Centre, Glan Clwyd Hospital/United Kingdom
Background: Paraneoplastic neurological syndrome 
(PNS) affects less than 1:10,000 patients with cancer 
and can involve any part of the nervous system. 
Condition is caused by autoimmune processes and 
production of onco-neural antibodies, directed 
against antigens expressed by both the tumour and 
the nervous system.1 
Methods: We report a case of patient who presented 
with a central cord syndrome caused by lung 
adenocarcinoma, to our knowledge such presentation 
has not been previously described. 
Results: A 49 year old female presented to our 
hospital with acute urinary retention, weakness and 
altered sensation descending from umbilical level 
to both lower limbs. Symptoms were associated 
with two months history of night sweats and weight 
loss. Systemic examination revealed a sensory 
level around T10 and decreased anal tone but no 
signiÀcant motor deÀcit. The patient was a smoker 
with a 10 year pack history. Routine laboratory 
tests, hepatitis B, hepatitis C and HIV screen were 
negative. Antinuclear antibodies were positive to 
titre 1:640 but with negative antibodies to extractable 
nuclear antigens. Paraneoplastic anti-neuronal 
antibodies Hu and Ri were also negative. Chest x-ray 
showed widening of the right paratracheal region 
conÀrmed on enhanced computer tomography (CT) 
sympathy for people with lung cancer. It was thought 
that a new strategy should be planned to improve 
sympathy for patients with lung cancer. 
Keyword: Patient advocacy, lung cancer, 
Perceptions
Poster Session 4 - AdvocacyThursday, 7 July 2011 10:00-12:30
P4.096 IGNORANCE AND PREJUDICE 
IN RELATION TO LUNG CANCER ARE 
WIDESPREAD INTERNATIONALLY
Matthew Peters, Win Boerckel, Carolyn Aldige, 
Jesme Fox 
Global Lung Cancer Coalition, Global Lung Cancer 
Coalition/United Kingdom
Background: Lung cancer ranks poorly on the 
public policy agenda. Ignorance of its impact and 
negativity resulting from smoking as a causative 
factor may cause this. Additionally, stigma 
associated with lung cancer is a reality for many 
patients and self-reported stigma and blame are 
associated with poorer symptom control. However 
generally accepted it may be that these views are 
prevalent, they have not been measured. The aim of 
this study was to conduct an international survey that 
would quantify these attitudes.
Methods: A representative sample of 1,000-1,200 
adults was interviewed between February and May 
2010 in each of 15 countries. Two questions were 
added to a standard, national Ipsos MORI survey. 
For the Àrst question, from a list that included lung, 
breast, bowel or colon, prostate and skin cancer, 
respondents were asked to nominate which cancer 
kills the most people in their country. Up to two 
answers were allowed. For the second question, 
using a Àve point scale from ‘strongly agree’ to 
‘strongly disagree’ they were asked whether they 
agreed with the proposition that, as lung cancer was 
mainly caused by smoking, they had less sympathy 
for patients with lung cancer than people with other 
types of cancers. 
Results: Lung cancer is the commonest cause 
of lung cancer in each country surveyed. The 
proportion of respondents who nominated lung 
cancer as within the top two causes of cancer death 
in their own country varied from 35%, less than 
chance, in Australia and Bulgaria, to a high of 65% 
in Japan and Norway. The number of respondents 
who stated that they had less sympathy for patients 
with lung cancer than those with other cancers varied 
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J Neurol Neurosurg Psychiatry 75:1411–1415,2004. 
Keywords: Adenocarcinoma, Central cord 
syndrome, Non-small cell lung cancer, 
Paraneoplastic neurological syndrome
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P4.098 MAINTENANCE TREATMENT 
IN ADVANCED STAGE NON SMALL 
CELL LUNG CANCER RESULTING 
IN PROLONGED SURVIVAL; SINGLE 
CENTER EXPERIENCE: CASE SERIES
Kashyap B. Patel1, Akshay Daji1, Asutosh J. Patel1, 
Niyati Nathwani2, Asutosh Gor1, Sashi Naidu1, 
Maharshi Patel1, James Welsh1 
1Medical Oncology, Carolina Blood And Cancer 
Care/United States Of America, 2Carolina Blood And 
Cancer Care/United States Of America
Background: Advanced stage non small cell 
lung cancer is an aggressive and invariably fatal 
malignancy that carries a very poor prognosis with 
a median survival of less than a year. Five year 
survival is reported to be less than 5% in these 
patients. We present case reports of three patients 
with advanced lung cancer who have survived 
over three years without any detectable disease. 
All of them were non smokers and presented at an 
advanced age. They received Erlotinib (Tarceva®) 
maintenance therapy. 
Methods: This was a retrospective case series. 
Data was collected from electronic health records 
(Agastha Healthcare). Demographics, stage and 
treatment details were carefully reviewed and 
analyzed. 
Results: Case reports: NW, a 70-year-old Caucasian 
female presented to our ofÀce in the summer of 
2007 for newly diagnosed stage III lung cancer 
(adenocarcinoma). During her initial consultation, 
she developed seizures in the ofÀce. Imaging of her 
brain revealed one large metastasis adjacent to the 
motor cortex. She underwent radiosurgery followed 
by resection of metastasis. She then received whole 
brain radition and then was started on systemic 
treatment with paclitaxel/cisplatin. Follow up PET 
imaging revealed no evidence of disease. She was 
placed on maintenance Tarceva®. Fifteen months 
later she developed ataxia and generalized weakness. 
Her imaging studies revealed recurrence of brain 
metastases in three different locations. She received 
additional radiotherapy. She has had no evidence 
of thorax to be an upper mediastinal mass displacing 
and compressing the SVC. Whole spine MRI 
revealed a long central cord lesion extending from 
the mid-cervical area down to the lower thoracic 
region. Transbronchial biopsies were negative 
and patient underwent mediastinoscopy, biopsies 
from this procedure showed poorly differentiated 
adenocarcinoma with immunostaining suggestive 
of lung primary. The patient received four cycles 
of Carboplatin and Gemcitabine. A month after 
completion of chemotherapy she was readmitted 
with worsening paraesthesia in lower limbs. 
Neurological examination did not reveal any new 
Àndings and repeated the whole spine MRI looked 
normal. The patient received further treatment with 
radiotherapy (55Gy) to the right lung. Follow-up 
CT thorax showed almost complete resolution of 
mediastinal changes. She remains in remission with 
mild lower limbs altered sensation and residual 
numbness. Currently no further treatment is being 
considered. 
Conclusion: Anti-neuronal antibodies despite a high 
speciÀcity of 96-98% are detectable only in 30-50% 
of the clinical deÀned PNS cases.2, 3 Use of the PNS 
Euronetwork diagnostic criteria can aid diagnosis if 
anti-neuronal antibodies are not detected. 4 Patients 
who receive tumour therapy are 1.5 times more 
likely to have stable or improved neurological 
disease compared with those who are not treated. 
5 Treatment of lung adenocarcinoma in our patient 
resulted in a signiÀcant cancer regression but also 
in the complete resolution of radiological spine 
changes and improvement in central cord syndrome 
symptoms resulting from PND. 1.Paraneoplastic 
neurological syndromes.
Honnorat J et al. Orphanet Journal of Rare Diseases 
22:22,2007.
2.Diagnostic value of anti-neuronal antibodies for 
paraneoplastic disorders of the nervous system.
Moll JW et al.
J Neurol Neurosurg Psychiatry 53:940-943,1990.
3.Antinuclear antibodies deÀne a subgroup 
of paraneoplastic neuropathies: clinical and 
immunological data.
Tschernatsch M et al.
J Neurol Neurosurg Psychiatry 76:1702–1706,2005.
4.Recommended diagnostic criteria for PNS.
Graus F et al.
J Neurol Neurosurg Psychiatry 75:1135-1140,2004.
5.A follow up study of patients with paraneoplastic 
neurological disease in the UK.
Candler PM et al.
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complications following lung cancer resection. 
The bronchopleural Àstula pollutes the only lung 
with Áuid from the contralateral hemithorax, 
and leads to contamination and empyema of the 
post-pneumonectomy space. Historically this was 
treated with open window drainage, converting that 
hemithorax into a chronic draining wound, and/or 
obliteration of the empty cavity with Áaps such as 
omentum, latissimus dorsi, and/or serratus anterior 
muscle. Thoracoplasty, or removal of ribs, allows 
intercostal muscle and soft tissues to move medially 
and obliterate the cavity allowing clearance of the 
infection. Unfortunately, even after thoracoplasty, 
contraction and healing of the wound is a lengthy 
process involving multiple frequent dressing 
changes. Negative pressure therapy in the form of 
a wound VAC system (Vacuum Assisted Closure- 
Kinetic Concepts Inc, San Antonio, Texas, USA) has 
been applied to acute and chronic wounds with the 
goals of facilitating wound contraction, promoting 
granulation tissue, and decreasing the frequency of 
dressing changes. Negative pressure therapy can be 
administered as an outpatient with dressing changes 
every 72 hours rather than twice or three times daily.
Methods: Two patients were transferred to our 
facility with bronchopleural Àstulae and empyema. 
The Àrst developed bronchial stump dehiscence after 
right pneumonectomy which was treated with open 
window drainage for 20 months. Multidrug resistant 
pseudomonas aeruginosa developed in the cavity; at 
that point he was referred for evaluation. Latissimus 
and serratus muscles were previously severed, and 
omentum was nearly nonexistent due to cachexia. 
Restaging CT/PET, and bronchoscopy revealed 
no recurrent disease. Nutrition was optimized and 
Àve rib thoracoplasty was performed with use 
of a wound VAC. The second patient developed 
bronchopleural Àstula and empyema one month after 
left pneumonectomy, initially treated by serratus 
anterior muscle Áap, but the Àstula and empyema 
recurred within 3 weeks, accompanied by aspiration 
pneumonia. At that point he was referred. Surgical 
exploration to cleanse the cavity was performed 
along with closure of the bronchial stump. The 
preexisting muscle Áap was inadequate to Àll the 
infected cavity, thus a three rib thoracoplasty was 
performed along with wound VAC management.
Results: Both patients were managed with 
antibiotics guided by culture results, and serial 
changes of the wound VAC dressings every 72 to 
96 hours. Initially, dressings were changed in the 
operating room, then on the hospital ward with 
of recurrence since then. It is over three years now 
since her original diagnosis. There is no evidence of 
systemic recurrence. DM, a 67 year old Caucasian 
male developed headaches, audiovisual disturbances 
and altered mental status while driving his car 
in the winter of 2006. He was taken to local ER. 
Work up revealed evidence of parietal lobe mass. 
He underwent resection of the same. Pathology 
revealed adenocarcinoma with possible lung primary. 
PET scan conÀrmed hilar mass with precarinal 
lymphadenopathy. He underwent systemic treatment 
with paclitaxel and cisplatin. He also received whole 
brain radiation. After six months of systemic treatment 
there was no evidence of residual disease anywhere. 
He then was placed on maintenance treatment with 
Tarceva®. Due to personal reasons he discontinued 
Tarceva® after two years. At the time of writing this 
abstract, he is alive and has no evidence of disease. JP, 
a 78 year old Caucasian male, non smoker presented 
with stage IIIB non small cell lung cancer (pleural 
effusion). He initially received treatment with taxanes 
and platinum. He had partial response with resolution 
of effusion. Treatment then was changed over to 
Gemcitabine/vinorelbine. He continued to respond. 
After four months, he did not wish to have any further 
parentral chemotherapy. He then was placed on 
erlotinib in fall of2006. He has no evidence of disease 
and continues on erlotinib. 
Conclusion: All of these cases demonstrate 
unusually long survival in the elderly patients who 
initially presented with advanced stage disease. 
All of these patients were non smokers. We feel 
that biology and disease progression in elderly 
non-smoker patient with adenocarcinoma may be 
different and they clearly beneÀt from maintenance
Keyword: lung cancer, maintenence treatment, 
erlotinib
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P4.099 VACUUM ASSISTED 
CLOSURE WITH THORACOPLASTY 
FOR POST PNEUMONECTOMY 
BRONCHOPLEURAL FISTULA AND 
EMPYEMA
Patricia L. Franklin, Matthew A. Steliga 
Cardiothoracic Surgery, University Of Arkansas/
United States Of America
Background: Post-pneumonectomy bronchopleural 
Àstula is one of the most feared, life-threatening 
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was constructed to determine predictors for receiving 
treatment and survival. 
Results: There were 988 patients in the study 
population of whom 504 were presented at a 
MDT meeting and 484 not. The median age was 
69 and 73 years respectively (p<0.01). There was 
no pathological diagnosis for 13% of non-MDT 
patients compared with 4% of MDT patients 
(p<0.01). Treatment utilisation for MDT vs non-
MDT patients was 12% vs 13% for surgery (p=NS), 
66% vs 33% for radiotherapy (p<0.001), 46% vs 
29% for chemotherapy (p<0.001), and 66% vs 53% 
for palliative care (p<0.001). In patients with good 
performance status (ECOG 0-2), the MDT group 
had signiÀcantly better radiotherapy utilisation in 
Stage I-IV NSCLC and chemotherapy utilisation 
in Stage IV NSCLC. Treatment utilisation in 
SCLC was similar. Regression analysis showed 
that MDT discussion was an independent predictor 
for receiving radiotherapy, chemotherapy and for 
referral to palliative care. MDT discussion did not 
inÁuence survival. 
Conclusion: Patients discussed at a Lung Cancer 
MDT meeting were more likely to receive non-
surgical treatments and be referred to palliative care. 
Although this did not change survival, the increased 
utilisation of these modalities may have improved 
quality of life in these patients. 
Keywords: Small cell lung cancer, Multidisciplinary 
Teams, Treatment utilisation, Non-small cell lung 
cancer
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P4.101 OVERVIEW OF PRIMARY 
ENDPOINTS, PROGRESSION-FREE 
SURVIVAL (PFS) AND OVERALL 
SURVIVAL (OS) FOR NON-SMALL 
CELL LUNG CANCER (NSCLC): THEIR 
VALUE IN TREATMENT DECISIONS AND 
PATIENT CARE
Louise Heron1, Christos Chouaid2, Alain 
Vergnenègre3, Helge Bischoff4, Stefan Walzer5 
1Value Insight & Communication, Mapi Values/
United Kingdom, 2Hôpital Saint Antoine/France, 
3Chu/France, 4Thoracic Oncology, Thoraxklinik / 
University Of Heidelberg/Germany, 5F. Hoffmann-La 
Roche Pharmaceuticals AG/Switzerland
Background: NSCLC (accounting for 80% of all 
cases of lung cancer) causes high morbidity and 
sedation, and within two weeks were stable to transition 
to care at home with visiting nurses. Both patients had 
complete resolution of the infected cavities and closure 
of the Àstulae, with subsequent weight gain and return 
to normal activities of daily living.
Conclusion: Post-pneumonectomy bronchopleural 
Àstula is a life-threatening complication requiring 
closure of the Àstula and collapse or Àlling of the 
empyema cavity. When local Áaps are inadequate 
to allow healing, thoracoplasty can be performed. 
Application of the wound VAC system to this type 
of wound has not been routinely used. We have 
demonstrated that it has been safe and allowed fewer 
dressing changes than traditional gauze packing, 
and in addition allows therapy to continue as an 
outpatient.
Keywords: Bronchopleural Àstula, Negative 
Pressure Therapy, Lung cancer, Complication
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P4.101 DO MULTIDISCIPLINARY 
TEAM (MDT) MEETINGS MAKE A 
DIFFERENCE IN THE MANAGEMENT 
OF LUNG CANCER?
Shalini K. Vinod1, Miriam M. Boxer1, Jesmin 
ShaÀq1, Kirsten J. Duggan2 
1Collaboration For Cancer Outcomes, Research & 
Evaluation, Liverpool Hospital/Australia, 2Sydney 
South West Area Health Service Clinical Cancer 
Registry, Liverpool Hospital/Australia
Background: Lung cancer multidisciplinary 
team (MDT) meetings are recommended by many 
international guidelines. However there is limited 
evidence regarding their effectiveness. The aim 
of this study was to compare patterns of care and 
outcomes of lung cancer patients presented at a lung 
cancer MDT meeting with those not presented. 
Methods: All patients with a new diagnosis of lung 
cancer in South West Sydney (SWS), NSW, Australia 
between 1st December 2005 and 31st December 
2008 were identiÀed from the local Clinical Cancer 
Registry (CCR). This included non-small cell lung 
cancer (NSCLC), small cell lung cancer (SCLC) and 
those with clinical diagnosis alone. Patients who 
were discussed at the Lung Cancer MDT meeting 
were identiÀed from an oncology database. The 
MDT and non-MDT populations were compared in 
terms of patient and tumour characteristics, treatment 
utilisation and survival. A logistic regression model 
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may be regarded as having true clinical relevance. 
PFS has also been accepted by regulatory bodies 
as a valid measure of the clinical efÀcacy of cancer 
treatments in other disease settings, particularly in 
situations where it is expected that further lines of 
treatment may impede detection of a signiÀcant OS 
beneÀt. 
Conclusion: Despite the challenges of demonstrating 
an OS beneÀt of new therapies for NSCLC, OS is 
generally regarded as the preferable endpoint (from 
a payer’s perspective) for demonstrating clinical 
efÀcacy in this disease. However, PFS data may 
be more appropriate for use in certain situations, 
especially those (for example NSCLC) in which 
subsequent lines of therapy exist.
Keywords: Progression, survival, endpoints
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P4.102 SYNCHRONOUS PULMONARY 
METASTASES FROM EXTRATHORACIC 
MALIGNANCIES AND PRIMARY LUNG 
CANCER
Hisayuki Shigematsu, Akio Andou, Ryohei Higashi 
Department Of Chest Surgery, NHO Okayama 
Medical Center/Japan
Background: In the management of multiple lung 
nodules suspecting pulmonary metastases from 
extrathoracic malignancies, routine biopsy of 
all pulmonary lesions and obtaining histological 
diagnosis is not practical. The exact diagnosis for 
such lesions before treatment is sometimes difÀcult 
despite improvement of diagnostic procedures. 
Methods: We experienced two patients who 
underwent pulmonary metastasectomy from 
extrathoracic malignancies showed synchronous 
pulmonary metastases and primary non-small cell 
lung cancer.
Results: [Case 1] A 66-year old man with a 
history of renal cell carcinoma showed multiple 
pulmonary nodules bilaterally. Patient received 
sorafenib and subsequently underwent pulmonary 
metastasectomies by video-assisted thoracic 
surgery (VATS). Among Àve lesions, four 
lesions were diagnosed with metastatic renal cell 
carcinoma and one lesion was diagnosed with 
bronchioloalveolar carcinoma (measuring 9mm). 
Bone metastases and new pulmonary lesions 
appeared 4 months after metastasectomy. [Case 2] 
A 68-year old woman was diagnosed as stage IV 
mortality. Various treatment lines are available for 
NSCLC, and there are ongoing discussions on the 
most appropriate endpoint to measure treatment 
efÀcacy for reimbursement decisions. We examined 
the use of two of these endpoints, progression-free 
survival (PFS) and overall survival (OS) in NSCLC 
from a payer’s perspective.
Methods: Randomised controlled trials reporting 
the efÀcacy of bevacizumab-based therapies and 
licensed doublet-chemotherapy combinations for 
Àrst-line advanced or metastatic NSCLC treatment 
were identiÀed in a systematic literature review. 
Additional targeted literature searches to identify 
payer and regulatory perspectives on the use of 
different endpoints in NSCLC were conducted in 
MEDLINE® and the Cochrane Database of Reviews 
using clinical and health economic-related key words 
and limited from 2000 to 2010. The results from both 
searches were reviewed and formed the analysis of the 
outcomes and use of these endpoints in this period.
Results: OS can be measured easily and accurately 
in terms of both event and time and is the endpoint 
preferred by regulatory bodies including the FDA 
and EMA. Moreover, it provides a distinct clinical 
beneÀt for patients. Over the last 10 years the length 
of OS achieved for Àrst-line treatment of NSCLC has 
risen, surpassing the historical one-year benchmark. 
Nevertheless it has become increasingly difÀcult to 
demonstrate statistically signiÀcant OS beneÀt, as 
the efÀcacy of treatments (as shown by results from 
clinical trials) has generally improved by modest 
increments over time. Demonstrating improvements 
in OS over best supportive care is less challenging 
than against an active comparator; however, this 
former comparison may ultimately be less clinically 
meaningful. In order to demonstrate OS beneÀt, 
large, adequately powered studies are required — 
a challenging situation, especially with a limited 
patient population for trials of Àrst-line NSCLC 
treatments. Demonstrating a signiÀcant PFS beneÀt 
in a randomised controlled trial is also challenging, 
requiring frequent assessments and precise event 
deÀnition. Nevertheless, PFS provides a well-
accepted alternative endpoint to OS. It primarily 
measures the effect of the study drug (depending on 
the censoring rules applied to the analysis), which 
is important when it is expected that a signiÀcant 
proportion of patients will receive second- or third-
line therapy after a progression event. Furthermore, it 
is a measure of treatment effect on tumour burden — 
the means through which most anticancer therapies 
achieve success. A signiÀcant PFS beneÀt therefore, 
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evident on preoperative CT scan.
Methods: We describe the case of a 72-year old 
man with a large hilar mass of the left lung, in whom 
thrombosis of the left superior pulmonary vein was 
discovered at operation, after intrapericardial ligation 
and division of that vein.
Results: The patient was subjected to a left 
intrapericardial pneumonectomy, due to invasion of 
the pericadium by tumor. After ligation and division 
of the left superior pulmonary vein, it was discovered 
full by thrombus. A vascular clamp was applied at 
the left atrium at a distance of 1.5 cm from the cut 
edge of the vein. Left atrium was resected Áush with 
the clamp and a double running suture of 3-0 prolene 
was used to close the atrium beneath the clamp. 
The patient had an uneventful postoperative course 
with no complications and he is well and alive three 
months after operation.
Conclusion: Although not quite common, the 
thoracic surgeon must have in mind that unexpected 
thrombi of the pulmonary veins and left atrium 
may be discovered, while performing a potentially 
curative operation for lung cancer, especially one 
for a centrally placed tumor. When that happens, the 
surgeon must be prepared for partial resection of the 
left atrium.
Keywords: Lung cancer, pneumonectomy, 
pulmonary vein thrombus, atrial thrombus
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P4.104 TREATMENT OF 
INFLAMMATORY MYOFIBROBLASTIC 
TUMOR WITH MALIGNANT 
TRANSFORMATION BY 
RADIOTHERAPY AND STEROID.
Andres Yepes1, David Gómez2 
1Cancerology Unit, Hospital Pablo Tobon Uribe/
Colombia, 2Radiotherapy, Hospital Pablo Tobon 
Uribe/Colombia
Background: InÁammatory MyoÀbroblastic Tumor 
(IMT) is a rare tumor of proliferating myoÀbroblasts 
that rarely undergoes malignant transformation, are 
associated with frecuent inÀltration, obstruction, 
local recurrence and rare metastasis. IMT was 
initially recognized as a pulmonary lesion in adults 
but has been reported to ocurr in multiple anatomic 
locations such as the bladder, breast, colon, liver, 
pancreas, prostate, soft tissue and spleen. The 
neoplastic nature of IMT has been supported by 
rectal cancer (lung metastases). Patient received 
12 courses of bevacizumab in combination with 
FORFIRI and subsequently underwent low anterior 
resection for primary rectal cancer and pulmonary 
metastasectomies by VATS. Among Àve lesions, 
two lesions were diagnosed with metastatic rectal 
cancer and three lesions were diagnosed with 
bronchioloalveolar carcinoma (measuring 7mm, 
7mm and 2mm, respectively). No recurrence was 
observed for 8 months postoperatively.
Conclusion: In our case, since all primary lung 
cancers were diagnosed as bronchioloalveolar 
carcinomas less than 10mm in diameter, 
metastasectomies with adequate surgical margin 
should be potentially curable resection. One 
should consider the possibility of coexistence 
of primary lung cancer at the time of pulmonary 
metastasectomy. In case of synchronous pulmonary 
metastases and primary lung cancer, additional 
treatment should be considered according to the 
tumor biology of each primary disease. 
Keywords: pulmonary metastasis, primary lung 
cancer
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P4.103 EXTENDED LEFT 
PNEUMONECTOMY WITH PARTIAL 
RESECTION OF THE LEFT ATRIUM, 
FOR SUPERIOR PULMONARY VEIN 
AND LEFT ATRIUM TUMOR THROMBUS 
DISCOVERED UNEXPECTEDLY AT 
OPERATION FOR LUNG CANCER
George Philippakis1, Marios Moustardas2 
1Department Of Thoracic Surgery, General Hospital 
Of Chania/Greece, 2Department Of Thoracic And 
Vascular Surgery, General Hospital Of Chania/
Greece
Background: There are limited reports of curative 
resection for bronchogenic carcinoma invadind 
the left atrium. There are techniques of resection 
that permit a complete resection in selected cases 
of lung cancer invading the left atrium. All these 
techniques entail using vascular clamps on the left 
atrium and closing the left atrium by running suture. 
Alternatively cardiopulmonary bypass can be used 
for that purpose. The same applies in situations, 
where tumor thrombi of the pulmonary veins or 
the left atrium exist. In most of these cases, tumor 
thrombi of the pulmonary veins or the left atrium are 
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P4.105 PULMONER CYSTIC 
MESENCHYMAL HAMARTOMA: 
BECAUSE OF INTERESTING 
RADIOLOGY
Pinar Mutlu1, Atila Akkoclu1, Ayd×n Sanl×2, Ahmet 
Onen2, Aydanur Karg×3, Erkan Y×lmaz4 
1Chest Diseases, Dokuz Eylul Universty/Turkey, 
2Thoracic Surgery, Dokuz Eylul Universty/
Turkey, 3Pathology, Dokuz Eylul Universty/Turkey, 
4Radiology, Dokuz Eylul Universty/Turkey
Background: 35 years old male patient with chronic 
renal failure being treated by peritoneal dialysis, 3 
years ago and the last 1 year continuous hemoptysis 
(50cc) were admitted with the complaint. He had 
medical history of hypertension and 75 years / pack 
smoking. Renal failure and cirrhosis in his sister’s 
medical history were available.
Methods: At PA (posterior-anterior) chest 
radiograph and thorax CT in both lungs smooth 
edges,homogeneous nodular and cystic-cavitary 
lesions were present (Figure 1, 2A, 2B). Grade 
1-2 bilateral renal were seen at abdomen 
ultrasonography, abdominal MRI was normal.
Results: The patient’s age, history, hemoptysis 
symptoms, physical examination and radiological 
Àndings, when considered as a priority in the 
differential diagnosis of benign (tuberculosis, 
fungal disease, hydatid cyst, sarcoidosis, Wegener’s 
granulomatosis) and malignant (lymphoma, 
metastatic tumors) lung disease under consideration 
of further tests made. PPD test and three times 
negative AFB in sputum and sputum AFB cultures 
reproduction was not pegged. Hand-foot radiographs 
in the assessment for sarcoidosis and 24-hour 
urine calcium levels were normal. Hydatid panel 
cytogenetic evidence of clonality and recurrent 
involvement of chromosomal region 2p23. The 
treatment of choice is radical surgical resection, but 
if not possible there is no standard management.
Methods: A 57-year-old man was admitted to 
emergency department with chest pain of 2 months. 
The Àndings in the Computed tomography (CT) 
of the chest incluiding the upper abdomen showed 
a mass in the anterior segment of left upper lobe 
inÀltrating the chest wall, with size of 8 x 5 x 6 cm, 
with two anterior mediastinal lymph nodes.
Open biopsy was performed by chest surgery. 
The biopsy diagnosis of IMT with malignant 
transformation. Is presented in the oncology staff and 
he was considered a candidate for radiation therapy 
which receives lung volume of 3800 cGy and boost 
1600 cGy. The patient was treated with steroids 1 
mg / kg / day of prednisone for 3 months and then 
gradual withdrawal strategy. 
Results: Follow-up CT at 1 and 3 months after 
radiation therapy showed partial response by 
RECIST criteria. Follow-up CT at 6 months after 
radiation therapy showed complete response and 
persisted only pleural thickening and bronchiectasis. 
(CT of the chest 2).
Follow-up CT scans 12 and 24 months off therapy 
with radiotherapy and steroids have shown no 
evidence of recurrent disease.
Conclusion: Radiation therapy and steroids for 
unresectable IMT can be considered as management 
options in highly selected patients. 
Keywords: InÁammatory myoÀbroblastic tumor, 
InÁammatory pseudotumor, Spindle cell granuloma
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then reffered to our department. No other diagnostic 
examination was performed and the patient was 
scheduled for surgery. At operation a wedge excision 
was initially performed and frozen section of the 
specimen revealed malignancy, but the pathology 
could not clarify the organ of origin . We decided 
to proceed to right lower lobectomy immediately. 
Final pathology report revealed the nodule to be lung 
adenocarcinoma.
Conclusion: It is appropriate to consider enrolling 
patients with CLL in screening programmes for 
lung cancer, because early diagnosis and surgical 
treatment appear to offer the best opportunity for 
cure. These patients should be informed about 
their increased risk of developing lung cancer and 
smoking cessation should be encouraged. We feel 
that these patients need a more agressive diagnostic 
and therapeutic strategy, whenever suspicious lung 
nodules are discovered.
Keywords: Lung cancer, lung adenocarcinoma, 
chronic lymphocytic leukemia, Lung nodule
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P4.107 MALIGNANT PLEURAL 
MESOTHELIOMA (MPM), THE 
BRONCHUS, TRACHEA, LYMPH 
NODE, TONGUE AND SUBMENTAL 
METASTASES (A CASE REPORT)
Pinar Mutlu1, Atila Akkoclu1, Aydanur Karg×2, 
Kutsal Yorukoglu3, Taner Erdag3, Pinar Balci4, Erkan 
Y×lmaz4 
1Chest Diseases, Dokuz Eylul Universty/Turkey, 
2Pathology, Dokuz Eylul Universty/Turkey, 
3Otolaryngology, Dokuz Eylul Universty/Turkey, 
4Radyodiagnostic, Dokuz Eylul Universty/Turkey
Background: MPM is a very poor prognosis, in our 
country generally, environmental way, by inhaling 
asbestos and other minerals occur.However, as in 
developed countries can be seen with occupational 
exposure to asbestos.Often, local invasion but 
rarely do metastasize to distant organs.We wanted 
to present a case with metastasis at the trachea, 
bronchus, lymph node, tongue and submental region.
Methods: CASE: 49-year-old male, electrical 
technician, father died of prostate cancer, uncle died 
of lung cancer.History, with a diagnosis of MPM 
underwent pleural decortication and pleurodesis, 4 
cycles of chemotherapy (cisplatin + pemetrexed) 
received.At the CT angiography, because of dyspnea 
ELISA was negative. For Wegener’s granulomatosis 
paranasal sinus computed tomography examination 
was normal observation, autoantibodies (ANA, 
p-ANCA, c-ANCA) negative pegged. Within normal 
limits tumor markers (CA-125, CEA, CA 19-9) was 
found.At bronchoscopic examination the active 
bleeding and endobronchial lesions weren’t found, 
BAL cytology and bronchoscopic lavage cytology 
were normal.At renal biopsy Focal Segmental 
Glomeruloskleroz was pegged.
Conclusion: DIAGNOSIS: Mesenchymal Cystic 
Hamartoma. The patient’s diagnosis was found 
especially interesting because of it’s radyology and it 
was seen rarely.
Keywords: Hamartoma, cystic, Pulmonary
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P4.106 A CASE OF LUNG CANCER 
IN A PATIENT WITH CHRONIC 
LYMPHOCYTIC LEUKEMIA
George Philippakis1, Foteini Micha-Philippakis2, 
Marios Moustardas1 
1Department Of Thoracic Surgery, General Hospital 
Of Chania/Greece, 2Department Of Thoracic And 
Vascular Surgery, General Hospital Of Chania/
Greece
Background: Patients with chronic lymphocytic 
leukemia (CLL) are at increased risk of developing 
second primary malignancies. For patients with 
CLL there is a 60 % increase in the incidence of 
lung cancer, especially non-small cell lung cancer. 
Approximately 2 % of patients with CLL develop 
lung cancer. Prognosis of these patients is better if 
lung cancer is discovered at an early stage. 
Methods: We describe the case of a 55-year 
old male, diagnosed with CLL Àve years before 
presentation, with a nodule at the superior segment 
of the lower lobe of the right lung, which had not 
been growing for about two years, but Ànally proved 
to be lung adenocarcinoma.
Results: The patient had been diagnosed with 
CLL Àve years ago. He had a smoking history of 
40 pack-years. Two years ago a lung nodule about 
1.5 cm in diameter was discovered at the superior 
segment of the right lower lobe. The patient was put 
under observation with chest CT scans performed 
at regular intervals. CT scan on December 2010 
showed an increase of the size of the nodule, which 
reached a diameter of about 2 cm and the patient was 
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Benign mediastinal teratomas usually don’t 
cause any symptoms and the diagnosis is reached 
accidentally. As they enlarged they may cause 
symptoms by compressing the nearby structures of 
thorax, mostly the trachea and bronchi.
The case who had giant mediastinal mature cystic 
teratoma, in a 25-year-old-woman with a cough 
and left-sided thoracic pain. Computed tomography 
of the chest revealed a giant cystic mass with a 
minimally pleural free effusion in left intrathoracic 
region, measuring approximately 12 by 15 by 15 cm 
in diameter.
Laboratory tests were normal, but clinical and X-Ray 
Àndings were suggestive of a huge hydatide disease 
of the lung.
Results: We performed left thoracotomy, 
intraoperative Àndings were suggestive giant benign 
tumor like a cystic mature teratoma which was 
originated from anterior mediastinum. we performed 
complete and radically excision of the tumor. 
In the same time, additionally, we noticed there 
was a minimal aortic coarctation anomally in the 
descending aorta.
The histopathological investigation conÀrmed of 
giant mediastinal mature teratoma located into the 
left intrathoracic region with left free pleural effusion 
without evidence of pulmonary invasion.
Conclusion: In conclusion, clinical characteristics 
of mediastinal mature teratomas are non-speciÀc, 
and the unusual presentation of the tumor makes its 
diagnosis difÀcult preoperatively.
Mature cystic teratoma is a benign tumor, but, 
surgical resection is recommended owing to its 
potential complications.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.109 PRIMARY GEFITINIB-
RESISTANCE IN A PATIENT WITH 
METASTATIC ADENOCARCINOMA 
OF THE LUNG HARBORING A PR836C 
EGFR-MUTATION
Beatrice Voss1, Berthold Fischer1, Mike Otto2, 
Simin Schadmand-Àscher3, Wibke Klaas1, Andreas 
Kümmel1, Martin Sebastian1, Roland Buhl1 
1Department Of Hematology, Oncology 
And Pneumology, Johannes Gutenberg-
with bilateral lobar, segmental and subsegmental 
emboli, multiple lymphadenopathies and bilateral 
Áuid was detected.
Results: Thorax CT of the lower end of tracheal 
stenosis and right lung upper lobe metastasis, at 
the bronchoscopy total occlusion of the left main 
bronchus, trachea and left main bronchus mucosal 
plaque, as a result of the trachea in the lower end 
of the biopsy revealed a metastasis of MPM.On 
the left supraclavicular LAP 2x3 cm in diameter 
were found, and examination of the language 
hyperemic, edematous and swollen mucosa lesions 
0.5X0.5 cm and 1 cm in diameter mass in the right 
submental region and submental region, expressed 
as metastases evaluated.Under the mandible on the 
right maxillary CT 40X20X33 mm submental level, 
elevated language, and oral cavity with Àne needle 
aspiration biopsy taken from the mass lesion were 
diagnosed with metastasis in MPM.
Conclusion: We wanted to present this rare case 
with metastases.
Keywords: rare metastases, malignant pleural 
mesothelioma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.108 HUGE MEDIASTINAL MATURE 
TERATOMA UNUSUAL PRESENTATION 
MIMICKING WITH LUNG HYDATIDE 
DISEASE
Abdullah Erdogan1, Ozgur Cengiz1, Emine Kol1, 
Gulay Ozbilim2 
1Thoracic Surgery, Akdeniz University, School Of 
Medicine/Turkey, 2Pathology, Akdeniz University, 
School Of Medicine/Turkey
Background: Benign mature teratomas are the most 
common type of germ cell tumors that arise in the 
anterior mediastinum. But its an unusual presentation 
with huge left intrathoracic mass mimicking lung 
hydatide disease.
Methods: We present an interesting clinical 
presentation of benign mediastinal cystic mature 
teratoma as unusual presentation in left intrathoracic 
region presenting with left free pleural effusion and 
huge left intrathoracic mass like a lung hydatide 
disease.
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Conclusion: EGFR-mutation is usually regarded 
as predictive marker for response to TKI-therapy 
in patients with non-small-cell lung cancer. We 
describe a patient with pR836C mutation at exon 21 
showing primary resistance to geÀtinib and cisplatin/
pemetrexed. The clinical course of patients with this 
mutation hasn’t been described yet. 
Keywords: EGFR mutation, primary TKI-resistance
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P4.110 HOW TO TAGET LUNG AND 
RENAL CARCINOMAS?
Pascale Tomasini1, Marjorie Baciuchka1, Delphine 
Trousse2, Fabrice Barlesi1 
1Oncologie Multidisciplinaire Et Innovations 
Thérapeutiques, Hôpital Nord/France, 2Service De 
Chirurgie Thoracique, Hôpital Nord/France
Background: Non small cell lung cancer (NSCLC) 
and renal cell carcinoma (RCC) are both common 
and associated with smoking. Their association is not 
unusual. However, no data is available to guide the 
management of synchronous RCC and NSCLC. We 
report an example of concomitant treatment of RCC 
and NSCLC using the association of chemotherapy 
and targeted therapy.
Methods: A 47 year-old man, former smoker, was 
refered for a stage pT3bN0M1R0 polymorphic RCC 
with pulmonary metastases. He received adjuvant 
targeted therapy with sunitinib 50mg daily. A month 
later, a 50mm pulmonary lesion appeared and was 
diagnosed as a cT2N2M0 NSCLC.
The multidisciplinary team discussion (MTD) 
proposed to target both diseases using 4 
chemotherapy cycles (carboplatin AUC6 and 
University Medical Center Mainz/Germany, 
2Molekularpathologie Trier/Germany, 3Department 
Of Radiology, Johannes Gutenberg-university 
Medical Center Mainz/Germany
Background: Activating mutations of the epidermal 
growth factor receptor (EGFR) gene have been 
identiÀed to be predictive markers for response 
to targeted therapy with tyrosine kinase inhibitors 
(TKI) such as geÀtinib in patients with non-small-
cell lung cancer. Primary resistance to EGFR-TKIs 
occurs in about 5 % and is mostly described as part 
of rare mutations like insertion in exon 20. 
Methods: A 49-year-old female patient with 
a smoking history of 30 pack years and no 
comorbidities presented with swelling of 
supraclavicular lymph nodes (ECOG performance 
status 0-1). Specimens were taken from these lymph 
nodes as well as from subcutaneous skin metastases. 
Histopathological assessment showed a low 
differentiated pulmonary adenocarcinoma. Staging 
(UICC 7th edition) was cT3 pN3 pM1b. Further 
molecular analysis of the EGFR gene showed a 
wild-type for exons 18 and 19, but a point mutation 
pR836C in exon 21 (replacement of arginine by 
cysteine at codon 836) was detected by Sanger 
bidirectional sequencing. Therefore targeted therapy 
with geÀtinib (250 mg once-daily) was started. We 
were aware of the fact that this mutation and its 
signiÀcance for response to TKI-therapy had not as 
yet been well described. 
Results: One month after start of treatment the 
patient showed a clinically progressive disease 
with reduced overall state of health (ECOG 
performance status 2) and progressive and new 
subcutaneous metastases. CT-scans of chest and 
abdomen documented severe tumor progression 
in the lung, the right adrenal gland, the bones and 
the skin as well as of the lymph node metastases 
in different localizations. We switched treatment 
to a combination of cisplatin (75 mg/m² BSA) 
and pemetrexed (500 mg/m² BSA). Three weeks 
later, after one cycle of chemotherapy, the patient 
presented in an even worse condition (ECOG 
3-4) and started to develop dyspnea. By clinical 
standards skin metastases as well as palpable 
lymph node metastases were growing. Imaging 
showed a progressive disease with pleural effusion 
and pulmonary inÀltration suspected to be due to 
lymphangitis carcinomatosa. The patient Ànally died 
from respiratory failure two weeks later, only two 
months after treatment initiation. 
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P4.111 MULTIMODAL THERAPY FOR 
MEDIASTINAL NONSEMINOMATOUS 
GERM CELL TUMOR WITH SOMATIC-
TYPE MALIGNANCY WITH BRAIN 
METASTASIS; REPORT OF A CASE
Ikuo Kamiyama, Norimasa Tsukada, Makoto 
Sawafuji 
General Thoracic Surgery, Kawasaki Municipal 
Hospital/Japan
Background: Mediastinal nonseminomatous germ 
cell tumor (NSGCT) with brain metastasis is rare 
and has a poor prognosis. We report a clinical case 
of NSGCT with malignant transformation of the 
somatic component with brain metastasis.
Methods: Case: An 18-year-old male presented with 
chest pain and an anterior mediastinal mass was seen 
on the image exams. Chest CT and MRI revealed a 
large heterogeneous lesion measuring 14 x 11 cm. 
Histological Àndings of needle-biopsied specimens 
suspected teratoma. Although immature component 
was not deÀned, tumor markers (AFP, HCG-
beta) have elevated. Four courses of BEP therapy 
(bleomycin, etoposide, cisplatin) made tumor markers 
decrease, but the tumor showed further growth. And 
brain MRI revealed several metastatic lesions within 
5 mm in diameter. Because the huge tumor markedly 
compressed mediastinal structures, en bloc resection 
of the primary tumor was performed after gamma 
knife surgery for multiple brain metastases.
Results: The tumor, measuring 21 x 14.5 x 8.5 cm in 
size, was completely resected with partial resection 
of pericardium and right upper lung. Microscopic 
examination revealed most of the tumor was mature 
teratoma consisted of skin, gastrointestinal glands, 
bones, cartilage, neural tissues, pancreatic tissues, 
etc., and necrotic tissues. Partially atypical cells 
were detected in some areas but there were no viable 
tumor cells. The pathological and immunohistlogical 
studies showed germ cell tumor with somatic-type 
malignancy. The concentrations of serum AFP 
and HCG-beta decreased within normal limits 
after surgery. While stereotactic radiosurgery 
was performed for second brain metastases three 
month after surgery, then, there has been no sign of 
recurrence for 14 months.
Conclusion: NSGCT with somatic-type malignancy 
is recognized to be difÀcult to treat. In this case, we 
experienced to have good control of the disease by 
multimodal therapy.
paclitaxel 175mg/m²) plus sunitinib 37,5mg. The 
tolerance was good. The evaluation showed a 
complete response of the RCC pulmonary metastases 
and a 76% reduction of the NSCLC. 
A lobectomy was performed. The pathological 
demonstrated a pT0N0M0R0. Sunitinib was 
continued without any relapse after 15 months of 
follow up.
Results: Previous studies showed that standard 
chemotherapy of NSCLC is not effective for 
the treatment of RCC and, in the same way, that 
multitarget tyrosin kinase inhibitors (TKI) such 
as sunitinib is poorly effective for the treatment 
of NSCLC. On the other hand, targeting VEGF 
or PDGF seems suitable for the management of 
NSCLC with regards to molecular patterns and 
results of phase III studies or meta-analyses. This 
case suggests that the combination of chemotherapy 
and antiangiogenic TKI may increase outcomes 
of NSCLC patients and highlights the need for 
predictive biomarkers in this Àeld. It also suggests a 
possible strategy for patients with synchronous RCC 
and NSCLC in an area where data are missing. These 
cases always need a MTD.
Conclusion: The association of sunitinib with 
chemotherapy may improve the management of 
synchronous RCC and NSCLC but needs to be 
evaluated.
Keywords: Lung cancer, renal cell carcinoma, 
targeted therapy
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P4.113 A RARE CASE OF MIDDLE 
MEDIASTINAL THYMOMA 
COMPRESSING THE BIFURCATION OF 
THE TRACHEA
Tsunehiro Ii, Shogo Toda 
General Thoracic Surgery, Otsu Municipal Hospital/
Japan
Background: Most thymomas are found in the 
anterior mediastinum. Occasionally, some have 
been found in the neck, pulmonary hilus, and 
posterior mediastinum. We present here a case of 
middle mediastinal thymoma that was markedly 
compressing the bifurcation of the trachea. 
Methods: A 32-year-old man was referred to our 
hospital for further examination of an asymptomatic 
mediastinal mass detected on a chest X-ray at an 
annual checkup. Chest computed tomography 
(CT) revealed a well-deÀned and highly enhanced 
solid mass with multiple foci of tiny and irregular 
calciÀcation, measuring 81 × 47 mm in the middle 
mediastinum between the superior vena cava and the 
bifurcation of the trachea. The tracheal bifurcation 
was severely compressed by the large mass, but 
there was no sign of invasion. With a preliminary 
diagnosis of benign mediastinal tumor, such as 
teratoma or neurogenic tumor, the patient underwent 
surgical intervention.
Results: The patient was operated on through the 
anteroaxillary thoracotomy in the 4th right intercostal 
space with a video-assisted procedure. The tumor 
was overlaid by the mediastinal pleura and located 
between the superior vena cava and the trachea, 
Keywords: somatic-type malignancy, Brain 
Metastasis, multimodal therapy, mediastinal 
nonseminomatous germ cell tumor
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P4.112 EFFECTIVE CHEMOTHERAPY 
WITH CAFFEINE FOR CLEAR CELL 
SARCOMA OF CHEST WALL
Shozo Fujino1, Masato Watanabe1, Motoyuki Sasaki1, 
Takahiro Nakajima1, Hiroyuki Mushiake1, Kaname 
Maruno1, Yasuyuki Sugiyama1, Isamu Shibuya2 
1Department Of Surgery, University Hospital 
Mizonokuchi, Teikyo University School Of Medicine/
Japan, 2Department Of Orthopedics, University 
Hospital Mizonokuchi, Teikyo University School Of 
Medicine/Japan
Background: Caffeine can safely enhance the 
cytocidal effects of anticancer drugs through its DNA 
repair-inhibiting effect. It has been demonstrated 
in several studies that caffeine-potentiated 
chemotherapy induces a high complete response rate 
in patients with osteosarcoma. We report a rare case 
of clear cell sarcoma in chest wall and a good effect 
of caffeine-potentiated chemotherapy in this case. 
Methods: A 39-year old man was hospitalized 
with local recurrent clear cell sarcomas 3 months 
after surgery of his right chest wall. We applied 3 
cycles of CDDP+ADM regimen with caffeine for 
this case (CDDP 120mg/m2 day1, ADM 60mg/m2 
day1(48hrs), caffeine 2200mg day1-3). 
Results: We got a very good response (Àgures). 
Sleep disturbance and palpitation are main 
complications.
Conclusion: Caffeine-potentiated chemotherapy has 
a possibility of enhancement of effects of anticancer 
drugs for other kinds of chest malignant tumors. 
Keywords: caffeine-potentiated chemotherapy, clear 
cell sarcoma
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initially done as clear cell adenocarcinoma, stage 
I, raising the possibility that the same would be a 
metastasis from external sources, while holding the 
suspected renal main origin. Was then performed 
a full restage of the patient, not being identiÀed 
neoplastic lesions in any other location. It was 
also realized immunohistochemistry of the tumor 
removed. The imunohistochemistry was positive for 
low weight cytokeratin, surfactant and cytokeratin 7; 
and negative for valentine, HMB45, cytokeratin 20, 
CD10 and TTF1. 
Methods: This study was performed by reviewing 
the medical history of the patient.
Results: The Ànal diagnosis was lung squamous 
clear cell carcinoma with accumulation of glycogen, 
stage I which led the patient at this moment does not 
need another type of treatment. After six months, 
the patient presented hepatic metastasis and then 
undergoing chemotherapy treatment. 
Conclusion: Lung squamous clear cell carcinoma 
is an rare pulmonary tumor that can lead to 
confusion with lung adenocarcinoma and pulmonary 
metastasis, mainly from kidney tumors, and with 
the benign clear cell tumor (sugar tumor) (1.2). Its 
diagnosis is done through imunohistochemistry 
study, wherein presents positive result for 
Cytokeratin, especially Cytokeratin 7 and other 
markers of primary pulmonary neoplasm. 
Concurrently there is negativity towards others lung 
tumors as benign clear cell tumor (HMB45) and 
metastatic lesions (CD10 and vimentin – kidney 
metastases; Cytokeratin 20 – gastro intestinal tract 
neoplasm and TTF1 - neoplasm of thyroid) (3). It is 
also possible to use electron microscopic features to 
establish the proper diagnosis(2). It is important to 
differentiate this rare tumor and distinguish it from 
the renal metastasis and benign clear cell tumor (4), 
as well from all others forms of clear cell tumours of 
the lung(2). The treatment as well as the prognosis is 
quite different in these different conditions. 
Keywords: Clear Cell Carcinoma, Lung cancer
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P4.115 ATRIAL FLUTTER AS FIRST 
PRESENTING SIGN OF MALIGNANT 
MESOTHELIOMA: A CASE REPORT
Aiza Jamil, B. Prathibha 
Medicne, East Kent Hospitals Nhs Trust/United 
Kingdom
extending to the inferior part of middle mediastinum. 
Although the tumor severely adhered to the trachea 
and bronchus, there were no obvious invasion of the 
any structures of the mediastinum, and the tumor 
was completely extirpated. The postoperative course 
was uneventful and the patient left the hospital on 
the 4th postoperative day. The resected specimen 
was a solid tumor with a Àbrous capsule that 
measured 115 × 74 × 41 mm and weighed 150 g. 
The cut surface of the tumor was white or yellowish-
white in color, and multiple calciÀcations were seen 
on its surface. Microscopic examination revealed 
that the tumor consisted of mixture of a spindle 
cell-predominant component and a lymphocyte-
predominant component. There were many 
trabecular Àbrous bands with marked hyalinization 
or calciÀcation in the tumor. Extracapsular tumor 
invasion was not seen. Histopathologically, the 
tumor was diagnosed type AB thymoma based on the 
World Health Organization (WHO) classiÀcation, 
and stage I according to the Masaoka staging system. 
The patient is well, with no evidence of recurrence 
15 months after the operation.
Conclusion: We present a case of middle 
mediastinal thymoma compressing the bifurcation of 
the trachea. Thymoma should be considered in the 
differential diagnosis of middle mediastinal tumors, 
although it is rarely found in this location. 
Keywords: video-assisted thoracic surgery, 
Thymoma, middle mediastinum
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P4.114 LUNG SQUAMOUS CARCINOMA 
OF CLEAR CELLS – A RARE LUNG 
CANCER
Romero Fenili1, Luzete Cristina D.S. Granero2 
1Medicina, Universidade Regional De Blumenau/
Brazil, 2Patologia, Cipac - Laboratorio De 
Patologia/Brazil
Background: A 70-year-old patient presents with 
right pulmonary nodule found at chest x-ray, with 
features suspicious of pulmonary neoplasm. After 
performing the initial examination, it was decided 
to perform thoracoscopic (VATS) resectiony with 
transoperatory biopsy. The result of intraoperatory 
histopathology was compatible with lung 
adenocarcinoma. The incision was converted to 
posterolateral thoracotomy and lobectomy was 
performed. The postoperative pathology result was 
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available therapeutic interventions. The authors 
of this report have been unsuccessful in Ànding a 
similar case report upon reviewing the literature.
Keywords: Malignant mesothelioma, atrial Áutter
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P4.116 PRIMARY PULMONARY 
LYMPHOMA: CLINICAL FEATURES, 
PROGNOSTIC FACTORS, AND 
OUTCOMES
Domenico Galetta, Alessandro Borri, Roberto 
Gasparri, Francesco Petrella, Piergiorgio Solli, 
Stefano Donghi, Juliana Guarize, Adele Tessitore, 
Monica Casiraghi, Lorenzo Spaggiari 
Division Of Thoracic Surgery, European Institute Of 
Oncology/Italy
Background: Primary pulmonary lymphoma 
(PPL) is a rare neoplasm with a favorable prognosis 
compared with lung cancer. In order to assess clinical 
features, patient management, prognostic factors and 
outcomes, we hereby report our single-institution 
experience.
Methods: A retrospective review of a prospective 
database of patients operated on for PPL between 
1998 and 2010 was performed. Univariate and 
multivariate analysis was performed to identify 
prognostic factors. Survival was calculated by 
Kaplan-Meier method. 
Results: There were 33 patients (18 men; median 
age, 59 years). Twenty-one patients had marginal 
zone B-cell lymphoma of mucosal-associated 
lymphoid tissue (MALT), 4 had large B-cell 
lymphoma, 6 had Hodgkin’s disease, and 2 had 
follicular lymphoma. Twelve patients (36.4%) 
were asymptomatic at presentation, and 21 (63.6%) 
had pulmonary symptoms, systemic symptoms, 
or both. Radiological Àndings at computer 
tomographic (CT) scan included nodules, masses 
inÀltrates or consolidation. Bilateral pulmonary 
lesions were detected in 10 patients. PET scan 
was performed in 24 patients (72.7%): in 14 
cases it was negative, in 10 it showed a median 
standardized uptake value of 4.3. CT-guided 
biopsy was diagnostic in 3 of 13 attempts. A 
deÀnitive diagnosis was obtained by thoracotomy 
in 27 patients 81.8% - one pneumonectomy, 10 
lobectomies, and 16segmentectomies and wedge 
resections) and thoracoscopy in 6 (18.2% - 4 
pulmonary wedge resections and 2 lung biopsies). 
Background: Atrial Áutter is the second most 
common tachyarrhythmia, after atrial Àbrillation,the 
most common causes being ischaemic heart disease
,hypertension,cardiomyopathy and abnormalities of 
the heart valves. We present here a very rare case of 
primary malignant mesothelioma presenting as atrial 
Áutter.
Methods: A 74-year-old Caucasian man was 
admitted to East Kent Hospital NHS Trust 
complaining of palpitations and exertional dyspnea. 
There was no history of pleuritic chest pain or 
hemoptysis. The patient did not have any previous 
signiÀcant cardiac or any other medical history 
and was leading a fairly healthy life. He worked in 
British telecom in the past and used to lay cables and 
was exposed to asbestos during that time.
Results: Laboratory investigations showed he was 
anaemic with haemoglobin of 5g/dl(13-18g/dl) 
and required blood transfusion. His ECG showed 
atrial Áutter which was treated with Digoxin and 
Verapamil. The chest x-ray showed complete 
obliteration of right hemithorax simulating the 
appearance of a pleural effusion. Attempts were 
made to aspirate the chest but it was a dry tap. 
Subsequently, the patient underwent a CT scan of his 
chest, abdomen and pelvis which showed extensive 
lobulated pleural thickening encircling the right 
hemithorax and extending into the mediastinum 
both anteriorly and posteriorly and involving part 
of the pericardium with some associated Áuid. 
Compressive atelectasis was also noted in the right 
lung. The left lung Àeld was clear. Rest of the viscera 
including liver, spleen pancreas etc were normal. 
The histology of CT guided biopsy of the lesion 
showed appearance of an epitheliod malignant 
mesothelioma. Immunohistochemistry showed 
showed that the tumor was positive for cytokeratin 
5/6 and calretinin. Ocassional asbestos bodies 
were identiÀed in the lung tissue. The patient was 
managed symptomatically was referred to oncologist 
and offered radiotherapy owing to the extensive 
nature of the disease. After a few sessions the patient 
eventually died after 8 months in the due course of 
treatment.
Conclusion: Malignant mesothelioma is an insidious 
neoplasm with a dismal prognosis. Diagnosis of 
mesothelioma can be challenging and often requires 
a multimodal imaging approach including CT, biopsy 
and PET scans. Mesothelioma exerts its morbidity 
and mortality via inexorable local invasion. The 
median survival of patients is between 6 and 18 
months, and is not signiÀcantly affected by currently 
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resection. 
Results: The inÁuence of estrogen through the 
estrogen receptor-B (ERB) has been hypothesized 
in the development of a class of tumors that are 
comprised of biotin-rich, optically clear nuclei 
(BROCN). B-Catenin, a cell-adhesion molecule, 
is also known to be expressed in the BROCN-
family which includes well-differentiated fetal 
adenocarcinomas. Apparently, aberrant nuclear/
cytoplasmic co-localization of ERB and B-Catenin 
is a feature that is common to tumors producing 
morules within the BRCON-family of tumors. The 
current case represents one of a few case reports of 
a fetal adenocarcinoma in the literature presenting 
during pregnancy or in the immediate post-partum 
period. Whether these cases are due to chance 
or whether there is in fact an association with 
pregnancy is not currently know. Other BROCN 
tumors have shown a stronger preponderance 
for young females while WDFA, in contrast, 
has been reported in equal incidence and with a 
slight predilection for females. Eighty percent of 
patients with WDFA are smokers and 40% may be 
asymptomatic. When symptomatic, the literature 
reveals that the most common presentations are 
hemoptysis, cough, or chest pain, but incidental 
Àndings on a chest X-ray remains the most common 
overall presentation. 
Conclusion: Estrogen may play a role in the 
differentiation and possibly the proliferation of 
WDFA and other BROCN-family tumors but further 
studies are necessary. 
Keyword: Fetal Adenocarcinoma
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P4.118 NON SMALL CELL LUNG 
CANCER (NSCLC) PRESENTING AS 
OBSTRUCTIVE JAUNDICE IN A YOUNG 
PATIENT
Ivana Sullivan, Cinta Pallarès, Margarita Majem 
Medical Oncology, Hospital De Sant Pau/Spain
Background: A 44-year-old male with a history 
of smoking and alcoholism and a previous episode 
of acute alcoholic pancreatitis presented with 
progressive jaundice,choluria and acholia.Physical 
examination revealed the presence of hepatomegaly.
Blood tests showed a normocytic anemia and a 
cholestatic pattern. 
Methods: An abdominal CT scan showed 
Treatment methods included surgery only (n=13), 
surgery plus chemotherapy (n=17), surgery plus 
radiotherapy (n=2), and surgery plus chemotherapy 
plus radiotherapy (n=1). Median follow-up was 
110 months (range, 2-322 months). Overall 5-year, 
10-year, and 20-year survival rates were 69%, 
42.3%, and 7.7%, respectively. Patients with MALT 
lymphoma had a best prognosis (p= 0.01). None of 
the prognostic factors studied signiÀcantly inÁuenced 
survival.
Conclusion: PPL have non-speciÀc clinical features. 
Surgery should be the treatment of choice in 
localized forms while a combination of treatment 
should be used for diffuse diseases.
Keywords: lymphoma, Surgery
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P4.117 FETAL ADENOCARCINOMA
Manuel I. Rodriguez1, Clark Kholeif, Msiii2, Daniel 
L. Schneider3 
1Surgery, Texas Tech University Health Science 
Center-som/United States Of America, 2Medical 
Student, Texas Tech University Health Science 
Center-som/United States Of America, 3Pathology, 
Amarillo Pathology Group/United States Of America
Background: Well-differentiated fetal 
adenocarcinoma (WDFA) also called monophasic 
pulmonary blastoma or pulmonary endodermal 
tumor resembling fetal lung tissue is classiÀed 
by the World Health Organization as a variant of 
adenocarcinoma. 
Methods: A 39 year old female presented 3 
months post-partum after being referred for surgery 
consultation after recognition of a lobulated 
pulmonary mass on chest X-ray for pre-operative 
workup for a bilateral tubal ligation. The patient was 
otherwise asymptomatic and healthy, with a 20 pack 
year smoking history. A CT- guided needle biopsy 
of the mass was reported as having suspicious/
atypical architectural features. A left thoractomy 
for left upper lobe wedge resection was performed 
and frozen sections obtained. Adenocarcinoma 
and a subsequent left upper lobe lobectomy and 
mediastinal lymph node dissection was performed. 
The 3.7 x 3.0 x 3.5 cm tumor was later identiÀed 
as fetal adenocarcinoma. All margins were free and 
peribronchial and mediastinal nodes were negative 
for metastatic disease. The patient continues to be 
recurrence and metastases free at 24 months post-
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from renal cell carcinomas, sarcomas or carcinoid 
tumors, with a survival rate of 35% and 17% at 2 and 
4 years,respectively. Two case reports of pulmonary 
adenocarcinoma with solitary pancreatic metastasis 
have also been published. The Àrst case described a 
pancreatic metastasis two years after a radical surgery 
for lung adenocarcinoma with a complete response of 
the metastasis after the third cycle of cisplatin-based 
chemotherapyT.he second case described a complete 
resection of a pancreatic mass prior to the diagnosis of 
lung carcinoma that was also resected; the patient was 
free of disease 18 months after diagnosis.These data 
suggest that surgical treatment of isolated pancreatic 
metastases in patients with NSCLC may be considered 
in these patients. 
Keywords: Non-small cell lung cancer, pancreatic 
metastases
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P4.119 THYMIC CARCINOID
Manuel I. Rodriguez1, Clark Kholeif, Msiii2, Robert 
M. Todd3 
1Surgery, Texas Tech University Health Science 
Center-som/United States Of America, 2Medical 
Student, Texas Tech University Health Science 
Center-som/United States Of America, 3Pathology, 
Amarillo Pathology Group/United States Of America
Background: A 53 year-old male presented with 
chest pain and dyspnea on exertion, dysphagia for 
solids, cough for 3 months, and an unintentional 
weight loss of 10kg. The patient’s past medical 
history was insigniÀcant. On general physical exam 
there were decreased breath sounds in the left lung 
and dullness to percussion. Also noted was left 
cervical and supraclavicular lymphadenopathy. 
Chest X-ray revealed an anterior mediastinal mass. 
Cardiovascular and cardiopulmonary structures were 
displaced posteriorly. The mass displaced the trachea 
and esophagus to the right. Also noted on CT was 
signiÀcant left cervical adenopathy and evidence of 
thyroid nodule. 
Methods: A Tru-cut CT guided needle biopsy was 
subsequently obtained which indicated malignancy 
but yielded indeterminate results. Excisional biopsy 
of the left cervical lymph node revealed well-formed 
lymphoid tissue with follicles. The cervical lymph 
node tissue was compared with slides from the 
needle core biopsy of the mediastinal mass and was 
found to exhibit a distinctly different morphology. 
hepatomegaly with severe dilation of bile ducts,an 
irregular hypodense lesion of 45 mm with 
heterogeneous enhancement in the pancreatic 
head causing biliary obstruction,and a distended 
gallbladder,which was conÀrmed by a Cholangio-
MRI.CEA and CA19-9 levels were within normal 
levels.The patient also presented dysphonia in 
subsequent days,a chest radiograph showed a 
parahiliar mass.A bronchoscopy revealed a paralysis 
of the left vocal cord and an endobronchial lesion 
in the left anterior upper lobe.Biopsies revealed a 
poorly differentiated adenocarcinoma.Thorax CT 
scan showed a 6 cm left parahilar mass invading 
the aortopulmonary window and the left pulmonary 
artery.
Results: At this point we raised the differential 
diagnosis between a synchronous NSCLC and 
a primary pancreatic carcinoma,a NSCLC with 
a metastasis to pancreas and primary pancreatic 
carcinoma with a lung metastasis.An stent was 
placed in the principal bile duct using endoscopic 
retrograde cholangiopancreatography and cholestasis 
was resolved.Fine needle aspiration of the 
pancreatic mass revealed an inÀltration of a poorly 
differentiated carcinoma.The immunohistochemical 
proÀle was positive for Citokeratine AE1-AE3, CK-7 
and TTF-1, conÀrming that it was a metastasis of the 
lung carcinoma. The Ànal diagnosis was an stage IV 
lung adenocarcinoma (T4N0M1). 
Conclusion: Pancreatic metastases constitute 2-3% 
of malignant masses of the pancreas.Most cases 
occur in the context of widespread disease.Several 
retrospective studies have shown that the primary 
tumor that most commonly spreads to the pancreas is 
renal cell carcinoma, followed by breast, colorectal, 
melanoma, sarcoma and lung (predominantly 
small cell lung carcinoma) tumors. In a series of 
234 patients, 68% of all cases corresponded to 
renal cell carcinoma metastasis, 6.4% were breast 
metastasis, 7.3% were colorectal metastasis, 7.3% 
were melanoma metastasis, 3.8% were sarcoma 
metastasis, 3.8% were lung metastasis and 1.3% 
were ovarian metastasis. Patients with pancreatic 
metastases from melanomas and lung carcinomas 
have worse prognosis than patients with metastasis 
from renal cell carcinomas.By contrary, survival 
does not differ signiÀcantly between patients with 
metastases from the breast, colon or sarcomas. 
However, this was a retrospective study and included 
patients with different stage and prognosis. Some 
authors have proposed resection of the pancreatic 
metastasis in selected cases, specially in metastasis 
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Background: Lung cancer remains one of the most 
common and malignant cancers worldwide. It most 
often diagnosed at Stage IV, where it has already 
presented distal metastases. We aim to describe 
the clinical presentation of gastrointestinal tract 
metastases from primary lung cancer.
Methods: We describe 3 synchronous and 
metachronous cases of upper and lower 
gastrointestinal tract metastases (esophagus, stomach 
and sigmoid colon) from primary lung cancer.
Results: Although gastrointestinal metastases have 
been noted in a signiÀcant percentage of autopsies, 
only sporadic cases of diagnosed symptomatic 
intestinal metastases exist in medical literature. 
Most common are metastases at the small bowel, 
rather than the stomach or the colon. Review of 
the literature shows that the most common clinical 
presentations of the metastatic sites are abdominal 
pain, intestinal bleeding, obstruction and perforation.
Conclusion: Despite being rare, symptoms and 
complications of intestinal metastases from primary 
lung cancer should be early indentiÀed, as they are 
associated with signiÀcant morbidity and mortality, 
making the prognosis extremely poor. 
Keywords: gastrointestinal metastases, Lung cancer, 
NSCLC
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P4.121 RADIATION INDUCED INJURY 
RESULTING IN LIFE-THREATENING 
HYPERCAPNIC RESPIRATORY FAILURE 
, PERFORATED OESOPHAGITIS AND 
PNEUMOMEDIASTINUM: A CASE 
REPORT.
Andrea Tazbirkova1, Guy Bryant2, Simon Bowler3, 
David Serisier3, Zarnie Lwin1 
1Medical Oncology, Mater Adult Hospital/Australia, 
2Radiation Oncology, Mater Adult Hospital/
Australia, 3Thoracic Medicine, Mater Adult Hospital/
Australia
Background: Concurrent chemoradiotherapy as 
deÀnitive treatment for inoperable stage III non small 
cell lung cancer can be complicated by dose limiting 
toxicities such as radiation induced oesophagitis 
and pneumonitis. We report a unique case of severe 
radiation induced tissue injury resulting in perforated 
oesophagitis and pneumomediastinum, together 
with recurrent mechanical airway obstruction 
from necrotic inÁammatory debris leading to acute 
Additionally, the mediastinal mass was noted to be 
TTF-1 negative, while the cervical specimen is TTF-
1 positive suggesting that the cervical specimens 
were consistent with a papillary thyroid carcinoma. 
There were therefore two primary neoplasms. 
Results: The patient underwent an enbloc resection 
of the mediastinal tumor via a transverse sternotomy. 
The patients lungs and pulmonary vasculature 
re-expanded appropriately after removal of the 
mass. The patient had an uneventful 1 week stay 
in the hospital and returned 3 weeks later for an 
uncomplicated total thyroidectomy and left neck 
dissection. All margins were determined clear. 
Conclusion: Thymic carcinoid is a rare malignancy 
of the thymus with about 200 cases reported to 
date. These tumors are unique in their capacity to 
present with a variety of clinical onsets. Patients 
can be asymptomatic, manifest symptoms related 
to endocrinopathy, particularly Cushing syndrome, 
or it may manifest as part of the multiple endocrine 
neoplasia syndrome type 1. Or, the tumor may 
follow a more endocrinologically silent course and 
present with symptoms of intrathoracic compression. 
Finally, there is an association with thyroid cancer 
(follicular, papillary, and medullary carcinoma), in 
patients with carcinoid tumors of the thymus. This 
case represents the sequelae of an endocrinologically 
silent tumor with a delayed presentation as a giant 
thymic carcinoid and symptoms of intrathoracic 
compression. This is an exceptionally rare case 
particularly because of the unique size of the tumor. 
Keyword: THYMIC CARCINOID
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P4.120 UPPER AND LOWER 
GASTROINTESTINAL TRACT 
METASTASES FROM PRIMARY 
LUNG CANCER: CASE REPORTS AND 
LITERATURE REVIEW
Nikolaos Katirtzoglou1, Fotis Perlikos2, Andromahi 
Kougioumtzopoulou1, Manolis Merikas1, 
Muhammad W. Saif3, Kostas N. Syrigos1 
13rd University Department Of Internal Medicine, 
Oncology Unit, Sotiria General Hospital Of Chest 
Diseases/Greece, 212th Pulmonary Medicine 
Department, Sotiria General Hospital Of Chest 
Diseases/Greece, 3Division Of Hematology/
oncology, Herbert Irving Comprehensive Cancer 
Center,columbia University/United States Of 
America
S1460 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
stridor due to recurrent airway obstruction requiring 
removal of copious thick inÁammatory debris 
through bronchoscopy. He had marked symptom 
relief and his current ECOG is 1.Further update on 
his progress will be presented. 
Conclusion: We report an unusual case of severe 
delayed life threatening radiation toxicity. To 
date, no reliable predictors of individual radio-
sensitivity are available for such patients. Emerging 
evidence suggests certain genetic variants in key 
inÁammation-related genes might play a role and 
further research is warranted. 
Keywords: stage III non small cell lung cancer, 
radiation oesophagitis, radiation pneumonitis, 
concurrent chemoradiotherapy
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P4.122 PRIMARY ADENOID CYSTIC 
CARCINOMA OF THE LEFT LUNG 
MIMICKING SWYER-JAMES-MACLEOD 
SYNDROME
Ivan Aleric1, Darko Katalinic2, Stjepko Plestina2 
1Department Of Pulmonary Medicine, University 
Hospital Centre (kbc)/Croatia, 2Department Of 
Oncology, University Hospital Centre (KBC)/Croatia
Background: Adenoid cystic carcinoma (ACC) 
of the lung is aggressive epithelial tumour arising 
from the bronchial glands and accounting for about 
0.04-0.2% of all lung cancers. It is well known for 
its indolent course and ultimately poor prognosis. 
This report presents the clinical course of a patient 
diagnosed with suspected Swyer-James-MacLeod 
syndrome (SJMS), coexisting with this rare tumour 
entity. 
Methods: A 50-year-old female patient presented 
with chronic dyspnea for several months before 
hospital admission. Chest radiography and high 
resolution computed tomography (HRCT) of the 
chest (Figure 1a) showed hyperlucent left lung with 
diminished vascular structures without any signs 
of intrathoracic mass. Radionuclid imaging with 
Tc99-m revealed complete absence of perfusion in 
the left lung while pulmonary angiography showed 
small left pulmonary artery due to suspected 
extravasculary tumor compression. A Áexible 
Àberoptic bronchoscopy showed a tumour in the 
left main bronchus (Figure 1b). Histopathologic 
and histochemical analysis of biopsy specimens 
conÀrmed the diagnosis of ACC. The surgical 
hypercapnic respiratory arrest. 
Methods: In April 2010, a 49 year old Caucasian 
male diagnosed with stage III B ( T2N3M0) non 
small cell lung cancer, squamous histology, was 
presented at the Multidisciplinary Tumour Board 
meeting at our institution. Imaging including PET 
scan deemed our patient inoperable. Past medical 
history included a transient ischaemic attack at 
33 years and an acute myocardial infarction at the 
age of 42. Curative intent chemoradiotherapy was 
planned. 60 Gy of radiotherapy was delivered in 
30 fractions, concurrently with weekly carboplatin 
and paclitaxel at a dose of AUC 2 and 50mg/m2 
respectively. Carboplatin was chosen due to concerns 
regarding patient’s tolerance of Áuid load as per 
standard cisplatin hydration protocols. Planned 
chemotherapy during the 6th (last) week was not 
delivered due to intercurrent febrile illness. No other 
toxicities occurred and Computerized Tomography 
(CT) scan performed 6 weeks following completion 
of treatment showed near-complete response with 
signiÀcant reduction in size of a right hilar mass 
and almost entire resolution of mediastinal and hilar 
lymphadenopathy. 
Results: 2 months after completing treatment 
our patient developed severe dysphagia and 
odynophagia. Upper gastrointestinal endoscopy 
revealed extremely fragile, “paper thin” oesophagus 
with multiple mucosal tears requiring insertion of 
percutaneous endoscopic gastrostomy (PEG) feeding 
tube. Despite treatment with corticosteroids, proton 
pump inhibitors and antifungal agents his dysphagia 
progressed over 4 months rendering him unable to 
swallow saliva. Oesophageal biopsies performed on 
3 occasions revealed Àbro-inÁammatory ulcer slough 
and reactive squamous mucosa with no evidence of 
neoplasia. Repeat CT showed stable right hilar lesion 
and lymph node but extensive oesophageal wall 
thickening. Patient requested oesophageal dilatation 
for quality of life and one week after dilatation he 
rapidly deteriorated with hypercapnic respiratory 
failure requiring intubation and ventilation. Imaging 
revealed pneumomediastinum. Bronchoscopy 
performed via endotracheal tube revealed almost 
complete obstruction of main airways with thick, 
white, inÁammatory debris which was mechanically 
removed and resulted in signiÀcant improvement 
of respiratory function and extubation. Histology 
showed peeling respiratory mucosa with mixed 
inÁammatory inÀltrate and atypical stromal cells 
consistent with radiation effect. High dose steroids 
were commenced. Two weeks later he developed 
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Methods: We studied non-small-cell lung cancer 
(NSCLC) patients that were found with elevated 
serum ơ-HCG level during clinical trial screening. 
The Àrst case is a 45-year-old woman who presented 
with a stage IV undifferentiated carcinoma of the 
lung eligible for chemotherapy. When screening the 
patient for a clinical trial combining platinum-based 
chemotherapy and targeted therapy, the plasma 
ơ-HCG level was 19 IU/L (0-5 IU/L). The second 
case is a 64-year-old woman presented with stage IV 
poorly differentiated adenocarcinoma of the lung. 
When screening the patient for the same clinical 
trial combining platinum-based chemotherapy 
and targeted therapy, the plasma ơ-HCG level was 
ơ-HCG is 13 IU/L (0-5 IU/L). 
Results: The serum dosages were double checked 
and conÀrmed elevated ơ-HCG level. The 
gynecological work-up deÀnitely rules out an 
improbable pregnancy. The pathological examination 
was also checked and conÀrmed in the two cases 
a primary lung cancer. An immuno-histochemical 
reassessment of the pathological specimens with 
additional tests was performed: for one patient 25% 
of tumor cells expressed ơ-HCG. As pregnancies 
were ruled out, the two cases were extensively 
discussed with the promoter and the patients Ànally 
treated within this clinical trial. The treatments are 
ongoing. 
Conclusion: ơ-HCG is a speciÀc marker for 
trophoblastic tumors of placenta and gestational 
tumors. Ectopic expression of ơ-HCG was found 
in 20-40% of all common epithelial carcinoma, 
especially for tumors of the stomach, ovary, liver 
and lung. Only few cases have been reported in the 
literature. However, in a young patient with high 
serum levels of Beta HCG two questions arise: 
Is there a place for pregnancy? Are the pathology 
results accurate? All this could delay the appropriate 
management of these patients and also potentially 
prevents the participation of innovative therapeutic 
strategies. Therefore, knowing this rare but possible 
expression of ơ-HCG by lung tumors may speed 
out the gynecological work-up and the reevaluation 
of the histological samples in order to minimize the 
delay in the care of these patients and give them a 
chance to have new innovative drugs within clinical 
trial. 
Keywords: Lung cancer, Clinical Trials, ơ-HCG
approach required total left pneumonectomy due to 
the extent of tumour spreading and postoperative 
palliation radiotherapy was also administered. 
Unfortunately, two years after the diagnosis of ACC, 
the patient died as a result of pulmonary embolism.
Results: SJMS is a rare condition characterized 
by unilateral hyperlucency of the lung, lobe or 
part of the lobe due to a decreased vascularity 
and air-trapping in bronchial airways. It occurs 
after recurrent pulmonary infection in childhood 
but the majority of cases are diagnosed at a later 
age. The condition should be differentiated from 
congenital anomalies of airway/pulmonary vessels 
and bronchial obstruction due to mucus plug or a 
foreign body. In our case, bronchial tumour caused 
air-trapping and a lung hyperlucency mimicking 
SJMS. Considering our patient’s anamnestic data 
of recurrent lower respiratory tract infections 
in childhood, it remains unclear whether SJMS 
existed earlier in life or a hyperlucent lung was the 
consequence of a slowly growing ACC.
Conclusion: All patients with hyperlucent lung on 
chest radiographs should undergo full diagnostic 
work-up in order to distinguish SJMS and possible 
secondary reasons for lung hyperlucency. 
Keywords: Primary adenoid cystic carcinoma, 
Swyer-James-MacLeod syndrome
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P4.123 ȕ HUMAN CHORIONIC 
GONADOTROPIN (HCG) DOSAGE AND 
LUNG CANCER – A PITFALL WHEN 
SCREENING PATIENTS FOR CLINICAL 
TRIALS
Nataliya Khobta1, Pascale Tomasini1, Marie-Eve 
Garcia1, Fabrice Barlesi2 
1Service D’oncologie Multidisciplinaire Et 
Innovations Therapeutiques, Chu Nord/France, 
2University Of Mediterranee - Assistance Publique 
Hopitaux De Marseille/France
Background: ơ-HCG belongs to the glycoprotein 
hormone family and is usually assess to exclude 
pregnancy for patients potentially eligible to 
chemotherapy, especially during clinical trials. 
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of the suprascapular nerve with local anesthetic 
signiÀcantly and safely reduces this shoulder pain, 
potentially allowing the ideal goal of a pain-free 
thoracotomy. 
Conclusion: We present 18/9 cases in which an 
ultrasound-guided suprascapular nerve block was 
immediately effective for severe postthoracotomy 
ipsilateral shoulder pain. The block resulted in no 
related complications, and it provided long-lasting 
relief and a high degree of patient satisfaction. 
Keyword: Epidural analgesia, pain, thoracotomy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.125 MULTIPLE SPLENIC METASTASIS 
FROM PRIMARY NON SMALL CELL 
CARCINOMA OF THE LUNG-A CASE 
REPORT
Mehtap Calis1, Varol Calis2, Oktay Incekara1 
1Radiation Oncology, Sisli Eftal Resarch And 
Traning Hospital/Turkey, 2Neurosurgery, Istinye 
State Hospital/Turkey
Background: Metastatic disease of the spleen is 
uncommon and associated with widely disseminated 
disease. Patients are usually asyptomatic or have 
nonspesiÀc symptoms such as fatigue and abdominal 
pain. We report a 64 year old man who presented 
with fatigue, weight loss, sweating and abdominal 
pain and was diagnosid with multiple splenic 
metastasis from primary non small cell carcinoma of 
the lung. 
Methods: We report a 64 year old man.
Results: A 64 year old man who presented to 
the hospital with fatigue, weight loss, sweating 
and abdominal pain. He was an ex-smoker who 
quit 5 years after smoking 2 pack per day for 40 
years. Computed tomograpy scan of the abdomen 
showed multiple metastases in the spleen. Contrast 
enhanced Computed tomograpy scan of the chest 
showed multiple bullous lesions in the lungs, and 
emphysematous changes, no mass selected. Right 
submandibular, superior mediastinal, paratracheal 
and subcarinal lymph nodes were enlarged. PET-CT 
was performed. The outer edge of a bullous lesion 
revealed a slight increase in activity. Increased 
level of activity of pathological lymph nodes were 
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P4.124 ULTRASOUND-GUIDED 
SUPRASCAPULAR BLOCK FOR 
POSTTHORACOTOMY IPSILATERAL 
SHOULDER PAIN
Emine Ozyuvaci1, Turkan Dubus2, Sule Vatansever1, 
Naile Toprak1, Hakan Topacoglu3 
1Department Of Anaesthesia And Pain Management, 
Istanbul Education And Research Hospital/
Turkey, 2Department Of Thoracic Surgery, 
Istanbul Education And Research Hospital/Turkey, 
3Emergency Department, Istanbul Education And 
Research Hospital/Turkey
Background: Pain after thoracotomy is very 
severe, probably the most severe pain experienced 
after surgery. Thoracic epidural analgesia has 
greatly improved the pain experience and its 
consequences and has been considered the standard 
for pain management after thoracotomy. Despite 
receiving thoracic epidural analgesia, severe 
ipsilateral shoulder pain is common in patients after 
thoracotomy. 
Methods: We recruited 18 patients into a double-
blinded randomized placebo-controlled study to 
investigate whether ultrasound-guided suprascapular 
nerve block would treat postthoracotomy pain. 
All patients received a standard anesthetic with a 
midthoracic epidural. The aim of this study is to 
compare the effectiveness of the thoracic epidural 
analgesia (TEA) and the thoracic epidural analgesia 
add suprascapular nerve block (SNB) methods in 
relieving the pain caused by a thoracotomy incision 
and shoulder pain. Thoracic epidural catheter 
placed between T4 and T8 with the C-arm scope. 
All operations were open thoracotomies done by 
the same team of surgeons and anesthesiologists. 
A thoracic epidural catheter was placed before 
induction of general anesthesia. Ultrasound-guided 
suprascapular block was placed one hour before 
operations. Postoperative period haemodynamic 
effects, pruritus, nausea, vomiting, sensory and 
motor block, pain score, additional analgesic 
requirement, sedation, and patient satisfaction were 
registered immediately after the surgical operation 
and on the Àrst, second, and third postoperative days. 
Results: SigniÀcantly less number of patients 
required rescue analgesia in SNB group (P< 0.05). 
Pain relief was better both at rest and during 
coughing (P< 0.05) in SNB group as compared 
to alone TEA.We have shown that inÀltration 
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TTF-1, CK 7, CK 20, P63 and synaptophysin, this is 
consistent with an epitheliod hemagioendothelioma. 
He was treated with intravenous ‘bolus’ i.v. 
methylprednisolone for 3 days and then radiation 
therapy. The patient experienced initial signiÀcant 
symptomatic improve. Despite radiation therapy, 
our patient had progressive dissemination to the 
mediastinum and bone. He died 6 months after 
diagnosis.
Conclusion: Epithelioid hemangioendothelioma 
should be distinguished mainly from primary 
or metastatic carcinomas, angiosarcoma and 
lymphoproliferative disease when presenting a 
mediastinal tumor. Despite the different treatment 
strategies, there is currently no standard treatment 
and their prognosis in some cases is very poor. 
Keywords: mediastinum, immunohistochemistry 
CD34, epithelioid hemangioendothelioma
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P4.127 STRESS INDUCED 
CARDIOMYOPATHY DURING 
LOBECTOMY FOR LUNG CANCER
Min-Woong Kang1, Shin Kwang Kang1, Myung 
Hoon Na1, Jae Hyeon Yu1, Seung-Pyung Lim2 
1Chungnam National University Hospital/Korea, 
2Department Of Cardiothoracic Surgery, Chungnam 
National University Hospital/Korea
Background: Stress induced cardiomyopathy is 
caused by emotional or physical stressors and it 
mimic acute myocardial infarction but this disease 
is characterized by reversible left ventricular (LV) 
apical ballooning in absence of signiÀcant coronary 
artery disease.
Methods: 51-year-old male was admited for the left 
upper lobe lobectomy due to non small cell lung 
cancer.
Results: During the lobectomy, cardiogenic arrest 
occurred due to stress induced cardiomyopathy. 
Conclusion: This was successfully managed by 
intra-aortic balloon pumping and extracorporeal 
membrane oxygenation and the patients was 
discharged without complication.
Keywords: Stress induced cardiomyopathy, 
lobectomy, Extracorporeal membrane oxygenation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
identiÀed. Right submandibular lymph node biopsy 
was positive for invasive,high grade non small cell 
carcinoma metastasis. PET-CT revelated normal 
liver and adrenals,with no bone or other side 
metastasis. The patient was treated with concurrent 
chemoradiotherapy with cisplatin and etoposide. 
Splenectomy was not performed. So tissue diagnosis 
from splenic lesion were not attempted. 
Conclusion: metastatic disease involving the spleen 
is uncommon and mostly occurs in patient with 
widely disseminated metastatic disease. Lung cancer, 
malignant melanoma and breast cancer were the 
most frequent primary tumors all spleen metastases. 
Except for metastasis differential diagnosis of 
splenic masses include, lymphoma, granulomatous 
diseases, hemangioma and inÁammatory 
pseudotumor. Management has to be individualized 
and splenectomy should be offered to patients with 
otherwise favorable primary tumor features and 
absence of dissemination.
Keywords: Non small cell lung cancer, splenic 
metastasis
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P4.126 REPORT A CASE OF EPITHELIOID 
HEMAGIOENDOTHELIOMA OF THE 
MEDIASTINUM
Jaime Triana1, Luis G. Gonzalez2, Andres Yepes2 
1Radiotherapy, Hospital Pablo Tobon Uribe/
Colombia, 2Clinical Oncology, Hospital Pablo Tobon 
Uribe/Colombia
Background: Epithelioid hemangioendothelioma 
is a rare epithelial-appearing vascular tumor usually 
presenting in soft tissues and was Àrst described 
in 1982 by Weiss and Enzinger. The mediastinal 
localization has been identiÀed as an exceptional 
event and diagnosis is most often established 
postoperatively.
Methods: A report of case of epitheliod 
hemagioendothelioma in the mediastinum is 
reported. 
Results: We report the case of a 54-year-old patient 
with a superior vena cava syndrome (SVCS), 
mediastinal mass and large pleural effusion. 
Radiological Àndings favoured the initial diagnosis 
of a lymphoproliferative disease. A mediastinoscopic 
biopsy employed for tumor sampling. 
Immunohistochemically the cells were positive for 
keratine-cocktel, CD34 and CD 31 and negative for 
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P4.129 TREATMENT OF MULTIFOCAL 
INTRACRANIAL PROGRESSION OF 
ADENOCARINOMA OF THE LUNG 
WITH HIGH-DOSE PULSED ERLOTINIB 
COMPLICATED BY HEMORRHAGE AND 
GENERALIZED CEREBRAL EDEMA.
Amanda Tufman1, Jutta Stief1, Andreas Jung2, Rudolf 
M. Huber1 
1Department Of Respiratory Medicine, Ludwig 
Maximilians University/Germany, 2Institute For 
Pathology, Ludwig Maximilians University/Germany
Background: The development of isolated 
intracranial metastases is increasingly recognized as 
a relevant clinical problem in patients who respond 
well to EGFR tyrosine kinase inhibitors (TKIs). 
Single case reports of successful and well-tolerated 
treatment with high-dose, pulsed erlotinib have 
been published. (Hata et al, JTO 2011; Dhruva and 
Socinski, JCO 2009) 
Methods: We analyze the course of patient who 
developed intracranial hemorrhage and generalized 
cerebral edema during treatment with high-dose 
erlotinib.
Results: A 44 year old Caucasian female never-
smoker presented in 12/08 with left arm weakness. 
Computed tomography (CT) revealed several brain 
lesions, and a mass in the right lung. Positron 
emission tomography (PET) showed metastases in 
the liver and right kidney. Following bronchoscopic 
biopsy, adenocarcinoma of the lung, clinical stage 
IV, was diagnosed. Whole brain irradiation (35 Gy) 
and three cycles of chemotherapy (cisplatin 75mg/
m2 and pemetrexed 500mg/m2 day 1 every 3 weeks) 
led to a partial response; however, during the Àfth 
cycle a clear progression occurred. A pulmonary 
embolus was treated with tinzaparin (10,000 I.U. 
sc od). Genetic analyses showed an activating 
mutation in EGFR exon 19, and treatment with 
erlotinib was initiated. This led to regression of all 
tumor sites, including the kidney. After 13 months 
of erlotinib, magnetic resonance imaging (MRI) 
showed progression of the cerebral metastases. 
The primary tumor and intraabdominal metastases 
were stable, and so the intracerebral metastases 
were stereotactiacally irradiated. Three months 
later one further metastasis was irradiated, however 
multifocal intracranial progression soon developed. 
A neurosurgical biopsy showed the same mutation 
as in the primary tumor, with no known resistance 
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P4.128 SYNCHRONOUS BILATERAL 
LUNG AND GASTRIC TUMORS
Altug Kosar, Hatice Eryigit, Recep Demirhan, Ersin 
Cardak 
Thoracic Surgery, Dr.lutÀ Kirdar Kartal Training 
And Research Hospital/Turkey
Background: Patients with lung cancers have 
sometimes other malignancies simultaneously. 
Methods: Sixty six years old man had chest pain, 
cough, sputum, vomiting, abdominal pain and 10% 
of body weight loss about eight months. 
Results: In computerized tomography, 10L and 11R 
calciÀc lymphadenopathies of mediastinal region, 
calciÀcation on wall of aorta, pleural thickening and 
Àbrotic sequelae in the left lower lobe of lung were 
seen. In abdominal CT, calciÀcation in 8th segment 
of liver, minimal perihepatic Áuid, and a benign 
cysts in the right kidney and prostatic hyperplasia 
were detected. Mucosal inÀltration was seen in 
apicoposterior segment of the left upper lobe by 
Àberoptic bronchoscopy. Squamous cell carcinoma 
(in situ) was reported as result of mucosal biopsy. 
Thickening small curvature of gastric wall (suvmax: 
20.5) were detected in PET-CT. Gastroscopy 
showed an ulcerated polypoid structure on fundus-
corpus junction and hyperemic antrum. The result 
of polypoid lesion biopsy was adenocarcinoma. 
Total gastrectomy + total omentectomy + 
esophagojejunostomy were done. Postoperative 
pathology was invasive adenocarcinoma (poorly 
differentiated). Bronchoscopy was repeated one 
month after abdominal surgery and the mucosal 
irregularity was found in the superior segment 
of right lower lobe. Atypical cells were seen in 
histology of this region. Argon laser destruction 
of the right lower lobe lesion was performed. Left 
upper lobe lobectomy was done for the treatment of 
squamous cell carcinoma of left upper lobe. Results 
of pathology were tumor size 0.8x 0.8 cm length, 
1 cm surgical margin, squamous cell carcinoma 
(moderately differentiated), lymph node involvement 
was negative. 
Conclusion: Surgery can be performed to selective 
patients who have synchronous lung and gastric 
tumors. 
Keywords: Synchronous tumor, in situ carcinoma, 
gastric tumor
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inhibitor and some patients experiences rapid, 
durable, and most frequently partial responses. 
Often some tumor tissue can still be visualized 
on a Computed Tomography (CT) or a Magnetic 
Resonance Imaging (MRI) but may be negative on a 
Positron Emission Tomography(PET)
Methods: Two patients with multiple bone 
metastases and pathologically veriÀed 
adenocarcinoma in the lung were followed after start 
of treatment with erlotinib by clinical parameters 
and CT/MRI/PET of both lung tumor and bone 
metastasis. Pretreatment biopsies and blood samples 
were examined for the presence of EGF receptor 
mutations and lobectomy was performed by standard 
procedure after 10 and 30 months of treatment 
respectively. 
Results: Both patients responded clinically to 
treatment with erlotinib and both patients displayed 
a mutated EGF receptor. After 10 and 30 months of 
treatment respectively, both still displayed a mass in 
the lung and underwent lobectomy. No cancer cells 
could be identiÀed in the resected lung tumor tissue. 
Conclusion: Treatment with erlotinib may induce 
complet pathological responses in lung tumors 
in patients with metastatic NSCLC. This opens 
up the question if treatment with erlotinib can be 
discontinued in these patients. 
Keywords: metastatic NSCLC, erlotinib, EGFR 
mutation, complet response
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P4.131 PERCUTANEOUS STENT 
MANAGEMENT OF SUPERIOR VENA 
CAVA SYNDROME WITH ADVANCED 
LUNG CANCER
Andre G. Leite1, Márcia A. Leite2, Fabio Miguel3, 
Francisco Wisintainer3 
1General Thoracic Surgery, Hospital Do Circulo/
Brazil, 2Universidade De Caxias Do Sul/Brazil, 
3Instituto Devita De Oncologia E Hemoterapia/
Brazil
Background: The authors introduce the case of 
a 61-year-old male who had been experiencing 
acute dispnea, headache, edema and cyanosis of the 
face and arms. The patient had bronchial scamous 
cancer diagnosis two years ago, staging IIIB by 
mediastinal extension of the cancer. In addition, the 
patient had undergone Àrst line chemotherapy with 
gemcitabine plus vinorelbine (PS 2) with parcial 
mutations. High dose pulsed erlotinib was added 
(600 mg q 4d). After 2 weeks hemorrhage into three 
of the metastases (before hemorrhage: 35x27mm, 
11x19mm, 9x8mm) occurred. Anticoagulants 
were stopped, and due to 6mm midline shift the 
largest hematoma (35 x 23 mm) was evacuated. 
MRI showed a trend to partial response in the 
other intracerebral metastases and so the erlotinib 
pulses were continued with a 25% dose reduction. 
Unfortunately, 24 days later, cerebral edema and 
subdural hygroma developed and the patient died, 24 
months after initial diagnosis. 
Conclusion: Brain metastases despite systemic 
control increasingly pose a problem (Lee et al., 
Cancer, 2010). Inadequate dosing across the blood 
brain barrier is one explanation, but has not been 
proven. The absence of resistance mutations, as 
well as the multifocal nature of the intracerebral 
progression, support this theory in our case. The 
efÀcacy of high dose erlotinib for brain metastases 
has been previously reported. Previous reports 
describe minimal toxicity during treatment. The 
signiÀcant multi-focal hemorrhage and cerebral 
edema which developed in our patient have not been 
previously described in this setting. Simultaneous 
anticoagulation as well as previous stereotactic 
radiation of the brain metastases may have 
predisposed our patient to hemorrhage, and may 
prove to be relative contraindications to high-dose 
pulsed erlotinib. Because most centers only see a few 
patients in this clinical situation, cooperative efforts 
are needed to collect and analyze these cases, and to 
develop appropriate treatment strategies. 
Keywords: erlotinib, Non-small cell lung cancer, 
brain metastases
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P4.130 COMPLET RESPONSE DESPITE 
A VISIBLE TUMOR MASS IN NON-
SMALL CELL LUNG CANCER PATIENTS 
TREATED WITH ERLOTINIB
Britta Weber1, Boe S. Sorensen1, M. M. Knap1, H. H. 
Madsen1, Ebba Nexo1, Peter Meldgaard2 
1Department Of Clinical Biochemistry, University 
Hospital Of Aarhus/Denmark, 2Department Of 
Oncology, University Hospital Of Aarhus/Denmark
Background: Non-small cell lung cancer patients 
with a sensitizing mutation in the EGF receptor 
are likely to respond to treatment with an EGFR 
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P4.132 A RARE CASE OF 
INFLAMMATORY PSEUDOTUMOR IN 
AN OCTOGENARIAN: NECESSARY 
PNEUMONECTOMY
Salvatore Griffo1, Giuseppe De Luca2, Francesco 
Petteruti2, Antonella Luciano2, Dino Casazza1, Nello 
Vicidomini1, Lucia Beneduce1 
1Thoracic Surgery Unit, University Of Naples/Italy, 
2Cardiothoracic And Vascular Unit, Pineta Grande 
Hospital/Italy
Background: InÁammatory pseudotumors are 
reactive lesion simulating a neoplasm characterized 
by a proliferation of Àbroblasts and myoÀbroblasts 
mixed with varying numbers of inÁammatory 
cells. Pseudotumors of the lung are rare disease 
predominantly occurring in younger patients. 
Diagnosis is difÀcult because its unspeciÀc clinical 
and radiological presentation.
Methods: A 81-year-old woman was admitted to 
our hospital complaining astheny, fever (38°C) and 
nonproductive cough. The patient was a non-smoker 
and had a history of hypertension. Chest X-ray and 
CT scan showed a suspected consolidation in the 
left lower lobe (Fig.1A). After two weeks antibiotic 
therapy there was no clinical symptomatology 
regression; a new CT scan demonstrated signiÀcantly 
increased mass within abscessualized areas (Fig.1B). 
Bronchoscopy not revealed airways obstruction. 
TBNA and CT guided TTNA cytology were not 
diriment for malignancy. Increasing mass size 
combined with the onset of dyspnea, asthenia, 
sudden weight loss put an indication for surgery.
Results: A left pneumonectomy with 
lymphadenectomy was performed because of tumor 
involvement of left upper lobe. The resected tumor 
measured 58 mm × 47 mm × 35 mm and resection 
margins and all regional lymph nodes were free of 
disease. InÁammatory myoÀbroblastic tumor was 
diagnosed. At the last follow-up (12 months after 
operation), the patient was symptom free and there was 
no evidence of tumor recurrence on chest CT scan. 
response after three cicles of chemotherapy. There 
was disease progression with ocorrency of superior 
vena cava syndrome, which was treated by second 
line chemotherapy with paclitaxel plus carboplatin 
and total dosis radiotherapy (45Gy). This treatment 
determined a good response with regression of 
the vena cava superior syndrome. The disease 
remainded stable for Àve months. Two months ago 
the patient again developed vena cava superior 
syndrome with acute symptoms. It was submitted 
to angiotomography wich evidencied vena cava 
superior obstruction (Àgure 1).
Methods: The patient was submitted to a digital 
angiography with total obstruction of the vena cava 
superior (Figure 2A). It was performed a superior 
vena cava stent placement (Wall stent - Boston 
ScientiÀc, MA) at this time.
Results: After stent placement we can observe the 
restoration of the blood Áow through superior vena 
cava (Àgure 2B). The patient remainded withouth 
symptoms for a follow-up period of six months apter 
stent replacement. The control angiotomography 
performed at this time did not demonstrate vascular 
obstruction. 
Conclusion: The standard treatment of the malignant 
superior vena cava syndrome is the chemotherapy 
and radiotherapy association. This treatment may 
determine several side effects besides the results may 
be delayed. Stent placement is a minimally invasive 
treatment wich determine a rapid restoration of 
the blood Áow. Several authors have demonstrated 
the superiority of stent placement in patients with 
superior vena cava syndrome due to cancer, in 
particular in the patients with acute symptoms.
Keywords: superior vena cava syndrome, wall stent
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Results: The immunoistochemical positive 
expression of the antibodies:S-100,SMA,CEA,CD-
117(c-Kit) and Keratin was identical to all 
cases(primary and metastatic to lung).The expression 
of the TTF-1 and CD-56 was such as to offer a novel 
point of view in the istological differential diagnosis 
between primary and metastatic to lung adenoid 
cystic carcinoma. 
Conclusion: The immunoistochemical positive 
expression of the antibodies:S-100,SMA,CEA,CD-
117(c-Kit) and Keratin was identical to all 
cases(primary and metastatic to lung).The expression 
of the TTF-1 and CD-56 was such as to offer a novel 
point of view in the istological differential diagnosis 
between primary and metastatic to lung adenoid 
cystic carcinoma. 
Keyword: Adenoid cystic carcinoma, lung, TTF-1
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P4.134 ASPERGILLUS INFECTION 
IN LUNG CANCER PATIENTS.OUR 
EXPERIENCE
Nektarios Alevizopoulos, Michael Vaslamatzis, 
Theodoros Vagdatlis, Efstathia Perivolioti, Apostolos 
Laskarakis, Evaggelos Ntouvelis, Vasiliki Ntalapera, 
Evaggelos Mpallis, Theodoros Argirakos 
Oncology, Evaggelismos Hospital/Greece
Methods: To present the aspergillus infection 
recorded among 40 lung cancer patients with febrile 
neutropenia consecutively admitted in our oncology 
department in the prior two years. 
Results: Case 1: A 72 years old lady with 
mesothelioma was admitted with febrile neutropenia 
post Àve days of her chemotherapy .She had 
persistent productive cough and worsening right 
pleural effusion albeit her myelotoxicity recovery. 
The prolonged respiratory discomfort led to 
imaging tests and multiple microcystic lesions 
with a right median lobe encapsulated cyst were 
documented. She underwent bronchoscopy and the 
diagnosis of invasive aspergillosis was histological 
conÀrmed. She was offered antifungal therapy 
with voriconazole and experienced rapid clinical 
improvement. The patient died 9 months later due 
to her disease progression. Case2: A 76 year old 
man never smoker with diabetes and cardiovascular 
disease presented with persistent neutropenic fever 
post his chemotherapy for his lung cancer. His 
respiratory function although his hematological 
Conclusion: InÁammatory pseudotumors are 
rare in elderly, surgery is required to differentiate 
inÁammatory pseudotumors from primary or 
metastatic lung cancers. Even though the elderly 
should be considered always an high risk patient 
an aggressive approach is advised to maximize the 
likelihood of long-term cure. 
Keywords: inÁammatory myoÀbroblastic, 
pseudotumor
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.133 ADENOID CYSTIC 
CARCINOMA:PRIMARY AND 
METASTATIC LOCATION TO THE 
LUNG.
Ioannis Vamvakaris1, Maria Anagnostopoulou2, 
Lamprini Chiochou1, Ioannis Gkiozos3, Andriani G. 
Charpidou3, Kostas N. Syrigos4 
13rd Department Of Athens Medical School, 
“sotiria” General & Chest Hospital ”., Oncology 
Unit/Greece, 2Icu Red Cross General Hospital/
Greece, 3Oncology Unit, 3rd Dept Of Medicine, 
Sotiria General Hospital/Greece, 4Oncology Unit, 
3rd Department Of Medicine, Sotiria General 
Hospital, Athens School Of Medicine/Greece
Background: Adenoid cystic carcinoma is the 
most common type of salivary gland type tumor of 
the upper respiratory track. It is usually centered 
in the major bronchi but peripheral examples are 
also referred. Aim: These salivary type neoplasms 
probably arise from the submucus bronchial glands. 
Metastasis to lung from an adenoid cystic carcinoma 
of the salivary gland has the same features with the 
primary neoplasm. We investigate the possibility of 
deÀning the primary or metastatic disease by the use 
of immunoistochemistry. 
Methods: We examined Àve (5) cases of adenoid 
cystic carcinoma of the lung by performing 
immunoistochemistry methods of three steps(avidine-
biotin-peroxidase).The antibody used were 
:S-100,SMA,CEA,CD-117(c-Kit),Keratin,TTF-1 
and CD-56. After the conclusion of the 
immunoistochemistry study, we looked further back to 
the rest clinical and laboratory data on the purpose to 
deÀne the origin of the neoplasm(primary or meta). 
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are referred to physiotherapy practice in order to 
enhance the lung perfusion and ventilation ratio, 
conventionally with respiratory exercise support. 
OBJETIVE: To analyze the physiologic changes 
caused by respiratory exercise in patients submitted 
to segmentectomy for lung tumor
Methods: 10 lung cancer patients with average 
age of 40 years old were submitted to the protocol. 
PROCEDURE: Heart rate, respiratory rate and blood 
pressure were analyzed in all patients, before and 
after the application of the protocol. The protocol is 
based on the application of 5 sets of 10 repetitions of 
the following exercises: maximum inhalation held 
for six seconds, fractioned inhalation and exhalation. 
The results were statistically analyzed through test-t 
students.
Results: The respiratory rate after the protocol 
decreased in 18,8% (from 19,6 ± 1,2 to 15,9 ± 1,5 
rpm) (p < 0,05), the heart rate had a non signiÀcative 
increase of 6,9% after the protocol (from 81,8 ± 
5,0 to 87,5 ± 5,3 bpm) (p>0,05), the systolic blood 
pressure had a non signiÀcative increase of 1,15% 
(from 130,5 ± 8,7 to 132 ± 9,8 mmHg) (p> 0,05) and 
the diastolic blood pressure had a non signiÀcative 
decrease of 3,2% (from 76,5 ± 2,7 to 74 ± 2,6 
mmHg) (p> 0.05).
Conclusion: The respiratory exercise when 
applied under a standard don’t present a signiÀcant 
interference on the vitals readings of a lung 
resected patient, however can be responsible for the 
adequation of the respiratory rate of those patients. 
Keywords: Physiotherapy, postoperative of lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.136 OVARIAN METASTASIS 
OF PULMONARY SMALL CELL 
CARCINOMA
Serdar Akp×nar1, Nazire Ucar1, Yetkin Agack×ran2, 
Olcay Kandemir3, Tugrul ûipit1 
1Chest Disease Department, Atatürk Chest Disease 
And Chest Surgery Hospital/Turkey, 2Pathology, 
Atatürk Chest Disease And Chest Surgery Hospital/
Turkey, 3Department Of Gynecology And Obstetrics, 
Ataturk Education And Research Hospital/Turkey
improvement was deteriorated and a computer chest 
tomography was performed revealing a dirty opacity 
of the right lower lobe whereas the cancer mass on 
the upper lobe was still stable. High suspicion for 
disease progression or opportunistic infection led 
to a bronchoscopy reevaluation. An intrabronchial 
mass with necrosis was found. Histological test 
conÀrmed its asperlillus origin .The patient although 
was initiated on voriconazole, he died because of 
respiratory shock. Case 3: A 78 years old man with 
extra pulmonary small cell lung cancer was admitted 
with febrile neutropenia and respiratory stress post 
his 3rd consequent chemo therapy. No speciÀc lung 
imaging Àndings were found but blood cultures 
revealed aspergillus growth. The patient had severe 
liver failure and did not manage to recover although 
was initiated on caspofungin treatment. All the above 
stated cases were tested for antigen of aspergillus 
but no positive results were found. The use of 
the galactomannan assay was not performed All 
diagnoses were documented according to histological 
species. The imaging pictures are really interesting. 
Conclusion: Among febrile neutropenic patients 
post chemotherapy, fungal infections of unusual 
appearance should be thoroughly considered.The 
clinical management remains a challenge in the 
setting of the compromised host defence system 
The mortality is really very critically high and 
all diagnostic tests should be performed , even 
aggressively when pulmonary aspergillosis is 
suspected. 
Keyword: Aspergillus Infection,Febrile Neutropenia
Poster Session 4  - Clinical Cases Thursday, 7 July 2011 10:00-12:30
P4.135 PHYSIOTHERAPY IN THE 
POSTOPERATIVE OF LUNG CANCER
Juliana D. Leandro1, Rogerio Traballi2, Tiaki M. 
Lopes2, Renata F. Medeiros2, Bruno Muller2, Camila 
Guerra2 
1Unip/Brazil, 2Fisioterapia, Unip/Brazil
Background: Lung cancer is a malign expansion 
and transformation of the lung tissue. It is the most 
lethal type of cancer in the whole world, responsible 
for 1,2 million deaths every year. Smoking habits are 
the main cause of the disease. The treatment depends 
specially on the type, “stage” and estadio (dispersion 
grade) of the cancer. Surgery, chemotherapy and 
radiotherapy are the most common treatments 
available. Usually after a lung surgery, patients 
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reported by Dail and Liebow in 1975 as an 
intravascular bronchioloalveolar tumor (IVBAT). 
Immunohistochemical and electron microscopic 
studies revealed that IVBAT is of endothelial 
origin, and the tumor was renamed epithelioid 
hemangioendothelioma.These tumors are usually 
multifocal and more common in females. 
Methods: We report a case of PEH presenting as a 
Pancoast tumour causing diagnostic dilemma and 
was managed with Radical RT.
Results: A 49 year old gentleman was referred to 
our hospital with complaints of dyspnea and pain 
radiating to the right upper arm since 1 month.
On examination, patient’s general condition was 
stable with an ECOG performance score of II.A 
hard immobile swelling was present in the right 
supraclavicular region of size 8 x 7 cm.The swelling 
was non tender and was non pulsatile.Auscultation 
revealed diminished air entry in both lung bases. 
Initial lab investigations revealed leucocytosis.CXR 
showed a heterogeneous opacity in right upper zone 
with bilateral moderate pleural effusion.CECT chest 
done to ascertain the nature of the mass revealed 
a irregular soft tissue mass lesion of size 5.5 x 4.3 
cm in the right upper lobe in apical and anterior 
segments.Right subclavian vessels were engulfed 
by the tumor mass.The mass was seen eroding 
the anterior aspect of the Àrst rib.Few mediastinal 
nodes were noted in the right paratracheal and 
subcarinal region.Bilateral moderate pleural 
effusion with atelectatic changes were also noted.
Screening of abdomen showed a soft tissue lesion 
in right adrenal gland measuring 3.7 x 2.5 cm size,? 
Metastasis.Pleural Áuid cytology was reported as 
InÁammatory effusion.FNAC from the mass was 
reported as poorly differentiated malignant tumor.
Hence a CT guided Core needle biopsy was done 
for categorization.Histopathological examination 
showed Àbrocollageneous tissue inÀltrated by 
pleomorphic cells with high N:C ratio,nuclear 
pleomorphism and moderate eosinophilic cytoplasm.
Immunohistochemistry studies showed that the 
tumor cells stained positive for vimentin and 
CD 31 and stained negative for Cytokeratin, 
Chromogranin,Desmin, Synaptophysin and S100. 
Based on the above Àndings , a Ànal diagnosis of 
Epitheloid Hemangioendothelioma was arrived at.An 
USG guided FNAC of the adrenal gland lesion did 
not reveal any malignant cells.Patient was initially 
managed with analgesics.He underwent bilateral 
therapeutic pluerocentesis to relieve dyspnea.The 
case was discussed in tumor board and planned 
Background: Small cell lung cancer which is 
an aggressive tumour, has worse prognosis and 
constitute 20% of lung cancers. Small cell carsinoma 
may originate from organs other than lung. Clinical 
course and treatment of extrapulmonary small cell 
carsinomas are smilar to the tumour of lung. 
Methods: Small cell lung carsinoma has wide 
spectrum of distant metastases that may be 
confused with extrapulmonary primary tumours.
So that the exact diagnosis may be difÀcult for 
clinicians and pathologists.Small cell lung cancer 
metastasizes to many different organ, but genital 
metastasis,especially ovarian metastasis is very 
rare. A 51 year old –woman with pulmonary small 
cell carsinoma was admitted to our hospital with 
abdominal pain during the following 18th month of 
lung cancer diagnosis. 
Results: Left ovarian mass and gastrointestinal 
metastasis was found during the examinations 
.Bilateral ovarian ,uterus,omentum and appendix 
metastasis was detected by total abdominal 
hysterectomy and bilateral salpingo-oopherectomy. 
Conclusion: In this report we presented a pulmonary 
small cell cancer case which metastasized to ovaries 
beside gastrointestinal metastasis. 
Keywords: small cell carsinoma, ovarian metastaz
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P4.137 PULMONARY EPITHELOID 
HEMANGIOENDOTHELIOMA 
PRESENTING AS PANCOAST TUMOUR- 
A CASE REPORT.
Vijayabhaskar Ramakrishnan1, Kirushna Kumar 
Kosanam Subramanian2, Krishnakumar Rathinam3, 
Anand Selvakumar2 
1Department Of Surgical Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
2Department Of Radiation Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
3Department Of Medical Oncology, Meenakshi 
Mission Hospital And Research Centre/India
Background: Pulmonary epithelioid 
hemangioendothelioma (PEH) is a rare vascular 
tumor categorized into borderline or low-
grade malignancy. The disease was originally 
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tumors, there are limitations in measuring size of 
ill-deÀned, irregular, or subsolid lesions, as well 
as tumors with postobstructive pneumopathy or 
peribronchial inÀltration. In addition, measurement 
of maximal diameter of tumors either on multiplanar 
reconstruction images or only on axial images has 
not been established. Invasive nodal disease may be 
interpreted as the primary tumor, and whether the 
mediastinal invasion of primary tumor or concurrent 
mediastinal lymphadenopathy is sometime difÀcult 
to determine. Staging of axillary, diaphragmatic, 
and other unusual nodal group is also tough. 
Management guideline for many additional nodules 
which are frequently observed during CT evaluation 
is lacking. Lymphangitic metastasis does not have 
a designated T or M descriptor. Despite of wide 
availability of PET and its integral role in staging, 
there is lack of explicit reference in utilization of this 
newer imaging modality in staging of lung cancer.
Conclusion: It is hoped that many of these 
radiologic issues in staging lung cancer will be 
addressed in the future TNM system. 
Keywords: Lung cancer, radiologic staging, CT
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P4.139 SQUAMOUS CELL LUNG 
CANCER IN A 17-YEAR-OLD GIRL 
WITH JUVENILE LARYNGEAL 
PAPILLOMATOSIS. A CASE REPORT. 
GOMEZ R., VILLALBA V., YOFFE I. 
ONCOLOGY DEPARTMENT. CLINICAL 
HOSPITAL. FCM.-UNA. PARAGUAY 2011.
Villalba A. Villalba, Romy M. Gomez 
Oncologia Medica, Hospital De Clinicas/Paraguay
Background: Introduction: Juvenil Laryngeal 
Papillomatosis (JLP) is a neoplasia that generally 
shows a benign but recurrent behavior.
It is induced by the Human Papilloma Virus (VPH) 
speciÀcally serotypes 6, 11, 16, and18. JPL can 
produce hoarseness because it’s association with 
verrucous nodules on the vocal cords, and rarely can 
disseminate to the lungs, and produce a signiÀcant 
morbidity. JLP treatment is difÀcult because its 
recurrences and lung extension. It´s treatment is 
surgery (laser vaporization, micro-instrumental, 
among others) chemical, and biologic aproaches, 
as Alfa Interferon (AIF), none of them eradicate 
the disease and multiple treatments are usually 
required. When malignization occurs it is treated 
for Radical RT.Patient received RT to the right 
supraclavicular region 38 GY/19#.On the 20th day 
,patient complained of severe pain in the left chest 
radiating to left arm in the early morning and became 
unconscious. He was evaluated by the cardiologist 
and was diagnosed as acute coronary syndrome.He 
was started on inotropes and antiplatelet drugs. But 
patient’s condition continued to deteriorate and had a 
cardiac arrest from which he could not be revived. 
Conclusion: This case has been presented for its 
rarity and the diagnostic dilemma it posed. A strong 
index for suspicion should be there to rule out PEH 
in poorly differentiated carcinomas as their behavior 
is unpredictable. 
Keywords: Pancoast tumor, Pulmonary epitheloid 
hemangioendothelioma
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P4.138 PITFALLS IN RADIOLOGIC 
EVALUATION OF TNM STAGING IN 
LUNG CANCER
Myeong Im Ahn1, D.-H. Han1, I.-R. Yoo2, J. H. 
Kang3, Y.-K. Kim4, S.-W. Sung5, Jae Kil Park5, Y.-P. 
Wang5, Yeon-Sil Kim6, Kyo Young Lee7 
1Radiology, Seoul St. Mary’s Hospital, The Catholic 
University Of Korea/Korea, 2Nuclear Medicine, 
Seoul St. Mary’s Hospital, The Catholic University 
Of Korea/Korea, 3Division Of Medical Oncology, 
Department Of Internal Medicine, College Of 
Medicine,catholic University, Seoul St. Mary’s 
Hospital, The Catholic University Of Korea/Korea, 
4Pulmonology, Seoul St. Mary’s Hospital, The 
Catholic University Of Korea/Korea, 5Thoracic 
Surgery, Seoul St. Mary’s Hospital, The Catholic 
University Of Korea/Korea, 6Radiation Oncology, 
Seoul St. Mary’s Hospital, The Catholic University 
Of Korea/Korea, 7Pathology, Seoul St. Mary’s 
Hospital, The Catholic University Of Korea/Korea
Background: Although new 7th TNM classiÀcation 
provides improved prognostic relevance of its 
descriptors, problems in radiologic staging of 
lung cancer have not been fully addressed. With 
increasing role of imaging in staging of disease, 
both radiologists and clinicians should recognize its 
limitation. 
Methods: Comprehensive imaging demonstration 
of variable difÀculties in radiologic staging of lung 
cancers will be presented.
Results: In terms of T descriptors, i.e., primary 
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P4.140 ENDOSCOPICAL TREATMENT OF 
TRACHEAL AND TRACHEOBRONCHIAL 
LESIONS WITH A NEW SHAPED 
METALLIC STENT
Massimo Torre, Serena Conforti, Adriana Lomonaco 
Thoracic Surgery Division, Niguarda Hospital/Italy
Background: The use of airway stent for the 
treament of tracheal and tracheobronchial lesions 
is increasingly advocated. However the long term 
safety and efÀcacy of these devices has not yet 
been established because of many complications.
At present silicon and covered metallic stent have 
been proposed by different authors as a therapeutical 
option. The treatment of carinal lesions remain a 
major challenge since the anatomical structure may 
require an y stent.
Methods: In this paper we present a series of 
23 patients with benign and malignant tracheal 
and carinal lesions successfully treated with a 
new metallic tracheal stent system . This stent is 
composed of biomedical monoÀlament wire braided 
in a tubular mesh or in an Y conÀguration.
Results: In the last two years we endoscopically 
treated 18 patients with benign and malignant 
tracheal stricture and 5 patients with carinal lesions.
All procedures were performed under general 
anestesia through rigid bronchoscope. In all patients 
the stent was delivered under direct visualization. 
In all patients the outcome was satisfactory without 
major complications 
Conclusion: Our clinical results indicates that this 
new serie of metallic stent provide immediate and 
satisfactory results in patients with benign lesions 
. Since palliation remain the main purpose of 
malignant lesions the Y metallic stent proposed in 
this experience may represent a new therapeutical 
option in patients with tracheal and carinal 
obstruction . 
Keywords: airway stenting, tracheobronchial 
lesions, Y stent
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P4.141 MALIGNANT PLEURAL 
MESOTHELIOMA WITH A CENTRAL 
NERVOUS SYSTEM METASTASES
Agostina Stradella1, Margarita Majem1, Cinta 
Pallarès1, Alfonso Gomez De Liaño Lista2 
with worldwide approved protocols. A malignant 
transformation could occur in the larynx and more 
rarely in the lungs. In Paraguay lung cancer is the 
second cause of cancer related death in males and the 
Àfth in females. Squamous Cell Carcinoma (SCC) 
of the lungs represents between 35 to 50% of lung 
cancers and it‘s generally associated to tobacco use. 
There is strong, but controversial evidence regarding 
it´s association with Human Papilloma Virus 
infection (HPV) especially genotypes 16 and 18. We 
report a case of a 17 year old girl with JLP and SCC 
of lung. 
Material and Methods: Case: A 17 years old girl, 
with JLP diagnosed at age 2, with multiples relapses 
leading to 140 resections during her life. She was 
treated with interferon when she was 3 years old, for 
8 weeks, in the ENT department of the ORL service 
of our Hospital. For Ànancial reason she couldn’t 
receive the two years protocol. 
Results: In January 2009 a CT-scan showed 
multiple areas of consolidation in the lungs with a 
predominant area in left low lobe. She underwent a 
low left lobectomy in March 2009 in which a lung 
carcinoma was founded, and it was staged as a T3 
N0 M0, EC IIb. The histological feature was of a 
7,3 cm. Squamous cell lung cancer well to moderate 
differentiated aroused in papilomatous lesions. She 
was admitted to the Oncology Department in April 
2009 and treated with Carboplatin and Gencitabine. 
Treatment was irregularly delivered because of 
recurrent lung infections. She completed two cycles 
in august 2009. Since then she remains asymptomatic 
for her lung tumor but with JLP relapses. JPL relapses 
seemed to slow down after chemotherapy with less 
frequents needs of resections. 
Discussions and Conclusions: JLP is an entity 
associated to HPV. It has a recurrent behavior and 
it is potentially deadly due its complications. In the 
other hand, some studies had related squamous cell 
lung cancer with HPV infection. Lung cancer is very 
rare at the age of our patient. In fact we were unable 
to found other cases of this particular histology in 
teenager patients. We report the case of a 17 years 
old girl who after 14 years of a diagnosis of JLP 
developed a SCC lung cancer 
Keywords: dragon, lung cancer and jlp, Lung 
cancer, jlp
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.142 AN UNUSUAL CASE OF AN 
UNUSUAL LUNG CANCER
Donna M. Graham1, Louise Burke2, John Hinchion3, 
Derek G. Power1 
1Mercy/cork University Hospitals, Department 
Of Medical Oncology/Ireland, 2Department Of 
Pathology, Cork University Hospital/Ireland, 
3Department Of Cardiothoracic Surgery, Cork 
University Hospital/Ireland
Background: Mucoepidermoid carcinoma of 
the lung is a rare tumour subtype comprising 
approximately 0.1% of lung cancers. There is no 
standard of care to manage this disease. We present 
a case of asymptomatic mucoepidermoid carcinoma 
of lung identiÀed on follow-up imaging for another 
malignancy.
Methods: Case A 75 year old female with a 
signiÀcant smoking history underwent a radical 
cystectomy for an extensive bladder tumour which 
was causing bilateral hydronephrosis. Pathology 
revealed a grade II, 10cm superÀcial urothelial 
carcinoma of the bladder without muscle invasion 
(Ta N0). No adjuvant therapy was given. Three years 
later, a routine chest x-ray demonstrated a lesion in 
the upper lobe of her left lung. Pathology revealed a 
non-small cell carcinoma with overall features that 
were favouring a metastasis from the prior bladder 
tumour, however, clinicopathological correlation was 
advised. 
Results: A multidisciplinary team decision 
recommended a trial of systemic chemotherapy and 
then consideration of surgery or radiation therapy. 
Platinum and gemcitabine chemotherapy was 
administered over a 2 month period and treatment 
was stopped early secondary to persistent grade 3 
myelosuppression. Positron Emission Tomography 
(PET) scan conÀrmed no further metastatic disease 
and a modiÀed lingular resection of the lung was 
performed. Histology conÀrmed a non-small 
cell lung carcinoma (NSCLC)/Mucoepidermoid 
Carcinoma with focal high grade features (pT2b, 
pN2), stage IIIA. Epidermal growth factor analysis 
was wild type. Our patient received adjuvant 
radiotherapy, 59.4Gy in 33 fractions. Adjuvant 
chemotherapy was not given and she remains well 8 
months following lung resection. 
Conclusion: Urothelial carcinoma can often be 
confused with other histologies. Mucoepidermoid 
carcinoma is a rare subtype of NSCLC and there 
1OncologÍa Medica, Hospital De La Santa Creu I 
Sant Pau/Spain, 2Oncologia Medica, Hospital De La 
Santa Creu I Sant Pau/Spain
Background: We present the case of a patient of 
66 years, ex- smoker, with antecedents of labor 
exhibition to asbestos diagnosed of Malignant 
pleural Mesothelioma Stage III that progress to 1º Qt 
line into de central nervous system 
Methods: Patient of 66 years, ex- smoker, with 
antecedents of labor exhibition to asbestos, that 
consulted in March of 2010 by pleurític pain being 
diagnosed Malignant pleural Mesothelioma Stage III
Results: Was made irradiation on the scar of 
thoracotomy made for the biopsy by the high risk 
of dissemination in the zone, administering itself 
20 a total dose of Gy (5s of 4 Gy) Ànalizing the 
09.03.2010.
The patient received treatment of QT with 
CCDP+Premetrexed. 6 cycles were administered 
(last the 22.06.2010), being obtained Stable Disease. 
The patient required entrance in August of 2010 by 
bad control of the pain. A TC of thorax made then 
showed tumor plural progression level with vertebral 
bony commitment (D10) and bag by contiguity. It 
made antialgic RT on the costal zone affects. During 
the entrance the patient presented/displayed picture 
of disorientation and bradypsychia. After discarding 
infectious pathology, metabolic alterations and 
picture of poisoning by opiate, cranial TC was made 
that showed compatible injury with metastases in 
right temporary area. The patient was considered 
tributary of holocraneal RT that Ànally did not 
receive by deterioration of the general state. 
Conclusion: This case is about a 66 years old man 
diagnosed to Malignant pleural Mesothelioma 
Stage III that progress into central nervous system 
after 1º line chemotherapy. The interest to present/
display this patient is due to the infrequent cerebral 
dissemination of this tumor, being an almost 
anecdotal presentation. They are less than the 60 
cases published in present Literature. The handling 
of these patients can be made with RT or surgery 
according to the extension of the disease at this level 
and systemic level. 
Keyword: Malignant pleural mesothelioma , central 
nervous system metastases
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adenocarcinoma pathology. The staging was thus 
T4, N3, M1. His physical state score was ECOG-
1. Gemcitabine – Carboplatin chemotherapy was 
given until 5 cycles, intercalated with Erlotinib 
150 mg orally on day 15-28 of each cycles. After 5 
cycles, he is continuously received oral Erlotinib as 
maintenance therapy.
Results: Follow-up visit was scheduled for 
every month to evaluate clinical data, physical 
performance, hematology and clinical chemistry 
laboratory data, drug side effects and CT-scan 
according to RECIST criteria. After 2 months 
follow-up (post cycle 2) target lesion mass was 
disappeared. The patient also reported improvement 
of the symptoms and gain weight. After 9 months 
follow-up (maintenance phase) all non-target lesion 
(atelectasis, lymph node enlargement, and liver 
metastasis) were disappeared. The physical state 
improved to ECOG-0. Side effects encountered 
were mild anemia, mild to moderate leucopenia after 
cycles 3. An increased in creatinin and blood urea 
nitrogen were observed after cycles 5. Mild skin rash 
also found during maintenance therapy. 
Conclusion: Erlotinib used as intercalated therapy 
with conventional chemotherapy may induce 
complete remission of advanced NSCLC on properly 
selected patient. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.144 ACCESSIBILITY OF BURKITT 
LYMPHOMA (BL) TREATMENT IN 
CAMEROON
Joshua N. Menang1, Edward N. Ngwa2 
1Pediatric Ward, Calmef Health Centre/Cameroon, 
2Clinical, Diproloc Linic/Cameroon
Background: A high per centage of about 60-65% 
of children diagnosed with the commonest form 
of childhood cancers in Cameroon; just like in any 
other African country known as Burkitt lymphoma 
(BL) are cured with either single cyclophosphamide 
(CPM) therapy or combined with methrothrexate 
(MTX); yet these drugs are very rare, expensive 
and inaccessible. Besides, there are very few 
professionals, care and diagnostic centres, located 
mainly in the capital cities and the masses, already 
is little data on adjuvant chemotherapy after 
surgical resection. In fact this disease is thought to 
be chemotherapy insensitive unlike conventional 
NSCLC. EGFR gene changes are variably reported 
in several series and may impact prognosis. In 
our case the histological appearances resembling 
urothelial carcinoma resulted in preoperative 
chemotherapy being given which may not have 
been necessary. This case highlights the importance 
of consideration of other primary rare lung tumour 
subtypes even when there is a history of another 
malignancy. 
Keyword: mucoepidermoid carcinoma
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P4.143 COMPLETE REMISSION OF 
ADVANCED NON SMALL CELL 
LUNG CANCER INDUCED BY 
ERLOTINIB INTERCALATED WITH 
CONVENTIONAL CHEMOTHERAPY - A 
CASE REPORT
Laksmi Wulandari, Ana Febriani, Benjamin Margono 
Pulmonology Department, Dr. Soetomo General 
Hospital/Indonesia
Background: In Dr. Soetomo General Hospital, 
Non-Small-Cell Lung Cancer (NSCLC) accounts 
for approximately 80% of all lung cancers, 40% of 
which present with distant metastases. Conventional 
chemotherapy usually only give a short survival, 
but with the advance of epidermal growth factor 
receptor tyrosine kinase inhibitor, the new drug 
can be intercalated with combined conventional 
chemotherapy with very surprising results. We 
reported a patient with liver metastatic NSCLC 
which achieved complete remission after treatment 
with Erlotinib intercalated with Gemcitabine – 
Carboplatin chemotherapy. 
Methods: A 66 year old man was admitted to our 
hospital due to chronic cough for 1 month. He 
also complained of left sided chest pain, loss of 
appetite, and weight loss. Chest CT-scan conÀrmed 
the presence of a solid mass on anterior segment 
superior lobe of left lung (Æ 42 mm), with satellite 
nodule on anterior segment of right lung (Æ 17.2 
mm). The mass caused atelectasis on inferior 
lobes of both lungs. There were inÀltrations of 
mediastinal, peribronchial, and pretracheal lymph 
nodes. There were also multiple metastatic nodules 
on the liver. Fine needle aspiration biopsy showed 
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Methods: From January 2006 to march 2007 
thirty-one-lung cancer patients staged as IIIB 
according with the 6th edition TNM classiÀcation 
were treated with a combination of sequential 
chemotherapy and radiotherapy. Eligible patients 
for this retrospective analysis were required to have 
histological proven non-small cell lung cancer, stage 
IIIB with no pleural or pericardial effusion and no 
previously treated. Patients were required to have a 
Karnofsky performance status of 80 to 100; adequate 
bone marrow reserve and renal function and no 
previous malignancy and tumour volume, which 
can be incorporated within a tolerable radiotherapy 
treatment Àeld. Before initiation of treatment, all 
patients underwent history and physical examination, 
determination of performance status and fully 
staging with CT scan. No PET scan was available 
for staging. Sixteen patients were men and eight 
women. Patient’s ages ranged from 43 to 80 years 
with median age 65.3 years. All patients’ received 
four cycles of carboplatin AUC 5 and gemcitabine 
1250mgs/m2 followed by a course of radiation 
receiving 55Gy/20 fractions or 36/12 in patients who 
had progressed to induction chemotherapy. 
Results: Toxicity was predominantly haematological 
with grade 3-4 neutropenia occurring in 45% of 
patients during chemotherapy and no grade 3-4 
thombocitopenia occurred. The overall response rate 
after chemotherapy was 41.5 % partial response, 45. 
% stable disease and 12.5% progressive disease to 
chemotherapy. The estimated median survival was 
21.1 months (5-55). The 1-year survival probability 
was 50% and 2-year and 3-year survival was 
respectively 30% and 25%. The estimated time to 
progression was 14.9 months and 5 patients (16.6%) 
are still alive and disease free after 49 months 
follow-up. 
Conclusion: The NWCTC results in highly selected 
patients with stage IIIB NSCLC are comparable 
with published randomised trials of induction 
chemotherapy followed by radiation and those 
using concurrent chemo radiation. Patients who 
can tolerate the treatment should be treated with 
combined radio chemotherapy modality and although 
there is some evidence that concurrent modality 
is better than sequential; however with the use of 
new radiotherapy techniques, new chemotherapy 
agents and accelerated radiotherapy schedules, 
how concurrent chemo radiotherapy compares 
with sequential treatments remains unresolved. 
Individualization of treatment is of paramount 
relevance in lung cancer patients 
hit by the prevailing global economy recession are 
left with little or no other choice to spending the last 
days with a sorcerer, witch doctor or herbalist who 
are untrained and their practices dangerous. There is 
neither any national palliative nor oncology society. 
Methods: Touring national BL treatment Centres, 
questionnaire surveys and analysis of clinic data on 
BL.
Results: Basic oncology and palliative care needs 
especially treatments like chemotherapeutic and 
opiods agents are very rare, expensive and afforded 
mainly by the very rich class whereas the disease has 
nothing to do with social status and about 35% of 
affected children die without commencing treatment 
or even undiagnosed. 
Conclusion: Malaria-the highest killer disease; 
endemic in Africa, is strongly believed that the 
Plasmodium vivax has a major causative role to 
play in BL. Sadly, if as much as 50%+ of BL can be 
cured with single CPD regimen and as many as 35% 
of kids die without diagnosis or a single treatment 
attempt; then there is great need for support and 
funding of intensive research on this domain in 
Cameroon and Africa. This has also greatly retarded 
the MDG. There is also the need for funding and 
supporting interested professionals from Africa in 
international events like the upcoming as to transmit 
the current expertise in research, care and education. 
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P4.145 OUTCOME OF SEQUENTIAL 
CHEMO RADIATION IN STAGE IIIB 
LUNG CANCER PATIENTS. THE 
NORTH WALES CANCER CENTRE 
EXPERIENCE.
Angel Garcia-alonso, N Smith, C Smith, G Drury, A 
Gostage 
Oncology, North Wales Cancer Centre/United 
Kingdom
Background: NSCLC Stage III B represents a 
heterogeneous group of patients with a total of seven 
different designations included within the 6th edition 
of TNM classiÀcation. The addition of induction 
chemotherapy to radiotherapy in locally advanced 
NSCLC have demonstrated a survival beneÀt 
conÀrmed with several phase III trials and three 
meta-analysis. There is still controversy to whether 
the use of concurrent chemo radiation in selected 
locally advance lung cancer is superior to sequential 
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Results: 21 patients aged 75 years or older who 
underwent surgery for non-small cell lung cancer and 
metastatic lung cancer at our hospital in 2010 were 
studied. The postoperative pneumonia did not occur 
in all cases.
Conclusion: Oral care is important for prevention 
of postoperative pneumonia in the elderly after lung 
surgery. We cooperate with staffs of the other type 
of job and will practice oral care of elderly patients 
before lung surgery by the oral care team.
Keyword: naechan
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P4.147 A TRIAL OF THE PREVENTION 
OF POSTOPERATIVE PNEUMONIA 
OF ELDERLY PATIENTS(75 YEARS 
OR OLDER) OF NON-SMALL LUNG 
CANCER, ABOUT THE ROLE OF 
THE NURSE TO RESPIRATORY 
REHABILITATION
Chiaki Matsumoto1, Naemi Abo1, Keiko Yamamoto1, 
Osamu Kawamata2 
1Depatment Of Nurse, Onomichi Municipal Hospital/
Japan, 2Surgery, Onomichi Municipal Hospital/
Japan
Background: Japan is becoming the aging 
society, and aging goes ahead through Onomichi 
in particular(75years and older 10.4% in Japan 
comparison to 16.3% in Onomichi). Due to the 
aging of the general population, non-small cell 
lung cancer is a typical disease of the elderly, and 
is becoming increasingly. The opportunity of lung 
surgery in the elderly is increasingly. Preoperative 
preparation and postoperative care are very 
important in chest surgery, and particulary in elderly 
patients. Especially elderly patients are at high risk 
of postoperative pneumonia after lung surgery. It is 
important that we prevent the onset of postoperative 
pneumonia. We wrestle with critical prevention of 
postoperative pneumonia in performing respiratory 
rehabilitation before lung surgery of aged 75 years or 
older at our hospital. We report the role of the nurse 
in the respiratory rehabilitation team at our hospital.
Methods: We make a personal prescription of 
elderly patients who undergo lung surgery and we 
teach respiratory rehabilitation using a pamphlet. 
Elderly patients(aged 75 years or older) of non-
small cell lung cancer and metastatic lung cancer 
at our hospital have a check up in department of 
Keywords: sequential, Chemotherapy, Radiotherapy, 
survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.146 A TRIAL OF THE PREVENTION 
OF POSTOPERATIVE PNEUMONIA 
OF ELDERLY PATIENTS(75 YEARS 
OR OLDER) OF NON-SMALL LUNG 
CANCER, ABOUT THE ROLE OF THE 
NURSE TO ORAL CARE
Naemi Abo1, Chiaki Matsumoto2, Keiko Yamamoto2, 
Osamu Kawamata3 
1Department Of Nurse, Onomichi Municipal 
Hospital/Japan, 2Depatment Of Nurse, Onomichi 
Municipal Hospital/Japan, 3Surgery, Onomichi 
Municipal Hospital/Japan
Background: Japan is becoming the aging 
society, and aging goes ahead through Onomichi 
in particular(75years and older 10.4% in Japan 
comparison to 16.3% in Onomichi). Due to the 
aging of the general population, non-small cell 
lung cancer is a typical disease of the elderly, and 
is becoming increasingly. The opportunity of lung 
surgery in the elderly is increasingly. Preoperative 
preparation and postoperative care are very 
important in chest surgery, and particulary in elderly 
patients. Especially elderly patients are at high risk 
of postoperative pneumonia after lung surgery. It is 
important that we prevent the onset of postoperative 
pneumonia. We wrestle with critical prevention of 
postoperative pneumonia in performing oral care 
before lung surgery of aged 75 years or older at our 
hospital. We report the role of the nurse in the oral 
care team at our hospital.
Methods: We make a personal prescription of 
elderly patients who undergo lung surgery and 
we teach oral care using a pamphlet. Elderly 
patients(aged 75 years or older) of non-small cell 
lung cancer and metastatic lung cancer at our 
hospital have a check up in dentist after having 
received explanation of oral care from the nurse of 
the oral care team and have intraoral examination. 
We conÀrm by a telephone whether elderly patients 
continue and perform oral care according to the 
schedule during before hospitalization.
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class from rural India. Nutritional status: At pre 
treatment phase on clinical and anthropometrical 
ground based on height, weight, body mass index 
and waist hip ratio were normal = 6, mild under 
nutrition = 3, moderate under nutrition = 4, severe 
under nutrition = 5 and corresponding Àgure at 
6 week post-treatment phase were 9, 5, 7 and 
4 respectively. Hematological and biochemical 
assessment: Done with parameters of Hb, ESR, 
WBC count, 
Conclusion: Nutritional status is grossly affected 
in Lung-cancer-patients. Dysphasia to liquid and 
solid is the main reason for poor nutritional status. 
In developing nations socio-economic factors play 
vital role in nutrition & subsequently survival 
period , QOL in lung cancer sufferers. Normal and 
mild under-nutrition patients tolerate treatment 
related toxicities well; recover better in post-
treatment phase. So nutritional assessment and its 
supplementation plays an important roll in treatment 
of cancer Lung. Due to resource constraints we 
limited sample size & evaluation parameters. But 
Our Indian cancer NGO seeking multi-institutional-
collaborations to conduct more-scientiÀc pilot 
project on this unexplored issue in Indian lung-
cancer-patients community 
Keywords: NGO, nutrition, lung-cancer
Poster Session 4 – Nursing Thursday, 7 July 2011 10:00-12:30
P4.149 TRAINED NURSING CARE TO 
LUNG CANCER SUFFERERS : STATUS 
IN RESOURCE POOR COUNTRIES OF 
SOUTH
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[ngo]/India
Background: Patient Advocacy Issue : Trained 
nursing care for lung cancer sufferers is a dream by 
patients community. Trained nursing care facilities 
available only in few city hospitals in India. 
Especially cancer sufferers who return to villages 
in rural parts of India after taking chemotherapy/
surgery in city hospitals need this assistance. NGO’s 
can play key role in providing Trained nursing care .
Current status: Very little nursing research has been 
conducted within lung cancer patients in Asia. Even 
national cancer registry doenot provide scientiÀc 
information on this crucial issue. Oncologists need to 
propose increase research activity of nurse specialists 
rehabilitation after having received explanation 
of respiratory rehabilitation from the nurse of the 
respiratory rehabilitation team. We conÀrm by a 
telephone whether elderly patients continue and 
perform respiratory rehabilitation according to the 
schedule during before hospitalization.
Results: 21 patients aged 75 years or older who 
underwent surgery for non-small cell lung cancer and 
metastatic lung cancer at our hospital in 2010 were 
studied. The postoperative pneumonia did not occur 
in all cases.
Conclusion: Respiratory rehabilitation is important 
for prevention of postoperative pneumonia in the 
elderly after lung surgery. We cooperate with staffs 
of the other type of job and will practice respiratory 
rehabilitation of elderly patients before lung surgery 
by the respiratory rehabilitation team.
Keyword: chiaki
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P4.148 ROLE OF NUTRITION IN 
TREATMENT OUTCOMES OF LUNG 
CANCER
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[NGO]/India
Background: Lung cancer 2nd most common cancer 
in Asia. Lung cancer is usually associated with 
poor intake of food due to mechanical obstruction 
affecting nutritional status of patient. No study has 
been undertaken on this issue in Indian population 
till now. Our Indian cancer NGO performed this 
retrospective study through hospital based database 
search. Aim was to determine nutritional status in 
pre-treatment and post-treatment phase and how it 
affects the treatment outcome.
Methods: 23 carcinoma of Lung sufferers who 
would be treated by chemo-radiation were enrolled 
for nutritional status assessment in pre-treatment 
phase and categorized as normal, mild, moderate 
or severe under nutrition group by clinical, 
hematological, biochemical, anthropometrical, 
dietary and immunological criteria. At six week 
post treatment phase the nutritional status was re-
assessed by same parameters and compared with pre-
treatment phase. Analysis of treatment outcome done 
with clinical, endoscopic and radiological Àndings. 
Results: n = 23, 21 males, 4 females. Age 45-60 
years. 18 from lower middle class. 60% uneducated 
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P4.150 OCCUPATIONAL THERAPY 
INTERVENTION TO IMPROVE 
FUNCTION AND QUALITY OF LIFE 
FOR PATIENTS LIVING WITH LUNG 
CANCER
Kahren White, Beth Ivimey 
Department Of Occupational Therapy, Prince Of 
Wales Hospital/Australia
Background: Occupational Therapists are specialists 
in assessing function and intervening to improve a 
person’s ability to engage in their occupational roles. 
People living with lung cancer often experience 
a change in their function. Breathlessness can 
severely limit a patient’s ability to perform their 
daily activities across all areas of their occupational 
performance. These include self-maintenance, 
productivity, leisure and rest. Occupational 
Therapists are able to utilise interventions to assist 
patients with the management of their breathlessness. 
The intervention of an Occupational Therapist can 
have a positive impact on the function and quality of 
life for the person living with lung cancer and those 
they share their life with. This paper will outline the 
development of occupational therapy interventions 
for people living with lung cancer with the oncology 
and palliative care teams at the Prince of Wales 
Hospital. Occupational Therapists can assist 
individuals prioritise their goals while managing 
the side effects of curative treatment, also having 
a vital role in assisting individuals as their roles 
and function change with progressive non-curative 
disease. The involvement of the Occupational 
Therapist with the Lung Cancer Multidisciplinary 
Team has led to the development of specialist skills 
in the management of occupational performance 
dysfunction in lung cancer at Prince of Wales 
Hospital.
Methods: The use of task analysis, energy 
conservation and pulse oximetry assessment with 
functional activities by the occupational therapist has 
improved patient education and understanding of the 
reasoning behind task modiÀcation. Changes in pulse 
oximetry readings allow occupational therapists to 
make objective recommendations to patients on ways 
to manage their breathlessness and hypoxaemia with 
functional activity. This assists patients to achieve 
optimal independence and safety with their chosen 
human occupations.
Results: It is the Occupational Therapists unique 
working with patients with lung cancer. Here module 
of training must be devised suitable to Asian hospital 
care setup. Due to lack of resources for Training 
nurses, this issue has been neglected. 
Methods: Our Indian cancer NGO palliative care 
team plans to mobilize training resources from local 
Health-centers. In phase I of our project 6 tertiary 
care hospitals and two NGOs will be included. 
Primary Training imparted to nurses by Tam-
experts invited from city hospitals. This Team will 
have social worker & nurse trainer & oncologists. 
Local traditional faith-healers & community 
leaders involved for more community acceptance/
participation. Aim to provide physical-comfort to 
patient, improve relationship with family members 
for terminal lung cancer disease 
Results: Our NGO proposed plan will present 
our Àndings/need & ways to overcome obstacles 
in providing nursing care. Survey questionnaire 
will be sent to Team members asking them to 
identify important areas for nursing research in 
lung cancer care. Trainee nurses will be asked to 
suggest possible research. The Àndings of this 
survey will be presented. Plan about Àndings 
may be used to generate nursing research studies 
will also be discussed. We present our NGO’s 
proposed Nursing-Training-Module [NTM] project 
Ànding in printed chart-format at WCLC-2011 
conference, Amsterdam. We need strong platform 
like IASLC-2011-conference to show our Àndings to 
researchers/activists from developed world and get 
their guidance on this difÀcult issue. Government 
hospitals in collaboration with NGO-clinics must 
carry out supportive-care-programmes with NGO-
counselors to bring down incidence of frailty/
depression in thoracic cancer patients. 
Conclusion: Our Indian cancer NGO has taken 
initiative on this front by forming education 
module for nurses and rural physicians. Our project 
has been awaiting further guidance/funding for 
implementation to serve poor rural/tribal geriatric 
lung cancer populations If resources like fellowship/
training-grants are made available to oncology 
nurses, then NGO’s can perform good job of 
providing economical home based nursing care for 
Lung & other cancer sufferers in remote areas of 
India.
Keywords: nurses, NGO, Asia
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experience that their rehabilitation needs are 
identiÀed and that they receive support in getting 
back to everyday life, addressing symptoms and 
problems, and achieve a rehabilitated lifestyle. 
Hence, the intervention group experienced less 
uncertainty after discharge, as they gained greater 
knowledge of issues relating to their disease and 
emotional reactions that accompany a cancer 
diagnosis. Furthermore, the patients have felt that 
they were personally involved in their discharge 
process and received support afterwards. 
Conclusion: The patients have, based on a 
concluding conversation and a follow-up phone 
call, gained greater insight into how issues of 
rehabilitation and post-surgical consequences can 
be handled after discharge. Thus, they have less 
uncertainty after returning home. Perspective: This 
study can be characterised as a pilot study due to 
the fact that the empirical material (eight patients) 
collected is not large enough to make statistical 
generalisations. A new intervention study has started 
on these grounds, including 120 patients. 
Keywords: lung cancer surgery, discharge, 
Rehabilitation, conversation
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P4.152 DERMATOLOGIC TOXCICITIES 
ASSOCIATED WITH TARGETED 
THERAPIES: NURSING IMPLICATIONS 
(POSTER)
Massey Nematollahi 
Medical Oncology, Stronach Regional Cancer 
Center/Canada
Background: As treatment of cancer becomes more 
sophisticated, nurses continue to be challenged 
with management of multiple toxicities. The skin 
is assaulted from many avenues: tumour burden, 
radiation, chemotherapy, surgery, and now targeted 
therapies.The approach to cancer has changed over 
the last 10 years, due to improved understanding of 
how tumors develops and grow. Targeted therapies 
demonstrate signiÀcant clinical activity with 
manageable adverse events. 
Methods: Oncology nurses with patients 
experiencing skin toxicities related to targeted 
therapies should understand the pathophysiology of 
the toxicity and provide ongoing assessment with 
consistent criteria and photo documentation.
Results: Patient education remains vital to minimize 
ability to analyse and modify functional tasks 
that has improved function and achievement of 
occupational performance goals for patients towards 
the end of life. The results of the occupational 
therapy functional assessments are a crucial factor 
in the medical teams decision for the prescription of 
palliative home oxygen.
Conclusion: This presentation will explore the 
role of the Occupational Therapist in the specialist 
setting of lung cancer. Through task analysis, task 
modiÀcation, energy conservation and goal setting 
people living with lung cancer can continue to live 
with increased conÀdence, independence and safety, 
while achieving their chosen goals towards the end 
of life.
Keywords: function, Quality of Life, Management 
of Breathlessness
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P4.151 POSTOPERATIVE 
REHABILITATION CONVERSATION 
– FOR RADICALLY OPERATED LUNG 
CANCER PATIENTS
Malene Frost, Anne Marie Olesen, Malene Missel 
Department Of Thorax Surgery 3151/2, Heart 
Centre, Copenhagen University Hospital, Denmark/
Denmark
Background: Lung cancer patients feel uncertain, 
after being discharged, following a surgical 
procedure and experience physical and psychosocial 
problems. Patients who receive concluding 
conversations are less likely to feel uncertain post 
discharge compared to other patients. However, 
these concluding conversations are not conducted 
at a regular basis and the need for rehabilitation has 
not been charted. Aim: The objective of this study is 
to test whether systematic concluding rehabilitation 
conversations, combined with a follow up phone 
call, can help patients handle issues post discharge in 
order to minimise their uncertainty. 
Methods: The methodology is quasi-experimental 
consisting of a control and intervention group. It 
is based on phone interviews and questionnaires 
with eight patients aged 54-74. The patients have 
assessed their level of satisfaction on issues such 
as information, communication, rehabilitation and 
support. Furthermore, the patients’ understanding of 
rehabilitation and lifestyle has been examined. 
Results: Patients in the intervention group 
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reported a “sharp”, “exhausting”, and “splitting” 
pain. The investigation of the factors increasing 
pain during the postoperative period revealed that 
most of the patients (85.7%) reported that their pain 
increased due to movement in bed and/or walking 
while 74.3%, 68.6%, 54.3% and 37.1% of them 
stated that their pain increased due to breathing, 
coughing, and chest tube movement respectively. 
Each pain characteristics, throbbing, stabbing and 
stinging, can be speciÀcally relief using one or more 
methods such as place of ice on the incision site, 
little press on the thoracotomy region, preoperative 
pain education etc. 
Conclusion: In conclusion, it was determined 
that the patients experienced a sharp, stabbing and 
unbearable pain in the Àrst 48 postoperative hours 
and their pain exacerbated with activities such as 
movement and coughing. 
Keywords: pain charactheristic, Surgery, Post-
thoracotomy pain
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.154 PHARMACOECONOMIC IMPACT 
OF DOSE ROUNDING FOR CANCER 
THERAPY
Nagwa A.R. Ibrahim 
Pharmacy, Rmh/Saudi Arabia
Background: The past ten years have seen a 
signiÀcant and progressive cost rising in medical 
oncology, largely due to the increase in cancer 
prevalence and the incorporation into clinical 
practice of novel, highly expensive drugs. Dose 
rounding is increasingly used in oncology 
departments to improve efÀciency of outpatient 
clinics. The purpose of this project was to determine 
the theoretical cost saving related to a dose rounding 
process for adult biological and chemotherapy agents 
at Riyadh Military Hospital. 
Methods: Data was obtained prospectively during 
December 2010. All chemotherapy and targeted 
therapy orders prescribed in adult oncology out 
patient clinics as well as in-patient adult oncology 
wards have been collected. Prescriptions that include 
cancer therapy in doses that might be rounded 
according to study criteria were identiÀed. 
these toxicities, maximize clinical beneÀt and should 
include the goals of therapy, the importance of 
compliance, assessment of response to therapy, and 
management of drug- and disease-related issues The 
management of these toxicities which include patient 
assessment, counselling, and education, are a critical 
role of the oncology nurses. 
Conclusion: The best way to manage dermatologic 
toxicities associated with the administration of 
targeted therapies is through an early, proactive 
approach.Nursing education prior to treatment 
initiation is imperative, this enable patients to 
tolerate higher doses of cancer treatment for longer 
time which leads to better control of illness. 
Keywords: Epidermal growth factor inhibitors, 
EGFRI,anti-EGFR, side effects, skin rash, 
dermatologic toxicity, Pro-active approach
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P4.153 NATURE AND INTENSITY OF 
PAIN AFTER THORACOTOMY
Emine Kol1, Abdullah Erdoøan1, Bilge Karsli2 
1Thoracic Surgery, Akdeniz University/Turkey, 
2Algology, Akdeniz University/Turkey
Background: The aim of this study is to clearly 
deÀne the pain which disturbs the patients having 
thoracotomy in postoperative period. Because, it 
can be possible to manage to get pains under control 
according to pain characteristics without using drugs. 
Methods: The study included 70 patients 
who underwent thoracotomy (lobectomy or 
segmentectomy and mean duration of surgery was 90 
minutes) and were hospitalized in the intensive care 
unit of the Thoracic Surgery Department of Akdeniz 
University Hospital between 01.11.2007 and 
15.11.2008. In this study, 68.6% (24) of the patients 
were male and mean age was 49.90 ± 11.62. The 
study was achieved. Considering that the patients 
have pain in the Àrst 24 hours postoperatively and 
the effect of sedation, the Behavioral Pain Scale, 
which is Àlled out by a researcher, and the Verbal 
Category Scale, which allows the patient to deÀne 
his/her pain with short responses, were used for pain 
assessment. Pain was assessed at the postoperative 
4th, 8th, 16th, 24th and 48th hours, following 
extubation. 
Results: The patients mostly reported throbbing 
(65.7%), stabbing (65.7%) and stinging (62.9%) 
pain in the incision site while 40% of them (n=28) 
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in cancer care of rural health set-up.
Methods: 11 tertiary care hospitals & two NGOs 
included in study. 132 healthcare providers 
given questionnaire on needs of geriatric cancer 
patients, their needs. 209 terminally ill geriatric 
cancer patients with life expectancy of 2 yrs were 
interviewed/evaluated.Geriatric Depression Scale 
used for geriatric evaluation. A standardized 
geriatric evaluation is essential for multidisciplinary 
discussion of elderly patients with lung cancer. 
oncological evaluation mandatory to offer to these 
patients best therapeutic option and improve their 
prognosis as well as their quality of life Patients 
were asked to mark cancer care as satisfactory or 
non-satisfactory & asked to rate incidence/severity 
of depression on diagnosis of Ca. Due to enormity 
of project we had initially taken frailty/depression 
as primary parameter for evaluation. Then responses 
of cancer service providers were rated against 
suggestions given by patients. 
Results: GIT solicited for 209 patients over 2-year 
period. mean age 61.2 ± 4,6 years old), 61% male, 
39% females. 64% subjects had symptoms of 
cognitive disorder [Folstein MMSE] . .The mini-
GDS used to detect depression, was positive in 68% 
of the evaluations. we can clearly identify frailed 
patients (68%) who did not received any counseling/
psychotherapy. 82% patients pointed to lack of 
psycho-social care. counseling as major lacunas 
in current set-up. Inadequate patient education 
on nutrition, social support & absence of trained 
psychologist were mentioned as dominant factor 
in responses by 132 healthcare providers who 
participated in our project. these were clubbed to 
referred as geriatrics care. 
Conclusion: Our two year on-hand experiences 
clearly show need & beneÀt of close collaboration 
between geriatricians and oncologist. Sadly 
counseling/geriatric care is virtually non existent 
in india. In daily management of elderly patients, 
alteration are nedded in 68% of patients by 
geriatric assessment. We need strong platform like 
IASLC-2011 to show our Àndings to researchers/
activists from developed world & get their guidance 
on this difÀcult issue. Government must carry out 
supportive-care-programmes with NGO-counselors 
to bring down incidence of frailty/depression in 
Lung cancer patients. Lessons learned : Our Indian 
cancer NGO has taken initiative on this front by 
forming operational module for nurses & rural 
physicians. Our project has been awaiting further 
guidance/funding from government agencies for 
Results: Two hundred and thirty three orders of 
chemotherapy and targeted therapy were processed 
by Adult Oncology Satellite Pharmacy and adult 
oncology wards during the period of data collection. 
Forty percent of the collected prescriptions 
fulÀlled the criteria. We considered rounding to 
an amount within 15% for targeted therapy and 
10% for cytotoxic drugs. Chemotherapy dosing 
was calculated according to body surface area. The 
potential cost savings from dose rounding per year 
was US $ 192,800. Data was extrapolated from the 
determined monthly cost savings. The highest cost 
saving was for breast cancer drugs US $ 80,819 
(42%), followed by colorectal cancer US $ 47,965 
(25%), while in non-Hodgkin’s lymphoma cost 
savings was US $ 45,107 (23%) and for other types 
of cancer that include non small cell lung cancer, 
prostate and ovarian cancer, in addition to head and 
neck cost savings was US $ 18,867 (10%). 
Conclusion: Dose rounding of chemotherapy to 
an amount within 10% and up to 15% for targeted 
therapy would lead to signiÀcant cost savings. 
Although controversial, routine minor dose 
reductions might be acceptable to oncologists. 
Acceptance and opinion of oncologists in Saudi 
Arabia need to be surveyed.
Keyword: Pharmacoeconomic, Chemotherapy, 
Targeted therapy
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P4.155 LUNG CANCER & GERIATRICS
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[ngo]/India
Background: Elderly patients of lung cancer 
provide challenging situation for oncologists. We 
undertook this one year old project targeted at 
geriatric cancer patients from rural/tribal india. Since 
geriatrics specialty is unheard of in rural india, we 
decided to address this burning issue of geriatric 
cancer patients. standardized geriatric evaluation is 
essential for multidisciplinary approach of cancer 
Rx in patients with lung cancer. In developed 
nations geriatric as well as an oncological evaluation 
are mandatory to offer to these patients the best 
therapeutic option and improve their prognosis as 
well as their quality of life. But this facility is luxury 
in asian/African nations. Hence our Cancer NGO 
team evaluated frailty & suggested plan to include it 
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cancer-care workshops. Our Holistic approach 
helped overcome hopelessness/fear depression. Pain 
management/supportive care emerged very serious 
issue affecting QOL in colorectal-patients. Cancer-
NGO’s need Improved access to specialized training/
CME’s on Counseling/rehabilitation. 
Conclusion: If resources like Lung-Cancer 
fellowship/training are made available to oncology 
workers, then NGO’s can perform good job of 
Counseling/rehabilitation for Lung & other cancer 
sufferers. Restricted resource-limitations didn’t 
permit us to analyze this issue in large-sample-
size, but we can collaborate with other NGO’s 
at IASLC-2011-conference for larger effort. Our 
recommendations most suitable to resource-poor-
settings. 
Keywords: NGO, Rehabilitation, counseling
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P4.157 LONG-TERM FOLLOW-UP OF 
ADVANCED NSCLC PATIENTS TREATED 
WITH CISPLATIN-VINORELBINE
Gilberto Castro Jr1, Tiago K. Takahashi1, Carolina R. 
Victor2, Fernando J. Bigaton2, Olavo Feher1, Tereza 
Y. Takagaki3, Paulo M. Hoff1 
1Clinical Oncology, Instituto Do Cancer Do Estado 
De Sao Paulo/Brazil, 2Faculdade De Medicina Da 
Universidade De Sao Paulo/Brazil, 3Pneumology, 
Instituto Do Cancer Do Estado De Sao Paulo/Brazil
Background: Platinum-doublets remain the standard 
chemotherapy regimens for advanced/metastatic 
NSCLC. Here we aimed to study the long-term 
outcomes of NSCLC pts treated with the cisplatin-
vinorelbine combination as Àrst-line chemotherapy.
Methods: It is a retrospective study on pts diagnosed 
with advanced/metastatic NSCLC and consecutively 
treated with cisplatin (DDP) 80 mg/m2 d1 and 
vinorelbine (VIN) 30 mg/m2 d1, d8, d15, every 21 
days, 4-6 cycles, in our institution, between Sep/02 
and Oct/08. Overall survival (OS) was estimated by 
the Kaplan-Meier method and curves were compared 
with log-rank. A multivariable Cox proportional 
hazards model was used to control for prognostic 
factors.
Results: 142 pts were treated with DDP-VIN. 
Median age 63 y (34-87) and 95 pts were male 
(67%); 121 active smokers (86%) with a median of 
45 pack-years. Histology: 58 pts were diagnosed 
with adenocarcinoma (42%) and 49 pts with 
implementation to serve poor rural/tribal geriatric 
populations. 
Keywords: Lung cancer, NGO, Asian population
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P4.156 COUNSELING/REHABILITATION 
IN RESOURCE POOR NATIONS : LUNG 
CANCER PATIENTS ISSUES
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[ngo]/India
Background: Counseling/rehabilitation facilities 
available only in few city hospitals in India. 
Especially cancer sufferers who return to villages 
after chemotherapy need of these assistance. NGO’s 
play key role in psychosocial-support/ Counseling/
rehabilitation . Our Project aimed to formulate policy 
for trained personals to give better & cost-effective 
rehab-services. 
Methods: Our Indian cancer NGO palliative care 
team mobilized training resources from local Health-
centres. Primary Training in Counseling & pain-
management imparted to nurses. Team consisted 
social worker & nurse trained by physician. 
Local traditional faith-healers & community 
leaders involved for more community acceptance/
participation. Four nurses & 10 volunteers trained 
till now. Aim to provide physical-comfort to patient, 
improve relationship with family members. for 
terminal cancer diseases, gradually we prepared 
patient/family for death with dignity. counselor 
managed pain & broke bad news of cancer status 
to family. Discomfort/anxiety due to severe pain 
decreases overall treatment efÀcacy 63 Patients 
enrolled during community out-reach-programs. 
Data collected on feedback-questionnaire. Most 
difÀcult tasks is discussing end of life issues” telling 
diagnosis/its outcome, managing pain in terminal 
cases. Till today 32 lung Ca patients shifted to 
specialty hospital due to intractable pain. 
Results: Counseling/rehabilitation must be made 
more accessible in rural-areas. This technique is 
also very cost-effective. Due to non-availability of 
trained-oncologists in rural areas this approach helps. 
We noted 94% responded favorably to counseling/
nursing care, 80% showed willingness to motivate 
fellow cancer-patients to facilitate supportive-care-
program of NGO’s. Infact 19 patients themselves 
became regular active facilitators in our NGO’s 
S1482 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Maximum stress was to improve communication 
channels between cancer care multidisciplinary team 
and community workers. 
Results: A retrospective analysis lung cancer data 
base from cancer care centers registry was taken as 
reference: We evaluated how many patients referred 
to lung cancer team from June 2007 till Jan 2011. 
how many patients diagnosed of lung cancer, and 
how many patients were referred to Palliative care 
team. On rationalized protocol, case study proforma 
devised to study nature of the lung nurse/ palliative 
care team relationship.
Conclusion: Results The Lung Cancer team saw 
120 patients from june 2007. 102 were diagnosed 
with lung cancer. 90 patients with known lung 
cancer were referred to the palliative care team. 
: Conclusion: lung cancer incidence very high, 
relationship between MSW/nurse and palliative 
care team is crucial for survival period & Quality 
of QOL . This close relationship provides support 
for speciÀed module for training of MSW/Nurse 
and continuous care for both patient and their 
families. Our project outlines need for developing 
collaborative working relationship between MSW/
Nurse and hospital-based palliative care team. 
Resource limitations & lack of expertise in rural 
area limited our project duration. But we suggest 
collaborative studies with IASLC on this fertile topic 
of lung cancer research in developing nations of the 
southern countries. 
Keywords: palliative care, QOL, social worker
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P4.159 EVALUATION OF PAIN AS 
PARAMETER OF QOL IN LUNG CANCER
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[ngo]/India
Background: When assessing QOl parameters of 
Lung cancer, pain is very commonly observed . No 
uniform approach on pain management. Lung cancer 
patients are traditionally followed up in hospital 
outpatient clinics with the emphasis of care on 
surveillance for disease progression, recurrence, or 
metastatic spread. CAM-Therapy highly preferred 
by Asian cancer patients. Cultural/psychological/
spiritual/social factors inÁuence quality-of-life 
(QOL) of Lung cancer patients Current approach :
The work-up of pain in the individual with cancer 
squamous cell carcinoma (36%). The median number 
of cycles was 4 (1-7). Median OS (mOS) was 7.5 
mo, and 99% of all pts were dead in the most recent 
follow-up. Better 1-year OS was observed in those 
pts with better Karnofsky perfomance status (KPS  
70% vs. KPS < 70%: 39% vs. 11%, HR 0.46, 95%CI 
0.12-0.82, p=0.019), hemoglobin level  12 g/dL vs. 
< 12 g/dL (42% vs 19%, HR 0.67, 95%CI 0.39-1.01, 
p=0.054), and normal platelet count (< 400 K/mL) 
at the beginning of chemotherapy (42% vs. 20%, 
HR 0.61, 95%CI 0.33-0.97, p=0.040). Hemoglobin 
level  12 g/dL at the beginning of chemotherapy 
remained signiÀcant as a favorable prognostic factor 
in terms of OS in a multivariate analysis.
Conclusion: DDP-VIN remains a valid 
chemotherapy regimen in unselected pts diagnosed 
with advanced/metastatic NSCLC. Some pts, like 
those with hemoglobin level  12 g/dL, seems 
to present better outcomes. Supported in part by 
FAPESP 2010/15761-9 and 16134-8.
Keywords: Non-small cell lung cancer, Cisplatin, 
Vinorelbine
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P4.158 QOL IN LUNG CANCER : 
OPTIONS AVAILABLE
Pramod Shankpal 
Community Medicine, Health Alert 
Organsiation[ngo]/India
Background: The QOL & survival rate for lung 
ca patients depends on relationship between the 
medical social worker [MSW]/Nurse and palliative 
care team, providing continuity of care and a smooth 
transition from diagnosis to death. It is essential that 
a good collaborative relationship exists between 
the Lung Nurse and Palliative care team. Aims: To 
determine qualities relationship between a nurse/
MSW and a Hospital-based Palliative care team. 
To asses needs of lung ca patients. To forward 
these recommendations to NGO clinics &cancer 
care institutes. The effort was to overall increase in 
quality of life in rural areas. 
Methods: We evaluated roles of MSW & cancer 
nurse within a multidisciplinary team. Devise 
methodologies by which their services can be 
integrated together. In phase II of project it was 
decided to rationalize their training module & to 
see how MSW/nurse and palliative care team work 
together to enable support for patients and families. 
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P4.160 THE URINE CORTISOL LEVEL 
IS RELATED TO THE PERFORMANCE 
STATUS OF LUNG CANCER PATIENTS.
Kensuke Suzuki1, Tomomi Ichikawa1, Ryuji 
Hayashi1, Toshiro Miwa2, Tatsuhiko Kashii2, 
Kazuyuki Tobe1 
1First Department Of Medicine, Toyama University/
Japan, 2Division Of Clinical Oncology, Toyama 
Uniersity Hospital/Japan
Background: Patients with advanced cancer often 
experience symptoms such as pain, anorexia, and 
fatigue. It is well known that the cortisol plays an 
important role with terminal cancer who are now 
facing death, but it is not clear in advanced stage 
lung cancer when considering chemotherapy.
To examine the association between urine cortisol 
levels and performance status or TNM stages in pre-
teratment patients with lung cancer. 
Methods: A total of 14 persons, twenty-four hours 
urine cortisol concentrations were measured for two 
days, and the mean value of them was compaired 
with the clinical data.
Results: Twenty-four hour urine cortisol level was 
increased in lung cancer patients with performance 
status 2 or 3 compared PS 1 (p < 0.05), and increased 
proportionally to performance status (R2 = 0.32, p 
< 0.05). It was increased in patients with regional 
lymph node metastasis status N2 or N3 compared 
with N1 (p < 0.01) , and has a tendency to increase 
in patients with stageIV compaired with other stages 
(p = 0.088). The urine cortisol levels were shown a 
positive correlation with serum potassium level (R2 = 
0.33, p < 0.05), and negatively correlated with serum 
sodium level (R2 = 0.42, p < 0.05). 
Conclusion: Twenty-four hour urine cortisol levels 
was increased not only in end stage, but also in 
rather earlier stage lung cancer when considering 
chemotherapy. The serum levels of potassium 
and sodium ion might indicate relative adrenal 
insufÀency. 
Keywords: Chemotherapy, cortisol, Lung cancer
begins with a thorough pain assessment, including 
a comprehensive history combined with a complete 
physical examination. But very few institutions have 
specialized pain care team. 
Past studies/experiences:
The management of pain due to Lung cancer 
requires a sound understanding of pharmacotherapy, 
including drug mechanisms, adverse effects, and 
potential drug-drug interactions. Three primary 
categories of analgesics include non-opioids, 
opioids, and adjuvant agents. opioids analgesics 
represent most useful agents for the treatment of pain 
associated with Lung cancer.
A wide variety of non-opioids medications from 
several pharmacological classes used additionally 
are anticonvulsants, antidepressants, corticosteroids, 
local anesthetics. Chemotherapy -with-CAM & 
spirituality/psycho-social-support emerging new 
hope pain management. Spiritual well-being prevents 
end-of-life-despair. Effect of spiritual/psycho-
social-community support fertile ground for further 
investigations
Methods: Done by interviews on 23 patients who 
had completed Rx for Lung cancer who were having 
intractable pain. Score on pain perception before 
treatment & after treatment noted. Any optional 
alternative therapy treatment [complimentary 
medicines ] taken noted. Patients receiving palliative 
care evaluated for overall improvement in QOL 
before treatment & after treatment support. 
Results: This was a qualitative evalution project 
in phase II. all Àndings will be presented at WCLC 
Amsterdam congress in leaÁet format. copies will 
be available to all conference participants at venue. 
[Masking identity of patients]
Conclusion: 21 out of 23 lung cancer cases-
participants in our survey felt that pain due to 
Lung cancer is distressing and can be challenging 
to manage. In most cases, available therapies can 
provide relief. A comprehensive assessment is 
critical, along with knowledge of analgesic agents 
and their use. If palliative care team can co-ordinate 
with counselors/psycho-therapists on this issue then 
maybe we will get better results. 
Keywords: pain, Lung cancer, QOL
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dyspnea was Àxed in 50%, cough in 50%, fatigue in 
12.5% and sputum in 37.5% , in group 2, dyspnea in 
16.7% , cough in 58.3%, fatigue in 50% and sputum 
complaint in 41.7% were founded. The distribution 
of symptoms were similar in both groups (p>0.05). 
Disease cell types were recorded squamous cell 
carcinoma in 62 % of group1, adenocarcinoma in 25% 
of group 1 and squamous cell carcinoma in 41.7 % of 
group 2, adenocarcinoma in 50% of group 2. In group 
2, FEV
1
 and FVC were lower (p=0.04), peripheral 
muscle strength were lower (p>0.05), dyspnea (p=0.72) 
and depression and anxiety levels were higher (p<0.01), 
and in HRQL scores especially the category of 
functional capacity were lower (p>0.05) according to 
group 1. Examining exercise capacity according to the 
stages, walking distance were found 402.50±82.46 m 
in group 1 patients and 355.58 ± 116.75 m in group 2 
patients (p=0.31). 
Conclusion: However in patients with less than stage 
2 non-small cell lung cancer, exercise capacity and 
HRQL values were lower according to greater than 
stage 2, especially the respiratory function in these 
patients, as well as with increased levels of anxiety and 
depression is striking. Although the number of patients 
were insufÀcient, the results give rise to thought that 
exercise capacity and HRQL assessments for lung 
cancer patients should be made systematically and it is 
important that results should be commented according 
to stages and should be take into consideration for 
pulmonary rehabilitation programmes. 
Keyword: Exercise Capacity, Health-Related 
Quality Of Life, Non-Small Cell Lung Cancer
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P4.162 DIAGNOSIS OF BONE 
METASTASIS IN PATIENTS WITH LUNG 
CANCER USING URINARY AND SERUM 
COLLAGEN TYPE I TELOPEPTIDE 
(NTX)
Motohiro Tamiya1, Hideaki Okada2, Masashi 
Kobayashi1, Norio Okamoto1, Shinji Sasada1, 
Hidekazu Suzuki1, Naoko Morishita1, Yuka 
Matsuura1, Shinya Tokunaga2, Haruko Daga2, 
Koichi Taira2, Shinya Kobayashi2, Ayako Tanaka2, 
Natsuko Miyamoto2, Michiyo Hattori2, Koji Takeda2, 
Tomonori Hirashima1 
1Thoracic Malignancy, Osaka Prefectural Medical 
Center For Allergic And Respiratory Diseases/
Japan, 2Clinical Oncology, Osaka City General 
Hospital/Japan
Poster Session 4 - Palliative Care Thursday, 7 July 2011 10:00-12:30
P4.161 COMPARISON OF EXERCISE 
CAPACITY AND HEALTH-RELATED 
QUALITY OF LIFE ACCORDING TO 
STAGES IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER
Elvan Yilmaz1, Ayse Yegin2, Sevgi Ozalevli1, Hasan 
Ersoz3, Ahmet Onen3, Atila Akkoclu2 
1School Of Physical Therapy And Rehabilitation, 
Dokuz Eylul University/Turkey, 2Department Of 
Chest Disease, Dokuz Eylul University/Turkey, 
3Department Of Thoracic Surgery, Dokuz Eylul 
University/Turkey
Background: Non-small cell lung cancer represents 
approximately 80% of the total lung cancers. 
Surgery, chemotherapy and/or radiotherapy are 
planned for treatment of non-small cell lung cancer 
according to stages. Associated with disease and/
or the treatments in lung cancer survivors, serious 
side effects are occurred, changes are appeared in 
their functional capacity and health related quality 
of life (HRQL). Accordingly, the success of medical 
treatment and pulmonary rehabilitation programmes 
can also negatively affected. For these reasons, 
HRQL and exercise capacity is important to plan 
treatment of patients with non small cell lung cancer 
and monitor patients during and after the therapy. 
With the reasons, the aim of our study was to 
compare exercise capacity and HRQL parameters 
in patients with non-small cell lung cancer and to 
discuss the results with clinical characteristics of 
patients. 
Methods: Twenty patients with less than stage 2 
(Group 1, n=8) and greater than stage 2 non-small 
cell lung cancer (Group 2, n=12) were included. 
The demographic and clinical characteristics of the 
patients were recorded. Exercise capacity (6 minute 
walking test), back and legs strength (Back-Leg 
Dynamometer), HRQL (European Organization for 
Research and Treatment of Cancer Questionnaire 
and Short Form-36 Health Survey), depression and 
anxiety (Hospital Anxiety and Depression Scale), 
pulmonary functions (spirometry), severity of 
dyspnea (Medical Research Council Scale) were 
evaluated. 
Results: No difference was found in age, body mass 
index and pulmonary symptoms between 2 groups 
compared with patients with less than stage 2 group and 
greater than stage 2 group (p>0.05). When distribution 
of respiratory symptoms was examined, in group 1, 
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P4.163 ANTIBIOTIC PROPHYLAXIS 
IN CHEMOTHERAPY-INDUCED 
NEUTROPENIA IN PATIENTS WITH 
LUNG CANCER
Vasileios Kouranos1, Antonios Vassias1, George 
Dimopoulos2, Kostas N. Syrigos1 
13rd Oncology Unit, University Of Athens/Greece, 
22nd Department Intensive Care Unit, Attikon 
Hospital University Of Athens/Greece
Background: Chemotheapy-induced neutropenia 
can potentially cause fatal bacterial infection 
in cancer patients. Human granulocyte colony-
stimulating factor (G-CSF) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) are 
usually recommended as prophylaxis. Alternatively, 
prophylactic antibiotics have been administered to 
prevent the development of bacterial infections.
Methods: A literature search in PubMed and Scopus 
was performed to identify randomized control 
trials and comparative cohort clinical studies that 
evaluated the role of antibiotic prophylaxis in 
chemotherapy-induced neutropenia in lung cancer 
patients.
Results: Five randomized controlled trials, 2 non-
randomized cohort studies, 1 comparative non-
randomized case control study and 1 case report were 
identiÀed as eligible for inclusion in this systematic 
review. A total of 1175 patients with lung cancer 
were evaluated to receive antibiotic prophylaxis 
during the expected neutropenic period after widely 
used chemotherapy regimens and doses associated 
with a known risk of cyclic severe neutropenia (on 
days 4-13 after chemotherapy) or from the beginning 
of chemotherapy until the completion of 3 cycles of 
chemotherapy. The main histologic diagnosis was 
small cell lung cancer in 720/1175 (61.7%) patients. 
Quinolones and trimethoprime/sulfomethoxazole 
were the main antibiotics used as prophylaxis in 
these studies while G-SCF were administered in 
2 studies and totally 260/1175 (22.1%) patients. 
Studies showed that prophylactic use of antibiotics 
in lung cancer patients undergoing chemotherapy 
reduced signiÀcantly the number of episodes of 
febrile neutropenia, documented infections and 
the duration of hospitalizations due to suspected 
infections.
Conclusion: Although routine antibiotic prophylaxis 
remains controversial due to the lack of survival 
advantage, and risk for antibiotic resistance, this 
Background: Many cancers metastasize to bone. 
Bone metastasis may cause an increase in bone 
resorption due to direct effects of the tumor itself 
or osteoclastic activation. This study evaluates the 
bone resorption biomarkers urinary NTx (uNTx) 
and serum NTx (sNTx) for the diagnosis of bone 
metastasis in patients with lung cancer. 
Methods: The uNTx and sNTx were measured 
in 100 patients with lung cancer and 50 control 
patients with benign respiratory diseases using the 
uNTx:OSTEOMARK® and sNTx:OSTEOMARK® 
serum NTx assays (Inverness Medical Japan). Bone 
metastasis was characterized by scintigraphy. The 
extent of disease (EOD) was determined by the 
number of sites of bone metastasis. Area under the 
curve (AUC) for receiver operating characteristic 
(ROC) analysis was used to evaluate the detection of 
bone metastasis. Sensitivity and speciÀcity of uNTx 
and sNTx to detect bone metastasis were calculated 
using cutpoints of 64 nM BCE/mM Cr for uNTx and 
22 nM BCE/L for sNTx. All patients were required 
to provide written informed consent. 
Results: Patients with bone metastasis had 
signiÀcantly higher levels of both uNTx and sNTx 
(uNTx; 93.2 +/- 105.1 nM BCE/mM Cr., sNTx; 24.0 
+/- 14.6 nM BCE/L) vs. lung cancers without bone 
metastasis (uNTx; 51.6 +/- 26.8 nM BCE/mM Cr., 
sNTx;17.2 +/- 4.1 nM BCE/L), or benign respiratory 
diseases (uNTx; 42.8 +/- 21.8 nM BCE/mM Cr., 
sNTx; 16.8 +/- 7.9 nM BCE/L.). There was good 
correlation between uNTx and sNTx (R = 0.807). 
ROC AUC for the detection of bone metastasis was 
0.743 for uNTx and 0.712 for sNTx. The sensitivity 
and speciÀcity for the diagnosis of bone metastasis 
using uNTx was 48% and 86%, and using sNTx 
was 40% and 87%, respectively. Levels of uNTx 
and sNTx were increased in patients classiÀed as 
EOD grade I compared to controls and in patients 
classiÀed as EOD grade II or greater, compared to 
patients classiÀed as EOD grade I. 
Conclusion: Both biomarkers may have value as an 
aid in the diagnosis of bone metastasis in patients 
with lung cancer. 
Keyword: serum NTx, urinary NTx, NTx, lung 
cancer, bone metastasis
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of infection. Mortality decreased in patients with 
and without cardiovascular dysfunction (22% and 
2% TLF/29% and 23% P), in patients with organ 
failure (1 organ – 7%TLF/13% P, 2 organs – 8% 
TLF/34% P, 3 organs – 28% TLF/29% P, 4 organs 
– 67% TLF/40% P, 5 organs 0% TLF/50% P) and 
in patients with various types of infection. The most 
common sites of infection were lung (46% TLF/52% 
P) and urinary tract (21% TLF/23% P). A positive 
culture was obtained in 66% TLF/71% P pts. Of the 
positive cultures, Gram + isolates were the most 
common (73% TLF/79% P) followed by Gram - 
(36% TLF/44% P) and fungal (16% TLF, 6% P). Of 
the positive cultures, blood was the most common 
site for isolation (59% TLF/49% P). Polymicrobial 
infection was present in 28% TLF/34% P pts. There 
was a consistent mortality decrease in the TLF 
arm by sites of infection (lung: 18% TLF/38% P 
p=0.04; urinary tract 5% TLF/29% P p=0.09), with 
the exception of intra-abdominal infection (31% 
TLF/14% P p=0.38). A consistent reduction in 
mortality also occurred in pts with a single isolate 
(19% TLF/29% P) and polymicrobial isolates (15% 
TLF/22% P). For single isolates, mortality was lower 
for Gram + (22% TLF/32% P) and Gram – (18% 
TLF/33% P) infections. The decrease in mortality 
was also seen across age groups in the study and 
men saw a greater reduction in mortality than women 
(11% TLF/36% P, 18% TLF/17% P).
Conclusion: The effect of TLF on mortality 
reduction appears consistent across a broad range 
of patients with severe sepsis. Further study of TLF 
in severe sepsis and in cancer patients with severe 
sepsis is warranted.
Keyword: Sepsis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.165 SYMPTOM BURDEN IN PATIENTS 
WITH ADVANCED LUNG CANCER 
ADMITTED TO HOSPITAL FOR 
PALLIATIVE CARE
Eeva-Maija Nieminen1, Pirkko Bellaoui1, Riitta 
Vuorinen2, Henrik Riska1 
1Dept. Of Medicine, Div. Of Respiratory Diseases, 
Helsinki University Central Hospital/Finland, 
2Helsinki University Central Hospital/Finland
systematic review showed that the prophylactic 
use of wide spectrum antibiotics in chemotherapy-
induced neutropenia in patients with lung cancer 
is as effective as the G-CSF and GM-CSF 
recommended and, thus, could be considered as 
therapeutic strategy.
Keywords: neutropenia, Cancer, malignancy, 
prophylaxis
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P4.164 TALACTOFERRIN ALFA (TLF) 
REDUCES MORTALITY ACROSS A 
BROAD RANGE OF PATIENTS WITH 
SEVERE SEPSIS
Jeffrey Crawford1, Kalpalatha K. Guntupalli2, Nathan 
C. Dean3, Peter E. Morris4, Rajesh K. Malik5, John P. 
Schaunberg6 
1Medicine, Duke University Medical Center/United 
States Of America, 2Internal Medicine, Baylor 
Clinic/United States Of America, 3Pulmonary 
Medicine, Schmidt Chest Clinic At Intermountain 
Medical Center/United States Of America, 
4Pulmonary Medicine, Wake Forst University Baptist 
Medical Center/United States Of America, 5Chief 
Medical OfÀcer, Agennix Incorporated/United States 
Of America, 6Sr Vp Clinical & Reg Affairs, Agennix 
Incorporated/United States Of America
Background: This randomized, placebo-controlled, 
double-blind study evaluated TLF, an oral agent with 
immunomodulatory and antibacterial properties, 
on 28-d all-cause mortality in patients with severe 
sepsis. TLF previously showed activity in NSCLC 
as monotherapy in the 2nd/3rd line setting and when 
added to a 1st line chemotherapy doublet.
Methods: Eligible pts had onset of severe sepsis (at 
least 1 organ dysfunction) within 24 hours prior to 
randomization to TLF 1.5 g or placebo enterally (oral 
or by feeding tube) q 8 h for a maximum of 28 d in 
addition to standard care including drotrecogin alfa 
(activated).
Results: Baseline characteristics of 190 randomized 
pts (97 TLF; 93 Placebo [P]) were similar. The 
study met the primary endpoint of reducing 28-d 
mortality in the modiÀed ITT population (14.4% 
TLF/26.6% P; 2-tailed P = 0.052 [Guntupalli ATS 
2010]). The effect on mortality was seen across 
a broad range of patients in the study including 
those with and without cardiovascular function, 
varying degrees of organ failure and different types 
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P4.166 REFUSAL OF PALLIATIVE 
CHEMOTHERAPY TREATMENT IN 
ADVANCED LUNG CANCER PATIENTS 
–PERSPECTIVE FROM A TERTIARY 
CARE CENTRE IN SOUTH INDIA
Kirushna Kumar Kosanam Subramanian1, 
Vijayabhaskar Ramakrishnan2, Krishna Kumar 
Rathnam3 
1Department Of Radiation Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
2Department Of Surgical Oncology, Meenakshi 
Mission Hospital And Research Centre/India, 
3Department Of Medical Oncology, Meenakshi 
Mission Hospital And Research Centre/India
Background: Palliative chemotherapy treatment is 
a very important in Lung cancer Patients , as most 
of the patients present in an advanced stage of the 
disease. Palliative treatment includes symptom care, 
anti cancer Treatment, Psychosocial care, palliative 
surgeries etc. Patients refuse palliative treatment 
due to various reasons. We are trying to identify the 
reasons for declining palliative care treatment in our 
hospital. 
Methods: A Prospective study was done on 
Lung cancer patients who had presented to our 
hospital during January 2010 and december 2010 
for palliative care. 82 patients presented to our 
outpatient clinic for treatment, 61 patients had stage 
IIIB and IV disease and were eligible for palliative 
chemotherapy only. Questionnaire were given either 
to the patient or the relatives to Àll up. 52 of our 
patients were not knowing about the disease status, 
due to the request of the family members, in such 
instances the attenders were allowed to Àll the same. 
Results: Sixty one patients were evaluable for the 
study. Thirty three patients were started on palliative 
treatment of which only 24 patients completed the 
prescribed treatment of the oncologist. Twenty 
eight patients had refused any kind of treatment due 
to various reasons of which 8 (28.57%) patients 
had refused due to the discouragement by the 
society, 15(53.57%) patients were not affording the 
medicines, 4(14.28%)patients were not willing in 
view of the poor prognostic nature of the disease, 
3(10.71%)patients refused due to the lack of family 
support. two patients had more than 2 reasons to 
say. Out of 61 patients who were offered palliative 
chemotherapy 33 patients were initiated on the 
treatment. Twenty four patients completed treatment 
Background: Treatment of cancer symptoms is an 
integral part in lung cancer care. Patients with lung 
cancer in advanced stage have a high prevalence 
of multiple symptoms affecting their daily life 
at home. Lung cancer patients are frequently 
admitted to unscheduled hospital care due to cancer 
symptoms like dyspnea and pain. To assess the 
variety of symptoms at admission we mad a pilot 
study to increase our understanding and awareness 
of symptom burden in lung cancer patients. We 
asked used Edmonton Symptom Assessment Scale 
(ESAS) as a tool to elucidate what are teh symptoms 
the patient is not able to cope with at home. The 
following symptoms were assessed: pain at rest, 
pain during motion, fatigue, dyspoea, appetite, 
nausea, dry mouth, constipation, depression, anxiety, 
insomnia and well-being.
Methods: During 3 month period all lung cancer 
patients admitted to hospital ward due to cancer 
associated symptoms were asked to complete ESAS 
form in the beginning and at the end of hospital care. 
Patient demographic data and ESAS scores were 
summarized using descriptive statistics.
Results: ESAS was completed by 32 patients 
admitted to pulmonary ward at Helsinki University 
Central Hospital during collection period of three 
months in 2010 (June, July and August). 15 patients 
completed the second ESAS at the time of hospital 
discharge. 15 (47 %) were male and 17 (53 %) were 
female. The mean age was 65 years (range 45-87). 
At baseline all patients suffered from fatigue. The 
percentage of patients suffering from pain, dyspnoea, 
loss of apetite, nausea, dry mouth, constipation, 
depression, anxiety and insomnia were 84, 69, 81, 
66, 81,53,56, 56, and 63, respectively. Those patients 
who completed ESAS at discharge had a little lower 
ESAS scores in all symptoms assessed. However, 
anxiety was increased during hospital stay.
Conclusion: The patients with advanced lung 
cancer have a high prevalence of symptoms when 
they are acutely admitted to hospital care. There is a 
variety of symptoms driving tha patient to seek help. 
Awareness of these symptoms is needed for planning 
an adequate treatment for these patients. ESAS 
provides a tool to symptom assessment in patients 
with advanced lung cancer.
Keywords: Edmonton Symptom Assessment Scale, 
palliative care
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Methods: TREATMENT: It was performed 
endobronchial dilatation with complacent balloon 
following UltraÁex® expandable endobronchial stent 
placement (Figure 2).
Results: The results were dyspnea relief and a good 
permeability of the right main bronchus (Figure 1 – 
D,E,F). 
Conclusion: The Wallstent® and UltraÁex® metalic 
expandable stents have a good compression 
resistence and a uniform radial centrifugal force, 
excusing the hook necessity to Àx it. They easily 
adapt yourself to airway tortuosity, remain an 
effective permeability. The complications include 
difÀculty to remove it, granulation tissue formation 
and secretion retention. Chhajed,et al performed the 
unique comparative trial analyzing three different 
stents. The Gianturco®, Wallstent ® and UltraÁex® 
were analyzed and the last one had lesser reestenosis 
index (60%, 27% and 0, respectively), lesser 
secretion retention (0, 27% and 0, respectively) 
and lesser migration index. They concluded that 
UltraÁex® have less long time complications than 
Gianturco® and Wallstent® prosthesis. 
Keywords: ultraÁex, bronchial stent
and 9 patients discontinued treatment in between. 
The reasons for dropouts were, 2(22.22%) had been 
discouraged by their neighbours, 3(33.33%)patients 
had dropped due to the toxicities of treatment and 
5(55.55%)patients cited Ànancial reasons. One 
patient had more than two reasons to say. 
Conclusion: Major reason for refusing treatment 
was the non-affordability of cancer drugs and some 
times even general drugs, which is less expensive. 
Lack of family support has also been a major 
problem because they were not ready to adjust, as 
they are not aware that palliative care treatment is 
going to give them a good Quality of life. 
Keywords: Refusal, Palliatve chemotherapy, Lung 
cancer
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P4.167 EXPANDABLE METAL 
TRACHEOBRONCHIAL STENT 
(ULTRAFLEX®) PLACEMENT IN THE 
RIGHT MAIN BRONCHUS STENOSIS 
DUE TO BRONCHIAL CARCINOMA.
Andre G. Leite1, Márcia A. Leite2, Fabio Miguel3, 
Francisco Wisintainer3 
1General Thoracic Surgery, Hospital Do Circulo/
Brazil, 2Universidade De Caxias Do Sul/Brazil, 
3Instituto Devita De Oncologia E Hemoterapia/
Brazil
Background: CASE REPORT: The authors 
introduce a case of a 54 years old female, with 
non small cell lung cancer localized in the upper 
right lobe (T4N3M0 stage). Patient was receiving 
third line chemotherapy and received total chest 
radiotherapy dose. Flexible bronchoscopy detected 
eight percent stenosis of the right main bronchus due 
to recurrent bronchial carcinoma. The symptoms 
were dyspnea, non-productive cough and localized 
sibilance. PHYSICAL EXAMINATION: localized 
sibilance in the upper third right hemithorax 
and ipsilateral reduced vesicular breath sounds. 
THORACIC CT SCAN: endobronchial tumor 
determining subtotal stenosis of the right main 
bronchus (Figure 1 – A,B,C). Complete athelectasy 
of the upper right bronchus. FLEXIBLE 
BRONCHOSCOPY: conÀrm eighty percent right 
main bronchus stenosis due to endobronchial 
carcinoma and complete obstruction of upper right 
bronchus. 
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P4.169 T-CELL CD38 EXPRESSION IN 
B-CHRONIC LYMPHOCYTIC LEUKEMIA
Nashwa K. Abousamra1, Manal Salah El-Din1, Emad 
Azmy2 
1Department Of Medical Oncology, Oncology 
Center, Mansoura Faculty Of Medicine/Egypt, 
2Department Of Clinical Hematology, Mansoura 
Faculty Of Medicine/Egypt
Background: -cell chronic lymphocytic leukemia 
(B-CLL) is a heterogeneous disease with some 
patients having an indolent course never needs 
treatment, while others having rapidly progressive 
one requires intensive treatment. In recent decades, 
numerous prognostic markers, such as IgVH 
mutational status, ZAP-70 and the expression of 
CD38 on leukemic cells were introduced to screen 
for patients likely to have progressive course of 
B-CLL bearing the potential to facilitate risk-
adapted treatment strategies. In B-CLL, T cell 
function is shown to be dysregulated. CD38 has been 
demonstrated to be an important transmembrane 
signaling molecule of T cell with a direct effect on its 
function.
Methods: By using Áow cytometry, CD38 
expression on T cells were analysed in 88 unselected 
B-CLL patients.
Results: CD38 expression level on T cells was 
shown to predict the clinical course of B-CLL 
in male patients but not in female patients. Male 
patients showed CD38 expression on T cells in 
a stage-dependent manner, in contrast to female 
patients who showed higher expression irrespective 
to clinical staging. CD38 expression on T cells 
negatively interacted with treatment-free survival 
in male patients. Multivariate analysis revealed that 
CD38 expression level on T cells is an independent 
prognostic factor in B-CLL male patients.
Conclusion: A simultaneous evaluation of CD38 
expression on both B-CLL cells and T cells allowed 
predicting male patient groups with the most 
favorable prognosis as well as those with the worst. 
Keyword: B-CLL • T cell • CD38 • prognostic 
factors
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P4.168 RENEWED HOPE THROUGH 
THEIR JOURNEY: LUNG CANCER 
CHALLENGES AND THE CLINICAL 
TRIALS
Penny Chipman, Carol Burnett 
Department Oncology, Clinical Research Program, 
Mcgill University/Canada
Background: The number of lung cancer patients 
in the world is steadily increasing. In 2010, in 
Canada alone, there were approximately 24,000 
new cases (Canadian Cancer Society). Many of 
these survivors have advanced disease with a poor 
prognosis. Clinical trials offer patients renewed hope 
for prolongation of life, improved quality of life 
(QOL), and effective symptom control. Being able 
to offer all patients best possible care coordinated 
and monitored by a specialized team, should be an 
ultimate goal. 
Methods: In spite of the fact that trials have been 
part of Oncology care for a long time and their 
outcomes help to demonstrate safer and more 
effective treatments, less than 5% of all patients with 
cancer will take part in clinical trials. At our McGill 
University health centers, the number of patients 
with a lung cancer diagnosis has increased over the 
past several years and many are enrolled to clinical 
trials. 
Results: The challenges due to the increasing 
numbers cannot be underestimated. Issues related 
to new, often complex treatment options, the aging 
population, emphasis on quality of life, and most 
importantly the need for earlier and improved 
palliation, are just a few. Can access to enhanced 
knowledge and possible participation through the 
rigorous clinical trials program help prepare lung 
cancer patients for this difÀcult journey? Would a 
database expand our knowledge and understanding 
in this therapeutic area? Through our clinical trials 
based approach, can we offer improved symptom 
management, end of life care and better outcomes? 
Conclusion: This presentation will describe the 
initiatives of our Clinical Trial Team, and the 
potential beneÀts of clinical trials for lung cancer 
patients as they move through their journey. 
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The internal vascular reticulum developed into a 
dense solid component. As the tumor progressed, 
dominance of the solid component increased from 
13% in AIS to 89% in patients who were positive 
for ADC-related factors. In the solid component 
of ADC, external arteries and veins appeared to 
bend and converge into the nodule. Contraction 
differences between the major axis and minor axis 
were emphasized on 3D images. In patients who 
were positive for ADC-related factors, nodule growth 
was seen in 60% on CT history and the diameter of 
the external draining veins and the internal bronchi 
were increased.
Conclusion: Imaging of EGFR-mutated non-
mucinous lung adenocarcinoma demonstrated that 
contraction and thickening of the lepidic septa 
originated in AIS. During minimal invasion, vascular 
reticulum was visualized as a nonsolid component. 
During early progression, dense vascular reticulum 
became a solid component, often demonstrating a 
long elliptical nodule, suggesting contraction along 
the bronchovascular trees, while nodule growth 
was restricted by the contraction and the external 
neighboring vessels became closer to the internal 
nodule component. During late stage of progression, 
nodule growth was advanced and draining veins 
developed.
Keyword: vascular reticulum
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P4.171 PROGNOSTIC IMPACT OF 
THE PRIMARY TUMOR LOCATION 
BASED ON THE HILAR STRUCTURES 
IN NON-SMALL CELL LUNG CANCER 
WITH MEDIASTINAL LYMPH NODE 
METASTASIS
Masaoki Ito1, Yoshinori Yamashita1, Yoshihiro 
Miyata2, Masahiro Ohara2, Yasuhiro Tsutuni2, 
Takuhiro Ikeda2, Keizo Misumi1, Hiroaki Harada1, 
Morihito Okada2 
1Department Of General Thoracic Surgery, National 
Hospital Organization Kure Medical Center And 
Chugoku Cancer Center/Japan, 2Department Of 
Surgical Oncology, Research Institute For Radiation 
Biology And Medicine, Hiroshima University/Japan
Background: The status of lymph node metastasis 
is an important factor determining the treatment 
strategy and predicting the prognosis in lung 
cancer. By the typical nodal metastatic process 
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P4.170 IMAGING CHANGE OF EGFR-
MUTATED LUNG ADENOCARCINOMA 
DURING THE TRANSITION FROM AIS 
TO MIA AND ADC. CORRELATION WITH 
STROMAL ELASTOSIS
Takashi Eto1, Nobuaki Nakajima2 
1Respiratory Medicine, Shizuoka General Hospital/
Japan, 2Radiology, Shizuoka General Hospital/Japan
Background: In the early development peripheral 
adenocarcinoma, there is preservation of the elastotic 
framework of the stroma due to contraction and 
thickening of the alveolar septa by approximately 
three to nine-fold (Eto et al. Cancer 1996). EGFR-
mutated non-mucinous adenocarcinoma shows 
moderate stromal elastosis during the transition 
from in situ (AIS) to minimally invasive (MIA) 
and invasive adenocarcinoma (ADC). Therefore, 
contraction of EGFR-mutated adenocarcinoma 
should be expressed on imaging analysis. We 
investigated the characteristic imaging changes in 
EGFR-mutated non-mucinous lung adenocarcinoma 
during the transition from AIS to MIA and ADC. 
Methods: EGFR-mutated non-mucinous 
adenocarcinoma measuring less than 7 cm in 
diameter were obtained from patients who underwent 
resection at our institute between April 2007 and 
March 2010 and these specimens were studied. 
Seventy-eight patients were enrolled and divided in 
four groups 1.AIS (n=8), 2. MIA (n=10), 3. Negative 
for ADC-related factors (absence of any lymphatic, 
vascular, pleural or nodal invasion) (n=21), 4. 
Positive for ADC-related factors (the remaining 
adenocarcinomas) (n=39). Imaging was evaluated 
with regard to internal veins, arteries and bronchi in 
the nonsolid component, as well as external veins 
and arteries. Retrospective CT history could be 
analyzed in 20 patients (AIS 4, MIA 4, negative for 
ADC-related factors 3 and positive for ADC-related 
factors 9) who were followed for more than 90 days, 
ranging from 97 to 2017 days.
Results: In all of AIS and 90% of MIA, imaging 
studies showed that small arteries and veins 
were visualized at close intervals in the nonsolid 
component, seen as vascular reticulum. In the CT 
history of patients with MIA and those negative for 
ADC-related factors, external neighboring vessels 
gradually approached or were captured by the 
nodule, while the nodule size grew along the major 
axis but hardly grew or shrank along the minor axis. 
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included 13 patients with skip metastasis (32.5%). 
However, lobe-speciÀc tendency for metastatic 
lymph nodes was noted regardless of the skip or non-
skip metastatic cases and the prognostic signiÀcance 
between the two tumor groups did not change after 
excluding the skip metastatic cases (51.3% vs. 
12.5%, P = 0.034). 
Conclusion: Our study indicates that evaluation of 
the primary tumor location based on the hilar and 
bronchial structures is useful to predict the tumor 
extended status in N2 NSCLC. Furthermore, it is 
suggested that this assessment might be valid even to 
unusual case with skip metastasis. 
Keyword: extrapulmonary bronchus, mediastinum, 
non-small cell lung cancer, prognosis, skip 
metastasis, TNM cl
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.172 EGFR AND K-RAS MUTATIONS IN 
JAPANESE PATIENTS WITH RESECTED 
NSCLC
Takayuki Shiina, Gaku Saito, Toshiki Ushiyama, 
Masayuki Toishi, Kazutoshi Hamanaka, Makoto 
Kurai, Keiichiro Takasuna, Ryoichi Kondo, Kazuo 
Yoshida, Jun Amano 
Thoracic Surgery, Shinshu University Hospital/
Japan
Background: The theory that existence of somatic 
mutations in the tyrosine kinase domain of the 
epidermal growth factor receptor (EGFR) gene is 
corresponded with therapeutic sensitivity of tyrosine 
kinase inhibitors (TKIs) in patients with non-small 
cell lung cancer (NSCLC), has been recognized 
widespread. The response of EGFR-TKIs is expected 
70-80% in patient with EGFR mutation, but is 
estimated around 10% to a wild-type EGFR. On the 
other hand, the presence of the V-Ki-ras2 Kirsten 
rat sarcoma (K-RAS) mutation is shown oppositely 
to the EGFR mutation. EGFR-TKIs would not be 
responded in the NSCLC patients with K-RAS 
mutation. We examined whether the presence of 
EGFR or K-RAS mutation became a prognostic 
factor in NSCLC patients who had received lung 
resection.
Methods: We intended consecutive 126 cases of 
that lymphatic drainage develops from interlobe to 
mediastinum through the hilum, metastatic lymph 
nodes located in the intrapulmonary, ipsilateral, and 
contralateral mediastinum are deÀned as N1, N2, and 
N3, respectively. Namely, the farther the metastatic 
lymph node from the primary tumor, the worse is 
the prognosis. On the other hand, little attention 
has been paid to location of the T descriptor in lung 
cancer. Our hypothesis is that if mediastinal lymph 
node metastasis comes from further located tumor, it 
might be unfavorable result reÁecting wider spread 
metastasis. The aim of this study was to estimate 
the prognostic value of the primary tumor location 
on the basis of the hilar structures in NSCLC with 
mediastinal lymph node metastasis. 
Methods: Among 337 patients with NSCLC who 
underwent mediastinal lymph node dissection 
between January 1995 and December 2004, 40 
patients with pathological T1a-2bN2M0 NSCLC 
were retrospectively analyzed. All the pN2 patients 
were preoperatively regarded not to have metastatic 
mediastinal lymph nodes. To determine the primary 
tumor location anatomically, we divided the cases 
into two groups on the basis of the primary tumor 
proximity to the hilar and bronchial structures: 
tumors located close to the Àrst branch of the 
extrapulmonary bronchus were deÀned as central-
type tumors, and those not meeting this criterion 
were deÀned as peripheral-type tumors. We analyzed 
only small size tumors (pT1a-T2b) and excluded 
advanced cases with pleural invasion (PL3) not 
to include unusual metastasis such as subpleural 
lymphatic pathway metastasis. The overall survival 
time was estimated by the Kaplan–Meier method and 
the inÁuence of variables on survival was analyzed 
by using the log-rank test for discrete variables. The 
Cox proportional hazards model was employed for 
multivariate analysis. 
Results: Of the 40 patients with N2 NSCLC, 18 
and 22 had central- and peripheral-type tumors, 
respectively. There was no signiÀcant difference 
between the tumor groups with regard to age, 
gender, tumor side, primary lobe, histological type, 
pathological stage, surgical procedure, pleural 
invasion, lymphatic invasion, and vascular invasion. 
The Àve-year survival rate was signiÀcantly higher 
with the central-type tumors than the peripheral-
type tumors (51.5% vs. 21.2%, P =0.034). The 
multivariate analysis showed that the primary 
tumor location (hazard ratio = 2.760, 95% CI = 
1.132–6.326; P = 0.026) was a signiÀcant prognostic 
factor for overall survival. The 40 analyzed patients 
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P4.173 THE PROGNOSTIC VALUE OF 
LYMPHANGIOGENESIS ON NON-SMALL 
CELL LUNG CANCER
Yang Shentu 
Thoracic Surgery, Shanghai Chest Hospital/China
Background: Lymph nodes invasion is common and 
one of the most important prognostic factor during 
the progress of cancer. Until now, some papers 
indicated that lymphangiogenesis promoted the 
metastasis of primary tumor cells to surround tissue 
and lymph nodes on breast and gastric carcinoma. 
Also, the research of lymphangiogenesis on non-
small lung cancer had been involved recently, but 
the relationship of the lymphangiogensesis and 
the clinicopathological parameters on non-small 
lung cancer was not clear. The prognostic value of 
lymphangiogensis still need to explore. We study 
the relationship of the patients’ clinicopathological 
parameters and peritumoral/ introtumoral lymphatic 
vessel density, lymphatic vessels invasion and the 
lymph nodes metastasis. And the prognostic value of 
lymphangiogensesis on non-small lung cancer was 
analyzed. 
Methods: The introtumoral lymphatic vessel 
density (79 cases) and the peritumoral lymphatic 
vessel density (45 cases) of parafÀn-embed 
tissues were tested with the D2-40 marker 
(Immunohistochemistry method), respectively. 
And, the relevance of lymphangiogenesis-related 
clincopathological parameters was evaluated.
Results: The average number of introtumoral and 
peritumoral lymphatic vessel density was 11.32 
and 7.80, respectively. The number of introtumoral 
lymphatic vessel density were high in those patients 
who suffer from mediastinal lymph nodes metastasis 
(p=0.015), lymphangiogenesis tumor invasion 
(p=0.022) and tumor cell poorly differentiation 
grade(p=0.005). The lymphangiogenesis was the 
independent prognostic factor of patients (p=0.000). 
Lymphangiogenesis tumor invasion obvious affect 
the survival rate of patients (p=0.006). But there 
was no signiÀcant statistical difference between the 
tumor diameter and lymphangiogenesis (p=0.436) 
or lymphangiogenesis tumor invasion (p=0.269). 
Peritumoral lymphatic vessel density was no relation 
to the prognosis of patients (p=0.278).
Conclusion: D2-40 was the special marker of 
lymphatic endothelia. The lymphangiogenesis and 
lymphangiogenesis tumor invasion might play an 
the NSCLC for this study. All of these cases were 
performed lung resections in Shinshu University 
Hospital form December 2000 to August 2008. We 
evaluated retrospectively whether the gene mutation 
could be detected using the lung specimen; EGFR 
mutation was analyzed by the PCR-invader method 
and K-RAS was by the PCR-clamp method. The 
relationships between the presence of EGFR or 
K-RAS mutation and the clinicopathological features 
of the NSCLC were also analyzed.
Results: All patient characteristics in the study were 
displayed as following: the ages varied between 35 
and 87 years (mean 69.3 years), the genders were 
72 men and 54 women, and smoking history had in 
68 cases. Histological Àndings included 93 cases 
of adenocarcinoma (AD), 22 cases of squamous 
cell carcinoma (SCC) and 11 cases of the other 
histological types. The EGFR mutations were found 
in 52 cases (41.3%), and the K-RAS mutations were 
found in 12 cases (9.5%). The presence of these gene 
mutations were recognized exclusively each other. 
The EGFR mutation was detected in the following 
characteristics: histological types were 52 ADs, 
the genders were 15 men and 37 women, and 39 
cases were non-smoker. The K-RAS mutation was 
detected in the following characteristics: histological 
types were 9 ADs, 2 SCCs and one of pleomorphic 
carcinoma, the genders were 8 men and 4 women, 
and 10 cases were heavy smoker. The EGFR-TKIs 
treatment was enforced in 23 cases (18.3%). 16 
cases of them were detected the EGFR mutation; 
14 cases were good response and 2 cases were 
progression disease. The EGFR-TKIs treatment for 
patients with wild-type EGFR was shown in 7 cases, 
and was invalid in all cases. We did not administer 
EGFR-TKI to a KRAS mutation patient. The median 
overall survival time (MST) was 78.6 months of all 
patients. The MST according to the EGFR mutation, 
the K-RAS mutation, and the double wild-type 
were 90.1 months, 31.5 months, and 65.6 months, 
respectively. The overall survival of EGFR mutation 
was signiÀcantly longer than K-RAS mutation.
Conclusion: The EGFR mutation was accepted 
a lot by AD and a woman. On the other hand, the 
K-RAS mutation was recognized a lot by a man and 
heavy smoker. The EGFR mutation extended overall 
survival than wild-type EGFR and K-RAS mutation.
Keywords: EGFR, Kras, NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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dyspnoe.
Conclusion: BS is the principle examination for 
veriÀcation of LC. From history of illness we may, 
with some probability, suppose which type of BS 
Àndings pts with LC probably will have. In the 
opposite, deÀnite BS Àndings signiÀcantly correlate 
with deÀnite types of LC. Knowledge of coherence 
of BS Àndings with other pts data may contribute to 
precise and more rapid diagnosis in LC pts.
Keywords: lung cancer, bronchoscopy, morphology, 
diagnostics
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P4.175 INVASION OF THE INNER 
AND OUTER LAYERS OF THE 
VISCERAL PLEURA IN PT1 LUNG 
ADENOCARCINOMA: CORRELATION 
WITH MALIGNANT AGGRESSIVENESS 
AND PROGNOSIS
Makoto Hamasaki1, Fumiaki Kato2, Yoshihiro 
Miyake3, Takayuki Shirakusa4, Akinori Iwasaki5, 
Kazuki Nabeshima6 
1Department Of Pathology, Fukuoka University 
Hospitalfukuoka University Hospital Faculty 
Of Medicine/Japan, 2Department Of Pathology, 
Fukuoka University Faculty Of Medicine/Japan, 
3Department Of Public Health, Fukuoka University 
Faculty Of Medicine/Japan, 4Department Of 
Thoracic Surgery, Fukuseikai Hospital/Japan, 
5Department Of Thoracic Surgery, Fukuoka 
University/Japan, 6Department Of Pathology, 
Fukuoka University Hospital Faculty Of Medicine/
Japan
Background: The visceral pleura consists of 
Àve layers including two elastic layers. Visceral 
pleural invasion (VPI) is deÀned as penetration 
by tumor cells of the elastic layers of the pleura. 
However, there is no mention in the literature which 
elastic layer is more important for the diagnosis of 
pleural invasion even in the tumor-node-metastasis 
(TNM) classiÀcation of malignant tumors (7th ed., 
International Union Against Cancer, UICC). The 
purpose of this study was to investigate whether the 
invasion of the inner or outer elastic layer is more 
critical in terms of patient survival. 
Methods: We reviewed 120 pT1 lung 
adenocarcinomas that had been surgically resected 
at the Department of Thoracic Surgery, Fukuoka 
University Hospital, between January 1993 and 
important roles during the procedure of enhanced the 
mediastium lymphatic nodes metastasis on non-small 
lung cancer. The lymphangiogenesis was a valuable 
prognostic factor of non-small lung cancer.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.174 CORRELATION OF 
BRONCHOSCOPIC FINDINGS WITH 
OTHER DATA IN 429 LUNG CANCER 
PATIENTS.
Miloslav Marel1, František Krejbich2 
1Faculty Hospital Prague, Motol, Charles 
University, Pulmonary Department/Czech Republic, 
21st Pulmonary Department Of Charles University, 
Charles University Prague/Czech Republic
Background: Lung cancer remains to be the 
big health problem in the Czech republic. The 
diagnostic process is unprecise and slow. We intend 
to evaluate the contribution of bronchoscopy (BS) 
for morphological veriÀcation of LC and Ànd out 
correlations of BS Àndings with other data of the 
patients (pts) with LC
Methods: Prospective study on 429 pts with LC 
examined in 2004-2009. The BS Àndings were 
divided into the four categories: visible direct tumor 
masses, extramural or intramural compression of 
the bronchi and/or widening of the carina as indirect 
tumor changes, normal Àndings and BS not done.
Results: 151 pts (35%) had direct tumor changes 
and were veriÀed during BS in 95,3%. Most of them 
(36%) suffered from small cell LC. In 110 pts (25%) 
indirect tumor changes were veriÀed by BS in 55%. 
Most of them (33%) suffered by adenocarcinoma. In 
93 pts were found normal Àndings. These pts were 
veriÀed by BS in 22,8%. Most of them (38%) had 
adenocarcinoma. BS was not done in 75 pts. Only 
30% from these pts were veriÀed by other methods 
then BS. Groups of pts with smoking history, weight 
loss, alcohol overuse, cough and haemoptysis had 
signiÀcantly more frequently direct tumor changes. 
Pts with direct BS tumor changes had lower FEV1. 
The indirect BS tumor changes were more frequently 
found in pts with adenocarcinoma. The BS Àndings 
did not correlate with number of smoked cigarettes, 
fever in the time of diagnosis and the grade of 
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service in 2010 aimed at researching EGFR mutations in 
diagnostic samples of NSCLC obtained by:CT guided 
transthoracic needle aspiration biopsy (FNAB); broncho-
alveolar lavage(BAL); endobronchial ultrasound guied 
transbronchial needle aspiration (EBUS-TBNA) and the 
classic methodology used in brushing(EB) and bronchial 
biopsy(BB); surgical samples; pleural biopsy and Áuid.
Comparison between the average times for result 
acquisition in the various samples. 
Methods: In EB, BB, pleural Áuid and biopsy and 
surgical samples, EGFR sequencing made with DNA 
from cytological or histological slides or parafÀn block 
by classical techniques described in literature. In FNAB 
and EBUS-TNBA, cellular debris in needle were 
recovered by saline solution washing and preserved 
in buffer at -20ºC.The extemporaneous cytological 
conÀrmation of NSCLC was followed by DNA 
extraction of those cellular debris and EGFR sequencing.
In samples containing clots a parafÀn block was used 
with posterior histological analysis and sequencing. In 
NSCLC diagnosed by BAL, performed centrifugation 
of BAL with separation of suspension cells and 
supernatant, which was preserved in 400ƫl of buffer at 
-20ºC.The supernatant was puriÀed and subject to DNA 
concentration and EGFR sequencing. Linear regression 
analysis for comparison of average times for result 
acquisition, statistical signiÀcance for p<0.05. 
Results: Sequenced 126 patients:24 BAL; 2 EB; 5 
EBUS-TBNA; 43 BB; 27 FNAB; 8 pleural biopsy; 
3 pleural Áuid; 13 surgical samples; 1 hepatic 
metastasis biopsy. 
Average waiting time (days) Time difference (days) p 
Paraf¿n block 8.32 - 
Cytological slides 14 5.6721 0.0255 
Histological slides 20.42 12.0888 7.11e-08 
Cellular debris 6.5556 -1.7723 0.1789 
Table1 – Average time for sequencing result 
acquisition. 
Diagnostic 
method 
Type of material Average waiting 
time (days) 
Time difference 
(days) 
p 
BAL Cellular debris 5.714 -12.286 0.000286 
Cytological slides 18.000 
FNAB Cellular debris 6.05 -10.807 0.0188 
Paraf¿n block 16.857 
EBUS-TBNA Cellular debris 6.144 -10.856 9.63e-05 
Paraf¿n block 17.000 
BB Histological slides 19.000 11.812 1.03e-05 
Paraf¿n block 7.188 
Surgical samples Histological slides 26.00 18.833 3.68e-05 
Paraf¿n block 7.167 
Table2 – Average acquisition time for each type of 
sample depending on the diagnostic method.
December 2001. We classiÀed the tumors into three 
groups according to invasion of the inner and outer 
elastic layer, which was determined by EvG staining: 
group A, no invasion; group B, invasion of the inner 
layer but not the outer one; group C, invasion of 
both layers. The relashionship between VPI and the 
endpoint (death) was analyzed by univariate and 
multivariate analyses.
Results: The invasion of the inner and outer elastic 
layer was recognized in 22.8% (21/92) and 21.7% 
(20/92), respectively. The 5-year survival rate was 
82% (51/92, 55.4%), 59% (21/92, 22.8%) and 38% 
(20/92, 21.7%) in patients of groups A, B and C, 
respectively. Invasion of the outer elastic layer (HR 
5.92, 95% CI 2.197-15.957, P=0.0004) correlated 
more signiÀcantly with shorter survival than that 
of the inner layer (HR 3.56, 95% CI 1.151-10.992, 
P=0.0275). Invasion of the outer elastic layer was 
also signiÀcantly associated with lymph node 
metastasis and frequent lymphatic involvement, 
higher stromal invasion grade and presence of small 
cluster invasion within tumors. Univariate analysis 
showed that invasion of the outer elastic layer 
correlated signiÀcantly with poor prognosis. However, 
multivariate analysis identiÀed lymph node metastasis 
as the most signiÀcant predictor of poor prognosis. 
Conclusion: VPI is a signiÀcant pathological 
predictor of poor prognosis in pT1 lung 
adenocarcinoma.
Keywords: lung adenocarcinoma, Pleura, Elastic 
layers, Pleural invasion
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P4.176 STUDY OF THE MUTATIONAL 
STATE OF EGFR IN DIAGNOSTIC 
SAMPLES OF NSCLC - NEW APPROACH 
METHODS
Ana Antunes1, Sergio Campainha1, Ana Castro1, 
Pedro Brinca2, Ana Barroso1, Sara Conde1, SoÀa 
Neves1, Jose Carlos Machado3, Barbara Parente1 
1Pulmonology, Centro Hospitalar Vila Nova Gaia/
Espinho, Epe/Portugal, 2Department Of Economics, 
Stockholm University/Sweden, 3Diagnostics, Institute 
Of Molecular Pathology And Immunology Of The 
University Of Porto/Portugal
Background: Sequencing EGFR is important in all 
NSCLC diagnostic samples, in a quick and effective 
manner, in order to allow a better therapeutic strategy. 
Aim:Presentation of the technology developed in our 
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a metropolitan hospital campus were identiÀed using 
surgical log books in the period 2009 – 10. The 
initial analysis was undertaken using the original 
cytologic and histologic reports. Other information 
was obtained by chart review. 
Results: Fifty seven cases were identiÀed: 23 male, 
34 female. Median age was 69 years (range 44-
87). Cytologic diagnosis was obtained by CT-FNA 
(Àne needle aspiration) in 46 (81%), bronchoscopy 
in 9 (16%) and endobronchial ultrasound (EBUS) 
in 2 (3%). NSCLC subtypes by cytology were: 20 
(35%) adenoCa, 9 (16%) SCC, 23 (40%) large cell, 
3 (5%) mixed, 1 sarcomatoid and 1 bronchoalveolar 
carcinoma (BAC). By histology, Ànal subtypes 
were: 30 (55%) adenoCa, 11 (19%) SCC, 5 (9%) 
large cell and 7 (12%) mixed. Pathologic staging 
included Stages: IA 11 (19%), IB 15 (26%), IIA 
9 (16%), IIB 9 (16%), IIIA 12 (21%) and IIIB 1 
(2%). In the primary analysis of cytology v Ànal 
histopathology, concordance was moderate at 58%, 
k = 0.43 (95% CI 0.26-0.61). For cytology obtained 
by CT-FNA, concordance was 61% (k = 0.44, 95% 
CI 0.24-0.64), but for bronchoscopic cytologic 
diagnosis concordance was poorer at 44% (k = 0.15, 
95% CI -0.35 – 0.65). Applying the results from the 
reports to 2x2 tables, for adenoCa, the sensitivity 
of cytologic diagnosis was 60%, speciÀcity 78% 
with positive predictive value (PPV) of 78% and 
negative predictive value (NPV) of 61%; for SCC 
the sensitivity of cytologic diagnosis was 64%, 
speciÀcity 95%, PPV 75% and NPV 92%; and for 
large cell carcinoma, the sensitivity of cytologic 
diagnosis was 80%, speciÀcity 60%, PPV 17% and 
NPV 97%. 
Conclusion: Routine cytologic diagnosis is 
associated with moderate agreement for histo-
subtype, with CT-FNA superior to bronchoscopy in 
our setting. The PPVs of cytology for adenoCA and 
SCC were comparable and reasonable, but poor for 
large cell carcinoma. The NPV of cytology for SCC 
was very high. These Àndings may have implications 
for therapeutic decision-making. Results from 
blinded pathology review will be presented at the 
meeting. 
Conclusion: EGFR sequencing is possible in all 
NSCLC diagnostic samples. DNA sequencing made 
from cellular debris is quicker than from microscopic 
slides or parafÀn block.This difference is statistically 
signiÀcant and has impact in treatment beginning. 
Keywords: EGFR, Diagnostic sample
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P4.177 MODERATE DIAGNOSTIC 
ACCURACY OF INITIAL CYTOLOGIC 
DIAGNOSIS IN RESECTED NON-SMALL 
CELL LUNG CARCINOMA (NSCLC): 
IMPLICATIONS FOR THERAPEUTIC 
DECISION-MAKING IN ADVANCED/
METASTATIC DISEASE
Csilla Hasovits1, Peter Brady2, David Marshman2, 
Ben Harris2, Anthony Gill2, Bryn Atmore2, Nick 
Pavlakis2 
1Department Of Medical Oncology, Royal North 
Shore Hospital/Australia, 2Royal North Shore 
Hospital/Australia
Background: The medical management of NSCLC 
has evolved with the emergence of targeted 
biological agents targeting speciÀc activating 
gene mutations, the increasing recognition of 
a treatment-by-histology interaction (different 
chemotherapy regimens show differential activity for 
adenocarcinoma (adenoCa) v Squamous cell (SCC) 
). The majority of NSCLC cases are metastatic, so 
accurate initial cytologic diagnosis for histo-type 
is extremely important in guiding chemotherapy 
options and for selecting patients for mutational 
testing for targeted agents. We aimed to evaluate the 
accuracy of initial diagnostic cytology in predicting 
Ànal histology in resected NSCLC. 
Methods: The primary objective was to determine 
the diagnostic agreement (concordance-by kappa 
(k) score) between cytologic diagnosis and the 
gold standard of histology in resected NSCLC 
specimens. Secondary objectives included 
examining concordance by method of obtaining 
cytology, determining the sensitivity and speciÀcity 
of community cytology for Ànal histology 
subtype and examining the diagnostic accuracy 
of the original cytologic diagnosis, the impact of 
immunohistochemistry and inter-observer agreement 
using two blinded lung cancer pathologists. The 
design was a retrospective cross-sectional analytic 
study of patients with resected NSCLC. Cases from 
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0.68±2.03 g/dl after 56–63 days (n=245, p<0.0001). 
Results for NSCLC and SCLC pts are shown in 
Table 1. TEAEs were causally related to ET in 
1.3% of events. Thrombovascular TEAE’s (TVE) 
occurred in 65 pts (6.9%); 12 events were assessed 
as having at least a possible causal relation to ET. On 
study 100 pts died, of which 66 were attributed to 
disease progression. Five reported TVE’s resulted in 
death: cerebrovascular accident (3) and pulmonary 
embolism (2); none assessed to be causally related 
to ET. 
Table 1. Results for NSCLC and SCLC sub-groups. 
NSCLC (n=676) SCLC (n=232) 
BT independent 
response (%) 51.7% 50.2% 
Hb at ET start (g/dl) 10.83 ± 1.16 (n=395) 10.83 ± 1.02 (n=147) 
Hb increase after
28-35 days (g/dl) 0.01 ± 1.59 (n=334, NS) -0.04 ± 1.65 (n=127, NS) 
Hb increase after
56-63 days (g/dl) 0.77 ± 2.05 (n=169, p<.0001) 0.31 ± 1.97 (n=65, NS) 
ET duration (wks) 9.4 (95% CI: 8.9-9.8) 9.6 (95% CI: 9.0-10.1) 
BT beyond 4 wks of 
ET (%) 15.4% 22.4% 
Conclusion: Results show that ET generally started 
according to CIA treatment guidelines and is an 
effective treatment of CIA in lung cancer patients. 
Differences seen between NSCL and SCLC patients 
in terms of Hb-response and BT could be caused by 
differences in disease characteristics and treatment 
for SCLC and NSCL. TEAEs seem in line with 
current label for epoetin alfa.
Keywords: anemia management, epoetin alfa, Lung 
cancer
Poster Session 4 – Pathology Thursday, 7 July 2011 10:00-12:30
P4.179 MDM2 SNP309 IS ASSOCIATED 
WITH THE CIGARETTE SMOKING 
QUANTITY IN EGFR WILD-TYPE 
ADENOCARCINOMA OF THE LUNG
Jun Atsumi, Kimihiro Shimizu, Seiichi Kakegawa, 
Tetsuhiro Nakano, Masayuki Sugano, Yohei 
Miyamae, Izumi Takeyoshi 
Department Of Thoracic And Visceral Organ 
Surgery, Gunma University/Japan
Background: Cigarette smoking is a well-known 
risk factor of lung cancer, inducing DNA damage and 
oncogene activation. The tumor suppressor protein 
p53 plays a crucial role in the prevention of cancer 
formation through DNA repair, cell cycle arrest 
and apoptosis. The murine double minute-2 protein 
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P4.178 DUTCH OBSERVATIONAL 
STUDY ON CHEMOTHERAPY-
INDUCED ANAEMIA MANAGEMENT 
WITH EPOETIN ALFA (EPREX®) – 
SUB-ANALYSIS ON LUNG CANCER 
PATIENTS
N. J. J. Schlösser1, R. Lunde2, Joachim Aerts3, M. 
Heijsteeg4, W. F. M. Strankinga5, R. G. P. M. Brok6, 
M. Lahaye6, Mira Franken6 
1Pulmonary Diseases, University Medical Centre 
Utrecht/Netherlands, 2St. Laurentius Hospital/
Netherlands, 3Pulmonary Diseases, Amphia 
Hospital/Netherlands, 4Maasstad Hospital/
Netherlands, 5Bovenij Hospital/Netherlands, 
6Janssen-Cilag B.V./Netherlands
Background: The medical practice with Epoetin alfa 
(Eprex®) treatment (ET) for chemotherapy-induced 
anaemia (CIA) in the Netherlands was evaluated in 
an observational study; a pre-speciÀed sub-analysis 
on 943 lung cancer patients (pts) enrolled from 2005-
2009 is presented here. Objectives were safety and 
efÀcacy of ET.
Methods: Eligible pts were 18 years and diagnosed 
with a solid tumour, Multiple Myeloma or (non-)
Hodgkin’s disease for which chemotherapy (CT) 
was initiated. Data on haemoglobin level (Hb), 
blood transfusion (BT), CT, ET, iron status & 
supplementation and treatment-emergent adverse 
events (TEAE) (attribution upon investigator’s 
assessment) were collected. Hb response to ET, not 
inÁuenced by a transfusion within 28 days prior to 
reaching response, was deÀned in the protocol as ³1 
g/dl Hb rise within Àrst 4 weeks ET or ³2 g/dl Hb-
rise from baseline or Hb within range 11–13 g/dl 
after 4 weeks of ET until end of study.
Results: Average age was 63.4±9.4 years, 57.8% 
were male and all pts started with 40.000IU ET 
once-weekly. Pts had NSCLC (71.7%), SCLC 
(24.6%) or mesothelioma (3.6%). The majority of 
pts had metastatic disease (58.1%) and received 
3-weekly (98.6%), platinum-containing (91.3%) CT. 
ET predominantly started during the Àrst 2 cycles of 
CT (74.5%). The mean duration of ET was 9.4 weeks 
(95% CI: 9.1-9.8). During CT, 21.1% of pts received 
iron supplementation (mostly oral). Transfusion-
independent response to ET was reached in 51.8% of 
pts. ET started at an Hb of 10.84±1.14 g/dl (n=562) 
and resulted in a transfusion-independent Hb-rise 
of 0.01±1.61 g/dl after 28–35 days (n=478, NS) and 
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by less amount of cigarettes than the cases with T/T 
type in Japanese population. This is the Àrst report 
to analyze the association between genotypes of 
MDM2 SNP309 and EGFR mutational status in lung 
adenocarcinoma.
Keywords: MDM2, Adenocarcinoma, EGFR, 
cigarette smoking
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.180 DIAGNOSTIC VALUE OF CAIX 
PROTEIN LEVEL IN MALIGNANT 
PLEURAL EFFUSIONS BY ENZYME-
LINKED IMMUNOSORBENT ASSAY
Wen-Ying Lee, Nai-Ding Liao 
Department Of Cytopathology, Chi Mei Medical 
Center/Taiwan
Background: Conventional cytology for the 
detection of malignant cells in pleural effusion is the 
most speciÀc routine diagnostic method, however 
its sensitivity of 50-60% is insufÀcient. Most 
cancer cells produce energy by aerobic glycolysis, 
which gives rise to increased acid production. 
Carbonic anhydrase IX (CAIX), a transmembrane 
glycoprotein, catalyzes the reversible hydration of 
carbonic dioxide to carbonic acid and functions 
in regulating pH and eliminating the acid load in 
cancer cells. CAIX is undetectable in most normal 
epithelial tissues and benign epithelial tumors but 
is overexpressed in many cancers, including lung, 
breast, stomach and colon. The aim of the present 
study was to evaluate the utility of CAIX protein 
level for differentiating benign and malignant pleural 
effusions.
Methods: A total of 131 pleural effusions including 
56 benign effusions, 42 probable malignant effusions 
and 33 malignant effusions according to the 
cytological diagnosis and etiology, were subjected 
to detect CAIX protein level by enzyme-linked 
immunosorbent assay (ELISA).
Results: The mean level of CAIX was signiÀcantly 
higher in malignant effusions (18019.2 pg/dL) 
than probable effusion (1712.7 pg/dL) and benign 
effusion (555.7 pg/dL) (p0.05). Using cutoff values 
of 2000 pg/dL, the sensitivity and speciÀcity were 
63.6% and 94.6% in differentiating malignant and 
(MDM2) is a central node in the p53 pathway and a 
direct negative regulator of p53. A functional single 
nucleotide polymorphism (SNP309, T to G change 
at the 309th nucleotide in the Àrst intron, rs2279744) 
in the promoter region of MDM2 has been shown to 
increase the afÀnity of the transcriptional activator 
Sp1, resulting in the subsequent attenuation of the 
p53 pathway. This SNP was reported to be associated 
with carcinogenesis of non-small-cell lung cancer 
(NSCLC) and G/G genotype was reported to be 
a higher risk of NSCLC, especially in smoker. 
Epidermal growth factor receptor (EGFR) is a 
receptor tyrosine kinase that plays a crucial role in 
cell proliferation. EGFR mutations are less frequent 
in adenocarcinomas associated with smoking, unlike 
p53 mutations, suggesting distinct molecular genetic 
pathways underlying lung carcinogenesis in patients 
with different tobacco exposures. However, little has 
been studied about the relation for MDM2 SNP309 
and EGFR mutations. In this study, we analyzed the 
association of genetic polymorphisms of MDM2, 
cumulative cigarette smoking and EGFR mutations 
in patients with adenocarcinoma of the lung. 
Methods: Among the adenocarcinoma of the lung 
resected at Gunma university hospital in the period 
between June 2003 and May 2008, 146 cases were 
registered. Genomic DNA was extracted from 
peripheral blood lymphocytes according to standard 
procedures. PCR and RFLP analysis were used to 
genotype the T/G MDM2 SNP309 polymorphism. 
Mutations of EGFR in exon 19 and 21 were detected 
using a smart-ampliÀcation process (Smart Amp) 
method. 
Results: There were 83 females and 63 males and 
the mean age was 66 years. There were 67 ever 
smokers (35 current and 32 former smokers) and 
79 never smokers. The average values of pack-
years are 19.6 among all cases and 42.7 among 
ever smokers. The genotype distributions of the 
MDM2 polymorphisms are as follows; T/T: 28 cases 
(19.2 %), T/G: 73 (50%), G/G: 45 (30.8%). No 
signiÀcant associations were found between MDM2 
genotypes and clinical factors including age, gender, 
smoking status, pack-year, and EGFR mutational 
status. In the cases with wild-type EGFR, pack-
year was signiÀcantly lower in G/G and T/G than 
T/T genotype (G/G vs T/T: p = 0.019, T/G vs T/T: 
p=0.015), while in the cases with EGFR mutation no 
signiÀcant difference was detected. 
Conclusion: In summary, our Àndings indicate that 
the cases with G/G or T/G type of MDM2 SNP309 
will easily develop wild-type EGFR adenocarcinoma 
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found in 38% (25/65). Among males with EGFR 
mutations, there were fewer subjects who had never 
smoked or were light smokers (7/64) compared to 
the number of smokers (18/64). EGFR wild type was 
strongly represented in the group that was positive 
for ADC-related factors (44/63, 70%), and was 
especially high among male smokers (36/43, 84%), 
but was apparently limited during progression from 
AIS to lesions that were negative for ADC-related 
factors. Moderate stromal elastosis was detected in 
94% of those showing EGFR mutations, and 49% 
of those showing EGFR wild type. Compared to the 
group that was positive for ADC-related factors, the 
prevalence of moderate stromal elastosis was high 
in the group showing EGFR mutations (89%), but 
limited in those showing EGFR wild type (34%), and 
severely limited in smokers (25%). KRAS mutation 
was detected in 14% (9/63) of those with EGFR wild 
type and these patients were male dominant (8/9) 
and were all smokers showing codon 12 mutational 
status. In patients with KRAS mutation, 78% were 
positive for ADC-related factors and 67% showed no 
or mild stromal elastosis.
Conclusion: EGFR mutation-related 
adenocarcinoma progressed from AIS to ADC 
in speciÀc mutational-status order and was 
accompanied by moderate stromal elastosis. 
EGFR wild type adenocarcinoma mostly showed 
progression of stromal invasion with no or mild 
elastosis, especially in male smokers. KRAS 
mutation may play a limited role in EGFR-wild type 
non-mucinous adenocarcinoma in East Asia.
Keywords: stromal elastosis, EGFR mutation, 
KRAS mutation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.182 DETECTION OF HUMAN 
PAPILLOMAVIRUS (HPV) GENOTYPES 
IN BRONCHIAL CANCER USING 
SENSITIVE MULTIMETRIX HPV-
GENOTYPING TECHNIQUE
Maria Silvoniemi1, Eeva Salminen2, Tuula 
Vasankari1, Stina Syrjänen3, Kari Syrjänen2 
1Respiratory Medicine, Turku University 
Hospital/Finland, 2Department Of Oncology And 
Radiotherapy, Turku University Hospital/Finland, 
benign effusions. The area under Receiver Operating 
Characteristic (ROC) curve was 0.775.
Conclusion: Detection of CAIX protein level by 
ELISA might be a complementary tool for the 
detection of malignant pleural effusions.
Keywords: Carbonic anhydrase IX, Pleural effusion, 
ELISA, cytology
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P4.181 THE ROLE OF EGFR AND KRAS 
MUTATION IN THE PROGRESSION 
OF NON-MUCINOUS LUNG 
ADENOCARCINOMA FROM AIS TO MIA 
AND ADC
Takashi Eto1, Nobuaki Nakajima2 
1Respiratory Medicine, Shizuoka General Hospital/
Japan, 2Radiology, Shizuoka General Hospital/Japan
Background: Progression of non-mucinous lung 
adenocarcinoma from in situ (AIS) to minimally 
invasive (MIA) and then invasive adenocarcinoma 
(ADC) is associated with molecular genetic 
alteration. EGFR is a smoking-independent form 
of carcinogenesis, whereas KRAS is a smoking-
dependent form of carcinogenesis. Smoking history, 
gender and ethnicity affect the EGFR and KRAS 
mutations. This study investigated the different roles 
of EGFR and KRAS mutations in the progression 
of non-mucinous lung adenocarcinoma from AIS to 
MIA and ADC. 
Methods: Between April 2007 and March 2010, 147 
patients with non-mucinous lung adenocarcinoma 
underwent resection at our institute. These patients 
were divided into four histologic grades: 1. AIS 
(n=13); 2. MIA (n=16); 3. Negative for ADC-related 
factors (absence of any lymphatic, vascular, pleural 
or nodal invasion, n=29); 4. Positive for ADC-related 
factors (the remaining adenocarcinomas, n=89). The 
EGFR mutational status and differences in smoking 
history, gender and elastosis in the lepidic septa 
during the progression from AIS to MIA and ADC 
were evaluated.
Results: EGFR mutations became increasingly 
pronounced in the progression from AIS to ADC in 
females (59/83, 71%), and were especially high in 
those who had never smoked or were light smokers 
(50/66, 76%). The mutational status of exon 21 
point mutation was dominant over exon 19 deletion 
and both mutational spots increased proportionally 
from AIS to ADC. In males, EGFR mutations were 
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counterparts (p=0.012, Mann-Whitney). In univariate 
analysis, none of the other clinical variables were 
signiÀcant predictors of HPV. When analysed 
in multivariate logistic regression model (with 
following variables entered: age, gender, smoking 
history, pack years, asbestos exposure), the only 
signiÀcant determinant of HPV-positivity was pack 
year, with OR=0.94, 95%CI 0.88-0.99, p=0.045.
Conclusion: Less pack years (30.0 vs. 37.3) being 
associated with HPV, despite the older age of the 
patients, it is tempting to speculate that oncogenic 
HPV can substitute a part of the smoking exposure 
in bronchial carcinogenesis. HPV prevalence of 
5.2% reported in the present series closely parallels 
the data from a recent meta-analysis, where 
HPV prevalence levelled off at 5% (C.Peters, 
unpublished). This is a substantially lower Àgure 
than directly counted from the published world 
literature in 2002; i.e., 21.7% , 536/2468 (J. Clin. 
Pathol. 2002;55:885-891). In the era of prophylactic 
HPV vaccination, there is an urgent need to provide 
more data on the role of HPV in these implicated 
HPV-associated neoplasia at non-genital sites, 
bronchial cancer in particular. 
Keywords: Lung cancer, human papillomavirus
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P4.183 PROGNOSTIC VALUE OF 
VISCERAL PLEURAL INVASION IN THE 
NEW TNM CLASSIFICATION OF NON-
SMALL CELL LUNG CANCER
Yujin Kudo1, Hisashi Saji1, Shuji Ichinose1, 
Masaharu Nomura2, Jun Matsubayashi2, Hiroaki 
Kataba1, Masatoshi Kakihana1, Seisuke Nagase1, 
Jitsuo Usuda1, Naohiro Kajiwara1, Tatsuo Ohira1, 
Norihiko Ikeda1 
1Surgery, Tokyo Medical University/Japan, 
2Pathology, Tokyo Medical University/Japan
Background: Visceral pleural invasion (VPI) is 
a poor prognostic factor in lung cancer. Possible 
VPI tumor cell pathways include the subpleural 
lymphatics and hilar lymph nodes into the 
mediastinal lymph nodes. Tumors  3 cm with P1 
were classiÀed as T1 in the previous Japan Lung 
Cancer Society classiÀcation, but in the new TNM 
classiÀcation (7th Edition) tumors with PL1 or PL2 
are upgraded to T2a. 
Methods: We retrospectively reviewed 1023 
patients (617 men, 406 women, mean age 64.8, 
3Department Of Oral Pathology And Radiology, 
University Of Turku/Finland
Background: Bronchial carcinoma consists a major 
disease burden worldwide, showing increasing 
trends particularly among women in many societies. 
Epidemiological and experimental data suggest that 
cigarette smoke, radiation, and asbestos exposure 
are the prime etiological agents of this malignancy. 
Following the primary report in 1979 (by the senior 
author), evidence for the involvement of human 
papillomavirus (HPV) in bronchial carcinogenesis 
has accumulated through several lines of research: 
1) HPV DNA has been detected in around 50% of 
benign bronchial squamous cell papillomas (SCP); 
2) detection of morphological changes suggesting 
HPV in bronchial cancer and its precursors on light 
microscopy; 3) expression of HPV structural proteins 
by immunohistochemistry; 4) detection of HPV 
DNA by different hybridization assays and PCR in 
around 20% of bronchial carcinomas analyzed in 
almost 100 published studies; and 5) in vitro studies, 
i.e., transformation of bronchial epithelial cells by 
oncogenic HPV types. The causal role of HPV in 
bronchial carcinogenesis still remains controversial, 
however, and more data are needed particularly on 
the genotype distribution and cofactors of HPV in 
this process. 
Methods: The present series consists of 93 
consecutive non-small cell lung cancer patients 
treated with chemotherapy at the Department of 
Respiratory Medicine, Turku University Hospital, 
(Finland) during 2008-2010. Diagnosis of bronchial 
cancer was conÀrmed using cytology, bronchoscopic 
biopsy or operative biopsy. All available histological 
samples (n=77) were subjected to HPV genotyping 
with Luminex-based Multimetrix kit (Progen 
Biotechnik GmbH, Heidelberg, Germany), detecting 
24 LR- (low-risk) and HR- (high-risk) HPV-types. 
HPV data were correlated with clinico-pathological 
variables in univariate and multivariate regression 
models to disclose eventual cofactors of HPV in 
bronchial carcinogenesis
Results: Of the 77 histological samples analysed, 
4 (5.2%) were shown to contain HPV DNA. Of 
these 4, three represented single-type infections 
by HPV16, while one was double-infection by 
HPV6 and HPV16. All 4 patients were males, all 
were smokers (30 pack years by all), and all but 
one reported asbestos exposure in his occupation. 
Patients with HPV-positive tumors were signiÀcantly 
(>11 years) older than their HPV-negative 
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P4.184 CORRELATION BETWEEN 
ENVIRONMENTAL TOBACCO SMOKE 
(ETS) EXPOSURE AND ANAPLASTIC 
LYMPHOMA KINASE (ALK) RE-
ARRANGEMENT POSITIVE NSCLC 
PATIENTS WHO ARE NEVER-SMOKERS
Sai-Hong I. Ou1, Christina Siwak-Tapp2, Tomoya 
Kawaguchi3 
1Department Of Internal Medicine, Chao Family, 
Comprehensive Cancer Center/United States Of 
America, 2Chao Family Comprehensive Cancer 
Center/United States Of America, 3Internal 
Medicine, National Hospital Organization Kinki-
chuo Chest Medical Center/Japan
Background: Anaplastic lymphoma kinase (ALK) 
re-arrangement positive NSCLC patients are 
generally never-smokers similar to patients with 
epidermal growth factor receptor (EGFR) activation 
mutations. However, the correlation between 
environmental tobacco smoke (ETS) exposure and 
the occurrence of ALK re-arrangement in NSCLC 
patients who are never-smokers is unknown. 
Methods: ALK re-arrangement positive NSCLC 
patients who screened positive (FISH, RT-PCR) on 
one of the 3 crizotinib trials (A8081001, A8081005, 
A8081007) and who are never-smokers (< 100 
cigarettes lifetime) were given detailed questionnaire 
about ETS. Cumulative ETS were tabulated and 
divided into childhood, adult, home, and work 
exposure. 
Results: 29 ALK re-arrangement positive NSCLC 
patients were identiÀed through screening. 26 were 
never-smokers and detailed ETS were available from 
25 patients (14 females, 11 males) (18 US-born, 7 
foreign-born). All 25 ALK re-arrangement positive 
NSCLC patients have wildtype EGFR. The mean 
age of all patients was 49.6 years (range; 31-80). 8 
patients (32%) had no cETS. The mean cETS (total 
years exposed) were: 16.5 years (total), 6.9 years 
(childhood), 9.6 years (adult), 11.3 years (home), 
and 5.2 years (work) respectively. ALK positive 
patients with no cETS were generally younger than 
ALK positive patients with any cETS. The mean 
age of patients who had no cETS was 45.3 years 
compared to mean age of 51.6 years for patients with 
any cETS (p = 0.1367) and is independent of source 
of exposure: childhood ETS (45.9 yo [no] versus 
53.6 yo [yes], p = 0.0965); adult ETS (46.3 yo [no] 
versus 53.2 yo [yes], p = 0.1646), home ETS (45.3 
median follow-up 47.1 months) with pathologically 
conÀrmed T1a-T3 non-small cell lung cancer 
(NSCLC) who underwent complete resection of 
a minimum of lobectomy with lymphadenectomy 
between 2000 and 2007. There were 736 patients 
with adenocarcinoma, 212 with squamous cell 
carcinoma, 54 with large cell carcinoma and 21 with 
other cancer types. We assessed their prognostic 
factors based on the new classiÀcation and examined 
their suitability. 
Results: Patients at various stages determined 
using the new staging system comprised IA, 432; 
IB, 283; IIA, 126; IIB, 56; IIIA, 126. Patients in 
the T classiÀcation using the new staging system 
comprised T1, 562; T2, 408; T3, 46; T4, 7; T1a, 291; 
T1b, 207; T2a, 403; T2b, 56; T3, 66. Patients in the 
N category in the previous system comprised N0, 
787; N1, 123; N2, 113. Those in the PL category 
using the new system comprised PL0, 751; PL1, 145; 
PL2, 75; PL3, 52. The 5-year survival rate according 
to the degree of VPI (tumor size  3 cm) was 82.9% 
in PL0 (n = 498), 68.4% in PL1 (n = 76), and 62.6% 
in PL2 (n = 28; PL0 vs. PL1/2, p = 0.01). The 5-year 
survival rate (tumor size 3-5 cm) was 73.4% in 
PL0 (n = 217), 68.4% in PL1 (n = 49), and 49.3% 
in PL0 vs. PL1/2 (n = 31; p = 0.001). The 5-year 
survival rate was 66.7% in tumors  3 cm in PL1-2, 
and 69.5% in tumors between 3 and 5 cm in PL0-2 
(p = 0.42). The 5-year survival rate (tumor size 5-7 
cm) was 44.7% in PL0 (n = 31), 36.6% in PL1 (n 
= 16), and 20.8% (n = 9; PL0 vs. PL1 vs. PL2, p 
= not signiÀcant). Tumor size, vascular invasion, 
lymph node involvement and VPI were signiÀcant 
prognostic factors on multivariate analysis. 
Univariate 
P value 
Multivariate 
P value 
Hazard 
Ratio 95 % CI 
Sex (Women vs. Men) <0.0001 0.052 0.75 0.55-1.00 
Tumor size (  3cm vs. > 3cm) <0.0001 0.01 0.70 0.53-0.93 
Vascular invasion (v- vs. v+) <0.0001 <0.0001 0.48 0.34-0.68 
Lymphatic invasion (ly- vs. ly+) <0.0001 0.92 0.98 0.69-1.39 
Histological type (Non-SCC vs. SCC) 
SCC: Squamous cell carcinoma <0.0001 0.23 0.83 0.62-1.12 
Pathologic N status (N0 vs. N1-2) <0.0001 <0.0001 0.47 0.36-0.64 
Visceral pleural invasion (pl0 vs. pl1-3) <0.0001 0.02 0.71 0.54-0.95 
Conclusion: Tumors  3 cm with PL1 are correctly 
classiÀed as T2a. VPI is an independent prognostic 
factor in NSCLC. 
Keywords: Visceral Pleural Invasion, Non-small cell 
lung cancer, TNM classiÀcation
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However, the expression pattern and biological role 
of these genes in neuroendocrine tumours of the lung 
(NELT) is largely unknown. In the current study, 
expression levels of EZH2 and BMI1 were evaluated 
in a large panel of NELT, and data were correlated 
to Ki67-expression and clinical features including 
survival. 
Methods: A tissue panel comprising 96 resected 
NELT (50 typical carcinoids (TC), 13 atypical 
carcinoids (AC), 23 large cell neuroendocrine 
carcinomas (LCNEC) and 10 small cell 
lung carcinomas (SCLC)) was assessed by 
immunohistochemisty using monoclonal antibodies 
against EZH2 and BMI1 and scored semi 
quantitatively for the percentage and intensity 
of tumour cells stained on whole tumour slides. 
The correlation of the scores to clinical data was 
analysed. 
Results: High expression of EZH2 was found in 
high grade NELT (LCNEC + SCLC), whereas high 
expression of BMI1 was observed in low grade 
NELT (TC + AC) (p < 0.0001 for EZH2, p = 0.02 
for BMI1). TC fell into two groups of either high 
expression of BMI1 or no expression. A correlation 
between the expression of EZH2 and Ki67 was 
observed (R2 = 0.49, p< 0.001)). In univariate 
analyses EZH2 and BMI1 were predictors for 
survival in all patients (p < 0.0001 for EZH2, p 
= 0.02 for BMI1, whereas multivariate analyses 
revealed TNM stage (p < 0.001) and diagnosis (p < 
0.001) as the only independent predictors of overall 
survival. 
Conclusion: The EZH2 and BMI1 expression 
pattern as measured by immunohistochemistry is 
signiÀcantly different in low versus high grade 
NELT. This difference might relate to NELT 
tumourigenesis. The markers have no independent 
prognostic impact in NELT. Whether EZH2 and 
BMI1 could be target molecules for the development 
of new treatments strategies against NELT remains 
to be elucidated. 
Keywords: EZH2, BMI1, pulmonary 
neuroendocrine tumours, immunohistochemistry
yo [no] versus 53.0 yo [yes], p = 0.0999); and work 
ETS (48.3 yo [no] versus 51.9 yo [yes], p = 0.3493). 
Foreign-born ALK positive patients were generally 
younger than US-born ALK positive patients (45.9 
years vs. 51.1 years; p = 0.6276). The mean cETS for 
foreign-born ALK psoitive patients was lower than 
US-born ALK positive patients (11 years vs. 18.6 
years; p = 0.4599) and is independent of source of 
exposure except work exposure where US-born ALK 
positive patients had lower exposure: childhood (5.0 
years vs. 7.6 years; p = 0.3266), adult (6.0 years 
vs. 11 years; p = 0.6477), home (5.0 years vs. 13.8 
years; p = 0.2052), and work (6.0 years vs. 4.8 years; 
p = 0.7513). 
Conclusion: ALK re-arrangement positive NSCLC 
patients who were never-smokers had low cETS. 
32% of the ALK re-arrangement positive NSCLC 
patients who are never-smokers in our series at the 
University of California Irvine had no cETS. ALK 
re-arrangement positive NSCLC patients who had 
no ETS tend to be younger than their counterparts 
who had any ETS regardless of source of exposure. 
Foreign-born ALK positive patients had lower 
cETS than US-born ALK positive patients and 
is independent of exposure source except work 
exposure where US-born ALK positive patients 
had lower cETS exposure at work. Comparison of 
cETS between ALK positive NSCLC patients and 
cumulative cETS in activating EGFR mutations 
positive patients is ongoing. 
Keywords: environmental tobacco exposure, ALK 
re-arranged NSCLC
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P4.185 DIFFERENT EXPRESSION OF 
EZH2 BMI-1 AND KI67 IN LOW AND 
HIGH GRADE NEUROENDOCRINE 
TUMORS OF THE LUNG
Anna-Louise R.. Bondgaard1, Thomas T. Poulsen1, 
Hans S. Poulsen1, Birgit G. Skov2 
1Department Of Radiation Biology, Copenhagen 
University Hospital/Denmark, 2Pathology, 
Bispebjerg University Hospital/Denmark
Background: The polycomb group genes Enhancer 
of Zeste homolog 2 (EZH2) and B lymphoma 
Mo-MLV insertion region 1 polycomb ring Ànger 
(BMI1) function as transcriptional repressors and 
are involved in the malignant transformation and 
biologic aggressiveness of many human carcinomas. 
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one was inexperienced). . The inexperienced observer 
was chosen to assess the inÁuence of experience and 
to evaluate the learning curve between the two rounds. 
The cytopathologists were asked to make a diagnosis 
on each case based on the MGG stained slide and the 
cytoscrape. For statistical purposes the diagnoses were 
categorized in 5 groups: squamous cell carcinoma, 
adenocarcinoma of the lung, non-squamous cell 
carcinoma, benign lesion and malignancy other than 
the former including metastases from other organs. 
Kappa statistics was applied to test the intra- and inter 
observer reproducibility. 
Results: The reproducibility of the diagnoses in the Àrst 
round was good to very good (kappa 0.57 - 0.71). One 
value was under 0.60 and involved the inexperienced 
observer. We are waiting for the results of round two 
where the intraobserver-reproducibility and the effect of 
the teaching session will also be presented. 
Conclusion: The reproducibility of cytopathologic 
diagnoses with only one MGG stained smear and 
immunohistochemistry on cytoscrape from FNA 
was very good among experienced cytopathologists. 
When only sparse material from FNA is available 
without the possibility to make a clot directly from 
the aspirate, cytoscrape is a new method to achieve 
material for immunohistochemistry, useful for 
making clinical relevant diagnoses, including sub 
typing of non-small cell lung cancer. 
Keywords: cytology, Fine needle aspiration, 
reproducibility, immunohistochemistry
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.187 THE ASSOCIATION OF 
TOPOISOMERASE 2Į EXPRESSION 
WITH CLINICAL, PATHOLOGICAL 
PARAMETERS AND PROGOSIS IN 
SURGICALLY RESECTED NON-SMALL 
CELL LUNG CANCER PATIENTS
Hulya Celenk Erguden1, Deniz Koksal1, Funda 
Demirag2, Hulya Bayiz1, Neslihan Mutluay1, Bahadir 
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P4.186 REPRODUCIBILITY OF 
CYTOPATHOLOGIC DIAGNOSES 
WITH MGG STAINED SMEAR AND 
CYTOSCRAPE FROM FINE NEEDLE 
ASPIRATES WITH EMPHASIS ON SUB 
TYPING OF NON-SMALL CELL LUNG 
CANCER.
Silje Omland1, Henrik Hager2, Karen E. Olsen3, 
Birthe M. Thomsen1, Birgit G. Skov1 
1Pathology, Bispebjerg University Hospital/
Denmark, 2Pathology, Aarhus University Hospital/
Denmark, 3Pathology, Odense University Hospital/
Denmark
Background: Cytologic examination of Àne-needle 
aspiration (FNA) material is being increasingly 
used in the diagnosis of non-small cell lung cancer 
(NSCLC). New treatment modalities make a 
reproducible subdivision of NSCLC necessary. 
A high interobserver agreement in the distinction 
between small-cell lung cancer and NSCLC on 
cytologic material has been demonstrated, but 
the distinction between subgroups of NSCLC is 
difÀcult based on cytological criteria only. A clot 
made directly from the aspirated material has been 
shown efÀcient for immunohistochemical staining. 
However, sometimes the aspirated material is too 
sparse to make a clot and in these cases a new 
method called cytoscrape makes it possible to 
convert cytological material into tissue fragment 
useful for immunohistochemistry. 
Methods: A consecutive series of MGG stained 
smears and cytoscrape from FNA from 79 patients 
with a possible malignant pulmonary inÀltrate or 
metastasis to lymph nodes or liver seen on CT or 
PET of the chest/abdomen were included. Cytoscrape 
material was obtained by gently scraping cells from 
one slide pr case. Cytoscrape clots were made and the 
sections were stained with H&E and a relevant panel 
of immunohistochemical antibodies. These clots are 
often tiny, and the panel of immunohistochemical 
staining must be carefully selected with respect to 
the morphological changes on the smear and the 
clinical history. This was done by an experienced 
cytopathologist not included in the reproducibility 
part of the study. One smear together with the 
immunohistochemical stained cytoscrape slides were 
circulated 2 times (with minimally 2 months between 
the rounds) to a panel of 4 pathologists (3 of the 
observers were experienced cyto/histopathologists and 
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P4.188 THE STATE OF PATHOLOGY 
EXAMINATIONS AFTER RESECTION 
OF LUNG CANCER: A TREND ANALYSIS 
BEFORE AND AFTER QUALITY 
IMPROVEMENT INTERVENTIONS AND 
SUMMARY OF ONGOING PROBLEMS.
Christopher Wang1, Robert A. Ramirez2, Laura E. 
Miller3, Aamer Farooq4, Jeffrey W. Allen2, Alva B. 
Weir5, Allen Berry6, Thomas O’brien7, Francis H. 
Cole8, Raymond U. Osarogiagbon2 
1Internal Medicine, University Of Tennessee Health 
Sciences Center/United States Of America, 2Internal 
Medicine, University Of Tennessee/United States 
Of America, 3Department Of Internal Medicine, 
University Of Tennessee Health Science Center/
United States Of America, 4Medical Oncology, 
Roswell Park Cancer Institute/United States Of 
America, 5Medical Oncology, Memphis Veterans’ 
Affairs Medical Center/United States Of America, 
6Department Of Pathology, Saint Francis Hospital/
United States Of America, 7Pathology, Duckworth 
Pathology Group/United States Of America, 
8Surgery, Memphis Veterans’ Administration Medical 
Center/United States Of America
Background: Pathology Àndings after lung resection 
guides post-operative management of lung cancer. 
The College of American Pathologists (CAP) 
developed a checklist of mandatory report items as 
a quality improvement effort. Our previous analysis 
of a 2004-2007 Memphis lung resection cohort 
revealed major reporting problems: <5% contained 
all the mandatory CAP items; 34% failed to report 6 
crucial items, including pT and pN category; when 
reported, we found inaccuracies in nodal staging, 
for example 15% of reported pN1 cases were 
actually pN2; 12% of reports had no information on 
lymph nodes (pNx). We have shown that patients 
with pNx have a signiÀcantly inferior long-term 
survival than T-category matched patients with 
pN0. Because examination of N1 nodes is primarily 
the pathologist’s responsibility, the proportion of 
lung resection cases with no N1 lymph nodes is 
a pathology quality measure. We discussed our 
Àndings with regional pathologists and hospital 
Cancer Committees in 2008. Quality improvement 
efforts were recommended, including the use of 
report templates and synoptic reports. Here we report 
a preliminary analysis of the early impact of these 
interventions. 
Background: Topoisomerase 2Ơ is a nuclear 
enzyme that alters the topology of DNA. It’s 
essential for normal chromosome segregation during 
cellular division. It’s also a molecular target for 
some antineoplastic drugs. In this study, we aimed 
to investigate the association of topoisomerase 2Ơ 
expression with clinical, pathological parameters and 
prognosis in surgically resected non-small cell lung 
cancer (NSCLC) patients. 
Methods: The study comprised of 100 NSCLC patients 
(91 male/ 9 female) with a mean age of 59.7±10.5 years 
(range 37-78). Patients underwent lobectomy (82%) 
or pneumonectomy (18%) with hilar and mediastinal 
lymph node sampling. Histopathological diagnosis 
was squamous cell carcinoma and adenocarcinoma in 
50 patients each. There were 5 patients with stage 1a, 
28 patients with stage 1b, 21 patients with stage 2a, 21 
patients with stage 2b, 25 patients with stage 3a. The 
parafÀn embedded tumor sections of these pateints 
were retrieved for expression of topoisomerase 2Ơ. 
Nuclear (positive/ negative) and cytoplasmic (weak/ 
moderate/ intense) expression of topoisomerase 2Ơ 
were determined by immunohistochemistry. Clinical, 
pathological data and survival of patients were 
determined from the hospital Àles. Median follow-up 
time was 35 (range:4-120) months.
Results: Nuclear expression of topoisomerase 2Ơ 
was positive in 41 (41%) patients. Cytoplasmic 
expression of topoisomerase 2Ơ positive in 66 
(66%) patients. There were not any signiÀcant 
association between nuclear or cytoplasmic 
expression of topoisomerase 2Ơ and age, gender, 
smoking history (p>0.05). While cytoplasmic 
expression of topoisomerase 2Ơ was not different, 
nuclear expression was signiÀcantly increased in 
squamous cell carcinoma (p=0.008), OR (95%CI): 
3.01 (1.31-6.92). Both nuclear and cytoplasmic 
expression of topoisomerase 2Ơ did not show any 
association with tumor diameter, pathological stage, 
tumor differentiation and presence of relapse. There 
wasn’t any signiÀcant association between nuclear 
or cytoplasmic expression of topoisomerase 2Ơ and 
survival (p>0.05). Tumor diameter (p=0.031) and 
involvement of N2 lymph nodes (p=0.005) were 
independent prognostic factors. 
Conclusion: In conclusion there was no association 
between topoisomerase 2Ơ expression and survival 
in surgically resected NSCLC patients. Nuclear 
expression of topoisomerase 2Ơ was signiÀcantly 
higher in patients with squamous cell carcinoma. 
Keywords: Non-small cell lung cancer, 
topoisomerase 2Ơ, Prognosis
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P4.189 PATHOLOGICAL PROGNOSTIC 
FACTORS OF NON-SMALL CELL LUNG 
CANCER PATIENTS WITH MULTIPLE 
LUNG TUMORS
Joo Young Kim, Hee Jin Lee, Se-Jin Jang 
Department Of Pathology, Asan Medical Center, 
University Of Ulsan College Of Medicine/Korea
Background: In patients with multiple lung cancers, 
distinction of intrapulmonary metastasis and 
independent primary tumors is clinically important 
because it determines staging, prognosis and 
potentially treatment plan. However, the distinction 
is difÀcult on routine histopathologic practice, and 
often requires a series of molecular test for clonality 
analysis. We studied histopathologic prognostic 
factors of multiple lung cancer patients, which 
potentially substitute Martini and Melamed criteria 
and the complex process of the differential diagnosis 
of intrapulmonary metastasis and independent 
primary tumors.
Methods: With 65 patients having multiple lung 
cancers, we analyzed patients’ survival according 
to clinicopathologic parameters, including 
histologic subtypes, size difference between paired 
tumors, location of paired tumors, presence of 
lymphovascular tumor invasion, size of the largest 
tumor, lymph node status, and morphology of tumor 
margin, and immunohistochemical stainings proÀle 
of each tumor.
Results: The mean survivals of the 18 multiple 
primary lung cancer patients and the 47 
intrapulmonary metastasis patients based on Martini 
and Melamed criteria were 53.0±7.4 and 91.0±11.1 
months, respectively (p=0.654), suggesting Martini-
Melamed criteria alone is insufÀcient to predict the 
prognosis. There were no signiÀcant associations 
between the each clinicopathologic parameter and 
the mean survival, except for the size of the largest 
tumor. We evaluated 5 clinicopathologic parameters 
(presence of lymphovascular invasion, presence 
of pushing margin, size difference between paired 
tumors, lobar location of paired tumors, and size 
of the largest tumor over 5cm in diameter) and 
devided into two groups, having at least three of 
Àve parameters and less than three parameters and 
the mean survivals were 49.5±10.9 and 111.5±9.3 
months, respectively (p=0.010). Also we evaluated 
4 histologic parameters, excluding size of the largest 
tumor, known independent prognostic factor, and 
Methods: Retrospective study of pathology 
reports for all lung cancer resections in the 
Memphis Metropolitan Area from January 1, 
2004 to December 31, 2009. We compared the 
comprehensiveness of pathology reports in two eras, 
pre-intervention (2004-2008) and post-intervention 
(2009), by the chi-squared test. 
Results: There were pathology reports from 9 
hospitals. Reportage on speciÀc mandatory CAP 
items was highly variable (Table). Reportage on all 
CAP items increased signiÀcantly from 5.4% in the 
pre-intervention era to 15.4% in the post-intervention 
era (p<0.0001); reportage on the six crucial items 
(denoted by * in table) also increased from 61% to 
83.2% (p<0.0001). When reported, the overall error 
rate in TNM staging was 7.6%. Under-staging errors 
were four times more common than over-staging errors, 
for example 8.1% of pN1 cases were more correctly 
staged as pN2. Nineteen percent of resections had no 
examined N1 lymph nodes; after elimination of sub-
lobar resections (because submitted material may have 
had no intrapulmonary lymph nodes) the N1 lymph 
node examination failure rate was still 11%. 
CAP Checklist Item Reported, N (%) Not Reported, N (%) 
Reported at high frequency 
Specimen type (extent of 
resection)* 
1346 (100) 0 (0) 
Laterality 1344 (99.9) 2 (0.2) 
Histologic type* 1344 (99.9) 2 (0.2) 
Margin status* 1316 (97.8) 30 (2.2) 
Tumor site (ie lobe) 1310 (97.3) 36 (2.7) 
Tumor size* 1309 (97.3) 37 (2.8) 
Direct extension 1277 (94.9) 69 (5.1) 
Reported at intermediate frequency 
Histologic grade 1115 (82.8) 231 (17.2) 
pM-category 1040 (77.3) 306 (22.7) 
Margin distance 945 (70.2) 401 (29.8) 
pT-category* 923 (68.6) 423 (31.4) 
pN-category* 904 (67.2) 442 (32.8) 
Reported at low frequency 
Lymphatic invasion 602 (44.7) 744 (55.3) 
Large vessel invasion 382 (28.4) 964 (71.6) 
Conclusion: Corrective interventions are 
producing early improvement in the completeness 
of pathology reports. Major problems remain, 
including a relatively high rate of failure to examine 
intrapulmonary lymph nodes. Wider adoption of the 
template reporting system should improve the quality 
and accuracy of reports. The need for continuing 
quality improvement measures remains. 
Keywords: quality of care, Pathology reports, 
Staging, CAP checklist items
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and the speciÀcity of thyroid transcription 
factor-1 (TTF1) and CK5/6 on CS as measured by 
immunohistochemistry in SCLC and SQCC and 2) 
to see if improved diagnostic information from FNA 
could be achieved when these markers were applied 
to CS and added to May-Grunwald-Giemsa (MGG) 
stained slides. 
Methods: 78 tumours (63 SCLC and 15 (SQCC) 
from which FNA as well as histologic biopsies were 
available were randomly collected from archives. 
From each aspirate one MGG stained smear was 
processed to obtain a CS by scraping cells of 
the slides. Clots were made and sections were 
immunostained with TTF-1 and CK5/6 together 
with staining of the corresponding biopsies (“gold 
standard”) with the same antibodies. No further 
immunohistochemical reactions were applied, as 
we wanted to see if only two well-tested antibodies 
applied to this scanty material could improve 
the diagnostic information. The utility of the CS 
technique was evaluated by assessing the sensitivity 
and speciÀcity of the method and by quantifying 
improved diagnostic information relative to smear 
alone. 
Results: SCLC: Sensitivity of TTF-1: 0.78 (95% CI 
0.65-0.88). SpeciÀcity of TTF1: 0.80 (95% CI 0.28-
1.00). Sensitivity of CK5/6: 0 (95% CI 0.00-0.71). 
SpeciÀcity of CK5/6: 0.97 (95% CI 0.88-1.00). 
SQCC: Sensitivity of TTF-1: 0 (95% CI 0.00-
0.71). SpeciÀcity of TTF1: 1 (95% CI 0.74-1.00). 
Sensitivity of CK5/6: 0.71 (95% CI 0.42-0.92). ). 
SpeciÀcity of CK5/6: 0 (95% CI 0.00-0.98). The 
diagnoses made on smears were improved by CS in 
4 cases (5.1%), which could be classiÀed as either 
SCLC or SQCC in contrast to “malignant tumor 
NOS” on MGG stained smear. 
Conclusion: Even if only spare material is available, 
immunohistochemical staining with TTF1 and 
CK5/6 on CS allows distinction between SCLC and 
SQCC. For experienced pathologists, the improved 
diagnostic information from these markers is modest 
compared to MGG stained slides only. However, 
the immunohistochemistry on CS can conÀrm the 
diagnosis made on MGG stained smear in difÀcult 
cases. Whether the markers could improve diagnostic 
information in a clinically relevant way for less 
trained pathologists remains to be solved. If enough 
material is available from CS, a panel including 
more antibodies might further improve the diagnostic 
information. 
Keywords: cytoscrape, immunohistochemistry, Fine 
needle aspiration, classiÀcation
devided into two groups, having at least three of 
four parameters and less than three parameters and 
the mean survivals were 49.7±12.4 and 104.0±10.6 
months, respectively (p=0.017). And this grouped 
4 parameter was identiÀed as an independent 
prognostic factor in the patients with 5cm and less in 
size of the largest mass (p=0.022). The differences of 
immunohistochemical staining results of the paired 
tumor were not relevant with the mean survivals 
(p=0.174).
Conclusion: Having at least three parameters 
among the presence of LVI, pushing margin without 
peripheral lepidic pattern, size differences over 
80% between paired tumors, and different lobar 
location of the paired tumors could be considered as 
an independent prognostic factor of multiple lung 
cancer patients with 5cm and less in diameter (size 
of the T2a stage) of the largest mass. 
Keywords: multiple lung cancers, Martini-Melamed 
criteria, clinicopathologic parameters, prognostic 
factors
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P4.190 DIAGNOSIS ON FINE NEEDLE 
ASPIRATION WITH SPARSE MATERIAL: 
HIGH DIAGNOSTIC INFORMATION 
OF CK5/6 AND TTF1 ON CYTOSCRAPE 
IN THE DIAGNOSIS OF SMALL CELL 
LUNG CANCER AND SQUAMOUS CELL 
CARCINOMA
Annette K. Boesen1, Katalin Kiss2, Birgit G. Skov1 
1Pathology, Bispebjerg University Hospital/
Denmark, 2Pathology, Copenhagen University 
Hospital, Rigshospitalet/Denmark
Background: Cytologic examination of Àne-needle 
aspirations (FNA) from the lung and lymph nodes 
in the mediastinum is used increasingly for the 
diagnosis of pulmonary lesions. Correct distinction 
between small cell lung carcinomas (SCLC) and 
non small cell lung cancer is of great therapeutic 
importance. SCLC and squamous cell carcinomas 
(SQCC) are often necrotic tumours and it may be 
difÀcult to separate these tumours on cytologic 
material. FNA often provides insufÀcient material 
to make a clot and is not always diagnostic on 
conventional smears. We describe a method, called 
cytoscrape (CS), which can be used for ancillary 
methods including immunohistochemistry. The 
aim of this study was 1) to assess the sensitivity 
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expression group.
Results: Of all the samples, 12 samples were 
classiÀed as Bmal1-low, and the other 66 were 
classiÀed as Bmal1-high. In like manner, 19 samples 
were classiÀed as Per2-low, and the other 59 were 
classiÀed as Per2-high. Expression of both proteins 
was not correlated with any clinicopathological 
factors. The 5-years overall survival of patients with 
low and high Bmal1 expression was 75% and 43%, 
respectively. On analysis of the relations between 
outcomes and circadian related proteins expression, 
high expression of Bmal1 protein was associated 
with signiÀcant worse outcomes than low expression 
of Bmal1 in stage I (p=0.024). Nevertheless, there 
was no signiÀcant differences between patients with 
Per2-high and low.
Conclusion: Circadian related protein Bmal1 
expression was associated with outcomes of 
surgically resected stage I NSCLC patients.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.192 THE ROLE OF ELASTIC STAINS 
FOR PERIPHERAL LUNG CANCER: IS IT 
MANDATORY?
Koji Kawaguchi, Noriyasu Usami, Toshiki Okasaka, 
Takehiko Okagawa, Haruko Suzuki, Koichi 
Fukumoto, Kohei Yokoi 
General Thoracic Surgery, Nagoya University 
Graduate School Of Medicine/Japan
Background: The 7th edition of the TNM 
classiÀcation for lung cancer has been adopted since 
2009, and some revision including visceral pleural 
invasion (VPI) was made. VPI has been deÀned as 
invasion beyond the elastic layer and upstaged to 
T2, so the use of elastic stains is recommended to 
distinguish between pl0 and pl1. However, because 
elastic stains to assess VPI are not so commonly 
used by pathologists including our institution’s, we 
investigated the role of elastic stains to evaluate VPI 
in comparison with conventional hematoxylin and 
eosin (H&E) stains. 
Methods: From March 2010 to January 2011, 126 
patients underwent pulmonary surgical resection 
for primary lung cancer at our institution. Of them, 
69 tumors which were abut on the visceral pleura 
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P4.191 CLINICOPATHOLOGICAL 
SIGNIFICANCE OF THE CIRCADIAN 
PROTEINS EXPRESSION IN PATIENTS 
WITH NON-SMALL CELL LUNG 
CANCER
Teppei Nishii1, Takashi Oshima2, Taketsugu 
Yamamoto3, Kazue Yoshihara2, Hiromasa Arai1, 
Kenji Inui1, Takeshi Kaneko1, Akinori Nozawa4, 
Munetaka Masuda3, Toshio Imada3 
1Respiratory Disease Center, Yokohama 
City University Medical Center/Japan, 
2Gastroenterological Center, Yokohama City 
University Medical Center/Japan, 3Surgery, 
Yokohama City University/Japan, 4Department 
Of Pathology, Yokohama City University Medical 
Center/Japan
Background: Most life on this planet has biological 
rhythms corresponding to cycle of the earth’s 
rotation. In particular, physiological variables 
that occur in an approximately 24 hour cycle are 
called circadian rhythms. Circadian rhythms are 
controlled by the circadian clock mechanism. 
The molecular mechanism of circadian clock is 
based on the transcriptional feedback loops of core 
circadian genes, Clock, Bmal1, Period (Per1, 2, 
3), Cryptochrome (Cry1, 2), and casein kinase I 
Ƥ (CKIƤ). Recently, it has been reported that the 
circadian clock is related to oncogenesis. Bmal1 was 
shown to be a positive regulator of tumor growth 
and metastasis in cancer. Furthermore, because 
c-Myc expression was increased, the morbidity rate 
of cancer had risen in the Per2 knockout mouse. 
This study examined the relationship of circadian 
related protein, especially in Bmal1 and Per2, 
to clinicopathological factors and postoperative 
outcomes in patients with lung cancer.
Methods: A total of 78 consecutive patients with 
pathological stage I to III non-small cell lung cancer 
(NSCLC) were examined, retrospectively. The 
patients underwent complete tumor resection and 
nodal dissection without any pre-operative therapy. 
We evaluated the expression of the Bmal1 protein 
and the Per2 protein by immunohistochemistry. 
The staining intensity was evaluated as follows: 
grade 1, weak staining; grade 2, moderate stainig 
and grade 3, strong staining. We classiÀed the 
samples categorized into grade1 intensity as the 
low expression group, irrespectively of the cell 
distribution. The others were classiÀed as the high 
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P4.193 ADEQUACY OF TISSUE 
OBTAINED BY SEMIRIGID 
PLEUROSCOPY
Matthew K.Y. Wong1, Sl Fung2, David C. Lam1, 
Terence C. Tam1, Jamie C. Lam1, James Ho1, Mary 
Ip1 
1Medicine, University Of Hong Kong Queen Mary 
Hospital/Hong Kong, 2Tb & Chest Hospital, The 
Grantham Hospital/Hong Kong
Background: For investigation of undiagnosed 
exudative pleural effusion, the use of semirigid 
pleuroscopy is getting more popular among 
pulmonologists as the technique is similar to that of 
a Áexible bronchoscope. Concerns have been raised 
for the smaller size biopsy samples obtained by 
semirigid pleuroscopy when compared with the rigid 
counterpart. However, it is unknown if the smaller 
biopsy size will affect the diagnostic performance. 
Methods: From Dec 2008 to Oct 2010, all 
consecutive cases with undiagnosed exudative 
pleural effusion after nondiagnostic thoracentesis 
(with or without closed pleural biopsy) and referred 
for pleuroscopy were recruited. After obtaining 
written informed consent from the patients, semirigid 
pleuroscopy was performed in a bronchoscopy suite 
under local anaesthesia +/- conscious sedation. 
EfÀcacy was measured by diagnostic yield – tissue 
adequacy for immunohistochemical (IHC) staining 
including cytokeratin, CDX2, TTF-1, calretinin, 
EGFR and EBV-encoded RNA (EBER) analysis 
where appropriate in addition to microbiology. Talc 
poudrage was also performed in the same sitting if 
malignancy was suggested during the procedure. 
Complications would be recorded if there were 
any bleeding, postoperative fever, desaturation, re-
expansion pulmonary oedema, infection related to 
the procedure, persistent air leak and mortality. All 
the procedures were performed by the same operator 
with initial experience in pleuroscopy.
Results: Fifteen patients (12 men) aged 63.9 (range 
35-89) had pleuroscopy performed. Malignancy 
was conÀrmed in 11 patients (73.3%). Among those 
conÀrmed with malignancy, IHC was performed in 
all specimens. The results showed that there were 
7 cases (46.7%) of adenocarcinoma with lung as 
primary origin; 2 cases (13.3%) of adenocarinoma 
with gastrointerestinal origin (13.3%); and 1 case 
each (6.7%) with metastasis from nasopharyngeal 
carcinoma or malignant mesothelioma. For those 
or showed pleural indentations on preoperative 
computed tomography (CT) were re-evaluated using 
Elastic van Gieson stains after the judgement on 
H&E stains by pathologists. 
Results: There were 51 adenocarcinomas, 11 
squamous cell carcinomas, 5 adenosquamous 
carcinomas, and 2 large cell carcinomas. Our 
pathologists assessed 27 tumors at pl0, 28 at pl1, 
10 at pl2, and 4 at pl3 by H&E stains, respectively. 
Under re-evaluations using EVG stains, 12 
specimens were re-classiÀed from pl1 to pl0 (false-
pl1 group) and 1 from pl2 to pl1, whereas 12 tumors 
reconÀrmed pl1 (true-pl1 group). Four specimens 
assessed as pl1 on H&E stains could not be evaluated 
for VPI because of inÁammation. There were 11 
adenocarcinomas (92%) and 1 adenosquamous 
carcinoma in false-pl1 group. In comparison 
between true- and false- pl1 groups, tumor size less 
than 2cm, ground glass opacity ratio more than 
50% on preoperative CT, or well differentiation on 
pathological Àndings were preferable factors in false-
pl1 group, whereas the Ànding of pleural indentation 
was not reliable to differentiate pl0 from pl1 (Table 
1). Table 1. Relationship between pl0 and pl1 
according to some factors 
Factors False-pl1 (pl0) True-pl1 p value 
Tumor size 0-2 cm 6 1 0.079 
2-3 cm 2 4 
3- cm 4 7 
GGO ratio 100-75% 2 0 0.055 
75-50% 3 0 
50-25% 2 1 
25- 0% 5 11 
Pleural indentation yes 7 5 0.414 
no 5 7 
Histology AD 11 9 0.333 
AS 1 1 
SQ 0 2 
Differentiation well 2 0 0.144 
moderate 7 6 
poor 1 4 
Conclusion: We conclude it is difÀcult to evaluate 
VPI and distinguish between pl0 and pl1 with H&E 
stains alone, especially in adenocarcinoma. Elastic 
stains and some factors might help the correct 
assessment for visceral pleural invasion in lung 
cancer. 
Keyword: Visceral Pleural Invasion
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histology obtained by bronchial biopsy. 
Methods: Over a period of 8 months, we 
performed diagnostic Àberoptic bronchoscopy 
in 61 consecutive patients with suspected lung 
cancer (based on clinical data, chest CT-scan and 
evidence of endobronchial lesion) and screened 
for EGFR mutations simultaneously in bronchial 
biopsy specimens and the corresponding bronchial 
lavage, performed right after the biopsy. Exons 18, 
19, 20 and 21 of EGFR gene were analyzed using 
automated sequencing of tumor DNA. Patients with 
early stage disease (IIA and IIB, n=2), small cell 
lung cancer histology (n=8) and those with bronchial 
biopsy not conclusive for malignancy (n=18) 
were excluded. Four cases were also excluded for 
technical procedures reasons. 
Results: A total of 29 non-Asian patients (24 
male, 5 female) with advanced non-small cell lung 
cancer (24,1% on stage IIIB; 75,9% on stage IV) 
were included. Adenocarcinoma was the most 
frequent histological type (65,5%), followed by 
squamous cell carcinoma (27,6%). Twenty-Àve 
patients were current or past-smokers (median 40 
pack-year) and 4 were non-smokers (all female 
patients). EGFR mutation was detected in 5 patients 
(17,2%), both in the bronchial biopsy specimens 
and the corresponding bronchial lavage. All these 5 
patients with positive EGFR mutations (Table 1) had 
adenocarcinoma, being 4 female and 1 male and 40% 
were smokers. These Àve patients presented EGFR 
mutation predictive of response to EGFR TKIs. In 
the remaining 24 patients, EGFR mutation detection 
was negative in both bronchial biopsy and bronchial 
lavage. Table 1- Patients with EGFR mutations, in 
both bronchial lavage and bronchial biopsy 
Patient Age 
(years) 
Gender Smoking 
habits 
Tumor 
Stage 
Tumor Histology Exon EGFR Mutation 
1 53 Male 15 PY IIIB Adenocarcinoma 20 Asn771_His773dup 
2 77 Female Nonsmoking IV Adenocarcinoma 21 Leu858Arg 
3 77 Female Nonsmoking IV Adenocarcinoma 19 Glu746_Ala750del 
4 66 Female 30 PY IV Adenocarcinoma 21 Leu861Gln 
5 70 Female Nonsmoking IV Adenocarcinoma 19 Glu746_ala750del 
PY: pack-year 
Conclusion: This study suggests that both 
cytological sample from bronchial lavage and 
histological sample from bronchial biopsy seem to 
have a comparable sensitivity for EGFR mutation 
detection. 
Keywords: Epidermal growth factor receptor, 
cytology, Non-small cell lung cancer
specimens conÀrmed with lung cancer, tissues 
were all adequate (100%) for EGFR assessment. 
Mutations were found in Exon 19 or 21 in Àve 
patients and wild type in the remaining two patients. 
Talc poudrage was performed in nine patients during 
the same sitting of pleuroscopic examination and all 
of them were conÀrmed malignancy subsequently. 
All except two patients had complete control (no 
reaccumulation of Áuid on X-ray) three months 
afterwards. Three patients were conÀrmed to have 
tuberculosis pleurisy. Only one patient received non-
speciÀc diagnosis after pleuroscopy. He remained 
asymptomatic with no recurrence of pleural effusion 
after a year of follow-up. The overall diagnostic 
yield was 93.3%, with the assumption that patient 
with no speciÀc diagnosis was false negative. No 
complications were detected. 
Conclusion: Semirigid pleuroscopy was found to 
have high diagnostic yield with adequate tissue 
showing the origin of malignancy and for EGFR 
analysis. It is a safe procedure and even suitable for 
operator with initial experience.
Keywords: Semirigid pleuroscopy, Lung cancer
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P4.194 COMPARISON BETWEEN 
EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATIONS IN CYTOLOGY 
AND HISTOLOGY SAMPLES OF 
ADVANCED NON-SMALL CELL LUNG 
CANCER
Sandra Saleiro1, João Bento1, Teresina Amaro2, Ana 
Peixoto3, Manuel Teixeira3, Luís Rocha1 
1Pulmonology, Portuguese Oncology Institute - 
Porto/Portugal, 2Pathology, Portuguese Oncology 
Institute - Porto/Portugal, 3Genetics, Portuguese 
Oncology Institute - Porto/Portugal
Background: Somatic mutations in the epidermal 
growth factor receptor (EGFR) occur in ~10% of 
non-small cell lung cancer and are correlated with 
increased response to treatment with EGFR tyrosine 
kinase inhibitors (TKIs). Until now, most the studies 
required tumor tissue for mutation screening, 
because testing cytological samples can pose some 
problems, such as sparse cellularity or interference 
from non-malignant cells within the sample. The 
aim of this study was to determine whether or not 
cytology specimen obtained by bronchial lavage is 
suitable for EGFR mutation, in comparison with 
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*PT = paratracheal, SC = subcarinal, H = hilar 
lymph node groups. 
Conclusion: This analysis demonstrates that in our 
institution EBUS has become an important part of 
locoregional diagnosis and staging of lung cancer. 
Over the four years since its introduction the uptake, 
precision and scope of EBUS lymph node biopsy has 
expanded and is set to provide the material for the 
molecular analysis now regarded as fundamental in 
lung cancer management. 
Keyword: EBUS, lymph node, molecular
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P4.196 A PILOT EXTERNAL QUALITY 
ASSURANCE SCHEME FOR SOMATIC 
EGFR MUTATION TESTING IN NON-
SMALL CELL LUNG CANCER
Simon Patton1, Erik Thunnissen2, Samuel Murray3, 
Susana Benlloch4, Rachel Butler5, Manfred Dietel6, 
Martin Filipits7, K M. Kerr8, Nicola Normanno9, 
Sanjay Popat10, Andrew Wallace1, Ralf Stahel11, 
Miquel Taron12, Fiona Blackhall13 
1Genetic Medicine, Central Manchester Healthcare 
Trust/United Kingdom, 2Pathology, Vumc/
Netherlands, 3Oncology, Genekor/Greece, 4Pangaea 
Biotech, Dexeus University Institute/Spain, 5All 
Wales Medical Genetics Service/United Kingdom, 
6University Of Berlin/Germany, 7Cancer Research 
Center, Medical University/Austria, 8Aberdeen 
Hospital/United Kingdom, 9Int-Fondazione Pascale, 
Naples/Italy, 10National Heart And Lung Institute, 
Imperial College/United Kingdom, 11University 
Hospital Zürich/Switzerland, 12Oncology, Catalan 
Institute Of Oncology, Hospital Germans Trias I 
Pujol/Spain, 13Medical Oncology, Christie Hospital/
United Kingdom
Background: The clinical signiÀcance of somatic 
epidermal growth factor receptor (EGFR) gene 
mutations in non-small cell lung cancer (NSCLC) is 
now established. Testing for EGFR gene mutations 
is routine for the diagnosis and treatment of lung 
cancer. External Quality Assurance (EQA) is deÀned 
by the WHO as ‘a system of objectively checking 
laboratory results by an external agency’. The main 
objective is to establish inter-laboratory consistency. 
The process establishes, harmonises and standardises 
best practice in correctly identifying mutation(s), 
interpretation of the results and clerical accuracy. 
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P4.195 EBUS IN PRIMARY LUNG 
CANCER
Emily Stone1, Amanda Goldrick2, Rebecca Pearson1, 
Andrew Field3, Marshall Plit1 
1Thoracic Medicine, St Vincent’s Hospital/Australia, 
2Medical Oncology, St Vincent’s Hospital/Australia, 
3Anatomical Pathology, St Vincent’s Hospital/
Australia
Background: EBUS is becoming standard practice 
in the workup of lung cancer. In expert hands, 
multiple passes can yield precise and adequate 
material for diagnosis and staging, including 
sufÀcient material for molecular analysis. In this 
analysis of three years single-institutional experience 
with EBUS the number of passes, nodes sampled and 
cytological yield are reviewed. 
Methods: EBUS-TBNA was performed under 
sedation using a curved linear scanning ultrasound 
endoscope (BF-UC160F-0L8, Olympus Corporation, 
Japan). Ultrasound-guided transbronchial needle 
aspirations were undertaken using a 22-gauge Àne 
needle (EBUS-needle; NA-201SX-40122, Olympus) 
with on site cytological assessment. Data for analysis 
was retrieved from a dedicated EBUS procedural 
database, anatomical pathology records and the 
institutional thoracic oncology multidisciplinary 
team (MDT) database. 
Results: EBUS was introduced into our institution 
in 2007. This analysis included cases from 2008 
to 2010. The total number of cases of lung cancer 
conÀrmed by EBUS was 69 from 207 procedures 
in total. There was an almost 3-fold increase in the 
number of lung cancers diagnosed using EBUS over 
this period. By 2010 the majority of new lung cancer 
cases discussed at our thoracic oncology MDT had 
a positive diagnosis made by EBUS. The average 
number of passes in total increased substantially 
and the more difÀcult hilar sampling increased Àve-
fold. Recent false negative rates were less than 3%. 
Review of pathology records indicates sufÀcient 
material is available for molecular analysis in the 
majority of cases. Table 1. Results from cases of lung 
cancer conÀrmed with EBUS lymph node sampling. 
Year No. of cases Cases per nodal group Average passes/case 
PT* SC* H* 
2008 12 9 4 2 4.5 
2009 24 14 12 5 4.3 
2010 33 21 16 10 5.6 
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P4.197 UTILITY OF NON-SURGICAL 
DIAGNOSTIC SPECIMENS IN 
CELLULAR DIFFERENTIATION AND 
GENETIC PROFILING OF NON-SMALL 
CELL LUNG CANCER
Amr S. Albanna1, Goulnar Kasymjanova2, Chantal 
Robitaille2, Victor Cohen3, Guilherme Brandao4, 
Carmela Pepe2, David Small2, Jason Agulnik2 
1Respiratory Medicine, Montreal Chest Institute/
Canada, 2Division Of Pulmonary Diseases, 
Jewish General Hospital/Canada, 3Department 
Of Oncology, Jewish General Hospital/Canada, 
4Department Of Pathology, Jewish General Hospital/
Canada
Background: Until recently, the management 
of lung cancer was based predominantly on the 
classiÀcation of small vs. non-small cell lung cancer 
(NSCLC). However as treatments for NSCLC 
become increasingly personalized, the cellular 
differentiation and genetic proÀle of the tumor is 
becoming essential for the selection of appropriate 
treatment regimens. The utility of different non-
surgical specimens for the accurate determination 
of molecular and histologic subtypes of NSCLC has 
yet to be established. Our objective is to determine 
and compare the yield of non-surgical specimens for 
the accurate cellular differentiation of NSCLC and 
analysis of epidermal growth factor receptor (EGFR) 
mutation.
Methods: This retrospective cohort study included 
all patients with a histologic diagnosis of NSCLC 
from January 2004 to September 2010. Information 
including histologic subtypes and EGFR mutation 
analysis was extracted from the pulmonary oncology 
database. Diagnostic specimens were divided into 
pathology specimens (PS) and cytology specimens 
(CS). PS included surgical and non-surgical 
biopsies. CS included Àne needle aspirate (FNA) 
(i.e. transbronchial (TBNA) and transthoracic needle 
aspirates (TTNA)) and body Áuid samples. These 
groups were compared using c2 analyses. Yield of 
histologic analysis was compared in a subgroup 
of patients who underwent both surgical and non-
surgical procedures.
Results: Among the 715 included patients, 270 
were investigated for EGFR mutation status. The 
yield of CS, when compared with PS, was lower for 
cellular differentiation (76% vs. 91%, p <0.0001), 
immunohistochemistry (IHC) (70% vs. 89%, p 
The European Molecular Genetics Quality Network 
(EMQN; www.emqn.org) is an independent, not-
for-proÀt EQA scheme organiser that runs 28 EQA 
schemes for 850 laboratories around the world. 
The EQA process can identify systematic errors in 
methodology that may not be revealed by internal 
QA processes. The European Society for Pathology 
(ESP), The European Thoracic Oncology Platform 
(ETOP) and the European Society of Medical 
Oncology (ESMO) with other leading European 
groups are collaborating with the EMQN in a pilot 
EQA scheme for EGFR. 
Methods: The EQA process does not specify the 
methodology to be used for genotyping. Samples 
generated from cell lines are validated by 5 
laboratories and then provided to 30 laboratories 
participating in the pilot. Each sample is supplied 
with a mock clinical case. Participating laboratories 
register with the EMQN, perform DNA extraction 
and analysis using their usual method, and are 
requested to submit their results within a 4 week 
timeframe. The anonymised results are assessed 
and made available to all participants in order to 
enable comparisons between laboratories and assess 
individual laboratory performance.
Results: Following two meetings in 2010 a 
consensus was reached for the pilot phase and for 
the preparation of EQA materials using cell lines 
embedded in parafÀn. It was agreed that the EQA 
would also include a pathology review component to 
allow assessment of the tumour cell content in each 
test sample.
Conclusion: The pilot EQA scheme brings together 
the expertise of pathology (ESP) with genetics 
(EMQN) and lung cancer clinicians and scientists 
(ETOP, ESMO, AIOM). It is envisaged that the 
pilot will expand in Q4 2011 to a scheme that will 
be open to laboratories worldwide. There will be 
no restriction on the type of participant laboratory. 
The scheme and the lessons learned from it will 
serve as a paradigm for schemes of other clinically 
relevant somatic gene mutations. The collaborators 
are also integrated with ESP and UKNEQAS 
providers of EQA for K-RAS, C-KIT and EGFR. 
Robust EQA will harmonize reporting and analytical 
practices which should ultimately beneÀt patients 
diagnosed with NSCLC, and be transferrable to 
future mutational testing. The results of the Àrst pilot 
scheme will be discussed. 
Keywords: EGFR, Quality Assurance, Genetic 
testing
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cell lines, and to clarify the clinicopathological 
characteristics of IGBP1 expression in human lung 
adenocarcinoma.
Methods: We obtained 22 specimens of atypical 
adenomatous hyperplasia (AAH), 96 specimens of 
small adenocarcinomas less than 2 cm in diameter, 
and 10 specimens of organizing pneumonia. Using 
these specimens, we examined the expression levels 
of IGBP1 and PP2Ac by immunohistochemistry, and 
compared the results with the clinicopathological 
data for each case.
Results: No immunostaining for IGBP1 was evident 
in organizing pneumonia and AAH (0/32; 0%), but 
IGBP1 immunostaining was evident in 26.7% (8/30) 
of non-invasive carcinomas with lepidic growth and 
in 80.4% (37/46) of invasive adenocarcinomas with 
lepidic growth. All of the small adenocarcinomas 
showing a non-lepidic growth pattern were positive 
for IGBP1 (20/20, 100%). The IGBP1 positivity 
rate increased during the course of sequential cancer 
progression. All of the cases showing lymphatic 
permeation, vascular invasion, pleural invasion or 
lymph node metastasis were positive for anti-IGBP1. 
Furthermore, all cancers that proved ultimately fatal 
were positive for anti-IGBP1.Log-rank analysis 
showed that IGBP1 positivity was signiÀcantly 
correlated with a poor outcome. In contrast, organizing 
pneumonia, AAH and all lung adenocarcinomas were 
uniformly positive for anti-PP2Ac.
Conclusion: We have demonstrated that IGBP1 
is expressed universally in advanced lung 
adenocarcinomas, and that its overexpression is 
signiÀcantly related to outcome.
Keywords: IGBP1, PP2Ac, small lung 
adenocarcinoma
<0.0001), and EGFR mutation status (74% vs. 
93% p < 0.0001). Among the CS, TTNA provided 
better yield than TBNA for cellular differentiation 
(89% vs. 67%, p < 0.0001), IHC (85% vs. 72%, p 
= 0.023), and EGFR mutation analysis (90% vs. 
70%, p = 0.045). Body Áuid samples were least 
likely (59%) to provide EGFR mutation status. 94 
patients underwent both surgical and non-surgical 
procedures. As compared to surgical biopsies, 
the yield of non-surgical procedures for cellular 
classiÀcation was 81% in body Áuid samples, 68% in 
FNA, and 88% in non-surgical biopsies. 
Conclusion: TTNA provided high yield for 
both molecular and histologic analyses. Cellular 
differentiation of NSCLC is satisfactory with 
cytology specimens, however body Áuid samples had 
poor yield for EGFR mutation analysis in our patient 
population. Further prospective studies are needed to 
conÀrm our Àndings. 
Keywords: Lung cancer, cytology, cellular 
differentiation, EGFR
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P4.198 IMMUNOGLOBLIN BINDING 
PROTEIN 1 (IGBP1) IS A KEY 
PROTEIN RELATED TO ANTI-
APOPTOTIC ACTIVITY IN LUNG 
ADENOCARCINOMA
Shingo Sakashita1, Dongping Li1, Keisei Tachibana2, 
Yuko Minami1, Tsutomu Yoshida1, Taiki Sato1, Yukio 
Morishita1, Masayuki Noguchi1 
1Department Of Pathology, Graduate School Of 
Comprehensive Human Sciences, University Of 
Tsukuba/Japan, 2Univercity Of Kyorin/Japan
Background: Lactoferrin (Lf) is an iron-binding 
protein that plays an important role in cancer 
prevention by inducing apoptosis. After exposure to 
bovine Lf (bLf), several lung adenocarcinoma cell 
lines, including PC-14, show apoptotic change. To 
investigate the molecular mechanism of apoptosis 
induced by bLf, a major Lf-binding protein was 
screened using a protein microarray with bLf protein 
as the probe. This yielded immunoglobulin (CD79a) 
binding protein 1 (IGBP1), which binds speciÀcally 
with bLf. IGBP1 is a 36-kDa protein that interacts 
with protein phosphatase 2A, thus exerting an 
anti-apoptotic effect in various human carcinomas. 
The aim of the present study was to conÀrm the 
functional activity of IGBP1 in lung adenocarcinoma 
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40% presented with metastatic disease and 25% had 
squamous histology). Between March and December 
2010, 2104 requests were received for EGFR 
mutation testing. All patients had non-squamous 
histology. Demographic details are as follows: 
adenocarcinoma (91.6%); Asian ethnicity (13.9%); 
female (58%); light/never smoker (41.3%); stage 
IV disease (87.1%). In the Àrst 2 months 225 tests 
were requested. The number of tests requested in 
each subsequent 2 month period increased from 439 
– 496. 1998 samples were received by the labs and 
results were pending in 82 patients. Mutation testing 
was conducted in 1771 patients. The median time to 
get samples to the reference laboratories was 7 days 
(sd 9.6 d), median time to complete testing 11 days 
(sd 5.5 d) and median total test time 18 days (sd 9.7 
d). Some variability was observed across provinces, 
primarily in the time taken to get samples to the 
reference laboratories. GeÀtinib was prescribed in 
302 (17.1%) patients. Mutation rates were highest 
in those of Asian ethnicity (45.3%), followed by 
light/never smoker (27.9%), female sex (20.3%) 
and adenocarcinoma histology (17.5%). There 
was signiÀcant variation across the provinces in 
EGFR mutation rate: BC (20.1%); AB (18.7%); ON 
(16.7%); QC-Jewish General Hospital (12%): and 
QC- Centre de Lutte Contre le Cancer du CHUM 
(13.8%, p<0.001).
Conclusion: There was rapid uptake of EGFR 
mutation status into routine clinical practice 
in Canada. Patient demographics suggest that 
oncologists are adopting a selective approach to 
testing using clinical characteristics to select patients. 
However, the time to receive test results was nearly 
3 weeks which might limit uptake in certain patient 
groups. Expansion in the number of testing centres 
might further increase uptake.
Keywords: Non small cell lung cancer, EGFR 
mutation testing, geÀtinib, Àrst line therapy
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P4.200 CARCINOEMBRYONIC ANTIGEN 
STAINING PATTERN RELATE WITH 
SUBTYPES OF PATHOLOGICAL STAGE 
IA PULMONARY ADENOCARCINOMA
Tomoyuki Nakagiri1, Noriyoshi Sawabata1, Eiichi 
Morii2, Masayoshi Inoue1, Yoshiki Kadota1, Soichiro 
Funaki1, Yuko Ohno3, Meinoshin Okumura1 
1Department Of General Thoracic Surgery, Osaka 
University Graduate School Of Medicine/Japan, 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.199 IMPLEMENTATION OF A 
NATIONAL EGFR TESTING STRATEGY 
IN A PUBLICLY FUNDED HEALTH 
SYSTEM
Peter M. Ellis1, Sunil Verma2, Sandeep Sehdev3, 
Jawaid Younas4, Natasha Leighl5 
1Faculty Of Health Sciences, Mcmaster University/
Canada, 2Division Of Medical Oncology, University 
Of Toronto/Canada, 3Medical Oncology, William 
Osler Health Centre/Canada, 4Medical Oncology, 
London Regional Cancer Centre/Canada, 5Princess 
Margaret Hospital/Canada
Background: Data from Àve recent randomized 
clinical trials have demonstrated that EGFR mutation 
status is predictive of improved PFS and quality of 
life from Àrst-line EGFR TKI therapy compared 
with platinum-based chemotherapy. However, 
the preferred strategy in patients who are EGFR 
wildtype would be platinum-based chemotherapy. 
These results have had a signiÀcant impact on 
clinical practice making testing for the presence of 
EGFR mutations standard of care for patients with 
advanced non-small cell lung cancer. When geÀtinib 
received regulatory approval in Canada in January 
2010, no mechanism for EGFR mutation testing was 
in place. A national EGFR mutation testing program 
supported by AstraZeneca Canada was launched 
in March 2010. This study reports on the uptake of 
EGFR mutation testing in the initial 10 months of 
this program. 
Methods: Five laboratories across Canada 
underwent a validation and quality control 
exercise for EGFR mutation testing using RT-
PCR. Subsequently samples were sent to these 
5 laboratories for testing. Oncologists registered 
patients for EGFR mutation testing using a web 
based platform. Basic demographics were collected 
including age, histology, sex, smoking status, and 
ethnicity. The decision to prescribe geÀtinib was 
subsequently registered on the system.
Results: We estimate there were 5600 cases of 
NSCLC that were potentially suitable for EGFR 
mutation testing diagnosed in Canada in 2010 
(assuming 85% of all cases had NSCLC histology, 
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Conclusion: CEA staining pattern related 
with morphological appearance, and that is an 
independent and signiÀcant prognostic factor for 
p-stage IA pulmonary adenocarcinoma.
Keywords: CEA, immunohistochemical pattern, 
stage IA, lepidic component in adenocarcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.201 ASSOCIATION OF KRAS 
MUTATION IN NON SMALL CELL LUNG 
CANCER AND 18F-FDG UPTAKE IN PET/
CT
Tania Labiano1, Carlos Caicedo2, Maria José García-
Velloso3, Jose luis Perez-Gracia4, Luis M. Seijo5, 
Jose I. Echeveste6, Maria D. Lozano1 
1Pathology, University Of Navarra Clinic/Spain, 
2Nuclear Medicine, University Of Navarra Clinic/
Spain, 3Nuclear Medicine, Clínica Universidad De 
Navarra/Spain, 4Oncology, University Of Navarra/
Spain, 5Respiratory Medicine, University Of 
Navarra/Spain, 6Pathology, University Of Navarra/
Spain
Background: Mutation of the KRAS gene is one 
of the most important events in carcinogenesis of 
the lung. We hypothesize that there exists relation 
between KRAS mutation status and 18F-FDG 
uptake in non-small cell lung cancer (NSCLC). This 
retrospective study was performed to evaluate a 
possible association between the presence of KRAS 
mutation and 18F-FDG uptake in these patients. 
Methods: We included 52 NSCLC (35 M, 17 F, 
mean age 60.46±10,67) at the time of diagnosis 
who were tested for KRAS mutations by direct 
sequencing using DNA obtained from cytological 
samples, and who underwent staging PET/CT. The 
association of KRAS mutation status with patient 
characteristics, maximum standardized uptake value 
(SUVmax) by the primary tumor, lymph nodes and 
metastasis from the 18F-FDG PET was evaluated.
Results: KRAS mutations were identiÀed in 22 
(42%) smoker patients, 16 male and 6 female. Seven 
never smoker and 23 ever smoker patients had no 
mutation (23% versus 77%). There was a statistically 
signiÀcant association between smoking and KRAS 
mutation (p = 0.01). The SUVmax ranged from 
2Departments Of Pathology, Osaka University 
Graduate School Of Medicine/Japan, 3Department 
Of Mathematical Health Promotion Science, Osaka 
University Graduate School Of Medicine/Japan
Background: Carcinoembryonic antigen (CEA) 
is a prognostic indicator for various carcinomas. 
Several studies about colon cancer have reported 
that the CEA immunohistopathological staining 
pattern of tumors was strongly related with patient 
prognosis, with similar Àndings reported for clinical 
stage I (c-stage I) pulmonary adenocarcinoma. 
Recently, lepidic pattern tumor in histopathological 
analysis has been reported to be useful in diagnosis 
of adenocarcinoma in situ. In addition, some gene 
mutations, such as K-ras and epidermal growth 
factor receptor (EGFR), have been the focus of 
interest as a prognostic factor and a pathogenesis of 
lung cancer. We conducted an observational study of 
CEA staining patterns in patients with pathological 
stage IA pulmonary adenocarcinoma, to investigate 
a signiÀcant relation with lepidic component and the 
gene mutations.
Methods: We assessed 103 patients, who were 
completely resected for pathological stage IA 
(p-stage IA) lung adenocarcinoma at Osaka 
University from January 1993 to December 2002. 
CEA staining patterns were classiÀed as apico-
luminal (AL) or diffuse-cytoplasmic (DC), and 
patient survival of the groups. Morphological 
classiÀcations based on lepidic component and gene 
mutations were compared with the CEA staining 
pattern.
Results: AL was observed in 33 patients and DC 
in 70 patients with 5-year survival rates of 96.7 and 
86.4%, respectively (p=0.022). adenocarcinoma in 
situ and minimally invasive adenocarcinoma (AIS) 
was observed in 8 patients, lepidic predominant 
invasive adenocarcinoma (LPIA) was observed in 
12 patients, and non-lepidic predominant invasive 
adenocarcinoma (non-LPIA) was observed in 83 
patients, with 5-year survival rates of 100, 66.7, 
and 92.3%, respectively (p=0.0011; LPIA vs. non-
LPIA). The relation between CEA staining pattern 
and lepidic component was signiÀcant on Ƶ2 test 
(p=0.0085). There was no signiÀcant relation 
between CEA staining pattern and gene mutations 
on Ƶ2 test (p=0.761). Cox proportional hazard model 
revealed that the morphological classiÀcation and the 
CEA staining pattern had a statistical independence 
and signiÀcance in this cohort on multivariate 
analysis (p=0.0006, p=0.0363, respectively).
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presence of EGFR mutation was determined in the 
histologic sample of the primary tumour of all the 
patients with advanced NSCLC with diagnosed at the 
three centers from July 2009 to December 2010. The 
mutation detection methods were: direct sequencing 
(39,5%) and PCR with Thera Screen kit®(60,5%).
Results: A total of 118 patients were included in 
this trial with a median age of 67 (35-76) years. All 
patients were Chilean. The distribution of histology 
was: adenocarcinoma 80,5%, NOS carcinoma 9,3%, 
large cell carcinoma 7,6% and other histologies 
2,6%. In 8,4 % of patients the sample was 
insufÀcient for DNA analysis. The EGFR mutation 
was determined in the remaining 91,6% samples, 
a total of 108. In 24 patients (22,2%) the EGFR 
mutation was positive. Fourteen patients (58,4%) 
had exon 19 deletion, and ten patients (41,6%) had 
21 exon L858R mutations. Fifteen patients (62,5%) 
were female and 9 (37,5%) were men. In females, 
the exon 21 L858R mutation was more frequent 
(53,3% vs 46,7% exon 19 deletion). In men, the 19 
exon deletion was more frequent (77,8% vs 22,2% 
exon 21 L858R mutation). 
Conclusion: In this sample of the Chilean NSCLC 
population the detected incidence of activating 
EGFR mutation (22,2%) was superior to the 
reported incidence for Europe and USA. Further 
studies in larger samples accross Chile would be 
needed to conÀrm this difference which could be 
due to geographic variability in NSCLC biologic 
behaviour. The knowledge of the molecular proÀle of 
NSCLC in Chile would be useful to guide the design 
and implementation of therapeutic guidelines and 
rationalize the use of expensive therapeutic resources 
such as tirosine-kinase inhibitors.
Keywords: NSCLC, exon 19 deletion and exon 21 
L858R mutation, EGFR mutation, Chile
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P4.203 CHARACTERISATION OF 
TRANSCRIPTION FACTORS IN ASIAN 
PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
Ross Soo1, Bhavin Thakkar2, Min En Nga3, Yin 
Huei Pang3, Marie Loh2, Byoung-Chu Cho4, Susumu 
Kobayashi5, Dan G. Tenen2, Richie Soong2 
1Haematology-Oncology, National University 
Hospital/Singapore, 2Cancer Science Institute 
Of Singapore, National University Of Singapore/
Singapore, 3Pathology, National University Hospital/
1.35 to 31.02 (9.67±5.42). The 18F-FDG uptake 
was higher in KRAS-mutated primary tumors 
(SUVmax=11,55±6,72) than in wild-type tumors 
(SUVmax =8,29±3,78) and the differences were 
statistically signiÀcant (p=0.03). Nodal metastases 
were observed in 42 patients. 18F-FDG uptake in the 
lymph nodes was higher in KRAS-mutated primary 
tumors (SUVmax=9,15±5,78) than in wild-type 
tumors (SUVmax=6,19±3,12) and differences were 
statistically signiÀcant (p=0.04). Distant metastases 
were observed in 33 patients and SUVmax was 
higher in patients with KRAS-mutated primary 
tumors (SUVmax=8,90±4,95) than in those with 
wild-type tumors (SUVmax=6,96±2,49) but without 
statistically signiÀcant differences. 
Conclusion: Among western patients with advanced 
lung cancer, those smokers, men and with higher 
SUVmax on primary and nodal metastases in 
18F-FDG PET/CT are more likely to carry KRAS 
mutations. 18F-FDG uptake might be helpful to 
discriminate patients who harbor KRAS mutations.
Keywords: KRAS mutation, Non small cell lung 
cancer, 18F-FDG PET/CT
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P4.202 NON SMALL CELL LUNG 
CANCER(NSCLC) WITH ACTIVATING 
EGFR MUTATION IN CHILE
Osvaldo Aren1, Conrado Vogel2, Eric Orellana3, 
Sergio Kleinmann2, Mauricio Fica4, Humberto 
Cerda1, Claudio Suarez4 
1Servicio De Oncologia Medica, Instituto Nacional 
Del Cancer/Chile, 2Servicio De Oncologia Medica, 
Clinica Alemana/Chile, 3Servicio De Oncologia 
Medica, Clinica Santa Maria/Chile, 4Cirugia 
Toracica, Clinica Santa Maria/Chile
Background: The presence of activating EGFR 
mutations is a well recognized prognostic factor 
with therapeutic implications in NSCLC. Several 
trials have shown the incidence of this mutation 
to be geographically variable. In this context, it is 
interesting to determine the incidence of EGFR 
mutations in NSCLC in the Chilean population.
Methods: We conducted a descriptive, prospective 
exploratory trial to determine the incidence 
of activating EGFR mutations in the NSCLC 
population in 3 cancer centers in Santiago de Chile. 
The centers were: Instituto Nacional del Cáncer, 
Clínica Alemana and Clinica Santa María. The 
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intriguing and further studies are needed to conÀrm 
this relationship. 
Keywords: CEBP alpha, transcription factors, tissue 
array, Non small cell lung cancer
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P4.204 SOX2 OVEREXPRESSION IN 
PULMONARY SQUAMOUS CELL 
CARCINOMA ASSOCIATED WITH 
INTERSTITIAL PNEUMONIA
Takeshi Fujii1, Kazuma Kishi2, Tadasu Kohno3, 
Kenichi Ohashi1 
1Department Of Pathology, Toranomon Hospital/
Japan, 2Department Of Respiratory Medicine, 
Respiratory Center, Toranomon Hospital/Japan, 
3Department Of Thoracic Surgery, Toranomon 
Hospital/Japan
Background: Sex determining region Y-box 2 
(SOX2) is a transcription factor gene located at 
chromosome 3q26, the most often ampliÀed segment 
in squamous cell carcinomas, and is considered to 
be a potential cell-lineage gene highly expressed in 
the pathogenesis of squamous cell carcinomas of the 
lung.
Methods: We examined SOX2 expression by 
immunohistochemistry in 46 non-small cell 
carcinomas surgically resected from patients with 
interstitial pneumonia. The patients were 38 men and 
eight women, ranging from 38 to 83 (median 72) 
years old. Anti-SOX2 (D6D9) XP rabbit monoclonal 
antibody (Cell Signaling Technology, Danvers, MA) 
was used at 1:50 for immunohistochemistry, which 
was performed on an automated Ventana BenchMark 
XT system using an iView DAB detection kit after a 
heat-mediated antigen retrieval procedure.
Results: We observed an abnormal nuclear 
accumulation of SOX2 protein in six cases (22.2%) 
of 27 squamous cell carcinomas, but not in non-
squamous lung carcinomas (16 adenocarcinomas, 
1 adenosquamous, 2 large-cell neuroendocrine 
carcinomas) or non-neoplastic various tissues. 
SOX2 overexpression tends to be observed in heavy 
smokers (SOX2+: 750-3660 (mean 1536) cigarette-
years; SOX2-: 0-2400 (mean 953) including Àve 
non-smokers). The presence or absence of SOX2 
ampliÀcation is currently being evaluated by 
Áuorescent or chromogenic in situ hybridization 
using BAC DNA probes.
Conclusion: SOX2 overexpression was observed 
Singapore, 4Division Of Medical Oncology, Yonsei 
Cancer Center/Korea, 5Medicine, Beth Israel 
Deaconess Medical Center/United States Of America
Background: The transcription factors CCATT/
enhancer binding protein alpha (C/EBPƠ), 
hepatocyte nuclear factor3ơ (HNF3ơ, FOXA2) and 
thyroid transcription factor-1 (TTF-1) are involved in 
lung morphogenesis and also have a putative role in 
non-small cell lung cancer (NSCLC) with C/EBPƠ 
and HNF3ơ acting as tumor suppressors and TTF-1 
as an oncogene. The epidemal growth factor receptor 
(EGFR) is frequently overexpressed in NSCLC and 
EGFR mutations are more frequent in East Asian 
patients. The relationship between C/EBPƠ and the 
other transcription factors and EGFR mutations has 
not been previously described. 
Methods: A tissue microarray (n=164) was 
constructed from patients with resected NSCLC and 
slides were stained by immunohistochemistry (IHC) 
with antibodies against CEBPƠ, HNF3b, TTF-1, and 
the two most common EGFR mutations (exon19 
deletion and exon 21 L858R). IHC staining intensity 
was independently scored by two pathologists 
blinded to patient factors. A categorical value of 
positive vs negative was used for statistical analyses 
of marker expression. The association between 
CEBPƠ intensity and clinicopathologic factors, 
survival and with HNF3b, TTF-1 expression, and 
EGFR mutation status was analysed. The likelihood 
ratio test and Fisher’s exact test was used where 
appropriate. Kaplan-Meier curves and log-rank test 
was used to compare the overall survival between 
groups. 
Results: The median age was 64 years with the 
majority of patients being male (69%) and Chinese 
(85%). The commonest histologic subtype was 
adenocarcinoma (68%) and most were AJCC stage I 
disease (54%). Loss of CEBPƠ expression was seen 
in 63% of cases and was associated with advanced 
stage disease (p=0.023). No signiÀcant association 
was seen between CEBPƠ expression and any other 
clinicopathological features or with overall survival. 
CEBPƠ was associated with the TTF-1 (p<0.001) 
and HNF3ß expression (p<0.001) and was possibly 
associated with EGFR mutation status (p=0.07). 
Conclusion: Absent CEBPƠ expression was 
similar to previous reports and was associated 
with late stage disease. Unlike previous reports, 
we found no association with histological subtype 
or tumor differentiation. The possible association 
between CEBPƠ expression and EGFR mutations is 
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Ultrastructural Pathol 2009;33:6-15). Electron 
microscopic features of myoÀbroblasts were 
quantiÀed systematically. 
Results: The cells cultured from lung cancer tissue 
were mixture of Àbroblasts and myoÀbroblasts. 
The amount of Àbroblasts and myoÀbroblasts 
varied highly in different patients. Typical features 
of myoÀbroblasts were detectable in the cells by 
electron and immunoelectron microscopy, such as 
a-SMA positive strands in the cell cytoplasm and 
extracellular Àbronectin-containing structures on the 
surface of the myoÀbroblast. Many cases exhibited 
adherens-junction like cell junctions between cells. 
Conclusion: Stromal cells of lung cancers comprised 
of Àbroblasts and myoÀbroblasts the amount of 
which varied highly between different patients. The 
ultrastructural analyses of cultured cells revealed 
typical features of myoÀbroblasts with Àbronexus, 
dilated rough endoplasmic reticulum (rER) and 
cell junctions. Using the cell culture method of 
tumour cells and the electron and immunoelectron 
microscopy may help one to achieve a new 
information of the structure of stromal cells of lung 
cancers. In the future, invasion and differentiation 
properties as well as cell junctions of intratumoural 
myoÀbroblasts of lung cancers will be characterized. 
Keywords: myoÀbroblast, alpha-smooth muscle 
actin, Àbronectin, Lung cancer
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P4.206 EGFR DIAGNOSIS IN THE 
CLINICAL PRACTICE
Ina Koch1, Diana Steinhart2, Alicia Morresi-Hauf2, 
Thomas Duell2, Joachim Von Pawel2, Rudolf Hatz3, 
Michael Lindner3 
1Thoracic Oncology, Asklepios Fachkliniken 
München-Gauting/Germany, 2Asklepios Fachkliniken 
München-Gauting/Germany, 3Thoracic Surgery, 
Asklepios Fachkliniken München-Gauting/Germany
Background: Since the approval of GeÀtinib as 
Àrst- and second-line treatment for lung cancer 
patients with advanced disease harbouring activating 
EGFR mutations in June 2009, evaluation of EGFR 
mutational status is developing into a routine 
diagnostic procedure. 
Methods: Point mutations in exon 18 were assessed 
by direct sequencing, deletion in exon 19 by gene 
scan analysis and the L858R mutation in exon 21 
by a HybProbe assay in 205 patients of european 
in some squamous cell carcinomas of the lung in 
patients (especially heavy smokers) with interstitial 
pneumonia.
Keywords: interstitial pneumonia, squamous cell 
carcinoma, SOX2
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.205 ELECTRON AND 
IMMUNOELECTRON MICROSCOPIC 
ANALYSIS OF STROMAL 
CELLS CULTURED FROM 
ADENOCARCINOMAS AND SQUAMOUS 
CELLS CARCINOMAS OF THE LUNG
Riitta Kaarteenaho1, Henna Karvonen2, Elisa Lappi-
blanco3, Raija Sormunen4, Johanna Mäkinen5, Siri 
Lehtonen6 
1Respiratory Research Unit, Oulu University 
Hospital/Finland, 2Respiratory Research Unit, 
University Of Oulu/Finland, 3Pathology, Oulu 
University Hospital/Finland, 4Biocenter Oulu, 
University Of Oulu/Finland, 5Pathology, University 
Of Oulu/Finland, 6Dept. Of Anatomy And Cell 
Biology, University Of Oulu/Finland
Background: In addition to cancer cells, lung 
tumours contain stromal cells i.e. Àbroblasts and 
myoÀbroblasts, which may have a role in the 
growth of lung cancer. The aim of the study was to 
standardize the process for culturing cells from lung 
cancer tissues and to characterize the ultrastructural 
features of stromal cells isolated from lung cancer 
tissue of the patients with various types of lung 
cancers with special interests on the Àbronexus-
structure of myoÀbroblast. 
Methods: Lung tissue material from 6 patients 
with adenocarcinoma, 3 patients with squamous 
cell carcinoma and 1 patient with adenosquamous 
carcinoma was obtained from surgical operations (2 
female, 8 male; 2 nonsmokers, 8 smokers). Tissue 
samples were disrupted mechanically and digested 
by collagenase treatment in order to obtain single 
cell suspensions. The cells were visualized by 
electron and immunoelectron microscopic methods 
using speciÀc antibodies for alpha-smooth muscle 
actin (a-SMA), Àbronectin and ED-A-Àbronectin 
as previously described (Kaarteenaho-Wiik et al. 
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Background: The fusion of the anaplastic 
lymphoma kinase (ALK) with the echinoderm 
microtubule-associated protein-like 4 (EML4) and 
epidermal growth factor receptor (EGFR) mutations 
are considered mutually exclusive. Advanced 
non-small cell lung cancer (NSCLC) patients with 
EML4-ALK did not beneÀt from EGFR tyrosine 
kinase inhibitors (TKIs).
Methods: Multiplex reverse transcriptase-
polymerase chain reaction (RT-PCR) followed by 
sequencing was performed for EML4-ALK fusion 
status detection. EGFR and KRAS mutations were 
determined by direct DNA sequencing. Positive 
results of EML4-ALK fusion were also conÀrmed by 
RACE-coupled PCR sequencing.
Results: From April 2010 to January 2011, 412 
patients (398 with NSCLC; 14 with SCLC) were 
tested for mutation status of EGFR, KRAS and 
EML4-ALK respectively. Frequency of EML4-ALK 
fusion was 10.6% (42/398) in NSCLC patients. No 
patients with SCLC were found to have positive 
EML4-ALK fusion. Frequency of concomitant 
EGFR and EML4-ALK gene mutations was 1.0% 
(4/398) in NSCLC patients, and their variants of 
EML4-ALK gene mutations were Variant 1 (3 
patients) and Variant 6 (1 patient); being never 
smokers, all of them were diagnosed with advanced 
(3 with stage and 1 with stage B) adenocarcinoma 
harbouring wild type KRAS. Two female stage 
patients with double gene mutations (1 with L858R 
and Variant 1; 1 with exon19 deletion and Variant 
6) received Àrst-line geÀtinib which is one kind of 
EGFR TKIs and achieved partial response.
Conclusion: Though being rare events, NSCLC 
patients harbouring concomitant EGFR mutation 
and EML4-ALK gene fusion are sensitive to Àrst-
line EGFR TKIs. Whether they could also beneÀt 
from ALK inhibition after failure to EGFR TKIs 
warranted further investigation.
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P4.208 RT-PCR VERSUS 
IMMUNOHISTOCHEMISTRY FOR 
CORRELATION AND QUANTIFICATION 
OF ERCC1, BRCA1, TUBB3 & RRM1 IN 
NSCLC
Adam Vilmar1, Jesus Garcia-Focillas2, Marisol 
Huarriz2, Eric Santoni-Rugiu3, Jens B. Sorensen1 
1Oncology, National University Hospital, Finsen 
Centre/Denmark, 2University Of Navarra, 
origin with disease stage IIIb and IV or at relapse 
after surgery. For 99 patients this was part of the 
diagnostic procedure. 
Results: We found 1 G719A mutation in exon 18 
(0.5%), 19 inframe deletions and 2 inframe insertions 
in exon 19 (10.2%) and 13 L858R mutation (6.3%), 
resulting in an overall mutational frequency of 17 %. 
Tissue from the original tumor and from a metastasis 
or at relapse after standard chemotherapy was 
available in 1 not mutated and 2 mutated cases, with 
stable mutational status. Of 99 patients diagnostically 
analysed, 19 harboured one of the activating mutations. 
Patients were chemonaiv or had recieved 1 or 2 
chemotherapies before. Of 14 patients with follow-
up, 4 recieved a standard chemotherapy, with planned 
maintenance TKI therapy in 2 cases. 8 were treated 
with GeÀtinib or Erlotinib, 6 of those in Àrst line. While 
1 patient discontinued the therapy, clinical response 
was seen in the 5 (1 stable disease, 4 remissions) and 
2 patients are not yet available. 2 patients had been 
successfully treated with Erlotinib for 1 and 3 years 
respectively before relaps and tumor progression. 
Conclusion: Routine EGFR mutational analysis in 
patients with lung adenocarcinoma helps to identify 
patients likely to respond to EGFR-TK inhibitor 
therapy in clinical daily routine with marked beneÀt 
for as much as 20 % of all lung adenocarcinoma 
patients. The mutational status was stable in the 
original tumor and metastasis or at relapse in 3 of 3 
cases, which, after conÀrmation in a larger number 
of cases, will facilitate reliable EGFR diagnostic in 
the original operated tumor for patients at relapse 
even if no recent biopsy is available. 
Keywords: EGFR, TKI, activating mutation, clinical 
routine
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P4.207 CONCOMITANT EGFR 
MUTATION AND EML4-ALK GENE 
FUSION IN NON-SMALL CELL LUNG 
CANCER
Jinji Yang1, Xuchao Zhang2, Jian Su3, Hua-Jun 
Chen1, Hong-Xia Tian3, Yi-Sheng Huang3, Chong-
Rui Xu3, Yi-Long Wu3 
1Division Of Pulmonary Oncology, Guangdong 
General Hospital, Guangdong Academy Of Medical 
Sciences/China, 2Guangdong General Hospital/
China, 3Guangdong Lung Cancer Institute, 
Guangdong General Hospital And Guangdong 
Academy Of Medical Sciences/China
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P4.209 SYSTEMATIC QUANTIFICATION 
OF TUMOUR CONTENT IN 
CRYOPRESERVED SAMPLES STORED 
IN A LUNG TUMOUR BANK
Edwina Duhig1, Belinda Clarke1, Maria Martins2, 
Felicia Goh2, Ian Yang3, Kevin Matar2, Morgan 
Windsor2, Paul Zimmerman2, Morgan Davidson3, 
Casey Wright3, Rayleen Bowman2, Kwun M. Fong2 
1Anatomical Pathology, The Prince Charles 
Hospital/Australia, 2Tpch/Australia, 3University Of 
Qld/Australia
Background: The success of molecular 
characterisation of carcinomas depends upon 
the presence of a sufÀcient amount of tumour in 
submitted samples. Few studies on the volume of 
tumour represented in pathology specimens have 
been published, mainly focussing on bronchoscopic 
biopsies1. We analysed tumour cell content and 
percentage of necrosis in snap frozen tumour pieces 
harvested from resected lung cancers to assess 
suitability for genomic studies.
Methods: Patients gave informed consent to donate 
part of their resected tumour tissue for research, and 
data is based on 272 adenocarcinomas (AC) and 
191 squamous cell carcinomas (SCC). Portions of 
surgical lung cancer specimens were harvested fresh 
by macroscopic dissection between 1992 and 2011 
(one to fourteen portions per case), snap frozen in 
liquid nitrogen, and stored at -80oC for up to 18 
years as a resource of The Prince Charles Hospital 
lung tumour bank. Two pathologists independently 
recorded percentage of tumour cell nuclei and 
percentage of necrosis in a single four micron H and 
E section from each portion (3.98±3.92 sections per 
AC case and 4.48± 2.93 sections per SCC case). 
Tumours with fewer than 30% tumour cell nuclei 
were reviewed to determine the reason for the low 
tumour content.
Results: The mean percentage of tumour cells 
in each section of adenocarcinoma (n=493) was 
33.6±24.7% for Reader 1, and 30.5±24.9% for 
Reader 2, and in SCC (n=545) 35.2±26.1% (Reader 
1) and 32.9±26.7% (Reader 2). The percentage of 
tumour cells recorded by both readers was slightly 
higher in SCC than AC (statistically signiÀcant for 
Reader 2, p=0.027). Mean percentage necrosis for 
adenocarcinoma was 7.5±19.1% (Reader 1) and 
8.6±20.8% (Reader 2), and for SCC 15.2±24.1% 
(Reader 1) and 18.4±27.2 (Reader 2). The two 
Laboratory Of Pharmacogenomics, Division Of 
Oncology, Center For Applied Medical Research 
(cima),/Spain, 3Pathology, Diagnostic Center, 
National University Hospital/Denmark
Background: Customized chemotherapy is 
increasingly used in the management of patients 
with advanced non-small cell lung cancer (NSCLC). 
However, the most reliable methodology to 
determine biomarker status is neither fully elucidated 
nor agreed upon. Accordingly, we evaluated the 
pedictive information of quantitative real-time 
reverse transcriptase polymerase chain reaction 
(qRT-PCR) and immunohistochemical analysis 
(IHC) on excision cross complementation group 
1 (ERCC1), breast cancer susceptibility gene 
1 (BRCA1), ribonucleotide reductase subunit 
M1 (RRM1) and class III b-tubulin (TUBB3). 
Furthermore, we correlated mRNA and protein 
expression. 
Methods: IHC and qRT-PCR on ERCC1, BRCA1, 
RRM1 and TUBB3 were performed on surgically 
resected tissue samples from patients with advanced 
NSCLC included in a randomized phase III trial. 
The median values of the biomarker expression 
dichotomized the population into negative and 
positive subgroups and were correlated to response 
rates (RR), median progression free survival (PFS) 
and median overall survival (OS). 
Results: Representative tissue samples from 33 
patients were explored and no signiÀcant correlations 
were found between mRNA and protein expression. 
Predictive impact was demonstrated for all four 
biomarkers, when assesed by IHC, and reached 
signiÀcance for OS in ERCC1 negative (14,3 vs. 8,5 
months, P = 0,018) and TUBB3 negative (18,5 vs. 
11.10, P = 0,027) tumors, while this was not the case 
for qRT-PCR. 
Conclusion: IHC discriminated more effectively 
than qRT-PCR across four different biomarkers 
in a subgroup of patients with advanced NSCLC 
having representative tissue samples. These Àndings 
are further supported by the demonstrated lack of 
correlation between transcript and protein. 
Keyword: NSCLC, predictive markers, 
methodology, qRT-PCR, immunohistochemical 
evaluation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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between January 2007 and January 2009.
Results: A total of 238 patients were diagnosed with 
advanced (stage IV) NSCLC and had 274 diagnostic 
samples. 42 patients (17%) required a second 
procedure to conÀrm the diagnosis of malignancy. 
Bronchoscopy (26%) and CT-guided procedures 
(25%) were the most common Àrst methods of 
procuring a sample. 150/274 (55%) of the samples 
were from the primary tumour. Among the samples, 
37% were core biopsies, 42% were Àne-needle 
aspirate biopsies (FNAB). The rest were variable 
and included cytologic assessment of bronchial 
washings and pleural effusions. Successful diagnosis 
of malignancy was associated with sample type 
(p<0.001): 61% for exfoliative cytology (effusion, 
bronchial washings), 89% for FNA, and 90% for 
core biopsy. The method of procuring the sample 
was also associated with success of the initial 
attempt (p=0.0001). CT-guided sampling with an 
on-site cytopathologist yielded a diagnosis in all 
cases. Site of initial sample was also an important 
predictor of diagnostic success of the initial sample 
with metastatic site (96%) and primary tumour 
(84%) having the highest rate of success. Pleural 
effusion had the lowest yield at 70%. Pathologic 
subtypes were determined in majority of cases: 61% 
adenocarcinoma, 13% squamous cell carcinoma 
(SCC), however, large cell and NSCLC not 
otherwise speciÀed (NOS) comprised 6% and19% of 
cases. 40% of all samples had immunohistochemistry 
(IHC) studies performed. IHC was performed 
more frequently in adenocarcinoma cases (73%) to 
conÀrm site of origin. Only 28% of SCC cases had 
IHC performed. IHC was more commonly performed 
in cases of NSCLC NOS, 64% (29/45) versus 36% 
(70/193) in other pathologic subtypes (p=0.0006). 
Type of sample was signiÀcantly associated with 
NOS and Large cell diagnosis (p=0.008): 34% of 
those with FNA biopsies were either NOS and/or 
Large cell, compared to only 17% of those with core 
biopsies.
Conclusion: Up to 19% of cases of NSCLC 
diagnosed at a major cancer centre may not have 
a speciÀc pathologic subtype deÀned based on 
available diagnostic material. IHC was performed 
more commonly in those without a deÀned subtype, 
likely in an attempt to determine the subtype. CT-
guided FNA and core biopsies of the primary were 
associated with the highest diagnostic yield.
Keywords: Non-small cell lung cancer, pathology, 
immunohistochemistry
readers’ independent scores for both tumour content 
and necrosis were highly correlated (Pearson > 0.90, 
n=989 sections, p<0.01). Percentage necrosis scored 
by both readers was signiÀcantly higher in SCC than 
AC (p<0.001). There was no strong relationship 
between the area of the tissue section on the slide 
and percentage of tumour cell content or necrosis (all 
correlation coefÀcients <0.25). Review of samples 
with tumour content below 30% revealed inclusion 
of adjacent normal alveolated lung, Àbrosis, 
inÁammation, elastotic scarring, bronchial wall, 
organising pneumonia, blood vessel wall and lymph 
node in samples harvested as “tumour”.
Conclusion: In this study there was good 
agreement between the two pathologists, but only 
approximately one third of cell nuclei in both AC 
and SCC were tumour. Necrosis was greater in SCC 
than AC. Whether specimens are obtained at surgical 
resection or by small biopsy, all should be assessed 
for tumour volume prior to molecular testing.
1. Coghlin CL, Smith LJ, Bakar S, et al. Quantitative 
analysis of tumor in bronchial biopsy specimens. J 
Thorac Oncol 2010; 5: 448-452.
Keywords: tumour content, lung cancer resctions
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P4.210 DIAGNOSTIC PATTERNS OF 
NON-SMALL CELL LUNG CANCER AT 
PRINCESS MARGARET HOSPITAL.
Maral NadjaÀ1, Gilda D.C. Santos2, Lisa Le3, David 
M. Hwang2, Ming S. Tsao4, Natasha Leighl5 
1Medicine, University Of Toronto/Canada, 
2Pathology, Uhn Toronto General Hospital/Canada, 
3Biostatistics, Princess Margaret Hospital/Canada, 
4Department Of Pathology, University Health 
Network, Princess Margaret Hospital And University 
Of Toronto/Canada, 5Medical Oncology, University 
Health Network/princess Margaret Hospital/Canada
Background: Pathologic subtypes of non-small 
cell cancer (NSCLC) may have differential beneÀt 
with selected systemic treatments. Hence, NSCLC 
subtyping is becoming increasingly important in 
therapeutic decision-making. We reviewed the 
methods of diagnosing NSCLC at our institution and 
how often a speciÀc pathologic subtype is provided.
Methods: Retrospective chart review was 
undertaken at a major cancer center, identifying 
patients with advanced stage NSCLC diagnosed 
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were: solid (n=21,36.2%), acinar (n=20,34.5%), 
micropapillary (n=12,21%), papillary (n=3,5.2%), 
and colloid (n=2,3.4%). EGFR and KRAS 
mutations occurred in 16 (28%) and 12 (21%) 
tumors respectively. EGFR mutations occurred 
most commonly in predominant acinar subtype 
(n=8,47%) compared to 5 (29%) micropapillary 
and two (12%) solid (p=0.048). In contrast, KRAS 
mutations occurred primarily in solid predominant 
tumours (n=7,58%). On univariate analysis acinar 
predominant tumours were associated with improved 
survival (p=0.02) and KRAS mutant tumours 
with inferior survival (p=0.003) (Figures 1 and 
2). In multivariate analysis inclusive of age, sex 
and mutation status, acinar predominant histology 
remained an independent predictor of improved OS 
(HR 0.35;95%CI 0.15-0.80;p=0.014) and KRAS 
mutant tumors independently predicted poorer 
outcome (HR 3.35;95%CI 1.43-7.85;p=0.005).
Conclusion: In stage III adenocarcinoma, acinar and 
solid predominant tumours were the most frequent 
subtypes. Acinar predominant tumours were more 
likely to harbour EGFR mutations. KRAS mutation 
status provides important prognostic information 
that is independent of histologic subclassiÀcation. 
OS was superior in acinar predominant tumours 
regardless of mutation status. Histologic 
subclassiÀcation provides important prognostic 
information, independent of mutation status.
Keywords: Adenocarcinoma, Stage III, Predominant 
histologic subtype, EGFR
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P4.212 DIFFERENTIATING SUBTYPES 
OF NON SMALL CELL CARCINOMAS OF 
THE LUNG BY THE COMPLEXITY OF 
THEIR CELLULAR ARCHITECTURE
Lik hang Lee1, Mauro Tambasco2, Alexander C. 
Klimowicz3, Stephanie Petrillo3, Shannon Otsuka3, 
Anthony M. Magliocco4, Dafydd G. Bebb5 
1Department Of Pathology And Laboratory 
Medicine, University Of Calgary, Foothills Medical 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.211 CORRELATION OF 
PREDOMINANT HISTOLOGIC 
SUBTYPE, MUTATION STATUS AND 
OVERALL SURVIVAL IN STAGE III 
LUNG ADENOCARCINOMA.
Prudence A. Russell1, Stephen A. Barnett2, Marzena 
Walkiewicz3, Zoe Wainer4, Gavin M. Wright2, Simon 
Knight5, Rochelle Wynne6, Siven Seevanayagam5, 
Julian Gooi5, Naveed Alam2, Matthew Conron7, 
Richard A. Williams1, Thomas John8 
1Department Of Anatomical Pathology, St Vincent’s 
Hospital/Australia, 2Department Of Thoracic 
Surgery, St Vincent’s Hospital/Australia, 3Austin 
Health, Ludwig Institute For Cancer Research/
Australia, 4Department Of Surgery, University Of 
Melbourne/Australia, 5Department Of Thoracic 
Surgery, Austin Health/Australia, 6School Of Health 
Sciences, University Of Melbourne/Australia, 
7Department Of Respiratory Medicine, St Vincent’s 
Hospital/Australia, 8Medical Oncology, Ludwig 
Institute For Cancer Research/Australia
Background: A robust, reproducible 
adenocarcinoma classiÀcation system, with 
molecular correlate, is essential to facilitate 
research, deÀne prognosis and inform treatment 
choice. The recently published IASLC/ATS/
ERS adenocarcinoma classiÀcation correlates 
predominant histologic subtype with survival in 
stage I adenocarcinoma and demonstrated it to 
be prognostic. We investigated stage III(N2) lung 
adenocarcinomas to determine the relationships 
between histologic subclassiÀcation, mutational 
proÀle and overall survival (OS).
Methods: Histologic slides from 58 resected stage 
III adenocarcinomas were classiÀed according to 
the IASLC/ATS/ERS classiÀcation. Predominant 
subtype was circled on the slide, a core punched 
from the parafÀn block, DNA isolated and 
mutational proÀling performed using Sequenom’s 
MassArray platform. Predominant subtype, mutation 
status and OS were correlated using univariate and 
multivariate models.
Results: Median age was 64 (Range 29-86) years 
with 30 (52%) females. Predominant subtypes 
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a pulmonary pathologist, were compared using the 
independent t-test. 
Results: 137 cases of resected NSCLCs and 139 
cases of stage IV NSCLC biopsies were identiÀed. 
The resection series contained 89 cases of ADC 
and 48 cases of SCC. The stage IV biopsy series 
contained 90 cases of ADC and 49 cases of SCC. 
Pan-cytokeratin staining and automated image 
analysis was successful on all specimens. We found a 
statistically signiÀcant difference (p = 0.01) between 
the mean correlation dimension of ADC (M = 1.74, 
SD = 0.06) and SCC (M = 1.77, SD = 0.07) in the 
stage IV biopsies. The resected specimens yielded 
better discrimination than the stage IV biopsies 
because of greater architectural integrity. 
Conclusion: Architectural complexity, as 
represented by the correlation dimension of the 
epithelial structure of NSCLC, has potential as a 
reproducible and automated measure to subtype 
NSCLCs into ADC and SCC from biopsy and 
resection specimens. This potentially objective 
method may provide an adjunct test in differentiating 
different NSCLCs and help reduce intra-observer 
variability. This is of growing importance as the 
distinction between subtypes of NSCLC, particularly 
between squamous and non-squamous NSCLC, 
is clinically important in patient management 
decisions. 
Keywords: Non small cell carcinoma of the lung, 
architectural complexity, fractal dimension
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.213 IMMUNOISTOCHEMICAL 
EXPRESSION OF NEUROENDOCRINE 
DIFFERENTIATION IN NON-SMALL 
CELL CARCINOMA OF THE LUNG.
Ioannis Vamvakaris1, M. Anagnostopoulou2, 
E. Pigadioti1, Ioannis Gkiozos3, Andriani G. 
Charpidou3, Kostas N. Syrigos4 
13rd Department Of Athens Medical School, 
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Sotiria General Hospital/Greece, 43rd University 
Department Of Internal Medicine, Oncology Unit, 
Sotiria General Hospital Of Chest Diseases/Greece
Centre, And Tom Baker Cancer Centre/Canada, 
2Department Of Medical Physics, University Of 
Calgary And Tom Baker Cancer Centre/Canada, 
3Department Of Oncology, Tom Baker Cancer 
Centre/Canada, 4Department Of Pathology And 
Laboratory Medicine, University Of Calgary And 
Tom Baker Cancer Centre/Canada, 5Department Of 
Medical Oncology, University Of Calgary And Tom 
Baker Cancer Centre/Canada
Background: Lung cancer is most common cause of 
cancer mortality worldwide. Traditionally, carcinomas 
of the lung required only classiÀcation into small cell 
lung carcinoma and non-small cell lung carcinomas 
(NSCLC) for management decisions. However, 
NSCLCs, comprising 85% of lung cancers, consist 
of clinically and pathologically heterogenous entities. 
Differences in management between squamous and 
non-squamous NSCLCs are emerging highlighting 
the growing importance of accurate histopathologic 
classiÀcation. Furthermore, increasingly the diagnoses 
must be made with less tissue as minimally invasive 
procedures become more common and more tissue is 
kept for molecular studies. Inter-observer variability 
increases with smaller biopsy specimens, resulting in a 
need for an objective measure to distinguish histologic 
subtypes. We hypothesize that the complexity of the 
epithelial architecture, mathematically quantiÀed by 
the correlation dimension, can be used to classify 
NSCLC subtypes. We have previously demonstrated 
that this is a promising approach in breast cancer. The 
objective of this study is to evaluate the potential of 
computing the architectural complexity of NSCLCs to 
differentiate adenocarcinoma (ADC) from squamous 
cell carcinoma (SCC), and compare such an approach 
in resected early stage cases against biopsies taken 
from patients with metastatic disease. 
Methods: Patients with resected NSCLC tumors 
and patients with biopsies of stage IV NSCLC were 
identiÀed from the Glans-Look lung cancer database 
at the Tom Baker Cancer Centre for the years 2003-
2006. Tissue micro arrays (TMAs) were generated 
from formalin-Àxed parafÀn embedded resected 
tumor specimens and diagnostic biopsies of stage IV 
patients. These were stained with pan-cytokeratin to 
highlight the epithelial structure of the carcinoma, 
and digitally imaged using the HistoRx PM-2000 
automated image acquisition platform. Architectural 
complexity of the carcinoma, as represented by the 
correlation dimension of the epithelial structure, was 
analyzed by computer. Mean correlation dimension 
of lung sections of ADC and SCC, as assigned by 
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Background: Recent clinical trials have 
demonstrated differential survival beneÀts from 
chemotherapy regimens according to NSCLC 
histology, increasing the importance of accurate 
subtyping in small biopsy samples. While 
histological distinction between small cell and non-
small cell lung carcinoma can be made on small 
biopsy samples with high accuracy and consistency, 
discrimination between NSCLC subtypes (squamous 
cell carcinoma, adenocarcinoma and large cell 
carcinoma) is more difÀcult. In some cases a lack 
of diagnostic features renders subtyping impossible 
and a diagnosis of NSCLC, not otherwise speciÀed 
(NOS), has to be made. Cytological procedures are 
frequently used, but their ability to discriminate 
between NSCLC subtypes is not always possible.
Methods: We conducted a retrospective analysis 
in 415 NSCLC patients (p) diagnosed between 
January 2007 and December 2010. We analysed the 
distribution of NSCLC subtypes and correlated them 
with the histological diagnostic technique employed.
Results: Malignant diagnosis included squamous 
cell carcinoma in 199 p (48%), adenocarcinoma in 
116 p (28%), large cell carcinoma in 12 p (2.9%) 
and and other carcinomas including NOS in 88 
p (21.2%). The proportion of NSCLC patients 
diagnosed by biopsy as compared to the proportion 
of NSCLC patients diagnosed by cytology was 
87.6% vs 12.4% respectively. Carcinoma NOS was 
most frequently diagnosed cytologically, 32% vs 
11% (p=0.0001).
Conclusion: Carcinoma NOS is a common 
histologic diagnosis and is signiÀcantly higher in 
those p diagnosed citologically. An increased effort 
is needed to obtain sufÀcient tumour tissue in order 
to identify adequately NSCLC subtypes.
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P4.215 ANTITUMOR TREATMENT 
ON PULMONARY EPITHELOID 
HEMANGIOENDOTHELIOMA
Regina Palfoldi1, Marianna Radacs2, Edit Csada3, 
Zoltan Rozsavolgyi3, Laszlo Tiszlavicz3, Zsuzsanna 
Valkusz3, Attila Somfay3, Jozsef Molnar3, Marta 
GalÀ3 
1Department Of Pulmonology, University Of Szeged, 
Faculty Of Medicine, Hungary, Deszk/Hungary, 
2University Of Szeged,/Hungary, 3University Of 
Szeged/Hungary
Background: At the end of the 20th century, the 
lung cancer represent the most often malignancy 
and cause of death of neoplasm worldwide. 
Neuroendocrine neoplasms, represent the 16-17% 
of the primary lung carcinomas. Furthermore 
exist a non negligible percent (10-30%) of the 
non small cell lung carcinomas which present 
elements of neuroendocrine differentiation. Multiple 
research programs have been affected. Aim : To 
present our observations and studies about the 
immunoistochemical neuroendocrine expression of 
non-small cell lung carcinomas, on the purpose to 
classify the neoplasms of low grade differentiation 
in neuroendocrine tumors and/or neoplasms with 
neuroendocrine features 
Methods: We examined ten (10) cases of non-
small cell lung carcinomas with neuroendocrine 
differentiation and ten (10) cases of neuroendocrine 
small and large cell lung carcinomas. The 
immunoistochemistry methods used were of three 
steps (avidine-biotin-peroxidase) in parafÀne 
embeded tissues. 
Results: Differential diagnosis between 
neuroendocrine neoplasms of the lung and 
non small cell neoplasms with neuroendocrine 
differentiation requires the study of histological and 
immunoistochemical neuroendocrine characteristics. 
Furthermore the cytoplasmatic neuroendocrine 
positive expression of CD56 vs its membranic 
positivity can offer an additional parameter to the 
differential diagnosis and accurate deÀnition of the 
neoplasm.
Keyword: Neuroendocrine differentiation, lung 
cancer, immunoistochemical neuroendocrine markers
Poster Session 4 – Pathology Thursday, 7 July 2011 10:00-12:30
P4.214 CARCINOMA NOS (NOT 
OTHERWISE SPECIFIED) IS A COMMON 
HISTOLOGIC DIAGNOSIS IN NON-
SMALL-CELL LUNG CANCER (NSCLC) 
PATIENTS AND IS MOST FREQUENTLY 
DIAGNOSED CYTOLOGICALLY: 
RETROSPECTIVE ANALYSIS IN A 
COMMUNITY-BASED HOSPITAL.
Guillermo Alonso-Jáudenes1, Rosario Garcia-
Campelo2, Ana Roldán2, Laura Sande2, Natalia 
Fernández2, Luis Antón Aparicio2 
1Medical Oncology, C. H. U. A Coruña/Spain, 2C. H. 
U. A Coruña/Spain
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Chu-Yun Huang1, Chun-Ming Tsai1, Yu-Chin Lee1, 
Reury-Perng Perng1, Yuh-Min Chen2 
1Taipei Veterans General Hospital/Taiwan, 2Chest 
Department, Taipei Veterans General Hospital/
Taiwan
Background: The possible association between 
pulmonary tuberculosis (TB) and lung cancer 
development has been studied for several decades, 
and many studies revealed that history of pulmonary 
TB infection is associated with increased risk of 
lung cancer. In addition, lung cancer tumor EGFR-
mutations occurred most frequently in patients with 
adenocarcinoma. However, the relationship between 
EGFR mutation in lung cancer and pulmonary 
tuberculosis is unknown. 
Methods: We retrospectively reviewed and updated 
the data of our adenocarcinoma patients about 
whether or not they had pulmonary TB infection 
history or their chest CT image showed pre-existing 
TB lesions at or before initial diagnosis of lung 
cancer, in those patients who had tumor tissue 
samples sent for tumor EGFR sequence analysis. The 
associations of EGFR mutation and history of TB 
infection or TB lesions on image were analyzed.
Results: 345 lung cancer patients who received 
tumor EGFR sequence analysis between 2008 and 
2010 were enrolled into present study. Among them, 
238 patients had tumor EGFR mutations and 107 
patients had wild-type tumor EGFR. In these 345 
patients, 17 patients had pulmonary TB infection 
history, and 67 patients had chest CT lesions in favor 
of previous TB infection, in addition to lung cancer 
lesions. There are statistically signiÀcant association 
between EGFR mutations and TB lesions on chest 
CT scan (p=0.003); EGFR mutations and scar 
cancer (p=0.028); exon 19 deletions and pre-existing 
TB lesions on chest CT scan (p<0.001); exon 19 
deletions and scar cancer (p<0.000); and exon 21 
mutations and pre-existing TB lesions on chest CT 
scan (p=0.011). 
Conclusion: There are signiÀcant association of 
previous pulmonary tuberculosis infection and 
occurrence of tumor EGFR mutations in NSCLC 
patients.
Keywords: EGFR, tuberculosis
Background: Pulmonary epitheloid 
hemangioendothelioma (PEHE) is a rare tumour of 
endothelial origin, which is of borderline malignancy. 
It is often problematic to diagnose PEHE. This 
disease does not have any standard treatment. For 
this reason we made an in vitro experiment testing 
chemotherapeutic agents in cell cultures. 
Methods: The histological examination of biopsy 
proved that the patient has PEHE. Cell cultures 
(monolayer, explant, 3D) were made from one 
part of bronchoscopy sample. The tissues were 
dissociated enzimatically and mechanically. These 
cell cultures were used to examine the efÀciency 
of the chemotherapeutic agents by examining the 
activity of proliferation (3H-thymidine incorporation, 
protein production) and the markers of toxicity. 
According to our in vitro examination, chemotherapy 
treatment was introduced by giving carboplatin-
etoposide and docetaxel. 
Results: The patient received 6 cycles (CBP-
Vp) which resulted in partial regression. The 
chemotherapy treatment was completed by January 
2010. After the chemotherapy treatment was started, 
osteolytic lesions were detected on the left lower 
arm resulting in pain. It was regarded to be bone 
metastases, so biphosphonate treatment was initiated. 
The patient was observed regularly, and progression 
was detected in May 2010. It was about 20 %, so 
second line docetaxel was begun. The patient received 
4 cycles which resulted in partial regression (30 %). 
Conclusion: Combining in vitro and in vivo 
methods proved to be a very effective anticancer 
treatment in case of our female patient. If there is 
not standard therapeutic protocol in any kind of 
tumour type, it is useful testing efÀciency of different 
chemotherapeutic agents in the related cell cultures 
for Ànding the most effective anticancer treatment 
modality. This work was supported by: TAMOP 
4.2.1./B-09-1/KNOV-210-0005 
Keyword: hemangioedothelioma, therapeutic 
protocol, the activity of proliferation, cell culture
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P4.216 ASSOCIATION BETWEEN TUMOR 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION AND 
PULMONARY TUBERCULOSIS IN 
PATIENTS WITH ADENOARCINMA OF 
THE LUNGS
Yung-Hung Luo1, Chieh-Hung Wu1, Wen-Shuo Wu1, 
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NSCLC. This data can be of help to the adjuvant 
–chemotherapy decision-making process with 
patients with this rare tumor entity. 
Keywords: LCC, LCNEC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.218 ANALYSIS OF LUNG CANCER 
HISTOLOGY BY FAMILY ONCOLOGIC 
HISTORY IN A UNIVERSITY HOSPITAL 
IN LATVIA
Jelena Grusina Ujumaza1, Genadijs Ambalovs2, 
Andrejs Vanags2, Ilze Strumfa3, Jazeps Basko4, Jănis 
Gardovskis2, Uldis Kopeika4, Ainis Pirtnieks4 
1Division Of Doctoral Studies, Riga Stradins 
University/Latvia, 2Department Of Surgery, 
Riga Stradins University/Latvia, 3Department 
Of Pathology, Riga Stradins University/Latvia, 
4Department Of Thoracic Surgery, Pauls StradiƇš 
Clinical University Hospital/Latvia
Background: There are contradictory data in 
the literature on eventual connection between 
family anamnesis and histological type of lung 
cancer. Some studies mention close connection 
between squamose cell cancer and positive family 
cancer history, however, the data obtained from 
Swedish Cancer Register could indicate the higher 
incidence of adenocarcinoma in family lung cancer 
(Li and Hemminki, 2003). Recently summarized 
epidemiological data reveal that the number of 
adenocarcinoma-type cancer increase in people who 
have never smoked, mostly in women (Brambilla 
et al., 2010). In total the connection to the family 
history is more expressed in non-smokers than 
smokers, and it is more connected to non small cell 
cancer (Gao et al., 2009). Objective of the work: 
make analysis of tumour histogenesis in connection 
with the patient’s family anamnesis.
Methods: Lung cancer patients who underwent 
treatment in the Centre of Thoracic Surgery of 
university hospital in Latvia due to histologically 
conÀrmed lung cancer diagnosis were included in the 
study. We assessed the lung cancer patient’s family 
oncological history, presence and stage of tumour 
which was determined using modern examination 
methods (computer tomography of thoracic and 
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P4.217 LARGE CELL CARCINOMAS 
(LCC) OF THE LUNG: A MONOCENTRIC, 
CLINICOLPATHOLOGIC STUDY OF 
FIFTY-TWO PATIENTS.
Angelo Delmonte1, Tommaso De Pas2, Fabio 
Vecchio2, Edoardo Botteri2, Crisitina Noberasco2, 
Gianluca Spitaleri2, Francesca Toffalorio2, Chiara 
Catania2, Giovannini Monica2, Lorenzo Spaggiari2, 
Filippo De Braud2, Massimo Barberis2 
1New Drug Development Division, Medical 
Oncology Department, European Institute Of 
Oncology/Italy, 2European Institute Of Oncology/
Italy
Background: The rarety of large cell carcinoma of 
the lung (LCC) lead to the lack of clinical evidence 
based data for clinical decision making. Moreover 
LCC were previously diagnosed on morphologic 
features while at present electron microscopy and 
immunohistochemistry conÀrmed that different 
lineages can occur in LCC including squamous (in 
basaloid and some clear cell variants), glandular 
(LCC with rhabdoid features) or neuroendocrine 
differentiation (large cell neuroendocrine carcinoma 
-LCNEC- or LCC with neuroendocrine features). 
Methods: The histologic characteristics of the 
patients with an initial diagnosis of LCC, of which 
113 underwent to radical surgery in our Institution 
from November 1995 to December 2009, were 
retrospectively reviewed according to 2004 World 
Health Organization criteria. Immunohistochemistry 
with a panel of markers for glandular, squamous and 
neuroendocrine differentiation was performed in 
order to conÀrm different phenotypes. Outcomes and 
other clinical characteristics of LCC patients were 
retrospectively analyzed and compared with those of 
patients with not conÀrmed LCC. 
Results: Among 130 tumors evaluated, 52 didn’t 
change the diagnosis of LCC after the histologic 
review, while the further 88 patients shifted to 
poorly differentiated non-small-cell lung carcinomas 
(NSCLC). LLC were LCNEC (33), basaloid (8), 
clear cell (5), lymphoepithelioma like (1) and LCC 
with rhabdoid phenotype (2). With a median follow-
up was of 3 years, no difference in overall survival 
was observed neither between LCC and poorly 
differentiated NSCLC patients, nor between LCNEC 
and the other LCC subtypes. 
Conclusion: Prognosis of patients with revised LCC 
is not different from that of poorly differentiated 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1525
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1Medicine, Memorial Sloan Kettering Cancer 
Center/United States Of America, 2Epidemiology 
And Biostatistics, Memorial Sloan Kettering Cancer 
Center/United States Of America, 3Pathology, 
Memorial Sloan Kettering Cancer Center/United 
States Of America
Background: A pathologic grading system based on 
histological patterns of pulmonary adenocarcinoma 
was recently described which has prognostic 
signiÀcance for patients with stage I disease [Sica, 
Am J Surg Pathol 34(8), 2010]. In this study 
we evaluated the prognostic signiÀcance of this 
histological grading system in patients with stage 
I-III lung adenocarcinoma that received adjuvant 
chemotherapy.
Methods: Clinical information was collected 
on patients with resected stage I-III lung 
adenocarcinoma at Memorial Sloan Kettering 
Cancer Center who has surgery between Jan 
2002-Oct 2009. All patients in data base received 
chemotherapy as per standard practice. Mutation 
status for EGFR and KRAS was available for 
all patients. Histological sections of 122 excised 
pulmonary adenocarcinomas were reviewed 
and scored according to the histological grading 
system previously described(Grade I- lepidic, 
grade II- acinar and papillary, grade III- solid and 
micropapillary patterns). Tumors were scored based 
on the sum of the two most predominant grades. 
Overall survival (OS) was calculated starting 8 
weeks post-resection, by which time all patients had 
started adjuvant treatment.
Results: There were 34 patients with pathological 
stage I (10 Ia and 24 Ib), 43 with stage II ( 25 IIa 
and 18 IIb), and 45 stage III (37 IIIa and 8 IIIb). 
The histological score distribution was: 9 patients 
with histological score 3, 43 patients in score 4, 62 
patients in score 5, and 8 patients in score 6. Because 
of the low number of patients in grade 3 and 6, the 
analysis was performed by combining patients with 
scores of 3 and 4 (low-risk) and those with scores 
of 5 and 6 (high risk). Patients in the low-risk group 
had signiÀcantly better overall survival (3yr OS = 
75%) compared to patients in the high-risk group 
(3yr OS = 55%, p=0.033). This result was conÀrmed 
when patients were grouped by pathological stage, 
with low-risk group showing consistently better 
OS compared to the high-risk group. We did not 
detect any signiÀcant associations between EGFR/
KRAS mutation status and histological score in this 
population. 
abdominal organs, Àber-optic bronchoscopy, 
mediastinoscopy), histological type and immune 
phenotype of the tumour. All patients gave consent 
to their participation in the study. The permission of 
Ethics Committee was obtained for the study. 
Results: 55 patients were included in the preliminary 
patients’ group, from them 11 patients had at least 
1 blood relative with lung cancer in the family 
history, 17 patients had relatives with malignant 
tumours of different localisation, but 27 patients 
had no oncological diseases in their family history. 
The patients with lung cancer in their family history 
were diagnosed withy squamose cell cancer (46%), 
adenocarcinoma (18%), large cell cancer (9%), small 
cell cancer (18%), carcinoid (9%). The patients 
with extrapulmonary malignant tumours in their 
family history, were diagnosed with squamose cell 
cancer (35%), adenocarcinoma (24%), large cell 
cancer (17.5%), small cell cancer (17.5%), large 
cell neuroendocrine cancer (6%). The patients with 
negative family oncological history were diagnosed 
with squamose cell cancer (40.8%), adenocarcinoma 
(18.5%), large cell cancer (18.5%), small cell cancer 
(18.5%), and large cell neuroendocrine cancer (3.7%). 
Conclusion: Tumours of various histogenesis were 
found in all groups of patients irrespective of their 
family anamnesis, moreover, a considerable part of 
the cases consists of non-small cell cancer which can 
be surgically treated in early stages. In order to Ànd 
the eventual correlation between histological type of 
tumour and family history, the study has to be carried 
out in a larger group of patients. Hypothetically 
histological heterogeneity of tumours can indicate 
various hereditary mutations. 
Keywords: histological type, Lung cancer, family 
anamnesis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.219 A HISTOLOGICAL GRADING 
SYSTEM HAS PROGNOSTIC 
SIGNIFICANCE FOR PATIENTS WITH 
RESECTED LUNG ADENOCARCINOMA 
THAT RECEIVED ADJUVANT 
CHEMOTHERAPY.
Sandra P. D’Angelo1, Camelia S. Sima2, Christopher 
G. Azzoli1, Andre L. Moreira3 
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tumour samples (the majority of cases being 
adenocarcinoma) across varying populations. We 
reviewed all cases where EGFR genetic analysis was 
performed on NSCLC tissue in our institution.
Methods: A prospectively maintained database was 
retrospectively reviewed for all cases sent for EGFR 
analysis between December 2009 and December 
2010. Clinicopathologic variables, e.g. tumour stage, 
smoking status, and ECOG performance status (PS) 
were recorded. Treatments were also documented. 
EGFR mutation analysis was carried out using real-
time PCR to detect 6 key EGFR mutations in exons 
18, 19, 20 and 21 in DNA extracted from formalin-
Àxed parafÀn-embedded tumour.
Results: Sixty-six tumour samples were sent for 
analysis. Of these patients, 100% were Caucasian. 
Two patients were Dutch and 1 was Croatian, the 
remainder were Irish (95%). Forty-four patients 
(67%) were female and 10 (15%) were non-smokers. 
Median age at diagnosis was 66 years (range: 29-
82). 73% of patients had ECOG performance status 
0 or 1 at the time of diagnosis and 60% had disease 
stage IV. Thirty-nine patients (59%) remain alive 
at the time of analysis. Of all samples, 57 (86%) 
were adenocarcinoma. Tumour samples of 3 patients 
(4.5%) demonstrated an EGFR mutation. All of these 
were adenocarcinoma, two with L858R mutation 
in exon 21 and one with deletion in exon 19. All 
of these patients had stage IV disease at diagnosis, 
and were non-smoking, Irish females. Two patients 
with mutations in exon 21 received therapy with 
EGFR tyrosine kinase inhibitors (TKI) and are 
alive at the time of analysis, 10.5 and 18.8 months 
following diagnosis. Ten tumour samples were 
deemed unsuitable for analysis due to insufÀcient 
sample (15%). Sampling was deemed inadequate 
in 5 (13%) histopathology samples and 5 (19%) of 
cytology samples. Differences in sampling adequacy 
by modality used were compared using Àsher’s 
exact test and were not signiÀcant (p=0.729). One 
patient received an EGFR TKI following insufÀcient 
sampling. This was a 31 year old female, non-smoker 
with stage IV adenocarcinoma and ECOG PS of 1. 
Overall survival was 12.8 months with progression 
free survival of 5 months on TKI therapy. 
Conclusion: The number of EGFR mutations 
detected among the population with NSCLC was 
markedly lower than documented in other European 
countries. A number of samples were deemed 
unsuitable for analysis, however, this did not appear 
to be due to sampling modality. Standardised and 
validated methods of EGFR mutation analysis 
Conclusion: Histological grading is a good 
prognostic indicator in a population of patients with 
resected pulmonary adenocarcinoma that received 
adjuvant chemotherapy. Similar to what has been 
established for stage I patients treated by surgery 
only, the histological score is also capable of 
stratifying patients with pathologic stage II and III 
treated with resection and adjuvant chemotherapy 
with respect to their risk of recurrence. In this small 
group of patients, we did not observe any association 
of histological grade and the incidence of EGFR or 
KRAS mutation. These results do not indicate that 
the histological grading system may predict beneÀts 
from adjuvant chemotherapy given prognostic 
trends are similar in populations who did not receive 
chemotherapy. An analysis of tumors from patients 
randomly assigned to adjuvant chemotherapy in a 
prospective trial would be necessary to explore this 
further.
Keywords: Adenocarcinoma, adjuvant therapy, 
prognostic marker, histological grade
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.220 EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION 
ANALYSIS IN NON-SMALL CELL 
LUNG CANCER (NSCLC) IN AN IRISH 
POPULATION
Donna M. Graham1, Kate O’Connor2, Min Y. Teo1, 
Louise Burke2, Julie Mccarthy3, Pauline O’Dea1, 
Margaret O’Keefe4, Eugene J. Moylan5, Derek G. 
Power4, Seamus O’Reilly1 
1Department Of Medical Oncology, Cork University 
Hospital/Ireland, 2Department Of Pathology, Cork 
University Hospital/Ireland, 3Pathology, Cork 
University Hospital/Ireland, 4Department Of Medical 
Oncology, Mercy University Hospital/Ireland, 
5Department Of Medical Oncology, Kerry General 
Hospital/Ireland
Background: The presence of activating mutations 
in the EGFR in NSCLC provides prognostic 
and predictive information. Therefore, tumoural 
assessment of EGFR gene status has become 
standard. Series report EGFR mutations and 
deletions in approximately 10%-20% of NSCLC 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1527
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in the period 2008-2011 were collected. Most of 
these results had been obtained by PCR followed by 
sequencing of the EGFR (exons 19, 20 and 21) and 
KRAS (exons 1 and 2) genes. For part of the more 
recent cases, the tests consisted of high resolution 
melting analysis, followed by sequencing only if the 
obtained melting curve was abnormal. The tests were 
performed on formalin-Àxed parafÀn-embedded 
tissue or cytological material of both primary lung 
tumors and metastases.
Results: EGFR mutation status was determined in 
605 samples (78.0% adenocarcinomas (AC), 5.6% 
squamous cell carcinomas (SC), and 16.4% others 
(mainly undifferentiated large cell carcinomas)). 
EGFR mutations were detected in 51 out of these 
605 (8.4%) samples. The frequency of EGFR 
mutations in AC was 48/472 (10.2%). These 
mutations comprised mainly deletions in exon 19 
(53.8%) and point mutations in exon 21 (36.5%). 
EGFR mutations were signiÀcantly more common 
in female than in male patients (12.7% vs. 4.8%, 
p<0.001). KRAS mutations were found in 224 out of 
651 (34.4%) tested samples, and in 192 out of 507 
(37.9%) AC. 
Conclusion: In the investigated cohort, 
the frequency of EGFR mutations in lung 
adenocarcinomas is 10.2%. KRAS mutations 
are observed in 37.9% of lung adenocarcinomas. 
Compared to East Asian populations, the frequency 
of EGFR mutations is considerably lower and that 
of KRAS mutations is considerably higher. The 
frequencies observed in the present study are more 
comparable to those observed in North American and 
South European populations. 
Keywords: lung carcinoma, EGFR mutation, KRAS 
mutation, NSCLC
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P4.222 TTF-1: STILL A RELIABLE 
TOOL FOR ASSESSING PRIMARY 
ORIGIN. STUDY OF 650 CASES OF NON 
PULMONARY NEITHER THYROID 
PRIMARY CARCINOMAS
Natalia Tallada, Carmela Iglesias, Steffania LandolÀ, 
Josep Castellvi, Angel Garcia, Santiago RamÓn Y 
Cajal, Vicente Peg 
Pathology, H.universitari Vall D’hebron/Spain
Background: TTF-1 is used in daily practice as a 
highly speciÀc marker for lung and thyroid primary 
were used in all cases. The prevalence of EGFR 
mutations in NSCLC within the Irish population 
has not been previously studied. If representative 
of the region, review of this patient cohort suggests 
a low incidence of EGFR mutations in the Irish 
NSCLC population. In a similar fashion to enzyme 
polymorphisms, EGFR genetic change may 
reÁect ethnicity or geography which could have 
implications for outcomes and the design of clinical 
trials in the future. 
Keyword: epidermal growth factor receptor 
mutation
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P4.221 THE FREQUENCY OF EGFR AND 
KRAS MUTATIONS IN NON-SMALL 
CELL LUNG CARCINOMAS IN THE 
DUTCH POPULATION
Alexander J.J. Smits1, J. A. Kummer1, John 
Hinrichs2, Gerarda J.M. Herder3, N. M. Jiwa4, 
T. E.G. Ruijter5, P. T.G.A. Nooijen6, Monika G. 
Looijen-salamon7, M. J. Ligtenberg7, Frederik B. 
Thunnissen8, Daniëlle A. Heideman8, .R A. De 
Weger2, Aryan Vink2 
1Pathology, St. Antonius Hospital/Netherlands, 
2Pathology, University Medical Center Utrecht/
Netherlands, 3St. Antonius Hospital/Netherlands, 
4Medisch Centrum Alkmaar/Netherlands, 5Alysis 
Zorggroep Arnhem/Netherlands, 6Jeroen Bosch 
Hospital ‘s Hertogenbosch/Netherlands, 7Radboud 
University Nijmegen Medical Center/Netherlands, 
8Pathology, VU University Medical Center/
Netherlands
Background: Recently tyrosine kinase inhibitors 
have been introduced in the treatment of non-small 
cell lung cancer (NSCLC). Only patients who have 
tumors bearing certain EGFR mutations are eligible 
for this treatment, whereas patients whose tumors 
harbor KRAS mutations do not beneÀt from it. Thus 
far, EGFR mutation frequencies have been determined 
mostly in East Asian and North American populations, 
showing large differences between these populations. 
For the North European population, the prevalence of 
the mutations is not clear. The aim of the present study 
was to determine the frequency of EGFR and KRAS 
mutations in NSCLC in the Dutch population.
Methods: Results of EGFR and KRAS mutation 
tests performed at Àve large Dutch hospitals (four 
large regional hospitals and one academic hospital) 
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P4.223 ALK GENE REARRANGEMENT 
: PREVALENCE AND CLINICAL 
OUTCOMES IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER 
(NSCLC) IN EUROPE – A EUROPEAN 
THORACIC ONCOLOGY GROUP (ETOP) 
LUNGSCAPE STUDY
Fiona Blackhall1, Solange Peters2, Keith M. Kerr3, 
Kimary Kulig4, Lukas Bubendorf5, Erik Thunnissen6, 
Rafal Dziadziuszko7, Kenneth J. O’Byrne8, Paul 
Baas9, Walter Weder10, Miquel Taron11, Rafael 
Rosell11, Ralf Stahel12 
1Department Of Medical Oncology, The Christie 
NHS Foundation Trust/United Kingdom, 
2Oncology, Lausanne University Hospitals/
Switzerland, 3Department Of Pathology, Aberdeen 
Royal InÀrmary/United Kingdom, 4Molecular 
Epidemiology Research, PÀzer Oncology/United 
States Of America, 5Departement Of Pathology, 
University Hospital Basel/Switzerland, 6Pathology, 
Vumc/Netherlands, 7Medical University Of Gdansk/
Poland, 8Department Of Clinical Medicine, St. 
James’s Hospital/Ireland, 9Thoracic Oncology, NKI-
AVL/Netherlands, 10Division Of Thoracic Surgery, 
University Hospital Zurich/Switzerland, 11Oncology, 
Catalan Institute Of Oncology, Hospital Germans 
Trias I Pujol/Spain, 12University Hospital Zürich/
Switzerland
Background: ALK gene rearrangement (ALK+) 
has been identiÀed as a viable therapeutic target 
for NSCLC but its prevalence appears to be low, 
varies depending on the population screened, 
and on the method used for detection. There is 
little data on ALK+ in European populations or 
the natural history of ALK+ NSCLC. Also, there 
is no consensus on the gold standard test for 
ALK+. ETOP has established the LUNGSCAPE 
translational research program to address the 
challenges of studying rare molecular subtypes of 
NSCLC by creating a decentralised NSCLC tissue 
bank linked to clinical, pathological and molecular 
data held in a central web-based database. The Àrst 
LUNGSCAPE study will investigate the prevalence 
and clinical outcomes of ALK + in NSCLC patients 
in Europe. 
Methods: ETOP members will retrospectively 
identify NSCLC cases (resected stage I-III) with 
tumour tissue available for research. Clinical 
(demographic and outcome) and pathological 
tumors. Patients with previous breast cancer have 
an increased risk to develop a second neoplasm, 
frequently pulmonary cancer. In such clinical 
setting, it is very important to conÀrm its origin in 
order to avoid misdiagnosis and treatment. Similar 
situation is observed in other primary tumors and 
their metastasis to the lung. Our aim was to study the 
expression of TTF-1 (Novocastra SPT24) in a wide 
serie of non pulmonary neither thyroid tumors. 
Methods: 650 primary tumors, including gastric 
(51), ovarian (102), prostate (99), pancreatic (42), 
breast (74), colon (137), endometrial (45) and 
urothelial bladder (100) primary carcinomas were 
collected from our Àles . Tissue micro arrays (TMA) 
were performed, taking three samples for each case. 
Negative controls (lymph node tissue) were also 
included in each TMA. TTF-1 staining was evaluated 
by two independent pathologists ( percentage 
and intensity of staining ). Whenever a major 
discrepancy was observed, the cases were discussed 
under a multiheaded microscope. In order to see the 
pattern of expression, immunohistochemistry was 
repeated in whole parafÀn sections of every positive 
case and in 25 negative tumors. 
Results: TTF-1 expression was observed in 29 cases 
(4,4 %), mainly in urothelial (1,4 %) and colonic 
carcinomas (0,8 %). Weak and focal expression 
was observed in 7,1 % of pancreatic , 4,4 % of 
endometrial, 4 % of prostatic, 3,6 % of gastric and 
2,7 % of breast cancer .However, strong and diffuse 
expression (>50% of positive cells), was only found 
in 8 cases (1,2 %: 3 urothelial, 3 ovarian, 1 colonic 
and 1 endometrial carcinomas).
Conclusion: In our opinion strong and diffuse TTF-
1 positivity is highly speciÀc for pulmonary and 
thyroid primary tumors. Similar results were only 
found in a low percentage of cases (1,2%), mainly 
in ovarian and urothelial carcinomas. These results 
support the role of TTF-1 as an important tool to 
differentiate primary pulmonary from metastasis. 
However, weak and focal expression seen in some 
tumors has not to be interpreted as indicative 
of pulmonary or thyroid origen and can lead to 
misdiagnosis in small biopsy or cell blocks from 
Àne needle aspiration. In these setting others speciÀc 
markers have to be performed 
Keywords: speciÀc markers, Lung cancer, TTF-1
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.223 INVESTIGATION OF POLY (ADP-
RIBOSE) POLYMERASE 1 (PARP1) AS 
A NOVEL THERAPEUTIC TARGET IN 
SMALL CELL LUNG CANCER (SCLC)
Lauren A. Byers1, Monique Nilsson1, Junya 
Fujimoto2, Pierre Saintigny1, Jing Wang3, Lixia 
Diao3, Michael Peyton4, You-Hong Fan1, Uma Giri1, 
Stephanie Weber4, Boris Duchemann1, Luc Girard4, 
Kevin Coombes5, John Weinstein5, John D. Minna4, 
Ignacio Wistuba2, John V. Heymach1 
1Thoracic/head And Neck Medical Oncology, 
MD Anderson Cancer Center/United States Of 
America, 2Pathology, The University Of Texas MD 
Anderson Cancer Center/United States Of America, 
3Bioinformatics And Computational Biology, MD 
Anderson Cancer Center/United States Of America, 
4Hamon Center For Therapeutic Oncology Research, 
University Of Texas Southwestern Medical Center/
United States Of America, 5MD Anderson Cancer 
Center/United States Of America
Background: Small cell lung cancer (SCLC) is an 
aggressive disease characterized by initial sensitivity 
to chemotherapy and radiation followed by the 
invariable development of treatment resistance. 
New therapies are needed to improve clinical 
outcomes for these patients. Using high-throughput 
protein array proÀling, we previously demonstrated 
overexpression of poly (ADP-ribose) polymerase 1 
(PARP1) in a panel of 35 SCLC cell lines. Here we 
investigated PARP1 expression in patient tumors and 
as a potential new therapeutic target. 
Methods: PARP1 mRNA levels were assessed 
in publically available databases. At the 
protein level, total PARP1 was measured by 
immunohistochemistry (IHC) in a tissue microarray 
of archival tumor specimens. IHC scores were 
calculated based on the percentage of tumor cells 
staining positive times the staining intensity (0-3+) 
(possible scores 0-300). For the in vitro studies, cells 
were treated with a commercially available PARP 
inhibitor for 14 days +/- 7 days of chemotherapy and 
relative cell viability assessed by cell count. 
Results: PARP1 mRNA was overexpressed in 
SCLC tumors relative to non-small cell lung cancer 
(NSCLC) (p=0.005) and normal lung tissue (p=9.7 
x 10-8) when compared by t-test. In neuroendocrine 
lung tumors, total PARP1 protein levels correlated 
with the degree of differentiation. Highest levels 
were seen in SCLC (n=12, mean IHC score 
data will Àrst be submitted to the central database 
then tissue samples of cases meeting predeÀned 
acceptance criteria, to control quality of clinical 
data, will be analysed. Tissue samples will be 
analysed at local sites using the same methods, 
and after the site has passed a pathology quality 
assurance exercise. The objectives are to 1) 
evaluate the expression and clinical signiÀcance of 
ALK+ in a cohort of 1500 NSCLC patients with 
resected stage I-III tumors. 2) Conduct a nested 
case-control study of ALK+ versus ALK- patients 
(matched 1:2) with a target sample size of 50 ALK+ 
patients to give a HR for survival of 1.72 with 80% 
power, p=0.05 (80% events). 3) Compare a panel of 
antibodies for ALK+ using immunohistochemistry 
(IHC) on full tissue sections and on a tissue 
microarray (TMA) 4) Compare IHC to Áuorescent 
in situ hybridization (FISH) in TMA (all ) samples 
5) Compare IHC ALK+ cases with FISH in full 
sections 6) Correlate TMA results with results for 
full sections. 
Results: 19 ETOP member sites have registered 
to participate. More than 5000 surgically resected, 
clinically annotated samples with at least 3 and 
not more than 8 years of follow up are potentially 
available. The database is constructed with data 
entry scheduled to commence in April 2011 and 
analysis of tissue samples through Q2 - Q3. 
The organizational structure, standard operating 
procedures for clinical data collection and 
molecular testing, results from the pathology QA 
exercise, and the progress of the study will be 
reported. 
Conclusion: A consortium approach is essential 
to rapidly acquire knowledge of the prevalence 
and context of rare molecular subtypes. The 
ETOP LUNGSCAPE 001- ALK study provides a 
mechanism to address the questions of who to test 
and how to test in a large cohort of patients. The 
coordinated effort with built in QA processes and 
sharing of knowledge will harmonise practices and 
raise standards of tissue biobanking, clinical data 
collection and molecular testing across Europe, 
ultimately for the beneÀt of patients and better 
access to new treatments.
Keywords: Non-small cell lung cancer, ALK gene 
rearrangement
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effectiveness of TBNA in the diagnosis of hilar 
or mediastinal lymphadenopathy in patients with 
a concurrent or previous known extrathoracic 
malignancy. 
Methods: Between 2007 and 2010, 451 consecutive 
TBNA (conventional and EBUS-guided) 
procedures were performed in the our Chest 
Department. We analyzed data of patients with a 
concurrent or previously diagnosed extrathoracic 
malignancy referred for TBNA with a suspicion of 
mediastinal or hilar metastasis based on 10mm 
lymphadenopathy or <10mm lymph node with 
2-Áuoro-2-deoxy-D-glucose (FDG) uptake on 
positron emission tomography (PET). Previous 
hemopathy were excluded. Procedures were realized 
in outpout patients. Rapid on site examination was 
systematically performed. Tumor differentiation 
markers (TTF1, P63, CK7/CK20, Hormonal 
Receptors...) were performed whenever it was 
needed, depending on the diagnostic orientation and 
morphology. 
Results: 68 patients with concurrent (n=15) 
or previously diagnosed (n=53) extrathoracic 
malignancies were evaluated. They were 21 
breast, 11 head and neck, 8 kidney, 7 prostatic, 6 
colorectal carcinomas, 5 melanomas and 18 others 
various sites; 8 patients having two extrathoracic 
malignancies. A total of 70 procedures were 
performed among which 16 conventional TBNA 
and 54 EBUS-TBNA (2 patients had the both 
procedures). A total of 129 lymph nodes was 
analyzed. Mean number of needle passes performed 
by procedure was 5 (1 to 10). The median size of 
lymph nodes was 12mm (6 to 40). All procedures 
were contributive except 2 (Ànal diagnosis were 
SCLC). In 40 procedures (59%), TBNA detected 
lymph node metastatic spread: 20 metastasis of 
the known extrathoracic tumour (29%), 18 from 
a second malignancy (26%) (12 NSCLC and 6 
SCLC) and 2 from undifferentiated carcinoma. In 
28 procedures (41%), lymph node material was 
obtained, without malignancy (negative TBNA) 
but in 4 cases, epitheliod cells granulomas were 
observed suggesting sarcoidosis or sarcoid-like 
reaction. In cases with negative TBNA, 9 subsequent 
surgical stagings were performed: malignancy was 
diagnosed in only 1 patient. Contributive material 
was obtained in 97% of the procedures and a Ànal 
pathological diagnosis available in 49 (72%). In the 
contributive procedures with pathological diagnosis 
available, sensitivity and negative predictive values 
of lymph node metastatic spread were 97% and 85% 
262/300) and large cell neuroendocrine (n=20, 
mean 237/300), while intermediate levels were 
seen in atypical carcinoid (n=9, mean 230/300) and 
typical carcinoid (n=55, mean 197/300). In contrast, 
PARP1 expression was signiÀcantly lower in 
NSCLC with squamous (n=15, mean 120/300) and 
adenocarcinoma (n=24, mean 104/300) histologies. 
Preliminary in vitro testing showed sensitivity of 
SCLC and LCNEC cell lines to PARP inhibition, but 
resistance in NSCLC lines. When combined with 
cisplatin and etoposide in a SCLC line, cell viability 
was further decreased beyond that of chemotherapy 
or PARP inhibitor alone. 
Conclusion: PARP1 is highly expressed in high-
grade neurodendocrine lung tumors at the mRNA 
and protein level. PARP1 inhibition alone and in 
combination with chemotherapy showed activity 
in SCLC and LCNEC lines. These Àndings support 
further investigation of PARP1 as a potential novel 
therapeutic target in high-grade neuroendocrine lung 
cancers. 
Keywords: SCLC, PARP1, Large cell 
neuroendocrine
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P4.224 HILAR OR MEDIASTINAL 
LYMPHADENOPATHY IN PATIENTS 
WITH CONCURRENT OR PREVIOUSLY 
DIAGNOSED EXTRATHORACIC 
MALIGNANCY : RELEVANCE 
OF TRANSBRONCHIAL NEEDLE 
ASPIRATION (TBNA)
Valerie Gounant1, Amandine Briault2, Joseph 
Gligorov3, Khaldoun Kerrou4, Jacques Cadranel2, 
Jalal Assouad5, Jocelyne Fleury-Feith6, Jean-François 
Bernaudin6 
1Service De Pneumologie, Service De Chirurgie 
Thoracique, Hôpital Tenon/France, 2Service De 
Pneumologie, Hôpital Tenon/France, 3Service 
D’oncologie, Hôpital Tenon/France, 4Service De 
Médecine Nucléaire, Hôpital Tenon/France, 5Service 
De Chirurgie Thoracique, Hôpital Tenon/France, 
6Service D’histologie Biologie Tumorale, Hôpital 
Tenon/France
Background: Transbronchial needle aspiration 
(TBNA), conventional or ultrasound-guided (EBUS-
TBNA), is a minimally invasive method in the 
initial staging (N) of patients with NSCLC. Other 
applications can be discussed. We investigated the 
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97.7%, and there was no false positive, which means 
speciÀcity was 100%. On the other hand, 5 false 
negative had occurred. Among 219 malignant cases, 
it was quite easy to predict pathological subtypes in 
adenocarcinoma (86%) and squamous cell carcinoma 
(92%), but had difÀculty in large cell carcinoma 
(17%), pleomorphic carcinoma (0%), and metastatic 
tumors (21%). There was no recurrent case which 
is suspected involvement in dissemination due 
to puncture. IFNAC was extremely costless in 
comparison to VATS lung biopsy.
Conclusion: This study showed IFNAC is a reliable 
(high sensitivity and speciÀcity), safe, and cost-
effective approach for diagnosis on lung tumors.
Keywords: intraoperative diagnosis, Àne needle 
aspiration cytology, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.227 IMPORTANCE OF 
IMMUNOHISTOCHEMISTRY (IHC) ON 
THE DIAGNOSIS OF LUNG CANCER
Haris Charalambous1, Marios P. Decatris1, 
Nikos Katodritis1, Demetrios Vomvas1, Charis 
Charalambous2 
1Oncology, Boc Oncology Centre/Cyprus, 
2Histopathology, Nicosia General Hospital/Cyprus
Background: Increasingly in Lung Cancer central 
review of initial histopathology reports is being 
undertaken. This allows for site specialized Lung 
pathologists to review the histology specimens and 
also for IHC to be undertaken in central pathology 
laboratories. This is especially important in the sub-
classiÀcation of Lung Cancer, not only into Small 
cell Lung Cancer (SCLC) or Non Small cell Lung 
Cancer (NSCLC), but also for the subclassiÀcation 
of NSCLC into squamous and non-squamous, which 
now has major therapeutic implications.
Methods: Between 2006 and 2010, histopathology 
specimens from patients referred to the BOCOC 
in Nicosia, coming from private histopathologists 
in Cyprus (without IHC being undertaken) were 
referred for central review to a specialized Lung 
pathologist (CC) in the Nicosia General Hospital. 
This was undertaken in 86 cases. Comparison was 
made between the initial histology diagnosis and the 
with 100% speciÀcity. No complication had occured. 
Conclusion: TBNA is a safe and effective modality 
to evaluate mediastinal or hilar lymphadenopathy 
in patients with extrathoracic malignancy. The 
application of this diagnostic tool is likely to have 
signiÀcant clinical implications : to conÀrm the 
lymph node spread by extrathoracic malignancies or 
to perform alternative diagnosis as a second cancer, 
especially lung cancer or granulomatosis. 
Keywords: EBUS, TBNA, Staging, lymphnode
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P4.226 EVALUATION OF DIAGNOSTIC 
ACCURACY AND COST-
EFFECTIVENESS ON INTRAOPERATIVE 
FINE NEEDLE ASPIRATION CYTOLOGY 
FOR LUNG TUMORS
Wakako Hamanaka1, Yasuhiro Yoshida1, Fumiaki 
Kato1, Makoto Hamasaki2, Yutaka Kamihara2, 
Kazuki Nabeshima2, Sou Miyahara1, Jun 
Yanagisawa1, Daisuke Hamatake1, Naoyuki 
Imakiire1, Toshiro Obuchi1, Yasuteru Yoshinaga1, 
Takeshi Shiraishi1, Akinori Iwasaki1 
1Department Of Thoracic Surgery, Fukuoka 
University Hospital/Japan, 2Department Of 
Pathology, Fukuoka University Hospital/Japan
Background: The number of small-sized lung 
tumors is increasing in association with development 
of imaging methods such as multi detector-row 
CT (MDCT) and PET. In some cases we Ànd 
difÀculty to diagnose preoperatively even though 
transbronchial lung biopsy (TBLB) or percutaneous 
CT-guided biopsy is done. We perform intraoperative 
Àne needle aspiration cytology (IFNAC) in such 
cases. We evaluate whether IFNAC is reliable, safe, 
and cost-effective approach or not.
Methods: We performed 234 IFNAC during 
Àve years from 2005 to 2009. After intrathoracic 
observation, a central part of tumor was aspirated 
through 22G needle and the diagnosis was reported 
within 30minutes. We examined the speciÀcity, 
sensitivity, false positive, false negative, and a 
correlate of pathological diagnosis. Amount of cost 
was also calculated.
Results: Among 234 cases, 219 were diagnosed 
as malignant tumors (including 200 primary lung 
cancers, 19 metastatic tumors), and 15 belonged 
to Class I and II (5 lung cancers, 7 granulomas, 
2 benign tumors, 1 fungus ball). Sensitivity was 
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mutations in EGFR, KRAS and BRAF in a large 
panel of formalin-Àxed parafÀn-embedded tissue 
(FFPET) samples of NSCLC, using 3 investigational 
PCR-based assays. 
Methods: EGFR mutation status was assessed using 
the cobas EGFR Mutation Test which is designed 
to detect 43 mutations within exon 18 to exon 21 of 
the EGFR gene, including G719A/S/C in exon 18, 
deletions in exon 19, S768I/T790M and insertions 
in exon 20, and L858R/L861Q in exon 21. KRAS 
mutation status was assessed using the cobas KRAS 
Mutation Test, which detects > 21 mutations within 
codons 12, 13, and 61 of the KRAS gene. BRAF 
mutation status was assessed using the cobas 4800 
BRAF V600 Mutation Test, which was designed to 
detect the V600E (1799T>A) mutation in exon 15 
of the BRAF gene. Test results for each assay, which 
requires 100-150 ng DNA, can be generated within 
8 hours. 
Results: A total of 941 FFPET NSCLC vendor-
purchased samples were analyzed. Among 941 
samples, 904 (96.1%) were NSCLC, 17 (1.8%) 
were small cell lung cancer (SCLC), 11 (1.2%) 
had indeterminate histology; and 9 (1.0%) had no 
tumor cell present. The 904 NSCLC and 17 SCLC 
samples were analyzed for EGFR mutations. 893 
of 921 (97%) (876 NSCLC and 17 SCLC) samples 
gave a valid test result. Among the 17 SCLC, no 
EGFR mutations were detected. In the 876 NSCLC 
samples, EGFR mutations were detected in 90 
(10.3%) samples, including 85 (11.5%) in non-
squamous cell carcinoma and 5 (3.0%) in squamous 
cell carcinoma. . The EGFR mutations detected 
included: 46 exon 19 deletions, 22 L858R, 4 
G719X, 5 L861Q, and 6 exon 20 insertions as single 
mutations. Interestingly, there were 6 samples with 
more than one EGFR mutation ( 5 samples with 2 
mutations, 1 sample with 3). Three of these cases 
involved L861Q mutations and 4 involved exon 
20 insertions. 544 NSCLC samples which had no 
detectable EGFR mutations were further analyzed 
for KRAS and BRAF mutations. 127 of 541 (23.3%) 
samples contained KRAS mutations. 122/127 (96%) 
KRAS mutations were located at codon 12/13 and 
5/127 (4%) were located at codon 61. Only 4 of 544 
(0.7%) samples contained a BRAF V600E mutation. 
Conclusion: These data indicate that: a) EGFR 
mutations occur in approximately 11% of unselected 
non-squamous NSCLC and 3% of squamous 
NSCLC; b) multiple EGFR mutations within a 
sample are not unusual, especially involving L861Q 
and S768I; c) EGFR mutations are rare in SCLC; d) 
Ànal diagnosis following central review and IHC.
Results: There were 18 major changes in diagnosis 
(21%): 4 NSCLC changed into SCLC, 2 SCLC 
into lymphoma, 2 SCLC changed into NSCLC, 2 
adenocarcinoma into mesothelioma, 1 squamous 
into SCLC, 1 lymphoma into adenocarcinoma, 1 
carcinoid into metastasis from bladder cancer and 
Ànally 5 patients with poorly differentiated tumours 
or wide differential diagnosis were classiÀed into 
1 lymphoma, 1 SCLC, 2 adenocarcinomas and 1 
squamous cell cancers. There were also 22 minor 
changes (26%) where the subclassiÀcation of 
NSCLC changed, only 19 (22%) with treatment 
implications, ie from squamous to non-squamous 
and vice versa. Hence in total for 37 patients (43%) 
there were potential treatment implications as a 
result of this review.
Conclusion: This study shows the importance of 
undertaking central review including IHC for all 
patients referred with an initial diagnosis of lung 
cancer
Keywords: histology review, immunohistochemistry, 
Lung cancer
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P4.228 PREVALENCE OF MUTATIONS IN 
EGFR, KRAS AND BRAF IN ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC) AS ASSESSED BY A PANEL OF 
PCR-BASED ASSAYS
Patrick O’Donnell1, Robert Current1, Jane Ferguson1, 
Shih-Chang Chien2, Wei Wen2, Alison Tsan2, 
Nick Newton2, Laura Jung2, Keith Bauer2, Rachel 
Langland2, Victoria Brophy2, Nancy Schoenbrunner2, 
Thomas Myers2, Stephen Soviero1, Jeffrey 
Lawrence3, Lin Wu2 
1Development, Roche Molecular Systems/United 
States Of America, 2Research, Roche Molecular 
Systems/United States Of America, 3Medical Affairs, 
Roche Molecular Systems/United States Of America
Background: The identiÀcation of speciÀc 
somatic mutations is increasingly important in the 
clinical management of NSCLC as they identify 
molecular subsets of lung cancer and may predict 
responsiveness to speciÀc therapies. For example, 
EGFR mutations identify patients with advanced 
NSCLC who have a high likelihood of responding to 
anti-EGFR tyrosine kinase inhibitors. We performed 
a systematic assessment of the prevalence of 
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were actual LNs, of which 32 (10%) had metastasis. 
Six patients (15%) were pathologically upstaged 
by the special pathology examination: two with 
satellite nodules, four with LN metastasis. Of the 12 
patients with LN metastasis detected by the routine 
pathologic examination, 6 (50%) were found to 
have additional positive LNs. The median size of 
metastatic LNs was 1.3cm (range 0.1-2.4cm) versus 
non-metastatic LNs 0.6cm (range 0.1-2.7), p<0.0001. 
The median time for the special examination was 30 
minutes (range 12-80 minutes) for the entire trial and 
decreased signiÀcantly from the Àrst group of ten 
cases (median 44 minutes) to the last group of ten 
cases (median 25 minutes), p=0.0029. 
Median number of N1 
LNs examined (range) 
Median number of all 
LN examined (range) 
Control, era before special protocol 2 (0-13) 3 (0-19) 
After routine pathology examination 4 (0-15) 7 (1-27) 
After special pathology examination 6 (0-46) 6 (6-46) 
Routine pathologic examination + 
special pathologic examination 
10 (0-61) 15 (1-62) 
Median patient increase 
in total LNs examined 
P-value 
Control compared to routine 
pathology examination 
3 0.0045 
Routine pathology examination 
compared to routine pathology 
examination + special pathology 
examination 
6 <0.0001 
Control compared to routine 
pathology examination + special 
pathology examination 
8 <0.0001 
Conclusion: A special pathologic examination 
protocol retrieved a signiÀcant number of 
undetected N1 LNs, some of which harbored 
metastatic disease. A clinically meaningful number 
of patients were pathologically upstaged with the 
special examination, indicating a potential impact 
on prognosis and treatment recommendations. 
Despite a statistical difference in the size of LNs 
containing metastasis, broad overlap precludes using 
size as a discriminating characteristic. The time 
for the special examination declined signiÀcantly 
throughout the trial, demonstrating the value of 
experience and supporting the clinical feasibility of 
the special protocol. Additional studies are indicated 
to determine if the use of this technique inÁuences 
outcomes.
Keywords: Lymph node, Lung cancer, Staging
P
in NSCLC, KRAS and BRAF V600E mutations are 
mutually exclusive; e) all 3 assays can be performed 
on as little as 375 ng of total FFPET-derived DNA. 
Keywords: EGFR mutations, Kras mutations, BRAF 
mutations, molecular diagnostics
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P4.229 SPECIAL PATHOLOGIC 
EXAMINATION IMPROVES LYMPH 
NODE (LN) RETRIEVAL IN RESECTED 
LUNG CANCER.
Robert A. Ramirez1, Christopher G. Wang2, Laura E. 
Miller2, Courtney A. Adair3, Thomas O’Brien3, Allen 
Berry4, Raymond U. Osarogiagbon1 
1Department Of Hematology/oncology, University 
Of Tennessee Cancer Institute/United States Of 
America, 2Department Of Internal Medicine, 
University Of Tennessee Health Science Center/
United States Of America, 3Department Of 
Pathology, Duckworth Pathology Group/United 
States Of America, 4Department Of Pathology, Saint 
Francis Hospital/United States Of America
Background: Pathologic nodal staging is the main 
determinant of prognosis in patients following 
resection for lung cancer. Both surgeons and 
pathologists share the responsibility for examination 
of mediastinal LNs, however, the examination of 
intrapulmonary LNs is exclusively performed in 
the pathology laboratory. A prior analysis from the 
Memphis Metropolitan Area Quality of Surgical 
Resection Cohort showed that the median number of 
N1 LNs was 3. This was similar to the Àndings of the 
multi-institutional ACOSOG Z0030 study in which 
the median number was 5. We sought to determine 
the frequency with which intrapulmonary LNs are 
left unexamined and test the impact of a special 
pathology examination protocol on nodal staging. 
Methods: Prospective case-control study of 
remnant lung cancer resection specimens using a 
special pathology examination protocol of thin-
section lung dissection and light microscopy on 
all retrieved material, after completion of routine 
pathologic examination. We compared Àndings 
of this examination to the routine pathologic 
examination, and an external control cohort matched 
for pathologist and extent of resection.
Results: Additional LNs were discovered in 93% 
of specimens (table, N=41). Four hundred and sixty 
one LN-like samples were submitted, 305 (66%) 
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to be pN0 after routine examination. The non-LN 
tissue was signiÀcantly smaller than LN material 
(p<0.0001); LN with metastases were signiÀcantly 
larger than those without metastases (p <0.0001). 
However, there was signiÀcant overlap in size 
between non-LN and LN tissue and between LN 
with and without metastasis (Table 1). 
Conclusion: A third of material retrieved as LN was 
non-LN tissue. This probably also occurs during 
routine pathologic examination and likely contributes 
to the low LN counts from N1 stations. However, we 
also found a mean of 7 discarded LN per patient. The 
statistically signiÀcant difference in size between 
non-LN and LN, and between LNs harboring and 
not harboring metastasis, is clinically meaningless 
because of the broad overlap in size between the 
3 different types of tissue material. Therefore, LN 
size is not an adequate arbiter of likelihood of LN 
metastasis. The protocol for routine pathologic 
examination of lung resection specimens needs to be 
modiÀed to facilitate more thorough examination for 
intrapulmonary LN. 
Keywords: Staging, pathology, Lymph node, quality 
of care
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P4.231 EXAMINATION OF THE 
INFLUENCE THAT VASCULAR 
INVASION AND LYMPHATIC 
INVOLVEMENT GIVES PROGNOSIS 
OF STAGE I NON SMALL-CELL 
LUNG CANCER IN NEW TNM 
CLASSIFICATION
Katsuo Kojima1, Naoyuki Fujiwara2, Kenichi Okubo2 
1Thoracic Surgery, Musashino Red-cross Hospital/
Japan, 2Thoracic Surgery, Tokyo Medical And Dental 
University Hospital/Japan
Background: Some reports that vascular invasion 
and lymphatic involvement is a prognostic factor 
have appeared in Stage I non small-cell lung cancer in 
previous TNM classiÀcation. The new classiÀcation 
(UICC-TNM 7th) has been already used, but in this 
classiÀcation, the vascular invasion and lymphatic 
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P4.230 SIZE CHARACTERISTICS OF 
LYMPH NODE MATERIAL RETRIEVED 
FROM REMNANT TISSUE AFTER 
ROUTINE PATHOLOGY EXAMINATION 
OF LUNG CANCER RESECTION 
SPECIMENS.
Raymond U. Osarogiagbon1, Robert A. Ramirez1, 
Christopher G. Wang2, Laura E. Miller2, Courtney A. 
Adair3, Allen Berry4, Thomas O’Brien3 
1Internal Medicine, University Of Tennessee/
United States Of America, 2Department Of Internal 
Medicine, University Of Tennessee Health Science 
Center/United States Of America, 3Department Of 
Pathology, Duckworth Pathology Group/United 
States Of America, 4Department Of Pathology, Saint 
Francis Hospital/United States Of America
Background: Lymph node (LN) stage is the most 
important prognostic determinant after resection 
of lung cancer. Eighteen percent of all lung cancer 
resections in the US and 12% of our Memphis 
Metropolitan Area Quality of Surgical Resection 
(MMA-QSR) cohort have no LN examined (pNx). 
We previously showed that patients with pNx 
have inferior survival to T-category matched pN0 
patients with at least 1 examined LN. Only a median 
of 3 N1 LNs are examined after resection of lung 
cancer in the US, this is identical to the MMA-QSR 
cohort. We hypothesized that a signiÀcant number 
of intrapulmonary LN are left unexamined in lung 
resection specimens and sought to determine the 
proportion of such nodes that harbor undiagnosed 
metastases. We report the size characteristics of the 
additional material retrieved by our re-dissection 
protocol. 
Methods: Prospective study of lung resection 
specimens re-dissected after signout of the Ànal 
pathology report. Remnant lung material was 
dissected with thin cuts and all anthracotic material 
was retrieved for microscopic examination, 
irrespective of size or location. The size of non-
LN tissue, LN without metastasis and LN with 
metastases were compared using the Wilcoxon-
Mann-Whitney test. 
Results: 41 remnant lung resection specimens were 
examined, from which 461 LN-like materials were 
retrieved. Of these, 156 (34%) proved to be non-LN 
tissue. Thirty two of the 305 (10%) LN retrieved 
had metastasis. These LN were found in 16 of 41 
(39%) patients, 4 of whom (25%) had been reported 
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and coronary artery disease. Smoking is even more 
harmful when associated with a sedentary lifestyle, 
which is seen as a primary factor for cardiovascular 
disease. The six-minute walk test is being used as 
an alternative to evaluate the physical capacity of 
patients with heart or lung disease. The test measures 
the distance a patient can walk on their own in 
a corridor for six minutes. Along with the test, 
the Borg scale was used, therefore the subjective 
perception of intensity of effort by the patient could 
be measured in numerical values (degree of fatigue), 
contributing greatly to the interpretation of results. 
OBJECTIVE: Investigate the effects on tolerance to 
physical exercise in sedentary young women. 
Methods: The evaluation of 40 sedentary women 
was divided into two groups: Control group (20 
non-smokers) and Smoking group (20 smokers). 
Firstly, data was collected on respiratory rate, heart 
rate and blood pressure. In sequence, they took the 
six-minute walk test. Immediately after the test, the 
level of effort on the Borg scale was veriÀed and 
the women were assessed again, according to the 
parameters mentioned above. The distance covered 
in the walking test was also measured. The data were 
analyzed using the “Student’s t test” 
Results: In the control group of nonsmokers, there 
was no statistically signiÀcant difference between 
the results of the pre-test and the test. Taking into 
consideration the distance traveled by these patients 
(628m), the difference was statistically greater 
than the distance traveled by the smoking group 
(536m). The smokers showed statistically signiÀcant 
difference for heart rate and respiratory rate in 
relation to its preliminary assessment. As for the 
Borg scale, this group had an average value of Àve, 
higher than the control group, whose average value 
was three. 
Conclusion: After the six-minute walk, there was 
a marked increase in respiratory rate, heart rate and 
feeling of tiredness in the smoking group. Also, 
the distance traveled by the smoking group was 
statistically lower than the distance traveled by the 
control group. 
Keywords: physical exercise, Smoking effects
involvement is not yet considered in the stage.
Methods: We investigated the inÁuence that 
vascular invasion and lymphatic involvement 
(assumed v/ly factor as follows) gives recurrence 
rate of Stage I non small-cell lung cancer in new 
TNM classiÀcation. We analyzed 250 Stage IA-IB 
cases that prognosis is clear among 563 cases of non 
small-cell lung cancer to whom radical operation was 
performed in Tokyo medical and Dental University 
Hospital in Nov.1993 - Jan.2006. We used Kaplan 
Meyer analysis for survival rate, the chi-square 
test for comparison of recurrence rate and Logistic 
regression analysis for multivariate analysis.
Results: In 250 cases, p-T1a, p-T1b and p-T2a cases 
were 80, 55 and 115. And Àve year survival rate 
was 95%, 87% and 73% in each stage. Analysis of 
all cases showed that recurrence rate is signiÀcantly 
high in v/ly factor positive cases (p<0.001), and 
subclass analysis in p-T1a groups showed the same 
results (p-T1a:p=0.003). In multivariate analysis of 
the p-T2a group, p factor was the only signiÀcant 
recurrence factor (p=0.04), but v/ly factor was the 
only signiÀcant recurrence factor (p=0.005) when the 
p2 cases were excluded from this group.
Conclusion: It is supposed that vascular invasion 
and lymphatic involvement may be an important 
recurrence factor of Stage I non small-cell lung 
cancer (except p2 cases) in a new classiÀcation same 
as a previous classiÀcation.
Keywords: Stage I non small-cell lung cancer, 
vascular invasion and lymphatic involvement, 
recurrence factor, Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.232 SMOKING EFFECTS ON 
TOLERANCE TO PHYSICAL EXERCISE 
IN SEDENTARY YOUNG WOMEN
Juliana D. Leandro, Rogerio Traballi, Renata 
Medeiros, Bruno Muller, Camila Guerra, Tiaki M. 
Lopes 
Fisioterapia, Unip/Brazil
Background: Introduction: Smoking is now 
worldwide considered a public health problem, 
which is responsible for the increased prevalence of 
lung cancer, chronic obstructive pulmonary diseases 
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expression rate of ROS in NSCLC was 34.4% 
(33.3% for squamous cell carcinoma, 34.5% for 
adenocarcinoma, 42.9% for NSCLC, NOS). Patients 
were followed up to 8.8 years (median follow-up 
period; 4.0 years). ROS expressing group showed lower 
recurrence-free survival (RFS) rate than non-expressing 
group (p=0.121). In subgroup analysis, ROS expressing 
adenocarcinomas showed signiÀcantly lower RFS 
than non-expressing adenocarcinoma group (p=0.032). 
However, RFS of ROS expressing squamous cell 
carcinomas and overall survival of ROS expressing 
adenocarcinomas were not signiÀcantly different in 
each subgroup (p=0.592 and p=0.253, respectively). 
Array CGH analysis showed copy number gain 
in 15.8% (3/19) of adenocarcinomas, which was 
conÀrmed by FISH analysis. Methylation study showed 
no meaningful result. 
Conclusion: A subset of NSCLC showed over-
expression of ROS receptor tyrosine kinase 
possibly in relation to gene copy number gain. In 
adenocarcinoma patients, its over-expression is 
related to poorer prognosis. The results suggest 
that ROS can be a potential therapeutic target of a 
subgroup of NSCLC. Further studies are needed to 
validate our results and to elucidate the mechanism 
of ROS activation in NSCLC. 
Keywords: receptor tyrosine kinase, Non-small cell 
lung cancer, ROS
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P4.234 DIAGNOSTIC ACCURACY 
OF TUMOR MARKERS IN SEROUS 
EFFUSION
Jaume Trapé1, Jesus Montesinos2, Rafael Molina3, 
Joan Lopez1, Montserrat Domenech1, Esperanza 
Martin1, Josep Roca1, Emili Marquilles1, Concepcion 
Perez1, Rosana Blavia1, Damia Perich1, Fina 
Franquesa1, Josep Badal1 
1Althaia,xarxa Assistencial De Manresa/Spain, 
2Oncology, Althaia,xarxa Assistencial De Manresa/
Spain, 3Hospital Clinic Barcelona/Spain
Background: Elucidation of the etiology of serous 
effusions is a challenge for the clinical diagnosis. 
Several studies have demonstrated the clinical 
utility of tumor markers (TM) for diagnosing 
neoplastic effusions, but the results are highly 
disparate. The reported sensitivity varies from 20% 
to 80%, depending on the combination of markers, 
and the speciÀcity from 70% to 100%. The main 
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P4.233 ROS RECEPTOR TYROSINE 
KINASE EXPRESSION IN NON-SMALL 
CELL LUNG CANCERS AND CLINICAL 
IMPLICATION
Hee Jin Lee1, Hyang Sook Seol2, Young-Ah Suh3, 
Chang-Min Choi4, Seung-Il Park5, Dong Kwan Kim5, 
Yong Hee Kim5, Se Jin Jang1 
1Department Of Pathology, Asan Medical Center, 
University Of Ulsan College Of Medicine/Korea, 
2Life Science Lab, Asan Medical Center/Korea, 
3Institute For Innovative Cancer Research, Asan 
Medical Center/Korea, 4Oncology, Asan Medical 
Center/Korea, 5Thoracic And Cardiovascular 
Surgery, Asan Medical Center, University Of Ulsan 
College Of Medicine/Korea
Background: Several microarray analyses showed 
signiÀcantly elevated ROS expression in 20 to 
30% of non-small cell lung cancers (NSCLC). 
As a mechanism, oncogenic translocation of ROS 
in NSCLC has been identiÀed. However, there is 
great difference in the frequencies of expression 
by microarray data and gene translocation. Recent 
report of an epigenetic mechanism of gene activation 
in brain tumors suggests presence of alternative 
mechanism of ROS activation in NSCLC other than 
translocation. We aimed to evaluate the frequency 
of ROS expression in NSCLC at protein level and 
its prognostic signiÀcance for future use of recently 
developed ROS kinase inhibitors. 
Methods: Four hundred and twenty Àve cases 
of resected stage I NSCLC between 2000 and 
2005 were recruited to tissue microarray. Among 
them, 252 adenocarcinomas, 159 squamous cell 
carcinomas and 14 NSCLC, NOS were included. 
Immunohistochemistry using monoclonal antibody 
against ROS protein and statistical analyses with 
clinicopathologic data were performed. As a positive 
and negative control, we used HCC78 and NCI-H460 
cell blocks, respectively after conÀrmation of their ROS 
expression status by real time PCR. The expression 
levels were arbitrarily scored and more than moderate 
intensity is considered as positive. To elucidate 
mechanism of expression, a subset of samples was 
subjected to copy number measurement by array CGH 
and FISH, and methylation analysis of the gene. 
Results: Cell block of HCC78 showed strong 
membranous and cytoplasmic ROS expression, 
in contrast to complete negativity of NCI-H460 
cells. Similarly to pervious microarray data, overall 
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Netherlands. We explored the number of tumour 
biopsies used for EGFR and KRAS mutation. 
Methods: Between November 2008 and August 
2010 chest physicians from 8 hospitals in the 
Northern Netherlands send in lung biopsies to the 
laboratory of Molecular Pathology at the department 
of Pathology within the University Medical Center 
of Groningen for EGFR/KRAS mutation analysis 
and EGFR FISH status using Colorade criteria. 
For the detection of mutations in exons 18-21 of 
EGFR and exon 1 of KRAS bidirectional sequence 
analysis was performed on DNA extracted from an 
enriched region in the PFFE slide marked by the 
pathologist containing >50% tumor cells. Patient 
Àles were studied for sex, smoking status, age, stage 
at diagnosis, Àrst three lines of treatment (including 
TKI), progression free survival (PFS) and overall 
survival. A total of 257 tumour biopsies were tested 
and for 187 patients complete clinical data were 
available. Median age at diagnosis of patients was 
61 (38- 88) with 43% of patients being women. 
Smokers 40%, non smokers 16%, former smokers 
42%. Two patients had a second primary tumor 
which were both analysed. 
Results: We were able to extract adequate DNA 
from 144 of 189 samples send to our lab (76%). 
A relative large number of biopsies (42/189; 24%) 
was not used for DNA testing because no sufÀcient 
tumor cells were present. In 3 cases the quality of 
DNA was not suitable for mutation testing. 11/144 
(8%) patients had an EGFR mutation, 2 patients 
had non-functional mutations. No TKI-resistant 
mutations were found. 49/120 (40%) patients had 
a positive FISH according to the Colorado criteria 
(43 EGFR polysomy and 6 ampliÀcation). 46/144 
(32%) patients had a KRAS mutation, 1 patient had 
both a EGFR and KRAS mutation. Of the 189 tested 
patients, 55 were treated with an EGFR TKI. Of 
these 55 patients, 28 had wildtype EGFR and 9 had 
an EGFR mutation, 1 patient had an intron mutation 
and EGFR mutational status was unknown in 16 
patients because of insufÀcient material for mutation 
testing. Presently, follow-up data of these patients 
are collected to evaluate the TKI-response in relation 
to EGFR-mutations 
Conclusion: Increasing EGFR mutation testing is 
implemented in advanced NSCLC. SufÀcient tumour 
tissue for adequate mutation analysis remains an 
issue in testing advanced NSCLC both by better 
instruction of chest physicians regarding biopsy 
material and selection of appropiate samples, and 
the introduction of EGFR-mutation tests with 
conditions resulting in false-positive TM results, 
tuberculous, complicated parapneumonic effusions 
and empyema, can be identiÀed by analysis of 
several biological magnitudes, such as adenosine 
deaminase (ADA), C-reactive protein (CRP) and % 
of polymorphonuclear (%PN). The aim of tihs study 
is to evaluate the diagnosis performance of TM in 
serous effusions and to assess whether ADA, CRP 
and %PN allow identify false positives. 
Methods: We determinated in 537 serous effusions 
CEA, CA19-9, CA15-3, ADA, CRP and leukocyte 
differential count. We classiÀed in two groups: those 
effusions with ADA <45U/L, CRP <50mg/L or 
differential leukocyte count <90% PN group A and 
those with ADA >45U/L, CRP >50mg/L or >90%PN 
group B (identify most frequent diseases with no 
malignant elevations of TM). In group A (n=438) 
the effusions were considered to have a malignant 
etiology when TM values were over the serum cut-
off for CEA, CA15-3, and CA19-9; and when Áuid/
serum ratio was >1.2 for CEA, CA15-3 and CA19-9.
Results: Based on these criteria, sensitivity for 
the combination of all TMs was 77.65% at 100% 
speciÀcity. In Group B (n=109) cut-off established 
for CEA, CA15-3 and CA 19-9 was 50 ng/mL, 70 
U/mL and 7700 U/mL respectively. We obtained 
a sensitivity of 68.4% at 100% speciÀcity. With a 
sensitivity for while effusion of 84% at a maximum 
speciÀcity
Conclusion: The identiÀcation of pathological 
conditions and other factors that result in false-
positive TM Àndings when analyzing serous 
effusions yields high sensitivity and maximum 
speciÀcity for these determinations.
Keywords: Serous effusions, Tumour markers, 
Diagnostic accuracy, Neoplasia
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P4.235 TESTING FOR EGFR AND KRAS 
MUTATIONS IN THE NORTHERN 
NETHERLANDS: BIOPSIES WITH 
SUFFICIENT TUMOUR TISSUE
Gerald S.M.A. Kerner1, Ed Schuuring2, Hannie 
Sietsma2, Wim Timens2, Harry J.M. Groen1 
1Pulmonary Disease, Umcg/Netherlands, 2Pathology, 
Umcg/Netherlands
Background: The availability of EGFR and KRAS 
testing in patients with advanced non small cell lung 
cancer has recently been introduced in the Northern 
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account, care should be taken not to overdiagnose 
AIS as PA. This overdiagnosis of PA may be 
avoided, by 1) realization that the chance to cut a 
papilla exactly longitudinal is as small as an exactly 
longitudinal hair in the skin 2) by using an elastic 
stain as elastin is a component of pre-existing 
alveolar wall and NOT produced by a papillary 
tumor (absent in papillary tumors in other organs and 
absent in metastases of papillary carcinomas of the 
lung). 
Keywords: papillary carcinoma, overdiagnosis, 
elastin, adenocarcinoma in situ
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P4.237 CLINICAL VALUE OF 
INTRAOPERATIVE PLEURAL LAVAGE 
CYTOLOGICAL POSITIVITY IN LUNG 
CANCER PATIENTS
Masatoshi Kakihana, Koichi Yoshida, Masahiro 
Taira, Hisashi Saji, Jitsuo Usuda, Naohiro Kajiwara, 
Tatsuo Ohira, Norihiko Ikeda 
First Dept. Of Surgery, Tokyo Medical University/
Japan
Background: The clinical signiÀcance of 
intraoperative pleural lavage cytology (PLC) for lung 
cancer has been insufÀciently elucidated. Whether 
the intraoperative PLC has effect on the independent 
factor as a prognostic marker or the impact of a 
positive result on stage-adjusted survival. 
Methods: Between 2000 and 2008, PLC was 
performed both after thoracotomy of the thoracic 
cavity in patients with lung cancer without malignant 
pleurisy .
Results: We examined 30cases. this was shown to be 
correlated with lyhph-angio-invasion.
Conclusion: PLC status after thoracotomy provides 
useful information in the detection of high-risk 
subgroup for pleural recurrence. Although PLC 
status is closely associated with survival, its 
prognostic value is not independent.
Keywords: Pleural lavage cytology, Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
higher analytical sensitivity such as High-Melting-
Resolution-Analysis.
Keywords: EGFR, EGFR TKI, Kras, EGFR FISH
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P4.236 THREE-DIMENSIONAL 
RECONSTRUCTION OF PAPILLARY 
ADENOCARCINOMA OF THE LUNG: 
SHEEP LOOKING LIKE A WOLF?
Erik Thunnissen, Jeroen Belien 
Pathology, VUMC/Netherlands
Background: Recently new multidisciplinary 
classiÀcation of lung adenocarcinoma has 
been described. The Papillary predominant 
adenocarcinoma (PA) shows a major component of a 
growth of glandular cells along central Àbrovascular 
cores. MyoÀbroblastic stroma is not needed to 
diagnose this pattern. During resection of the lung, 
compression / atelectasis of the lung is a normal 
phenomenon. The hypothesis is that if the air 
component is minimal a seemingly papillary pattern 
may arise. The clinical relevance is that in contrast to 
AIS, PA is by deÀnition invasive. The purpose of this 
study was to make 3- dimensional reconstruction of a 
strongly “papillary” tumor. 
Methods: From a patient with transthoracic biopsy 
(TTB) and lobectomy of a tumor serial hematoxilin-
eosin (H&E) stained sections were available for 
review. From the resection specimen 30 serial H&E 
slides were digitised (20x objective). The panoramic 
viewer software in combination with the 3D module 
(3DHISTECH, Budapest, Hungary) was used to 
make a 3 dimensional reconstruction. 
Results: For a papillary tumor it was expected to 
Ànd cross sections of papillae. However, this was 
rarely the case. In contrast the ‘so called’ papillae 
appeared to be continuous in space and were thin 
walls. Moreover, this architecture was similar to 
that of the adjacent lung and tumor cells at the edge 
were merging seamless with the pre-existing alveolar 
walls. Thus the papillary pattern was created by 
strongly compressed cut alveolar walls covered with 
monotonous tumor cells, making the diagnosis AIS 
in stead of PA. In addition the TTB consistently 
showed not-compressed lung with AIS. 
Conclusion: In microscopic sections of strongly 
compressed resection specimen with AIS a 
pseudopapillary pattern may be present mimicking 
true PA. Taken the clinical consequences into 
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before treatment and induced acute toxicity CTC 
2. PS  2 led to discontinuation of chemotherapy 
(0.009) and hospital admission (0.05) in concurrent 
chemo radiotherapy. 
Conclusion: Co-morbidity and upfront weight loss, 
do not have a signiÀcantly clinical impact on acute 
toxicity induced by concurrent chemo radiotherapy. 
Although baseline poor performing status and age  
75 contributes to discontinuation and hospitalisation 
during treatment, no relation was seen with toxicity. 
Keyword: non small cell lung cancer, chemo 
radiotherapy, co-morbidity, toxicity
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.239 A SAFETY ANALYSIS 
OF CONCOMITANT 
CHEMORADIOTHERAPY AND 
CETUXIMAB IN STAGE III NON-SMALL 
CELL LUNG CANCER (NSCLC): SECOND 
COHORT OF THE SCRATCH STUDY
Asad Qureshi1, Simon Hughes1, Nazia Mohammed2, 
Virginia Laurence3, Shahreen Ahmad1, James 
Spicer4, Grace Asante-Ntoni5, Sharon Delena6, David 
Landau1 
1Clinical Oncology, Guy’s And St Thomas’ NHS 
Foundation Trust/United Kingdom, 2Clinical 
Oncology, Nhs Greater Glasgow And Clyde/United 
Kingdom, 3Clinical Oncology, Poole Hospital 
NHS Foundation Trust/United Kingdom, 4Medical 
Oncology, Guy’s And St Thomas’ NHS Foundation 
Trust/United Kingdom, 5The Joint Clinical Trials 
OfÀce, King’s Health Partners Academic Health 
Sciences Centre/United Kingdom, 6Oncology And 
Haematology Clinical Trials, Guy’s And St Thomas’ 
NHS Foundation Trust/United Kingdom
Background: Cetuximab is under investigation 
in a number of trials in stage III NSCLC. The 
SCRATCH cohort I study showed early and late 
toxicity of synchronous cetuximab and radical RT 
to be acceptable in patients with stage III NSCLC 
following induction chemotherapy. The SCRATCH 
study cohort II assessed the safety of concomitant 
chemoradiotherapy and cetuximab. The early 
toxicity data (during treatment and until 6 weeks 
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P4.238 CORRELATION OF 
CO MORBIDITY, PATIENT 
CHARACTERISTICS AND THE 
OCCURRENCE OF TOXICITY DUE TO 
CONCURRENT, SEQUENTIAL CHEMO 
RADIOTHERAPY OR HIGH DOSE 
RADIOTHERAPY ALONE, IN PATIENTS 
WITH LOCALLY ADVANCED NON 
SMALL CELL LUNG CANCER
Wilma Uyterlinde1, Michelle M. Van Den Heuvel1, 
José Belderbos2 
1Thoracic Oncology, NKI-AVL/Netherlands, 
2Radiation Oncology, NKI-AVL/Netherlands
Background: The prognosis of locally advanced 
non-small cell lung cancer (NSCLC) is poor with a 
median overall survival of 15 months. The treatment 
of choice is concurrent chemo radiotherapy with 
a 12% increase in the overall survival compared 
to radical radiotherapy alone. Sequential chemo 
radiotherapy or radiotherapy alone is indicated in 
case of a large involved Àeld and the estimation of 
poor tolerance. Objective parameters for patient 
selection are missing 
Methods: . Prospective study in patients with 
locally advanced NSCLC in the Netherlands Cancer 
Institute- Antoni van Leeuwenhoek hospital, , 
treated in 2008 and 2009 with radical radiotherapy 
with or without chemotherapy, except SBRT. 
Patients were referred from Àeld hospitals or 
presented as new patients directly to the Antoni 
van Leeuwenhoek hospital. Tailored treatment was 
identiÀed during multi disciplinary consultation. 
Because of the incompleteness of data in patients 
receiving sequential chemo radiotherapy and 
radiotherapy alone, analysis on toxicity was done 
in the concurrent group. .For the assessment of co-
morbidity the Charlson Index and for acute toxicity 
scores the Common Toxicity Criteria of Adverse 
Events (Vs. 3.0) were used. Statistical methods 
included for age Wilcoxon Mann-Whitney Rank 
Sum Test, for treatment Fisher’s Exact Test for Count 
Data, for the Charlson index and performing status 
Linear-by-Linear Association Test 
Results: 155 patients underwent concurrent 
chemo radiotherapy, 33 patients sequential chemo 
radiotherapy and 62 patients radiotherapy alone. 
No signiÀcant correlations were found between co 
morbidity, age 75, weigh loss  10%, 6 months 
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cetuximab does not add signiÀcantly to toxicity.
Keywords: cetuximab, chemoradiotherapy, Stage 
III, Lung cancer
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P4.240 LONG TERM RESULTS OF 
MULTIDISCIPLINARY TREATMENT 
OF CARCINOMA OF THE SUPERIOR 
PULMONARY SULCUS
Abdelrahman M. Abdelrahman1, Rabab M. Gaafar2, 
Hoda A. Baki3 
1Surgery, National Cancer Institute/Egypt, 2Medical 
Oncology, National Cancer Institute/Egypt, 
3Radiation Therapy, National Cancer Institute/Egypt
Background: Superior sulcus tumors are a complex 
subset of tumors, because of their speciÀc anatomical 
location, these tumors pose signiÀcant technical 
challenges to thoracic surgeons .They are relatively 
rare tumors accounting for less than 5% of lung 
cancer. 
Methods: Between 2001 - 2009, 27 patients with 
superior pulmonary sulcus tumor were included. 
Contrast enhanced CT scan of the chest was 
considered the primary diagnostic and staging 
investigation for all patients. Pre operative tissue 
diagnosis was achieved in all patients by trans 
thoracic CT guided biopsy. Pre operative cervical 
mediastinoscopy was done in 18 patients . Radiation 
therapy was given pre operative to 24 patients in a 
dose of 45 Grays. Neo adjuvant chemotherapy was 
given to17 patients. 
Results: There were 25 males and 2 female. The 
mean age was 55 years. Lobectomy was performed 
in 24 patients and wedge resection was done for 
3 patients. Three to Àve ribs were resected in all 
patients . Extended resections were performed 
in 9 patients. Positive mediastinal lymph nodes 
were found 6 patients. Squamous cell carcinoma 
was found in 18 patients , 4 with undifferentiated 
carcinoma and the remaining 5 patients had 
adenocarcinoma. The Ànal staging was: Stage IIB 
(T3N0M0) 14, Stage IIIA (T3N2M0) 4, Stage IIIB 
(T4N0M0) 7 and Stage IV (T4N2M0) 2. Negative 
microscopic resection margin was achieved in 17 
patients. Morbidity developed in 10 (37%) patients, 
we had one operative related mortality. Tumor 
recurrence developed in 18 (66.6%) patients and was 
loco-regional in 7 patients, distant in 7 patients, and 
following completion of treatment) of this phase I 
study are presented below.
Methods: 18 patients with inoperable stage III 
NSCLC were recruited into the study between Feb 
2009 and Oct 2010. Participants received cisplatin 
75mg/m2 on days 1 and 29 with vinorelbine 20mg/
m2 on days 1, 8, 29 and 36 in addition to weekly 
intravenous cetuximab (initial dose 400mg/m2; 
maintenance dose 250mg/m2) weeks 0-7 and 
concomitant radiotherapy (64Gy/32 fractions/45 
days). The primary end-point, toxicity, was assessed 
using NCI and RTOG Common Toxicity Criteria 
(CTC) version 3.0 during RT and at regular follow-
up intervals.
Results: The median age was 63 years (range 31-
72). All patients commenced treatment according to 
the study protocol and completed RT as scheduled. 
1 patient withdrew from the study for personal 
reasons and received no further chemotherapy or 
cetuximab after the loading dose of cetuximab. 4 
patients (22%) had chemotherapy and/or cetuximab 
interrupted or discontinued due to toxicity (1 
upper GI bleed, 1 rash, 1 pneumonia, 1 diarrhoea 
with renal impairment). Rates of grade 3 or 4 
haematological toxicity follows with rates from 
other chemoradiotherapy trials in parentheses. 
Anaemia 6% (10% Furuse et al., 1999); neutropenia 
22% (58% Gandara et al., 2003); thrombocytopenia 
11% (12-52%). 22% reported grade 3 infection 
(3-20%). Rates of grade 3 or 4 RT-related toxicity 
were: pneumonitis 6% (1-16% O’Rourke et al., 
2010); oesophagitis 17% (18% Auperin et al., 2010). 
1 patient died 2 weeks following completion of 
treatment as a result of massive haemoptysis. Table 
of all grade 3 and 4 toxicities 
Grade Anaemia Thrombo-cytopenia
Neutro-
penia
Infection 
(neutropenic)
Infection
(non-
neutropenic)
Alopecia Skin Fatigue Oesophagitis Pneumo-nitis
Pneumo-
thorax Dehydration
3 0 2 1 1 3 1 1 4 3 1 1 1
4 1 0 3 0 0 0 0 0 0 0 0 0
Conclusion: Chemoradiotherapy and cetuximab was 
well tolerated in the majority of patients and could 
be completed as scheduled in 13 patients (72%). 
2 patients (11%) experienced massive bleeding. 
The patient who experienced upper GI bleeding 
was known to have a history of duodenal ulcers 
and in the case of fatal haemoptysis imaging had 
shown a poor response to treatment with disease 
adjacent to major pulmonary vessels. Toxicity 
results from this series compares favourably to other 
chemoradiotherapy studies suggesting the addition of 
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advanced stage III NSCLC and a good performance 
status, although a clearly superior regimen has 
not been identiÀed. D has been shown to possess 
good single agent activity against NSCLC as well 
as radiosensiziting properties, both alone and 
sinergisitically with C. The aim of our study was to 
evaluate the feasibility of induction chemotherapy 
with D-C followed by CChRT with biweekly D-C. 
Methods: 85 p with inoperable locally advanced 
NSCLC, stage IIIAN2/IIIB (no pleural T4), 
were included in a phase II study with induction 
chemotherapy consisting of three cycles of D 75 
mg/m2 on day 1 and C 40 mg/m2 days 1-2 every 
3 weeks and, if no surgery and no progresion, then 
underwent CChRT with D 30 mg/m2 and C 30 mg/
m2 every 2 weeks for four courses, during conformal 
thoracic radiotherapy (60-66 Gys, 180 cGy/day). 
The primary objective was overall survival (OS); 
secondary objectives were progression free survival 
(PFS), response rate (RR) and toxicity. Median 
follow-up: 16 months. 
Results: The p characteristics were: mean age 61 
years (44-75); male/female 77/8; ECOG PS 0/1 
in 25/60 p; squamous/adeno/large cell carcinoma: 
51.8%/28.2%/20%; stage IIIAN2 20 p (23.5%) 
and stage IIIB 49 p (76.5%). 78 p were evaluable 
for response and 82 p for toxicity. Induction D-C 
response: 2 CR, 46 PR (RR 61.5%; 95% CI:51-
72), 21 SD (26.9%) and 9 PD (11.6%). 9 p were 
treated with surgery: 1 pCR, 5 pPR, 1 pEE and 2 p 
unresectable. 56 p completed CChRT and 55 p were 
evaluable (one toxic death) with 8 CR, 37 PR (RR 
80%; 95% CI:70-90), 3 SD and 7 PD. The median 
PFS was 11 months (95% CI:8-14) and median OS 
was 19 months (95% CI:15-23). The PFS and OS at 
1/2 years were 46%/21% and 64%/33% respectively. 
A total of 235 cycles of D-C were given (2.8 per 
p); main toxicities (NCI-CTC 3.0) per p Grade (g) 
1-2/3-4 (%) were as follows: neutropenia 10.9/25.6; 
anemia 30.4/3.5; nausea/vomiting 30.4/7.3; fatigue 
28/0; diarrhea 17/9.7; there were ten episodes of 
febrile neutropenia and there was one treatment-
related death. Main toxicities per p in CChRT (D-C 
doses: 211, 3.6 per p; mean doses RT: 55,4 Gys) 
were: g1-2 neutropenia/anemia 12/34.4%; g1-2/3 
esophagitis in 51.7/1.7% and g1-2 pneumonitis in 
24.5%; there was one treatment-related death. 
Conclusion: Induction chemotherapy with 
Docetaxel and Cisplatin followed by concurrent 
thoracic radiotherapy with biweekly Docetaxel and 
Cisplatin is a feasible treatment option for locally 
advanced stage III Non Small Cell Lung Cancer, 
both loco-regional and distant in 4 patient. We had 
only 2 patients with local recurrence are surviving 
with disease, all the remaining patients with tumor 
recurrence died due to disease progression. Another 
2 patients died during follow up period and were free 
of recurrence. The mean survival time was 2.9 years 
and the overall 5 years survival was 33.3%. 
Conclusion: Radical surgery as part of multi 
modality treatment gives satisfactory results with 
low morbidity and mortality rates and acceptable 
survival in patients with superior pulmonary sulcus 
tumors. Surgery is considered the cornerstone 
therapy for this type of lung tumors. Great effort 
should be made to achieve microscopic negative 
resection margin. 
Keyword: superior , sulcus , carcinoma , 
multidisciplinary, treatment
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P4.241 DOCETAXEL (D) AND CISPLATIN 
(C) INDUCTION CHEMOTHERAPY 
FOLLOWED BY BIWEEKLY D AND 
C WITH CONCURRENT THORACIC 
RADIOTHERAPY FOR STAGE III NON-
SMALL CELL LUNG CANCER (NSCLC). 
A GALICIAN LUNG CANCER GROUP 
STUDY.
Joaquin Casal1, S. Vazquez2, U. Anido3, Martin 
Lazaro4, E. Hernandez5, P. Calvo6, Begoña Campos2, 
C. Grande1, J.L. Firvida7, F. Baron3, C. Azpitarte1, V. 
Ochagavia5, E. Fernandez6, S. Varela2, M. Amenedo8, 
M.D. Lopez9, M.C. Silva10 
1Oncoloxia Médica, Complexo Hospitalario 
Universitario De Vigo/Spain, 2Oncoloxia Médica, 
Hospital Universitario Lucus Augusti/Spain, 
3Oncoloxia Médica, Complexo Universitario/
Spain, 4Oncoloxia Médica, Complexo Hospitalario 
Universitario/Spain, 5Oncolxia Radioterápica, 
Complexo Universitario/Spain, 6Oncoloxia 
Radioterápica, Complexo Universitario/Spain, 
7Oncoloxia Médica, Complexo Cristal-Piñor/
Spain, 8Oncoloxia Médica, Centro Oncoloxico/
Spain, 9Oncoloxia Radioterápica, Complexo Cristal-
Piñor/Spain, 10Oncoloxia Radioterápica, Centro 
Oncoloxico/Spain
Background: Concurrent chemoradiation (CChRT) 
is recommended as the evidence-based approach 
for the management of patients (p) with locally 
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effusions, forced expiratory volume in one second 
1.3 L, and adequate organ function. Staging 
positron emission tomography scans were not 
routinely performed. Patients received pemetrexed 
500 mg/m2 on day 1 and cisplatin 20 mg/m2 on 
days 1-5, q21 days, for two cycles concurrent 
with RT (61-66 Gy in 32-35 fractions over 6-6.5 
weeks) followed by pemetrexed/cisplatin alone for 
two cycles q21 days (pemetrexed 500 mg/m2 and 
cisplatin 75 mg/m2 on day 1). Patients were fully 
supplemented with folic acid and vitamin B
12
.
Results: As of data lock, January 11, 2011, 39 
patients were accrued (median follow up, 14.2 
months). Demographics included: median age of 
63 years (range: 37-79); male/female (18/21); stage 
IIIA/B (15/24); ECOG PS 0/1 (23/16); and histology 
of adenocarcinoma (21), squamous (10), large cell 
(2), and NSCLC-NOS (6). Median RT dose was 64.0 
Gy (range: 14.4-66.0); 5 patients received signiÀcant 
RT dose reductions (total doses of 52.0, 50.8, 45.0, 
40.0, and 14.4 Gy). All four cycles of chemotherapy 
were delivered in 30/39 patients; three, two, and 
one cycle(s) only were delivered in 3, 5, and 1 
patient(s), respectively, due to adverse events (5), 
disease progression (1), patient refusal (1), and other 
(2). Preliminary toxicity analysis demonstrated 
that at least one high-grade (grade 3) toxicity 
(excluding leuko/lymphopenia) deemed possibly/
probably/deÀnitely related to study treatment was 
experienced by 29/39 patients. High-grade toxicity 
occurred mainly during concurrent therapy, with 
a maximum grade of 3/4/5 in 19/6/1 patient(s), 
respectively. Common toxicities during therapy 
included grade 3/4 neutropenia in 8/4 patients, and 1 
death due to neutropenic sepsis; grade 3 esophagitis 
in 2 patients, and grade 3/4 syncope (in the absence 
of high-grade esophagitis) in 3/1 patient(s); and 
grade 3/4 electrolyte abnormalities in 11/2 patients. 
After completion of therapy, grade 3/4 pneumonitis 
occurred in 1/1 patients and grade 3 esophageal 
stenosis in 1 patient. Median overall survival was 
28.7 months (95% conÀdence interval [CI]: 19.6-
30.5) and median progression-free survival was 
20.2 months (95% CI: 13.9-30.5). One-year overall 
survival was 79.0% (95% CI: 66.1%-92.0%) and 
1-year progression-free survival was 75.4% (61.4%-
89.4%).
Conclusion: Full-dose concurrent and adjuvant 
pemetrexed/cisplatin with full-dose RT is relatively 
well tolerated compared with other concurrent 
chemo-radiation regimens for stage IIIA/B NSCLC 
and shows encouraging efÀcacy. These data provide 
showing good clinical activity and tolerability with 
acceptable long-term survival. 
Keyword: Concurrent radiotherapy and 
chemotherapy
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P4.242 A PHASE II STUDY EVALUATING 
CONCURRENT PEMETREXED/
CISPLATIN/RADIATION (RT) FOR 
UNRESECTABLE STAGE IIIA/B NON-
SMALL CELL LUNG CANCER (NSCLC)
Anthony M. Brade1, Andrea Bezjak1, Robert 
Macrae2, Scott A. Laurie3, Ronald Burkes4, Quincy 
Chu5, Lisa Wang6, John R. GofÀn7, Sheth Grishma8, 
Stephanie Capobianco9, Neill Iscoe10, Frances A. 
Shepherd11 
1Radiation Oncology, Princess Margaret Hospital - 
University Of Toronto/Canada, 2Radiation Oncology, 
The Ottawa Hospital Cancer Centre, University 
Of Ottawa/Canada, 3Medical Oncology, Ottawa 
Hospital Cancer Centre/Canada, 4Mount Sinai 
Hospital/Canada, 5Alberta Health Services/Canada, 
6Biostatistics, Princess Margaret Hospital/Canada, 
7Oncology, Juravinski Cancer Centre/Canada, 
8Biostatistics, I3 Statprobe/United States Of America, 
9Medical Oncology - Drug Development Program, 
Princess Margaret Hospital - University Of Toronto/
Canada, 10Eli Lilly Canada/Canada, 11Department 
Of Medical Oncology, University Health Network, 
Princess Margaret Hospital And Univeristy Of 
Toronto/Canada
Background: Although concurrent 
chemoradiotherapy is standard treatment for 
patients with unresectable stage IIIA/B NSCLC, 
the best chemotherapy regimen/schedule has 
not been established. In a previous phase I study 
(Brade et. al, Int J Radiat Oncol Biol Phys, 2010 
ePub), pemetrexed was the Àrst third-generation 
chemotherapeutic deliverable at full dose 
concurrently with full-dose RT and cisplatin. This 
combination was evaluated further in this completed 
phase II study.
Methods: SFrom April 16, 2007 to August 24, 
2009, patients with unresectable stage IIIA/B 
NSCLC entered this single-arm, phase II trial at 
Àve Canadian centers. Patients had to have 5% 
weight loss, Eastern Cooperative Oncology Group 
performance status (ECOG PS) 0/1, no malignant 
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60 yrs, ranging from 36 to 81), squamous cell 
carcinoma subtype (41%), preoperative stage IIIA 
(67%), smokers (95%), PS 0 /1 (100%). Induction 
CT consisted in platinum-based association in 93%. 
Median number of cycles was 2 (ranging from to 1 
to 8), ³ 3 side effects were found in 12%. Clinical 
response rate to CT was 73%, ranging from 61% 
to 79%, according to the stage. Complete response 
rate was 3 % and major response (>50%) rate 45%. 
Surgery included pneumonectomy, lobectomy, 
wedge / segmentectomy or exploratory thoracotomy 
in respectively 26%, 58%, 5% and 10%. There 
were 10 postoperative deaths. Pathologic complete 
resection was performed in 79%. A pathologic 
mediastinal downstaging was found in 53% and 
a pathologic complete response in 9% of pts The 
OS was 36% at 5 years (median: 30 months). For 
patients who had complete resection, the median 
survival and 5-year survival were respectively 42 
months and 42%. Multivariated analyses identiÀed 
stage, radicality, and type of resection as strongly 
prognostic for increased OS. Age, number of CT 
cycles and radicality were associated with response 
to CT. 
Conclusion: These results demonstrate that 
induction CT produces high rates of response and 
complete resection.
Keywords: Non small cell lung cancer, preoperative 
chemotherapy, Surgery
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P4.244 PHASE II STUDY OF 
CONCURRENT RADIOCHEMOTHERAPY 
WITH WEEKLY CISPLATIN PLUS 
ORAL VINORELBINE IN FIT ELDERLY 
PATIENTS WITH NONRESECTABLE 
LOCALLY ADVANCED NON-SMALL-
CELL LUNG CANCER (RACCOSA, GFPC 
08-06 STUDY).
Chrystele Locher1, Nicolas Pourel2, Benoit Marin3, 
Alain Vergnenegre4 
1Pneumologie, Ch Saint Faron/France, 2Pôle De 
Radiothérapie, Institut Sainte Catherine/France, 
3Unité Fonctionnelle De Recherche Clinique Et De 
Biostatistique, Chu Limoges/France, 4Pathologie 
Respiratoire, Hôpital Du Cluzeau/France
Background: Non small cell lung cancer (NSCLC) 
in elderly patients is an important problem because 
support for an ongoing phase III registration trial 
(PROCLAIM) evaluating a similar regimen.
Keywords: Non-small cell lung cancer, Pemetrexed, 
Cisplatin, Radiotherapy
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P4.243 INDUCTION CHEMOTHERAPY 
FOR NSCLC: INSTITUTIONAL 
EXPERIENCE WITH 343 PATIENTS
Elizabeth Fabre1, Françoise Le Pimpec-barthes2, 
Aurélie Cazes3, Alain Badia2, Marie-Pierre Revel4, 
Guy Meyer5, Marc Riquet2 
1Medical Oncology, Hopital Européen Georges 
Pompidou, Medical Oncology Department/France, 
2Hopital Européen Georges Pompidou, Thoracic 
Surgery Department/France, 3Hopital Européen 
Georges Pompidou, Pathology Department/France, 
4Hopital Europén Georges Pompidou, Radiology 
Department/France, 5Hopital Européen Georges 
Pompidou, Pneumology Department/France
Background: As a means of reducing the risk of 
recurrence after surgery, there has been a growing 
interest in combining chemotherapy (CT) with 
surgical resection. However, the role of induction 
chemotherapy in resectable non-small cell lung 
cancer (NSCLC) remains undeÀned. Thus it is 
necessary to select patients who are suitable to 
receive CT. The purpose of the present study is to 
assess the activity of induction CT in stage I-IV 
NSCLC patients (pts) and to identify prognostic 
factors for CT efÀcacy. 
Methods: We reviewed the prospective database 
(2000-2007) of all NSCLC patients operated at our 
centre after CT. The database included patients’ 
complete medical history. Staging was performed 
according to 1997 Mountain’s revision. Stage IV 
pts were included in cases of previous complete 
resection of their metastasis. The prognostic factors 
of overall survival (OS) and response to CT were 
respectively investigated using Cox model and 
multiple linear regression. 
Results: 343 pts entered the study. Indications 
for induction CT were: clinical trial (n = 35), N2 
involvment (n = 104) or lung sparing in case of 
respiratory insufÀciency (n = 13), metastasis (n = 
9), initially unresectable tumour (n = 68), other n.p. 
(113). Main clinico-pathological features included: 
male gender (81%), age < 60 yrs (53%, median 
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P4.245 CONSOLIDATION S-1 AFTER 
CONCURRENT CHEMORADIOTHERPAY 
WITH CISPLATIN AND VINORELBINE 
FOR LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCER: JAPAN 
NATIONAL HOSPITAL STUDY GROUP 
FOR LUNG CANCER 0501
Tomoya Kawaguchi1, Minoru Takada2, Masahiko 
Ando3, Shinji Atagi4, Kyoichi Okishio1, Yuka Fujita5, 
Yoshio Tomizawa6, Kenji Hayashihara7, Yoshio 
Okano8, Shiro Takahashi9, Ryusei Saito6, Akihide 
Matsumura4, Atsuhisa Tamura10 
1Internal Medicine, National Hospital Organization 
Kinki-chuo Chest Medical Center/Japan, 2Kinki 
University Sakai Hospital/Japan, 3Kyoto University/
Japan, 4National Hospital Organization Kinki-chuo 
Chest Medical Center/Japan, 5National Hospital 
Organization Asahikawa Medical Center/Japan, 
6National Hospital Organization Nishigunma 
Hospital/Japan, 7National Hospital Organization 
Ibaraki-higashi Hospital/Japan, 8National Hospital 
Organization Kochi Hospital/Japan, 9Kitazato 
University/Japan, 10National Hospital Organization 
Tokyo Hospital/Japan
Background: To evaluate the efÀcacy and feasibility 
of S1 consolidation therapy after concurrent 
chemoradiotherapy for unresectable stage III non–
small cell lung cancer
Methods: The eligibile patients had unresectable 
stage III NSCLC, no previous treatment, age 
between 20 and 74 years, and performance status 
0 or 1. Chemoradiotherapy consisted of cisplatin 
80 mg/m2 on days 1 and 29, vinorelbine 20 mg/
m2 on days 1, 8, 29 and 36, and concurrent 
thoracic radiotherapy at total dose of 60Gy. 
Sequential consolidation S1 at dose of 120 mg/m2 
per day started on day 57 with 2 cycle of 4 week 
administration and 2 week withdrawal. 
Results: Of 67 patients enrolled between 2006 
and 2009, 66 (56 males and 10 females with a 
median age of 63:45-73) could be evaluated. 
Chemoradiotherapy was well tolerated and was 
completed in 58 (87.9%). Grade 3 or 4 neutropenia, 
anemia, esophagitis, and pneumonitis developed 
in 35, 5, 2, and 1 patients, respectively. S-1 
consolidation was administered in 45 (68.2%) 
patients, but two cycles were completed in 31 
(47.0%) patients. During consolidation therapy, 
of the increase of the incidence of NSCLC and the 
aging of the population. Elderly patients constitute a 
heterogeneous population with a group of Àt patients 
which should beneÀt from the reference treatment. 
Currently the reference treatment of a locally 
advanced NSCLC (nonresectable IIIA and IIIB) 
is concomitant radio-chemotherapy. Few studies 
appraise this treatment in elderly patients. 
Methods: This phase II multicentric nonrandomized 
opened frensch study aims to evaluate tolerance of 
concomitant radio-chemotherapy in elderly patients 
(more than 70 years old) juged Àt after a geriatric 
evaluation with locally advanced NSCLC. The other 
main inclusion criteria are: PS  1, weight loss < 
10% during last 3 month, creatinine clearance ³ 
50 ml/mn calculed with shortened Levey-MDRD 
formula, appropriate respiratory function with 
VEMS ³ 40%, PaO2 ³ 60 mm Hg, KCO ³ 60%. The 
treatment is oral vinorelbine (30 mg/m²/week) and 
cisplatine IV (30 mg/m²/week) during 6 weeks in 
concomitance with radiotherapy (66 Gy, 33 fractions, 
6 and a half weeks). The Àrst end-point is to evaluate 
tolerance of the treatment. The secondary end-points 
are evaluation of efÀciency 4 weeks after treatment 
end, quality of life, tolerance of the treatment 
6 month after the end of the treatment, survival 
without progression and overall survival at 1, 2 and 
3 years. We used a Simon’s optimal plan in 2 steps. 
The total number of patients to be included is 59 
with an intermediate analysis at 19 inclusive patients. 
An independent committee of experts oversees 
toxicities. 
Results: The study started in july 2010. 35 teams of 
the GFPC team participate to the study. Currently 6 
of planned 59 patients have been enrolled. The end 
of the study is expected in july 2012. 
Conclusion: Our study aims at demonstrating that Àt 
elderly patients can beneÀt from concomitant radio-
chemotherapy. It will permit to improve the care of 
Àt elderly patients with locally advanced NSCLC 
by allowing them to beneÀt from the reference 
treatment. 
Keywords: Concomitant radiochemotherapy, elderly 
patients, Non small cell lung cancer
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of the concurrent association of cetuximab with two 
worldwide standard cisplatin-based CRT regimens 
(cisplatin-vinorelbine-radiotherapy and cisplatin-
etoposide-radiotherapy) in selected stage III A/B 
NSCLC patients, with a planned sample size of 62 
randomised patients (PTS) (31 per arm). 
Methods: Eligibility criteria included age  70 
years, performance status (PS) 1, weight loss 10% 
over the past 3 months, FEV1 40% th, and adequate 
hematologic, renal and hepatic functions. After 
inclusion, PTS received on day 1 (D1) one cycle of 
cisplatin (75mg/m2)-docetaxel (75mg/m2) induction 
chemotherapy. On D21, PTS with suitable dosimetric 
parameters (V20  35% and Mean Lung dose 
(MLD)  20 grays) were randomized and received 
an initial dose of 400 mg/m2 cetuximab. Concurrent 
treatment started on D28. Between D28 and D71, 
PTS received a concurrent combination of weekly 
cetuximab (250mg/m2, 7 doses), radiotherapy (66 
Gy/6.5 weeks) and two cycles of cisplatin (80 mg/
m2 D1)-vinorelbine (15mg/m2 D1, 8) in arm A, or 
two cycles of cisplatin (50 mg/m2 D1,8)-etoposide 
(50 mg/m2 D1-5) in arm B. Toxicity and compliance 
were monitored every week between D1 and D71. 
The primary endpoint was feasibility, evaluated by 
the percentage of PTS developping  grade 3 non 
hematologic toxicities (NHT) (NCI-CTC V3) at D71 
in each arm. Secondary endpoints were compliance, 
toxicity and response evaluated at D113. Toxicities 
and responses were centrally reviewed. 
Results: On January 2011, 76 PTS had been enrolled 
in the study. PTS characteristics were: 75 % male, 
median age: 58 years, 63 % PS=0, 38% stage IIIA, 
64% non squamous histology. 52 PTS have been 
randomised (28 in arm A, 24 in arm B, randomisation 
rate=66%). The major reason for non-randomisation 
was dosimetric failure at D21 (V20>35% or MLD 
>20Gy). 29 grade  3 NHT were reported at D71: 
4 before randomisation, 18 in arm B (11/24 PTS, 
45%) and 7 in arm A (5/28 PTS, 17%). Two patients 
died: 1 before randomisation from acute respiratory 
failure, and one on D71 from massive hemoptysis. No 
toxic death was noted. The most common toxicities 
were grade 3 oesophagitis (6 PTS, 11%) and febrile 
neutropenia (5 PTS, 9%). Only one grade 3 acne was 
recorded. Responses were reviewed in 23 PTS, with 1 
CR, 17 PR (73%), 1 SD and 4 PD (17%). 
Conclusion: In this preliminary evaluation, the 
concurrent association of cetuximab with cisplatin-
based CRT seems to be safe in both arms, with 
promising responses rates. Uptated results will be 
presented at the meeting. 
grade 3 or 4 neutropenia, anemia, esophagitis, and 
pneumonitis developed in 1,4, 0, and 0 patients, 
respectively. One patient died of pneumonitis. The 
response rate was 61.5% (95% conÀdence interval 
[CI], 48.6– 73.3%), with 1 complete and 39 partial 
responses. The median progression-free survival was 
9.3 (CI, 10.2–15.4) months, and median survival 
was 19.4 (CI, 24.5–36.3) months. The 1-and 3-year 
survival rates were 72.7% (62.0-83.5) and 33.5% 
(20.9-46.2), respectively. 
Conclusion: This regimen produced tolerable 
toxicity and promising overall survival in patients 
with stage III NSCLC. 
Keywords: consolidation, S1, chemoradiotherapy, 
stage III NSCLC
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P4.246 A RANDOMISED PHASE II 
STUDY OF CETUXIMAB (ERBITUX®) IN 
COMBINATION WITH TWO CISPLATIN-
BASED CHEMORADIATION REGIMENS 
IN PATIENTS WITH STAGE IIIA/B NON 
SMALL CELL LUNG CANCER (NSCLC). 
PRELIMINARY RESULTS OF THE GFPC 
08-03 TRIAL
Laurent Greillier1, Isabelle Martel-Lafay2, 
Dominique Arpin3, Nicolas Pourel4, Sylvie 
Chabaud2, Regine Lamy5, Benedicte Etienne-
Mastroianni3, Alain Vergnenegre6, Renaud Descourt7, 
Pierre Fournel8 
1Service D’oncologie Multidisciplinaire Et 
Innovations Thérapeutiques, Hôpital Nord, 
Assistance Publique- Hôpitaux De Marseille/France, 
2Centre Léon Bérard/France, 3Hospices Civils De 
Lyon/France, 4Institut Sainte Catherine/France, 
5Centre Hospitalier De Bretagne Sud/France, 
6Hôpital Du Cluzeau/France, 7Chu Morvan/France, 
8Institut De Cancérologie De La Loire/France
Background: Concurrent chemoradiotherapy (CRT) 
with cisplatin doublets represents the standard of 
care in patients with unresectable stage III NSCLC. 
The anti-Epidermal Growth Factor Receptor 
monoclonal antibody cetuximab has recently 
demonstrated efÀcacy in Àrst-line combination with 
chemotherapy, and feasibility in combination with 
radiotherapy in patients with stage III NSCLC. 
The purpose of this non comparative phase II 
randomised trial was to demonstrate the feasibility 
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EGFR mutant group (5 of 9 patients).
Conclusion: Frequency of EGFR mutation in locally 
advanced adenocarcinoma of the lung was about 
30%. EGFR mutation was not a predictive marker 
treated with conventional CCR. But, EGFR mutant 
patients demonstrated better locoregional control 
compared with EGFR wild type patients.
Keyword: locally advanced,NSCLC,EGFR,chemor
adiotherapy
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P4.248 CONCOMITANT CHEMO-
RADIOTHERAPY IN LOCALLY 
ADVANCED NON SMALL CELL 
CARCINOMA OF LUNG: A SINGLE 
CENTRE EXPERIENCE
Abhro Chaudhuri, Martin Cawley 
Oncology, Lincoln County Hospital/United Kingdom
Background: Concomitant chemo-radiotherapy 
(cCRT) has been superior to sequential (sCRT) 
therapy in terms of progression-free and overall 
survival in stage III non-small-cell-lung-cancer 
(NSCLC) in multiple randomized controlled trials 
(RCT) and meta-analyses, albeit at the expense of 
greater loco-regional toxicity. 
Methods: At the Lincoln County Hospital we 
treated 12 patients with inoperable NSCLC with 
cCRT from December’2009 till December’2010. 
All patients had a baseline PET, after staging CT 
of chest and abdomen. Patients with equivocal/
negative mediastinal nodes on PET underwent 
mediastinoscopy and biopsy to complete staging. 
All had good performance status (WHO 0-1) and 
lung function (FEV11 litre, FVC1.5 litre). 
Patients older than 65 years received primary 
prophylaxis against neutropenia with GCSF. 
There were six stage IIIA, Àve IIIB and one IIA. 
Nine were male and three were female. There 
were six squamous-cell-carcinomas, two adeno-
carcinomas, three unspeciÀed NSCLC and one 
patient had carcinoma-in-situ but declined further 
biopsy. Median age was 60 years (47–73 years). 
Chemotherapy comprised of cisplatin 75 mg/m2 on 
day-1 and vinorelbine on days 1 and 8 for four 21 
day cycles. Radiotherapy commenced on day-1 of 
second cycle. Vinorelbine dose was 25 mg/m2 iv 
on day-1 and 60 mg/m2 orally on day-8 in cycle-1, 
reduced to 15 mg/m2 iv on day-1 and 40 mg/m2 
Keywords: cetuximab, concurrent 
chemoradiotherapy, stage III NSCLC, feasibility
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P4.247 THE IMPACT OF EGFR 
MUTATION STATUS ON CLINICAL 
OUTCOMES IN PATIENTS WITH 
LOCALLY ADVANCED LUNG 
ADENOCARCINOMA.
Hiroaki Akamatsu1, Haruyasu Murakami1, Akira 
Ono1, Takehito Shukuya1, Asuka Tsuya1, Yukiko 
Nakamura1, Tateaki Naito1, Hirotsugu Kenmotsu1, 
Toshiaki Takahashi1, Masahiro Endo2, Hideyuki 
Harada3, Takashi Nakajima4, Nobuyuki Yamamoto1 
1Thoracic Oncology, Shizuoka Cancer Center/Japan, 
2Diagnostic Radiology, Shizuoka Cancer Center/
Japan, 3Radiation Oncology, Shizuoka Cancer 
Center/Japan, 4Diagnostic Pathology, Shizuoka 
Cancer Center/Japan
Background: Concurrent chemoradiotherapy (CCR) 
is the standard care for locally advanced non-small 
cell lung cancer (LA-NSCLC). Epidermal growth 
factor receptor (EGFR) mutation is well known 
predictive marker in metastatic NSCLC. In vitro, 
NSCLC cell lines with EGFR mutation demonstrated 
radio-sensitivity, but it has not been fully evaluated 
about the role of EGFR mutation in LA-NSCLC 
patients treated with CCR.
Methods: Between September 2002 and December 
2009, 83 adenocarcinomas of 166 LA-NSCLC 
patients who received CCR were retrospectively 
reviewed. Forty-four tissues of these 83 
adenocarcinoma were available. The 44 patients 
were included in this study, and EGFR mutation 
status was investigated.
Results: EGFR mutation was observed in 12 
(27.3%) of 44 adenocarcinoma patients. The median 
progression free survival was 10.8 months in EGFR 
wild type group (n=32) and 9.1 months in EGFR 
mutant group (n=12), demonstrating no signiÀcant 
difference (p=0.60). Median survival time was 
29.7 months in EGFR wild type group and 57.1 
months in EGFR mutant group, demonstrating no 
signiÀcant difference (p=0.18). Different pattern of 
relapse was revealed between EGFR mutation status 
(locoregional relapse; 8.3% among EGFR mutant 
group versus 31.3% among EGFR wild type group), 
and most frequent site of relapse was brain among 
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P4.249 BENEFITS AND ADVERSE 
EVENTS AMONG ELDERLY PATIENTS 
RECEIVING CONCURRENT 
CHEMORADIOTHERAPY FOR 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER: ANALYSIS OF 
THE OKAYAMA LUNG CANCER STUDY 
GROUP TRIAL 0007
Hiroshi Ueoka1, Yoshihiko Segawa2, Tadashi Maeda2, 
Keisuke Aoe2, Kenichi Chikamori2, Daizo Kishino2, 
Katsuyki Hotta3, Nagio Takigawa3, Masahiro Tabata3, 
Katsuyuki Kiura3, Mitsune Tanimoto3 
1Internal Medicine, Yamaguchi-ube Medical Center/
Japan, 2Yamaguchi-ube Medical Center/Japan, 
3Okyama University Hospital/Japan
Background: Standard treatment for elderly patients 
with locally advanced non-small cell lung cancer 
(LA-NSCLC) is thoracic radiotherapy (RT) without 
chemotherapy. The OLCSG 0007 phase III trial with 
patients up to 75 years old showed that with concurrent 
RT, docetaxel and cisplatin (DP) chemotherapy was 
preferable to mitomycin, vindesine, and cisplatin 
(MVP) chemotherapy. We analyzed the beneÀts and 
adverse events according to patient age.
Methods: Of the 99 patients the DP arm of the 
OLCSG 0007 trial, 73 were <70 years old and 26 
were 70 years old. Of the 101 patients in the MVP 
arm, 75 were <70 years old and 26 were 70 years 
old. Overall survival (OS) and progression-free 
survival (PFS) were calculated according to age and 
treatment arm using the Kaplan-Meier method and 
were compared using an early period weighted log-
rank test. Toxicities and treatment intensities were 
compared by chi-square and t-tests, respectively.
Results: OS and PFS tended to be longer in the 
DP arm vs. MVP arm: median OS (months), 27.5 
vs. 22.9 (P = 0.109) and 25.6 vs. 23.4 (P = 0.064) 
in the 70-y and <70-y groups, respectively; 
median PFS (months), 19.0 vs. 11.5 (P = 0.175) 
and 12.0 vs. 9.3 (P = 0.132) in the 70-y and <70-y 
groups, respectively. Severe toxicity (neutropenia, 
esophagitis, pneumonitis) rates did not differ 
between age groups. Radiation intensity was similar 
between the groups, but chemotherapy intensity was 
lower in the 70-y group.
Conclusion: Chemotherapy with concurrent RT may 
be effective and tolerable in elderly patients with 
LA-NSCLC.
orally on day-8 in cycles 2-4 in the concomitant 
phase. Radiotherapy was by 3D conformal planning 
to a dose of 64 Gy in 32 fractions over 6.5 weeks. 
Following dose constraints were maintained for 
critical organs – lung V2035%; spinal cord–44 
Gy; oesophagus–33%<60 Gy, 100%<55 Gy ; 
heart–33%<60 Gy, 66%<45 Gy and 100%<40 Gy. 
Toxicity was monitored weekly as per the RTOG 
acute radiation toxicity score, during the course 
and repeated a month after completion. There were 
no grade 3/4 toxicities. Commonest toxicity was 
acute oesophagitis that was treated with antacid/
oxetacaine preparations and NSAID. No patient 
developed any grade 3/4 chemotherapy related 
toxicity. 
Results: Response was assessed with three-weekly 
chest x-rays whilst on treatment and with a CT 
scan 3 months after completion. Patients with an 
excellent response on CT, had a PET to assess for 
surgery of residual disease. Two patients underwent 
lobectomy and mediastinal lymph node sampling 
for residual PET abnormality conÀrming complete 
pathological response (CR). A third patient showed 
CR on post-treatment PET. Remaining 9 patients 
showed partial response (PR). There was 100% 
response with 25% CR and 75% PR. All three CRs 
had squamous-cell-cancer with two IIIA and one 
IIIB disease. 
Conclusion: cCRT is an effective and safe option in 
an appropriately selected group of patients. Toxicity 
can be minimized by modern RT techniques and 
adherence to critical organ dose constraints. The 
follow up period in our centre was not long enough 
at the time of submission to comment on survival 
although several other studies have demonstrated 
improvement in survival with cCRT. There was 
considerable variation in the degree of response 
among partial responders. This suggests the need 
for a RCT of cCRT with tailored chemotherapy to 
improve the response rate and survival. 
Keywords: concomitant chemo-radiotherapy, 
locally advanced non small cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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81.22% for non-N3 NSCLC after neoadjuvant 
CTRT (2 atypical resections, 9 lobectomies, and 
2 pneumectomies) with mediastinal lymph node 
dissection. Tolerance of concurrent CTRT was 
excellent. Maximum toxicity was grade 3 non-
febrile neutropenia in a 15.4% of cases. No grade 
4-5 toxicity, pneumonitis or esophagitis were 
reported. Two patients died after lobectomy due to 
surgery complications (aspergillosis and massive 
hemoptysis), and a case of bronchopleural Àstula was 
reported also after pneumectomy. 
Conclusion: This protocol of neoadjuvant CTRT 
based on cisplatin or carboplatin plus vinorelbine is 
feasible and tolerable, simple to applied and with a 
high rate of operability. 
Keywords: treatment, Neoadjuvant 
chemoradiotherapy, Non small cell lung cancer
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P4.251 RISK OF MORBIDITY AND 
MORTALITY AFTER INDUCTION 
CHEMORADIOTHERAPY AND SURGERY 
FOR LOCALLY LUNG CANCER: AN 
ANALYSIS OF 108 RESECTED PATIENTS
Alessandro Marra1, Olaf M. Koch2, Wolfgang 
Wagner3, Ludger Hillejan1 
1Thoracic Surgery, Niels Stensen Clinics/Germany, 
2Haematology And Oncology, Klinikum Osnabrück/
Germany, 3Radiation Oncology, Paracelsus Klinik/
Germany
Background: The role of multimodal treatment 
including surgery for locoregionally advanced lung 
cancer is still matter of debate. Aim of the study was 
to evaluate the risk of treatment-related morbidity 
and mortality of a trimodality approach as well as to 
identify predictors of complications.
Methods: The charts of 108 consecutive patients 
undergoing trimodality therapy for loco-regionally 
advanced (stage IIB-IIIB) lung cancer were 
reviewed. Induction therapy consisted of two to three 
cycles of platin-based doublet (platin/etoposide [PE] 
in 45%, platin/gemcitabine [PG] in 44%, platin/other 
substance in 11% of cases), followed by concurrent 
radiochemotherapy (45 Gy hyperfractionated 
accelerated radiotherapy combined with cisplatin 
weekly). All patients underwent thoracotomy. 
Toxicity of induction therapy, mortality and surgical 
morbidity were statistically analyzed.
Keywords: Non-small cell lung cancer, Elderly, 
RADIATION, Chemotherapy
Poster Session 4 – Combined Modality Thursday, 7 July 2011 10:00-
12:30
P4.250 TOLERANCE AND FEASIBILITY 
OF NEOADJUVANT CONCURRENT 
CHEMORADIOTHERAPY WITH 
PLATINUM AND VINORELBINE IN 
THE UNIVERSIY HOSPITAL ARNAU DE 
VILANOVA OF LLEIDA (SPAIN).
Diego Márquez Medina1, Virginia García Reglero2, 
María Deu Martín3, José Miguel Durán Alamá4, 
Silvia Gómez Falguera4 
1Medical Oncology, University Hospital Arnau De 
Vilanova/Spain, 2Radiotherapy, University Hospital 
Arnau De Vilanova/Spain, 3University Hospital Vall 
D’hebrón/Spain, 4Pneumology, University Hospital 
Arnau De Vilanova/Spain
Background: Chemoradiotherapy (CTRT) is the 
standard treatment for N3 non-small cell lung cancer 
(NSCLC), and a promising approach for neoadjuvant 
therapy in non-N3 locally advanced NSCLC. 
Methods: We retrospectively analyzed 27 male 
patients diagnosed of stage II (T>5cm)-IIIB 
NSCLC and consecutively treated with 4 cycles 
of neoadjuvant Cisplatin 75 mg/m2 (N= 21) or 
Carboplatin AUC 5 (N= 3) day 1 plus Vinorelbine 30 
mg/m2 day 1 and 8 every 21 days with concurrent 
radiotherapy to 50 Gy in the third and fourth cycle 
since May, 2008 to May, 2010. Three patients 
received CBDCA plus concurrent radiotherapy 
only, due to elderly or comorbidity. After a second 
evaluation, operable cases underwent surgery and the 
non-operable ones continued radiotherapy to radical 
dose of 60 Gy.
Results: Mean age of the patients was 68.3 ± 
10.16 years old, and all of them referred antecedent 
of smoking. Initial ECOG was 0-1 (92.6%) or 2 
(7.4%). Initial stage was IIA 3.7%, IIIA 44.4% and 
IIIB 51.9%. Initial clinical T-size was T2 22.2%, 
T3 40.7% and T4 37.1 initial N was N0 7.4%, N1 
11.1%, N2 51.9%, and N3 29.6%. Histological 
subtypes were squamous carcinoma 77.8%, 
adenocarcinoma 11.1% and non-deÀned NSCLC 
11.1%. The 81% of patients received the whole 
programmed program of CTRT (mean cycles 3.8+/-
0.56). A 48.1% of them underwent surgery and a 
51.9% received radical radiation. Operability was 
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lung cancer (NSCLC) and act as radiosensitizers in 
preclinical models. Vorinostat is an HDAC inhibitor 
that is FDA-approved for the treatment of cutaneous 
T-cell lymphoma in speciÀc circumstances, and 
under investigation in NSCLC in combination with 
systemic chemotherapy. This study was designed 
to assess the tolerability of vorinostat given 
concurrently with thoracic radiotherapy in patients 
with advanced or metastatic NSCLC. 
Methods: Eligible patients had metastatic NSCLC, 
or locally advanced NSCLC not suitable for curative 
therapy, and were referred for palliative thoracic 
radiotherapy. Patients were treated with a standard 
palliative regimen of 30 Gy in 10 fractions, and 
were enrolled in cohorts of escalating vorinostat 
dose using a standard 3 x 3 design. Vorinostat was 
administered orally one hour prior to radiation, on 
each day of radiation, in cohorts of 200mg, 300mg, 
and 400mg per day. Following the completion of 
thoracic radiation, vorinostat could be continued as 
a single agent (400 mg daily) or in combination with 
carboplatin and paclitaxel (400 mg daily for 14 days, 
every 21 days). Toxicity was graded by the NIH 
common toxicity criteria for adverse events, version 
4.0. The primary endpoint was to determine the 
maximum tolerated dose of vorinostat when given 
concurrently with thoracic radiotherapy.
Results: Between July 2009 and December 2010, 
17 patients were enrolled and 12 patients completed 
study therapy. Five patients were withdrawn from the 
study: two were ineligible, two withdrew consent, 
and one died of unrelated cause. Patients were 
enrolled in cohorts of escalating vorinostat dose: 3 
completed therapy at 200mg per day, 3 at 300mg per 
day, and 6 at 400mg per day. Most adverse events 
were grade 1 or 2, and included fatigue, nausea, 
anorexia, and hematologic changes. Grade 3 adverse 
events included anemia, thrombocytopenia, nausea, 
and fatigue. Treatment-related dose-limiting toxicity 
occurred in one of six patients in the 400mg cohort 
(nausea). The maximum tolerated dose of vorinostat 
given concurrently with thoracic radiotherapy was 
therefore found to be 400 mg per day. 
Conclusion: Vorinostat can be safely combined 
with thoracic radiotherapy in patients with advanced 
or metastatic NSCLC. This study suggests that the 
combination of an HDAC inhibitor with radiotherapy 
may be worthy of investigation as a component of 
chemoradiotherapy, in the treatment of patients with 
locally advanced disease. 
Keyword: Histone deacetylase inhibitor
Results: Of 108 consecutive patients, 87 (81%) 
had a NSCLC, and 21 (19%) a SCLC. Overall 
compliance to induction therapy was 95%. Grade 3-4 
toxicity was observed in 16% of patients. Resections 
included 69 (64%) lobectomies, 25 (23%) sleeve-
lobectomies, and 12 (11%) pneumonectomies; 2 
(2%) patients had an exploratory only. Surgical 
mortality rate was 5.6%. Twenty-three (21%) 
patients suffered one or more major complications: 
bronchial stump/anastomosis Àstula (14%), 
pneumonia/ARDS (12%), bleeding requiring 
reoperation (2%), myocardial infarction (1%), and 
pulmonary embolism (1%). SigniÀcant risk factors 
for morbidity were chemotherapy protocol other than 
PE/PG (P=.007), pneumonectomy (P=.034), and 
perioperative blood transfusions (P<.001); mortality 
was inÁuenced by perioperative blood transfusions 
(P=.006). Among patients with major complications, 
the associated risk of death for pneumonia was 33%, 
for bronchial Àstula 33%, and for bleeding 50%, 
respectively.
Conclusion: In patients with locoregionally 
advanced lung cancer, trimodality therapy including 
surgery can be feasible with acceptable mortality and 
morbidity. As major complications are linked to high 
risk of death, accurate preoperative patient selection 
and intraoperative management including protection 
of bronchial stump/anastomosis are mandatory. 
Sleeve lobectomy – when technically feasible – 
should be preferred to pneumonectomy.
Keywords: Surgery, Lung cancer, multimodality 
therapy, chemoradiotherapy
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P4.252 VORINOSTAT, A HISTONE 
DEACETYLASE INHIBITOR, IN 
COMBINATION WITH THORACIC 
RADIOTHERAPY IN ADVANCED NON-
SMALL CELL LUNG CANCER: A DOSE 
ESCALATION STUDY
Roy H. Decker1, Scott N. Gettinger2, Peter M. 
Glazer1, Lynn D. Wilson1 
1Therapeutic Radiology, Yale University School 
Of Medicine/United States Of America, 2Medical 
Oncology, Yale University School Of Medicine/
United States Of America
Background: Histone deacetylase (HDAC) 
inhibitors have shown activity against non-small cell 
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P4.254 SURVIVAL IN PATIENTS WITH 
STAGE III NON-SMALL CELL LUNG 
CANCER (NSCLC) RECEIVING 
CONCURRENT CHEMOTHERAPY 
WITH HYPOFRACTIONATED 
RADIOTHERAPY: EXPERIENCE AT THE 
NORTHERN CENTRE FOR CANCER 
CARE (NCCC), UK
Gregory Webb1, Rhona Mcmenemin2, Fiona 
Mcdonald2, Goudarz Mazdai2, Philip Atherton2, 
Paula Mulvenna2 
1Medical School, University Of Newcastle Upon 
Tyne/United Kingdom, 2Clinical Oncology, Northern 
Centre For Cancer Care/United Kingdom
Background: Standard treatment for stage III 
NSCLC involves bimodality therapy, but varies 
between either sequential or concurrent regimens. 
A meta-analysis1 has conÀrmed an absolute and 
progression-free survival beneÀt using concurrent 
chemoradiotherapy compared to sequential 
modalities. However, Auperin and colleagues 
excluded the SOCCAR trial2 (sequential or 
concurrent chemotherapy and radiotherapy) as the 
data from that (Phase II) trial was not yet mature 
at time of the meta-analysis. We wished to assess 
if we could deliver safe and effective concurrent 
chemoradiation using this UK hypofractionated 
radiotherapy technique to a North of England 
population of patients. Reference: 1. Auperin, A., et 
al., Meta-analysis of concomitant versus sequential 
radiochemotherapy in locally advanced non-small-
cell lung cancer. Journal of Clinical Oncology, 
2010. 28(13): p. 2181-90. 2. A Randomized Phase 
III Trial of Sequential Chemotherapy Followed By 
Radical Radiotherapy Versus Concurrent Chemo-
Radiotherapy Followed by Chemotherapy in Patients 
With Inoperable Stage III Non-Small Cell Lung 
Cancer and Good Performance Status NCT00309972 
Methods: We performed a retrospective audit of the 
notes for patients who were diagnosed with stage III 
NSCLC and received concurrent chemoradiotherapy 
at the Northern centre for Cancer Care during a Àve 
year period from January 2005 to December 2009.
The main end point was overall survival, which was 
evaluated from the date of diagnosis until death due to 
any cause. Living patients were censored at the date 
of their last clinic appointment. We also assessed the 
completeness of chemotherapy regimen attained. 
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P4.253 NEOADJUVANT TREATMENT 
AND SURGERY FOR CLINICAL T4 NON-
SMALL CELL LUNG CANCER WITHOUT 
N2 DISEASE
Kenan C. Ceylan, Seyda O. Kaya, Ahmet Ucvet, 
Hakan Polat, Deniz Akpinar, Soner Gursoy, Ozan 
Usluer Thoracic Surgery, Dr Suat Seren Chest 
Disease And Thoracic Surgery Training And 
Education Hospital/Turkey
Background: In this study, the results of 
neoadjuvant treatment followed by surgery for 
clinical T4 non-small cell lung cancer without N2 
disease is investigated. 
Methods: The medical records and follow-up data 
of 115 patients (112 males, 3 females) with clinical 
T4N0/1M0 non-small cell lung cancer operated 
after neoadjuvant treatment between January 1998 
and January 2010 is analyzed. The patients having 
histopathologically proven preoperative N2 disease 
are not included in the study. Adjuvant theraphy is 
applied for patients having pT4 or pN1-2 diseases.
Results: The histological type of the tumor was 
squamous cell carcinoma in 78 and adenocarcinoma 
in 23 pateints. 14 patients had tumor necrosis 
which did not allow the subclassiÀcation of the 
histopathological type. The type of the resection 
performed was pneumonectomy in 55 (47.8%) 
lobectomy in 60 (52.2%) patients. Two patients 
(1.7%) died in the early postoperative period. 
Median follow-up time was 35.0±2.3 months. Five 
year overall survival was 55.5%. The Àve year 
survival rates of patients having a downstaged 
tumor according to T factor was 58% versus 0% 
in pT4 patients and the difference was statistically 
signiÀcant (p=0,005). Survival was better in pN0-1 
diseases than pN2 disease (p=0,035).
Conclusion: Neoadjuvant treatment for clinical 
T4 non-small cell lung cancer improves the chance 
of resectability. pT4 or pN2 disease are the poor 
prognostic factors. 
Keywords: Neoadjuvant Therapy, Non-small cell 
lung cancer, Surgery, T4 diseases
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standard treatment for unresectable or medically 
inoperable localised NSCLC. We retrospectively 
analysed treatment outcome and toxicity data of 
patients with localised NSCLC, treated with CRT at 
our institution, over a 10-year period.
Methods: Medical records of eligible NSCLC 
patients who received CRT at Flinders Medical 
Centre and Flinders Private Hospital in Adelaide, 
South Australia, were reviewed. Details of 
demographics, management, toxicity and survival 
were recorded and analysed.
Results: 68 patients were identiÀed to have received 
concurrent CRT for NSCLC between May 2000 and 
June 2010. Median age was 66.4 yrs (range 44 - 85 
yrs). 63% were male, 63 % were ex-smokers and 
10% never smokers. Diagnosis was conÀrmed in 
the majority of patients by bronchial biopsy (41%), 
bronchial washings (18%) and image guided biopsy 
(18%). PET scan staging was performed in 65% of 
patients. Histology included adenocarcinoma (40%), 
large cell (26%) and squamous cell carcinoma 
(23.5%). Stage IIIB (41%) and IIIA (22%) 
constituted the bulk of our patients and a minority 
of stage IV (2.9%) were also given concurrent 
CRT. Median time to initiation of radiotherapy and 
chemotherapy from the date of cancer diagnosis was 
34 days and 39 days respectively. Radiotherapy was 
given with 60 Gy in 30 fractions in the majority of 
cases applying a three Àeld single phase or a two-
phase technique. The majority of patients (81%) 
received platinum based doublet chemotherapy; 
Cisplatin/Etoposide (59%) and Cisplatin/Vinblastine 
(11.7%) being the most common regimens. Eight 
patients (11.7%) were treated as part of clinical trial. 
34% of patients had CRT interrupted due to toxicity. 
Most frequent grade 3/4 early side effects included 
neutropenia (28%) and oesophagitis (10%). There 
were 2 episodes of febrile neutropenia. Radiation 
induced pneumonitis (28%) was the predominant 
delayed toxicity. 34% of patients had local relapse 
and 32% had distant metastasis. Sixty three patients 
were evaluable for survival. Median progression 
free survival was 13.6 months and median overall 
survival was 20.9 months. Survival at 2yrs, 3 years 
and 5 years was 49 %, 35% and 20% respectively.
Conclusion: Our data conÀrms that CRT for 
localised inoperable NSCLC is associated with 
signiÀcant toxicity but long-term survival is 
achievable, with 1 in 5 patients alive at 5 years. 
Further studies aimed at optimising outcome while 
minimising toxicity in this group of patients are 
needed.
Results: 35 patients received concurrent 
chemoradiotherapy with vinorelbine and cisplatin 
plus radical Radiotherapy as management of their 
stage III NSCLC. The radiation regimen was 55Gy 
in 20 fractions delivered once daily, Àve days per 
week. 83% patients completed chemotherapy. One 
fatal PE occurred. 
Characteristic No. % 
Male Female 23 12 65.7 34.3 
Median age, years 55.5 
Performance Status 0 1 2 Not recorded 17 10 1 7 48.6 28.6 2.9 20 
Chemotherapy Regimen Single therapy Double therapy 1 34 2.9 97.1 
Overall survival (%) Progression-free survival (%) 
NCCC (n= 31) Meta-analysis NCCC (n=35) Meta-analysis 
1 year survival 73.3 NA 48.6 40.5 
3 year survival 26.7 23.8 25.7 16 
Conclusion: This study conÀrms that the 
NCCC can provide safe and effective concurrent 
chemoradiotherapy for patients diagnosed with 
stage III NSCLC - using a UK hypofractionated RT 
regimen. 
Keywords: concurrent chemoradiotherapy, Non-
small cell lung cancer
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P4.255 CONCURRENT 
CHEMORADIOTHERAPY (CRT) FOR 
LOCALISED UNRESECTABLE NON-
SMALL CELL LUNG CANCER (NSCLC): 
10-YEAR EXPERIENCE FROM AN 
AUSTRALIAN GENERAL TEACHING 
HOSPITAL.
Kunal Jain1, Marleesa Ly2, John Leung3, Bogda 
Koczwara2, Shawgi Sukumaran2, Ganessan 
Kichenadasse2, Kanupriya Jain2, Tony Woo3, Adnan 
Khattak2, Sarwan Bishnoi4, Alison Richards2, 
Christos S. Karapetis2 
1Department Of Medicine, Christian Medical 
College And Hospital Ludhiana/India, 2Medical 
Oncology, Flinders Medical Centre/Australia, 
3Radiation Oncology, Flinders Medical Centre/
Australia, 4Medical Oncology, Queen Elizabeth 
Hospital/Australia
Background: Lung cancer is the leading cause 
of cancer related mortality worldwide. CRT is the 
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Methods: This was a mono-institutional, phase I, 
dose-escalation study to assess the dose-limiting of 
docetaxel concurrently with HT in stage III, NSCLC 
patients. Eligibility criteria: NSCLC with multiple 
N2 or N3 mediastinal lymph nodes (excluding 
sovraclavear lymph nodes and pleural effusion), PS 
0-1. At baseline and during follow-up, whole-body 
PET/CT scan, consisting of helical CT scanning 
followed by a 2D PET acquisition, and pulmonary 
function test were mandatory. In the induction all 
patients received 3 cycles of cisplatin 80 mg/m2 and 
docetaxel 75 mg/m2. Patients with stable disease 
(SD) or partial response (PR) were included in the 
phase I chemo-radiotherapy, consisting of once-
weekly docetaxel concurrently with HT, 2.4 Gy/day, 
5 days/week for 5 consecutive weeks (total dose: 60 
Gy). Docetaxel was escalated in cohorts of 3 patients 
according to a modiÀed Fibonacci design, starting 
from 10 mg/m2/week. 
Results: From 2008 overall 28 patients were treated; 
3/28 patients did not proceed into concurrent chemo-
radiotherapy, 1 for PD and 2 for consent withdrawal; 
F:M=6:22, median age: 61 years (40-77), 13 patients 
with squamous cell- (46%) and 15 with adeno-
carcinoma (64%), PS 1 in 13 patients (44%) and 0 
in 15 (64%), 50% in stage IIIA and 50% IIIB. All 28 
patients were evaluable for response after induction 
chemotherapy: PR was achieved in 22/28 (78%), 1 
(3.5%) showed PD, 5/28 (18%) SD. 25 patients were 
subsequently enrolled in dose-escalation study. In 
the concurrent treatment 2 patients had leucopenia 
G2, esophagitis was G2 in 25% of patients; no late 
esophageal toxicity was observed. No pneumonitis 
was ever reported. 
Conclusion: Data reported here are at the 
completion of dose-level of 30 mg/m2 of docetaxel; 
till now radiotherapy HT concurrently with docetaxel 
is not more toxic than standard radiotherapy. For 
the time of the meeting we will show the completed 
study. 
Keywords: combined modality, Tomotherapy, 
NSCLC, local advanced disease
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Keywords: concurrent chemoradiotherapy, localised 
NSCLC, median overall survival
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P4.256 CONCURRENT 
CHEMORADIOTHERAPY WITH 
TOMOTHERAPY IN LOCALLY 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): PHASE I, DOSE-
ESCALATION STUDY
Alessandra Bearz1, Emilio Minatel2, Imad Abu 
Rumeileh3, Carlo Gobitti3, Tanja Baresic4, Annalisa 
Drigo5, Renato Talamini6, Emanuela Vaccher1, 
Sandra Santarossa1, Gianni Franchin3 
1Medical Oncology, Cro-irccs/Italy, 2Radiotherapy 
Department, Cro-irccs/Italy, 3Radiotherapy, Cro-
irccs/Italy, 4Nuclear Medicine, Cro-irccs/Italy, 
5Medical Physics, Cro-irccs/Italy, 6Epidemiology, 
Cro-irccs/Italy
Background: Concurrent chemoradiotherapy is the 
standard treatment for patients affected by stage III, 
unresectable NSCLC and good PS. Recommended 
systemic treatment in stage III NSCLC consists 
of 2-4 cycles of platin-combination. To improve 
overall survival (OS) different schemes for induction 
or consolidation therapy have been used, without 
any clear superiority between them. It is believed 
that higher radiation doses may result in improved 
local tumour control; however, current radiation 
delivery techniques, in particular concurrently 
with chemotherapy, may lead to unacceptable lung 
toxicity. Therefore, the search for better radiotherapy 
approaches is important. Helical Tomotherapy (HT) 
is a novel approach to deliver highly conformal dose 
distributions using intensity-modulated radiation 
fan beams, bringing adequate radiation dose to the 
tumor, while limiting the dose to surrounding tissues. 
Integral dose (ID) delivered to the normal tissues 
during intensity modulated radiotherapy (IMRT) 
treatment is clinically relevant. Aim of the study 
was to evaluate any change in lung toxicity due to 
ID received by healthy lungs, in combination with 
chemotherapy. In Phase II studies radiotherapy with 
concurrent docetaxel and after cisplatin-docetaxel 
induction has been shown to be feasible, with 
encouraging OS in NSCLC; recommended dose of 
docetaxel concurrently with radiotherapy is up to 30 
mg/m2/week from previous Phase I studies. 
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18 Gy in 3 fractions). No grade 3/4 toxicity was 
recorded during, at 30 and 60 days from the end of 
radiotherapy. We recorded 14 (47%) partial response, 
13 (43%) stable disease 2 (6%) progression disease 
and 1 (4%) not evaluable disease, with an overall 
thoracic control of disease of 90%. Preliminary 
efÀcacy results show a 24 months overall survival of 
62% (95% ConÀdence Interval: 42 – 83). 
Conclusion: In our series, induction chemotherapy 
followed by 3D-HAR produces efÀcacy results 
similar to those reported by concomitant chemo-
radiotherapy administrated with standard 
fractionation. The advantage of 3D-HAR is 
represented by reducing the incidence of severe 
pulmonary and esophageal toxicity. Supported by 
GIPO. 
Keyword: 3-dimensional hypofractionated 
accelerated radiotherapy (3D-HAR)
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.258 CONCURRENT 
CHEMORADIOTHERAPY (CONCRT) 
USING CISPLATIN-VINORELBINE IN 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER (LA NSCLC) 
FROM THE BANK OF CYPRUS 
ONCOLOGY CENTRE (BOCOC).
Marios P. Decatris1, Haris Charalambous1, Vanessa 
Avgousti2, Gregoris Christodoulides3, Nikos 
Katodritis1 
1Thoracic Oncology Unit, Bank Of Cyprus Oncology 
Centre/Cyprus, 2Clinical Outcomes Unit, Bank Of 
Cyprus Oncology Centre/Cyprus, 3Department Of 
Cardiothoracic Surgery, Areteio Private Hospital/
Cyprus
Background: ConCRT is considered the standard of 
care in LA NSCLC. We used cisplatin-vinorelbine 
concurrently with RT for appropriately selected 
patients with LA NSCLC since 2005. This updated 
analysis includes consecutively treated patients over 
the last 6 years.
Methods: From Feb 2005 to Feb 2011 we treated 
44 consecutive patients with LA NSCLC, most of 
who were deemed unresectable. This included LA 
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P4.257 INDUCTION CHEMOTHERAPY 
FOLLOWED BY 3-DIMENSIONAL 
HYPOFRACTIONATED ACCELERATED 
RADIOTHERAPY (3D-HAR) IN LOCALLY 
ADVANCED (LA) NON-SMALL CELL 
LUNG CANCER (NSCLC): OUR 
EXPERIENCE.
Giovenzio Genestreti1, Sara Piciucchi2, Antonino 
Romeo3, Elisabetta Parisi3, Emanuela Scarpi4, Andrea 
Moretti5, Federica Matteucci6, Rolando Polico3 
1Oncology, Irst Meldola/Italy, 2Radiology, Irst/Italy, 
3Radiotherapy, Irst/Italy, 4Unit Of Biostatistics, 
Irst/Italy, 5Nucleear Medicine, Irst/Italy, 6Nuclear 
Medicine, Irst/Italy
Background: Standard treatment of LA-NSCLC is 
represented by chemotherapy infused concomitantly 
to standard fractionated radiotherapy. Actually there 
is no worldwide agreement neither to chemotherapic 
nor radiotherapic schedule. Hence 3D-HAR may 
improve local disease control and reduce the duration 
and incidence of side effects due to therapy. 
Methods: Patients with LA-NSCLC treated with 
induction chemotherapy containing platin combined 
to third generation drug followed by 3D-HAR were 
eligible for the analysis. 
Results: From May 2007 to December 2010, 30 
patients were analyzed of whom 6 (20%) females 
and 24 (80%) males with a median age of 65 years 
(range: 50 – 74) and with a biopsy proven of NSCLC 
(17 adenocarcinoma, 1 great cell carcinoma, 10 
squamous cell carcinoma, 2 NSCLC not other 
speciÀed). Side disease was left in 13 (43%) patients, 
right in 14 (47%) patients and unknown in 3 (10%) 
patients. Stage disease was IIIA in 15 (50%) patients 
and IIIB in 15 (50%) patients; biopsy proven 
mediastinal lymph node involvement was available 
in 13 (43%) patients. All patients received 3 – 4 
courses of induction chemotherapy containing platin 
and in particular: 6 (20%) patients with Carboplatin 
associated to Gemcitabine (4 patients), Paclitaxel 
(1 patient) or Vinorelbine (1 patient) whereas 
24 (80%) patients with Cisplatin associated to 
Docetaxel (9 patients) or Gemcitabine (15 patients). 
Afterword all patients received 3D-HAR (25-30 
Gy in 5 fractions at the reference isodose delivered 
by helical tomotherapy) on the primary tumor and 
mediastinal lymph nodes involved; responders 
patients performed a rechallenge of 3D-HAR (15-
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considering most patients in this cohort had IIIB 
disease. The 20.2 month median OS achieved is 
higher than that reported previously from some 
randomized phase III studies of ConCRT. The 
Kaplan-Meier OS plot suggests that 35% patients 
treated may achieve long-term survival. This Cis-Vin 
ConCRT regimen appears effective and we therefore 
believe it merits further investigation.
Keywords: concurrent chemoradiotherapy, cisplatin-
vinorelbine, Locally advanced non-small cell lung 
cancer
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P4.259 A RANDOMIZED PHASE II TRIAL 
OF ADJUVANT CHEMOTHERAPY WITH 
DOCETAXEL (DOC) PLUS CISPLATIN 
(CIS) VERSUS PACLITAXEL (PAC) PLUS 
CARBOPLATIN (CAR) IN PATIENTS 
WITH COMPLETELY RESECTED NON-
SMALL CELL LUNG CANCER (NSCLC): 
TORG 0503
Tatsuo Ohira1, Kaoru Kubota2, Takashi Seto3, 
Hideo Kunitoh4, Naoki Shimada5, Norihiko Ikeda1, 
Masahiro Tsuboi6, Hiroaki Okamoto7, Noriyuki 
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Of Thoracic Surgery, Kanagawa Cancer Center/
Japan, 7Department Of Respiratory Medicine, 
Yokohama Municipal Citizen’s Hospital/Japan, 
8Kitasato University School Of Medicine/Japan, 
9Surgery, Nippon Steel Yawata Memorial Hospital/
Japan, 10Department Of Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center 
Komagome Hospital/Japan
Background: Adjuvant chemotherapy is standard 
of care for patients with completely resected stage 
IB, II and IIIA NSCLC. However, the optimum 
chemotherapy regimen has not been determined. 
TORG 0503 was conducted to evaluate platinum-
based third generation regimens in this clinical setting.
Methods: Patients with completely resected stage 
IB, IIA, IIB or stage IIIA NSCLC were stratiÀed 
by stage (IB/IIA vs. IIB/IIIA) and institution and 
randomized to receive 3 cycles of DOC (60mg/
NSCLC staged (using the 6th Edition of TNM) as 
T4/ N3/ “bulky” N2 disease or locally recurrent 
disease after initial surgery. Patients had ECOG 
performance status (PS) 0-2 and were treated with 
Cisplatin (Cis, 75mg/m2 d1) and Vinorelbine 
(Vin, 30mg/m2 d1-8) 3-weekly. Chemotherapy 
was administered at full doses for 1-2 cycles and 
thereafter radical RT was delivered concurrently 
with subsequent chemotherapy cycles. During the 
phase of concurrent CRT Vinorelbine was reduced to 
12.5mg/m2 d1-8. After ensuring the toxicity of the 
Àrst 11 patients treated was acceptable, subsequent 
patients received Vinorelbine at 15mg/m2 d1-8 
during ConCRT. The number of treatment cycles was 
also escalated to a maximum of 6. Patients received 
deÀnitive CRT (59.4 Gy) unless, surgery was 
planned. This decision was taken following restaging 
evaluation, for potentially resectable patients, 
performed at 45Gy. Since 2008 we have used PET-
CT increasingly to stage patients at baseline.
Results: Patient and disease demographics: Of 44 
patients there were 39 men and 5 women. Median 
age was 64 (43-81); PS 0-1 n=37, PS 2 n=6, 
unknown n=1; 42/44 were smokers with a median 
66 (0-140) pack-year history and 10/44 (23%) had 
documented weight loss 5% of baseline weight; 
radiological stage IIIB n=30 (68%), IIIA n=9 
(20%) , IIB n=5 (11%); histology, squamous n=26, 
adenocarcinoma n=9, unspeciÀed NSCLC n=9. 
Treatment delivered: total cycles of chemotherapy 
190, median 4 (range 1-7). 40 patients (91%) 
received concurrent therapy most commonly during 
cycles 2-4. Radiological response rates: Objective 
responses n=26 (4 complete(CR), 22 partial(PR)), 
yielding a response rate of 59%; stable disease(SD) 
n=5; progressive disease(PD) n=6; of the remaining 
7 non-evaluable patients 2 had a PR and 1 SD on 
chest radiograph. 6/40 (15%) patients who received 
ConCRT underwent surgery (5 lobectomies, 1 
pneumonectomy). 5 of these 6 patients had a 
complete pathologic response (pCR) and 1 a near 
pCR. After median follow-up of 23.7 months (for 
patients who are alive) the survival Àgures are: 
median progression-free survival (PFS) 15.4 months 
(95% C.I. 9.1-21.7) and median overall survival 
(OS) 20.2 months (95% C.I. 12.2-28.3). Toxicity was 
manageable. The incidence of grade 3-4 oesophagitis 
or pneumonitis was < 10%. There was 1 toxic death 
from neutropenic sepsis in a patient who did not seek 
medical attention promptly. Detailed toxicity data 
will be presented in due course.
Conclusion: These results are very encouraging 
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Background: Intratumoural hypoxia is a recognised 
adverse prognostic factor in several cancers, and 
may contribute to resistance to radiation and 
chemotherapy but its importance in lung cancer is 
unproven. This trial evaluated tumoural hypoxia 
using [18F]-Áuoroarabinofuronosyl-2-nitroimidazole 
(18F-FAZA) positron emission tomography (PET) 
scans among patients with locally advanced non-
small cell lung cancer (NSCLC) treated with 
deÀnitive chemoradiation. 
Methods: Patients with stage IIIA-IIIB NSCLC 
underwent 18F-FAZA PET scans and [18F]-2-
deoxyglucose (FDG)-PET scans within 4 weeks prior 
to commencing and 8 weeks following completion of 
concurrent platinum-based chemoradiation (60 Gy). 
Intra-tumoural hypoxic volumes were determined 
for the primary and nodal masses, and compared 
with FDG-PET tumoural volumes to determine the 
intratumoural hypoxic fraction. The presence of 
baseline intratumoural hypoxia was correlated with 
metabolic volume and disease free survival. 
Results: 17 patients underwent baseline 18F-FAZA 
PET and FDG-PET scans. Intra-tumoural and/
or nodal hypoxia was qualitatively identiÀed 
on 11 scans (65%). Tumoural hypoxic volumes 
were consistently smaller than volumes of FDG 
metabolic activity at baseline evaluation (median 
FDG-PET volume 42.22 cm3 [6.42-137.47]; median 
18F-FAZA PET volume 15.18 cm3 [0.51-82.88], 
p=0.012). FDG-PET volumes were not, however, 
statistically different according to hypoxia status 
(p=0.38). Eight patients with baseline hypoxia had 
post treatment 18F-FAZA scans - 6 of 8 (75%) 
patients had resolution of imageable hypoxia 
following chemoradiation. Two of 6 patients without 
imageable baseline hypoxia were alive at last follow 
up 7.8 years after treatment. Only 1 of 11 patients 
with baseline hypoxia did not experience disease 
progression, and died of heart failure at 6 years. The 
disease free survival was not signiÀcantly different 
m2, day 1) plus CIS (80mg/m2, day 1) or 3 cycles 
of PAC (200mg/m2, day 1) plus CAR (AUC 6, day 
1). Both regimens were repeated every 3-4 weeks. 
Other eligibility criteria included ECOG PS 0-1, age 
>=20, and =<70 years old, adequate organ function, 
no prior chemotherapy or radiotherapy. Patients who 
underwent pneumonectomy were excluded. The 
primary endpoint was 2-year relapse free survival 
(RFS), and secondary endpoints were overall survival 
(OS), quality of life (QOL), feasibility and toxicity.
Results: 111 patients were randomized between April 
2006 and July 2008, 58 patients to DOC+CIS (DC) 
and 53 to PAC+CAR (PA). Patients’ demographics 
(DC/PA): median age 63/59 years, 60%/66% male, 
17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% 
of patients were stage IB/IIA, 60%/60% IIB/IIIA. The 
two-year RFS rate was 74.1% (95%CI: 68.4-79.8) 
in the DC arm and 72.5% (66.3-78.7) in the PA arm. 
The two-year survival rate was 89.6% (85.6-93.6) 
in the DC arm and 86.3% (81.5-91.1) in the PA arm. 
Feasibility: 93% (54/58) of patients allocated to DC 
and 92% (49/53) patients in the PA arm completed 3 
planned cycles of chemotherapy. Toxicities: DC vs. PA: 
Grade (G) 3/4 neutropenia (86%/75%), G3/4 anemia 
(2%/0%). G 3 febrile neutropenia (10%/4%), G2 ALT 
(0%/10%), G2 creatinine (17%/0%), G2-4 allergy 
(0%/4%), G2/3 anorexia (43%/22%), G2/3 nausea 
(47%/22%), G2/3 vomiting (31%/12%), G2 diarrhea 
(12%/8%), G2/3 sensory neuropathy (3%/33%), 
G2/3 arthralgia (0%/31%), G2 myalgia (2%/8%). No 
treatment related deaths were observed in either arm.
Conclusion: Docetaxel plus cisplatin demonstrated 
promising activity with favorable 2-year RFS, safety 
and feasibility as adjuvant chemotherapy in patients 
with completely resected NSCLC. Updated survival 
data will be presented at the meeting. 
Keywords: phase II trial, Adjuvant chemotherapy, 
Non-small cell lung cancer, TORG
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P4.260 MEASUREMENT OF HYPOXIA 
WITH 18F-FAZA PET IN PATIENTS WITH 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER TREATED WITH 
DEFINITIVE CHEMORADIOTHERAPY
Robert Blum1, Mateya Trinkaus2, Jason Callahan3, 
Mathias Bressel4, Tatiana Segard3, Peter Roselt5, 
David Binns5, Michael P. Macmanus6, David Ball7, 
Rodney J. Hicks5, Danny Rischin2 
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patients, 36 (58,1%) patients and 2 (3,2%) patients, 
there were N1, N2 and N3 disease, respectively. 
Recurrence was observed in 24 (54,8%) patients. 
Twenty-six (41,9%) patients had an operations. 20 
(32,3%) patiens received chemotherapy (mostly 
vinorelbine+cisplatinum) and 16 (25,8%) received 
chemoradiotherapy. Of all patients who had 
operation, 15 (57,6%) also receieved neoadjuvant 
chemotherapy. There was signigicant association 
found between surgery and overall survival in 
locally advanced NSCLC patients. However, this 
signiÀcant association was not observed between, 
age of the patient at diagnosis, gender, nodal statatus, 
hisyologic subgroups, stage at the diagnosis, results 
of PET-CT scan and disease and overall survival of 
the patients. 
Conclusion: Our preliminary results indicate that, 
multimodality approach for treatment of locally 
advanced NSCLC is obligatory and neoadjuvant 
chemotherapy with cisplatin+vinorelbine is well 
tolerated and effective teratment option.
Keywords: locally advanced, Non-small cell lung 
cancer, Vinorelbine, neoadjuvant
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P4.262 HIGH DOSE PREOPERATIVE 
CHEMORADIATION PRODUCES HIGH 
RATE OF COMPLETE RESPONSE IN 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER
Aaron M. Allen1, Dov Flex2, Mordechai Kramer3, 
Ronen Galili4, Oren Fruchter3, Sara Gardin1, Milton 
Saute4 
1Radiation Oncology, Rabin Medical Center/Israel, 
2Oncology, Rabin Medical Center/Israel, 3Instiute 
Of Pulmonology, Rabin Medical Center/Israel, 
4Division Of Thoracic Surgery, Rabin Medical 
Center/Israel
Background: Trimodality therapy has been shown 
to be an effective treatment for stage III Non-small 
cell lung cancer (NSCLC). In the Intergroup trial 
(Albain et al) 45 Gy of radiation was delivered with 
a nodal downstaging rate of 46%. We hypothesized 
that with advanced radiotherapy techniques high 
dose radiotherapy ( >66 Gy) could be given without 
increasing toxicity.
Methods: Patients who underwent preoperative 
chemoradiation at Rabin Medical Center followed 
between the baseline hypoxic and non-hypoxic 
groups (median 0.8 years and 1.3 years respectively, 
p=0.42). 
Conclusion: Intratumoural hypoxia, as detected by 
18F-FAZA PET, was present in 65% of patients with 
locally advanced NSCLC and became undetectable 
in the majority of patients who had repeat scans 
following chemoradiation. Larger studies are 
required to evaluate the prognostic signiÀcance of 
the presence and resolution of imageable tumour 
hypoxia in NSCLC. 
Keywords: Hypoxia, FAZA PET scan, Non-small 
cell lung cancer, chemoradiation
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P4.261 TREATMENT RESULTS IN 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS: A 
SINGLE CENTER EXPERIENCE
Ozden Altundag1, Vedat Kilic2, Nadire Kucukoztas2, 
Selim Yalcin2 
1Medical Oncology, Baskent University/Turkey, 
2Baskent University/Turkey
Background: Although combined-modality 
treatment with chemotherapy and radiotherapy 
has improved survival in some patients with stage 
III NSCLC, most still succumb to the underlying 
disease. Tumor progression remains problematic, 
both locally within the chest and in extrathoracic 
sites.
Methods: Sixty-two patients with a diagnosis of 
locally advanced non-small cell patients followed at 
Medical Oncology Department in Baskent University 
School of Medicine were enrolled into the study. 
Patients and clinico-pathologic charactheristics 
including age, gender, lymph node status, smoking 
history, histopathology that may affect disease free 
and overall survival were analyzed. 
Results: Of all patients, 4 (6,5%) were female and 
58 (93,5%)were male. Median age was 60(range, 
43-). Median follow-up period was 24 months. 
For histopathologic subgroups, 34 (54,8%) 
were squuamouscell carcinoma, 17 (27,4%) 
adenocarsinomo, 2 (3,2%) large cell carcinoma and 
9 (14,5%) other NSCLC subtypes. Twenty seven 
(43,5%), patients were in stage IIIA, 35 patients 
in stage IIIB (56,5%) . In 7 (11,3%) patients, 
there were positive lymph nodes. In 7 (11,3%) 
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P4.263 PULMONARY RESECTION 
AFTER HIGH DOSE RADIATION 
THERAPY (>59 GY) AND CONCURRENT 
CHEMOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER.
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Devisetty1, Nicholas Choong2, William Tisol3, 
George Haasler3 
1Radiation Oncology, Medical College Of Wisconsin/
United States Of America, 2Hematology/Oncology, 
Medical College Of Wisconsin/United States Of 
America, 3Cardiothoracic Surgery, Medical College 
Of Wisconsin/United States Of America
Background: Preoperative concurrent 
chemoradiotherapy (ChT/RT) for locally advanced 
NSCLC improves local control and has curative 
potential. Standard preoperative RT dose is 45-
50 Gy. Higher dose RT results in higher response 
rates and has resulted in longer survival but is also 
plagued with higher complication rates, particularly 
after pneumonectomy. RT dose of 60-66 Gy is 
routinely used to treat LA-NSCLC at the Medical 
College of Wisconsin (MCW) with curative intent 
and also in the preoperative setting for resectable and 
marginally resectable locally advanced disease. High 
dose radiation is used to improve response rates and 
resectability and also to avoid treatment interruptions 
if surgical resection is not performed. 
Methods: The medical records of patients 
undergoing surgery at the MCW who received RT 
>59 Gy between 2000 and 2010 were reviewed. Data 
abstracted included demographics, complications, 
pathologic response rates, failure patterns, and 
survival. 
Results: Forty patients were identiÀed with a 
median age of 61 (40-82 years). 23% were over 
70 years. Median radiation dose was 63 Gy (59.4-
68.4 Gy). The most common dose was 66 Gy. All 
but one patient received concurrent ChT. Reasons 
for concurrent ChT/RT included pathologic 
conÀrmation of N2 disease (9), marginally resectable 
or unresectable primary tumor (18), clinical 
N2 disease (12), and recent cardiac surgery (1). 
Median time from completion of RT to surgery 
was 75 days (20-602). Surgeries performed 
following ChT/RT were: 27 lobectomies, 9 left 
pneumonectomies, and 4 right pneumonectomies. 
Muscle Áaps were used in 3 cases. 20% of patients 
by surgery were retrospectively reviewed. 
Chemotherapy was either Carboplatin (AUC 6) and 
Paclitaxcel (200 mg/m2) q3 wk or Cisplatin d1&8 
(50mg/m2)/Etoposide d1-5 (50mg/m2)concurrent 
with RT. No induction chemotherapy was given. RT 
was limited to the involved tumor and nodes based 
on FDG-PET, no elective nodes were treated. RT 
was delivered with IMRT using ECLIPSE treatment 
planning system with dynamic multileaf collimator 
delivery. One month following completion of CRT a 
restaging FDG-PET was performed. Patients without 
progressive disease were taken to surgery.
Results: From November 2007- August 2010 thirty 
patients underwent preoperative chemoradation 
followed by surgery. A majority of patients were 
male (53%) and the median age was 62 years (range 
47-76). Performance status was ECOG 0-1 in all 
but one patient. 54% presented with stage IIIA and 
46% were staged IIIB. 75% received cisplatin/
etoposide concurrent with RT and the remainder 
received carboplatin/paclitaxcel. Median PTV dose 
of RT was 72 Gy (range 66-72). Median gross tumor 
volume was 110 cm3 (range 27.3-353 cm3) 13/30 
(43%) underwent pneumonectomy and the remainder 
lobectomy. There were no post-operative deaths. 
97% of patients underwent nodal downstaging . 
74% of patients had pathologic compete response. 
The median V20 was 24% and median mean 
lung dose was 14 Gy. With median follow-up of 
14.5 months four patients have died. One patient 
developed a fatal pulmonary artery rupture 3 months 
after surgery and two patients developed grade 3 
radiation pneumonitis. 6 patients have experienced 
distant failure, 5 with brain metastases and one with 
pleural effusion. No patients have developed local 
recurrence. 67% of patients remain alive without 
evidence of disease. The median survival has not yet 
been reached.
Conclusion: High dose preoperative CRT produces 
provocative response rates and is tolerable. 
This approach is ongoing and worthy of further 
investigation.
Keywords: combined modality, NSCLC, Surgery, 
Radiotherapy
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Background: The encouraging, but modest beneÀts 
from concurrent chemoradiotherapy (CRT) in 
patients with locally advanced NSCLC warrant 
more effective treatment regimen. Cetuximab, a 
monoclonal antibody against the epidermal growth 
factor receptor has shown activity in NSCLC and 
in combination with RT in head and neck cancer. 
We report on the Ànal safety assessment of the 
combination of daily dose Cisplatin and CRT with 
or without weekly Cetuximab. Feasibility data have 
been published previously.
Methods: Patients with non-operable locally 
advanced NSCLC received high dose accelerated 
RT (66 Gy in 24 fractions) and concurrent daily 
Cisplatin (6 mg/m2) with (arm A) or without (Arm 
B) additional weekly Cetuximab (400 mg/m2 
loading dose one week prior to the RT start followed 
by weekly 250 mg/m2).
Results: Between February 2009 and February 
2011, 87 patients entered this multicenter phase II 
study. The median age was 63 years (range: 29-78) 
and 70% were male. Baseline NSCLC staging was: 
II (10%), IIIa (41%), and IIIb (49%). 52 patients 
were evaluable for toxicity. The CRT was generally 
well tolerated. Radiation esophagitis was the most 
common side effect (grade 3 according to CTCAE 
v 3.0) (see table). Using a prophylactic regimen 
against acneiform dermatitis the percentage of grade 
III skin toxicity was 11%. All other side effects were 
comparable between both groups. In the arm A 16 
patients had SEAs reported and 7 in arm B.
experienced major 30-day complications with no 
30-day postoperative deaths. Acute perioperative 
complications requiring reoperation included: 
3 hemorrhages, 2 bronchopleural Àstulas, and 1 
chylothorax. Muscle Áaps were not used in these 
cases. Late complications included: 2 contralateral 
pneumothoraces, 1 hemorrhage, 1 chest-wall 
abscess, and 1 esophageal Àstula. 50% (2/4) patients 
with right pneumonectomy and 11% (1/9) with 
left pneumonectomy experienced major 30-day 
complications including hemmorrage, pulmonary 
embolus, and SVC obstruction. Complete 
pathological response (pCR) rate was 60% for all 
patients. For patients with preoperative biopsy 
proven N2 involvement pCR was 56% and complete 
nodal clearance was 78%. Median follow-up from 
end of RT was 26 months (5 months -10 years). 
Overall survival (OS) and disease free survival 
(DFS) at 1 year was 95% and 77% and at 3 years 
55% and 44%. Three-year OS for pN0 and pN+ 
disease was 64% and 17%, (p=0.0051). 40% of 
patients had surgery for radiographic residual or 
progressive disease > 90 days after completing RT. 
50% are alive without disease with median follow-up 
of 32 months and no major complications. 
Conclusion: Pulmonary resection, including 
pneumonectomy after high dose RT/ChT can safely 
be performed with high pCR, OS, and DFS rates. 
Long term survival is possible in patients with 
residual N2 disease after high dose ChT/RT. Surgical 
salvage > 90 days after high dose ChT/RT is well 
tolerated. 
Keywords: Non-small cell lung cancer, high dose 
radiation therapy, Surgery, chemoradiotherapy
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P4.264 RANDOMIZED, MULTI-CENTER 
PHASE II STUDY INVESTIGATING 
ADDITIONAL WEEKLY CETUXIMAB TO 
CONCURRENT CHEMORADIOTHERAPY 
IN LOCALLY ADVANCED NON-SMALL 
CELL LUNG CARCINOMA: FINAL 
REPORTING ON SAFETY
Michel M.V.D. Heuvel1, Wilma Uyterlinde1, A 
Vincent2, Joachim Aerts3, Henk Codrington4, Peter 
Kunst5, Lon Uitterhoeve6, Paul V.D. Vaart7, Marcel 
Verheij8, José Belderbos8 
1Thoracic Oncology, The Netherlands Cancer 
Institute / Antoni Van Leeuwenhoek Hospital/
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is some preliminary evidence that response to 
chemoradiotherapy varies with histology. Xu and 
Colleges (XuY,etal. Concomitant chemoradiotherapy 
using pemetrexed and carboplatin for unresectable 
stage III non-small cell lung cancer (NSCLC): 
Preliminary results of a phase II study. Lung Cancer 
(2010),doi:10.1016/j.lungcan.2010.09.012) treated 
21 patients with pemetrexed (500mg/m2) plus 
carboplatin (AUC 5) and simultaneous radiotherapy, 
and found that the patients with adenocarcinoma 
(n=16) experienced longer progression free survival 
(p= 0.068) than those with squamous cell carcinoma 
(n=5).
The CTRT 99/97 Study from the Bronchial 
Carcinoma Therapy (BROCAT) Group. (Huber et 
al., JCO 2006) showed that, following induction 
chemotherapy with paclitaxel and carboplatin, 
simultaneous chemoradiotherapy with weekly 
paclitaxel is superior to radiotherapy alone. The role 
of histology in the response to chemoradiotherapy 
with paclitaxel and carboplatin has not yet been 
described.
Methods: We conducted a retrospective analysis 
of histology-based subgroups in the CTRT99/97 
BROCAT study, looking at overall survival as well 
as progression free survival.
Results: Three hundred and three patients were 
enrolled in the BROCAT trial including 59 
adenocarcinoma, 171 squamous cell, 28 large cell, 
10 mixed and 35 NSCLC not otherwise speciÀed 
(NOS). After induction chemotherapy 214 patients 
were randomized to either radiotherapy alone (22 
adenocarcinoma, 67 squamous cell, 12 large cell, 4 
mixed, 7 NOS) or radiotherapy plus simultaneous 
paclitaxel (19 adenocarcinoma, 62 squamous cell, 4 
large cell, 3 mixed, 8 NOS).
Independent of histology, patients randomized to 
receive chemoradiotherapy experienced longer 
progression free survival than those who received 
radiotherapy alone (11.5 vs. 6.3 months, HR 1.747, 
p<0.001), and there was a strong trend towards 
improved overall survival (18.7 vs. 14.1 months, 
p=0.091).
Analyses of histology subgroups showed a 
trend towards improvement in overall survival 
in all subgroups which did not reach statistical 
signiÀcance. Patients with squamous cell carcinoma 
showed a statistically signiÀcant improvement 
in progression free survival after randomization 
to chemoradiotherapy compared to radiotherapy 
alone (HR 1.75, p=0.007). In the adenocarcinoma, 
mixed histology and NSCLC NOS subgroups there 
Conclusion: Concurrent chemoradiotherapy 
consisting of high dose accelerated radiotherapy 
and daily dose Cisplatin with additional weekly 
Cetuximab in patients with NSCLC was well 
tolerated. These results justify further evaluation of 
the efÀcacy of this multimodal regimen.
Keywords: chemoradiotherapy, Non-small Cell 
Lung Carcinoma, cetuximab, safety
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.265 THE IMPACT OF HISTOLOGY 
ON OVERALL SURVIVAL AND 
PROGRESSION FREE SURVIVAL 
FOLLOWING INDUCTION 
CHEMOTHERAPY WITH PACLITAXEL 
AND CARBOPLATIN AND 
RADIOTHERAPY OR SIMULTANEOUS 
RADIOCHEMOTHERAPY WITH 
WEEKLY PACLITAXEL
Amanda Tufman1, Tibor Schuster2, Astrid 
Borgmeier1, Michael Schmidt3, Kurt Ulm2, Michael 
Flentje3, Rudolf M. Huber1 
1Department Of Respiratory Medicine, Ludwig 
Maximilians University/Germany, 2Technical 
University Of Munich/Germany, 3University Of 
Wuerzburg/Germany
Background: The choice of systemic therapy in 
stage IV NSCLC is increasingly individualized; 
the precise histology and, increasingly, tumour 
molecular biology, are taken into account. However, 
this approach has not yet been broadly applied 
to patients treated with chemoradiotherapy for 
inoperable stage IIIa and IIIb disease. There 
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hence survival for this group of patients. To test 
this hypothesis, we have conducted a randomised 
phase II trial in which patients received a radiation 
dose of 55Gy in 20 fractions in four weeks, given 
either sequentially after four cycles of cisplatinum 
and vinorelbine or concurrently with the same 
chemotherapy
Methods: 130 patients were randomised to receive 
55Gy at the ICRU reference point in 20 fractions 
over 4 weeks, with four cycles of cisplatinum and 
vinorelbine given either prior to RT or starting 
concurrently with the Àrst fraction of radiation.
Trial entry required: pathologically conÀrmed stage 
III NSCLC judged inoperable by a thoracic surgeon, 
and treatable within a radical RT volume with v20 
30% and 12 cm of oesophagus within PTV; PS 
0 or 1, FEV1 1L and TLCO 50%. Patients with 
weight loss and N3 disease were included, with 
no upper age limit. Treatment was with either 3D 
conformal RT or 4D. Required GTV-PTV margin 
was 1.5 cm for conformal and 1cm for 4D planning.
Median age was 62(range 39-77); 61% were male; 
histology 64% squamous, 27% adenoca; 52% were 
PS 0; 44% had IIIA and 56% had IIIB disease. 
Patient characteristics were well balanced between 
the two arms.
Results: 67 patients received concurrent (con) 
treatment and 60 sequential (seq). This report is at a 
median follow up of 31 months.
The median number of chemotherapy cycles 
was 3 con vs 4 seq; 53% vs 60% of patients had 
chemotherapy dose delays. Incidence of SAEs was 
46% con vs 47% seq. there were 43 grade 3 or 4 
toxicities (29% vs 38%) - 15 were grade 4 (7 con, 
8 seq). Six con patients and one seq suffered grade 
3 oesophagitis. Grade 4 oesophagitis did not occur.
There were two treatment related deaths in the 
con arm and one in the seq arm. Deaths within six 
months of randomisation were three con vs two seq. 
52.2% of patients in the con arm and 68.3% in the 
seq arm have died. Median survival in months is 
27.4 con vs 18.6% seq. Two year survival is 54% in 
the concurrent arm and 42% for patients receiving 
sequential treatment. Survival at three years is 38% 
con vs 27% seq.
The incidence of local tumour recurrence within 
the radiation treatment volume was 10% in the 
concurrent arm and 22% in the sequential arm.
Conclusion: This is the Àrst randomised trial in 
stage III NSCLC to achieve a two year survival rate 
in excess of 50%, with a local relapse rate of 10% for 
patients receiving concurrent treatment. A strategy 
was a trend to improved progression free survival 
following chemoradiotherapy. Unexpectedly, patients 
with large cell tumours showed a trend towards 
shorter progression free survival after treatment with 
chemoradiotherapy (HR 0.589).
Conclusion: This analysis did not identify a 
statistically signiÀcant effect of histology on the 
efÀcacy of induction therapy with paclitaxel plus 
carboplatin and simultaneous chemoradiotherapy 
with paclitaxel in locally advanced NSCLC. 
However the beneÀt of simultaneous 
chemoradiotherapy was most clear in patients with 
squamous cell carcinoma. There was a surprising 
trend towards worsened progression free survival in 
patients with large cell tumours.
Further analyses are required to bring clarity to the 
role of histology in the treatment of locally advanced 
tumours. In particular in studies investigating new 
combinations of systemic therapy (including EGFR-
TKIs and other targeted therapies) and radiation, 
the relevance of histology, and of tumour molecular 
biology, is likely to increase.
Keywords: paclitaxel, Carboplatin, 
Radiochemotherapy, histology
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P4.266 SOCCAR: SEQUENTIAL OR 
CONCURRENT CHEMOTHERAPY AND 
HYPOFRACTIONATED ACCELERATED 
RADIOTHERAPY IN INOPERABLE 
STAGE III NSCLC
Joe Maguire1, Noelle O’Rourke2, Clive Peedell3, 
Rhona Mcmenemin4, Michael P. Snee5, Stuart 
Mcnee2, Veronica Kelly1, Iftekhar Khan6, Rachel 
Slade6 
1Oncology, Liverpool Heart And Chest Hospital/
United Kingdom, 2Beatson Oncology Centre/United 
Kingdom, 3James Cook University Hospital/United 
Kingdom, 4Clinical Oncology, Northern Centre For 
Cancer Care/United Kingdom, 5St James’s Institute 
Of Oncology/United Kingdom, 6UCL Cancer Trials 
Centre/United Kingdom
Background: Local tumour control and recurrence 
is a major problem in the management of inoperable 
stage III NSCLC. A strategy to avoid the detrimental 
effects of accelerated repopulation - administration 
of a radical radiotherapy dose within a period of 
28 days - might improve local control rates and 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1561
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was chosen to facilitate assessment of the effects of 
the two treatment arms on QoL, while avoiding the 
detrimental effects of tumour progression on QoL 
scores.
Results: Patient compliance was high, with pre-
randomisation assessments completed by 63/67 
patients receiving con treatment and 50/60 patients 
in the seq arm. This compliance rate was maintained 
at three months from randomisation; six months 
after randomisation the completion rate was 41/67 
con and 35/60 seq and slightly more forms were 
completed by patients at twelve months after starting 
treatment.
Patient scores using the QLQ-C30 prior to 
randomisation were fairly well matched in both 
the “role functioning “ and “physical functioning 
“ domains across both the con and seq groups, 
with mean scores of 85.2 con vs 79.3 seq in role 
functioning and 88.6 con vs 84.5 seq for physical 
functions. At three months scores dropped in both 
treatment arms - mean scores for role functioning 
were 71.0 con and 60.7 seq, and for physical 
functions 80.0 con vs 74.6 seq. QoL scores appeared 
to recover more quickly in patients receiving 
sequential treatment; at six months mean role 
functioning scores were 69.1 con vs 72.4 seq, and 
mean scores in the physical function domains were 
77.7 con vs 80.1 seq.
At twelve months after starting treatment mean role 
functioning scores were 73.8 in the con group and 
70.4 for seq patients, and mean scores for physical 
function were 80.8 con vs 78.1 seq.
Conclusion: QoL measurement is feasible in a trial 
of chemoradiation in stage III NSCLC. Our Àndings 
indicate that patient reported QoL falls at three 
months for patients receiving both concurrent and 
sequential treatment; recovery towards pretreatment 
levels occurs more quickly in seq patients. Twelve 
months after commencing treatment the degree of 
recovery towards pre treatment levels of QoL is 
similar for patients in both concurrent and sequential 
treatment arms. The overall degree of recovery in 
reported QoL is slightly greater for physical function 
compared to role functioning as assessed using the 
QLC-C30 instrument.
Keywords: Quality of Life, chemoradiation
to minimise the effects of accelerated repopulation 
using accelerated hypofractionated radiotherapy 
with chemotherapy is feasible, safe and effective for 
patients with stage III NSCLC.
Keywords: accelerated, hypofractionated, 
Radiotherapy
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P4.267 PATIENT QUALITY OF LIFE 
IN A RANDOMISED TRIAL OF 
SEQUENTIAL VERSUS CONCURRENT 
CHEMORADIATION USING 
ACCELERATED HYPOFRACTIONATED 
RADIOTHERAPY (SOCCAR)
Joe Maguire1, Rhona Mcmenemin2, Noelle 
O’rourke3, Clive Peedell4, Michael P. Snee5, Stuart 
Mcnee3, Veronica Kelly1, Iftekhar Khan6, Rachel 
Slade6 
1Oncology, Liverpool Heart And Chest Hospital/
United Kingdom, 2Clinical Oncology, Northern 
Centre For Cancer Care/United Kingdom, 3Beatson 
Oncology Centre/United Kingdom, 4James Cook 
University Hospital/United Kingdom, 5St James’s 
Institute Of Oncology/United Kingdom, 6UCL 
Cancer Trials Centre/United Kingdom
Background: SOCCAR is the Àrst trial comparing 
concurrent and sequential chemotherapy and 
radiotherapy in stage III NSCLC to prospectively 
measure quality of life (QoL) in both treatment arms. 
In this phase II trial patients received four cycles 
of cisplatinum and vinorelbine, with 55Gy in 20 
fractions over four weeks either sequentially after 
four cycles of chemotherapy (seq) or concurrently 
with the same radiotherapy schedule starting on day 
one of radiotherapy (con). We have reported a two 
year survival rate of 54% in the concurrent arm and 
42% for patients in the sequential arm.
Methods: 67 patients received con and 60 seq. 
Patients were asked to complete the QLC-C30, LC-14 
and EQ-5D questionnaires prior to randomisation and 
at speciÀc intervals during treatment and follow up.
This report relates to patient reported QoL using 
the QLC-C30 instrument at three and six months 
from randomisation, and twelve months after 
starting treatment, in patients who remained free 
from recurrence at 18 months from randomisation. 
Scores were compared with the patient’s pre-
randomisation assessments. This group of patients 
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resection and mediastinal lymphadenectomy with 
10 pneumonectomies (38%) and 16 lobectomies 
(62%) performed. Length of stay was 6 days (range 
4-20 days) and median ICU care was 1 day (range 
1-9). Only one patient required a perioperative 
blood transfusion. At least one major peri-operative 
complication occurred in 10 of 26 patients (38%) 
with atrial Àbrillation (17%) and pulmonary 
insufÀciency (10%) being the most common. There 
were no operative mortalities. Final pathologic 
assessment showed that 12 of the initial 30 patients 
(40%) were down-staged by this induction regimen. 
There were no late surgical complications and all 
patients recovered sufÀciently to begin consolidation 
therapy as planned.
Conclusion: Surgical resection following an 
induction chemoradiation therapy with concomitant 
EGFR receptor inhibition (erlotinib) for stage IIIA/B 
NSCLC is technically feasible and safe. No surgical 
mortality was seen in this preliminary study, even 
after pneumonectomy, and a surprisingly high 
percent of patients completed their entire intended 
therapy. Longer follow-up will be important to 
establish efÀcacy prior to expanding this novel 
treatment regimen.
Keywords: Non-small cell lung cancer, erlotinib, 
chemoradiation, Surgery
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P4.269 THE RETROSPECTIVE ANALYSES 
OF 96 CASES WITH PRIMARY LUNG 
CARCINOMA
Turkan Dubus1, Ozlem Uzman2, Dilay Demiryontar2 
1Department Of Chest Surgery, Istanbul Research 
And Training Hospital/Turkey, 2Department Of Chest 
Diseases, Istanbul Research And Training Hospital/
Turkey
Background: Lung cancer is the most common 
cause of cancer death and closely associates with 
cigarette smoking. In early stage of disease the 
patients are usually asymptomatic and when the 
symptoms consist, the cancer is in advanced stage. 
Methods: According to clinical, radiological and 
bronchoscopical Àndings 96 cases which were 
diagnosed pathologically between January 2007 and 
December 2010 years were analyzed retrospectively. 
Results: Male/Female: 87/9, median age: 59. 
Eighty- two (85.4 %) patients were smokers (mean 
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P4.268 INDUCTION CHEMORADIATION 
THERAPY WITH EGFR RECEPTOR 
INHIBITOR (ERLOTINIB) FOR STAGE 
IIIA/B NON-SMALL CELL LUNG 
CANCER IS WELL TOLERATED AND 
DOES NOT COMPLICATE SUBSEQUENT 
RESECTION.
Siva Raja1, Nathan Pennell2, David P. Mason2, 
Thomas W. Rice2, David Adelstein2, Gregory M. 
Videtic2, Marc Shapiro2, Sudish Murthy1 
1Cardiothoracic Surgery, Cleveland Clinic 
Foundation/United States Of America, 2Cleveland 
Clinic Foundation/United States Of America
Background: Survival from locally advanced (Stage 
IIIA/B) non-small cell lung cancer (NSCLC) is poor 
despite aggressive multimodality therapy. We report 
the feasibility and surgical outcomes of a novel 
phase 1 induction. 
Methods: Thirty patients with resectable pathologic 
stage IIIA/B NSCLC were enrolled in a non-
randomized trial of induction therapy. Patients 
received three cycles of paclitaxel (50mg^m2/
week) and carboplatin (AUC 2/week) with hyper-
fractionated radiotherapy (150cGy BID X 2 weeks). 
In addition, patients were treated with concomitant 
erlotinib (150mg/daily) during their induction period. 
After restaging, non-progressors as well as those 
deemed Àt enough for surgery, underwent pulmonary 
resection. Consolidation therapy (identical to the 
induction course) was planned and there was an 
intent to maintain patients on erlotinib (150mg/daily) 
for 2 years. Charts were reviewed and down-staging, 
operability, surgical mortality/morbidity, and ability 
to complete the intended treatment were assessed.
Results: The median age of participants was 
61 yrs (32-76) and 43% were male (13/30). The 
planned induction course was completed in 29 of 30 
patients. Interval assessment demonstrated a 13% 
progression rate to stage IV disease (4/30), and of 
the remaining 26 patients, all underwent resection. 
The median interval from staging mediastinoscopy 
until operative intervention was 10.7 weeks (7-13.7 
weeks) and the FEV
1
 pre and post induction therapy 
was unchanged (89% vs. 88.5%. Dermatologic and 
gastrointestinal toxicities from the induction regimen 
were seen in almost 90 % of patients, though only 
one was signiÀcant enough to truncate/alter therapy. 
All 26 patients underwent anatomic pulmonary 
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P4.270 THE EARLY DETECTION 
OF LUNG CANCER WHEN 
ENDOBRONCHIAL LESION IS 
VISUALIZED BY FLEXIBLE 
BRONCHOSCOPY (FB)
Rosa M. Sanchez-Munoz1, Juan L. Rodríguez 
Hermosa2, Miriam Calle Rubio2, Jose R. Jarabo1, 
Ana M. Gomez1, Lucia Milla Collado1, Florentino 
Hernando Trancho1, Jose Luis Alvarez-Sala Walther2 
1Thoracic Surgery Division, Clinico San Carlos 
Hospital/Spain, 2Pneumology Department, Clinico 
San Carlos Hospital/Spain
Background: Malignant lesions of the respiratory 
system may present as endobronchial lesions. 
Flexible bronchoscopy (FB) is the most often 
used invasive technique in the examination of the 
tracheobronchial tree; it is also the most helpful 
technique in the diagnosis and staging of bronchial 
carcinoma. Objetive: To evaluate the role of FB in 
the detection of endoscopically visible pulmonary 
malignacies which indicate the presence of lung 
cancer, and to compare the role of endobronchial 
biopsies with cytological examinations, including 
bronchial brushings and washings.
Methods: From June 2008 to August 2009, 84 
consecutive patients with endoscopically visible 
tumors were enrolled. All patients underwent FB and 
6 patients underwent repeated FB, before a deÀnitive 
histological or cytological diagnosis of pulmonary 
malignancy was made.
Results: Eighty four patients underwent FB, and 
an endoscopically visible tumour was identiÀed 
in all 84 patients. Eighty three percent of the 
patients were males. Their average age was 67,3 
years old. Of the 84 procedures using FB, 73 were 
followed by a deÀnitive histological or cytological 
diagnosis of pulmonary malignancy, amounting to 
81% of the endoscopically visible tumours. Repeat 
bronchoscopy for inconclusive results improved the 
diagnostic yield in four patients. Seventy patients (85 
%) of the 82 who underwent endobronchial biopsy 
were found to have pulmonary malignancy; 40 
patients of the 55 who underwent bronchial brushing 
(73%) had the malignancy conÀrmed; and 46 of the 
81(57%) patients who underwent bronchial washing 
also had the malignancy conÀrmed. The histological 
type of lung cancer diagnosed by FB included 55 
nonsmall-cell lung cancer (NSCLC) (75%), 16 
exposure = 45 ±22.5 packet/year). According clinical 
Àndings, cough (n: 86) 89.58 %, weight loss (n: 
74) 77.08 %, phlegm ( n: 68) 70.83 % were seen 
in the most patients. The most Àndings detected on 
chest X-ray were mass (n: 90) 93.75 %, mediastinal 
enlargement (n:54) 56.25 %, atelectasis (n: 52 ) 54.6 
%. Histological subtypes of these 96 patients were 
6 small cell lung cancers (SCLC) (6.25 %), 82 non-
small cell lung cancers (NSCLC) (85.41 %); (32 
unclassiÀed 39, 2 %, 12 adenocarcinoma 14.6 %, 
38 squamous cell cancer 46.3 % ) and 8 malignant 
epithelial tumors (8.33 %). Radiological and 
bronchoscopical examination revealed that primary 
tumor was located more frequent on the left lung 56 
(58.33 %) and the lower lobes (right: 20, (20.8 %), 
left: 40, ( 41.6 %) respectively). The tumorial lesions 
were evaluated as endobronchial n:54 (56.25 % ) 
and 26 submucosial (27.8 %) during bronchoscopy. 
The most diagnostic methods were Àberoptic 
bronchoscopy and transthorasic needle biopsy, 
83 % and 16 % respectively. SCLC patients were 
deÀned as 2 limited 33.3 % and 4 66.6 % extensive 
stage. NSCLC and malignant epithelial tumors were 
deÀned as 38 (39.58 %) operable and 52 (54.16 %) 
inoperable. Metastases were detected in 25 patients 
(26.4 %). The most frequent metastatic organ was 
bone. 
Conclusion: Detailed history, physical examination, 
radiological investigations are precious for staging 
due to treatment of patient with suspected lung 
cancer. As a result, squamous cell carcinoma was 
the most common type of lung cancer and it was 
frequently related with smoking habbit (p<0.05). The 
common site of tumor localization, independent of 
histopathological classiÀcation, was the left lung and 
lower lobes. 
Keyword: Lung cancer, cigarette, symptom, 
radiology, bronchoscopy, transthorasic needle biopsy, 
location.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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conformal radiotherapy) in locally advanced 
unresectable non small cell lung cancer (NSCLC).
Methods: Radiotherapy Àles of 101 patients who 
completed the treatment were reviewed by the GFPC 
panel of Radiation Oncologists and compared to the 
trial radiotherapy guidelines for major (MD) and 
minor (md) deviations. The impact of deviations on 
survival and toxicities were analysed.
Results: MD and md were observed respectively 
in 69 (68.3%) and 27 (26.7%) patients. There is a 
signiÀcant correlation between the 2-years overall 
survival (OS) and total radiation dose (TD) < 60 
Gy (0% vs. 47.8 % respectively, p = 0.0001) and 
treatment interruption (TI) > 7 days (p = 0.003) wich 
was correlated with total dose. The 2-years OS was 
lower, but non-signiÀcantly for patients with one MD 
as compared to those without MD (40% vs. 53.1% 
respectively). Median V20 was 31.4% (9% to 64%), 
without correlation with OS and pulmonary toxicity.
Conclusion: This study demonstrates a high rate 
of deviations from the trial radiotherapy guidelines 
with a detrimental impact on 2-years OS of treatment 
interruption.
Keywords: unresectable NSCLC, combined 
modality treatment, prolonged treatment time
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P4.272 PATIENT-REPORTED HEALTH 
OUTCOMES AFTER LUNG CANCER 
TREATMENT: AN INTERNET BASED 
STUDY
James Metz, Carolyn Vachani, Margaret Hampshire, 
Gloria Di Lullo, Christine Hill-Kayser 
Radiation Oncology, University Of Pennsylvania/
United States Of America
Background: Lung cancer patients may be at risk 
for myriad late effects after multimodality therapy, 
the impact of which may difÀcult to evaluate using 
conventional methods. In addition, lung cancer 
patients are at risk for numerous co-morbidities. This 
Internet based study evaluates patient perceptions of 
health outcomes after treatment for lung cancer. 
Methods: Patient-reported data was gathered via 
a convenience sample frame from lung cancer 
survivors voluntarily utilizing a publically available, 
free, Internet-based tool for creation of survivorship 
care plans. Available at ) website, the tool allows 
survivors to enter data regarding diagnosis, 
small-cell lung cancer (SCLC) (22%), and two 
carcinoid tumors (3%). NSCLC subtypes included 
26 squamous carcinoma, 21 adenocarcinoma, and 1 
large-cell carcinoma. In eight cases we were unable 
to specify a NSCLC subtype.
Conclusion: Flexible bronchoscopy is highly 
sensitive in the detection of endobronchial 
disease. Bronchial biopsy and brush cytology 
are exceptionally valuable tools in the diagnosis 
of lung cancer. Bronchial wash cytology is also 
a valuable tool. Thus, all three tests combined 
should be performed routinely in cases of suspected 
malignancy. The distinction between SCLC and 
NSCLC, including histologic types of NSCLC 
by all three tests appears to be accurate. Repeat 
bronchoscopy for inconclusive results with adequate 
sampling improves the diagnostic yield of suspected 
endobronchial lesions.
Keywords: Áexible bronchoscopy, endobronchial 
biopsy
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P4.271 IMPACT OF PROLONGED 
IRRADIATION TIME FOR 
UNRESECTABLE STAGE III NON-
SMALL-CELL-LUNG-CANCER 
PATIENTS TREATED WITH 
CONCURRENT CHEMORADIATION: 
QUALITY ASSURANCE RESULTS OF 
THE GFPC-IFCT 02.01 STUDY
Isabelle Martel-Lafay1, Pierre Clavère2, Jean 
Paul Labat3, Jean Noël Talabard4, Eric Teissier5, 
Emmanuel Touboul6, Marie Cécile Bozonnat7, Sylvie 
Chabaud8, Pierre Fournel9 
1Radiation Therapy, Centre Léon Bérard/France, 
2Radiation Therapy, University Hospital Limoges/
France, 3University Hospital/France, 4Institut 
Cancérolgie Loire/France, 5Centre Azuréen 
Radiotherapy/France, 6Tenon Hospital Aphp Paris 
VI/France, 7Clinical Research Institute/France, 
8Biostatistics Department, Centre Léon Bérard/
France, 9Institut De Cancérologie De La Loire/
France
Background: To study deviations from the 
radiotherapy trial guidelines and their potential 
consequences on patients’ outcome in a multicentre 
randomized phase II trial of combined modality 
treatment (cisplatin-vinorelbine with 66 Gy 3D 
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Background: The OBSERVE observational, 
prospective study was designed to describe the 
use of G-CSF in Italian practice, after a series of 
expert panels had suggested that many different 
administration schedules were employed.
Methods: Patients were eligible at their Àrst 
administration of a G-CSF following chemotherapy 
(CT) for a non-hematologic malignancy. Primary 
outcome measures were G-CSF type, timing of 
administration and number of doses administered 
during each CT cycle.
Results: 512 eligible patients, of whom 93 (18.2%) 
had lung cancer, were enrolled at 23 Oncology Units 
in Italy. Of the 93 lung cancer patients, 68.8% had 
NSCLC and 31.2% had SCLC. 191 CT cycles with 
G-CSF support were observed overall: 133 (69.6%) 
with daily G-GSFs and 58 (30.4%) with pegÀlgrastim. 
While 91.4% of pegÀlgrastim was administered 24-
72 hours post CT, only 56.4% of daily G-CSFs were 
initiated within the 24-72 hours post CT timeframe. 
When using daily G-CSFs, less than 4 daily doses 
were given in 51.9% of CT cycles with daily G-CSF 
support, 4 to 5 daily doses in 31.6% of cycles, and at 
least 6 daily doses in 16.5% of cycles. In 18.4% of 
cycles with daily G-CSF support, daily G-CSF doses 
were not administered on consecutive days.
Conclusion: Study outcomes suggest G-CSF 
administration practice frequently does not 
correspond to the recommendations of Italian 
(AIOM) guidelines, and current practice for 
daily G-CSFs with short duration of treatment 
is unsupported by an evidence-based rationale; 
obtaining a better adherence to guidelines through 
educational initiatives would be highly desirable.
Keywords: G-CSF, Myelotoxicity
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.274 ANALYSIS OF PERITUMORAL 
EDEMA AROUND THE LUNG CANCER 
BRAIN METASTASIS
Eszter Podmaniczky, Katalin Fabian, Gyorgy 
Losonczy, Judit Moldvay 
Department Of Pulmonology, Semmelweis 
University/Hungary
demographics, and treatments, and provides 
customized guidelines for future care. During use of 
the tool, lung cancer survivors are queried regarding 
late effects associated with speciÀc treatments, as 
well as potential co-morbidities, and asked to answer 
“yes,” “no,” or “I don’t know.” All data have been 
maintained with IRB approval. 
Results: 106 lung cancer survivors answered 
queries regarding health outcomes; 58% were 
female and 92% Caucasian. Median diagnosis age 
was 57 (range 25 – 83) and median current age 60 
(27 – 85). Most reported receiving follow-up care 
from an oncologist only (56%), 10% a primary care 
physician only, and 29% both. Most had undergone 
chemotherapy (82%), surgery (67%; of these, 83% 
lobectomy/ pneumonectomy, 37% lymph node 
dissection), and radiation (48%). Health outcomes 
and comorbidities reported by lung cancer survivors 
included hypertension (30%), hyperlipidemia (19%), 
restrictive lung disease (29%), and hypothyroidism 
(7%). Survivors using this tool also reported the 
following symptoms following treatment: hearing 
loss (31%), peripheral neuropathy (36%), cognitive 
changes (47%), chronic pain related to surgery 
(34%), difÀculty swallowing/speaking/breathing 
(22%), and sexual changes (27%). 
Conclusion: Survivors using this tool anonymously 
and voluntarily report signiÀcant comorbidities and 
late effects after lung cancer treatment. Many are 
followed only by an oncologist, and may require 
attention to major health concerns in survivorship. 
This tool offers a unique way for survivors to report 
their experiences; the data reported here may be of 
signiÀcant impact in future study of quality of life, as 
well as patient counseling and survivor care.
Keywords: survivorship care plan, late effects after 
lung cancer, Patient Reported Outcomes, internet
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P4.273 G-CSF ADMINISTRATION IN 
PATIENTS WITH LUNG CANCER: AN 
OBSERVATIONAL STUDY OF CURRENT 
ITALIAN PRACTICE.
Manlio Mencoboni1, Sandro Barni2, Vito Lorusso3, 
Andrea Bruzzone1, Lisette Delcorso4 
1Medical Oncology, Villa Scassi Hospital/Italy, 
2Medical Oncology, General Hospital/Italy, 3Medical 
Oncology, Hospital Vito Fazzi/Italy, 4Observe Study 
Group/Italy
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Pavlov Under The Federal Agency For Healthcare 
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Background: Bronchoscopy is a subjective method of 
research, where success depends largely on the level 
of specialist training. In recent years, developed and 
implemented techniques that allow to objectify this 
method of diagnosis, in particular spectroscopy. The 
aim of our study was to estimate the informativity 
of autoÁuorescence bronchoscopy and spectroscopy 
for evaluating the effectiveness of neoadjuvant 
chemotherapy (NCT) for lung cancer. 
Methods: The study included 46 patients with central 
NSCLC IIIa / IIIb stage who underwent 2-4 courses 
of platinum-based NCT. Endoscopy was done before 
treatment started and repeated each 21 day. Combined 
endoscopic investigation included: bronchoscopy in 
conventional mode (CB), spectroscopy in conventional 
mode (CS), bronchoscopy in autoÁuorescence mode 
(AFB) and spectroscopy in autoÁuorescence mode 
(AFS). Integrated system for autoÁuorescence and 
spectroscopy was used. The data obtained were 
compared with the results of histological study of 
biopsy samples from the respective sites.
Results: The sensitivity and speciÀcity of the 
combination of AFB and AFS was 97.1% and 88.3%, 
respectively vs. CB and CS - 66,7% and 86,9%, 
respectively. Combined endoscopy revealed that the 
NCT was effective in 41,3% cases (n = 19 - partial 
endoscopic response), in 4 patients (10,3%) endoscopic 
tumor progression was found. Endobronchial spread 
of the tumor in 30.4% of cases (p = 0.03) was deÀned 
more accurately by AFB and AFS in comparison with 
CB and CS, it was important for choosing a volume of 
further resection. In 97,1% of cases, the data AFB and 
AFS is fully consistent with the results of histological 
studies (p = 0,02). 
Conclusion: The combination of AFB and AFS is 
effective in determination of margins of central lung 
cancer spread and effectiveness of NCT.
Keywords: Endoscopy, AutoÁuorescence, 
spectroscopy, Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Background: The peritumoral edema surrounding brain 
metastases in lung cancer is very common, although the 
exact mechanisms of its development during bronchial 
carcinogenesis has barely been studied.
Methods: We analyzed the clinicopathological data 
of 163 lung cancer patients with brain metastasis 
diagnosed and treated at the Semmelweis University.
The peritumoral edema surrounding brain metastases 
was determined and categorized according to CT and 
MRI results. The edema was considered signiÀcant if it 
was wider than 10 mm, moderate: between 1-10 mm.
Results: Solitary brain metastasis was found in 
70 cases and 93 patients developed multiple brain 
metastases. 127 patients had the appearance of 
peritumoral edema (77.9%), of them 77 patients had 
signiÀcant, 50 patients moderate edema. No edema 
was detected in 36 patients. In case of no detectable 
edema, tumor diameter was signiÀcantly smaller 
(16,1 mm vs 23,6 mm p< 0,05). The presence of 
peritumoral edema predicted worse survival (4,4 
months vs 6,6 months). When compared small cell 
lung cancer either to adenocarcinoma or to squamous 
cell carcinoma, the appearance of wider edema was 
signiÀcantly lower in both cases (20% vs 59,7% 
or 63,6% p<0,05). These differences were also 
signiÀcant in chemotherapy-naïve patients. In 48.8 
% of small cell lung cancer patients no edema was 
detected. Among the adenocarcinoma and squamous 
cell carcinoma patients the proportion of early brain 
metastasis (within 3 months after the diagnosis of 
primary tumor) was signiÀcantly higher than in small 
cell lung cancer cases (p<0,05). 
Conclusion: Our study indicates that in lung 
adenocarcinoma and squamous cell carcinoma the 
development of remarkable peritumoral oedema is 
more frequent when compared to small cell lung 
cancer cases and not inÁuenced by the Àrst-line 
chemotherapy. The presence of peritumoral edema 
may be considered a wrong prognostic factor. 
Keywords: peritumoral edema, Brain Metastasis
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METHOD FOR MONITORING THE 
EFFECTIVENESS OF NEOADJUVANT 
CHEMOTHERAPY OF NSCLC WITH 
THE USE OF AUTOFLUORESCE AND 
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delay of treatment for more than 2 weeks. In addition 
to pharmacokinetics, pharmacodynamic analyses 
using dynamic FDG-PET were performed on days 0, 
5 and 14. Response after 8 weeks of treatment was 
assessed by CT. 
Results: Seventeen patients have been enrolled. 
The DLT was not reached according to protocol 
deÀnition. However, at a dose level of 1x 10mg E 
daily and 2x 400mg S daily the following toxicities 
occurred in the non DLT interval: pneumonia III°, 
treatment delay caused by leukopenia III° and 
thrombopenia III° and sudden cardiac death probably 
due to arrhythmia. Based on these observations, the 
dose level of 1x 7.5mg E daily and 2x 400mg S daily 
was deÀned as MTD. Currently 5 patients are treated 
on MTD without any DLT. Response after 8 weeks 
could be evaluated in 9 patients, showing progressive 
disease in one patient (pancreatic cancer) and stable 
disease in 8 patients (NSCLC, melanoma, CUP, 
ovarian, colorectal, vaginal and breast cancer). The 
median progression free survival and overall survival 
were 4 and 5.1 months, respectively. 
Conclusion: Combination of S and E is feasible for 
the treatment of patients with advanced solid tumors. 
The full analysis including pharmacodynamics and 
pharmakokinetics will be presented. Extension phase 
in NSCLC patients is planned. 
Keywords: everolimus, sorafenib, solid tumors, 
NSCLC
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P4.277 TREATMENT OUTCOMES OF 
STAGE III NON-SMALL CELL LUNG 
CARCINOMA (NSCLC) IN THE ELDERLY 
(AGE >70)
Paul D. Aridgides1, Steven M. Duffy2, Adam Janik1, 
Ajeet Gajra2, Jeffrey A. Bogart1 
1Radiation Oncology, Suny Upstate Medical 
University/United States Of America, 2Division Of 
Hematology Oncology, Department Of Medicine, 
Suny Upstate Medical University/United States Of 
America
Background: The standard of care for treatment of 
inoperable stage III non-small cell lung carcinoma 
(NSCLC) consists of radiation therapy with 
concurrent chemotherapy, however elderly patients 
are under-represented in clinical trials. In this study, 
the treatment patterns (radiation, chemotherapy) 
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P4.276 THE COMBINATION OF 
SORAFENIB AND EVEROLIMUS IN 
PATIENTS WITH SOLID TUMORS – 
RESULTS OF A PHASE I STUDY
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Harbeck7, Markus Dietlein6, Jurgen Wolf1 
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Germany, 4University Hospital Cologne, Dep. I Of 
Internal Medicine/Germany, 5Max Planck Institut 
Für Neurologische Forschung Mit Klaus-Joachim-
Zülch-Laboratorien Der Max-Planck-Pesellschaft 
Und Der Medizinischen Fakultät Der Universität 
Zu Köln/Germany, 6University Hospital Cologne, 
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Hospital Cologne, Clinic For Obstetrics And 
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Background: The combination of the multi-kinase 
inhibitor sorafenib (S) and the mTOR inhibitor 
everolimus (E) may increase anti-tumor efÀcacy by 
dual inhibition of key nodules of signaling pathways 
regulating angiogenesis and cellular proliferation. 
FDG-PET might be a suitable method for the 
assessment of pharmacodynamic activity of E. 
Methods: Patients with advanced solid tumors after 
failure of standard therapy were treated with E in 
a dose escalating schedule of 1x 2.5-10mg daily 
in combination with a Àxed dose of 2x 400mg S 
daily. The primary objective was to determine the 
maximum tolerated dose (MTD) of the combination. 
Dose limiting toxicity (DLT) was deÀned as any of 
the following toxicities occurring during the Àrst 29 
treatment days (DLT interval): hematological or non-
hematological toxicity of CTC grade IV, any toxicity 
requiring hospitalization or any toxicity leading to 
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P4.278 PREOPERATIVE TREATMENT 
WITH CHEMOTHERAPY (CHT) AND 
HIGH DOSE RADIOTHERAPY (RT) 
(>59GY) IN PATHOLOGICALLY PROVEN 
CLINICAL STAGE IIIA-N2 NON SMALL 
CELL LUNG CANCER (NSCLC). INITIAL 
RESULTS OF A CLINICAL PROTOCOL.
Carme Obiols1, Sergi Call1, Ramon Rami-Porta1, 
Josep Maria Sole2, Joan C. Trujillo1, Manuela 
Iglesias1, Roser Saumench1, Mireia Serra1, Roma 
Bastus-Piulats3, Guadalupe Gonzalez-Pont4, Josep 
Belda1 
1Thoracic Surgery Service, Mutua Terrassa 
University Hospital/Spain, 2Radiation Oncology 
Department, Institut Oncologic Del Valles/Spain, 
3Oncology/Hematology Service, Mutua Terrassa 
University Hospital/Spain, 4Department Of 
Pathology, Mutua Terrassa University Hospital/
Spain
Background: The role of preoperative ChT-RT 
in patients with stage IIIA-N2 NSCLC is not well 
established. The use of high dose RT is supposed 
to provide a better local control of the tumour. The 
objective of this preliminary study is to evaluate the 
results of multimodal treatment with high dose RT in 
patients with stage IIIA-N2 NSCLC. 
Methods: Prospective study (April09-January11) 
of 13 patients (9 men, median age: 56 years; range: 
44-72 years) with N2 NSCLC who underwent 
cisplatinum-based induction ChT-RT with high dose 
RT (average: 60.5 Gy; range: 46-70 Gy). One patient 
was given 46 Gy because of a grade III esophagitis 
(included in the intention to treat study). N2 disease 
was diagnosed by mediastinoscopy in 10 patients, 
and by endoscopic ultrasound-guided Àne needle 
aspiration in 3 cases. Re-staging included: thoracic/
abdominal computerized tomography (CT), positron 
emission tomography and brain CT. Patients in 
whom these studies didnt show tumour progression 
underwent surgical exploration of the mediastinum 
(SEM), and those with no evidence of mediastinal 
disease underwent thoracotomy for lung resection 
and systematic nodal dissection (SND). SND was 
considered the gold standard to validate the negative 
results of the SEM. The follow-up was completed in 
February11. 
Results: Three patients out of 13 showed distance 
tumour progression after or during the induction 
for elderly patients with stage III NSCLC in our 
institution were reviewed and comparisons were 
made to a series of younger patients (age <70).
Methods: A retrospective review was conducted 
of patients treated with radiotherapy for stage III 
NSCLC between January 1998 and February 2010. 
Patient and treatment characteristics analyzed 
included age, performance status, weight loss, 
pre-treatment hemoglobin, radiation therapy intent 
(palliative vs. deÀnitive), chemotherapy sequencing 
(concurrent vs. sequential), chemotherapy dosing 
(systemic vs. low-dose weekly), and platinum drug 
used (cisplatin vs. carboplatin). Fisher’s exact test 
of signiÀcance and Kaplan-Meier survival analysis 
were utilized, as well as log-rank testing of variables 
to determine impact on survival. 
Results: 189 stage III NSCLC patients were treated 
with ages ranging from 28 to 92 years. Patients age 
> 70 (n=86) were more likely to have performance 
status 2 (p=.035) and pre-treatment hemagloblin 
less than 12g/dL (trend, p=.067). Elderly patients 
were more likely to be treated with palliative intent 
(29% versus 13% respectively, p<.007) and to a 
lower total radiotherapy dose (median 60Gy versus 
66Gy respectively, p<.01) than the younger cohort. 
Likewise, elderly patients were less likely to receive 
concurrent chemoradiotherapy (p<.0001), concurrent 
full-dose cisplatin (p=.04), or systemic doses of 
chemotherapy (52% vs. 70%, p<.03). Median survival 
was 10.3 months for elderly patients compared to 17.2 
months for younger patients (p =.001). Additionally, 
elderly patients with good performance status had 
inferior outcomes when compared to the younger 
cohort (12.1 vs 19.8 months, p=.006). A similar 
effect was seen for patients treated with deÀnitive 
concurrent chemo-radiotherapy: median survival 
for elderly patients was 12.2 months compared 
to 18.9 months for younger age (p=.01). Factors 
associated with improved outcome in elderly patients 
include deÀnitive treatment (p=.04), the addition of 
chemotherapy to radiotherapy (p=.026), performance 
status of 0-1 (p<.0004), and pre-treatment hemoglobin 
>12 g/dL (p<.05). 
Conclusion: Overall, elderly patients with stage III 
NSCLC experience inferior outcomes than younger 
patients with comparable disease, but are also more 
likely to receive suboptimal therapy. Further studies 
are needed to determine whether advanced age alone 
portends a worse prognosis, or if more aggressive 
treatment is appropriate. 
Keywords: Elderly, chemoradiotherapy, locally 
advanced, Non-small Cell Lung Carcinoma
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P4.279 LONG-TERM RESULTS OF 
A PHASE II STUDY OF COMBINED 
MODALITY THERAPY WITH 
CONCURRENT RADIATION THERAPY 
PLUS DOCETAXEL AND CARBOPLATIN 
FOR UNRESECTABLE STAGE III NON-
SMALL-CELL-LUNG CANCER
Ruth E. Gauden1, Greg Haug2, James Markos2, Scott 
Parkes2, Stan Gauden3 
1WP Holman Clinic/Australia, 2Launceston General 
Hospital/Australia, 3WP Holman Clinic/Australia
Background: Concurrent chemoradiotherapy is 
emerging as standard treatment for patients with 
inoperable stage III non-small-cell lung cancer 
(NSCLC).
However, the optimal combination of chemotherapy 
and radiation therapy (RT) in patients with locally 
advanced NSCLC remains unknown. Docetaxel and 
carboplatin have demonstrated activity as radiation 
sensitisers in pre-clinical studies. Both drugs are 
active against NSCLC and can safely be combined 
with RT at effective systemic doses, making them 
attractive study agents against locally advanced 
NSCLC.
The objective of this phase II study was to document 
the activity and to evaluate the toxicity of concurrent 
docetaxel and carboplatin with thoracic RT in locally 
advanced stage III NSCLC.
Methods: Eligible patients had stage IIIA or IIIB 
NSCLC, baseline performance status of 0 to 1, 
forced expiratory volume in 1 second 1 L, and less 
than 5% weight loss. Carboplatin was administered 
at an AUC of 4 on days 1 and 29 of radiation therapy. 
Patients received docetaxel, 30 mg/m2 intravenously 
(IV) on days 1, 8, 22, and 29, concurrently with 
three dimensional conformal thoracic RT to 60 Gy 
in 30 fractions (2 Gy per fraction, 5 fractions per 
week). The primary end point was to determine the 
overall response rate. The secondary endpoint was to 
evaluate survival and the safety proÀle.
Results: Patient characteristics (n = 48) were as 
follows: 48% female, 52% male; median age 67 
years (range 40-84 years); 56% stage IIIA; and 44% 
stage IIIB. The overall response rate was 80.9%. The 
median survival time for all patients was 24 months 
(range 4-102 months), and the 1-year overall survival 
rate was 70.8%, while 5-year survival was 27.1%. 
Toxicity was moderate: grade 2 neutropenia was seen 
treatment. The rest underwent mediastinal restaging 
with a technique providing cyto-histologic 
evidence (10 SEM): 2 mediastinoscopies and 8 re-
mediastinoscopies. A bleeding of the superior vena 
cava was treated by median sternotomy, but the 
patient died in the postoperative period. SEM was 
negative in 8 patients and all underwent thoracotomy. 
SND validated that all these SEM were true negative. 
There was pathologic complete response (PCR) 
in 5 cases. The postoperative morbidity rate was 
25% (1 pneumonia and 1 empyema) with no post-
thoracotomy deaths. 3 out of 8 patients with resected 
tumours presented with disease progression: 2 cases 
with single brain metastases that were resected (both 
with PCR post-thoracotomy), and another with 
hepatic and bone metastases. 
N Sex Age 
Cyto-
histological 
con¿mation 
of N2 
RT dose 
(Gy) 
Re-staging
(CT, PET) 
Mediastinal 
re-staging Thoracotomy ypTNM 
1 F 52 EUS (#7) 60 Hepatic and bone M1 - - - 
2 M 55 EBUS (#4R) 66 No progression Negative MS RUL ypT0N0M0 
3 F 55 MS (#4R) 60 No progression Negative reMS RUL ypT0N0M0 
4 M 57 MS (#4R) 65 No progression Negative reMS RUL ypT0N0M0 
5 M 47 MS (#7) 60 No progression Negative reMS Left Pneum. ypT0N0M0 
6 M 56 MS (#4L) 60 Meningeal carcinomatosis * - - - 
7 M 57 EUS (#5) 60 No progression Negative MS LLL ypT1aN0M0 
8 M 72 MS (#4R) 60 No progression Positive reMS (#4R) - - 
9 M 45 MS (#5) 70 No progression Negative reMS Left Pneum. ypT1aN0M0 
10 M 44 MS (#4L) 60 Bilateral pulmonary M1 - - - 
11 F 61 MS (#4R) 60 No progression Negative reMS 
Superior Bi-
lobectomy ypT0N0M0 
12 M 63 MS (#4R and 7) 46 No progression 
Negative 
reMS RLL ypT1aN0M0 
13 F 69 MS (#4R) 60 No progression 
reMS (post-
operative 
death) 
- - 
* lumbar puncture diagnosis
Abbreviations: N: number of patients; RT: radiotherapy; CT: computerized tomography; PET: positron 
emission tomograpy; ypTNM: post-induction phatologic TNM; EUS: trans-esophageal ultrasound 
guided puncture; EBUS: trans-bronchial ultrasound guided puncture; MS: mediastinoscopy; reMS: 
remediastinoscopy; #7: subcarinal station; #4R: right inferior paratracheal station; #4L: left inferior 
paratracheal station; #5: subaortic station; RUL: right upper lobectomy; LLL: left lower lobectomy; 
RLL: right lower lobectomy; Pneum.: Pneumonectomy; M1: metastases. 
Conclusion: Induction treatment with ChT and high 
dose RT is feasible with a high rate of PCR and 
acceptable postoperative morbidity. Therefore, we 
can consider that ChT associated to high dose RT is 
a valid option in the preoperative treatment of locally 
advanced NSCLC.
Keywords: Radiotherapy, INDUCTION 
TREATMENT, Surgery
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between endostar and irradiation in xenografts of 
Lewis lung in mice. The critical mechanism of which 
is tumor vasculature normalization occurred in a 
certain duration. We designed this study to evaluate 
safety and efÀcacy of endostar combined with 
standard current chemoradiation therapy (CCRT) in 
patients with unresectable stage III NSCLC. 
Methods: Patients were administered with 
endostatin 7.5mg/m2 (week0, 2, 4, 6), docetaxel 
65mg/m2 (Day 1, 29) and cisplatin 65mg/m2 (Day1, 
29). Radiotherapy consists of 2.0 Gy in 30-33 
fractions over 6-7 weeks to a total dose of 60-66 
Gy. Tumor response was evaluated with thoracic 
CT scans performed 4 weeks after completion of 
treatment in accordance with RECIST criteria. Acute 
toxicities was evaluated with NCI-CTC AE version 
3.0 
Results: From March 2009 to December 2010, 37 
patients completed treatment and were available 
for evaluation. Thirty-three patients remain alive. 
The median follow-up time was 9.5 months (1-22 
months). Six (16.2%) patients achieved complete 
response (CR), 21 (56.8%) partial response (PR), 
6 (16.2%) stable disease (SD), and 4 (10.8%) 
progressive disease (PD). Endostar did not 
increase toxicity to CCRT. Hematological and non-
hematological toxicities were acceptable. No patient 
developed cardiovascular toxicity. Table 1. Acute 
Hematological toxicity 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Leucopenia 15(40.5%) 5(13.5%) 5(13.5%) 11(29.7%) 
Neutropenia 4(10.8%) 3(8.1%) 4(10.8%) 10(27.0%) 
Lymphocytopenia 2(5.4%) 3(8.1%) 19(51.4%) 12(32.4%) 
Anemia 18(48.6%) 5(13.5%) 1(2.7%) 0 
Thrombocytopenia 3(8.1%) 4(10.8%) 2(5.4%) 0 
Table 2. Acute Non-hematological toxicity 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Esophagitis 2(5.4%) 31(83.8%) 4(10.8%) 0 
Dermatitis 34(91.9%) 1(2.7%) 2(5.4%) 0 
Alopecia 30(81.1%) 7(18.9%) 0 0 
Pneumonitis 5(13.5%) 4(10.8%) 6(16.2%) 0 
Anorexia 19(51.4%) 16(43.2%) 2(5.4%) 0 
Nausea 18(48.6%) 6(16.2%) 0 0 
Vomiting 7(18.9%) 3(8.1%) 2(5.4%) 0 
Peripheral neuritis 2(5.4%) 0 0 0 
Allergy 0 1(2.7%) 0 0 
Fatigue 11(29.7%) 6(16.2%) 0 0 
Cough 16(43.2%) 5(13.5%) 7(18.9%) 0 
cardiovascular 0 0 0 0 
Conclusion: The preliminary results showed that 
endostar combined with CCRT for unresectable stage 
III NSCLC was safe and the short term outcomes 
in 4 patients, and grade 3 neutropenia in 1 patient. 
Grade 2 thrombocytopenia was seen in 2 patients, 
and grade 3 thrombocytopenia was not observed. 
Nonhaematological toxicities were moderate: grade 3 
oesophagitis occurred in 2 patients. Grade 1 asthenia/
fatigue was observed in 6 patients, and grade 2 
asthenia/fatigue in 4 patients. Grade 3 pulmonary 
toxicity occurred in 1 patient.
Conclusion: In this single institution study, 
we have identiÀed a well-tolerated and active 
chemoradiotherapy regimen in the treatment of 
patients with unresectable Stage III NSCLC. 
Concurrent docetaxel and carboplatin along with 
thoracic radiation therapy is feasible and tolerable. 
Survival results are promising and warrant further 
study in large randomised studies to document and 
conÀrm the effectiveness of this regimen.
Keywords: Non-small cell lung cancer, Stage III, 
concurrent chemoradiotherapy
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P4.280 A PROSPECTIVE PHASE I/
II STUDY OF RECOMBINANT 
ENDOSTATIN (ENDOSTAR) 
COMBINED WITH CONCURRENT 
CHEMORADIOTHERAPY IN PATIENTS 
WITH UNRESECTABLE STAGE III 
NON-SMALL CELL LUNG CANCER: A 
PRELIMINARY REPORT
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Zhong H. Yu2, Yue C. Cai3, Jian C. Li4, Zhi B. 
Cheng5, Long Chen6, Yan Wang1, Jin Wang1, Fang 
Peng1, Zu M. Xu1, Hong L. Ma1, Ru B. Lu1, Hui Q. 
Dai1 
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Center/China, 2Oncology, AfÀliated Hospital Of 
Guangdong Medical College/China, 3Department Of 
Cancer, First People Hospital Of Zhaoqing/China, 
4Radiation Oncology, Fujian Provincial Tumor 
Hospital/China, 5Radiation Oncology AfÀliated 
Hospital Of Sun Yat-sen University, The Fifth/China, 
6Radiation Oncology, AfÀliated Hospital Of Guangxi 
Medical College/China
Background: More than 3000 patients with 
advanced non-small cell lung cancer (NSCLC) have 
been treated with recombinant endostatin (endostar) 
combined with chemotherapy in China. Recently 
our experimental study showed a synergistic effect 
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compared using a log-rank test. Clinical outcomes 
were measured from the date of diagnosis and 
disease-free survival was deÀned as interval between 
the date of diagnosis to the date of disease recurrence 
or death. 
Results: 27 patients were identiÀed who met the 
criteria. Median follow-up was 24 months (range, 
8-151). Several neoadjuvant ChT regimens were 
utilized, most commonly carboplatin with paclitaxel 
(44%) or vinorelbine (30%). The median number 
of involved mediastinal lymph node stations at 
diagnosis was 1 (range, 1-3). An R0 resection was 
performed after neoadjuvant ChT in 20 (74%), 
consisting of lobectomy in 13, pneumonectomy in 
2, and wedge/segmentectomy in 5. There were no 
postoperative deaths. Postoperative therapy (RT and/
or further ChT) was administered to 11 (55%). The 
remaining 7 patients received deÀnitive RT, with or 
without further ChT. Median survival for all patients 
was 22 months. Overall and disease-free survival 
at 1, 3 and 5 years was 78%, 38%, 38% and 63%, 
37%, and 30%, respectively. Survival was similar 
between patients undergoing R0 resection (38%) and 
deÀnitive RT +/- ChT (36%) (p=0.42). 
Conclusion: Disease-free and overall survival was 
sufÀciently high to warrant aggressive local therapy 
(surgery or RT) in patients with persistent N2 disease 
after neoadjuvant ChT.
Keywords: Induction Chemotherapy, Surgery, N2, 
combined-modality therapy
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P4.282 A PHASE II TRIAL OF 
NIMOTUZUMAB IN COMBINATION 
WITH CHEMORADIOTHERAPY 
IN LOCALLY ADVANCED LUNG 
SQUAMOUS CELL CARCINOMA
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Gong1, Xin-Xing Zhang1, Jin Wang1, Yong Xu1, Mei-
Juan Huang1, Seng Bai3, Ping Duan2, You Lu1 
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Background: Concurrent chemoradiotherapy 
was the standard treatment for locally advanced 
were promising. Further investigation is warranted. 
Keywords: Non-small cell lung cancer, recombinant 
endostatin, multi-modality treatment
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P4.281 PERSISTENT N2 DISEASE AFTER 
NEOADJUVANT CHEMOTHERAPY- 
NOW WHAT?
Kristin A. Higgins1, Neal E. Ready2, Thomas A. 
D’amico3, Mark W. Onaitis3, Jeffrey Crawford2, 
Robert Clough1, Mark F. Berry3, David Yoo1, David 
H. Harpole3, Frank Dunphy2, Chris R. Kelsey1 
1Radiation Oncology, Duke University Medical 
Center/United States Of America, 2Medical 
Oncology, Duke University Medical Center/United 
States Of America, 3Cardiothoracic Surgery, Duke 
University Medical Center/United States Of America
Background: The optimal treatment for stage 
IIIA (N2) non-small cell lung cancer (NSCLC) is 
controversial. Neoadjuvant chemotherapy (ChT) 
followed by surgery is a common approach. 
Approximately 20-50% of patients achieve a 
mediastinal pathological complete response (pCR) 
with ChT alone. Several studies have shown that 
patients who clear their mediastinal lymph nodes 
have improved outcomes compared with patients 
with persistent N2 disease. How to manage those 
patients with persistent N2 disease after ChT is 
unclear. Whether surgery provides any beneÀt 
or whether deÀnitive radiation therapy (RT) 
with further ChT should be pursued remains an 
unanswered question. We explored this further by 
evaluating our own experience at Duke University 
Medical Center. 
Methods: All patients who initiated preoperative 
therapy for IIIA (N2) NSCLC between 1995 and 
2008 were evaluated. Patients were excluded if they 
received preoperative RT, had evidence of distant 
progression after neoadjuvant ChT by imaging or 
intraoperative assessment, did not have pathologic 
documentation of mediastinal lymph node status, or 
achieved a mediastinal pCR with neoadjuvant ChT. 
Disease-free and overall survival was calculated 
using the Kaplan-Meier product-limit method and 
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additional beneÀts or toxicities as compared to 
previous data with chemoradiotherapy alone, further 
follow-up and including more patients are necessary.
Keywords: nimotuzumab, chemoradiotherapy, Lung 
cancer
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P4.283 SIMULTANEOUS 
CHEMORADIOTHERAPY VERSUS 
SEQUENTIAL IN INOPERABLE NON-
SMALL CELL LUNG CANCER.
Yury Ragulin1, Yury Mardynsky2, Alexey Zolotkov2, 
Igor Gulidov2, Irina Ivanova2, Victor Medvedev1, 
Danil Gogolin2, Larisa Kursova2 
1Thoracic Department, Medical Radiological 
Research Center/Russian Federation, 2Radiology, 
Medical Radiological Research Center/Russian 
Federation
Background: Chemoradiotherapy with cisplatin-
based chemotherapy is standard treatment for 
inoperable stage III non-small cell lung cancer 
(NSCLC). There has been conÁicting evidence 
concerning the best sequence of radiotherapy 
(RT) and chemotherapy (CT) for locally advanced 
NSCLC. The aim of our study is to deÀne the best 
sequence of radiotherapy and chemotherapy for 
inoperable stage IIB-IIIB NSCLC. 
Methods: A nonrandomised retrospective trial 
in locally advanced non-small cell lung cancer, 
compared simultaneous and sequential regimens of 
chemoradiotherapy. 96 consecutive patients with 
histologically/cytologically proven NSCLC stage 
IIB-IIIB were enrolled. All patients were inoperable 
because of local spread, medical contraindications or 
refused surgery. Patients resieved radical course of 
radiotherapy by a CHART method with non-uniform 
crushing of a day dose (two daily fractions 1+1.5 
Gy, the interval between fractions 5-6 hours) to a 
total dose 60 -70 Gy and 4 courses of chemotherapy 
(cisplatin+ethoposide). 35 patients received 
concurrent chemoradiotherapy (group A), 61 patients 
received sequential treatment (group B). 
Results: The overall three-year survival rate in the 
group A - 37.5%, in the group B - 19%. Complete 
tumor response was observed in 45% in group A and 
19% in the group B. Local recurrence developed in 
32% patients with a sequential chemoradiotherapy 
and 25% in the simultaneous group. The incidence of 
NSCLC. The aim of this study was to evaluate 
efÀcacy and toxicity of nimotuzumab in combination 
with concurrent chemoradiotherapy followed by 
consolidation chemotherapy for locally advanced 
lung squamous cell carcinoma. 
Methods: During March 2009 and December 2010, 
11 locally advanced (stage IIIB) lung squamous cell 
carcinoma patients were included in this prospective 
Phase II trial, included 9 male patients and 2 female 
patients, the median age was 54 (range 41-64). 
All patients received thoracic radiotherapy (6MV 
X-ray, IMRT) to involved-Àeld with the median 
dose of 60Gy/30f (range 50Gy/25f-66Gy/33f), and 
concurrent with nimotuzumab (200mg, weekly) 
for the median of 6 weeks (range 6-8 weeks) plus 
docetaxel (60mg/m2)/carboplatin (AUC=5) on 
day 1 administered intravenously every 21 days 
for 2 cycles, patients with stable disease or better 
after concurrent chemoradiotherapy received 
consolidation chemotherapy of docetaxel (75mg/
m2)/carboplatin (AUC=5) on day 1 administered 
intravenously every 21 days for 2 cycles.
Results: After a median follow-up of 11 months 
(range 2.5-23 months), conÀrmed responses included 
2 CR, 6 PR, 1 SD and 2 PD, the best objective 
response rate (CR plus PR rate) was 72.7% (8/11). 
Median progression-free survival was 12 months 
(95%CI: 0.85-23.15 months), median survival was 
not reached (overall survival range 2.5-23 months), 
and six-month survival was 81.8%. At the end 
of follow-up, there were 6 patients had disease 
progression, included 3 patients of locoregional 
failure and 3 patients of distant metastases (1 with 
brain metastases, 1 with retroperitoneal lymph nodes 
metastases, 1 with brain and bone metastases), 2 
disease progressions occurred during concurrent 
chemoradiation (both with distant metastases and 
died sooner after) and other 4 disease progressions 
occurred after consolidation chemotherapy. Grade 
1 to 3 radiation pneumonitis were observed in 7 
(63.6%); 2 (18.2%), 2 (18.2%) patients; grade 1 to 
3 radiation esophagitis were observed in 2 (18.2%) 
, 7 (63.6%) and 2 (18.2%) patients; grade 1 to 2 
radiation dermatitis were observed in 9 (81.8%) and 
2 (18.2%) patients; grade 2 to 4 neutropenia were 
observed in 3 (27.2%), 4 (36.4%) and 4 (36.4%) 
patients; grade 1 to 3 thrombocytopenia were 
observed in 3 (27.2%), 1 (9.1%) and 2 (18.2%) 
patients, no skin rash or allergic toxicities appeared.
Conclusion: Although plus nimotuzumab to 
concurrent chemoradiotherapy followed by 
consolidation chemotherapy seemed not to take 
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Group I: Radiotherapy (40 Gy/20 fractions) plus 
study drug Group II: Chemoradiotherapy (60 Gy/30 
fractions with cisplatin [50 mg/m2 IVI d1 and 8, d29 
and 36] and etoposide [50 mg/m2 IVI d1-5, d29-33]) 
plus study drug The 3 dose cohorts of LBH589 are 
20mg, 30 mg and 45 mg given as orally twice a week 
for duration of radiation starting the day before Àrst 
radiation dose. Response assessment is at week 4 
with CT and PET/CT scan. The primary objective 
of the study is to Ànd DLT and MTD of LBH589 in 
combination with radiotherapy or chemoradiotherapy 
and the secondary objectives are response rate, 
progression free survival, and time to progression. 
Results: Six patients have been treated so far. All 
6 patients completed per protocol treatment. The 
treatment has been tolerated well so far. Transient 
thrombocytopenia was the commonest side effect 
(50%) (Table). Grade III or IV side effects included 
thrombocytopenia (33%) and syncope (16%). Other 
side effects were mainly Gr I or II and included 
nausea, vomiting, fatigue, chest pain, constipation, 
diarrhea, anemia and taste alteration. No dose 
limiting toxicity has been found so far. Best response 
was partial response (50%), together with stable 
disease (17%) and progressive disease (33%). The 
third cohort of radiation and LBH589 and Àrst cohort 
of chemoradiation and LBH589 are currently open. 
LBH 589 
dose (mg) 
Radiation 
dose (Gy) 
Gr III, IV toxicity Nadir platelet 
count 
Time to 
recovery 
Best 
response 
1 20 40 thrombocytopenia 46- D22 <7 days PR 
2 20 40 - 94- D25 - PR 
3 20 40 - 157- D25 - SD 
4 30 40 - 101- D18 - PD 
5 30 40 thrombocytopenia 60- D18 4 days PR 
6 30 40 thrombocytopenia 48-D11 19- D32 4 days PD 
Conclusion: The combination of radiation and 
LBH589 exhibited a tolerable toxicity proÀle with 
mechanism-related and transient thrombocytopenia 
as the dominant treatment-related side effect.
Keywords: chemoradiation, HDAC inhibitor
hematology and gastrointestinal toxicity was twice as 
high in simultaneous chemoradiotherapy group.
Conclusion: Simultaneous regimens of 
chemoradiotherapy are more effective then 
sequential regimens in locally advanced non-small 
cell lung cancer with low levels of toxicity. A 
higher potential of chemoradiation therapy might be 
reached by increasing the dose. 
Keywords: Non-small cell lung cancer, 
chemoradiotherapy, sequential, simultaneous
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P4.284 FIRST REPORT: A PARALLEL 
PHASE I STUDY OF LBH589 IN 
COMBINATION WITH EXTERNAL 
BEAM RADIOTHERAPY OR 
CHEMORADIATION FOR LOCALLY 
ADVANCED NON SMALL CELL LUNG 
CANCER
Nimit Singhal, Michael Penniment, Raghu Gowda, 
Michael Brown 
Cancer Centre, Royal Adelaide Hospital/Australia
Background: The standard treatment for stage 
III Non small cell lung cancer is combined 
chemoradiation. However, not all patients are 
eligible. Limiting factors include large tumor size or 
radiation Àeld constraints. LBH589 (panobinostat) 
is an oral histone deacetylase inhibitor (HDACi) 
drug that acts to hyperacetylate histones thus 
decondensing chromatin and activating expression 
of previously repressed genes such as pro-apoptotic 
genes. Major mechanisms of HDACi action 
include induction of apoptosis, promotion of cell 
differentiation and anti-angiogenesis. HDACi are 
potent radiosensitizers with potentially synergistic 
interactions with radiation. HDACi selectively kill 
tumour cells at concentrations that are 10-fold lower 
than those toxic to normal cells, which suggests that 
a favorable therapeutic window could be achieved. 
The HDACi drug, vorinostat, is approved for use in 
cutaneous lymphomas.
Methods: This is a parallel design, open label, phase 
I trial allocating patients to one of two treatment 
groups via dose-escalation cohorts of three subjects: 
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Àbrosis (“Àbrosis” group). Eleven patients were 
characterized as having measurable viable tumor 
(“viable” group). Median PFS was 42 months in 
the “Àbrosis” group vs. 9 months in the “viable” 
group (p=0.068). Median OS was 44 months in the 
“Àbrosis” group vs. 19 months in the “viable” group 
(p=0.051). Of the patients who underwent resection, 
ten (45%) are still alive, seven with no evidence 
of disease (NED). Five of 11 (45%) patients with 
“Àbrosis” remain NED vs. 2 of 11 (18%) “viable” 
patients. Ten patients (45%) relapsed distally (three 
with CNS as site of Àrst relapse) and three (14%) 
relapsed locally. Two (9%) patients who died of 
unrelated causes were NED at the time of death. 
Seventeen patients (77%) had sterilization of 
mediastinal lymph nodes; Àve patients (23%) had 
residual nodal disease. Four of the Àve patients with 
lymph node involvement after neo-adjuvant therapy 
were in the “viable” group. There was minimal post-
operative morbidity and the length of stay following 
surgery was under four days. When patients with 
adenocarcinoma were compared to patients with 
squamous cell carcinoma, there was no difference in 
either PFS or OS.
Conclusion: Neoadjuvant chemotherapy with 
concomitant radiation followed by surgery can safely 
be performed in selected patients. The presence 
of residual active tumor bodes poorly and these 
patients may not beneÀt from deÀnitive resection. 
In moving forward we will utilize PET-CT to assess 
tumor response as well as pathologically stage the 
mediastinum before and after induction therapy with 
either endoscopic bronchoscopic ultrasound (EBUS) 
or mediastinoscopy. We anticipate that sterilization 
of mediastinal lymph nodes and a decrease in SUV 
on PET-CT will predict the pathologic response of 
the primary tumor and better select those patients 
who should complete surgical resection.
Keyword: Neo-adjuvant chemoradiation therapy
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P4.286 TREATMENT PATTERNS FOR 
LUNG CANCER IN SOUTH WESTERN 
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P4.285 NEO-ADJUVANT 
CHEMOTHERAPY AND RADIATION 
THERAPY IN PATIENTS WITH STAGE 
IIIA (N2) NON-SMALL CELL LUNG 
CANCER (NSCLC). A RETROSPECTIVE 
ANALYSIS WITH LESSONS LEARNED.
Eliot Friedman1, Michael Szwerc2, Charles 
Andrews3, Robert Kruklitis4, Ferdy Santiago5, 
Kathleen Leies1 
1Medical Oncology, Lehigh Valley Health Network/
United States Of America, 2Thoracic Surgery, Lehigh 
Valley Health Network/United States Of America, 
3Radiation Oncology, Lehigh Valley Health Network/
United States Of America, 4Pulmonary Medicine, 
Lehigh Valley Health Network/United States Of 
America, 5Internal Medicine, Lehigh Valley Health 
Network/United States Of America
Background: At the present time, there is no 
consensus for deÀnitive treatment for patients 
presenting with stage IIIA (N2+) non-small cell lung 
cancer (NSCLC). We report twenty-six consecutive 
patients with stage IIIA NSCLC seen at our 
Interdisciplinary Clinic for Thoracic Malignancies 
treated with concomitant neo-adjuvant chemotherapy 
and radiation therapy followed by deÀnitive 
surgery. This represents a community based, single-
institution, retrospective analysis.
Methods: Twenty-six patients with stage IIIA (N2+) 
NSCLC received neo-adjuvant therapy included 
radiation; (4500 cGy) with concomitant weekly 
chemotherapy (paclitaxel + carboplatin), followed by 
deÀnitive lung resection.
Results: Of the twenty-six patients selected for 
therapy, twenty-three patients completed surgical 
resection. Seventeen patients underwent lobectomy; 
six, pneumonectomy. The mean age of this group 
was 57.6 years (19 - 79 years). Two patients 
progressed after neo-adjuvant therapy and did not 
have surgery. One patient had unexpected pleural 
disease at surgery, resection was aborted. One patient 
who underwent surgery was lost to follow-up and 
is excluded from the analysis. For the twenty-two 
patients completing resection, median progression 
free survival (PFS), was 14.5 months and median 
overall survival (OS) was 19.5 months (analysis 
as of December 1, 2010). Review of pathology 
of the surgical resection identiÀed eleven patients 
with fewer than 10% cancer cells admixed with 
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P4.287 RADICAL PLATINUM-BASED 
SEQUENTIAL OR CONCURRENT 
CHEMORADIOTHERAPY FOR 
NON-SMALL CELL LUNG CANCER. 
DIFFERENCES IN TOLERANCE, 
OPERABILITY, PATHOLOGIC 
RESPONSES AND SURVIVAL IN THE 
EXPERIENCE OF THE UNIVERSITY 
HOSPITAL ARNAU DE VILANOVA OF 
LLEIDA (SPAIN).
Diego Márquez Medina1, Teresa Taberner Bonastre1, 
Virginia García Reglero2 
1Medical Oncology, University Hospital Arnau De 
Vilanova/Spain, 2Radiotherapy, University Hospital 
Arnau De Vilanova/Spain
Background: Chemoradiotherapy is the standard 
treatment for locally advanced N3 non-small cell 
lung cancer (NSCLC).
Methods: We retrospectively compared evolution 
of 23 patients diagnosed of stage II (T>5cm)-IIIB 
NSCLC and treated with neoadjuvant platinum-
based chemotherapy (CT-RT N= 19) with or without 
concomitant radiotherapy to 50 Gy maximum (CTRT 
N= 33) that, after a second evaluation, were assumed 
N3 or non-resectable and received sequential radical 
radiotherapy (N= 7) or complete radiation dose to 
60Gy (N= 16).
Results: Radiologic responses were 28.6% vs. 
50.1% for stabilization, 57.1% vs. 25% for minor 
radiologic response, and 14.3% vs. 25.1 for bigger 
than 75% radiologic responses in the CT-RT and 
CTRT group, respectively (p= 0.5). There was no 
grade 3-4 toxicity neither in the CT-RT or the CTRT 
group. Medium relapse free survival (RFS) was 
15.47 months in the CT-RT group and 11.3 months 
in the CTRT group (p= 0.4), and 6-month RFS were 
71.4% and 82.4% respectively (p= 0.46). Overall 
survival was 25.76 months in the CT-RT group and 
19.65 months in the CTRT. 1-year overall survival 
71.4% and 58.8% (p= 0.47).
Service/Australia, 2Collaboration For Cancer 
Outcomes, Research & Evaluation, Liverpool 
Hospital/Australia
Background: Australian patterns of care studies 
in lung cancer have previously shown that the 
management of patients is suboptimal, with signiÀcant 
under-utilization of radiotherapy and chemotherapy 
and a high proportion of patients receiving no anti-
cancer therapy at all. However, most of these studies 
predated the publication of the Australian National 
Health & Medical Research Council (NHMRC) 
Guidelines for the management of Lung Cancer 
in 2004. The impact of these guidelines on lung 
cancer treatment in Australia has not been evaluated. 
We aim to evaluate the proportion of lung cancer 
patients in South Western Sydney (SWS) who 
were treated according to guidelines and to identify 
factors associated with receipt of such treatment in a 
contemporary population-based cohort.
Methods: Data on patients with newly diagnosed 
lung cancer from 2006 to 2008, who resided within 
SWS Local Government Area (LGA) postcodes at 
diagnosis, were gathered from the SWS Area Clinical 
Cancer Registry (CCR). Data investigated included 
tumour information, stage, initial treatment and 
performance status at diagnosis (ECOG). Patients with 
unknown stage and/or unknown ECOG performance 
status were excluded so that analysis was limited 
to patients for whom guideline therapy could be 
evaluated. Associations were tested using Chi Square 
and t-tests. Odds ratios were calculated using logistic 
regression. 
Results: 815 new cases of Lung cancer were 
identiÀed. 60% were male and the median age at 
diagnosis was 70 years. 86% of tumours were Non 
Small Cell Lung Cancer (NSCLC) and 14% were 
Small Cell Lung Cancer (SCLC). 10% of cases 
had no stage documented. Pre-therapy ECOG was 
documented in 64% of cases. Overall, 31% of patients 
received no initial anti-cancer therapy. The utilisation 
of guideline therapy by stage was 61% for Stage I&II 
NSCLC, 39% for Stage III NSCLC, 56% for Stage 
IV NSCLC, 22% for limited stage SCLC and 66% for 
extensive stage SCLC. Variables associated with the 
receipt of guideline therapy included age, stage, and 
ECOG status at diagnosis. 
Conclusion: Adherence to national recommended 
guidelines has only been seen in approximately half 
of the population studied. Further investigation into 
the reasons for receipt of non-guideline therapy is 
required. 
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response 16% vs. 17.7%, p= 0.016). The presence 
of pathologic complete response o minimal residual 
disease trends to impact on relapse free survival 
(p= 0.1) and overall survival (p= 0.2). Anyway, 
no relapse was reported in the Àrst 6 months after 
surgery. On depend of toxicity, grade 3-4 events were 
more common in the CTRT group (11.8% vs. 0%), 
but none pulmonary or esophageal adverse event was 
observed.
Conclusion: Neoadjuvant CTRT is feasible and 
tolerable. It obtains a similar survival beneÀt that 
neoadjuvant CT, but it is capable to increase the rate 
of major pathological responses. A longer follow-up 
is warranted to observe if increment of pathological 
response impact in survival. 
Keywords: neoadjuvant chemorradiation, Non small 
cell lung cancer, locally advanced
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P4.289 NEOADJUVANT CONCURRENT 
CHEMORADIOTHERAPY WITH 
PLATINUM AND VINORELBINE. 
RESULTS IN THE PROTOCOL OF THE 
ARNAU DE VILANOVA UNIVERSITY 
HOSPITAL OF LLEIDA (SPAIN).
Diego Márquez Medina1, Teresa Taberner Bonastre1, 
Virginia García Reglero2, José Miguel Durán Alamá3, 
Silvia Gómez Falguera3 
1Medical Oncology, University Hospital Arnau De 
Vilanova/Spain, 2University Hospital Arnau De 
Vilanova/Spain, 3Pneumology, University Hospital 
Arnau De Vilnaova/Spain
Background: Chemoradiotherapy (CTRT) is the 
standard treatment for N3 non-small cell lung cancer 
(NSCLC), and a promising approach for neoadjuvant 
therapy in non-N3 locally advanced NSCLC.
Methods: We retrospectively analyzed 27 male 
patients with stage II (T>5cm)-IIIB NSCLC and 
consecutively treated with 4 cycles of neoadjuvant 
Cisplatin (N= 21) or Carboplatin AUC 5 (N= 3) 
plus Vinorelbine with concurrent radiotherapy to 
50 Gy during the third and fourth cycle since May, 
2008 to May, 2010. Three patients received CBDCA 
AUC5 with concurrent radiotherapy only, due to 
comorbidity. After a second evaluation, operable 
cases underwent surgery and non-operable cases 
continued radiotherapy to 60 Gy.
Results: Mean age of the patients was 68.3 years 
Conclusion: Neoadjuvant concurrent CTRT is a 
feasible and tolerable treatment for non-operable 
NSCLC. It seems to improve response rate and RFS 
over sequential CT-RT, with a similar toxicity. 
Keywords: chemoradiotherapy, locally advanced, 
Non small cell lung cancer
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P4.288 NEOADJUVANT PLATINUM-
BASED CHEMOTHERAPY WITH 
OR WITHOUT CONCURRENT 
RADIOTHERAPY. DIFFERENCES 
IN TOLERANCE, OPERABILITY, 
PATHOLOGIC RESPONSES AND 
SURVIVAL IN THE EXPERIENCE OF 
THE UNIVERSITY HOSPITAL ARNAU DE 
VILANOVA OF LLEIDA (SPAIN).
Diego Márquez Medina1, Teresa Taberner Bonastre1, 
Virginia García Reglero2, José Miguel Durán Alamá3, 
Silvia Gómez Falguera3, María Deu Martín4 
1Medical Oncology, University Hospital Arnau De 
Vilanova/Spain, 2University Hospital Arnau De 
Vilanova/Spain, 3Pneumology, University Hospital 
Arnau De Vilanova/Spain, 4University Hospital Vall 
D’hebrón/Spain
Background: Neoadjuvant chemotherapy is 
a consolidated approach for locally advanced 
non-N3 non-small cell lung cancer (NSCLC), but 
it is not clear if to add concurrent radiotherapy to 
chemotherapy improves clinical beneÀts.
Methods: We retrospectively analyzed 53 cases 
of stage II (T>5cm)-IIIB NSCLC treated with 
neoadjuvant platinum-based chemotherapy (CT N= 
19) with or without concurrent radiotherapy to 50 Gy 
maximum (CTRT N= 33), and their courses after a 
potential surgical resection.
Results: There were no signiÀcant differences in 
radiologic responses between neoadjuvant CT or 
CTRT group (Minor responses 84.2 vs. 69.7%; and 
bigger than a 75% radiologic responses 10.6 vs. 
24.2%, p= 0.293). Twenty nine patients underwent 
surgery. There was no signiÀcant differences in 
operability between CT or CTRT group (63.2 vs. 
50%, p= 0.2), but it was bias by a higher initial 
presence of stage IIIB in the CTRT group (21.1 vs. 
50%). Pathologic responses were frankly better in 
the CTRT group (complete response 8.3% vs. 29.4%; 
minimal residual disease 0% vs. 23.5%; partial 
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patients with stage IIIA(N2) non-small cell lung cancer 
(NSCLC) is uncertain. We performed a systematic 
review and meta-analysis to test the hypothesis that the 
addition of radiotherapy to induction chemotherapy 
prior to surgical resection does not improve survival 
compared to induction chemotherapy alone. 
Methods: A systematic review and meta-analysis 
were performed by searching English articles in 
PubMed and the Cochrane Database over the years 
1990-2010. Additional studies were identiÀed by 
searching bibliographies of published review articles 
on lung cancer. All studies of stage IIIA(N2) NSCLC 
that reported outcomes on both patients treated with 
induction chemotherapy alone and patients treated 
with induction chemoradiotherapy were included in 
the overall systematic review. In addition, randomized 
controlled studies comparing induction chemotherapy 
and induction chemoradiotherapy that reported survival 
data were considered for use in the meta-analysis. The 
number of patients in each treatment group, survival 
data, and hazard ratios were extracted from each study. 
Results: The initial database search yielded review 
3276 potential studies, 205 of which were screened 
based on the inclusion and exclusion criteria. Six 
studies eligible for analysis were found, including 
1 randomized control trial, 1 phase II study, 2 
retrospective reviews, and 2 published abstracts of 
randomized controlled trials (Table). None of the 
studies demonstrated a survival beneÀt to adding 
radiation therapy to induction chemotherapy versus 
chemotherapy alone. There was inadequate survival 
data available to perform a meta-analysis speciÀcally 
on stage IIIA(N2) patients. A meta-analysis was 
performed on randomized controlled trials (N=336 
patients) with available survival data on stage III 
patients, which showed no beneÀt of the addition of 
radiation to induction chemotherapy (odds ratio 0.88, 
95% conÀdence interval 0.56-1.36, P=0.55). 
Chemotherapy Chemotherapy & 
Radiation 
P 
First 
Author 
Study Design Study Years n Survival n Survival 
Thomasa Randomized 
Control Trial 
1995-2003 154 33 (median) 142 32.4 (median) 0.54 
Sauvaget Randomized 
Control Trial 
(Abstract) 
1991-2000 N/A 19 (median) N/A 18.5 (median) NS 
Flecka Randomized 
Control Trial 
(Abstract) 
N/A 15 17% (3yr) 25 23% (3yr) NS 
Girard Phase II Trial 2003-2007 14 24 (median) 17b 13 (median) 0.29 
Higgins Retrospective 
Review 
1995-2006 31 39% (3yr) 70 41% (3yr) 0.65 
Pezzetta Retrospective 
Review 
1994-2003 36 40%c (5yr) 46 40%c (5yr) NS 
old, and initial ECOG was 0-1 (92.6%) or 2 
(7.4%). There was a 3.7% of stage IIA tumors, a 
44.4% of IIIA, and a 51.9% of IIIB in the initial 
evaluation. Clinical T4 tumor were a 37.1%, N2 
a 51.9%, and N3 a 29.6%. Histological subtypes 
were: squamous carcinoma 77.8%, adenocarcinoma 
11.1% and non-deÀned NSCLC 11.1%. 
Radiological responses appeared in a 92.6% of 
cases (stabilization 18.5%, partial response 70.3%, 
and bigger than 90% response 3.7%). Metabolic 
responses by PET-CT scan appeared in a 96.3% 
(stabilization 33.3%, partial response 51.9%, and 
bigger than 90% response 11.1%). An 81.22% of 
non-N3 NSCLC after CTRT underwent surgery 
(2 two atypical resections, 9 lobectomies, and 2 
pneumectomies) with mediastinal lymph node 
dissection. Contraindications for surgery were 
initial N3 (50%), progression to CTRT (14.3%), bad 
respiratory function (7.1%), and persistence of T4-
tumor (28.6%). Pathologic responses were: partial 
response 53.9%; minimal residual disease 23.1%; 
and complete pathological response 23.1%. Mean 
relapse free survival was 9.56 months, and 6-months 
RFS was 88.9%. 1-year OS was 65%. RFS was not 
related with metabolic (p= 0.49) nor pathological 
response (p= 0.41).
Conclusion: Neoadjuvant CTRT with platinum 
and vinorelbine is a feasible treatment for locally 
advanced NSCLC. Maybe a longer sample size and 
follow-up could allow appreciating differences in 
survival according tumor response. 
Keywords: neoadjuvant chemoradiation, locally 
advanced, Non small cell lung cancer
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P4.290 INDUCTION 
CHEMORADIOTHERAPY IS 
NOT SUPERIOR TO INDUCTION 
CHEMOTHERAPY ALONE IN PATIENTS 
WITH STAGE IIIA(N2) NON-SMALL 
CELL LUNG CANCER: A SYSTEMATIC 
REVIEW AND META-ANALYSIS
Asad A. Shah1, Mark F. Berry2, Ching Tzao3, Dimple 
Rajgor1, Ricardo Pietrobon1, Thomas A. D’Amico2 
1Surgery, Duke University Medical Center/United 
States Of America, 2Cardiothoracic Surgery, Duke 
University Medical Center/United States Of America, 
3Surgery, Tri-service General Hospital/Taiwan
Background: The optimal treatment strategy for 
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occurred. In 31 pts evaluable after induction therapy 
we observed: 11 partial responses (30,5%) and 
20 stable diseases (55,5%); 5 pts (14%) were not 
evaluable for response (restaging not done). Toxicity 
observed was: 1 patient with dysphagia WHO grade 
III and 1 WHO grade IV, no toxic deaths have 
occurred. After concurrent radio-chemotherapy in 
34 pts (because in 2 pts treatment not yet completed) 
clinical responses were: 14 partial response (41%), 15 
stable disease (44%) and 5 progressive disease (15%). 
In all patients median survival was 14,9 months (range 
+1,3 to +81,1), median time to progression 10,3 
months (range 2,9 to 51,6). By stratifying patients in 
stage IIIA and IIIB at diagnosis we observed that in 
stage IIIA median survival was 17,2 months (range 12 
to +79,3 months) and median time to progression was 
12.8 months (range 2,9 to 27,7 months). In stage IIIB 
median survival was 14,4 months (range +1,3 to +81,1 
months) and time to progression 9,7 months (range 
3.7 to 51,6 months). After the multimodality treatment 
of 34 pts evaluable 6 patients (17.6%) were submitted 
to thoracic surgery: at the diagnosis 4 patients were 
stage IIIA and 2 patients stage IIIB. Actuarial survival 
curve showed that at 1 year the probability was 74% 
and at 2 years 25% (stage IIIA 1 year 86% and at 
2 year 37%: stage IIIB at 1 year 71% and at 2 year 
25%). At this writing 6 pts (16,6%) were alive.
Conclusion: Preliminary results of this 
multimodality treatment are promising as concern 
activity, local control of disease, median and overall 
survival. Toxicity proÀle of this schedule was mild 
and reversible with a good patients compliance. A 
larger accrual will be required to verify these data.
Keyword: Vinorelbine
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P4.292 PHASE II TRIAL EVALUATING 
GEMCITABINE-IFOSFAMIDE-
CISPLATIN AS INDUCTION 
TREATMENT FOR MEDIASTINOSCOPY 
PROVEN STAGE IIIA-N2 NON-SMALL 
CELL LUNG CANCER.
SoÀe Derijcke1, Johan Vansteenkiste1, Paul De 
Leyn2, Yolande Lievens3, Kristiaan Nackaerts1, 
Christophe Dooms1 
1Respiratory Oncology Unit, University Hospitals 
Leuven/Belgium, 2Thoracic Surgery, University 
Hospital Leuven/Belgium, 3Radiation Oncology, 
University Hospitals Leuven/Belgium
a includes all stage III patients b arm B. Arm C not 
chosen given lack of survival data c overall survival 
of both groups, which was not signiÀcantly different 
between groups 
Conclusion: The use of radiation therapy in 
induction regimens for stage IIIA(N2) NSCLC is 
not supported by published evidence. Given the 
potential disadvantages of adding RT preoperatively, 
clinicians should consider using this treatment 
strategy only in the context of a clinical trial to allow 
better assessment of its effectiveness.
Keywords: neoadjuvant, Radiotherapy, stage 
IIIA(N2), Chemotherapy
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P4.291 VINORELBINE (VNR) IN 
CONCURRENT RADIATION THERAPY 
(TRT) IN NON SMALL CELL LUNG 
CANCER (NSCLC) STAGE III
Luigi Portalone, Stefania Greco, Mauro Signora, 
Guido Pallone, Alessandra Lombardi 
2 Chest Oncology Unit, S.camillo/Forlanini 
Hospital/Italy
Background: A retrospective analysis was performed 
to evaluate Therapeutic Index of VNR with concurrent 
TRT in pts with stage III unresectable NSCLC in 
objective response or in stable disease after induction 
therapy with Platinum compounds and Gemcitabine.
Methods: Multimodality treatment consisted of 
induction therapy with Platinum (80 mg/m2/i.v.) or 
Carboplatinum (AUC 5) plus Gemcitabine (1200 
mg/m2/i.v.)(GP) weekly day 1-8 every 21 days. In 
complete remission (CR), partial remission (PR) and 
stable disease (SD), patients, after induction therapy, 
were treated with Docetaxel (DCT) (25 mg/m2/i.v.) 
weekly and VNR os (12 mg/m2) or i.v. (5 mg/m2) 
three-times weekly 2 hours before concurrent TRT (2 
Gy/day for 6 wks).
Results: From November 2002 to February 2011, 
36 chemotherapy and radiotherapy-naive pts were 
treated: males/females 21/15; median age 58 years 
(range 18 to 77); median ECOG PS 0 (range 0-1); 
no weight loss: 10% in all pts; stage IIIA 8 pts 
(22%), stage IIIB 28 pts (78%). 21 Pts (85 cycles 
of chemotherapy) showed 6 WHO grade III toxic 
events (7%), mainly hematological (neuthropenia 
and thrombocytopenia) and 1 WHO grade IV (1.1%) 
hematological (neuthropenia). No toxic deaths have 
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in 46% (67% with squamous histology). The ITT 
median survival was 19 months, with a 2- and 3-year 
overall survival rate of 50% and 31%, respectively. 
Conclusion: While triplet GIP induction 
chemotherapy resulted in a high ORR of 63%, the 
mediastinal downstaging rate and median survival 
was moderate compared to speciÀc cisplatin 
doublets, probably explained by the high grade 3-4 
hematological toxicity rate responsible for impaired 
dose intensity in 56% of patients. Remarkably, 
we observed a high rate of central nervous relapse 
mainly in squamous cell histology.
Keywords: combined modality treatment, Non-
small cell lung cancer, Induction Chemotherapy
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P4.293 LONG-TERM SURVIVAL OF NON-
SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS WITH T4N0-N1 DISEASE 
TREATED WITH SEQUENTIAL OR 
CONCURRENT CHEMO-RADIATION.
Bart Reymen1, Angela Van Baardwijk1, Rinus 
Wanders1, Jacques Borger1, Ruud Houben1, Anne-
Marie C. Dingemans2, Gerben Bootsma3, Cordula 
Pitz4, Ragnar Lunde5, Wiel Geraedts6, Philippe 
Lambin1, Dirk De Ruysscher1 
1Radiation Oncology, MAASTRO Clinic, Grow 
- School For Oncology And Developmental 
Biology, Maastricht University Medical Centre/
Netherlands, 2Department Of Pulmonology, 
Maastricht University Medical Center, Grow - 
School For Oncology And Developmental Biology/
Netherlands, 3Department Of Pulmonology, 
Atrium Mc Parkstad/Netherlands, 4Department Of 
Pulmonology, Laurentius Ziekenhuis/Netherlands, 
5Department Of Pulmonology, St. Jansgasthuis/
Netherlands, 6Department Of Pulmonology, Orbis 
MC/Netherlands
Background: The optimal treatment strategy for 
Stage IIIb NSCLC patients with a T4N0-1 tumor is a 
matter of debate. In prospective combined modality 
series including surgery, the median overall survival 
(OS) is approximately 24 months. As in most non-
surgical series, multiple-level N2 or N3 disease 
are included, the outcome after chemo-radiation is 
unclear. We hypothetised that results comparable to 
regimens including surgery can be achieved with 
concurrent chemo-radiation in this patient group.
Background: Induction chemotherapy is an option 
for the treatment of resectable locally advanced non-
small cell lung cancer (LA-NSCLC). We evaluated 
the efÀcacy and safety of gemcitabine – ifosfamide 
– cisplatin (GIP) as an induction chemotherapy 
regimen. 
Methods: Between October 2003 and October 2007, 
we prospectively treated 16 histologically proven 
LA-NSCLC (clinical stage T1-3 N2 M0) patients 
with three cycles GIP induction chemotherapy 
followed by attempted surgical resection. Each cycle 
consisted of gemcitabine 1000 mg/m2 on days 1 and 
8, ifosfamide 3 g/m2 on day 8, and cisplatin 80 mg/
m2 on day 1. A CT scan was performed at baseline 
and after 3 cycles. The primary endpoint was 
objective response rate. Toxicity, mediastinal nodal 
downstaging, pattern of disease relapse and 3-year 
overall survival were secondary endpoints. 
Results: Baseline characteristics of patients included 
were: median age 60 years (range 35-75); M/F 
ratio 11:5; histology adeno (n=7), squamous (n=7), 
large cell (n=1), mixed adenosquamous (n=1); 
single level N2 (n=11) and multilevel N2 (n=5) at 
mediastinoscopy; median lymph node size 15mm 
(range 9-34). Only 44% of patients received the 
planned full dose induction chemotherapy. Full 
dose cisplatin was administered in 88% of patients. 
Among the grade 3-4 toxicities, haematological 
toxicity was the most frequent (81% of patients) 
followed by gastrointestinal toxicity (nausea/
vomiting) in 13% of patients. Ten patients (63%) 
obtained a partial remission after induction therapy 
(RECIST 1.0), Àve patients (32%) had stable disease 
and one patient had progressive disease. Surgical 
resection was performed in 12 patients. Mediastinal 
nodal downstaging occurred in 5 of 12 patients 
(42%), persistent N2 occurred in 5 of 12 (42%), 
while mediastinal disease progressed in 2 of 12. 
R0 resection rate was 92%. All patients without 
nodal downstaging received adjuvant postoperative 
radiotherapy. Locoregional radiotherapy only 
was performed in 4 patients: radical radiotherapy 
in 3 patients based on a multidisciplinary board 
meeting decision (one patient became medically 
inoperable after induction and two patients yielded 
a stable disease on CT considered as clinical trend 
to progression) and palliative radiotherapy in one 
patient with objective disease progression after 
induction. During 3 year follow-up, disease relapse 
occurred in 88%: one patient had an intrathoracic 
relapse only, while all other patients had distant 
relapses of whom a central nervous relapse occurred 
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treatment strategy for stage IIIb, T4N0-1 NSCLC 
patients yielding very promising OS results with low 
toxicity. 
Keywords: NSCLC, Radiotherapy, Chemotherapy, 
T4
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P4.294 SURGERY IN PATIENTS WITH 
ADVANCED NSCLC FOLLOWING 
INDUCTION POLYCHEMOTHERAPY.
Vladimir Porhanov1, Igor Polyakov2 
1Cardiothoracic Surgery Center/Russian Federation, 
2Oncological Department, Cardiothoracic Surgery 
Center/Russian Federation
Background: About 80% of primarily diagnosed 
patients with NSCLC were found to have non-
operated stages and they are administered therapeutic 
or radiotherapy. Polychemotherapy administration 
before the operation in patients with NSCLC is to 
improve postoperative results.
Methods: From January 2003 to January 2009, 
31 patients referred for neo-adjuvant (induction) 
therapy. Of those 14 patients were found to have 
non-resected tumore - Ð¢4 (Àve had bifurcation 
invasion, 3 SVS invasion, 4 apical tumors, in 2 cases 
tumor affected lobar bronchus and surrounding 
tissues, but pneumonectomy was contraindicated), 
in other 17 patients we noticed multiple invasion 
of mediastinal lymph nodes N2-3. Patients were 
diagnosed with videomediastinoscopy, VATS, 
transthoracic biopsy was taken in all cases before 
surgery. Functional status of patients corresponded to 
ECOG 0-2.
Results: After induction therapy we performed 
restaging and then we chose surgical or therapeutic 
treatment. Six patients (42%) with T 4 demonstrated 
response to the therapy – they were included to the 
surgical group. They underwent 2 pneumonectomies 
with resection of bifurcation and SVS plasty, in three 
cases we carried out pneumonectomy, in 1 – upper 
lobe resection with bronchoplasty. Of 17 patients 
with N2-3, surgery of various volume was indicated 
in Àve patients (29%). Postoperative complication 
rate was 9%, there were no cases of mortality. 
Survival rates in groups of operated and nonoperated 
patients were 7 months and 23 months, respectively. 
Conclusion: Induction therapy was able to widen 
combined treatment modalities for NSCLC and 
Methods: In our prospectively collected database 
of NSCLC patients, all patients with T4(mediastinal 
invasion) N0-1 NSCLC receiving concurrent or 
sequential chemoradiation (WHO-PS 0-2; FEV
1
/
DLCO >30%) were included. One patient had a 
recurrence after previous pneumonectomy. Patients 
were irradiated using an individualized accelerated 
prescribed total tumor dose (TTD) based on normal 
tissue dose constraints (maximal doses: mean lung 
dose (MLD): 19 Gy, spinal cord: 54 Gy, brachial 
plexus: 66 Gy) (van Baardwijk et al. J Clin Oncol 
2010). In the sequentially irradiated patients a 
maximal dose of 79.2 Gy was prescribed, in the 
concurrently irradiated patients the maximal dose 
was 69 Gy. All patients were given 3 cycles of 
chemotherapy, radiotherapy (RT) was started at the 
2nd course of chemotherapy (cisplatin-vinorelbine or 
-etoposide) or after chemotherapy. RT planning and 
staging was PET-CT based. OS was calculated from 
date of diagnosis (Kaplan-Meier method). Toxicity 
was scored according to CTCAEv3.0.
Results: 42 patients (8 female, 34 male) with a 
median age of 62.5 ± 9 years (44-80 years) were 
included from October 11th 2005 until December 
30th 2009. Stage distribution: 86% T4N0 (n=36), 
14% T4N1 (n=6). 16 patients received sequential 
chemoradiation, 26 patients received concurrent 
chemoradiation. The median dose delivered to tumor 
and nodes was 65.0 ± 10 Gy (21.6 -79.2 Gy) given 
in an overall treatment time of 30 (28-32) days. The 
median prescribed MLD was 15 ± 4.4 Gy (5.03 -19.9 
Gy). Acute toxicity: 1 patient experienced grade 3 
dyspnea during RT. Grade 3 dysphagia occurred in 
5 patients (12%) during RT requiring tube feeding 
in 3 of these patients (7%). Dysphagia persisted 
later than 1 month after RT in 1 patient (2%). 
Grade 3 dysphagia only occurred in patients treated 
concurrently. Grade 3 cough occurred in 1 patient 
during RT, no patient experienced >= grade 3 cough 
1 month after RT. 2 patients died within 3 months 
after start of RT, one due to myocardial infarction, 
one of unknown causes. Severe late toxicity was 
not present: no grade 3 complications more than 3 
months after the end of radiotherapy. With a median 
FU of 42 months, the median OS for the whole 
group is 34 months (95% CI 24-43 months), 2-year 
survival is 55 %. The median OS for the sequential 
group is 27 months (95% CI 13-40 months), while 
the median OS for the concurrent group is not yet 
reached.
Conclusion: Concurrent accelerated chemoradiation 
using an individualized dose prescription is a valid 
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patients were; mean age 60.6 years (range, 51-70 
years), gender male/female 8/1 cases, stage I/II/III/
IV 0/2/6/1, and histologic type adenocarcinoma/ 
squamous cell carcinoma 4/5. Seven patients (78%) 
received four cycles of chemotherapy, and 2 patients 
(22%) did not complete four cycles. No treatment-
related death was observed and the hematologic 
toxicities included grades 3-4 leukopenia 
(22%), neutropenia (44%), anemia (11%), and 
thrombocytopenia (0%). Nonhematologic toxicities 
included grade 3-4 nausea/vomiting, anorexia, and 
fever did not be observed.
Conclusion: Adjuvant chemotherapy of nedaplatin 
plus docetaxel was shown to be well tolerable 
in patient with resected NSCLC. On the basis of 
these results, phase II study of the combination 
of nedaplatin plus docetaxel as an adjuvant 
chemotherapy is required
Keywords: Nedaplatin, Docetaxel, Adjuvant 
chemotherapy, Non-Small-Cell Lung Cancer
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P4.296 PROGNOSTIC FACTORS IN THE 
RADICAL NON-SURGICAL TREATMENT 
OF STAGE IIIB NON-SMALL CELL LUNG 
CANCER
Brian Healy1, Kent Russell1, Jason Pantarotto2, 
Elham Sabri3, Scott Laurie1, Robert Macrae2, Paul 
Wheatley-Price1 
1Medical Oncology, The Ottawa Hospital Cancer 
Center/Canada, 2Radiation Oncology, The Ottawa 
Hospital Cancer Center/Canada, 3The Ottawa 
Hospital Research Institute, University Of Ottawa/
Canada
Background: Many patients diagnosed with Stage 
IIIb (AJCC 6th Edition; T4 and/or N3, no pleural 
effusion) non-small cell lung cancer (NSCLC) are 
treated with curative intent, despite a very low cure 
rate. Guidelines are required to help select patients 
for radical therapy, thus sparing many patients 
toxicities of aggressive treatment. We performed 
a retrospective analysis to investigate factors 
inÁuencing outcomes in these patients.
Methods: From 2002-2009, all cases of stage 
IIIb NSCLC from our institution were identiÀed. 
Patients treated with radical radiotherapy (minimum 
dose 50Gy), with or without chemotherapy, 
were included. With ethics approval, charts were 
we carried out resections in cases which had been 
diagnosed as inoperable and performed restaging. 
Thus, overall rates of mortality and morbidity were 
decreased
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.295 A PILOT STUDY OF NEDAPLATIN 
PLUS DOCETAXEL AS ADJUVANT 
CHEMOTHERAPY IN PATIENTS WITH 
RESECTED NON-SMALL-CELL LUNG 
CANCER
You Kawaguchi, Tetsuo Hori, Shoji Kitamura, Koji 
Teramoto, Jun Hanaoka, Noriaki Tezuka 
Department Of Surgery, Shiga University Of Medical 
Science/Japan
Background: Recent clinical trials have shown 
that adjuvant cisplatin-based chemotherapy 
improved survival for patients with completely 
resected stage II-IIIA non-small-cell lung cancer 
(NSCLC). In terms of toxicities, hematological 
or nonhematological toxicities are frequently 
observed in cisplatin-based chemotherapy. Adjuvant 
chemotherapy should be conducted safely, with 
potent activity. Thus, more suitable regimen with 
these criteria needs to be developed as adjuvant 
chemotherapy. Nedaplatin is a cisplatin derivative 
developed in Japan. It has similar activity to cisplatin 
in NSCLC when combined with vindesine, and 
causes less nausea/vomiting and nephrotoxicity 
compared with cisplatin. The purpose of this pilot 
study was to evaluate the safety of combination 
chemotherapy with nedaplatin plus docetaxel as 
adjuvant chemotherapy in patients with resected 
NSCLC.
Methods: In this pilot study, patients with resected 
NSCLC were received nedaplatin (64 mg/m2) and 
docetaxel (48 mg/m2) on day 1, every 4 weeks, 4 
cycles. The primary end point was the feasibility. 
Adverse events were graded according to National 
Cancer Institute Common Toxicity Criteria (version 
4.0).
Results: Between April 2009 and December 2011, 
9 patients received combination chemotherapy of 
nedaplatin plus docetaxel. The demographics of 
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P4.297 A NOVEL APPROACH FOR 
FOLLOW UP OF RADICALLY TREATED 
LUNG CANCER PATIENTS -THE 
FEASBABILITY OF A PROSPECTIVE 
STUDY OF TELEPHONIC CONTACT AND 
SUBSEQUENT PHYSICAL FOLLOW UP
Jai Prakash Agarwal1, Anusheel Munshi1, Rajesh 
Dikshit2, Sarbani Ghosh Laskar1, C.S. Pramesh3, G. 
Karimundackal3, Prabash Kumar4, Vanita Narohna5, 
Sandeep Tandon6, Nirmala Jambhekar7 
1Radiation Oncology, Tata Memorial Hospital/
India, 2Epidemiology, Tata Memorial Hospital/India, 
3Surgical Oncology, Tata Memorial Hospital/India, 
4Medical Oncology, Tata Memorial Hospital/India, 
5Medical Oncology, Tata Memorial Hospital/India, 
6Pulmonary Medicine, Tata Memorial Hospital/
India, 7Pathology, Tata Memorial Hospital/India
Background: Patients of lung cancer, after their 
primary treatment are subsequently called for follow 
up visits to assess the disease status. Patients often 
have to travel long distances to report to the hospital 
and have to take care of other logistics as well. The 
present study deals with assessment of the utility of a 
telephonic conversation with the patient to assess the 
disease status before the patient’s scheduled physical 
visit to the hospital. 
Methods: 200 patients of lung cancer treated with a 
radical aim are being taken in this prospective study. 
A set of questions are asked to the patient in his /her 
vernacular during the telephonic interview. Based on 
this questionnaire an impression of clinical control/
recurrence/progression/uncertain is made. After the 
telephonic interview, the patients report to the cancer 
care specialist at the Tata Memorial Hospital for the 
due follow up visit.. This telephonic impression is 
corroborated with the physician impression when 
the patient physically reports to the hospital. The 
primary end point of the study is the concurrence 
between the telephonic interview and the subsequent 
physician Ànal impression. Calculation of sensitivity, 
speciÀcity, PPV and NPV shall be done using 
Hospital visit Ànal impression as gold standard. 
Using Kappa statistics, the score of more than 80% 
shall be considered as good agreement.
Results: Till now 31 patients have been taken into 
this study. 18 patients have been called before their 
Àrst follow up visits. The average time needed for 
each call was 3.51(SD 1.29) minutes. 14 patients 
reviewed for patient demographics, baseline 
bloodwork, tumour factors, treatment factors and 
hospitalizations. The primary outcome was overall 
survival (OS), measured from time of diagnosis.
Results: Of 230 patients identiÀed; we report 
results of the Àrst 140 eligible cases reviewed. 
Baseline demographics are shown in the table. The 
median follow-up for all patients was 16 months. 
Median survival was 18 months, and OS was 69%, 
40% and 28% at 1, 2 and 3 years respectively. 
Numerically longer median survival was seen in 
women (22 versus 17 months), good performance 
status patients (19 versus 13), patients without N3 
disease (19 versus 16), patients who received 60Gy 
radiation (18 versus 11) and patients who received 
chemotherapy (18 versus 13). In multivariate 
analysis the most favourable characteristics were 
female sex (HR 0.57, 95% CI 0.35 – 0.93 , p=0.02), 
<5% weight loss (HR 0.65, 95% CI 0.40 – 1.05, 
p=0.08) and absence of N3 disease (HR 0.61, 95% 
CI 0.37-1.02, p=0.06). (See Figure).
Conclusion: As in advanced NSCLC, overall 
survival was signiÀcantly longer in women than 
men. Additionally, patients with <5% weight loss 
and those without N3 disease, trended towards 
signiÀcantly longer survival. Good patient selection 
remains important in the radical treatment of stage 
IIIb NSCLC.
Keywords: Stage IIIb, NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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doses from 54 to 60 Gy of conformal or intensity-
modulated radiotherapy (2Gy/Fx) in combination 
with geÀtinib 250mg daily during RT and 60 days 
after the completion of RT to determine the MTD 
(maximum tolerated dose). Toxicities are evaluated 
according to Common Terminology Criteria for 
Adverse Events version 3.0 (CTCAE v3.0).
Results: To Feb 2011, 4 cohorts, a total of 40 
were enrolled with medium age of 55 yr (32-
79): 28 male and 12 female;20 smokers and 20 
nonsmokers;18 stage IIIB and 22 stage IV; 35 
adenocarcinomas (86%), 4 squamous carcinomas 
and 1 poor differentiated carcinoma; Prior-
chemotherapy regimen was consisted of NP, GP 
and TP for a median of 3 cycles (95% CI:, 1-6).
With a median follow-up of 13.7 months (95% 
CI:2.7-28.1 months), 35 patients progressed, 5 
patients remained progression-free to date. Median 
progression-free survival time was 6.2 months (95% 
CI: 3.4-8.9 months). Median overall survival time 
was 14.2 months (95% CI: 11.7-16.7 months).1-year 
survival rate was 60%.One patient developed acute 
ILD in both lungs one week after the completion 
of radiation therapy,and died of respiratory failure 
30 days after. Except of this patient, other adverse 
events were generally mild to moderate. 29 (73%) 
experienced grade 1 to 2 pulmonary inÀltrates/
pneumonitis ( grade 1 33%,grade 2 40%).Otherwise, 
the most common grade 1 - 2 toxicities were rash 
(60%), and esophagitis (40%). 
Conclusion: Thoracic radiotherapy up to 60 
Gy concurrent with geÀtinib 250 mg daily was 
feasible and clinically active in this group of pre-
treated patients with NSCLC. Close monitoring for 
pulmonary toxicity remains necessary, as serious 
complication of ILD was observed in one patient 
(2.5%). Otherwise, adverse events were well 
tolerated. (NCT00497250)
Keywords: Radiotherapy, geÀtinib, Non-small cell 
lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
were reachable on the Àrst attempt while 4 patients 
needed more than one attempt to be contacted. 15 
patients deemed to be disease free in telephonic 
follow up were actually disease free during physical 
follow up. Only one patient was deemed to have 
local recurrence during telephonic follow up. Two 
patients were reported dead by the relatives during 
telephonic contact. This patient did not have a 
recurrence on physical examination. The average 
money spent by each patient for travel to hospital for 
the follow up visit was Rs 7148 (USD 142.9) and the 
average money spent on stay during the follow up 
visit was Rs 3971 (USD 79.4).
Conclusion: Telephonic follow up contact with 
lung cancer patients is a viable strategy and has the 
potential to save money, time and hospital resources 
as well. These preliminary Àndings need to be 
conÀrmed by mature results emerging from our 
study. 
Keywords: Physcical follow up, Telephonic follw 
up, combined modality, Lung cancer
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P4.298 FINAL REPORT OF A PHASE I 
STUDY OF CONCURRENT THORACIC 
RADIOTHERAPY AND GEFITINIB IN 
PRE-TREATED PATIENTS WITH IIIB/
IV NON-SMALL CELL LUNG CANCER 
(NSCLC)
Yu-Xin Shen1, Min Fan1, Jia-Yan Chen1, Li-Yi Xie1, 
Xuan-Li Xu1, Guo-Q Zhang1, Xiao-Long Fu2, Guo-
Liang Jiang2 
1Radiation Oncology, Fudan University Shanghai 
Cancer Center/China, 2Department Of Radiation 
Oncology, Fudan University Cancer Hospital/China
Background: Preclinical data suggest that geÀtinib 
(an epidermal growth factor receptor tyrosine kinase 
inhibitor) in combination with radiation resulted 
in additive to synergistic anti-proliferative effect 
against NSCLC. This study was designed to evaluate 
the safety and activity of radiotherapy (RT) with 
concurrent daily GeÀtinib 250mg in Chinese patients 
with IIIB/IV of NSCLC after failure of platinum-
based chemotherapy. 
Methods: Patients with stage IIIB or stage IV, 
failure of platinum-based chemotherapy regimen 
NSCLC were eligible. Four Cohorts of eight patients 
each were planned to be treated with escalating 
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exploratory thoracotomy was performed for 
mediastinal invasion, seeing a downstaging in 
46.9% of all the cases Over-all 5 year survival was 
27.8% with a median of 52.9 months (95% CI 38.1-
67.6). This survival is dependent on the response 
to neoadjuvant treatment (responders: 55.7 months 
on average and non-responders: 30.5 months on 
average, p<0.05). 
Conclusion: Neoadjuvant treatment reduces tumor 
size resulting in a downstaging and improving 
the resectability of locally advanced NSCLC. The 
neoadjuvant therapy could be a viable therapeutic 
option to improve survival of these patients. 
Keywords: Lung cancer, neoadyuvant
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.300 A SYSTEMATIC REVIEW 
AND META-ANALYSIS COMPARING 
SURVIVAL AFTER INDUCTION 
TREATMENT IN PATIENTS WITH N2 
DISEASE RANDOMISED TO EITHER 
SURGERY OR RADIOTHERAPY.
Amir Sadri, May Al Sahaf, Lyn Edmonds, Fujian 
Song, Eric Lim 
Academic Department Of Thoracic Surgery, Royal 
Brompton Hospital/United Kingdom
Background: Chemotherapy and radiotherapy is 
often considered to be the “standard of care” in the 
management of patients with N2 disease. The aim 
of this study is to ascertain the treatment effect on 
overall survival using meta-analysis. 
Methods: A literature search was conduction from 
1966-2009 for all studies of patients with N2 disease 
who received either induction chemotherapy or 
induction chemo-radiotherapy and randomised to 
surgery or radiotherapy. Fixed and random effects 
meta-analysis were performed. 
Results: In all, 5 randomised trials were identiÀed 
(Johnstone, Shepherd, Van Meerbeck, Stephens 
and Albain et al), consisting of 674 patients. 
The study groups were broadly comparable for 
age and gender. In three trials, patients received 
induction chemotherapy and in one trial, patients 
received induction chemo-radiotherapy. There 
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P4.299 IMPACT OF NEOADJUVANT 
THERAPY ON TUMOR RESECTABILITY 
AND SURVIVAL OF PATIENTS WITH 
LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER
Samantha Aso Gonzalez1, Raquel Pascual Cascon1, 
Mariana Muñoz Esquerre1, José Ignacio Martínez 
Ballarin1, Susana Padrones1, Ivan Macia Vidueira2, 
Francisco Rivas Doyague2, Felipe Cardenal3, Maria 
Dolores Arnaiz Fernandez4, Sergio Morchon Ramos5, 
Jordi Dorca1 
1Pulmonology, Hospital Universitari De Bellvitge/
Spain, 2Thoracic Surgery, Hospital Universitari De 
Bellvitge/Spain, 3Medical Oncology, Institut Català 
D’oncologia/Spain, 4Radiotherapy Oncology, Institut 
Català D’Oncologia/Spain, 5Preventive Medicine, 
Hospital Universitari De Bellvitge/Spain
Background: Surgery is the treatment of choice 
in patients with early stage non small cell lung 
cancer (NSCLC). It is also used in some cases 
of locally advanced tumors, but with a low cure 
rate. Therefore, preoperative treatment is seeking 
to improve survival in these patients. The aim of 
this study was to evaluate tumor resectability and 
survival in patients with locally advanced stage 
(IIIA and IIIB) NSCLC treated with chemotherapy 
(CT) or chemotherapy and radiotherapy (CT-RT) 
neoadjuvant. 
Methods: This was a cross-sectional observational 
study that evaluated patients with locally advanced 
NSCLC in a university hospital during 2000 and 
2006, that received induction therapy. The collected 
variables were anthropometric values, lung function, 
histology, stage of the tumor, neoadjuvant treatment 
and therapeutic response. Kaplan-Meier curve was 
used to evaluate survival. T-Test was used when 
variables accomplished normal criteria and analysis 
of variance to compare values among groups. 
Differences were considered signiÀcant when p 
values were < 0.05. 
Results: A total of 32 patients were included; 9 
subjects (28.1%) were diagnosed with stage IIIA 
and 23 (71.9%) stage IIIB, being the IIIB the 
most common indication for induction therapy. 
All patients were treated with CT, showing a 
treatment response in 80% of cases and only 7 
were also required radiotherapy. Surgical resection 
was indicated in 31 patients and only in 6 subjects 
Copyright © 2011 by the International Association for the Study of Lung Cancer S1585
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Karnofsky Performance Status (KPS) of 70, 
adequate end organ function, and ability to provide 
informed consent. Patients received premedication 
with folic acid, vitamin B12, and dexamethasone and 
pemetrexed 500 mg/m2 IV every 21 days starting 
within 5 days of the WBRT. Patients received WBRT 
with 2.5 Gy, 5 days a week, for 3 weeks to a total dose 
of 3750 cGy. The initial 5 patients were enrolled and 
treated sequentially to monitor for toxicity. After the 
trial initiated the trial was amended, and eligibility 
was restricted to treatment naïve patients with a KPS 
of 70 or age 70 years. The primary-endpoint was 
response to intra-cranial lesions according to RECIST. 
The null hypothesis was the response rate would 30% 
and a response rate of >50% would be determined as 
clinically meaningful. If 4 of 15 patients responded 
the trial would be stopped for lack of efÀcacy, and if 
10 of 15 patients responded then the trial would be 
stopped and the response rate would be considered 
>50%. If 5-9 patients responded the trial would 
proceed to the second-stage and enrollment would 
continue to 30. The trial was stopped for poor accrual.
Results: Between May 2005 and April 2008 10 
patients were enrolled and treated on trial. The median 
age was 62.5 (range 46 to 82), the majority of patients 
were white (white (n=8), Native America (n=1), and 
African American (n=1)) and most patients had a 
good performance status (KPS of 90-100 (n=3), KPS 
of 70-80 (n=6), and the KPS unknown (n=1)). The 
median number of cycles was 3 (range 1 to 6). Of 
the 10 patients, 6 patients were evaluable for intra-
cranial response; 2 patients experienced progressive 
disease, 1 patient experienced a partial response and 
3 patients experienced stable disease. Four patients 
were unevaluable due to extra-cranial disease 
progression or decline in performance status prevent 
re-evaluation. The median progression-free survival 
was 3.4 months (95% CI, 1.4 to 6.0), and the median 
overall survival was 6.0 months (95% CI, 1.7 to 8.3). 
The toxicities observed were grade 1 or 2. Grade 2 
toxicities observed were dry skin (n=1), fatigue (n=1), 
anemia (n=2), pulmonary infection with grade 1 or 2 
neutropenia (n=1), and nausea (n=2).
Conclusion: Treatment with patients with NSCLC 
with brain metastases remains a challenge. The 
combination of pemetrexed and WBRT appears to 
have been well tolerated in this limited trial, but both 
extra-cranial and intra-cranial disease control remain 
problematic.
Keywords: Pemetrexed, brain metastases, 
chemoradiotherapy, whole brain radiation therapy
was no evidence of heterogeneity with I2 as 0% 
(P=0.770). The overall hazard ratio comparing 
patients randomised to post-induction surgery versus 
was 0.942 (95% CI 0.813 to 1.090) in favour of 
surgery, although this was not statistically signiÀcant 
(P=0.421). 
Conclusion: In the randomised studies of N2 
disease, after induction treatment, radiotherapy 
was not found to be superior to surgery. Published 
evidence does not support the premise that 
chemotherapy and radiotherapy should be considered 
the standard of care, surgery is an acceptable 
alternative.
Keywords: Non-small cell lung cancer, meta-
analysis, survival, treatment
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P4.301 A PHASE II TRIAL OF 
PEMETREXED IN COMBINATION WITH 
WHOLE BRAIN RADIATION THERAPY 
(WBRT)
Juneko Grilley-Olson1, David Morris2, Janak K. 
Choksi3, Mark A. Socinski2, Thomas Stinchcombe2 
1Medicine, Division Of Hematology/oncology, 
University Of North Carolina/United States Of 
America, 2University Of North Carolina/United 
States Of America, 3Alamance Regional Medical 
Center/United States Of America
Background: The treatment of patients with 
non-small cell lung cancer (NSCLC) with brain 
metastases (BM) is a frequent clinical problem. 
Patients frequently require WBRT for treatment 
of the brain metastases initially. While patients 
are receiving WBRT, patients may experience 
extra-cranial disease progression and/or decline 
in performance status, and consequently not be 
candidates for systemic therapy. Earlier initiation of 
systemic therapy and improvements in local control 
of BM could extend survival.
Methods: We performed a single arm, two-stage 
phase II trial of pemetrexed in combination with 
WBRT. Eligibility criteria included: histologically or 
cytologically proven NSCLC, computed tomography 
or magnetic resonance imaging evidence of BM, 
S1586 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
was related to dermatitis severity (3.7 mo grade 0, 10 
months grade 1, and 17 months grade > 2).
Conclusion: Early Àndings from this study suggest 
that erlotinib+WBRT may prolong survival among 
patients with NSCLC and brain metastases. Our 
unexpected Ànding of a high rate of EGFR mutations 
in primary tumors in this group suggests that patients 
with NSCLC and mutated EGFR may be at higher 
risk of brain metastases. Longer term follow-up 
is needed to assess local control, survival, and 
neurotoxicity.
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P4.303 ALSO ELDERLY PATIENTS (75 
YEARS OR OLDER) WITH STAGE III 
NON-SMALL CELL LUNG CANCER 
(NSCLC) HAVE SURVIVAL GAINS 
WITH RADICAL TREATMENT: A 
PROSPECTIVE POPULATION-BASED 
STUDY
Jessie Steevens1, Dirk De Ruysscher2, Anita 
Botterweck3, Bart Reymen4, Angela Van Baardwijk4, 
Rinus Wanders4, Jacques Borger4, Anne-Marie C. 
Dingemans5, Gerben Bootsma6, Cordula Pitz7, R 
Lunde8, Wiel Geraedts9, Philippe Lambin2 
1Comprehensive Cancer Center The Netherlands, 
Location Maastricht/Netherlands, 2Department Of 
Radiation Oncology (MAASTRO), Grow, Maastricht 
University Medical Centre/Netherlands, 3MAASTRO 
Clinic/Netherlands, 4Radiation Oncology, MAASTRO 
Clinic/Netherlands, 5Department Of Pulmonology, 
Maastricht University Medical Center, Grow - 
School For Oncology And Developmental Biology/
Netherlands, 6Pulmonology, Atrium Mc Parkstad/
Netherlands, 7Pulmonology, Laurentius Ziekenhuis/
Netherlands, 8St. Laurentius Hospital/Netherlands, 
9Pulmonology, Orbis MC/Netherlands
Background: Randomised studies with palliative 
systemic treatment have shown a survival beneÀt in 
favour of active therapy in elderly patients, this is 
still unclear in stage III NSCLC. We hypothesised 
that active treatment should lead to improved overall 
survival (OS) rates in the elderly.
Methods: All patients with a pathological 
diagnosis of NSCLC in South- and Middle 
Limburg (Maastricht Cancer Registry, MCR), The 
Netherlands, and with stage III (UICC 6th Edition) 
from 2002 to 2008 were included. MCR covers > 
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P4.302 PHASE II STUDY OF ERLOTINIB 
WITH CONCURRENT WHOLE-BRAIN 
RADIATION THERAPY FOR PATIENTS 
WITH BRAIN METASTASES FROM NON-
SMALL CELL LUNG CANCER
James Welsh1, Arya Amini1, Edward Kim2, Pamela 
K. Allen1, Joe Y. Chang1, Linda Garland3, Ritsuko 
Komaki1, Baldassarre Stea4 
1Radiation Oncology, MD Anderson/United States 
Of America, 2Thoracic And Head & Neck Medical 
Oncology, University Of Texas M.D. Anderson 
Cancer Center/United States Of America, 3Medical 
Oncology, University Of Arizona/United States 
Of America, 4Radiation Oncology, University Of 
Arizona/United States Of America
Background: Brain metastasis is a leading cause 
of death from non-small cell lung cancer (NSCLC). 
Because some patients with NSCLC have mutations 
in the epidermal growth factor receptor (EGFR) and 
because EGFR inhibition plus irradiation has clinical 
beneÀt in head and neck cancer, we developed a 
phase II clinical trial to test whole-brain radiation 
therapy (WBRT) with the anti-EGFR agent erlotinib 
for patients with NSCLC and brain metastases.
Methods: This study opened in February 2006 and 
enrolled 40 patients with brain metastases from 
NSCLC. Patients were given erlotinib 150 mg PO/
day ï‚´ 1 wk, then erlotinib concurrently with WBRT, 
followed by erlotinib only until disease progression. 
Dose reduction was allowed but all patients had to 
remain on erlotinib until completion of radiation to 
be evaluable. EGFR mutation status was assessed 
in primary tumor samples from 18 patients by DNA 
sequencing at MD Anderson’s core facility.
Results: All 40 enrolled patients (median age 59 
y; 19 male, 21 female; median 20 pack-y smoking) 
completed erlotinib+WBRT. Six patients had grade 
3 dermatologic toxicity requiring dose reduction; 
2 patients had grade 3 diarrhea; and 2 patients had 
grade 3 neurotoxicity (one at 12 and the other at 
18 months). At a median follow-up of 21 months, 
the median survival time (10.9 months) compared 
favorably to historical outcomes and to the most 
recent phase III trial of WBRT (RTOG 0118; median 
survival time 3.9 months). Nine of the 18 patients for 
whom EGFR mutation status was known (50%) had 
mutations; most (77%) of the patients with mutations 
were female (odds ratio 0.036, P=0.012). Survival 
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P4.304 LONG TERM FOLLOW-UP OF 
CONSOLIDATION CHEMOTHERAPY 
AFTER CHEMORADIOTHERAPY FOR 
STAGE III NSCLC
Michael Franco1, Sachin S. Joshi2, Peter Briggs1, 
Greg Wheeler2 
1Medical Oncology, Monash Cancer Centre/
Australia, 2Oncology Department, Monash Cancer 
Centre/Australia
Background: The place of adjuvant chemotherapy 
for resected early stage NSCLC has been 
established in several randomised trials. However 
there is no proven role for adjuvant consolidation 
chemotherapy (CC) after radical combined modality 
chemoradiotherapy (CRT) despite the high risk 
of relapse over Àve years. This likely reÁects 
the inadequacy of currently available cytotoxic 
agents and the variable natural history of NSCLC 
. Following encouraging phase II data using 
consolidation taxane therapy, our institution explored 
this approach. This practice was abandoned after 
publication of Hoosier Oncology Group’s negative 
phase III trial. We present initial characteristics and 
outcome of patients treated with CC. Comparison 
is made with patients treated during the same time 
period who were not considered by their treating 
oncologist as candidates for consolidation docetaxel 
therapy.
Methods: All patients treated between January 
2005 and June 2007 had data available. Thirty-
eight consecutive patients were treated for stage III 
NSCLC during this time. All patients received CRT 
with weekly carboplatin (AUC2) and docetaxel 
(25mg/m2) and concurrent radiotherapy (60Gy in 30 
fractions). Fourteen patients of the thirty-eight then 
received CC with two cycles of carboplatin (AUC5) 
and docetaxel (75mg/m2) given three weekly.
Results: Despite no predetermined randomisation, 
the two patient groups (CRT vs CRT/CC) were found 
to be equivalent with regard to stage, histology, 
biochemical measurements of organ function and 
ECOG score. Overall, 1 and 2 year survival were 
improved in the CRT/CC arm. Grade 3 or 4 toxicities 
were not signiÀcantly more frequent in the CRT/
CC group (35.7% vs 29.1%) and the solitary fatal 
toxicity was seen with CRT
98 % of all lung cancer cases. Patients were staged 
with a whole body FDG-PET scan and a CT or 
MRI of the brain and treated according to standard 
regional protocols: Period 1: 2002-2005 3 cycles 
of cisplatin or carboplatin-gemcitabine followed by 
chest radiotherapy (60 Gy/ 30 fractions/ 6 weeks); 
Period 2: 2006-2007 the same 3 cycles of induction 
chemotherapy, but followed by individualised 
accelerated radiotherapy (INDAR) (mean dose 64.8 
Gy/ 36 fractions/ 3.6 weeks = biological equivalent 
82 Gy/ 41 fractions/ 8.2 weeks); Period 3: 2008 
concurrent cisplatin-vinorelbine and INDAR (mean 
dose 65 Gy/ 40 fractions/ 5.5 weeks = biological 
equivalent 74 Gy/ 36 fractions in 7.4 weeks). The 
minimal follow-up of all patients is 2 years.
Results: 1002 patients with stage III were diagnosed, 
of which 545 were less than 70 years, 220 between 
70 and 74 years and 237 75 years or older. 51.4 % 
were treated with curative intent; in the >= 75 years 
47.7 % were treated with curative intent. In the >= 
75 years group, no signiÀcant difference in Charlson 
co-morbidity, age or gender was found between 
patients referred for curative or palliative treatment. 
In all age groups, treatment with curative intent 
increased OS: < 70 years: median OS 19.1 vs. 8.0 
months, 2-year OS 42.7 % vs. 19.6 %; 70-74 years: 
median OS 16 vs. 5.7 months (5.3-4.6), 2-year OS 
32.9 % vs. 13.7 %; >= 75 years: median OS 14.2 
months vs. 5.2 months, 2-year OS 35.5 % vs. 12.1 % 
(all differences p<0.001) (Fig. OS of => 75 years). 
Patients younger than 75 years had a better OS with 
more intense treatment (p<0.001), but not the >= 75 
years (p>0.40).
Conclusion: In this prospective series a clear 
increase in survival occurred in all age groups with 
curative intent treatment. Patients of 75 years or 
older do not seem to beneÀt from more intensive 
treatment. 
Keywords: Elderly, combined modality treatment, 
Non-small cell lung cancer
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and other organ function for pulmonary resection 
were eligible. S-1(40 mg/m²/dose b.i.d) was taken 
orally twice a day on days 1-14 and cisplatin (60mg/
m2) was administered on day 1. The combination 
chemotherapy with SP was repeated twice with a 3 
week-interval concurrently with thoracic radiation 
(2Gy/fraction, once a day, total 40Gy). At 2 to 
4 weeks after the completion of the concurrent 
chemoradiotherapy, curative-intent pulmonary 
resection was planned.
Results: 30 patients between July 2005 and April 
2009 were reviewed, and 28 patients were underwent 
surgical resection. Median follow-up time was 
22.4 months. The mean age was 58 (range 47-77) 
year-old, 23 men and 7 women, 16 Stage IIIA and 
14 IIIB. Histologically: 13 adenocarcinoma (Ad), 
9 squamous cell carcionoma (Sq), and 8 others. 
Twenty-seven patients (90.0%) completed SP-RTx. 
Grade 3/4 toxicities during SP-RTx consisted mainly 
of leukopenia (10.0%/ 0%), neutropenia (3.3%/ 
0.0%) and anemia (6.6%/ 0%). There was one febrile 
neutropenia (3.3%). Objective tumor response was 
obtained in 50.0 % (95% CI: 29-71%) after SP-
RTx: 15 PR cases and 15 SD cases. Lobectomy 
was performed in 15 cases and pneumonectomy in 
13 cases. Twelve cases experienced comorbidity: 
3 arrhythmias, 3 excessive pleural effusion, 2 
chylothorax, 2 postoperative bleedings, and each 1 
pneumothorax, pulmonary edema, empyema and 
spinal cord injury. However, no bronchial Àstula 
was observed. One patient died due to bleeding 
from empyema lesion on 136th postoperative day. 
During the follow-up period, 11 cases experienced 
recurrence. The Àrst recurrence site was distant 
lesion in 10 cases and one in mediastinal lymph 
node. The 3-year disease free survival rate was 
58.8 and 3-year over all survival rates was 64.6%, 
respectively.
Conclusion: SP-RTx as an induction treatment 
followed by surgery for Stage III NSCLC might be 
feasible. However, careful patient selection would be 
warranted, and phase III study would be necessary to 
conÀrm survival beneÀt of this strategy.
Keywords: S-1 and cysplatine, surgical 
resection, stage III NSCLC, Induction concurrent 
chemoradiotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Conclusion: Patients selected for consolidation 
chemotherapy had signiÀcantly better overall 
survival, but did not show more favourable 
prognostic features. This data suggests a subset of 
patients beneÀted from more aggressive treatment 
or alternatively that clinicians intuitively selected a 
better prognostic group not deÀned by usual clinical 
characteristics. More sophisticated prognostic and 
predictive markers are required.
Keywords: Consolidation Chemotherapy, Stage III 
unresectable Non Small cell lung Cancer
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P4.305 INDUCTION CONCURRENT 
CHEMORADIOTHERAPY FOLLOWED 
BY SURGICAL RESECTION FOR STAGE 
III NON-SMALL CELL LUNG CANCER: A 
FEASIBILITY STUDY
Masafumi Yamaguchi, Taro Ohba, Takuro Kometani, 
Fumihiko Hirai, Motoharu Hamatake, Hiroaki 
Takeoka, Kaname Nosaki, Hiromoto Kitajima, 
Takashi Seto, Kenji Sugio, Yukito Ichinose 
Thoracic Oncology, National Kyushu Cancer Center/
Japan
Background: S-1 consists of tegafur and uracil 
at a 1:4 molar ratio concentration (5-FUprodrug), 
and has been clinically used in Japan. Based on 
the favorable result in response rate and treatment 
safety of concurrent chemoradiotherapy using 
combination chemotherapy of S-1 and cisplatin 
(SP) for unresectable non-small cell lung cancer 
(NSCLC) conÀrmed by multicenter Phase II trial 
in Japan, we conducted a feasibility study for 
concurrent chemoradiotherapy using SP (SP-RTx) as 
an induction treatment followed by surgery for Stage 
III NSCLC.
Methods: A single institutional feasibility study. 
Patients with stage III NSCLC, ECOG PS 0–1, age 
20 to 80 year-old and preserve adequate pulmonary 
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cN3- disease underwent surgery. Grade III radiation 
pneumonitis was recorded in 2.4% of the 46-50Gy 
CT-RT compared to 9.5% in the 60-66Gy CT-RT 
(p=.31). Half of all operated patients (46.7%) had 
1 major post-operative complication, but this did 
not differ between the two dose levels (p=.14). Two 
patients (6.7%) died within 90-days after surgery. 
Median disease free survival was 13.6 months and 
was not signiÀcantly different between groups 
(p=.052). In multivariate analysis, prognostic 
indicators for local control were better performance 
status (p=.006) and absence of cN3-nodes (p=.045). 
Locoregional control was similar between CT-
RT-S and CT-RT (13% for CT-RT versus 25.4% 
for CT-RT-S; p=.42). Brain metastasis was the Àrst 
manifestation of distant failure in 13.7% of the entire 
cohort. Median time to local and distant failure was 
17.1 months and 8.3 months, respectively in total 
cohort (p=.27). A median overall survival of 25.8 
months was attained in all patients and did not differ 
signiÀcantly between surgery versus non-surgery 
groups (p=.124). 
Conclusion: Despite careful selection to identify 
favorable stage III NSCLC patients for surgery, no 
signiÀcant differences in disease free survival were 
observed in this retrospective, single-institution 
analysis, between patients who were operated (CT-
RT-S) compared to only CT-RT. 
Keywords: NSCLC, trimodality, advanged stage
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P4.307 LONG-TERM SURVIVAL OF 
NON-SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS WITH SINGLE 
STATION N2 DISEASE TREATED 
WITH CONCURRENT CHEMO-
RADIOTHERAPY.
Bart Reymen1, Angela Van Baardwijk1, Rinus 
Wanders1, Jacques Borger1, Ruud Houben1, Anne-
Marie C. Dingemans2, Gerben Bootsma3, Cordula 
Pitz4, Ragnar Lunde5, Philippe Lambin1, Dirk De 
Ruysscher1 
1Radiation Oncology, MAASTRO Clinic, Grow - 
School For Oncology And Developmental Biology, 
Maastricht University Medical Centre/Netherlands, 
2Department Of Pulmonology, Maastricht 
University Medical Center, Grow - School For 
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Background: Concurrent chemoradiotherapy (CT-
RT) is the standard of care in Àt patients with stage 
III NSCLC. A previous phase III study suggested 
that patients with small-volume disease who could 
undergo a lobectomy, may still beneÀt from surgery 
after induction CT-RT. Until 2008, selected patients 
at our center who had ‘downstaged’ mediastinal 
nodal disease after 46-50Gy CT-RT were operated 
upon. After 2008, delivery of 66Gy was routinely 
possible as intensity modulated radiotherapy (IMRT) 
became available. In order to assess the role of 
surgery after high-dose CT-RT, we retrospectively 
evaluated toxicity and outcomes in all stage III lung 
cancer patients who received CT-RT to a dose of 
either 46-50Gy or 60-66Gy.
Methods: Between 2004-2010, 204 NSCLC 
patients with stage III disease received involved-
Àeld concurrent platinum-based CT-RT at a single 
center. Pancoast tumors were excluded from analysis 
(n=26). Median follow-up of the entire group was 
29.9 months. In total, 30 patients underwent surgery 
after concurrent CT-RT and all were operated by the 
same operating team. Patients were selected by the 
multidisciplinary team if they had partial response 
to preceding CT-RT, limited co-morbidity, and 
when a pneumonectomy could be avoided. A total 
of 46 patients were treated to 46-50Gy, of which 15 
(32.6%) subsequently underwent surgery (CT-RT-S). 
In the group treated to 60Gy or higher, 15 (10.9%) 
out of 137 patients underwent CT-RT-S. Median 
follow-up was 50 months in the 46-50Gy group, and 
21.7 months in the 60-66Gy group.
Results: The CT-RT-S group was signiÀcantly 
younger than CT-RT only patients (P=.001), and 
had less co-morbidity according to the Charlson 
Comorbidity Index (P=.009). No patients with 
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1 at 1 month after RT in all patients. No patients 
died within 3 months after start of RT. Late toxicity 
was infrequent: 1 patient experienced a thoracic 
empyema and 1 patient had radiation pneumonitis 
3 months after radiotherapy. At a median FU of 34 
months, the median OS was 33 months (95% CI 
25-40 months). Median PFS is 26 months (95% CI 
16.5-35.5 months) with an estimated survival at 2 
years of 57%. 
Conclusion: Concurrent individualized accelerated 
chemoradiotherapy is a valid treatment strategy 
for stage III, N2 NSCLC patients with single 
station disease yielding very promising overall and 
progression free survival results with low toxicity, 
even in this patient group with 40 % station 7 
involvement. 
Keywords: NSCLC, Concurrent, Radiotherapy, 
Chemotherapy
Netherlands, 4Department Of Pulmonology, 
Laurentius Ziekenhuis/Netherlands, 5Department Of 
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Background: The optimal treatment strategy for 
Stage III NSCLC patients with a single involved 
nodal site is heavily debated. In prospective surgical 
series median survival is approximately 24 months. 
As in most non-surgical series, multiple-level N2 
or N3 disease are included, outcome after chemo-
radiation in single-station N2 disease is unclear. We 
hypothetised results comparable to surgery can be 
achieved with concurrent accelerated individualized 
chemo-radiation.
Methods: In our prospectively collected database of 
NSCLC patients, all patients with stage III NSCLC 
receiving concurrent chemoradiation (WHO-PS 
0-2; FEV
1
/DLCO >30%) with N2 disease at 1 
single location (Mountain Dressler) were included. 
A total tumor dose (TTD) between 51 and 69 Gy 
was prescribed in 1.5 Gy fractions twice daily up 
to 45 Gy, followed by once daily fractions of 2 
Gy up to an individualized TTD based on normal 
tissue constraints (maximal doses: mean lung dose 
(MLD): 19 Gy, spinal cord: 54 Gy, brachial plexus: 
66 Gy) (van Baardwijk et al. J Clin Oncol 2010). 
Radiotherapy (RT) was started at the 2nd course of 
chemotherapy (cisplatin-vinorelbine or cisplatin-
etoposide). RT planning was 4D-PET-CT based. 
Nodal staging was PET-CT based, and conÀrmed by 
pathology whenever posible. Overall Survival (OS) 
and Progression Free Survival (PFS) were calculated 
from date of diagnosis (Kaplan-Meier method). 
Toxicity was scored according to CTCAEv3.0.
Results: 30 patients (12 female, 18 male) with a age 
of 65 years (44-77 years) were included from April 
1st 2006 until December 31st 2009. Stage distribution: 
10% T0N2 (n=3), 23% T1N2 (n=7), 30% T2N2 
(n=9), 20% T3N2 (n=6), 17% T4N2 (n=5). 2 patients 
(T0N2) had recurrent disease post-lobectomy. Nodal 
stations involved: station 7 in 12 patients (40%), 
4R in 7 patients (23%), region 5 in 8 patients (27%) 
and region 4L, 8 and 2R in 1 patient (3%) each. The 
median dose delivered to the PTV was 65.0 ± 4.9 Gy 
(52.5-69.0 Gy) given in an overall treatment time of 
35 days. The median MLD was 15.2 ± 3.55 Gy (8.3-
19.66 Gy). Acute toxicity: no patients experienced 
grade 3 dyspnea, 1 patient had grade 4 dyspnea 
during RT. 1 month after radiotherapy no grade 3 
dyspnea was found. Grade 3 dysphagia occurred in 
6 patients (20%) during RT, requiring tube feeding 
in 5 of these patients (17%), but subsiding to grade 
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